Back grey_arrow_rt.gif
 
Recent articles on HIV. Check out articles on HIV related Bone Issues and HIV and Aging.
 
null.gif
 
 
  1. Glasgow Manifesto; recorded aging webinars: IAS; Global Action on aging ICOPE
     
  2. CROI: Summary from CROI 2023 for HIV and liver disease What is new in viral hepatitis coinfection? Is fatty liver disease a growing concern? New insights from CROI 2023. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/16/23)
     
  3. CROI: Clinical Pharmacology at CROI 2023 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center - (03/31/23)
     
  4. CROI: Summary from CROI 2024 for HIV and liver disease - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/25/24)
     
  5. Glasgow: Evaluation of T-cell immunosenescence markers in virologically suppressed people living with HIV aged over 60 years on BIC/FTC/TAF or DTG/3TC: the Collateral study - (11/18/24)
     
  6. Glasgow: VIROLOGICAL EFFICACY OF DOLUTEGRAVIR PLUS DARUNAVIR IN MULTI-DRUG-RESISTANT HIV PATIENTS: A REAL-WORLD COHORT STUDY WITH DATA FROM THE PRESTIGIO REGISTRY - (11/18/24)
     
  7. Glasgow: Long-term efficacy and safety of dolutegravir/ lamivudine in virologically suppressed persons with HIV and history of resistance to lamivudine: week 96 results of VOLVER clinical trial - GESIDA 11820 - (11/18/24)
     
  8. Glasgow: Efficacy of dolutegravir plus lamivudine in treatment-naïve people living with HIV without baseline drug-resistance testing available: 48-week results from the randomized D2ARLING study - (11/18/24)
     
  9. Glasgow: Doravirine plus raltegravir (DOR/RAL) two-drug regimen as a maintenance ART in virally suppressed PWH: results of the international randomised DORAL trial - (11/18/24)
     
  10. Glasgow: Long-term outcomes following liver transplantation (LT) in patients with HIV (PWH): a retrospective single-centre case-control study - (11/18/24)
     
  11. Glasgow: Acute/Recent Infections and Reinfections by HCV in MSM with and without HIV in the Region of Madrid (ATHENS Study) - (11/18/24)
     
  12. Glasgow: Prevalence Trends of Active HCV Infection Among People with HIV in Spain (2002-2023): Nearing Elimination - (11/18/24)
     
  13. Glasgow: Kidney Transplant HIV+ Donor to Positive Recipient - Should be SOC - (11/17/24)
     
  14. Glasgow: Comparison of 4 Frailty scores to predict adverse health outcomes and mortalit yin people living with HIV aged 70 years and more (ANRS EP66 SEPTAVIH study) - (11/17/24)
     
  15. Glasgow: Acceptability and feasibility of digital assessment of falls risk, frailty and mobility impairment using wearable sensors in PLWH as part of HIV care - (11/17/24)
     
  16. Glasgow: Antiretroviral therapy, comorbidities and concomitant medication in people with HIV aged over 75 years in one centre in London, UK - (11/17/24)
     
  17. Glasgow: Long-term change of renal function among people with HIV who received tenofovir alafenamide (TAF)-containing ART - (11/17/24)
     
  18. Glasgow: poster - Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study - (11/17/24)
     
  19. Glasgow: Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real- world OncoVIHAC ANRS CO24 cohort study - (11/17/24)
     
  20. Glasgow: Randomized, multicenter, double-blind clinical trial designed to evaluate the safety and convenience of switching from dolutegravir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV, good virologic control and neuropsychiatric comorbidities: Week 24 results from the GESIDA 11920 - MIND Study. - (11/17/24)
     
  21. Glasgow: Depression (20%) and anxiety (15%) symptoms among people with HIV in the UK: prevalence, correlates and treatment. Results from the Positive Voices 2022 study - (11/17/24)
     
  22. Glasgow: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Naïve People With Both HIV-1 and Hepatitis B: 3-Year Outcomes From ALLIANCE - (11/16/24)
     
  23. Glasgow: LEN PrEP PURPOSE-2 Twice-Yearly Gilead Glasgow Press Release - (11/16/24)
     
  24. Glasgow: PrEP-Associated Stigma in Europe: Findings From a Real-World Survey - (11/16/24)
     
  25. Glasgow: Cost-effectiveness and Public-Health Impact of Cabotegravir Long-Acting Injectable for HIV Pre-exposure Prophylaxis in Canada - (11/16/24)
     
  26. Glasgow: PURPOSE 1 LEN PrEP Summary - (11/16/24)
     
  27. Glasgow: Len LA PrEP PURPOSE 2 Summary - (11/16/24)
     
  28. Glasgow: Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2) - (11/16/24)
     
  29. Glasgow: Annual persistence in use of twice-yearly lenacapavir versus daily oral PrEP in the PURPOSE 1 phase 3 trial - (11/16/24)
     
  30. Glasgow: Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirin - (11/15/24)
     
  31. Glasgow: Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: Week 48 safety, efficacy, and metabolic changes - (11/15/24)
     
  32. Glasgow: Treatment-Emergent Integrase Strand Transfer Inhibitor (INSTI) Resistance-Associated Mutations Among People Living With HIV-1 Treated With Dolutegravir (DTG) + Lamivudine (3TC) With Pre-existing M184V/I From Real-world and Interventional Studies - (11/15/24)
     
  33. Glasgow: Real-world Experience of DTG + 3TC Regimen: Results From the French Dat'AIDS Cohort (2015-2022) - (11/15/24)
     
  34. Glasgow: Similar Virologic Outcomes and Frequency of Isolated Viremic Events (Blips, Low-Level Viremia and Suspected Virologic Failure) Between Oral and Long-acting Antiretroviral Therapy: A Pooled Analysis of Phase 3/3b Cabotegravir + Rilpivirine Long-Acting Studies - (11/15/24)
     
  35. Glasgow: Real-World Utilization of Cabotegravir/Rilpivirine: An Observational Analysis of Adherence and Persistence using a Patient Support Program in Canada, Preliminary Results - (11/15/24)
     
  36. Glasgow: Reduction in estimated Glomerular Filtration Rate (eGFR) Observed With Doravirine (DOR) is Caused by Inhibition of Organic Cation Transporter 2 (OCT2) - (11/15/24)
     
  37. Glasgow: HIV Pipeline, Daily, Oral, LA. New Treatments and Future Combinations - (11/15/24)
     
  38. Glasgow: 2nd generation INSTI resistance in randomized trials and cohorts - (11/15/24)
     
  39. Glasgow: INSTI resistance global data trends - (11/15/24)
     
  40. Glasgow: Clinical features and resistance patterns during second-generation InSTI failure: The ROSETTA-registry - (11/15/24)
     
  41. Glasgow: Safety and Immunogenicity of GS-1966+GS-1144 Vaccines in Virally Suppressed Adults Living With HIV-1: A Phase 1b, Randomized, Placebo-Controlled Study - (11/15/24)
     
  42. Glasgow: Metabolic Changes at 48 Weeks in Virologically Suppressed People With HIV Switching From Complex Antiretroviral Regimens to Bictegravir Plus Lenacapavir: ARTISTRY-1 Trial - (11/15/24)
     
  43. Glasgow: Risk of Hypertension in Treatment-Naïve People With HIV in the US Receiving INSTI Versus NNRTI, or TAF- Versus Non-TAF-Based Regimens: Pooled Analysis of Blood Pressure Data From Five Clinical Trials - (11/15/24)
     
  44. Glasgow: Replication-Competent HIV-1 Harboring Resistance-Associated Mutations is Present in the Viral Reservoir - (11/15/24)
     
  45. Glasgow: Four-Year Outcomes From the BICSTaR Study: Observational Analysis of B/F/TAF in Treatment-Naïve and Treatment-Experienced People With HIV in Canada, France, and Germany - (11/15/24)
     
  46. Glasgow: Comparison of Treatment-emergent Resistance-associated Mutations Among Single-tablet Regimens and Cabotegravir + Rilpivirine for the Treatment of Virologically Suppressed People With HIV: A Systematic Literature Review and Network Meta-analysis - (11/14/24)
     
  47. Glasgow: Comparison of Treatment-emergent Resistance-associated Mutations Among Single-tablet Regimens and Cabotegravir + Rilpivirine for the Treatment of Virologically Suppressed People With HIV: A Systematic Literature Review and Network Meta-analysis - Supplementary Materials - (11/14/24)
     
  48. Glasgow: Long-acting treatment for non-virally suppressed individuals: real world evidence - (11/14/24)
     
  49. Glasgow: Efficacy and Safety Analysis of Lenacapavir With Broadly Neutralising Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Highly Sensitive to One or Both Broadly Neutralising Antibodies - (11/14/24)
     
  50. Glasgow: Pharmacokinetics of oral islatravir plus lenacapavir given once weekly in an open-label, active-controlled, phase 2 study of virologically suppressed people living with HIV-1 - (11/14/24)
     
  51. Glasgow: Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: Week 48 safety, efficacy, and metabolic changes - (11/14/24)
     
  52. Glasgow: Post-exposure prophylaxis with doxycycline (doxyPEP) in a cohort of men who have sex with men (MSM) in high risk for sexually transmitted infections (STI). The PRIDOX study - (11/14/24)
     
  53. Glasgow: A provider's perspective of doxyPEP, Community Thoughts - (11/14/24)
     
  54. Glasgow: ViiV HEALTHCARE ANNOUNCES DATA DEMONSTRATING DOVATO (DTG/3TC) IS HIGHLY EFFECTIVE IN TREATMENT-NAIVE PEOPLE WITH ADVANCED HIV - (11/14/24)
     
  55. Glasgow: Comparable efficacy and safety of dolutegravir/ lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: The DOLCE study. - (11/14/24)
     
  56. High Rates of Comorbidities in HIV+ MAC Men & WIHS Women, in WIHS Quality of Life Declines as the Number of Comorbidities Increase - (11/11/24)
     
  57. Glasgow: New treatments and future combinations - (11/11/24)
     
  58. Glasgow: Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic - (11/06/24)
     
  59. Glasgow: ViiV HEALTHCARE EXPANDS ON REAL-WORLD DATA SUPPORTING USE OF LONG-ACTING THERAPIES IN DIVERSE PATIENT POPULATIONS AT HIV GLASGOW - (11/06/24)
     
  60. AASLD: Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024 - (11/07/24)
     
  61. ID Week: Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024 - (11/06/24)
     
  62. HIVMA-IDSA Guidance on Screening for Frailty, Neurocognitive Decline, Bone
    Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America     - (11/05/24)
     
  63. AGE: Incorporating Clinical Geriatrics into HIV care: The Silver Clinic Experience; 'PWH frail 10 years earlier" - (11/01/24)
     
  64. AGE: Integrating geriatrics expertise into HIV primary care: The HIV-Endurance (HIVE) Clinic at Boston Medical Center - (10/31/24)
     
  65. AGE: Polypharmacy & Deprescribing PWH; Polypharmacy Impact - (10/31/24)
     
  66. AGE: Older PWH Loneliness & Facial Emotional Perception Related/Factors; Epigenetic Clock Reflects Coginitve Impairment; Model of Geriatric/Aging Care - (10/31/24)
     
  67. AGE: Detecting Brain Structural Changes with Portable Low-Field MRI Among Older People with HIV; Patterns of Brain Atrophy HIV vs without HIV - (10/31/24)
     
  68. AGE: Depressive Symptoms are Associated with Cortical Thickness, Regional Brain Volumes, and Cerebral Blood Flow Across Younger and Aging Persons with HIV - (10/31/24)
     
  69. AGE: Undiagnosed Sleep Disorders & HIV; Detecting Brain Changes Older PWH with Portable MRI; Depression & Brain Changes; Men with HIV have 42% higher odds of sleep apnea - (10/31/24)
     
  70. AGE: Undiagnosed PWH Dementia & Cognitive Impairment Older PWH & Higher Rates - (10/31/24)
     
  71. AGE: Clinical & Immunologic Features of People Living with Perinatally Acquired HIV - (10/31/24)
     
  72. Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial - (10/30/24)
     
  73. AGE: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV Aged ≥ 50 Years: 48-Week Follow-Up From Four Phase 3 Studies - (10/30/24)
     
  74. AGE: Interim demographics, clinical characteristics, and effectiveness in the REGAL cohort: A REtrospective real-world study of the effectiveness and tolerability of the antiretroviral treatment reGimens DTG/3TC compAred to BIC/FTC/TAF in older persons Living with HIV - (10/30/24)
     
  75. AGE: Switching to B/F/TAF in a Real-World Cohort of Older People With HIV and a High Burden of Non-AIDS-Related Comorbidities - (10/30/24)
     
  76. AGE: Unraveling the Intricate Triangle: HIV, Frailty, and Inflammation - (10/30/24)
     
  77. AGE: Prevention and Treatment of Frailty in PLWH - (10/30/24)
     
  78. ID Week: Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System - (10/24/24)
     
  79. ID Week: Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System - (10/24/24)
     
  80. ID Week: Opportunities for PrEP Awareness and Engagement: A Survey among Cisgender Women Seeking Healthcare in the US - (10/24/24)
     
  81. ID Week: Improving HIV Pre-exposure Prophylaxis (PrEP) among Transgender Individuals - (10/24/24)
     
  82. ID Week: Integrating PrEP Services into a Gynecology Clinic in Alabama: A Qualitative Analysis of Key Determinants - (10/24/24)
     
  83. ID Week: Concerns and opinions of people currently or previously on oral and long acting injectable forms of HIV preexposure prophylaxis (PrEP) - (10/24/24)
     
  84. ID Week: Predictors of Undetectable HDV RNA 48 Weeks After Completion of Finite Treatment With Bulevirtide and Pegylated-Interferon Alpha-2a - (10/24/24)
     
  85. ID Week: Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta in Patients With and Without Cirrhosis: Results From the Week 144 Interim Analysis of a Phase 3 Randomized Study - (10/24/24)
     
  86. ID Week: Efficacy and Safety of B/F/TAF in Black Adults With HIV Who Are Treatment Naïve: 5-Year Follow-Up From Two Phase 3 Studies - (10/23/24)
     
  87. ID Week: Trends in HIV-Related Mortality Among People of Reproductive Potential in the United States HIV Deaths Plunge in Reproductive-Age US Women From 1999 to 2020 - Mark Mascolini (10/23/24)
     
  88. ID Week: Antiretroviral prophylaxis to prevent perinatal HIV infection in Medicaid-insured infants, 2009-2021: Over Half of HIV Infections in First Year of Life Reflect No Postnatal HIV Prophylaxis...majority Black Race - Mark Mascolini (10/23/24)
     
  89. ID Week: Effects of Antiretroviral Resistance on Outcomes and Healthcare Resource Use of People with HIV in the United States and Europe: a real-world survey - (10/23/24)
     
  90. ID Week: Treatment Patterns and Healthcare Resource Utilization of Heavily Treatment Experienced People With HIV - (10/23/24)
     
  91. ID Week: Impact of Pharmacoenhancers on the Pharmacokinetics and Safety of Lenacapavir in People with HIV > - (10/23/24)
     
  92. ID Week: Characterization of People With HIV Who Are Virologically Suppressed With Treatment Experience Using a US Real-World Database - (10/23/24)
     
  93. ID Week: Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living With HIV-1 From Pregnancy Data With Combination DTG and/or 3TC Antiretroviral Therapies - (10/23/24)
     
  94. ID Week: Characteristics of Women Initiating CAB+RPV LA in the OPERA Cohort - (10/23/24)
     
  95. ID Week: LAI CAB/RPV plus SC LEN Effective in PWH with Poor Long-term Adherence and INSTI or NNRTI RAMs - (10/23/24)
     
  96. ID Week: Assessment of Failures of Long-Acting Cabotegravir and Rilpivirine in a Real-World Treatment Setting - (10/23/24)
     
  97. ID Week: PWH Mortality Declined. Disparities Blacks, Socially Vulnerable, Older PWHL: CDC Analysis - Mark Mascolini (10/23/24)
     
  98. ID Week: Metformin reduces the risk of Long COVID or Death over 6 months in an Emulated Target Trial of Primarily Omicron-infected Adults without Diabetes or Prediabetes New-User, Active-Comparator Analysis - (10/23/24)
     
  99. ID Week: Obeldesivir for the Treatment of COVID-19 in People With Risk Factors for Progression to Severe Disease: The BIRCH Study - (10/22/24)
     
  100. ID Week: Obeldesivir for Treatment of COVID-19 in Adults and Adolescents Without Risk Factors for Progression to Severe Disease: The OAKTREE Study - (10/22/24)
     
  101. ID Week: Incidence of Long COVID Symptoms During the Year Post Admission Among Patients Hospitalized for COVID-19; for Immunocompromised - (10/22/24)
     
  102. ID Week: Obeldesivir Reduced SARS-CoV-2 Infectious Titers in the BIRCH Phase 3 Clinical Trial - (10/22/24)
     
  103. ID Week: Paxlovid Cuts Severe COVID Risk in People With Prior Infection or Vaccination - Mark Mascolini (10/22/24)
     
  104. ID Week: Efficacy and Safety of B/F/TAF in Treatment-Naïve People With HIV Aged  50 Years: 5-Year Follow-Up From Two Phase 3 Studies - (10/22/24)
     
  105. ID Week: Breast Cancer (BC) and Colorectal Cancer (CRC) Screenings among Persons with HIV (PWH): The Role of Individual and System-Level Factors on Screening Completion - (10/22/24)
     
  106. ID Week: Comorbidities and Healthcare Resource Utilization Among People With HIV: Real-World Data From a Large Israeli Healthcare Provider - (10/22/24)
     
  107. ID Week: T-cell Immune Exhaustion and the Atherogenic Index of Plasma in People Living with HIV on Antiretroviral Therapy - (10/22/24)
     
  108. ID Week: Trajectories of Newly Initiated Pre-Exposure Prophylaxis (PrEP) Use among Priority Populations with Unmet Needs for PrEP in the USA - (10/21/24)
     
  109. ID Week: Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort - (10/21/24)
     
  110. ID Week: Missed opportunities for HIV Prevention and Treatment in People Hospitalized with Serious Injection Related Infections: The CHOICE+ Cohort - (10/21/24)
     
  111. ID Week: Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting - (10/21/24)
     
  112. ID Week: Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort - (10/21/24)
     
  113. ID Week: Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic - (10/21/24)
     
  114. ID Week: Change in Healthcare Professionals' Identification, Counseling, and Adherence With Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women's Health, Primary Care, and Infectious Diseases Sites: Findings From the EBONI Study - (10/21/24)
     
  115. ID Week: PrEP Decision Factors: a CHORUS Healthcare Professional Survey - (10/21/24)
     
  116. ID Week: Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis (PrEP): A Real-World Study - (10/21/24)
     
  117. ID Week: Update on Lenacapavir for PrEP: Results from the Interim Analyses of PURPOSE 1 and PURPOSE 2 - (10/21/24)
     
  118. ID Week: Over 80% Adhere to Long-Acting CAB+RPV Despite Prior Non-Adherence - Mark Mascolini (10/21/24)
     
  119. ID Week: People With HIV in the United States (US) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) From Oral Antiretroviral Therapy (ART) Have Numerous Real-World Benefits, Including High Adherence and Treatment Satisfaction - (10/21/24)
     
  120. ID Week: Long-acting Injectable HIV Treatment in Individuals with Adherence Challenges: - (10/21/24)
     
  121. ID Week: Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir - (10/20/24)
     
  122. ID Week: Similar Efficacy, Safety and CD4 T-cell Increase up to Week 96 Observed With Fostemsavir (FTR)-Based Regimens in the BRIGHTE Study and Dolutegravir (DTG)-Based Regimens in the VIKING-3 Study in Individuals With Multidrug-Resistant (MDR) HIV-1 - (10/20/24)
     
  123. ID Week: CD4 T-cell, CD4/CD8 Ratio Improvement and a General Reduction in Inflammatory Biomarkers With Low-Level Viremia (LLV) up to Week 192 With Fostemsavir (FTR)-Based Regimens in Individuals With Multidrug-Resistant (MDR) HIV-1 - (10/20/24)
     
  124. ID Week: Racial/Ethnic Disparities of Renal Outcomes in People With HIV on Tenofovir Alafenamide-Based Antiretroviral Therapy Regimens in the Real World - (10/20/24)
     
  125. ID Week: Lenacapavir Sustains HIV Control and Keeps Boosting CD4s Through 3 Years - Mark Mascolini (10/20/24)
     
  126. ID Week: Optimizing 2-Drug Switch HBV Screening: pilot intervention to increase HBV screening - (10/20/24)
     
  127. ID Week: Long-Acting Subcutaneous Lenacapavir in People with HIV-1 Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study - (10/20/24)
     
  128. ID Week: Pharmacokinetics and Safety of GS-1720 Following Multiple Ascending Doses in a Phase 1a Study in People Without HIV-1 - (10/20/24)
     
  129. ID Week: PAIRED - PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): A diverse sample of people with HIV-1 (PWH) reporting high treatment satisfaction, good adherence, and high quality of life - (10/20/24)
     
  130. ID Week: ViiV HEALTHCARE SHOWS MORE THAN 99% EFFECTIVENESS IN REAL-WORLD STUDIES FOR APRETUDE (CABOTEGRAVIR LONG-ACTING), THE ONLY APPROVED LONG-ACTING HIV PREP, IN DATA PRESENTED AT IDWEEK 2024 - (10/16/24)
     
  131. HIVR4P The role of healthcare-related experiences in willingness and preference for long-acting injectable PrEP (LA-PrEP) among transfeminine persons in the US Transgender Women's Internet Survey and Testing (TWIST) study - (10/16/24)
     
  132. HIVR4P Gap Between Oral and Injectable PrEP Awareness in US Transgender Women - Mark Mascolini (10/16/24)
     
  133. HIVR4P Managing inflammation from STIs as an HIV prevention strategy Can Cutting STI-Linked Inflammation Prevent HIV Infection? - Mark Mascolini (10/16/24)
     
  134. HIVR4P STI Risk Falls 80% After Milan MSM Get DoxyPEP Prescription - Mark Mascolini (10/16/24)
     
  135. HIVR4P Use of HIV rapid detection tests when initiating long-acting cabotegravir for HIV prevention, within an implementation science project - (10/16/24)
     
  136. HIVR4P Acceptability, adherence, preference and safety of placebo Long-Acting Pre-exposure Prophylaxis (LA-PrEP) injections and implants for HIV-prevention in South African men: the SAMURAI study - (10/16/24)
     
  137. HIVR4P HIV PEP-in-Pocket ("PIP") facilitates the de-medicalization of HIV prevention - (10/16/24)
     
  138. HIVR4P PrEP uptake and adherence among transgender women: findings from a randomized clinical trial of a multicomponent intervention (HPTN 091) PrEP Uptake Over 85% in Big US/Brazil Transgender Woman Study - Mark Mascolini (10/16/24)
     
  139. HIVR4P Greater PrEP use in a community-based needle and syringe program versus facility-based medication for opioid use disorder program for people who use drugs in Uganda - (10/16/24)
     
  140. HIVR4P PrEP choice for women in Africa: uptake of oral PrEP and PrEP ring - (10/16/24)
     
  141. HIVR4P Patterns of PrEP use among women in the context of choice: early results from CATALYST, an implementation study offering oral PrEP and PrEP ring across five African countries - (10/16/24)
     
  142. HIVR4P Provider and client perspectives on PrEP choice: quality of PrEP choice and factors influencing its provision in the CATALYST implementation study - (10/16/24)
     
  143. HIVR4P Integration of oral and injectable PrEP services for adolescents at the community level in Sao Paulo - (10/16/24)
     
  144. HIVR4P Switching between oral and injectable pre-exposure prophylaxis (PrEP) regimens in the United States: an investigation of reasons for switching in the real world - (10/12/24)
     
  145. HIVR4P Early implementation of long-acting injectable cabotegravir for HIV prevention in a safety net primary care center in U.S. South at Grady in Atlanta - (10/12/24)
     
  146. HIVR4P Pharmacokinetic superiority of a 3-month dapivirine vaginal ring (100 mg) compared to the 1-month dapivirine vaginal ring (25 mg) - (10/12/24)
     
  147. HIVR4P Short-term combination immunotherapy with broadly neutralizing antibodies and CCR5 blockade mediates ART-free viral control in infant rhesus macaques - (10/11/24)
     
  148. Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023 - (10/11/24)
     
  149. HIVR4P 17-Clinic US Study Pinpoints Keys to Giving Long-Acting Injected PrEP: Overcoming Challenges Integrating Injectable PrEP Into Care: Key Strategies From The PILLAR Study - Mark Mascolini (10/11/24)
     
  150. HIVR4P High CAB-LA PrEP On-Time and Retention Rates in US Urban Safety-Net Clinic Population. SF, Ward-86 - Mark Mascolini (10/11/24)
     
  151. HIVR4P Long-acting injectable Cabotegravir (CAB-LA) pilot implementation at primary healthcare level in resource-limited settings: early real-world evidence from the USAID DISCOVER-Health Project in Zambia - (10/11/24)
     
  152. HIVR4P HIV pre-exposure prophylaxis (PrEP) access preference among men who have sex with men in China: a discrete choice experiment - (10/10/24)
     
  153. HIVR4P Phase 1 dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics and neutralization activity of PGDM1400LS in combination with VRC07-523LS and PGT121.414.LS in healthy participants without HIV (HVTN 140/HPTN 101) - (10/10/24)
     
  154. HIVR4P HIV Trends in Metropolitan US Cities from 2014-2022: Baseline For The Ending The Epidemic Initiative - (10/10/24)
     
  155. HIVR4P Early virologic success on ART following breakthrough infection on CAB-LA PrEP - Mark Mascolini (10/10/24)
     
  156. HIVR4P Gilead Lenacapavir Access Statement & Voluntary Licensing Agreement - (10/10/24)
     
  157. HIVR4P PURPOSE-2 & Other PURPOSE Studies - (10/10/24)
     
  158. HIVR4P Global racial, ethnic, and gender diversity among participants enrolled in the PURPOSE-2 trial of lenacapavir for pre-exposure prophylaxis (PrEP) - (10/10/24)
     
  159. HIVR4P Development of a long-acting biodegradable hydrogel injectable system for single or multi-purpose prevention of HIV and/or pregnancy - (10/10/24)
     
  160. HIVR4P Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender men and transgender women at elevated risk for acquiring HIV-1 - (10/10/24)
     
  161. HIVR4P Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender women at elevated risk for acquiring HIV-1 - (10/10/24)
     
  162. HIVR4P Scaling a non-human primate physiologically-based pharmacokinetic model of extended-release MK-2048 and combination MK-2048/vicriviroc (MK-2048A) intravaginal rings into humans using phase 1 MTN-027 and MTN-028 studies - (10/09/24)
     
  163. HIVR4P Weekly oral prophylaxis with MK-8527 protects rhesus macaques from rectal challenge with simian-human immunodeficiency virus - (10/09/24)
     
  164. HIVR4P ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-INCOME COUNTRIES - (10/06/24)
     
  165. HIVR4P Preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among transfeminine persons in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST) study - (10/06/24)
     
  166. HIVR4P Preferences for telePrEP among people who access HIV self-testing in Philadelphia - (10/06/24)
     
  167. HIVR4P Implementing long-acting cabotegravir for HIV Pre-Exposure Prophylaxis in a large academic hospital-based urban HIV clinic - (10/06/24)
     
  168. HIVR4P Examples of studies - CATALYST South Africa - (10/06/24)
     
  169. HIVR4P Examples of studies - DCE results on service delivery preferences - (10/06/24)
     
  170. HIVR4P Examples of studies - Project PrEP - (10/06/24)
     
  171. HIVR4P Implementing PrEP Choice: Experiences from South Africa - (10/06/24)
     
  172. HIVR4P History of injectable contraception was associated with women's willingness to use long-acting injectable PrEP: findings from US women across nine cities - (10/06/24)
     
  173. HIVR4P Characterizing the Levels of Knowledge, Attitudes, and Behaviors Regarding the Use and Risks Associated with Oral HIV-1 Pre-Exposure Prophylaxis (PrEP) Among People Prescribed PrEP in Canada - (10/06/24)
     
  174. HIVR4P Understanding preferences for pre-exposure prophylaxis (PrEP) among people who would benefit from PrEP in the United States - (10/06/24)
     
  175. HIVR4P Interest in long-acting PrEP modalities among women in the United States with a history of injectable medication use: findings from the MACS/WIHS combined cohort study - (10/06/24)
     
  176. HIVR4P Safety, Pharmacokinetics, and Degradation of Ultra-Long-Acting Injectable, Biodegradable, and Removable In-Situ Forming Implant with Cabotegravir for HIV Prevention - (10/06/24)
     
  177. Untangling the causal ties between antiretrovirals and obesity: Comment. 'Body Weight Changes CASCADE Cohort' - (09/25/24)
     
  178. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomized, controlled, phase 3 trial; Commentary - (09/25/24)
     
  179. Gilead's Twice-Yearly Lenacapavir for HIV Prevention
    Reduced HIV Infections by 96% and Demonstrated Superiority
    to Daily Truvada® in Second Pivotal Phase 3 Trial
     - (09/14/24)
     
  180. Updated Statement on Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention - (09/14/24)
     
  181. HRSA Issues Aging/HIV Letter on Older HIV; Long-Term Survivors in Ryan White HIV/AIDS Program - (09/05/24)
     
  182. HIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis - (09/03/24)
     
  183. Patterns of HIV treatment preferences (oral, LA, implant) among people with diverse demographic, social, and behavioral characteristics who are living with HIV in the United States - (08/26/24)
     
  184. Missed Opportunities: Characteristics of People Who Received a Concurrent HIV/AIDS Diagnosis in New York State From 2016 to 2021....19.0% had a CDX (late diagnosis) - (08/26/24)
     
  185. Switching to long-acting cabotegravir/rilpivirine: data from an Italian monocentric cohort - (08/26/24)
     
  186. Aging with HIV - An Epidemiological Profile of Persons with Diagnosed HIV Aged 50 Years and Older in New York State, 2012-2021, new HIV more likely to have late diagnosis/stage 3 HIV, female white, heterosexual sex, IDU....heart disease/cancers leading cause of death NYC - (08/26/24)
     
  187. Prevalence and correlates of frailty among older people with and without HIV in rural Uganda - (08/26/24)
     
  188. THE ASSOCIATION OF ANEMIA WITH SURVIVAL AMONG PEOPLE WITH HIV FOLLOWING ANTIRETROVIRAL INITIATION IN THE NA-ACCORD 2007-2016 - (08/26/24)
     
  189. IAS: The DoxyPEP Debate: To DoxyPEP or not to DoxyPEP? - (08/26/24)
     
  190. IAS: Negative Perception of Self & Stigma & Depression associated with Worse Expectations of Aging in Brazil - (08/26/24)
     
  191. FRAX assessment in people ageing with HIV - (08/19/24)
     
  192. Impact of rosuvastatin on pulse-wave velocity in men with HIV at moderate cardiovascular risk, plus Editorial Comment - (08/19/24)
     
  193. Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV - (08/19/24)
     
  194. Medical comorbidities and lower myelin content are associated with poor cognition in young adults with perinatally acquired HIV - (08/19/24)
     
  195. IAS: Differences between integrase strand transfer inhibitors on glucose tolerance: a role for mitochondrial stress - (08/19/24)
     
  196. IAS: New HIV Drug Development at IAS 2024 - (08/19/24)
     
  197. IAS: Aging, Metabolics & Weight Studies at IAS 2024 - (08/12/24)
     
  198. IAS: Switching to doravirine in the absence of genotypic resistance tests in people living with HIV virally suppressed on antiretroviral treatment at a London HIV clinic - (08/06/24)
     
  199. IAS: Phase 1, open-label study to evaluate the drug interaction between MK-8527, an HIV-1 nucleoside reverse transcriptase translocation inhibitor, and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females - (08/06/24)
     
  200. IAS: Population pharmacokinetics (POPPK) for thigh as alternative Rilpivirine Long-Acting (RPV LA) injection site - (08/06/24)
     
  201. IAS: Cabotegravir/rilpivirine long-acting therapy real world experience in a large clinical cohort of HIV patients - (08/06/24)
     
  202. IAS: CAB/RPV-LA in patients with history of failure and/or drug resistance mutations to NNRTIs or INSTIs: the experience of a French university hospital - (08/06/24)
     
  203. IAS: Resistance Analyses During Treatment of Lenacapavir with Broadly Neutralizing Antibodies in People with HIV - (08/06/24)
     
  204. IAS: Assessment of Longitudinal Changes in Renal Function of HIV-1 Oral Pre-Exposure Prophylaxis Users Using Real-World Data in the United States - (08/06/24)
     
  205. IAS: Assessment of Longitudinal Changes in Renal Function of HIV-1 Oral Pre-Exposure Prophylaxis Users Using Real-World Data in the United States - (08/06/24)
     
  206. IAS: Experiences and Quality of Life with Long-Acting Lenacapavir from People with Multidrug-Resistant HIV-1 Enrolled in the Phase 2/3 CAPELLA Study - (08/06/24)
     
  207. IAS: Predicting Retention in Care Before and After the COVID-19 Pandemic Among People With HIV - (08/06/24)
     
  208. IAS: Long-acting oral PrEP is preferred to injections: findings from an online sample of American gay, bisexual, and other men who have sex with men - (08/06/24)
     
  209. IAS: Weight Gain and Health-Related Quality of Life in PWH on ART - (08/06/24)
     
  210. IAS: Lack of Understanding of Undetectable Equals Untransmittable (U=U) is High Among PLWH in US - (08/06/24)
     
  211. IAS: Bone health in Malaysian women living with HIV: uncovering the pores in osteoporosis screening and management in a high-risk population - (08/05/24)
     
  212. Low Compliance (10%) with Bone Mineral Density Screening Recommendations for People with HIV Despite High Fracture Rates...."critical to prioritize health screenings" (08/04/24)
     
  213. IAS: ART Use and HTLV-1 Tied to hrHPV Persistence in Kenyan Women With HIV - Mark Mascolini (08/03/24)
     
  214. IAS: Changes in body mass index before and after starting dolutegravir and compared to protease inhibitors in children and adolescents living with HIV in Europe and Thailand - (08/03/24)
     
  215. IAS: PAIRED - PAtIent Reported Experiences and perceiveD Benefit of Treatment With Dolutegravir/Lamivudine (DTG/3TC) - Qualitative Interviews: Diverse Group of People With HIV-1 (PWH) Reflect on Life and Health - (08/03/24)
     
  216. IAS: Prenatal Dolutegravir-Based Regimen Use, and Pregnancy and Birth Outcomes: Data From The Antiretroviral Pregnancy Registry - (08/03/24)
     
  217. IAS: Effectiveness and durability of dolutegravir/rilpivirine in older people with HIV from the Veterans Aging Cohort Study (VACS) - (08/03/24)
     
  218. IAS: Adolescents and young adults with HIV using long-acting injectable cabotegravir/rilpivirine as a standard of care: outcomes of the observational cohort at 26 months - (08/03/24)
     
  219. IAS: Increased incidence of emergent integrase drug resistance with cabotegravir versus dolutegravir in randomised switching trials - (08/03/24)
     
  220. IAS: Early experiences with usage of injectable cabotegravir (CAB-LA) among Kenyan and Ugandan adults participating in the SEARCH Dynamic Choice HIV Prevention trial: a qualitative study....self & external stigma, convenience, feeling healthy - (08/03/24)
     
  221. IAS: Pre-Exposure Prophylaxis product choice of participants in HPTN 083 - (08/03/24)
     
  222. IAS: Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention: the HPTN 084-01 study - (08/03/24)
     
  223. IAS: CAB-LA for PrEP Earns High Satisfaction Rates (90%) in Rural Kenya and Uganda - Mark Mascolini (08/03/24)
     
  224. IAS: HCV incidence among MSM using HIV PrEP and MSM with HIV in a New York City Health Care System over 2 decades - (08/02/24)
     
  225. IAS: (Implants) Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort - (08/02/24)
     
  226. IAS: An assessment of clinical frailty and early aging among a cohort of people living with HIV in Ontario, Canada - (08/01/24)
     
  227. IAS: Comprehensive geriatric assessment for people living with HIV and frailty: a feasibility randomized controlled trial - (08/01/24)
     
  228. IAS: Perceptions on frailty and frailty screening of people living with HIV and their healthcare professionals in Ethiopia: a qualitative study - (08/01/24)
     
  229. IAS: Frailty and multimorbidity in mid-aged and older adults living with HIV: a cross-sectional study in Zimbabwe - (08/01/24)
     
  230. IAS: Polypharmacy Contributes to Frailty & Falls - CHANGE-Rx: frailty, falls, polypharmacy, and inappropriate medication use in a Canadian cohort of people aged 65 and older living with HIV....53% of older PWH have frailty - (08/01/24)
     
  231. IAS: Hypertension management and risk of dementia in people with and without HIV infection - (08/01/24)
     
  232. IAS: Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort - (08/01/24)
     
  233. Dolutegravir with recycled nucleoside reverse transcriptase inhibitors maintains better viral suppression than protease inhibitor based antiretroviral therapy over 144 weeks: VISEND Trial - (08/01/24)
     
  234. IAS: Influencers and Decision-Making Factors for Choosing Injectable PrEP Among Men Who Have Sex With Men and Transgender Men in the United States - (08/01/24)
     
  235. IAS: Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) in the U.S currently using daily-oral PrEP - (08/01/24)
     
  236. IAS: Need for Improved HIV Testing Prior to and During Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injections in Routine Clinical Care in the United States: Low Rates of HIV Tesing - (08/01/24)
     
  237. IAS: Only 9% PrEP Use Among Transfeminine Persons: HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons with high likelihood of HIV in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST) - (08/01/24)
     
  238. IAS: "The simplest way to go:" A mixed methods analysis of why women who inject drugs selected long-acting injectable cabotegravir instead of daily oral PrEP.....95% of women initiated CAB Lai PrEP !!! - (07/31/24)
     
  239. IAS: Efficacy of dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the phase 3/3b GEMINI-1/-2, STAT, TANGO, and SALSA - (07/31/24)
     
  240. IAS: Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 - (07/31/24)
     
  241. IAS: Switching from a second-line ritonavir-boosted protease inhibitor (PI/r)-based regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): results of a randomized clinical trial - (07/31/24)
     
  242. IAS: Extended efficacy and safety of dolutegravir and darunavir containing regimens at week 96 in the international randomised clinical trial: D2EFT - (07/31/24)
     
  243. IAS: Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies - (07/31/24)
     
  244. IAS: What drives Comorbidities in PWH ? Highlights From Aging Pre-Conference Talks, at AIDS 2024 - (07/31/24)
     
  245. IAS: Assessing Comorbid Conditions in HIV/AIDS Patients: Insights from the CHAO (Comorbidities of HIV/AIDS Outpatients) Study in Meru County, Kenya and Their Role in Shaping Integrated Health Care Approaches - (07/31/24)
     
  246. IAS: Prevalence and associated factors of chronic kidney disease in young people living with HIV in Uganda - (07/31/24)
     
  247. IAS: Increased cardiovascular risk in perinatally HIV-acquired adolescents (PHIV) may linked to proinflammatory NK cells - (07/31/24)
     
  248. IAS: ViiV HEALTHCARE ANNOUNCES POSITIVE NEW DATA FOR APRETUDE USE DURING PREGNANCY AT AIDS 2024 - (07/30/24)
     
  249. IAS: ViiV HEALTHCARE ANNOUNCES POSITIVE DATA DEMONSTRATING 2-DRUG REGIMEN DOVATO IS AS EFFECTIVE AS 3-DRUG REGIMEN BIKTARVY FOR MAINTENANCE THERAPY OF HIV-1 - (07/30/24)
     
  250. IAS: ViiV HEALTHCARE PREMIERES EARLY DATA SHOWING ANTIVIRAL ACTIVITY AGAINST INTEGRASE RESISTANCE FROM ITS INVESTIGATIONAL, THIRD-GENERATION INTEGRASE INHIBITOR - (07/30/24)
     
  251. IAS: Switching to B/F/TAF in a Real-World Cohort of Older People With HIV and a High Burden of Non-AIDS-Related Comorbidities - (07/30/24)
     
  252. IAS: Fine Differences Among Five Anal Cancer Screening Strategies in HIV Group - Mark Mascolini (07/30/24)
     
  253. IAS: Preclinical Assessments of a Cabotegravir Prodrug Predicting Human Dosing Durations of >6 Months - (07/30/24)
     
  254. IAS: Prevalence of high risk penile human papillomavirus in men who have sex with men (MSM) and transgender women (TGW) - (07/30/24)
     
  255. IAS: Pre-Clinical Profiles of HIV-1 Capsid Inhibitors VH4004280 (VH-280) and VH4011499 (VH-499) - (07/30/24)
     
  256. IAS: GS-8588, A Novel Envelope-Targeting Bispecific T-Cell Engager for HIV Cure - (07/30/24)
     
  257. IAS: Injection Site Reactions with Subcutaneous Lenacapavir Administration at Alternate Injection Sites - (07/30/24)
     
  258. IAS: Nonclinical Pharmacology Profile of GS-1720, a Novel, Highly Potent, Once-Weekly Oral HIV-1 Integrase Strand Transfer Inhibitor in Clinical Development - (07/29/24)
     
  259. IAS: Safety and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GS-4182, an Oral Prodrug of Lenacapavir, in Participants without HIV-1 - (07/29/24)
     
  260. IAS: Clinical Pharmacokinetics and Safety of Orally Administered VH4004280 (VH-280), a Novel HIV-1 Capsid Inhibitor, in Adults Without HIV - (07/29/24)
     
  261. IAS: Clinical Outcomes at Month 12 After Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND) - (07/29/24)
     
  262. IAS: Perspectives of People With HIV (PWH) 12 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) - (07/29/24)
     
  263. IAS: Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Cohort Study - (07/29/24)
     
  264. IAS: 12-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study Who Switched Off Suppressive Oral Daily ART - (07/29/24)
     
  265. IAS: Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile - (07/29/24)
     
  266. IAS: In vitro characterization of VH4524184 (VH-184, S-365598), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile - (07/29/24)
     
  267. IAS: The next Berlin patient: sustained HIV remission surpassing five years without antiretroviral therapy after heterozygous CCR5 WT/Δ32 allogeneic hematopoietic stem cell transplantation - (07/29/24)
     
  268. IAS: Subcutaneous injections of cabotegravir + rilpivirine in virally suppressed adults with HIV-1: a substudy of the Phase 3 FLAIR study - (07/29/24)
     
  269. IAS: Long-acting cabotegravir (CAB) plus rilpivirine (RPV) in the first, virologically-suppressed adolescents with HIV-1 to receive an every 8-week, all-injectable regimen in a multicenter, multinational Study: IMPAACT 2017 week 48 outcomes - (07/29/24)
     
  270. IAS: CAB LA Plus RPV Every 2 Months Controls HIV in Adolescents - Mark Mascolini (07/29/24)
     
  271. IAS: Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study - (07/29/24)
     
  272. IAS: Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the DYAD study - (07/29/24)
     
  273. IAS: Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial - (07/28/24)
     
  274. IAS: Detailed modelling of viremia exposure does not independently predict cardiovascular disease in people with HIV - (07/28/24)
     
  275. IAS: Risk of major cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: retrospective cohort analyses using routine, de-identified data from South Africa - (07/28/24)
     
  276. IAS: Integrating non-communicable disease screening and treatment in antiretroviral clinics: insights from Malawi - (07/28/24)
     
  277. IAS: A pilot study assessing changes in cerebral function parameters in persons with insomnia switching integrase inhibitors - (07/28/24)
     
  278. IAS: Third-Generation Integrase Inhibitor Remains Active Against Resistant HIV in Lab - Mark Mascolini (07/27/24)
     
  279. IAS: Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral regimens at baseline - (07/27/24)
     
  280. IAS: Bictegravir Plus Lenacapavir Keep Control of HIV in People on Complex Regimens - Mark Mascolini (07/27/24)
     
  281. IAS: Dolutegravir-containing antiretroviral therapy and incident hypertension: findings from a prospective cohort in Kenya, Nigeria, Tanzania, and Uganda - (07/27/24)
     
  282. IAS: Additional Time PostIntegrase Inhibitor to Protease Inhibitor Switch Shows Trend to Weight Loss: DEFINE 48-week Results - (07/27/24)
     
  283. IAS: Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASO-DOBLE (GeSIDA 11720) randomized clinical trial. - (07/27/24)
     
  284. IAS: Viral suppression, viral failure and safety outcomes in children and adolescents on dolutegravir (DTG) in Europe and Thailand - (07/27/24)
     
  285. IAS: Failure to achieve undetectable viral load caused by HIV expression from defective proviruses and large reservoir size - (07/27/24)
     
  286. IAS: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae (GC) infections among MSM on Doxycycline post-exposure prophylaxis. - (07/24/24)
     
  287. IAS: Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study - (07/24/24)
     
  288. IAS: No Confirmed Virological Failures (CVF) for 144 Weeks When Switching 2-/3-/4-Drug ART to DTG/3TC in Heavily Treatment-Experienced PLWHA with Prior M184V/I and Multiple Virological Failures in the Prospective SOLAR-3D Study - (07/24/24)
     
  289. Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia - (07/10/24)
     
  290. 21% of adults with diagnosed HIV were out-of-care - (07/05/24)
     
  291. Prevalence of anal HPV infection and anal HSIL among MSM 50 years and older living with or without HIV - (07/05/24)
     
  292. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024 - (07/05/24)
     
  293. Food Is Medicine for Human Immunodeficiency Virus: Improved Health and Hospitalizations in the Changing Health Through Food Support (CHEFS-HIV) Pragmatic Randomized Trial - (06/21/24)
     
  294. Dasatinib + Quercetin Drugs Reduced Senescent-Associated Secretory Phenotype (SASP) in PLWH PBMCs - (06/21/24)
     
  295. Age-associated dementia (30%) among older people aging with HIV in the United States: a modeling study - (05/24/24)
     
  296. Comparison of dementia risk after age 50 between individuals with and without HIV infection: 58% Higher Risk, 10 years Earlier - (05/24/24)
     
  297. CROI: Rethinking the Definition of Late HIV Diagnosis Using Florida Surveillance Data, 2015-2021 - (05/28/24)
     
  298. CROI: A Multistate Analysis of Longitudinal Care Outcomes Among People Newly Linked to HIV Care in Missouri - (05/28/24)
     
  299. EuroHIV-HepMtg2024: Prevalence of HIV1 Resistance
    Mutations to Rilpivirine and Cabotegravir in Treatment-Naïve Patients     - (05/24/24)
     
  300. Extrapolating Expected Efficacy, Safety, and Pharmacokinetics of Dolutegravir/Lamivudine in Pregnant People Living With HIV-1 From Pregnancy Data With Combination Dolutegravir and/or Lamivudine Antiretroviral Therapies - (05/24/24)
     
  301. EuroHIV-HepMtg2024: Efficacy of Dolutegravir (DTG) and Lamivudine (3TC) in Adults With HIV-1 and Isolated Reactive Hepatitis B Core Antibody (Anti-HBc): Results From the Phase 3 GEMINI-1/-2, TANGO, and SALSA Studies - (05/24/24)
     
  302. The relationship between anti-LGBTQ+ legislation and HIV prevention among sexual and gender minoritized youth - (05/23/24)
     
  303. Impact of HIV pre-exposure prophylaxis prescriptions on HIV diagnoses in New York city: disparities in new HIV diagnosis - (05/23/24)
     
  304. EuroHIV-HepMtg2024: Acute Hepatitis B Infections after Reducing ART among Vaccinated Patients Living with HIV: HBV "PrEP-effect" of TDF/FTC? - (05/23/24)
     
  305. EuroHIV-HepMtg2024: Multivariable Models to Identify Predictors of Virologic Response to Fostemsavir in BRIGHTE - (05/23/24)
     
  306. EuroHIVMtg2024: Evaluation of Weight Gain on Incident Hypertension Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials Through 96 Weeks - (05/23/24)
     
  307. 2 Doravirine+Islatravir Studies Published - (05/13/24)
     
  308. Incidence of non-AIDS defining comorbidities among young adults with perinatally-acquired HIV in North America, 2000-2019 - (05/13/24)
     
  309. FDA Approves Biktarvy®Label Update With Data for Pregnant Adults With HIV - (05/13/24)
     
  310. Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection - (05/08/24)
     
  311. CROI: HIV Transcription Persists in the Brain of People With HIV and Viral Suppression - (05/01/24)
     
  312. CROI: Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH - (05/01/24)
     
  313. CROI: Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation - (05/01/24)
     
  314. CROI: Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection - (05/01/24)
     
  315. CROI: Mini-Lecture on HIV Persistence in the CNS: Considerations for Current Cure Strategies - (05/01/24)
     
  316. Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study - (05/01/24)
     
  317. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study - (05/01/24)
     
  318. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study - (05/01/24)
     
  319. 3 New Papers on Integrase Inhibitors & TAF and Weight Changes, Metabolics - (05/01/24)
     
  320. 3 New Papers on Integrase Inhibitors & TAF and Weight Changes, Metabolics - (04/17/24)
     
  321. CROI: EPIGENETIC IMPACT IN CSF CELLS FROM 48 WEEKS OF ADJUNCTIVE TELMISARTAN IN ACUTE HIV - (04/15/24)
     
  322. CROI: Prevalence of HIV Testing and HIV Positivity in the Hispanic Community Health Study/Study of Latino - (04/15/24)
     
  323. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV - (04/15/24)
     
  324. ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV - (04/15/24)
     
  325. CROI: EPIGENETIC IMPACT IN CSF CELLS FROM 48 WEEKS OF ADJUNCTIVE TELMISARTAN IN ACUTE HIV - (04/12/24)
     
  326. CROI: Epigenetic Age Advancement Is Associated With Cognition, Frailty, and Mortality in Older PWH - (04/12/24)
     
  327. CROI: Differential Expression Analysis Reveals Pervasive Transcriptional Changes in the Brains of PWH - (04/12/24)
     
  328. CROI: ANTIRETROVIRAL REGIMENS ARE ASSOCIATED WITH COGNITIVE FUNCTION IN PEOPLE WITH HIV - (04/12/24)
     
  329. CROI: CD4 Count Predicts Longitudinal Trajectories of Central Executive Network Connectivity in PLWH - (04/12/24)
     
  330. CROI: Pro-Inflammatory Glycomic Dysregulations Define HIV-Associated Neurocognitive Impairments - (04/12/24)
     
  331. CROI: Predictors of CD4/CD8 T-cell Inversion After 96 Weeks of ART Initiated During Acute HIV - (04/12/24)
     
  332. CROI: Immune Checkpoint Signatures Associated With Impaired Cognition in People Living With HIV - (04/12/24)
     
  333. CROI: A New Measure of ART Activity in CSF and Association with Persistence and Cognitive Function - (04/12/24)
     
  334. CROI: Cumulative exposure to CVD risk factors more adversely affects cognition in women than men with and without HIV - (04/12/24)
     
  335. CROI: ASCVD Risk score Predicts Lower Cognitive Function, Bigger Affect in Women- Atherosclerotic Cardiovascular Disease Risk Score and Cognition by HIV Serostatus and Sex - (04/11/24)
     
  336. CROI: Brain White Matter Hyperintensity Accumulation in an Acute HIV Cohort over Two Years - (04/11/24)
     
  337. CROI: HIV-1 Infection and Alzheimer's Disease Pathobiology in a Novel Humanized APP-Knock in Mouse Model - (04/11/24)
     
  338. CROI: Effects of Recent Air Pollution Exposure on Cognition, Inflammation, and Neurodegeneration in HIV - (04/11/24)
     
  339. CROI: ASYMPTOMATIC CSF HIV-1 ESCAPE: INCIDENCE AND EFFECTS ON CNS BIOMARKERS - (04/11/24)
     
  340. CROI: Anti-α4β7 antibody facilitates improved renal function during SIV infection in macaques - (04/11/24)
     
  341. CROI: Pattern of Age-Related Cognitive Decline in People With HIV Depends on Viral Suppression - (04/11/24)
     
  342. CROI: Clonal Hematopoiesis in HIV and Atherosclerosis, Arterial Inflammation, and Hematopoietic Activity - (04/11/24)
     
  343. CROI: Description of clonal hematopoiesis in a hospital-based cohort of people living with HIV - (04/11/24)
     
  344. CROI: Clonal Hematopoiesis and HIV Infection are Associated with Geriatric Outcomes: the ARCHIVE Study - (04/11/24)
     
  345. CROI: PWH 50% Unknown Causes of Death Latin America: Registered Causes of Death Remain Largely Unknown Among People with HIV in Latin America - (04/08/24)
     
  346. CROI: Older/Poor PWH Have Worse Hospital Readmission Rates vs PWoH: Trends in Hospital Readmissions Among Adults With (two-thirds higher) and Without HIV in the US, 2010-2020: indicates poor quality-of-care; women had higher rates - (04/08/24)
     
  347. CROI: CARE INTERRUPTIONS AND MORTALITY AMONG ADULTS ON ART IN EUROPE AND NORTH AMERICA - (04/08/24)
     
  348. CROI: Impact of accessing care at an advanced stage on mortality in PWH in France, 2002-2016 - (04/08/24)
     
  349. CROI: Life-Years Lost Associated With Mental Illness in People With HIV in South Africa and North America: anxiety, depression - (04/08/24)
     
  350. CROI: Prevalence of diagnosed and undiagnosed depression among U.S. adults with HIV - (04/08/24)
     
  351. CROI: Targeting Inflammation and Cardiovascular Disease in People with HIV: 2024 and onward, Priscilla Hsue MD - (04/03/24)
     
  352. CROI: Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment & Prevention for People Experiencing Homelessness - (04/03/24)
     
  353. CROI: Case Series Examining the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial - (04/03/24)
     
  354. CROI: EHE "May not be feasible in many US cities" - Charting Achievable Milestones for HIV Care Enhancement and Prevention in the US Through 2035 - (04/02/24)
     
  355. CROI: First Case of HIV Seroconversion With Emergence of InSTI Resistance on CAB-LA PrEP in Routine Care - (04/02/24)
     
  356. CROI: HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women - (04/02/24)
     
  357. CROI: Met and unmet health and welfare services needs amongst people with HIV in the UK: mental health, physical health, welfare - (04/02/24)
     
  358. CROI: Routine Collection of Patient-Reported Outcomes in HIV Clinics: Findings After >100,000 Assessments.....rates of depression, binge drinking, drug use, intimate partner violence CNICS Cohort - (04/02/24)
     
  359. CROI: Effect of Obesity on Response to Antiretroviral Therapy in SIV-infected Rhesus Macaques - (04/02/24)
     
  360. CROI: DOLUTEGRAVIR TARGETS THE HYPOTHALAMUS TO SUPPRESS ENERGY EXPENDITURE VIA ESTROGEN RECEPTOR - (04/02/24)
     
  361. CROI: Biomarkers Influence Kidney Function Estimates More So Than Race Among Persons with HIV - (04/02/24)
     
  362. CROI: Markers of Macrophage Activation and Kidney Function in People With and Without HIV - (04/02/24)
     
  363. CROI: Association Between Social Vulnerability, HIV Testing and Positivity, United States, 2020-2022: High Social Vulnerability, racial/economic disparities Worst Outcomes - (04/01/24)
     
  364. CROI: Evaluating Barriers to Care Among Adults Living with HIV Who Are Virally Unsuppressed in Philadelphia, Using Medical Monitoring Project Data, 2015-2021 - (04/01/24)
     
  365. CROI: Ending the HIV Epidemic in Atlanta: A Mixed-Methods Study to Support the Local HIV/AIDS Response racial/ethnic & geographic disparities-service delivery gaps - (04/01/24)
     
  366. CROI: Barriers to Early Enrollment and Rapid ART Initiation Among U.S. HIV Care Facilities: low rates for 1st appontment - (04/01/24)
     
  367. CROI: The HIV Care Cascade in Medicaid, 2001-2015: 35% adherent/retained in care; Black-white disparities - (04/01/24)
     
  368. CROI: Using the ICE Method to Examine Income/Racial Segregation and HIV Outcomes -US, 2021: structural racism - (04/01/24)
     
  369. CROI: The Opioid Use Disorder Care Cascade for PWH Experiencing Homelessness in Low-Barrier HIV Care - (04/01/24)
     
  370. CROI: The Impact of the COVID-19 Pandemic on Substance Use Disorder Risk among People with HIV in the US - (04/01/24)
     
  371. CROI: Preclinical Pharmacokinetics of a Novel Long-Acting Bictegravir Solid Injectable in Rats - (04/01/24)
     
  372. CROI: A Shape-Shifting Tail Decay is the Pharmacokinetic ; Profile of an Ultra-Long Acting Bictegravir Prodrug - (04/01/24)
     
  373. CROI: Switching to DTG+3TC vs 3-Drug Regimens in Routine Clinical Care: Long-term Swedish Data - (04/01/24)
     
  374. CROI: SHORT AND LONG-TERM BODY WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (04/01/24)
     
  375. CROI: Mechanisms to Therapeutics: TACK Molecules Kill HIV-Infected Cells Through Inflammasome Activation: "potential to cure HIV via reduction in viral reservoir" ? - (04/01/24)
     
  376. CROI: SHORT AND LONG-TERM BODY WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (03/28/24)
     
  377. CROI: Trends in Black-White Disparities in HIV Diagnosis: 2017-2021, United States; relative black-white disparities increase; increase for male-to-male sexual contact; for IDU - (03/28/24)
     
  378. CROI: Estimating Lifetime Risk of a Diagnosis of HIV Infection Among MSM: United States, 2017-2021: it persists with racial disparities - (03/28/24)
     
  379. CROI: Virologic Failure with Cabotegravir-Rilpivirine Injections: A Single-Site Experience; independent infusion center - (03/28/24)
     
  380. CROI: A Randomized Trial Switching Adults ≥ 60 Years Old From First-Line ART to B/F/TAF: Week 48 Results - (03/28/24)
     
  381. CROI: Disparities in HIV care among Hispanic/Latino persons by birthplace and social vulnerability-United States, 2021 - (03/28/24)
     
  382. CROI: TRENDS IN SUICIDE-RELATED EMERGENCY DEPARTMENT VISITS AMONG PEOPLE WITH AND WITHOUT HIV IN BRONX, NY: increasing among 50 yrs old+ - (03/28/24)
     
  383. CROI: Trends and Correlates of Methamphetamine Use Among Men Who Have Sex With Men in the US, 2014-2021 - (03/28/24)
     
  384. CROI: Prescription Opioid Use and Disorder Among Older Adults With HIV in the US From 2008-2019 - (03/28/24)
     
  385. CROI: HIGH COMPLETION AND CURE RATES WITH A DECENTRALIZED, INTEGRATED HCV TREATMENT APPROACH IN VIETNAM (PWH) - (03/28/24)
     
  386. CROI: Nationwide HCV Elimination Program and the Status of Microelimination in People With HIV in Taiwan - (03/28/24)
     
  387. CROI: High rate of Hepatitis C incidence in Vietnamese MSM living with HIV; substance use; group sex; STIs - (03/28/24)
     
  388. CROI: HIV-1 coinfection skews iNKT cells towards anergy and exhaustion in persons living with hepatitis C virus - (03/28/24)
     
  389. CROI: Trends in HIV and HCV Prevention Efforts and Incidence Among People Who Inject Drugs in Baltimore: not enough HCV treatment - (03/28/24)
     
  390. CROI: HIV and HCV Screen Rates for Hospitalized PWUD Are Heterogeneous & Suboptimal Across 11 States - (03/28/24)
     
  391. CROI: Inflammatory profile of B/F/TAF, DTG/ABC/3TC, and DTG+F/TAF over 5-years and effects of viral blips: 'transient viral blips may contribute to inflammation in Art-treated' - (03/27/24)
     
  392. CROI: The (no) Effect of Dolutegravir on Whole-Body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers - (03/27/24)
     
  393. CROI: Temporal Trends of Cardiovascular Disease Incidence in People with HIV from 2001-2021: high prevalence of risk factors - (03/27/24)
     
  394. CROI: Global Trends in CD4 Count Measurement and Prevalence of CD4 <200 cells/μL at ART Initiation: high prevalence remains for <200 cd4 at ART start (30%) - (03/27/24)
     
  395. CROI: Pregnancy History Affects Age-Related Comorbidity Burden in U.S. Women With and Without HIV - (03/27/24)
     
  396. CROI: Consequences of Low-Level Viremia by Sex Among People With HIV in the United States - (03/27/24)
     
  397. CROI: InSTI Switch During Menopause Is Associated With Accelerated Body Composition Change: 'early accelerated increases in waist circumference & BMI' - (03/27/24)
     
  398. CROI: Age Modifies the Association Between Sex and the Plasma Inflammatory Proteome in Treated HIV: HIV+ women have more inflammation at older ages in particular, mortality associated - (03/27/24)
     
  399. CROI: Cabotegravir Population Pharmacokinetic Analysis of Adults & Adolescents Living with HIV or at Risk for HIV Receiving PrEP - (03/27/24)
     
  400. CROI: Why Is Cabotegravir Rollout So Slow? - (03/27/24)
     
  401. CROI: HIV Post-exposure Prophylaxis (PEP) Prescription Trends (underutilized) - United States, 2013-2022 - (03/27/24)
     
  402. CROI: PEP2PrEP: an effective HIV risk-reduction strategyn - (03/27/24)
     
  403. CROI: Preclinical Characterization of GS-5894, a Potent NNRTI With Once Weekly Oral Dosing Potential - (03/26/24)
     
  404. CROI: 31st Conference on Retroviruses and Opportunistic Infection Eric S. Daar, M.D. - Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/26/24)
     
  405. CROI: Lipidome composition and weight changes at 48week 3TC-DTG and FTC/TAF/BIC: data of the ICONA cohort - (03/25/24)
     
  406. CROI: Switching to Integrase Strand Transfer Inhibitors and the Risk of Diabetes in Persons with HIV - (03/25/24)
     
  407. CROI: Weight Gain in People With HIV (PWH) vs People Without HIV (PWoH) Over a 3-Year Period - (03/25/24)
     
  408. CROI: Dolutegravir, Body Mass Index, and Metabolic Syndrome in the IeDEA Sentinel Research Network - (03/25/24)
     
  409. CROI: Weight Gain After Initiating ART Close to HIV Seroconversion: Is There a Return to Health Effect? - (03/25/24)
     
  410. CROI: Weight Change After Starting Doravirine Among ART-Experienced Individuals in the US - (03/25/24)
     
  411. CROI: Effect of TDF and TAF on Duodenal Enterocytes - a Hypothesis on Different Effect on Body Weight - (03/25/24)
     
  412. CROI: Virologic Outcomes with Tenofovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure - (03/22/24)
     
  413. CROI: SHORT AND LONG-TERM BODY WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITORS DIFFERS BY SEX - (03/22/24)
     
  414. CROI: Resistance to second-Generation InSTIs in Mexican PLWH: Emergence of the R263K Mutant - (03/22/24)
     
  415. CROI: Emerging Dolutegravir Resistance in Lesotho - (03/22/24)
     
  416. CROI: Dolutegravir (DTG) resistance among ART-experienced viremic patients in Kenya receiving DTG-based ART - (03/22/24)
     
  417. CROI: ACTG 5381: Virologic and Resistance Outcomes After Switch to TLD for Failing 1st or 2nd Line ART - (03/22/24)
     
  418. CROI: Viremia and drug resistance over 2 years after routine switching to dolutegravir-based first-line ART - (03/22/24)
     
  419. CROI: Emerging Dolutegravir Resistance Among Children Being Investigated for Treatment Failure in Malawi - (03/22/24)
     
  420. CROI: Switching From a Second-Line Boosted PI Regimen to B/F/TAF: Results of a Randomized Clinical Trial - (03/22/24)
     
  421. CROI: 24-Week Viral Suppression in Patients Starting Long-Acting CAB/RPV Without HIV Viral Suppression - (03/22/24)
     
  422. CROI: Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH - (03/22/24)
     
  423. CROI: BIC/FTC/TAF as HIV PEP was well-tolerated with high adherence and no seroconversions - (03/22/24)
     
  424. CROI: Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda - (03/22/24)
     
  425. CROI: Transaminase elevations among patients with occult HBV infection on two-drug antiretroviral regimens - (03/21/24)
     
  426. CROI: Hepatitis B Reactivation in PLWH With Anti-Core Antibody After Switch to an Anti-HBV Sparing Regimen - (03/21/24)
     
  427. CROI: HepB-CpG Vaccine Superior to HepB-alum in HIV Group With Prior Nonresponse - Mark Mascolini (03/21/24)
     
  428. CROI: A Shape-Shifting Tail Decay is the Pharmacokinetic Profile of an Ultra-Long Acting Bictegravir Prodrug - (03/20/24)
     
  429. CROI: 62% of new HIV infections and 63% of deaths now reported in countries outside Southern/East Africa - (03/20/24)
     
  430. CROI: ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART - (03/20/24)
     
  431. CROI: Predictors of weight gain in the ADVANCE, NAMSAL and WRHI trials; EFV, TDF, and baseline CD4 count - Mark Mascolini (03/20/24)
     
  432. CROI: More Than 60% of New HIV and HIV Deaths Now in "Low-Prevalence" Countries - Mark Mascolini (03/20/24)
     
  433. CROI: ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART - Mark Mascolini (03/20/24)
     
  434. CROI: Intramuscular Injection vs Intravenous Infusion of Ibalizumab for HTE PWH: The Results of TMB-302 - (03/20/24)
     
  435. CROI: Real-World Utilization of Cabotegravir + Rilpivirine in the US: Data From Trio Health Cohort - (03/20/24)
     
  436. CROI: Real-World Effectiveness of Cabotegravir + Rilpivirine vs Standard of Care Oral Regimens in the US in OPERA Cohort - (03/20/24)
     
  437. CROI: Effects of Pitavastatin on COVID-19 Incidence and Seriousness among People with HIV - (03/20/24)
     
  438. CROI: Hypertension in a randomized trial of DTG- vs EFV-based ART in pregnant and postpartum women - (03/19/24)
     
  439. CROI: Activated and exhausted CD8+ T Cell subsets associate with carotid atherosclerotic plaques in PLHIV - (03/19/24)
     
  440. CROI: Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation - (03/19/24)
     
  441. CROI: Suppressing Asymptomatic CMV with Letermovir Reshapes Cardiometabolic Proteome in Treated HIV - (03/19/24)
     
  442. CROI: Plasma Proteome Signature of Immune Inhibition is Associated with CMV Coinfection in People with HIV - (03/19/24)
     
  443. CROI: Latent Viral Infections Are Associated With Veterans Aging Cohort Study Index in People With HIV - (03/19/24)
     
  444. CROI: Clinical Profiles Predicting Cognitive Decline (24%) over 10 years Among Older Adults with HIV in Canada - (03/19/24)
     
  445. CROI: High Plasma GFAP in older PWH with Low Nadir CD4 Support Legacy Brain Injury and Reactive Gliosis - (03/19/24)
     
  446. CROI: Application of STOPP Criteria in an Urban Cohort of People Aging with HIV, 50%+ PWH Taking Inappropriate Prescriptions - (03/19/24)
     
  447. CROI: Endothelial Dysfunction in HIV: Exploring Cytokine and Chemokine Dynamics - (03/19/24)
     
  448. CROI: ELEVATED TRIGLYCERIDES AND ENDOTHELIAL VASODILATOR DYSFUNCTION IN ADULTS LIVING WITH HIV-1 - (03/19/24)
     
  449. CROI: Biomarkers of Microbial Translocation and Inflammation Associated with Frailty among People with HIV 58% Frail/Prefrail - (03/19/24)
     
  450. CROI: OPTIMIZING LONG-TERM EXERCISE BENEFITS FOR OLDER ADULTS WITH HIV THE MOVIHNG STUDY - (03/19/24)
     
  451. CROI: Frailty and Health-Related Quality of Life (QOL 24% Lower) in an Aging Cohort of People with HIV 2012-2022 - (03/19/24)
     
  452. CROI: Neighborhood Vulnerability Predicts Non-Communicable Disease Risk Among People With HIV - (03/19/24)
     
  453. CROI: Semaglutide Trims Muscle Volume but Physical Function Not Lost - Mark Mascolini (03/19/24)
     
  454. CROI: Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE - Mark Mascolini - (03/19/24)
     
  455. CROI: Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE - (03/19/24)
     
  456. CROI: A Skewed NK Cell Repertoire Persists in People with HIV-1 Despite Long-Term ART - (03/19/24)
     
  457. CROI: Immunological Non-Responders have CD4+ Immunosenescence and Impaired Lymphocyte Cytokine production - (03/19/24)
     
  458. CROI: DNA Methylation-Based Telomere Length Is Associated with HIV Infection and Cancer in Relation to HIV Frailty and All-Cause Mortality - (03/19/24)
     
  459. CROI: Ultra-Low Level HIV p24 Production as a Driver of Immune Activation in Individuals Treated with ART - (03/19/24)
     
  460. CROI: CSF ART Exposure, Population Pharmacokinetic Approaches to Standardize Antiviral Exposure in the Cerebrospinal Fluid - (03/19/24)
     
  461. CROI: MRI With T2 Maps and Spectroscopy Show Chronic Progressive Brain Damage Despite HIV Suppression - (03/19/24)
     
  462. CROI: US States With More PrEP Coverage See Bigger Drops in HIV Diagnoses - Mark Mascolini (03/18/24)
     
  463. CROI: Safety Study of Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Early Pregnancy - (03/18/24)
     
  464. CROI: Strong Oral PrEP Uptake and Persistence in 3000 African Girls and Young Women in INSIGHT Cohort - Mark Mascolini (03/18/24)
     
  465. CROI: < HIV Incidence in Users of HIV Preexposure Prophylaxis in Australia: A Whole-of-Population Analysis - (03/18/24)
     
  466. CROI: HIV incidence in users of HIV preexposure prophylaxis in Australia: a whole-of-population analysis - Mark Mascolini (03/18/24)
     
  467. CROI: Associations between a polygenic risk score for Alzheimers disease and brain integrity in HIV - (03/18/24)
     
  468. CROI: Doxy-PEP Associated with Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco.....increase in gonorrhea after SF Guidelines Oct 2022 - (03/18/24)
     
  469. CROI: Doxy-PEP Effectiveness in Men Who Have Sex with Men (MSM) and Transgender Women (TGW) on HIV PrEP - (03/18/24)
     
  470. CROI: Doxycycline Post-Exposure Prophylaxis (DoxyPEP): High uptake and Significant Decline in STIs after Clinical Implementation - (03/18/24)
     
  471. CROI: Randomized Trial Shows Huge Uptake Success of HIV Prevention Choices in Kenya, Uganda - Mark Mascolini (03/18/24)
     
  472. CROI: CSF ART Exposure, Population Pharmacokinetic Approaches to Standardize Antiviral Exposure in the Cerebrospinal Fluid - (03/16/24)
     
  473. CROI: No neurocognitive benefit of immediate vs delayed tesamorelin in virally suppressed people with HIV - (03/16/24)
     
  474. CROI: Socio-Demographics Were Stronger Classifiers of Cognitive Profiles Than Neuroimaging in HIV - (03/16/24)
     
  475. CROI: EXTRA-CVD: A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention - (03/16/24)
     
  476. CROI: Treatment of Prehypertension in People Living With HIV: A Randomized Controlled Trial - (03/16/24)
     
  477. CROI: Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE - (03/16/24)
     
  478. CROI: Performance of the ACC/AHA Pooled Cohort Equations or Risk Prediction in the Global REPRIEVE Trial - (03/16/24)
     
  479. CROI: Factors Contributing to Risk of Major Adverse Cardiovascular Events among People with HIV in REPRIEVE - (03/16/24)
     
  480. CROI: Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE - (03/16/24)
     
  481. CROI: Aging at CROI 2024 - (03/16/24)
     
  482. CROI: Semaglutide at CROI 2024 - (03/16/24)
     
  483. CROI: Relating Pitavastatin Effects on Inflammatory Biomarkers to Plaque Changes in REPRIEVE - (03/16/24)
     
  484. CROI: Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection - (03/16/24)
     
  485. CROI: HepB-CpG vaccine is superior to HepB-alum in people with HIV and prior vaccine non-response (A5379) - (03/15/24)
     
  486. CROI: Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With HIV-1 and HBV - (03/15/24)
     
  487. Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study - (03/14/24)
     
  488. CROI: Amyloid-β PET Positivity Among Cognitively Impaired People with HIV Over Age 60 - (03/13/24)
     
  489. CROI: Plasma Inflammatory Biomarkers Link to Worse Cognition Among Africans Living With HIV - (03/13/24)
     
  490. CROI: Age-Adjusted Mortality Rates Among Persons With HIV, by Race and Ethnicity and Cause of Death....22% due to comorbidities - (03/13/24)
     
  491. CROI: Leading Causes of Death Among People With HIV in the US, 2001-20194x greater death risk than gen. pop., cancer & heart disease, HIV leading causes of death, Blacks have higher death rates - (03/13/24)
     
  492. CROI: Progress Toward Achieving National Goals for Improved Quality-of-Life Among Black Women With HIV.....worse unmet mental health needs, self-rated good or better health worsened - (03/13/24)
     
  493. CROI: Immunoregulatory Pathways Predict Mortality More Strongly in People With Versus Without HIV - (03/13/24)
     
  494. CROI: Prostate cancer characteristics and outcomes for veterans: Higher Advanced Prostate Cancer Risk in Veterans With Than Without HIV, 67% Blacks in Study - Mark Mascolini (03/13/24)
     
  495. CROI: Low-Level HIV Viremia Affects T-Cell Activation and Senescence in InSTI Era - (03/13/24)
     
  496. CROI: Excess Inflammation Associated with AIDS and Non-AIDS Complications in Adults on ART...deferring ART increased inflammation, complications & Death Rates - (03/13/24)
     
  497. CROI: Sleep Deprivation Contributes to Immune Activation in People With HIV Control - Mark Mascolini (03/13/24)
     
  498. CROI: Association Between Depressive Symptom Severity and Incident Stroke among People with HIV - (03/13/24)
     
  499. CROI: HIV Clinical Factors and Cardiovascular Disease Risk Predict White Matter Hyperintensity Burden (brain) - (03/13/24)
     
  500. CROI: Assessing Blood-Based Biomarkers as Predictors of Cognitive Decline in PWH: ACTG A5322 (HAILO) - (03/13/24)
     
  501. CROI: Associations between Nadir CD4 and Subsequent Immune Measures with Long-Term Cognitive Function in HAILO (ACTG 5322) - (03/13/24)
     
  502. CROI: Phone calls for PrEP persistence in Kenyan women in postabortal care: a cluster randomized trial. - Mark Mascolini (03/12/24)
     
  503. CROI: PrEP Non-Persistence and New HIV Diagnoses: A Real-World Analysis of >120,000 People Prescribed PrEP - (03/12/24)
     
  504. CROI: Safety of dapivirine vaginal ring and oral PrEP for HIV prevention in the second trimester. - Mark Mascolini (03/12/24)
     
  505. CROI: CHANGES IN HIV PREP AWARENESS & USE AMONG PWID IN 19 U.S. CITIES, 2018 & 2022 ....very low PrEP use - (03/12/24)
     
  506. CROI: Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083 - (03/12/24)
     
  507. CROI: Healthcare Staff Acceptability and Feasibility of Telehealth Delivery of Cabotegravir for PrEP - (03/12/24)
     
  508. CROI: Interest in Long-Acting Injectable PrEP Among Transgender Women in the United States - (03/12/24)
     
  509. CROI: Real-World Use of Cabotegravir Long-Acting for Preexposure Prophylaxis: Trio Health Cohort - (03/12/24)
     
  510. CROI: Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort - (03/12/24)
     
  511. CROI: Hospital and Death Rate Almost Twice Higher After SARS-CoV-2 in Unvaccinated - Mark Mascolini (03/11/24)
     
  512. CROI: COVID Incidence and Severity in Persons with Reinfection vs Post-vaccination Breakthrough Infection....>65, comorbidities protected more - (03/11/24)
     
  513. CROI: Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies - (03/11/24)
     
  514. CROI: A DOSE ESCALATION STUDY OF SAFETY & PK OF TMB-365 & TMB-380 IN PEOPLE WITH SUPPRESSED HIV - (03/11/24)
     
  515. CROI: aHSIL and Nadir CD4s Below 200 Boost Invasive Anal Cancer Risk With HIV - Mark Mascolini (03/11/24)
     
  516. CROI: Implementing Long-Acting Cabotegravir for HIV Preexposure Prophylaxis in a Large Urban HIV Clinic - (03/11/24)
     
  517. CROI: Is the Weight Over?: GLP-1 Receptor Agonists Are Here - Background - (03/11/24)
     
  518. CROI: IMPAACT 2017 Adolescent/Parent Experiences with LA Cabotegravir Plus Rilpivirine for HIV Treatment - (03/11/24)
     
  519. CROI: EFFICACY, SAFETY, AND PK OF BIC/FTC/TAF IN ADULTS WITH HIV AND TUBERCULOSIS ON RIFAMPICIN AT WEEK 24 - (03/11/24)
     
  520. CROI: Twice-Daily BIC/FTC/TAF With Rifampicin Effective in People With HIV and TB - Mark Mascolini (03/11/24)
     
  521. CROI: Long-Acting CAB + RPV Gains Favor in UK Community, But Less in Blacks - Mark Mascolini (03/11/24)
     
  522. CROI: DoxyPEP Cuts Chlamydia and Syphilis Incidence in MSM Using PrEP - Mark Mascolini (03/11/24)
     
  523. CROI: Long-Acting Injectable CAB/RPV is Superior to Oral ART in PWH With Adherence Challenges: ACTG A5359 - (03/11/24)
     
  524. CROI: Bone Mineral Density in Children With HIV-1 Receiving TAF-Based Antiretroviral Therapy - (03/11/24)
     
  525. CROI: No Virologic Failures, Good Safety With LA I njected CAB + RPV for Adolescents IMPAACT 2017 MOCHA Study - Mark Mascolini (03/11/24)
     
  526. CROI: IMPAACT 2017 Adolescent/Parent Experiences with LA Cabotegravir Plus Rilpivirine for HIV Treatment - (03/11/24)
     
  527. CROI: New HIV Therapies, Drugs at CROI 2024 - (03/11/24)
     
  528. CROI: Impact of Semaglutide on Weight Change Among People with HIV: A Stratified Analysis by Baseline BMI - (03/11/24)
     
  529. CROI: Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy....people with severe lipoatrophy were excluded from study, so were diabetics & CVD - (03/11/24)
     
  530. CROI: Four of 6 Early-Treated Infants Attain Sustained ART-Free Remission - Mark Mascolini (03/11/24)
     
  531. CROI: Weight Loss 5.7% at 1 Year With Semaglutide in HIV - Mark Mascolini (03/11/24)
     
  532. CROI: Associations Between Interest in Oral vs Long-Acting Injectable ART Among US Women With HIV - (03/11/24)
     
  533. CROI: Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Elderly Using PBPK Modelling - (03/11/24)
     
  534. CROI: Functional Brain Network Changes Among People With HIV and Viral Suppression - (03/11/24)
     
  535. CROI: One-Year Declines in Bone Mineral Density Among Young Women in Uganda Using TDF-Based PrEP and DMPA - (03/11/24)
     
  536. CROI: Chronic comorbidities in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of antiretroviral therapy - (03/07/24)
     
  537. CROI: Aging & Perinatally Acquired HIV: Cardiometabolic Risks and Comorbidities: Adolescents and Young Adults with Perinatally Acquired HIV - (03/07/24)
     
  538. CROI: Doxycycline PEP Study Extension: High uptake and significant decline in STIs after clinical implementation - Mark Mascolini - (03/07/24)
     
  539. CROI: Doxycycline PEP: High uptake and significant decline in STIs after clinical implementation - Mark Mascolini - (03/07/24)
     
  540. CROI: Final Results of ANRS 174 DOXYVAC: A Randomized trial to Prevent STIs in MSM on PrEP - (03/07/24)
     
  541. CROI: Lung Function, HIV and Mortality: Analyses From the AIDS Linked to the Intravenous Experience Cohort: age 51, 81% black, 84% current smokers, 34% (28%) current injectors -study demographics - (03/07/24)
     
  542. CROI: ViiV HEALTHCARE PRESENTS PHASE I CLINICAL TRIAL FINDINGS OF A CABOTEGRAVIR LONG-ACTING INJECTABLE INVESTIGATIONAL FORMULATION ALLOWING AT LEAST FOUR MONTHS BETWEEN DOSES - (03/07/24)
     
  543. CROI: InSTI Switch During Menopause Is Associated With Accelerated Body Composition Change - (03/07/24)
     
  544. CROI: Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 - (03/07/24)
     
  545. CROI: High PrEP uptake and adherence with point of care tenofovir testing among young African women: Results from the INSIGHT cohort - (03/07/24)
     
  546. CROI: Randomized trial of Cabotegravir and Rilpivirine Long-acting in Africa (CARES):Week 48 Results - (03/07/24)
     
  547. CROI: Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study - (03/07/24)
     
  548. CROI: ViiV HEALTHCARE ANNOUNCES INTERIM DATA AT CROI INDICATING SUPERIOR EFFICACY OF LONG-ACTING INJECTABLE HIV TREATMENT CABENUVA (CABOTEGRAVIR + RILPIVIRINE) COMPARED TO DAILY ORAL THERAPY IN INDIVIDUALS LIVING WITH HIV WHO HAVE ADHERENCE CHALLENGES - (03/06/24)
     
  549. CROI: ABBV-382, an Anti-a4b7 Ab That Enhances HIV-1 Antigen Presentation for Immune-Mediated Viral Control - (03/06/24)
     
  550. CROI: Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI - (03/06/24)
     
  551. CROI: Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial - (03/06/24)
     
  552. CROI: Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1 - (03/06/24)
     
  553. CROI: Antiviral Activity, Safety, and Pharmacokinetics of GS-1720, a Novel Weekly Oral INSTI - (03/06/24)
     
  554. CROI: A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236 - (03/06/24)
     
  555. CROI: Trispecific bNAb Hits 3 Targets but Has Modest Antiviral Activity in First Human Studies - Mark Mascolini - (03/06/24)
     
  556. Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV - (03/06/24)
     
  557. CROI: Safety and efficacy of VRC07-523LS plus long-acting cabotegravir in the phase II ACTG A5357 tria - Mark Mascolini (03/06/24)
     
  558. CROI: Lenacapavir Plus bNAbs for People with HIV and Susceptibility to Either Teropavimab or Zinlirvimab - (03/06/24)
     
  559. CROI: ViiV HEALTHCARE PRESENTS PHASE I CLINICAL TRIAL FINDINGS OF A CABOTEGRAVIR LONG-ACTING INJECTABLE INVESTIGATIONAL FORMULATION ALLOWING AT LEAST FOUR MONTHS BETWEEN DOSES - (03/06/24)
     
  560. CROI: Phase 1 Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval - (03/06/24)
     
  561. CROI: VH3810109 (N6LS) in Antiretroviral Therapy-Naive Adults With HIV-1: Phase 2a BANNER Efficacy Data - (03/06/24)
     
  562. CROI: Longitudinal Analysis of Preexisting Resistance-Associated Mutations Prior to B/F/TAF Switch - (03/04/24)
     
  563. CROI: Model-Based Comparison of Cabotegravir Pharmacokinetics Following Thigh and Gluteal Injections - (03/04/24)
     
  564. CROI: Lenacapavir Efficacy in CAPELLA Patients with No Fully Active Agents in Optimized Background Regimen - (03/04/24)
     
  565. CROI: Impact of Archived Minority Populations With M184V/I on DTG/3TC for Maintenance of Viral Suppression - (03/04/24)
     
  566. CROI: Discovery of MK-8527, a long-acting HIV nucleoside reverse transcriptase translocation inhibitor - (03/04/24)
     
  567. CROI: Switching to Doravirine/Islatravir Maintains Viral Suppression Regardless of Archived Mutations - (03/04/24)
     
  568. CROI: The Preclinical Profile of Maturation Inhibitor VH3739937 - (03/04/24)
     
  569. CROI: High-Dose VH3810109 (N6LS) ± Recombinant Human Hyaluronidase PH20: Phase 1 SPAN Study Safety Results - (03/04/24)
     
  570. CROI: Next-Generation Maturation Inhibitor GSK3640254 Showed Broad Spectrum Potency Without MI Resistance - (03/04/24)
     
  571. CROI: Phase 2 Study of Switch to Daily BIC + LEN in Individuals on a Complex HIV Treatment Regimen - (03/04/24)
     
  572. CROI: Discovery of GS-9770 - a Novel, Unboosted, Once Daily Oral HIV-Protease Inhibitor - (03/04/24)
     
  573. New HHS HIV Treatment Guidelines on Statin Therapy in PWH - (02/29/24)
     
  574. U.S. FDA Approves Expanded Indication for Gilead's Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance - (02/27/24)
     
  575. Non-AIDS Deaths 80% of All deaths for PWH >60: Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies - (02/26/24)
     
  576. NIH LA CAB/RPV Superior to Daily for Non-Adherent PWH - (02/26/24)
     
  577. Latent Profile Analysis of Cognitive Performance and Depressive Symptoms Among People with HIV - (02/26/24)
     
  578. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation - (02/16/24)
     
  579. CD4 Non-Responders to ART; Older PWH with Limited ART Options - (02/15/24)
     
  580. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy: 96-week pooled analysis - (02/15/24)
     
  581. PWH Internalized Stigma High Rates, 36%-48% - (02/15/24)
     
  582. Explaining racial and ethnic disparities in antiretroviral therapy adherence and viral suppression among U.S. men who have sex with men - (02/12/24)
     
  583. Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women, Editorial. Why it didn't work for women? - (02/12/24)
     
  584. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial - (02/12/24)
     
  585. PTSD is also a common mental disorder among individuals living with HIV/AIDS, 7 Times Greater. HIV itself can be a Traumatic PTSD Event - (02/12/24)
     
  586. Polypharmacy Is Associated With Slow Gait Speed and Recurrent Falls in Older People With HIV- in ACTG HAILO Cohort where average age is only 51 - (02/12/24)
     
  587. ViiV Healthcare announces new packaging option (blister pack) now available in the U.S. for Dovato(dolutegravir/lamivudine) - (02/07/24)
     
  588. Life expectancy of people with HIV on antiretroviral therapy in Spain: gap of 8.3 & 13.9 years persists in men & women compared to general population - (02/02/24)
     
  589. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study & Commentary - (02/02/24)
     
  590. Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery: each day that ART was delayed was associated with a lower likelihood of achieving a CD4>900 cells and CD4/CD8 >1.0 - (02/02/24)
     
  591. Study (Phase 2/3) to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen - (01/30/24)
     
  592. SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020-2022 - (01/29/24)
     
  593. LAI PrEP Barriers & Facilitators US Primary Care Setting - (01/29/24)
     
  594. Lenacapavir Safety - Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial - (01/29/24)
     
  595. Lenacapavir 5 PrEP Global Studies - (01/29/24)
     
  596. Unmet needs for HIV ancillary services among persons with diagnosed HIV aged 55 years and older - (01/19/24)
     
  597. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes - (01/19/24)
     
  598. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2 - (01/15/24)
     
  599. Long COVID: major findings, mechanisms and recommendations - (01/15/24)
     
  600. Tablet-Based Cognitive Impairment Screening for Adults With HIV Seeking Clinical Care: Observational Study - (01/15/24)
     
  601. Prenatal Social Disadvantage Affects Brain - (01/15/24)
     
  602. Non-AIDS Deaths/Comorbidities Lead Causes of Death for PWH - (01/15/24)
     
  603. Tablet-Based Cognitive Impairment Screening for Adults With HIV Seeking Clinical Care: Observational Study - (01/15/24)
     
  604. PWH Internalizing HIV Stigma, Depression - (01/15/24)
     
  605. Hypertension and one-year risk of all-cause mortality among women (WIHS) with treated HIV in the United States - (01/15/24)
     
  606. Diet & Hypertension/High Blood Pressure for PWH - (01/15/24)
     
  607. Selection of cognitive impairment screening tools for longitudinal implementation in an HIV clinical care setting - (01/15/24)
     
  608. Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013 - (01/15/24)
     
  609. Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure - (01/15/24)
     
  610. Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study - (01/15/24)
     
  611. The Longitudinal Effects of Blood Pressure and Hypertension on Neurocognitive Performance in People Living With HIV - (01/15/24)
     
  612. Current and temporal exposure to integrase strand transfer inhibitors are not associated with hypertension or arterial stiffness in people with HIV - (01/10/24)
     
  613. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial - (01/10/24)
     
  614. Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada - (01/10/24)
     
  615. TelePrEP in NYC - (01/10/24)
     
  616. Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness - (01/10/24)
     
  617. PrEP Use and HIV Incidence Among Youth At-Risk for HIV Infection in Los Angeles and New Orleans: Findings From ATN 149 - (01/10/24)
     
  618. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants - (01/10/24)
     
  619. Preexposure Prophylaxis Use History in People With Antiretroviral Resistance at Human Immunodeficiency Virus (HIV) Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022 - (01/10/24)
     
  620. HHS EHE (PrEP) Leaders Reflect on 2023 and Look Ahead to 2024 - (01/09/24)
     
  621. Understanding Psychosocial Determinants (Beliefs, Attitudes) of PrEP Uptake Among Cisgender Women Experiencing Heightened HIV Risk: Implications for Multi-Level Communication Intervention - (01/09/24)
     
  622. Advancing the community plan to end the HIV Epidemic in Philadelphia: a qualitative descriptive evaluation of low-threshold PrEP services in sexual health clinics - (01/09/24)
     
  623. 2 Studies on PrEP for Women IDUs, Demonstrate PrEP is a Necessary Tool for Women, to EtE - (01/09/24)
     
  624. Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for HIV in the US, 2008-2019 - (01/08/24)
     
  625. Prioritising the values of potential users to promote uptake of HIV pre-exposure prophylaxis - (01/08/24)
     
  626. Person-centered HIV PrEP for cisgender women - (01/08/24)
     
  627. Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women - (01/08/24)
     
  628. Cocaine Eats Up Brain Twice as Fast as Normal Aging - (01/08/24)
     
  629. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence - (01/08/24)
     
  630. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts - (01/08/24)
     
  631. Management and Prevention of CVD in HIV: Where are we in 2023? - (01/02/24)
     
  632. Best Use of Doravirine - Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials - (12/29/23)
     
  633. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection - (12/28/23)
     
  634. Long COVID in people living with HIV - (12/28/23)
     
  635. NATAP/LongCOVIDWk: Current treatments for Long COVID - (12/28/23)
     
  636. Paxlovid Reduced Long COVID Conditions - (12/28/23)
     
  637. Long COVID Clinics by State - (12/28/23)
     
  638. NYC Post COVID Care Clinics, Rehabs - (12/28/23)
     
  639. HIV Infection is Associated with Higher Risk of Post-Acute Sequelae of SARS-CoV-2 (PASC) However Vaccination is Protective - (12/28/23)
     
  640. CDC study: People with HIV have elevated COVID reinfection rate - (12/28/23)
     
  641. Paxlovid Treatment for Long COVID Trial Ongoing - (12/28/23)
     
  642. Psychological Trauma and PTSD in HIV-Positive Women: A Meta-Analysis - (12/27/23)
     
  643. High Trauma Rates in PWH-MSM, Women, Drug Users - (12/27/23)
     
  644. High Trauma Rates African-American HIV+ MSM - (12/27/23)
     
  645. HIV Stigma and Health Care Discrimination Experienced by Hispanic or Latino Persons with HIV - United States, 2018-2020 - (12/27/23)
     
  646. Accelerated Health Declines among African Americans in the USA: "weathering" or traumas as we say in HIV - (12/27/23)
     
  647. "6-fold increase in PWH >75 Projected" The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030 - (12/21/23)
     
  648. Long COVID in the United States - (12/21/23)
     
  649. EACS: Effect of doravirine on body weight and body mass index in treatment naïve adults with HIV-1 - (12/20/23)
     
  650. EACS: Efficacy and safety of topical trichloroacetic acid vs. electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive patients (TECAIN) - a randomized controlled trial - (12/20/23)
     
  651. Frailty screening is Feasible & Recommended by EACS. Implementation of frailty screening for older people living with HIV in Brighton, UK - (12/18/23)
     
  652. A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV - (12/08/23)
     
  653. New IAS-USA Papers on Heart Disease in PWH,
    DoxyPEP, Infant Feeding Updated Guidelines     - (12/08/23)
     
  654. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study - (12/05/23)
     
  655. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants: a modelling study - (12/05/23)
     
  656. EACS: The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants: a modelling study - (12/4/23)
     
  657. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants - (12/04/23)
     
  658. CDC Reports Disparities in PrEP USE: 'particularly Black and Hispanic/Latino men and women.' - (12/04/23)
     
  659. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants: a modelling study - (12/04/23)
     
  660. Considerations for long-acting antiretroviral therapy in older persons with HIV - (12/04/23)
     
  661. AASLD: Food Insecurity, Low Income Drive MASLD in US Adolescents - Mark Mascolini (11/29/23)
     
  662. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial - (11/29/23)
     
  663. Ageism: the -ism affecting the lives of older people living with HIV - (11/29/23)
     
  664. AGE: High Rate of Metabolic Comorbidities in Young Adults With HIV Acquired Around Birth - (11/16/23)
     
  665. AASLD: Vir Biotechnology to Present Late-Breaking Data from
    Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials
    at AASLD's The Liver Meeting® 2023     - (11/14/23)
     
  666. Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy - (11/08/23)
     
  667. Retaining PWH in Care; Mortality Increased with ART Interruptions >6 months - (11/08/23)
     
  668. Comparing cancer incidence in an observational cohort of Medicaid beneficiaries with and without HIV, 2001-2015 - (11/08/23)
     
  669. Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada - (11/08/23)
     
  670. Integrating a Resilience Framework to Assess Implementation of a Novel HIV Care Re-Engagement Model in NYC - (11/08/23)
     
  671. Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies - (11/08/23)
     
  672. AASLD: Increased Risk for NAFLD, MASLD to 34% - (11/08/23)
     
  673. EACS: To the liver and beyond: the impact of HCV clearance with direct antiviral agents in people living with HIV/HCV - (11/8/23)
     
  674. EACS: The status of hepatitis C micro-elimination among people living with HIV in Central and Eastern Europe in 2022 - data from Euroguidelines in Central and Eastern Europe Network Group - (11/8/23)
     
  675. EACS: Impact of directly acting-antivirals and behaviour change on HCV micro-elimination in MSM due to the COVID 19 pandemic in Germany - Results from the NoCo cohort - (11/8/23)
     
  676. EACS: Frailty Accelerates Aging/Mortality: INTEGRATE Care for Older PWH
    Integrating [differential] approaches to older people living with HIV     - (11/07/23)
     
  677. EACS: COVID-19 Associated with 35% Increased Risk for Major Cardiovascular events in PWH During Subsequent Yea - (11/06/23)
     
  678. EACS: Despite Very Early ART Inflammation is Reduced But Persists - (11/06/23)
     
  679. EACS: Mental health disorders in people living with HIV - (11/06/23)
     
  680. EACS: Early Onset Frailty in PWH at UK Silver Clinic; Implementation of Frailty Screening - (11/06/23)
     
  681. EACS: HIV in the elderly is becoming an easily manageable pathology: reality is contradictory. Much More Complex - (11/06/23)
     
  682. Association of Higher Intake of Plant-Based Foods and Protein With Slower Kidney Function Decline in Women With HIV - (11/06/23)
     
  683. Cervical Cancer Screening Positivity Among Women Living With HIV in CDC-PEPFAR Programs 2018-2022 - (11/06/23)
     
  684. Doravirine Plus Integrase Strand Transfer Inhibitors as a 2-Drug Treatment-Switch Strategy in People Living with HIV: The Real-Life DORINI Multicentric Cohort Study - (11/06/23)
     
  685. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial - (11/06/23)
     
  686. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis - (11/06/23)
     
  687. AGE: HIV-1 Soluble GP120 Is Associated With Immune Dysfunction and Inflammation in Individuals With Undetectable Viremia - in 33% of PWH - (11/06/23)
     
  688. AGE: Epigenetic Age Advancement [5.4 years] is Associated with Lower CD4 T-cell Count, Increased Mortality Risk, and Frailty in Older Adults with HIV - (11/03/23)
     
  689. AGE: Immunogenicity of High Dose Flu Vaccine in Aging PWH, Premature Senesence - (11/03/23)
     
  690. AGE: The CD38-NAD+ Axis: A Key Mediator of Inflammaging in HIV Infection: immune exhaustion, age-associated comorbiditied - (11/03/23)
     
  691. Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in Treatment-Experienced (TE) People With HIV With a History of CKD - (11/03/23)
     
  692. AGE: Aging with HIV: social Isolation & Loneliness, Animal Therapy Intervention - (11/02/23)
     
  693. AGE: CNS complications in people aging with HIV - (11/02/23)
     
  694. AGE: Session 5: Lightning Poster Presentations - (11/02/23)
     
  695. AGE: Plasma proteomic signatures capture unique cardiovascular risk phenotypes among persons living with and without HIV in the United States: Plasma Proteome [biomarkers] Offers Insights Beyond Traditional CVD Risk Factors - Reported by Mark Mascolini for NATAP and Academic Medical Education(11/02/23)
     
  696. AGE: Clustering Frailty Components May Enable Sharper Comorbidity Insights - (11/02/23)
     
  697. AGE: Multifactorial Risk Factors for Cognitive Impairment - (11/02/23)
     
  698. AGE: Cognitive Frailty in People Living With HIV and Its Association With Geriatric Syndromes - (11/02/23)
     
  699. AGE: Session 2: Sarcopenia and Frailty Prevention & Treatment - (11/02/23)
     
  700. AGE: Underlying Mechanisms of Asymptomatic Neurocognitive Impairment - (11/01/23)
     
  701. AGE: Emotional, Not Social, Loneliness Is Related to Objective Cognitive Function in Older People With HIV - (11/01/23)
     
  702. AGE: 2 Oral Talks - PLWH: Sarcopenia, Mitochondrial Function - (11/01/23)
     
  703. AGE: Underlying Mechanisms of Asymptomatic Neurocognitive Impairment - (11/01/23)
     
  704. AGE: Emotional, Not Social, Loneliness Is Related to Objective Cognitive Function in Older People With HIV - (11/01/23)
     
  705. AGE: 2 Oral Talks - PLWH: Sarcopenia, Mitochondrial Function - (11/01/23)
     
  706. EACS: Virus-Related and AIDS Cancer Incidence Fell in HIV Group But Still Exceed Rates in General Population - (10/31/23)
     
  707. EACS: Factors influencing discontinuation of care of women seeking Pre-Exposure Prophylaxis (PrEP) - (10/31/23)
     
  708. EACS: Doravirine Does Not Drive up ASCVD Risk Through 4 Years - Mark Mascolini (10/31/23)
     
  709. EACS: Temporal trends and impact of COVID-19 on the HIV cascade of care across Europe between 2016-2021 - Mark Mascolini (10/31/23)
     
  710. EACS: One in Eight Amsterdam ART Responders May Have PTSD - Mark Mascolini (10/31/23)
     
  711. AGE: HIV Smoking Quitters Older and Have More Comorbidities Than Current Smokers - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/31/23)
     
  712. AGE: Switching to a Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed, Treatment-Experienced People with HIV (PWH) ≥ 65 Years Old - (10/31/23)
     
  713. AGE: Relationships between plasma neurofilament light chain protein, cognition, and brain aging in people with HIV - (10/31/23)
     
  714. AGE: An integrated HIV-Geriatric Clinic Model: Lessons from Newlands Clinic, Harare Zimbabwe - (10/31/23)
     
  715. AGE: PWH Have Higher depression Rates Than People without HIV: Some Depressive Symptoms Wane With Age in HIV Group-Some Do Not - (10/31/23)
     
  716. AGE: The longitudinal impact of depressive symptoms and frailty on social support: depression contributes to declining social support - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/31/23)
     
  717. AGE: Emotional (but not Social) Loneliness Tied to Cognition in Older People With HIV - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  718. AGE: Implementation of a multidisciplinary approach to care for people living with HIV aged over 80 years - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  719. AGE: Global Survey: "62% in low and middle income & 29% in high income countries are mostly unaware for developing health complications as they get older" - (10/30/23)
     
  720. AGE: Cognitive Function Fell in 25% of Canadian HIV Group Over 10 Years - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  721. AGE: Long-term effect of dolutegravir use on more depressive symptoms among older people with HIV - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  722. AGE: Cognitive Frailty Threatens People With HIV at a Younger Age - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  723. AGE: Older Age, More Comorbidities Mean Lower Chance of ART With Medicare - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  724. AGE: Prefrail or frail older people with HIV live in more disadvantaged areas than older HIV-positive nonfrail people - Reported by Mark Mascolini for Academic Medical Education and NATAP (10/30/23)
     
  725. AGE: High Rate of Metabolic Comorbidities in Young Adults With HIV Acquired Around Birth - Reported by Mark Mascolini for Academic Medical Education and NATAP (10/30/23)
     
  726. AGE: Aging, Comorbidities, Frailty, Polypharmacy for PLWH > 80 Years at Chelsea Westminster London HIV Clinic - Reported by Mark Mascolini for NATAP and Academic Medical Education (10/30/23)
     
  727. AGE: HIV in the Brain & Cognitive Impairment: Despite Viral Suppression [blood brain permeability] women with HIV have double stroke risk & non-Hispanic African-Americans have 3.5 higher stroke incidence - the 6Ms for managing PLWH in the clinic; neurotoxicity of ARTs - (10/30/23)
     
  728. EACS: Factors influencing discontinuation of care of women seeking Pre-Exposure Prophylaxis (PrEP) - (10/30/23)
     
  729. ViiV HEALTHCARE RECEIVES APPROVAL FROM CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) FOR VOCABRIA (CABOTEGRAVIR) USED IN COMBINATION WITH REKAMBYS (RILPIVIRINE), THE FIRST AND ONLY COMPLETE LONG-ACTING HIV-1 INJECTABLE TREATMENT - (10/26/23)
     
  730. EACS: Total and LDL Cholesterol Climb After HCV Cure in People With HIV - Mark Mascolini (10/26/23)
     
  731. EACS: HDV Prevalence 16% in French Group With HBV and HIV - Mark Mascolini (10/26/23)
     
  732. EACS: In 70 and Older HIV Group, Frailty Worsens in Some, Improves in Others - Mark Mascolini (10/26/23)
     
  733. EACS: Classic Fracture Risk Factors May Need Replacing in Older People With HIV - Mark Mascolini (10/26/23)
     
  734. EACS: Weight gain and loss and stable weight in relation to fat and lean mass in PWH - (10/26/23)
     
  735. EACS: Early and Durable Reductions in Soluble CD14 Concentrations Among Treatment-Experienced Persons With HIV-1 Through 96 Weeks of Fostemsavir Treatment in a Phase 2b Clinical Trial - (10/26/23)
     
  736. EACS: Bictegravir alters glucose tolerance and metabolism - (10/26/23)
     
  737. EACS: Persistent Low-Level Viremia May Increase Risk of Cardiovascular Disorders in PWH - (10/26/23)
     
  738. EACS: Lessons from the Swiss Cohort study: Metabolic and cardiovascular co-morbidities among people living with HIV - (10/26/23)
     
  739. EACS: Single center study on participants living with HIV with isolated anticore antibody (anti-HBc) switching to long acting cabotegravir-rilpivirine therapy: Results from the SCohoLART study - (10/25/23)
     
  740. EACS: Long-Acting CAB + RPV Fails With Resistance in 5 After Long Control on Oral Regimens - Mark Mascolini (10/25/23)
     
  741. EACS: Failure Rate Similar With Long-Acting CAB + RPV and Standard Oral Combos - Mark Mascolini (10/25/23)
     
  742. EACS: Fostemsavir use in the OPERA cohort: immunologic and virologic response - (10/25/23)
     
  743. EACS: EFFICACY AND DURABILITY OF FOSTEMSAVIR, IBALIZUMAB, OR LENACAPAVIR-INCLUDING REGIMENS IN PEOPLE LIVING WITH MULTIDRUG-RESISTANT HIV-1: RESULTS FROM THE PRESTIGIO REGISTRY - (10/25/23)
     
  744. EACS: FOSTEMSAVIR IN ASSOCIATION WITH DORAVIRINE FOR THE TREATMENT OF HEAVILY TREATMENT-EXPERIENCED (HTE) PLWH WITH MULTI-DRUG RESISTANT (MDR) HIV-1 INFECTION: DATA FROM CLINICAL PRACTICE - (10/25/23)
     
  745. EACS: How to choose the optimized background therapy with fostemsavir in viremic people with multidrug-resistant HIV? A clinical case - (10/25/23)
     
  746. EACS: Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving Fostemsavir for up to 5 Years in the BRIGHTE Study - (10/25/23)
     
  747. EACS: Real-world Effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naive People With HIV-1 and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review - (10/25/23)
     
  748. EACS: Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir + Lamivudine (DTG + 3TC) in People With HIV-1 Aged ≥50 Years - (10/25/23)
     
  749. EACS: Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir: The DOLOMITE-EPPICC Study - (10/25/23)
     
  750. EACS: One Third of French Group Has Not Changed Antiretrovirals for Over 10 Years - Mark Mascolini (10/25/23)
     
  751. EACS: Real-world retrospective observational study on the use of Doravirine (DOR) based regimens in clinical practice in Europe - (10/25/23)
     
  752. EACS: Annual Antiretroviral Switch Rate Jumps From 8% to 18% in Last Decade - Mark Mascolini (10/24/23)
     
  753. EACS: HBcAb positivity is a risk factor for failure to achieve complete virologic suppression of HIV-RNA after antiretroviral switch to 3TC+DTG - Mark Mascolini (10/24/23)
     
  754. EACS: Real-world 2-year weight changes among people with sustained HIV suppression: a multicenter French retrospective cohort study - Mark Mascolini (10/24/23)
     
  755. EACS: Cabotegravir/rilpivirine based long acting therapy with insufficient drug levels in routine drug monitoring - Mark Mascolini (10/24/23)
     
  756. EACS: Non-AIDS Non-Hepatitis Cancers Lead Causes of Death With HIV in Switzerland - Mark Mascolini (10/24/23)
     
  757. EACS: Effect of ART, Immunologic-virologic status and Prior TB on Mortality Among People with HIV in Europe - (10/24/23)
     
  758. EACS: Switch to Fixed-Dose Doravirine/Islatravir (100/0.75 mg) Once Daily in Adults with HIV-1 Virologically Suppressed on Biktarvy - week 96 results of a phase 3, randomized, double-blind, non-inferiority trial - (10/24/23)
     
  759. EACS: Below 200 Relevance of low-Level Viremia (50-200) in Participants on ART in the Swiss HV Cohort Study - (10/24/23)
     
  760. EACS: Prevalence and Clinical Impact of Doravirine-associated Resistance Mutations in a Real-World Population of NNRTI-Naive and NNRTI-Experience Individuals - (10/24/23)
     
  761. EACS: Failure Following Switch from Long-Term Suppressive Oral ART to Long Acting Cabotegravir/Rilpivirine injections - (10/24/23)
     
  762. EACS: Effectiveness of LA Injectable Cabotegravir+Rilpivirine for the Treatment of HIV-1: results from the Dutch Athena national observation cohort - (10/24/23)
     
  763. EACS: Uptake/Discontinuation of LA CAB/RPV Swiss HIV Cohort - (10/24/23)
     
  764. EACS: Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 From the Phase 3 BRIGHTE Study Through Week 240 - (10/24/23)
     
  765. EACS: Persistent Low-Level Viremia Leads to Immune T-cell Exhaustion in PLWH - (10/24/23)
     
  766. EACS: A Screening Tool as Part of Routine Clinical Care Detects Post Traumatic Syndrome (PTSD) Symptoms in PWH - (10/24/23)
     
  767. EACS: Drivers of Discontinuation of Oral PrEP Within Europe: Findings From a Real-World Survey of PrEP Use - (10/24/23)
     
  768. EACS: Early virologic failure with Cabotegravir plus Rilpivirine in clinical practice - (10/24/23)
     
  769. EACS: Integrase inhibitor as cause of drug induced liver injury - (10/24/23)
     
  770. EACS: Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment-Naive Adults: 24-Week Results From the Phase IIb, Dose-Range Finding DOMINO Study - (10/25/23)
     
  771. EACS: Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + Dolutegravir as a 2-Drug Regimen in Treatment-Naive Adults:24-Week Results From the Phase IIb DYNAMIC Study - (10/24/23)
     
  772. EACS: Cabotegravir-Rilpivirine Long acting : Data in real life setting in a French Cohort - (10/24/23)
     
  773. EACS: Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 infection switching to long-acting cabotegravir and rilpivirine - (10/24/23)
     
  774. EACS: Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 for Cabotegravir + Rilpivirine Study - (10/24/23)
     
  775. EACS: Safety, pharmacokinetics, and exploratory efficacy of the PD-1 inhibitor budigalimab in antiretroviral treatment-suppressed people living with HIV-1: preliminary analysis of 2 Phase 1b studies including an analytical treatment interruption - (10/24/23)
     
  776. EACS: Doravirine Plus Dolutegravir 2-Drug Regimen as a Maintenance ART: results from a French cohort study - (10/24/23)
     
  777. EACS: Cardiovascular Risk Assessment After Continuing or Switching to a Doravirine-based Regimen Using the Atherosclerotic Cardiovascular (ASCVD) Risk Score Model - (10/24/23)
     
  778. EACS: Drivers of Satisfaction and Health-Related Quality of Life of People Living With HIV Within Europe: Findings From a Real-world Survey of People Living With HIV - (10/24/23)
     
  779. EACS: Penetration of doravirine combined to raltegravir in semen: preliminary results of the DORAL switch study - (10/24/23)
     
  780. EACS: New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV - press release - (10/23/23)
     
  781. EACS: Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment-Experienced People with HIV after 104 Weeks of Treatment - (10/23/23)
     
  782. EACS: Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities - press release - (10/23/23)
     
  783. EACS: CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine FDC in treatment-naïve adults and pre-treated adults who are virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results. - (10/23/23)
     
  784. EACS: Real-world Effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naive People With HIV-1 and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review - (10/23/23)
     
  785. EACS: Effectiveness, Safety, and Implementation Outcomes of Cabotegravir + Rilpivirine Long-Acting by Country in the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL) - (10/23/23)
     
  786. EACS: SOLAR 12-Month European Results: Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (10/23/23)
     
  787. EACS: Restarting bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: a pooled analysis of studies in people with HIV-1 - Mark Mascolini (10/23/23)
     
  788. EACS: Assessing Phenotypic Effect of Integrase Strand Transfer Inhibitor (INSTI)-Based Resistance Substitutions Linked to Failures on Cabotegravir - (10/23/23)
     
  789. EACS: Restarting Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After Virologic Rebound: A Pooled Analysis of Studies in People With HIV-1 - (10/23/23)
     
  790. EACS: Once-monthly islatravir has no meaningful effect on exposure to long-acting reversible contraceptives (LARCs) - (10/23/23)
     
  791. EACS: Efficacy and safety of doravirine-based regimens by sex and race: long-term results from three phase 3 clinical trials - (10/23/23)
     
  792. EACS: Investigational Studies to Understand the Decreases in Lymphocytes Seen Clinically with Islatravir (ISL) and Enabling 1the Initiation of New Clinical Trials - (10/23/23)
     
  793. EACS: Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in adults with HIV-1 virologically suppressed on antiretroviral therapy: week 96 results of a randomized, open-label, phase 3 trial - (10/23/23)
     
  794. EACS: Pharmacokinetics/Pharmacodynamics and Virological Activity of VH3810109 (N6LS) in Antiretroviral-Naive Viremic Adults From the Phase 2a BANNER Study - (10/23/23)
     
  795. EACS: No Relevant Difference in Incident Hypertension Observed by Gender, Race, Baseline BMI, or Other Key Subgroups Through Week 96 Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials - (10/23/23)
     
  796. EACS: Follow-Up of Injection Site Reactions in Clinical Studies of People Using Lenacapavir Every 6 Months for HIV Treatment - (10/23/23)
     
  797. EACS: Insights and Experiences from the CAPELLA Trial: Perspectives of Healthcare Professionals and Study Coordinators on Lenacapavir Use Amongst Heavily Treatment-Experienced People with HIV - (10/23/23)
     
  798. EACS: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment-Naïve (TN) and -Experienced (TE) People With HIV (PWH): 3-Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort - (10/23/23)
     
  799. EACS: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study - (10/23/23)
     
  800. EACS: Final Results of VICDOR: EffectiVeness of SwItChing to DOR-based Antiretroviral Therapy Under Real-world Conditions in Germany - (10/23/23)
     
  801. EACS: Efficacy and safety by subgroup at week 48 after switch to doravirine/islatravir (100 mg/0.75 mg) once daily in two phase 3 trials - (10/23/23)
     
  802. EACS: Efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: Week 49 results from a phase 3 trial - (10/23/23)
     
  803. EACS: Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial - (10/23/23)
     
  804. EACS: One-year frailty transitions among persons living with HIV aged 70 years or more on ART - (10/23/23)
     
  805. EACS: Estimated risk of all-cause mortality [higher] and cardiovascular events in a cohort of women living with HIV and socio-demographically similar HIV-negative controls ≥40 years old - (10/22/23)
     
  806. EACS: Evolution of cancers risk in PWH over 20 years and risks when immunity is restored and viral load is controlled Results from the ANRS CO4 FHDH cohort - (10/22/23)
     
  807. EACS: Frailty and Quality of Life for People with HIV in Cyprus: re-visiting the cascade of care: 70% Prefrail/frail at median age 41; 44% anxiety/depression - (10/22/23)
     
  808. EACS: Cognitive frailty in people living with HIV and its association with geriatric syndromes - (10/22/23)
     
  809. EACS: PREDICTORS OF QUALITY OF LIFE AMONG OLDER PEOPLE LIVING WITH HIV IN KAMPALA, UGANDA: assessmemt & mgt of frailty, low physical function, malnutrition & depression could improve QOL - (10/22/23)
     
  810. EACS: Uganda Elderly HIV+ Women Needs - (10/22/23)
     
  811. BMI vs body composition changes to predict metabolic outcomes in people with HIV - (10/22/23)
     
  812. EACS: LDL-c target achievement in people living with HIV according to individual cardiovascular risk: a retrospective single center observational study - (10/22/23)
     
  813. EACS: Suicide Mortality Trends and Predictors in the PISICS Cohort of People Living with HIV in Catalonia and the Balearic Islands, Spain; PWH >50 have highest rates - (10/22/23)
     
  814. EACS: Evolving trends in mortality patterns and predictors among people living with HIV in Catalonia and the Balearic Islands (Spain), 1998-2020: a multisite cohort study - Comorbidities ! - (10/22/23)
     
  815. EACS: Evolution of causes of death in people living with HIV: a retrospective single center observational study - CVD & Lung Cancer leading causes of death; 80% due to Comoridites - (10/22/23)
     
  816. EACS: Immunological and inflammatory profile of cerebrospinal fluid (CSF) and plasma of people living with HIV (PLWH) with or without Central Nervous System (CNS) involvement - (10/22/23)
     
  817. EACS: Subclinical coronary artery disease in persons living with HIV and uninfected controls: PWH at 2-3 fold higher risk - (10/22/23)
     
  818. EACS: NEW RISK FACTORS FOR FRAGILITY FRACTURES MUST BE CONSIDERED IN OLDER ADULTS WITH HIV - (10/22/23)
     
  819. EACS: Neurocognitve impairment & Anxiety Symptoms May Influence The Development of Prefrailty/Frailty in Japanese PLW Aged Over 40 Years 70% PreFrailty - (10/22/23)
     
  820. EACS: One-year frailty transitions among persons living with HIV aged 70 years or more on ART - (10/20/23)
     
  821. EACS: "Everyone seems already satisfied because people with HIV do not die from AIDS" iCOPe Global survey - (10/20/23)
     
  822. EACS: BICTEGRAVIR and DOLUTEGRAVIR have no impact on glucose levels 12 months after initiation - (10/20/23)
     
  823. EACS: Cognitive trajectories among people with HIV attending a dedicated memory clinic for PLWH - (10/20/23)
     
  824. EACS: Cardiovascular Risk Assessment with SCORE, SCORE2 and D.A.D in People Living with HIV with High Prevalence of Cardiovascular Risk Factors - (10/20/23)
     
  825. EACS: Statins and acetylsalicylic acid (ASA) use and LDL cholesterol value below 70 mg/dl in people living with HIV (PLWH): there is a gap between European AIDS Clinical Society guidelines and clinical practice - (10/20/23)
     
  826. EACS: Prevalence and predictors of non-alcoholic fatty liver disease (NAFLD) among Egyptian people living with HIV (PLHIV): A cross-sectional study - (10/20/23)
     
  827. EACS: Study of the Cardiovascular Disease Risk in People Living with HIV-1 in Portugal: high risk of CVD for PLWH 40-70 Years - (10/20/23)
     
  828. ID Week : High Death and Hospital Rates in US Group With HIV and Cirrhosis - Mark Mascolini (10/18/23)
     
  829. ID Week : Presence of mental health concerns is associated with poor adherence in people taking pre-exposure prophylaxis in real-world clinical practice in the United States - (10/18/23)
     
  830. ID Week : The First Ten Years of HIV Preexposure Prophylaxis Use and Missed Opportunities at an Urban Academic Children's Hospital - (10/18/23)
     
  831. ID Week : PEP-in-pocket (PIP): Long-term follow-up of on demand HIV post-exposure prophylaxis: Is PEP-in-Pocket Best Option for Low-Frequency High-Risk HIV Exposure? - Mark Mascolini (10/18/23)
     
  832. ID Week : Only Half Prescribed CAB PrEP Get at Least 1 Shot in US Outpatient Network - Mark Mascolini (10/18/23)
     
  833. ID Week : Expanding PrEP by Embedding Navigators in High STI Testing Clinical Sites - (10/18/23)
     
  834. ID Week : Racial and Sex PrEP Disparities Persist in US Veterans Study - (10/18/23)
     
  835. ID Week : Consequences of Low-Level Viremia (undetectable-199) Among Women with HIV in the United States: higher risk for viral failure & comorbidities - (10/17/23)
     
  836. ID Week : Pharmacist-Driven ART Start Cuts 37 Day Off Time From HIV Diagnosis to Undetectable - Mark Mascolini (10/17/23)
     
  837. ID Week : HBV Screening and Vaccination Dropping in PrEP Users; Vaccinations Adherence - Mark Mascolini (10/17/23)
     
  838. ID Week : Reasons Differ for Switch to DTG/3TC (Weight Concern) and B/F/TAF (Adherence, Substance Abuse, Poor HIV Control) - Mark Mascolini (10/17/23)
     
  839. ID Week : A Quality Improvement Initiative for HIV Prevention in Underserved Communities - (10/17/23)
     
  840. ID Week : Adherence to Antiretroviral Therapy and Its Effect on Quality of Life among Persons with HIV in the United States using Real-World Data - (10/17/23)
     
  841. ID Week : The Performance of a Multidimensional Frailty Index in Comparison to the Frailty Phenotype to Assess Frailty in an Urban HIV clinic......"most PLWH at clinic were pre-frail or frail" - (10/17/23)
     
  842. ID Week : Impact of Polypharmacy on Gait Speed and Recurrent Falls in Older People Living with HIV. - (10/17/23)
     
  843. ID Week : Association between integrase inhibitor plasma concentrations and body weight gain in women living with HIV - (10/17/23)
     
  844. ID Week : GLP-1 RECEPTOR AGONISTS PROMOTE WEIGHT LOSS AMONG PEOPLE WITH HIV - (10/17/23)
     
  845. ID Week : Clinical Outcome of People Living with HIV and Cirrhosis: A Clinical Cohort Study - (10/17/23)
     
  846. ID Week : A Prospective, Randomized Trial to Assess a Protease Inhibitor-based Regimen Switch Strategy to Manage Integrase Inhibitor-related Weight Gain: Post Hoc - (10/17/23)
     
  847. ID Week : Weight Loss or Gain Predictors Hard to Find in INSTI-to-PI Switch Trial - Mark Mascolini (10/17/23)
     
  848. ID Week : GLP-1 receptor agonists promote weight loss among people with HIV - Mark Mascolini (10/17/23)
     
  849. ID Week : Effects of Semaglutide on Adipose Tissue in HIV-Associated Lipohypertrophy - (10/17/23)
     
  850. ID Week : Predicted uptake of novel HIV treatment options in the United States - (10/17/23)
     
  851. ID Week : Predicted uptake of novel HIV treatment options in the United States - (10/16/23)
     
  852. ID Week : Tesamorelin reduces visceral tissue and liver fat in INSTI-treated persons with HIV - Mark Mascolini (10/16/23)
     
  853. ID Week : Factors driving decisions in the use of HIV Pre-Exposure Prophylaxis: Data from a real-world study in the United States - (10/16/23)
     
  854. ID Week : Increase in New HIV Diagnoses Following Decrease in Use of Pre-exposure Prophylaxis (PrEP) During the COVID-19 Pandemic - (10/16/23)
     
  855. ID Week : The Real-World Impact of Pre-Exposure Prophylaxis (PrEP) Prescription Uptake and Dispensing Status on HIV Infection Risk in the US - (10/16/23)
     
  856. ID Week : Evaluating Pre-Exposure Prophylaxis Use in a Large Integrated Rural US Health System - (10/16/23)
     
  857. ID Week : Facilitators and Barriers to Engaging in PrEP and Gender Affirming Therapy for Black and Latina Transgender Women in South Florida - (10/16/23)
     
  858. ID Week : A Quality Improvement Initiative for HIV Prevention in Underserved Communities - (10/16/23)
     
  859. ID Week : Black Race, Perceived Stress Affect CVD Risk Conditions in PLHIV - (10/16/23)
     
  860. ID Week : Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study - (10/16/23)
     
  861. ID Week : Virological Suppression in People With HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar Across Age Groups Despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis) - (10/16/23)
     
  862. ID Week : Dolutegravir/Rilpivirine STR Switch in Persons with HIV-1 and Chronic Kidney Disease: 48 Wk Results - (10/16/23)
     
  863. ID Week : SOLAR 12-Month North American Results: Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (10/16/23)
     
  864. ID Week : Clinical Outcomes at Month 6 After Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND) - (10/16/23)
     
  865. ID Week : Durable Efficacy and Robust CD4+ T-cell Count Improvement Observed Across Age, Race, Sex, and Geographic Subgroups of Heavily Treatment-Experienced People With Multidrug-Resistant HIV-1 After 240 Weeks of Fostemsavir Treatment - (10/16/23)
     
  866. ID Week : Perspectives of People With HIV 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World US Study (BEYOND) - (10/16/23)
     
  867. ID Week : Risk Factors, Risk Perception, and Long-Acting PrEP Awareness and Interest Among US Women: A National Survey - (10/16/23)
     
  868. ID Week : Exploring Cisgender Women's HIV Pre-Exposure Prophylaxis (PrEP) Needs and Preferences Across Settings: the Role of Social-Structural Factors - (10/16/23)
     
  869. ID Week : Integrating Long-Acting Injectable Cabotegravir for PrEP Into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex With Men: Results From the PILLAR & EBONI Studies - (10/16/23)
     
  870. ID Week : Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women - (10/16/23)
     
  871. ID Week : Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis Into Standard of Care: Baseline Results From the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR) - (10/16/23)
     
  872. ID Week : Steady-state PK of Fixed Dose Dolutegravir-Rilpivirine in Hemodialysis - (10/16/23)
     
  873. ID Week : Randomized-controlled trial evaluating the outcome between switching to tenofovir disoproxil fumarate(TDF)/lamivudine(3TC)/dolutegravir(DTG) versus maintaining the current NNRTI or boosted-PI-containing regimen in PLWH in Thailand - a pilot study from single center - (10/16/23)
     
  874. ID Week : Impact of Dolutegravir-based Regimen on Metabolic Syndrome and its Components in Adults living with HIV in Care at Hospital Roosevelt in Guatemala City - (10/16/23)
     
  875. ID Week : Stopping ARVs Tied to Weight Loss (EFV and TDF) Boosts Odds of Weight Gain on Integrase Drugs - Mark Mascolini (10/16/23)
     
  876. ID Week : Viral Blips While on Antiretroviral Therapy are Associated with Virologic Failure - (10/16/23)
     
  877. ID Week : Suppressed switch to bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir/lamivudine DTG/3TC Stopped More Than B/F/TAF After Switch From Suppressive Regimen - Mark Mascolini (10/16/23)
     
  878. ID Week : Hepatitis B Reactivation in Persons with HIV with Positive Hepatitis B Core Antibody after Switching to Antiretroviral Therapy without Hepatitis B Activity - (10/13/23)
     
  879. ID Week : HIV Following Oral Pre-Exposure Prophylaxis (PrEP) Initiation - (10/13/23)
     
  880. ID Week : Acceptability of an HIV Pre-Exposure Prophylaxis (PrEP) Shared Decision-Making Tool (SDT) for Diverse Populations and Healthcare Providers - (10/13/23)
     
  881. ID Week : Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort - (10/13/23)
     
  882. ID Week : Over 80% With Detectable HIV Load Respond to CAB + RPV LA - Mark Mascolini (10/13/23)
     
  883. ID Week : At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implemtentation Science Trial - (10/13/23)
     
  884. ID Week : Real-World Adherence and Persistence with Cabotegravir + Rilpivirine Long Acting (CAB + RPV LA) compared with Oral ART among PWH in the US: The ABOVE Study - (10/13/23)
     
  885. ID Week : Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence - (10/13/23)
     
  886. ID Week : Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of Antiretroviral Drug Resistance Mutations - (10/13/23)
     
  887. ID Week : Creating HCV Care Cascades in HIV Clinics in Real Time - (10/11/23)
     
  888. ID Week : Hepatitis C Virus infection and cure by priority population among New York City Ryan White HIV/AIDS Program Part A - (10/11/23)
     
  889. ID Week : Massachusetts HCV Treatment Report Card: Hepatitis C Virus Care Cascade for Females of Reproductive Age with Opioid Use Disorder, 2014-2021 - (10/11/23)
     
  890. ID Week : Hepatitis C Virus Among Inpatients in the Direct-acting Antiviral Era: Prevalence, Linkage to Care, Treatment Disparities, and Comorbidity Burden - (10/11/23)
     
  891. ID Week : Trends in viral hepatitis and hepatocellular carcinoma in New York City, 2001-2018 - (10/11/23)
     
  892. ID Week : An Analysis of Social Determinants of Health and their Implications for Hepatitis C Virus Treatment in People Who Inject Drugs: The Case of Baltimore. - (10/11/23)
     
  893. ID Week : Anti-HCV Therapy Starts Faster, Finishes More Often With Community Pharmacy Than Medicaid Mail-Order System - Mark Mascolini (10/11/23)
     
  894. ID Week : IMPACT OF AN INNOVATIVE COMMUNITY BASED CONTRACTED PHARMACY ON HCV ELIMINATION IN NEW JERSEY, USA - (10/11/23)
     
  895. ID Week : Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results - (10/11/23)
     
  896. ID Week : Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80 - (10/11/23)
     
  897. ID Week : Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence - (10/11/23)
     
  898. ID Week : Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter? - (10/11/23)
     
  899. ID Week : Each Added Comorbidity Cuts 4 Points Off QOL Index in US Women With HIV - Mark Mascolini (10/11/23)
     
  900. ID Week : Only Half of MSM With HIV Getting Screened for Anal Cancer - Mark Mascolini (10/11/23)
     
  901. ID Week : Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study - (10/11/23)
     
  902. ID Week : Virological Suppression in People With HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar Across Age Groups Despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis) - (10/11/23)
     
  903. ID Week : Dolutegravir/Rilpivirine STR Switch in Persons with HIV-1 and Chronic Kidney Disease: 48 Wk Results - (10/11/23)
     
  904. Exploring implementation considerations for geriatric-HIV clinics: A secondary analysis from a scoping review on HIV models of geriatric care - (10/09/23)
     
  905. Integrating HIV, hypertension, and diabetes primary care in Africa - (10/09/23)
     
  906. Dolutegravir + Doravirine Nuke Sparing for PWH with Severe Kidney Disease, PK, Drug Levels - (10/09/23)
     
  907. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss - (10/09/23)
     
  908. Diabetes, Lipids, Heart Disease: Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease - (10/04/23)
     
  909. Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease - (10/02/23)
     
  910. Differences in epigenetic age by HIV status among patients with a non-AIDS defining cancer - (09/28/23)
     
  911. Association of CD4+ cell count and HIV viral load with risk of non-AIDS-defining cancers - (09/28/23)
     
  912. Updated mortality and causes of death in 2020-2021 in people with HIV: a multicenter study in France - (09/28/23)
     
  913. A novel formulation enabled transformation of 3 HIV drugs tenofovir-lamivudine-dolutegravir (TLD) from short-acting to long-acting all-in-one injectable - (09/28/23)
     
  914. Investing in National HIV PrEP Preparedness (Over-the-Counter free PrEP) - (09/28/23)
     
  915. Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1 - (09/28/23)
     
  916. CDC: Long COVID in Adults: United States, 2022 - (09/26/23)
     
  917. Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential - (09/24/23)
     
  918. Pharmacokinetics, Safety, and Tolerability of Obeldesivir (OBV; GS-5245) in Healthy Participants - (09/24/23)
     
  919. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy - (09/24/23)
     
  920. Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy [viral failure]- Time to Modify Treatment Guidelines? - (09/24/23)
     
  921. NIH OAR Aging/HIV Virtual Meeting: HIV and Aging Research: Current Landscape and Opportunities, Sept 5 2023 - (09/24/23)
     
  922. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection - (09/24/23)
     
  923. Brief Report: Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion - (09/19/23)
     
  924. Reversal of epigenetic aging and immunosenescent trends in humans - (09/19/23)
     
  925. EUROPEAN COMMISSION AUTHORISES ViiV HEALTHCARE'S APRETUDE (CABOTEGRAVIR LONG-ACTING AND TABLETS) FOR HIV PREVENTION - (09/19/23)
     
  926. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults; HIV Pipeline: GSK/ViiV, Gilead, Merck - (09/19/23)
     
  927. A formula for the end [of HIV], Paradigm Shift by Pharma - (09/19/23)
     
  928. Abbvie ABBV-382+ Budigalimab with ATI in PWH - (09/19/23)
     
  929. Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study - (09/19/23)
     
  930. bNAb+Cabotegravir v SOC Phase 2b - (09/15/23)
     
  931. CROI: N6LS WITH RHUPH20 ENABLES SAFE HIGH DOSE MONOCLONAL ANTIBODY SUBCUTANEOUS DELIVERY - (09/15/23)
     
  932. CROI: Impact of Baseline Factors on Virologic Response to bNAb VH3810109 (N6LS) in BANNER - (09/15/23)
     
  933. Aging Begins at Time of HIV Infection, Frailty in PWH - (09/13/23)
     
  934. Age Exacerbates HIV-Associated White Matter Abnormalities - (09/12/23)
     
  935. The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030 - (09/12/23)
     
  936. Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages - (09/12/23)
     
  937. White Matter Abnormalities Linked to Interferon, Stress Response, and Energy Metabolism Gene Expression Changes in Older HIV-Positive Patients on Antiretroviral Therapy - (09/12/23)
     
  938. The importance of exercise and physical activity in older adults with HIV, editorial to 'prevent accelerated aging' - (09/12/23)
     
  939. Physical activity [steps] is associated with adiposity in older adults with HIV in the modern HIV era - (09/12/23)
     
  940. The incidence and dynamic risk factors of chronic kidney disease among people with HIV - (09/12/23)
     
  941. Lenacapavir for PrEP - (09/12/23)
     
  942. FACT SHEET: Biden-Harris Administration Announces First Ten Drugs Selected for Medicare Price Negotiation - (09/12/23)
     
  943. HIV-positive Ukrainian refugees in the Czech Republic - (09/12/23)
     
  944. Metabolic implications and safety of dolutegravir use in pregnancy - (09/12/23)
     
  945. Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study - (09/12/23)
     
  946. Antiretroviral treatment reveals a novel role for lysosomes in oligodendrocyte maturation - (08/31/23)
     
  947. Differential effects of integrase strand transfer inhibitors, elvitegravir and raltegravir, on oligodendrocyte maturation: A role for the integrated stress response - (08/31/23)
     
  948. Protease inhibitors, saquinavir and darunavir, inhibit oligodendrocyte maturation: Implications for Lysosomal Stress - (08/31/23)
     
  949. Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study - (08/29/23)
     
  950. IAS: Innovations and implementation of long-acting antiretroviral therapy - (08/29/23)
     
  951. IAS: Long-acting PrEP and the potential for resistance - (08/27/23)
     
  952. IAS: Long-acting PrEP: Programmatic considerations for HIV testing - (08/27/23)
     
  953. IAS: HIV testing approaches: Current and new approaches and considerations for long-acting PrEP - (08/27/23)
     
  954. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis - (08/27/23)
     
  955. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure - (08/27/23)
     
  956. FDA: Colchicine (marketed as Colcrys) Information - (08/27/23)
     
  957. Colchicine in Patients with Chronic Coronary Disease - (08/27/23)
     
  958. FDA Product Insert LODOCO (colchicine) tablets, for oral use - (08/27/23)
     
  959. IAS: Fostering cognitive and mental health in people aging and living with HIV while prioritizing the community and lived experience perspectives - (08/18/23)
     
  960. IAS: Venetoclax, alone and in combination with the BH3-mimetic S63845, depletes HIV latently infected cells and delays rebound in humanized mice - (08/15/23)
     
  961. IAS: Transformation of 3 current short-acting HIV drugs, Tenofovir, Lamivudine and Dolutegravir (TLD) into a novel, all-in-one long-acting TLD 3-drug-combination in a single injectable dosage that produces extended pharmacokinetics - (08/15/23)
     
  962. IAS: JABS 48 week results: Implementation of long-acting cabotegravir and rilpivirine in vulnerable populations with complex needs - (08/15/23)
     
  963. IAS: Incident Hypertension Risk in new Tenofovir Alafenamide Disoproxil users for HIV Pre-Exposure Prophylaxis: Analysis of data from an integrated health system in California - (08/15/23)
     
  964. IAS: Association Between Use of Tenofovir Alafenamide for HIV Pre-Exposure Prophylaxis and Statin Initiation in Adults in an Integrated Health System in California - (08/15/23)
     
  965. IAS: Immune activation is associated with low level viremia and noninfectious comorbidities in people living with HIV - (08/15/23)
     
  966. IAS: Hepatitis delta and liver disease among people living with hepatitis B in Senegal - (08/14/23)
     
  967. IAS: HIV-1 Low level viremia predicts virological failure in first-line and second-line ART experienced individuals in India - (08/14/23)
     
  968. IAS: Long COVID and HIV: Scientific and Biologic Intersections - (08/14/23)
     
  969. IAS: HIV-1 Low level viremia predicts virological failure in first-line and second-line ART experienced individuals in India - (08/14/23)
     
  970. IAS: Low-level viremia as a risk factor for virologic failure in children and adolescents living with HIV - (08/14/23)
     
  971. IAS: Thymosin α1 in restoring immune response in immunological nonresponders - (08/14/23)
     
  972. IAS: Persistent immune alterations in individuals with Long-COVID during a 6-months period - (08/14/23)
     
  973. IAS: Large decrease in the proportion of newly diagnosed HIV-1 infections grouping in large clusters in Spain - (08/14/23)
     
  974. IAS: PrEP Equity by sex and age, United States, 2012-2021 - (08/14/23)
     
  975. IAS: PrEP Equity by sex and age, United States, 2012-2021 - (08/14/23)
     
  976. IAS: Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV - (08/14/23)
     
  977. IAS: Accelerated biological aging is associated with intestinal barrier permeability and microbial translocation during antiretroviral therapy suppressed HIV infection - (08/14/23)
     
  978. IAS: Plasma derived extracellular vesicles modulate monocyte function in adults with HIV-related cognitive impairment - (08/14/23)
     
  979. IAS: Self-reported noncommunicable disease prevalence among older people living with HIV in Southern Africa - (08/14/23)
     
  980. IAS: Causes of mortality among people living with HIV: preliminary results from a cross-sectional study at 29 health facilities in Uganda - (08/14/23)
     
  981. IAS: CD4+ T lymphocyte recovery and cognitive function in women living with HIV: Cognitive Function WIHS Women: Viral Suppression/Menopause/Diabetes/HCV - (08/14/23)
     
  982. IAS: Determination of causes of deaths by verbal autopsy methods among people living with HIV in Nigeria - (08/14/23)
     
  983. IAS: Sustained aviraemia in the absence of anti-retroviral therapy in male children following in utero vertical HIV transmission - (08/11/23)
     
  984. DOH to Continue Medicaid Telehealth Coverage Through End of 2024 - (08/11/23)
     
  985. Free the PrEP - Over-the-Counter Access to HIV Preexposure Prophylaxis - (08/11/23)
     
  986. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Commentary. - (08/11/23)
     
  987. IAS: The prospect of elimination of HIV transmission through prevention programs - (08/09/23)
     
  988. IAS: Key REPRIEVE Results and the Utility of Statins Among PWH: What Have We Learned? - (08/09/23)
     
  989. IAS: 6 Key Aging/ HIV Messages at IAS 2023 - (08/08/23)
     
  990. IAS: Integrating hepatitis C services into ART clinics in low and middle income countries (LMICs) as an approach toward hepatitis C micro-elimination: pilot experience in Nigeria - (08/07/23)
     
  991. IAS: What's new in WHO guidelines ( HIV & hepatitis): innovations, treatment, integration and monitoring. Amplifying HIV Primary Care, Patent-Centered Care - (08/07/23)
     
  992. IAS: The REPRIEVE trial: Developing a cardiovascular disease prevention strategy for people living with HIV - "should be inserted in Guidelines" - (08/07/23)
     
  993. IAS: Unique aspects of cardiovascular disease among women with HIV: Lessons from REPRIEVE - (08/07/23)
     
  994. IAS: Blood pressure control among patients receiving Integrated care for HIV, diabetes and hypertension in primary health care facilities in Tanzania and Uganda - (08/07/23)
     
  995. IAS: The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review (IAS) - (08/07/23)
     
  996. IAS: New antiretrovirals and HIV treatment strategies - Plenary Long-acting technologies: A game changer? - (08/07/23)
     
  997. IAS: Cardiovascular disease among people living with HIV in high- and low-income countries: Can one strategy fit all? "put them in Guidelines globally" - (08/07/23)
     
  998. IAS: Scaling up cervical cancer prevention services among women living with HIV: lessons and experiences from FIKIA+ project in Mwanza, Tanzania - "99% with small & medium lesions were linked to treatment, large lesions 98%, lesions susceptible to cancer: linked to further care/diagnosis 99%" - (08/07/23)
     
  999. IAS: Willingness to access PrEP for adolescent girls and young women seeking emergency contraception at community pharmacies in Uganda - (08/07/23)
     
  1000. Calendar Year (CY) 2024 Medicare Physician Fee Schedule Proposed Rule - NEW "Patient-Centered" Care Broad/Expanded Reimbursement Proposal - (08/04/23)
     
  1001. Is the USA on track to end the HIV epidemic? - (08/04/23)
     
  1002. IAS: Prevalence and risk factors for renal insufficiency among adults living with HIV in Tanzania: results from a cross-sectional study - (08/04/23)
     
  1003. IAS: Group-based trajectory modelling to identify patterns and predictors of myocardial strain in people living with HIV: two-year longitudinal follow-up with speckle tracking echocardiography - (08/04/23)
     
  1004. IAS: Ambulatory blood pressure abnormalities and its determinants in people living with HIV and AIDS in an African setting - (08/04/23)
     
  1005. IAS: DoxyPEP use, acceptability, and associated health behaviors among a multisite sample of men who have sex with men and transgender women IAS - (08/04/23)
     
  1006. IAS: Ethical issues regarding the implementation of doxycycline post-exposure prophylaxis - (08/04/23)
     
  1007. IAS: Doravirine resistance patterns identified through week 192 in the DRIVE-FORWARD and DRIVE-AHEAD phase 3 clinical trials - (08/04/23)
     
  1008. IAS: Interpretation of Doravirine Resistance by Algorithm in Antiretroviral-Naïve People with HIV in Haiti - (08/04/23)
     
  1009. IAS: Incidence of infections across islatravir clinical development programs - (08/04/23)
     
  1010. IAS: Islatravir (MK-8591) has no meaningful effect on the pharmacokinetics of atorvastatin and metformin following coadministration - (08/04/23)
     
  1011. IAS: Risk of hepatitis C infection following bacterial sexually transmissible infections among gay and bisexual men in Australia 2016-2020 - Mark Mascolini (08/03/23)
     
  1012. IAS: Meningitis B vaccine for prevention of gonorrhoea: What is the evidence? - (08/03/23)
     
  1013. IAS: Doxycycline for STI prevention: Current research and future directions - (08/03/23)
     
  1014. IAS: Lenacapavir at 2023 IAS -(08/03/23)
     
  1015. IAS: A prospective, randomized trial to assess a protease inhibitor-based regimen switch strategy to manage integrase inhibitor-related weight gain - Mark Mascolini (08/03/23)
     
  1016. IAS: Triple Test and Treat for HIV/HBV/HCV-Simple Way to Slow Hep Epidemics? - Mark Mascolini (08/03/23)
     
  1017. IAS: Sleep Disorder 25% More Likely With Than Without HIV - Mark Mascolini (08/03/23)
     
  1018. IAS: Under 2% of San Franciscans With HIV Have All 5 CVD Risk Factors Controlled - Mark Mascolini (08/03/23)
     
  1019. IAS: Frailty Worsens in 25% of 50-and-Older Thai HIV Group-But Improves in Many-Through 5 Years - Mark Mascolini (08/03/23)
     
  1020. IAS: NASH or NAFLD Tied to ASCVD-and NASH to Cognitive Impairment-With HIV - Mark Mascolini(08/03/23)
     
  1021. IAS: A biodegradable, subcutaneous implant delivery platform to treat HIV for up to 6 months in young children - (08/03/23)
     
  1022. IAS: JAK Inhibitor Ruxolitinib Reverses Immune Dysfunction and Depletes HIV Reservoir - Mark Mascolini (08/03/23)
     
  1023. IAS: MEASURING INTRINSIC CAPACITY: A SCREENING TOOL FOR INTEGRATED CARE IN AGEING PEOPLE WITH HIV - (08/03/23)
     
  1024. IAS: The identification of intact HIV proviral DNA in human cerebrospinal fluid - (08/03/23)
     
  1025. IAS: Anatomic distribution of HIV-infected cells in tissues after long term antiretroviral therapy - (08/03/23)
     
  1026. IAS: Psychiatric multimorbidity among people with HIV aged >40 years in low- and middle-income countries in the Sentinel Research Network of IeDEA - (08/03/23)
     
  1027. IAS: Antiretroviral treatment as a protective factor for dysplasia and HPV infection in people living with HIV (PLHIV) - (08/02/23)
     
  1028. IAS: The effect of unplanned care interruptions on the mortality of adults resuming antiretroviral therapy in South Africa: a survival analysis - Mark Mascolini (08/02/23)
     
  1029. IAS: Global Meta-analysis Confirms Suboptimal Retention and HIV Suppression in Drug Users - Mark Mascolini (08/02/23)
     
  1030. IAS: Willingness to use Long-Acting Injectable Cabotegravir (CAB-LA) or Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) During Pregnancy in Africa: Findings from the HPTN-084 Qualitative Sub-study - (08/02/23)
     
  1031. IAS: AGEING WITH HIV (IAS Plenary): Prioritizing person-centred care - (08/02/23)
     
  1032. IAS: Gut dysfunction as an independent driver of neuroinflammation in ART-suppressed SIV - (08/02/23)
     
  1033. IAS: Aging of brain network connectivity corresponds to cognitive impairment in persons with HIV - (08/02/23)
     
  1034. IAS: Selected comorbidities and the risk of ART switch in the context of HIV-RNA suppressed to ≤50 copies/mL - (08/02/23)
     
  1035. IAS: Vitamin D and calcium intake are associated with bone deficits among adolescents living with HIV in Zambia and Zimbabwe: low bone density higher among HIV+ (10% v 6%) - (08/02/23)
     
  1036. IAS: Stigma and poor mental wellbeing: A global community approach to identifying and addressing common barriers to living well with HIV - Gilead Community Board Selects Barriers to Living Well with HIV - (08/02/23)
     
  1037. IAS: Disability in people living with HIV (PLWH) in Asia: a prospective multi-centre case-control study: PWH had higher rates of frailty (6.8% v 1.3%), anxiety, stress, polypharmacy (14.7% v 7%), worse mood - men avg age 53+/-10 - (08/02/23)
     
  1038. IAS: Frailty Worsens in 25% of 50-and-Older Thai HIV Group-But Improves in Many-Through 5 Years - Mark Mascolini (08/02/23)
     
  1039. IAS: Sedative drug burden is associated with concurrent physical frailty in people aging with HIV in Canada: findings from the Positive Brain Health Now Study (+BHN) - (08/02/23)
     
  1040. IAS: Association between non-alcohol steatohepatitis with significant activity and fibrosis and neurocognitive impairment in people with HIV - (08/02/23)
     
  1041. IAS: Willingness to use Long-Acting Injectable Cabotegravir (CAB-LA) or Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) During Pregnancy in Africa: Findings from the HPTN-084 Qualitative Sub-study - (08/01/23)
     
  1042. IAS: Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study - Mark Mascolini (08/01/23)
     
  1043. IAS: Preexisting and Post-Baseline Resistance Analyses in Pooled Pediatric Studies of Emtricitabine/Tenofovir Alafenamide (F/TAF)-Based Antiretroviral Therapy - (08/01/23)
     
  1044. IAS: Longitudinal Lymphocyte Dynamics in Virologically Suppressed Children With HIV Initiating Single-Tablet Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF) - (08/01/23)
     
  1045. IAS: Evaluation of Therapeutic Concentrations of Anti-HIV Antibodies 3BNC117/Teropavimab and 10-1074/Zinlirvimab Through PK-PD Modeling and Prediction of the Washout Duration in HIV Cure Studies - (08/01/23)
     
  1046. IAS: Evaluation of Cross-Sectional HIV Incidence Recency Testing in Samples from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial - (08/01/23)
     
  1047. IAS: Development of the HIV Care Continuum & Beyond Initiative: Key Focus Areas to End HIV in the Asia-Pacific Region - ViiV Community Global Board Selects Focus Areas to Improve Health Outcomes - (08/01/23)
     
  1048. IAS: Initial PrEP product choice: results from the HPTN 084 open-label extension - (08/01/23)
     
  1049. IAS: Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study - Bigger Blood Pressure Jump With DTG in 2nd-Line Therapy Trial - Mark Mascolini (08/01/23)
     
  1050. IAS: Lifestyle Program Yields Modest CVD Benefits in HIV+ South African Women - Mark Mascolini (08/01/23)
     
  1051. IAS: Healthcare provider experience of administering long-acting lenacapavir for people with HIV with heavy treatment experience, engaged through a compassionate use program in the United States - (08/01/23)
     
  1052. IAS: Week-96 Results of ALLIANCE, a Phase 3, Randomized, Double-Blind Study Comparing B/F/TAF Versus DTG + F/TDF in Treatment-Naïve People With Both HIV-1 and Hepatitis B - (08/01/23)
     
  1053. IAS: Association between HIV-related factors and hypertension and diabetes among people living with HIV in Cameroon - (08/01/23)
     
  1054. IAS: Incident hypertension in adults initiating tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis: analysis of data from an integrated health system in California - (08/01/23)
     
  1055. IAS: Cardiovascular Health Among Persons with HIV without Existing Atherosclerotic Cardiovascular Disease (not good) - (08/01/23)
     
  1056. IAS: Risk Characteristics, Risk Perception, and Long-Acting PrEP Awareness and Interest Among Black and Hispanic Men in the US: A National Social Media Survey - (08/01/23)
     
  1057. IAS: Patient-Reported Outcomes After 12 Months of Maintenance Therapy With CAB + RPV LA Compared With BIC/FTC/TAF in the Phase 3b SOLAR Study - (08/01/23)
     
  1058. IAS: Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in the United States: Trio Cohort Study - (07/30/23)
     
  1059. IAS: Inflammatory Markers After Switching to Cabotegravir + Rilpivirine Long-Acting vs. Continuing Bictegravir/Emtricitabine/Tenofovir Alafenamide: Data From the Phase 3b SOLAR Study - (07/30/23)
     
  1060. IAS: Cabotegravir + Rilpivirine Long-Acting Outcomes by Sex at Birth, Age, Body Mass Index, Race, and Ethnicity: A Subgroup Analysis of the Phase 3b SOLAR Study - (07/30/23)
     
  1061. IAS: Real-world observational study in Europe on the effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor (COMBINE-2): Week 96 stable switch population results - (07/30/23)
     
  1062. IAS: Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in Antiretroviral Therapy (ART)-Naive Adolescents Living With HIV-1: DANCE Study Week 96 Results - (07/30/23)
     
  1063. IAS: Acceptable Cost of CAB-LA vs TDF/FTC for PrEP in South African Girls, Young Women - Mark Mascolini - (07/30/23)
     
  1064. IAS: Impact of GLP-1 receptor agonists on body weight in patients with type 2 diabetes and HIV - (07/29/23)
     
  1065. IAS: Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes - (07/29/23)
     
  1066. IAS: Lifestyle Program Yields Modest CVD Benefits in HIV+ South African Women - Mark Mascolini (07/29/23)
     
  1067. IAS: 96-week update: change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide vs. a dolutegravir-based regimen among virologically suppressed adults living with HIV - (07/29/23)
     
  1068. IAS: Weight Change and Metabolic Assessment of Virologically Suppressed Children With HIV Aged ≥ 2 Years and Weighing 14 to < 25 Kg Who Received a TAF-Containing Regimen - (07/29/23)
     
  1069. IAS: Effect on weight changes upon discontinuation of dolutegravir from antiretroviral regimens among persons with HIV who experienced weight gain - (07/29/23)
     
  1070. IAS: Healthcare provider experience of administering long-acting lenacapavir for people with HIV with heavy treatment experience, engaged through a compassionate use program in the United States - (07/29/23)
     
  1071. IAS: Week-96 Results of ALLIANCE, a Phase 3, Randomized, Double-Blind Study Comparing B/F/TAF Versus DTG + F/TDF in Treatment-Naïve People With Both HIV-1 and Hepatitis B - (07/27/23)
     
  1072. IAS: Same-Day PrEP Popular With Adolescent MSM and TGW in Brazil - Mark Mascolini (07/27/23)
     
  1073. IAS: Association of HIV pre-exposure prophylaxis (PrEP) use and bacterial sexually transmitted infections (bSTI) among men who have sex with men (MSM) and transgender women (TGW) in HVTN 704/HPTN 085 - (07/27/23)
     
  1074. IAS: Initial PrEP product choice: results from the HPTN 084 open-label extension - (07/27/23)
     
  1075. IAS: Positive Predictive Value of HIV Serological Tests in HPTN 084 Trial - (07/27/23)
     
  1076. IAS: Acceptability of CAB-LA in cisgender female adolescents in South Africa, Uganda, and Zimbabwe (HPTN 084-01) - (07/27/23)
     
  1077. IAS: High in-hospital mortality in SARS-CoV-2 infected patients living with HIV during pre-Delta, Delta and Omicron variant waves: finding from the WHO Global Clinical Platform for COVID-19 - (07/27/23)
     
  1078. IAS: Doxycycline post-exposure prophylaxis for STIs: Time for implementation? - (07/27/23)
     
  1079. IAS: Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/27/23)
     
  1080. IAS: A Prospective, Randomized Trial to Assess a Protease Inhibitor-based Regimen Switch Strategy to Manage Integrase Inhibitor-related Weight Gain - (07/27/23)
     
  1081. IAS: Risks of hypertension with first-line dolutegravir and tenofovir alafenamide in the NAMSAL and ADVANCE trials - (07/27/23)
     
  1082. IAS: Impact of INSTI and TAF-related BMI changes and risk on hypertension and dyslipidemia in RESPOND - (07/27/23)
     
  1083. IAS: Routine Hypertension Rx Nearly Erases Blood Pressure Disadvantage With DTG (mediated by weight gain) - Mark Mascolini (07/27/23)
     
  1084. IAS: Prior M184V/I and Multiple Prior Virological Failures Have No Impact on the Efficacy of Switching HIV+ Adults to DTG/3TC Through 96Wks in SOLAR-3D - (07/27/23)
     
  1085. IAS: Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) - (07/27/23)
     
  1086. IAS: High rates of long-term HIV RNA re-suppression after virological failure on dolutegravir in the ADVANCE trial. - Mark Mascolini (07/27/23)
     
  1087. IAS: Renal safety parameters after switch to doravirine/islatravir (DOR/ISL 100/0.75 mg) once daily: week 48 results from 2 randomized, active-controlled Phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) - (07/27/23)
     
  1088. IAS: Feasibility of Long-Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C. - (07/27/23)
     
  1089. IAS: Feasibility, Acceptability, and Preliminary Efficacy of LifeSteps for PrEP for Youth Pilot Study (ATN 158) - Fenway Clinic Boston USA - (07/27/23)
     
  1090. IAS: Implementation of Doxycycline Post-Exposure Prophylaxis to Prevent Sexually Transmitted Infections at a Frontline Boston Community Health Center - (07/27/23)
     
  1091. IAS: Initiation of pre-exposure prophylaxis (PrEP) among key populations in PEPFAR-supported countries during 2019-2022 - not good - (07/27/23)
     
  1092. IAS: PrEP Use Up in Australian MSM With Regular Partners- Especially if They Also Have Casual Partners - Mark Mascolini (07/27/23)
     
  1093. IAS: Two Thirds of Oral PrEP Users in Kenya Study Would Prefer Long-Acting Injectable - Mark Mascolini (07/27/23)
     
  1094. IAS: Persistent accelerated epigenetic aging is associated with altered neuroimaging and immune biomarkers in a longitudinal cohort of vertically-acquired HIV-positive adolescents - (07/26/23)
     
  1095. IAS: Two Thirds of Oral PrEP Users in Kenya Study Would Prefer Long-Acting Injectable - Mark Mascolini (07/26/23)
     
  1096. IAS: No Rebound 20 Months After ART Stops After Novel Stem Cell Transplant - Mark Mascolini (07/26/23)
     
  1097. IAS: Evaluation of Incident Hypertension and Blood Pressure Changes Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Randomized Clinical Trials Through 96 Weeks - (07/26/23)
     
  1098. IAS: Dapivirine vaginal ring (DPV-R): An acceptable and feasible HIV prevention option. Evidence from Zimbabwe? - (07/26/23)
     
  1099. IAS: HIV among mpox cases: clinical characteristics and outcomes in the WHO global surveillance 2022 - (07/26/23)
     
  1100. IAS: High rate of hepatitis C and reinfection after direct-acting antiviral treatment among men-who-have-sex-with-men living with HIV in Bangkok, Thailand - (07/26/23)
     
  1101. IAS: Lenacapavir Oral Bridging (300 mg QW) Maintains Efficacy with a Similar Safety Profile When SC LEN Cannot Be Administered - (07/26/23)
     
  1102. IAS: Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/26/23)
     
  1103. IAS: Comparison of Long-Acting Lenacapavir Phase 2/3 Regimen vs Simplified Regimen Using Population-PK Analysis and Simulation - (07/26/23)
     
  1104. IAS: Recommendations for Missed Oral Lenacapavir Loading Doses Using Population-Pharmacokinetics-Based Simulations - (07/26/23)
     
  1105. IAS: Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing: week 24 results of the randomized D2ARLING study - (07/26/23)
     
  1106. IAS: Switching to Dolutegravir/Lamivudine (DTG/3TC) Is Non-inferior to Continuing Tenofovir Alafenamide (TAF)-Based Regimens at Week 196: TANGO Subgroup Analyses - (07/26/23)
     
  1107. IAS: Pharmacokinetics (PK), Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Pregnant Women With HIV - (07/26/23)
     
  1108. IAS: People living with HIV not more likely to be hospitalized with mpox unless immunosuppressed, finds WHO analysis - (07/25/23)
     
  1109. IAS: Cancer drug shows promise in HIV cure study in humanized mice - (07/25/23)
     
  1110. IAS: Cisgender women in seven African countries prefer long-acting injectable to daily oral PrEP for HIV prevention - (07/25/23)
     
  1111. IAS: Cardiovascular health among persons with HIV without existing atherosclerotic cardiovascular disease: low statin 44% & anti-hypertensives 39% use among eligible - poor control of risk factors. - (07/25/23)
     
  1112. IAS: Early outcomes of successful integration of mental health screening into routine HIV care in Malawi - (07/25/23)
     
  1113. IAS: Sleep disorder diagnoses in people with versus without HIV infection in an integrated healthcare system: Insomnia Most Common. PWH More Likely to have Sleep Disorder by 32%. - (07/25/23)
     
  1114. IAS: Depressive symptoms and metabolic syndrome among people living with and without HIV in urban Zambia and Zimbabwe - (07/25/23)
     
  1115. IAS: Estimating HIV incidence in the era of long-acting PrEP - (07/25/23)
     
  1116. IAS: Experience with Using Recency Assay to estimate HIV Incidence in an HIV Prevention Trial - (07/25/23)
     
  1117. IAS: Experience with using a registrational cohort to estimate HIV incidence: Lessons from PREPVAcc - (07/25/23)
     
  1118. IAS: Costs and cost-effectiveness of immediate initiation of antiretroviral therapy upon diagnosis of HIV (Rapid Start) in the United States - (07/25/23)
     
  1119. IAS: Starting ART Within 7 Days of Diagnosis Cuts Mortality in Thailand - Mark Mascolini - (07/25/23)
     
  1120. IAS: Perceptions of Cabotegravir + Rilpivirine Long-Acting (CAB + RPV LA) From People Living With HIV (PLHIV) in the CARLOS Study - (07/25/23)
     
  1121. IAS: Cabotegravir + Rilpivirine Long-Acting Outcomes by Sex at Birth, Age, Body Mass Index, Race, and Ethnicity: A Subgroup Analysis of the Phase 3b SOLAR Study - (07/25/23)
     
  1122. IAS: Participant-Reported Outcomes With Long-Acting Lenacapavir-Based Regimens Among Heavily Treatment-Experienced People Living With HIV in the CAPELLA Clinical Trial - (07/25/23)
     
  1123. IAS: Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV - (07/25/23)
     
  1124. IAS: Pharmacokinetic Bridging with Oral Lenacapavir for Missed Subcutaneous Q6M Dosing - (07/25/23)
     
  1125. IAS: ACTG Announces Publication of REPRIEVE Trial in New England Journal of Medicine and Presentation at IAS 2023 - (07/24/23)
     
  1126. IAS: REPRIEVE Results published: Pitavastatin to Prevent Cardiovascular Disease in HIV Infection - (07/24/23)
     
  1127. IAS: Each Higher Sedative Burden Unit Boosts Odds of Physical Frailty With HIV 35% - Mark Mascolini - (07/24/23)
     
  1128. IAS: STIs Tied to Higher Risk of New HCV Infection in Gay and Bisexual Men - (07/24/23)
     
  1129. IAS: ViiV HEALTHCARE'S CABOTEGRAVIR FOR HIV PREVENTION RECEIVES POSITIVE CHMP OPINION FROM EUROPEAN MEDICINES AGENCY - (07/24/23)
     
  1130. IAS: New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic Press Releases - (07/24/23)
     
  1131. IAS: DOR/ISL (100/0.75 MG) QD COMPARED TO B/F/TAF AS INITIAL HIV-1 TREATMENT: 48 WEEK RESULTS FROM A DOUBLE-BLIND PHASE 3 TRIAL - (07/24/23)
     
  1132. Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000-2020 - (07/19/23)
     
  1133. U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease - Colchicine 0.5 mg: Efficacy in Chronic Coronary Disease; Kidney Progression Risk Studies - (07/18/23)
     
  1134. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients - (07/10/23)
     
  1135. Dolutegavir Monotherapy in a Unique Unusual Patient Population - (07/07/23)
     
  1136. Efficacy and safety of three antiretroviral therapy regimens (DTG v EFV) started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial - (06/19/23)
     
  1137. ART Regimens: DTG/3TC; LA CAB/RPV; Biktarvy 5 Yrs - (06/16/23)
     
  1138. Study Links viral infections to Alzheimer, Parkinsons - with many caveats - (06/14/23)
     
  1139. Does shingles vaccination cut dementia risk? Large study hints at a link - (06/14/23)
     
  1140. PWH had a higher prevalence of AD (alzheimers)/ADRD. PWH had a higher burden of dementia - (06/05/23)
     
  1141. Impact of Multiple Social Determinants of Health on Incident Stroke - (06/05/23)
     
  1142. Stroke Incidence among White, Black, and Hispanic Residents of an Urban Community - (06/05/23)
     
  1143. Daily statin medication was found to reduce the risk of cardiovascular disease by 35% among people living with HIV; substantial CVD risk in Young PWH - REPRIEVE Study - (06/05/23)
     
  1144. COVID at CDC Conference: Update on Rapid Assessment of SARS-CoV-2 Transmission at 2023 EIS Conference - (06/01/23)
     
  1145. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022 - (05/30/23)
     
  1146. Several cases of Apparent Mpox Reinfection in Europe - (05/29/23)
     
  1147. LENACAPAVIR DISRUPTS HIV-1 CORE INTEGRITY WHILE STABILIZING THE CAPSID LATTICE - (05/30/23)
     
  1148. Population-PK Analysis to Guide Dosing Window Following Lenacapavir SC Administration - (05/30/23)
     
  1149. CROI: NO ANTAGONISM OR CROSS-RESISTANCE OBSERVED BETWEEN ISLATRAVIR AND LENACAPAVIR - (05/30/23)
     
  1150. Diagnoses of HIV Infection in the United States and Dependent Areas, 2021 HIV Declines Among Young People and Drives Overall Decrease in New HIV Infections - (05/25/23)
     
  1151. Antiretroviral Therapy Intensification for Neurocognitive Impairment in HIV - (05/25/23)
     
  1152. CVD After Switch to DTG Reassuring Editorial Comment - Reassuring data for cardiovascular health after switching a boosted protease inhibitor to dolutegravir - (05/25/23)
     
  1153. Associations of Menstrual Cycle Regularity and Length With Cardiovascular Diseases: A Prospective Study From UK Biobank - (05/25/23)
     
  1154. FULMINANT HEPATITIS B AFTER SWITCH IN ANTIRETROVIRAL THERAPY - (05/24/23)
     
  1155. Perceived Cognitive Deficits in Patients With Symptomatic SARS-CoV-2 and Their Association With Post-COVID-19 Condition - (05/22/23)
     
  1156. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies - (05/22/23)
     
  1157. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong - (05/22/23)
     
  1158. COVID-19 Vaccination and Hospitalization Among Persons Living With Diagnosed HIV in New York State - (05/22/23)
     
  1159. Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015 2021 - (05/22/23)
     
  1160. Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV - (05/22/23)
     
  1161. Weight Change Following Switch to Dolutegravir for HIV Treatment in Rural Kenya During Country Roll-Out - (05/22/23)
     
  1162. Trajectories of Antiretroviral Therapy Adherence and Virologic Failure in Women With HIV in the United States - (05/22/23)
     
  1163. HIV incidence and mortality in transgender women in the eastern and southern USA: a multisite cohort study - (05/22/23)
     
  1164. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy - (05/22/23)
     
  1165. Glasgow Manifesto; recorded aging webinars: IAS; Global Action on aging ICOPE - (05/22/23)
     
  1166. Long-acting antiretrovirals and HIV treatment adherence - Review - (05/19/23)
     
  1167. Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland - (05/19/23)
     
  1168. Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV - (05/18/23)
     
  1169. Long-Acting Cabotegravir and Rilpivirine: Every 2 Months, 152 Weeks ATLAS-2M. Innovation, New Challenges, and Opportunities - (05/17/23)
     
  1170. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials - (05/17/23)
     
  1171. Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy - (05/17/23)
     
  1172. Disparities in Adherence & Viral Suppression: "Racial and ethnic disparities in HIV care outcomes must be ameliorated if we are to meet the goals of the EHE and NHAS" - (05/15/23)
     
  1173. Incident diabetes in course of antiretroviral therapy - (05/15/23)
     
  1174. Comorbidities: HIV Controllers vs on ART - (05/12/23)
     
  1175. First two patients receive CAR T cell therapy for HIV - (05/12/23)
     
  1176. New NYS Clinical Guidance: Addressing the Needs of Older Patients in HIV Care - (05/11/23)
     
  1177. R.S.V. Vaccine Approved for Older Adults - (05/05/23)
     
  1178. PWH Suffer Increasing Depression & Anxiety with Age/Disease Duration - (05/02/23)
     
  1179. Dementias among older males and females in the U.S. Medicare system with and without HIV - (04/29/23)
     
  1180. AGING DOES NOT IMPACT DRUG-DRUG INTERACTION MAGNITUDES INVOLVING ANTIRETROVIRAL DRUGS - (04/26/23)
     
  1181. GREATER BURDEN OF INTRACRANIAL ARTERIAL-WALL ENHANCEMENT IN PERSONS LIVING WITH HIV - (04/26/23)
     
  1182. LA Cabotegavir & Rilpivirine During Pregnancy - (04/25/23)
     
  1183. Why we need to re-define long-term success for people living with HIV - (04/21/23)
     
  1184. Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists - (04/21/23)
     
  1185. People living with HIV at substantially higher risk of depression and suicide, especially in first 2 years after diagnosis.reported yesterday at 33rd ECCMID in Denmark - (04/20/23)
     
  1186. CROI: REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPY WITH AN HIV VACCINE, TLR-9 AGONIST, AND BROADLY NEUTRALIZING ANTIBODIES - (04/20/23)
     
  1187. CROI: Heterologous ChAd/samRNA SIV Vaccine Induces Robust T-Cell Responses in Macaques - (04/20/23)
     
  1188. CROI: Vesatolimod Pharmacodynamic Response Associates With Time to HIV Rebound - (04/20/23)
     
  1189. CROI: THE IMPACT OF 3BNC117, 10-1074, AND LEFITOLIMOD ON HIV-1 PERSISTENCE: THE TITAN TRIAL - (04/20/23)
     
  1190. CROI: Topics in Antiviral Medicine: early e-publication versions of our first six 2023 CROI review articles - (04/19/23)
     
  1191. Recorded Webinar and Slides - Taking Global Action Toward Improved Care, Quality of Life, and Empowerment for Older People with HIV - A Webinar
     
  1192. Glasgow: The Glasgow Manifesto International Coalition of Older People with HIV (iCOPe HIV)
     
  1193. IAS Recorded Feb 7 webinar - Growing older with HIV in the Treat-All Era
     
  1194. Development of Frail RISC-HIV: a Risk Score for Predicting Frailty Risk in the Short-term for Care of People with HIV - (04/19/23)
     
  1195. Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons - (04/19/23)
     
  1196. Sleep disturbances and their correlation with cardiovascular risk, obesity, and mood disorders in people with HIV - (04/19/23)
     
  1197. People living with HIV at substantially higher risk of depression and suicide, especially in first 2 years after diagnosis - (04/18/23)
     
  1198. Rates and risk factors for suicidal ideation, suicide attempts and suicide deaths in persons with HIV: a systematic review and meta-analysis - (04/18/23)
     
  1199. CROI 2023 and HIV prevention: Drs. Connie Celum and Renee Heffron - Connie Celum, MD, MPH Professor, Global Health & Medicine, Adjunct Professor Epidemiology University of Washington - Renee Heffron, PhD, MPH Professor, Department of Medicine Director, Center for AIDS Research University of Alabama at Birmingham - (04/03/23)
     
  1200. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis - (04/18/23)
     
  1201. Lenacapavir - recently published phase 2 safety/efficacy in treatment-naives; at CROI; + Preclinical Studies of New Prevention Interventions at CROI - (04/17/23)
     
  1202. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial - (04/17/23)
     
  1203. PLWH and Nursing Homes Report 5 Publications on Nursing Homes & PLWH - (04/13/23)
     
  1204. Daily statin reduces the risk of cardiovascular disease in people living with HIV, large NIH study finds - (04/11/23)
     
  1205. Premature Menopause & HRT, Alzheimers - Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography - (04/10/23)
     
  1206. EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL - (04/10/23)
     
  1207. MPOX IN PEOPLE LIVING WITH HIV AND CD4 COUNTS < 350 CELLS/MM3: A GLOBAL CASE SERIES - (04/10/23)
     
  1208. Trends in mortality in people living with HIV in an
    international cohort (RESPOND): comorbidities, cancer, CD4/viral load     - (04/10/23)
     
  1209. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections - (04/09/23)
     
  1210. Sudden Cardiac Death and Myocardial Fibrosis, Determined by Autopsy, in Persons with HIV - (04/09/23)
     
  1211. The number of new cases and deaths from liver cancer could rise by >55% by 2040. Global burden of primary liver cancer in 2020 and predictions to 2040 - (04/09/23)
     
  1212. Real world use of dolutegravir two drug regimens - (04/05/23)
     
  1213. Effectiveness of Dolutegravir + Lamivudine in Real-world Studies in People With HIV-1 With M184V/I Mutations: A Systematic Review and Meta-analysis - (04/05/23)
     
  1214. Lower anti-Müllerian hormone levels are associated with HIV in reproductive age women and shorter leukocyte telomere length among late reproductive age women - (04/04/23)
     
  1215. SPATIAL PROFILING OF CORONARY PLAQUE SUGGESTS UNIQUE IMMUNE PATHWAYS IN HIV, HIV Found in Coronary Arteries of Deceased PWH - (04/03/23)
     
  1216. U.S. at risk of mpox surge even worse than last year, CDC modelers warn - (03/31/23)
     
  1217. MEDICINES PATENT POOL SIGNS SUBLICENCES WITH AUROBINDO, CIPLA AND VIATRIS TO PRODUCE GENERIC VERSIONS OF ViiV HEALTHCARE'S INNOVATIVE LONG-ACTING HIV PREVENTION MEDICINE - (03/24/23)
     
  1218. In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation - (03/24/23)
     
  1219. Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals - EDITORIAL - (03/31/23)
     
  1220. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy - (03/31/23)
     
  1221. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy - (03/31/23)
     
  1222. CROI: CROI Oral PrEP Session - All Modes to PrEP - (03/31/23)
     
  1223. CROI: A Loss of ERα Attenuates DTG-mediated Disruption of Thermogenesis in Brown Adipocytes - (03/30/23)
     
  1224. CROI: Weight Gain at CROI 2023 - (03/29/23)
     
  1225. CROI: SARCOPENIA, FRAILTY, NUTRITION AND HCV INFECTION AMONG OLDER PEOPLE WITH HIV - (03/29/23)
     
  1226. CROI: COVID at CROI 2023 - (03/22/23)
     
  1227. CROI: Psychiatric Symptoms In PLHIV: Prevalences, Interactions And Consequences - here are slides in Themed Discussion & poster. - (03/27/23)
     
  1228. CROI: THE SCIENCE OF AGING: LESSONS FOR HIV AT THE INTERFACE OF COMMONALITY AND HETEROGENEITY, George Kuchel - (03/27/23)
     
  1229. CROI: COMPLICATIONS Oral Abstract Session-06 at CROI 2023 - (03/27/23)
     
  1230. CROI: Weight Gain: Does what Goes Up Come Down ? Themed Discussion - (03/27/23)
     
  1231. CROI: Anal Cancer Prevention & Microbiome Biomarkers - (03/27/23)
     
  1232. CROI: HIV-1 Host Reservoir Reactivation after a
    CCR5Δ32/32 Allogeneic Hematopoietic Stem Cell Transplant     - (03/27/23)
     
  1233. CROI: Paxlovid Reduced by 98% Hospitalization: COVID-19 HOSPITALIZATION RISK AFTER SARS-CoV-2 VACCINATION AND OUTPATIENT TREATMENT - (03/27/23)
     
  1234. CROI: Psychiatric Symptoms In PLHIV: Prevalences, Interactions And Consequences - here are slides in Themed Discussion & poster. - (03/27/23)
     
  1235. CROI: VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA (NSV) - (03/27/23)
     
  1236. CROI: ADVANCES IN HIV CURE at CROI 2023, John Mellors - (03/27/23)
     
  1237. CROI: Predictors of Post-Switch Viremia in Patients on Injectable Cabotegravir/Rilpivirine - (03/27/23)
     
  1238. CROI: LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (03/27/23)
     
  1239. CROI: LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (03/27/23)
     
  1240. CROI: SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF - (03/27/23)
     
  1241. CROI: Pharmacokinetics Inform Remdesivir Dosing for Patients With Severe Renal Impairment - (03/22/23)
     
  1242. CROI: MICROBIOME-DERIVED METABOLITES ARE POWERFUL BIOMARKERS FOR ANAL CANCER PREVENTION - (03/22/23)
     
  1243. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy (ART) Regimens: Results From the Quebec Human Immunodeficiency Virus (HIV) Cohort Study - (03/24/23)
     
  1244. VV116, GS-5245 for COVID - (03/24/23)
     
  1245. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition - (03/24/23)
     
  1246. Nonsuppressible viremia during HIV-1 therapy meets molecular virology - (03/22/23)
     
  1247. CROI: BULEVIRTIDE +/- PEG-IFN IN HIV/HBV/HDV CO-INFECTED PATIENTS IN REAL-LIFE SETTINGS - (03/22/23)
     
  1248. CROI: Persistent Low Level 'Non-Suppressible' HIV Viremia - (03/22/23)
     
  1249. CROI: VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA - (03/22/23)
     
  1250. CROI: Disparities in Mpox Vaccination Uptake in San Francisco Among PLWH and People on PrEP - (03/22/23)
     
  1251. CROI: CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT - (03/22/23)
     
  1252. CROI: Clonally expanded HIV-1 proviruses with 5'-leader defects can give rise to nonsuppressible residual viremia - (03/22/23)
     
  1253. CROI: Persistent HIV Low-Level Viremia Can Arise From An Active Proviral Clone - (03/22/23)
     
  1254. CROI: Low level viremia, Nonsuppressible - (03/22/23)
     
  1255. CROI: REMDESIVIR REDUCES MORTALITY IN IMMUNOCOMPROMISED PATIENTS HOSPITALIZED FOR COVID-19 - (03/22/23)
     
  1256. CROI: Remdesivir Retains Potent Antiviral Activity Against SARS-CoV-2 Variants of Concern - (03/22/23)
     
  1257. CROI: Any Level of Detectable Viremia is Associated with Serious Non-AIDS Events - (03/20/23)
     
  1258. CROI: Changes in Body Mass Index with Longer-Term Integrase Inhibitor Use in REPRIEVE - (03/20/23)
     
  1259. CROI: PSYCHIATRIC DISORDERS IN HIV EXPOSED UNINFECTED - VERSUS NON-HIV EXPOSED CHILDREN - (03/20/23)
     
  1260. CROI: HIV EXPOSED UNINFECTED (HEU) INFANTS DISPLAY UNIQUE PRO-INFLAMMATORY BIOPROFILES - (03/20/23)
     
  1261. CROI: Any Level of Detectable Viremia is Associated with Serious Non-AIDS Events - (03/20/23)
     
  1262. CROI: Academic Performance Among Children with Perinatal HIV Exposure in Botswana - (03/20/23)
     
  1263. CROI: PREGNANCY HORMONAL DYSREGULATION CORRELATES WITH HIV-EXPOSED INFANT GROWTH OUTCOMES - (03/20/23)
     
  1264. CROI: Effect of in-utero HIV and ART exposure on growth during infancy - (03/20/23)
     
  1265. CROI: CMV IgG is Associated with Muscle Function but not Quality or Mass in People with HIV - (03/20/23)
     
  1266. CROI: CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT - (03/16/23)
     
  1267. CROI: Risk factors for liver fibrosis progression in HIV: a multi-center longitudinal study - (03/16/23)
     
  1268. CROI: SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (03/16/23)
     
  1269. CROI: A 12-WEEK MULTICOMPONENT EXERCISE PROGRAM REVERSES FRAILTY IN OLDER ADULTS WITH HIV - (03/16/23)
     
  1270. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection - (03/16/23)
     
  1271. CROI: Any level of detectable viremia is associated with serious non-AIDS events Even Low-Level Viral Load Inflates Risk of Serious Non-AIDS Illness - Mark Mascolini (03/16/23)
     
  1272. CROI: Brain Aging Gap was significantly elevated in PWH compared to PWoH (p=0.001). - (03/16/23)
     
  1273. CROI: RACIAL AND HIV DISPARITIES IN HYPERTENSION CASCADE AMONG WOMEN - (03/14/23)
     
  1274. CROI: The BONDY Study: Bone density in youth living with perinatally acquired HIV - (03/14/23)
     
  1275. CROI: Metabolic Health and bone density in youth living with perinatal HIV - (03/14/23)
     
  1276. CROI: BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN-A2B + 3BNC117 & 10-1074 IN CHRONIC HIV INFECTION - (03/14/23)
     
  1277. CROI: Safety and Efficacy of Inhaled Interferon-β1a
    (SNG001) in a Phase II Randomized Controlled Trial of Adults with Mild-to-Moderate COVID-19     - (03/14/23)
     
  1278. CROI: Ensitrelvir for mild-to-moderate COVID-19: Phase 3 part of Phase 2/3 study - (03/14/23)
     
  1279. CROI: BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN-A2B + 3BNC117 & 10-1074 IN CHRONIC HIV INFECTION - (03/14/23)
     
  1280. CROI: Safety and Efficacy of Inhaled Interferon-β1a
    (SNG001) in a Phase II Randomized Controlled Trial of Adults with Mild-to-Moderate COVID-19     - (03/14/23)
     
  1281. CROI: Ensitrelvir for mild-to-moderate COVID-19: Phase 3 part of Phase 2/3 study - (03/14/23)
     
  1282. CROI: HIGH MORTALITY IN HOSPITALISED VIRALLY SUPPRESSED ADULTS WITH HIV IN SOUTH AFRICA - (03/14/23)
     
  1283. CROI: INFREQUENT DETECTION OF EMERGENT HIV DRUG RESISTANCE IN LOW VIRAL LOAD SPECIMENS - (03/14/23)
     
  1284. CROI: Sofosbuvir/Velpatasvir Pharmacokinetics in Pregnant Women with Hepatitis C Virus - (03/14/23)
     
  1285. Long COVID Incidence CDC 15%-20% - (03/14/23)
     
  1286. Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial - (03/13/23)
     
  1287. CROI: BONE DENSITY CHANGES WITH CAB-LA OR TDF/FTC PrEP IN MSM AND TGW IN HPTN 083 - (03/13/23)
     
  1288. CROI: Incidence of Long COVID Symptoms in Patients Previously Hospitalized With COVID-19 - (03/13/23)
     
  1289. CROI: Early Inflammatory Profiles Predict Maximal Disease Severity in COVID-19 - (03/13/23)
     
  1290. CROI: Inflammatory pathways associated with COVID-19 severity differ based on obesity status - (03/13/23)
     
  1291. CROI: LONG-TERM LIVER EVENTS IN PATIENTS WITH HCV CHRONIC INFECTION AFTER SVR - (03/13/23)
     
  1292. CROI: SYNDEMIC OF CHRONIC VIRAL INFECTIONS ON THE RISK OF END-STAGE RENAL DISEASE - (03/13/23)
     
  1293. CROI: ASSOCIATION OF HIV CONTROL AND IMMUNOSUPPRESSION WITH NADC RISK AMONG PATIENTS ON ART; CD4 Matters: >500 Better - (03/12/23)
     
  1294. CROI: Dolutegravir exposure and congenital anomalies in sub-Saharan Africa - (03/12/23)
     
  1295. CROI: Doubling dolutegravir dosage reduces HIV persistence markers in ART-treated adults - (03/12/23)
     
  1296. CROI: 15-MONTH ATTRIBUTES OF POST-COVID SYNDROME IN THERAPEUTICALLY VACCINATED OUTPATIENTS - (03/12/23)
     
  1297. CROI: CARDIOMETABOLIC RISK IN SOUTH AFRICAN POSTPARTUM WOMEN LIVING WITH HIV - (03/12/23)
     
  1298. CROI: 48 months anthropometric evolution of adolescents switching to Dolutegravir in Spain - (03/12/23)
     
  1299. CROI: Neurofilament light is related to cardiorespiratory and metabolic health in HIV - (03/12/23)
     
  1300. CROI: Weight change over 48 weeks after the transition to dolutegravir-based therapy- a prospective study in Uganda - (03/12/23)
     
  1301. CROI: RANDOMIZED CLINICAL TRIAL OF TRANSGENDER WOMEN SWITCHING TO B/F/TAF (MOBETTA TRIAL) - (03/12/23)
     
  1302. CROI: Intramuscular cabotegravir/ rilpivirine concentrations after switching from efavirenz - (03/12/23)
     
  1303. CROI: Neural tube and other birth defects by HIV status and ART regimen in Eswatini - (03/12/23)
     
  1304. CROI: Telomere Length in Aviremic PWH: How Different is it from Persons Without HIV? - (03/10/23)
     
  1305. Metformin Reduced Long COVID Incidence by 43% - (03/07/23)
     
  1306. CROI: Telomere Length in Aviremic PWH: How Different is it from Persons Without HIV? - (03/07/23)
     
  1307. CROI: PWH Had Worse Depression Scores than PWoH & IL-6 in Men Associated with Depression - (03/07/23)
     
  1308. CROI: Worse Brain Aging in PWH: factors - CVD, Social Determinants, HCV, Viral Load, Unemployment - (03/07/23)
     
  1309. CROI: Merck's MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study - (03/07/23)
     
  1310. CROI: PERICORONARY ADIPOSE TISSUE DENSITY AND SUBCLINICAL CORONARY ARTERY DISEASE IN HIV - (03/07/23)
     
  1311. CROI: INFUSION OF CCR5 GENE-MODIFIED T CELLS PROVIDES LONG-TERM HIV CONTROL - (03/07/23)
     
  1312. CROI: Proportion of deaths occurring outside of health facilities that is attributable to HIV/AIDS - (03/07/23)
     
  1313. CROI: Pharmacokinetics and X-ray Imaging of Long-acting Cabotegravir In Situ Forming Implant - (03/07/23)
     
  1314. CROI: Oral TDF/FTC Provides Early Mucosal Protection In Both On- Demand And Daily Regimen - (03/07/23)
     
  1315. CROI: KAPOSI SARCOMA IN ART-TREATED PLWH: DISTINCT VIRAL AND IMMUNE CHARACTERISTICS - (03/06/23)
     
  1316. CROI: Impact of COVID-19 and Host Factors on the Humoral Immune Repertoire in Treated HIV - (03/06/23)
     
  1317. CROI: Several InSTI Affect Immune Cell Mitochondrial, Proliferation and Apoptosis Ex Vivo - (03/06/23)
     
  1318. CROI: EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS - (03/06/23)
     
  1319. CROI: INCIDENCE OF NON-HEPATIC CANCERS IN HBV, HCV, AND HBV/HCV COINFECTED PERSONS - (03/06/23)
     
  1320. CROI: INCIDENCE OF NON-HEPATIC CANCERS IN HBV, HCV, AND HBV/HCV COINFECTED PERSONS - (03/06/23)
     
  1321. CROI: BURDEN OF CORONARY DISEASE IN TRANSGENDER WOMEN WITH AND WITHOUT HIV - (03/06/23)
     
  1322. CROI: Comorbidities and Symptoms Associated with Falls from 2020-2021 - (03/06/23)
     
  1323. CROI: Internalized HIV Stigma and Mental Health/Substance Use Over Time - (03/06/23)
     
  1324. CROI: US PATIENT PREFERENCES FOR LONG-ACTING HIV TREATMENT: A DISCRETE CHOICE EXPERIMENT - (03/06/23)
     
  1325. CROI: Mosaico (HPX3002/HVTN706) (Data as of Dec 12, 2022 as presented at a DSMB meeting on January 12, 2023) - (03/06/23)
     
  1326. CROI: DIFFERENTIAL ASSOCIATION OF CYTOMEGALOVIRUS WITH ACUTE AND POST-ACUTE COVID-19 - (03/06/23)
     
  1327. CROI: DOLUTEGRAVIR IS ASSOCIATED WITH MORE DEPRESSIVE SYMPTOMS IN OLDER PEOPLE WITH HIV - (03/06/23)
     
  1328. CROI: ONE-YEAR MORTALITY OF PEOPLE WITH HIV AFTER INTENSIVE CARE UNIT ADMISSION - (03/06/23)
     
  1329. CROI: ASSOCIATIONS BETWEEN PLASMA BIOMARKERS AND CHANGES IN COGNITIVE FUNCTION OVER 2 YEARS - (03/06/23)
     
  1330. CROI: Estradiol concentrations in trans women on INSTIs compared to those without HIV - (03/06/23)
     
  1331. CROI: ORAL AND INJECTABLE PrEP USE IN THE UNITED STATES, 2013 TO 2022 - (03/05/23)
     
  1332. CROI: CHARACTERIZATION OF SINGLE VERSUS DUAL ACTIVE MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 - (03/05/23)
     
  1333. CROI: WHAT INFLUENCES SWITCHING TO DTG/3TC VS B/F/TAF IN CLINICAL PRACTICE? - (03/05/23)
     
  1334. CROI: Pre-Exposure Prophylaxis Product Choice in United States Participants in HPTN 083 - (03/05/23)
     
  1335. CROI: IN SILICO PHARMACOKINETICS EVALUATION OF FORGIVENESS FOR DORAVIRINE & RILPIVIRINE - (03/05/23)
     
  1336. CROI: VASCULAR AGE AND COGNITIVE OUTCOMES IN AN ACUTE HIV COHORT AFTER 5.5 YEARS OF ART - (03/05/23)
     
  1337. CROI: Non-AIDS Defining Malignancy Mortality In People Living With HIV; CD4 is biggest risk factor, next is smoking - (03/05/23)
     
  1338. CROI: Incidence of cancer among Medicaid beneficiaries with and without HIV: 2001-2015, PLWH have higher risks for certain cancers - (03/05/23)
     
  1339. CROI: Effects of eplerenone on myocardial perfusion and function: the Miracle HIV study: May Stall Worsening Subclinical Heart Disease With HIV - Mark Mascolini (03/05/23)
     
  1340. CROI: TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV - (03/05/23)
     
  1341. CROI: OLFACTORY PERFORMANCE IN POST MILD-TO-MODERATE ACUTE COVID-19 ACROSS 2 YEARS - (03/05/23)
     
  1342. CROI: TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV - (03/05/23)
     
  1343. CROI: Post Covid Cognitive Impairment Neuro imaging Abnormalities on MRI- A Potential Biomarker - (03/05/23)
     
  1344. CROI: NIRMATRELVIR USE AND HOSPITALIZATIONS OR DEATH IN INDIVIDUALS WITH COVID-19 - (03/05/23)
     
  1345. CROI: Non-AIDS Cancer Risk Varies by Age in Medicaid Group With vs Without HIV - Mark Mascolini (03/03/23)
     
  1346. CROI: MEASURING EXCESS MORTALITY ASSOCIATED WITH HIV: ESTIMATES FROM THE PHIA PROJECT - (03/03/23)
     
  1347. High frequency of memory stem cells with a distinct gene signature in HIV patients with treatment interruption - (03/02/23)
     
  1348. CROI: Cognitive, Motor, & Negative Valence Systems in Neurologic PASC: A Preliminary Study - (03/02/23)
     
  1349. CROI: EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL - (03/02/23)
     
  1350. CROI: Screening approaches and clinical description of the anticholinergic burden & Symptoms in people with HIV - (03/02/23)
     
  1351. CROI: MUSCLE QUALITY IS ASSOCIATED WITH CORONARY ARTERY PLAQUE AND PHYSICAL FUNCTION IN PEOPLE WITH HIV - (03/02/23)
     
  1352. CROI: CMV IgG is Associated with Muscle Function but not Quality or Mass in People with HIV - (03/02/23)
     
  1353. CROI: EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV 2nd report - (03/02/23)
     
  1354. CROI: (NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION - (03/02/23)
     
  1355. CROI: Screening approaches and clinical description of the anticholinergic burden & Symptoms in people with HIV, Polypharmacy - (03/02/23)
     
  1356. CROI: Screening approaches and clinical description of the anticholinergic burden in people with HIV - (03/02/23)
     
  1357. CROI: TAF and Cobicistat-Boosted Drugs Tied to More Somatic Depressive Symptoms - Mark Mascolini (03/02/23)
     
  1358. CROI: Syringe Service Program Boosts Chances of COVID Testing in Drug Injectors - Mark Mascolini (03/02/23)
     
  1359. CROI: Every 10% Uptick in Masking at School Halves SARS-CoV-2 Detections - Mark Mascolini (03/02/23)
     
  1360. CROI: Second-Line DTG + DRV/r Controls HIV Better Than DRV/r + 2 NRTIs - Mark Mascolini (03/02/23)
     
  1361. CROI: Intervention efficacy on COVID-19 testing and vaccination in people who inject drugs - Mark Mascolini (03/02/23)
     
  1362. CROI: Travel Strictures in Canada Slowed SARS-Cov-2 Variant Arrivals-Briefly - Mark Mascolini - (03/02/23)
     
  1363. Delivering Preexposure Prophylaxis to People Who Use Drugs and Experience Homelessness, Boston, MA, 2018-2020 - (03/01/23)
     
  1364. CROI: CROI 2023: Lenacapavir Treatment, Prevention - (03/01/23)
     
  1365. CROI: CROI 2023: LA CAB/RPV Treatment, CAB Prevention Updates, New Data - (03/01/23)
     
  1366. CROI: Sleep disturbances are associated with cognitive function in women living with HIV - (03/01/23)
     
  1367. CROI: COVID-19 bivalent booster effectiveness in people with and without immune dysfunction - Mark Mascolini (03/01/23)
     
  1368. CROI: VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL - (03/01/23)
     
  1369. CROI: PRIMARY HCV INCIDENCE AMONG MSM USING PREP AND MSM WITH HIV IN NEW YORK CITY 2012-2022 - (03/01/23)
     
  1370. CROI: Subcutaneous Adipose Tissue Cell Composition is Associated with Visceral Fat Volume - (03/01/23)
     
  1371. CROI: Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in HIV - (03/01/23)
     
  1372. CROI: Four Distinct Biopsychosocial Phenotypes in HIV in the CHARTER Cohort-and Why They Matter - Mark Mascolini (03/01/23)
     
  1373. CROI: Islatravir at CROI 203: treatment, prevention, LA implant - (02/28/23)
     
  1374. CROI: Immune Activation Signals Similar in MSM With HIV and MSM on PrEP And Higher Than in HIV-Negative Controls - Mark Mascolini (02/28/23)
     
  1375. CROI: Dual-Active mAbs Better Than Single-Active Therapy in Stalling SARS-CoV-2 - Mark Mascolini (02/28/23)
     
  1376. CROI: LA CAB + RPV Every 4 Weeks Controls HIV in 131 of 133 With High Nonadherence Risk, Unstable Housing, Mental Illness, Homelessness, drug use - Mark Mascolini (02/28/23)
     
  1377. CROI: COVID in US Made HIV Diagnoses Plunge in 2020-But Why? - (02/28/23)
     
  1378. CROI: High Mpox Rate in MSM on PrEP, but MVA-BN Vax Stops Mpox Cold - Mark Mascolini (02/25/23)
     
  1379. CROI: Mpox Mortality 27% if CD4s Below 100 With HIV Infection - Mark Mascolini - (02/25/23)
     
  1380. CROI: Cocaine Tied to White Matter Lesions With HIV, a Factor in Poor Cognitive Function - Mark Mascolini (02/25/23)
     
  1381. CROI: Rates of Key Death Causes With HIV Falling in Europe/America. Deaths Due to Comorbidities - Mark Mascolini - (02/25/23)
     
  1382. CROI: Depression or Anxiety Linked to Type 1 or 2 MI in US People With HIV - Mark Mascolini - (02/25/23)
     
  1383. CROI: Effects of eplerenone on myocardial perfusion and function [subclinical heart disease]: the Miracle HIV study....."may prevent worsening of subclinical heart disease in HIV" - Mark Mascolini - (02/25/23)
     
  1384. CROI: New Heart Disease Rate Similar With Integrase Inhibitors and Other First ART - Mark Mascolini (02/25/23)
     
  1385. CROI: Good Rectal TAF/EVG Levels With Rectal Inserts in HIV-Negative Men and Women - Mark Mascolini (02/25/23)
     
  1386. CROI: Long-Acting CAB for PrEP Acceptable, Safe in Adolescent Female Africans - Mark Mascolini- (02/25/23)
     
  1387. CROI: Long-Acting Lenacapavir in a Combination Regimen for Treatment Naïve PWH: Week 80 - (02/25/23)
     
  1388. CROI: Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH - (02/24/23)
     
  1389. CROI: Lenacapavir Protects Against Rectal SHIV Acquisition in Macaque Model - (02/24/23)
     
  1390. CROI: Antiviral Activity of Lenacapavir Against HIV-2 Isolates - (02/24/23)
     
  1391. CROI: Weight and Metabolic Benefits With TDF/FTC/DTG After 4 Years of TAF/FTC+DTG - Mark Mascolini (02/24/23)
     
  1392. CROI: FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC - (02/24/23)
     
  1393. CROI: Weight Gain Among Participants Switching to a Dolutegravir-based HIV Regimen in Kenya - (02/24/23)
     
  1394. CROI: REVERSIBILITY OF TAF- AND/OR INSTI-ASSOCIATED WEIGHT GAIN - (02/24/23)
     
  1395. CROI: SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL - (02/24/23)
     
  1396. CROI: SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL - (02/24/23)
     
  1397. CROI: MODELING TO OPTIMIZE ISLATRAVIR QW DOSE IN HIV VIROLOGICALLY SUPRESSED PWH - (02/24/23)
     
  1398. CROI: Vaginal PrEP Efficacy of Biodegradable Islatravir Implants in Macaques Islatravir Implant Protects Macaques From Vaginal SHIV Infection - Mark Mascolini (02/24/23)
     
  1399. CROI: TARGET3D: glecaprevir-pibrentasvir for four weeks among people with recent HCV infection - (02/23/23)
     
  1400. CROI: Weight and Metabolic Changes With Cabotegravir + Rilpivirine Long-Acting or Bictegravir/Emtricitabine/Tenofovir Alafenamide - (02/23/23)
     
  1401. CROI: Heterologous ChAd/samRNA SIV Vaccine Induces Robust T-Cell Responses in Macaques - (02/23/23)
     
  1402. CROI: ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV - (02/23/23)
     
  1403. CROI: HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION - (02/23/23)
     
  1404. CROI: Projected Benefits of Long-Acting ART (LA-ART) in PWH Viremic Not Taking Oral Therapy - (02/23/23)
     
  1405. CROI: EFFICACY AND SAFETY OF 8-WK TUBERCULOSIS TREATMENT REGIMENS IN THE TRUNCATE-TB TRIAL - (02/23/23)
     
  1406. CROI: Impact of integrase inhibitors on cardiovascular events in persons starting ART; INSTI did not increase CVD events in Swiss Cohort - Mark Mascolini(02/23/23)
     
  1407. CROI: ViiV HEALTHCARE ANNOUNCES POSITIVE DATA DEMONSTRATING LONG-ACTING INJECTABLE CABENUVA (CABOTEGRAVIR, RILPIVIRINE) IS AS EFFECTIVE AS DAILY ORAL BIKTARVY (BIC/FTC/TAF) FOR THE TREATMENT OF HIV-1 - (02/23/23)
     
  1408. CROI: SOLAR (Switch Onto Long-Acting Regimen) 12-Month Results - Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (02/23/23)
     
  1409. CROI: LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV - (02/23/23)
     
  1410. CROI: EFFECT OF ISLATRAVIR ON TOTAL LYMPHOCYTE AND LYMPHOCYTE SUBSET COUNTS - (02/23/23)
     
  1411. CROI: D2EFT: DOLUTEGRAVIR AND DARUNAVIR EVALUATION IN ADULTS FAILING FIRST-LINE NNRTI THERAPY - (02/23/23)
     
  1412. CROI: Susceptibility Screening to bNAbs Teropavimab (GS-5423) and Zinlirvimab (GS-2872) in ART-Suppressed Participants - (02/23/23)
     
  1413. CROI: Low trough concentrations of cabotegravir and rilpivirine in patients infected with HIV switching to long-acting treatment - (02/23/23)
     
  1414. CROI: Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1 - (02/23/23)
     
  1415. CROI: 8+ Year Pooled Analysis: Adherence and HIV Incidence in >6000 Women on F/TDF for PrEP - adherence matters - (02/23/23)
     
  1416. CROI: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy - (02/23/23)
     
  1417. CROI: CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN - (02/23/23)
     
  1418. CROI: The LEVI Syndrome: Characteristics of early HIV infection with cabotegravir for PrEP - (02/23/23)
     
  1419. CROI: CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01) - (02/23/23)
     
  1420. Recorded Webinar and Slides - Taking Global Action Toward Improved Care, Quality of Life, and Empowerment for Older People with HIV - A Webinar
     
  1421. Glasgow: The Glasgow Manifesto International Coalition of Older People with HIV (iCOPe HIV) - (10/26/22)
     
  1422. IAS Recorded Feb 7 webinar - Growing older with HIV in the Treat-All Era
     
  1423. CROI: Cabotegravir Pharmacology in the Background of Delayed Injections in HPTN 084 - (02/22/23)
     
  1424. CROI: PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV - (02/21/23)
     
  1425. CROI: CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD - (02/21/23)
     
  1426. CROI: SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (02/21/23)
     
  1427. CROI: NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV - (02/21/23)
     
  1428. CROI: LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE - (02/21/23)
     
  1429. CROI: Comparison of Telomere Length Changes Over 48 Weeks in SALSA Study: DTG/3TC vs CAR - (02/21/23)
     
  1430. CROI: Six-Month Outcome of F/TAF Cobicistat-Boosted Darunavir in Children 14 to < 25 kg - (02/21/23)
     
  1431. CROI: Population-PK Analysis to Guide Dosing Window Following Lenacapavir SC Administration - (02/21/23)
     
  1432. CROI: SimpliciTB Results and Hepatic Safety of Pretomanid Regimens +/- Pyrazinamide - (02/21/23)
     
  1433. CROI: Editorial - Shortening Tuberculosis Treatment - A Strategic Retreat - (02/21/23)
     
  1434. CROI: Treatment Strategy for Rifampin-Susceptible Tuberculosis - TRUNCATE-TB Trial - (02/21/23)
     
  1435. CROI: STANDARD VERSUS DOUBLE DOSE DOLUTEGRAVIR WITH HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS - (02/21/23)
     
  1436. CROI: MUCOSAL PHARMACOLOGY OF DOXYCYCLINE FOR BACTERIAL STI PREVENTION IN MEN AND WOMEN - (02/21/23)
     
  1437. CROI: Doxy-PEP and antimicrobial resistance in S. aureus, N. gonorrhoeae, and commensal Neisseria - (02/21/23)
     
  1438. CROI: Doxycycline does not prevent STIs among cisgender women - (02/21/23)
     
  1439. CROI: Mortality 1 Year After ICU Admission Falls Over 20 Years in HIV Group - Mark Mascolini (02/20/23)
     
  1440. CROI: Trends in mortality in people living with HIV in an international cohort (RESPOND). - Mark Mascolini (02/20/23)
     
  1441. CROI: PREDICTORS OF HEPATITIS B TREATMENT RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION - (02/20/23)
     
  1442. CROI: Potential impact and efficiency of doxy-PEP among people with or at risk of HIV - (02/20/23)
     
  1443. CROI: One Year of Doxycycline PEP After STI May Prevent 40% of New STIs - Mark Mascolini (02/20/23)
     
  1444. CROI: DOXYCYCLINE POSTEXPOSURE PROPHYLAXIS FOR PREVENTION OF STIs AMONG CISGENDER WOMEN - (02/20/23)
     
  1445. CROI: DoxyPEP and Meningococcal Vax Keep Protecting MSM PrEP Users From STIs - Mark Mascolini (02/20/23)
     
  1446. Aging & Disproportionate disability in people with HIV - (02/20/23)
     
  1447. Long-term evolution of comorbidities and their disease burden in individuals with and without HIV as they age: analysis of the prospective AGEhIV cohort study - (02/19/23)
     
  1448. Alzheimers Blood Markers - Plasma Aβ42/Aβ40 Ratios in Older People Living With Human Immunodeficiency Virus - (02/19/23)
     
  1449. Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy - (02/15/23)
     
  1450. Lingering symptoms common after COVID hospitalization - (02/14/23)
     
  1451. CROI: ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023 - (02/14/23)
     
  1452. CROI: Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 - (02/14/23)
     
  1453. IAS: In Vitro Release and In Vivo PK of Antiretroviral Drugs from Ultra-Long-Acting Polymeric Implants: Towards Better Outcomes for HIV Prevention and Treatment - (02/13/23)
     
  1454. IAS: Biodegradable Polymeric Solid Implants for Ultra-Long-Acting Delivery of Single or Multiple Antiretroviral Drugs - (02/13/23)
     
  1455. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2 - (02/13/23)
     
  1456. Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors - (02/13/23)
     
  1457. Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US - (02/03/23)
     
  1458. Only 36% (1507 of 4171) received any ART regimen during an average of 11.6 months in Nursing Homes in USA - (02/02/23)
     
  1459. US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease - (02/02/23)
     
  1460. Sex and Race Disparities in Mortality and Years of Potential Life Lost Among People With HIV: A 21-Year Observational Cohort Study - (02/02/23)
     
  1461. "no safe amount of alcohol consumption for cancers and health can be established" - (01/30/23)
     
  1462. No level of alcohol consumption is safe for our health - (01/30/23)
     
  1463. Antisense Reduced LPa by 35% to 72% - (01/30/23)
     
  1464. Weight gain during pregnancy among women initiating dolutegravir in Botswana - (01/30/23)
     
  1465. Lenacapavir in first-line therapy - (01/27/23)
     
  1466. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial - (01/27/23)
     
  1467. Diabetic Kidney Disease, HIV, Women - (01/24/23)
     
  1468. NYS Aging HIV RFP May 2022 - People Aging with HIV (PAWH) - (01/24/23)
     
  1469. Exercise Reduced Heart Attacks & All-Cause Mortality - (01/24/23)
     
  1470. HTPN 078: an enhanced case management study to achieve viral suppression among viremic HIV-positive men who have sex with men in the United States; can we reach ETE & 90/90/90 ? - (01/23/23)
     
  1471. kidney disease increases 4-fold in NYC Clinic from <50 to > 75 from 7% to 31%; high Rates Mental & physical of Comorbidities at large NYC HIV clinic - (01/23/23)
     
  1472. Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000-2020: doubling & tripling - (01/23/23)
     
  1473. - (01/23/23)
     
  1474. Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer's Disease (EPAD) cohort - (01/23/23)
     
  1475. The prevalence of mental health disorders (55% and increasing) in people with HIV and the effects on the HIV care continuun - (01/23/23)
     
  1476. Phase 3 Mosaic-Based Investigational HIV Vaccine Study Discontinued Following Disappointing Results of Planned Data Review - (01/18/23)
     
  1477. Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial - (01/18/23)
     
  1478. Immune restoration affects 10-year survival in people living with HIV/AIDS: CD4 >500 & nadir CD4 matter - (01/17/23)
     
  1479. New Anti-Aging Drugs Senolytics & Mitochondria/Aging HIV, Brain/diabetes, Muscles - (01/13/23)
     
  1480. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US - CD4 <350 Increased Risk for Post Vaccine Severe Breakthrough - (01/13/23)
     
  1481. Long COVID Prevalence Outcomes - Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021 - (01/07/23)
     
  1482. Effects of the pandemic on HIV service provision - (01/07/23)
     
  1483. Most Long COVID Cases Started With Mild Symptoms: Study - (01/07/23)
     
  1484. NY sees a 30% spike in COVID deaths in December, most since early 2022 - (01/07/23)
     
  1485. Lecanemab in Early Alzheimer's Disease - (01/07/23)
     
  1486. FDA Grants Accelerated Approval for Alzheimer's Disease Treatment FDA NEWS RELEASE - (01/07/23)
     
  1487. IAS Recorded Feb 7 webinar - Growing older with HIV in the Treat-All Era - (02/09/23)
     
  1488. New ART Lenacapavir Update - FDA Approval - (01/05/23)
     
  1489.  "We can hardly even do it nowadays. So, what's going to happen in 5 years from now, 10 years from now?" The health and community care and support needs and preferences of older people living with HIV in Ontario, Canada: a qualitative study - (01/02/23)
     
  1490.  Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - (01/02/23)
     
  1491. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - (01/02/23)
     
  1492.  SGLT2 Reduced Death, Improved Kidney In Patients with Kidney Disease - Dapagliflozin in Patients with Chronic Kidney Disease - (01/02/23)
     
  1493. SGLT2 Improve Kidney Function - Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials - (01/02/23)
     
  1494. Empagliflozin in Patients with Chronic Kidney Disease - SGLT2 Empagliflozin Slows Kidney Disease - (01/02/23)
     
  1495. POTS, a debilitating heart condition is linked to COVID and to a lesser degree, vaccines - (01/02/23)
     
  1496. Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe - (12/29/22)
     
  1497. New Variant in NY - Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster - (12/29/22)
     
  1498. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial - (12/29/22)
     
  1499. FDA Product Insert - Sunlenca (lenacapavir) Receives FDA Approval - (12/29/22)
     
  1500. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster - (12/22/22)
     
  1501. Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV - (12/22/22)
     
  1502. New PrEP HRSA RFP   - (12/22/22)
     
  1503. FDA Approves New HIV Drug for Adults with Limited Treatment Options - (12/22/22)
     
  1504. 30 European HIV Specialists Review Aging/HIV Challenges, Recommendations - (12/19/22)
     
  1505. CD4/CD8 Ratio & Cancer Risk in PWH - (12/19/22)
     
  1506. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients - (12/15/22)
     
  1507. ViiV HEALTHCARE ANNOUNCES CHMP POSITIVE OPINION FOR TRIUMEQ PD, THE FIRST DISPERSIBLE SINGLE TABLET REGIMEN CONTAINING DOLUTEGRAVIR, A ONCE-DAILY TREATMENT FOR CHILDREN LIVING WITH HIV IN EUROPE - (12/15/22)
     
  1508. Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir Alafenamide - (12/15/22)
     
  1509. Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG - (12/15/22)
     
  1510. Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review - (12/14/22)
     
  1511. NYS AIDS Institute Aging & HIV 2022 - (12/14/22)
     
  1512. My Brain Fog; What is Brain Fog ? - (12/14/22)
     
  1513. Two-drug regimens for HIV treatment - (12/13/22)
     
  1514. Accelerated or Premature Aging & Comorbidities for PLWH & The Need To Fix Healthcare - (12/12/22)
     
  1515. Depression and Sexual Stigma Are Associated With Cardiometabolic Risk Among Sexual and Gender Minorities Living With HIV in Nigeria - (12/12/22)
     
  1516. Physician Reimbursement and Retention in HIV Care: Racial Disparities in the US South - (12/12/22)
     
  1517. CROI-2016 - Neurotoxicity Screening of Antiretroviral Drugs With Human iPSC-Derived Neurons - (12/12/22)
     
  1518. 20 Minutes Daily exercise at age 70 may reduce heart disease risk - (12/12/22)
     
  1519. New PrEP Studies - Lenacapavir; Adolescent Girls, Young Women - (12/12/22)
     
  1520. Update on Gilead's HIV Prevention Trials - (12/12/22)
     
  1521. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP) - (12/12/22)
     
  1522. Integrase Inhibitors Uniquely Target Thermogenesis In Brown Adipocytes And Combination Drugs Potentiate These Effects, Complications Workshop - (12/12/22)
     
  1523. Comparison of Recency Assays to Estimate HIV Incidence in the SIENA (Estimating HIV Incidence Among AGYW) Study in Uganda - (12/12/22)
     
  1524. Neurotoxicity Screening of Antiretroviral Drugs With Human iPSC-Derived Neurons CROI 2016 - (12/12/22)
     
  1525.  Dolutegravir and bictegravir-induced fat and adipocyte damage as a consequence of hypoxia-inducible factor 1 (HIF-1)-a activation. - (12/12/22)
     
  1526. Dolutegravir-containing HIV therapy reversibly alters mitochondrial health and morphology in cultured human fibroblasts and peripheral blood mononuclear cells - (12/09/22)
     
  1527. Prevalence and risk factors of frailty among adults living with HIV aged 70 years or older - (12/09/22)
     
  1528. Glasgow: Comparison of HIV Incidence as Determined by Different Recency Assays in Ugandan Women - (12/08/22)
     
  1529. Diabetes & HIV - Glucose Intolerance in Persons with HIV is Characterized by Subcutaneous Adipose Tissue Enriched For Lipid-processing Macrophages And Effector Memory T Cells With Discrete Transcriptional Phenotypes (Complications Workshop) - (12/07/22)
     
  1530. CHANGE IN BODY WEIGHT AFTER THE TRANSITION TO DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY, (COMPLICATIONS WORKSHOP) - (12/07/22)
     
  1531. Prevalence, incidence and risk factors for sarcopenic obesity in people with HIV, (Complications Workshop) - (12/07/22)
     
  1532. New HIV Guidelines IAS-USA Panel; Aging, Weight - (12/01/22)
     
  1533. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens - (12/01/22)
     
  1534. Higher epicardial fat in older adults living with HIV with viral suppression and relationship with liver steatosis, coronary calcium and cardiometabolic risks - (12/01/22)
     
  1535. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms - (12/01/22)
     
  1536. New HIV Drugs Include the LAI CAB+RPV & Lenacapavir, Merck restart of studying Islatravir, plus below I have included recent new study results from these therapies and Fostemsavir, the 2 drug combination of Dolutegravir/3TC, and 5-year update of Biktarvy (Bictegravir/TAF/3TC) - (12/01/22)
     
  1537. ViiV Healthcare unveils a new global study revealing three quarters of people believe there are still negative perceptions when it comes to people living with HIV - (12/01/22)
     
  1538. Elderly & Older PLWH Need New Standard of Care in Clinic & Support Social Services - (11/28/22)
     
  1539. The HIV healthcare system has ignored Aging Issues That Are Coming Back to Haunt Elderly PLWH Who Have Been Abandoned - (11/28/22)
     
  1540. NYS People Aging with HIV (PAWH) Pilot (NYC too) - (11/21/22)
     
  1541. Glasgow: Efficacy and Safety of Switching to Dolutegravir Plus Rilpivirine in Virologically Suppressed Older PLWH: Pooled Week 148 Results From SWORD-1 and SWORD-2 - (11/17/22)
     
  1542. Glasgow: Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in Black and Asian Participants From TANGO and SALSA: Pooled 48-Week Data Analyzed by Race - (11/17/22)
     
  1543. Glasgow: Effectiveness of Dolutegravir + Lamivudine in Real-world Studies in People With HIV-1 With M184V/I Mutations: A Systematic Review and Meta-analysis - (11/17/22)
     
  1544. Glasgow: Risk of tuberculosis after initiation of antiretroviral therapy among people living with HIV in Europe - (11/17/22)
     
  1545. Glasgow: Treatment-Emergent Integrase Inhibitor Resistance Among Pediatric and Adolescent Populations With HIV-1: A Systematic Review - (11/17/22)
     
  1546. Glasgow: Real-world Experience With the 2-Drug Regimen Dolutegravir and Lamivudine in Women With HIV: A Systematic Literature Review - (11/17/22)
     
  1547. Glasgow: Initial plasma HIV-1 RNA and CD4+ T-cell count are determinants of virological outcomes with initial integrase inhibitor-based regimens: a prospective multinational RESPOND cohort consortium - (11/17/22)
     
  1548. Food Insecurity Is Associated with Key Functional Limitations and Depressive Symptoms in Older People Living with HIV - (11/15/22)
     
  1549. Press Release: Older people living with HIV cannot be ignored and must NOT be left behind - (11/14/22)
     
  1550. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges (PrEP) - (11/14/22)
     
  1551. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges (PrEP) - (11/14/22)
     
  1552. Evidence for "substantial" monkeypox transmission before symptoms - (11/10/22)
     
  1553. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease - (11/10/22)
     
  1554. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection - (11/10/22)
     
  1555. Glasgow: Risk Factors Associated With ≥ ±10% Weight Change in Treatment-Naïve and Treatment-Experienced People Living With HIV Initiating or Switching to an NNRTI- or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies - (11/07/22)
     
  1556. CDC Update: Monkeypox and HIV - (11/02/22)
     
  1557. HHS renews public health emergency for monkeypox outbreak - (11/02/22)
     
  1558. ID Week: Single-Tablet Regimens (STR) Offer Better Persistence and Adherence, With Lower Costs by Adherence Status, Than Multiple-Tablet Regimens (MTR) for People Living With HIV (PLWH) Enrolled in Medicaid - (11/02/22)
     
  1559. Glasgow: An Increase in Single-Tablet Regimen (STR) Utilization for People Living With HIV (PLWH) Enrolled in Medicaid Had Minimal Impact on Pharmacy Costs - (11/02/22)
     
  1560. Glasgow: ART Regimen Persistence Among Treatment-Experienced Patients With HIV Switching to a MTR or STR Since 2018 - (11/02/22)
     
  1561. Glasgow: Real-world Effectiveness And Tolerability Of Dolutegravir- Based Two-drug Regimens - (11/02/22)
     
  1562. Glasgow: Resolution of neuropsychiatric adverse events after switching to a doravirine-based regimen in the open-label extensions of the DRIVE-AHEAD and DRIVE-FORWARD trials - (11/02/22)
     
  1563. Glasgow: Effectiveness of switching to DOR-based antiretroviral therapy (ART) under real-world conditions in Germany - (11/02/22)
     
  1564. Glasgow: New-onset Diabetes in Persons With HIV on BIC/FTC/TAF in Real-World Clinical Practice - (11/02/22)
     
  1565. Glasgow: Virologic Failure Rate 1.4% in 3 Years of CAB + RPV Phase 3 Trials: Pre-existing RPV Resistance, CAB and RPV Troughs Predict Failure - Mark Mascolini (11/01/22)
     
  1566. Glasgow: Single Infusion of VH3810109 bNAb Controls HIV at Two Doses - Mark Mascolini (11/01/22)
     
  1567. Glasgow: Factors Associated With Weight Loss or Stable Weight After Continuing or Switching to a Doravirine-Based Regimen - (11/01/22)
     
  1568. Glasgow: Metabolic and hepatic safety in ART experienced PLWH switching to a DOR-based regimen vs rilpivirine. Data from a real-life setting - (11/01/22)
     
  1569. Glasgow: Long-term Efficacy and Resistance Analyses of D/C/F/TAF in the Phase 3 AMBER and EMERALD Studies: Post 96-week Data - (11/01/22)
     
  1570. Glasgow: Drug-Related Neuropsychiatric Adverse Events Across Phase 3/3b Studies of Long-Acting Cabotegravir + Rilpivirine Through Week 48 - (11/01/22)
     
  1571. Glasgow: HIV-1 RNA Blips, Low-Level Viral Replication, and Mean CD4+/CD8+ Ratio During Phase 3/3b Cabotegravir + Rilpivirine Long-Acting Studies Up to 152 Weeks of Therapy - (11/01/22)
     
  1572. Glasgow: Effects of the HIV-1 Maturation Inhibitor GSK3640254 on QT Interval in Healthy Participants - (11/01/22)
     
  1573. Glasgow: Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study - (11/01/22)
     
  1574. Glasgow: Fostemsavir and QT Prolongation: Clinical Applications for Co-administration With Other Agents - (10/31/22)
     
  1575. Glasgow: A Multivariate Analysis of the Phase 3 BRIGHTE Trial, Through Week 24, to Identify Predictors of Virologic Response to Fostemsavir in Heavily Treatment-Experienced People Living With HIV - (10/31/22)
     
  1576. Glasgow: Adverse birth outcomes and risk of MTCT for dolutegravir versus efavirenz in 5 randomised trials of 1074 pregnant women - (10/31/22)
     
  1577. Glasgow: DTG Superior or Noninferior to PI/r After NNRTI Failure: Meta-Analysis of 4 Trials in Africa: VISEND, DAWNING, NADIA, 2SD - Mark Mascolini (10/31/22)
     
  1578. Glasgow: Obesity Risk Higher With DTG Than Other Regimens in 3 Big African Trials - ADVANCE, NAMSAL, VISEND - Mark Mascolini (10/31/22)
     
  1579. Glasgow: DTG Better Than PI or EFV for Resuppression of HIV After Apparent Virologic Failure in 4 African Trials - Mark Mascolini (10/31/22)
     
  1580. Glasgow: UK Survey: Monkeypox Vax Highly Acceptable, but Less Agreement on Public Health Measures - Mark Mascolini (10/31/22)
     
  1581. Glasgow: Low COVID Mortality in HIV+ Europeans Similar to General Population- COVID Testing Tied to Younger Age, Female Gender, CVD and TDF - Mark Mascolini (10/31/22)
     
  1582. Glasgow: Prevalence, risk factors and the impact of antiretroviral treatment in SARS-CoV-2 infection in people with HIV: A cross-sectional study - Mark Mascolini (10/31/22)
     
  1583. Glasgow: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and Late Diagnosis in a Multi-Country Cohort Study - (10/31/22)
     
  1584. Glasgow: Patient-Reported Outcomes After 152 Weeks of HIV Maintenance Therapy With Long-Acting Cabotegravir + Rilpivirine in the Phase 3b ATLAS-2M Study - (10/31/22)
     
  1585. Glasgow: Severity of Some Multimorbidity Clusters on the Rise in People With HIV - Mark Mascolini (10/31/22)
     
  1586. Glasgow: Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy for the Treatment of People Living With HIV With a Range of Comorbidities - (10/29/22)
     
  1587. EUROPEAN MEDICINES AGENCY VALIDATES ViiV HEALTHCARE'S MARKETING AUTHORISATION APPLICATION FOR CABOTEGRAVIR LONG-ACTING INJECTABLE FOR HIV PREVENTION - (10/28/22)
     
  1588. Glasgow: Perceptions of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) From Patients in the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/28/22)
     
  1589. Glasgow: Rapid ART Initiation Using B/FTF and TDF+3TC+EFV in HIV+ Patients in China - (10/28/22)
     
  1590. Glasgow: Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure Over 152 Weeks - (10/28/22)
     
  1591. Glasgow: 6-Month Outcomes of Every 2 Months Long-Acting Cabotegravir and Rilpivirine in a Real-World Setting - Effectiveness, Adherence to Injections, and Patient- Reported Outcomes of People Living With HIV in the German CARLOS Cohort - (10/28/22)
     
  1592. Glasgow: Impact of switch to 3TC/dolutegravir on the intact and total HIV-1 viral reservoir in the Rumba Study - (10/28/22)
     
  1593. Glasgow: Durable Efficacy of Switching From a 3-/4-Drug Tenofovir Alafenamide (TAF)-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine (DTG/3TC) in the TANGO Study Through Week 196 - (10/28/22)
     
  1594. Glasgow: Total Lymphocyte and lymphocyte subset changes in participants receiving islatravir (0.25, 0.75, and 2.25 QD) and doravirine (DOR) +/- lamivudine (3TC): post-hoc analysis from a phase 2b dose-ranging study (P011) - (10/28/22)
     
  1595. Glasgow: Modeling and Simulation to Optimize Islatravir Once Daily (QD) Doses in HIV Treatment Naive and Virologically Suppressed Populations - (10/28/22)
     
  1596. Glasgow: HIV Doubles Death Risk in National French Comparison With Matched Controls - Mark Mascolini (10/28/22)
     
  1597. Glasgow: External validation of the Dat'AIDS score for predicting 5-year mortality among elderly people living with HIV in the Swiss HIV Cohort Study - (10/28/22)
     
  1598. Glasgow: Common Adverse Events in Clinical Studies of People Using Lenacapavir for HIV Treatment - (10/28/22)
     
  1599. Glasgow: Patient-Reported Symptom Outcomes Following DTG/3TC Use in a Test-and-Treat Setting: Results From the STAT Study - (10/28/22)
     
  1600. Glasgow: 2-Year Outcomes of Dolutegravir (DTG) and Lamivudine (3TC) in Art-Naive and Pre-treated People Living With HIV in Germany: Real-world Data From the German URBAN Cohort - (10/28/22)
     
  1601. Glasgow: Age-Related Differences in Quality-of-Life Outcomes of People Living With HIV - (10/28/22)
     
  1602. Glasgow: Outcomes After Switching From 144 Weeks of Blinded DTG/ABC/3TC to 96 Weeks of Open-label B/F/TAF - (10/28/22)
     
  1603. Glasgow: Low Use of Preventive CVD Measures - Use of Preventive Measures for Cardiovascular Disease in People Living with HIV - (10/28/22)
     
  1604. Glasgow: High Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Naive Adults With HIV-1 and High Baseline Viral Load (VL): 48-Week Subgroup Analyses of the GEMINI-1/-2 and STAT Trials - (10/28/22)
     
  1605. Glasgow: Older people with well-controlled HIV have similar antibody and higher T-cell responses after vaccination against SARS-CoV-2 compared to demographically and lifestyle-comparable people without HIV - Mark Mascolini (10/28/22)
     
  1606. Glasgow: ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV - (10/28/22)
     
  1607. Glasgow: Laboratory analysis of HIV infections in the year 1 unblinded period of HPTN 083: injectable cabotegravir for PrEP in MSM and TGW - (10/28/22)
     
  1608. Glasgow: Patterns of Doravirine Use in a US Cohort - (10/27/22)
     
  1609. Glasgow: Real World Utilisation of Doravirine Among People Living With HIV in England (DRIVE-REAL) - (10/27/22)
     
  1610. Glasgow: Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study) - (10/27/22)
     
  1611. Glasgow: Overcoming Barriers and Achieving Optimal Implementation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA): Staff Study Participant (SSP) Results From the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/27/22)
     
  1612. Glasgow: Implementation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA): Primary Results From the CAB + RPV Implementation Study in European Locations (CARISEL) - (10/27/22)
     
  1613. Glasgow: ViiV HEALTHCARE PRESENTS POSITIVE DATA SHOWING VOCABRIA (CABOTEGRAVIR) AND REKAMBYS (RILPIVIRINE) CAN BE SUCCESSFULLY IMPLEMENTED ACROSS A RANGE OF EUROPEAN HEALTHCARE SETTINGS - (10/27/22)
     
  1614. Glasgow: The Glasgow Manifesto International Coalition of Older People with HIV (iCOPe HIV) - (10/26/22)
     
  1615. ID Week: Screening for Hepatitis C as Part of an Opioid Stewardship Initiative: Identifying Infected Patients and Analyzing Linkage to Care - (10/26/22)
     
  1616. ID Week: A Case Series of Lo-Level HBV Viremia After Switching to Long-Acting Injectable Cabotegravir/Rilpivirine in Patients with HIV, Hepatitis B Core Antibody Positivity, and Hepatitis B Surface Antigen Negativity - (10/26/22)
     
  1617. ID Week: Switching to an Integrase Inhibitor Tied to Liver Fibrosis Score in US Women - Mark Mascolini - (10/25/22)
     
  1618. ID Week: On-Demand and Long-Acting PrEP Both Stir Interest in US Survey of MSM - Mark Mascolini (10/25/22)
     
  1619. ID Week: High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/25/22)
     
  1620. ID Week: B/F/TAF for 48 Weeks in US Group With Substance Use and Other Challenges - Mark Mascolini (10/25/22)
     
  1621. ID Week: CAB + RPV LA in Europe: HIV Control in 87% With Standard or Enhanced Support - Mark Mascolini (10/25/22)
     
  1622. ID Week: Ivermectin, Fluticasone, Fluvoxamine Can't Beat Placebo for Mild/Moderate COVID - Mark Mascolini (10/25/22)
     
  1623. ID Week: Postacute COVID Less Common in US Youth Than Reported Earlier - Mark Mascolini (10/25/22)
     
  1624. ID Week: Age, Immune Conditions, Comorbidities Drive Severe COVID Risk After Vaccination - Mark Mascolini (10/25/22)
     
  1625. ID Week: In Big US HIV Group, Hispanics, Blacks, Southerners, Overweight Run Higher COVID Risk - Mark Mascolini (10/25/22)
     
  1626. ID Week: Impaired Fitness Peaks 1 Month After COVID Onset but May Persist 12 Months - Mark Mascolini (10/25/22)
     
  1627. ID Week: CAB + RPV LA in Europe: HIV Control in 87% With Standard or Enhanced Support - Mark Mascolini (10/24/22)
     
  1628. ID Week: On-Demand and Long-Acting PrEP Both Stir Interest in US Survey of MSM - Mark Mascolini (10/24/22)
     
  1629. ID Week: Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race - (10/24/22)
     
  1630. ID Week: B/F/TAF an Effective and Safe Switch for HIV/HBV: 24-Week Results - Mark Mascolini (10/24/22)
     
  1631. ID Week: Lenacapavir: 75% Sub-50 Response at 52 Weeks Despite Heavy ART Experience - Mark Mascolini (10/24/22)
     
  1632. ID Week: High Exposure to Antilipid Drugs Tied to Lower Mortality in Older HIV Group - Mark Mascolini (10/24/22)
     
  1633. ID Week: Some "Excess Risk" of Delayed ART in START Trial Persists for Years - (10/24/22)
     
  1634. ID Week: HIV, Dementia, Cognitive Concerns Tied to Death in COVID Patients - (10/24/22)
     
  1635. ID Week: CARISEL: A Hybrid Type III Implementation Effectiveness Study of Implementation of Cabotegravir + Rilpivirine Long-Acting (CAB + RPV LA) in European Health Care Settings; Key Clinical and Implementation Outcomes by Implementation Arm - (10/24/22)
     
  1636. ID Week: 76% of PLWH >50 Report Suboptimal Health - Clinical and Sociodemographic Characteristics Associated With Poor Self-rated Health Across Multiple Domains Among Older North American Adults Living With HIV - (10/24/22)
     
  1637. ID Week: Factors Associated with Viremia in Transgender Individuals Living with HIV - (10/24/22)
     
  1638. ID Week: Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year - (10/24/22)
     
  1639. ID Week: Update on PrEP Knowledge and Attitudes Among Adults Attending Public Health Clinics in Southern Arizona - (10/24/22)
     
  1640. ID Week: Life-years Gained among non-Hispanic Black and White Men who have Sex with Men in the United States with Improvements in the HIV Care Continuum A Simulation Modeling Study - (10/24/22)
     
  1641. ID Week: Relative patient preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among US men who have sex with men, 2021-2022 - (10/24/22)
     
  1642. ID Week: PrEP Awareness and Use among Reproductive Age Women in Miami, Florida - (10/23/22)
     
  1643. ID Week: PrEP Interest and Preferences Among US Black and Hispanic Men - A 2021 National Survey - (10/23/22)
     
  1644. ID Week: Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir and Lamivudine in People With HIV Who Would Not Have Met Inclusion Criteria for the Phase 3 Clinical Program - (10/23/22)
     
  1645. ID Week: Awareness and Interest in PrEP Options Among US Cisgender Women - A National Survey - (10/23/22)
     
  1646. ID Week: High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/23/22)
     
  1647. ID Week: Awareness and Interest in PrEP Options Among US Cisgender Women - A National Survey - (10/23/22)
     
  1648. ID Week: High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/23/22)
     
  1649. ID Week: A Real-World Observational Study on Patients With HIV Who Switched From Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada - (10/23/22)
     
  1650. ID Week: Durability and effectiveness of fostemsavir in heavily treatment-experienced people with HIV - (10/23/22)
     
  1651. ID Week: Effectiveness and Durability of Dolutegravir (DTG) Based Regimens in Older People Living With HIV (PLWH) From the Veterans Aging Cohort Study (VACS) - (10/23/22)
     
  1652. ID Week: Real-world Treatment Experience of Single-tablet Dolutegravir/Lamivudine in those Naïve to Treatment with Baseline Viral Loads ≥100,000 copies/mL the United States - (10/23/22)
     
  1653. ID Week: Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens - (10/23/22)
     
  1654. ID Week: Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People With Multi-Drug Resistant HIV: Week 52 Results - (10/23/22)
     
  1655. ID Week: Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects - (10/23/22)
     
  1656. ID Week: Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects - (10/23/22)
     
  1657. ID Week: Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022 - (10/23/22)
     
  1658. ID Week: Real-world Treatment Experience of Treatment-naïve People Living with HIV who Initiated Treatment with Single-tablet Dolutegravir/Lamivudine in a Test and Treat Setting in the United States - (10/23/22)
     
  1659. ID Week: Real-world Geographic Variations of HIV Diagnosis Rates Among Individuals Prescribed and Not Prescribed Oral HIV Pre-Exposure Prophylaxis Regimens in the United States - (10/23/22)
     
  1660. ID Week: Estimated Background HIV Diagnosis Rates Among People Who Could Benefit From Pre-Exposure Prophylaxis at the Metropolitan Statistical Area Level in the United States, 2012-2019 - (10/23/22)
     
  1661. ID Week: Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ≥65 Years: Pooled Results From the TANGO and SALSA Studies - (10/23/22)
     
  1662. ID Week: 76% >50 PLWH Report Suboptimal Mental, Physical Health- Clinical and Sociodemographic Characteristics Associated With Poor Self-rated Health Across Multiple Domains Among Older North American Adults Living With HIV - (10/23/22)
     
  1663. ID Week: 5-Year Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Treatment of HIV-1 in Adults With High Baseline HIV-1 RNA and/or Low CD4 Count in Two Phase 3 Randomized Clinical Trials - (10/23/22)
     
  1664. AGE: Brief Summary, Highlights- 13th Intl Aging & HIV Workshop - (10/20/22)
     
  1665. AGE: Brief Evaluation of Cognitive Impairment and IADL Among Art-Treated People With HIV in a Primary Care Setting - (10/19/22)
     
  1666. AGE: Frontostriatal white matter microstructure alterations in HIV and aging - (10/19/22)
     
  1667. AGE: TENOFOVIR ALAFENAMIDE IS ASSOCIATED WITH SHORTER TELOMERE LENGTH IN PEOPLE WITH HIV - (10/18/22)
     
  1668. AGE: "CD38 is a potential therapeutic target for mitigating chronic inflammation that likely drives cellular aging, comorbidities, and end organ disease in PWH." - (10/18/22)
     
  1669. AGE: Persistent CD38 expression on CD8+ T lymphocytes contributes to chronic inflammation in people with HIV, despite ART - (10/18/22)
     
  1670. AGE: Glucose Changes Among Aging Female PWH in Southeast United States - (10/18/22)
     
  1671. AGE: Aging Accelerates Brain Metabolic Abnormalities in HIV Clade-C Infected Young Adults - (10/18/22)
     
  1672. AGE: DTI and DKI Markers of Brain Microstructural Integrity Show Similar Aging Between HIV Clade-C Infected and Healthy Young Adults - (10/18/22)
     
  1673. AGE: Prevalence of Anal Human Papillomavirus and High-Grade Squamous Intraepithelial Lesions Among Men Who Have Sex With Men Ages 50+ - (10/18/22)
     
  1674. AGE: Non-White & Low Income HIV+ Women Take Less Vitamin D: Rates of Vitamin D Supplementation and Barriers to Uptake Among Women Living with and Without HIV In Canada - (10/18/22)
     
  1675. AGE: Comparing a Novel Virtual Reality Assessment Device, DETECT, to Best-Practices in Assessing HIV-Associated Cognitive Impairment and Mild Cognitive Impairment - (10/18/22)
     
  1676. AGE: Post COVID Frailty Reversible: Frailty transitions in people with post-acute COVID syndrome - (10/18/22)
     
  1677. AGE: Mortality among adult PLHIV in all PEPFAR-supported countries and regions-, October 2019-June 2022 - (10/17/22)
     
  1678. AGE: Aging/HIV: Early interruptions in treatment among PLHIV over 50 years of age starting antiretroviral therapy in PEPFAR-supported low and middle-income countries - (10/17/22)
     
  1679. AGE: Social support network factors linked to neuropsychological-verbal performance among disadvantaged persons living with HIV who use drugs - (10/17/22)
     
  1680. AGE: Aging and HIV: What Is the Gap Between Clinical Practice and Guideline Recommendations? In Europe - (10/17/22)
     
  1681. AGE: Prevalence of Geriatric Syndromes, Frailty and Comorbidities and their Association with Quality of Life in Older Adults with HIV in the Spanish FUNCFRAIL Cohort. - (10/17/22)
     
  1682. AGE: Needs and Involvement of HIV Specialists and Geriatricians in the Care of Older Adults with HIV - A National Survey - (10/17/22)
     
  1683. AGE: e-SMART/EST Telehealth Intervention to Reduce Depression in Older Women with HIV - (10/17/22)
     
  1684. AGE: An Exploration of the Role of Intersectional Stigma and Discrimination on Cardiovascular Risk, among Aging Women with HIV - (10/17/22)
     
  1685. AGE: New York State AIDS Institute Initiatives to Improve Care For Older People With HIV and Long-Term Survivors: An Example of a Government-Academic-Community Partnership - (10/17/22)
     
  1686. AGE: Exploring Experiences Engaging in Exercise from the Perspectives of Women Living with HIV: a Qualitative Study - Barriers, Challenges - (10/17/22)
     
  1687. AGE: Hormonal Intervention Combined with Allopregnanolone Alleviates Premature Age-Related Comorbidities in Female Mice Exposed to Ovarian Failure and HIV-1 Tat - (10/17/22)
     
  1688. AGE: Physical frailty among older HIV-positive and HIV-negative women in Mombasa, Kenya: A cross-sectional study - (10/17/22)
     
  1689. AGE: 50% Frail or Pre-Frail in Uganda: Risk Factors for Frailty in a Geriatric Cohort on Long Term Antiretroviral Treatment in Uganda - (10/17/22)
     
  1690. AGE: Frailty & Hospitalization Associated at Kaiser - Evaluation of an electronic health record-based frailty index in people with and without HIV in a primary care setting - (10/17/22)
     
  1691. AGE: Frailty and physical performance assessments as part of a comprehensive geriatric care model in an urban HIV clinic: 73% Pre-frail or Frail 50% Weak - (10/17/22)
     
  1692. AGE: Physical Functioning in Older Adults with HIV - 80% Impaired Physical Function in Baltimore Clinic SPBB & IADL Measured - (10/17/22)
     
  1693. AGE: Gaps in HIV Care Cascade for Older South Africans Raise Concern - Mark Mascolini - (10/15/22)
     
  1694. AGE: Clinical Care Priorities and Service Needs Among People Aging with HIV in the Bronx, NY - (10/15/22)
     
  1695. AGE: Assessing the Impact of HIV Status and Menstrual Abnormalities on Longitudinal Bone Density Loss in Women Living With and Without HIV - (10/15/22)
     
  1696. AGE: Overlap Between Cognitive and Physical Frailty in Persons with HIV - (10/15/22)
     
  1697. AGE: Aging, HAND & Alzheimers -Alzheimers pathology?? - (10/15/22)
     
  1698. AGE: Increasing Neuroinflammation in People With HIV Tied to Worse Neurodegeneration - Mark Mascolini - (10/15/22)
     
  1699. AGE: More Than Half of Kampala ART Responders Are Prefrail or Frail - Mark Mascolini - (10/15/22)
     
  1700. AGE: Use of Senolytics: Anti-Aging Drugs; in PLWH Study - (10/14/22)
     
  1701. AGE: Three Quarters of Spanish Geriatricians Uncomfortable With HIV Patients - Mark Mascolini - (10/14/22)
     
  1702. AGE: Survey in Italy Finds Lack of Special Care for Elderly With HIV - Mark Mascolini - (10/14/22)
     
  1703. AGE: Polypharmacy, Anxiety, Low Cognitive Score Tied to Frailty With HIV - Mark Mascolini - (10/14/22)
     
  1704. AGE: NRTIs Do Not Protect Against Alzheimer-Type Amyloidosis - Mark Mascolini - (10/14/22)
     
  1705. AGE: Critical Physical Function Loss in Three Quarters of Over-50 HIV Group - Mark Mascolini - (10/14/22)
     
  1706. AGE: Lower Verbal Fluency Tied to Poor Social Support in HIV+ Drug Users - Mark Mascolini - (10/13/22)
     
  1707. AGE: Standard Integrase Regimens Have Minimal Glucose Impact in Older Black Women - Mark Mascolini - (10/13/22)
     
  1708. AGE: Frailty Rate Falls Over Time During Postacute COVID Syndrome - Mark Mascolini - (10/13/22)
     
  1709. AGE: Heart Disease, HCV, Poverty, Early-Life Stress Tied to Brain Aging With HIV - Mark Mascolini - (10/13/22)
     
  1710. AGE: Depression Tied to Noncommunicable Disease Rate in People With HIV - Mark Mascolini - (10/13/22)
     
  1711. AGE: Hyperactivated CD38 Cells Higher With HIV and May Drive Chronic Inflammation - Mark Mascolini - (10/13/22)
     
  1712. AGE: People Over 50 Face High Risk of ART Suspension in First Months: PEPFAR - Mark Mascolini - (10/13/22)
     
  1713. FDA Approves Trogarzo for 30-Second IV Push, Simplifying HIV Treatment for Heavily Treatment-Experienced People - (10/13/22)
     
  1714. ViiV HEALTHCARE TO SHOWCASE INNOVATIVE HIV TREATMENT AND PREVENTION PORTFOLIO AT IDWEEK™ AND HIV GLASGOW - (10/11/22)
     
  1715. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial - (10/11/22)
     
  1716. Weightlifting & Aerobics Reduce Mortality Independently, Together Better - (10/11/22)
     
  1717. What It Means to Age With HIV Infection Years Gained Are Not Comorbidity Free - (10/11/22)
     
  1718. Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study - (10/11/22)
     
  1719. Severe Manifestations of Monkeypox among People who are Immunocompromised Due to HIV or Other Conditions - (10/06/22)
     
  1720. CDC warns of severe illnesses from monkeypox as Ohio reports death of a monkeypox patient - (10/06/22)
     
  1721. CDC- Future MPX Trajectory - (10/06/22)
     
  1722. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection - (10/06/22)
     
  1723. Projected Impact of Expanded Long-Acting Injectable PrEP Use Among Men Who Have Sex With Men on Local HIV Epidemics - (10/06/22)
     
  1724. Provision of HIV pre-exposure prophylaxis to female patients seeking family planning services in the United States - (10/06/22)
     
  1725. HIV and Cardiac End-Organ Damage in Women: Findings from an Echocardiographic Study Across the United States - (10/06/22)
     
  1726. Earlier menopause is associated with higher risk of incident frailty in community-dwelling older women in England - (10/03/22)
     
  1727. Lenacapavir: a first-in-class HIV-1 capsid inhibitor - (10/03/22)
     
  1728. A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117 - (10/03/22)
     
  1729. Causes and outcomes of hepatic fibrosis in persons living with HIV - (10/03/22)
     
  1730. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review - 2017 - (09/30/22)
     
  1731. Exciting New Alzheimer's Treatment Study Results - (09/28/22)
     
  1732. Brain Decline & Frailty in PLWH - (09/28/22)
     
  1733. Unraveling the mechanisms of HIV-induced hearing loss - (09/27/22)
     
  1734. (Fibroscan) Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis [with NASH] - (09/27/22)
     
  1735. Two Cases of Monkeypox-Associated Encephalomyelitis - Colorado and the District of Columbia, July August 2022 - (09/26/22)
     
  1736. Dementia Care, Screening Awareness Needs Attention. PLWH are at Risk - World Alzheimers Report - (09/22/22)
     
  1737. Aging in PLWH Increased Heart Attack Risk by 30% per Decade/BUT by 85% if HCV+ - (09/22/22)
     
  1738. Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection - (09/20/22)
     
  1739. NYC Daily New Cases Monkeypox as of 9/13/22 - (09/19/22)
     
  1740. The Future of Monkeypox- Cases in the US Are Falling. There's No One Reason Why - (09/19/22)
     
  1741. CDC opening applications for Monkeypox Vaccine Equity Pilot Program - (09/19/22)
     
  1742. CDC/IDSA Monkeypox: Sept 10 - Clinical Illness; Transmission; US & Global Case Count & Trends; Race/Ethnicity Characteristics - (09/19/22)
     
  1743. New CDC guidance: Only high-risk groups should get monkeypox antiviral - (09/19/22)
     
  1744. TPOXX Resistance Risk Guidance for Tecovirimat Use Under Expanded Access Investigational New Drug Protocol during 2022 U.S. Monkeypox Outbreak - (09/19/22)
     
  1745. 2 Press Briefings by White House Monkeypox Response Team and Public Health Officials - (09/19/22)
     
  1746. New York Announces Thousands of Additional Monkeypox Vaccine Doses - Where/How to Get Vaccine in NYC - (09/19/22)
     
  1747. 50,000 monkeypox vax appointments-NYC online Friday - (09/17/22)
     
  1748. CDC opening applications for Monkeypox Vaccine Equity Pilot Program - (09/17/22)
     
  1749. Monkeypox Vac Expanded Eligibility in New York - Sex Workers - (09/16/22)
     
  1750. The Impact of Frailty on All-Cause Mortality in Patients with HIV Infection: A Systematic Review and Meta-Analysis - (09/14/22)
     
  1751. Dying at Home Due to Coronavirus Disease 2019 - (09/14/22)
     
  1752. CDC TPOXX Study Results Monkeypox Treatment - (09/13/22)
     
  1753. Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus - (09/12/22)
     
  1754. Hormone therapy and fractures [VMS] in postmenopausal women - (09/12/22)
     
  1755. Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus - (09/12/22)
     
  1756. Monkeypox Treatment & Prophylaxis in PLWH; NIAID STOMP TPOXX Study - (09/12/22)
     
  1757. Paxlovid Outcomes during the Omicron Surge in Israel- Young vs Old - (09/09/22)
     
  1758. NIH Monkeypox Vaccine Study Evaluating Dose Reductions of MVA-BN - (09/09/22)
     
  1759. Obamacare can't require coverage for some HIV drugs, federal judge rules Texas judge rules HIV [PrEP] drug mandate violates religious freedom - (09/09/22)
     
  1760. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients - (09/03/22)
     
  1761. Prevalence and risk factors for falls and fall-related injuries in the 2018 National Post-acute and Long-term Care Study (25%) & for PLWH - (09/02/22)
     
  1762. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States - (09/02/22)
     
  1763. Compassionate Use [treatment results] of Tecovirimat for the Treatment of Monkeypox Infection - (08/31/22)
     
  1764. Nearly 40% of older adult brains studied showed signs of LATE pathology - (08/31/22)
     
  1765. Failure to Address Aging in New NHAS Strategy Implementation Plan - (08/31/22)
     
  1766. Social stress contributes to accelerated aging of the immune system, study finds - (08/31/22)
     
  1767. FDA Memo Monkeypox Dose Vaccine - JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non- replicating) - (08/30/22)
     
  1768. Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply - (08/30/22)
     
  1769. Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding - (08/30/22)
     
  1770. Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing antiretroviral therapy - (08/30/22)
     
  1771. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I - (08/30/22)
     
  1772. Risk of premature death in adulthood influenced by patterns of early childhood adversity - (08/25/22)
     
  1773. Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine - (08/25/22)
     
  1774. HHS Facilitates Agreement to Accelerate Delivery of Additional Smallpox and Monkeypox Vaccines Using New U.S. Production Line - (08/25/22)
     
  1775. Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor - (08/25/22)
     
  1776. Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice- Yearly HIV Treatment Option - (08/25/22)
     
  1777. Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir - (08/25/22)
     
  1778. HIV & Monkeypox - (08/20/22)
     
  1779. Lean NAFLD can range from 7% to 10% in the United States - (08/18/22)
     
  1780. Non-Invasive Testing - Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis - (08/18/22)
     
  1781. Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency - (08/18/22)
     
  1782. ViiV HEALTHCARE ANNOUNCES SUPPORT FOR COMMUNITY-BASED ORGANIZATIONS WITH NEW MONKEYPOX EMERGENCY RESPONSE FUND IN THE US - (08/18/22)
     
  1783. Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity - (08/18/22)
     
  1784. Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care - (08/18/22)
     
  1785. Pharma Cos. Team Up With LGBTQI+ and HIV Organizations To Address Monkeypox - (08/17/22)
     
  1786. Asymptomatic Monkeypox Reported - (08/17/22)
     
  1787. HIV Infection and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus (HBV) Co-infection: a Propensity Score-matched Cohort Study HIV/HBV confected 1.2% HCC (n=7) vs HBV Monoinfected 3.2% (n=75). - (08/17/22)
     
  1788. Principles for Ending HIV as an Epidemic in the United States: A Policy Paper of IDSA and HIVMA - (08/16/22)
     
  1789. Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022 - (08/16/22)
     
  1790. Non-AIDS-events in individuals with spontaneous control of HIV-1: a systematic review - (08/16/22)
     
  1791. IAC: Randomised study of switch to DTG/RPV in subjects with HIV RNA <50c/ml and archived K103N over 48 weeks - (08/15/22)
     
  1792. IAC: Causes of death for persons with HIV in an integrated healthcare system in Northern California, 2013-2017 - (08/15/22)
     
  1793. IAC: WHO LA-CAB PrEP Guidelines at IAS 2022 - (08/13/22)
     
  1794. Low Dose Monkeypox Vaccine - (08/12/22)
     
  1795. IAC: A phase IV open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1 - (08/11/22)
     
  1796. IAC: Supporting Achievement of the State of Georgia's 25% HIV Incidence Reduction Target Among MSM: A Mathematical Model to Evaluate the Potential Impact of Long-acting Pre-exposure Prophylaxis in Atlanta - (08/11/22)
     
  1797. IAC: Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study - (08/11/22)
     
  1798. IAC: Risk factors linked to age-related comorbidities among people living with HIV aged over 40 years - (08/11/22)
     
  1799. IAC: Advanced HIV infection in the US: immune response to ART initiation - (08/11/22)
     
  1800. IAC: Audience Segmentation of Preferences for Long-Acting Injectable PrEP Among U.S. MSM: A Latent Class Analysis - (08/11/22)
     
  1801. IAC: Willingness & Preferences for Long-Acting Injectable PrEP Among US Men Who Have Sex with Men: A discrete choice experiment - (08/11/22)
     
  1802. First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable HIV Viremia in an Urban HIV Clinic - (07/28/22)
     
  1803. IAC: High prevalence of asymptomatic Omicron carriage and correlation with CD4 T cell count among adults with HIV enrolling in COVPN 3008 Ubuntu clinical trial in sub-Saharan Africa - (08/10/22)
     
  1804. IAC: HIV/HBV coinfection in pregnancy and response to antiretroviral therapy - (08/09/22)
     
  1805. IAC: Incidence and disease severity of non-alcoholic fatty liver disease among people living with HIV in Thailand - (08/09/22)
     
  1806. IAC: HIV in 2022 and beyond: A view from NIAID - non-adherence, disengagement from care, PrEP, vaccine - cure research - (08/09/22)
     
  1807. IAC: Bacterial translocation of LPS is associated with lower cognitive abilities in men living with HIV receiving antiretroviral therapy - (08/09/22)
     
  1808. IAC: Use of the Patient Generated Index to identify physical health challenges among people living with HIV - (08/09/22)
     
  1809. IAC: Early Implementation and Clinical Outcomes of Long-Acting Injectable Cabotegravir and Rilpivirine in a Safety-Net Clinic - (08/09/22)
     
  1810. IAC: Assessment of cardiovascular health using the "Life's Simple 7" among the Canadian HIV and Aging Cohort study participants: a cross-sectional observational study - (08/09/22)
     
  1811. IAC: Burden of chronic comorbidities among people living with and without HIV: disability-adjusted life years in British Columbia, Canada - (08/09/22)
     
  1812. IAC: Selection of Cabotegravir Dosing Regimens For HIV Treatment and Pre-Exposure Prophylaxis (PrEP) in Adolescents by Leveraging Adult Data - (08/09/22)
     
  1813. IAC: Association of prenatal PrEP exposure with neurodevelopmental and growth outcomes beyond 24 months among Kenyan children - (08/09/22)
     
  1814. IAC: Determinants of long-term survival in late HIV diagnosed individuals: the PISCIS Cohort study - (08/09/22)
     
  1815. IAC: High HIV incidence and mortality in a multi-site cohort of transgender women in the eastern and southern United States - (08/09/22)
     
  1816. IAC: Prevalence of adverse birth outcomes and external birth defects among women living with HIV in Malawi - (08/09/22)
     
  1817. IAC: Chronic injection opioid use increases the systemic inflammation and T cell immune activation in virally suppressed people living with HIV - each separately HIV & Opioid Use increase immune activation, inflammation - (08/09/22)
     
  1818. IAC: Arterial remodeling is associated with CD4 T cell count and plasma IL-10 in persons with HIV - (08/08/22)
     
  1819. IAC: Age Associated with Comorbidites in Spain - Risk factors linked to age-related comorbidities among people living with HIV aged over 40 years - (08/08/22)
     
  1820. IAC: Comorbidity Rate Rose 1% to 2% Yearly in 2008-2018 for HIV+ in Hospital - Mark Mascolini (08/08/22)
     
  1821. IAC: Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies Integrase Inhibitor in First ART Poses Some Cardio Risks in Big US Analysis - Mark Mascolini(08/07/22)
     
  1822. IAC: Characterization of the absorption, metabolism, and excretion of islatravir, an HIV nucleoside reverse transcriptase translocation inhibitor, in humans - (08/07/22)
     
  1823. IAC: No pharmacokinetic interaction between islatravir and methadone - (08/07/22)
     
  1824. IAC: Resistance mutations in the HIV integrase coding region among INSTI-naïve pregnant women in Argentina: a baseline survey - (08/07/22)
     
  1825. IAC: Weight Gain After Antiretroviral Therapy Initiation in People Living with HIV - (08/07/22)
     
  1826. IAC: Weight Gain After Non-nucleoside Reverse Transcriptase-to-Integrase Inhibitor Switch in the United States - (08/07/22)
     
  1827. IAC: Current Pain, Black Race, Age Tied to Higher Frailty Risk With HIV in USA - Mark Mascolini (08/07/22)
     
  1828. IAC: INSTIs Plus PIs-But Not INSTIs Alone-Tied to Rising Body Mass Index in Children - Mark Mascolini (08/07/22)
     
  1829. IAC: Alcohol, Smoking, Drugs, Liver Disease-But Not TDF-Predict Fracture With HIV - Mark Mascolini (08/07/22)
     
  1830. IAC: Long-term Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) With a Third Agent in Children Living With HIV - (08/07/22)
     
  1831. IAC: Long-term Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) With a Third Agent in Children Living With HIV - (08/06/22)
     
  1832. IAC: Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Long-Acting Lenacapavir for Treatment of HIV - (08/06/22)
     
  1833. IAC: One Year Outcome of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Children ≥ 2 Years Weighing 14 to < 25 kg - (08/06/22)
     
  1834. IAC: Long-Acting Cabotegravir + Rilpivirine Injection Site Reactions: Pooled Week 96 Results - (08/06/22)
     
  1835. IAC: Factors Associated with Healthcare Providers' Preference for Forgoing an Oral Lead-in Phase when Initiating Long-acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial - (08/06/22)
     
  1836. IAC: Initiating long-acting cabotegravir and rilpivirine in a real-world setting: clinical characteristics and switch reasons from PLHIV and health care provider perspective in the German CARLOS cohort - (08/06/22)
     
  1837. IAC: Safety and Effectiveness From the CARISEL Study: Phase 3b Hybrid-III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings - (08/06/22)
     
  1838. IAC: What women want - results [survey] from discrete choice experiment about preferred PrEP method from Khomas region of Namibia - (08/06/22)
     
  1839. IAC: "Give It a Shot": Best Practices From HCPs for Administering Long-Acting Cabotegravir + Rilpivirine - (08/05/22)
     
  1840. IAC: Low Level of Virologic Failure and Resistance in ART-Experienced, Integrase Inhibitor-Naive Participants Receiving Dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Combined Regimens: 10-Year Follow-up in the SAILING Study - (08/05/22)
     
  1841. IAC: Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study in Spain - (08/05/22)
     
  1842. IAC: Efficacy and Safety of Switching to Dolutegravir/Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis - (08/05/22)
     
  1843. IAC: Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years: Pooled Results From the TANGO and SALSA Studies - (08/05/22)
     
  1844. IAC: REAL-WORLD TREATMENT EXPERIENCE OF SINGLE TABLET DOLUTEGRAVIR/LAMIVUDINE IN THE US: RESULTS FROM THE TANDEM STUDY - (08/05/22)
     
  1845. IAC: Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care - (08/05/22)
     
  1846. IAC: Improvements in Patient-Reported Outcomes in Older Adults Aged ≥50 Years With HIV-1 After Switching to a 2-Drug Regimen of Fixed-Dose Combination DTG/3TC: 48-Week Results From the SALSA Study - (08/05/22)
     
  1847. IAC: A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: Data from DOLOMITE-NEAT ID Network study - (08/05/22)
     
  1848. IAC: Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus Phase 2/3 regimen - (08/05/22)
     
  1849. IAC: Simulations for once weekly dosing of oral lenacapavir - (08/05/22)
     
  1850. IAC: Exceptional Post-Treatment HIV Control in an Acute HIV-Infected Woman During More than 15 Yearsbr Exceptional post-treatment control associated with strong NK and gamma delta ? cytotoxic T cells - (08/05/22)
     
  1851. IAC: ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced - (08/03/22)
     
  1852. IAC: An immunological signature for subclinical atherosclerosis in people living with HIV-1 receiving antiretroviral therapy - (08/03/22)
     
  1853. IAC: Putting HBV/HCV Testing and Treatment in HIV Clinics Has Benefits in Vietnam - Mark Mascolini - (08/03/22)
     
  1854. IAC: Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine (DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis - (08/03/22)
     
  1855. IAC: Disappointing Results With VRC01 bNAb Plus ART to Limit Infant Reservoirs - Mark Mascolini - (08/03/22)
     
  1856. IAC: Arrests, City Stress, Life Events Tied to Suicide Attempts in Young With HIV - Mark Mascolini (08/03/22)
     
  1857. IAC: High Loneliness Score in Half of Ontario HIV Cohort-Tied to Poor ART Adherence - Mark Mascolini - (08/03/22)
     
  1858. IAC: View on Targeted Violence, Being a Teen, Tied to PTSD in US MSM - Mark Mascolini - (08/03/22)
     
  1859. IAC: Different Factors Drive Mental Health Desires and Referrals for Black MSM - Mark Mascolini - (08/03/22)
     
  1860. IAC: Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study - (08/03/22)
     
  1861. IAC: Exceptional Post-Treatment HIV Control in an Acute HIV-Infected Woman During More than 15 Years Exceptional post-treatment control associated with strong NK and gamma delta ? cytotoxic T cells - (08/03/22)
     
  1862. IAC: Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People With HIV After 52 Weeks of Treatment - (08/03/22)
     
  1863. IAC: Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People With HIV at 54 Weeks - (08/03/22)
     
  1864. IAC: Transgender Women (TGW) in HPTN 083: An Evaluation of Safety, Efficacy, and Gender Affirming Hormonal Therapy (GAHT) Interactions with Long-acting Cabotegravir (CAB-LA) - (08/03/22)
     
  1865. IAC: The fast and the continuous: dolutegravir-based antiretroviral therapy achieves impressive viral load suppression in CALHIV in the short- and long-term - Mark Mascolini - (08/02/22)
     
  1866. IAC: Subcortical brain volumes of children who are HIV-exposed and uninfected in the first three years of life: a South African birth cohort study - (08/02/22)
     
  1867. IAC: MSM Used HIV Sex-Negotiating Skills to Protect Themselves From COVID - Mark Mascolini - (08/02/22)
     
  1868. IAC: Combining Illicit Drugs Tied to Risky Sex in Mexican MSM - Mark Mascolini - (08/02/22)
     
  1869. IAC: Simplified PrEP Dispensing Halves Clinic Visits, Maintains or Improves Adherence in Kenya - Mark Mascolini - (08/02/22)
     
  1870. IAC: Depression, Not Gender Identity, Tied to CVD Risk in US HIV+/HIV- Women - Mark Mascolini - (08/02/22)
     
  1871. IAC: Trial Finds Neither NTX nor SOF/DCV Can Prevent SARS-CoV-2 - Mark Mascolini - (08/02/22)
     
  1872. IAC: Macrophage Activation for 2 Years After Switch From 3 to 2 Antiretrovirals - Mark Mascolini - (08/02/22)
     
  1873. IAC: Integrated Screening/Diagnosis for Alcohol, Tobacco, Depression May Extend Life With HIV - Mark Mascolini - (08/02/22)
     
  1874. IAC: Smaller Volumes of 2 Brain Regions in Children Exposed to HIV in Utero - Mark Mascolini - (08/02/22)
     
  1875. IAC: Survival in advanced AIDS patients treated with efavirenz or dolutegravir in Brazil: a multicenter, observational study - (08/01/22)
     
  1876. IAC: Efficacy and safety of dolutegravir plus emtricitabine vs combined antiretroviral therapy for the maintenance of viral suppression: 144-week results of the SIMPL'HIV trial - (08/01/22)
     
  1877. IAC: Trends in PrEP Inequity by Race and Census Region, United States, 2012-2021 - (08/01/22)
     
  1878. IAC: Dual therapy based on DRVr plus 3TC in HIV-1 naïve patients: global 48 week results from ANDES Study - (08/01/22)
     
  1879. IAC: Combined Drinking, Smoking, Depression Tied to Higher Mortality in HIV+ US Women - Mark Mascolini (08/01/22)
     
  1880. IAC: Meta-Analysis Confirms Higher COVID Death Risk With HIV - Mark Mascolini (08/01/22)
     
  1881. IAC: Low CD4 Count Linked to DAA Failure in People With HIV - Mark Mascolini - (08/01/22)
     
  1882. IAC: Frailty Linked to Subclinical Cardio Risk in Older People With/Without HIV - Mark Mascolini - (08/01/22)
     
  1883. IAC: Younger Age at Diagnosis of CVD and HTN With HIV Suggests Premature Aging - Mark Mascolini - (08/01/22)
     
  1884. IAC: Dolutegravir versus efavirenz-400 as first-line ART in Cameroon: week 192 data of NAMSAL trial - (08/01/22)
     
  1885. IAC: Switching From Integrase Inhibitor to PI Trims Weight in HIV Patient Database - Mark Mascolini - (08/01/22)
     
  1886. IAC: US Team Offers Fourth Candidate for Stem Cell Transplant HIV Cure - Mark Mascolini - (08/01/22)
     
  1887. IAC: Lp(a) in people living with HIV - (08/01/22)
     
  1888. IAC: COVID Hospital Death Risk 50% Higher With HIV, WHO Says- Risk Factors Are Under 200 CD4s, CKD, Diabetes, Hypertension - Mark Mascolini - (08/01/22)
     
  1889. IAC: Final week 192 results from the ADVANCE trial: first-line TAF/FTC/DTG, TDF/FTC/DTG vs TDF/FTC/EFV - weight gain - (08/01/22)
     
  1890. IAC: A propensity-score matched cohort study investigating premature age in people living with HIV - (08/01/22)
     
  1891. IAC: Switching From Integrase Inhibitor to PI Trims Weight in HIV Patient Database - Mark Mascolini - (08/01/22)
     
  1892. IAC: Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana - (08/01/22)
     
  1893. IAC: Real-World Utilization of HIV Pre-Exposure Prophylaxis (PrEP) by Cisgender and Transgender Individuals in the United States - (08/01/22)
     
  1894. IAC: Week 48 of a phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/ tenofovir disoproxil fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE) - Mark Mascolini - (07/30/22)
     
  1895. IAC: Long-Acting CAB Maintains Superiority to TDF/FTC in Preventing HIV in Women - Mark Mascolini - (07/30/22)
     
  1896. IAC: IBALIZUMAB LONG-TERM EFFICACY IS NOT IMPACTED BY PARTIALLY ACTIVE ANTIRETROVIRALS - (07/30/22)
     
  1897. IAC: Patrick Sullivan on AIDSVu's Landmark PrEP Use Data by Race/Ethnicity - (07/30/22)
     
  1898. IAC: Pharmacokinetic Modeling and Simulation of Intramuscular and Subcutaneous Ibalizumab Delivery - (07/30/22)
     
  1899. IAC: Doxycycline PEP Cuts Bacterial STI Rate Over 60% After Condomless Sex - Mark Mascolini - (07/30/22)
     
  1900. IAC: Trends in PrEP Inequity by Race and Census Region, USA, 2012-2021 - (07/30/22)
     
  1901. IAC: Long acting injectable cabotegravir: updated efficacy and safety results from HPTN 084 - (07/30/22)
     
  1902. IAC: Week 96 Weight and Lipid Changes From Baseline Among Participants Receiving Cabotegravir + Rilpivirine Long-Acting or Comparator Therapy in the ATLAS-2M and FLAIR Studies - (07/30/22)
     
  1903. IAC: Pharmacokinetics and Tolerability of Cabotegravir and Rilpivirine Long-Acting Intramuscular Injections to the Vastus Lateralis (Lateral Thigh) Muscles of Healthy Adult Participants - (07/29/22)
     
  1904. IAC: People With HIV Now Face Chronic Disease In Living Longer - (07/29/22)
     
  1905. IAC: Long-term Integrated Analysis of B/F/TAF in Treatment-Naïve Adults With HIV Through Five Years of Follow-up - (07/29/22)
     
  1906. IAC: Lipid Parameters and Lipid-Modifying Agent Use in Participants Initiating F/TAF or F/TDF for PrEP in the DISCOVER Trial - (07/29/22)
     
  1907. IAC: Real-World HIV Renal Outcomes With TDF to TAF Switch - (07/29/22)
     
  1908. IAC: Long-Acting Cabotegravir + Rilpivirine in Older Adults: Pooled Phase 3 Week 96 Results - (07/29/22)
     
  1909. IAC: Longitudinal Analysis of Weight Change in HIV-1 Treatment-Naïve and -Experienced People Living With HIV (PLWH) Initiating/Switching to an NNRTI- or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies - (07/29/22)
     
  1910. IAC: Injection-Site Reaction Experience in Clinical Studies of People Using Lenacapavir For HIV Treatment - (07/29/22)
     
  1911. IAC: Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies - (07/29/22)
     
  1912. IAC: Can ART switch mitigate or reverse INSTI-related weight or BMI gain in high risk people living with HIV-1? - (07/29/22)
     
  1913. IAC: Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study - (07/29/22)
     
  1914. IAC: ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced - (07/29/22)
     
  1915. IAC: AIDS 2022 News Release: Doxycycline Reduced STIs; Functional cure case; Stem Cell Transplant Cure Care; TAF vs TDF for HBV in ART regimen. - (07/29/22)
     
  1916. IAC: AVAC, BMGF, CIFF, MEDACCESS, UNITAID AND VIIV HEALTHCARE ANNOUNCE COLLABORATION TO CATALYSE MORE AFFORDABLE ACCESS TO LONG-ACTING CABOTEGRAVIR FOR HIV PREVENTION - (07/29/22)
     
  1917. IAC: ViiV HEALTHCARE AND THE MEDICINES PATENT POOL SIGN NEW VOLUNTARY LICENSING AGREEMENT TO EXPAND ACCESS TO INNOVATIVE LONG-ACTING HIV PREVENTION MEDICINE - (07/29/22)
     
  1918. IAC: AIDS 2022: New insights into HIV latent cells yield potential cure targets - (07/29/22)
     
  1919. IAC: AIDS 2022: Two HIV Patients Appear to Have Beaten Virus, Offering Hope for Cure - (07/29/22)
     
  1920. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084 - (07/28/22)
     
  1921. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial - (07/28/22)
     
  1922. Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir - (07/28/22)
     
  1923. IAC: ViiV HEALTHCARE TO PRESENT NEW DATA FROM INNOVATIVE HIV TREATMENT AND PREVENTION PORTFOLIO AT AIDS 2022 - (07/22/22)
     
  1924. ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD? Editorial - (07/25/22)
     
  1925. IAC: Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic - (07/22/22)
     
  1926. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 - New clinical symptoms identified - (07/22/22)
     
  1927. Title: RFA 22-0003 People Aging with HIV - (07/21/22)
     
  1928. Skeletal muscle mitochondrial dysfunction in contemporary antiretroviral therapy: a single cell analysis - (07/19/22)
     
  1929. Integrase Strand Transfer Inhibitors Are Associated With Lower Risk (21%) of Incident Cardiovascular Disease in People Living With HIV - (07/19/22)
     
  1930. Integrase inhibitors hand us a new HIV clinical puzzle - Comment - (07/18/22)
     
  1931. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium - (07/18/22)
     
  1932. Pfizer and BioNTech Announce Omicron-Adapted (BA.5) COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron - (07/14/22)
     
  1933. Pfizer and BioNTech Announce Omicron-Adapted (BA.5) COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron - (07/14/22)
     
  1934. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children - (07/11/22)
     
  1935. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study - (07/07/22)
     
  1936. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers - (07/07/22)
     
  1937. Accelerated aging [by 5 years] with HIV begins at the time of initial HIV infection - (07/05/22)
     
  1938. EASL: Simvastatin May Boost Beta Blocker Carvedilol Impact on Portal Hypertension, Modulates Systemic Inflammation - Mark Mascolini - (07/01/22)
     
  1939. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial - (06/30/22)
     
  1940. EASL: Health-related quality of life is impaired in people living with HIV and hepatic steatosis - (06/30/22)
     
  1941. Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor - (06/27/22)
     
  1942. Greater risk of post-vaccination breakthrough severe COVID-19 illness in people with HIV and CD4 <350 - (06/13/22)
     
  1943. Failing Fragmented HIV Care Continuum for Aging & Elderly PLWH & all PLWH - (06/13/22)
     
  1944. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States - (06/13/22)
     
  1945. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 - (06/13/22)
     
  1946. Greater risk of post-vaccination breakthrough severe COVID-19 illness in people with HIV and CD4 <350 - (06/13/22)
     
  1947. CROI: Clinical Pharmacology at CROI 2022 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center - (03/28/22)
     
  1948. CROI: CROI 2022 and HIV prevention - NATAP Report by Renee Heffron, PhD and Connie Celum, MD, University of Washington (03/28/22)
     
  1949. CROI: Summary from virtual CROI 2022 for HIV and liver disease Hepatitis elimination for 2030 on track? Is fatty liver disease a growing concern? New insights from CROI 2022. - Prof. Dr. Jurgen K. Rockstroh Department of Medicine I University Hospital Bonn Venusberg-Campus 1 53127 Bonn Germany - (03/21/22)
     
  1950. CROI: HIV Prevention and Resistance on PrEP - By Christina K. Psomas MD PhD - (04/20/22)
     
  1951. Health Department Launches Monkeypox Vaccine Clinic for People Who May Have Been Exposed to Monkeypox - (06/25/22)
     
  1952. Lenacapavir for HIV-1 - Potential Promise of a Long-Acting Antiretroviral Drug - EDITORIAL - (06/25/22)
     
  1953. Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV - (06/25/22)
     
  1954. A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) - (06/21/22)
     
  1955. THE EFFECT OF MENOPAUSAL STATUS, AGE, AND HIV ON NON-AIDS COMORBIDITY BURDEN AMONG U.S. WOMEN - (06/20/22)
     
  1956. Disability Measured in PLWH in London: 39.5% Severe Disability; 70.5% Moderate Disability - (06/03/22)
     
  1957. bNabs Combination Study new reports & antibody-resistance - (06/02/22)
     
  1958. PLWH Had 3 X Worse Fatigue. Fatigue associated with Worse Cognition, Daily Functioning - (06/02/22)
     
  1959. Medicines Patent Pool, ViiV Healthcare enter negotiations over voluntary licensing of cabotegravir Long-Acting for HIV pre-exposure prophylaxis - (06/01/22)
     
  1960. PLWH Had 3x Worse Fatigue. Fatigue Associated with Worse Cognition (but not in HIV-neg.) & Worse Daily Function in PLWH - (06/01/22)
     
  1961. COVID 5th Wave So Africa - Boosters "Stay Up-To-date" White House Briefing - (06/01/22)
     
  1962. Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors - (06/01/22)
     
  1963. Brain Affects by Integrase Inhibitors & ARTs - Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors - (05/31/22)
     
  1964. Maraviroc-Does it Improve Cognitive Function? New Research This Week in Mice - (05/31/22)
     
  1965. Interferon therapy shows striking results against COVID-19 - (05/31/22)
     
  1966. Peginterferon Lambda Single Injection for Newly Diagnosed COVID - TOGETHER Phase 3 Study - (05/31/22)
     
  1967. Interferon [lambda] therapy shows striking results against COVID-19 - (05/31/22)
     
  1968. Biden Administration Announces Launch of First COVID Federally-Supported Test to Treat Site - (05/26/22)
     
  1969. CDC 2020 HIV Surveillance report - COVID Impact, Racial Disparities in Low Viral Suppression Rates, Death Rates, Linkage to care, Care, PrEP, Geography - (05/26/22)
     
  1970. Maraviroc Restores Middle Age Memory Loss in Mice, "Could Be Used To Reverse Cognitive Deficits Caused by HIV" - (05/26/22)
     
  1971. CROI: Increased Physical Strength is Associated with Improved Brain Integrity in Older People Living with HIV - (05/23/22)
     
  1972. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapies - (05/24/22)
     
  1973. Molnupiravir for the Treatment of COVID-19 in Immunocompromised Patients: Efficacy, Safety, and Virology Results from the Phase 3 MOVe-OUT Trial - (05/24/22)
     
  1974. PrEP for Individuals who Inject Drugs - (05/18/22)
     
  1975. Associations Between Central Obesity and Lifelong Antiviral Therapy in Adults Living With HIV Acquired From Early Childhood - (05/16/22)
     
  1976. FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV - Press Release - (05/16/22)
     
  1977. Carotid Intima-Media Thickness and Midlife Cognitive Function- - (05/16/22)
     
  1978. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection - (05/13/22)
     
  1979. NAFLD Is Increasingly Affecting Patients With HIV - (05/11/22)
     
  1980. Duke's Klotman is under consideration as the next NIH head - (05/09/22)
     
  1981. New Funding for HIV+ Women's Program: HIV Prevention & Care for Black Women - (05/05/22)
     
  1982. Abnormal cognitive aging in people with HIV: Evidence from Data Integration between two countries' cohort studies - (05/03/22)
     
  1983. HIV is associated with elevated FibroScan-AST (FAST) score - (05/03/22)
     
  1984. TaiMed Receives from Theratechnologies Notification of Returning Commercialization Rights for Trogarzo in European Territory - (04/28/22)
     
  1985. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study - (04/28/22)
     
  1986. THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY - Trogarza - (04/27/22)
     
  1987. HIV Neurocognitive Impairment Starts at 40-50 Years Old - (04/22/22)
     
  1988. Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples - (04/20/22)
     
  1989. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis - (04/20/22)
     
  1990. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study - patients with MetS had the highest prevalence of NAFLD (71%) - (04/20/22)
     
  1991. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association - (04/20/22)
     
  1992. Testosterone Therapy is Associated With Depression, Suicidality, and Intentional Self-Harm: Analysis of a National Federated Database - (04/18/22)
     
  1993. Real-world safety of pre-exposure prophylaxis for HIV - Comment - (04/18/22)
     
  1994. HIV Death Rates Almost Double in NYC Compared to General Population; Heart Disease is A Leading Increasing Cause of Death in NYC - (04/18/22)
     
  1995. Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission. - (04/18/22)
     
  1996. "clinicians must recognize that patients with HIV have a unique CVD risk profile that may dictate different approaches" - need for tailored cardiovascular prevention strategies in patients with HIV - (04/18/22)
     
  1997. Brain Decline in Frail PLH Not Detectable By Standard Neuropsych Tests - (04/18/22)
     
  1998. Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples - (04/18/22)
     
  1999. New York State Department of Health Announces Emergence of Recently Identified, Highly Contagious Omicron Subvariants in New York and Urges Continued Vigilance Against COVID-19 - (04/18/22)
     
  2000. Reduced Cardiac Strain Among Women with HIV Relates to Inflammatory Monocyte Activation - (04/13/22)
     
  2001. SUBCLINICAL ATHEROSCLEROSIS AND IMMUNE ACTIVATION AMONG US FEMALES VS MALES WITH HIV women have more immune activation - (04/13/22)
     
  2002. Aging & Immune System: Women-Specific Aspects (higher inflammation; estrogen; menopause; response to HIV by women) - (04/13/22)
     
  2003. CV Risk Factors Common Among 50 Yr Old PLWH - "Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial" - (04/13/22)
     
  2004. Among WWH in the REPRIEVE trial, more advanced reproductive age is associated with metabolic dysregulation and region of residence - (04/13/22)
     
  2005. Health systems must adapt to the special needs of ageing people with HIV and comorbid diseases to improve both patient-centred and population-centred health outcomes - (04/13/22)
     
  2006. Double the Relative Risk for HIV+ Women for Heart Attacks Highest rates at 65-74 Years Old - (04/12/22)
     
  2007. Arc of Aging with HIV 1996-2022: from promise to disappointment & despair: a broken HIV healthcare system. Slide talk by Jules Levin - (04/11/22)
     
  2008. SAGE-718 in Parkinson's Disease Mild Cognitive Impairment: Results from the Phase 2 PARADIGM Study (Part A) - Improvements Observed in Study - (04/08/22)
     
  2009. NYC DOH COVID PrEP, Treatment - Evusheld for pre-exposure prophylaxis - (04/08/22)
     
  2010. Therapeutic Management of Nonhospitalized Adults With COVID-19 - (04/06/22)
     
  2011. HIV Funding from Lil Was X & Elton John at Oscar Post Party
     
    Lil Nas X Teams Up with Gilead COMPASS Initiative® to Raise Nearly $500,000 for Community Organizations Addressing HIV in the Southern United States     - (04/05/22)
     
  2012. SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center - (04/05/22)
     
  2013. Cognitive Impairment at Midlife in Long-Term Cannabis Users - (04/05/22)
     
  2014. Quality of Life Worse for Long-Term Survivors; Frailty/Function worse for >65 - (04/01/22)
     
  2015. CROI: Oral TDF/FTC Provides Early Mucosal Protection In Both On- Demand And Daily Regimen - (04/01/22)
     
  2016. CROI: Contributions to the Decline in HIV Incidence among GBM in the UK: A Modelling Study - HIV Elimination in 25 Years - (03/31/22)
     
  2017. CROI: DEEPHIV: DEEP LEARNING TO PREDICT DDI RELEVANCE FOR ARVS - (03/31/22)
     
  2018. CROI: Machine Learning Quantifies Accelerated White Matter Aging in Persons with HIV - (03/31/22)
     
  2019. ViiV HEALTHCARE ANNOUNCES US FDA APPROVAL OF TRIUMEQ PD, THE FIRST DISPERSIBLE SINGLE TABLET REGIMEN CONTAINING DOLUTEGRAVIR, A ONCE-DAILY TREATMENT FOR CHILDREN LIVING WITH HIV - (03/29/22)
     
  2020. ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg - (03/29/22)
     
  2021. CROI: Long acting doravirine for treatment and prevention of vaginal HIV transmission - (03/30/22)
     
  2022. CROI: CROI 2022 Key Aging & Comorbidities Highlights - (03/28/22)
     
  2023. CROI: CROI 2022 Aging & HIV Symposium - (03/28/22)
     
  2024. Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere - (03/28/22)
     
  2025. Gilead's Aging Positively 2nd Round Grantees Announced - (03/28/22)
     
  2026. Excess cancer prevalence in men with HIV: A nationwide analysis of Medicaid data - (03/28/22)
     
  2027. Mortality Is Greater For Some PLWH: African-Americans, Elderly, Frail, Comorbidities, Women - (03/28/22)
     
  2028. ViiV HEALTHCARE ANNOUNCES LABEL UPDATE FOR ITS LONG-ACTING HIV TREATMENT, CABENUVA (CABOTEGRAVIR, RILPIVIRINE), TO BE INITIATED WITH OR WITHOUT AN ORAL LEAD-IN PERIOD - (03/24/22)
     
  2029. Senolytics for Poets - (03/24/22)
     
  2030. Jak-STAT Inhibition: Therapeutic Intervention for Inflammaging and Comorbidities in PWH - (03/24/22)
     
  2031. ViiV HEALTHCARE ANNOUNCES LABEL UPDATE FOR ITS LONG-ACTING HIV TREATMENT, CABENUVA (CABOTEGRAVIR, RILPIVIRINE), TO BE INITIATED WITH OR WITHOUT AN ORAL LEAD-IN PERIOD - (03/24/22)
     
  2032. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/22/22)
     
  2033. CROI: CROI Symposium: Aging & HIV "care of PLWH has NOT kept up with the reality of this aging population" - (03/23/22)
     
  2034. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/22/22)
     
  2035. CROI: ADHERENCE IN THE ACTG A5360 HCV MINIMAL MONITORING (MINMON) TRIAL - (03/22/22)
     
  2036. CROI: CANNABIS USE AND HEPATIC STEATOSIS BY MRI-PDFF - (03/22/22)
     
  2037. CROI: Regional Variation in HBV Prevalence in People Living with HIV in Botswana - (03/22/22)
     
  2038. CROI: LOW RATES OF HEPATITIS B VACCINATION AMONG PEOPLE WITH HIV - (03/22/22)
     
  2039. CROI: Randomized Trial of HBV Revaccination in MSM Born in the Neonatal Vaccination Era - (03/22/22)
     
  2040. Alzheimer's disease and related dementias among older U.S. Medicare beneficiaries with and without HIV - (03/21/22)
     
  2041. CROI: NEW HEPATITIS B INFECTION AMONG HIV PATIENTS: WHO IS AT RISK? - (03/21/22)
     
  2042. CROI: ACTG A5324: A RANDOMIZED TRIAL OF ART INTENSIFICATION FOR COGNITIVE IMPAIRMENT IN PWH - Mark Mascolini (03/21/22)
     
  2043. CROI: FEASIBILITY AND VIRAL RESPONSE TO TREATING ACUTE/EARLY HIV IN A MULTINATIONAL STUDY - (03/21/22)
     
  2044. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/21/22)
     
  2045. CROI: Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/21/22)
     
  2046. EACS: SOLAR 3D: A PROSPECTIVE STUDY SWITCHING TO DTG/3TC FROM 3- OR 4-DRUG ART FOR MAINTENANCE OF VIRAL SUPPRESSION WITH HISTORIC M184V/I MUTATION AND PRIOR VIROLOGICAL FAILURES: 48 WEEK PRIMARY ENDPOINT RESULTS - (03/21/21)
     
  2047. CROI: Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/18/22)
     
  2048. CROI: A RETROSPECTIVE ANALYSIS OF BONE LOSS IN EMTRICITABINE/TENOFOVIR THERAPY FOR HIV PrEP - (03/18/22)
     
  2049. Finding the 'Tipping Point' to Permanent Kidney Damage - (03/15/22)
     
  2050. Long- Covid in PLWH & Immune Responses in PLWH Recovering From COVID Prior to Vaccine Availability - (03/15/22)
     
  2051. CROI: SARS-CoV-2 CSF N Antigen Detection is Associated with CNS Inflammation in Neuro-COVID - (03/15/22)
     
  2052. CROI: NIH Launches Clinical Trial of Three mRNA HIV Vaccines - (03/14/22)
     
  2053. South Africa Approves Dapivirine Vaginal Ring for Use by Women - (03/14/22)
     
  2054. CROI: HIV-1 RNA TRANSCRIPTS IN CSF CD4+ T CELLS, NOT MONOCYTES, ARE LINKED TO BRAIN INJURY - (03/14/22)
     
  2055. 210,000 PLWH in USA Over >60 years Old - (03/11/22)
     
  2056. CROI: Treatment with Broadly Neutralizing Antibodies in Children with HIV in Botswana (The Tatelo Study) - (03/11/22)
     
  2057. CROI: NON-OBESE NAFLD IS ASSOCIATED WITH HIGHER SCD14 CONCENTRATIONS IN ADULTS WITH HIV - (03/11/22)
     
  2058. CROI: 11% - HIGH INCIDENCE RATE OF CT-MEASURED NAFLD IN MACS MEN WITH AND WITHOUT HIV INFECTION - (03/11/22)
     
  2059. CROI: DETERMINANTS OF LIVER STEATOSIS IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY - ALT matters - (03/11/22)
     
  2060. CROI: IMPACT OF NASH ON THE SURVIVAL OF PEOPLE LIVING WITH HIV - (03/11/22)
     
  2061. CROI: PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE VERTICALLY HIV-INFECTED YOUTHS - (03/11/22)
     
  2062. CROI: Effect of Tenofovir on T-cell Maturational Subsets in Long Term Aviraemic HIV Adults - (03/11/22)
     
  2063. CROI: NEUROSYMPTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS - (03/11/22)
     
  2064. Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose - (03/08/22)
     
  2065. More alcohol, less brain: Association begins with an average of just one drink a day - (03/07/22)
     
  2066. CROI: Effect of Tenofovir on T-cell Maturational Subsets in Long Term Aviraemic HIV Adults - (03/08/22)
     
  2067. CROI: NEUROSYMPTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS - (03/07/22)
     
  2068. CROI: PBR28 PET IMAGING IN PEOPLE WHO STARTED ART DURING ACUTE VERSUS CHRONIC HIV INFECTION - (03/07/22)
     
  2069. CROI: HPV Genotyping in a Study of Adjunctive Vaccine For Treatment of Cervical Dysplasia - (03/07/22)
     
  2070. More alcohol, less brain: Association begins with an average of just one drink a day - (03/07/22)
     
  2071. Evaluation of Computerized Cognitive Training and Cognitive and Daily Function in Patients Living With HIVA Meta-analysis - (03/07/22)
     
  2072. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment - (03/07/22)
     
  2073. More alcohol, less brain: Association begins with an average of just one drink a day - (03/07/22)
     
  2074. Evaluation of Computerized Cognitive Training and Cognitive and Daily Function in Patients Living With HIVA Meta-analysis - (03/07/22)
     
  2075. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment - (03/07/22)
     
  2076. CROI: STATIN USE IN ART-TREATED HIV REVEALS AN ALTERED MACROPHAGE TRANSCRIPTOMIC PROFILE - (03/04/22)
     
  2077. CROI: PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA: aging, Blacks, women, Hispanics have higher risk - (03/04/22)
     
  2078. CROI: Impaired response of memory Treg to HDL is associated with high cardiovascular disease risk in persons with HIV - (03/04/22)
     
  2079. CROI: Carl Dieffenbach Highlights Aging & Comorbidities for PLWH, Frailty & Research & the Need for Better Care: "care of people living with HIV has NOT kept up with the reality of this aging population" - (03/04/22)
     
  2080. Booster Waning Benefit vs Omicron UK Study NEJM just published - Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant - (03/04/22)
     
  2081. CROI: PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION....no perinatal transmission in this analysis - (03/03/22)
     
  2082. CROI: LONG-ACTING INJECTABLE FOR PREVENTION OF HIV AND UNPLANNED PREGNANCY - (03/02/22)
     
  2083. CROI: Phase 2b Efficacy Trial of Mosaic HIV-1 Vaccine Regimen in African Women (Imbokodo) - (03/02/22)
     
  2084. CROI: PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION - (03/02/22)
     
  2085. CROI: ARCHIVED RESISTANCE AND RESPONSE TO <40 C/ML AND TND - DTG/3TC FDC AT WEEK 48 IN SALSA - (03/01/22)
     
  2086. CROI: Estimating the Lifetime Risk of a Diagnosis of HIV Infection in the United States, Blacks have highest risk - (03/01/22)
     
  2087. Risk, resiliency in aging brain focus of $33 million grant - (03/01/22)
     
  2088. Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues - (03/01/22)
     
  2089. CROI: Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques Ad26/MVA+PGT121+Vesatolimod - (03/01/22)
     
  2090. CROI: Development of Viral Biomarkers in SHIV Infected Non-Human Primates in Reservoirs - (03/01/22)
     
  2091. CROI: Adolescent and Parent Experiences with Long-acting Injectables in the MOCHA Study - (03/01/22)
     
  2092. CROI: The FUNCFRAIL Score to discriminate Frailty in Older Adults with HIV - (02/28/22)
     
  2093. CROI: Potent Targeted Activator of Cell Kill (TACK) Molecules Eliminate HIV Infected Cells - (02/28/22)
     
  2094. CROI: 2DR vs. 3DR INTEGRASE INHIBITOR-BASED REGIMENS INITIATION AND CD4+/CD38+ RATIO RECOVERY - (02/26/22)
     
  2095. CROI: CORONARY FLOW RESERVE ON DTG/ABC/3TC AT BASELINE AND AFTER SWITCH TO BIC/FTC/TAF - (02/26/22)
     
  2096. CROI: EFdA OFFERS COMPLETE PROTECTION FROM REPEATED PENILE HIV CHALLENGES - (02/26/22)
     
  2097. CROI: Association of Sleep Disruption with Kynurenine Pathway Activation in Women Living with HIV - (02/26/22)
     
  2098. CROI: Lifetime HIV Risk 1 in 120 in US, Highest in Black and Hispanic Males - Mark Mascolini (02/26/22)
     
  2099. CROI: REVERSIBILITY OF CENTRAL NERVOUS SYSTEM ADVERSE EVENTS IN COURSE OF ART - (02/25/22)
     
  2100. CROI: Atrial Fibrillation Risk Factors Among Patients in HIV Care in the United States - (02/25/22)
     
  2101. CROI: Sleep and Frailty Among Men with and Without HIV - poor sleep for PLWH - (02/25/22)
     
  2102. CROI: POOR SLEEP IS LINKED TO CVD RISK IN PLWH IN A SOUTHWESTERN US CLINIC - 40% Have Sleeping Difficuties - (02/25/22)
     
  2103. CROI: A novel comorbidity index predicts cognitive change in people with chronic HIV - (02/24/22)
     
  2104. CROI: Aging Symposium 2022 - Jules Levin slides, talk - NATAP - National AIDS Treatment Advocacy Project (02/24/22)
     
  2105. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants (02/24/22)
     
  2106. CROI: Impact of Rheumatologic Therapies on Cardiovascular Outcomes in People with HIV (02/24/22)
     
  2107. CROI: Inflammatory clusters are associated with multimorbidity and Cardiovascular disease in People with HIV on effective treatment (02/24/22)
     
  2108. CROI: Effects of Air Pollutants on Neuroimaging Measures Diverge by HIV Status: poverty-neighborhood area & HIV effect brain structure (02/24/22)
     
  2109. CROI: HIV-INDUCED CELLULAR SENESCENCE IN PLWH IS DECREASED EX VIVO BY D+Q SENOLYTIC DRUGS (02/24/22)
     
  2110. CROI: Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH (02/24/22)
     
  2111. CROI: COUNTERFACTUAL ESTIMATION OF CAB-LA EFFICACY AGAINST PLACEBO USING EXTERNAL TRIAL DATA (02/24/22)
     
  2112. CROI: INFLAMMATION AND IMMUNE ACTIVATION NOT DRIVEN BY ON-ART HIV-SPECIFIC IMMUNE RESPONSES - "Die is Cast Before ART" HIV Long-Lasting Immune Dysreguation (02/24/22)
     
  2113. CROI: A RANDOMIZED TRIAL OF DTG PLUS DRV/c AS A SWITCH STRATEGY IN SUBJECTS WITH MDR HIV-1 (02/24/22)
     
  2114. CROI: Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH (02/24/22)
     
  2115. CROI: PRECLINICAL STUDIES TOWARD A PHASE I/IIA TRIAL USING ANTI-HIV DUOCAR-T CELL THERAPY (02/24/22)
     
  2116. CROI: Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH (02/23/22)
     
  2117. CROI: The Bi-directional Effects of Hormone Therapy and PrEP in Transgender Individuals (02/23/22)
     
  2118. CROI: NEURAL TUBE DEFECTS AND PRENATAL EXPOSURE TO DOLUTEGRAVIR: UNITED STATES, 2008-2019 (02/23/22)
     
  2119. CROI: No Interactions Between Hormone Therapy and PrEP in Transgender Women or Men - Mark Mascolini (02/23/22)
     
  2120. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  2121. Young PLWH at Low-Risk for CVD: 50% have Plaque 23% Vulnerable Plaque, CAC in 35% - (02/22/22)
     
  2122. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  2123. CROI: The role of HIV/HBV/HCV triple infection in end stage liver disease (ESLD) and all cause mortality in Europe (02/23/22)
     
  2124. CROI: Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF: the randomized IMPAACT 2010 trial - (02/22/22)
     
  2125. CROI: ACTG A5351s: Effect of Immune-Modulatory Interventions on CMV Replication during ART - (02/22/22)
     
  2126. CROI: More Adverse Birth Outcomes With COVID Plus HIV in Botswana - Mark Mascolini (02/22/22)
     
  2127. CROI: Post-COVID19 Quality of Life: Low Satisfaction With Physical and Mental Health Status - (02/22/22)
     
  2128. CROI: SARS-CoV-2 Prevalence Similar in Adults and Children in 15-Site US Study - Mark Mascolini (02/22/22)
     
  2129. CROI: From NAFLD to MAFLD: implications of change in terminology in PWH - (02/22/22)
     
  2130. CROI: NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS - (02/22/22)
     
  2131. CROI: HBIg-Free Strategy Prevents Vertical HBV Transmission-If Mothers Start TDF Soon Enough - Mark Mascolini (02/22/22)
     
  2132. CROI: Proteinuria Is Common Among People with HIV With Controlled Viremia - (02/22/22)
     
  2133. CROI: MUSCLE QUALITY AND PHYSICAL FUNCTION IN MEN WITH AND WITHOUT HIV - (02/22/22)
     
  2134. CROI: IS THERE A ROLE OF NOVEL ART REGIMENS IN THE DECLINING PREVALENCE OF HAND? HAND 22% Today in Italy- Asymptomatic Remains Prevalent 10%-24% - (02/22/22)
     
  2135. CROI: SERUM AND CSF ULTRA-SENSITIVE DETECTION OF NFL AND ALZHEIMER'S BIOMARKERS IN PLWH - (02/22/22)
     
  2136. CROI: Triple & Double bNAbs Studies - (02/21/22)
     
  2137. CROI: Injectable, Biodegradable, Removable PrEP/Contraceptive Tested in Mice - Mark Mascolini (02/21/22)
     
  2138. CROI: HIV-Infected Cells Recirculate Throughout Organs During Suppressive ART - Mark Mascolini (02/21/22)
     
  2139. CROI: Lenacapavir Shots or Tabs Control HIV in First-Line ART Combinations - Mark Mascolini (02/21/22)
     
  2140. CROI: Most Large HIV Molecular Clusters in US Primarily Involve MSM - Mark Mascolini (02/21/22)
     
  2141. CROI: Dolutegravir Pharmacokinetics In People with HIV Receiving Daily 1HP for Latent TB Treatment (ACTG A5372) - (02/20/22)
     
  2142. CROI: The Impact of COVID-19 on Adverse Birth Outcomes in Botswana by HIV Status - (02/20/22)
     
  2143. CROI: Role of Renin-Angiotensin-Aldosterone System Activation in Arterial Inflammation in HIV - (02/20/22)
     
  2144. Sex differences in type 2 diabetes mellitus prevalence among persons with HIV: women with HIV appear to have greater risk & >65 worse - (02/18/22)
     
  2145. CROI: DURABILITY OF SARS-COV-2 mRNA VACCINE IMMUNE RESPONSE IN PLWH WITH ADVANCED DISEASE - (02/18/22)
     
  2146. CROI: Immunogenicity and reactogenicity to COVID-19 mRNA vaccine additional dose in PLWH - (02/18/22)
     
  2147. CROI: SARS-CoV-2 Vaccine Immunogenicity in PLWH in The Netherlands & age, CD4, HIV viral load effects - (02/18/22)
     
  2148. CROI: Sotrovimab mAb Limits Progression to Severe COVID Regardless of Serostatus - Mark Mascolini (02/18/22)
     
  2149. CROI: Intramuscular Sotrovimab Noninferior to IV for Mild/Moderate COVID - Mark Mascolini (02/18/22)
     
  2150. CROI: One Quarter Ordering Free HIV Self-Tests in US Never Tested Before - Mark Mascolini (02/18/22)
     
  2151. CROI: Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH: 67% prefer ring vs 31% oral PrEP - (02/18/22)
     
  2152. CROI: PHASE III TRIAL OF MOLNUPIRAVIR IN ADULTS WITH MILD SARS-COV2 INFECTION IN INDIA - (02/18/22)
     
  2153. CROI: PREDICTORS OF NEURODEVELOPMENT IN HIV-EXPOSED UNINFECTED INFANTS - (02/18/22)
     
  2154. CROI: Casirivimab and Imdevimab Combination Provides Long-Term Protection Against COVID-19 - phase 3 study in preventing COVID in household contacts of infected individuals - (02/18/22)
     
  2155. CROI: Camostat Does Not Relieve COVID Symptoms or Clear Virus in Placebo Trial - Mark Mascolini(02/17/22)
     
  2156. CROI: Dolutegravir Reversibly Induces Mitochondrial Fragmentation and Toxicity In Vitro - (02/17/22)
     
  2157. CROI: IMPROVING INTESTINAL BARRIER USING GLP-2 AGONIST REDUCES ARTERIAL INFLAMMATION IN PWH - (02/16/22)
     
  2158. CROI: Dual Monoclonal Antibody Cuts COVID Risk in 8-Month Placebo Trial - Mark Mascolini (02/16/22)
     
  2159. CROI: COVID-19 BOOSTER VACCINE EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - in reducing breakthrough, duration of benefit (02/16/22)
     
  2160. CROI: 00136: A RANDOMIZED TRIAL OF SWITCHING TREATMENT-EXPERIENCED ADULTS FROM PI/r TO DTG - (02/17/22)
     
  2161. CROI: Bolstering ART With DTG +/- MVC Does Not Help Neurocognitive Performance - Mark Mascolini (02/16/22)
     
  2162. CROI: LONGITUDINAL MODELING OF EARLY HIV BURDEN IN THE CENTRAL NERVOUS SYSTEM (02/16/22)
     
  2163. CROI: New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor - press release (02/16/22)
     
  2164. CROI: Lenacapavir as part of a Combination Regimen in Treatment-Naï ve People with HIV: Week 54 Results (02/16/22)
     
  2165. CROI: Big Drops in HIV/STI Testing (But Sometimes Not Diagnoses) When COVID Arrived - Mark Mascolini (02/16/22)
     
  2166. CROI: African NADIA Trial Favors 2nd-Line TDF Over ZDV, and DRV/r Over DTG - Mark Mascolini (02/16/22)
     
  2167. CROI: Switching From NNRTI to DTG-Even With Same NRTIs-Superior to PI - Mark Mascolini (02/16/22)
     
  2168. CROI: Phase 1 Study of Long-Acting 3BNC117 and 10-1074 in Viremic Adults Living With HIV (02/16/22)
     
  2169. CROI: Lenacapavir as part of a Combination Regimen in Treatment-Naï ve People with HIV: Week 54 Results (02/16/22)
     
  2170. POST-ACUTE SEQUELAE AND ADAPTIVE IMMUNE RESPONSES IN PEOPLE LIVING WITH HIV RECOVERING FROM SARS-COV-2 INFECTION - (02/16/22)
     
  2171. CROI: PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING (02/16/22)
     
  2172. CROI: EFFECT OF DIRECT-ACTING ANTIVIRALS ON HCV INCIDENCE AMONG PEOPLE LIVING WITH HIV (02/16/22)
     
  2173. CROI: COVID Pushes USA Farther Off Course to Meet HCV Elimination Goals - Mark Mascolini (02/16/22)
     
  2174. CROI: Asymptomatic SARS-CoV-2 Infection is Extremely Common among People with HIV (02/16/22)
     
  2175. CROI: Long COVID Definition - POST-ACUTE SEQUELAE OF SARS-COV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT (02/16/22)
     
  2176. CROI: COVID Symptoms Reported Lasting Longer in US Than South Africa, Peru - Mark Mascolini (02/16/22)
     
  2177. CROI: Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer (02/15/22)
     
  2178. CROI: Treating Anal Lesions in HIV+ Cuts Anal Cancer Rate 57% in Randomized Trial - Mark Mascolini (02/15/22)
     
  2179. CROI: Outpatient Clinics Efficient in Spotting Recent HIV in 3 African Countries - Mark Mascolini (02/15/22)
     
  2180. CROI: RNA Assay Spots HIV Earlier in CAB-LA PrEP Users, May Avert Resistance - Mark Mascolini (02/15/22)
     
  2181. CROI: CAB-LA PrEP Keeps Advantage Over TDF/FTC in 1-Year Unblinded Phase- Seven Breakthrough Infections Despite On-Time CAB-LA Injections - Mark Mascolini (02/15/22)
     
  2182. CROI: ISLATRAVIR DISTRIBUTION IN MUCOSAL TISSUES, PBMC & PLASMA AFTER MONTHLY ORAL DOSING (02/15/22)
     
  2183. CROI: PHASE IIA TRIAL OF ISLATRAVIR QM FOR HIV PrEP: WEEK 24 METABOLIC AND RENAL OUTCOMES (02/15/22)
     
  2184. CROI: THE IMPACT OF 3BNC117 AND ROMIDEPSIN TREATMENT AT ART INITIATION ON HIV-1 PERSISTENCE - Mark Mascolini (02/15/22)
     
  2185. CROI: Long COVID Definition - Cardiac Rhythm Upsets, Diabetes, GU Symptoms Emerge as Persistent COVID Problems (02/15/22)
     
  2186. CROI: ANGIOGENIC FACTORS IN RNA-SEQ OF SKIN AND GASTROINTESTINAL KAPOSI SARCOMA LESIONS (02/15/22)
     
  2187. CROI: NONSMALL CELL LUNG CARCINOMA IN PLWH HARBORS IMMUNOREGULATORY TUMOR MICROENVIRONMENT (02/15/22)
     
  2188. CROI: GUT MICROBIOTA, PLASMA METABOLOMICS, AND ATHEROSCLEROSIS IN HIV INFECTION (02/15/22)
     
  2189. CROI: MI Risk Not Falling in HIV Group, as It Is in non-HIV Peers - Mark Mascolini (02/15/22)
     
  2190. CROI: CROI Monday Feb 14: 5 Key Aging & Metabolic Oral Presentation Studies - (02/15/22)
     
  2191. CROI: TENOFOVIR ALAFENAMIDE IS ASSOCIATED WITH SHORTER TELOMERE LENGTH IN PEOPLE WITH HIV - (02/15/22)
     
  2192. CROI: Macrophage-specific arterial infiltration relates to plaque type and immune activation in HIV - (02/14/22)
     
  2193. CROI: PLWH Have Higher levels of Fat Tissue Fibrosis - INFLAMMATION AND KYNURENINE PATHWAY LINKED TO TYPE 2 DIABETES AND FAT FIBROSIS IN HIV - (02/14/22)
     
  2194. CROI: Trends in Myocardial Infarction Risk by HIV Status in Two US Healthcare Systems - (02/14/22)
     
  2195. Effect of HIV and Interpersonal Trauma on Cortical Thickness, Cognition, and Daily Functioning - (02/14/22)
     
  2196. CROI: One Third on ART 48 Hours From Birth Eligible for ART Interruption - Mark Mascolini (02/14/22)
     
  2197. CROI: TREATMENT WITH SOF/VEL/VOX IN HIV-HCV COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs - (02/14/22)
     
  2198. CROI: Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population - (02/14/22)
     
  2199. CROI: Two or More Anticholinergics Tied to Falls, Frailty in People With HIV - Mark Mascolini (02/14/22)
     
  2200. CROI: Geographical Differences in Functional Impairment of PLWH: Over One Third in Global HIV Analysis Have Impaired Physical Function - Mark Mascolini (02/14/22)
     
  2201. CROI: IV PUSH ADMINISTRATION OF IBALIZUMAB: PHARMACOKINETICS, SAFETY, AND EFFICACY - (02/14/22)
     
  2202. CROI: Infant Stunting Worse With Maternal EFV Than DTG, Similar With TAF and TDF - Mark Mascolini (02/14/22)
     
  2203. CROI: IMPACT OF TREATMENT INTERRUPTION ON COLONIC MUCOSA IN ACUTELY TREATED PARTICIPANTS - (02/14/22)
     
  2204. CROI: COVID Vax More Likely in Older, Heavier Men (vs Women) in Global HIV Trial - Mark Mascolini (02/14/22)
     
  2205. CROI: COVID mRNA Vaccines Appear to Protect Against Infection Transmission - Mark Mascolini (02/14/22)
     
  2206. CROI: COVID Vax Booster Cuts Breakthrough Infections, Hospital Use, Death - Mark Mascolini (02/14/22)
     
  2207. CROI: Post-Acute Long COVID: Lower Heart Rates During Exercise Point to Autonomic Dysfunction Causing Symptoms - Mark Mascolini (02/14/22)
     
  2208. CROI: Impact of the COVID-19 Pandemic on HIV Outpatient Care and Viral Suppression in NYC - (02/14/22)
     
  2209. CROI: PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA - (02/14/22)
     
  2210. Long-term cardiovascular outcomes of COVID-19 - (02/13/22)
     
  2211. CROI: Assessing health-related quality of life in people with HIV and cognitive issues - (02/13/22)
     
  2212. CROI: Impact of COVID outbreak on prevention and care for HIV and other STI's at a large hospital - (02/13/22)
     
  2213. CROI: SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH - (02/13/22)
     
  2214. CROI: Impact of COVID outbreak on prevention and care for HIV and other STI's at a large hospital - (02/13/22)
     
  2215. CROI: SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH - (02/13/22)
     
  2216. CROI: PETRAM RESULTS: BONE TURNOVER CHANGES ON 18F-NaF PET/CT AFTER A RANDOMISED SWITCH TO TAF - (02/13/22)
     
  2217. CROI: Decreased Myelin Content and Cognitive Performance in Adults with Perinatal HIV - (02/13/22)
     
  2218. CROI: SAFETY AND PK OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN ADOLESCENTS - (02/13/22)
     
  2219. CROI: EFFECT OF L74I POLYMORPHISM ON FITNESS OF HIV-1 SUBTYPE A6 RESISTANT TO CABOTEGRAVIR - (02/13/22)
     
  2220. CROI: Birth Outcomes following Prenatal Exposure to Dolutegravir: the Dolomite-EPPICC study - (02/13/22)
     
  2221. CROI: IMPAACT 2019: PK & Safety of Dispersible ABC/DTG/3TC in Children with HIV 6 to <14kg - (02/13/22)
     
  2222. CROI: COGNITIVE PREDICTORS OF EVERYDAY FUNCTIONING IN THE WOMEN'S INTERAGENCY HIV STUDY - (02/12/22)
     
  2223. CROI: ADHERENCE TO ANTIRETROVIRAL THERAPY IN MEDICARE FEE-FOR-SERVICE BENEFICIARIES WITH HIV - (02/12/22)
     
  2224. CROI: Islatravir does not prolong QTc in a thorough QT study in healthy participants - (02/12/22)
     
  2225. CROI: Kinetics of Lenacapavir in Participants With Severe Renal Impairment - (02/12/22)
     
  2226. CROI: Evaluation of Potential Drug-Drug Interactions Between Islatravir and Lenacapavir - (02/12/22)
     
  2227. CROI: Absence of Cross-Resistance to Lenacapavir in HIV Entry Inhibitor-Resistant Isolates - (02/12/22)
     
  2228. CROI: Immunogenicity and Prophylactic Efficacy of Arenavirus-Based SIV Vaccine in Macaques - (02/12/22)
     
  2229. CROI: LONG ACTING LENACAPAVIR PROTECTS AGAINST INTRAVENOUS CHALLENGE WITH SIMIAN-TROPIC HIV - (02/12/22)
     
  2230. CROI: WEEK 48 METABOLIC HEALTH AFTER SWITCH TO DTG/3TC VS CAR BY BASELINE REGIMEN (SALSA) - (02/12/22)
     
  2231. CROI: B/F/TAF Five-Year Outcomes in Treatment-Naïve Adults - (02/12/22)
     
  2232. CROI: COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts - (02/12/22)
     
  2233. CROI: Long-Acting Lenacapavir in People With Multidrug-Resistant HIV-1: Week 52 Results - (02/12/22)
     
  2234. CROI: FEMINIZING HORMONAL THERAPIES WORSEN CARDIOMETABOLIC PROFILES IN TRANSGENDER WOMEN - (02/12/22)
     
  2235. CROI: IMPACT OF INTEGRASE STRAND TRANSFER INHIBITORS ON COGNITION IN THE HAILO COHORT - (02/12/22)
     
  2236. CROI: Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults - (02/12/22)
     
  2237. CROI: Abnormal cognitive aging is detected despite clinically defined cognitive stability - (02/12/22)
     
  2238. CROI: LONG-ACTING CABOTEGRAVIR+RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M WEEK 152 RESULTS - (02/12/22)
     
  2239. CROI: VIIV HEALTHCARE TO PRESENT NEW LONG-TERM FINDINGS FROM ITS INNOVATIVE 2-DRUG AND LONG-ACTING HIV MEDICINES PORTFOLIO AT CROI 2022 - (02/12/22)
     
  2240. CDC - HIV+ Black Adults More Social Vulnerabilty; Higher Mortality; More Commorbidites - (02/10/22)
     
  2241. Fatty Liver (NAFLD) in HIV+ Young, Children, Adolescents - (02/08/22)
     
  2242. CROI: Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs - (02/08/22)
     
  2243. Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs - (02/08/22)
     
  2244. A New Class of Antiviral Therapy Could Treat COVID-19 - (02/08/22)
     
  2245. PLWH in NYC-COVID Vaccinations Disparities - (02/08/22)
     
  2246. Undertreated midlife symptoms for women living with HIV linked to lack of menopause discussions with providers - menopausal hormone therapy under-utilized - (02/07/22)
     
  2247. Transitioning to Frailty for PLWH 2 fold higher, Risk Factors - (02/06/22)
     
  2248. ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals - (02/06/22)
     
  2249. PCSK9 (Repatha) in HIV+, Affect on Plaque - (02/06/22)
     
  2250. Long-Haul COVID Cases Could Spike after Latest Wave - (02/05/22)
     
  2251. Mortality & Elderly PLWH - (02/05/22)
     
  2252. Updated cholesterol guidelines offer more personalized risk assessment, additional treatment options for people at the highest risk - risk factors - (02/05/22)
     
  2253. HIV CVD Guidelines - 2019 - Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association - (02/05/22)
     
  2254. FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year - (02/05/22)
     
  2255. NIA: Data shows racial disparities in Alzheimer's disease diagnosis between Black and white research study participants - (02/03/22)
     
  2256. Protection by 4th dose of BNT162b2 against Omicron in Israel - (02/04/22)
     
  2257. Merck readies oral, macrocyclic PCSK9 inhibitor for phase II test - (02/03/22)
     
  2258. NIA: Data shows racial disparities in Alzheimer's disease diagnosis between Black and white research study participants - (02/03/22)
     
  2259. ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment - (02/03/22)
     
  2260. Fatty Liver in HIV: higher prevalence, progresses faster, ALT/AST Predict - (02/02/22)
     
  2261. Cabenuva Long-Acting New Paradigm in HIV Treatment - (02/01/22)
     
  2262. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study - (02/01/22)
     
  2263. Perceived Barriers to Long-Acting Cabotegravir/Rilpivirine Better Than Expected - (02/01/22)
     
  2264. IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology - (01/27/22)
     
  2265. Impact of long-acting therapies on the global HIV epidemic - (01/27/22)
     
  2266. Evolocumab (PCSK9 Inhibitor for Heart Disease) in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study - (01/27/22)
     
  2267. Peripheral artery disease and physical function in women with and without HIV - (01/27/22)
     
  2268. Evolocumab (PCSK9 Inhibitor for Heart Disease) in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study - (01/27/22)
     
  2269. Peripheral artery disease and physical function in women with and without HIV - (01/27/22)
     
  2270. PLWH Survival Declines with Comorbidities Danish Cohort - (01/25/22)
     
  2271. Mutimorbidity Increases 50% in PLWH Over Past Several Years; 76% of HIV Have Polypharmacy. - (01/25/22)
     
  2272. HIV Care Fragmentation - PLWH Did Not Receive Good Specialty Care for Hypertension & Hyperlipidemia - (01/25/22)
     
  2273. HIV infection is associated with an increased risk of PAD, Peripheral Artery Disease - (01/25/22)
     
  2274. Telomere Length, Traditional Risk Factors, HIV-related Factors and Coronary Artery Disease Events in Swiss Persons Living with HIV - (01/25/22)
     
  2275. 26%, 10x HIGHer Prevalence of Peripheral Artery Disease in African-American Women with HIV in WIHS - (01/25/22)
     
  2276. What is Frailty in PLWH ? 25% of HIV+ Men in MACS >65 Were Frail in 2013; 42% of HIV+ Women >60 in WIHS in 2019 were Frail/Pre-Frail. Frailty Increases Mortality - (01/25/22)
     
  2277. EHE Goals Unmet - Two-Thirds of New HIV Infections Occur Among MSM - Inequities & Disparities - (01/25/22)
     
  2278. Genital Inflammation is Not Associated with Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP - (01/20/22)
     
  2279. One Alcohol Drink A Day Increases Cancers Risk - (01/20/22)
     
  2280. No amount of alcohol is good for the heart, new report says, but critics disagree on science - (01/20/22)
     
  2281. Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population During 2001 2015 - (01/19/22)
     
  2282. Menopause Is Associated With Immune Activation in Women With HIV - (01/19/22)
     
  2283. Gilead says counterfeiting network sold $250 mln worth of its HIV drugs - (01/18/22)
     
  2284. NYS Guidelines COVID Oral & Monoclonal Antibodies Treatments Eligibility - (01/18/22)
     
  2285. Fall & Frailty Increase Mortality in Older PLWH Frailty Assessments In Routine Care - (01/18/22)
     
  2286. Doravirine/3TC/TDF In EACS Initial Combination ART Guidelines as well as Raltegravir - (01/16/22)
     
  2287. Older adult opioid overdose death rates on the rise - 4 times higher for African-American Men - (01/16/22)
     
  2288. San Francisco Dept of Public Health: 71% >50, 29% >65 PLWH - (01/16/22)
     
  2289. HIV Capsid Lenacapavir Review Treatment & Prevention, PK, Mechanism, Resistance - (01/15/22)
     
  2290. 2 Recent study publications from Kaiser on Dementia & Heart Failure in PLWH - (01/15/22)
     
  2291. Long-term HIV Pre-exposure Prophylaxis Trajectories Among Racial & Ethnic Minority Patients: Short, Declining, & Sustained Adherence - (01/15/22)
     
  2292. Transgender Women and PrEP Care in NYC - (01/15/22)
     
  2293. Impact of Heroin and HIV on Gut Integrity and Immune Activation - (01/15/22)
     
  2294. Reduced Levels of NAD in Skeletal Muscle and Increased Physiologic Frailty Are Associated With Viral Coinfection in Asymptomatic Middle-Aged Adults - (01/13/22)
     
  2295. Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System - (01/12/22)
     
  2296. Life Expectancy Decreases with Comorbidities - Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies - (01/12/22)
     
  2297. Preeminence of Dolutegravir-Based Antiretroviral Therapy in Children and Adolescents - (01/12/22)
     
  2298. Life expectancy estimates based on comorbidities and frailty to inform preventive care - (01/11/22)
     
  2299. 60% in NYC >50 years old & 30% > 60 years old - (01/09/22)
     
  2300. Sex Differences in People Aging With HIV - women have worse quality of life & physical function & suffer more exhaustion - (01/09/22)
     
  2301. Women with HIV Have More Comorbidities, Worse Physical Function, & Inflammation - (01/07/22)
     
  2302. Faces of Frailty [women] in Aging with HIV Infection - (01/07/22)
     
  2303. Body Changes for Young Adults Acquiring HIV at Early Age & Perinatally - (01/06/22)
     
  2304. Life Expectancy for PLWH: disparities for Blacks, Women; Frailty High Rates in MACS, Physical Impairments by Age Worsen; Cognitive Impairment in Older PLWH - (01/04/22)
     
  2305. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children - (01/03/22)
     
  2306. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data - (01/03/22)
     
  2307. More evidence for worse COVID-19 outcomes in people with HIV - (01/03/22)
     
  2308. Comparison of dementia incidence and prevalence between individuals with and without HIV infection in primary care from 2000 to 2016 - (01/03/22)
     
  2309. CVD Score Predicts Frailty? - Cardiovascular risk score associations with frailty in men and women with or at risk for HIV - (01/03/22)
     
  2310. Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques - (01/03/22)
     
  2311. Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with HIV: data from the PANNA Network - (12/30/21)
     
  2312. 25% PLWH Report Discrimination Experience in Health Care Setting - (12/30/21)
     
  2313. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment - (12/29/21)
     
  2314. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US - (12/29/21)
     
  2315. New CDC Vital Signs Report Reveals a Decade of Continuing HIV Inequities on Eve of World AIDS Day - (12/28/21)
     
  2316. PLWH - Women; Life Expectancy-disparities; Social Determinants; Frailty; Physical & Cognitive Impairment - (12/28/21)
     
  2317. Pfizer COVID Protease & DDIs with HIV ARTs - (12/28/21)
     
  2318. FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year - (12/23/21)
     
  2319. Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment - (12/23/21)
     
  2320. Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19 - (12/23/21)
     
  2321. ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention - (12/23/21)
     
  2322. PLWH who adhere to ART but smoke are substantially more likely to die from lung cancer than from AIDS-related causes - (12/23/21)
     
  2323. Excess Black Deaths PLWH & Higher Morbidity - (12/23/21)
     
  2324. Social Determinants of Health & African-Americans Associated with Chronic Comorbidities & Brain Aging - (12/23/21)
     
  2325. The shifting age distribution of people with HIV using antiretroviral therapy in the United States, 2020 to 2030......23% >65y, 20% >70y (200,000+) and Impact - (12/23/21)
     
  2326. Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns - (12/21/21)
     
  2327. PrEP Barriers & Challenges - (12/21/21)
     
  2328. COVID-19 Vaccination Rates in a Global HIV Cohort - (12/13/21)
     
  2329. "I'm Just Forgetting and I Don't Know Why": Exploring How People Living With HIV-Associated Neurocognitive Disorder View, Manage, and Obtain Support for Their Cognitive Difficulties - study interviewing 25 PLWH average age 51 diagnosed with HAND (HIV-associated neurocognitive disorder) - (12/13/21)
     
  2330. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter? - (12/13/21)
     
  2331. SARS-CoV-2 Infection Among People Living With HIV Compared With People Without HIV: Survey Results From the MACS-WIHS Combined Cohort Study - (12/10/21)
     
  2332. Experimental mRNA HIV Vaccine Safe, Shows Promise in Animals NIAID Scientists Developed Vaccine Platform - (12/10/21)
     
  2333. EACS: Distinct groupings of people with HIV and pain associate differently with pain-related healthcare use and health-related quality-of-life (HRQoL): findings from the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study - (12/03/21)
     
  2334. Safety & Efficacy of SARS-CoV-2 Monoclonal Neutralizing Anibodies BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients - (12/03/21)
     
  2335. Remdesivir For the Treatment of High-Risk Non-Hospitalized Individuals with COVID-19: A Randomized, Double, Blind, Placebo-Controlled Trial PINETREE Study -RDV for 3 day 87% reduction in hospitalization, there were no deaths in either arm - (12/03/21)
     
  2336. New Aging/HIV Language in New US AIDS Strategy 2022-2026 - (12/02/21)
     
  2337. Gender Inequity-Inappropriate Prescribing for Elderly PLWH in Swiss Cohort - (11/30/21)
     
  2338. Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study - (11/30/21)
     
  2339. The Clinical Safety, Pharmacokinetics, and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor - (11/30/21)
     
  2340. Einstein and Montefiore Researchers Awarded $7.6 Million in NIH Grants to Study Depression in People Living with HIV - (11/22/21)
     
  2341. "I'm Just Forgetting and I Don't Know Why": Exploring How People Living With HIV-Associated Neurocognitive Disorder View, Manage, and Obtain Support for Their Cognitive Difficulties - (11/21/21)
     
  2342. High-Dose Marine Omega-3s Raise Risk for Atrial Fibrillation - (11/19/21)
     
  2343. The Esperanza Patient: More Hope for a Sterilizing HIV-1 Cure: A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation - (11/17/21)
     
  2344. AASLD: INSTIs and DAAs Boost Liver Transplant Survival in HIV+ and HIV+/HCV+ in US - (11/16/21)
     
  2345. AASLD: Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)
     
  2346. AASLD: HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)
     
  2347. AASLD: Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)
     
  2348. AASLD: HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)
     
  2349. Weight Change in NEAT-022, Switch to dolutegravir from boosted PI, 96 weeks at Glasgow 2018 - (11/11/21)
     
  2350. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV - (11/10/21)
     
  2351. No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults - (11/10/21)
     
  2352. EACS: Efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing nrti resistances: real world data - (11/10/21)
     
  2353. EACS: Integrase inhibitor drug resistance in clinical practice in the United Kingdom - (11/10/21)
     
  2354. Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults - (11/08/21)
     
  2355. EACS: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study - (11/06/21)
     
  2356. EACS: People with HIV and suppressed viremia on ART are not at increased risk for acquiring SARS-CoV-2 infection SARS-CoV-2 Risk No Higher With Well-Controlled HIV Than in HIV-Negatives - Mark Mascolini (11/06/21)
     
  2357. EACS: Tolerability and antiviral activity of bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) treatment switch in patients aged 55 years or older with HIV: the BIO study - (11/06/21)
     
  2358. EACS: Gender-related differences in safety after switching to BICTEGRAVIR/TAF/FTC in "real life" - (11/06/21)
     
  2359. EACS: Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study) - (11/06/21)
     
  2360. EACS: Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study - (11/06/21)
     
  2361. EACS: More than half of well-treated persons living with HIV have angiography verified coronary artery disease Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/06/21)
     
  2362. EACS: Increased neurocognitive impairment and white matter damaged in young adults with perinatal HIV infection. A case-control study - (11/06/21)
     
  2363. EACS: EACS: Long-Acting Injectable Cabotegravir + Rilpivirine. - (11/06/21)
     
  2364. EACS: A fog that impacts everything: understanding quality of life in people living with HIV and cognitive impairment - poor mental & physical function - (11/06/21)
     
  2365. EACS: Long-term HIV survivors and adults 65 or over with HIV: two separate profiles with different needs - (11/03/21)
     
  2366. EACS: Comorbidities in women living with HIV: a systematic review - higher rates for kidney, bone, heart, neurocognitive diseases - (11/03/21)
     
  2367. EACS: Themes of Aging from Older PLWH: A fog that impacts everything: understanding quality of life in people living with HIV and cognitive impairment - (11/03/21)
     
  2368. EACS: Comparison of baseline characteristics and cardiovascular outcomes of a multicentre UK cohort of people living with HIV with previously reported cohorts - (11/03/21)
     
  2369. EACS: Correlation between inflammatory biomarkers with four cardiovascular disease (CVD) risk models in aging patients living with HIV - (11/03/21)
     
  2370. EACS: Incidence of diabetes mellitus in PLWHIV: impact of antiretroviral therapy - (11/03/21)
     
  2371. EACS: Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors - (11/03/21)
     
  2372. EACS: Liver disease in people living with HIV (PLWHIV) after the microelimination of HCV infection: non-viral hepatitis & NAFLD - (11/02/21)
     
  2373. EACS: Factors associated with excess depressive disorders in women and men living with HIV in south-western France compared to the general French population - see slides below - (11/02/21)
     
  2374. EACS: Faster lung function decline in well-treated people living with HIV compared with uninfected controls: a longitudinal matched cohort study - Mark Mascolini (11/02/21)
     
  2375. EACS: Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort Study (SHCS) - (11/02/21)
     
  2376. EACS: Stigma Drives Higher Depression Rate in HIV+ Men and Women in France - Mark Mascolini (11/02/21)
     
  2377. New HRSA Funding Opportunities Focus on HIV and Aging Oct 28 published - (11/02/21)
     
  2378. EACS: Bacterial Pneumonia Incidence Drops Sharply in Swiss HIV Cohort Study - Mark Mascolini (11/02/21)
     
  2379. EACS: Incidence and risk factors for suicide, violent/accidental deaths, and substance abuse deaths in persons living with HIV - (11/02/21)
     
  2380. EACS: Change in body mass index (BMI) and association with clinical outcomes after initiation of contemporary HIV antiretroviral (ARV) regimens in EuroSIDA - (11/02/21)
     
  2381. EACS: Maraviroc or Metformin Does Not Lower Liver Fat in People With HIV and NAFLD - Mark Mascolini (11/02/21)
     
  2382. EACS: Hepatitis C elimination in time of COVID-19 pandemic: the experience of University Hospital Center in Paris, France - (11/01/21)
     
  2383. EACS: Maraviroc or Metformin Does Not Lower Liver Fat in People With HIV and NAFLD - Mark Mascolini (11/01/21)
     
  2384. EACS: Hepatic steatosis associated with integrase strand transfer inhibitors - does the substance matter? - (11/01/21)
     
  2385. EACS: Insulin resistance in PWH is associated with abdominal obesity and prior exposure to thymidine analogues and/or didanosine - (11/01/21)
     
  2386. EACS: Safety Profile of Cabotegravir + Rilpivirine During Oral Lead-In and Through Long-Acting Therapy: Pooled Analysis of the Phase 3 FLAIR, ATLAS, and ATLAS-2M Studies - (11/01/21)
     
  2387. EACS: UNDERSTANDING THE PERCEIVED THERAPEUTIC NEED AND VALUE ASSOCIATED WITH NOVEL LONG-ACTING ANTIRETROVIRAL REGIMENS AMONG PEOPLE LIVING WITH HIV IN 12 EUROPEAN COUNTRIES - (11/01/21)
     
  2388. EACS: European Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes - (11/01/21)
     
  2389. EACS: Highly Effective Two-drug Regimens of an Integrase Inhibitor and Reverse Transcriptase Inhibitor in Real-World Setting - Data from COMBINE-2 Study - (11/01/21)
     
  2390. EACS: 12-month outcomes - patient satisfaction - of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and pre-treated PLHIV in Germany: Real-world data from the German URBAN cohort - (11/01/21)
     
  2391. EACS: Evaluating the relationship between inflammation biomarker interleukin-6 (IL-6) levels and residual, low-Level viraemia in HIV-1 suppressed participants in the TANGO study at week 96 (WK96) - (11/01/21)
     
  2392. EACS: The potential clinical impact of the observed differences in IL-6, a marker of inflammation, associated with some antiretroviral regimens - (11/01/21)
     
  2393. EACS: Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/01/21)
     
  2394. EACS: PLW Presented Late To Care in WHO European Region 2019 - (11/01/21)
     
  2395. EACS: Viral Suppression in 40 Countries in Europe & Central Asia 2020 - (11/01/21)
     
  2396. EACS: Angiography Confirms Coronary Artery Disease in Over Half With HIV in Copenhagen - Mark Mascolini (11/01/21)
     
  2397. EACS: SWITCHING TO DTG/3TC IS NON-INFERIOR TO CONTINUING CURRENT ANTIRETROVIRAL REGIMEN AT WEEK 48: SALSA SUBGROUP ANALYSES - (10/31/21)
     
  2398. EACS: SWITCHING TO DTG/3TC IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN AT WEEK 144: TANGO SUBGROUP ANALYSES - (10/31/21)
     
  2399. EACS: 2 year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: Real-world data from the German JUNGLE cohort - (10/31/21)
     
  2400. EACS: Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): Examining Healthcare Staff Attitudes During a Hybrid III Implementation-Effectiveness Trial Implementing Cabotegravir + Rilpivirine Long-Acting Injectable (CAB + RPV LA) for People Living With HIV - (10/30/21)
     
  2401. EACS: Perspectives on the Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators From Patients Receiving Cabotegravir + Rilpivirine Long-Acting Injectable Treatment (CAB + RPV LA): Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) - (10/30/21)
     
  2402. EACS: Healthcare Staff Perspectives on the Implementation of HIV Injectable Treatment: Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) - (10/30/21)
     
  2403. EACS: Characteristics, treatment patterns, and viral load for treatment-experienced people living with HIV and switching to an MTR or STR ARV after 2018 - (10/30/21)
     
  2404. EACS: Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips - (10/30/21)
     
  2405. EACS: Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide - (10/30/21)
     
  2406. EACS: Evaluating virological outcomes in people with HIV on stable ART with reduced frequency of HIV viral load monitoring during the COVID-19 pandemic Less Viral Load Tracking During COVID Has No Immediate Ill Effects - Mark Mascolini (10/30/21)
     
  2407. EACS: Domestic abuse (DA) screening in people living with HIV (PLWH) More Domestic Abuse Screening in HIV+ During COVID Discloses Spike in Reports - Mark Mascolini (10/30/21)
     
  2408. EACS: Immunogenicity of mRNA vaccination against SARS-CoV-2 in persons living with HIV (PLWHs) with low CD4 count or previous AIDS Immune Response to mRNA COVID Vaccines Weaker in HIV+ With Low CD4s - Mark Mascolini (10/30/21)
     
  2409. EACS: Chemsex practice in men who have sex with men: reduction or relapse during lockdown? Results of the CheRRLock study COVID Lockdown Boosts Chemsex Use, Cuts Sex Partners in Paris MSM - Mark Mascolini (10/30/21)
     
  2410. EACS: New HCV Diagnoses Down by Two Thirds in HIV+ Swiss MSM 2010-2020 - Mark Mascolini (10/30/21)
     
  2411. EACS: Chemsex practice in men who have sex with men: reduction or relapse during lockdown? Results of the CheRRLock study COVID Lockdown Boosts Chemsex Use, Cuts Sex Partners in Paris MSM - Mark Mascolini (10/29/21)
     
  2412. EACS: Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting - (10/29/21)
     
  2413. EACS: Progression to Anal Cancer Precursor 11 Per 100 Person-Years in HIV+ MSM - Mark Mascolini (10/29/21)
     
  2414. EACS: Renal Safety of On-demand and Daily TDF-FTC for HIV Pre-exposure Prophylaxis in the ANRS-PREVENIR Study - (10/29/21)
     
  2415. EACS: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 12-month effectiveness, persistence, and safety in a multi-country cohort study - (10/29/21)
     
  2416. EACS: Patient-reported outcome (PRO) measures at 12 months in a real-world cohort of people living with HIV with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel - (10/29/21)
     
  2417. EACS: COMPARATIVE EFFICACY OF FOSTEMSAVIR VERSUS IBALIZUMAB IN HEAVILY TREATMENT-EXPERIENCED HIV PATIENTS - (10/29/21)
     
  2418. EACS: LONG-TERM INFLAMMATION BIOMARKER CHANGES WITH FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY ANALYSES OF THE PHASE 3 BRIGHTE STUDY - (10/29/21)
     
  2419. EACS: IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED WEEK 144 ANALYSIS OF THE GEMINI-1 AND GEMINI-2 CLINICAL STUDIES - (10/29/21)
     
  2420. EACS: Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV (CAPELLA study) - (10/29/21)
     
  2421. EACS: EMERGENT RESISTANCE TO ANTIRETROVIRAL AGENTS USED IN OPTIMIZED BACKGROUND THERAPY WITH FOSTEMSAVIR: WEEK 96 RESULTS OF THE PHASE 3 BRIGHTE STUDY IN HEAVILY TREATMENT-EXPERIENCED ADULTS LIVING WITH MULTIDRUG-RESISTANT HIV-1 - (10/29/21)
     
  2422. EACS: Recent Abacavir Use and Incident Cardiovascular Disease in Contemporary Treated PLWH within the RESPOND Cohort Consortium - (10/29/21)
     
  2423. EACS: Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials - (10/29/21)
     
  2424. EACS: Outcomes for Participants During Long-Term Follow-Up After Discontinuation of Cabotegravir + Rilpivirine Long-Acting in the Phase 3/3b Clinical Trials - (10/29/21)
     
  2425. EACS: Efficacy and Safety of Islatravir in Combination With Doravirine Through 144 Weeks for Treatment-Naïve Adults With HIV-1 Infection in a Phase 2b Trial - (10/29/21)
     
  2426. EACS: Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 26 weeks of treatment - (10/28/21)
     
  2427. EACS: Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV (PLWH) within the RESPOND cohort consortium - Mark Mascolini - (10/28/21)
     
  2428. EACS: Multiclass Resistance to Antiretrovirals Waning in Europe - Mark Mascolini - (10/28/21)
     
  2429. EACS: High HIV Positivity Rate When Self-Tests Distributed by LGBT Health Center Clients - Mark Mascolini - (10/28/21)
     
  2430. EACS: Kidney Toxicity Rare With Daily or On-Demand (As-Needed) PrEP - Mark Mascolini - (10/28/21)
     
  2431. EACS: Safety and Efficacy of Doravirine in Treatment-Naïve Adults with HIV-1: 4 Years of Experience From the DRIVE-FORWARD and DRVIVE-AHEAD Clinical Trials - (10/28/21)
     
  2432. EACS: ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be implemented successfully in a variety of European healthcare settings - (10/28/21)
     
  2433. EACS: ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV - (10/28/21)
     
  2434. The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries - (10/27/21)
     
  2435. Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018 - (10/27/21)
     
  2436. EACS: Evaluating the relationship between inflammation biomarker interleukin-6 (IL-6) levels and residual, low-Level viraemia in HIV-1 suppressed participants in the TANGO study at week 96 (WK96) - (10/27/21)
     
  2437. EACS: Durable efficacy and safety of DTG + 3TC in treatment-naive people with HIV-1 stratified by age: 144-week results from GEMINI-1 and -2 - (10/27/21)
     
  2438. EACS: Incidence of hypertension in people living with HIV receiving InSTI versus other third-drug ART regimens in the RESPOND cohort - (10/27/21)
     
  2439. EACS: High incidence of subclinical peripheral artery disease in people living with HIV in Denmark: a 2-year follow-up study - (10/27/21)
     
  2440. EACS: Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF - (10/27/21)
     
  2441. EACS: Week 192 bone and renal markers from the ADVANCE trial - (10/27/21)
     
  2442. EACS: ViiV Healthcare presents real-world evidence at EACS 2021 reinforcing the use of its 2-drug regimens Dovato (dolutegravir/lamivudine) and Juluca (dolutegravir/rilpivirine) for the treatment of people living with HIV - (10/27/21)
     
  2443. EACS: Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors - (10/27/21)
     
  2444. EACS: GENDER DIFFERENCES OF SUBCLINICAL ATHEROSCLEROSIS BURDEN IN CAROTID AND FEMORAL TERRITORIES IN PEOPLE LIVING WITH HIV: A SUBANALYSIS OF THE VASI STUDY - (10/27/21)
     
  2445. EACS: Comorbidities and antiretroviral utilization among people living with HIV in the United States - (10/27/21)
     
  2446. EACS: Change in body mass index (BMI) and association with clinical outcomes after initiation of contemporary HIV antiretroviral (ARV) regimens in EuroSIDA - (10/27/21)
     
  2447. EACS: Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021 - (10/27/21)
     
  2448. EACS: Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection - (10/25/21)
     
  2449. Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018 - (10/27/21)
     
  2450. Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults - (10/26/21)
     
  2451. EACS: Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection - (10/25/21)
     
  2452. U.S. Food and Drug Administration Approves Expanded Indication of Gilead's Biktarvy® for Treatment of HIV-1 in Pediatric Populations - (10/22/21)
     
  2453. Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040 - (10/20/21)
     
  2454. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data - (10/20/21)
     
  2455. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study - (10/20/21)
     
  2456. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization - (10/20/21)
     
  2457. Focus Groups - 2015 - WIHS-Wash DC - Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts - (10/17/21)
     
  2458. Black Cisgender Women's PrEP Knowledge, Attitudes, Preferences, and Experience in Chicago - (10/17/21)
     
  2459. "PrEP"ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women - (10/17/21)
     
  2460. Co-located HIV Services Can Help Women Who Inject Drugs Access PrEP, Study Shows - (10/17/21)
     
  2461. Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States - (10/17/21)
     
  2462. Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California - (10/17/21)
     
  2463. IDWeek: Reasons for not using PrEP and actions that may facilitate PrEP uptake in Ontario and British Columbia, Canada - (10/17/21)
     
  2464. IDWeek: Barriers to PrEP Implementation Among Patient-Facing Staff in Three Urban Clinics - (10/17/21)
     
  2465. IDWeek: A Survey of HIV PrEP Prescribing Practices at an Academic Medical Center in the Pacific Northwest United States - (10/17/21)
     
  2466. IDWeek: SUBOPTIMAL UPTAKE, RETENTION, AND ADHERENCE OF DAILY ORAL PREP AMONG PEOPLE WITH OUD RECEIVING HCV TREATMENT - (10/17/21)
     
  2467. IDWeek: Bridging the Gap in PrEP Provider Training: An Implementation Science Study. insurance navigation for PrEP - (10/17/21)
     
  2468. Renal impairment in a large-scale HIV pre-exposure prophylaxis implementation cohort - (10/14/21)
     
  2469. Task Force Issues Draft Recommendation Statement on Aspirin Use to Prevent Cardiovascular Disease - (10/12/21)
     
  2470. Providers PrEP: Identifying Primary Health care Providers' Biases as Barriers to Provision of Equitable PrEP Services - (10/07/21)
     
  2471. IDWeek: Preliminary Findings from a HIV Self-Testing Program among People Who Use Drugs - (10/06/21)
     
  2472. PLWH Have Higher COVID Testing, Diagnosis & Hospitalization at Kaiser Permanente So. Calif. - (10/07/21)
     
  2473. IDWeek: Racial and Ethnic Disparities in COVID-19 Incidence among Persons with HIV in a Multisite-Cohort - (10/05/21)
     
  2474. Cross-sectional study of correlates and prevalence [high rates] of functional and high-risk multimorbidity in an academic HIV practice in New York City at Cornell-Weill HIV Clinic - (10/05/21)
     
  2475. Menopause Is Associated With Immune Activation in Women With HIV; mortality, heart disease, discrimination, stigma - (10/05/21)
     
  2476. IDWeek: Lower SARS-CoV-2 IgG and Surrogate Virus Neutralization Titers Post-mRNA Vaccination among People Living with HIV - (10/05/21)
     
  2477. IDWeek: Switch to DTG/3TC Noninferior to Maintaining TAF Regimen for 144 Weeks - Mark Mascolini (10/04/21)
     
  2478. IDWeek: In Vitro Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence - (10/04/21)
     
  2479. IDWeek: Increasing trends in multimorbidity and polypharmacy over a 5-year period in people living with HIV in the United States - Big US Study Confirms Ballooning Multimorbidity, Polypharmacy With HIV - (10/04/21)
     
  2480. Weight Increases with Reyataz & Efavirenz in Treatment-Naives A5202 - (09/27/21)
     
  2481. Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults - Results of a Controlled Trial - (09/22/21)
     
  2482. CROI: Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)
     
  2483. IDWeek: EFFICACY AND SAFETY OF LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN PARTICIPANTS WITH HIV/HCV CO-INFECTION: ATLAS-2M 48-WEEK RESULTS - (10/04/21)
     
  2484. IDWeek: Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1-Infected Participants - (10/03/21)
     
  2485. IDWeek: Implementation of Long-acting Injectable Cabotegravir-Rilpivirine for HIV-1 treatment at a Ryan White-funded Clinic in the U.S. South - (10/03/21)
     
  2486. IDWeek: Renal function, Lipid profile, and Cardiovascular Events After Switching to Abacavir-containing Regimen in Antiretroviral-therapy-experienced People Living with HIV in Northern Thailand - (10/03/21)
     
  2487. IDWeek: Use of tenofovir disoproxil fumarate shows weight loss vs placebo: a meta-analysis of 7 clinical trials in 19,359 HIV-negative individuals - (10/03/21)
     
  2488. IDWeek: Interim Analysis of Real-World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start The RoCHaCHa Study a Pilot Study - (10/03/21)
     
  2489. IDWeek: Long-term clinical outcomes following SARS-CoV-2 infection include persistent symptoms and cardiovascular disease beyond 3 months post-infection - (10/03/21)
     
  2490. IDWeek: Monoclonal Regdanvimab Cuts COVID Progression Risk in Placebo Trial - Mark Mascolini (10/03/21)
     
  2491. IDWeek: CHARACTERIZATION OF HEAVILY TREATMENT-EXPERIENCED HIV-1-INFECTED CLINICAL TRIAL PARTICIPANTS INFECTED WITH SARS-COV-2 COVID-19: FOSTEMSAVIR BRIGHTE PHASE 3 CLINICAL TRIAL - (10/03/21)
     
  2492. IDWeek: Improvement in Diet Attenuates Antiretroviral Therapy (ART) Associated Weight Gain in Persons with Human Immunodeficiency Virus (PWH) Improved Diet Tied to Lower ART-Related Weight Gain in 870-Person US Study - Mark Mascolini (10/02/21)
     
  2493. IDWeek: EFFECTIVENESS AND TOLERABILITY OF DTG+3TC IN CLINICAL PRACTICE: EVIDENCE IN PLHIV FROM REAL-WORLD DATA - (10/02/21)
     
  2494. IDWeek: COVID-19 Symptoms Persist Beyond 1 Month in 25% of US Military Group - Mark Mascolini (10/02/21)
     
  2495. IDWeek: Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 weeks. Low and Similar Rates of New Metabolic Problems: 3 Years With 3 ART Regimens - Mark Mascolini (10/02/21)
     
  2496. IDWeek: Sex and race disparities in premature mortality among people with HIV: a 21-year observational cohort study - Premature Mortality Higher in Women and Blacks in US HIV Group - (10/01/21)
     
  2497. IDWeek: Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens - Mark Mascolini (10/01/21)
     
  2498. IDWeek: EFFECTS OF THE "UNDETECTABLE = UNTRANSMITTABLE" ("U=U") EDUCATIONAL CAMPAIGN ON TREATMENT OUTCOMES AND PERCEPTIONS AMONG PEOPLE LIVING WITH HIV IN NORTH AMERICAN COUNTRIES - (10/01/21)
     
  2499. IDWeek: Strong HIV Control for 72 Weeks With B/F/TAF in US Blacks - Mark Mascolini (10/01/21)
     
  2500. IDWeek: North American Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes - (10/01/21)
     
  2501. IDWeek: REAL-WORLD PERSISTENCY OF PATIENTS RECEIVING TENOFOVIR-BASED PRE-EXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE US - (10/01/21)
     
  2502. IDWeek: Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies - (10/01/21)
     
  2503. IDWeek: Pre-exposure prophylaxis (PrEP) prescriptions among individuals at high risk for HIV in the United States, 2012-2018 - (10/01/21)
     
  2504. IDWeek: Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis (PrEP): A Real-World Evidence Analysis in the United States - (10/01/21)
     
  2505. IDWeek: Offering Drug Injectors PrEP While ID Inpatients Not Successful - Mark Mascolini (10/01/21)
     
  2506. IDWeek: Lower CD4s and Higher Viral Load-Not Antiretrovirals-Tied to Excessive Weight Gain - Mark Mascolini (10/01/21)
     
  2507. IDWeek: Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021 - (09/30/21)
     
  2508. IDWeek: COVID Brings Drops in HIV Care Visits, Viral Load Measures, and ART Stops - Mark Mascolini (09/30/21)
     
  2509. IDWeek: Remdesivir Linked to Viral Clearance Only in Certain Subsets - Mark Mascolini (09/30/21)
     
  2510. IDWeek: Treatment with molnupiravir in the MOVe-In and MOVe-Out clinical trials results in an increase in transition mutations across the SARS-CoV-2 genome - (09/30/21)
     
  2511. IDWeek: Use of immune-viral dynamics modeling to understand molnupiravir drug effect for COVID-19 - (09/30/21)
     
  2512. IDWeek: Clinical Characteristics of Patients Living with HIV Hospitalized for COVID-19 - PLWH have Higher Mortality Rate - (09/30/21)
     
  2513. IDWeek: Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies - (09/30/21)
     
  2514. IDWeek: Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021 - (09/30/21)
     
  2515. IDWeek: CHARACTERISTICS, COMORBIDITIES, AND MEDICATION BURDEN AMONG PEOPLE LIVING WITH HIV IN THE US MEDICARE PROGRAM - (09/30/21)
     
  2516. IDWeek: Increasing trends in multimorbidity and polypharmacy over a 5-year period in people living with HIV in the United States - (09/30/21)
     
  2517. IDWeek: The Efficacy and Safety of Maintenance With Doravirine Plus Two NRTIs After Initial Suppression in Adults With HIV-1 in the DRIVE-FORWARD Clinical Trial: Results From the Study Extension Through 192 Weeks - (09/30/21)
     
  2518. IDWeek: High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in African-American Adults With HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence - (09/30/21)
     
  2519. IDWeek: QUALITATIVE PATIENT-PARTICIPANT PERSPECTIVES ON IMPLEMENTATION OF MONTHLY CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB+RPV LA) INJECTABLE IN THE UNITED STATES (CUSTOMIZE) - (09/30/21)
     
  2520. IDWeek: Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living With HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials - (09/30/21)
     
  2521. IDWeek: MATERNAL DOLUTEGRAVIR (DTG) USE, AND PREGNANCY AND BIRTH OUTCOMES: THE ANTIRETROVIRAL PREGNANCY REGISTRY (APR) - (09/29/21)
     
  2522. IDWeek: HIGH RATES OF VIROLOGIC SUPPRESSION WITH DTG/3TC IN NEWLY DIAGNOSED ADULTS WITH HIV-1 INFECTION AND BASELINE VIRAL LOAD ≥500,000 C/ML: 48-WEEK SUBGROUP ANALYSIS OF THE STAT STUDY - (09/29/21)
     
  2523. IDWeek: Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks (CALIBRATE) - (09/29/21)
     
  2524. IDWeek: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 144 WEEKS (TANGO STUDY) - (09/29/21)
     
  2525. IDWeek: Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial - (09/29/21)
     
  2526. IDWeek: Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 weeks. Low and Similar Rates of New Metabolic Problems: 3 Years With 3 ART Regimens - Mark Mascolini (09/29/21)
     
  2527. IDWeek: Monoclonal Lenzilumab Cuts Need for Ventilation in Phase 3 COVID Trial - Mark Mascolini (09/29/21)
     
  2528. IDWeek: Invasive Pneumococcal Disease Rate 17-Fold Higher With HIV in US - Mark Mascolini - (09/29/21)
     
  2529. IDWeek: ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021 - (09/29/21)
     
  2530. PWH -Higher Rates of Frailty Transitioning & Deaths - (09/28/21)
     
  2531. ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals - (09/28/21)
     
  2532. FDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir long-acting for prevention of HIV - (09/28/21)
     
  2533. AGE: Factors influencing psychological distress during the COVID-19 pandemic in people aging with HIV - (09/28/21)
     
  2534. AGE: Rapid Aging of HIV Immune System Reported in 2011 and Earlier by Rita Effros & UCLA Researchers. - (09/28/21)
     
  2535. AGE: Frailty and resilience in people living with HIV during the COVID era: two complementary constructs? Sarcopenia, frailty & % of adipose tissue worsened. 37% were Frail & Non-Resilient - (09/28/21)
     
  2536. AGE: Factors influencing psychological distress during the COVID-19 pandemic in people aging with HIV - (09/27/21)
     
  2537. Pharm: Tenofovir alafenamide concentrations are reduced by half in pregnant women living with HIV: data from the PANNA Network. - By Mark Mascolini - (09/27/21)
     
  2538. AGE: Pain Linked to Depression, Worse Physical Function, Falls, Frailty and Inflammation in Older People With HIV - By Mark Mascolini - (09/27/21)
     
  2539. AGE: Burden of age-associated chronic comorbidities among people living with and without HIV: Years of life lost to premature mortality in British Columbia, Canada - (09/27/21)
     
  2540. AGE: COVID Vaccine Effectivity in Aging & HIV Populations - (09/27/21)
     
  2541. AGE: NYC Ryan White Part A: Program Model of Care for HIV and Aging - (09/25/21)
     
  2542. AGE: Black and Hispanic women in the United States are disproportionally affected by the HIV infection - (09/25/21)
     
  2543. AGE: Preliminary Hearing Data in Older Adults Living with 1HIV from 2the DETECT Study - (09/25/21)
     
  2544. AGE: Survey of Consumers, Clinicians and Service Providers about Needs of Long-Term Survivors and People Aging with HIV in New York State - (09/25/21)
     
  2545. AGE: Cognitive Impairment in Aging PLWH - Bruce Brew, MD lecture - (09/25/21)
     
  2546. AGE: NAFLD Independently Tied to Worse Physical Quality of Life With HIV - By Mark Mascolini - (09/25/21)
     
  2547. AGE: NAFLD Independently Tied to Worse Physical Quality of Life With HIV - (09/24/21)
     
  2548. AGE: Polypharmacy Halves Odds of Nonadherence to ART-Frailty Boosts Odds - (09/24/21)
     
  2549. AGE: Life Years Lost Due to Comorbidities 2.5 Time Greater With HIV - (09/24/21)
     
  2550. AGE: Less Healthy Response to Skeletal Muscle Damage in Older Men With HIV - Mark Mascolini (09/23/21)
     
  2551. AGE: Higher Viral Load Predicts Thromboembolism in People With HIV - Mark Mascolini (09/23/21)
     
  2552. AGE: Rare Menopausal Hormone Therapy in HIV+ Women Tied to Lack of Clinician Discussion - Mark Mascolini (09/23/21)
     
  2553. Intl Wrkshp Clin Pharm: Clinical Application for Coadministration of FTR and HCV medications - (09/22/21)
     
  2554. Intl Wrkshp Clin Pharm: Special Populations Including End Organ Failure: Focus on Long-Acting Cabotegravir and Rilpivirine - (09/22/21)
     
  2555. Intl Wrkshp Clin Pharm: Prevalence of clinically significant drug-drug interactions with antiretrovirals against HIV over time: a systematic review of the literature - (09/21/21)
     
  2556. Intl Wrkshp Clin Pharm: Risk of Low-Level HIV Rises With Each Worse TDF Adherence Level - Mark Mascolini - (09/21/21)
     
  2557. Intl Wrkshp Clin Pharm: Proposed Fostemsavir Precautions With HCV Meds - Mark Mascolini - (09/21/21)
     
  2558. Intl Wrkshp Clin Pharm: Dolutegravir Troughs Higher With 3TC, Lower With TAF - Mark Mascolini - (09/21/21)
     
  2559. Intl Wrkshp Clin Pharm: First 2 Reports of Bictegravir in Pregnancy Suggest Efficacy - Mark Mascolini - (09/21/21)
     
  2560. Intl Wrkshp Clin Pharm: No Drop in Rate of Drug-Drug & Interactions With HIV Drugs Since 1985 - Mark Mascolini - (09/21/21)
     
  2561. Congresswoman Barbara Lee and Jenniffer González continue to fight for those living with HIV Congressional HIV/AIDS Caucus Co-chairs introduce bipartisan bill (supporting aging/HIV & goals of HIV Awareness Ageing Day) - (09/21/21)
     
  2562. IAS: COMORBIDITIES AND AGEING; IMMUNOMETABOLISM AND HIV PATHOGENESIS; TB & HIV; HIV Natural Controllers - Christina K. Psomas, MD (09/20/21)
     
  2563. Intl Wrkshp Clin Pharm: Drug-Drug Interaction Risk High With COVID Meds in Hospital - Mark Mascolini - (09/20/21)
     
    2564. Intl Wrkshp Clin Pharm: New Oral Ribonucleoside Optimal at 800 mg Twice Daily vs SARS-CoV-2 - Mark Mascolini - (09/20/21)
     
    Intl Wrkshp Clin Pharm: Phase 1 Trial Suggests Antidiarrheal Nitazoxanide Dose for COVID - Mark Mascolini - (09/20/21)
     
  2564. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study - (09/20/21)
     
  2565. Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial - (09/20/21)
     
  2566. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz - (09/17/21)
     
  2567. Life-long Antiretroviral Therapy: Playing the Long Game (weight gain) - (09/17/21)
     
  2568. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults - (09/16/21)
     
  2569. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial - (09/16/21)
     
  2570. Behavioral and Clinical Characteristics of Persons Living with Diagnosed HIV Infection-Medical Monitoring Project, United States, 2019 Cycle - (09/15/21)
     
  2571. Behavioral and Clinical Characteristics of Persons Living with Diagnosed HIV Infection-Medical Monitoring Project, United States, 2019 Cycle - (09/15/21)
     
  2572. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study - (09/14/21)
     
  2573. Ultra-long-acting removable drug delivery system for HIV treatment and prevention - (09/14/21)
     
  2574. Long-acting implants to treat and prevent HIV infection - (09/14/21)
     
  2575. IL-6 BLOCKADE DECREASES INFLAMMATION AND INCREASES CD127 EXPRESSION IN HIV INFECTION - (09/10/21)
     
  2576. HIV and antiretroviral therapy-related fat alterations - (09/02/21)
     
  2577. Fat & ART Effects in HIV, Comorbidities: Initiating ART Is Associated With Decreased Fat Density in People Living With HIV - (09/02/21)
     
  2578. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials - (09/02/21)
     
  2579. IAS: Anxiety and Alcohol Consumption in the Miami Adult Studies on HIV (MASH) Cohort During the COVID-19 Pandemic - (09/01/21)
     
  2580. Food Insecurity Affects HIV+ Minorities & Associated with Comorbidities & Mortality - (09/01/21)
     
  2581. Managing frailty in people living with HIV: establishing and reviewing a new clinical service at Royal Free HIV Clinic London UK - (09/01/21)
     
  2582. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV - (09/01/21)
     
  2583. IAS: Long-Acting Treatment: Cabotegravir/rilpivirine; Long-Acting Injectable PrEP HPTN 083, 084 - (08/31/21)
     
  2584. Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa - (08/31/21)
     
  2585. Heart Disease & HIV: statement from American Heart Association Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association - (08/31/21)
     
  2586. The challenge of HIV treatment in an era of polypharmacy - (08/31/21)
     
  2587. Aging, Comorbidities Screening Tests PWH Should Be Doing - (08/31/21)
     
  2588. IAS: DECLINE IN HIV TESTING AND CHANGES IN POSITIVITY RATES DURING THE COVID-19 PANDEMIC - (08/30/21)
     
  2589. IAS: Lenacapavir; Islatravir, Doravirine at IAS 2021 - (08/30/21)
     
  2590. IAS: Co-morbidity and HIV: What Matters to Patients ? - IAS Symposium - Growing old with HIV: Co-morbidities and ageing (CME) - (08/25/21)
     
  2591. Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1 - (08/24/21)
     
  2592. Switch to Doravirine 2 Studies, DRIVE-SHIFT Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV - (08/24/21)
     
  2593. Cerebrovascular Contributions to Neurocognitive Disorders in People Living With HIV - (08/24/21)
     
  2594. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine - FDA Grants Full Approval - (08/24/21)
     
  2595. IAS: HIV Immune Response to COVID - 2 studies: 1- Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIV, 2 - SARS-Cov-2 immunity in COVID-19 convalescent individuals living with HIV: bulk immune profiling and SARS-CoV-2 specific humoral and cellular immune responses - (08/24/21)
     
  2596. IAS: Virological suppression in people living with HIV infection is not protective of subclinical atherosclerosis - (08/24/21)
     
  2597. IAS: Low rates of testing for sexually transmitted infections in an insured cohort of men and women living with HIV - (08/24/21)
     
  2598. IAS: Chronic morphine administration alters gut-brain homeostasis in SHIV infected rhesus macaques - (08/24/21)
     
  2599. IAS: Food insecurity is associated with increased immune activation in people living with HIV - (08/24/21)
     
  2600. European Medicines Agency Validates Gilead's Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options - (08/23/21)
     
  2601. NYC Forum on Older People with HIV: Developing a Service Model for PWH Over 50 in NYC - (08/23/21)
     
  2602. IAS: Changes in Inflammation Scores Among People Living with HIV (PLWH) Under Different Antiretroviral Treatment (ART) Regimes - (08/23/21)
     
  2603. IAS: Baricitinib reduces macrophage-mediated inflammation in HIV infection - (08/23/21)
     
  2604. IAS: Ageing and renal insufficiency in persons living with and without HIV in AFRICOS - (08/23/21)
     
  2605. IAS: Daily Variations- HIV & Immunity, T-Cell Exhaustion in Vertically Acquired HIV-children/adolescents/adults - (08/23/21)
     
  2606. IAS: Circulating GDF15 levels [cellular stress] are associated with aging, risk of non-AIDS comorbidities and integrated HIV DNA in ART-treated people living with HIV - (08/23/21)
     
  2607. IAS: Stress & Aging, Sleep & Brain - (08/23/21)
     
  2608. IAS: Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, open¬ label safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancy - (08/23/21)
     
  2609. IAS: Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention Among Women Who Engaged in Transactional Sex - (08/23/21)
     
  2610. Working HAND in HAND: Central nervous system complications in people with HIV - (08/21/21)
     
  2611. IAS: Dolutegravir + 3TC at IAS 2021 - (08/19/21)
     
  2612. IAS: Metabolics, Comorbidities & Aging at IAS 2021 - (08/15/21)
     
  2613. ACIP Aug 13 slides Immunocompromsed: Evidence to Recommendation Framework: An Additional Dose of mRNA COVID-19 Vaccine Following a Primary Series in Immunocompromised People - (08/13/21)
     
  2614. IAS: PSYCHOLOGICAL STRESS IS ASSOCIATED WITH CAROTID INFLAMMATION IN PERSONS WITH TREATED HIV INFECTION - (08/13/21)
     
  2615. IAS: Proteomic evidence of vesatolimod-induced enhancement of 'cross-talk' • between innate and adaptive immune cells in HIV controllers on ART - (08/11/21)
     
  2616. IAS: GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell culture - (08/11/21)
     
  2617. IAS: LOWER HIV RESERVOIR SIZE IN INDIVIDUALS WHO MAINTAIN HIGHER CD4+ T CELL COUNTS PRIOR TO ANTIRETROVIRAL THERAPY INITIATION: THE STRATEGIC TIMING OF ANTIRETROVIRAL TREATMENT (START} HIV RESERVOIR STUDY. - (08/11/21)
     
  2618. IAS: Early treated individuals had lower reservoir size, lower viral diversity and higher susceptibility to bNAbs
    Evaluation of HIV-1 reservoir size and broadly neutralizing antibody (bNAb) susceptibility in individuals who initiated ART during acute and chronic infection     - (08/11/21)
     
  2619. Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States - (08/09/21)
     
  2620. Weight Change - Dolutegravir - Children, Adolescents - Intl Workshop on Pediatrics, HIV - (08/09/21)
     
  2621. HIV-1 PERSISTENCE IN THE CNS: MECHANISMS OF LATENCY, PATHOGENESIS AND AN UPDATE ON ERADICATION STRATEGIES - (08/09/21)
     
  2622. IAS: Switch to INSTI more than offset negative effects of weight gain on incidence of insulin resistance in people living with HIV - (08/09/21)
     
  2623. IAS: Combination of high liver and visceral fat predict diabetes in people living with HIV - (08/09/21)
     
  2624. B/F/TAF In Virologically Suppressed Adolescents and Children: Two-year Outcomes in 6 to <18 Year Olds and Six-month Outcomes in Toddlers - (08/06/21)
     
  2625. Long-term Safety & Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Single-Tablet Regimen in Children and Adolescents Living With HIV - (08/06/21)
     
  2626. IAS: The association of coronary calcification with visceral adiposity in people living with HIV. Results from the Liverpool multiparametric imaging collaboration - (08/06/21)
     
  2627. IAS: Prevalence and predictors of elevated arterial blood pressure in ageing people living with HIV attending care in Zambia - (08/06/21)
     
  2628. IAS: Sexual Minority Stress and Accelerated Cellular aging in Treated HIV Infection - (08/06/21)
     
  2629. Weight Change - Dolutegravir - Children, Adolescents - Intl Workshop on Pediatrics, HIV - (08/05/21)
     
  2630. HIV-1 PERSISTENCE IN THE CNS: MECHANISMS OF LATENCY, PATHOGENESIS AND AN UPDATE ON ERADICATION STRATEGIES - (08/05/21)
     
  2631. IAS: Long-Acting Treatment & PrEP Key Studies at IAS 2021 - (08/04/21)
     
  2632. ACTG Starts New weight Gain, HIV Study Including Switch to Doravirine - (07/30/21)
     
  2633. Exposure to dolutegravir from two formulations in children in the ODYSSEY trial - Intl Pediatrics Workshop - (07/26/21)
     
  2634. Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial - Intl Pediatrics Workshop - (07/26/21)
     
  2635. Efficacy, Safety and Tolerability of Guideline-Recommended ARVs from Pediatric Clinical Trials: A Systematic Review - Intl Pediatrics Workshop - (07/26/21)
     
  2636. Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial - Intl Pediatics Workshop - (07/26/21)
     
  2637. DOLUTEGRAVIR-BASED ART IS SUPERIOR TO STANDARD OF CARE IN YOUNG CHILDREN LIVING WITH HIV - Intl Pediatrics Workshop - (07/26/21)
     
  2638. ART & Cervical Cancer Women with HIV Risk - (07/26/21)
     
  2639. IAS: Immunoscenescence and HIV: mutual interactions? - (07/26/21)
     
  2640. IAS: Poor sleep quality in people with HIV linked to lower CSF amyloid beta 42 - (07/26/21)
     
  2641. IAS: HCV Reinfection Rate Almost 4% in Global Analysis of People With HIV - Mark Mascolini (07/26/21)
     
  2642. IAS: Drug Injecting Remains Barrier to HCV Elimination in Netherlands - Mark Mascolini (07/26/21)
     
  2643. IAS: HCV Cure Rate 92% in Hard-to-Reach Vietnam Drug-Injecting Group - Mark Mascolini (07/26/21)
     
  2644. Coronavirus Disease 2019 (COVID-19) Infection Among People With Human Immunodeficiency Virus in New York City: A Population-Level Analysis of Linked Surveillance Data - Commentary & paper 50% Higher COVID Deaths, hospitalizations & ICU due to COVID for PLWH vs HIV-Neg in NYC - (07/22/21)
     
  2645. IAS: Aging PLWH & Higher Readmission Hospital Rates than the General Population Hospital Readmissions Fall in Big HIV Group But Still High vs Non-HIV Patients - Mark Mascolini (07/23/21)
     
  2646. IAS: Good Adherence to Vaginal Ring and Daily PrEP in Half of Young African Women - Mark Mascolini (07/23/21)
     
  2647. IAS: Improving Hormone Levels in Transgenders Receiving Hormone Therapy - Mark Mascolini (07/23/21)
     
  2648. IAS: Fostemsavir Serious Adverse Events More Frequent in People Over 50, Men, North Americans - Mark Mascolini (07/23/21)
     
  2649. IAS: Integrase strand transfer inhibitor (INSTI) use and cancer incidence - Mark Mascolini (07/23/21)
     
  2650. IAS: Trichloroacetic Acid an Alternative to Electrocautery for Anal Cancer Precursor? - Mark Mascolini (07/23/21)
     
  2651. IAS: US MSM Seem Eager for Injectable PrEP-Side Effects, Cost Biggest Concerns - Mark Mascolini (07/23/21)
     
  2652. IAS: Achievement of Undetectable HIV-1 RNA in the B/F/TAF Treatment-Naïve Clinical Trials - (07/22/21)
     
  2653. IAS: Long-acting Capsid Inhibitor Effective as PrEP Against Vaginal SHIV Transmission in Macaques - (07/22/21)
     
  2654. IAS: Barriers to Expanding PrEP Uptake among cis-gender African American Women in the US South - (07/22/21)
     
  2655. IAS: Understanding participant experiences and preferences in an injectable PrEP trial: A qualitative substudy of barriers, facilitators, and preferences for PrEP use among MSM and TGW - (07/22/21)
     
  2656. IAS: CLINICAL IMPACT OF ANTIRETROVIRAL AGENTS USED IN OPTIMIZED BACKGROUND THERAPY WITH FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY ANALYSES OF THE PHASE 3 BRIGHTE STUDY - (07/22/21)
     
  2657. IAS: LONG-TERM (96-WEEK) SAFETY OF FOSTEMSAVIR (FTR) IN HEAVILY TREATMENT-EXPERIENCED (HTE) ADULTS INFECTED WITH MULTIDRUG-RESISTANT (MDR) HIV-1 (BRIGHTE PHASE 3 STUDY) - (07/22/21)
     
  2658. IAS: Safety Analysis of Islatravir in Combination With Doravirine in Treatment-Naïve Adults With HIV-1 Infection Through 96 Weeks Islatravir/Doravirine Adverse Events Less Frequent in Second Half of 96-Week Trial - Mark Mascolini (07/22/21)
     
  2659. IAS: High interest in long-acting injectable HIV pre-exposure prophylaxis among nationwide online sample of United States men who have sex with men, 2019 - (07/22/21)
     
  2660. IAS: Variation in preferences for long-acting injectable PrEP among US men who have sex with men: a latent class analysis - (07/22/21)
     
  2661. IAS: Preferences for implementing long-acting injectable pre-exposure prophylaxis among cisgender men who have sex with men in the US - Online Survey - (07/22/21)
     
  2662. IAS: Safety Analysis of Islatravir in Combination With Doravirine in Treatment-Naïve Adults With HIV-1 Infection Through 96 Weeks - (07/22/21)
     
  2663. IAS: Safety and Pharmacokinetics of Oral Islatravir Once Monthly for HIV Pre-exposure Prophylaxis (PrEP): Week 24 Analysis of a Phase 2a Trial - (07/22/21)
     
  2664. IAS: Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform - (07/22/21)
     
  2665. IAS: Unsuppressed plasma HIV-RNA is associated with worse COVID-19 outcomes among people living with HIV. - (07/22/21)
     
  2666. IAS: The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study - (07/21/21)
     
  2667. IAS: The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)
     
  2668. IAS: Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV - (07/21/21)
     
  2669. IAS: Higher comorbidity and comedication burden in women and young people living with HIV More Comorbidities, Polypharmacy With HIV-But Subgroup Differences Abound - (07/21/21)
     
  2670. IAS: Mitochondrial disorders in activated memory CD4+ T cells derived from HIV-infected immunological non-responders - (07/21/21)
     
  2671. IAS: Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)
     
  2672. IAS: Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019-June 2020. - (07/21/21)
     
  2673. IAS: Outcomes of Participants Switching from F/TDF to F/TAF for PrEP: Week 48 Results from the DISCOVER Open Label Phase - (07/21/21)
     
  2674. IAS: Long-term Analysis of B/F/TAF in Treatment-Naïve Adults Living With HIV Through Four Years of Follow-up - (07/21/21)
     
  2675. IAS: Sub-40-Copy Virologic Hints May Favor DTG/3TC Over Multidrug Combos in TANGO - Mark Mascolini (07/21/21)
     
  2676. IAS: Only 1 More Virologic Failure on CAB + RPV in Weeks 96 to 124 of FLAIR - Mark Mascolini - (07/21/21)
     
  2677. IAS: CAB + RPV Failure Risk Factor in 10% of Large French Cohort - Mark Mascolini - (07/21/21)
     
  2678. IAS: Higher CVD Risk With HIV, Especially in People Younger Than 40 - Mark Mascolini - (07/21/21)
     
  2679. IAS: Impact of HIV on COVID-19 Outcomes among Hospitalized Adults in the U.S. - (07/21/21)
     
  2680. IAS: Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 - (07/21/21)
     
  2681. IAS: WEEK 124 OF THE RANDOMIZED, OPEN-LABEL, PHASE 3 FLAIR STUDY EVALUATING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR TREATMENT IN ADULTS WITH HIV-1 INFECTION - (07/21/21)
     
  2682. IAS: Low Proportion of Individuals Develop Metabolic Syndrome (MetS) or Hepatic Fibrosis After Switch to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed Patients: A Post Hoc Metabolic Analysis - (07/21/21)
     
  2683. IAS: Prevalence of genotypic baseline risk factors of Cabotegravir + Rilpivirine failure among ARV-naïve patients - (07/21/21)
     
  2684. IAS: Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study) - (07/20/21)
     
  2685. IAS: CLINICAL OUTCOMES DURING CUSTOMIZE: A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY FOCUSED ON IMPLEMENTATION OF CABOTEGRAVIR PLUS RILPIVIRINE (CAB + RPV) LA IN US HEALTHCARE SETTINGS - (07/20/21)
     
  2686. IAS: CUSTOMIZE: OVERALL RESULTS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY EXAMINING IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE FOR HIV TREATMENT IN US HEALTHCARE SETTINGS; FINAL PATIENT AND PROVIDER DATA - (07/20/21)
     
  2687. IAS: CAB + RPV LA IMPLEMENTATION OUTCOMES AND ACCEPTABILITY OF MONTHLY CLINIC VISITS IMPROVED DURING COVID-19 PANDEMIC ACROSS US HEALTHCARE CLINICS (CUSTOMIZE: HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY) - (07/20/21)
     
  2688. IAS: Every-6-Month Lenacapavir With F/TAF Controls HIV Through 28 Weeks - Mark Mascolini (07/20/21)
     
  2689. IAS: Single-Pill DTG/3TC Effective in Suppressed People for 48 Weeks: SALSA - Mark Mascolini (07/20/21)
     
  2690. IAS: Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) - (07/20/21)
     
  2691. IAS: lntegrase strand transfer inhibitor (INSTI) use and cancer incidence - (07/20/21)
     
  2692. IAS: FEASIBILITY, EFFICACY, AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): 48-WEEK RESULTS OF THE STAT STUDY - (07/20/21)
     
  2693. IAS: SWITCHING TO THE 2-DRUG REGIMEN OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) FIXED-DOSE COMBINATION IS NON-INFERIOR TO CONTINUING A 3-DRUG REGIMEN THROUGH 48 WEEKS IN A RANDOMIZED CLINICAL TRIAL (SALSA) - (07/20/21)
     
  2694. IAS: COMPARISON OF VIRAL REPLICATION FOR THE 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) VERSUS A 3/4-DRUG TENOFOVIR ALAFENAMIDE-BASED REGIMEN (TBR) IN THE TANGO STUDY THROUGH WEEK 96 - (07/20/21)
     
  2695. IAS: Comparing adherence to HIV Pre-Exposure Prophylaxis (PrEP) among new, male PrEP users initiating F/TAF vs. F/TDF - (07/20/21)
     
  2696. IAS: Long-term Efficacy Among Participants Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) with Preexisting Resistance and Viral Blips - (07/20/21)
     
  2697. IAS: Week 72 Outcomes and COVID-19 Impact From the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in Black American Adults With HIV - (07/20/21)
     
  2698. IAS: Higher comorbidity and co-medication burden in women and young people living with HIV - (07/20/21)
     
  2699. IAS: Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019-June 2020 - Mark Mascolini (07/20/21)
     
  2700. IAS: METABOLIC HEALTH OUTCOMES AT WEEK 144 IN THE TANGO STUDY, COMPARING A SWITCH TO DTG/3TC VERSUS MAINTENANCE OF TAF-BASED REGIMENS - (07/20/21)
     
  2701. IAS: DTG + 3TC IN GEMINI-1 & -2: HIV-1 REPLICATION AT <50 C/ML AND VL 'BLIPS' THROUGH 144 WEEKS - (07/20/21)
     
  2702. IAS: Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: week 96 results from an international, Phase 3b, open-label trial - (07/19/21)
     
  2703. IAS: The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: Results from the DRIVE-AHEAD clinical trial - (07/19/21)
     
  2704. IAS: Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine - (07/19/21)
     
  2705. IAS: SARS-CoV-2 Rate Similar in TDF PrEP Users and Matched No-TDF Controls - Mark Mascolini (07/19/21)
     
  2706. IAS: ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19 - (07/19/21)
     
  2707. IAS: ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs - (07/19/21)
     
  2708. IAS: ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 - (07/19/21)
     
  2709. IAS: Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults - (07/19/21)
     
  2710. IAS: New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor - (07/19/21)
     
  2711. IAS: Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research - (07/19/21)
     
  2712. WHO warns that HIV infection increases risk of severe and critical COVID-19 - (07/15/21)
     
  2713. ART & Cervical Cancer Women with HIV Risk - (07/14/21)
     
  2714. An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging - (07/14/21)
     
  2715. IAS: Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research - (07/12/21)
     
  2716. IAS: Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021 - (07/12/21)
     
  2717. 2 New studies: Diabetes-Depression-Women & High Suicide Rates PLWH - (07/09/21)
     
  2718. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) - (07/09/21)
     
  2719. Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With HIV and a Proposed Way Forward - (07/09/21)
     
  2720. EASL: Mortality risk following HCV cure among people with HCV/HIV co-infection (07/06/21)
     
  2721. ACTG Reports REPRIEVE Study HIV+ Heart Disease Risk with CT Angiography - (07/05/21)
     
  2722. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options - (07/02/21)
     
  2723. ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV - (06/22/21)
     
  2724. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial - (06/29/21)
     
  2725. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir - (06/22/21)
     
  2726. Sudden Cardiac Death and Myocardial Fibrosis, Determined by Autopsy, in Persons with HIV - (06/21/21)
     
  2727. NYC Planning Council talk by Jules: Aging with HIV in the US & NYC-clinical & community care & services needs, unmet needs - (06/14/21)
     
  2728. Medicare PLWH: Blacks & Latinos 4-Fold Greater Risk - (06/14/21)
     
  2729. HHS-Older PLWH Reduced Survival by 3.6 times & More Comorbidities - (06/14/21)
     
  2730. Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015 - (06/09/21)
     
  2731. Redistribution of brain glucose metabolism in people with HIV after antiretroviral therapy initiation - (06/09/21)
     
  2732. Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers - (06/09/21)
     
  2733. Assessing the health status and mortality of older people over 65 with HIV - greater mortality, more comorbidities - (06/07/21)
     
  2734. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study - (06/05/21)
     
  2735. Clinical features and outcomes of COVID-19 among people living with HIV in the United States: A multicenter study from a large global health research network (TriNetX) - PWH had higher rates of poor COVID outcomes - (06/05/21)
     
  2736. Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus - (06/05/21)
     
  2737. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial - (06/05/21)
     
  2738. HIV/AIDS at 40: COVID Could Increase by 10% Rates in HIV-related Deaths; PLWH with HIV & Undetectable HIV RNA may Experience 13 years Accelerated Aging, Fauci - (06/05/21)
     
  2739. HIV and Hepatitis C Linkage-to-Care Initiative for New Orleans Residents Experiencing Homelessness During the COVID-19 Pandemic - (06/01/21)
     
  2740. With No End in Sight on Omega-3 Debate, Nissen Calls for More Trials - Fish Oils/New Study "No strong evidence they prevent CVD events" - (05/18/21)
     
  2741. Organ Reserve, Excess Metabolic Capacity, and Aging - (05/18/21)
     
  2742. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir - (05/16/21)
     
  2743. HIV disease duration, but not active brain infection, predicts cortical amyloid beta deposition - (05/11/21)
     
  2744. New Data on Colchicine Bring Conflicting Results - (05/10/21)
     
  2745. Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity - (05/10/21)
     
  2746. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus - undetectable HIV viral load reduced risk - (05/10/21)
     
  2747. Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis - (05/10/21)
     
  2748. Changes in Glomerular Kidney Function Among HIV-1 Uninfected Men and Women Receiving Emtricitabine Tenofovir Disoproxil Fumarate Preexposure Prophylaxis -A Randomized Clinical Trial - (05/10/21)
     
  2749. HPV vaccination to prevent recurrence of Anal Intraepithelial Neoplasia in HIV+ MSM - a randomised, placebo-controlled multicentre trial - (05/10/21)
     
  2750. Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202 - (05/10/21)
     
  2751. Cabotegravir for PrEP -083, 084 recent data - (05/04/21)
     
  2752. ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV - (05/04/21)
     
  2753. Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus Coinfected Persons in North America - (05/03/21)
     
  2754. Accelerated Brain Aging and Cerebral Blood Flow Reduction in Persons With Human Immunodeficiency Virus - (04/29/21)
     
  2755. Genital Inflammation & HIV Acqusition Associated in Women.....STIs also associated with Inflammation & HIV Acquisition - new study - (06/26/15)
     
  2756. LATEST UPDATE ON HIV LIPODYSTROPHY: Interview with Dr Grace McComsey - (04/17/17)
     
  2757. 75-85% in SF-NY-Florida-Boston with HIV Are Over 40 Years Old....25% over 60 in SF-Florida-NY - (09/04/19)
     
  2758. CROI: COVID & HIV - Antiviral Molnupiravir, monoclonal antibody combinations, Convalesecent Plasma - (03/19/21)
     
  2759. CROI: CANNABIS USE ASSOCIATED WITH DECREASED ART ADHERENCE IN AGING PEOPLE WITH HIV - (05/10/21)
     
  2760. CROI: FEMINIZING THERAPY DECREASES D-DIMER BUT WORSENS INSULIN SENSITIVITY IN TRANS WOMEN - (05/08/21)
     
  2761. CROI: 28th Virtual Conference on Retroviruses and Opportunistic Infection March 7-10, 2021 Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center - (04/27/21)
     
  2762. CROI: CROI 2021 Highlights
    By Christina K. Psomas
    European Hospital Marseille, Marseille, France - (04/26/21)
     
  2763. CROI: Clinical Pharmacology at CROI 2021. New Drugs & Formulations; PrEP; HIV Treatment - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center - (04/21/21)
     
  2764. CROI: LOWER UPTAKE OF DOLUTEGRAVIR AMONG WOMEN OF REPRODUCTIVE POTENTIAL VS MEN-KENYA - (04/14/21)
     
  2765. CROI: DRAMATIC DECLINE IN PUBLIC SECTOR HIV/STI TESTING DURING SARS-CoV-2 PANDEMIC, OREGON - (04/13/21)
     
  2766. CROI: HIV Prevention at CROI 2021. NATAP Report by Renee Heffron, PhD and Connie Celum, MD, University of Washington - (04/13/21)
     
  2767. CROI: Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)
     
  2768. CROI: SERUM BIOMARKERS IDENTIFY CARDIAC DYSFUNCTION IN (perinatally infected) YOUTH LIVING WITH HIV - (04/06/21)
     
  2769. CROI: QUINOLINIC ACID IS ASSOCIATED WITH CAROTID INTIMA-MEDIA THICKNESS IN HIV - (04/06/21)
     
  2770. CROI: DORAVIRINE CONCENTRATIONS AND HIV-1 RNA SUPPRESSION IN MALE AND FEMALE GENITAL FLUIDS - (04/06/21)
     
  2771. CROI: TRENDS IN TRUVADA AND DESCOVY PRESCRIPTIONS FOR PrEP IN THE UNITED STATES, 2014-2020 - (04/05/21)
     
  2772. CROI: TOTAL AND UNBOUND DORAVIRINE CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF OF HIV+ PTS - (04/05/21)
     
  2773. CROI: VIRUS REMISSION WITH AN OPTIMIZED EARLY ART REGIMEN IN MACAQUES - (04/05/21)
     
  2774. CROI: IMPAACT 2014 24-WEEK PK AND SAFETY OF DORAVIRINE/3TC/TDF IN ADOLESCENTS WITH HIV-1 - (04/05/21)
     
  2775. CROI: REMDESIVIR VERSUS STANDARD OF CARE FOR SEVERE COVID-19 - (04/05/21)
     
  2776. CROI: ACUTE KIDNEY INJURY IN PATIENTS WITH MODERATE COVID-19 TREATED WITH RDV VERSUS SoC - (04/05/21)
     
  2777. CROI: TREATMENT AND OUTCOMES OF COVID-19 IN THE US: ARE THEY DIFFERENT ACCORDING TO RACE? - (04/05/21)
     
  2778. CROI: SAFETY AND EFFICACY OF REMDESIVIR IN A PEDIATRIC COVID-19 POPULATION - (04/05/21)
     
  2779. CROI: VASCULAR INJURY MARKERS ASSOCIATED WITH COGNITIVE IMPAIRMENT IN HIV PATIENTS ON ART - (03/30/21)
     
  2780. CROI: SEX DIFFERENCES IN WHITE-MATTER LOSS AND ASSOCIATED AXONAL INJURY IN PLWH - (03/30/21)
     
  2781. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV - A Cohort Study - (03/28/21)
     
  2782. CROI: RELATIONSHIP OF T-CELL MITOCHONDRIAL GENE EXPRESSION AND DIABETES IN PERSONS WITH HIV - (03/28/21)
     
  2783. CROI: ELUCIDATING THE ORIGINS OF HIV-1 IN THE CEREBROSPINAL FLUID - (03/28/21)
     
  2784. CROI: CORONARY ARTERY DISEASE, TRADITIONAL RISK, AND INFLAMMATION AMONG PWH IN REPRIEVE - (03/28/21)
     
  2785. CROI: Women & HIV at CROI - (03/28/21)
     
  2786. CROI: Neurocognition & PLWH - CROI 2021 - (03/28/21)
     
  2787. CROI: Laboratory Analysis of HIV Infections in HPTN 083: Injectable CAB for PrEP - (03/26/21)
     
  2788. CROI: HIV AMBULATORY CARE DURING COVID-19 PANDEMIC IN US: VISITS AND VIRAL LOAD TESTING - "dropped precipitously" - (03/20/21)
     
  2789. CROI: IMPACT OF COVID-19 ON COMMERCIAL LABORATORY TESTING FOR HIV IN THE UNITED STATES - (03/22/21)
     
  2790. CROI: COVID & HIV - Antiviral Molnupiravir, monoclonal antibody combinations, Convalesecent Plasma - (03/19/21)
     
  2791. CROI: Weight Gain / Loss - (03/19/21)
     
  2792. CROI: New PrEP at CROI 2021 - (03/19/21)
     
  2793. CROI: CROI 2021 - Complications: HIV, COVID - (03/19/21)
     
  2794. CROI: CROI 2021 - New HIV Drugs - (03/19/21)
     
  2795. CROI: Aging & HIV Highlights at CROI 2021 - (03/25/21)
     
  2796. CROI: STATIN USE AND COGNITIVE PERFORMANCE IN THE MULTICENTER AIDS COHORT STUDY - (03/26/21)
     
  2797. CROI: DECREASED HIV DIAGNOSES AMONG MSM OF COLOR IN THRIVE-FUNDED JURISDICTIONS, 2014-2018 - (03/25/21)
     
  2798. CROI: GENDER-AFFIRMING SURGERY ASSOCIATED WITH HIGH VIRAL SUPPRESSION AMONG TRANSGENDER PWH - (03/25/21)
     
  2799. CROI: IMPACT OF COMMON SIDE EFFECTS ON PrEP PERSISTENCE DURING PREGNANCY IN SOUTH AFRICA - (03/25/21)
     
  2800. CROI: COST-EFFECTIVENESS OF LONG-ACTING PrEP AMONG MSM/TGW IN THE US - (03/25/21)
     
  2801. CROI: EPIGENETIC AGING ASSOCIATED WITH COGNITIVE IMPAIRMENT IN OLDER BLACK ADULTS WITH HIV - (03/24/21)
     
  2802. CROI: DEMENTIA INCIDENCE AMONG ART-TREATED PEOPLE WITH HIV IN A PRIMARY CARE SETTING - (03/24/21)
     
  2803. CROI: NEUROCOGNITIVE DYSFUNCTION, INFLAMMATION, AND ADIPOSITY IN TREATED HIV PATIENTS - (03/24/21)
     
  2804. CROI: PWH AND ALZHEIMER'S DISEASE RISK: CLARIFYING THE HAND PHENOTYPE OVER TIME - (03/24/21)
     
  2805. CROI: HEPATITIS B SEROPROTECTION AMONG YOUNG ADULTS LIVING WITH PERINATALLY ACQUIRED HIV - (03/23/21)
     
  2806. CROI: BARRIERS IMPACTING TELEHEALTH MEDICAL-APPOINTMENT ADHERENCE AMONG PLWHA - (03/23/21)
     
  2807. CROI: PrEP USE AND REFERRAL: BLACK PARTNERS OF PEOPLE WITH HIV IN PARTNER SERVICES, 2019 - (03/22/21)
     
  2808. CROI: A SURVEY-BASED PILOT STUDY TO ASSESS THE EFFECTS OF COVID-19 ISOLATION ON OLDER PLWH - (03/22/21)
     
  2809. CROI: LOW PROPORTIONS OF LINKAGE & PRESCRIPTIONS OF PrEP IN BLACK WOMEN (THRIVE, 2015-2020) - (03/22/21)
     
  2810. CROI: CHANGES IN ACCESS TO CARE FOR WOMEN LIVING WITH HIV DURING THE COVID-19 PANDEMIC - (03/22/21)
     
  2811. CROI: PLWH AND CANCER EXHIBIT UNIQUE PATTERN OF ACTIVATED AND EXHAUSTED CD38+ T CELLS - (03/22/21)
     
  2812. CROI: RANDOMIZED CONTROLLED TRIAL OF MARAVIROC FOR HIV-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT - (03/22/21)
     
  2813. CROI: THE USE OF LESS NEUROTOXIC ANTIRETROVIRALS: SECONDARY ENDPOINTS OF THE MARAND-X STUDY - (03/22/21)
     
  2814. CROI: IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345 - (03/22/21)
     
  2815. CROI: PHARMACY REVERSALS: A NOVEL INDICATOR OF GAPS IN THE HIV PrEP CARE CASCADE - (03/21/21)
     
  2816. CROI: A NOVEL APPROACH TO MEASURE PrEP UPTAKE AMONG POPULATIONS WITH PERSISTENT HIV RISK - (03/21/21)
     
  2817. CROI: IMMUNE MARKERS AND TO TIME TO REBOUND DURING HIV TREATMENT INTERRUPTION IN ACTG A5345 - (03/21/21)
     
  2818. CROI: PREDICTORS OF PrEP UPTAKE IN A SEXUAL HEALTH CLINIC WITH IMMEDIATE PrEP INITIATION - (03/20/21)
     
  2819. CROI: RISK OF CANCER BY HIV STATUS AND BIRTH REGION: A NATIONWIDE REGISTER-BASED STUDY - (03/20/21)
     
  2820. CROI: ACTIVATING PKC-ε INDUCES HIV EXPRESSION WITH IMPROVED TOLERABILITY - (03/19/21)
     
  2821. CROI: HIV REBOUND IN CONTROLLERS IS ASSOCIATED WITH SPECIFIC FECAL MICROBIOME PROFILE - (03/19/21)
     
  2822. CROI: MATHEMATICAL MODELING OF PREDICTORS OF POSTTREATMENT CONTROL IN HIV CURE TRIALS - (03/19/21)
     
  2823. CROI: EVALUATION OF bNAb SENSITIVITY BY GENOTYPING AND PHENOTYPING FOR HIV CLINICAL TRIALS - (03/19/21)
     
  2824. CROI: ULTRASENSITIVE HIV-1 DRUG-RESISTANCE ANALYSIS IN THE DISCOVER PrEP TRIAL - (03/19/21)
     
  2825. CROI: THE ANTIRETOVIRAL PREGNANCY REGISTRY: 30 YEARS OF MONITORING FOR CONGENITAL ANOMALIES - (03/19/21)
     
  2826. CROI: SEX DIFFERENCES IN DIABETES PREVELANCE AMONG PERSONS WITH HIV IN THE UNITED STATES...40% of HIV+ Women >65 have diabetes. - (03/19/21)
     
  2827. CROI: IMPACT OF REPRODUCTIVE AGING ON HIV PERSISTENCE IN CISGENDER MEN AND WOMEN WITH HIV - (03/19/21)
     
  2828. CROI: ACCELERATED CEREBRAL BLOOD-FLOW REDUCTION AND BRAIN AGING IN PEOPLE LIVING WITH HIV PLWH associated with accelerated brain age - (03/18/21)
     
  2829. CROI: INCIDENT DIABETES ASSOCIATED WITH INTEGRASE STRAND TRANSFER INHIBITOR INITIATION - (03/18/21)
     
  2830. CROI: CSF MARKERS OF AD-RELATED PATHOLOGY AND MEMORY DEFICITS IN OLDER PEOPLE WITH HIV - (03/18/21)
     
  2831. CROI: Incidence of HIV infection with daily or on-demand oral PrEP with TDF/FTC in France - (03/18/21)
     
  2832. Burden of Hypertension, Diabetes, Cardiovascular Disease, and Lung Disease Among Women Living With Human Immunodeficiency Virus (HIV) in the United States - (03/18/21)
     
  2833. Global data shows increasing PrEP use and widespread adoption of WHO PrEP recommendations - (03/18/21)
     
  2834. CROI: Incidence of HIV infection with daily or on-demand oral PrEP with TDF/FTC in France - (03/17/21)
     
  2835. CROI: NEURON DAMAGE AND RESERVOIR ARE SECONDARY TO HIV TRANSCRIPTS DESPITE SUPPRESSIVE ART - (03/17/21)
     
  2836. CROI: DRUG-USE STIGMA AND HEPATITIS C VIRUS INFECTION AMONG PWID IN INDIA - (03/17/21)
     
  2837. CROI: ACCESS TO HCV CARE AMONG HIV/HCV-COINFECTED PEOPLE WHO INJECT DRUGS ACROSS CANADA - (03/16/21)
     
  2838. CROI: HIV/HCV COINFECTION TRENDS IN SPAIN (2015-2019) - (03/16/21)
     
  2839. CROI: NO CHANGE IN INCIDENCE OF RECENTLY ACQUIRED HCV IN HIV+ MSM IN GERMANY (NOCO COHORT) - (03/16/21)
     
  2840. CROI: HEPATITIS C CASCADE OF CARE IN HIV/HCV-COINFECTED PERSONS IN EUROPE IN THE DAA ERA - (03/16/21)
     
  2841. CROI: SELF-TESTING FOR HCV: MULTICOUNTRY EVIDENCE ON USABILITY AND ACCEPTABILITY - (03/16/21)
     
  2842. CROI: COST-EFFECTIVENESS OF HCV TESTING STRATEGIES FOR HCV ELIMINATION AMONG MSM IN THE US - (03/16/21)
     
  2843. CROI: REINFECTION WITH THE HEPATITIS C VIRUS IN MEN WHO HAVE SEX WITH MEN - (03/16/21)
     
  2844. CROI: PREVALENCE AND FACTORS ASSOCIATED WITH SARS-CoV-2 ANTIBODIES IN A SPANISH HIV COHORT - (03/16/21)
     
  2845. CROI: COVID-19 IN HOSPITALIZED HIV-POSITIVE AND HIV-NEGATIVE PATIENTS: A MATCHED STUDY - (03/16/21)
     
  2846. Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV - (03/15/21)
     
  2847. CROI: SECOND ANTIRETROVIRAL THERAPY REGIMEN IN VIREMIC PEOPLE WITH HIV IN THE US, 2008-2018 - (03/15/21)
     
  2848. CROI: CHARACTERIZING FIRST VIRAL FAILURES AMONG ANTIRETROVIRAL THERAPY INITIATORS IN THE US - (03/15/21)
     
  2849. CROI: Dual mAb Prevents Symptomatic COVID-19 in Household-Exposed Group: Interim Results of Placebo-Controlled Trial - Mark Mascolini (03/15/21)
     
  2850. CROI: RISK FACTORS FOR HOSPITALIZATION IN PEOPLE WITH HIV AND COVID-19 - (03/15/21)
     
  2851. CROI: T-CELL IMMUNE DYSREGULATION AND MORTALITY IN WOMEN WITH HIV - (03/15/21)
     
  2852. CROI: Risk factors for progression from prediabetes to diabetes in persons with HIV - Integrase Inhibitors Tied to Lower Risk of Progression from Prediabetes to Diabetes - HAILO - Mark Mascolini - (03/15/21)
     
  2853. CROI: PREDICTED 10-YEAR RISKS OF CARDIOVASCULAR DISEASE AND DIABETES IN THE ADVANCE TRIAL - (03/15/21)
     
  2854. CROI: CARDIOMETABOLIC HEALTH IN HIV+ AND HIV- PREGNANT SOUTH AFRICAN WOMEN - (03/15/21)
     
  2855. CROI: CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS - (03/15/21)
     
  2856. CROI: PREDICTED LONG-TERM ADVERSE BIRTH AND CHILD HEALTH OUTCOMES IN THE ADVANCE TRIAL - (03/15/21)
     
  2857. CROI: In US Groups COVID Testing More Likely With HIV, But Positivity Similar With/Without HIV - Mark Mascolini (03/15/21)
     
  2858. CROI: HIV-1 DNA GENOTYPING IS OFTEN VARIABLE IN REPEAT TESTING FROM SINGLE BLOOD DRAWS - (03/15/21)
     
  2859. CROI: URINE MITOCHONDRIAL DNA, WEIGHT LOSS, AND BODY COMPOSITION IN OLDER ADULTS WITH HIV - (03/14/21)
     
  2860. CROI: COMORBIDITY BURDEN IS ASSOCIATED WITH HOSPITALIZATION FOR COVID-19 AMONG PWH - (03/14/21)
     
  2861. CROI: CHARACTERIZING COVID-19 PRESENTATION AND CLINICAL OUTCOMES IN HIV PATIENTS IN THE US - (03/14/21)
     
  2862. CROI: Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir - (03/14/21)
     
  2863. CROI: Online Mindfulness Lessons Ease Depression, Anxiety in Older HIV+ During COVID - Mark Mascolini (03/14/21)
     
  2864. CROI: IN VITRO MODEL TO ASSESS ANTIRETROVIRAL THERAPY ON ADIPOCYTE BIOLOGY - (03/14/21)
     
  2865. CROI: BEYOND PAIN: PRESCRIPTION OPIOID USE IN THE WOMEN'S INTERAGENCY HIV STUDY - (03/14/21)
     
  2866. CROI: ASSOCIATION BETWEEN INTEGRASE INHIBITORS (InSTIs) AND CARDIOVASCULAR DISEASE (CVD) - (03/14/21)
     
  2867. CROI: INFLAMMATORY AND ATHEROGENESIS MARKERS 148 WEEKS POSTSWITCH TO DTG+RPV IN SWORD-1/ -2 - (03/14/21)
     
  2868. CROI: RENAL/BONE OUTCOMES AFTER LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN ATLAS + ATLAS-2M - (03/14/21)
     
  2869. CROI: WEIGHT GAIN POST-ART IN HIV+ LATINOS/AS DIFFERS IN THE US, CANADA, AND LATIN AMERICA - (03/14/21)
     
  2870. CROI: CHARACTERISTICS OF HIV+ AND HIV- PATIENTS UNDERGOING BARIATRIC SURGERY: OBEVIH STUDY - (03/14/21)
     
  2871. CROI: HEROIN USE IS ASSOCIATED WITH HIGH-AORTIC BUT LOW-SPLEEN/ MARROW UPTAKE BY PET IN HIV - (03/14/21)
     
  2872. CROI: HIV Linked to 4.5-Fold Higher Risk of Aortic Aneurysm - Mark Mascolini (03/14/21)
     
  2873. CROI: BEYOND PAIN: PRESCRIPTION OPIOID USE IN THE WOMEN'S INTERAGENCY HIV STUDY - (03/12/21)
     
  2874. CROI: Acute Kidney Injury Less Frequent With Remdesivir Than Standard of Care - Mark Mascolini (03/12/21)
     
  2875. CROI: HIV REPLICATION IN THE CNS IS ASSOCIATED WITH NEUROCOGNITION AND DEPRESSION PRE-ART - (03/12/21)
     
  2876. CROI: FACTORS ASSOCIATED WITH SYSTEMIC IMMUNE ACTIVATION IN A GLOBAL HIV COHORT - (03/12/21)
     
  2877. CROI: INTRANASAL INSULIN IMPROVES ATTENTION AND MEMORY IN PEOPLE WITH HIV - (03/12/21)
     
  2878. CROI: HIV-1, INSUFFICIENT SLEEP, AND ENDOTHELIAL VASODILATOR FUNCTION - (03/12/21)
     
  2879. CROI: FTC-TP in Dried Blood Spots Predicts Future Detectable Viral Load in US Study - Mark Mascolini (03/12/21)
     
  2880. CROI: Resistance and Response in Phase 2a Study of HIV Maturation Inhibitor - Mark Mascolini (03/12/21)
     
  2881. CROI: Favipiravir Has Clinical Pluses vs Standard Care for In-Hospital COVID-19 - Mark Mascolini (03/12/21)
     
  2882. CROI: A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION - (03/12/21)
     
  2883. CROI: DIET QUALITY BY GLOBAL BURDEN OF DISEASE REGION IN PWH IN THE REPRIEVE TRIAL - (03/12/21)
     
  2884. CROI: MATERNAL WEIGHT AND ADVERSE PREGNANCY OUTCOMES AMONG WOMEN ON ART AT CONCEPTION - (03/11/21)
     
  2885. CROI: ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010 - (03/11/21)
     
  2886. CROI: SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/POSTPARTUM: IMPAACT 2010 TRIAL - (03/11/21)
     
  2887. CROI: Complex Vaccine-Escape Mutation Profiles in 947 People With HBV - Mark Mascolini - (03/11/21)
     
  2888. CROI: PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS - (03/11/21)
     
  2889. CROI: RCT OF AN ONLINE MENTAL HEALTH INTERVENTION AMONG OLDER PLWH DURING COVID-19 PANDEMIC - Improved Depression, Anxiety & Loneliness - (03/11/21)
     
  2890. CROI: HIGHER COMORBIDITY BURDEN PREDICTS WORSENING NEUROCOGNITION IN PEOPLE WITH HIV - (03/11/21)
     
  2891. CROI: New PrEP at CROI 2021 - (03/11/21)
     
  2892. CROI: WEEK 96 EFFICACY AND SAFETY OF CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M - (03/11/21)
     
  2893. CROI: Three-Month Vaginal Ring Yields Higher Dapivirine Levels in US Study - Mark Mascolini (03/10/21)
     
  2894. CROI: Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021 - (03/10/21)
     
  2895. CROI: ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV - (03/10/21)
     
  2896. CROI: DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI-BASED ART IN CHILDREN AND ADOLESCENTS - (03/10/21)
     
  2897. CROI: BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH- RISK AMBULATORY PATIENTS - (03/10/21)
     
  2898. CROI: Convalescent Plasma Has No Effect on Survival or Disease Course With Severe COVID-19 - Mark Mascolini (03/10/21)
     
  2899. CROI: mAb Bamlanivimab Lowers Odds of SARS-CoV-2 and Symptomatic COVID-19 in Nursing Facilities - Mark Mascolini - (03/10/21)
     
  2900. CROI: BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING - (03/10/21)
     
  2901. CROI: REDUCTION IN INFECTIOUS SARS-CoV-2 IN TREATMENT STUDY OF COVID-19 WITH MOLNUPIRAVIR - (03/10/21)
     
  2902. CROI: DoLPHIN2 FINAL RESULTS DOLUTEGRAVIR VS EFAVIRENZ IN LATE PREGNANCY TO 72W POSTPARTUM - (03/10/21)
     
  2903. CROI: COVID Virus Can Linger in Gut a Half-Year After Symptoms Clear - Mark Mascolini - (03/10/21)
     
  2904. CROI: Disrupted Gut Integrity, Other Gut Factors, Tied to COVID-19 Severity - Mark Mascolini - (03/10/21)
     
  2905. CROI: Low New-HIV Rate With Both Daily and On-Demand PrEP in Paris MSM - Mark Mascolini - (03/10/21)
     
  2906. CROI: Resistance and Response in Phase 2a Study of HIV Maturation Inhibitor - Mark Mascolini - (03/10/21)
     
  2907. CROI: Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI - (03/10/21)
     
  2908. CROI: Racial/Ethnic Minorities With HIV More Likely to Get COVID-19 in US - Mark Mascolini (03/09/21)
     
  2909. CROI: NNRTI MK-8507 Selects V106 Mutations, Active Against Common NNRTI Mutations - Mark Mascolini (03/09/21)
     
  2910. CROI: PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254 - (03/09/21)
     
  2911. CROI: HIV AND COVID-19 INPATIENT OUTCOMES: A MATCHED RETROSPECTIVE MULTICENTRE ANALYSIS - (03/09/21)
     
  2912. CROI: In-Hospital COVID-19 Outcomes Not Worse With HIV in 6-Center UK Analysis - Mark Mascolini (03/09/21)
     
  2913. CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR - (03/09/21)
     
  2914. CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH - (03/09/21)
     
  2915. CROI: RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT - (03/09/21)
     
  2916. CROI: ASSESSMENT OF OBESITY AND METABOLIC PROFILE BY INTEGRASE INHIBITOR USE IN REPRIEVE - (03/09/21)
     
  2917. CROI: Resistance Testing Did Not Boost HIV Control Rates in Randomized African Trial - Mark Mascolini - (03/09/21)
     
  2918. CROI: DISPARITIES IN TIMELY RECEIPT OF ART PRESCRIPTION IN HIV CARE IN THE US, 2012-2018 - (03/09/21)
     
  2919. CROI: Faster Time to Viral Suppression in US South, But Suppression Rates Still Modest - Mark Mascolini (03/09/21)
     
  2920. CROI: Time to ART Improves for Blacks, Southerners in US, But Still Lags for Drug Users - Mark Mascolini (03/09/21)
     
  2921. CROI: Second-Line DTG Noninferior to DRV/r in African NADIA Trial - Mark Mascolini (03/09/21)
     
  2922. CROI: COVID-19 HOSPITALIZATION AMONG PEOPLE WITH HIV OR SOLID ORGAN TRANSPLANT IN THE US - (03/09/21)
     
  2923. CROI: REDUCED SUSCEPTIBILITY TO TEMSAVIR IS NOT LINKED TO IBA OR MVC RESISTANCE - (03/09/21)
     
  2924. CROI: GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE - (03/09/21)
     
  2925. CROI: ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP - (03/08/21)
     
  2926. CROI: NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS - (03/08/21)
     
  2927. CROI: IDENTIFICATION OF UNIQUE PROTEINS PREDICTIVE OF MORTALITY AND MECHANISMS IN HIV - (03/08/21)
     
  2928. CROI: BIOLOGICAL PROFILES PREDICT CORONARY ARTERY DISEASE IN PWH AND RISK-MATCHED CONTROLS - (03/08/21)
     
  2929. CROI: Short-course alendronate for the prevention of art-associated bone loss Alendronate for 14 Weeks Before and During First ART Wards Off 48-Week Bone Loss - Mark Mascolini (03/08/21)
     
  2930. CROI: PREVENTION OF CARDIOVASCULAR DISEASE IN PERSONS WITH AND WITHOUT HIV - (03/08/21)
     
  2931. CROI: Control of Lipids and Diabetes-But Not BP-Cuts Cardio Risk With HIV - Mark Mascolini (03/08/21)
     
  2932. CROI: 12-Year Cognitive Decline is Associated with Lung Disease, Diabetes, and Depression - (03/08/21)
     
  2933. CROI: Diabetes, Lung Disease, Depression, Cannabis Tied to 12-Year Cognitive Drop With HIV - (03/08/21)
     
  2934. CROI: Avoid CYP, P-gp, UGT Inducers With HIV Capsid Inhibitor Lenacapavir - Mark Mascolini (03/08/21)
     
  2935. CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS - (03/08/21)
     
  2936. CROI: Multimorbidity in people with HIV using ART in the US: Projections to 2030 - (03/08/21)
     
  2937. CROI: Female Sex Modifies Link Between Inflammation and Non-AIDS Vascular Events - Mark Mascolini (03/08/21)
     
  2938. CROI: SEX MODIFIES THE ASSOCIATION BETWEEN INFLAMMATION AND VASCULAR EVENTS IN TREATED HIV - (03/08/21)
     
  2939. CROI: INTEGRASE INHIBITORS TARGET MITOCHONDRIA IN BROWN ADIPOCYTES DISRUPTING THERMOGENESIS - (03/08/21)
     
  2940. CROI: WEIGHT GAIN AMONG PWH WHO SWITCH TO ART-CONTAINING InSTIs OR TAF - (03/08/21)
     
  2941. CROI: HIV WITH TRANSMITTED DRUG RESISTANCE IS DURABLY SUPPRESSED BY B/F/TAF AT WEEK 144 - (03/08/21)
     
  2942. CROI: ASSESSMENT OF OBESITY AND METABOLIC PROFILE BY INTEGRASE INHIBITOR USE IN REPRIEVE - (03/07/21)
     
  2943. CROI: WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS - (03/07/21)
     
  2944. CROI: IMPACT OF REPRODUCTIVE AGING ON IMMUNE FUNCTION IN CISGENDER MEN AND WOMEN WITH HIV - (03/07/21)
     
  2945. CROI: WEIGHT GAIN AFTER SWITCHING DIFFERENT INTEGRASE STRAND TRANSFER INHIBITORS (InSTIs) - (03/07/21)
     
  2946. CROI: ASSOCIATION BETWEEN NEWER ANTIRETROVIRALS AND INCREASE IN BODY MASS INDEX IN RESPOND - (03/07/21)
     
  2947. CROI: COMORBIDITY BURDEN IN PEOPLE LIVING WITH HIV IN THE UNITED STATES - (03/06/21)
     
  2948. CROI: HIV DIFFERENTIALLY IMPACTS AGE-RELATED COMORBIDITY BURDEN AMONG US WOMEN AND MEN - (03/06/21)
     
  2949. CROI: MODEL-INFORMED DOSE SELECTION FOR ISLATRAVIR/MK-8507 ORAL ONCE-WEEKLY PHASE 2B STUDY - (03/06/21)
     
  2950. CROI: WEEK 96 ANALYSIS OF VIRAL BLIPS FROM A PHASE 2B TRIAL OF ISLATRAVIR AND DORAVIRINE - (03/06/21)
     
  2951. CROI: 4-YEAR OUTCOMES OF B/F/TAF IN TREATMENT-NAIVE ADULTS - (03/06/21)
     
  2952. CROI: SWITCHING TO DTG/3TC FDC IS NONINFERIOR TO TBR FOR 96 WEEKS: TANGO SUBGROUP ANALYSES - (03/06/21)
     
  2953. CROI: DURABLE EFFICACY OF DTG+3TC IN GEMINI-1&2: YEAR 3 SUBGROUP ANALYSES - (03/06/21)
     
  2954. CROI: WEEKLY ORAL TENOFOVIR ALAFENAMIDE PROTECTS MACAQUES FROM VAGINAL SHIV INFECTION - (03/06/21)
     
  2955. CROI: LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PrEP IN A SHIV RHESUS MACAQUE MODEL - (03/06/21)
     
  2956. CROI: LONG-ACTING CABOTEGRAVIR+RILPIVIRINE IN OLDER ADULTS: POOLED PHASE 3 WEEK-48 RESULTS - (03/06/21)
     
  2957. CROI: CABOTEGRAVIR PPK SIMULATION TO INFORM Q2M STRATEGIES FOLLOWING DOSING INTERRUPTIONS - (03/06/21)
     
  2958. CROI: POPPK MODELING OF Q2M IM RPV LA FOR MANAGING DOSING INTERRUPTIONS IN HIV-1 PATIENTS - (03/06/21)
     
  2959. CROI: ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks - (03/06/21)
     
  2960. HIV PrEP Poor Persistence - (03/04/21)
     
  2961. Non-Viral Liver Disease in HIV+ - Increased Prevalence of Liver Fibrosis in PLWH Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls - (03/02/21)
     
  2962. HIV+ Women Have Higher Burden of Comorbidities vs HIV- Women / Accelerated-Earlier by 10 Years - (03/02/21)
     
  2963. CROI: ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021 - (03/02/21)
     
  2964. ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months - (02/26/21)
     
  2965. Cognitive ageing is premature among a community sample of optimally treated people living with HIV - (02/26/21)
     
  2966. Motor function declines over time in human immunodeficiency virus and is associated with cerebrovascular disease, while HIV-associated neurocognitive disorder remains stable - (02/26/21)
     
  2967. HIV+ Women & MSM: aging & other issues - (02/22/21)
     
  2968. Loss of viral suppression by 31% in SF is deleterious to the individual and hinders treatment-as-prevention: the COVID-19 pandemic is threatening the goals of the US EHE initiative. - (02/22/21)
     
  2969. Indirect HIV morbidity and mortality due to COVID-19- PLWH presenting with more advanced HIV - (02/22/21)
     
  2970. Aging Guidelines Called For by HIV Researchers /Women with HIV... "What It Means to Age With HIV Infection, Years Gained Are Not Comorbidity Free" - (02/13/21)
     
  2971. Incident Non-AIDS Comorbidity Burden among Women with or at-risk for HIV in the U.S - suggest high susceptibility to -premature aging - (02/13/21)
     
  2972. New PrEP Long-Acting Lenacapavir Trials - (02/13/21)
     
  2973. COVID Impact on Older HIV+ / Quality of Life NOT Viral suppression Is Endpoint !!!! - (02/11/21)
     
  2974. Impact of COVID on HIV & Aging in Era of ART - (02/11/21)
     
  2975. New PrEP Studies: Long-Acting HIV-1 Capsid Inhibitor Lenacapavir Every 6 Months - (02/10/21)
     
  2976. Resilience and frailty in people living with HIV during the COVID era: two complementary constructs? - (02/09/21)
     
  2977. Immunodeficiency and Cancer in 3.5 Million People Living with Human Immunodeficiency Virus: the South African HIV Cancer Match Study - (02/08/21)
     
  2978. Accelerated Aging, Senesence & New Senolytic Therapeutic drugs - (02/08/21)
     
  2979. New HIV "Cure" Strategy - (02/08/21)
     
  2980. GLS1 inhibitor selectively eliminates senescent cells, ameliorates age-associated disorders
  2981. HIVR4P: The AMP Studies: Phase 2b Proof-of-Concept Trials Designed to Test the Efficacy of VRC01 Antibody to Prevent HIV Acquisition - (02/05/21)
     
  2982. HIVR4P: Social, economic, mental health, and medical care impacts of COVID-19 in a US cohort of sexual and gender minority adolescents and young adults (SGM AYA) at-risk for HIV - (02/05/21)
     
  2983. HIVR4P: US COVID-19 Prevention Network Outlines Goals, Shows Moderna Trial Impact - Mark Mascolini - (02/04/21)
     
  2984. HIVR4P: With COVID Here, Mental Health, Money Woes Grow in US Sex- and Gender-Minority Youth - Mark Mascolini - (02/04/21)
     
  2985. HIVR4P: Low and Transient Rectal Dapivirine Levels in 7-Day Rectal Gel Trial - Mark Mascolini - (02/04/21)
     
  2986. HIVR4P: Higher Rectal Penetration Needed With PC-1005 Microbicide Gel - Mark Mascolini - (02/04/21)
     
  2987. HIVR4P: Climbing Rectal Gonorrhea Rate But Falling HIV Rate in British MSM - Mark Mascolini - (02/04/21)
     
  2988. HIVR4P: Bottoms are up at the HIV Research for Prevention Virtual Conference - (02/04/21)
     
  2989. HIVR4P: Only Half in Representative US Sample Intends to Get COVID Vaccine - Mark Mascolini - (02/03/21)
     
  2990. HIVR4P: More Than One Quarter of People Feel No COVID Symptoms Before Shedding Virus - Mark Mascolini - (02/03/21)
     
  2991. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States - (02/01/21)
     
  2992. HIVR4P: Most US MSM Unaware of-and Not Interested in-As-Needed PrEP - Mark Mascolini - (01/29/21)
     
  2993. HIVR4P: COVID Restraints Followed by More Condom-Free Sex, Less PrEP, in Amsterdam MSM - Mark Mascolini (01/29/21)
     
  2994. HIVR4P: Steep Dapivirine Drops in Vaginal Fluid With Cyclic Use of DPV/LNG Vaginal Ring - Mark Mascolini- (01/29/21)
     
  2995. HIVR4P: PK Goals Met With 90-Day TFV/LNG Vaginal Ring in 47-Woman Randomized Trial - Mark Mascolini - (01/29/21)
     
  2996. HIVR4P: Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021 - (01/29/21)
     
  2997. HIVR4P: Early Data Hint Once-Monthly Oral PrEP Feasible With Novel Antiretroviral - Mark Mascolini - (01/29/21)
     
  2998. HIVR4P: VARIABLE HIV SEROINCIDENCE RATES IN A COHORT OF HIGH-RISK MEN WHO HAVE SEX WITH MEN AND TRANSGENDER WOMEN IN CHINA - (01/29/21)
     
  2999. HIVR4P: Impact of UGT Induction by Rifampin and Rifabutin on Cabotegravir Long-Acting Pharmacokinetics for HIV Pre-exposure Prophylaxis (PrEP) using Population Pharmacokinetic Modeling and Simulation - (01/29/21)
     
  3000. HIVR4P: MRI EXAMINATION OF CABOTEGRAVIR LONG-ACTING FORMULATION DEPOT KINETICS IN HEALTHY ADULT VOLUNTEERS - (01/29/21)
     
  3001. HIVR4P: DISTRIBUTION OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) IN PLASMA, MUCOSAL TISSUES, AND ASSOCIATED FLUIDS AFTER A SINGLE ULTRASOUND-GUIDED INTRAMUSCULAR (IM) INJECTION IN HEALTHY ADULT PARTICIPANTS - (01/29/21)
     
  3002. HIVR4P: Utilization Patterns and HIV Incidence Within the First Year of Initiation of TDF/FTC for HIV Pre-exposure Prophylaxis (PrEP) Among Insured Individuals in the US - (01/28/21)
     
  3003. HIVR4P: Biodegradable TAF Implants Protect 6 of 6 Macaques From Vaginal SHIV - Mark Mascolini - (01/28/21)
     
  3004. HIVR4P: Trial design, enrollment status, demographics, and pharmacokinetic (PK) data from a blinded interim analysis from a phase 2a trial of islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP) - (01/28/21)
     
  3005. HIVR4P: Over One Third of New HIV Diagnoses in North Carolina Involve Recent Infection - Mark Mascolini - (01/28/21)
     
  3006. HIVR4P: Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084 - (01/28/21)
     
  3007. HIVR4P: Design and testing of a cabotegravir reservoir implant for HIV prevention - (01/28/21)
     
  3008. HIVR4P: User Wish List for Microarray Patch to Prevent HIV and Pregnancy: Small, Discreet, Easy to Use, Long-Acting - Mark Mascolini - (01/28/21)
     
  3009. HIVR4P: High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamide - (01/27/21)
     
  3010. HIVR4P: Understanding HIV prevention from the perspective of adolescent girls and young women at high risk of HIV infection - (01/26/21)
     
  3011. HIVR4P: Sex work in the wake of SARSCoV2 in Zimbabwe: A qualitative study - (01/26/21)
     
  3012. HIVR4P: Shelter-in-place but at what cost? Barriers to healthcare and other social determinants of health among young women under South Africa's COVID-19 lockdown - (01/26/21)
     
  3013. HIVR4P: High resolution and 3D ultrasound imaging of implant and intravaginal ring drug delivery devices during HIV pre-exposure prophylaxis (PrEP) preclinical and clinical studies - (01/26/21)
     
  3014. HIVR4P: Switching from F/TDF to F/TAF for HIV Pre-exposure Prophylaxis: An Analysis of the Real-World Data - (01/26/21)
     
  3015. HIVR4P: Long-Acting CAB Superior to Daily Oral TDF/FTC in Preventing HIV in Women - Mark Mascolini - (01/26/21)
     
  3016. HIVR4P: Antibody Infusions Prevent Acquisition of Some HIV Strains, NIH Studies Find - (01/26/21)
     
  3017. Optimal Allocation of Societal HIV Prevention Resources to Reduce HIV Incidence in the United States - (01/25/21)
     
  3018. Prevalence and Incidence of Human Papillomavirus Infection in Men Having Sex With Men Enrolled in a Pre-exposure Prophylaxis Study: A Sub-study of the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales "Intervention Preventive de l'Exposition aux Risques avec et pour les hommes Gays" Trial - (01/25/21)
     
  3019. J&J COVID Vaccine- Interim Results of a Phase 1 2a Trial of Ad26.COV2.S Covid-19 Vaccine - (01/15/21)
     
  3020. ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe - (01/14/21)
     
  3021. Five Year Lower Extremity Function is Associated with White Matter Abnormality in Older Adults - (01/14/21)
     
  3022. COVID-19 death in people with HIV: interpret cautiously - Comment - (01/12/21)
     
  3023. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use - (01/11/21)
     
  3024. AASLD: Efficacy and safety of subcutaneous semaglutide once-daily versus placebo in patients with nonalcoholic steatohepatitis
    Semaglutide Resolves NASH in Big Placebo-Controlled Trial     - (01/07/21)
     
  3025. IAC 2020 Virtual: 2 HIV Vaccine Studies/Functional Cure & mRNA Vaccine for HIV
    Functional HIV Cure in Monkey with 3 Monoconal antibodies     - (01/06/21)
     
  3026. Blunted muscle mitochondrial responses to exercise training in older adults with HIV - (01/05/21)
     
  3027. COVID/Long-Acting 2-Antibody Combination for prevention/Treatment by AstraZeneca - (01/05/21)
     
  3028. Discovery of Virus Variant in Colorado and California Alarms Scientists - (01/05/21)
     
  3029. How HIV Research Laid the Foundation for Covid Vaccines - (01/05/21)
     
  3030. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol - (01/05/21)
     
  3031. Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19 - (01/05/21)
     
  3032. HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status - (01/05/21)
     
  3033. Disparities in HIV Viral Suppression in the USA - (01/05/21)
     
  3034. CROI: Summary from virtual CROI 2020 for HIV and liver disease HIV and the liver: what is new? - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/25/20)
     
  3035. COVID-19 Susceptibility and Outcomes Among People Living With HIV in San Francisco - (12/21/20)
     
  3036. AASLD: HIGH PREVALENCE OF FATTY LIVER DISEASE [FLD] AND ADVANCED FIBROSIS IN AN URBAN MULTIETHNIC US COHORT OF PERSONS WITH HIV - (12/21/20)
     
  3037. AASLD: PREVALENCE AND RISK FACTORS OF HEPATIC STEATOSIS AND FIBROSIS IN AMERICAN ADULTS: A POPULATION-BASED STUDY - (12/21/20)
     
  3038. AASLD: GLOBAL PREVALENCE OF HEPATITIS C VIRUS IN WOMEN OF CHILDBEARING AGE IN 2019: A MODELING STUDY - (12/21/20)
     
  3039. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (12/21/20)
     
  3040. ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe - (12/21/20)
     
  3041. NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications: Summary and Recommendation for Future Research - (12/21/20)
     
  3042. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study - (12/21/20)
     
  3043. Using health technology to capture digital phenotyping data in HIV-associated neurocognitive disorders - (12/21/20)
     
  3044. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (01/08/21)
     
  3045. AASLD: Distinct lipidomic signatures between persons living with HIV and seronegative persons: combined analysis of the ACTG 5260s and the MACS/WIHS Combined Cohort Study - (12/18/20)
     
  3046. AdverseReactComor: Distinct lipidomic signatures between persons living with HIV and seronegative persons: combined analysis of the ACTG 5260s and the MACS/WIHS Combined Cohort Study - (12/17/20)
     
  3047. Lenacapavir (GS-6207): A First-in-Class Long Acting HIV Capsid Inhibitor - (12/15/20)
     
  3048. Progress in long-acting Agents for HIV Treatment & PrEP: ViiV healthcare program: Focus on Cabotegravir Long-Acting Injection; Future ViiV LA programs at HIV-DART - (12/15/20)
     
  3049. AdverseReactComor: Non-alcoholic fatty liver disease (NAFLD) in HIV-monoinfected patients: results from the European ECHAM study - (12/14/20)
     
  3050. Islatravir Long-Acting Implant: RECENT PROGRESS IN DEVELOPMENT OF LONG-ACTING INJECTABLES FOR HIV TREATMENT at HIV DART - (12/14/20)
     
  3051. Life expectancy in HIV-positive persons in Switzerland - (12/14/20)
     
  3052. Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV - (12/14/20)
     
  3053. Pregnant Women/Poor outcomes & Neighborhood/Crime/violence/education - Association of Adverse Neighborhood Exposures With HIV Viral Load in Pregnant Women at Delivery - (12/14/20)
     
  3054. ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available - (12/11/20)
     
  3055. An Approach to Improve Diversity and Inclusion in Clinical Trials: The DEFINE Trial (D/C/F/TAF Evaluated As a Fixed-dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain) - (12/10/20)
     
  3056. HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United States......HIV+ Elevated Cancer Mortality-BREAST/PROSTATE/Colorectal - (12/09/20)
     
  3057. AdverseReactComor: The Impact of Covid-19 and Its Response on the Psychosocial Wellbeing and Medical Care among Persons Living with HIV and COPD - (12/08/20)
     
  3058. AdverseReactComor: Attitudes Toward COVID-19 Among People Living with HIV Attending a Multiethnic Outpatient Center in Houston, Texas - (12/08/20)
     
  3059. Are LDL as Important in CVD ? Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk - (12/08/20)
     
  3060. AdverseReactComor: Greater Incident Proteinuria in Pre-Diabetic Men with HIV than Without HIV: The Multicenter AIDS Cohort Study - (12/07/20)
     
  3061. AdverseReactComor: Greater Increases Over Time in BMI, Waist Circumference and Subcutaneous and Visceral Fat Area Among Men with HIV - (12/07/20)
     
  3062. AdverseReactComor: Prevalence of Silent Atherosclerosis and Other Comorbidities in an Outpatient Cohort of Adults Living with HIV - (12/07/20)
     
  3063. AdverseReactComor: Faster decline in lung function in treated HIV-positive vs. HIV negative AGEhIVcohort participants independent of smoking behavior - (12/07/20)
     
  3064. AdverseReactComor: Effect of tesamorelin on risk of development or progression of diabetic retinopathy and glycemic control in HIV-infected subjects with diabetes and central adiposity - (12/07/20)
     
  3065. AdverseReactComor: Vitamin D & Muscoskeletal Health Among Youth with HIV presented today at Comorbidities Workshop - (12/07/20)
     
  3066. AdverseReactComor: Hypertension Prevalence Higher in US vs Global reported today at Comorbidities Workshop - (12/07/20)
     
  3067. AdverseReactComor: Carotid Artherosclerosis in Suppressed HIV+ at Comorbidties Workshop - (12/07/20)
     
  3068. AdverseReactComor: NAFLD in HIV+ today at Comorbidities Workshop - (12/07/20)
     
  3069. AdverseReactComor: COVID Affect on HIV+ reported at Comorbidities Workshop - (12/07/20)
     
  3070. AdverseReactComor: Sleep & HIV - Presented Today at Comorbidities Workshop - (12/04/20)
     
  3071. AdverseReactComor: PrEP - FTC, TDF - Changes Mitochondria & Cardiovascular Function presented at Comorbidities Workshop - (12/04/20)
     
  3072. AdverseReactComor: Proteinuria 3 x Higher in HIV+ in MACS just presented at Comorbidities Workshop - (12/04/20)
     
  3073. AdverseReactComor: In vitro exposure of leukocytes to HIV pre-exposure prophylaxis (PrEP) decreases mitochondrial function and alters gene expression profiles. - (12/04/20)
     
  3074. AdverseReactComor: Mitochondria & Accelerated Aging in HIV - presented at the Comorbidities Workshop - (12/04/20)
     
  3075. IPM's Dapivirine Ring for Women's HIV Prevention Receives WHO Prequalification - (12/02/20)
     
  3076. A High Percentage of People with HIV on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following COVID-19 - (11/28/20)
     
  3077. AASLD: Can low liver fat be bad for your heart? Visceral Fat & Heart Disease - (11/24/20)
     
  3078. AASLD: Breastfeeding Linked to Lower Chance of Severe Fibrosis in US Women With NAFLD - Mark Mascolini - (11/24/20)
     
  3079. ViiV Healthcare announces results of the PROgress study demonstrating that the inclusion of patient reported outcomes into clinical practice can improve HIV care - (11/18/20)
     
  3080. ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention - (11/18/20)
     
  3081. Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1 - (11/18/20)
     
  3082. AASLD: Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis - (11/17/20)
     
  3083. AASLD: Sugary Drinks, High Trans Fats Lead Dietary Risks for Death With NAFLD - Mark Mascolini (11/17/20)
     
  3084. AASLD: The Lipidomics of HIV-related NAFLD - (11/17/20)
     
  3085. AASLD: Dietary Risks for Liver Related Morality Among Nonalcoholic Fatty Liver Disease (NAFLD) - (11/17/20)
     
  3086. AASLD: Treatment with Growth Hormone-Releasing Hormone Analog ReducesVEGFA, TGFβ1, and CSF1: Mechanisms of Tesamorelin Effect in Nonalcoholic Fatty Liver Disease - (11/17/20)
     
  3087. AASLD: Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)
     
  3088. AASLD: Statins Tied to Lower HCC Risk in HBV Group Without Cirrhosis - Mark Mascolini (11/17/20)
     
  3089. ViiV Healthcare announces CHMP positive opinion for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe - (11/13/20)
     
  3090. Treatment Is More Than Prevention: Perceived Personal and Social Benefits of Undetectable = Untransmittable Messaging Among Sexual Minority Men Living with HIV - (11/12/20)
     
  3091. Statement-NIH Study Finds Long-Acting Injectable Drug Prevents HIV Acquisition in Cisgender Women - (11/09/20)
     
  3092. ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women - (11/09/20)
     
  3093. Recent Weight Changes Studies - (11/05/20)
     
  3094. Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial - (11/04/20)
     
  3095. Additive effects of green tea and coffee on all-cause mortality in patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry - (11/04/20)
     
  3096. GLASGOW: Fat distribution and density in PLWH with ≥5% weight gain - (11/03/20)
     
  3097. Inflammation Marker D-Dimer Associated with cell-associated HIV RNA in Virally Suppressed HIV+..... Aging is associated with inflammation and non-significantly higher ca-HIV RNA levels - (11/03/20)
     
  3098. New NYC Funding for Care & Services for Black & Latino Older PLWH - Geriatric Clinic - Men & & Women, Transgender, Young - 5 Service Categories, including Hepatitis C - (11/03/20)
     
  3099. CDC: HIV Mortality - HIV+ Dying Increasingly Consist of Women, Blacks/African-Americans, South residents, older HIV+ - cancer, heart disease, suicide among leading causes of death - (11/03/20)
     
  3100. ID Week: Gilead Sciences' Commitment to the COVID-19 Pandemic - (11/03/20)
     
  3101. ID Week: Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients - (11/03/20)
     
  3102. ID Week: Safety of Remdesivir vs Standard of Care in Patients With Moderate COVID-19 - (11/03/20)
     
  3103. ID Week: Baseline Characteristics Associated With Clinical Improvement in Hospitalized Patients With Moderate COVID-19 - (11/03/20)
     
  3104. ID Week: Remdesivir vs Standard Care in Patients With Moderate COVID-19 - (11/03/20)
     
  3105. ID Week: Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated With Remdesivir - (11/03/20)
     
  3106. ID Week: Rates of COVID Testing, Diagnosis, and Hospital Admission Higher With HIV - Mark Mascolini (11/02/20)
     
  3107. ID Week: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States - increased risk of COVID & had worse outcomes, heroin the worst - (11/02/20)
     
  3108. ID Week: HCV Treatment Less Likely for Women, Current Drug Users, Detectable HIV Load - Mark Mascolini (11/02/20)
     
  3109. ID Week: Opioid Clinic Use Doubles After COVID Arrives at Alabama HIV Center - Mark Mascolini (11/02/20)
     
  3110. ID Week: HAVES VS HAVE-NOTS IN HEALTHCARE COMMUNICATION: EXAMINING THE PARADOX WHERE PLHIV WHO NEED QUALITY DISCUSSIONS WITH THEIR PROVIDERS THE MOST, ACCESS IT THE LEAST - (11/02/20)
     
  3111. ID Week: Health Technology Assessment of New Long-Acting, Directly-Observed HIV Treatments in Canada: Impact of Real-World Adherence to Daily Oral Therapy on Treatment, Transmission and Cost-Effectiveness - (11/02/20)
     
  3112. ID Week: Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance - (11/02/20)
     
  3113. ID Week: Bone mineral density screening in veterans living with HIV : Only One Quarter of US HIV+ Veterans Group Screened for Low BMD - Mark Mascolini (11/02/20)
     
  3114. ID Week: IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED ANALYSIS OF THE GEMINI-1 AND -2 CLINICAL STUDIES - (11/02/20)
     
  3115. ID Week: SAFETY, EFFICACY, AND DURABILITY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE AS MAINTENANCE THERAPY FOR HIV-1 INFECTION: LATTE-2 WEEK 256 RESULTS - (11/02/20)
     
  3116. ID Week: HIV-1 RNA BLIPS AND LOW-LEVEL REPLICATION DURING PHASE III/IIIB CABOTEGRAVIR + RILPIVIRINE LONG-ACTING STUDIES ARE SIMILAR TO ORAL 3-DRUG THERAPY AND NOT ASSOCIATED WITH WEEK 48 VIROLOGIC OUTCOME - (11/02/20)
     
  3117. ID Week: LONG-TERM PATIENT ADHERENCE AND MANAGEMENT OF TREATMENT INTERRUPTIONS WITH LONG-ACTING INJECTABLE CABOTEGRAVIR + RILPIVIRINE FOR MAINTENANCE THERAPY IN PHASE 2B/3 STUDIES - (11/02/20)
     
  3118. ID Week: Association of Aging, Frailty and Place of Residence with Skin, Oral and Gut Microbiome Characteristics and Pathogenicity Reservoirs - (11/02/20)
     
  3119. ID Week: TREATMENT-RELATED PHYSICAL, EMOTIONAL, AND PSYCHOSOCIAL CHALLENGES AND THEIR IMPACT ON INDICATORS OF QUALITY OF LIFE - (10/30/20)
     
  3120. ID Week: NO DOSE ADJUSTMENT OF METFORMIN WITH FOSTEMSAVIR COADMINISTRATION BASED ON MECHANISTIC STATIC AND PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS - (10/30/20)
     
  3121. ID Week: HEALTH CARE RESOURCE UTILIZATION AND COST OF PEOPLE LIVING WITH HIV (PLWH) IN US COMMERCIAL AND MEDICARE ADVANTAGE HEALTH PLANS - (10/30/20)
     
  3122. ID Week: Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH) - (10/30/20)
     
  3123. ID Week: Real World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start - The RoCHaCHa Study, a Pilot Study - (10/30/20)
     
  3124. ID Week: Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis - (10/30/20)
     
  3125. ID Week: PATIENT-REPORTED OUTCOMES ON LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: FLAIR 96-WEEK RESULTS - (10/30/20)
     
  3126. ID Week: Older Age, Comorbidities Predict Hospital Trip for COVID-19 in HIV Group - Mark Mascolini - (10/30/20)
     
  3127. ID Week: Four in 5 on ART Resume Therapy in Hospital, One Third Change ARVs - Impact of hospitalization on antiretroviral therapy for people living with HIV - Mark Mascolini - (10/30/20)
     
  3128. ID Week: B/F/TAF Controls HIV in 10 of 10 on Hemodialysis for Kidney Disease - (10/28/20)
     
  3129. ID Week: SUMMARY OF COVID-RELATED IMPACT ON CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB + RPV LA) DOSING ACROSS THE SIX ONGOING GLOBAL PHASE IIB and III CLINICAL TRIALS - (10/28/20)
     
  3130. ID Week: Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF) - (10/28/20)
     
  3131. ID Week: Increased Diagnosis Acute HIV Through Routine ED Screening & Rapid Linkage to Care & Initiation of HAARTDuring the COVID-19 Pandemic - (10/28/20)
     
  3132. ID Week: Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV Incidence: Results From the DISCOVER Trial - (10/28/20)
     
  3133. ID Week: ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability - (10/28/20)
     
  3134. ID Week: Database Links Bictegravir and Dolutegravir to Metabolic Problems - Mark Mascolini (10/28/20)
     
  3135. ID Week: ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine - (10/28/20)
     
  3136. ID Week: ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices - (10/28/20)
     
  3137. ID Week: Database Links Bictegravir and Dolutegravir to Metabolic Problems - Mark Mascolini (10/28/20)
     
  3138. ID Week: PATIENT PERSPECTIVES ON IMPLEMENTATION OF A LONG-ACTING INJECTABLE ANTIRETROVIRAL THERAPY REGIMEN IN HIV US HEALTHCARE SETTINGS: INTERIM RESULTS FROM THE CUSTOMIZE STUDY - (10/28/20)
     
  3139. ID Week: Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline - (10/28/20)
     
  3140. ID Week: Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine - (10/28/20)
     
  3141. ID Week: Gastrointestinal (GI) Adverse Events With Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Through Week 96: An AMBER Post Hoc Analysis - (10/26/20)
     
  3142. ID Week: Who does not show up for followup in an HIV PrEP clinic? More Education Favors Steady PrEP-Bisexuals, Heterosexuals Need More Support - Mark Mascolini (10/26/20)
     
  3143. ID Week: Week-48 Outcomes From the BRAAVE 2020 Study: a Randomized Switch to B/F/TAF in African-American Adults With HIV - (10/26/20)
     
  3144. ID Week: Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline - (10/26/20)
     
  3145. ID Week: Efficacy and Safety of Doravirine in Treatment-Naïve Adults ≥50 Years Old With HIV-1 - (10/26/20)
     
  3146. ID Week: IMPACT OF TREATMENT ADHERENCE ON EFFICACY OF DTG + 3TC AND DTG + TDF/FTC: POOLED ANALYSIS OF THE GEMINI-1 AND -2 CLINICAL STUDIES - (10/26/20)
     
  3147. ID Week: Preexisting resistance and week 48 virologic outcomes after switching to B/F/TAF in African American adults with HIV - Frequent Resistance Before B/F/TAF Does Not Dim Week-48 Viral Response - Mark Mascolini (10/26/20)
     
  3148. ID Week: Empiric Antibiotics Frequent-But Usually Not Needed-for COVID-19 - Mark Mascolini (10/26/20)
     
  3149. ID Week: Pain in Two Thirds of Older US HIV Group Tied to Comorbidities - Mark Mascolini (10/26/20)
     
  3150. ID Week: Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with Severe COVID-19 Pneumonia Early Steroids Cut Need for Ventilation, Shorten ICU Stay, With COVID - Mark Mascolini (10/26/20)
     
  3151. ID Week: Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis- Sleep Apnea Rate Rises 5-Fold Among Hospital Inpatients With HIV - (10/26/20)
     
  3152. ID Week: One Quarter of 65+ Group With HIV and Polypharmacy Fall, 10% Seek Emergency Care - (10/26/20)
     
  3153. ID Week: One Quarter of 65+ Group With HIV and Polypharmacy Fall, 10% Seek Emergency Care - (10/23/20)
     
  3154. ID Week: Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence - (10/23/20)
     
  3155. ID Week: Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study - (10/23/20)
     
  3156. ID Week: Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial - (10/23/20)
     
  3157. ID Week: QUALITATIVE FINDINGS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY TO EXPLORE PERSPECTIVES OF HEALTHCARE STAFF ON EARLY IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE IN THE UNITED STATES (CUSTOMIZE) - (10/22/20)
     
  3158. ID Week: Weight change associated with switching to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed people with HIV Weight Climbs With Switch to Bictegravir Across Baseline Regimens - Mark Mascolini - (10/22/20)
     
  3159. ID Week: Congestive heart failure in persons living with HIV: are we providing standard of care? Most People With HIV and CHF Get Correct CHF Care-With Notable Exceptions - Mark Mascolini - (10/22/20)
     
  3160. ID Week: Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence - (10/22/20)
     
  3161. ID Week: HIV Control With Ibalizumab for 7.8 to 9.5 Years With Few Regimen Tweaks - Mark Mascolini - (10/22/20)
     
  3162. ID Week: Increasing incidence of obstructive sleep apnea in patients with HIV: A nationwide database analysis Sleep Apnea Rate Rises 5-Fold Among Hospital Inpatients With HIV - Mark Mascolini - (10/22/20)
     
  3163. ID Week: Risk Factors and Metabolic Implications of Integrase Inhibitor Associated Weight Gain - Mark Mascolini - (10/22/20)
     
  3164. ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV - (10/20/20)
     
  3165. Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine - (10/20/20)
     
  3166. HRSA New Resources Available on HIV and Aging: Care, Screening Tools & Staff Training - (10/20/20)
     
  3167. GLASGOW: Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago - (10/20/20)
     
  3168. GLASGOW: Integrase based first-line HIV antiretroviral treatment in the Mediterranean Resistance (MeditRes) HIV collaboration - (10/20/20)
     
  3169. GLASGOW: FOSTEMSAVIR AND ETHINYL ESTRADIOL DRUG INTERACTION: CLINICAL APPLICATION FOR CO-ADMINISTRATION - (10/20/20)
     
  3170. GLASGOW: MODEL-BASED APPROACH OF DOSE SELECTION AND OPTIMAL PK SAMPLING OF FOSTEMSAVIR FOR PEDIATRIC PATIENTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION - (10/20/20)
     
  3171. GLASGOW: EVALUATION AND CLINICAL APPLICATION OF FOSTEMSAVIR CO-ADMINISTRATION WITH TUBERCULOSIS MEDICATIONS - (10/20/20)
     
  3172. GLASGOW: FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS - (10/20/20)
     
  3173. GLASGOW: CLINICAL SIGNIFICANCE OF GP120 POLYMORPHISMS, TMR IC50 FC, AND HIV-1 SUBTYPE IN BRIGHTE - (10/20/20)
     
  3174. GLASGOW: Starting or switching to bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study - (10/20/20)
     
  3175. GLASGOW: Long-Term Follow-Up After a Switch to Bictegravir, Emtricitabine, Tenofovir Alafenamide (B/F/TAF) from a Boosted Protease Inhibitor-Based Regimen - (10/20/20)
     
  3176. GLASGOW: The clinical relevance of potential drug-drug interactions (DDIs) with bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF) -Real-world data from the German IQVIA prescription database - (10/20/20)
     
  3177. GLASGOW: FACTORS ASSOCIATED WITH INTEREST IN A LONG-ACTING HIV REGIMEN: PERSPECTIVES OF PEOPLE LIVING WITH HIV, AND PHYSICIANS IN WESTERN EUROPE - (10/15/20)
     
  3178. GLASGOW: Bictegravir/ emtricitabine/ tenofovir alafenamide (B/F/TAF)shows high efficacy in clinical study participants infected with HIV-1 subtype F - (10/15/20)
     
  3179. GLASGOW: CABOTEGRAVIR + RILPIVIRINE LONG-ACTING AS HIV-1 MAINTENANCE THERAPY: ATLAS WEEK 96 RESULTS - (10/15/20)
     
  3180. GLASGOW: Rapid DTG/3TC Safe and Usually Effective in US Test-and-Treat Trial - Mark Mascolini (10/15/20)
     
  3181. GLASGOW: Lenacapavir resistance analysis in a phase Ib clinical proof of-concept study: Resistance to HIV Capsid Inhibitor Rare and Linked to Single Mutation - Mark Mascolini (10/15/20)
     
  3182. GLASGOW: Islatravir in Combination With Doravirine Maintains HIV-1 Viral Suppression Through 96 Weeks - (10/15/20)
     
  3183. GLASGOW: Associations with weight change and patient reported outcomes after switching from efavirenz/ emtricitabine/ tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/ emtricitabine/ tenofovir alafenamide (BIC/FTC/TAF) - (10/15/20)
     
  3184. GLASGOW: Unmet Needs PLWH, ViiV Positive Perspectives Global Study - (10/15/20)
     
  3185. GLASGOW: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN (TBR) IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 96 WEEKS (TANGO STUDY) - (10/15/20)
     
  3186. GLASGOW: A COMBINATION OF VIRAL AND PARTICIPANT FACTORS INFLUENCE VIROLOGIC OUTCOME TO LONG-ACTING CABOTEGRAVIR + RILPIVIRINE: MULTIVARIABLE AND BASELINE FACTOR ANALYSES ACROSS ATLAS, FLAIR AND ATLAS-2M PHASE 3 STUDIES - (10/15/20)
     
  3187. GLASGOW: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN (TBR) IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 96 WEEKS (TANGO STUDY) - (10/15/20)
     
  3188. GLASGOW: Increased levels of immune activation and exhaustion in vertically HIV-1 infected young adults - (10/12/20)
     
  3189. GLASGOW: SAFETY AND EFFICACY OF CABOTEGRAVIR + RILPIVIRINE LONG-ACTING WITH AND WITHOUT ORAL LEAD-IN: FLAIR WEEK 124 RESULTS - (10/12/20)
     
  3190. GLASGOW: Frailty of Greek PLWHIV in association with clinical markers and psychological factors; Preliminary results of a nationwide study. - (10/12/20)
     
  3191. GLASGOW: Multidrug Resistance Still Boosts Death Risk in 31,000-Person Italian Study - Mark Mascolini (10/12/20)
     
  3192. GLASGOW: Clinically Relevant Transmitted Integrase Resistance Low in Mediterranean Countries - Mark Mascolini - (10/12/20)
     
  3193. GLASGOW: Lenacapavir Resistance Analysis in a Phase 1b Proof-of-Concept Clinical Study - (10/12/20)
     
  3194. GLASGOW: The clinical relevance of potential drug-drug interactions (DDIs) with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) - Real-world data from the German IQVIA prescription database - (10/12/20)
     
  3195. GLASGOW: Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol (UK): a prospective observational study - (10/12/20)
     
  3196. GLASGOW: Safety, Tolerability and Pharmacokinetics Following Single- and Multiple-Dose Administration of the Novel NNRTI MK-8507 With a Midazolam Interaction Arm - (10/12/20)
     
  3197. GLASGOW: Lenacapavir Resistance Analysis in a Phase 1b Clinical Proof-Of-Concept Study - (10/12/20)
     
  3198. GLASGOW: SINGLE DOSES OF MK-8507, A NOVEL HIV-1 NNRTI, REDUCED HIV VIRAL LOAD FOR AT LEAST A WEEK - (10/09/20)
     
  3199. GLASGOW: Islatravir Plus Doravirine Maintains HIV Control Through 96 Weeks - Mark Mascolini - (10/09/20)
     
  3200. GLASGOW: Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): The BICSTaR cohort - (10/09/20)
     
  3201. GLASGOW: Starting or switching to bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study - (10/09/20)
     
  3202. GLASGOW: Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 72 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (10/09/20)
     
  3203. GLASGOW: Sustained Viral Suppression After Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Among Clinical Trial Participants With Preexisting M184V/I - (10/09/20)
     
  3204. GLASGOW: 12-month outcome of Dolutegravir/Rilpivirine in virologically suppressed HIV-infected patients: Real-world data from the German JUNGLE cohort - (10/09/20)
     
  3205. GLASGOW: Real-world data from the prospective URBAN cohort study on the use of Dolutegravir (DTG) + Lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany - (10/08/20)
     
  3206. GLASGOW: FEASIBILITY, EFFICACY, AND SAFETY OF USING DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): THE STAT STUDY - (10/08/20)
     
  3207. GLASGOW: EFFICACY AND SAFETY OF DOLUTEGRAVIR IN TREATMENT-NAIVE PEOPLE LIVING WITH HIV-1 STRATIFIED BY AGE (>50): META-ANALYSIS OF 48-WEEK RESULTS FROM ARIA, FLAMINGO, SINGLE, AND SPRING-2 - (10/08/20)
     
  3208. GLASGOW: Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US - Mark Mascolini (10/08/20)
     
  3209. GLASGOW: DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION- 3-YEAR RESULTS FROM THE GEMINI STUDIES - (10/08/20)
     
  3210. GLASGOW: Real-word characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen between 2015 and 2017 -REALITY Study - RAL Persistence 49 Yr Olds with Comorbidities - (10/08/20)
     
  3211. GLASGOW: Islatravir Selects for HIV-1 Variants in MT4-GFP Cells That Profoundly Reduce Replicative Capacity in Peripheral Blood Mononuclear Cells - (10/08/20)
     
  3212. GLASGOW: Analysis of Protocol-Defined Virologic Failure Through Week 96 From a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults WithHIV-1 Infection - (10/08/20)
     
  3213. GLASGOW: Long-term Treatment Efficacy and Safety Following Switch to Doravirine/ Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF): Week 144 Results of the DRIVE-SHIFT Trial - (10/08/20)
     
  3214. GLASGOW: Comorbidity Rate Does Not Affect F/TAF Persistence Through 24 Months - Mark Mascolini - (10/06/20)
     
  3215. GLASGOW: The relationship between smoking, current CD4, viral load and cancer in PLWH - (10/06/20)
     
  3216. GLASGOW: "WHAT ABOUT ME?" THE UNMET NEEDS OF MEN WHO HAVE SEX WITH WOMEN AND DIFFERENCES IN HIV TREATMENT EXPERIENCES, PERCEPTIONS, AND BEHAVIORS BY GENDER AND SEXUAL ORIENTATION IN 25 COUNTRIES - (10/06/20)
     
  3217. GLASGOW: Prevalence of pain in women living with HIV aged 45-60: associated factors and impact on patient-reported outcomes - (10/06/20)
     
  3218. GLASGOW: Impact of adherence on viral suppression with bictegravir and dolutegravir (DTG) containing triple therapy in clinical practice - Mark Mascolini (10/06/20)
     
  3219. GLASGOW: Merck to Present New Data from the Company's Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020 - (10/06/20)
     
  3220. GLASGOW: OUTCOMES FOR WOMEN RECEIVING LONG-ACTING CABOTEGRAVIR + RILPIVIRINE MONTHLY AND EVERY 2 MONTHS: ATLAS-2M STUDY WEEK 48 RESULTS - (10/05/20)
     
  3221. GLASGOW: Highest Cancer Risk in HIV+ Current Smokers and Those With Poor HIV Control - Mark Mascolini - (10/05/20)
     
  3222. GLASGOW: SUBGROUP ANALYSIS OF PATIENT-REPORTED OUTCOMES AMONG PARTICIPANTS IN 2 PHASE III CLINICAL TRIALS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE (ATLAS AND FLAIR) - (10/05/20)
     
  3223. GLASGOW: Fat Distribution and density in PLWH with ≥ 5% weight gain - (10/05/20)
     
  3224. GLASGOW: Renal Safety Through 96 Weeks in a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults With HIV-1 - (10/05/20)
     
  3225. GLASGOW: COMPARABILITY OF 48-WEEK EFFICACY AND SAFETY OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING EVERY 8 WEEKS TO STANDARD OF CARE IN SUPPRESSED PEOPLE LIVING WITH HIV-1 - (10/05/20)
     
  3226. GLASGOW: Virologic and CD4 Responses to DTG Generally Steady With Advancing Age - Mark Mascolini (10/05/20)
     
  3227. GLASGOW: GILEAD SCIENCES PRESENTS DATA FROM HIV RESEARCH AND DEVELOPMENT PROGRAMS AT HIV GLASGOW 2020 - (10/05/20)
     
  3228. GLASGOW: Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020 - (10/05/20)
     
  3229. GLASGOW: ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1 - (10/05/20)
     
  3230. GLASGOW: Over Half in UK HIV Women's Study Report Moderate or Severe Pain - Mark Mascolini - (10/05/20)
     
  3231. GLASGOW: Switch to Integrase Drug Incites BMI Gain But Perhaps Improved "Fat Quality" - Mark Mascolini (10/05/20)
     
  3232. GLASGOW: ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress - (09/28/20)
     
  3233. AGE Wrkshp: Dozing or Napping Has Bigger Cognitive Impact in People With HIV - By Mark Mascolini - (10/05/20)
     
  3234. AGE Wrkshp: A Study of Neurocognitive Performance in Women Living With and Without HIV in South Africa - (10/05/20)
     
  3235. AGE Wrkshp: Polypharmacy in 94% of Older HIV Group, Inappropriate Meds Frequent - By Mark Mascolini - (10/05/20)
     
  3236. AGE Wrkshp: Aging with HIV in Latin America and The Caribbean: a systematic review - (10/05/20)
     
  3237. AGE Wrkshp: Urine mtDNA Signals Lower Muscle, Fat Mass, Weight in Older Group With HIV - By Mark Mascolini - (10/05/20)
     
  3238. AGE Wrkshp: Effects of HIV and Aging on the brain - (10/05/20)
     
  3239. AGE Wrkshp: Age-Related Trajectories of C-Reactive Protein Among Men With and Without HIV Infection in the Multicenter AIDS Cohort Study - (10/05/20)
     
  3240. AGE Wrkshp: Bictegravir/FTC/TAF Effective at 48 Weeks in Elderly: 4-Trial Analysis - By Mark Mascolini (10/02/20)
     
  3241. AGE Wrkshp: HIV & Aging Geriatric Clinics - (10/02/20)
     
  3242. AGE Wrkshp: Increased Neuropathy in Older PLWH - (10/02/20)
     
  3243. AGE Wrkshp: Should we still care about bone? Screening, treatment, TDF vs TAF - (10/02/20)
     
  3244. AGE Wrkshp: Sex Hormone-Binding Globulin Tied to Frailty, Low BMD in Women, Not Men - By Mark Mascolini (10/02/20)
     
  3245. AGE Wrkshp: Frailty Common in HIV+ Middle-Aged: Tied to Depression, HCV, Substance Use - By Mark Mascolini (10/02/20)
     
  3246. ViiV Healthcare presents a new podcast about the Power of Being Seen - (10/01/20)
     
  3247. AGE Wrkshp: Latent Class Analysis--Unique Predictor of Hospitalization, Death in Older HIV+ - (10/01/20)
     
  3248. AGE Wrkshp: Getting HIV Infection Speeds Up Epigenetic Clock (and Biologic Aging) Right Away - By Mark Mascolini - (10/01/20)
     
  3249. AGE Wrkshp: Heart Failure Diagnosed 6 to 16 Years Earlier in Veterans With vs Without HIV - By Mark Mascolini - (10/01/20)
     
  3250. AGE Wrkshp: A Multidisciplinary Approach (Exercise Program) to Chronic Pain and Frailty Among Those Aging with HIV: Lessons Learned - (10/01/20)
     
  3251. AGE Wrkshp: ART-Associated Issues, Fat & Muscle Density, The Significance of ART-associated Weight Gain in HIV - (10/01/20)
     
  3252. AGE Wrkshp: Associations between Frailty and Clinical Characteristics, Comorbidities, and Substance Abuse Among PLWH.....12% frailty in CNICS Cohort (CAR).....past drug use associated with frailty....average age only 47 - (10/01/20)
     
  3253. AGE Wrkshp: Lack of Transportation Tied to Array of Health Measures in Aging US HIV Group - By Mark Mascolini - (10/01/20)
     
  3254. Clin Pharm: Ledipasvir Exposure Linked to SVR, But Overall Response Rate High - By Mark Mascolini (10/01/20)
     
  3255. Clin Pharm: Neonatal Liquid Dolutegravir Comparable to Pediatric Dispersible Tablets - By Mark Mascolini (10/01/20)
     
  3256. Clin Pharm: Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets - (10/01/20)
     
  3257. Clin Pharm: Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (10/01/20)
     
  3258. GLASGOW: ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress - (09/28/20)
     
  3259. Clin Pharm: No Interactions Between HIV-1 Maturation Inhibitor and TAF/FTC - By Mark Mascolini (09/30/20)
     
  3260. Clin Pharm: Levels of Long-Acting Anti-HIV bNAb High in Infants After 1 or 2 Doses--But Not High Enough - By Mark Mascolini (09/30/20)
     
  3261. Clin Pharm: Model Predicts Long-Acting IM Rilpivirine Safe With Liver Impairment - By Mark Mascolini (09/30/20)
     
  3262. Clin Pharm: Antiretroviral Drug-Drug Interaction Profile of Long-Acting Cabotegravir and Rilpivirine - (09/30/20)
     
  3263. Clin Pharm: Three Phase I Drug Interaction Studies Investigating the Next-Generation Maturation Inhibitor GSK3640254 With Oral Contraceptive Ethinyl Estradiol/Levonorgestrel, Dolutegravir, and Tenofovir Alafenamide/Emtricitabine - (09/30/20)
     
  3264. Clin Pharm: Dolutegravir (DTG) plasma concentrations under different combinations regimens for ART-pre-treated adults living with HIV - (09/30/20)
     
  3265. Clin Pharm: FOSTEMSAVIR DRUG-DRUG INTERACTION PROFILE, AN ATTACHMENT INHIBITOR AND ORAL PRODRUG OF TEMSAVIR, FOR PATIENTS WITH MULTIDRUG-RESISTANT HIV-1 INFECTION - (09/30/20)
     
  3266. Clin Pharm: No Adverse Pregnancy Outcome Patterns With Common Antiretrovirals - By Mark Mascolini (09/30/20)
     
  3267. Clin Pharm: PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF DOLUTEGRAVIR/RILPIVIRINE (JULUCA) IN HEALTHY JAPANESE ADULTS - (09/28/20)
     
  3268. Clin Pharm: THE PHARMACOKINETICS (PK) OF DOVATO (50 MG DOLUTEGRAVIR [DTG]/ 300 MG LAMIVUDINE [3TC]) FIXED-DOSE COMBINATION IN HIV-INFECTED PATIENTS - (09/28/20)
     
  3269. Clin Pharm: TFV Levels Far Lower in Milk Than Plasma With Dried Milk and Blood Spots - Mark Mascolini - (09/28/20)
     
  3270. Clin Pharm: FTC Exposure Higher in Young Transgender Men Than Cisgender Controls - Mark Mascolini - (09/28/20)
     
  3271. ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices press release - (09/28/20)
     
  3272. Rates of Detectable Viral Load & condomless Sex Among HIV+ MSM, Discordant Couples - (09/25/20)
     
  3273. Cost of Comorbidities/HIV: Mean costs of care increased from $30,312 for those without an identified comorbidity to over $46,000 for those with 2 comorbidities, and up to $219,000 for people with 11 or more. - (09/25/20)
     
  3274. TAF vs TDF in DISCOVER PrEP Trial - Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial - (09/24/20)
     
  3275. Cost Analysis Questions Value of F/TAF vs Generic F/TDF for PrEP - Mark Mascolini (09/25/20)
     
  3276. TAF vs TDF in DISCOVER PrEP Trial - Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial - (09/24/20)
     
  3277. Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model. - (09/23/20)
     
  3278. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016 - Updated HIV Life Expectancy Study: 9 yrs difference; 6.8 for HIV+ >500 CD4 at ART start - (09/23/20)
     
  3279. Cost of Comorbidities/HIV: Mean costs of care increased from $30,312 for those without an identified comorbidity to over $46,000 for those with 2 comorbidities, and up to $219,000 for people with 11 or more. - (09/21/20)
     
  3280. Gaps in Monitoring Older HIV+ in UK - (09/21/20)
     
  3281. Structural and functional brain abnormalities in HIV disease revealed by multimodal MRI fusion: association with cognitive function - (09/21/20)
     
  3282. Aging HIV+ in SF & NYC: 58% in NYC & 69% in SF >50 - A tale of 2 different epidemics - (09/21/20)
     
  3283. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016 - Updated HIV Life Expectancy Study: 9 yrs difference; 6.8 for HIV+ >500 CD4 at ART start - (09/18/20)
     
  3284. Rapid ART - (09/17/20)
     
  3285. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials - (09/16/20)
     
  3286. EDITORIAL: Is Modern Antiretroviral Therapy Causing Weight Gain? - (09/16/20)
     
  3287. (Vascepa) Final EVAPORATE Results for Vascepa Raise Eyebrows - (09/16/20)
     
  3288. ADHOC Aging-HIV Database Community Call Today Sept 3 2020 - (09/16/20)
     
  3289. Sexual transmission of an extensively drug-resistant HIV-1 strain - (09/16/20)
     
  3290. Cardiovascular disease risk among transgender women living with HIV in the United States - (09/16/20)
     
  3291. EASL THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT OF NASH IN THE GENERAL POPULATION - (09/15/20)
     
  3292. Risk of Cataract Surgery in HIV-Infected Individuals: A Danish Nationwide Population-Based Cohort Study - (08/25/20)
     
  3293. New HIV ART & Long-Acting Drugs - (08/25/20)
     
  3294. CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY - (08/25/20)
     
  3295. ViiV Healthcare announces data demonstrating the feasibility of Dovato (dolutegravir/lamivudine) as a treatment option for rapid initiation after diagnosis in adults with HIV-1 - PRESS RELEASE - (08/25/20)
     
  3296. FEASIBILITY, EFFICACY, AND SAFETY OF USING DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): THE STAT STUDY - (08/25/20)
     
  3297. IAC 2020 Virtual: The first long-term remission of chronic HIV-1 infection without myeloablation? (nicotinemide + maraviroc) - (08/24/20)
     
  3298. IAC 2020 Virtual: IAC 2020: Aging, Comorbidities, weight changes, HCV-MSM, NAFLD, Challenges-Unmet Needs of elderly PLWH - (08/24/20)
     
  3299. IAC 2020 Virtual: Characteristics and Predictors of Death among Hospitalized Patients with COVID-19 in Spain - (08/14/20)
     
  3300. Cabenva (cabotegravir/rilpivirine Resubmitted for FDA Approval - (08/10/20)
     
  3301. Lower CD4 Increased Risk: Frailty and HIV Disease Severity Synergistically Increase Risk of HIV-Associated Neurocognitive Disorders - (08/10/20)
     
  3302. Sociodemographic, ecological, and spatiotemporal factors associated with HIV drug resistance in Florida: a retrospective analysis implications for 'End AIDS' - (08/10/20)
     
  3303. IAC 2020 Virtual: Is NAFLD the same disease in HIV infected patients? - (08/10/20)
     
  3304. IAC 2020 Virtual: Early weight changes associated with bictegravir-based regimens compared to other integrase inhibitors following ART-initiation in ART-naïve people living with HIV - (08/10/20)
     
  3305. ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1 - (08/07/20)
     
  3306. APLA Health Announces Statewide Strategic Planning Meeting to Address Urgent Needs of People Aging with HIV - (08/05/20)
     
  3307. IAC 2020 Virtual: Patterns of Antiretroviral Use and Immunologic Correlates at Study Entry in the REPRIEVE Trial - (08/04/20)
     
  3308. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy - (08/03/20)
     
  3309. IAC 2020 Virtual: Illicit Opioid Use After Changes in Opioids Prescribed for Chronic Pain Among People Living With and Without HIV - (08/01/20)
     
  3310. IAC 2020 Virtual: Plenary: Casualties on the road to ending HIV: Context matters in addressing HIV disparities. From the very beginning of the 40-year HIV pandemic until today, HIV disparities have remained an intractable issue. - (08/01/20)
     
  3311. IAC 2020 Virtual: Cabotegravir+Rilpivirine Long-Acting Injectable Treatment and Cabotegravir for PrEP study HPTN 083 at IAC 2020 - (08/01/20)
     
  3312. Aging/HIV AIDS United Policy/Advocacy Paper - (07/31/20)
     
  3313. Worse Short-Term Memory Predicts Poor COVID Distancing in US - Mark Mascolini (07/27/20)
     
  3314. The changing HIV epidemic: a view from the front line in the United States -holistic care needed - (07/29/20)
     
  3315. Black Cisgender Women's PrEP Knowledge, Attitudes, Preferences, and Experience in Chicago - (07/29/20)
     
  3316. Ending Epidemic??? - HIV+ MSM Condomless Sex/Detectable Viral Load Behavior USA - Blind Spot ? For Ending the Epidemic....efforts not good enough - (07/29/20)
     
  3317. Antiretroviral drug concentrations in brain tissue of adult decedents - (07/29/20)
     
  3318. High Stigma Towards Those Living with HIV Remains, GLAAD Survey: State of HIV Stigma Survey - stigma persists - GLAAD survey - (07/29/20)
     
  3319. High Stigma Towards Those Living with HIV Remains, GLAAD Survey: State of HIV Stigma Survey - stigma persists - GLAAD survey - (07/28/20)
     
  3320. from the NIH Comorbidities Workshop held Sept 2019 at NIH - Report Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop - (07/27/20)
     
  3321. IAC 2020 Virtual: Persons Living With HIV (PLWH) in Japan on 2-Drug Regimen Reveal More Complex Patient Profiles Than That of 3-Drug Regimen Cohort - (07/27/20)
     
  3322. IAC 2020 Virtual: Cardiovascular and metabolic comorbidities in HIV-infected patients in Colombia: A multicenter study - (07/27/20)
     
  3323. IAC 2020 Virtual: Vesatolimod induces dose-dependent immune responses in HIV controllers - (07/27/20)
     
  3324. IAC 2020 Virtual: Changes in Body Mass Index Over Time in Persons With and Without HIV - Kaiser - (07/27/20)
     
  3325. IAC 2020 Virtual: COVID-19 in the Largest US HIV Cohort - (07/19/20)
     
  3326. IAC 2020 Virtual: To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment - (07/19/20)
     
  3327. ViiV Healthcare announces new strategic alliance to enable greater access to antiretroviral medicines in Brazil - PRESS RELEASE - (07/17/20)
     
  3328. Moderna's Covid-19 Vaccine Moves to Bigger Study - (07/17/20)
     
  3329. IAC 2020 Virtual: PUTTING THE HEART BACK INTO HAART: GREATER HCP-PATIENT ENGAGEMENT IS ASSOCIATED WITH BETTER HEALTH OUTCOMES AMONG PERSONS LIVING WITH HIV (PLHIV) ON TREATMENT - (07/17/20)
     
  3330. IAC 2020 Virtual: Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana - (07/16/20)
     
  3331. IAC 2020 Virtual: Overdose Deaths Cut 10 Years Off HIV Life Expectancy: British Columbia - Mark Mascolini (07/16/20)
     
  3332. IAC 2020 Virtual: Characteristics of Patients Living with HIV (PLWH) and HIV Treatment Outcomes in Community Practices in Southern vs Non-Southern US Regions - (07/16/20)
     
  3333. IAC 2020 Virtual: FACTORS ASSOCIATED WITH RESILIENCE AMONG OLDER PEOPLE LIVING WITH HIV - (07/16/20)
     
  3334. IAC 2020 Virtual: HIV-1 DNA Testing in Viremic Patients Demonstrates a Greater Ability to Detect Drug Resistance Compared to Plasma Virus Testing - (07/16/20)
     
  3335. IAC 2020 Virtual: MODEL-BASED APPROACH OF DOSE SELECTION AND OPTIMAL PK SAMPLING OF FOSTEMSAVIR FOR PEDIATRIC PATIENTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION - (07/16/20)
     
  3336. IAC 2020 Virtual: COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/16/20)
     
  3337. Cognitive disorders in people living with HIV - (07/16/20)
     
  3338. Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV (cure) - (07/16/20)
     
  3339. PrEP in YBMSM Atlanta -. high rates of discontinuation - (07/16/20)
     
  3340. COVID Congress: Baseline Characteristics Associated With Clinical Improvement and Mortality in Hospitalized Patients With Severe COVID-19 Treated With Remdesivir - (07/16/20)
     
  3341. COVID Congress: Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care - (07/16/20)
     
  3342. GILEAD SCIENCES STATEMENT ON THE INITIATION OF CLINICAL TESTING OF AN INHALED SOLUTION OF REMDESIVIR FOR POTENTIAL OUTPATIENT TREATMENT OF COVID-19 - (07/16/20)
     
  3343. European Commission Grants Conditional Marketing Authorization for Gilead's Veklury® (remdesivir) for the Treatment of COVID-19 - (07/16/20)
     
  3344. IAC 2020 Virtual: Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (07/16/20)
     
  3345. IAC 2020 Virtual: ADEQUATE PLASMA LEVELS OF DOLUTEGRAVIR IN COMBINATION WITH RITONAVIR-BOOSTED DARUNAVIR: A PHARMACOKINETIC SUBGROUP-ANALYSIS OF THE DUALIS STUDY - (07/16/20)
     
  3346. IAC 2020 Virtual: The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) - (07/15/20)
     
  3347. IAC 2020 Virtual: Global Positive Perspectives Study, Wave 2: Understanding the Unmet Needs of People Living with HIV - (07/15/20)
     
  3348. IAC 2020 Virtual: Cardiovascular Risk Estimation is Sub-optimal Across Two HIV Cohort - (07/15/20)
     
  3349. IAC 2020 Virtual: COMPARATIVE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF DOLUTEGRAVIR AND LAMIVUDINE VS 3-DRUG ANTIRETROVIRAL REGIMENS IN TREATMENT-NAIVE HIV-1 INFECTED PATIENTS AT 96 WEEKS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS - (07/15/20)
     
  3350. IAC 2020 Virtual: Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - Mark Mascolini (07/15/20)
     
  3351. IAC 2020 Virtual: COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/15/20)
     
  3352. IAC 2020 Virtual: The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection. - Mark Mascolini (07/15/20)
     
  3353. IAC 2020 Virtual: COVID-19 Disrupts PrEP Starts, Refills, HIV/STI Testing in Boston Clinic - Mark Mascolini (07/15/20)
     
  3354. IAC 2020 Virtual: With COVID Here, 90% of Australian MSM Have Less Sex, 40% Stop PrEP - Mark Mascolini (07/15/20)
     
  3355. IAC 2020 Virtual: High HCV Rate in Both Young and Older Drug Injectors--HIV Ups HCV Risk - Mark Mascolini (07/15/20)
     
  3356. IAC 2020 Virtual: FEASIBILITY OF IMPLEMENTING LONG-ACTING INJECTABLE ANTI-RETROVIRAL THERAPY TO TREAT HIV: A SURVEY OF HEALTH PROVIDERS FROM THE 13 COUNTRIES PARTICIPATING IN THE ATLAS-2M TRIAL - (07/15/20)
     
  3357. IAC 2020 Virtual: PrEP Halves New HIV Rate When Offered in Contraceptive Trial - Mark Mascolini - (07/15/20)
     
  3358. IAC 2020 Virtual: Doravirine Resistance Profile in Clinical Isolates and Impact of Baseline NNRTI Resistance-Associated Mutations Observed in Treatment-Naïve Participants from Phase 2 and 3 Clinical Trials - (07/15/20)
     
  3359. IAC 2020 Virtual: IS DTG+3TC EFFECTIVE AND SAFE IN CLINICAL PRACTICE? EVIDENCE FROM REAL WORLD DATA - (07/15/20)
     
  3360. IAC 2020 Virtual: COMPARISON OF VIRAL REPLICATION AT <40 C/ML FOR 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC FDC) VERSUS 3-DRUG REGIMEN (3DR) BASED ON TENOFOVIR ALAFENAMIDE (TAF) (TBR) IN THE TANGO STUDY - (07/15/20)
     
  3361. IAC 2020 Virtual: Is DTG+3TC effective and safe in clinical practice? Evidence from real world data - (07/15/20)
     
  3362. IAC 2020 Virtual: Almost Half of Older HIV+ Adults Report Poor Overall Health in 25-Country Survey - (07/15/20)
     
  3363. IAC 2020 Virtual: HCV Drugs for COVID-19? Three Small Studies Have Positive Hints - Mark Mascolini (07/15/20)
     
  3364. IAC 2020 Virtual: The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection - More Weight, Trunk Fat, Metabolic Syndrome With DTG+TAF/FTC in South African Trial - Mark Mascolini (07/15/20)
     
  3365. IAC 2020 Virtual: Faster virological suppression with dolutegravir versus efavirenz in pregnancy does not lower the risk of HIV mother-to-child-transmission: A meta-analysis of 5 clinical trials in 1074 pregnant women - Mark Mascolini (07/15/20)
     
  3366. IAC 2020 Virtual: The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial. - Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - Mark Mascolini (07/15/20)
     
  3367. IAC 2020 Virtual: Racial Disparities, Communal Living in Boston COVID-19 Patients With HIV - Mark Mascolini (07/15/20)
     
  3368. IAC 2020 Virtual: Prevalence and Incidence of Hepatitis C Virus Infection in Men Who Have Sex With Men: A Global Systematic Review - (07/13/20)
     
  3369. IAC 2020 Virtual: Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: A longitudinal analysis - (07/13/20)
     
  3370. IAC 2020 Virtual: HCV Reinfection Rate 40% in Netherlands HIV+ MSM 5 Years After Clearance - Mark Mascolini (07/13/20)
     
  3371. IAC 2020 Virtual: Global HCV Burden Greater in MSM, Especially HIV+ Men: Meta-Analysis - Mark Mascolini (07/13/20)
     
  3372. IAC 2020 Virtual: Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center - (07/13/20)
     
  3373. IAC 2020 Virtual: Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders - (07/11/20)
     
  3374. IAC 2020 Virtual: Rapid Initiation of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Acute and Early Human Immunodeficiency Virus (HIV)-1 Infection: A DIAMOND Subgroup Analysis - (07/11/20)
     
  3375. IAC 2020 Virtual: Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR) - (07/11/20)
     
  3376. IAC 2020 Virtual: Weight change among treatment naive women initiating dolutegravir in the ARIA study - (07/11/20)
     
  3377. IAC 2020 Virtual: COMPASSIONATE USE OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) AND RILPIVIRINE (RPV) FOR PATIENTS IN NEED OF PARENTERAL ANTIRETROVIRAL THERAPY - (07/11/20)
     
  3378. IAC 2020 Virtual: PATIENT-REPORTED OUTCOMES THROUGH WEEK 48 OF ATLAS-2M: A STUDY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE ADMINISTERED EVERY FOUR OR EIGHT WEEKS - (07/11/20)
     
  3379. IAC 2020 Virtual: Same COVID Mortality With/Without HIV at NY Center--More Intubations With HIV - Mark Mascolini (07/11/20)
     
  3380. IAC 2020 Virtual: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Treatment-naïve (AMBER) and Virologically Suppressed (EMERALD) Patients With Neurologic and/or Psychiatric Comorbidities: Week 96 Subgroup Analysis - (07/11/20)
     
  3381. IAC 2020 Virtual: Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)
     
  3382. IAC 2020 Virtual: WEIGHT CHANGE AMONG TREATMENT-NAIVE WOMEN INITIATING DOLUTEGRAVIR IN THE ARIA STUDY - (07/10/20)
     
  3383. IAC 2020 Virtual: Double Drug Use, Double No-Condom Sex Boost HIV Risk With Already-Positive Partner - Mark Mascolini (07/10/20)
     
  3384. IAC 2020 Virtual: MSM Testing Drive Works Well in Australia-Except for One Thing - Mark Mascolini (07/10/20)
     
  3385. IAC 2020 Virtual: Prescribed Opioid Dose Increase Tied to Future Heroin Use in HIV+ People - Mark Mascolini - (07/10/20)
     
  3386. IAC 2020 Virtual: Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)
     
  3387. IAC 2020 Virtual: HIV Risk and Treatment Disparities Persist in US Hispanic vs White MSM - Mark Mascolini (07/10/20)
     
  3388. IAC 2020 Virtual: Neuropathy and Neuropathic Pain Still on Rise in HIV+, But No Clear Links to ART - Mark Mascolini (07/10/20)
     
  3389. IAC 2020 Virtual: Quarter Million More With HIV in US-Mostly Women-Should Get Hep A Vaccine: CDC Now Recommends HAV Vax for Everyone With HIV at Least 1 Year Old - Mark Mascolini (07/10/20)
     
  3390. IAC 2020 Virtual: Deep Sequencing With Unique Molecular Identifiers for Evaluation of HIV-1 Drug Resistance in the DISCOVER Pre-Exposure Prophylaxis Trial - (07/10/20)
     
  3391. IAC 2020 Virtual: Prevalence and Risk Factors of Preexisting NNRTI Resistance Among Suppressed PLWH in B/F/TAF Switch Studies - (07/10/20)
     
  3392. IAC 2020 Virtual: Clinical and sociodemographic characteristics associated with poor self-rated health across multiple domains among older adults living with HIV - (07/10/20)
     
  3393. IAC 2020 Virtual: Weight gain and hyperglycemia during the dolutegravir transition in Africa - (07/10/20)
     
  3394. IAC 2020 Virtual: Prevalence and risk factors of pre-existing NNRTI resistance among suppressed PLWH in B/F/TAF switch studies - (07/10/20)
     
  3395. IAC 2020 Virtual: Baseline NRTI resistance in suppressed participants did not lead to viral blips on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF through week 48 in study 380-4030 - (07/10/20)
     
  3396. IAC 2020 Virtual: Lenacapavir Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/10/20)
     
  3397. IAC 2020 Virtual: Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study - (07/10/20)
     
  3398. IAC 2020 Virtual: HPTN 083: Efficacy of Pre-exposure Prophylaxis (PrEP) containing Long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations - (07/10/20)
     
  3399. IAC 2020 Virtual: Projecting the burden of multimorbidity among men who have sex with men living with HIV in the US - (07/09/20)
     
  3400. IAC 2020 Virtual: Lenacapavir (GS-6207) Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/09/20)
     
  3401. IAC 2020 Virtual: Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection - (07/09/20)
     
  3402. IAC 2020 Virtual: Islatravir Safety Through 48 Weeks With Doravirine in Phase 2 Trial - Mark Mascolini (07/09/20)
     
  3403. IAC 2020 Virtual: Almost Half in US Women's Group Make PrEP Visit--But Only 10% Start PrEP - Mark Mascolini - (07/09/20)
     
  3404. IAC 2020 Virtual: UNDERSTANDING THE CHANGING TREATMENT CONCERNS OF OLDER PEOPLE LIVING WITH HIV (PLHIV) AND DIFFICULTIES WITH PATIENT-PROVIDER COMMUNICATION - (07/09/20)
     
  3405. IAC 2020 Virtual: Pooled Analysis of 4 International Trials of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Adults Aged ≥ 65 Years Demonstrating Safety and Efficacy: Week 48 Results - (07/09/20)
     
  3406. IAC 2020 Virtual: Doravirine, Islatravir at AIDS2020 IAC - (07/09/20)
     
  3407. IAC 2020 Virtual: DISCOVER Study for HIV Pre-exposure Prophylaxis: No Evidence of Risk Compensation in Participants Taking F/TDF or F/TAF for PrEP Through 96 Weeks - (07/09/20)
     
  3408. IAC 2020 Virtual: Weight/Body Mass Index Gains Following Initiation of Integrase Strand Transfer Inhibitor Versus Protease Inhibitor Among People Living With Human Immunodeficiency Virus in the United States - (07/09/20)
     
  3409. IAC 2020 Virtual: Weight/Body Mass Index Gains Following Initiation of Integrase Strand Transfer Inhibitor Versus Protease Inhibitor Among People Living With Human Immunodeficiency Virus in the United States - (07/09/20)
     
  3410. IAC 2020 Virtual: Lenacapavir (GS-6207) Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/09/20)
     
  3411. IAC 2020 Virtual: One Third in US Stopped PrEP During COVID Shutdown, 90% Trimmed HIV Risk - Mark Mascolini (07/09/20)
     
  3412. ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available - PRESS RELEASE - (07/08/20)
     
  3413. IAC 2020 Virtual: Baseline NRTI Resistance in Suppressed Participants Did Not Lead to Viral Blips on Bictegravir/Emtricitabine/Tenofovir Alafenamide B/F/TAF or Dolutegravir DTG + F/TAF Through Week 48 in Study 380-4030 - (07/08/20)
     
  3414. IAC 2020 Virtual: The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) - (07/08/20)
     
  3415. IAC 2020 Virtual: Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis. - (07/08/20)
     
  3416. IAC 2020 Virtual: Sexually Transmitted Infections in the DISCOVER HIV PrEP Trial - (07/08/20)
     
  3417. IAC 2020 Virtual: IMPROVED METABOLIC PARAMETERS AFTER SWITCHING FROM TAF-BASED 3- OR 4-DRUG REGIMEN TO THE 2-DRUG REGIMEN OF DTG/3TC (DOLUTEGRAVIR/LAMIVUDINE): THE TANGO STUDY - (07/08/20)
     
  3418. IAC 2020 Virtual: Prevalence and Risk Factors of Preexisting NNRTI Resistance Among Suppressed PLWH in B/F/TAF Switch Studies - (07/08/20)
     
  3419. IAC 2020 Virtual: HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men - (07/08/20)
     
  3420. IAC 2020 Virtual: Doravirine resistance profile in clinical isolates and impact of baseline NNRTI resistance-associated mutations observed in treatment-naïve participants from phase 3 clinical trials - (07/08/20)
     
  3421. IAC 2020 Virtual: ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAÏVE ADULTS WITH HIV-1 INFECTION - (07/08/20)
     
  3422. IAC 2020 Virtual: Challenges faced by a population aging with HIV: Baseline data from the CORE healthy aging initiative (CHAI) - (07/07/20)
     
  3423. IAC 2020 Virtual: Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 results - (07/07/20)
     
  3424. IAC 2020 Virtual: WEIGHT CHANGES AFTER SWITCH TO DORAVIRINE/LAMIVUDINE/TDF IN THE DRIVE-SHIFT TRIAL - (07/07/20)
     
  3425. IAC 2020 Virtual: Reducing ART to less than 3-ARV regimen linked to increased systemic inflammation - (07/07/20)
     
  3426. IAC 2020 Virtual: ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAïVE ADULTS WITH HIV-1 INFECTION - (07/07/20)
     
  3427. IAC 2020 Virtual: Weight gain before and after switch from TDF to TAF - (07/07/20)
     
  3428. IAC 2020 Virtual: New Findings on Gilead's Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults (and pre-existing resistance) - (07/06/20)
     
  3429. IAC 2020 Virtual: Early Weight Gain Up to 4.5 Kg/Year With Switch From TDF to TAF: Data Suggest Independent Effect of TAF on Weight - Mark Mascolini (07/06/20)
     
  3430. IAC 2020 Virtual: ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices - (07/06/20)
     
  3431. IAC 2020 Virtual: Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207) - (07/06/20)
     
  3432. IAC 2020 Virtual: Heavily Pretreated US HIV Patients Face Clinical Hurdles, Higher Death Risk - Mark Mascolini (07/06/20)
     
  3433. IAC 2020 Virtual: No HIV Infections in PrEP Adherers, But Only 56% Continue PrEP 5 Years - Mark Mascolini (07/06/20)
     
  3434. IAC 2020 Virtual: High STI Rate in IPERGAY PrEP Study, But Concentrated in Subgroup - Mark Mascolini (07/06/20)
     
  3435. IAC 2020 Virtual: Viral Rebound No Slower When Stopping Modern ART Combinations - Mark Mascolini (07/06/20)
     
  3436. IAC 2020 Virtual: People With HIV Gaining Weight 3 Times Faster Than HIV-Negatives in US - Mark Mascolini (07/06/20)
     
  3437. IAC 2020 Virtual: Time to HIV Diagnosis Falling in US, But Half With HIV Undiagnosed After 3 Years - (07/06/20)
     
  3438. IAC 2020 Virtual: Time to HIV Diagnosis Falling in US, But Half With HIV Undiagnosed After 3 Years - Mark Mascolini (07/06/20)
     
  3439. IAC 2020 Virtual: Only Small Weight Gains After Trial Switch to Doravirine/3TC/TDF - Mark Mascolini (07/06/20)
     
  3440. IAC 2020 Virtual: ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life - (07/06/20)
     
  3441. IAC 2020 Virtual: Kidney Disease, Diabetes Could Jump in US MSM With HIV - But Not High Lipids - Mark Mascolini (07/06/20)
     
  3442. IAC 2020 Virtual: Cigarette Smoking and Substance Use Each Independently Cuts Chances of HIV Control - Mark Mascolini (07/06/20)
     
  3443. IAC 2020 Virtual: ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) - PRESS RELEASE - (07/06/20)
     
  3444. IAC 2020 Virtual: Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual - press release - (07/06/20)
     
  3445. IAC 2020 Virtual: Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual - (07/06/20)
     
  3446. IAC 2020 Virtual: ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) - PRESS RELEASE - (07/02/20)
     
  3447. IAC 2020 Virtual: Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual - press release - (07/02/20)
     
  3448. Hypertension/79% in >65 HIV+ Causes-Risk Factors - (07/01/20)
     
  3449. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients - (07/01/20)
     
  3450. Disparate Impact of HIV/Aging on women - (06/30/20)
     
  3451. HIV Neuropathy: Women & Men/Prevalence-Risk Factors - (06/30/20)
     
  3452. ViiV Healthcare announces grantees selected as part of 3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic - PRESS RELEASE - (06/30/20)
     
  3453. Remdesivir Pricing - - An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences - press release - (06/30/20)
     
  3454. Combination of healthy lifestyle traits may substantially reduce Alzheimer's disease risk & Dietary flavonols too - (06/29/20)
     
  3455. Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir - (06/29/20)
     
  3456. HIV-Aging/Senescence/CAR-T-Cells. Senolytic Agents or Senolytic Therapeutics - (06/25/20)
     
  3457. Senolytic drugs reverse damage caused by senescent cells in mice - (06/25/20)
     
  3458. Urine Tenofovir Levels Measured by a Novel Immunoassay Predict HIV Protection - (06/25/20)
     
  3459. IAC: Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual - (06/24/20)
     
  3460. CROI: GUT INTEGRITY MARKERS AND ASSOCIATIONS WITH ADIPOSITY IN PEOPLE WITH AND WITHOUT HIV - (06/24/20)
     
  3461. Risk of Increased Physical Inactivity During COVID 19 Outbreak in Older People: A Call for Actions - Editorial - (06/22/20)
     
  3462. Burden of Aging with HIV: "better Care Systems Needed" UCSF - (06/22/20)
     
  3463. Fatty Liver in HIV: what the HIV Clinician Needs to Know - (06/19/20)
     
  3464. Lean NAFLD in HIV+ 14% - Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus - (06/19/20)
     
  3465. HCV Testing for HIV+ - Only 50% Are Tested - (06/18/20)
     
  3466. Older Adults on ART Have Double the Mortality Risk of Their HIV-Negative Counterparts.....Survival of people aged 50 years and older by HIV and HIV treatment status: findings from three waves of the SAGE-Wellbeing of Older People Study (SAGE-WOPS) in Uganda - (06/18/20)
     
  3467. Senolytics improve physical function and increase lifespan in old age - (06/17/20)
     
  3468. Senescent cells: an emerging target for diseases of ageing - Senotherapeutics for healthy ageing - (06/17/20)
     
  3469. senolytics might become an entirely new path for alleviating currently untreatable chronic diseases and enhancing human health span. - (06/17/20)
     
  3470. HIV and cardiovascular disease - Review - (06/16/20)
     
  3471. ART Reduced HPV Prevalence - Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis - (06/16/20)
     
  3472. FDA Approves Merck's GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers - (06/16/20)
     
  3473. HIV & Neurocognitive Impairment - 2 recent studies - (06/15/20)
     
  3474. On-demand HIV prevention pills worked well for San Francisco patients, Kaiser - (06/15/20)
     
  3475. Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco - (06/15/20)
     
  3476. Questioning statin therapy for older patients - (06/12/20)
     
  3477. ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV - (06/12/20)
     
  3478. HIV infects astrocytes in vivo and egresses from the brain to the periphery - After ATI - (06/12/20)
     
  3479. Metabolic Syndrome and Neurocognitive Deficits in HIV Infection - 'Metabolic syndrome most strongly associated with neurocognitive impairment......' - (06/11/20)
     
  3480. Senotherapeutics and HIV-1 Persistence & Aging/Senescence - (06/09/20)
     
  3481. Metabolic Syndrome and Neurocognitive Deficits in HIV Infection - (06/09/20)
     
  3482. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO) - (06/09/20)
     
  3483. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy - (06/09/20)
     
  3484. Statin use is associated with insulin resistance in participants of the Canadian Multicentre Osteoporosis Study - (06/08/20)
     
  3485. Frailty in People Living with HIV - new review following several CROI reports on frailty, mitochondrial damage & brain function & frailty - (06/01/20)
     
  3486. Letter from Gilead: Update on HIV PrEP Research Among Cisgender Women - (05/28/20)
     
  3487. Fatty Liver in HIV - (05/28/20)
     
  3488. New Merck COVID Efforts-2 Vaccines+Antiviral Drug EIDD-2801; Acquisition & Collaborations - (05/26/20)
     
  3489. Long-acting drug acts like a short-term AIDS vaccine (Cabotegravir injectable long-acting HPTN-083 study) - (05/22/20)
     
  3490. Cabotegravir Injectable Long Acting PrEP Study HPTN-083 Stopped Due To Higher Efficacy - (05/22/20)
     
  3491. Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial - (05/21/20)
     
  3492. CROI: Creation of Long - Acting Nanoformulated Tenofovir Prodrugs - (05/21/20)
     
  3493. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection FLAIR - (05/21/20)
     
  3494. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression ATLAS - (05/21/20)
     
  3495. CROI: Study Suggests PrEP Access Issue: Disparity in Prior Authorizations Across US Regions - (05/20/20)
     
  3496. CROI: INFILTRATION OF VRC01 INTO THE CEREBROSPINAL FLUID IN HUMANS IN THE RV397 STUDY - (05/20/20)
     
  3497. CROI: Tenofovir Diphosphate in Dried Blood Spots Predicts Virologic Failure and Resistance - (05/20/20)
     
  3498. CROI: REAL-LIFE MANAGEMENT OF DRUG-DRUG INTERACTIONS BETWEEN ANTIRETROVIRALS AND STATINS - (05/20/20)
     
  3499. Reported preexposure prophylaxis use among male sex partners of HIV-positive men 2016-2018 - (05/19/20)
     
  3500. COVID & Genetics - CCR5 Leronlimab therapy checked COVID-19 inflammation - (05/19/20)
     
  3501. CROI: Use of an HIV Prediction Model to Evaluate PrEP Coverage in a Large Healthcare System - (05/19/20)
     
  3502. CROI: Implementation of On-Demand PrEP in a Large Integrated Healthcare System - (05/19/20)
     
  3503. CROI: Non-Daily Use of HIV Preexposure Prophylaxis in a Large Online Sample in the U.S. - (05/19/20)
     
  3504. CROI: Clinical Pharmacology at CROI 2020 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (05/19/20)
     
  3505. CROI: Biodegradable Implant for Sustained Delivery of Antiretroviral (ARV) - (05/18/20)
     
  3506. Leaning on Community-Based Participatory Research to Respond During COVID-19 - Aging HIV+ - (05/18/20)
     
  3507. CROI: Bictegravir/FTC/TAF CSF Diffusion in HIV-Infected Patients with CNS Impairment - (05/18/20)
     
  3508. CROI: Safety and Tolerability of Once Daily BIC/FTC/TAF for Post-Exposure Prophylaxis - (05/18/20)
     
  3509. CROI: There is a long Long History of Sexual Transmission of HCV in MSM, Heterosexual Men, Women, IDUs & Reinfection too - (05/18/20)
     
  3510. CROI: TFV-DP in DBS for pregnant/postpartum adolescent and young women on PrEP in Africa - (05/18/20)
     
  3511. Long-acting injectable drug prevents HIV infections - (05/18/20)
     
  3512. Global HIV prevention study to stop early after ViiV Healthcare's long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP - (05/18/20)
     
  3513. Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men - (05/18/20)
     
  3514. CROI: TFV-DP in DBS for pregnant/postpartum adolescent and young women on PrEP in Africa - (05/18/20)
     
  3515. Low-Level Viremia Increased Mortality & Comorbidities - (05/15/20)
     
  3516. Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA - ATI Risks, Functional Not Sterilizing Cure the Goal - (05/15/20)
     
  3517. NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19 - (05/15/20)
     
  3518. New HCV Infections Tripled: 4 times Higher than in 2009 - (05/14/20)
     
  3519. COBRA/Europe-Aging Epidemic/ Increased Brain Aging in HIV+ - (05/13/20)
     
  3520. Older HIV+ Women Have Worse Increasing Comorbidities / HOPS 95% >50 Years Old Have Increasing Numbers of Comorbidities - (05/13/20)
     
  3521. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis - (05/13/20)
     
  3522. HIV Preexposure Prophylaxis Among Adolescents in the USA Review - (05/12/20)
     
  3523. Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD - (05/12/20)
     
  3524. Cognitive Impairment among HIV-Infected Men with Longitudinal Follow-ups - (05/11/20)
     
  3525. Heart Disease in HIV - (05/11/20)
     
  3526. CROI: Effect of Integrase Inhibitors on Weight Gain in Children and Adolescents with HIV - (05/11/20)
     
  3527. CROI: Fat & HIV was a big part of CROI 2020 - (05/11/20)
     
  3528. CROI: Body Composition Changes Over The Menopausal Transition In Women With and At Risk For HIV - (05/11/20)
     
  3529. Hepatic Fibrosis Determined with MRE Significantly Predicts Cognitive Impairment - (05/08/20)
     
  3530. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen - (05/08/20)
     
  3531. HIV health system in South Africa is ill-equipped to handle the rising tide of HTN , CVD, Aging, Comorbities - Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa - (05/08/20)
     
  3532. PrEP & Lipids, Weight Gain - (05/08/20)
     
  3533. CROI: TELMISARTAN DECREASES MONOCYTE CX3CR1 EXPRESSION IN TREATED HIV - (05/07/20)
     
  3534. CROI: Cognitive Impairment among HIV-Infected Men with Longitudinal Follow-ups - (05/07/20)
     
  3535. CROI: RESISTIN GENE POLYMORPHISM RELATED TO WEIGHT GAIN AND PSYCHIATRIC SYMPTOMS ON InSTI - (05/07/20)
     
  3536. CROI: MEASURES OF ADIPOSE TISSUE REDISTRIBUTION AND ATHEROSCLEROTIC CORONARY PLAQUE IN HIV - (05/06/20)
     
  3537. CROI: Fat/Weight Gain/Aging Faster-mitochondria/Fat Tissue/Genetics/Metabolic Rate-Calorie Intake - (05/06/20)
     
  3538. CROI: INCREASED INFLAMMATORY CX3CR1+GPR56+CD57+ CD4+ T CELLS IN FAT FROM HIV+ DIABETICS - (05/06/20)
     
  3539. CROI: FAT GAINS OCCUR AFTER ART WITHOUT CHANGES IN METABOLIC RATE OR CALORIC INTAKE - (05/06/20)
     
  3540. CROI: Cardiac Events in HIV-infected Patients Who Use Tenofovir-Alafenamide - (05/06/20)
     
  3541. CROI: CYP2B6 GENOTYPE AND WEIGHT-GAIN DIFFERENCES BETWEEN DOLUTEGRAVIR AND EFAVIRENZ - (05/06/20)
     
  3542. CROI: Pharmacogenetics of Weight Gain after Switch from Efavirenz to Integrase Inhibitors - (05/06/20)
     
  3543. CROI: ViiV COVID-19 Community Response Fund - May 15 Deadline for Research & Community Organizations - (05/05/20)
     
  3544. Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection - (05/05/20)
     
  3545. Heart Disease in HIV - (05/05/20)
     
  3546. CROI: Kidney Disease Rates in DAD & West Africa at Young Ages: VALIDATION OF THE D:A:D CHRONIC KIDNEY DISEASE (CKD) RISK SCORE IN A LARGE AFRICAN COHORT - (05/05/20)
     
  3547. CROI: Unexpectedly High Rate of Intolerance for Dolutegravir in Real Life Setting - (05/05/20)
     
  3548. CROI: HIV Prevention at CROI 2020 - Written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (05/05/20)
     
  3549. IAS AIDS 2020 Virtual - (05/01/20)
     
  3550. New York City by Far has the Highest Rates of PLWH >55 in the USA, SF 2nd Rates by City - (04/29/20)
     
  3551. Rates HIV+ Over 55/60 Mapped, NYC, USA, by County - (04/29/20)
     
  3552. Rates by Race/Aging: Over 55 HIV+ - (04/29/20)
     
  3553. Accelerated Aging - HIV+ Appear to be 5-17 Years Older Chronologic Age - (04/28/20)
     
  3554. Depressive Disorders in HIV/AIDS:....older PLWH, social isolation, stigma, survivor guilt, shame & guilt, existential issues - (04/28/20)
     
  3555. Rates HIV+ Over 55/60 Mapped - (04/28/20)
     
  3556. NATAP: Rates by Race/Aging: Over 55 HIV+ - (04/28/20)
     
  3557. CROI: HIV Stigma Predicts Retention in Care Among US Patients in Care - (04/27/20)
     
  3558. CROI: Postpartum weight changes in women initiating DTG vs EFV in pregnancy: DolPHIN-2 - (04/27/20)
     
  3559. CROI: Dolutegravir+3TC - 2 Drug ART at CROI 2020 - (04/27/20)
     
  3560. A RANDOMIZED TRIAL OF THE IMPACT OF 3BNC117 AND ROMIDEPSIN ON THE HIV-1 RESERVOIR - (04/24/20)
     
  3561. PrEP at CROI / AIDSVu Releases Landmark County-Level Data and Interactive Maps on PrEP Use Across the U.S. - (04/22/20)
     
  3562. HIV-Experienced Clinician Workforce Capacity: Urban-Rural Disparities in the US South - (04/22/20)
     
  3563. New Long-Acting PrEP: MK-8591 - (04/22/20)
     
  3564. Theratechnologies responses to current COVID-19 pandemic - (04/22/20)
     
  3565. CROI: Cardiovascular Risk Profile: A Clinic-Based Sample of Youth Living with HIV in the US - (04/20/20)
     
  3566. CROI: Low Bone Mineral Density in Older People Living with HIV: the Renal-Bone Axis and ART - (04/20/20)
     
  3567. CROI: Comorbidities at CROI - mortality, aging..... - (04/20/20)
     
  3568. CROI: PrEP at CROI 2020 - (04/20/20)
     
  3569. CROI: INTACT PROVIRAL DNA LEVELS DECLINE IN PEOPLE WITH HIV ON ANTIRETROVIRAL THERAPY - new intact proviral DNA assay - (04/20/20)
     
  3570. Company Statements Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials - (04/16/20)
     
  3571. WHO Report: HIV+ COVID Responses - (04/16/20)
     
  3572. WHO Report: HIV+ COVID Responses - (04/14/20)
     
  3573. CROI: THE LONG AND THE SHORT OF IT: WHAT'S NEXT FOR LONG-ACTING DRUGS (04/13/20)
     
  3574. CROI: Trends in Marijuana, Alcohol, and Opioid Use in Pregnant and Postpartum Women with HIV (04/13/20)
     
  3575. CROI: MK-8504 and MK-8583 (Tenofovir Prodrugs) Single-Dose PK and Antiviral Activity in HIV Infection (04/13/20)
     
  3576. CROI: Barriers To Direct-Acting Antiviral Therapy Among HIV/HCV-Coinfected Adults (04/10/20)
     
  3577. CROI: COMPARABLE EFFICACY OF IBALIZUMAB IN COMBINATION WITH ONE OR TWO FULLY ACTIVE AGENTS (04/10/20)
     
  3578. CROI: HIV VIRAL BLIPS IN ADULTS TREATED WITH InSTI-BASED REGIMENS THROUGH 144 WEEKS........no real difference in blips between arms, non-adherence found to cause blips. (04/10/20)
     
  3579. CROI: CLINICAL AND LABORATORY OUTCOMES 24 WEEKS AFTER STARTING DTG VERSUS EFV IN ACUTE HIV (04/10/20)
     
  3580. CROI: NOD2 and TLR8 Agonists Enhance IL-15 Mediated Activation of HIV Expression (04/10/20)
     
  3581. CROI: SAFETY AND EFFICACY OF DTG VS EFV AND TDF VS TAF IN PREGNANCY: IMPAACT 2010 TRIAL (04/10/20)
     
  3582. CROI: RENAL IMPAIRMENT IN A PREEXPOSURE PROPHYLAXIS IMPLEMENTATION COHORT IN AUSTRALIA (04/10/20)
     
  3583. CROI: SUSTAINED HIV REMISSION IN THE LONDON PATIENT: THE CASE FOR HIV CURE (04/09/20)
     
  3584. CROI: PGT121 AND VESATOLIMOD IN CHRONICALLY TREATED SHIV-INFECTED RHESUS MONKEYS (04/09/20)
     
  3585. CROI: Post-Discharge Outcomes Following Acute Coronary Syndrome in HIV [ Disparities for PLWH ] (04/09/20)
     
  3586. CROI: HIV-1 Drug Resistance in the DISCOVER Pre-exposure Prophylaxis Trial (04/09/20)
     
  3587. CROI: COMBINED ACTIVE AND PASSIVE IMMUNIZATION IN SHIV-INFECTED RHESUS MONKEYS (04/09/20)
     
  3588. CROI: PREVALENCE OF RESISTANCE AND LIMITED THERAPEUTIC OPTIONS IN PATIENTS VIREMIC ON ART (04/09/20)
     
  3589. CROI: Drug Resistance is USA & Europe: 2 studies at CROI 2020 (04/09/20)
     
  3590. CROI: MK-8591/Islatravir vs ART Resistance / Metabolics (04/09/20)
     
  3591. CROI: PRO 140 IN VITRO ACTIVITY IN HTE SUBJECTS WITH A 4-CLASS DRUG-RESISTANT HIV-1 VIRUS (04/08/20)
     
  3592. CROI: CLEARANCE OF HPV ANAL HIGH-GRADE INTRAEPITHELIAL LESIONS WITH LOW-DOSE POMALIDOMIDE (04/08/20)
     
  3593. CROI: ON-DEMAND HIV POSTEXPOSURE PROPHYLAXIS BY TAF/EVG VAGINAL INSERTS IN MACAQUES (04/08/20)
     
  3594. CROI: CROI ART/HIV Drug Studies (04/08/20)
     
  3595. CROI: BRAIN AGE BASED ON SLEEP ENCEPHALOGRAPHY IS ELEVATED IN HIV+ ADULTS ON ART (04/08/20)
     
  3596. CROI: Dolutegravir in Malawai (04/08/20)
     
  3597. CROI: HIV TRANSCRIPTION PROFILE IN BLOOD, GUT, LIVER, AND GENITAL TRACT IN SUPPRESSED WOMEN (04/08/20)
     
  3598. CROI: Need for optimization of screening methods for anal intraepithelial neoplasia in people living with HIV (04/08/20)
     
  3599. CROI: High Resolution Anoscopy (HRA) in the Real World: Predictors of Guideline-Based Follow Up at a Large Academic Medical Center (04/08/20)
     
  3600. CROI: ANAL PRECANCER SCREENING AMONG MSM: WHAT IS THE BEST STRATEGY? (04/08/20)
     
  3601. CROI: START OR SWITCH OF INTEGRASE INHIBITORS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV (04/08/20)
     
  3602. CROI: CLINICAL SIGNIFICANCE OF gp120 POLYMORPHISMS, TMR IC50FC AND HIV-1 SUBTYPE IN BRIGHTE (04/08/20)
     
  3603. CROI: 2-Drug Regimen Comparable to 3-Drug Regimens up to 18 Months in a Real-World Setting (04/07/20)
     
  3604. CROI: INTEGRASE INHIBITOR START OR SWITCH IMPACTS LEARNING IN WOMEN WITH HIV (04/07/20)
     
  3605. CROI: Anal Cancer Screening: Is it Time for Cytology and High-risk HPV Co-testing? (04/07/20)
     
  3606. CROI: IN VITRO IMPACT OF TAF ON MITOCHONDRIAL FUNCTION IN IMMUNE CELLS (04/07/20)
     
  3607. CROI: TRICARBOXYLIC ACID METABOLITES PREDICT METABOLIC COMORBIDITIES AND DEATH IN AGING PWH (04/07/20)
     
  3608. CROI: TRICARBOXYLIC ACID METABOLITES PREDICT METABOLIC COMORBIDITIES AND DEATH IN AGING PWH (04/07/20)
     
  3609. CROI: Baseline and Acquired Comorbidities in Patients Initiating ART in the HOPS, 2008-2018 (04/07/20)
     
  3610. CROI: Race Impact on Dolutegravir-Associated Weight Gain Among Previously ART-Naïve People Living with HIV (04/07/20)
     
  3611. CROI: MORTALITY AMONG PEOPLE WITH HIV WITH A HISTORY OF INJECTION DRUG USE, NEW YORK CITY, 2008-2017 (04/07/20)
     
  3612. CROI: Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI (04/06/20)
     
  3613. CROI: IMPACT OF ANTIRETROVIRAL THERAPY INITIATION ON EPIGENETIC AGING AND TELOMERE LENGTH (04/06/20)
     
  3614. CROI: VIROLOGIC FAILURE AND RESISTANCE IN DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS (04/06/20)
     
  3615. CROI: Dolutegravir+3TC - 2 Drug ART at CROI (04/06/20)
     
  3616. J&J COVID Vaccine: "We are counting on a 10 euro vaccine against coronavirus" - (04/06/20)
     
  3617. Letter from Gilead: Message from Amy Flood: Supporting our friends and partners - (04/06/20)
     
  3618. COVID & HIV+ China Report Preliminary Data, How do PLWH Fare? - (04/06/20)
     
  3619. CROI: Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI (04/04/20)
     
  3620. CROI: DOLUTEGRAVIR USE IS ASSOCIATED WITH HIGHER POSTPARTUM WEIGHT COMPARED TO EFAVIRENZ (04/04/20)
     
  3621. CROI: GREATER INCIDENCE OF DIABETES OVER 10 YEARS AMONG DEPRESSED US VETERANS WITH HIV (04/04/20)
     
  3622. CROI: Diabetes, Weight Gain, & Integrase Inhibitor Use in North American HIV+ Persons (04/04/20)
     
  3623. CROI: Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Disease "LIFE HIV Study" (04/04/20)
     
  3624. CROI: Low-level viremia during ART and the risk of death, AIDS, and serious non-AIDS events (04/04/20)
     
  3625. CROI: EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (04/04/20)
     
  3626. CROI: EXPLAINING RACIAL DISPARITIES IN VIRAL SUPPRESSION AMONG MSM LIVING WITH HIV (04/04/20)
     
  3627. CROI: EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA (04/04/20)
     
  3628. CROI: Long Island has 6,649 cases with both counties combined. (04/04/20)
     
  3629. CROI: HCV INCIDENCE AMONG HIV-INFECTED MSM IN FRANCE: RESULTS FROM THE FHDH-ANRS CO4 COHORT (04/04/20)
     
  3630. CROI: Clinical Features and Outcomes of Patients Stopping DTG for Neuropsychiatric Symptoms (04/04/20)
     
  3631. CROI: INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID - 20% ALIVE Cohort (04/02/20)
     
  3632. CROI: NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONOINFECTED PATIENT (04/02/20)
     
  3633. Letter from Gilead: Message from Amy Flood: Supporting our friends and partners - (04/02/20)
     
  3634. CROI: EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (04/01/20)
     
  3635. CROI: Understanding Who Does and Does Not Gain Weight with Integrase Inhibitors (INSTI) (04/01/20)
     
  3636. CROI: Adipocyte Dysfunction Despite Reduced Adipose Inflammation in Diabetics with HIV (04/01/20)
     
  3637. CROI: Once-daily etravirine/raltegravir (400/800 mg) as maintenance regimen (04/01/20)
     
  3638. CROI: Losartan does not improve lymphatic tissue fibrosis or T-cell recovery in HIV infection (04/01/20)
     
  3639. CROI: EFFECTS OF HIV, AGE, AND SEX ON SKELETAL MUSCLE MASS AND DENSITY (04/01/20)
     
  3640. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? - (04/01/20)
     
  3641. Dysregulation of immune response in patients with COVID-19 in Wuhan, China - (04/01/20)
     
  3642. ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV - (04/01/20)
     
  3643. CROI: EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA AMONG PWID (03/31/20)
     
  3644. CROI: EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE (03/31/20)
     
  3645. CROI: IMPACT OF ANTIRETROVIRAL THERAPY INITIATION ON EPIGENETIC AGING AND TELOMERE LENGTH (03/31/20)
     
  3646. CROI: Women with HIV Have High Overall Burden and Early Accrual of Non-AIDS Comorbidities (03/31/20)
     
  3647. CROI: VIROLOGIC FAILURE AND RESISTANCE IN
    DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS     (03/31/20)
     
  3648. CROI: VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRE-TREATMENT IN THE DUALIS STUDY (dolutegravir+bDarunavir) (03/31/20)
     
  3649. CROI: DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 (03/31/20)
     
  3650. CROI: Low-level viremia during ART and the risk of death, AIDS, and serious non-AIDS events (03/31/20)
     
  3651. CROI: (03/31/20)
     
  3652. ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV - (03/31/20)
     
  3653. CROI: Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Disease "LIFE HIV Study" (03/30/20)
     
  3654. CROI: EFFICACY AND DURABILITY OF 2-DRUG VS 3-DRUG INSTI-BASED REGIMENS: DATA FROM REAL-LIFE (03/30/20)
     
  3655. CROI: SHALL WE DANCE? EXTENDING TANGO'S RESULTS TO CLINICAL PRACTICE (03/30/20)
     
  3656. CROI: EFFECT OF PAST VIROLOGICAL FAILURE ON DOLUTEGRAVIR + LAMIVUDINE AS MAINTENANCE REGIMEN (03/30/20)
     
  3657. CROI: VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRE-TREATMENT IN THE DUALIS STUDY (03/30/20)
     
  3658. CROI: LONG-TERM DTG+3TC SWITCH EFFICACY IN PATIENTS WITH ARCHIVED 3TC RESISTANCE (03/30/20)
     
  3659. CROI: Rising BMI Tied to Risk of Diabetes But Not CVD in D:A:D Analysis - Mark Mascolini (03/30/20)
     
  3660. CROI: Retinal Thinning in Well-Controlled HIV-infected Patients (03/30/20)
     
  3661. CROI: Retinal Thinning in Well-Controlled HIV-infected Patients (03/30/20)
     
  3662. CROI: EFFECTS OF HIV INFECTION AND IMMUNE REGULATION ON LONGITUDINAL LUNG FUNCTION DECLINE (03/30/20)
     
  3663. CROI: Modifiable Risk Factors for Kidney and Heart Disease Have Less Impact in HIV+ Than HIV- - Mark Mascolini (03/30/20)
     
  3664. CROI: Increased overall life expectancy but not comorbidity-free years for people with HIV - Mark Mascolini (03/27/20)
     
  3665. CROI: HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/27/20)
     
  3666. CROI: 50% PREVALENCE OF PHYSICAL FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH - age 46-55 (03/27/20)
     
  3667. CROI: Effects of HIV on Myelin Maps (03/27/20)
     
  3668. CROI: NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV (03/27/20)
     
  3669. CROI: EFFECTS OF HIV INFECTION AND IMMUNE REGULATION ON LONGITUDINAL LUNG FUNCTION DECLINE (03/27/20)
     
  3670. CROI: RAPID START LEADS TO SUSTAINED VIRAL SUPPRESSION IN YOUNG PEOPLE IN THE SOUTH (03/26/20)
     
  3671. CROI: Assessment of Immediate Initiation of Antiretroviral Therapy (ART) in New York City (03/26/20)
     
  3672. CROI: ASSESSMENT OF IMMEDIATE INITIATION OF ANTIRETROVIAL THERAPY IN NYC (03/26/20)
     
  3673. CROI: Summary from virtual CROI 2020 for HIV and liver disease HIV and the liver: what is new? - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/25/20)
     
  3674. CROI: TRENDS AND CHARACTERISTICS OF HIV-1 DRUG RESISTANCE IN THE UNITED STATES (2012-2018) (03/25/20)
     
  3675. CROI: Retinal Thinning in Well-Controlled HIV-infected Patients (03/23/20)
     
  3676. CROI: EFFECT OF ANTICHOLINERGIC MEDICATIONS ON BRAIN INTEGRITY IN OLDER HIV-POSITIVE ADULTS (03/23/20)
     
  3677. CROI: BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS (03/23/20)
     
  3678. CROI: Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/23/20)
     
  3679. CROI: Fibrosis Progression Over 6-Fold Higher in NAFLD With vs Without HIV - Mark Mascolini (03/23/20)
     
  3680. CROI: VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/23/20)
     
  3681. RAPID START LEADS TO SUSTAINED VIRAL SUPPRESSION IN YOUNG PEOPLE IN THE SOUTH (03/26/20)
     
  3682. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD (03/23/20)
     
  3683. CROI: Bictegravir/Emtricitabine/Tenofovir Alafenamide Low-Dose Tablet Relative Bioavailability in Healthy Volunteers and PK in Children With HIV (03/20/20)
     
  3684. CROI: Much Higher Death Rate After Cancer Diagnosis in People With HIV - Mark Mascolini (03/20/20)
     
  3685. CROI: HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/20/20)
     
  3686. CROI: CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY DOSING: WEEK 48 RESULTS FROM THE ATLAS-2M STUDY (03/20/20)
     
  3687. CROI: CROI ART/HIV Drug Studies (03/20/20)
     
  3688. CROI: PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY (03/20/20)
     
  3689. CROI: 50% PREVALENCE OF PHYSICAL FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH - age 46-55 (03/20/20)
     
  3690. CROI: PWH had a greater burden (5x) of primarily eccentric arterial wall enhancement compared with persons without HIV (03/20/20)
     
  3691. CROI: HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART (03/27/20)
     
  3692. CROI: PWH had a greater burden (5x) of primarily eccentric arterial wall enhancement compared with persons without HIV (03/27/20)
     
  3693. CROI: PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY (03/27/20)
     
  3694. CROI: SINGLE-CELL GENOMIC ANALYSIS OF BLOOD AND CSF T CELLS IN HIV+ AND HIV- ADULTS......T Cell Exhaustion in CNS HIV (03/17/20)
     
  3695. CROI: HIV-1 REPLICATION AT <50 C/ML TO 148 WEEKS FOR SWORD 1 TO 148 WEEKS FOR SWORD-1/SWORD-2 Studies with DTG+RPV (03/17/20)
     
  3696. CROI: MITOCHONDRIAL DNA, COGNITIVE FUNCTION, AND FRAILTY IN OLDER ADULTS WITH HIV (03/17/20)
     
  3697. CROI: CABOTEGRAVIR PHARMACOKINETIC TAIL IN PREGNANCY AND NEONATAL OUTCOMES (03/17/20)
     
  3698. CROI: BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM (03/17/20)
     
  3699. CROI: Bictegravir/Emtricitabine/Tenofovir Alafenamide Low-Dose Tablet Relative Bioavailability in Healthy Volunteers and PK in Children With HIV (03/17/20)
     
  3700. CROI: Less Coronary Intervention, Higher Mortality in HIV+ People With Acute Coronary Syndrome - Mark Mascolini (03/17/20)
     
  3701. CROI: Starting ART With a PI or an InSTI (Mainly Raltegravir) May Heighten Risk of Diabetes - Mark Mascolini (03/17/20)
     
  3702. CROI: METABOLIC COMPLICATIONS OF HIV AND ITS THERAPIES (03/17/20)
     
  3703. CROI: Rising BMI Tied to Risk of Diabetes But Not CVD in D:A:D Analysis - Mark Mascolini (03/17/20)
     
  3704. CROI: Predicted 10-year risks of diabetes and cardiovascular disease in the ADVANCE trial (03/17/20)
     
  3705. CROI: Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV (03/17/20)
     
  3706. CROI: VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/17/20)
     
  3707. CROI: Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/17/20)
     
  3708. CROI: BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM (03/16/20)
     
  3709. CROI: Safety, PK, and Efficacy of Low-Dose B/F/TAF in Children ≥2 Years Old Living With HIV (03/16/20)
     
  3710. CROI: Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in vivo: The AMC-095 Study (03/16/20)
     
  3711. CROI: Use of D/C/F/TAF With Neurologic/Psychiatric Comorbidities: AMBER Subgroup Analysis (03/16/20)
     
  3712. CROI: DISCOVER: NO EFFECT OF HORMONES ON F/TAF OR F/TDF PK, EFFICACY & SAFETY IN TRANSWOMEN (03/16/20)
     
  3713. CROI: IMPLEMENTATION OF MOBILE PrEP, STI, AND HIV PREVENTION SERVICES IN SOUTH FLORIDA (03/16/20)
     
  3714. CROI: PK, Food Effect, and Safety of Oral GS-6207, a Novel HIV-1 Capsid Inhibitor (03/16/20)
     
  3715. CROI: Cabotegravir + Rilpivirine PK Following Long-Acting HIV Treatment Discontinuation (03/16/20)
     
  3716. CROI: Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/16/20)
     
  3717. CROI: ABSENCE OF GS-6207 PHENOTYPIC RESISTANCE IN HIV Gag CLEAVAGE SITE AND OTHER MUTANTS (03/16/20)
     
  3718. CROI: DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207 (03/16/20)
     
  3719. CROI: CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (03/16/20)
     
  3720. CROI: FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS (03/16/20)
     
  3721. CROI: DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 (03/16/20)
     
  3722. CROI: IMPACT OF PrEP AND TasP ON INCIDENCE OF HIV DIAGNOSES IN 48 HIGHEST-BURDEN US AREAS (03/16/20)
     
  3723. CROI: Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/13/20)
     
  3724. CROI: ASSESSING THE VIROLOGIC IMPACT OF ARCHIVED RESISTANCE IN AN HIV-1 Switch Study TANGO Through Week 48 (03/13/20)
     
  3725. CROI: INSOMNIA AND RISK OF INCIDENT MYOCARDIAL INFARCTION AMONG PEOPLE LIVING WITH HIV (03/13/20)
     
  3726. CROI: DRUG LEVELS, ADHERENCE, AND RISKS FOR LOW ADHERENCE IN THE DISCOVER PrEP STUDY (03/13/20)
     
  3727. NYS & NYC COVID-19 Announcements - Prescriptions for Uninsured & More - (03/13/20)
     
  3728. CROI: Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG - Mark Mascolini (03/12/20)
     
  3729. Phase 3 Doravirine/Islatravir - (03/12/20)
     
  3730. CROI: Modeling-Supported Islatravir Dose Selection for Phase 3 - (03/12/20)
     
  3731. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/12/20)
     
  3732. CROI: 144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years - (03/12/20)
     
  3733. CROI: NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV - (03/11/20)
     
  3734. CROI: HORMONE USE AND HIV ALTER CARDIOVASCULAR BIOMARKER PROFILES IN TRANSGENDER WOMEN - (03/11/20)
     
  3735. CROI: Testosterone Use Tied to Signals of Atherosclerosis Progression in Men With HIV - Mark Mascolini (03/11/20)
     
  3736. CROI: DISCOVER: 96-Week Follow-up of Black and Hispanic/Latinx Study Participants - (03/11/20)
     
  3737. CROI: Themed Discussion FAT IN FOCUS - (03/11/20)
     
  3738. CROI: Pre-ART CD4% and HIV Load Tied to Reservoir Size in Early-Treated Infants - Mark Mascolini (03/11/20)
     
  3739. CROI: GREATER WEIGHT GAIN AFTER SWITCH TO INSTI-BASED REGIMEN FROM NNRTI VS. PI REGIMENS - (03/11/20)
     
  3740. CROI: Life Expectancy With HIV Improving--But Added Years Often Not Healthy - Mark Mascolini (03/11/20)
     
  3741. CROI: Community- Versus Clinic-Based ART Boosts HIV Control in African Study - Mark Mascolini (03/11/20)
     
  3742. CROI: Low Adherence to Treatment and Follow-up of Anal Cancer Precursor - Mark Mascolini (03/11/20)
     
  3743. CROI: Doubled Risk of non-HIV Mortality in US People at Risk for HIV - Mark Mascolini (03/11/20)
     
  3744. CROI: Intact Proviral HIV DNA Drops During Long-Term Suppressive ART - Mark Mascolini (03/11/20)
     
  3745. CROI: Weekly Islatravir Protects Monkeys Against IV Challenge With SIV - Mark Mascolini (03/11/20)
     
  3746. CROI: Losartan Does Not Improve Inflammation or Fibrosis Markers in Older People on ART - Mark Mascolini (03/11/20)
     
  3747. CROI: Pomalidomide Clears Anal Cancer Precursor in High Proportion With or Without HIV - Mark Mascolini (03/11/20)
     
  3748. CROI: Lower CD4/CD38 Ratio Boosts Cancer Risk in US/Canada HIV Group - Mark Mascolini (03/11/20)
     
  3749. CROI: F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks - Mark Mascolini (03/11/20)
     
  3750. CROI: Initial Weight, Low CD4/CD38, Low Activity Drive Weight Gains After InSTI Switch - Mark Mascolini (03/11/20)
     
  3751. CROI: DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 - (03/11/20)
     
  3752. CROI: WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)
     
  3753. CROI: FTC/TAF + BIC Postexposure Prophylaxis Protects Macaques Against Rectal SHIV Infection - (03/11/20)
     
  3754. CROI: Longer Term Efficacy and Safety of F/TAF and F/TDF For HIV PrEP: DISCOVER Trial Week 96 Results - (03/11/20)
     
  3755. CROI: ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership - (03/11/20)
     
  3756. CROI: ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting injectable treatment regimen in adults living with HIV-1 - (03/11/20)
     
  3757. CROI: Glucose Upsets Tied to Worse Physical Function in Men With or Without HIV - Mark Mascolini (03/11/20)
     
  3758. CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS - (03/11/20)
     
  3759. CROI: STRUCTURAL ANALYSES OF A BOUND ANTI-CD4 ADNECTIN INHIBITOR OF HIV-1 [Combinectin GSK3732394] - (03/11/20)
     
  3760. CROI: Mortality 4-Fold Higher With HIV in Canadian Group--in Sync With Comorbidity Tally - Mark Mascolini (03/11/20)
     
  3761. CROI: Safety & Analytic Treatment Interruption Outcomes of Vesatolimod in HIV Controllers - (03/11/20)
     
  3762. CROI: HIV Severity and Incident Heart Failure Among Adults in a Large Healthcare System - (03/11/20)
     
  3763. CROI: WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)
     
  3764. CROI: ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing - (03/11/20)
     
  3765. CROI: New Data on Gilead's Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults - (03/11/20)
     
  3766. CROI: HIV cure from bench to bedside.....and to community - (03/11/20)
     
  3767. Could Colchicine Be the New Aspirin? - (03/09/20)
     
  3768. HIV Itself Ages PLWH - Immunosenescence - (03/09/20)
     
  3769. HIV Causes Aging In HIV & Contributes to the Onset Prematurelly & in Greater Rates of Comorbidities - (03/09/20)
     
  3770. Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate? - (03/09/20)
     
  3771. CROI: Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)
     
  3772. CROI: SAFETY & PHARMACOKINETICS OF GS-9722 IN HIV-NEGATIVE PARTICIPANTS AND PEOPLE WITH HIV - (03/09/20)
     
  3773. CROI: A RANDOMIZED TRIAL OF THE IMPACT OF 3BNC117 AND ROMIDEPSIN ON THE HIV-1 RESERVOIR - (03/09/20)
     
  3774. CROI: Greater Population-Level Viral Control Tied to Lower HIV Incidence in 4 Large Trials - Mark Mascolini - (03/09/20)
     
  3775. CROI: Every-2-Month Maintenance CAB + RPV Noninferior to Monthly Dosing for 48 Weeks. ATLAS-2M study - Mark Mascolini (03/09/20)
     
  3776. CROI: ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing - press release - (03/09/20)
     
  3777. CROI: Merck Announces New Data from Broad HIV Program at CROI 2020 - (03/02/20)
     
  3778. Geriatric model & screening assessments ALL HIV clinics should have - (02/28/20)
     
  3779. Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study - (02/27/20)
     
  3780. FDA approves drug that lowers cholesterol in a new way
    Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance     - (02/24/20)
     
  3781. CROI: Changes in markers of T-cell Senescence and Exhaustion With HIV Therapy - (02/21/20)
     
  3782. Aging of HIV+ in US.....an epidemic coming - (02/21/20)
     
  3783. Multiple roles for HIV broadly neutralizing antibodies - (02/21/20)
     
  3784. Understanding The Relationship Between HPV and Anal Cancer - (02/14/20)
     
  3785. Loss of Preexisting Immunological Memory Among Human Immunodeficiency Virus-Infected Women Despite Immune Reconstitution With Antiretroviral Therapy - (02/14/20)
     
  3786. Novel Antiretroviral Agents - (02/14/20)
     
  3787. Increased Healthcare Costs for Older HIV+ - (02/10/20)
     
  3788. The HIV Continuum of Care for Adolescents and Young Adults Attending 13 Urban US HIV Care Centers of the NICHD-ATN-CDC-HRSA SMILE Collaborative..... - (02/10/20)
     
  3789. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV - (02/10/20)
     
  3790. Preexposure Prophylaxis Indication Criteria Underidentify Black and Latinx Persons and Require Revision - (02/07/20)
     
  3791. Functional Interval Training for Veterans Exercising Through Telehealth. (FIT-VET) - (02/06/20)
     
  3792. Antiretroviral therapy in older people with HIV - HIV AND AGING: Edited by Kristine M. Erlandson - (02/04/20)
     
  3793. Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV - (02/04/20)
     
  3794. Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection - (02/03/20)
     
  3795. New End AIDS CDC Funding for Health Departments - (02/03/20)
     
  3796. HIV postexposure prophylaxis-in-pocket "PIP" - (02/03/20)
     
  3797. Weight Gain in HIV+ - (01/29/20)
     
  3798. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV - (01/29/20)
     
  3799. Weight GAIN - ARTs, Integrase - (01/29/20)
     
  3800. Harvard HIV and Aging Workshop: Perspectives and Priorities from Claude D. Pepper Centers and Centers for AIDS Research - (01/28/20)
     
  3801. Gender & Racial Aging/HIV Disparities - (01/28/20)
     
  3802. AGE: Food Insecurity and Frailty among Women Living with or At-risk for HIV in the U.S. - (01/24/20)
     
  3803. NIAID Launches First Clinical Trial to Test Antibody-Drug Combination for Long-Acting HIV Treatment - (01/27/20)
     
  3804. AGE: Can Frailty Be Prevented or Reversed???? - (01/24/20)
     
  3805. Epidemiological studies have identified a potential temporal link between marijuana use and myocardial infarction - (01/24/20)
     
  3806. Frailty & 5x Higher Mortality in HIV+ Women (WIHS) & Men (MACS) with HIV; frailty doubles fracture rate in older women with HIV; Ever opiate or cocaine use was also associated with increased risk - (01/24/20)
     
  3807. A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1 A Multicenter Trial of the AIDS Clinical Trials Group (ACTG) - A5357 - (01/24/20)
     
  3808. CROI: Longitudinal Phenotyping of Declarative Memory Among Women Living with HIV - (01/24/20)
     
  3809. Aging in NYC: Black/Latino 25% >60 Yrs Old; 75% >40. 23,000 >60 - (01/23/20)
     
  3810. HIV/Aging in NYC 80%+ over 40 Yrs Old/IDUs 95%/HIGH Death Rates for Older HIV - (01/23/20)
     
  3811. AGE: Frailty and Aging (worse mortality): The last 10 years of aging research, and next steps. - (01/23/20)
     
  3812. EACS: Aging with HIV (01/22/20)
     
  3813. AGE: Loneliness & Social Isolation in HIV: Reduces Mental & Physical Health. The "Village Model in HIV study: pilot in San Diego, app" - (01/22/20)
     
  3814. Despite ART/Faster Immune Aging in HIV+ - (01/17/19)
     
  3815. New MK-8591 Publication - (01/17/19)
     
  3816. Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017 - (01/17/19)
     
  3817. Aging Successfully in WIHS...BUT. Prevalence and Correlates of Self-Rated Successful Aging Among Older Women Living With HIV - (01/17/19)
     
  3818. Alzheimers & Amyloid, Mild Cognitive Impairment in HIV - (01/17/19)
     
  3819. Dovato (dolutegravir/lamivudine), the once-daily, single-pill, 2-drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare - (01/16/19)
     
  3820. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV - (01/13/19)
     
  3821. 9th HIV Persistance During Therapy Workshop; Reservoirs & Eradication Strategies Workshop - (01/13/19)
     
  3822. Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University - (01/13/19)
     
  3823. Long-Term Impact of Calcium and Vitamin D Supplementation on Bone Density in HIV+ Patients with Documented Deficiencies - (01/06/19)
     
  3824. Prescribing in Elderly PLWH - Top Ten Drug Classes to Avoid in Elderly PLWH - (01/06/19)
     
  3825. Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017..... three times higher than in the general population - (12/20/19)
     
  3826. Doravrine - a relatively New ART [NNRTI] - (12/20/19)
     
  3827. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV [London]....'although there appear to be outliers' - (12/18/19)
     
  3828. HIV drug resistance in a cohort of HIV-infected MSM in the United States - (12/18/19)
     
  3829. HIV and African American Gay and Bisexual Men: HV incidence 8 Times Higher for African-Americans & 3 times Higher for Hispanics than whites. - (12/18/19)
     
  3830. Fauci: Comorbidities in Persons With HIV - The Lingering Challenge - (12/18/19)
     
  3831. The elusive end to HIV in the USA - Editorial - (12/16/19)
     
  3832. ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV - (12/16/19)
     
  3833. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back - (12/16/19)
     
  3834. HIV and the Aging Brain - Miami CFAR Aging Conference - (12/12/19)
     
  3835. Multimorbidity in Elderly Subjects according to the year of diagnosis of HIV-Infection - A Cross-Sectional DATAIDS Cohort Study....'40% diabetes, 10% cancers, 80% elevated cholesterol, 30% low kidney function eGFR <60, 20% osteoporosis, 80% high blood pressure - (12/12/19)
     
  3836. Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study; Commentary: Thinking About Getting Older With Human Immunodeficiency Virus "HIV Clinics Need To Expand Services" - (12/12/19)
     
  3837. Ruth M. Rothstein CORE Center and Cook County Health HIV Integrated Program launch 'CORE Healthy Aging Initiative 2.0' - (12/12/19)
     
  3838. EACS: Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes (12/12/19)
     
  3839. EACS: Comparable effectiveness of Raltegravir-based dual therapy versus other regimes in patients switched for maintenance (12/09/19)
     
  3840. EACS: Real World Utilisation of Raltegravir 1200mg Once Daily (The RETRO Study) (12/09/19)
     
  3841. Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study - (12/09/19)
     
  3842. Inflammaging: Discover the Fountain of Youth CFAR Miami Conference - (12/09/19)
     
  3843. ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available - (12/05/19)
     
  3844. People ageing with HIV face an uncertain future - (12/05/19)
     
  3845. HIV Outcomes Beyond Viral Suppression - Series Lancet HIV, - (12/05/19)
     
  3846. New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors - (12/05/19)
     
  3847. CT Fat Density Accurately Reflects Histologic Fat Quality in Adults With HIV On and Off Antiretroviral Therapy - Adipose/Fat Density & Quality - (12/05/19)
     
  3848. EACS: Depression and kynurenine/tryptophan ratio in people living with HIV (12/04/19)
     
  3849. EACS: Restless legs syndrome and health-related quality of life in HIV: results from the POPPY sleep substudy (12/04/19)
     
  3850. EACS: AIDS DEFINING AND NON-DEFINING CANCERS IN PERSONS LIVING WITH HIV IN A SINGLE CENTER COHORT FOLLOWED SINCE 1986 (12/04/19)
     
  3851. EACS: Non-Alcoholic Fatty Liver Disease is a significant predictor of cardiovascular risk in HIV-mono-infected patients (12/04/19)
     
  3852. EACS: Long-acting antiretroviral drugs / Marta Boffito MD (12/04/19)
     
  3853. Bisphosphonates and lower mortality risk, Heart Disease & Bone Disease Associated in HIV+ - (12/04/19)
     
  3854. Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults - (12/04/19)
     
  3855. EACS: Pharmacokinetics of Cabotegravir and Rilpivirine Long-Acting Injectables in HIV-Infected Individuals Through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies (12/02/19)
     
  3856. EACS: Prevalence of InSTI resistance and effectiveness of InSTI-based regimens in HIV-infected patients: results from a European cohort study (12/02/19)
     
  3857. EACS: HIV infection in individuals seeking post-exposure prophylaxis (PEP): a retrospective data linkage study (12/02/19)
     
  3858. EACS: Injectable Long Acting Antiretroviral for HIV Treatment or Prevention: The ANRS CLAPT Study (12/02/19)
     
  3859. EACS: Will HIV-infected patients Taking Oral ARV Switch to Long-Acting Injectable ART when It Becomes Available? (12/02/19)
     
  3860. IDWeek: Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1 Infected Subjects - (12/02/19)
     
  3861. EACS: POPULATION PHARMACOKINETIC ANALYSIS OF DOLUTEGRAVIR IN HIV/TB COINFECTED PEOPLE WITH AND WITHOUT RIFAMPICIN (11/26/19)
     
  3862. EACS: Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naïve people living with HIV (PLWH) (11/26/19)
     
  3863. EACS: POPULATION PHARMACOKINETIC ANALYSIS OF DOLUTEGRAVIR IN HIV/TB COINFECTED PEOPLE WITH AND WITHOUT RIFAMPICIN (11/26/19)
     
  3864. EACS: Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV (11/26/19)
     
  3865. EACS: Comparison of a Two-Drug Regimen (Dolutegravir/Rilpivirine) to Standard Three-Drug Regimens in Virologically Suppressed, Treatment Experienced Individuals in the Real World (11/26/19)
     
  3866. EACS: COPEDOL: a two-year French multicentric, observational, longitudinal retro-prospective study in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure (11/26/19)
     
  3867. EACS: Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-Drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations (11/26/19)
     
  3868. EACS: SWORD-1&-2: MAINTENANCE OR IMPROVEMENT IN RENAL FUNCTION IN PLWH THROUGH 148 WEEKS AFTER SWITCH TO THE DOLUTEGRAVIR + RILPIVIRINE 2-DRUG REGIMEN (11/26/19)
     
  3869. IWCADRH: Targeting Liver Fibrosis in Chronic Treated HIV with MitoQ - (11/26/19)
     
  3870. IWCADRH: Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes - (11/26/19)
     
  3871. IWCADRH: Colonic microbiota exhibits disparate associations with HIV infection and sexual practices - (11/26/19)
     
  3872. IWCADRH: BESIDE - Age- and sex-related differences in concomitant diseases and use of co-medication in patients with treated HIV-infection in Germany - (11/26/19)
     
  3873. IWCADRH: Correlation between cerebrospinal fluid and plasma NfL in treated HIV infection in the COBRA study - (11/25/19)
     
  3874. EACS: A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V/I (GS-US-292-1824): Week 24 Results (11/25/19)
     
  3875. EACS: Changes in LDL After Switch from TDF to TAF in the U.S. (11/25/19)
     
  3876. EACS: Biologic Sex Is Not the Only Difference Between Men and Women: Data From the Doravirine Phase 2/3 Clinical Trials (11/25/19)
     
  3877. EACS: Islatravir Efficacy and Safety for Selected Demographic and Baseline Subgroups From a Phase 2 Trial In Treatment-naïve Adults With HIV-1 Infection (11/25/19)
     
  3878. EACS: Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors (11/22/19)
     
  3879. EACS: Retrospective analysis of co-medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012-2018 using the Norwegian population-based prescription database (11/22/19)
     
  3880. EACS: Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies (11/22/19)
     
  3881. EACS: Unsupressed HIV in USA: 40% >55 Years Old Unsuppressed - CDC Reports (11/22/19)
     
  3882. EACS: Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV Greater BMD Decline With TDF Than ABC, But Similar Drop in Trabecular Bone Score - Mark Mascolini (11/21/19)
     
  3883. EACS: The ADVANCE trial: the impact of DXA-assessed bone mineral density of TDF/FTC/EFV and TDF/FTC+DTG versus TAF/FTC+DTG South Africa - Mark Mascolini (11/21/19)
     
  3884. EACS: More Antimicrobial Prescriptions May Be Clue to Undiagnosed HIV - Mark Mascolini- (11/21/19)
     
  3885. EACS: Only 1% HIV Diagnosis Rate More Than 6 Months After PEP in 975 People - Mark Mascolini (11/21/19)
     
  3886. EACS: Incidence of CKD With TDF and Non-TDF Containing Antiretroviral Regimens by Baseline D:A:D CKD Risk In People Living With HIV - (11/20/19)
     
  3887. EACS: Outcomes of antiretrovirals used as the third drug in subgroups of treatment naïve individuals living with HIV - (11/18/19)
     
  3888. EACS: Baseline and Emergent Genotypic and Phenotypic Results in HIV-1-Infected, Heavily Treatment-Experienced (HTE) Participants Meeting Protocol-Defined Virologic Failure (PDVF) Criteria Through Week 96 in the Fostemsavir (FTR) Phase 3 BRIGHTE Study - (11/18/19)
     
  3889. EACS: Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from the Randomized Cohort of the Phase 3 BRIGHTE Study - (11/18/19)
     
  3890. EACS: Absence of Naturally Existing Resistance Against The HIV-1 Capsid Inhibitor GS-6207 in HIV-1 Primary Isolates - (11/18/19)
     
  3891. EACS: Impact of Susceptibility Scoring on Virologic Response in Heavily Treatment-Experienced Participants with HIV-1 Receiving a Fostemsavir-Based Antiretroviral Regimen: Week 96 Results from the Randomized Cohort of the Phase 3 BRIGHTE Study - (11/18/19)
     
  3892. EACS: Absence of Naturally Existing Resistance Against The HIV-1 Capsid Inhibitor GS-6207 in HIV-1 Primary Isolates - (11/18/19)
     
  3893. EACS: HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance - (11/18/19)
     
  3894. EACS: Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results - (11/14/19)
     
  3895. EACS: Longer ART Linked to Clearance of High-Risk HPV in MSM With HIV - Mark Mascolini - (11/14/19)
     
  3896. EACS: Rapid Initiation of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Patients With Human Immunodeficiency Virus (HIV)-1 Infection: Age, Race/Ethnicity, and Gender Subgroup Analyses From the DIAMOND Study - (11/14/19)
     
  3897. EACS: Prevalence of Archived HIV-1 DNA Resistance-associated Mutations and their Lack of Effect on Virologic Outcome at Week 96 in Antiretroviral Treatment-experienced, Virologically Suppressed Patients Receiving the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the EMERALD Phase III Trial - (11/14/19)
     
  3898. EACS: Short-term Neuropsychiatric Tolerability of Bictegravir Combined with FTC/TAF in Clinical Practice - (11/14/19)
     
  3899. EACS: EACS New Aging/Screening Guidelines / HIV+ Case 69 Year Old Aging in Spain - Brighton UK Geriatric HV Clinic - (11/14/19)
     
  3900. EACS: Maintenance DTG/3TC Controls HIV in People With Historical 3TC Resistance "Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)" - Mark Mascolini - (11/14/19)
     
  3901. EACS: More Than Half of Adult Group With Perinatal HIV Have Neurocognitive Impairment - Mark Mascolini - (11/13/19)
     
  3902. EACS: Fibrosis, Steatosis, and NAFLD Boost Odds of Frailty in HIV Group - Mark Mascolini (11/13/19)
     
  3903. EACS: Short-term Neuropsychiatric Tolerability of Bictegravir Combined with FTC/TAF in Clinical Practice - (11/13/19)
     
  3904. EACS: Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in routine clinical practice - (11/13/19)
     
  3905. EACS: Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: Data from the Antiretroviral Pregnancy Registry (APR) - (11/13/19)
     
  3906. EACS: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN THROUGH 48 WEEKS: SUBGROUP ANALYSES FROM THE TANGO STUDY - (11/13/19)
     
  3907. EACS: Precancer Anal Lesion Arises in 10% of Australian MSM--But Clearance Common - Mark Mascolini - (11/13/19)
     
  3908. EACS: Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results - (11/13/19)
     
  3909. EACS: Safety and Efficacy of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People With HIV Aged 50 Years and Older - (11/12/19)
     
  3910. EACS: DISCOVER in Europe: a Subanalysis of the Phase 3, Randomized, Controlled Trial of Daily Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-exposure Prophylaxis - (11/12/19)
     
  3911. EACS: Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naïve Adults - (11/12/19)
     
  3912. EACS: Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 48 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (11/12/19)
     
  3913. EACS: Sustained Viral Suppression among Participants with Pre-existing M184V/I Who Switched to Bictegravir/Emtricitabine/TenofovirAlafenamide - (11/12/19)
     
  3914. EACS: Risk Score Predicts Diabetes Better Than HOMA-IR and Other Equations "Comparing a risk score against physiological markers for predicting diabetes incidence in HIV+ individuals" - (11/12/19)
     
  3915. EACS: New HIV Comorbidity Index Linked to Mortality, Can Outperform Other Tools - (11/12/19)
     
  3916. EACS: One Third of MSM PrEP Users in French Analysis Quit in 30 Months - Mark Mascolini - (11/12/19)
     
  3917. EACS: Switch From TDF to TAF in HIV/HBV+ Maintains Viral Control, Helps Kidneys - Mark Mascolini (11/12/19)
     
  3918. EACS: INI Resistance Remains Rare in INI-Naive--Initial CD4, Viral Load Predict Failure - Mark Mascolini - (11/12/19)
     
  3919. EACS: Integrase Inhibitors Tied to Weight Gain, Hepatic Steatosis in Longitudinal Cohort - Mark Mascolini - (11/12/19)
     
  3920. EACS: Is modern antiretroviral therapy causing weight gain? - (11/12/19)
     
  3921. EACS: Prevalence of and risk factors for low Bone Mineral Density assessed by Quantitative Computed Tomography in people living with HIV and uninfected controls Very Low BMD More Frequent With HIV--But Not After Statistical Adjustment - Mark Mascolini - (11/12/19)
     
  3922. EACS: Single Doses of Long-Acting Capsid Inhibitor GS-6207 Administered by Subcutaneous Injection Are Safe and Efficacious in People Living With HIV - (11/12/19)
     
  3923. EACS: GS-6207 Long Acting Capsid Inhibitor Safety & PK Subcutaneous - (11/12/19)
     
  3924. EACS: Safety and Efficacy of Triple Therapy with Dolutegravir plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Patients - 48 weeks results from a Phase II Study in Portugal - (11/12/19)
     
  3925. EACS: Non inferiority of dolutegravir+emtricitabine dual therapy to standard combination antiretroviral therapy in maintaining HIV suppression throughout 48 weeks: The SIMPL'HIV study - (11/12/19)
     
  3926. EACS: The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC+DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV Weight Keeps Rising Through 96 Weeks With TAF/FTC+DTG in Black Africans - (11/12/19)
     
  3927. EACS: ASSESSMENTS OF VERY-LOW-LEVEL HIV REPLICATION FOR DOLUTEGRAVIR + LAMIVUDINE (DTG + 3TC) VS DOLUTEGRAVIR + TENOFOVIR DISOPROXIL/EMTRICITABINE (DTG + TDF/FTC) IN THE GEMINI-1&-2 STUDIES THROUGH WEEK 96 - (11/08/19)
     
  3928. EACS: Uptake and discontinuation of Integrase Inhibitors (INSTIs) in a large cohort setting (DTG, EVG, RAL) DTG Easily Most Popular INI Across Europe, With Lowest Quitting Rate - Mark Mascolini (11/08/19)
     
  3929. EACS: Changes in bone mineral density in men who have sex with men on tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis: longitudinal cohort data - (11/08/19)
     
  3930. EACS: BMD Drops More Than 3% in up to One Third of MSM Using TDF PrEP for 2 Years - Mark Mascolini - (11/08/19)
     
  3931. EACS: Maintenance DTG/3TC Controls HIV in People With Historical 3TC Resistance "Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)" - Mark Mascolini - (11/08/19)
     
  3932. EACS: Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV Cohort Study - (11/08/19)
     
  3933. EACS: Shorter time to treatment failure in PLHIV switched to dolutegravir plus either rilpivirine or lamivudine compared to integrase inhibitor-based triple therapy in a large Spanish cohort - VACH Doubled Failure Risk After Switch to DTG/RPV or DTG/3TC Versus Triple-INI Regimen - Mark Mascolini - (11/08/19)
     
  3934. EACS: Menopause Does Not Affect HIV or CD4 Response in Multicenter Spanish Group - Mark Mascolini - (11/08/19)
     
  3935. EACS: Pregnancies and Live Births Stable/Rising Since 2002 in European Women With HIV - Mark Mascolini - (11/08/19)
     
  3936. EACS: Outcomes for Women in Phase 3 Trials of Long-Acting Cabotegravir + Rilpivirine: Pooled ATLAS and FLAIR Week 48 Results - (11/08/19)
     
  3937. EACS: Are new antiretroviral treatments increasing the risks of obesity? - (11/08/19)
     
  3938. EACS: Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naïve Adults - (11/08/19)
     
  3939. EACS: Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials - Mark Mascolini - (11/07/19)
     
  3940. EACS: Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen Through 48 Weeks: Subgroup Analyses From the TANGO Study - (11/07/19)
     
  3941. EACS: Once-a-Month CAB/RPV Effective in Women--Fewer Adverse Events Than Men - Mark Mascolini - (11/07/19)
     
  3942. EACS: Incidence of CKD with TDF and non-TDF containing antiretroviral regimens by baseline D:A:D CKD risk in people living with HIV (PLWH) - Mark Mascolini - (11/07/19)
     
  3943. EACS: Modest 96-Week Weight Gain in Trials of Doravirine, Darunavir, Efavirenz "EFFECT OF DORAVIRINE ON BODY WEIGHT AND BODY MASS INDEX IN TREATMENT NAïVE ADULTS WITH HIV-1" - Mark Mascolini - (11/07/19)
     
  3944. EACS: Weight Keeps Rising Through 96 Weeks With TAF/FTC+DTG in Black Africans - ADVANCE Study - Mark Mascolini - (11/07/19)
     
  3945. EACS: Delayed Weight Gain in Immediate Versus Deferred ART Arm in START - "Antiretroviral therapy and body weight in the START (Strategic Timing of Antiretroviral Treatment) trial" - Mark Mascolini - (11/07/19)
     
  3946. EACS: Switch to INI Does Not Affect Average Weight Gain in Middle-Aged/Older Group - Mark Mascolini - (11/07/19)
     
  3947. EACS: Will HIV-infected patients Taking Oral ARV Switch to Long-Acting Injectable ART when It Becomes Available? - (11/06/19)
     
  3948. EACS: Outcomes of antiretrovirals used as the third drug in subgroups of treatment naïve individuals living with HIV - (11/06/19)
     
  3949. EACS: Gilead's Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials - (11/06/19)
     
  3950. EACS: Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP® - (11/06/19)
     
  3951. EACS: EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV - PRESS RELEASE - (11/06/19)
     
  3952. EACS: Screening Program Cuts Anal Cancer Precursor Rate in 405 MSM With HIV - Mark Mascolini (11/06/19)
     
  3953. EACS: Long-term Antilipid Therapy Tied to 70% Lower Death Risk in VA Cohort - Mark Mascolini (11/06/19)
     
  3954. EACS: French Studies Find Eagerness for Long-Term Injectables--With Key Cautions - Mark Mascolini (11/06/19)
     
  3955. EACS: No Change in Kidney Function, Cholesterol Ratio, or Weight When 60+ Group Switches to TAF - Mark Mascolini (11/06/19)
     
  3956. EACS: Response Differences Between First-Line Regimens in Large European Group - Mark Mascolini (11/06/19)
     
  3957. Letter from Gilead to Community: Facts About Gilead's PrEP Medications Donation to Help Support Ending the HIV Epidemic Efforts - (11/04/19)
     
  3958. Screening for Anal Cancer in the Population Living With Human Immunodeficiency Virus: A Step Closer? - EDITORIAL - (11/04/19)
     
  3959. Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women - (11/04/19)
     
  3960. Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations - (11/04/19)
     
  3961. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era - Results From the Veterans Aging Cohort Study - (11/04/19)
     
  3962. AGE: Aging Workshop Report : DNA Methylation : Heart Disease ; Kidney Disease - Christina K. Psomas MD - (11/01/19)
     
  3963. AGE: The Utility of Olfactory Function in Distinguishing Early Stage Alzheimer's Disease from HIV-associated Neurocognitive Disorder: A Pilot Study - (11/01/19)
     
  3964. AGE: Lipidome abnormalities and altered macrophage phenotype may contribute to cardiovascular disease risk in the aging HIV population - (11/01/19)
     
  3965. AGE: FRAILTY PHENOTYPE IN OLDER VIROLOGICALLY SUPPRESSED PLWH IS STRONGLY CORRELATED WITH SPECIFIC COMORBIDITIES AND TOBACCO USE - (11/01/19)
     
  3966. Bictegravir with Pre-Existing NRTI Resistance - (10/29/19)
     
  3967. Time to change cardiovascular prevention in people with HIV - A more pragmatic approach is the direct measurement of cIMT to construct cIMT-based monitoring and prevention guidelines for HIV-positive people - comment - (10/25/19)
     
  3968. Editorial - Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives? - (10/25/19)
     
  3969. Brain Dysfunction/HIV-Neurologic Decline Shifting - (10/25/19)
     
  3970. Tesamorelin, liver fat, and NAFLD in the setting of HIV - Comment / Tesamorelin Prevented Progression to Liver Fibrosis in NIH Study - (10/25/19)
     
  3971. AGE: Pharmacokinetics of Cabotegravir and Rilpivirine Long-Acting Injectables in HIV-Infected Individuals Through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies - (10/24/19)
     
  3972. AGE: Frailty, Physical Function Impairment, Comorbidity Burden, and Falls are Predictive of Mortality Among Middle-Aged Adults with HIV - (10/24/19)
     
  3973. AGE: Slide Presentations - 10th HIV & Aging 2019 - (10/24/19)
     
  3974. AGE: Senescence-Associated β-Galactosidase Activity and Other Markers of Senescence in Human Peripheral Blood Immune Cells During Healthy Aging and HIV-Infection - (10/24/19)
     
  3975. IDWeek 2019: Diabetes/Weight Gain; NASH, Ethnicity in HIV+ at IDWeek 2019 Oct 2-6 Wash DC (10/24/19)
     
  3976. IDWeek 2019: Experiences and Emotional Challenges of Antiretroviral Treatment - Findings from the Positive Perspectives Study (10/24/19)
     
  3977. IDWeek 2019: "I feel empowered": Women's perspectives on and experiences with long-acting injectable anti-retroviral therapy in the United States and Spain (10/24/19)
     
  3978. IDWeek 2019: Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment Among People Living With HIV (10/24/19)
     
  3979. IDWeek 2019: PERCEPTIONS OF AND PREFERENCES FOR ORAL OR LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT REGIMENS IN THE UNITED STATES AND CANADA (10/24/19)
     
  3980. AGE: LONG-TERM PRE-HAART SURVIVORS OF HIV: A SPECIFIC GROUP WITH SPECIFIC NEEDS - 'high rates of mental & physical impairments' - (10/23/19)
     
  3981. AGE: Food Insecurity and Frailty among Women Living with or At-risk for HIV in the U.S. - 40% WIHS Women Have Food Insecurity - where us Ryan White Care Act? - No Safety Net - (10/23/19)
     
  3982. AGE: What is the lived experience of loneliness in older men living with HIV? A qualitative analysis to guide service development - (10/23/19)
     
  3983. AGE: Magnetic Resonance Spectroscopy Evidence of Accelerated Aging in Virally-Suppressed HIV - (10/23/19)
     
  3984. AGE: Poorer Muscle Quality and Quantity with ART Initiation is Associated with Greater Inflammation and Immune Activation - (10/21/19)
     
  3985. AGE: Blunted Increase in Muscle Mass After Exercise Training in People Aging with HIV - (10/21/19)
     
  3986. AGE: Frailty But Not HIV Tied to Falls in Large Group of Older US Women - Mark Mascolini (10/21/19)
     
  3987. IDWeek 2019: Grindr™ Use Correlates with HIV Risk & PrEP Use in Men who Have Sex with Men, San Diego (10/21/19)
     
  3988. IDWeek 2019: Clinical outcomes of patients treated with Dolutegravir functional monotherapy or Dolutegravir plus an active non-cytosine nucleoside analog: a retrospective observational cohort study of treatment-experienced patients (10/21/19)
     
  3989. IDWeek 2019: Pooled Resistance Analyses of Darunavir (DRV) Once-daily (QD) Regimens and Formulations Across 10 Clinical Studies of Treatment-naïve (TN) and Treatment-experienced (TE) Patients With Human Immunodeficiency Virus (HIV)-1 Infection (10/21/19)
     
  3990. IDWeek 2019: Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance associated mutations through 48 weeks of treatment (10/21/19)
     
  3991. IDWeek 2019: Epigenetic Age Acceleration and Non-AIDS Defining Cancers Among HIV Infected Adults (10/21/19)
     
  3992. IDWeek 2019: The Utility of Olfactory Function in Distinguishing Early Stage Alzheimer's Disease from HIV-associated Neurocognitive Disorder: A Pilot Study........"supports that these PLWH may be on an AD-like cognitive trajectory" (10/21/19)
     
  3993. ViiV HEALTHCARE SUBMITS NEW DRUG APPLICATION TO US FDA FOR THE FIRST MONTHLY, INJECTABLE, TWO-DRUG REGIMEN OF CABOTEGRAVIR AND RILPIVIRINE FOR TREATMENT OF HIV - (10/18/19)
     
  3994. Diabetes/Weight Gain; NASH, Ethnicity in HIV+ at IDWeek 2019 Oct 2-6 Wash DC - (10/18/19)
     
  3995. Injectable Cabotegravir/Rilpivirine, Oral - FDA, EMA - (10/18/19)
     
  3996. Letter from Gilead - PrEP Study in Cisgender Women and Adolescent Females - (10/18/19)
     
  3997. FDA NEWS RELEASE - FDA approves second drug (TAF) to prevent HIV infection as part of ongoing efforts to end the HIV epidemic - (10/18/19)
     
  3998. Ageing with and without HIV: will advanced age bring equity or greater disparity? Perspective by Amy Justice - (10/18/19)
     
  3999. AGE: Blunted Increase in Muscle Mass After Exercise Training in People Aging with HIV - (10/17/19)
     
  4000. AGE: Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV. - (10/17/19)
     
  4001. AGE: Comorbidities Are Key Frailty Risk Factors in Older French Group With HIV - Mark Mascolini (10/17/19)
     
  4002. AGE: Real-World Use of Ibalizumab in Physician Office infusion Centers (POICs) - (10/17/19)
     
  4003. AGE: The association between mitochondrial DNA copy number and longitudinal lung function decline among people with or at risk of HIV - Mark Mascolini (10/17/19)
     
  4004. AGE: Supplemental Testosterone Contributes to Strength Differences in Men With vs Without HIV - Mark Mascolini (10/17/19)
     
  4005. AGE: Characteristics Associated with Exercise Adherence in the Setting of a Supervised Intervention - (10/17/19)
     
  4006. AGE: HIV+ People Who Need Exercise More Are Less Likely to Adhere to Program - Mark Mascolini (10/17/19)
     
  4007. AGE: Physical Function, Falls, Comorbidity > Predict Death in Middle-Aged With HIV - Mark Mascolini (10/17/19)
     
  4008. AGE: Elevated Cardiac Risk Score by ASCVD Calculation is Associated with Albuminuria in Older People Living with HIV - (10/17/19)
     
  4009. AGE: Elevated Cardiac Risk Score by ASCVD Calculation is Associated with Albuminuria in Older People Living with HIV - (10/17/19)
     
  4010. AGE: Elevated Albuminuria Tied to ASCVD Risk in Older People With HIV - (10/17/19)
     
  4011. IDWeek 2019: FRAILTY PHENOTYPE IN OLDER VIROLOGICALLY SUPPRESSED PLWH IS STRONGLY CORRELATED WITH SPECIFIC COMORBIDITIES AND TOBACCO USE (10/17/19)
     
  4012. IDWeek 2019: Real-World Use of Ibalizumab in Physician Office infusion Centers (POICs) (10/17/19)
     
  4013. IDWeek 2019: Do People With HIV Have to Exercise Harder to Get Same Muscle Benefit? - Mark Mascolini (10/17/19)
     
  4014. IDWeek 2019: Implementation of an HIV and Aging Clinical Program / A Geriatrician's Approach To Aging With HIV (10/16/19)
     
  4015. IDWeek 2019: Iceland Making Progress Toward Eliminating HCV--But Challenges Remain - Mark Mascolini (10/16/19)
     
  4016. IDWeek 2019: Attaining SVR Drives Lower Liver Mortality With Treatment of HCV - Mark Mascolini (10/16/19)
     
  4017. IDWeek 2019: BMI Jumps Slightly With Major Maintenance Regimens, Not Just Integrase Drugs - Mark Mascolini (10/16/19)
     
  4018. IDWeek 2019: Hepatic Steatosis in People Living with HIV - Effect of Sex and Race/Ethnicity - (10/16/19)
     
  4019. IDWeek 2019: T Cell Subsets Associated with Diabetes in Veterans With and Without HIV - (10/16/19)
     
  4020. IDWeek 2019: Online US/Canada Survey Finds Preference for Long-Acting Injectable ART - Mark Mascolini (10/16/19)
     
  4021. IDWeek 2019: Gilead Presents New Data From the Company's HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019 - (10/16/19)
     
  4022. IDWeek 2019: The Effect of Initiating INSTI-based vs. NNRTI-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care - (10/16/19)
     
  4023. AGE: Physical Function, Falls, Comorbidity Predict Death in Middle-Aged With HIV - Mark Mascolini - (10/15/19)
     
  4024. IDWeek 2019: Household Income and its Relationship with Patient-reported Outcomes among Older People Living with HIV - (10/15/19)
     
  4025. IDWeek 2019: Characteristics Associated with Pre-Frailty in Older People Living with HIV (47% Pre-Frailty) - (10/15/19)
     
  4026. IDWeek 2019: Poor Mental Health & Quality of Life in Virally Suppressed HIV+ - (10/15/19)
     
  4027. IDWeek 2019: Durable Efficacy of Two-Drug Regimen of DTG + 3TC in Antiretroviral Treatment-Naive Adults With HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies - (10/15/19)
     
  4028. IDWeek 2019: Long-Term Efficacy, Safety and Durability of CAB and RPV as Two-Drug Oral Maintenance Therapy - LATTE Week 312 Results - (10/15/19)
     
  4029. IDWeek 2019: Antiretroviral Therapy Anchor-based Trends in Body Mass Index following Treatment Initiation among Military Personnel with HIV - (10/11/19)
     
  4030. IDWeek 2019: Weight Change Associated with Switching to Integrase Strand Transfer Inhibitor-based Antiretroviral Regimens in HIV-positive Subjects - (10/11/19)
     
  4031. IDWeek 2019: Real world utilization of ibalizumab (IBA) without an optimized background regimen (OBT) - (10/11/19)
     
  4032. IDWeek 2019: IBALIZUMAB EFFICACY AND SAFETY THROUGH 48 WEEKS OF TREATMENT: RESULTS OF AN EXPANDED ACCESS PROTOCOL (TMB-311) - (10/11/19)
     
  4033. IDWeek 2019: Drug Injectors Accept and Use Naloxone Offered at HCV Visits - Mark Mascolini (10/11/19)
     
  4034. IDWeek 2019: BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Infection Switching from TDF to TAF Containing ART - (10/11/19)
     
  4035. IDWeek 2019: PrEP Linked to Lower HIV Incidence in US, Independent of TasP - Mark Mascolini (10/11/19)
     
  4036. IDWeek 2019: Long-Term Efficacy, Safety and Durability of CAB and RPV as Two-Drug Oral Maintenance Therapy - LATTE Week 312 Results - (10/8/19)
     
  4037. IDWeek 2019: Effects of Integrase Strand-Transfer Inhibitor Use on Lipids, Glycemic Control, and Insulin Resistance in the Women's Interagency HIV Study (WIHS) - (10/8/19)
     
  4038. IDWeek 2019: A Geriatrician's Approach to People Aging with HIV - Co-Morbidities and Aging - (10/8/19)
     
  4039. IDWeek 2019: The prevalence and burden of non-aids comorbidities in women with or at-risk for hiv infection in the united states - (10/8/19)
     
  4040. IDWeek 2019: Risk of type-2 diabetes mellitus after initiating integrase and protease inhibitors in individuals living with HIV in the United States - (10/8/19)
     
  4041. IDWeek 2019: Changes in BMI associated with antiretroviral regimens in treatment-experienced, virologically suppressed individuals living with HIV - (10/8/19)
     
  4042. IDWeek 2019: Renal Outcomes for Participants Taking F/TAF versus F/TDF for HIV PrEP in the DISCOVER Trial - (10/8/19)
     
  4043. IDWeek 2019: Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically-Suppressed Adults Living With HIV and End Stage Renal Disease on Chronic Hemodialysis - (10/8/19)
     
  4044. IDWeek 2019: Oral Cabotegravir and Rilpivirine Durable for 5.5 Years in LATTE Trial - Mark Mascolini (10/8/19)
     
  4045. IDWeek 2019: PrEP Significantly Reduces the Rate of New HIV Diagnoses in US Metropolitan Statistical Areas independent of Treatment as Prevention (2012-2017) - (10/8/19)
     
  4046. IDWeek 2019: A Comparison Study of Prevalence and Risk Factors for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by Transient Elastography (TE) in HIV Infected Patients - (10/8/19)
     
  4047. IDWeek 2019: Initial DTG+3TC Noninferior to DTG+TDF/FTC - Mark Mascolini (10/8/19)
     
  4048. IDWeek 2019: Pregnancy outcomes following raltegravir exposure - Mark Mascolini (10/8/19)
     
  4049. IDWeek 2019: Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies - (10/8/19)
     
  4050. IDWeek 2019: Experiences and Emotional Challenges of Antiretroviral Treatment - Findings from the Positive Perspectives Study - (10/8/19)
     
  4051. IDWeek 2019: Fostemsavir Interaction Study Flags Strong CYP3A Inducers, Statins, Oral Contraceptives - Mark Mascolini (10/8/19)
     
  4052. IDWeek 2019: Older and Transgender People Less Likely to Get Integrase Drugs in Big DC Cohort - Mark Mascolini (10/8/19)
     
  4053. IDWeek 2019: HIV Care Continuum Outcomes among newly diagnosed PLWH in Washington, DC - (10/7/19)
     
  4054. IDWeek 2019: ART Adherence Falls Over 4 Years in 15,000 Insured People in US - Mark Mascolini (10/7/19)
     
  4055. IDWeek 2019: Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial - (10/7/19)
     
  4056. IDWeek 2019: Durable Efficacy of Two-Drug Regimen of DTG + 3TC in Antiretroviral Treatment-Naive Adults With HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies - (10/7/19)
     
  4057. IDWeek 2019: Weight Rises--But Lipids and HbA1c Don't--After Switch to Integrase Drugs - Mark Mascolini (10/7/19)
     
  4058. IDWeek 2019: High PrEP Uptake, Good Follow-up, With Mobile Screening in Florida - Mark Mascolini (10/7/19)
     
  4059. IDWeek 2019: Mental Health, Quality of Life, and Accessibility to Care Among Virally-Suppressed People Living With HIV in the United States - (10/7/19)
     
  4060. IDWeek 2019: High Rates of Virologic Suppression Achieved in HIV-1-infected Adults Rapidly Starting Antiretroviral Therapy (ART) With the Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial - (10/7/19)
     
  4061. IDWeek 2019: The Effect of Initiating INSTI-based vs. NNRTI-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care - (10/7/19)
     
  4062. IDWeek 2019: Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results From a Pooled Analysis of 7 Clinical Trials - (10/7/19)
     
  4063. IDWeek 2019: Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial - (10/7/19)
     
  4064. IDWeek 2019: Switching From TDF to TAF Tied to Higher BMI and Cardio Risk - Mark Mascolini (10/7/19)
     
  4065. IDWeek 2019: Online US/Canada Survey Finds Preference for Long-Acting Injectable ART - Mark Mascolini (10/4/19)
     
  4066. IDWeek 2019: Community Clinics Control HIV as Well as Hospital Clinic in Chicago MSM - Mark Mascolini (10/4/19)
     
  4067. IDWeek 2019: Possible Higher Diabetes Risk With INSTIs or PIs Than NNRTIs - Mark Mascolini (10/4/19)
     
  4068. IDWeek 2019: AIDS Mortality Does Not Differ by Race in US Group--But "Room for Improvement" - Mark Mascolini (10/4/19)
     
  4069. IDWeek 2019: MSM Grindr Users Take More Sex Risks But Seem More Open to PrEP - Mark Mascolini (10/4/19)
     
  4070. IDWeek 2019: Over Half of Mostly Black US HIV Group Has NAFLD--and Many Have NASH - Mark Mascolini (10/4/19)
     
  4071. IDWeek 2019: High HIV Control Rate With Rapid D/C/F/TAF in Newly Diagnosed - Mark Mascolini (10/4/19)
     
  4072. IDWeek 2019: HIV Suppression and Safety With Ibalizumab at 48 Weeks in Expanded Access - Mark Mascolini (10/4/19)
     
  4073. IDWeek 2019: Women With HIV and Prolonged Amenorrhea Run Higher Risk of Hip Bone Loss - Mark Mascolini (10/4/19)
     
  4074. IDWeek 2019: Lower Statin Prescription Rate for Blacks, Hispanics With HIV in US Military - Mark Mascolini (10/4/19)
     
  4075. IDWeek 2019: Syphilis, Gonorrhea Tied to HCV in MSM and Trans Women With HIV - Mark Mascolini (10/4/19)
     
  4076. IDWeek 2019: Higher Steatosis Risk in HIV+ Hispanics, But No Link to Integrase Inhibitors - Mark Mascolini (10/4/19)
     
  4077. IDWeek 2019: Lower Screening Rates for Breast and Cervical Cancer in Women With HIV - Mark Mascolini (10/4/19)
     
  4078. IDWeek 2019: High HIV Control Rate With Rapid D/C/F/TAF in Newly Diagnosed - Mark Mascolini (10/4/19)
     
  4079. IDWeek 2019: IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV - (10/03/19)
     
  4080. IDWeek 2019: IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV - (10/03/19)
     
  4081. Ageing with and without HIV: will advanced age bring equity or greater disparity? Perspective by Amy Justice - (10/03/19)
     
  4082. Reversal of epigenetic aging and immunosenescent trends in humans - (09/25/19)
     
  4083. HIV and Aging - Primary and secondary prevention of coronary artery disease among People living with HIV - HIV+ higher death risk after stroke or MI - (09/25/19)
     
  4084. Coronary atherosclerosis characteristics in HIV-infected patients on long-term antiretroviral therapy insights from coronary computed tomography-angiography - (09/24/19)
     
  4085. Excess heart age in adult outpatients in routine HIV care (HOPS) - excess heart age by 10-13 Years in HIV+ - (09/24/19)
     
  4086. Merck's PIFELTRO (doravirine) and DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed - (09/23/19)
     
  4087. Aging with HIV in the US / Proposed Research Implementation Study: clinical & community care & services needs, unmet needs - Jules Levin (09/23/19)
     
  4088. Two Thirds Higher Risk of Death After MI or Stroke With HIV in Sweden - Mark Mascolini (09/19/19)
     
  4089. New Analysis Challenges FRAX Use to Predict Osteoporosis in 40-to-49 HIV Group - Mark Mascolini (09/19/19)
     
  4090. Rates and Drivers of Quality of Life With HIV Differ in Netherlands and UK - Mark Mascolini (09/19/19)
     
  4091. Quality of Life in HIV+ in US & Globally: most unhappy - (09/13/19)
     
  4092. NEF, HIV Protein Causes CVD, Metabolic Abnormalities, Brain Disease - found in Reservoir - (09/13/19)
     
  4093. Inflammation in HIV+ Causes Mood Emotions Changes & Alters Social Interaction - (09/09/19)
     
  4094. Doxycycline prophylaxis for bacterial sexually transmitted infections - Review - (09/09/19)
     
  4095. Stigma and mental health challenges remain barriers to good quality of life for people living with HIV in urban settings - (09/09/19)
     
  4096. Mental health and HIV/AIDS the need for an integrated response. Depression Doubles Mortality in WIHS Women - (09/09/19)
     
  4097. Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent - Results of the Phase 3 ORION-11 trial - (09/09/19)
     
  4098. siRNA drug safely halved LDL cholesterol in phase 3 ORION-11 - (09/09/19)
     
  4099. (Phase 2 ) Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol (single dosing) - (09/09/19)
     
  4100. Treating Disease at the RNA Level with Oligonucleotides (siRNA) - Review - (09/09/19)
     
  4101. In People Living with HIV (PLWH), Menopause (natural or surgical) Contributes to the Greater Symptom Burden in Women: results from an online US survey - (09/06/19)
     
  4102. 9th Annual International Workshop on HIV & Aging 2018 Summary / Review
    Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging     - (09/06/19)
     
  4103. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV - (09/05/19)
     
  4104. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV - (09/05/19)
     
  4105. ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months - (09/05/19)
     
  4106. Cannabis Anti-Inflammatory/Reservoir Reduction(Cure)? - (09/05/19)
     
  4107. New ways of developing treatment of chronic inflammation - (09/04/19)
     
  4108. People Living With HIV in New York City Still Dying From Infections, Not Just Old Age - (09/04/19)
     
  4109. What is Frailty ? Burden of frailty in the elderly population: perspectives for a public health challenge - (09/04/19)
     
  4110. HIV+ 70-74 Have Same # of Comorbidities as HIV-Neg >85, Similarly for polypharmacy. Medicare study Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis - (09/04/19)
     
  4111. HIV in Atlanta/Georgia-Aging - (09/04/19)
     
  4112. 75-85% in SF-NY-Florida-Boston with HIV Are Over 40 Years Old....25% over 60 in SF-Florida-NY - (09/04/19)
     
  4113. Cardiovascular risk of smoking may last up to 25 years, new study - (09/04/19)
     
  4114. Neurpoathy Predictors in HIV in CHARTER Group - (09/04/19)
     
  4115. IAS: Hormonal control of HIV-1 latency by estrogen imparts gender-specific restrictions on the latent reservoir - (09/03/19)
     
  4116. IAS: Symptom Burden and Inflammatory Cytokines in PLWH in the US: an analysis by sex, menopause stage and menstrual cycle phase - (09/03/19)
     
  4117. IAS: Smoking and High HIV Viremia Damage Mitochondrial DNA and May Accelerate mtDNA Aging - (09/03/19)
     
  4118. IAS: 10th International AIDS Society Conference on HIV Science - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA (09/03/19)
     
  4119. IAS: TDF/FTC Pre-Exposure Prophylaxis (PrEP) from 2012 to 2018 in the OPERA Cohort - (08/16/19)
     
  4120. IAS: Cost-effectiveness of Dolutegravir in HIV-1 Treatment-Naive Patients in Mexico - (08/16/19)
     
  4121. IAS: Changing Rates of Heavily Treatment Experienced Persons with HIV in the United States, 2000-2017 - (08/16/19)
     
  4122. IAS: Is DTG+3TC and DTG+RPV Effective and Safe in Clinical Practice? Evidence From Real World Data - (08/16/19)
     
  4123. IAS: High HIV incidence among young women in South Africa: data from the ECHO trial - (08/14/19)
     
  4124. A Novel Therapeutic (NTRX-07) Targeting Neuroinflammation in Alzheimer's disease is Undergoing Phase I trials - (08/14/19)
     
  4125. Dementia/Sleep Aids-Drugs/Women HIV+ More Vulnerable - "Sleep aids and dementia: Studies find both risks and benefits" - (08/14/19)
     
  4126. Increased Risk of Subjective Cognitive Decline in the LGBT Community - (08/14/19)
     
  4127. 18-Month Results (Open Label Extension) of a Phase 2/3 Trial of Inhaled Insulin in People With MCI or Mild Alzheimer's - (08/14/19)
     
  4128. IAS: Shorter CD38 T Cell Subset Telomeres and Lower Proliferative:Senescent CD38 Ratio in People with Chronic/Latent Viral Coinfections - (08/13/19)
     
  4129. IAS: PrEP use in young African women in HPTN 082: Effect of drug level feedback - (08/13/19)
     
  4130. IAS: HIV Prevention at IAS 2019 10th IAS Conference on HIV Science, Mexico City, Mexico 21-24 July 2019 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (08/12/19)
     
  4131. HIV Prevention Trials Network (HPTN) Announces Initiation of HPTN 084: First Large-Scale Study in Women of a Long-Acting Injectable to Prevent HIV - (08/09/19)
     
  4132. HIV Prevention Trials Network Launches HPTN 083 - (08/09/19)
     
  4133. Gilead $17 Million RFP & ViiV Aging Projects - (08/09/19)
     
  4134. FDA Hearing Ongoing Wed Aug 7 2019 on Descovy for PrEP Vote - (08/08/19)
     
  4135. IAS: Substance Use--Especially Meth--Tied to Depression in Young HIV+/HIV- MSM - Mark Mascolini (08/06/19)
     
  4136. What Aging With HIV Means in the Year 2019 - (08/06/19)
     
  4137. IAS: "Dual epidemics: the impact of HIV and obesity on pregnancy outcomes among women in South Africa"
    'The impact of HIV and obesity on pregnancy outcomes among women in South Africa'
    Obesity in 36% of Pregnant HIV+ South African Women--But No Impact on Outcomes     - (08/05/19)
     
  4138. IAS: Adverse pregnancy outcomes among HIV-positive women in the era of universal antiretroviral therapy (ART) remain elevated compared with HIV-negative women in Lesotho - (08/05/19)
     
  4139. IAS: Higher Immune Activation With Methadone Than Naltrexone in Opioid Users With HIV - Mark Mascolini (08/05/19)
     
  4140. IAS: Inflammatory Marker and Immune Upsets After Single Forced Vaginal Penetration - Mark Mascolini (08/05/19)
     
  4141. IAS: DMPA May Have STI Advantage Over Copper IUD and Levonorgestrel Implant - Mark Mascolini (08/05/19)
     
  4142. IAS: Comorbidities Canadians: >70 HIGH Rates - (08/05/19)
     
  4143. IAS: Perspectives from the Front Lines: Encouraging Community Engagement in the Performance of Research at the Intersection of HIV and Aging - (08/05/19)
     
  4144. High CNS Penetration Increased HIV Dementia - (08/02/19)
     
  4145. CROI: CEREBRAL FUNCTION PARAMETERS IN PEOPLE LIVING WITH HIV SWITCHING INTEGRASE INHIBITOR - (08/02/19)
     
  4146. IAS: A SWITCH TO DOLUTEGRAVIR IN COMBINATION WITH BOOSTED DARUNAVIR IS SAFE AND EFFECTIVE IN SUPPRESSED PATIENTS WITH HIV - A SUBANALYSIS OF THE DUALIS STUDY - (08/02/19)
     
  4147. IAS: Five Times Higher Risk of ART Nonadherence on Days of Heavy Drinking - Mark Mascolini (08/02/19)
     
  4148. IAS: Dolutegravir use at conception: Additional surveillance data from Botswana (smaller signal) - (08/02/19)
     
  4149. IAS: No occurrences of neural tube defects among 382 women on Dolutegravir at pregnancy conception in Brazil - (08/02/19)
     
  4150. IAS: Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana - (08/02/19)
     
  4151. Treatment Adherence and Virologic Response Over 48 Weeks Among Patients Rapidly Initiating Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the DIAMOND Study - (08/02/19)
     
  4152. IAS: A SWITCH TO DOLUTEGRAVIR IN COMBINATION WITH BOOSTED DARUNAVIR IS SAFE AND EFFECTIVE IN SUPPRESSED PATIENTS WITH HIV - A SUBANALYSIS OF THE DUALIS STUDY - (08/01/19)
     
  4153. IAS: HCV Reinfection Rate in People With HCV/HIV 13% Across Europe - Mark Mascolini - (08/01/19)
     
  4154. IAS: Inconsistent Testing in HIV+ for Top Liver Cancer Risk Factors: HBV, HCV, Alcohol - Mark Mascolini (08/01/19)
     
  4155. IAS: Biomarkers Good at Predicting NAFLD or Excluding Advanced Fibrosis With HIV (FibroScan, CAP Score) - Mark Mascolini (08/01/19)
     
  4156. IAS: Virologic Failure In ART-Naive HIV Patients With High Pre-Therapy Viral Load Burden Initiating On Common Core Agents - (08/01/19)
     
  4157. IAS: Biomarkers Good at Predicting NAFLD or Excluding Advanced Fibrosis With HIV (FibroScan, CAP Score) - Mark Mascolini (07/31/19)
     
  4158. IAS: Collaborative Care Improves HIV Provider Confidence in Managing Chronic Opioid Therapy - Mark Mascolini (07/31/19)
     
  4159. IAS: Preventive HIV vaccine Enters Phase 3 Global Study - (07/30/19)
     
  4160. IAS: More Acute HIV Diagnoses, Shorter Time to Undetectable HIV, in Amsterdam MSM Program - Mark Mascolini (07/30/19)
     
  4161. IAS: Substance Use--Especially Meth--Tied to Depression in Young HIV+/HIV- MSM - Mark Mascolini (07/30/19)
     
  4162. IAS: HIV Control Rate Lower in Women Than Men in Inner-City Vancouver - Mark Mascolini (07/30/19)
     
  4163. IAS: Meta-Analysis Confirms Aerobic Exercise Benefit on Depression With HIV - Mark Mascolini (07/30/19)
     
  4164. IAS: Week 96 Resistance and Adherence Analyses of the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the AMBER and EMERALD Phase III Trials - (07/30/19)
     
  4165. IAS: Change in Kidney Function After TDF-to-TAF Switch: Who Benefits Most? - Mark Mascolini (07/30/19)
     
  4166. IAS: In Vitro Resistance Profile of GS-6207, a First-in-Class Picomolar HIV Capsid Inhibitor in Clinical Development as a Novel Long-Acting Antiretroviral Agent - (07/30/19)
     
  4167. IAS: Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen - (07/30/19)
     
  4168. IAS: Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen's Investigational Prophylactic HIV Vaccine - (07/30/19)
     
  4169. IAS: Long-Acting MK-8591 at IAS 2019, , New ART for Treatment, PrEP - (07/30/19)
     
  4170. IAS: Prevalence and Outcomes for Heavily Treatment-Experienced (HTE) Individuals Living with HIV in a European Cohort EuroSIDA - (07/28/19)
     
  4171. IAS: WHO recommends dolutegravir as preferred HIV treatment option in all populations - (07/28/19)
     
  4172. IAS: HPTN 078: Primary results of a randomized study to engage men who have sex with men (MSM) living with HIV who are virally unsuppressed in the USA - (07/28/19)
     
  4173. IAS: ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV - (07/28/19)
     
  4174. IAS: Efficacy of on-demand PrEP or PEP with single oral doses of combination tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat in macaques - (07/28/19)
     
  4175. IAS: Polypharmacy in Nearly All of 65+ HIV Group Tied to Inappropriate Prescribing - (07/28/19)
     
  4176. IAS: Loneliness Among Older People (44%) Living with HIV: Why the ''Older Old'' are Less Lonely Than the ''Younger Old'' (53%) - (07/28/19)
     
  4177. IAS: "There's no retirement plans for us": Re-analysis from a qualitative study of HIV-positive MSM who use substances - (07/27/19)
     
  4178. IAS: The ADVANCE trial: Phase 3, randomized comparison of TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection - (07/27/19)
     
  4179. IAS: Dolutegravir (DTG) Plus Lamivudine (3TC) Versus DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in the GEMINI Studies -Viral Load Rebound Including 'Blips' Through 48 Weeks - (07/27/19)
     
  4180. IAS: ARTS 4 Days A Week Instead of 7, not good, Jules. - "ANRS 170 QUATUOR 4/7 days maintenance strategy in antiretroviral treated adults with HIV-1 infection: an open randomised parallel non-inferiority phase III trial" - (07/27/19)
     
  4181. IAS: Twice-Daily 400-mg Raltegravir Not Noninferior to Efavirenz for HIV With TB - "Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1-infected adults with tuberculosis: W48 results of the ANRS 12300 REFLATE TB2 trial" - (07/27/19)
     
  4182. IAS: Twice-Daily 400-mg Raltegravir Not Noninferior to Efavirenz for HIV With TB - "Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1-infected adults with tuberculosis: W48 results of the ANRS 12300 REFLATE TB2 trial" - (07/27/19)
     
  4183. IAS: Rosuvastatin Does Not Slow Atherosclerosis in HIV+ With Moderate Risk - (07/27/19)
     
  4184. IAS: SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 48 WEEKS (TANGO STUDY) - (07/26/19)
     
  4185. IAS: Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months - Mark Mascolini - (07/26/19)
     
  4186. IAS: A Pooled Analysis of the Effect of Adherence on the Renal Safety of FTC/TDF (Truvada) for Prep: 7 International Demonstration Projects - (07/26/19)
     
  4187. IAS: ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance - PRESS RELEASE - (07/26/19)
     
  4188. IAS: Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019 - (07/26/19)
     
  4189. IAS: ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection - PRESS RELEASE - (07/26/19)
     
  4190. IAS: Vesatolimod (GS-9620) Is Safe and Pharmacodynamically Active in HIV-Infected Individuals - (07/26/19)
     
  4191. IAS: ISLATRAVIR (ISL, MK-8591) at doses of 0.25 to 2.25 mg QD in combination with doravirine maintains viral suppression through 48 weeks in adults with HIV-1 infection - (07/26/19)
     
  4192. IAS: Gilead Announces Latest Data in Ongoing HIV Cure Research Program - (07/25/19)
     
  4193. IAS: Gilead Presents New Findings on Profile of Descovy for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada - (07/25/19)
     
  4194. IAS: Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV - (07/25/19)
     
  4195. IAS: Incidence of HIV-Infection with Daily or On Demand PrEP with TDF/FTC in the Paris Area: An Update of the Prevenir Study - (07/25/19)
     
  4196. IAS: Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials - (07/25/19)
     
  4197. IAS: Oral TLR7 Agonist Administration Induces an Immunostimulatory Response in SIV-Infected ART-Suppressed Infant Rhesus Macaques - (07/25/19)
     
  4198. IAS: Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months - Mark Mascolini - (07/25/19)
     
  4199. IAS: Vision Impairment More Frequent in Older HIV+ Men--With Functional Consequences - Mark Mascolini - (07/25/19)
     
  4200. IAS: Lower HIV Rate With F/TAF Than F/TDF in Double-Blind Noninferiority Trial - Mark Mascolini - (07/25/19)
     
  4201. IAS: Neural Tube Defect Rate 0.40% With Dolutegravir in Pregnancy--But Data Still Slim - Mark Mascolini - (07/25/19)
     
  4202. IAS: High STI Prevalence in German MSM, But Low Rates of HIV, HCV, HBV - Mark Mascolini - (07/25/19)
     
  4203. IAS: About 10% With HIV in Europe Have Heavy Treatment Experience, Few Options - "Prevalence and outcomes for heavily treatment-experienced (HTE) individuals living with HIV in a European cohort" - Mark Mascolini - (07/25/19)
     
  4204. IAS: Almost No New HIV Infections in Paris Comparison of Daily vs As-Needed PrEP - Mark Mascolini - (07/25/19)
     
  4205. IAS: Higher GI Disorder Risk When Switching to RAL or DRV Versus DTG - Mark Mascolini - (07/25/19)
     
  4206. IAS: Young Men Driving Expanding HIV Epidemic in Latin America - Mark Mascolini - (07/25/19)
     
  4207. IAS: Better Predictive Power When Combining Traditional and HIV-Specific Cardio Risk Factors - "Impact of HIV specific and traditional risk factors on the incidence of cardiovascular events in HIV-positive males over time" - Mark Mascolini - (07/25/19)
     
  4208. IAS: Viral Suppression in 60% for 96 Weeks With Fostemsavir Salvage in BRIGHTE - Mark Mascolini - (07/25/19)
     
  4209. IAS: Week-96 Potency of Dolutegravir/3TC in GEMINI Trials of First-Line ART - "Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection--96-week results from the GEMINI studies" - Mark Mascolini - (07/25/19)
     
  4210. IAS: Sharp Drops in HIV Load After 10 Days of Capsid Inhibitor Monotherapy - Mark Mascolini - (07/25/19)
     
  4211. IAS: Simulated Driving Worse in Pro Drivers With Than Without HIV - "Cognitive functioning and driving ability in HIV-infected professional drivers" - Mark Mascolini - (07/25/19)
     
  4212. IAS: HIV Infection Rate Jumps 7.5-fold When US PrEP Users Stop - Mark Mascolini - (07/25/19)
     
  4213. IAS: Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs - (07/25/19)
     
  4214. IAS: Switching to a Single-tablet Regimen of Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) from Dolutegravir plus Either F/TAF or F/TDF - (07/25/19)
     
  4215. IAS: A Subgroup Analysis of the Week 96 Efficacy and Safety Results Evaluating Fostemsavir in Heavily Treatment-Experienced HIV-1 Infected Participants in the Phase 3 BRIGHTE Study: Results From The Randomized Cohort - (07/25/19)
     
  4216. IAS: First-in-Human Trial of MK-8591-Eluting Implants Demonstrates Concentrations Suitable for HIV Prophylaxis for at Least One Year - (07/25/19)
     
  4217. IAS: Keeping the Pressure on Archived NRTI Resistance: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Triple Therapy in Study 4030 - (07/25/19)
     
  4218. IAS: Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug-resistant HIV-1 (BRIGHTE Study) - (07/25/19)
     
  4219. IAS: Previously Undocumented Pre-existing Resistance and Maintenance of Virologic Suppression in HIV-1 RNA-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) - (07/25/19)
     
  4220. IAS: Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection - (07/25/19)
     
  4221. IAS: Longer-term (96-week) Efficacy and Safety of Switching to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF) in Women - (07/25/19)
     
  4222. IAS: Utilization of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States by Age, Gender and Race/Ethnicity (2014 - 2017) - (07/25/19)
     
  4223. IAS: Long-Acting Cabotegravir and Rilpivirine is Noninferior to Oral ART as Maintenance Therapy for HIV-1 Infection: Week 48 Pooled Analysis From the Phase 3 ATLAS and FLAIR Studies - (07/25/19)
     
  4224. IAS: Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 48-Week Results - (07/25/19)
     
  4225. IAS: Patient Views on Long-Acting HIV Treatment: Cabotegravir + Rilpivirine as Maintenance Therapy (ATLAS 48-Week Results) - (07/25/19)
     
  4226. IAS: DISCOVER STUDY for HIV Pre-Exposure Prophylaxis: F/TAF has a more Rapid Onset and Longer Sustained Duration of HIV Protection Compared with F/TDF - (07/25/19)
     
  4227. IAS: Forgiveness of Antiretroviral Regimens: In Vitro HIV-1 Viral Breakthrough with 2-Drug versus 3-Drug Regimens Simulating Variable Adherence to Treatment - (07/23/19)
     
  4228. IAS: Viral Suppression in 60% for 96 Weeks With Fostemsavir Salvage in BRIGHTE - Mark Mascolini - (07/23/19)
     
  4229. IAS: ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV - (07/23/19)
     
  4230. IAS: Gilead Presents New Data on Biktarvy for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance - (07/23/19)
     
  4231. IAS: Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV - (07/23/19)
     
  4232. Scales Tip Toward 'Fish Oil' PUFA Intake for Heart Failure Prevention Predicting Risk for Incident Heart Failure With Omega-3 Fatty Acids From MESA - 1 - (07/17/19)
     
  4233. Elderly HIV+ Physiologic Changes, Polypharmacy, Prescribing Issues - (07/17/19)
     
  4234. IAS: Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019 - (07/18/19)
     
  4235. Elderly HIV+ Physiologic Changes, Polypharmacy, Prescribing Issues Prescribing issues in elderly individuals living with HIV REVIEW - (07/17/19)
     
  4236. 2-3 Times Greater MI & Heart Failure Risk in HIV+ / "rates of CVD hospitalization were double in HIV infected" - "HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database" - (07/16/19)
     
  4237. Persistent HIV in central nervous system linked to cognitive impairment - (07/16/19)
     
  4238. IAS: IAS 2019: ViiV Healthcare showcasing innovation in HIV science - PRESS RELEASE - (07/16/19)
     
  4239. ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen - (07/11/19)
     
  4240. ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment - (07/10/19)
     
  4241. 2 News Reports on this story - Researchers have eliminated HIV in mice for the first time. Is a cure for humans next? - (07/10/19)
     
  4242. Acceptability and Preferences for Long-Acting Antiretroviral Formulations Among People Living with HIV infection - (07/10/19)
     
  4243. Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019 - (07/10/19)
     
  4244. 20th Intnl Wrkshp Clin Pharm: Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy - (07/10/19)
     
  4245. CROI: TOCILIZUMAB (monoclonal antibody) ALTERS LIPIDS IN HIV+ INDIVIDUALS IN A RANDOMIZED, DOUBLE-BLIND STUDY - (07/10/19)
     
  4246. Calcium Supplements May Damage the Heart - (07/09/19)
     
  4247. Most dietary supplements do not protect against heart attack and stroke - (07/09/19)
     
  4248. Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map - (07/09/19)
     
  4249. Dispense With Supplements for Improving Heart Outcomes - Editorials - (07/09/19)
     
  4250. HIV eliminated from the genomes of living animals - "Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice" - (07/09/19)
     
  4251. Aging/HIV & Senescence; NASH - (07/08/19)
     
  4252. Doubling of Rates of HIV in Nursing Homes - Nursing Home Residents by Human Immunodeficiency Virus Status: Characteristics, Dementia Diagnoses, and Antipsychotic Use - (07/08/19)
     
  4253. Fast Forward to Viral Suppression: Immediate Initiation of ARVs Following Reactive HIV+ Test Result or Engagement in HIV Care for the First Time at a Community Health Center in Washington, DC - (07/08/19)
     
  4254. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection - (07/02/19)
     
  4255. Women - greater weight gain than men associated with integrase inhibitors - all future ART studies should include looks at weight gain. - (07/02/19)
     
  4256. CROI: Cardiovascular Update from CROI 2019 - by Priscilla Hsue MD Professor of Medicine, UCSF (07/01/19)
     
  4257. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV...33% hepatic steatosis >/= grade 1 vs 10% controls - > grade 2 28% vs 5% controls - belly, metabolics - (06/28/19)
     
  4258. 20th Intnl Wrkshp Clin Pharm: The 20th International Workshop on Clinical Pharmacology of Antiviral Therapy - Courtney V. Fletcher, Pharm.D. Professor and Director, Antiviral Pharmacology Laboratory UNMC Center for Drug Discovery University of Nebraska Medical Center - (05/26/19)
     
  4259. Effect of HIV infection and antiretroviral therapy on immune cellular functions - integrase, mitochondria - (06/25/19)
     
  4260. When to use CT Angiography - Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: meta-analysis of individual patient data - (06/25/19)
     
  4261. Kidney Disease "Risk Factor for CVD" - (06/19/19)
     
  4262. Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base - (06/18/19)
     
  4263. Activation and Senescence Markers in HIV Patients with Chronic Kidney Disease - (06/17/19)
     
  4264. NEW DATA RELEASED BY THERATECHNOLOGIES DEMONSTRATE POSITIVE IMPACT OF TESAMORELIN IN PATIENTS WITH LIVER FIBROSIS - (06/17/19)
     
  4265. Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity - (06/14/19)
     
  4266. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in HIV-Infected Adults - (06/14/19)
     
  4267. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation A Randomized Clinical Trial - (06/14/19)
     
  4268. Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States - (06/14/19)
     
  4269. Aging Grant - NIH Grant Funds $23 Million Study of Diseases Affecting People Living with HIV - (06/12/19)
     
  4270. PrEP Recommended - "Preexposure Prophylaxis for the Prevention of HIV Infection - US Preventive Services Task Force Recommendation Statement" - (06/12/19)
     
  4271. New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP)Straight A's - Editorial - (06/12/19)
     
  4272. HIV Screening Recommended - Screening for HIV Infection - US Preventive Services Task Force Recommendation Statement - (06/12/19)
     
  4273. Preexposure Prophylaxis for the Prevention of HIV Infection Evidence Report and Systematic Review for the US Preventive Services Task Force - (06/12/19)
     
  4274. The Changing Face of HIV-Associated Malignancies: Advances, Opportunities, and Future Directions / Treatment Access Denied to HIV+ - (06/10/19)
     
  4275. HIV/Safe PD-1 Cancer Treatment / Studies Should Include HIV+ - (06/10/19)
     
  4276. New PrEP Long-Acting MK-8591, for HIV Treatment Too - (06/10/19)
     
  4277. Excess Vitamin D Linked to Kidney Damage - (06/10/19)
     
  4278. Interferon Stops Parkinson Disease: Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection - (06/07/19)
     
  4279. Short-term outcomes for lung cancer resection surgery in HIV infection - (06/05/19)
     
  4280. Cardiac ageing: extrinsic and intrinsic factors in cellular renewal and senescence - (06/05/19)
     
  4281. ACTG Long-Acting (LA) ART (Rilpivirine/Cabotegravir to Standard of Care (SOC) in persons living with HIV (PLWH) who have had barriers for adherence / LATITUDE Study Health Care Provider Fact Sheet - (06/05/19)
     
  4282. CROI: Lower bone strength by peripheral quantitative CT (pQCT) in children living with HIV - (06/05/19)
     
  4283. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association - (06/05/19)
     
  4284. Congestive Heart Failure and Chronic Kidney Disease The CardioRenal/NephroCardiology Connection - EDITORIAL COMMENT - (06/05/19)
     
  4285. Heart Disease Risk Factors in HIV+ This study just published: "Factors Associated With Excess Myocardial Infarction Risk in HIV-Infected Adults" But there are key crucial points NOT covered in this meta-analysis study...... - (06/05/19)
     
  4286. Arterial Stiffness in the Heart Disease of CKD - Kidney/Cardio Connection - (06/05/19)
     
  4287. Metabolic Bone Disease in Chronic Kidney Disease - Kidney-Bone-Cardio Connection - (06/03/19)
     
  4288. Impact of HIV/simian immunodeficiency virus infection and viral proteins on adipose tissue fibrosis and adipogenesis - (06/03/19)
     
  4289. Intranasal Insulin for Cognition / New study in HIV+ - (06/03/19)
     
  4290. Energy Drinks: Another Cause of QT Prolongation? - (06/03/19)
     
  4291. CROI: HIV Infection and the Risk of Fracture among Fallers - (06/03/19)
     
  4292. CROI: Senescence & Exhaustion of T Cell Memory Subsets Increased in Aging Persons with HIV - (06/03/19)
     
  4293. CROI: Mood Disorders & Increased Risk of Non-communicable Diseases in Adults Aging with HIV.....more HIV+ females had mood disorders 27% vs 22% - (05/31/19)
     
  4294. CROI: Bone, Frailty, and Aging at CROI 2019 - Todd Brown, MD, PhD Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (05/31/19)
     
  4295. Ageing with HIV: Emerging importance of chronic comorbidities in patients over 75: 2-3 times the numbers of Comorbidities vs 50-74 - (05/28/19)
     
  4296. Ageing with HIV: Emerging importance of chronic comorbidities in patients over 75: 2-3 times the numbers of Comorbidities vs 50-74 - (05/28/19)
     
  4297. Type 2 diabetes prevalence [doubled] and its risk factors in HIV: A cross-sectional study - (05/28/19)
     
  4298. "The absurdly high cost of insulin" - as high as $350 a bottle, often 2 bottles per month needed by diabetics - (05/28/19)
     
  4299. Diabetes Risk 39% Higher: BMI, Obesity, Old PIs and NRTIs Associated; Insulin Cost Tripled; Competition Limited - (05/28/19)
     
  4300. 20th Intnl Wrkshp Clin Pharm: Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir - (05/26/19)
     
  4301. Clinical significance of elevated liver transaminases in HIV-infected patients: clinicians practicing HIV care should promptly approach the finding of elevated liver transaminases for its diagnostic and prognostic implications. - (05/24/19)
     
  4302. Ageing with HIV: Emerging importance of chronic comorbidities in patients over 75 - (05/24/19)
     
  4303. Chronic kidney disease is associated with < low BMD at the hip but not at the spine - (05/24/19)
     
  4304. Long-Acting Once A Month Injection of Cabotegravi/rilpivirine in PLWH with History of Sub-Optimal Adherence Enrolling - (05/24/19)
     
  4305. Positive Action Southern Initiative Funding Announcement: Grants for Direct Linkage & Adherence Services in AR, FL, KY, NC, SC, TN, TX, VA - (05/24/19)
     
  4306. 20th Intnl Wrkshp Clin Pharm: Short-term intravenous proton pump inhibitors and histamine H2 antagonists do not negatively affect sustained virologic response in hepatitis C cirrhotic patients treated with ledipasvir or velpatasvir containing antiviral regimens: a case series (05/23/19)
     
  4307. 20th Intnl Wrkshp Clin Pharm: PLASMA AND INTRACELLULAR PHARMACOKINETICS OF COBICISTAT IN THE CLINICAL SETTING (05/23/19)
     
  4308. SWITCHING FROM ATAZANAVIR/RITONAVIR (ATV/RTV) TO ATV/COBICISTAT (COBI) IS ASSOCIATED WITH DECREASE OF PLASMA LIPIDS AND LIVER FIBROSIS - (05/21/19)
     
  4309. Beneficial associations of low and large doses of leisure time physical activity with all-cause, cardiovascular disease and cancer mortality: a national cohort study of 88,140 US adults - (05/21/19)
     
  4310. Recommendations [listed just below] for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting - (05/21/19)
     
  4311. 20th Intnl Wrkshp Clin Pharm: DRUGS ABUSE AND CHEMSEX: A NEW CHALLENGE FOR ANTIRETROVIRAL DRUG-DRUG INTERACTION - (05/20/19)
     
  4312. 20th Intnl Wrkshp Clin Pharm: An exploration of adherence measures to detect recent changes in Truvada® dosing patterns - (05/20/19)
     
  4313. 20th Intnl Wrkshp Clin Pharm: Population Pharmacokinetics of VRC01 in Infants and Adults - (05/20/19)
     
  4314. 20th Intnl Wrkshp Clin Pharm: Pharmacokinetics of Tenofovir Alafenamide 25mg with PK Boosters During Pregnancy & Postpartum - (05/20/19)
     
  4315. 20th Intnl Wrkshp Clin Pharm: Sofosbuvir and 007 Pharmacokinetics Among Persons with HCV and Active Drug Use - (05/20/19)
     
  4316. 20th Intnl Wrkshp Clin Pharm: Comparison of Relative Bioavailability of Pediatric Triumeq and Pediatric Dolutegravir/Lamivudine Dispersible Tablets to Conventional Film Coated Tablets in Healthy Adults - (05/20/19)
     
  4317. 20th Intnl Wrkshp Clin Pharm: Predose concentrations of DTG and RPV steady through 100 weeks in SWORD trials - "Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Characterization of the Two-drug Anti-Retroviral Regimen (2DR) Dolutegravir/Rilpivirine Following Switch From Current Anti-Retroviral Therapy in the SWORD-1 and SWORD-2 Phase 3 Studies" - Mark Mascolini (05/20/19)
     
  4318. 20th Intnl Wrkshp Clin Pharm: The Initial Phase I Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK3640254, a Next-Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (05/20/19)
     
  4319. 20th Intnl Wrkshp Clin Pharm: PHARMACOKINETICS OF ATAZANAVIR BOOSTED WITH COBICISTAT DURING PREGNANCY AND POSTPARTUM - (05/20/19)
     
  4320. 20th Intnl Wrkshp Clin Pharm: Two thirds of Montreal in-hospital HCV group have interactions with DAAs - Mark Mascolini (05/20/19)
     
  4321. 20th Intnl Wrkshp Clin Pharm: Proportion of serious drug interactions dropping on Liverpool antiretroviral website - Mark Mascolini (05/20/19)
     
  4322. 20th Intnl Wrkshp Clin Pharm: Lower cobicistat and atazanavir troughs in smokers with HIV - Mark Mascolini (05/20/19)
     
  4323. 20th Intnl Wrkshp Clin Pharm: Reported dolutegravir-valproic acid interaction probably not clinically relevant - Mark Mascolini (05/20/19)
     
  4324. 20th Intnl Wrkshp Clin Pharm: Model suggests physiologic changes with aging underlie ritonavir PK shifts - Mark Mascolini (05/20/19)
     
  4325. 20th Intnl Wrkshp Clin Pharm: Other than dolutegravir, no antiretroviral interactions with valproic acid in 134 people - Mark Mascolini (05/16/19)
     
  4326. Gilead Donating 2.4 Million Bottles of Truvada to CDC for PrEP - (05/17/19)
     
  4327. Osteoarthritis in HIV May Be Accelerated - new study - (05/17/19)
     
  4328. Mediterranean/Low Carb Diet Superior in Reducing Hepatic Fat for Fatty Liver/NAFLD & Non-NAFLD too - (05/17/19)
     
  4329. 20th Intnl Wrkshp Clin Pharm: Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV - (05/16/19)
     
  4330. 20th Intnl Wrkshp Clin Pharm: Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment - (05/16/19)
     
  4331. 20th Intnl Wrkshp Clin Pharm: One third of French HIV group uses illicit drugs, often risking antiretroviral interactions - Mark Mascolini - (05/16/19)
     
  4332. 20th Intnl Wrkshp Clin Pharm: IV PPIs and H2 antagonists did not thwart response to ledipasvir or velpatasvir - Mark Mascolini - (05/16/19)
     
  4333. 20th Intnl Wrkshp Clin Pharm: Two thirds of Montreal in-hospital HCV group have interactions with DAAs - Mark Mascolini - (05/16/19)
     
  4334. 20th Intnl Wrkshp Clin Pharm: Lower cobicistat and atazanavir troughs in smokers with HIV - Mark Mascolini - (05/16/19)
     
  4335. 20th Intnl Wrkshp Clin Pharm: Sofosbuvir exposure higher in opioid users, lower with darunavir - Mark Mascolini - (05/16/19)
     
  4336. 20th Intnl Wrkshp Clin Pharm: Predose concentrations of DTG and RPV steady through 100 weeks in SWORD trials - Mark Mascolini - (05/16/19)
     
  4337. 20th Intnl Wrkshp Clin Pharm: Phase 1 results show safety and once-daily potential of new HIV maturation inhibitor - Mark Mascolini - (05/16/19)
     
  4338. EASL: CANCER RISK AMONG PEOPLE WITH HIV, HBV AND/OR HCV INFECTIONS - (05/16/19)
     
  4339. Mediterranean/Low Carb Diet Superior in Reducing Hepatic Fat for Fatty Liver/NAFLD & Non-NAFLD too - (05/17/19)
     
  4340. MECHANISMS OF WHITE-MATTER LOSS DUE TO HIV INFECTION AND ANTIRETROVIRAL THERAPY - (05/13/19)
     
  4341. RELAPSE OF SYMPTOMATIC CSF HIV ESCAPE UPON PREVIOUSLY OPTIMIZED cART REGIMEN CHANGES / CNS Eradication Reservoir - (05/13/19)
     
  4342. EASL: Is it possible to successfully link migrants to HBV, HCV and HIV services upon arrival in the European Union? - (05/13/19)
     
  4343. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication - (05/13/19)
     
  4344. NAFLD in lipodystrophy - (05/10/19)
     
  4345. Increasing Cognitive Aging in HIV+ WIHS Women Despite Viral Suppression, MACS Men - (05/10/19)
     
  4346. HIV+ Women & Aging: worse for women with HIV - (05/10/19)
     
  4347. NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens - (05/10/19)
     
  4348. Increasing Cognitive Aging in HIV+ WIHS Women Despite Viral Suppression, MACS Men - (05/09/19)
     
  4349. Increasing Cognitive Aging in HIV+ WIHS Women Despite Viral Suppression, MACS Men - (05/09/19)
     
  4350. HIV+ Women & Aging: worse for women with HIV - (05/09/19)
     
  4351. NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens - (05/09/19)
     
  4352. Bictegravir and dolutegravir: head to head at 96 weeks, Comment + study - (05/08/19)
     
  4353. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial - (05/08/19)
     
  4354. AdverseReactComor: MSM Associated with Lower CD4/CD38 Ratio - (05/01/19)
     
  4355. New HIV Cure Approach - Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1 - (05/01/19)
     
  4356. 35% of HIV+ Taking > 10 Comedications at Northwestern ID Clinic - (05/01/19)
     
  4357. 50% Polypharmacy Rates in HIV MACS >5 Comoedications / Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016 - (05/01/19)
     
  4358. Frailty phenotype in older people living with HIV: concepts, prevention and issues - (04/29/19)
     
  4359. ViiV HEALTHCARE ANNOUNCES CHMP POSITIVE OPINION FOR DOVATO® (DOLUTEGRAVIR/LAMIVUDINE) AS A ONCE-DAILY, SINGLE-PILL, TWO-DRUG REGIMEN FOR THE TREATMENT OF HIV INFECTION - (04/29/19)
     
  4360. ViiV HEALTHCARE SUBMITS NEW DRUG APPLICATION TO US FDA FOR THE FIRST MONTHLY, INJECTABLE, TWO-DRUG REGIMEN OF CABOTEGRAVIR AND RILPIVIRINE FOR TREATMENT OF HIV - (04/29/19)
     
  4361. Complicated Complications at CROI - David Alain Wohl, MD - The University of North Carolina Institute of Global Health and Infectious Diseases - (04/26/19)
     
  4362. HIV is Associated with Lung Function Impairment in the Multicenter AIDS Cohort Study - (04/23/19)
     
  4363. 2 Studies on Sudden Cardiac Death in HIV+ at CROI 2019 with surprising findings regarding causes of deaths - (04/23/19)
     
  4364. PSYCHOLOGICAL BURDEN AND THE IMPACT ON ENGAGEMENT WITH CARE AMONG ETHNICALLY DIVERSE OLDER WOMEN WITH HIV - (04/23/19)
     
  4365. People living with HIV in the UK have a higher risk of progression to CNS disorders and other comorbidities than matched counterparts - (04/23/19)
     
  4366. FATTY LIVER in HIV+, alcohol, 50% have NAFLD, 27% Liver Fibrosis - The prevalence of liver fibrosis in HIV infected patients with abnormal liver function tests - (04/23/19)
     
  4367. Multimorbidity burden in an HIV population aged over 50 in South-East England - (04/23/19)
     
  4368. "I'm 51 but living in the body of a 65-year old":Exploring the experiences and needs of those living with HIV and multiple comorbidities - (04/23/19)
     
  4369. Comorbidities Prevalence & Clustering Together in 2 European Aging/HIV Cohorts - POPPY & AGEHIV - (04/18/19)
     
  4370. Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection - (04/18/19)
     
  4371. Study Finds No Benefit for Dietary Supplements - (04/18/19)
     
  4372. Aging & HIV: Gilead Funds 30 Organizations with $17 Million; ViiV Project - "Aging/HIV has become the #1 issue from at least a clinical perspective" - (04/17/19)
     
  4373. HIV and aging: time to bridge the gap between clinical research and clinical care - Editorial "PLWH seem to be biologically older than their chronological age..... something has to be done to bridge the gap between clinical research and clinical care." - (04/17/19)
     
  4374. Why are people with HIV considered "older adults" in their fifties? "immunosenescence" - (04/17/19)
     
  4375. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Rapid Initiation for HIV-1 Infection: Primary Analysis of the DIAMOND Study at ACTHIV - (04/15/19)
     
  4376. Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks - (04/15/19)
     
  4377. EASL: HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease- ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline - (04/12/19)
     
  4378. American Heart Association Recommends Depression Screening for Cardiovascular Disease Patients Cardiovascular Disease / 'Double the Concern in Older HIV+' - (04/10/19)
     
  4379. ViiV HEALTHCARE ANNOUNCES JULUCA (DOLUTEGRAVIR/RILPIVIRINE) MAINTAINS HIV VIRAL SUPPRESSION AT 148-WEEKS - (04/10/19)
     
  4380. Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to DTG + RPV 2-Drug Regimen: SWORD-1 and -2 Studies at BHIVA - (04/10/19)
     
  4381. US FDA APPROVES ViiV HEALTHCARE'S DOVATO (DOLUTEGRAVIR/LAMIVUDINE), THE FIRST, ONCE-DAILY, SINGLE-TABLET, TWO-DRUG REGIMEN FOR TREATMENT-NAïVE HIV-1 ADULTS (dolutegravir/3TC) - (04/10/19)
     
  4382. Clinical Pharmacology at CROI 2019 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE (04/09/19)
     
  4383. Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591 - (04/10/19)
     
  4384. US FDA APPROVES ViiV HEALTHCARE'S DOVATO (DOLUTEGRAVIR/LAMIVUDINE), THE FIRST, ONCE-DAILY, SINGLE-TABLET, TWO-DRUG REGIMEN FOR TREATMENT-NAïVE HIV-1 ADULTS (dolutegravir/3TC) - (04/10/19)
     
  4385. How all-type dementia risk factors and modifiable risk interventions may be relevant to the first-generation aging with HIV infection? Dementia Risk in HIV+ is Higher - (04/09/19)
     
  4386. Working memory revived in older adults by synchronizing rhythmic brain circuits - (04/09/19)
     
  4387. CROI: GS-6207, A POTENT AND SELECTIVE FIRST-IN-CLASS LONG-ACTING HIV-1 CAPSID INHIBITOR - (04/08/19)
     
  4388. CROI: Weight Gain in HIV - Integrase - (04/08/19)
     
  4389. New VIDEO - Staying Golden: Aging With HIV - (04/05/19)
     
  4390. Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies - (04/05/19)
     
  4391. Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy for HIV Pre-Exposure Prophylaxis - (04/05/19)
     
  4392. Letter from the OAR Director - (04/05/19)
     
  4393. CROI: HIGH RATES OF VIROLOGIC SUPPRESSION AFTER RAPID ART START IN A SAFETY-NET CLINIC - (04/05/19)
     
  4394. AMCP - Long-Term Benefits of Rapid Antiretroviral Therapy Initiation Among Medicaid-Covered Patients With Human Immunodeficiency Virus - (04/04/19)
     
  4395. AMCP - Rapid Initiation of Antiretroviral Treatment Following Diagnosis of Human Immunodeficiency Virus Among Commercially-Insured Patients in the United States - (04/04/19)
     
  4396. AMCP - Estimating Costs of Health Resource Utilization for Patients Living With Human Immunodeficiency Virus - (04/04/19)
     
  4397. CROI: Aging At CROI 2019 - (04/02/19)
     
  4398. Weight gain, blood pressure rise seen with JAK inhibitor therapy - (04/02/19)
     
  4399. Study Confirms Tesamorelin Significantly Reduces Liver Fat in HIV Patients With NAFLD - press announcement - (04/02/19)
     
  4400. CROI: EFFECT ON PLASMA NFL, A MARKER OF NEURONAL INJURY, AFTER SWITCHING FROM TDF TO TAF - (04/01/19)
     
  4401. CROI: EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S - (04/01/19)
     
  4402. CROI: BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT - (04/01/19)
     
  4403. CROI: 26th Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA - Eric S. Daar, M.D. - (03/29/19)
     
  4404. CROI: HIV Prevention at CROI 2019 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/29/19)
     
  4405. CROI: Changes in Kidney Function Among MSM Initiating On-Demand TDF/FTC for HIV Pre-Exposure Prophylaxis - (03/29/19)
     
  4406. CROI: I Keep Forgetting HIV, Aging, and Cognitive Disorders - (03/29/19)
     
  4407. CROI: THE PROJECTED AGE DISTRIBUTION OF WHITE, BLACK, AND HISPANIC MSM ON ART, 2009-2030 / 20% White MSM Projected to be over 70 by 2030 - (03/28/19)
     
  4408. CROI: THE PROJECTED AGE DISTRIBUTION OF WHITE, BLACK, AND HISPANIC MSM ON ART, 2009-2030 - (03/28/19)
     
  4409. CROI: Earlier Age of Onset and Higher Prevalence of Comorbidities in People Living with HIV: A Population-Based Cohort Study in British Columbia, Canada - (03/28/19)
     
  4410. CROI: PROJECTED GROWTH AND NEEDS OF AGING PLWH IN HRSA'S RYAN WHITE HIV/AIDS PROGRAM .....from 2010 through 2030 % > 50 years old doubles with curve sharply increasing-see graph below - (03/28/19)
     
  4411. CROI: Suicide rates among adults living with HIV, 2000-2015 - (03/28/19)
     
  4412. NHPC: Trends in HIV Testing, Diagnosis, and Linkage to Care among Transgender Women Tested in Tested in CDC-Funded Sites, 2012-2017 - (03/27/19)
     
  4413. NHPC: CDC Reports 57% Viral Suppression Rates - (03/27/19)
     
  4414. NHPC: CDC Viral Load Suppression Reporting - (03/27/19)
     
  4415. NHPC: Dental Care for HIV Difficult To Secure / Is Very Important - (03/27/19)
     
  4416. NHPC: CDC Prevention Conference: 9 Highlights - 50% Tested for HIV / Transmission Rate 0 if Undetectable / Florida: 73% in care - (03/27/19)
     
  4417. NHPC: HIV care engagement and sustained viral suppression among persons with diagnosed HIV Infection in Medicaid expansion and non-expansion states, United States, 2015 - (03/27/19)
     
  4418. NHPC: HIV care engagement and sustained viral suppression among persons with diagnosed HIV Infection in Medicaid expansion and non-expansion states, United States, 2015 - (03/27/19)
     
  4419. CROI: Delayed HCC Diagnosis in HIV/HCV Coinfected: HIV not linked to worse liver cancer survival in people with HCV - (03/26/19)
     
  4420. CROI: AIDS illness, living in US South, lower CD4s linked to longer hospital stay with HIV - (03/26/19)
     
  4421. CROI: Factors associated with therapeutic failure of 2-drug regimens, DAT'AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable - Mark Mascolini (03/26/19)
     
  4422. Neurocognitive SuperAging (SA) in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates (CHARTER) - (03/25/19)
     
  4423. CROI: Integrase Strand Transfer Inhibitors are Associated With Weight Gain in Women - (03/25/19)
     
  4424. CROI: Can HBV Be Cured? - "Single hepatocyte analysis in HIV-HBV co-infection shows transcriptional silencing" - (03/22/19)
     
  4425. CROI: Integrase Inhibitor Exposure and Central Nervous System & Neural Tube Defects - Data from the Antiretroviral Pregnancy Registry - (03/20/19)
     
  4426. NHPC: HIV risk in MSM, transgender people, high-school students, new mothers - Mark Mascolini (03/25/19)
     
  4427. NHPC: PrEP prescribers multiply as adherence and persistence get high marks - Mark Mascolini (03/22/19)
     
  4428. NHPC: US trends in HIV testing, linkage to care, and transmission - Mark Mascolini (03/22/19)
     
  4429. CROI: High maternal HBV with HIV tied to low infant weight and HIV transmission - Mark Mascolini (03/22/19)
     
  4430. NY Times article: This is Not A Cure for My H.I.V. - (03/22/19)
     
  4431. Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors - (03/22/19)
     
  4432. Aspirin Use Discourged / 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease - (03/22/19)
     
  4433. Ten Things I Learned About Aspirin at ESC 2018, 3 studies on aspirin use COMMENTARY - BOTH STUDIES ARE BELOW - (03/22/19)
     
  4434. CROI: Real-life efficacy and safety of Glecaprevir/Pibrentasvir in a large cohort of HCV-infected patients: the MISTRAL study - (03/20/19)
     
  4435. CROI: Liver stiffness at SVR predicts hepatic complications in HCV-infected patients - (03/20/19)
     
  4436. CROI: Integrase Inhibitor Exposure and Central Nervous System & Neural Tube Defects - Data from the Antiretroviral Pregnancy Registry - (03/20/19)
     
  4437. CROI: Inflammation, Arterial Stiffness and Directly-Acting ntivirals in HCV and HIV/HCV, no beneft observed in this study - (03/20/19)
     
  4438. CROI: Successful HCV treatment does not affect rate of heart disease or non-AIDS cancer - Mark Mascolini (03/20/19)
     
  4439. CROI: DAA therapy for HCV lowers risk of cardiovascular disease at all fibrosis stages - (03/20/19)
     
  4440. CROI: Maternal HBV Viremia Is Associated With Adverse Infant Outcomes In HIV/HBV Women: Post-Hoc Analysis of HPTN 046 - (03/20/19)
     
  4441. CROI: HCV treatment with DAAs halves risk of new diabetes diagnosis - Mark Mascolini (03/20/19)
     
  4442. CROI: High maternal HBV with HIV tied to low infant weight and HIV transmission - Mark Mascolini (03/20/19)
     
  4443. CROI: High endothelial dysfunction rate with recent HIV in young adults with low cardiovascular risk - Mark Mascolini (03/19/19)
     
  4444. CROI: ART IN EARLY INFECTION IMPROVES NEUROCOGNITION REGARDLESS OF INFECTION DURATION - (03/19/19)
     
  4445. CROI: GENOTYPIC AND PHENOTYPIC SUSCEPTIBILITY TO FOSTEMSAVIR IN MULTIDRUG-RESISTANT HIV-1 - (03/19/19)
     
  4446. CROI: DOLUTEGRAVIR: ABSENCE OF DEVELOPMENTAL TOXICITY INCLUDING NTDs IN ANIMAL STUDIES - (03/19/19)
     
  4447. CROI: NO INCREASE IN BIRTH DEFECTS IN INFANTS EXPOSED TO INTEGRASE INHIBITORS AT CONCEPTION - (03/19/19)
     
  4448. CROI: Integrase Inhibitor Exposure and CNS and Neural Tube Defects: Data from the Antiretroviral Pregnancy Registry (APR) - (03/19/19)
     
  4449. CROI: Reports of Neural Tube Defects for 8 ARVs in FDA, WHO, EMA and UK Pharmacovigilance Safety Databases - (03/19/19)
     
  4450. CROI: Antiretroviral Adherence and HIV-1 Drug Resistance in the US - (03/19/19)
     
  4451. CROI: RELAPSE OF SYMPTOMATIC CSF HIV ESCAPE UPON PREVIOUSLY OPTIMIZED C-ART REGIMEN CHANGES - (03/18/19)
     
  4452. CROI: Combination of CRISPR and LASER ART Eliminates Replication Competent Rebound in Humanized Mice - (03/18/19)
     
  4453. CROI: Lymphoid Tissue Pharmacokinetics of Tenofovir-alafenamide vs. disoproxil fumarate - (03/18/19)
     
  4454. CROI: MODERATE EFFICACY OF ORAL SINGLE-AGENT TAF AGAINST VAGINAL SHIV INFECTION IN MACAQUES - (03/18/19)
     
  4455. CROI: USING EHR DATA TO IDENTIFY POTENTIAL PREP CANDIDATES IN A LARGE HEALTH CARE SYSTEM - (03/18/19)
     
  4456. CROI: Prediction of Renal OAT1 and OAT3 Inhibition by Cabotegravir Using PBPK Modelling - (03/18/19)
     
  4457. CROI: Hormonal Contraceptives Do Not Alter Cabotegravir PK in HIV Uninfected Women: HPTN 077 - (03/18/19)
     
  4458. CROI: Immediate PrEP Initiation at New York City Sexual Health Clinics - (03/18/19)
     
  4459. CROI: One in 50 in NYC with recently diagnosed HIV used PrEP in preceding months..... PrEP Use in Persons With Undetected HIV Infections Contributes to Resistance - Mark Mascolini (03/18/19)
     
  4460. CROI: Sex-specific Patterns in HIV-associated Cardiovascular Mortality in New York City - (03/18/19)
     
  4461. CROI: New HIV/ART Drugs at CROI 2019 - (03/18/19)
     
  4462. CROI: THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS - (03/18/19)
     
  4463. CROI: THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS - (03/15/19)
     
  4464. CROI: GS-9722: First-in-Class, Effector-Enhanced, Broadly Neutralizing Antibody for HIV Cure - and PGT121 in HIV+ / PGT121 bNAb in HIV+ - (03/15/19)
     
  4465. CROI: CHARACTERIZING THE HIV DNA RESERVOIRS IN WHOLE-BODY TISSUES IN THE "LAST GIFT" COHORT - (03/15/19)
     
  4466. CROI: A Phase IIa Study of a Novel Maturation Inhibitor GSK2838232 in HIV patients - (03/15/19)
     
  4467. CROI: Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance - (04/08/19)
     
  4468. CROI: Susceptibility to Bictegravir in Highly ARV Experienced Patients After INSTI Failure - (03/15/19)
     
  4469. CROI: High Level of Preexisting NRTI Resistance Prior to Switching to B/F/TAF: Study 4030 - (03/15/19)
     
  4470. CROI: Sharp drop in acute HCV among London MSM with HIV after DAAs arrived - Mark Mascolini (03/15/19)
     
  4471. CROI: BICTEGRAVIR/FTC/TAF SINGLE-TABLET REGIMEN IN ADOLESCENTS & CHILDREN: WEEK 48 RESULTS - (03/15/19)
     
  4472. CROI: Half with HIV in US have virus over 3 years before diagnosis--some groups lag overall trends - "Duration of infectiousness among persons with HIV diagnosed during 2012-2016" - Mark Mascolini (03/15/19)
     
  4473. CROI: Frequent PSA screening, lower prostate cancer incidence, in veterans with HIV - Mark Mascolini (03/15/19)
     
  4474. CROI: In utero HIV exposure tied to obesity, reactive airway disease in adolescence - Mark Mascolini (03/15/19)
     
  4475. CROI: HIV Resistance Associated Mutations Observed in Cell-Associated DNA Sequencing Assay - (03/14/19)
     
  4476. CROI: Oral TAF alone offers modest protection against vaginal SHIV in monkeys - Mark Mascolini (03/14/19)
     
  4477. CROI: New fracture independently boosts death risk in big US HIV cohort - Mark Mascolini (03/14/19)
     
  4478. CROI: BICTEGRAVIR CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF of HIV-INFECTED PATIENTS - (03/14/19)
     
  4479. CROI: PRO 140 (leronlimab) SC: Long-Acting Single-Agent Maintenance Therapy (SAMT) for HIV-1 Infection - (03/14/19)
     
  4480. CROI: FAVOURABLE OUTCOME of IN VITRO SELECTIONS WITH NOVEL NRTI PRODRUG GS-9131 - (03/14/19)
     
  4481. CROI: PML-IRIS ensuing CNS and subsequent peripheral viral escape of ARV-resistant variants - (03/14/19)
     
  4482. CROI: Rebound Of HIV-1 In Cerebrospinal Fluid (CSF) After Treatment Interruption (TI) - (03/14/19)
     
  4483. CROI: Changes in HIV PrEP awareness and use among men who have sex with men, 2014 vs 2017 - (03/14/19)
     
  4484. CROI: Neurosymptomatic HIV-1 CSF Escape can Occur with Replication in CD4+ T Cells in the CNS - (03/13/19)
     
  4485. CROI: Estimated PrEP Eligibility in a National Sexual Network Study of US MSM - (03/13/19)
     
  4486. CROI: Neurosymptomatic HIV-1 CSF Escape can Occur with Replication in CD4+ T Cells in the CNS - (03/13/19)
     
  4487. CROI: Up to 95% virologic response rate with rapid ART in safety-net clinic - Mark Mascolini (03/13/19)
     
  4488. CROI: Estimate of US MSM eligible for PrEP jumps from 25% in 2015 to 45% today - Mark Mascolini (03/13/19)
     
  4489. TENOFOVIR ALAFENAMIDE VS TENOFOVIR DF IN WOMEN: POOLED ANALYSIS OF 7 CLINICAL TRIALS - (03/13/19)
     
  4490. CROI: DIFFERENTIAL BMI CHANGES FOLLOWING PI- AND INSTI- BASED ART INITIATION BY SEX AND RACE - (03/13/19)
     
  4491. CROI: Viral Suppression Among People Initiating HIV Care: Outcomes from iENGAGE Trial - (03/13/19)
     
  4492. CROI: Injecting drugs, HCV, race are syphilis risk factors in US women with HIV - Mark Mascolini (03/13/19)
     
  4493. CROI: More than 1 year to HIV control raises failure risk almost 10-fold - Mark Mascolini (03/13/19)
     
  4494. CROI: Single monoclonal antibody infusion controls HIV for over 5 months in 2 people - - Mark Mascolini (03/13/19)
     
  4495. CROI: ACTIVITY OF ECD4-IG AGAINST CCR5 ANTAGONIST-RESISTANT HIV-1 - (03/13/19)
     
  4496. CROI: IBALIZUMAB: 96-WEEK DATA AND EFFICACY IN PATIENTS RESISTANT TO COMMON ANTIRETROVIRALS - (03/13/19)
     
  4497. CROI: Rebound of HIV-1 in Cerebrospinal Fluid (CSF) after Treatment Interruption (TI). Themed discussion webcast - (03/13/19)
     
  4498. CROI: DTG vs LPV/r (DAWNING): Efficacy by Baseline NRTI Resistance and Second-Line NRTI Use - (03/13/19)
     
  4499. CROI: Efficacy and Safety of the Once-daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ART-naïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results - (03/13/19)
     
  4500. CROI: Efficacy and Safety of the Once-daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ART-naïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results - (03/13/19)
     
  4501. CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS - (03/11/19)
     
  4502. CROI: Obesity & Weight Gain on Antiretroviral Therapy - (03/11/19)
     
  4503. CROI: RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR-BASED ART - (03/11/19)
     
  4504. CROI: Dolutegravir and Insulin Resistance - (03/11/19)
     
  4505. CROI: MIDLIFE ADIPOSITY PREDICTS COGNITIVE DECLINE IN THE MULTICENTER AIDS COHORT STUDY (MACS) - (03/11/19)
     
  4506. CROI: Pharmacogenetics of Weight Gain after Switch from Efavirenz to Integrase Inhibitors - (03/11/19)
     
  4507. CROI: LONG-LASTING ALTERATIONS IN FAT DISTRIBUTION IN PLWH EXPOSED TO THYMIDINE ANALOGUES - (03/11/19)
     
  4508. CROI: Weight Gain During Treatment Among 3,468 Treatment-Experienced Adults with HIV - (03/11/19)
     
  4509. CROI: GREATER WEIGHT GAIN AMONG TREATMENT-NAIVE PERSONS STARTING INTEGRASE INHIBITORS - (03/11/19)
     
  4510. CROI: Weight Gain among Virally Suppressed Persons who Switch to INSTI-Based ART, The HIV Outpatient Study - (03/11/19)
     
  4511. CROI: Two thirds of HIV group report pain and 14% endure "widespread" pain [50% to 80% report pain, average age only 53] - Mark Mascolini (03/11/19)
     
  4512. CROI: The Impact of Weight Gain and Sex on Immune Activation Following Initiation of ART - (03/11/19)
     
  4513. CROI: INTEGRASE STRAND TRANSFER INHIBITORS ARE ASSOCIATED WITH WEIGHT GAIN IN WOMEN - (03/11/19)
     
  4514. CROI: Higher cardiovascular risk in older HIV group tied to worse cognitive function - Mark Mascolini (03/08/19)
     
  4515. CROI: One in 50 in NYC with recently diagnosed HIV used PrEP in preceding months - Mark Mascolini (03/08/19)
     
  4516. CROI: One third of elderly HIV group takes complex regimens and risks drug interactions - Mark Mascolini (03/08/19)
     
  4517. CROI: HIV-Cognitive Impairment/Obesity-Overweight-Exercise-Efavirenz-Age "OBESITY IS INDEPENDENTLY ASSOCIATED WITH NEUROCOGNITIVE DECLINE IN HIV".....16% had neurocognitive impairment (NCI) & 6% frailty at baseline (03/08/19)
     
  4518. CROI: Changes in Lipids After a Direct Switch from TDF to TAF (03/08/19)
     
  4519. CROI: Memory and Learning Dysfunction with Integrase Strand Transfer Inhibitor Use (03/08/19)
     
  4520. CROI: MK-8591 Potency and PK Provide High Inhibitory Quotients at Low Doses QD and QW (03/08/19)
     
  4521. CROI: Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis (03/08/19)
     
  4522. CROI: Obesity--but not frailty--predicts neurocognitive impairment with HIV - Mark Mascolini (03/08/19)
     
  4523. CROI: SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR (03/08/19)
     
  4524. CROI: Efficacy of the Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG+3TC) vs Dolutegravir Plus Tenofovir/Emtricitabine (DTG+TDF/FTC) at W48 in Antiretroviral Naive Women: GEMINI Studies Subgroup Analysis (03/08/19)
     
  4525. CROI: Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Women in the BRIGHTE Study (03/08/19)
     
  4526. CROI: ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection (03/08/19)
     
  4527. CROI: Monthly injected cabotegravir/rilpivirine noninferior to oral DTG at 48 weeks - Mark Mascolini (03/08/19)
     
  4528. CROI: Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy (03/08/19)
     
  4529. CROI: ANALYTIC TREATMENT INTERRUPTION (ATI) AFTER ALLOGENEIC CCR5-D32 HSCT FOR AML IN 2013 (03/08/19)
     
  4530. CROI: Lymphoid Tissue Pharmacokinetics of Tenofovir-alafenamide vs. disoproxil fumarate (03/08/19)
     
  4531. CROI: Lymphoid tissue PKs of tenofovir-alafenamide vs. -disoproxil fumarate / Tenofovir levels in human PBMCs and lymph nodes higher with TAF than TDF - Mark Mascolini (03/08/19)
     
  4532. CROI: Yearly suicide rate in white men with HIV usually far exceeds rate in US population - Mark Mascolini (03/08/19)
     
  4533. CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS (03/07/19)
     
  4534. CROI: SUSTAINED HIV-1 REMISSION FOLLOWING HOMOZYGOUS CCR5 DELTA32 ALLOGENIC HSCT (03/07/19)
     
  4535. CROI: Edoxaban lowers coagulation but not inflammation in people on ART - Mark Mascolini (03/07/19)
     
  4536. CROI: Cognitive impairment tied to doubled death risk in US and African HIV groups - Mark Mascolini (03/07/19)
     
  4537. CROI: Higher risk of recurrent venous thromboembolism with HIV in Dutch national study - Mark Mascolini (03/07/19)
     
  4538. CROI: THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS - (03/06/19)
     
  4539. CROI: EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S - (03/06/19)
     
  4540. CROI: BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT - (03/06/19)
     
  4541. CROI: CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HIV-NEGATIVE INDIVIDUALS - (03/06/19)
     
  4542. CROI: Evaluation of Neural Tube Defects After Exposure to Raltegravir During Pregnancy - (03/06/19)
     
  4543. CROI: BREAKING BONES IS BAD: INCIDENT FRACTURE AND MORTALITY IN THE HIV OUTPATIENT STUDY - 45% Increased Mortality Associated with Fracture - (03/06/19)
     
  4544. CROI: Antiactivation activity with kinase inhibitor - JAK Inhbitor - added to suppressive ART / "Safety, tolerability and immunologic activity of ruxolitinib added to suppressive ART" - Mark Mascolini (03/05/19)
     
  4545. CROI: Longer sustained use of levonorgestrel IUD than copper IUD by women with HIV / "Randomized controlled trial of intrauterine device safety in women living with HIV" - Mark Mascolini (03/05/19)
     
  4546. CROI: Better HIV control with dolutegravir than efavirenz started late in pregnancy / "RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: DOLPHIN-2" - Mark Mascolini (03/05/19)
     
  4547. CROI: COPD doubles heart attack risk with HIV regardless of smoking / "COPD and the risk of MI by type in people living with HIV" - Mark Mascolini (03/05/19)
     
  4548. CROI: Sudden cardiac death risk higher with HIV--but not with sustained HIV control / "Sudden cardiac death among HIV-infected and -uninfected veterans" - Mark Mascolini (03/05/19)
     
  4549. CROI: Probiotic does not alter inflammation/activation markers in group on stable ART / "Assessing the probiotic effect in treated HIV: results of ACTG A5350" - Mark Mascolini (03/05/19)
     
  4550. CROI: HIV tied to almost 2-fold lower breast cancer survival - Mark Mascolini (03/05/19)
     
  4551. CROI: Has a second person with HIV been cured? - (03/05/19)
     
  4552. CROI: UPDATE ON HIV PREVENTION CROI 2019 - (03/05/19)
     
  4553. CROI: UPDATE ON HIV CURE - CROI 2019 - (03/05/19)
     
  4554. CROI: NASH IN HIV - CROI 2019 - (03/05/19)
     
  4555. SHIVER: 1ST INTERNATIONAL WORKSHOP OF THE STEATOHEPATITIS IN HIV EMERGING RESEARCH (SHIVER) NETWORK - (03/01/19)
     
  4556. HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy - (03/01/19)
     
  4557. ViiV ADHOC - Aging with Dignity, Health, Optimism, & Community Study /Registry - (03/01/19)
     
  4558. ViiV ADHOC Aging/HIV Study Registry / Database - "Loneliness Among Older Adults HIV+" - (03/01/19)
     
  4559. Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV - (03/01/19)
     
  4560. 2 Very Recent Studies Linking Inflammation to Causing Cognitive Impairment / inflammation-telomerase connection - (02/27/19)
     
  4561. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials - (02/27/19)
     
  4562. Primary prevention with statins for older adults - Editorial / Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study - (02/27/19)
     
  4563. Primary prevention with statins for older adults - Editorial / Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study - (02/26/19)
     
  4564. ART - Lipodystrophy/Diabetes/Fat Tissue/Mitochondrial damage/Heart Disease: Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy - (02/26/19)
     
  4565. High-Fat Diets Linked With Changes in Gut - (02/26/19)
     
  4566. 2 Studies: Frailty Associated with 4 Times Increased Death Rates in HIV+, Associated with Comorbidities Onset, 2- Frailty and NCI (neurocognitive impairment) in study 2 Led to Increased disability, falls, in inability to Function Measuring by IADLs, independent living - (02/26/19)
     
  4567. OAR Advisory Council Meeting - Aging/HIV Discussion Slide Presentation by NIA HIV-Brain Researcher - Nov 15 2018 - (02/26/19)
     
  4568. Diagnosis and Treatment of Cognitive Impairment in HIV Patients - (02/25/19)
     
  4569. Clinical outcomes of young black men receiving HIV medical care in the United States, 2009-2014 - (02/25/19)
     
  4570. Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate - (02/25/19)
     
  4571. Fanconi Syndrome and Tenofovir Alafenamide: A Case Report - (02/25/19)
     
  4572. Statin Toxicity in HIV+ & Elderly - (02/25/19)
     
  4573. Systemic inflammation during midlife and cognitive change over 20 years - (02/15/19)
     
  4574. New Frailty HIV-Specific Index- see table below listing 37-item frailty list index used in this study / What is Frailty in HIV ??? / 52% Pre-Frail at 48 in this study - (02/15/19)
     
  4575. Fanconi Syndrome and Tenofovir Alafenamide: A Case Report - (02/13/19)
     
  4576. TAT Vaccine Study......decays HIV DNA, immune restoration: increased CD4, improved CD4/CD38 ratio, slowed disease progression - (02/13/19)
     
  4577. New Full Text AHA Heart Disease Guidelines & Recommendations - cholesterol, LDL, statins, PCSK inhibitors, ezetimibe therapy / Statin Safety published by AHA - (02/11/19)
     
  4578. HIV Viral Load and Transmissibility of HIV InfectionUndetectable Equals Untransmittable - Viewpoint - (02/11/19)
     
  4579. Ending the HIV Epidemic-A Plan for the United States - Editorial - (02/11/19)
     
  4580. Ultra-long-acting removable drug delivery system for HIV treatment and prevention/Dolutegravir Implant - (02/11/19)
     
  4581. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial Clinical Infectious Diseases, Volume 68, Issue 4, 1 February 2019 supplementary material - (02/11/19)
     
  4582. Cardiac dysfunction prevalent in patients with HIV. - Editorial - Myocardial Dysfunction With Contemporary Management of HIV Prevalence, Pathophysiology, and Opportunities for Prevention - Belly Fat-Lipodystrophy Connection - (01/30/19)
     
  4583. GLASGOW: Week 48 Resistance Analyses of the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the AMBER and EMERALD Phase 3 Trials - (02/6/19)
     
  4584. Cardiac dysfunction prevalent in patients with HIV. - Editorial - Myocardial Dysfunction With Contemporary Management of HIV Prevalence, Pathophysiology, and Opportunities for Prevention - Belly Fat-Lipodystrophy Connection - (01/30/19)
     
  4585. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? - (01/30/19)
     
  4586. Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study - (01/30/19)
     
  4587. MACS Frailty - HIV-1 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty - (01/30/19)
     
  4588. Myocardial Dysfunction With Contemporary Management of HIV Prevalence, Pathophysiology, and Opportunities for Prevention / Belly Fat-VAT-Lipodystrophy - (01/29/19)
     
  4589. Myocardial Dysfunction With Contemporary Management of HIV Prevalence, Pathophysiology, and Opportunities for Prevention / Belly Fat-VAT-Lipodystrophy - (01/29/19)
     
  4590. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction - (01/29/19)
     
  4591. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia - (01/28/19)
     
  4592. GLASGOW: Comorbidities, Comedication, and Polypharmacy Burden in Patients With HIV: Retrospective Claims Data in Germany - (01/28/19)
     
  4593. U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) - (01/23/19)
     
  4594. High Rates of Virologic Suppression Achieved in MSM or Black/African American Individuals Using a Rapid Initiation Model of Care for Patients Newly Diagnosed With HIV-1 Infection: A Week 24 Interim Analysis of the DIAMOND Study - (01/22/19)
     
  4595. Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm - (01/16/19)
     
  4596. Dolutegravir+3TC 2-Drug ART Awaiting FDA Approval - (01/14/19)
     
  4597. ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine (1) - (01/14/19)
     
  4598. HIV Viral Load and Transmissibility of HIV InfectionUndetectable Equals Untransmittable - (01/14/19)
     
  4599. Mild renal impairment is associated with calcified plaque parameters assessed by computed tomography angiography in people living with HIV - (01/14/19)
     
  4600. Fat redistribution phenotypes, characterized by SAT loss and/or VAT accumulation, may be linked to arterial injury and inflammation in HIV - (01/14/19)
     
  4601. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? Yes-Biological Age greater by 13 Years in HIV+ - (01/14/19)
     
  4602. Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (01/14/19)
     
  4603. Merck Exercises Option for NGM Bio's Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes - (01/08/19)
     
  4604. Aging & the Brain - Hyperactive Innate Immunity Causes Degeneration of Dopamine Neurons upon Altering Activity of Cdk5 - (01/04/19)
     
  4605. Weight Gain TAF vs TDF - A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017 - (01/04/19)
     
  4606. Cognitive Impairment and 1-Year Outcome in Elderly Patients with Hip Fracture.....hip fracture death rates are 11% to 34% - (01/04/19)
     
  4607. Unintended Harm Associated With the Hospital Readmissions Reduction Program - Editorial - (01/03/19)
     
  4608. CMS Incentivizes Bad Health Care - Hospital Readmissions Reduction Program Associated With Higher Mortality - (01/03/19)
     
  4609. Brain Atrophy in HIV+ > 60 is Progressive Despite Viral Suppression / ART Neurotoxicity /LIMC / Aging/ Mental & Substance Abuse Disorders - (01/02/19)
     
  4610. HIV-positive participants had worse complex motor performance than HIV-negative participants - (01/02/19)
     
  4611. HIV infection [slows brain activity] results in ventral-striatal reward system hypo-activation during cue processing - (01/02/19)
     
  4612. How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure - (01/02/19)
     
  4613. The Challenges of Improving Treatments for Depression - (01/02/19)
     
  4614. EVALUATING THE LINK BETWEEN MITOCHONDRIAL STATE & HIV-SPECIFIC CD38+ T CELL EXHAUSTION - (01/02/19)
     
  4615. Updated HHS ART Guidelines/Oct 25 2018 - (12/21/18)
     
  4616. HIV-Related Stigma Affects - impairs - Cognition, Physical Function & the Brain in Older Men Living with HIV - (12/19/18)
     
  4617. De novo NAD+ synthesis enhances mitochondrial function and improves health - (12/19/18)
     
  4618. ART Promise is Gone For Older Aging HIV+ - (12/19/18)
     
  4619. HIV Death Rates Will Increase Due To Aging/Comorbidities & Healthcare Costs Will Double Housing, This Must Get Close Attention - (12/19/18)
     
  4620. Beating Aging/HIV - How to Be More Resilient - (12/19/18)
     
  4621. Preclinical Biomarkers for Functional Decline in HIV and Aging - (12/19/18)
     
  4622. Cure: Little Progress & Disappointing thus far, Researchers say - (12/19/18)
     
  4623. The Demographic Shift in HIV: The Aging HIV Patient - (12/19/18)
     
  4624. Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men - (12/12/18)
     
  4625. Antiretroviral treatment interruptions in HIV clinical trials: A systematic review - (12/12/18)
     
  4626. Fracture Prevention with Zoledronate in Older Women with Osteopenia + Editorial - (12/11/18)
     
  4627. Cardiovascular Risk Reduction with Icosapent Ethyl (Vascepa) for Hypertriglyceridemia - (12/11/18)
     
  4628. NYC DOH Released New 2017 HIV Surveillance Report....23.9% over 60 years old, 77% over 40....55% over 50 - (12/05/18)
     
  4629. Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs - (12/05/18)
     
  4630. Initial Viral Load Decline and Response Rates by Baseline Viral Load Strata With Dolutegravir Plus Lamivudine Versus Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Results From the GEMINI Studies - (12/05/18)
     
  4631. Prevalence of Neuropsychiatric Conditions among HIV Positive Compared to HIV Negative Commercially Insured Individuals - (12/05/18)
     
  4632. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients - modest TG reduction - (11/30/18)
     
  4633. HIV & Liver Disease Research Grants up to $130,000 - (11/28/18)
     
  4634. European Commission Approves Merck's DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - (11/28/18)
     
  4635. 79 Year old HIV+ Alzheimers Case Reported - (11/28/18)
     
  4636. VITAL Signs for Dietary Supplementation to Prevent Cancer and Heart Disease - Editorial - (11/28/18)
     
  4637. CVD & Vascepa EPA Fish Oil 4000 mg Daily - "Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial" REDUCE-It Trial - (11/28/18)
     
  4638. The VITamin D and OmegA-3 TriaL (VITAL): Principal Results for Cardiovascular Disease and Cancer - (11/28/18)
     
  4639. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer - (11/28/18)
     
  4640. Reduction of Cardiovascular Events With Icosapent Ethyl (Vascepa) -Intervention Trial - REDUCE-IT / 20% to 28% improved CVD outcomes "highly impressive" ! - (11/27/18)
     
  4641. New Valsarten Recall by FDA / Mylan - (11/27/18)
     
  4642. Mylan Recalls 15 Lots of Valsartan Products in US - (11/27/18)
     
  4643. Vitamin D and Omega-3 Trial - VITAL - (11/27/18)
     
  4644. REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides - (11/27/18)
     
  4645. Icosapent Ethyl Reduces Ischemic Event Risk in Patients With Hypertriglyceridemia Despite Statin Use - (11/27/18)
     
  4646. REDUCE-IT: Cardiovascular Risk Reduction With Icosapent Ethyl for Hypertriglyceridemia - (11/27/18)
     
  4647. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials - (11/20/18)
     
  4648. AASLD: VITAMIN E IS AN EFFECTIVE TREATMENT FOR NASH IN HIV MONO-INFECTED PATIENTS: THE CTN-PT 024 TRIAL - (11/20/18)
     
  4649. HIVR4P: Anal Sex Frequent--and Often Condom-Free--in Global Female Sex Worker Study - Mark Mascolini (11/09/18)
     
  4650. HIVR4P: New HIV Rate Remains "Alarmingly High" in MSM and TGW of Sub-Saharan Africa - Mark Mascolini (11/09/18)
     
  4651. AGE: Comprehensive Geriatric Assessment (CGA) - (11/09/18)
     
  4652. GLASGOW: HIV and Cancer Curative Approaches Cross-disciplinary research - (11/09/18)
     
  4653. GLASGOW: Pharmacokinetics of MK-8591, Dolutegravir and Tenofovir Disoproxil Fumarate Are Not Altered After Coadministration When Compared to Single Agent Administration - (11/09/18)
     
  4654. GLASGOW: Factors associated with HIV associated neurocognitive disorder in an unselected cohort in East and South London-The HAND study - (11/08/18)
     
  4655. GLASGOW: Long-term survivors in a cohort of HIV+ patients diagnosed between 1985 and 1992: predictive factors associated with more than 25 years of survival - (11/08/18)
     
  4656. GLASGOW: HIV and Ageing Challenges and Goals - Plenary Talk at Glasgow 2018 - (11/08/18)
     
  4657. GLASGOW: Cumulative Safety Review of Elvitegravir and Bictegravir use During Pregnancy and Risk of Neural Tube Defects - (11/08/18)
     
  4658. GLASGOW: High Prevalence of Previously Undocumented Baseline M184V/I Does Not Affect Virologic Outcome in Virologically-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from a Boosted Protease Inhibitor-based Regimen - (11/08/18)
     
  4659. GLASGOW: ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV - (11/08/18)
     
  4660. GLASGOW: Analysis of Patients Completing the Ibalizumab Phase 3 Trial and Expanded Access Program - (11/07/18)
     
  4661. GLASGOW: E-Vaccine Registry Helps HIV Group Improve Poor Vaccination Record - Mark Mascolini (11/07/18)
     
  4662. GLASGOW: SVR With DAAs--and Darunavir--Tied to Lipid Jumps in Big HCV/HIV Group - Mark Mascolini (11/07/18)
     
  4663. GLASGOW: Viral Load and Genotypic Resistance Score Predict Response to 2-Drug ART Switch - Mark Mascolini (11/07/18)
     
  4664. GLASGOW: Two Thirds Reach Sub-50 Viral Load Through 48 Weeks With Ibalizumab - Mark Mascolini (11/07/18)
     
  4665. GLASGOW: HIV Linked to Higher Odds of Anemia, Neutropenia, and Thrombocytopenia - Mark Mascolini (11/07/18)
     
  4666. GLASGOW: Waist-to-Hip Ratio Predicts Hepatic Steatosis in People With HIV - Mark Mascolini (11/07/18)
     
  4667. GLASGOW: Viral Load and Genotypic Resistance Score Predict Response to 2-Drug ART Switch - Mark Mascolini (11/07/18)
     
  4668. Non-Smokers Are At Risk for COPD & Marijuana May Add to Risk, Smokers Are At Greater Risk. Lung Cancer in HIV+ is one of the more frequent cancers among men - (11/06/18)
     
  4669. Survey on Cure Research Among HIV+ presented at NIH Strategies for an HIV Cure Meeting - (11/06/18)
     
  4670. PrEP New in Development & Current at HIVR4P - (11/06/18)
     
  4671. HIVR4P: One Year Retention in PrEPCare Outcomes in a Three-site Implementation Science Program in the United States - (11/06/18)
     
  4672. HIVR4P: Tenofovir Rectal Douche Provides Protective Drug Levels in MSM Colon Tissue - on-demand, behaviorally-congruent - Mark Mascolini - (11/06/18)
     
  4673. HIVR4P: Safety and pharmacokinetics of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy - Mark Mascolini - (11/06/18)
     
  4674. HIVR4P: Subcutaneous TAF Implants Pass 63-Day Test in Rabbits for Long-Acting PrEP - Mark Mascolini (11/06/18)
     
  4675. HIVR4P: Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP) - (11/06/18)
     
  4676. HIVR4P: PrEP New in Development & Current at HIVR4P - (11/06/18)
     
  4677. Characterizing the HIV DNA Reservoirs in Whole-Body Tissues in the "Last Gift" Cohort - (11/05/18)
     
  4678. GLASGOW: Approaches towards a cure for HIV - (11/05/18)
     
  4679. GLASGOW: Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP - Mark Mascolini - (11/05/18)
     
  4680. GLASGOW: How safe is PrEP? An analysis of the safety of TDF(/FTC) as PrEP - (11/05/18)
     
  4681. GLASGOW: Prevalence of mental health problems among people living with HIV: - (11/05/18)
     
  4682. GLASGOW: Dolutegravir- versus an efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial - (11/05/18)
     
  4683. GLASGOW: Dolutegravir- versus an efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial - (11/02/18)
     
  4684. GLASGOW: Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 100 Results From the SWORD-1 and SWORD-2 Studies - (11/02/18)
     
  4685. GLASGOW: Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG + 3TC) Is Non-Inferior to Dolutegravir Plus Tenofovir/Emtricitabine (DTG + TDF/FTC) at 48 Weeks in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: Subgroup Analyses in the GEMINI Studies - (11/02/18)
     
  4686. GLASGOW: Comparison of Viral Replication Below 50 c/mL for Two-Drug (DTG + RPV) Versus Three-Drug Current Antiretroviral Regimen (CAR) Therapy in the SWORD-1 and SWORD-2 Studies - (11/02/18)
     
  4687. GLASGOW: Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 48 Subgroup Analysis in Randomised Cohort Participants - (11/02/18)
     
  4688. GLASGOW: Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients - (11/02/18)
     
  4689. GLASGOW: Safety, Efficacy and Durability of Long-acting Cabotegravir (CAB) and Rilpivirine (RPV) as Two-Drug IM Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 160 Results - (11/02/18)
     
  4690. GLASGOW: B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naïve adults with high baseline viral load or low baseline CD4 count in two phase III randomized, controlled clinical trials: week 96 results - Mark Mascolini (11/02/18)
     
  4691. AdverseReactComor: Switching tenofovir disoproxil fumarate to tenofovir alafenamide - not only bone and kidney - (11/01/18)
     
  4692. AdverseReactComor: HIV-negative men who have sex with men have lower CD4/CD38 ratios driven by higher absolute CD38 T-lymphocyte counts compared to HIV-negative heterosexual men - (11/01/18)
     
  4693. GLASGOW: Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients - oral talk has extra data - (11/02/18)
     
  4694. GLASGOW: Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study - (11/02/18)
     
  4695. GLASGOW: Impact of HIV on quality of life: Preliminary data exploring differences by sex and country (UK and US) using the HIV Dependent Quality of Life questionnaire (HIVDQoL) - (11/02/18)
     
  4696. GLASGOW: New Drugs and Strategies for the Treatment of HIV - (11/02/18)
     
  4697. GLASGOW: Safety and Efficacy of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1 Infected Adults With Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations - (11/02/18)
     
  4698. GLASGOW: The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir regimens prescribed in treatment-experienced patients - (11/02/18)
     
  4699. GLASGOW: Comparison of HIV-1 Intermittent Viremia for Two Drug (DTG+RPV) vs Three Drug Current Antiretroviral Therapy in the SWORD-1 and SWORD-2 Studies - (11/02/18)
     
  4700. GLASGOW: Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Participants (BRIGHTE Study) - (11/02/18)
     
  4701. GLASGOW: Patient Proportion With Above-Target LDL Rises 70% With TDF-to-TAF Switch - Mark Mascolini - (11/01/18)
     
  4702. GLASGOW: OUTCOMES OF PATIENTS NOT ACHIEVING PRIMARY ENDPOINT FROM AN IBALIZUMAB PHASE 3 TRIAL - Mark Mascolini - (11/01/18)
     
  4703. GLASGOW: Phase III Randomized, Controlled Clinical Trial of Bictegravir Coformulated with FTC/TAF in a Fixed-dose Combination (B/F/TAF) versus Dolutegravir (DTG) + F/TAF in Treatment-naïve HIV-1 Positive Adults: Week 96 - Mark Mascolini - (11/01/18)
     
  4704. GLASGOW: Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA® in Treatment-Naïve Adults with HIV-1 - Mark Mascolini - (11/01/18)
     
  4705. GLASGOW: Good HIV Response Rate, Sustained Safety Through 96 Weeks With D/C/F/TAF - Mark Mascolini - (11/01/18)
     
  4706. GLASGOW: Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates - (11/01/18)
     
  4707. GLASGOW: Efficacy of MK-8591 Against Diverse HIV-1 Subtypes and NRTI-Resistant Clinical Isolates - (10/31/18)
     
  4708. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study - (10/31/18)
     
  4709. GLASGOW: Viral Decay Similar With 2- and 3-Drug Dolutegravir Regimens - Mark Mascolini - (10/30/18)
     
  4710. GLASGOW: Good Later Responses in Some People Whose Ibalizumab "Failed" After 7 Days - Mark Mascolini - (10/30/18)
     
  4711. GLASGOW: Higher Hospital Rate With HIV in Women and Straight Men Than in MSM - Mark Mascolini - (10/30/18)
     
  4712. HIVR4P: Global Update: State of Oral PrEP Implementation and Scale-up - (10/30/18)
     
  4713. HIVR4P: Pharmacokinetic and Pharmacodynamic Evaluation of the Antiretroviral Compound MK-2048 Released From an Intravaginal Ring in Rhesus Macaques - (10/30/18)
     
  4714. HIVR4P: Cabotegravir (CAB) Long-Acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-Infected Adults - (10/30/18)
     
  4715. GLASGOW: No Uptick in HIV Replication After Switch to DTG/3TC in Randomized Trial - Mark Mascolini - (10/29/18)
     
  4716. GLASGOW: Mixed Signals With Cardiovascular Markers in Dolutegravir Switch Study - Mark Mascolini - (10/29/18)
     
  4717. GLASGOW: Neuro Impairment in Over One Third of London HIV Group--Anxiety Doubles Risk - Mark Mascolini - (10/29/18)
     
  4718. GLASGOW: TDF/FTC PrEP as Safe as Placebo in Meta-analysis of 13 Trials Across Globe - Mark Mascolini - (10/29/18)
     
  4719. GLASGOW: Higher Hospital Rate With HIV in Women and Straight Men Than in MSM - Mark Mascolini (10/29/18)
     
  4720. GLASGOW: Annual Comorbidity Cost Averages $8674 in German Analysis of People With HIV - Mark Mascolini (10/29/18)
     
  4721. GLASGOW: The economic burden of comorbidities among people living with HIV in Germany; A cohort analysis using health insurance claims data - (10/29/18)
     
  4722. GLASGOW: Multimorbidity and risk of death differs by gender in people living with HIV in the Netherlands - the ATHENA cohort study - (10/29/18)
     
  4723. GLASGOW: Non-HIV Comorbidity Predicts Mortality: Impact Greater in Women - Mark Mascolini - (10/29/18)
     
  4724. GLASGOW: Integrase Inhibitors, Once-Daily Dosing Boost First-ART Response in 77,999-Person Analysis - Mark Mascolini (10/29/18)
     
  4725. GLASGOW: Integrase Inhibitor Use Doubles in Big Elderly Cohort--No Jump in 2-Drug Regimens / Use of 2-Drug ART - Mark Mascolini (10/29/18)
     
  4726. GLASGOW: Polypharmacy in One Third of Big HIV Cohort vs One Fifth of Non-HIV Group - Mark Mascolini (10/29/18)
     
  4727. GLASGOW: ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen - (10/29/18)
     
  4728. HIVR4P: Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis - (10/29/18)
     
  4729. HIVR4P: Examining PrEP Interruptions in a Safety-net Primary Care Network: Missed Opportunities to Re-engage PrEP Users Accessing non-PrEP Services - (10/29/18)
     
  4730. HIVR4P: Decreased HIV Incidence Among PrEP Users Compared to Non-users in a Boston Community Health Center, 2012-2017 - (10/29/18)
     
  4731. HIVR4P: Cabotegravir (CAB) Long-Acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-Infected Adults - (10/29/18)
     
  4732. HIVR4P: "AMP" PREP Broadly Neutralizing Antibody Studies / Next Generation PrEP / Tracking Global PrEP Use - (10/29/18)
     
  4733. HIVR4P: Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do They Last? - (10/26/18)
     
  4734. HIVR4P: HIV Incidence in Persons Using Truvada (FTC/TDF) for HIV Pre-exposure Prophylaxis (PrEP): Worldwide Experience From 46 Studies - (10/26/18)
     
  4735. HIVR4P: Long-term Delivery of Anti-HIV Monoclonal Antibodies with Gene Therapy Approach in Monkeys - (10/26/18)
     
  4736. HIVR4P: Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077 - Mark Mascolini (10/25/18)
     
  4737. HIVR4P: PER ACT HIV TRANSMISSION RISK THROUGH ANAL INTERCOURSE: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS1 - (10/25/18)
     
  4738. HIVR4P: Tail-phase safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected individuals: HPTN 077 final results - Mark Mascolini - (10/25/18)
     
  4739. HIVR4P: CDC- New HIV Infections / Ending AIDS by Tony Fauci at HIVR4P 2018 - (10/24/18)
     
  4740. HIVR4P: Dapivirine Vaginal Ring Next Steps: Study Results Review, Planning for Introduction & Access, Regulatory Overview - (10/24/18)
     
  4741. HIVR4P: HIV Transmission Rate 10 Times Higher With Anal vs Vaginal Sex: Meta-Analysis - Mark Mascolini (10/24/18)
     
  4742. HIVR4P: Some Men With Urethritis Have HIV in Semen While Suppressed in Blood - Mark Mascolini (10/24/18)
     
  4743. HIVR4P: Low-Dose Aspirin Cuts Inflammation in Blood and HIV Target Cells in Female Genital Tract - Mark Mascolini (10/24/18)
     
  4744. HIVR4P: CD4s in "Normal" Anal Mucosa Are Activated in HIV+ Men With Anal Cancer Precursor - Mark Mascolini (10/24/18)
     
  4745. IDWeek: IMMEDIATE ACCESS TO POST-EXPOSURE PROPHYLAXIS (PEP) THROUGH A 24/7 NYC PEP HOTLINE - (10/22/18)
     
  4746. AdverseReactComor: High Levels of Impaired Physical Function in HIV+ 54 Years Old: Physical functioning among patients aging with HIV vs. HIV-uninfected: feasibility of using the Short Performance Physical Battery in clinical care of people living with HIV aged 50 or older, in the CNICS Cohort. - (10/22/18)
     
  4747. AdverseReactComor: Predictive performance of cardiovascular disease risk equations in people living with HIV - (10/22/18)
     
  4748. SF Aging Survey: Lack of Service; older aging-loneliness-depression, feeling abandoned - (10/22/18)
     
  4749. Low CD4 Measures Predict Virus-Related Cancers in HIV-Negative Gay/Bisexual Men - (10/19/18)
     
  4750. ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV - (10/19/18)
     
  4751. AdverseReactComor: Inflammatory biomarkers, adipokines and longitudinal changes in gait speed and fatigue in men with or at risk for HIV infection - (10/19/18)
     
  4752. AdverseReactComor: Coronary artery calcium scores (CAC) among long-term virologically suppressed non-diabetic HIV-infected elderly - (10/19/18)
     
  4753. Opioid Pain Medication in HIV+: affects brain, cognitive impairment; retention & viral suppression affects - (10/17/18)
     
  4754. Association of antiretroviral therapy with brain aging changes among HIV-infected adults - (10/17/18)
     
  4755. Combination HIV Antibody Infusions Safely Maintain Viral Suppression in Select Individuals: "phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption" - (10/17/18)
     
  4756. IAC: Tony Fauci Dismisses Cure/Eradication - Slides at IAC on Vedolizumab Study Imbedded in his talk, where Fauci said...in quotations marks just below - (10/17/18)
     
  4757. AdverseReactComor: Lung disease in HIV: Causes and consequences - (10/16/18)
     
  4758. AdverseReactComor: Alterations in oral microbiota in HIV-infected individuals related to pulmonary function - (10/16/18)
     
  4759. AdverseReactComor: Plasma desmosine/isodesmosine and lung function among people with or at risk of HIV infection - (10/16/18)
     
  4760. AdverseReactComor: ART Initiation with Integrase Inhibitors is Associated with Greater Weight Gain than with PI- or NNRTI-Based ART in the US and Canada - (10/15/18)
     
  4761. AdverseReactComor: HIV-infected individuals using integrase inhibitors are at high risk of weight gain - (10/15/18)
     
  4762. AdverseReactComor: Valganciclovir Reduces an Immune Activation Pathway that Strongly Predicts Morbidity and Mortality in Treated HIV Infection - (10/15/18)
     
  4763. AGE: Aging and Falls & Fractures in HIV+ - (10/15/18)
     
  4764. 50% Have Pain, Neuropathy in HIV+: its implications & psychological affects- distress opioid abuse, depression, adherence - (10/15/18)
     
  4765. IDWeek: With HIV, Does U=U (Undetectable = Untransmittable)? Uh, well, maybe not...... - (10/13/18)
     
  4766. IDWeek: U=U Pro.... - (10/15/18)
     
  4767. IDWeek: PHARMACOKINETIC PROFILE OF IBALIZUMAB FROM A PHASE 3 TRIAL - (10/13/18)
     
  4768. IDWeek: Investigating the Mechanism of a Unique Human Immunodeficiency Virus-1 (HIV-1) Entry Inhibitor, MF275 - (10/13/18)
     
  4769. IDWeek: No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-administration - (10/13/18)
     
  4770. IDWeek: MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol - (10/13/18)
     
  4771. IDWeek: Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States - good picture of the aging generation - (10/13/18)
     
  4772. IDWeek: Retrospective Analysis of Clinical Characteristics and Treatment Patterns among HIV Patients with Commercial and Medicare Advantage Health Insurance in the US: high comorbidities & polypharmacy rates increasing with age - (10/13/18)
     
  4773. IDWeek: Adherence and Persistency with Modern Single vs Multi-Tablet Antiretroviral (ARV) Regimens in 1st treatment of HIV in Clinical Practice - (10/13/18)
     
  4774. IDWeek: Evaluation of Relationships Between UGT1A1Genotypes and Cabotegravir Long-Acting Injection Pharmacokinetics Among HIV-Infected Subjects in the LATTE-2 Study - (10/13/18)
     
  4775. IDWeek: An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults - (10/13/18)
     
  4776. IDWeek: The aging epidemic: virologic control, immunologic recovery, treatment regimens, and clinical outcomes among older adults living with HIV in Washington, DC: Long-Term CD4 and Viral Rebound Trends Worse Over Age 59 Than at 18 to 35 - Mark Mascolini (10/12/18)
     
  4777. IDWeek: Hospitalization rates among persons with HIV who gained Medicaid or private insurance in 2014: Moving From Ryan White to Medicaid or Private Insurance Did Not Boost Hospital Use; BUT Older HIV+ 55-64 Had Double the Hospitalization Rate; Low CD4 & Detectable Viral load also had Higher Hospitalization Rates (10/12/18)
     
  4778. IDWeek: Immune recovery of acute HIV treated patients is characterized by an increase in immune senescence. (10/12/18)
     
  4779. IDWeek: Rational Design of Doravirine (DOR): A Review of Development From Bench to Patients (10/12/18)
     
  4780. IDWeek: The Hepatitis C Virus Cascade of Care at Stony Brook University Hospital: Risk Factors for Linkage to Care (20% linkage to care) (10/12/18)
     
  4781. IDWeek: Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results From the German Hepatitis C-Registry (10/12/18)
     
  4782. IDWeek: Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir (10/12/18)
     
  4783. IDWeek: Hospital Rates Rise With Age for Cancer, Cardio, Other Diseases in US HIV Group - Mark Mascolini (10/10/18)
     
  4784. IDWeek: HCV Testing Among Adolescents and Young Adults in a National Sample of Federally Qualified Health Centers - (10/10/18)
     
  4785. IDWeek: Key factors for treatment changes within one year after starting ART in the German ClinSurv Cohort; between 2005 and 2017: Higher Pretreatment Load, More Pills Predict Faster ART Stop or Switch - Mark Mascolini (10/10/18)
     
  4786. IDWeek: Improving HIV outcomes among HIV-infected patients diagnosed with cancer and followed in an integrated, multidisciplinary, infectious disease/cancer clinic: Better CD4 and Viral Load Outcomes After Meshing HIV and Cancer Care - Mark Mascolini - (10/10/18)
     
  4787. IDWeek: Serum Albumin is Associated with Higher Inflammation and Carotid Atherosclerosis in Treated HIV Infection - (10/10/18)
     
  4788. IDWeek: Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis - (10/10/18)
     
  4789. IDWeek: A RETROSPECTIVE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A NUCLEOSIDE-SPARING REGIMEN OF DARUNAVIR, RITONAVIR AND DOLUTEGRAVIR - (10/10/18)
     
  4790. IDWeek: Week 96 results of the phase 3, randomized, non-inferiority EMERALD trial: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed adults living with HIV-1 - (10/10/18)
     
  4791. IDWeek: Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir - (10/09/18)
     
  4792. IDWeek: Only 30% With HCV/HIV in Safety-Net System Get HCV Therapy in DAA Era - Hepatitis C eradication: who is being left behind in the HIV population? - Mark Mascolini (10/09/18)
     
  4793. IDWeek: Week 96 results of the phase 3, randomized, non-inferiority EMERALD trial: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed adults living with HIV-1 - (10/09/18)
     
  4794. IDWeek: Sustained viral suppression with dolutegravir and boosted darunavir dual therapy among highly treatment-experienced individuals. Sustained Viral Suppression After Switch to Darunavir/Dolutegravir - Mark Mascolini(10/09/18)
     
  4795. IDWeek: Antiretrovirals Perturb Cholesterol Biosynthesis in PBMCs of HIV-Infected Individuals - (10/09/18)
     
  4796. IDWeek: Lung Cancer Chemotherapy Less Frequent With HIV, But Toxicity No Greater - Mark Mascolini (10/09/18)
     
  4797. IDWeek: Primary CNS Lymphoma Treatment Less Aggressive With HIV, But Survival Similar - Mark Mascolini (10/09/18)
     
  4798. IDWeek: Mail-Order Pharmacy, Travel Time to Pharmacy Do Not Affect HIV Control - Mark Mascolini (10/09/18)
     
  4799. IDWeek: Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions following initiation of commonly prescribed antiretrovirals - (10/09/18)
     
  4800. IDWeek: Delayed ART, Smoking, Sleep Apnea, PI, (CVD) Tied to Erectile Dysfunction With HIV - Mark Mascolini (10/09/18)
     
  4801. IDWeek: Mental Health Medications (Non-ARV meds) in Older HIV+ Appear to Cause Cognitive Impairment & Slow Gait Speed - Ethnicity, Insurance Differ in Older HIV Group Taking Mental Health Meds - Mark Mascolini - (10/09/18)
     
  4802. IDWeek: Virally Suppressed PLH Switching From Abacavir To Tenofovir Alafenamide Did Not Have Changes in Immune Activation or Inflammation - (10/06/18)
     
  4803. AGE: Hospital Rates Rise With Age for Cancer, Cardio, Other Diseases in US HIV Group - Mark Mascolini (10/06/18)
     
  4804. AGE: Cumulative Affects of Aging & HIV: mental & physical affects Reported at 2018 aging Workshop - 'mental & physical functional Disabilities' - (10/06/18)
     
  4805. Combination HIV Antibody Infusions Safely Maintain Viral Suppression in Select Individuals: "phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption" - (10/06/18)
     
  4806. IDWeek: Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients - (10/06/18)
     
  4807. IDWeek: Doravirine/Lamivudine/Tenofovir DF continues to be Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-naïve Adults with HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial - (10/06/18)
     
  4808. IDWeek: Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial - (10/06/18)
     
  4809. IDWeek: A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 96 - (10/05/18)
     
  4810. IDWeek: Safety of in utero antiretroviral (ARV) exposure: neurologic outcomes in HIV-exposed, uninfected children - (10/05/18)
     
  4811. IDWeek: Results of Patient-Reported Outcome Data from the Phase III BRIGHTE Study of Fostemsavir - (10/05/18)
     
  4812. IDWeek: Half of 50-Plus HIV Group Lonely, But Loneliness Declines in the 60s - Mark Mascolini - (10/05/18)
     
  4813. IDWeek: In 60-Year-Plus HIV Group With Viral Suppression, 70% Have Low CD4:CD38 Ratio - Mark Mascolini - (10/05/18)
     
  4814. IDWeek: Predictors of cardiovascular outcomes in older HIV-infected patients: CORE50 Cohort 10-year follow-up / Framingham Score, Depression, Aspirin Predict Cardiovascular Events in Older People With HIV - Mark Mascolini - (10/05/18)
     
  4815. IDWeek: Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1 - (10/03/18)
     
  4816. IDWeek: Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy - (10/03/18)
     
  4817. IDWeek: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging - (10/03/18)
     
  4818. IDWeek: Virologic Failure Rate No Higher in Blacks Than Whites in US Military - Mark Mascolini - (10/03/18)
     
  4819. IDWeek: GS-6207: A Novel, Potent and Selective First-In-Class Inhibitor of HIV 1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long Acting Potential in Humans - (10/03/18)
     
  4820. IDWeek: Integrase Inhibitors-based HAART is Associated with Greater BMI Gains in Blacks and Hispanics. - (10/03/18)
     
  4821. IDWeek: HIV More Advanced at Diagnosis in Older People, ART Response Slower - Mark Mascolini - (10/03/18)
     
  4822. IAC: Digital Pre-Exposure Prophylaxis (PrEP): near real-time remote capture of medication ingestion for clinical use in trials and adherence support (09/28/18)
     
  4823. AGE: CD4 effector memory T cells connected to death in veterans living with HIV..... "suggest an accelerated aging of the immune system, and an increase in this particular risk factor for death" - (09/26/18)
     
  4824. AGE: Association between cognitive reserve and cognitive performance in people with HIV: a systematic review and meta-analysis - (09/26/18)
     
  4825. AGE: The Impact of Structured Exercise on Brain Health in Individuals with HIV: A Pilot Study from the Brain Positive Health Now Cohort (BHN).....Improved Physical Function - (09/26/18)
     
  4826. AGE: Falls Among Older Men With or at Risk for HIV Infection - (09/25/18)
     
  4827. AGE: Detectable viral load quadruples odds of recurrent falls in older men with HIV - Mark Mascolini (09/25/18)
     
  4828. Probiotic Safety-No Guarantees - (09/25/18)
     
  4829. Aspirin in Elderly "Healthy" Men Over 65 - Not Effective, Caused Excessive Bleeding, Increased Cancer Rates - (09/25/18)
     
  4830. AGE: 75% Projected to Be Over 50. 85% of HIV+ projected to Have Cadiovascular Disease in USA, 30% malignancy, 23% diabetes. Care Costs Increase by 40% due to Comorbidities. - (09/25/18)
     
  4831. AGE: Frailty Phenotype in Canadian Men and Women with HIV. from Jules: Fried Frailty test is too simple in HIV - (09/25/18)
     
  4832. AGE: How Different Are Invisible and Visible Disabilities in HIV? Over 60 functioning Very Limited - Important Report: mental & physical limitations in Aging HIV+ - (09/25/18)
     
  4833. AGE: Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Treatment-experienced, Virologically Suppressed (EMERALD) and Treatment-naïve (AMBER) Patients: Week 48 Subgroup Analysis by Age - (09/25/18)
     
  4834. AGE: Acute Exercise-Induced Inflammatory Response among Older Adults with and without HIV - (09/25/18)
     
  4835. AGE: Exercise-Induced Inflammatory Changes among Older Adults with and without HIV.... from Jules: look at slides at end showing improved functioning due to exercise with high intensity exercise appearing to show more benefits, and decreased CRP with high intensity. - (09/25/18)
     
  4836. AGE: HIV and the "Geri-ome": Linking Gut Dysbiosis to Inflammation - (09/25/18)
     
  4837. AGE: 'Premature Muscle Aging In Middle-Aged HIV+ men & women' - (09/25/18)
     
  4838. AGE: Aging with HIV? I'm fine, thanks for asking! - 14% Age Well in Canada Cohort - (09/21/18)
     
  4839. Viagra & Melanoma / Hearing-Vision Risk - Role of Sildenafil in Melanoma Incidence and Mortality - (09/20/18)
     
  4840. AGE: Associations of loneliness with cognitive function and quality of life (QoL) among older adults living with HIV - (09/19/18)
     
  4841. AGE: Considerations for The HIV Positive Woman during menopause - (09/19/18)
     
  4842. AGE: Frailty and the Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - (09/19/18)
     
  4843. AGE: Advance Directives and Medical Power of Attorney Assignment in Individuals with HIV - low rates: only 30%-50% or less leave advance directives or power of attorney before death - (09/19/18)
     
  4844. AGE: Cognitive aging in the era of effective antiretrovirals - (09/19/18)
     
  4845. AGE: More than 40% of HIV group has hepatic steatosis, regardless of age - Mark Mascolini (09/19/18)
     
  4846. AGE: Associations of loneliness with cognitive function and quality of life (QoL) among older adults living with HIV - 18% lonely quite often - Mark Mascolini (09/19/18)
     
  4847. AGE: Aging HIV+ Brain - The relationship between synaptodendritic neuropathology and HIV-associated neurocognitive disorders is moderated by age - (09/19/18)
     
  4848. AGE: Muscle mitochondrial function and contemporary anti-retroviral therapy - (09/19/18)
     
  4849. AGE: Physical function worse in older women than men with HIV, despite better CD4 recovery - Mark Mascolini (09/19/18)
     
  4850. AGE: Metabolic syndrome tied to neurocognitive deficit with (but not without) HIV - Mark Mascolini (09/19/18)
     
  4851. AGE: Older age raises odds of amnestic mild cognitive impairment (but not HAND) with HIV - by 5% per year of aging - Mark Mascolini (09/19/18)
     
  4852. AGE: 63% Frail at 65 Years Old-Itlalian Study/NEW HIV Index+Protective Index / HIV-related and social frailty predictors and protectors in 1612-person Italian cohort - (09/19/18)
     
  4853. AGE: HIV and frailty predict first fracture in middle-aged US women's cohort - doubled fracture rates - Mark Mascolini (09/19/18)
     
  4854. ASCEND: Aspirin Not Needed for Primary Prevention in Diabetes - (09/19/18)
     
  4855. ASCEND study results: Definitive data on the use of aspirin and omega-3 fatty acids in diabetic patients - (09/19/18)
     
  4856. AGE: Frailty Phenotype: A Clinical Marker of Age Acceleration in the older HIV-Infected Population - (09/18/18)
     
  4857. AGE: Exhausted & Depleted T Cells in HIV+ Cause Premature Aging & Comorbidities & Frailty Memory loss: T cell subsets associated with mortality in HIV+ and HIV- veterans - (09/18/18)
     
  4858. AGE: Effects of Comorbidity Burden and Age on Brain Integrity in HIV - (09/17/18)
     
  4859. AGE: The Impact of Number of Medications on Falls in Aging Persons Living with HIV - every increase in 1 medication increased risk by 10% for a fall - "50, the new 65?" - (09/17/18)
     
  4860. AGE: Frailty Predicts Fractures Among HIV-infected and Uninfected Women: Results from the Women's Interagency HIV Study - (09/17/18)
     
  4861. AGE: People taking more medications and women have higher fall risk in older HIV group - written by Mark Mascolini - (09/17/18)
     
  4862. AGE: Exercise-induced inflammatory changes among older adults with and without HIV Inflammation does not drop more with HIV after 24 weeks of exercise - written by Mark Mascolini - (09/17/18)
     
  4863. AGE: Only 42% in HIV group have an advance directive immediately before death - written by Mark Mascolini - (09/17/18)
     
  4864. AGE: "Aging well" more frequent than frailty in Canadian HIV group - written by Mark Mascolini - (09/17/18)
     
  4865. AGE: People taking more medications and women have higher fall risk in older HIV group - written by Mark Mascolini - (09/14/18)
     
  4866. AGE: Big HIV clinic sees more than 1000% jump in patients 65 and older - written by Mark Mascolini - (09/14/18)
     
  4867. AGE: Depression, bipolar disorder tied to noncommunicable disease risk with HIV - written by Mark Mascolini - (09/14/18)
     
  4868. Caffeine consumption and mortality in chronic kidney disease: a nationally representative analysis - new study reports caffeine can reduce mortality in chronic kidney disease - (09/14/18)
     
  4869. in NYC - Club drug users had higher odds of reporting a bacterial STI compared with non-club drug users: results from a cross-sectional analysis of gay and bisexual men on HIV pre-exposure prophylaxis - (09/14/18)
     
  4870. HIV testing and pre-exposure prophylaxis (PrEP) use, familiarity, and attitudes among gay and bisexual men in the United States: A national probability sample of three birth cohorts - (09/14/18)
     
  4871. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV - Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor - (09/11/18)
     
  4872. The Aging HIV Brain - HIV Accelerates Brain Aging by 3 to 15 Years in Various Studies over the Past 9 years - (09/11/18)
     
  4873. Caring for Older Adults Living with HIV Infection: policy needed - (09/11/18)
     
  4874. What is Cognitive impairment ? - (09/11/18)
     
  4875. Cognitive Burden of Common Non-antiretroviral Medications in HIV-Infected Women (WIHS) - (09/11/18)
     
  4876. Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials - (09/10/18)
     
  4877. Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy - (09/10/18)
     
  4878. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration - (09/10/18)
     
  4879. FDA Approves Merck's DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients - (09/10/18)
     
  4880. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus [75% were on statin]..,.also is study looking at n-3 fatty acids in sub study, also in diabetics with 75% using a statin, adherence was 77% - (09/10/18)
     
  4881. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial - (09/07/18)
     
  4882. Marijuana Impairs Brain Function - (09/07/18)
     
  4883. Swapping daily pills for monthly shots could transform HIV treatment and prevention - (09/07/18)
     
  4884. Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials - (09/05/18)
     
  4885. Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients - 'fatty liver & NASH in HIV mono-infected called non-viral hepatitis is a new aging comorbidty' - (09/05/18)
     
  4886. Met and unmet health, welfare and social needs of people living with HIV social isolation - (09/05/18)
     
  4887. Health-related quality of life of adults living with HIV in England and Wales: a utility analysis of EQ-5D-5L compared to the general population - (09/05/18)
     
  4888. The cost of comorbidities in treatment for HIV/AIDS in California - (09/05/18)
     
  4889. Does Social Isolation Predict Hospitalization and Mortality Among HIV+ and Uninfected Older Veterans? YES - (09/05/18)
     
  4890. HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition - (09/05/18)
     
  4891. Impact of glycemic status on longitudinal cognitive performance in men with and without HIV infection - (09/05/18)
     
  4892. IAC: French Cohort / Integrase inhibitors and neuropsychiatric adverse events in a large prospective cohort - (09/05/18)
     
  4893. HCV & HCV/HIV Coinfection Micro-Elimination Grants: funding for 30+ projects - - (09/04/18)
     
  4894. Eliminating Excess CVD Risk for Diabetic Type2 - Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes - (08/17/18)
     
  4895. IAC: Higher Prevalence NCI In Aging HIV-Infected Women Despite Lower Comorbidities Than Men (08/17/18)
     
  4896. IAC: Eliminating Excess CVD Risk for Diabetic Type2 - Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes (08/17/18)
     
  4897. IAC: Select Key IAC 2018 Highlight Reports / Coverage: ART drugs, PrEP, Aging/Comorbidities/Mortality/Fatty Liver/Heart & Kidney diseases (08/17/18)
     
  4898. IAC: PrEP & Prevention - HIV & HCV (08/17/18)
     
  4899. Accelerated and Premature Aging Characterizing Regional Cortical Volume Loss in Human Immunodeficiency Virus Infection: Contributions From Alcohol, Substance Use, and Hepatitis C Coinfection - (08/15/18)
     
  4900. Viral suppression and HIV transmission in serodiscordant male couples (Opposites Attract study): an international, prospective, observational, cohort study, Editorial - (08/15/18)
     
  4901. ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen - (08/15/18)
     
  4902. Elevated HIV Prevalence and Correlates of PrEP Use Among a Community Sample of Black Men who Have Sex with Men...more STIs, more drug use, more sex partners, less likely to use condoms...... - (08/15/18)
     
  4903. HIV Aging New Funding Grants RFPs from Gilead - (08/15/18)
     
  4904. IAC: HIV Prevention at AIDS 2018 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (08/15/18)
     
  4905. HIV Aging New Funding Grants RFPs from Gilead - (08/15/18)
     
  4906. IAC: Partners of people living with HIV (PLHIV): Findings from the positive perspectives survey (08/14/18)
     
  4907. IAC: Incidence and Prevalence of Diarrhea in HIV Clinical Trials in the Recent Post-cART Era: Analysis of Data From 38 Clinical Trials From 2008-2017 in Over 21,000 Patients (08/14/18)
     
  4908. Targeting HPV16 DNA using CRISPR/Cas inhibits anal cancer growth in vivo - (08/13/18)
     
  4909. New CDC HIV Surveillance Report/USA Statistics Overview - (08/13/18)
     
  4910. CDC - HIV in the United States: At A Glance - (08/13/18)
     
  4911. New CDC HIV Surveillance Report/USA Statistics Overview - (08/13/18)
     
  4912. IAC: Prevalence and immuno-metabolic associations of frailty in older Australian men living with HIV: a crosssectional analysis (08/08/18)
     
  4913. IAC: Antiretroviral Treatment Maintenance Strategies and Blood Telomere Length Change (08/08/18)
     
  4914. IAC: Weight Gain After ARV Initiation Correlates with Increased Inflammatory Biomarkers (08/08/18)
     
  4915. IAC: Severe menopausal symptoms double odds of poor ART adherence in UK women - Mark Mascolini (08/08/18)
     
  4916. Weight Gain & Integrase Inhibitors - (08/07/18)
     
  4917. IAC: CD4 count and viral load tied to atherogenic cholesterol in people with HIV - Mark Mascolini (08/07/18)
     
  4918. IAC: Vitamin D does not modulate immune-mediated bone loss during ART initiation: A5280 (08/07/18)
     
  4919. IAC: Liver enzyme spikes--then normalizes--when elderly start dolutegravir - Mark Mascolini (08/07/18)
     
  4920. High incidence of HCV (re-)infections among PrEP users in the Netherlands: implications for prevention, monitoring and treatment - (08/07/18)
     
  4921. IAC: Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia? - Mark Mascolini (08/06/18)
     
  4922. IAC: Shared HCV transmission networks among HIV-1 positive and HIV-1 negative men having sex with men in Paris (08/06/18)
     
  4923. IAC: Statins not linked to lower HIV persistence, inflammation, or immune activation - Mark Mascolini (08/06/18)
     
  4924. IAC: Partner Violence: A Significant Part of a Syndemic Among Black Men Who Have Sex With Men (08/06/18)
     
  4925. IAC: High uptake of yearly digital rectal exam for anal cancer in Australian MSM with HIV - Mark Mascolini (08/06/18)
     
  4926. IAC: COMPLACENCY IS THE NEW PROBLEM: COMPARATIVE ANALYSIS OF RECENT OUTBREAKS OF HIV AMONG PERSONS WHO INJECT DRUGS IN EUROPE AND NORTH AMERICA (08/06/18)
     
  4927. IAC: Steep virologic failure drop in Netherlands: initial VL and CD4 strong predictors - Mark Mascolini (08/06/18)
     
  4928. IAC: Alcohol screening less likely in blacks, people with AIDS, in big HIV group - Mark Mascolini (08/06/18)
     
  4929. IAC: HIV incidence drops in Melbourne MSM, reflecting changing HIV testing and control - Mark Mascolini (08/06/18)
     
  4930. IAC: DETERMINANTS OF POST-DISCLOSURE VIOLENCE AGAINST HIV POSITIVE WOMEN IN SERODISCORDANT UNIONS: A CROSSSECTIONAL STUDY IN KUMASI, GHANA (08/06/18)
     
  4931. IAC: One third of black MSM in NYC group experience partner violence - Mark Mascolini (08/06/18)
     
  4932. IAC: Treatment failure in 20% on ART in Australian group: toxicity main culprit - Mark Mascolini (08/06/18)
     
  4933. IAC: A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single-Tablet Regimen in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V and/or M184I (GS-US-292-1824): Week 24 Results (08/06/18)
     
  4934. IAC: Eight recent HIV outbreaks in drug injectors point to prevention complacency - Mark Mascolini (08/06/18)
     
  4935. IAC: Editorial - Cardiovascular Outcomes in Persons With HIV and Heart Failure Medication Class or Suboptimal Viral Suppression? - Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure (08/03/18)
     
  4936. IAC: HIV DNA reservoir size and make-up "remarkably" stable through 20 years of ART - Mark Mascolini (08/03/18)
     
  4937. IAC: Possible link between HIV and vestibular impairment in men and women - Mark Mascolini (08/03/18)
     
  4938. IAC: Half of adults in HIV group have insomnia--fewer than half of them treated (08/02/18)
     
  4939. IAC: Comparison of depression and anxiety between HIV-positive and HIV-negative people.... 3-7 Times Higher Rates for HIV+/Aging Increases Rates (08/02/18)
     
  4940. IAC: Population Pharmacokinetics of Cabotegravir in Healthy Adult Subjects and HIV-1 Infected Patients Following Administration of Oral Tablet and Long-Acting Intramuscular Injection (08/02/18)
     
  4941. IAC: Half of adults in HIV group have insomnia--fewer than half of them treated - Mark Mascolini (08/02/18)
     
  4942. IAC: Quantifying the Relationship Between HIV Patient and Treatment Characteristics, ART Adherence and Viral Suppression Using Contemporary Data (08/02/18)
     
  4943. IAC: Kick-and-kill with vaccines plus vorinostat has no impact on CD4 reservoir - Mark Mascolini (08/01/18)
     
  4944. IAC: Uptake and Effectiveness of Two-drug Compared to Three-drug Antiretroviral Regimens among HIV-positive Individuals in Europe (08/01/18)
     
  4945. IAC: Clinical Effectiveness of Guideline-Recommended Antiretroviral Therapy Core Agents in HIV/HCV Co-infected Patients in the OPERA Observational Database (08/01/18)
     
  4946. IAC: Virologic Outcomes Among Treatment Naive HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database (08/01/18)
     
  4947. IAC: A Comprehensive Assessment of Hepatobiliary Disorders in HIV-Infected Patients Treated With Dolutegravir, Elvitegravir, Raltegravir or Darunavir in the OPERA Database - Liver Chemistry Elevations/DILI (08/01/18)
     
  4948. IAC: Medication errors with Retrovir oral solution in neonates and infants ≤ 23 months (08/01/18)
     
  4949. IAC: Comparison of depression and anxiety between HIV-positive and HIV-negative people....3-7 Times Higher Rates for HIV+/Aging Increases Rates (08/01/18)
     
  4950. IAC: Healthcare Utilization and STI Incidence in Young Men on Pre-exposure Prophylaxis (PrEP) Compared to Young Men Who Are Not on PrEP: The PrEPARE Study (08/01/18)
     
  4951. IAC: Changes, Patterns and Predictors of Sexually Transmitted Infections in Gay and Bisexual Men Using PrEP - Interim Analysis from the PrEPX Study (08/01/18)
     
  4952. IAC: PrEP use rising in US MSM, but rectal STI rate remains stable - Mark Mascolini (08/01/18)
     
  4953. IAC: Cardiovascular Disease Risk Assessments and Fasting Lipid Changes in Virologically Suppressed Patients Randomized to Switch to Tenofovir Alafenamide versus Continuing Tenofovir Disoproxil Fumarate (08/01/18)
     
  4954. IAC: Changes in Cardiovascular Risk Estimation and Fasting Lipids in Virologically Suppressed Patients Randomized to Switch to Tenofovir Alafenamide versus Continuing Abacavir (07/31/18)
     
  4955. IAC: Switching from an Abacavir (ABC)/Lamivudine (3TC)-Based Regimen to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF): Cardiovascular Disease Risk Profile Analysis from a Randomized Controlled Study in Virologically-Suppressed Adults (07/31/18)
     
  4956. IAC: Noncommunicable disease rates with HIV lower in England than in 4 other countries - Mark Mascolini (07/31/18)
     
  4957. IAC: Adherence to Long-Acting CAB and RPV Injections Through 96 Weeks of Maintenance Therapy in LATTE-2 / Good adherence to injected cabotegravir and rilpivirine in 230 LATTE-2 participants - Mark Mascolini (07/31/18)
     
  4958. IAC: Virologic Outcomes Among Treatment Naive HIV+ Patients Initiating Common First Antiretroviral Therapy Core Agents in the OPERA Observational Database (07/31/18)
     
  4959. IAC: Resistance Through Week 48 in the DAWNING Study Comparing Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/r) Plus 2 NRTIs in Second-line Treatment (07/31/18)
     
  4960. IAC: ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018 (07/31/18)
     
  4961. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  4962. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  4963. IAC: Trends in mortality among HIV-infected subjects; differences by HCV coinfection - 70% of Deaths Non-AIDS: liver-HCV, psychiatric, malignancies, cardiovascular & pulmonary diseases common causes of death (07/31/18)
     
  4964. IAC: "Increased risk of both mortality and incident comorbidity among frail HIV-positive and HIV-negative participants and increased risk of frailty progression in those with HIV." (07/31/18)
     
  4965. IAC: HIV infection independently increases the risk of developing heart failure: The HIV HEART study - Mark Mascolini (07/30/18)
     
  4966. IAC: Very high levels of inflammation marker CRP in young MSM with or without HIV - Mark Mascolini (07/30/18)
     
  4967. IAC: Higher depression and anxiety rates with HIV across ART and viral load categories - Mark Mascolini (07/30/18)
     
  4968. IAC: Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA™ (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario (07/30/18)
     
  4969. IAC: Characterization of Doravirine-Selected Resistance Patterns From Participants in Treatment-Naïve Phase 3 Clinical Trials (07/30/18)
     
  4970. IAC: Surveillance for Neural Tube Defects following Antiretroviral Exposure from Conception (07/30/18)
     
  4971. IAC: Surveillance for Neural Tube Defects following Antiretroviral Exposure from Conception (07/30/18)
     
  4972. IAC: HIV-1 subtype (B or non-B) had no impact on the efficacy of B/F/TAF or resistance development in five phase 3 treatment-naïve or switch studies (07/30/18)
     
  4973. IAC: IL-10 contributes to and predicts viral persistence in ART-treated, SIV-infected rhesus macaques (07/30/18)
     
  4974. IAC: FDA-Approved Chemotherapeutic Drugs that Inhibit VEGF, RAF-1, B-RAF and the Proteosome Reverse HIV-1 Latency Without Global T cell Activation (07/30/18)
     
  4975. IAC: Understanding the Resistance Profile of the HIV-1 NNRTI Doravirine in Combination With the Novel NRTTI MK-8591 (07/30/18)
     
  4976. IAC: Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 24 Subgroup Analysis in Randomized Cohort Participants (07/27/18)
     
  4977. IAC: Durable Suppression 2 Years After Switch to DTG + RPV 2-Drug Regimen: SWORD-1 and SWORD-2 Studies (07/27/18)
     
  4978. IAC: Mortality and cause of death among HIV patients in London in 2016: 77% Die of Non-AIDS Conditions/Comorbidities/majority virally suppressed - Ending AIDS? Only applies to stopping new transmissions? (07/27/18)
     
  4979. IAC: Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to <6 years: results from IMPAACT P1093 (07/27/18)
     
  4980. IAC: Mortality 4.5 times higher in Canadian women with HIV than in general population - Mark Mascolini (07/27/18)
     
  4981. IAC: Patient Satisfaction, Tolerability and Acceptability of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting Therapy in HIV-1-Infected Adults: LATTE-2 Week 96 Results (07/27/18)
     
  4982. IAC: Emergence of resistance in HIV-1 Integrase following dolutegravir (DTG) treatment in 6 to <18 year old participants enrolled in the P1093 study (07/27/18)
     
  4983. IAC: Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/r) plus 2 NRTIs in second-line treatment - 48-week data from the DAWNING Study (07/27/18)
     
  4984. IAC: Pharmacokinetics, Safety, And Efficacy Of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Single-tablet Regimen In Children (6 To <12 Years) Living With HIV-1 (07/27/18)
     
  4985. IAC: B/F/TAF vs DTG/ABC/3TC or DTG + F/TAF in Treatment-Naïve Adults With High Baseline Viral Load or Low Baseline CD4 Count in 2 Phase 3 Randomized, Controlled Clinical Trials (07/27/18)
     
  4986. IAC: Efficacy and Safety of Switching From Boosted Protease Inhibitor-based Regimens to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide for Treatment of HIV-1 Infection: Subgroups Analysis by Baseline Regimen (07/27/18)
     
  4987. IAC: The Impact of Pre-exposure Prophylaxis with FTC/TDF on HIV Diagnoses, 2012-2016, United States (07/27/18)
     
  4988. IAC: Among 2590 US adolescents using PrEP, 83.5% are girls, 59% on Medicaid - Mark Mascolini (07/27/18)
     
  4989. IAC: Kaposi sarcoma incidence flat among black men in southern US (07/27/18)
     
  4990. IAC: Kaposi sarcoma incidence flat among black men in southern US - Mark Mascolini (07/27/18)
     
  4991. IAC: Incidence of HIV-infection in the ANRS Prevenir Study in the Paris Region with Daily or On Demand PrEP with TDF/FTC - (07/26/18)
     
  4992. IAC: Kaposi disease in HIV-infected patients with suppressed HIV viremia: the experience of the French national multidisciplinary committee ONCOVIH - New Kaposi disease in 21 people with 3 years of HIV control in France - Mark Mascolini (07/26/18)
     
  4993. IAC: DolPHIN-1: Randomised controlled trial of dolutegravir(DTG)-versus efavirenz(EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy - (07/26/18)
     
  4994. IAC: INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV CO-INFECTED ADULTS AT WEEK 48 - (07/26/18)
     
  4995. IAC: Universal test-and-treat improves population viral suppression in rural South Africa - Mark Mascolini -(07/26/18)
     
  4996. IAC: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in a Test-and-Treat Model of Care for HIV-1 Infection: Interim Analysis of the DIAMOND Study - (07/26/18)
     
  4997. IAC: Adolescent Use of Truvada (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: (2012-2017) - (07/26/18)
     
  4998. IAC: Adolescent Use of Truvada (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: (2012-2017) - (07/26/18)
     
  4999. IAC: Global Partners Pledge over $1.2 billion to Launch the MenStar Coalition (HIV in men) - (07/26/18)
     
  5000. IAC: ViiV Healthcare's commitments to accelerate the availability of dolutegravir for the treatment of HIV in children - (07/26/18)
     
  5001. IAC: Mortality after ART starts remains higher in women in Americas and Africa than in Europe - Mark Mascolini - (07/25/18)
     
  5002. IAC: Global Partners Pledge over $1.2 billion to & Launch the MenStar Coalition (HIV in men) - (07/25/18)
     
  5003. IAC: Beyond the 60s: Changing co-morbidities in people living with HIV aged over 60 attending clinic in 2010 and 2017 - (07/25/18)
     
  5004. IAC: HIV transmission risk through condomless sex in gay couples with suppressive ART: The PARTNER2 Study extended results in gay men - (07/25/18)
     
  5005. IAC: The Impact of Pre-exposure Prophylaxis With FTC/TDF on HIV Diagnoses, 2012-2016, United States - (07/25/18)
     
  5006. IAC: Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine - (07/25/18)
     
  5007. IAC: ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance - (07/25/18)
     
  5008. IAC: GILEAD SCIENCES PROVIDES GRANT TO AID FOR AIDS INTERNATIONAL TO EXPAND ACCESS TO HIV TREATMENT IN VENEZUELA - (07/25/18)
     
  5009. IAC: Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States - (07/25/18)
     
  5010. IAC: Dolutegravir/3TC noninferior to DTG/TDF/FTC at 48 weeks in big ART-naive group - Mark Mascolini (07/25/18)
     
  5011. IAC: Antiretroviral therapy (ART) interruption is associated with reduced cortical structures at age 5 years compared to uninterrupted. - (07/25/18)
     
  5012. IAC: Doravirine (DOR) Versus Ritonavir-Boosted Darunavir (DRV+r): 96-Week Results of the Randomized, Double-Blind, Phase 3 DRIVE-FORWARD Noninferiority Trial - (07/25/18)
     
  5013. IAC: the PARTNER Study: new results from PARTNER 2 - PDF - Q and A - (07/25/18)
     
  5014. IAC: Long-term data from APPROACH study - (07/25/18)
     
  5015. IAC: Variables Associated With Neuropsychiatric Symptoms in PLWH Receiving Dolutegravir-Based Therapy in Phase III Clinical Trials - (07/25/18)
     
  5016. IAC: PARTNER-2 Study No HIV transmissions in 8 years when gay HIV+ partner has undetectable load - Mark Mascolini (07/25/18)
     
  5017. IAC: Non-Inferior Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) vs DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in Antiretroviral Treatment-Naive Adults With HIV-1 Infection-Week 48 Results From the GEMINI Studies - (07/25/18)
     
  5018. IAC: Kick-and-kill with vaccines plus vorinostat has no impact on CD4 reservoir - Written by Mark Mascolini (07/24/18)
     
  5019. IAC: ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance - (07/24/18)
     
  5020. IAC: Rates of kidney and bone disease--and multiple comorbidities--rising in elderly HIV group - Written by Mark Mascolini (07/24/18)
     
  5021. CROI: Trends in Unsuppressed HIV RNA After Linkage to Care Among Key Populations - (07/24/18)
     
  5022. CROI: HIV Viral Suppression Assessed by Two Metrics in North Carolina during 2016 - (07/24/18)
     
  5023. CROI: Depression (24%) is Associated with Missed Visits, Emergency Room Utilization, and Drug Use - (07/24/18)
     
  5024. CROI: CLINIC-LEVEL FACTORS ASSOCIATED WITH TIME TO VIRAL SUPPRESSION IN WASHINGTON DC - (07/24/18)
     
  5025. IAC: Viral suppression for HIV treatment success and prevention of sexual transmission of HIV - (07/23/18)
     
  5026. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial - (07/23/18)
     
  5027. [low] HIV Viral Suppression, 37 States and the District of Columbia, 2014 - (07/23/18)
     
  5028. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine - (07/23/18)
     
  5029. What did we learn from the bictegravir switch studies? Comment - (07/23/18)
     
  5030. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial - (07/23/18)
     
  5031. Mortality in HIV - study Estimates Increased Death Risk of 1.6 vs General Population in HIV+ Over 50 Without Comorbidities, Higher in 65-70 Year Olds (2.5)....75% Over 45 Years Old in NY, SF, Boston, Florida - (07/23/18)
     
  5032. HIV+ Women's Issues - (07/23/18)
     
  5033. GILEAD SCIENCES AT THE 22ND INTERNATIONAL AIDS CONFERENCE (AIDS 2018) - For Immediate Release - (07/20/18)
     
  5034. FDA Approves Darunavir STR: DRV+Cobi+FTC+TAF - (07/19/18)
     
  5035. ViiV at IAS 2018 - ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018 - fostemsavir, DTG+3TC, DTG+RPV, Cabotegrvir - (07/19/18)
     
  5036. EATG Aging / HIV Project - Europe Addressing HIV & Aging - there is no such project in the USA. - (07/19/18)
     
  5037. Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection - (07/19/18)
     
  5038. Statins for the Elderly - efficacy ?? - (07/12/18)
     
  5039. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection - (07/12/18)
     
  5040. HPV Vaccine Anti-Cancer Treatments / HPV vaccine to treat patient with skin cancer - (07/10/18)
     
  5041. Managing blood pressure in older adults - Editorial - (07/10/18)
     
  5042. Aging/HIV - Gilead RFPs - (07/10/18)
     
  5043. Blood Telomere Length Changes after Ritonavir-boosted Darunavir Combined with Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-1 - (07/06/18)
     
  5044. Factors associated with deaths from suicide in a French nationwide HIV-infected cohort: mental health, substance abuse history, "Suicide prevention measures should target PLHIV with the psychological morbidities identified in our cohort." - (07/06/18)
     
  5045. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17 - (07/05/18)
     
  5046. PREP STIGMA AS A BARRIER TO UPTAKE - Women - Planned Parenthood Study - (07/05/18)
     
  5047. Factors associated with deaths from suicide in a French nationwide HIV-infected cohort - (07/05/18)
     
  5048. Blood Telomere Length Changes after Ritonavir-boosted Darunavir Combined with Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-1 - (07/05/18)
     
  5049. CROI: Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity - (07/05/18)
     
  5050. CROI: FAT QUALITY IS INDEPENDENTLY ASSOCIATED WITH CARDIOMETABOLIC RISK IN HIV INFECTION - (07/05/18)
     
  5051. CROI: HIV Immune Dysregulation Predicts Lean Tissue & Fat Changes During Chronic Disease - (07/05/18)
     
  5052. CROI: Lower Pretreatment Gut Integrity Associated With Fat Gains on Antiretrovirals - (07/05/18)
     
  5053. Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018 - (07/02/18)
     
  5054. Associations between antiretroviral use and subclinical coronary atherosclerosis..... - (06/28/18)
     
  5055. Cancer risk among the HIV-infected elderly in the United States - (06/22/18)
     
  5056. NIH: Is marijuana addictive? - Yes, You Can Become Addicted to Marijuana. And the Problem is Growing. - (06/15/18)
     
  5057. ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine - (06/15/18)
     
  5058. Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study - (06/13/18)
     
  5059. Older MACS Men - Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV - (06/12/18)
     
  5060. (MACS) Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected men - (06/12/18)
     
  5061. Travel Scholarships Available for the 2018 HIV Co-morbidity Workshop - NYC Oct 13-14 - (06/12/18)
     
  5062. ASM - Primary Efficacy Results of PRO 140 SC in a Pivotal Phase 2b/3 Study in Heavily Treatment-Experienced HIV-1 Patients - Mark Mascolini - (06/11/18)
     
  5063. HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies - (06/11/18)
     
  5064. Loneliness in Older Adults Living with HIV (58%) - (06/7/18)
     
  5065. TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy - (06/4/18)
     
  5066. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer - TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy - (06/4/18)
     
  5067. Pharm: Population pharmacokinetic analysis for darunavir and tenofovir alafenamide in HIV-1-infected patients on the darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (AMBER and EMERALD studies) - (06/4/18)
     
  5068. Pharm: SIMULATED PHARMACOKINETIC INTERACTIONS OF RIFAMPICIN WITH RITONAVIR-BOOSTED DARUNAVIR - (06/4/18)
     
  5069. Pharm: Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202 - (06/4/18)
     
  5070. Pharm: Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations - (05/31/18)
     
  5071. Pharm: Defining total-body AIDS-virus burden with implications for curative strategies - (05/31/18)
     
  5072. Recommendations Regarding the Use of Dolutegravir in Adults and Adolescents with HIV who are Pregnant or of Child-Bearing Potential - (05/30/18)
     
  5073. CROI: SWITCHING TO TAF IN EVG-BASED REGIMENS: CSF PHARMACOKINETICS AND ANTIVIRAL ACTIVITY - (05/30/18)
     
  5074. CROI: Seminal Tenofovir concentrations, viral suppression and semen quality with TAF vs TDF - (05/30/18)
     
  5075. Pharm: Differential brain tissue penetration of antiretrovirals and fluconazole - (05/30/18)
     
  5076. Pharm: Effects of Low and High Mineral Water Content on the Relative Bioavailability of a Co-Formulated TRIUMEQ (Abacavir/Dolutegravir/Lamivudine) Dispersible Tablet in Healthy Adults - (05/28/18)
     
  5077. Pharm: More than half of 75-and-older Swiss HIV group takes 5 or more non-ART drugs - Mark Mascolini (05/28/18)
     
  5078. Pharm: CSF is not on-target marker of antiretroviral and fluconazole levels in brain - Mark Mascolini (05/28/18)
     
  5079. Pharm: No oral cabotegravir dose adjustment expected with rifabutin - Mark Mascolini (05/28/18)
     
  5080. Pharm: Comparison of Relative Bioavailability of TIVICAY Immediate Release and Dispersible Pediatric Tablets to Immediate Release TIVICAY Adult Tablets - (05/28/18)
     
  5081. Pharm: Pharmacokinetics, Metabolism and Excretion of Radiolabeled Fostemsavir Administered With or Without Ritonavir in Healthy Male Subjects - (05/28/18)
     
  5082. Pharm: Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure Following Oral Co-administration - (05/28/18)
     
  5083. Pharm: Assessment of maternal and fetal dolutegravir exposure by integrating ex vivoplacental perfusion data and physiologically-based pharmacokinetic modeling - (05/28/18)
     
  5084. Pharm: Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon - (05/28/18)
     
  5085. Pharm: Bictegravir/Emtricitabine/Tenofovir Alafenamide Phase 3 Exposure-Response Analysis of Safety and Efficacy in the Treatment of HIV Infection - (05/28/18)
     
  5086. Pharm: PHARMACOKINETICS OF DOLUTEGRAVIR 100 MG ONCE-DAILY WITH RIFAMPICIN - (05/26/18)
     
  5087. Pharm: Elvitegravir pharmacokinetics during Pregnancy and Postpartum - (05/26/18)
     
  5088. Pharm: First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women - (05/26/18)
     
  5089. Pharm: Elvitegravir pharmacokinetics during pregnancy and postpartum Low elvitegravir troughs in third trimester confirm caution in pregnancy - Mark Mascolini - (05/25/18)
     
  5090. Pharm: First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women - Unbound dolutegravir trough similar in third trimester and postpartum - Mark Mascolini - (05/25/18)
     
  5091. Pharm: Elvitegravir pharmacokinetics during pregnancy and postpartum Low elvitegravir troughs in third trimester confirm caution in pregnancy - Mark Mascolini - (05/25/18)
     
  5092. Pharm: Does hepatic impairment affect the exposure of monoclonal antibodies? - Mark Mascolini - (05/25/18)
     
  5093. Pharm: Intracellular 007-TP Concentrations are Associated with Gradients of Adherence to Ledipasvir/Sofosbuvir - (05/25/18)
     
  5094. Pharm: Differing drug distribution in penis and rectum of men taking TDF/FTC PrEP - Mark Mascolini - (05/25/18)
     
  5095. Pharm: Adherence gradient strongly tied to sofosbuvir triphosphate level in HCV/HIV group - Mark Mascolini - (05/25/18)
     
  5096. Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study - (05/23/18)
     
  5097. CROI: Carotid IMT Progression is Most Striking in First 48 Weeks of Antiretroviral Therapy - (05/23/18)
     
  5098. CROI: Effects of Antiretroviral Therapy on Allele-Associated Lipoprotein(a) Levels in HIV - (05/23/18)
     
  5099. Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study - (05/22/18)
     
  5100. CROI: HIV+ Men Matched By Age And FRS With Controls Have More Cardiovascular Events - (05/22/18)
     
  5101. CROI: CARDIAC VENTRICULAR DISFUNCTION IN YOUNG VERTICALLY INFECTED HIV PATIENTS - (05/22/18)
     
  5102. CROI: Myocardial Steatosis in Relation to Cardiac Dysfunction Among Women Living with HIV - (05/22/18)
     
  5103. CROI: Coronary Arterial Wall Thickening and Association with Myocardial Diastolic Function in HIV - (05/22/18)
     
  5104. HHS - Statement on Potential Safety Signal in Infants Born to Women Taking Dolutegravir from the HHS Antiretroviral Guideline Panels - (05/21/18)
     
  5105. FDA Drug Safety Communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq) - (05/21/18)
     
  5106. Cutaneous Melanoma Risk among People with HIV in the United States and Canada - "These results suggest that HIV-induced immune dysfunction does not influence melanoma development." - (05/21/18)
     
  5107. Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV Following Dual CCR2 and CCR5 Antagonism - (05/21/18)
     
  5108. Janssen Announces European Commission Approval of JULUCA®∇ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1 - (05/21/18)
     
  5109. ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV - (05/21/18)
     
  5110. Increased dolutegravir peak concentrations in people living with HIV aged 60 and over and analysis of sleep quality and cognition - (05/17/18)
     
  5111. U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents - (05/17/18)
     
  5112. U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents - (05/16/18)
     
  5113. ATI and the Central Nervous System (CNS): Introduction - (05/16/18)
     
  5114. Impact of aging and HIV infection on serologic response to seasonal influenza vaccination - (05/15/18)
     
  5115. TMC120 displayed potent cytotoxic effect on human cervical carcinoma through enhancing the polymerization of microtubules - (05/15/18)
     
  5116. CROI: Mental Disability in HIV- Misunderstood & Unmet Need - (05/15/18)
     
  5117. CROI: The Mediterranean Portfolio diet in HIV dyslipidaemia: a pilot randomised controlled trial - (05/14/18)
     
  5118. Perinatally acquired HIV infection accelerates epigenetic aging in South African adolescents - (05/14/18)
     
  5119. Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia - (05/14/18)
     
  5120. CROI: Insurer Denial of DAA Prescription Requests Rising Across United States - Mark Mascolini (05/14/18)
     
  5121. CROI: Cardiovascular Update CROI 2018 - by Priscilla Hsue MD Professor of Medicine, UCSF - (05/11/18)
     
  5122. BHIVA - Muscle mitochondrial function and contemporary anti-retroviral therapy - (05/09/18)
     
  5123. HIV-Infected Women Gain More Weight than HIV-Infected Men Following the Initiation of Antiretroviral Therapy - (05/09/18)
     
  5124. Clinical Use of Brain Magnetic Resonance Imaging (MRI) for neurological symptoms in people with HIV - (05/08/18)
     
  5125. CROI: Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation - (05/8/18)
     
  5126. Dolutegravir and weight gain: an unexpected bothering side effect? - (05/07/18)
     
  5127. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens - (05/07/18)
     
  5128. Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals - (05/07/18)
     
  5129. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors - (05/04/18)
     
  5130. BHIVA - Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate -is there a true difference in efficacy and safety? - (05/04/18)
     
  5131. BHIVA - HIV as a risk factor in the initial presentation of a range of cardiovascular, coronary, cerebrovascular, and peripheral arterial diseases: a linked electronic health records study of 8 million adults in the UK - (05/04/18)
     
  5132. CROI: Longitudinal trajectory of brain volume and cortical thickness in primary infection - (05/04/18)
     
  5133. BHIVA - Supporting self-management of metabolic comorbidities in HIV: a multi-disciplinary model - (05/02/18)
     
  5134. EACS: Meta-analysis of safety for DTG versus other ARVs in randomized trials: Analysis of cardiovascular, CNS and IRIS endpoints - (01/04/18)
     
  5135. CROI: IMPACT OF PREVIOUS M184V ON VIROLOGICAL OUTCOME OF SWITCH TO 3TC-BASED DUAL THERAPIES - (05/01/18)
     
  5136. THERATECHNOLOGIES TO SEEK REGULATORY APPROVAL OF TROGARZO™ (IBALIZUMAB) IN EUROPE BASED ON EFFICACY AND SAFETY DATA USED FOR FDA APPROVAL - (05/01/18)
     
  5137. THERATECHNOLOGIES ANNOUNCES THAT TROGARZOTM (IBALIZUMAB-UIYK) INJECTION IS NOW AVAILABLE IN THE U.S. - (05/01/18)
     
  5138. BHIVA - Meta-analysis of dolutegravir for 7340 patients in 13 randomised trials: effects of current HIV RNA suppression on efficacy and safety - (05/01/18)
     
  5139. Disparities and determinants of cancer treatment in elderly Americans living with HIV/AIDS - (04/30/18)
     
  5140. Claims of sexual harassment and assault threaten UN agency - (04/30/18)
     
  5141. Editorial - UNAIDS - Sexual harassment and abuse-the sinister underbelly - (04/30/18)
     
  5142. HIV-infected people are living for years, but age-related diseases set in early - (04/23/18)
     
  5143. EASL: Safety And Efficacy At 1 Year After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide In Chronic HBV Patients With Risk Factors For TDF Use - (04/23/18)
     
  5144. CROI: Rapid reduction in HIV diagnoses after targeted PrEP implementation in New South Wales, Australia - (04/13/18)
     
  5145. A tale of two diseases: Aging HIV patients inspire a closer look at Alzheimer's disease - (04/11/18)
     
  5146. Bictegravir Phase 3 - (04/11/18)
     
  5147. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? - (04/11/18)
     
  5148. Grindr defends HIV-related data sharing - (04/11/18)
     
  5149. CROI: HIV Prevention at CROI 2018 and PrEP Updates on PrEP - Disparities; Current & Future; Delivery/Use/Barriers; Women. Transmission Clusters - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (04/9/18)
     
  5150. CROI: Clinical Pharmacology at CROI 2018 - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (04/9/18)
     
  5151. CROI: CROI 2018 Summary Report, Eric Daar M.D. - Boston, MA Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (04/4/18)
     
  5152. CROI: PrEP at CROI 2018 Report 2: uptake, HIV incidence; barriers/challenges - (04/10/18)
     
  5153. CROI: Geographic Access to PrEP Clinics among US MSM: Documenting PrEP Deserts - (04/10/18)
     
  5154. CROI: "RAPID REDUCTION IN HIV DIAGNOSES AFTER TARGETED PrEP IMPLEMENTATION IN NSW, AUSTRALIA" - PrEP NATAP Report 3 - (04/10/18)
     
  5155. CROI: Female HIV acquisition per sex act is elevated in late pregnancy and postpartum - (04/10/18)
     
  5156. CROI: Vaginal Contraceptive Hormone Exposure Profoundly Altered by EFV- And ATV/r-based ART AIDS Clinical Trials Group A5316 - (04/10/18)
     
  5157. CROI: RIFAMPIN EFFECT ON TENOFOVIR ALAFENAMIDE ONCE DAILY PLASMA AND INTRACELLULAR PHARMACOKINETICS - (04/10/18)
     
  5158. CROI: PrEP at CROI 2018 - (04/10/18)
     
  5159. CROI: Factors Impacting Appropriate HIV/STI Screening and PrEP Persistence in Primary Care in SF - (04/10/18)
     
  5160. CROI: STIMULANT USE AND CONDOMLESS SEX WITH MULTIPLE PARTNERS: EFFECT ON PREP ADHERENCE - (04/9/18)
     
  5161. CROI: High Discontinuation of Pre-Exposure Prophylaxis Within Six Months of Initiation - (04/9/18)
     
  5162. CROI: Predictors of Willingness to Take PrEP Among Black and Latina Transgender Women - (04/9/18)
     
  5163. CROI: Reported PrEP use among HIV-negative partners of US MSM receiving HIV medical care - (04/6/18)
     
  5164. CROI: HIV Risk Perception Among Men who have Sex with Men (MSM): A Randomized Controlled Trial - (04/6/18)
     
  5165. CROI: NEW DIAGNOSES OF HIV AMONG INJECTING DRUG USERS, NEW YORK CITY 2006-2016 - (04/6/18)
     
  5166. CROI: DRUG OVERDOSE DEATHS AMONG PERSONS WITH HIV IN NEW YORK CITY, 2007-2015 - (04/6/18)
     
  5167. CROI: Durability of Financial Incentives Effect on Viral Suppression and Continuity in Care - (04/6/18)
     
  5168. CROI: ART Reduces T Cell Activation and Immune Exhaustion Markers in HIV Controllers - (04/6/18)
     
  5169. CROI: In Silico Drug Interaction of Long-acting Rilpivirine and Cabotegravir With Rifampin - (04/6/18)
     
  5170. CROI: Female HIV acquisition per sex act is elevated in late pregnancy and postpartum - (04/6/18)
     
  5171. CROI: Reported PrEP use among HIV-negative partners of US MSM receiving HIV medical care - (04/5/18)
     
  5172. CROI: Assessing PrEP Needs Among Heterosexuals and People Who Inject Drugs, Washington, DC - (04/5/18)
     
  5173. CROI: Monitoring PrEP Use Among Washington State MSM: Results of an Internet Survey - (04/5/18)
     
  5174. CROI: HIGH SEROCONVERSION RATES FOLLOWING PrEP DISCONTINUANCE IN A MONTREAL CLINIC - (04/5/18)
     
  5175. CROI: DECREASES IN HIV INCIDENCE IN A MONTREAL CLINIC COINCIDE WITH EXPANDING PREP USE - (04/5/18)
     
  5176. CROI: PrEP USE HISTORY OF PERSONS NEWLY DIAGNOSED WITH HIV: NEW YORK CITY, 2015-2017 - (04/5/18)
     
  5177. CROI: Trends in PrEP Uptake, Adherence, and Discontinuation Among YMSM in Chicago - (04/5/18)
     
  5178. CROI: Patterns and Correlates of Participant Retention in the U.S. PrEP Demonstration Project - (04/5/18)
     
  5179. CROI: High Discontinuation of Pre-Exposure Prophylaxis Within Six Months of Initiation- Los Amgeles - (04/5/18)
     
  5180. CROI: INCREASING PREP UPTAKE, PERSISTENT DISPARITIES, IN AT-RISK PATIENTS IN A BOSTON COMMUNITY HEALTH CENTER - (04/5/18)
     
  5181. CROI: Seroconversion on PrEP [4th case]: A Protocol for Untangling Adherence vs. Resistance Failure - (04/4/18)
     
  5182. CROI: A Public Health Approach to Viremic Individuals With PrEP-resistant Virus - (04/4/18)
     
  5183. CROI: HIV Diagnoses Among People Who Inject Drugs -United States, 2010-2016 - (04/4/18)
     
  5184. CROI: Geographic Access to PrEP Clinics among US MSM: Documenting PrEP Deserts - (04/4/18)
     
  5185. Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial - (03/29/18)
     
  5186. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial - (03/29/18)
     
  5187. CROI: PREDICTORS OF PrEP ELIGIBILITY AMONG AT-RISK WOMEN IN THE SOUTHERN UNITED STATES - (03/29/18)
     
  5188. CROI: HIV BIOMEDICAL PREVENTION AMONG U.S. WOMEN: KNOWLEDGE, BELIEFS, AND PRACTICES - (03/29/18)
     
  5189. CROI: The PREP Cascade at NYC Sexual Health Clinics: Navigation is the Key to Uptake - (03/29/18)
     
  5190. CROI: PrEP Implementation and Persistence in a County Health Department in Atlanta, GA - (03/29/18)
     
  5191. CROI: Summary from CROI 2018 for viral Hepatitis HCV micro-elimination in HIV/HCV coinfection: successes and challenges - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/29/18)
     
  5192. CROI: A Multicenter Registry in HIV/HCV Co-infected Patients Initiating Ledipasvir/Sofosbuvir - (03/29/18)
     
  5193. CROI: HCV RNA and Antigen Detection for Diagnosis of Acute Hepatitis C Among MSM on PreP..... In the ANRS IPERGAY PrEP trial among high risk MSM - (03/29/18)
     
  5194. CROI: Nine of 100 MSM in German Cohort Get HCV Reinfection Every Year in DAA Era - Mark Mascolini (03/29/18)
     
  5195. Bictegravir Added to HHS Guidelines 1st-Line/Changes to Guidelines - (03/28/18)
     
  5196. CROI: Disparities in PrEP Uptake Among Primary Care Patients (03/28/18)
     
  5197. CROI: Getting to Zero New Diagnoses in San Francisco: The Potential Role of PrEP (03/28/18)
     
  5198. CROI: The PrEP Care Continuum and HIV Racial Disparities among Men Who Have Sex with Men (03/28/18)
     
  5199. CROI: By Race/ethnicity, Blacks Have Highest Number Needing PrEP in the United States, 2015 (03/28/18)
     
  5200. CROI: CVD Factors Tied to Cognitive Impairment Differ in Women and Men With HIV - Mark Mascolini (03/28/18)
     
  5201. CROI: The association of pain and long-term opioid therapy with HIV treatment outcomes - Chronic Pain Tied to Virologic Failure, While Long-Term Opioids Lower Odds of Failure - Mark Mascolini (03/28/18)
     
  5202. CROI: HCV incidence in HIV-infected and in PrEP-using MSM - New HCV Rate Similar in HIV+ MSM and HIV- MSM on PrEP in France - Mark Mascolini (03/27/18)
     
  5203. Bictegravir FDA Product Insert - BIKTARVY® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use Initial U.S. Approval: 2018 - (03/27/18)
     
  5204. CROI: Olfactory Mucosa HIV RNA Correlates With CSF RNA in People On/Off ART - Mark Mascolini (03/26/18)
     
  5205. CROI: QUANTIFICATION OF REPLICATION COMPETENT LATENT HIV-1 IN GALT AND SEMEN - Mark Mascolini (03/26/18)
     
  5206. CROI: High Level Resistance to Dolutegravir (DTG) after Emergence of T97A Mutation - Mark Mascolini (03/26/18)
     
  5207. CROI: Pharmacokinetcs of dolutegravir with and without darunavir/cobicistat in healthy volunteers (03/26/18)
     
  5208. CROI: Low Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations Across Botswana (03/26/18)
     
  5209. CROI: High Level Resistance to Dolutegravir (DTG) after Emergence of T97A Mutation (03/26/18)
     
  5210. CROI: Resistance Analyses of Bictegravir/Emtricitabine/Tenofovir Alafenamide Switch Studies (03/26/18)
     
  5211. CROI: [Bictegravir] Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1 (03/26/18)
     
  5212. CROI: PROGRESSIVE LYMPH NODE DYSFUNCTION DURING SIV INFECTION IS NOT REVERSED WITH ART (03/26/18)
     
  5213. CROI: Combined Effects of Bisphosphonates and TDF→TAF Switch in HIV+ Adults With Low BMD - Mark Mascolini (03/26/18)
     
  5214. CROI: Life Extectancy, Mental Comorbidities, Inflammation, /Anti-Inflammatories Drug Research - Life Expectancy Lags in Some HIV Groups: Black MSM, Drug Injectors, HCV+ (03/26/18)
     
  5215. CROI: Fat and Lean Mass Changes Similar With and Without HIV in Ireland Cohort - Mark Mascolini (03/23/18)
     
  5216. CROI: Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women - Cervical Outcomes Similar With Immediate Cryotherapy and Standard Cytology in HIV+ Women - Mark Mascolini (03/23/18)
     
  5217. CROI: CDC: Clinical outcomes of US young black men with HIV receiving medical care, 2009-2014 - More ART for Young Black Men in US, But Adherence and Suppression Flat - Mark Mascolini (03/23/18)
     
  5218. CROI: HIV Transmission Risk Higher With HIV+ Opioid Misusers, Especially Injectors - less adherence, viral suppression/more condomless sex - Mark Mascolini (03/23/18)
     
  5219. CROI: Comparing Strategies for Reducing Myocardial Infarction Rates in HIV Patients - Mark Mascolini (03/23/18)
     
  5220. CROI: HIV Diagnosis After Age 50 Often Delayed Despite Clear Clues - Should age-associated, Non-AIDS conditions Invite HIV Testing, YES - Mark Mascolini (03/23/18)
     
  5221. CROI: Prognosis Prediction in START Similar with IL-6, D-dimer, CD38s, and CD4:CD38 Ratio - Mark Mascolini (03/23/18)
     
  5222. CROI: New HCV Infections Still Rising Among MSM With HIV in France - Mark Mascolini (03/22/18)
     
  5223. CROI: Ablation Outcomes for HIV Infected and Uninfected Patients with High-Grade Anal Dysplasia (03/21/18)
     
  5224. CROI: CHANGES IN BRAIN VOLUME AND COGNITION IN MICE EXPOSED IN UTERO TO ABC/ 3TC-ATV/ RTV (03/21/18)
     
  5225. CROI: Safety, Pharmacokinetics, and Efficacy of FTC/TAF in HIV-Infected Adolescents (12-18 years) (03/21/18)
     
  5226. CROI: Comparative Impact of Antiretrovirals on Human Platelet Activation (03/21/18)
     
  5227. CROI: LEUKOCYTES ARE KEY TO THE PRO-THROMBOTIC EFFECTS OF ABACAVIR (03/21/18)
     
  5228. CROI: Antiretroviral Drugs Associated with Subclinical Coronary Artery Disease. (03/21/18)
     
  5229. CROI: HIV-1 VIRAL REBOUND AND SAFETY OUTCOMES OF POSTPARTUM TREATMENT INTERRUPTION IN WOMEN (03/21/18)
     
  5230. CROI: SHORT-TERM ART INTERRUPTION HAS LITTLE EFFECT ON LEVELS OF INTEGRATED PROVIRAL DNA (03/20/18)
     
  5231. CROI: A5340: BRIEF ATI DOES NOT ALTER THE SIZE OR COMPOSITION OF THE LATENT HIV-1 RESERVOIR (03/20/18)
     
  5232. CROI: Impact of Treatment Interruption on HIV Reservoirs and Immunologic Parameters (03/20/18)
     
  5233. CROI: QUANTIFICATION OF REPLICATION COMPETENT LATENT HIV-1 IN GALT AND SEMEN Replication Competent HIV-1 in Reservoir-GALT/Rectal/Semen/Blood - Mark Mascolini (03/20/18)
     
  5234. CROI: DETERMINANTS OF HIV-1 RESERVOIR SIZE AND LONG-TERM DYNAMICS UNDER SUPPRESSIVE ART - Mark Mascolini (03/20/18)
     
  5235. CROI: No Evidence for Ongoing HIV-1 Replication in Lymph Nodes During Suppressive ART - Mark Mascolini (03/20/18)
     
  5236. CROI: The Kidney at CROI 2018 -Christina Wyatt MD - Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY - (03/20/18)
     
  5237. CNS Monitoring of cART Interruption in Individuals Treated during Fiebig I Acute HIV - (03/18/18)
     
  5238. CROI: P38 MAPK in vivo inhibition impacts SIV-mediated immune activation & CD4 T-cell loss (03/16/18)
     
  5239. CROI: Prevalence of Active Hepatitis B Among New York City MSM Initiating PrEP and PEP, 2016-2017 (03/16/18)
     
  5240. CROI: IMPACT OF METHOTREXATE ON ARTERIAL INFLAMMATION IN PERSONS WITH TREATED HIV (03/16/18)
     
  5241. CROI: LONGITUDINAL COGNITIVE OUTCOMES AFTER TREATMENT IN ACUTE HIV INFECTION (03/16/18)
     
  5242. CROI: Results of ACTG A5288: A Strategy Study in RLS [resource limited setting] for 3rd Line ART Candidates (03/16/18)
     
  5243. CROI: METHAMPHETAMINE USE INDEPENDENTLY PREDICTS PREMATURE AGING IN HIV+ INDIVIDUALS (03/16/18)
     
  5244. CROI: Low Prevalence of Hepatitis C Virus Among New York City MSM Initiating PrEP and PEP, 2016-2017 at NYC Sexual Health Clinics (03/15/18)
     
  5245. CROI: A treatment as prevention trial to eliminate HCV in HIV positive men who have sex with men: The Swiss HCVree Trial - e-health assisted behavioral intervention to reduce risk in HCV re-infection in MSM - Mark Mascolini (03/15/18)
     
  5246. CROI: FUELING THE EPIDEMIC: Low Spontaneous HCV Clearance in Big European HCV/HIV Cohort - Mark Mascolini (03/15/18)
     
  5247. CROI: MITOCHONDRIAL DYSFUNCTION IN WELL-SUPPRESSED PERINATALLY HIV-INFECTED CHILDREN ON ANTIRETROVIRAL THERAPY (03/14/18)
     
  5248. CROI: ViiV Healthcare Announces Positive Action Southern Initiative Expansion and Request for Proposals (03/14/18)
     
  5249. CROI: Lopinavir/ritonavir Induces Mitochondrial Toxicity in HIV-exposed Uninfected Children (03/14/18)
     
  5250. CROI: Metabolic Shut Down of CD4 T Cells Activity Induced by HAART (03/14/18)
     
  5251. CROI: Statin exposure is associated with decreased risk of cancer - Mark Mascolini (03/14/18)
     
  5252. CROI: Change in Soluble Glycoprotein VI When Switching From ABC/3TC to TAF/FTC (03/14/18)
     
  5253. CROI: PLATELET FUNCTION UPON SWITCHING TO TAF VS CONTINUING ABC: A RANDOMIZED SUBSTUDY - Mark Mascolini (03/14/18)
     
  5254. CROI: Protection against repeated vaginal SHIV challenges by bNAb 3BNC117 and 10-1074 - Mark Mascolini (03/14/18)
     
  5255. CROI: Antiretroviral Therapy CROI 2018 New Agents/Combinations - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/13/18)
     
  5256. CROI: CROI 2018: Comorbidities and Inflammation - David H Shepp, MD Associate Professor of Medicine Zucker School of Medicine at Hofstra-Northwell Manhasset, NY - (03/13/18)
     
  5257. CROI: INCREASED RISK OF PERIPHERAL ARTERY DISEASE IN PERSONS WITH HIV COMPARED TO CONTROLS (03/13/18)
     
  5258. Recent abacavir use increases risk for Types 1 and 2 myocardial infarctions among adults with HIV (03/13/18)
     
  5259. CROI: Bictegravir at CROI (03/13/18)
     
  5260. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood - (03/12/18)
     
  5261. How Exercise May Help Protect Your Brain From Cognitive Decline and Dementia - (03/12/18)
     
  5262. CROI: HIV Incidence and Adherence in DREAM -An Open-Label Trial of Dapivirine Vaginal Ring (03/12/18)
     
  5263. CROI: 8 weeks of grazoprevir plus elbasvir for acute hepatitis C virus genotype 1 or 4 infection - the DAHHS 2 study - a single-arm, prospective, open-label, multicenter phase 3b trial (03/12/18)
     
  5264. CROI: BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/r AS FIRST LINE ART (03/12/18)
     
  5265. CROI: Amyloid uptake by PET imaging in older HIV+ individuals with cognitive impairment (03/12/18)
     
  5266. CROI: Asymptomatic Neurocognitive Impairment With HIV Marked by Brain Atrophy - Mark Mascolini (03/12/18)
     
  5267. CROI: Reversing Accelerated Aging in HIV patients: Metabolic and Mitochondrial Mechanisms (03/12/18)
     
  5268. CROI: LOWER MITOCHONDRIAL DNA COPY NUMBER IS ASSOCIATED WITH HIV & PREDICTIVE OF MORTALITY (03/12/18)
     
  5269. CROI: Cabotegravir long-acting protects macaques against repeated penile SHIV exposures (03/12/18)
     
  5270. CROI: IMPACT OF ART REGIMENS ON CSF VIRAL ESCAPE IN HIV-1 INFECTED ADULTS - Mark Mascolini (03/12/18)
     
  5271. CROI: Methotrexate Reins in CD38 Cells But Does Not Improve Endothelial Function - Mark Mascolini (03/12/18)
     
  5272. CROI: CROI - Non-AIDS Complications / Inflammation Markers-Kidney Disease-Plaque Predict Outcomes (03/12/18)
     
  5273. CROI: High HBV and HIV Suppression With Treatment of HIV/HBV Coinfection in B/F/TAF Studies (03/10/18)
     
  5274. CROI: NEUROIMAGING CORRELATES OF FRAILTY, COGNITION, AND HIV (03/09/18)
     
  5275. CROI: Virologic Response To 2-Drug ART Regimens Among Treatment-Experienced HIV+ Patients (03/09/18)
     
  5276. CROI: DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO-Recommended NRTI Backbone (03/09/18)
     
  5277. CROI: BRAIN 18F-FDG PET OF SIV-INFECTED MACAQUES AFTER TREATMENT INTERRUPTION OR INITIATION - s(03/09/18)
     
  5278. CROI: Oral TAF/FTC PrEP Prevents Vaginal SHIV Infection in Monkeys - Mark Mascolini (03/09/18)
     
  5279. CROI: IBALIZUMAB FDA Product Insert (03/09/18)
     
  5280. CROI: POORER NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART ACTG HIV Reservoirs Cohort study A5321 (03/09/18)
     
  5281. CROI: HIV-1 persists in CSF cells in half of individuals on long-term ART - Mark Mascolini (03/09/18)
     
  5282. CROI: New Positive Data on Trogarzo™ (ibalizumab-uiyk) Injection and EGRIFTA® (tesamorelin for injection) Presented at 25th Conference on Retroviruses and Opportunistic Infections (03/09/18)
     
  5283. CROI: SIV REBOUND IN THE SPINAL CORD AFTER STOPPING ART: A NOVEL CNS RESERVOIR (03/09/18)
     
  5284. CROI: Pharmacokinetics of Total and Unbound Darunavir in HIV-1-infected Pregnant Women Receiving a Darunavir/Cobicistat-based Regimen (03/09/18)
     
  5285. CROI: HIV Treatment-experienced Patients Switched to D/C/F/TAF: Age, Gender, and Race Analyses (03/09/18)
     
  5286. CROI: Analysis of HIV Patients Switching to D/C/F/TAF by Prior ARV Treatment Experience (03/09/18)
     
  5287. CROI: Retreatment of Hepatitis C Infection in Patients Who Failed Glecaprevir/Pibrentasvir (03/09/18)
     
  5288. CROI: Age, Gender, and Race Analyses of D/C/F/TAF in HIV-1 Treatment-naïve Patients (03/08/18)
     
  5289. CROI: IBALIZUMAB SUSCEPTIBILITY & Potency vs ART Resistance - New HIV Drug for Multi-Drug Resistant Patients (03/08/18)
     
  5290. CROI: Antiviral Activity of Tenofovir Alafenamide Against HIV-1 with Thymidine Analog Mutation(s) and M184V (03/08/18)
     
  5291. CROI: Efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in virologically-suppressed, treatment-experienced and treatment-naïve women with human immunodeficiency virus type 1 (03/08/18)
     
  5292. CROI: High uptake and reduced HIV-1 incidence in an open-label trial of the dapivirine ring (03/08/18)
     
  5293. CROI: The Rapid ART Program Initiative for HIV Diagnoses (RAPID) in San Francisco (03/08/18)
     
  5294. CROI: IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS (03/08/18)
     
  5295. CROI: EFV and ATV/r "Profoundly Alter" Levels of Vaginal Ring Hormonal Contraceptives - Mark Mascolini (03/07/18)
     
  5296. CROI: IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS - (03/07/18)
     
  5297. CROI: San Francisco RAPID ART Program Halves Span From HIV Diagnosis to Suppression - Mark Mascolini (03/07/18)
     
  5298. CROI: Starting ART on Day of Home HIV Test Improves Linkage, Viral Suppression - Mark Mascolini (03/07/18)
     
  5299. CROI: Hyperkyphosis and Aging in the Women's Interagency HIV Study - Mark Mascolini (03/07/18)
     
  5300. CROI: Impact of Low Dose Methotrexate on Immune Activation and Endothelial Function in Treated HIV - Mark Mascolini (03/07/18)
     
  5301. CROI: Statin Use Linked to Lower Cancer Risk With or Without HIV - Mark Mascolini (03/07/18)
     
  5302. CROI: No Evidence of Residual Virus Replication in a Randomised Controlled Trial of Dolutegravir Intensification - (03/07/18)
     
  5303. CROI: PGT121 Combined with GS-9620 Delays Viral Rebound in SHIV-Infected Rhesus Monkeys - (03/07/18)
     
  5304. CROI: Persistent Detection of HIV RNA+ Cells With ART Started in Fiebig 1 & 2 vs Fiebig 3-5 - (03/07/18)
     
  5305. CROI: ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis - (03/07/18)
     
  5306. CROI: Safety and Efficacy of E/C/F/TAF in HIV-Infected Adults on Chronic Hemodialysis - (03/07/18)
     
  5307. CROI: Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 - (03/07/18)
     
  5308. CROI: FDA approves new HIV treatment (Long-Acting Ibalizumab) for patients who have limited treatment options - (03/07/18)
     
  5309. CROI: SERIOUS CLINICAL EVENTS IN HIV-POSITIVE PERSONS WITH CHRONIC KIDNEY DISEASE (CKD) - D:A:D - (03/07/18)
     
  5310. CROI: IL-6, D-dimer or T-cells: which best predict events or explain benefits of early ART? - (03/07/18)
     
  5311. CROI: Progression of Coronary Plaque: The MACS Longitudinal Coronary CT Angiography Study" - Mark Mascolini (03/07/18)
     
  5312. CROI: Carotid Plaque Predicts All-Cause Mortality in Women and Men With HIV: "Association of carotid artery atherosclerosis with mortality in HIV+ women and men" - Mark Mascolini (03/07/18)
     
  5313. CROI: INSTI-based initial ART in the HIV Outpatient Study [Integrase s Non-Integrase Viral Suppression/Duration of ART] - (03/07/18)
     
  5314. CROI: Switching to RPV/FTC/TAF From RPV/FTC/TDF or EFV/FTC/TDF: Week 96 Results - (03/07/18)
     
  5315. CROI: Distribution of Active PrEP Prescriptions and the PrEP-to-Need Ratio, US Q2 2017 - (03/07/18)
     
  5316. CROI: Low-Dose Oral MK-8591 Protects Monkeys From Rectal SHIV Infection - Mark Mascolini (03/07/18)
     
  5317. CROI: Low-Dose Hydrocortisone Improves Learning and Memory in Women With HIV - Mark Mascolini (03/07/18)
     
  5318. CROI: High-Intensity Exercise Has Edge Over Moderate Intensity in Older Group With HIV - Mark Mascolini (03/06/18)
     
  5319. CROI: Integrase Inhibitor Penetration Generally Worse in Lymphoid Tissue Than Blood Cells - Mark Mascolini (03/06/18)
     
  5320. CROI: Antiretroviral Hair Levels Predict Failure in ACTG PI-Raltegravir Trial ACTG5257 - Mark Mascolini (03/06/18)
     
  5321. CROI: Multiple Low Doses of Nucleoside MK-8591 Strong in Healthy Volunteers - Long-Acting MK-8591 /Treatment / PrEP-vaginal/rectal tissue - Mark Mascolini (03/06/18)
     
  5322. CROI: Mortality Plateaued in 2001 in Large Baltimore Drug Injector Cohort / Mortality Steeply Increased due to Comorbidities - (03/06/18)
     
  5323. CROI: Pharmacokinetics of Bictegravir Administered Twice Daily In Combination With Rifampin - (03/06/18)
     
  5324. CROI: Similar Efficacy and Safety By Subgroup in DRIVE-AHEAD: DOR/3TC/TDF vs EFV/FTC/TDF - (03/06/18)
     
  5325. CROI: Bictegravir/FTC/TAF Single-Tablet Regimen in Adolescents: Week-24 Results - (03/06/18)
     
  5326. CROI: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Women - (03/06/18)
     
  5327. CROI: POORER NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART ACTG HIV Reservoirs Cohort study A5321 - (03/06/18)
     
  5328. CROI: Tenofovir Diphosphate in Dried Blood Spots is a Strong Predictor of Viral Suppression - (03/06/18)
     
  5329. CROI: Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen - (03/06/18)
     
  5330. CROI: DolPHIN-1: Dolutegravir vs Efavirenz when Initiating Treatment in Late Pregnancy - (03/06/18)
     
  5331. CROI: Impact of Raltegravir Intensification of first-line ART on IRIS in the REALITY trial (Reduction of EArly mortaLITY in HIV-infected adults and children starting ART) - (03/05/18)
     
  5332. CROI: MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV - (03/05/18)
     
  5333. CROI: Hair antiretroviral (ARV) levels strongly predict virologic outcomes in ACTG A5257 - (03/05/18)
     
  5334. CROI: Switch to Bictegravir/F/TAF Noninferior to Staying with DTG/ABC/3TC - written by Mark Mascolini (03/05/18)
     
  5335. CROI: Antiretroviral Hair Levels Predict Failure in ACTG PI-Raltegravir Trial - written by Mark Mascolini (03/05/18)
     
  5336. CROI: INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24 - (03/05/18)
     
  5337. CROI: Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy®(Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine - (03/05/18)
     
  5338. CROI: Switch to Bictegravir/F/TAF From DTG and ABC/3TC - (03/05/18)
     
  5339. LOW DOSE MK-8591 PROTECTS RHESUS MACAQUES AGAINST RECTAL SHIV INFECTION - (03/05/18)
     
  5340. CROI: NIH bNAB+PGT121 Keeps Viral Suppression in 45% of Monkeys After ART Stop - (03/05/18)
     
  5341. CROI: Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys - (03/05/18)
     
  5342. CROI: Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - (03/05/18)
     
  5343. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir with Once-Weekly Isoniazid and Rifapentine - (03/02/18)
     
  5344. New Cancer Guidelines Say HIV+ with Cancer Should get Appropriate Care - HIV+ are 2-3 times more likely to receive no cancer treatment - "Disparities in cancer treatment among patients infected with the human immunodeficiency virus" - (03/02/18)
     
  5345. HIV+ Women - Frailty / Falls / Fracture / Mortality - (03/02/18)
     
  5346. Aging in HIV-Infected Subjects: A New Scenario and a New View - (03/05/18)
     
  5347. New Cancer Guidelines: HIV+ 2-3 Times More Likely Not To receive Cancer Treatment. Cancer is 2nd Leading Cause of Death in HIV - (02/28/18)
     
  5348. Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: Implications for HIV-associated neurocognitive disorders (alzheimers in HIV+) - (02/28/18)
     
  5349. Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism - (02/28/18)
     
  5350. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women - (02/28/18)
     
  5351. Bone Mineral Density and Parathyroid Hormone as Independent Risk Factors for Mortality in Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study in Brazil. The Sao Paulo Ageing & Health (SPAH) Study - (02/28/18)
     
  5352. Gait Speed/Mitochondria/ Functional Decline in HIV+ - The Role of Mitochondrial DNA Variation in Age-Related Decline in Gait Speed Among Older Men Living with HIV - (02/28/18)
     
  5353. Bone Mineral Density and Parathyroid Hormone as Independent Risk Factors for Mortality in Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study in Brazil. The Sao Paulo Ageing & Health (SPAH) Study - (02/26/18)
     
  5354. Find drugs that delay many diseases of old age: class of drugs called geroprotectors / European Aging Researchers Unite for Aging Drug Development - (02/26/18)
     
  5355. Experienced HIV-Related Stigma in Health Care and Community Settings: Mediated Associations With Psychosocial and Health Outcomes - (02/23/18)
     
  5356. Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines - (02/23/18)
     
  5357. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial - (02/23/18)
     
  5358. Doxycycline post-exposure prophylaxis: let the debate begin - Comment - (02/23/18)
     
  5359. CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection - (02/23/18)
     
  5360. HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: a systematic review and meta-analysis - (02/23/18)
     
  5361. How Exercise May Help Protect Your Brain From Cognitive Decline and Dementia - (02/23/18)
     
  5362. Risks of HPV Infection in Men, Heterosexual Men, Screening - (02/23/18)
     
  5363. Nano-Formulated Long-Acting Dolutegravir - cell/tissue/reservoir penetration - (02/23/18)
     
  5364. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health - (02/23/18)
     
  5365. HIV: ageing, cognition and neuroimaging at 4-year follow-up - 'Accelerated Brain Aging' - (02/15/18)
     
  5366. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study - (02/14/18)
     
  5367. Vaginal microbes, inflammation, and HIV risk in African women - Comment - (02/12/18)
     
  5368. Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women - (02/12/18)
     
  5369. ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment (Dolutegravir+3TC) - (02/09/18)
     
  5370. 3TC - Epivir FDA Label, Prescribing Information, Product insert - (02/09/18)
     
  5371. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines - Perspective - (02/09/18)
     
  5372. U.S. Food and Drug Administration Approves Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection - (02/07/18)
     
  5373. (dolutegravir Generic) Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modeling study - (02/07/18)
     
  5374. Biohackers Disregard FDA Warning on DIY Gene Therapy - (02/07/18)
     
  5375. 'Block & Lock' Cure Approach - Exploiting immune cell metabolic machinery for functional HIV cure and the prevention of inflammaging - (02/07/18)
     
  5376. Gene Therapy Do-It-Yourself FDA WARNS of Dangers / Price Tag for Gene Therapy - (02/07/18)
     
  5377. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV - (02/07/18)
     
  5378. HIV Accelerates Brain Damage ; "Neurological Complications of HIV Infection" Review - (02/06/18)
     
  5379. FDA: Prezcobix Label Revised - (02/05/18)
     
  5380. FDA: Prezista Label Revised - (02/05/18)
     
  5381. Hypertension among persons living with HIV in medical care in the United States- Medical Monitoring Project, 2013-2014 - "We found that about 1 in 8 patients had undiagnosed and untreated hypertension." - (02/05/18)
     
  5382. Doctors Spend 30% of Their Time With Patient - (02/05/18)
     
  5383. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks (no benefit) - Meta-analysis of 10 Trials Involving 77 917 Individuals - (02/05/18)
     
  5384. CROI: HIV Cancer at CROI 2017 - (02/02/18)
     
  5385. CDC: Racial and Ethnic Disparities in Sustained Viral Suppression and Transmission Risk Potential Among Persons Receiving HIV Care - United States, 2014 - (02/02/18)
     
  5386. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study (HACM) - (02/02/18)
     
  5387. Cancers in HIV in Elderly - CD4 / Viral Load, Smoking, Lifestyle - (02/02/18)
     
  5388. MitoQ - An antioxidant to attenuate aortic aging / Mitochondria Treatment - (01/31/18)
     
  5389. Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes - (01/31/18)
     
  5390. Changes in viral suppression status among US HIV-infected patients receiving care - (01/31/18)
     
  5391. Single Viral Load Measurements Overestimate Stable Viral Suppression Among HIV Patients in Care: Clinical and Public Health Implications - (01/31/18)
     
  5392. Viral Suppression Patterns Among Persons in the United States With Diagnosed HIV Infection in 2014 - CDC - (01/31/18)
     
  5393. Long Term Outcomes: Mortality and Causes of Death in NAFLD - (01/30/18)
     
  5394. HIV & PTSD, Lifetime Trauma/Mental Health, Adherence - Aged HIV+ Deserve Better - (01/29/18)
     
  5395. WIHS HIV+ Women - More falls, comorbidities, cognitive impairment, isolation/loneliness, self-stigma, detectable viral load; CDC Viral Suppression is Over Estimated in the USA - (01/29/18)
     
  5396. Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression - (01/29/18)
     
  5397. Forgotten Aging HIV+ - An Explosive Devastating Problem Being Ignored - its scandalous - (01/24/18)
     
  5398. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer - (01/24/18)
     
  5399. PrEP - (01/24/18)
     
  5400. Marijuana / Cardiovascular Disease - (01/24/18)
     
  5401. Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in MenThe Cooper Center Longitudinal Study - (01/24/18)
     
  5402. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade - (01/24/18)
     
  5403. Coronary CT Angiography- Should We Use It? - (01/24/18)
     
  5404. Variable HIV Life Expectancy - (01/24/18)
     
  5405. Ten Take-Home Lessons From Top HIV-Aging Articles in 2017 - (01/22/18)
     
  5406. ViiV - Research study gathers real world insights from people living with HIV through mobile devices - (01/19/18)
     
  5407. Ageing-related receptors resolved - (01/19/18)
     
  5408. 'Liquid biopsy' for cancer promises early detection - (01/17/18)
     
  5409. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain - (01/17/18)
     
  5410. SVR in HIV/HCV Coinfected / DDIs - (01/17/18)
     
  5411. Brief Report: The Right People, Right Places, and Right Practices Disparities in PrEP Access Among African American Men, Women, and MSM in the Deep South - (01/17/18)
     
  5412. Partnerships Between a University-Affiliated Clinic and Community-Based Organizations to Reach Black Men Who Have Sex With Men for PrEP Care - (01/17/18)
     
  5413. Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States - (01/17/18)
     
  5414. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project - (01/17/18)
     
  5415. Combination ART: are two drugs as good as three? Comment - (01/13/18)
     
  5416. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies - (01/13/18)
     
  5417. Barriers & Challenges to Care - Gynecologic cancer in HIV-infected women: treatment and outcomes in a multi-institutional cohort - (01/11/18)
     
  5418. Psychiatric symptom burden in older people living with HIV with and without cognitive impairment: the UCSF HIV over 60 cohort study - (01/11/18)
     
  5419. Incidence of diabetes mellitus and factors associated with its development in HIV-positive patients over the age of 50 - at the clinic between 1997 and 2015 - (01/08/18)
     
  5420. HIV & Diabetes - risk factors/ARTs - (01/08/18)
     
  5421. FDA Accepts New Drug Applications for Merck's Doravirine, the Company's Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection - (01/08/18)
     
  5422. Doravirine Studies - efficacy, safety / FDA NDA Accepted - (01/08/18)
     
  5423. Accelerated Brain Aging: WHICH IS IT - No evidence for accelerated ageing-related brain pathology in treated HIV: longitudinal neuroimaging results from the Comorbidity in Relation to AIDS (COBRA) project - OR - Progressive Brain Atrophy Despite Persistent Viral Suppression in HIV Over Age 60 - (01/05/18)
     
  5424. HIV Cure: New Way to Find Hidden Cells Brings Scientists One Step Closer - (01/05/18)
     
  5425. A Cure for HIV? Cancer-Killing Immunotherapy Could Also Fight the Virus - (01/05/18)
     
  5426. EACS: HCV Reinfection Intervention in HCV/HIV MSM - Swiss Cohort - (01/04/18)
     
  5427. Inflammation-Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It? - (01/03/18)
     
  5428. Suicide in Aging Older HIV+ / Causes of Death in HIV-Infected Individuals with Immunovirologic Success in a National Prospective Survey - France - (01/03/18)
     
  5429. Selective suppression of inflammation could deplete HIV and control HIV activation - Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors - (01/03/18)
     
  5430. PrEP for IDUs - WHO, CDC, Study - (01/03/18)
     
  5431. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report - (01/03/18)
     
  5432. Gene therapy using CAR T-cells could provide long-term protection against HIV Public Release: 28-Dec-2017 - (01/03/18)
     
  5433. New HIV Drugs - Heavily Treated with Multi-Drug Resistance - (01/03/18)
     
  5434. Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men - (01/03/18)
     
  5435. Excess Clinical Comorbidity Among HIV-Infected Patients Accessing Primary Care in US Community Health Centers....[20% diabetes, 44% hypertension, 56% dyslipidemia, HPV, lymphoma & cancers were more prevalent in HIV+, so was stroke] - (12/22/17)
     
  5436. Institutionalizing HIV Healthcare - VALUE BASED CARE (VBC) is & will be a disaster - (12/21/17)
     
  5437. Eleven-year incident glucose disorders [45%] in treated HIV-infection. The St Vincent's HIV and Diabetes Study - (12/20/17)
     
  5438. Marijuana Reduced Neuro-Inflammation in vitro/new study/POT good or bad for you????? - (12/20/17)
     
  5439. Primary Prevention of Atherosclerosis Time to Take a Selfie? Editorial - Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors - (12/20/17)
     
  5440. Cure Research - Strategies to target HIV-1 in the central nervous system - (12/20/17)
     
  5441. Long-Term Outcomes of Diabetic Patients with Non-alcoholic Fatty Liver Disease (NAFLD) / HIV & the Liver, Fatty Liver/NALFD - (12/20/17)
     
  5442. HIV cure strategies [interruptions/viral rebound brain/immune affects]: response to ignore the central nervous system at your patients' peril - (12/20/17)
     
  5443. New Cure research studies, ART interruptions: biomarkers for viral rebound after interruptions, search for reservoirs where HIV rebounds from; intensified monitoring, safety concerns; patient consent - (12/20/17)
     
  5444. HIV cure strategies [interruptions/viral rebound brain/immune affects]: response to ignore the central nervous system at your patients' peril - (12/20/17)
     
  5445. Aging / HIV -USA - Time For Integrated Care / Beyond Viral Suppression / Payer Analysis - (12/15/17)
     
  5446. Social stress induces neurovascular pathology promoting depression - (12/14/17)
     
  5447. EACS: Characterization of the Aging Population Living with HIV in Portugal: a multicentre, observational study to evaluate comorbidities in patients above 50 years of age - AGING POSITIVE - (12/14/17)
     
  5448. apoB vs LDL/cholesterol - To help save the heart, is it time to retire cholesterol tests? - (12/13/17)
     
  5449. The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue - (12/13/17)
     
  5450. EACS: BESIDE - FIRST NATIONWIDE ANALYSIS OF RECREATIONAL/ILLICIT DRUG USE IN HIV-INFECTED INDIVIDUALS IN GERMANY SHOWS HIGH PREVALENCE OF SUBSTANCE ABUSE WITH A POTENTIAL FOR DRUG-DRUG INTERACTIONS WITH ANTIRETROVIRAL THERAPY - (12/13/17)
     
  5451. EACS: BESIDE - HIGH PREVALENCE OF COMORBIDITIES AND CONCOMITANT MEDICATION IN HIV-INFECTED PATIENTS IN GERMANY CARRIES A HIGH POTENTIAL FOR DRUG-DRUG INTERACTIONS WITH ANTIRETROVIRAL THERAPY - (12/13/17)
     
  5452. EACS: Safety and Efficacy of DTG+RPV in the Phase III SWORD-1 and SWORD-2 Studies: 48 Week Subgroup Analysis by Baseline Third Agent Class and Geographic Location - (12/13/17)
     
  5453. EACS: Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Results From the SWORD-1 and SWORD-2 Studies - (12/12/17)
     
  5454. ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women - (12/12/17)
     
  5455. ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine - (12/12/17)
     
  5456. HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders - (12/11/17)
     
  5457. FDA Ibalizumab Expected Approval Date / 2 New HIV Drugs for Heavily Treated with Multi-Drug resistance - (12/08/17)
     
  5458. Cancer rates Higher in HIV+ vs HIV- for many but not for all cancers - (12/08/17)
     
  5459. HIV New Cases among IDUs Alert / Mass Dept of Health - (12/11/17)
     
  5460. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States - (12/08/17)
     
  5461. HIV New Cases among IDUs Alert / Mass Dept of Health - Massachusetts Department of Public Health raises level of concern about increased HIV transmission through injection drug use, in light of the current epidemic of opiate/opioid misuse and recent observations. - (12/08/17)
     
  5462. Ixolaris Reduced Inflammation/Immune Activation, Prevented HIV Rapid Progression - (12/08/17)
     
  5463. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  5464. EACS: How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)
     
  5465. EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
     
  5466. JULUCA (dolutegravir and rilpivirine)FDA Prescribing Information - (12/07/17)
     
  5467. EACS: Aging in Portugal: The number of PLHIV aged 50+ will double in the next 20 years, representing 80% of the estimated overall prevalence in 2037. The proportion over 70 will increase 4.3 times going from 6% to 26%. - (12/06/17)
     
  5468. EACS: SAFETY ANALYSIS OF GERMAN REAL-LIFE COHORT WIP SHOWS LOW RATES OF NEUROPSYCHIATRIC EVENTS LEADING TO DISCONTINUATION OF RALTEGRAVIR THERAPY - (12/06/17)
     
  5469. ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV - (12/05/17)
     
  5470. HIV Cure Drugs Safety Issues - ART Interruption Brain Affects. HDAC Gene Changes Long Term Affects / Immune Checkpoint Cancer Drugs: cardiac toxicity - (12/05/17)
     
  5471. HIV Stigma / Women /Aging / Relationships / Isolation / Depression-Mental Health / CVD - (12/02/17)
     
  5472. - (12/05/17)
     
  5473. Does Social Isolation Predict Hospitalization and Mortality Among HIV+ and Uninfected Older Veterans? [yes] - (12/02/17)
     
  5474. European Researchers/Advocates Present HIV/Aging Recommendations/EATG to European Parliament - (12/02/17)
     
  5475. US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials - (11/29/17)
     
  5476. Ongoing HIV Replication During ART Reconsidered - (11/29/17)
     
  5477. Re-evaluating evolution in the HIV reservoir - (11/28/17)
     
  5478. FDA approves first two-drug regimen for certain patients with HIV - Fixed Dose dolutegravir and rilpivirine - FDA News Release - (11/28/17)
     
  5479. Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for themaintenance treatment of virologically suppressed HIV-1 infection - PRESS RELEASE - (11/28/17)
     
  5480. Stigma in HIV: 53% Report Social Stigma & 60% Report Self-Stigma.....high levels of depression, anxiety particularly for >50 Years Old - 63% Report 3 or more Comorbidities - (11/20/17)
     
  5481. Cardiovascular Disease & Risk Assessment in HIV - Editorial & New Study: "Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV" - (11/20/17)
     
  5482. New Hypertension Guidelines say systolic BP 120-129 & diastolic less than 80 are ELEVATED ! - (11/16/17)
     
  5483. EACS: Dynamics of viral rebound and development of resistance associated mutations in the DOlutegravir maintenance MONOtherapy (DOMONO) study. - (11/16/17)
     
  5484. EACS: Changes outside integrase in a patient failing on dolutegravir maintenance monotherapy points to a new resistance mechanism - (11/16/17)
     
  5485. Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018 - (11/16/17)
     
  5486. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  5487. IWCADRH: Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on Telomere Length Attrition in a Prospective Cohort of Aviremic HIV-Infected Participants - (11/10/17)
     
  5488. IWCADRH: RETROSPECTIVE OBSERVATIONAL STUDY TO DEFINE THE PREVALENCE OF SARCOPENIA IN HIV-INFECTED PATIENTS - (11/10/17)
     
  5489. IWCADRH: Intrahepatic triglyceride is more strongly associated with insulin-resistant glucose metabolism than visceral adiposity in HIV, and is improved with tauroursodeoxycholic acid (TUDCA) treatment - (11/10/17)
     
  5490. IWCADRH: Bone Mineral Density in a Cohort of Young Adult Women using Depo-provera and Tenofovir, Kampala, Uganda - (11/10/17)
     
  5491. IWCADRH: Bone density, microarchitecture and tissue quality after 48-weeks and 96-weeks of treatment with Tenofovir Disoproxil Fumarate. - (11/10/17)
     
  5492. IWCADRH: Analysis of serum metabolomics parameters associated with carotid intima-media thickness (c-IMT) and inflammation in HIV-infected, never-smoker men, naïve of ART or ART-controlled, compared to matched HIV-negative controls. - (11/10/17)
     
  5493. IWCADRH: A Randomized, Double-Blinded, Placebo-Controlled Trial of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection ACTG 5346 - (11/10/17)
     
  5494. IWCADRH: Patterns of Co-occurring Comorbidities in People Living with HIV - (11/10/17)
     
  5495. EACS: Weight Gain & Affects of Different cART Regimens: PIs, NNRTIs, Integrase - Mark Mascolini (11/08/17)
     
  5496. EACS: Higher Pre-ART Viral Load Predicts Death in 12,000-Person Italian Analysis - Mark Mascolini (11/08/17)
     
  5497. EACS: Treated people living with HIV show poorer cognitive performance at baseline but similar longitudinal changes over two years compared to appropriately chosen controls - (11/08/17)
     
  5498. Reducing Blood Pressure / Hypertension Targets - Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and MortalityA Systematic Review and Network Meta-analysis - (11/08/17)
     
  5499. CVD / Hypertension Targets in USA - "Maximizing Cardiovascular Event Reduction by Expanding and Intensifying the Targets" - (11/08/17)
     
  5500. EACS: Dolutegravir plus lamivudine maintains HIV-1 suppression through week 48 in a pilot randomized trial (ASPIRE) - (11/08/17)
     
  5501. EACS: Evolution of renal function during treatment with direct antiviral agents (DAA-t) in HIV/HCV infected patients in ICONA/HepaIcona cohorts - (11/08/17)
     
  5502. EACS: HIGH PREVALENCE AND BURDEN OF PAIN IN PEOPLE LIVING WITH HIV: THE POPPY STUDY - (11/08/17)
     
  5503. EACS: Associations Between Subcutaneous Fat Density and Metabolic and Inflammatory Biomarkers Differ by HIV Serostatus and Are Independent of Fat Quantity - (11/08/17)
     
  5504. IWCADRH: Utility of chronic kidney disease (CKD) risk prediction scores and the changing - prevalence of CKD has doubled from '09 to '15; risk scores are predictive - (11/06/17)
     
  5505. IWCADRH: Effect of Vitamin D Supplementation on Bone Turnover Markers (BTMs) During HIV Pre-Exposure Prophylaxis (PrEP) Using Tenofovir Disoproxil Fumarate-Emtricitabine (TDF-FTC) in Men who Have Sex with Men (MSM) A Matched Case-Control Substudy of CCTG 595 - (11/06/17)
     
  5506. IWCADRH: Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on Telomere Length Attrition in a Prospective Cohort of Aviremic HIV-Infected Participants - (11/06/17)
     
  5507. IWCADRH: Associations Between Subcutaneous Fat Density and Metabolic and Inflammatory Biomarkers Differ by HIV Serostatus and Are Independent of Fat Quantity - (11/06/17)
     
  5508. EACS: "Use of integrase inhibitors is an independent risk factor for immune reconstitution inflammatory syndrome (IRIS) in HIV-1 late presenters: an ATHENA cohort study" - Mark Mascolini (11/06/17)
     
  5509. EACS: Bigger Weight Gains With Contemporary PI Regimens Than With NNRTIs or INIs - Mark Mascolini (11/06/17)
     
  5510. EACS: Predictors of Stopping Dolutegravir or Elvitegravir in Large Netherlands Group - ATHENA Cohort - Mark Mascolini (11/06/17)
     
  5511. EACS: Impacts of HIV Duration (Under 10 vs Over 20 Years) in People 50 or Older - Mark Mascolini (11/06/17)
     
  5512. EACS: "Switching boosters: are they equal? An analysis of patients switching from ritonavir to cobicistat in a large London cohort" - Mark Mascolini (11/06/17)
     
  5513. EACS: Successful Attempt to Counter Hep A Outbreak in Paris MSM With HAV Vaccine - Mark Mascolini (11/06/17)
     
  5514. EACS: In Over-60 Group, Longer Known HIV Duration Tied to Kidney Disease - Mark Mascolini (11/06/17)
     
  5515. EACS: More HIV/STI Testing, Fewer Risk Habits With Chemsex Program for London MSM - Mark Mascolini (11/06/17)
     
  5516. EACS: Clinical outcomes among persons living with HIV (PLWH) initiating dolutegravir-based vs. other recommended regimens in clinical care from the Centers for AIDS Research Network of Integrated Systems (CNICS) - Mark Mascolini (11/06/17)
     
  5517. EACS: Twice-Daily TAF May Be Option With Rifampin for TB and HIV - Mark Mascolini (11/06/17)
     
  5518. EACS: Phase 3 randomized controlled trial of switching to emtricitabine/tenofovir alafenamide (F/TAF) from abacavir/lamivudine (ABC/3TC) in virologically suppressed adults: week 48 results - Mark Mascolini (11/06/17)
     
  5519. EACS: Switching from boosted protease inhibitors (PI/r) to dolutegravir (DTG) in virologically suppressed HIV-infected patients with high cardiovascular risk: 48-week effects on subclinical cardiovascular disease (CVD) - Mark Mascolini (11/06/17)
     
  5520. IWCADRH: Alterations of adipose tissue induced by HIV or SIV infection: Tat and Nef-induced senescence and fibrosis - (11/04/17)
     
  5521. IWCADRH: Frailty Predicts Recurrent but Not Single Falls 10 Years Later in HIV+ and HIV- Women - (11/04/17)
     
  5522. IWCADRH: Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCD ID Cohort - (11/04/17)
     
  5523. EACS: EU Patient Experience and Views on Antiretroviral Treatment: Findings From the Positive Perspectives Study - (11/02/17)
     
  5524. EACS: UNDERSTANDING PLWH AWARENESS AND WORRIES CONCERNING COMORBIDITIES AND OPTIMIZATION THERAPY: RESULTS FROM AN ITALIAN WEB SURVEY - (11/02/17)
     
  5525. EACS: Tolerability and persistence of dolutegravir-based regimens: Second interim analysis of the prospective multicenter DOL-ART cohort - (11/02/17)
     
  5526. EACS: Socio-structural Factors Surrounding Long Acting Injectable ART: A Qualitative Study Among PLHIV Participating in a Phase II Study of Cabotegravir + Rilpivirine (LATTE-2) in the US and Spain - (11/02/17)
     
  5527. EACS: Abacavir Hypersensitivity Reaction Reporting Rates in a Decade of HLA-B*5701 Screening as a Risk Mitigation Measure - (11/02/17)
     
  5528. EACS: Abacavir Usage Patterns and Hypersensitivity Reactions (HSR) in the EuroSIDA cohort - (11/02/17)
     
  5529. EACS: Rate of Progression to Osteoporosis in a Large Cohort of HIV-Infected Subjects. - (11/02/17)
     
  5530. EACS: Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Integrase inhibitors Results from the EuroSIDA study. - (11/02/17)
     
  5531. EACS: Effectiveness and tolerability of Triumeq(DTG/ABC/3TC) in routine clinical care in Germany: First interim analysis of the TRIUMPH cohort - (11/02/17)
     
  5532. EACS: Predictors of Changes in Bone Mineral Density and Proteinuria From 5 Randomized TDF-to-TAF Switch Studies: Pooled Analysis - full poster report - (11/02/17)
     
  5533. EACS: Predictors of Changes in Bone Mineral Density and Proteinuria from 5 Randomized TDF-to-TAF Switch Studies: Pooled Analysis - (11/02/17)
     
  5534. EACS: Twice Daily Administration of Tenofovir Alafenamide in Combination with Rifampin: Potential for Tenofovir Alafenamide Use in HIV-TB Coinfection - (11/02/17)
     
  5535. EACS: Planned 24-week analysis of two dolutegravir (DTG)-based simplification strategies - (11/02/17)
     
  5536. EACS: Relationships between bone density, bone quality and reported fractures within the HIV UPBEAT cohort - (10/31/17)
     
  5537. EACS: The contribution of HIV to reduced bone mineral density (BMD): the POPPY Study - (10/31/17)
     
  5538. EACS: Plasma and Seminal Pharmacokinetics of Etravirine and Raltegravir in a Dual Regimen maintenance strategy: ANRS-163 ETRAL - (10/31/17)
     
  5539. EACS: Efficacy of dolutegravir-based regimens in suppressing HIV-RNA in paired blood and semen samples in ART-naïve HIV-1 infected men - (10/31/17)
     
  5540. EACS: Dolutegravir-based Simplified Maintenance Therapy in HIV-infected Patients a Systematic Review and Meta-analysis - (10/31/17)
     
  5541. EACS: Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted protease inhibitor plus lamivudine for maintenance of virological suppression Gesida study 9717 - (10/31/17)
     
  5542. EACS: Subgroup Analyses From ONCEMRK: a Phase 3 Study of Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily in HIV-1-Infected Treatment-Naïve Adults at Week 96 - (10/31/17)
     
  5543. EACS: Subgroup Analyses From DRIVE-FORWARD, a Phase 3 Trial of Doravirine Versus Ritonavir-Boosted Darunavir in Treatment-Naïve HIV-1-Infected Participants at Week 48 - (10/31/17)
     
  5544. EACS: Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in antiretroviral treatment-naïve HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofoviralafenamide(D/C/F/TAF) versus darunavir/cobicistatplus emtricitabine/tenofovirdisoproxilfumarate - (10/30/17)
     
  5545. EACS: ABX464 Decreases Total HIV DNA and Integrated HIV DNA in PBMCs When Administered During 28 Days to HIV-infected Virologically Suppressed Patients - (10/30/17)
     
  5546. EACS: Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: Day 8 and Week 24 Primary Efficacy and Safety Results (BRIGHTE Study, Formerly 205888/AI438-047) - (10/30/17)
     
  5547. Bone and renal safety week 48 subgroup analysis of EMERALD: A Phase 3, randomised study evaluating switching from boosted protease inhibitors plus FTC/TDF to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults - 2/slides - (10/30/17)
     
  5548. EACS: Bone and renal safety Week 48 subgroup analysis of EMERALD:A Phase III, randomised study evaluating switching from boosted protease inhibitors plus FTC/TDF to darunavir/cobicistat/emtricitabine/tenofovir alafenamide(D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults - (10/30/17)
     
  5549. EACS: Relative Bioavailability of Darunavir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Single-Tablet Regimen When Administered as a Whole, Split, or Crushed Tablet - (10/30/17)
     
  5550. EACS: Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in antiretroviral treatment-naïve HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat plus emtricitabine/tenofovir disoproxil fumarate - (10/30/17)
     
  5551. EACS: High incidence of HCV reinfection in HIV-positive MSM in the DAA era - (10/30/17)
     
  5552. EACS: Big Gaps in HCV/HIV Care Continuum Across Europe at Start of 2015 - written by Mark Mascolini (10/30/17)
     
  5553. EACS: HCV Prevalence in HIV Patients Falls Nearly 50% in Spain in 1 Year - written by Mark Mascolini (10/30/17)
     
  5554. EACS: Impact of Diabetes and Age on Kidneys During DAA Therapy for HCV/HIV - written by Mark Mascolini (10/30/17)
     
  5555. EACS: Global Analysis Projects World Far From Goal of Eliminating HCV - written by Mark Mascolini (10/30/17)
     
  5556. EACS: High SVR 12 rates with grazoprevir/elbasvir ± ribavirin for 12-16 weeks guided by genotypic resistance testing among HIV/HCV coinfected MSM in the Swiss HCVree Trial (10/30/17)
     
  5557. EACS: Cure Rate 99% With Grazoprevir/Elbasvir in HCV/HIV-Infected MSM in Switzerland - written by Mark Mascolini (10/29/17)
     
  5558. EACS: Single-Tablet D/C/F/TAF Strong Through 48 Weeks in Naive AMBER Group - written by Mark Mascolini (10/29/17)
     
  5559. EACS: Women 65 or Older Have Worse Virologic Control Than Men in Italian Cohort - written by Mark Mascolini (10/29/17)
     
  5560. EACS: Atorvastatin Slows Kidney Function Drop More Than Nonstatin Antilipid Agents - written by Mark Mascolini (10/29/17)
     
  5561. EACS: Current Pain Risk Higher in Older HIV+ Group vs Older HIV- and Younger HIV+ - written by Mark Mascolini (10/29/17)
     
  5562. EACS: Nonavalent HPV Vaccine May Have Protected 77% of HIV+ Men With Anal HPV - written by Mark Mascolini (10/29/17)
     
  5563. EACS: Raltegravir/Etravirine Effective Maintenance Through 48 Weeks in 45 or Older Group - written by Mark Mascolini (10/29/17)
     
  5564. EACS: HIV Resistance Prevalence Flat in Italy Over Past 5 Years - written by Mark Mascolini (10/29/17)
     
  5565. EACS: AIDS, Liver Disease Down as Death Causes in Paris HIV Group; Cancer and CVD Up - written by Mark Mascolini (10/29/17)
     
  5566. EACS: Meta-analysis Finds Little Evidence of Worse Side Effect Rates With Dolutegravir - written by Mark Mascolini (10/29/17)
     
  5567. EACS: First-Line Responses Similar With Integrase Inhibitors and NNRTIs in UK - written by Mark Mascolini (10/29/17)
     
  5568. EACS: Resistance at Failure Less Likely With Dolutegravir Than Raltegravir or Elvitegravir - written by Mark Mascolini (10/29/17)
     
  5569. EACS: Antiretrovirals Pose Highest Cost in Large Swiss HIV Care Analysis - written by Mark Mascolini (10/29/17)
     
  5570. EACS: Bone Density Lower With Than Without HIV in People 50 or Older - written by Mark Mascolini (10/29/17)
     
  5571. EACS: Novel Antiretroviral Cuts HIV DNA in PBMCs When Added to Solo Darunavir - written by Mark Mascolini (10/29/17)
     
  5572. EACS: Meta-Analysis Sees Good Results With Dolutegravir-Based Dual Maintenance - written by Mark Mascolini (10/29/17)
     
  5573. EACS: Switch to Boosted PI/3TC Noninferior to Triple Therapy in 4-Trial Analysis - written by Mark Mascolini (10/29/17)
     
  5574. EACS: Single-Tablet D/C/F/TAF Strong Through 48 Weeks in Naive AMBER Group - written by Mark Mascolini (10/29/17)
     
  5575. Tivicay® and Celsentri® now included in the Essential Drug List in Russia - (10/28/17)
     
  5576. IDWeek: Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment (10/28/17)
     
  5577. IDWeek: Pharmacokinetics of Cabotegravir in Subjects With Severe Renal Impairment (10/28/17)
     
  5578. IDWeek: Pharmacokinetics of Cabotegravir in Subjects With Moderate Hepatic Impairment (10/28/17)
     
  5579. EACS: ViiV at EACS 2017 - Tackling HIV Challenges in Europe - (10/28/17)
     
  5580. EACS: New results from the Positive Perspectives global survey provide insights into the attitudes and perceptions of people living with HIV - self-stigma, treatment, attitudes - (10/26/17)
     
  5581. EACS: Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial - (10/26/17)
     
  5582. AASLD: No Resistance to Tenofovir Alafenamide Detected Through 96 Weeks of Treatment in Patients with Chronic Hepatitis B - (10/26/17)
     
  5583. Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1 - (10/18/17)
     
  5584. Updated - Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV - Oct 17 2017 - (10/18/17)
     
  5585. IAS: Metabolics at IAS 2017: bone, CVD, Comorbidities, Brain, Fatty Liver - (10/16/17)
     
  5586. Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research - (10/16/17)
     
  5587. Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir - (10/16/17)
     
  5588. Marijuana Use Impacts Midlife Cardiovascular Events in HIV-Infected Men in MACS - (10/16/17)
     
  5589. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation - (10/16/17)
     
  5590. IDWeek: HIV in the Brain - MANAGING COMORBIDITIES IN PATIENTS WITH HIV (10/16/17)
     
  5591. IDWeek: Medium Grade Proteinuria Is Not a Relevant Predictor of Chronic Kidney Disease in People Living with HIV/AIDS - Or Is It? (10/16/17)
     
  5592. IDWeek: Low Rate of Routine Proteinuria Screening among Male HIV Patients in an Urban Clinic (10/16/17)
     
  5593. IDWeek: Incidence of symptomatic CSF viral escape in HIV infected adults receiving atazanavir/ritonavir (ATV/r)-containing ART: A tertiary care cohort in western India (10/16/17)
     
  5594. IDWeek: Three-Part Strategy Boosts Extragenital STI Screening 23% in HIV Clinic - Mark Mascolini (10/13/17)
     
  5595. IDWeek: High Comfort Level With STI Self-Tests in HIV Group; Results Match Provider Tests - Mark Mascolini (10/13/17)
     
  5596. IDWeek: Primary Care Providers Have Limited Knowledge About STI Screening And HIV PrEP in Men Who have Sex with Men - Training Did Not Improve Provider Knowledge of STIs and PrEP for MSM - Mark Mascolini (10/13/17)
     
  5597. IDWeek: Three Quarters of Women in HIV Group May Have ART-Hormonal Interactions - Mark Mascolini (10/13/17)
     
  5598. IDWeek: Age, Gender, Race Predict Long-Term PrEP Adherence in Large Veterans Group - Mark Mascolini (10/13/17)
     
  5599. IDWeek: Should Guidelines Shorten Virologic Failure Cutoff for Integrase Inhibitors? - Mark Mascolini (10/13/17)
     
  5600. HIV Viral Suppression in USA, and Non-Adherence - (10/13/17)
     
  5601. IDWeek: Two Thirds in South Carolina With New HIV Missed Chance to Use PrEP - "Missed Opportunities to Initiate HIV Pre-exposure Prophylaxis in South Carolina - 2013-2016"....women, Blacks, young, MSM (10/12/17)
     
  5602. IDWeek: Cancer mortality among persons with Human Immunodeficiency Virus Infection, New York City, 2001-2015 - Lung (most) & Liver Cancer, Breast Cancer, Colorectal Cancers, Non-Hodgkins Lymphoma; RISK FACTORS: low CD4, unsupressed viral load; IDU; Hispanic (10/12/17)
     
  5603. IDWeek: Risk Behavior--and Sex Partner Type--Predict PrEP Adherence in MSM - Mark Mascolini (10/12/17)
     
  5604. IDWeek: Access to Online Tools Boosts Chances of HIV Control in Large US Group - "ASSOCIATION BETWEEN PATIENT PORTAL ACCESS & VIRAL SUPPRESSION AMONG PEOPLE LIVING WITH HIV" - Mark Mascolini (10/12/17)
     
  5605. IAS: LONG-ACTING IBALIZUMAB SUSCEPTIBILITY IN MULTI-DRUG RESISTANT HIV PATIENTS - (10/12/17)
     
  5606. Brain Damage - Cannabis / Nicotine / Stimulants (Cocaine/Meth), HIV - (10/13/17)
     
  5607. Cure Studies/ART Interruption & Brain Affects, Vorinostat - (10/13/17)
     
  5608. IDWeek: Similar Frequency of New HIV in US Group 45 or Older vs Younger - (10/11/17)
     
  5609. IDWeek: Prevalence of systemic hypertension among HIV-infected and HIV-uninfected young adults - Young Adults Perinatally Infected With HIV Run Higher Hypertension Risk - Mark Mascolini (10/11/17)
     
  5610. IDWeek: Effect of a multidisciplinary intervention for early ART initiation for inpatients with newly diagnosed HIV: Inpatient Program Yields Higher Linkage and ART Rates in Atlanta Hospital - Mark Mascolini (10/11/17)
     
  5611. IDWeek: Linkage and Anti-Retroviral Therapy Initiation Within 72-hours at a Ryan White-Funded FQHC in the Deep South in New Orleans - Mark Mascolini (10/11/17)
     
  5612. IDWeek: Under One Third of ID Fellows Think They Got Enough Training on ART or PrEP - Mark Mascolini (10/11/17)
     
  5613. IDWeek: 48-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1 - (10/11/17)
     
  5614. IDWeek: Cancer mortality among persons with Human Immunodeficiency Virus Infection, New York City, 2001-2015 - Lung (most) & Liver Cancer, Breast Cancer, Colorectal Cancers, Non-Hodgkins Lymphoma; RISK FACTORS: low CD4, unsupressed viral load; IDU; Hispanic (10/12/17)
     
  5615. IDWeek: Fatty Liver Disease in HIV: Predictors and Response to Statin Therapy - (10/11/17)
     
  5616. IDWeek: Faster Fatty Liver Progression With Statin Than Placebo in SATURN HIV Trial - Mark Mascolini (10/11/17)
     
  5617. AGE: Aging and Antiretroviral Neurotoxicity - - (10/11/17)
     
  5618. IDWeek: Trends and Associations with PrEP Prescription among 602 NYC Ambulatory Care Practices, 2014-16...... "PrEP prescriptIon increased 976% between Q1 2014 to Q2 2016 among 602 ambulatory care practIces in NYC" - (10/11/17)
     
  5619. IDWeek: Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Patients Coinfected With HCV GT 1 and HIV-1 - (10/11/17)
     
  5620. IDWeek: Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir among patients co-infected with HIV and HCV: Real World Data in a Black Population - (10/11/17)
     
  5621. IDWeek: High Asymptomatic STI Prevalence and Incidence in French MSM Starting PrEP - Mark Mascolini - (10/10/17)
     
  5622. IDWeek: Trends and Associations with PrEP Prescription among 602 NYC Ambulatory Care Practices, 2014-16......"PrEP prescriptIon increased 976% between Q1 2014 to Q2 2016 among 602 ambulatory care practIces in NYC" - (10/10/17)
     
  5623. IDWeek: Phase 3 Randomized, Controlled Trial of Switching to Fixed-Dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-Based Regimens in Virologically Suppressed Adults: Week 48 Results - (10/10/17)
     
  5624. IDWeek: Impact of Tablet Burden and Antiretroviral Therapy (ART) Choice on Virologic Outcomes in Treatment-Naive HIV+ Individuals Attending an Inner City Clinic - (10/10/17)
     
  5625. IDWeek: Switch to Darunavir/C/FTC/TAF Noninferior to Continued PI Plus TDF/FTC - Mark Mascolini - (10/10/17)
     
  5626. IDWeek: SWORD-1 & SWORD-2: Subgroup Analysis of 48-Week Results by Age, Race and Gender - Maintenance With DTG/RPV Effective Regardless of Age, Sex, or Race - Mark Mascolini - (10/10/17)
     
  5627. IDWeek: Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in HIV-Infected, Virologically Suppressed, Black and Nonblack Adults Through Week 96: Subgroup Analysis of a Randomized Switch Study - - (10/10/17)
     
  5628. IDWeek: Lack of Clinically Relevant Effect of Bictegravir on Metformin Pharmacokinetics and Pharmacodynamics - (10/10/17)
     
  5629. IDWeek: Viral Failure Among Persons Living with HIV Initiating Dolutegravir-Based vs. Other Recommended Regimens in Real-World Clinical Care Settings - (10/10/17)
     
  5630. IDWeek: Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data From Clinical Trials - (10/10/17)
     
  5631. IDWeek: Selected CNS Outcomes Among a Large Sample of Patients Treated with INSTI Antiretrovirals - (10/09/17)
     
  5632. IDWeek: Real-World Experience with Higher-Than-Recommended Doses of Lamivudine in Patients with Varying Degrees of Renal Impairment - (10/09/17)
     
  5633. IDWeek: WEIGHT GAIN AFTER SWITCH FROM EFAVIRENZ-BASED TO INTEGRASE INHIBITOR-BASED REGIMENS - Atripla-to-Integrase Inhibitor Switch Tied to Weight Gain Over 18 Months - Mark Mascolini - (10/09/17)
     
  5634. IDWeek: Three Quarters of International HIV Group Worry About Long-Term Effects of ART - "Patient Experience and Views on Antiretroviral Treatment-Findings From the Positive Perspectives Study" - Mark Mascolini - (10/09/17)
     
  5635. IDWeek: SWORD-1 & SWORD-2: Subgroup Analysis of 48-Week Results by Age, Race and Gender - (10/09/17)
     
  5636. IDWeek: A Randomized Trial of Bictegravir or Dolutegravir With Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open-label Switch to Bictegravir/F/TAF Fixed-Dose Combination - High Virologic Response Rates With Bictegravir or Dolutegravir Plus FTC/TAF - Mark Mascolini - (10/09/17)
     
  5637. IDWeek: Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial - (10/09/17)
     
  5638. IDWeek: Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens - (10/09/17)
     
  5639. IDWeek: Week 48 results of EMERALD: A Phase 3, randomized, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults - (10/09/17)
     
  5640. IDWeek: The Incidence and Risk Factors Associated with Chronic Liver Enzyme Elevation (cLEE) in HIV-Monoinfected Persons - Antiretroviral Use and Race Predict High Liver Enzymes in HIV-Monoinfected - Mark Mascolini - (10/09/17)
     
  5641. IDWeek: Echocardiography Spots Abnormalities in up to 26% of Air Force Members With Early HIV - Mark Mascolini - (10/09/17)
     
  5642. AGE: Current Reality: The San Francisco Experience / SF Aging Clinic: reality switch from 1990 to 2018 / a crisis ignored by many - written by Mark Mascolini - (10/06/17)
     
  5643. AGE: Hearing Loss and Quality of Life in Middle-Aged With or Without HIV - written by Mark Mascolini - (10/06/17)
     
  5644. AGE: NY Cornell Aging / Geriatric Clinic - Current Reality: The New York Experience - - (10/06/17)
     
  5645. AGE: Subjective and Objective Fatigue Greater in Older Group With vs Without HIV - written by Mark Mascolini - (10/06/17)
     
  5646. AGE: Adherence to Recommendations from Comprehensive Geriatric Assessment in an HIV+ Population - written by Mark Mascolini - (10/04/17)
     
  5647. IDWeek: Low Dietary Calcium Tied to Low Bone Density With HCV But Not HIV - Mark Mascolini - (10/06/17)
     
  5648. IDWeek: Incidence of Herpes Zoster in a Large Cohort of Persons Living with HIV - Herpes Zoster Incidence Falling in HIV Group But Still at 1% in 2011-2016 - Mark Mascolini - (10/06/17)
     
  5649. IDWeek: Two Thirds of HIV Group Who Need Statins Not Getting Them - Mark Mascolini - (10/06/17)
     
  5650. IDWeek: Framingham Cardio Risk Score Twice Higher in Premenopausal Women With HIV - Mark Mascolini - (10/06/17)
     
  5651. IDWeek: Multiple Missed Chances to Prevent Heart Disease in Urban HIV Clinic - Mark Mascolini - (10/06/17)
     
  5652. IDWeek: Low Screening Rates for HBV, HCV, and Diabetes in NYC HIV Cohort - Mark Mascolini - (10/06/17)
     
  5653. AGE: Adherence to Recommendations from Comprehensive Geriatric Assessment in an HIV+ Population - written by Mark Mascolini - (10/04/17)
     
  5654. AGE: Cognitive Impairment in Symptomatic HIV over age 60 - written by Mark Mascolini - (10/04/16)
     
  5655. AGE: Limited evidence of biological aging in early-treated HIV-infected children - written by Mark Mascolini - (10/04/17)
     
  5656. AGE: Lean Mass Declines Consistently Over 10 Years in HIV-Infected Adults on Antiretroviral Therapy, with Patterns Differing by Sex - written by Mark Mascolini - (10/04/17)
     
  5657. Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab Presented at IDWeek 2017™ - (10/04/17)
     
  5658. AGE: Metformin suppresses human CMV infection - written by Mark Mascolini - (09/27/17)
     
  5659. AGE: Antiretroviral Therapy Does Not Dial Back Advanced Epigenetic Age With HIV - written by Mark Mascolini - (10/03/17)
     
  5660. HIV Prematurely Ages the Brain: "Effect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study" - (10/02/17)
     
  5661. Long-Acting HIV PrEP & Treatment for Women & Men / Once A Month or 8 Weeks Injection - (10/02/17)
     
  5662. Sclerostin Inhibition for Osteoporosis [Romosozumab]- A New Approach - Editorial - (10/02/17)
     
  5663. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis - (10/02/17)
     
  5664. New Bone Drug: Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis - (10/02/17)
     
  5665. Hearing Loss and HIV....MACS & WIHS - (10/02/17)
     
  5666. ECLAIR Study of Cabotegravir (CAB) LA Injections: Characterization of Safety and PK During the "PK Tail" Phase - (10/02/17)
     
  5667. 2008-2011 / HIV 13 Year Gap Life Expectancy Projected HIV+ vs HIV-Neg: 11 years for Whites; 13 yrs for Blacks; Hispanic 16 yrs. - (09/29/17)
     
  5668. New Long Acting Potent Nuke MK-8591 + Doravirine Phase 2B Study Starts - (09/27/17)
     
  5669. GLASGOW: HIV+ Aging, Comorbidites & Mortality in Belgium - (09/26/17)
     
  5670. GLASGOW: Frailty in HIV+ in Italy....average age only 49 but 12% frail, 28% pre-frail, 33% some measure of depression, 51% cognitive impairment. - (09/26/17)
     
  5671. GLASGOW: Use of dolutegravir in combination with rifampicin based TB therapy in HIV/TB co-infected patients - (09/26/17)
     
  5672. IAS: Optimism and concern at IAS 2017 - Comment - (09/26/17)
     
  5673. IAS: Ending AIDS: myth or reality? New Infections Increase in Key Populations, UN Update - (07/23/17)
     
  5674. Reyataz Reduced CVD Risk - (09/25/17)
     
  5675. IAS 2017 Cure Workshop Report/Abstracts Published - (09/25/17)
     
  5676. Generic $75 Dolutegravir Fixed Dose - New single-day pill (dolutegravir) for HIV treatment promises more bang for less buck - (09/25/17)
     
  5677. Three-in-one antibody protects monkeys from HIV-like virus: NIH and Sanofi scientists prepare to test antibody in people - (09/25/17)
     
  5678. Reyataz Reduced CVD Risk - (09/25/17)
     
  5679. IAS 2017 Cure Workshop Report/Abstracts Published - (09/25/17)
     
  5680. New single-day pill (dolutegravir) for HIV treatment promises more bang for less buck - (09/25/17)
     
  5681. Three-in-one antibody protects monkeys from HIV-like virus: NIH and Sanofi scientists prepare to test antibody in people - (09/25/17)
     
  5682. IAS: Ending AIDS: myth or reality? New Infections Increase in Key Populations, UN Update - (07/23/17)
     
  5683. Increased brain-predicted aging in treated HIV disease - - (09/22/17)
     
  5684. HIV Broadly Neutralizing Antibodies Research; treatment/cure/interruptions - (09/22/17)
     
  5685. Three-in-One Antibody Protects Monkeys from SHIV - HIV-Like Virus - (09/20/17)
     
  5686. Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus - (09/20/17)
     
  5687. IAS: 2 ART Interruption Cure Studies at IAS 2017 - (09/20/17)
     
  5688. Mitochondrial energetics in the kidney.... "Hyperglycaemia is the main factor that contributes to the development of diabetic nephropathy" - (09/19/17)
     
  5689. Outdated HIV HealthCare Models - high need, aging ignored - (09/18/17)
     
  5690. ART Interruption Associated with HIV in the Brain: "Reseeding CNS during ART Interruption Leading to Intrathecal Immune Activation" - "HIV-1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment" - (09/18/17)
     
  5691. ARTs Brain Penetration: - do we need it? risks? / Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV - (09/15/17)
     
  5692. HIV Drug Pipeline - (09/14/17)
     
  5693. Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect - (09/14/17)
     
  5694. Ending AIDS - What is the Real prospect: New Infections Up in Key Populations, Unsupressed Viremia High in Key Populations - (09/14/17)
     
  5695. IAS: IAS 2017 Summary Report - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (09/03/17)
     
  5696. Aging with HIV: Redesigning healthcare models - (09/13/17)
     
  5697. HIV & Sleep Disorders: 100% of HIV+ with cognitive impairment have sleep disorder study reports - (09/11/17)
     
  5698. Stigma in HIV+ : 60% experience self-stigma....going along with this is 63% of older HIV+ have 3+ comorbidities which can only worsen stigma & self-stigma - (09/11/17)
     
  5699. Aging With HIV: Expert Insights on Complications and Challenges - (09/11/17)
     
  5700. Fats/Carbohydrates PURE Study Refuted by AHA - (09/11/17)
     
  5701. Fruits, vegetables, and legumes: sound prevention tools Comment questioning PURE study results - (09/11/17)
     
  5702. Fruits, vegetables, and legumes: sound prevention tools - Comment - (09/11/17)
     
  5703. Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease and Lung Cancer- CANTOS Study - (09/11/17)
     
  5704. Long acting injectable Cabotegravir for PrEP is in Phase 3 [every 4 or 8 weeks] - (09/09/17)
     
  5705. EASL: Hepatic Fibrosis is Associated With Histological Activity in Non-alcoholic Steatohepatitis: an Analysis From a Large Database of Screening Biopsies in the CENTAUR Trial - (09/09/17)
     
  5706. IAS: IAS: Stigma, New HIV Infections Up in Key Populations, PrEP Access Disparities, Poor Adherence in Medicaid, High Comorbidities in Canada, Immunosenescence in HIV+ Kids, Health Outcomes-Women who have Sex with Women/Transgender Women-US - (09/07/17)
     
  5707. IAS: Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum - (09/07/17)
     
  5708. IAS: Dolutegravir / tenofovir / emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz / tenofovir / emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana - (09/07/17)
     
  5709. IAS: Pharmacokinetic (PK) Modelling and Simulation to Support Weight-Based Dosing of Maraviroc (MVC) in Pediatric Subjects When Co-administered With Potent CYP3A Inhibitors - (09/07/17)
     
  5710. IAS: Maraviroc Pharmacokinetics and Dosing Recommendations in CCR5-Tropic HIV-1-Infected Children Aged 2 to <18 Years - (09/07/17)
     
  5711. IAS: Longer-Term Safety of Maraviroc in Pediatric Patients With R5 HIV: Follow-up Data From Study A4001031 - (09/07/17)
     
  5712. IAS: Uptake of HLA-B*5701 Screening and Its Impact on Clinically Suspected Hypersensitivity Reaction to Abacavir in the OPERA Observational Database - (09/07/17)
     
  5713. IAS: Inhibiting memory CD4+ T-cell self-renewal to reduce HIV persistence - (09/07/17)
     
  5714. IAS: Atypical Mutations for RAL Resistant Clinical Isolates and Associated Integrase Strand Transfer Inhibitor Susceptibility With Public Algorithms With Public Algorithms - (09/07/17)
     
  5715. IAS: The Effect of Fostemsavir on Methadone and The Effect of Fostemsavir on Methadone and Buprenorphine Pharmacokinetics - (09/07/17)
     
  5716. IAS: The Effect of Fostemsavir on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone (NE) in Healthy Female Subjects - (09/07/17)
     
  5717. IAS: Pregnancy and Neonatal Outcomes following Prenatal Exposure to Dolutegravir - (09/07/17)
     
  5718. IAS: Safety, Efficacy, and Dose-Response of GSK3532795/BMS-955176 Plus Tenofovir/Emtricitabine in Treatment-Naïve HIV-1-Infected Adults: Week 24 Primary Analysis - (09/07/17)
     
  5719. IAS: Resistance Profile of HIV-1 Maturation Inhibitor GSK3532795 / GSK28338232 - (09/07/17)
     
  5720. IAS: An Analysis of Neurologic and Psychiatric Adverse Events of Subjects Receiving the Investigational HIV-1 Maturation Inhibitor (MI) GSK3532795/BMS-955176 - (09/07/17)
     
  5721. IAS: BMD After Switch to Dolutegravir+Rilpivirine - (09/07/17)
     
  5722. IAS: IAS: How Many on PrEP in USA - Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (09/07/17)
     
  5723. IAS: Generic treatments for HIV, HBV, HCV, TB could be mass produced for < $90 per patient - (09/07/17)
     
  5724. IAS: Barriers to uptake of pre-exposure prophylaxis among respondents to the Flash! - PrEP in Europe survey - (09/02/17)
     
  5725. IAS: Pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in the Netherlands: motives to choose for, switch to, or stop with daily or event-driven PrEP - (09/02/17)
     
  5726. IAS: Self-Report and Medication Possession Ratio are Accurate Measures of HIV Pre-Exposure Prophylaxis Use in a Real-World Clinical Setting - (09/02/17)
     
  5727. First CAR T-Cell 'Living Drug' Approved by FDA / Safety Concerns - (09/02/17)
     
  5728. Trends in ART Prescription and Viral Suppression Among HIV-Positive Young Adults in Care in the United States, 2009-2013 - "sustainably virally suppressed significantly increased (29%-46%)" - (09/02/17)
     
  5729. Redefining HIV Preexposure Prophylaxis Failures - PrEP at Kaiser - (09/02/17)
     
  5730. Reassessing the benefits of plant-based eating (PURE) - fruit, vegetables, legumes - CVD risk, mortality - (09/01/17)
     
  5731. Stressed brain, stressed heart?..... Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study - (09/01/17)
     
  5732. CVD-PCSK9 Repatha Outcomes Study FOURIER - (09/01/17)
     
  5733. 3 studies report Hearing Loss in HIV is Worse and Suggests that Aging Worsens Hearing - (09/01/17)
     
  5734. Aging with HIV in U.S. Trans NIH Research Themes - (09/01/17)
     
  5735. Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients - (09/01/17)
     
  5736. HIV & Value Based Healthcare? .....Incorporating Geriatric Consultation Into HIV Care / Employers Plans for Value Based healthcare' - (09/01/17)
     
  5737. From One Syndrome to Many: Incorporating Geriatric Consultation Into HIV Care - (09/01/17)
     
  5738. Geriatric-HIV Medicine Is Born - Commentary - (09/01/17)
     
  5739. Fatty Liver in HIV+ / Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease - (09/01/17)
     
  5740. Antiretroviral initiation is associated with increased skeletal muscle area and fat content - (08/14/17)
     
  5741. Senescence, Telomerase, Aging HIV - (08/14/17)
     
  5742. IAS: Bone Mineral Density at the Hip Declines Twice as Quickly Among HIV-Infected Women than Men - (08/14/17)
     
  5743. IAS: HIV Prevention at IAS 2017 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (08/14/17)
     
  5744. Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (08/11/17)
     
  5745. IAS: PrEP at IAS 2017 / IAS Coverage: New HIV & HCV Drugs, Fatty Liver in HIV - (08/11/17)
     
  5746. IAS: Peripheral blood and cerebrospinal fluid viremia of 24-weeks MONOtherapy of DOlutegravir in HIV-1 virologically suppressed patients: MONODO study - (08/10/17)
     
  5747. IAS: Higher HDL, better brain? Higher HDL cholesterol is associated with better cognition in a cohort of older persons living with HIV infection - (08/10/17)
     
  5748. IAS: Fatty Acid Profiles Altered by HIV Infection Persist Despite Suppressive Antiretroviral Therapy (ART) and are Associated with Immune Activation in the ACTG 5248 Study - (08/10/17)
     
  5749. IAS: No HIV Infections With Generic TDF/FTC PrEP in Large London Group - Mark Mascolini (08/10/17)
     
  5750. IAS: Beyond viral suppression: the quality of life of people living with HIV in Sweden / EATG Aging/HIV Call To Action: 'Beyond Viral Suppression' - (08/09/17)
     
  5751. IAS: Microglial Cells That Are Latently Infected By HIV Are Activated By Inflammatory Stimuli and Induce Neuronal Damage - (08/09/17)
     
  5752. IAS: Prevalence over time and predictive factors of HIV-associated neurocognitive disorder (HAND) in HIV-positive patients - (08/09/17)
     
  5753. IAS: Assessing depression's impact on neurocognitive performance in the NAMACO study - (08/09/17)
     
  5754. IAS: New HIV & HCV Drugs at IAS / Dual ARTs / Fatty Liver in HIV+ - (08/09/17)
     
  5755. Cerebral blood flow and cognitive function in HIV-infected men with sustained suppressed viremia on combination antiretroviral therapy - (08/08/17)
     
  5756. HIV - The Brain, Exercise, Diet, Comorbidities, BBB, CNS Penetration, Cure, Interruptions - (08/08/17)
     
  5757. Diet/Brain-Heart Connection - (08/08/17)
     
  5758. IAS: Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) Event Rates in HIV-positive Persons at high Predicted CVD and CKD Risk: Results from the D:A:D Study - Combining Heart and Kidney Risk Scores Improves Prediction in HIV Group - Mark Mascolini (08/08/17)
     
  5759. IAS: Health behaviors and outcomes in a U.S. cohort of transgender women in HIV care - (08/08/17)
     
  5760. IAS: More Depression, Worse Quality of Life in Transgender Women vs Men With HIV - Mark Mascolini (08/08/17)
     
  5761. IAS: Cerebral Small Vessel Disease Signal Similar in Older Men With vs Without HIV - Mark Mascolini (08/08/17)
     
  5762. IAS: Inflammation and Obesity Tied to Incident Diabetes in Veterans With HIV - Mark Mascolini (08/07/17)
     
  5763. IAS: Effects of Syringe Distribution Policy Change at A Syringe Services Program in Baltimore, MD: A Forecast Analysis - (08/07/17)
     
  5764. IAS: Good HIV-Related Diarrhea Control With 20 to 24 Weeks of Crofelemer - Mark Mascolini (08/07/17)
     
  5765. IAS: Only 5% DAA Failure Rate in Large French Cohort With HCV/HIV - Mark Mascolini (08/07/17)
     
  5766. IAS: HIV Risk Factors and Associated Health Outcomes Among Sexual Minority Women in the United States - Sexual Violence, Drug Injecting, Risky Sex With Men Tied to STI Risk in US Lesbians - Mark Mascolini (08/07/17)
     
  5767. IAS: Widening Needle Distribution Cuts New HIV Cases in Baltimore - Mark Mascolini (08/07/17)
     
  5768. IAS: Estimating HIV incidence and the undiagnosed HIV population in the European Union/European Economic Area - Estimated 120,000 People With Undiagnosed HIV Across Europe in 2015 - Mark Mascolini (08/07/17)
     
  5769. IAS: Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents - Dapivirine Vaginal Ring Safe and Acceptable in US Adolescents - Mark Mascolini (08/07/17)
     
  5770. IAS: An Open Label Multiple Dose Phase 1 Assessment of Long Acting Rilpivirine - Long-Acting Rilpivirine Suppresses Replication in Rectal Explants - Mark Mascolini (08/07/17)
     
  5771. IAS: Half of HIV+ Medicaid Users Have Poor Adherence, Driving Up Costs - Mark Mascolini (08/07/17)
     
  5772. IAS: Half of HIV+ Medicaid Users Have Poor Adherence, Driving Up Costs - Mark Mascolini (08/06/17)
     
  5773. IAS: Atrial Fibrillation at an Earlier Age in People With HIV Infection - Mark Mascolini (08/06/17)
     
  5774. IAS: HIV Linked to Decreased Erectile Function in MSM 45 or Older - comorbidities, depression, frailty - Mark Mascolini (08/06/17)
     
  5775. IAS: Asians, Blacks, Young People Fall Short in US Viral Suppression Comparison - Mark Mascolini (08/06/17)
     
  5776. IAS: Fatty Liver in HIV+ at IAS - (08/05/17)
     
  5777. IAS: Mortality Benefit From DAAs Most Likely With Advanced Fibrosis in Canada - Trends in cause-specific mortality in HIV-HCV co-infected patients in Canada (2003-2016): Early impact of HCV therapy - Mark Mascolini (08/04/17)
     
  5778. IAS: HIV Disclosure Crime Convictions Differ by Race/Gender, Gay/Straight Status in US - Mark Mascolini (08/04/17)
     
  5779. IAS: PIs Plus Tenofovir Not Tied to Fracture in French Case-Control Study - Mark Mascolini (08/04/17)
     
  5780. IAS: No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus - Mark Mascolini (08/04/17)
     
  5781. IAS: Low HIV+ Cell Tally in Blood, Colon, Lymph Nodes in Earliest Infection Phase - Mark Mascolini (08/04/17)
     
  5782. IAS: TCM CD4 T cell infection extent before ART associated with immune failure and HIV persistence on ART - (08/04/17)
     
  5783. IAS: Successful switch to once-daily single-tablet regimen (STR) containing elvitegravir (EVG) or dolutegravir (DTG) in virologically suppressed HIV-1 infected patients despite archived resistant quasispecies - (08/04/17)
     
  5784. IAS: COMORBIDITIES IN PATIENTS LIVING WITH HIV (PLWHIV) COMPARED TO MATCHED NON HIV CONTROLS: AN EPIDEMIOLOGICAL ANALYSIS USING A CLAIMS DATABASE IN FRANCE - (08/04/17)
     
  5785. IAS: Switch to Dolutegravir Noninferior to Continued PI in Older Group With Heart Risk - Mark Mascolini - (08/04/17)
     
  5786. IAS: Overweight/Obesity Rate Rises After SVR in HCV/HIV-Coinfected People - Mark Mascolini - (08/04/17)
     
  5787. IAS: Depression, Brain Changes & cART in HIV+ / Role of basal ganglia in depression in HIV-infected individuals - (08/03/17)
     
  5788. IAS: One-year experience with Pre-Exposure Prophylaxis (PrEP) Implementation in France with TDF/FTC - (08/03/17)
     
  5789. IAS: Is on-demand PrEP with TDF/FTC effective among MSM with infrequent sexual intercourse? - (08/03/17)
     
  5790. IAS: More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex - (08/03/17)
     
  5791. IAS: Prevalence of Comorbidities and Impact of HIV and Comorbidities on Health Care Resource Utilization - (08/03/17)
     
  5792. IAS: Potential for HIV transmission among adolescents and young adults receiving antiretroviral therapy - 'PrEP missed opportunities' - (08/03/17)
     
  5793. IAS: Zoledronic Acid Boosts Bone Density More Than Switch From TDF - Mark Mascolini - (08/03/17)
     
  5794. IAS: Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (08/02/17)
     
  5795. IAS: Limited implementation of HIV pre-exposure prophylaxis among public health departments in North Carolina, United States - (08/02/17)
     
  5796. IAS: Impact of microbiota on female genital tissue and plasma concentrations of dapivirine - (08/02/17)
     
  5797. IAS: Experience of Living With HIV: Diagnosis and Disclosure - Findings From the Positive Perspectives Study - self-stigma is high, 63% of older HIV+ have 3+ Comorbidities - (08/02/17)
     
  5798. IAS: Dolutegravir Use During Pregnancy and Birth Outcomes: Data From the Antiretroviral Pregnancy Registry (APR) - (08/02/17)
     
  5799. IAS: Efficacy and Safety of Switching From RPV/FTC/TDF or EFV/FTC/TDF to RPV/FTC/TAF in Black Adults - (08/02/17)
     
  5800. IAS: Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir DF in HIV-Infected, Virologically Suppressed, Older Adults at Week 96: Subgroup Analysis of a Randomized Switch Study (Study 311-1089) - (08/02/17)
     
  5801. IAS: Adults With Renal Impairment Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety Through 144 Weeks - (08/02/17)
     
  5802. IAS: Factors associated with the occurrence of suicide among French people living with HIV in the HAART era: a nested case-control study in the Dat'AIDS cohort - (08/02/17)
     
  5803. IAS: T cell immune exhaustion in gut-associated lymphoid tissue during treated primary HIV infection: Implications for HIV persistence - (08/02/17)
     
  5804. IAS: Experiences and perceptions of PrEP among gay, MSM, and TGW in the PROUD study in England: 'Rules' of Sex, Psychological, Psychosocial Benefits - Mark Mascolini - (07/31/17)
     
  5805. IAS: Reasons for not using PrEP in a national on-line sample of U.S. men who have sex with men (MSM) - Cost, Side Effects, Access Lead Reasons for PrEP Nonuse by US MSM - Mark Mascolini - (07/31/17)
     
  5806. IAS: Maintenance Therapy With 400/100 mg of Darunavir/Ritonavir for 48 Weeks - Mark Mascolini - (07/31/17)
     
  5807. Cabotegravir-LA Safe in Women, Challenges Remain - (07/31/17)
     
  5808. ECLAIR Study of Cabotegravir (CAB) LA Injections: Characterization of Safety and PK During the "Pk Tail" Phase - (07/31/17)
     
  5809. IAS: Overweight/Obesity Rate Rises After SVR in HCV/HIV-Coinfected People - Mark Mascolini (07/31/17)
     
  5810. IAS: Early initiation of antiretroviral treatment post SIV infection does not resolve lymphoid tissue activation - (07/31/17)
     
  5811. IAS: HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual-therapy DTG+3TC in the maintenance DOLULAM pilot study - (07/31/17)
     
  5812. IAS: Adherence intentions, long-term adherence and HIV acquisition among PrEP users in the PROUD open-label randomised control trial of PrEP in England - (07/31/17)
     
  5813. IAS: Long term follow up of PROUD Evidence for high continued HIV exposure and durable effectiveness of PrEP - (07/31/17)
     
  5814. IAS: HIV mediated immunosenescence in young adults infected at birth [and HIV+ adults too despite undetectable VL] - (07/31/17)
     
  5815. IAS: Prolonged HIV-1 Remission in an Individual Treated During Hyperacute Infection - (07/31/17)
     
  5816. IAS: Evidence of production of HIV-1 proteins from "defective" HIV-1 proviruses in vivo: Implication for persistent immune activation and HIV-1 pathogenesis - (07/31/17)
     
  5817. IAS: ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml - (07/31/17)
     
  5818. IAS: ABX464 decreases total HIV DNA in PBMC's when administered during 28 days to HIV-infected patients who are virologically suppressed - (07/28/17)
     
  5819. IAS: New HIV Down in US MSM in 2008-2014, But Up in Hispanics, Younger Men - Mark Mascolini (07/28/17)
     
  5820. IAS: Is on-demand PrEP a suitable tool for MSM who practice chemsex? Results from a sub-study of the ANRS-IPERGAY trial - Chemsex Users in IPERGAY Twice as Likely to Use As-Needed PrEP - Mark Mascolini (07/28/17)
     
  5821. IAS: Evaluation of the risk of birth defects among children exposed to raltegravir in utero in the ANRS-French Perinatal Cohort EPF - Raltegravir Not Tied to Birth Defects in French Study of 479 Births - Mark Mascolini (07/28/17)
     
  5822. IAS: Heightened Risk of Peripheral Arterial Disease With HIV in Veterans (07/27/17)
     
  5823. IAS: Maintenance With Raltegravir/Etravirine Strong at 48 Weeks in Older Adults - Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial - Mark Mascolini (07/27/17)
     
  5824. IAS: CDC Transmission Study Puts Hispanic MSM at Leading Edge of HIV Spread - Analysis of U.S. HIV sequence data indicates that recent and rapid HIV transmission is focused among young Hispanic/Latino men who have sex with men - Mark Mascolini (07/27/17)
     
  5825. IAS: No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus - Mark Mascolini (07/27/17)
     
  5826. IAS: Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial - (07/27/17)
     
  5827. IAS: Slowing the premature aging process: the benefits of viral control and smoking cessation on telomere length - (07/27/17)
     
  5828. IAS: Phase 3 Randomized, Controlled, Clinical Trial of Bictegravir Coformulated With FTC/TAF in a Fixed-Dose Combination vs Dolutegravir + FTC/TAF in Treatment-Naïve HIV-1-Positive Adults: Week 48 Results - (07/27/17)
     
  5829. IAS: Impact of exposure to each antiretroviral treatment (ARV) on the risk of fracture in HIV-infected individuals - (07/27/17)
     
  5830. IAS: Sub-Study 202094 of SWORD-1 and SWORD-2: Switch From TDF-Containing Regimen to DTG + RPV Improves Bone Mineral Density and Bone Turnover Markers Over 48 Weeks - (07/26/17)
     
  5831. IAS: Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days - (07/26/17)
     
  5832. IAS: New HIV Drugs, Aging, Life Expectancy - (07/26/17)
     
  5833. IAS: Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral therapy - (07/26/17)
     
  5834. IAS: Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17)
     
  5835. IAS: New Nonnuke Doravirine Strong as Single-Tablet Regimen With TDF/3TC - Mark Mascolini - (07/26/17)
     
  5836. IAS: HIV Viral Remission in Child with Perinatal HIV - (07/25/17)
     
  5837. IAS: Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days - (07/25/17)
     
  5838. IAS: Merck's Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - (07/25/17)
     
  5839. IAS: Dolutegravir-Lamivudine as initial therapy in HIV-1 infected, ARV-naïve patients: 96 week results of the PADDLE trial - (07/25/17)
     
  5840. IAS: Fixed-Dose Combination of Doravirine/Lamivudine/TDF is Non-Inferior to Efavirenz/Emtricitabine/TDF in Treatment-Naïve Adults With HIV-1 Infection: Week 48 Results of the Phase 3 DRIVE-AHEAD Study - (07/25/17)
     
  5841. IAS: Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study - (07/25/17)
     
  5842. IAS: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxilfumarate regimens to the single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofoviralafenamide(D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults through 24 weeks: EMERALD Study - (07/25/17)
     
  5843. IAS: Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients: results of the METAFIB study - (07/25/17)
     
  5844. IAS: Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)
     
  5845. IAS: Evaluation of lead HIV-1 vaccine regimen in APPROACH: Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein - (07/24/17)
     
  5846. IAS: Dual regimen with Dolutegravir and Lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study - (07/24/17)
     
  5847. IAS: Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, in Combination With Tenofovir Disoproxil Fumarate/Emtricitabine, in Previously Untreated HIV-1 Infection Through Week 96 - (07/24/17)
     
  5848. IAS: Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17)
     
  5849. IAS: ANRS 146 - GeSIDA 7211 OPTIMAL Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defining event and/or CD4 counts > 200 cells/ mm3 - (07/24/17)
     
  5850. IAS: Darunavir/Ritonavir Plus 3TC Noninferior to Triple Therapy at 24 Weeks - ANDES Study - A Phase 4, Randomized, Open Label, Study of a Ritonavir-Boosted Darunavir in Fixed Dose Combination (FD-DRV/r) plus Lamivudine Versus FD-DRV/r plus Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects - Mark Mascolini - (07/23/17)
     
  5851. IAS: Low Failure Rate With Switch to Integrase Inhibitor STR Despite Archived Mutations - Mark Mascolini - (07/23/17)
     
  5852. IAS: Long-Acting 4/8-Week Cabotegravir/Rilpivirine Maintains Control at 96 Weeks - Mark Mascolini - (07/23/17)
     
  5853. IAS: MK-8591 Protects 8 of 8 Macaques From Rectal SHIV 6 Days After Dosing - Mark Mascolini - (07/23/17)
     
  5854. IAS: CD4 Count at ART Start Rising Across Globe, But Median Still Below 350 / 25% start at below 200 CD4 - Mark Mascolini - (07/23/17)
     
  5855. IAS: Virologic Success Rate 90% at Week 24 With First-Line DTG/3TC in ACTG A5353: ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml - Mark Mascolini - (07/23/17)
     
  5856. IAS: A Phase 3 Randomized Controlled Clinical Trial of Bictegravir in a Fixed Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 48 - (07/23/17)
     
  5857. IAS: More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex - (07/23/17)
     
  5858. IAS: Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (07/23/17)
     
  5859. IAS: Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17)
     
  5860. IAS: Ending AIDS: myth or reality? New Infections Increase in Key Populations, UN Update - (07/23/17)
     
  5861. IAS: A global survey of HIV-positive people's attitudes towards cure research - (07/23/17)
     
  5862. Pharm: HIGHER DOLUTEGRAVIR PLASMA TROUGH CONCENTRATION (Ctrough) in PATIENTS presenting SIDE EFFECTS : INTEREST of THERAPEUTIC DRUG MONITORING ? - (07/23/17)
     
  5863. Dual ART Therapy Regimens - (07/23/17)
     
  5864. A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? - (07/23/17)
     
  5865. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy - (07/23/17)
     
  5866. Johnson & Johnson at IAS 2017: Latest Innovations from its Janssen Pharmaceutical Companies Include First In-Human Data for Investigational Preventive HIV-1 Vaccine and Phase 3 Pivotal Trial Results for Darunavir-Based, Single-Tablet Regimen - (07/23/17)
     
  5867. The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review - (07/22/17)
     
  5868. Healthy Plant-Based Diet What Does it Really Mean? Editorial - Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults - (07/22/17)
     
  5869. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada - low CD4 at ART initiation reduced life expectancy 20 years - (07/22/17)
     
  5870. Life Expectancy in HIV / Reyataz Reduced CVD Risk vs PIs/NNRTIs/Integrase - (07/22/17)
     
  5871. CROI: CURE at CROI 2017 - (07/22/17)
     
  5872. Reyataz Reduced CVD Risk Compared with other ART Regimens - Cardiovascular outcomes among HIV-infected veterans receiving atazanavir: a US national historical cohort study - (07/21/17)
     
  5873. Prisoners - "Approximately 60% of participants had an undetectable plasma HIV RNA 24 weeks after release" - (07/21/17)
     
  5874. Undiagnosed HIV & Incidence Remain High - CDC CROI Report - (07/21/17)
     
  5875. ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017 - (07/21/17)
     
  5876. European Medicines Agency Validates Gilead's Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (07/21/17)
     
  5877. Pharm: The 18th International Workshop on Clinical Pharmacology of Antiviral Therapy - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Associate Professor School of Pharmacy University of Colorado at Denver - (07/20/17)
     
  5878. Toll-Like Receptor Agonists: Can They Exact a Toll on Human Immunodeficiency Virus Persistence? Editorial Commentary - (07/20/17)
     
  5879. Short-Course Toll-Like Receptor 9 Agonist [MGN1703 ] Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection - (07/20/17)
     
  5880. Beyond antiretroviral therapy: early interventions to control HIV-1 infection - Opinion - (07/20/17)
     
  5881. Toll-Like Receptor Agonists: Can They Exact a Toll on Human Immunodeficiency Virus Persistence? - EDITORIAL COMMENTARY - (07/20/17)
     
  5882. Progressive Brain Atrophy Despite Persistent Viral Suppression in HIV Over Age 60 - (07/19/17)
     
  5883. Life Expectancy reduced 20 years If ART Started at < 350 CD4s - Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada - (07/19/17)
     
  5884. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia - (07/19/17)
     
  5885. HIV prematurely ages the brain - new study & Commentary - (07/19/17)
     
  5886. Repatha Lipodystrophy - (07/19/17)
     
  5887. HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer - (07/19/17)
     
  5888. Higher Body Mass Index Is Associated With Greater Proportions of Effector CD38+ T Cells Expressing CD57 in Women Living With HIV - (07/19/17)
     
  5889. Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy: socioeconomic, neurocognitive impairment, Medicaid/Medicare - exercise, diet, smoking, obesity - (07/19/17)
     
  5890. Mental Health in Aging with HIV - Suicide Ideation Will Increase in Aging Older HIV+ - Successful aging and the epidemiology of HIV - (07/19/17)
     
  5891. IL-17 Treatment, Anti-Inflammatory in Diabetes/Oral Microbiome - Diabetes Enhances IL-17 Expression and Alters the Oral Microbiome to Increase Its Pathogenicity - (07/19/17)
     
  5892. "HIV and diabetes may have an additive effect on CKD risk " - HIV & the Aging Kidney - (07/11/17)
     
  5893. 2 New HIV CVD/Heart Disease Drugs: PCSK9 inhibitor & 1st CVD Anti-Inflammatory Canakinumab - (07/10/17)
     
  5894. HIV and Cardiovascular Disease: We Need a Mechanism, and We Need a Plan - Editorial - (07/10/17)
     
  5895. HIV Infection Itself May Not Be Associated With Subclinical Coronary Artery Disease Among African Americans Without Cardiovascular Symptoms - (07/10/17)
     
  5896. HIV & Heart Disease, Cognitive/Neurologic Disease, Bone Disease - (07/10/17)
     
  5897. Cancers Now in HIV..."cancer mortality much higher in HIV+" - Cancer-Attributable Mortality Among People With Treated HIV in North America - (07/10/17)
     
  5898. Merck to Present New Data from Clinical Trials Evaluating ISENTRESS® HD (raltegravir) and Investigational HIV Therapies Doravirine and MK-8591 at IAS 2017 - (07/10/17)
     
  5899. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease / Amgen Offers Refund / 'Value-Pricing' Contract Deals for PCKS9 Cholesterol Drug - (03/22/17)
     
  5900. Evolocumab - FOURIER Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk - (05/02/17)
     
  5901. Projecting 10-yr, 20-yr and Lifetime Risks of Cardiovascular Disease in Persons Living with HIV in the US - "HIV should be considered a major risk factor for CVD....risk similar to diabetes risk for CVD" - (07/06/17)
     
  5902. CVD & Renal Disease Risk in HIV+ / Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults - (07/06/17)
     
  5903. Aging / HIV / Latinos - Report Released Illuminating The Needs Of The Forgotten - "Olvidados": A National Health Assessment Of Latinos Growing Older With HIV - (07/06/17)
     
  5904. Fatty Liver: Fatty Liver in HIV+ / HIV Research Politics, Aging - Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy - (07/03/17)
     
  5905. Fatty Liver: Fatty Liver / NASH at EASL - (07/03/17)
     
  5906. Fatty Liver, NAFLD, NASH Definitions - (06/29/17)
     
  5907. Disability Among Middle-Aged and Older Persons With Human Immunodeficiency Virus Infection / ACTG HAILO Study - (06/29/17)
     
  5908. Mitochondrial toxicity and caspase activation in HIV pregnant women - (06/29/17)
     
  5909. Placental Mitochondrial Toxicity, Oxidative Stress, Apoptosis, and Adverse Perinatal Outcomes in HIV Pregnancies Under Antiretroviral Treatment Containing Zidovudine - (06/29/17)
     
  5910. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial - (06/28/17)
     
  5911. IWCADRH: Fat in and around the muscle: metabolism and pathophysiology - (06/26/17)
     
  5912. 1st CVD Anti-Inflammatory Canakinumab with Positive Phase 3 Results Announced - Studied in HIV at CROI - (06/26/17)
     
  5913. 1st CVD Anti-Inflammatory - Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack - (06/26/17)
     
  5914. Pharm: Effect of a high fat meal on the pharmacokinetics of the HIV integrase inhibitor, cabotegravir - (06/26/17)
     
  5915. Pharm: The Effect of Food on the Pharmacokinetics of the HIV-1 Attachment Inhibitor Temsavir, the Active Moiety of the Prodrug Fostemsavir - (06/26/17)
     
  5916. Pharm: The Effect of Increased Gastric pH on the Bioavailability of Extended Release Tablet of Fostemsavir in Healthy Subjects / Combinectin-GSK3732394 / 2nd Gen Maturation Inhibitor GSK2838232 - (06/26/17)
     
  5917. Pharm: Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study - (06/26/17)
     
  5918. IWCADRH: Regulation of muscle function and mass by the bone-derived hormone osteocalcin - Brain/Bones/Muscle Exercise Connection/Mortality Too/Comorbidities Workshop-NY 9/16 - (06/23/17)
     
  5919. IWCADRH: Clinical Implications of Nonalcoholic Fatty Liver Disease in Patients with HIV Infection - (06/23/17)
     
  5920. Aging with HIV in U.S. Trans NIH Research Themes - (06/22/17)
     
  5921. Using Imaging to Understand the Role of Epicardial Adipose Tissue in HIV-Related Atherosclerosis - (06/22/17)
     
  5922. Sudden Cardiac Death in Patients With Human Immunodeficiency Virus Infection (13%) - (06/22/17)
     
  5923. Types of Myocardial Infarctions in HIV+ - Type 2 vs Type 1 MIs - (06/22/17)
     
  5924. Pharm: A Comparison of the Pharmacokinetics of Dolutegravir in Pregnancy and Postpartum - (06/21/17)
     
  5925. Pharm: Confirmation of the Drug-drug Interaction Potential Between Cobicistat-boosted Antiretroviral Regimens and Hormonal Contraceptives - (06/21/17)
     
  5926. Pharm: Lack of Clinically Relevant Effect of Bictegravir on Metformin Pharmacokinetics and Pharmacodynamics - (06/21/17)
     
  5927. Pharm: The Effect of Hepatic or Renal Impairment on Bictegravir Pharmacokinetics - (06/21/17)
     
  5928. Pharm: Lack of Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate on Glomerular Filtration Rate in HIV-Infected Patients - (06/21/17)
     
  5929. Pharm: Effect of cobicistat on tenofovir disoproxil fumarate (TDF) durability: is it time to rethink at TAF trials? - Mark Mascolini (06/21/17)
     
  5930. TAF / ATV-Cobi / FTC PK, Interaction - (06/21/17)
     
  5931. TAF 10/25mg VS TDF Plasma Exposures - (06/21/17)
     
  5932. Aging & Diabetes - Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010 - YES - (06/21/17)
     
  5933. Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir DF/Emtricitabine or Abacavir/Lamivudine - (06/21/17)
     
  5934. Pharm: Evaluation of Drug-Drug Interaction Potential Between Sofosbuvir/Velpatasvir and Atorvastatin - (06/20/17)
     
  5935. Pharm: Doravirine Does Not Have a Clinically Meaningful Pharmacokinetic Interaction with Elbasvir Plus Grazoprevir - (06/20/17)
     
  5936. Pharm: Doravirine Does Not Have a Clinically Meaningful Pharmacokinetic Interaction with Ledipasvir/Sofosbuvitr (HARVONI) - (06/20/17)
     
  5937. Pharm: Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilapevir and Boosted or Unboosted HIV Antiretroviral Regimens - report 2 - Mark Mascolini - (06/20/17)
     
  5938. Pharm: Bioequivalence of a Fixed Dose Combination Tablet of Dolutegravir and Rilpivirine in Healthy Subjects - (06/20/17)
     
  5939. Pharm: Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis - (06/20/17)
     
  5940. Pharm: Early Safety, Tolerability and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (06/20/17)
     
  5941. Pharm: Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilapevir and Boosted or Unboosted HIV Antiretroviral Regimens - (06/20/17)
     
  5942. DTG +TMC-278 - TMC-278 Resistance / Profile Against EFV, NNRTI Resistance - (06/19/17)
     
  5943. Pharm: Effect of cobicistat on tenofovir disoproxil fumarate (TDF) durability: is it time to rethink at TAF trials? - Mark Mascolini - (06/19/17)
     
  5944. Pharm: High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600mg daily - (06/19/17)
     
  5945. Pharm: DAAs Glecaprevir and Pibrentasvir Double Levels of Statins and Dabigatran - Mark Mascolini - (06/19/17)
     
  5946. Pharm: Safety and Concentrations of GSK Maturation Inhibitor With or Without Ritonavir - Mark Mascolini - (06/19/17)
     
  5947. Pharm: Drug-Carrying Adherence Sensor Does Not Alter Levels of TDF/FTC - Mark Mascolini - (06/19/17)
     
  5948. Pharm: Dolutegravir Plus Rilpivirine Levels High Enough After Switch From NNRTI - Mark Mascolini - (06/19/17)
     
  5949. Pharm: Similar Darunavir Levels in CSF With RTV or COBI Boost - Mark Mascolini - (06/19/17)
     
  5950. Pharm: No Bictegravir Dose Adjustment With Liver or Kidney Impairment - Mark Mascolini - (06/19/17)
     
  5951. Pharm: COBI-PI Regimens Raise Drospirenone Levels in Oral Contraceptive - Mark Mascolini - (06/19/17)
     
  5952. Pharm: Dolutegravir Levels Similar in Third Trimester and After Delivery - Mark Mascolini - (06/19/17)
     
  5953. Pharm: Does TDF Need Dose Reduction When Given With Boosting Agent? - Mark Mascolini - (06/19/17)
     
  5954. Pharm: Dolutegravir Cmax Higher in Elderly, Tied to Shorter Sleep Duration - Mark Mascolini - (06/16/17)
     
  5955. Pharm: Evaluation of the Drug-Drug Interaction (DDI) Potential Between Cobicistat-Boosted Protease Inhibitors and Statins - (06/15/17)
     
  5956. Pharm: Pharmacokinetics of darunavir/cobicistat (DRV/c) and etravirine (ETR) alone and coadministered in HIV-infected patients - (06/15/17)
     
  5957. Pharm: Clinical Data Support 30 mg Daclatasvir with ATV or ATV/r, 90 mg With Etravirine - Mark Mascolini (06/15/17)
     
  5958. Pharm: Statin Levels Much Higher With Cobicistat-Boosted Atazanavir or Darunavir - Mark Mascolini (06/15/17)
     
  5959. Pharm: Etravirine Lowers Cobicistat Exposure and Darunavir Trough - Mark Mascolini (06/15/17)
     
  5960. Aging/Healthcare Costs-Europe & USA - (06/15/17)
     
  5961. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment - (06/13/17)
     
  5962. Strokes in HIV+ - (06/09/17)
     
  5963. PrEP: State of the Science (ASM/ICAAC June 2017) - (06/09/17)
     
  5964. CROI: Types of ischemic strokes among HIV-infected individuals across the United States - (06/07/17)
     
  5965. Immunologic and Virologic Responses to Antiretroviral Regimens in Treatment-naïve, HIV-infected Elderly Patients (ASM/ICAAC June 2017) - (06/07/17)
     
  5966. Identifying Cellular Factors that Silence HIV-1 Proviral Transcription (ASM/ICAAC June 2017) - (06/07/17)
     
  5967. CD4s Rise More Slowly in HIV Patients 50 or Older Starting Antiretrovirals (ICAAC June 2017) - Mark Mascolini - (06/07/17)
     
  5968. Key Select Aging & HIV Reports 2 An entire section on the NATAP website devoted to Aging & HIV. - (06/07/17)
     
  5969. Key Aging / HIV Reports 1 of 2 NATAP website devoted to Aging & HIV - (06/07/17)
     
  5970. Aerobic Interval Training Versus Continuous Moderate Exercise as a Treatment for the Metabolic Syndrome - (06/07/17)
     
  5971. PRO 140 CCR5 Monoclonal Antibody Strong in Highly Pretreated People: Week 25 - (ICAAC 2017 June 1) - Mark Mascolini (06/07/17)
     
  5972. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use - (06/07/17)
     
  5973. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women - (06/07/17)
     
  5974. ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines - (06/02/17)
     
  5975. Gilead's Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies - (05/30/17)
     
  5976. Merck Receives FDA Approval of ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients - (05/30/17)
     
  5977. Statins effects in Older Adults Risks/Benefits - Primary Prevention / ALLHAT-LLT Study "patients without atherosclerotic cardiovascular disease" - (05/25/17)
     
  5978. Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines - new analysis: "the evidence is lacking for older adults without major cardiovascular risk aside from age" - (05/25/17)
     
  5979. Statin (JUPITER study) in Elderly with Relatively Low Risk Factors - (05/25/17)
     
  5980. Study Casts Doubt on Need for Statins in the 'Healthy Old' - But specialists cite research flaws, limitations - (05/25/17)
     
  5981. Statins - Analysis of Efficacy and Safety in Patients Aged 65-75 Years at Randomization [from Jules: relatively low risk, with Diabetes] - (05/25/17)
     
  5982. Isentress Once Daily FDA Approval Pending - (05/22/17)
     
  5983. Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union - (05/22/17)
     
  5984. Long Acting HIV ARTs - is This the Future - implants, nano formulations - (05/22/17)
     
  5985. Significant health impact of accelerated aging in young HIV-infected individuals on antiretroviral therapy in Malaysia - higher mortality, health-care utilization, worse quality of life, more comorbidities/geriatric conditions matched to uninfected - (05/22/17)
     
  5986. Expanded Access Program for ibalizumab in Resistant HIV-1 - (05/17/17)
     
  5987. Marijuana use impacts midlife cardiovascular events in HIV-infected men - (05/17/17)
     
  5988. Another statin option in HIV - Comment - (05/17/17)
     
  5989. Brief Report: HIV Prevalence and the Prevalence of Unsuppressed HIV in New York City, 2010-2014 - (05/17/17)
     
  5990. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data - (05/17/17)
     
  5991. Increased brain-predicted aging in treated HIV disease / CROI 2017 Brain-Neurological Disorders Reports - (05/17/17)
     
  5992. CROI: Cardiovascular Update from CROI 2017 - by Priscilla Hsue MD Professor of Medicine, UCSF - (05/16/17)
     
  5993. LDL Debate - Role in CVD / Exercise, Diet Inflammation, Mortality - (05/12/17)
     
  5994. CROI: Peripheral endothelial function is suboptimal in HCV-untreated, HIV-suppressed adults - - (05/09/17)
     
  5995. Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - (05/04/17)
     
  5996. Value-Based Pricing For Pharmaceuticals In The Trump Administration
     
  5997. Gut Microbe-Generated Trimethylamine N-Oxide From Dietary Choline Is Prothrombotic in Subjects - (05/02/17)
     
  5998. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis / CROI: Higher Carnitine Levels Almost quadrupled MI Risk in HIV+ - (05/02/17)
     
  5999. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease - A Science Advisory From the American Heart Association - (05/02/17)
     
  6000. AGING CRISIS: Comorbidities Shorten Life & HALE: Healthy Years of Life Expectancy - (05/02/17)
     
  6001. Evolocumab - FOURIER Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk - (05/02/17)
     
  6002. CROI: Higher Carnitine Tied to Almost Quintupled MI Risk in People With HIV - Mark Mascolini - (05/01/17)
     
  6003. Exercise Effects on Mitochondria & Aging - Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans - (04/26/17)
     
  6004. Evaluation of Cardiovascular Disease (CVD) Risk in HIV-1-infected Patients Treated With Darunavir/Ritonavir (DRV/r) - (04/26/17)
     
  6005. Exercise Effects on Mitochondria & Aging - Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans - (04/26/17)
     
  6006. Evaluation of Cardiovascular Disease (CVD) Risk in HIV-1-infected Patients Treated With Darunavir/Ritonavir (DRV/r) - (04/26/17)
     
  6007. Demographic and Clinical Characteristics of Patients Living With HIV Treated With Darunavir- and Atazanavir-based Regimens in the Real-world Setting - (04/24/17)
     
  6008. CROI: CROI 2017 Summary Report - A lot Going On - good Conference with Lots of New Information - New HIV Drugs, Aging/Comorbidities, Cure & PrEP, Fatty Liver/HCV-HBV - - (04/19/17)
     
  6009. CROI: PHARMACOKINETICS OF RILPIVIRINE AFTER SWITCHING FROM EFAVIRENZ IN ADOLESCENTS - - (04/18/17)
     
  6010. CROI: Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation - - (04/18/17)
     
  6011. CROI: Pharmacokinetics, Safety, and Efficacy of Atazanavir or Darunavir With Cobicistat in Adolescents (12 to <18 years of age) - - (04/18/17)
     
  6012. Women with HIV - CDC: Over- Estimated Viral Suppression ...30-40% WIHS Women with Detectable Viral Load - that Doubles the MORTALITY Rate - (04/17/17)
     
  6013. LATEST UPDATE ON HIV LIPODYSTROPHY: Interview with Dr Grace McComsey - (04/17/17)
     
  6014. GSK Discontinues BMS' Maturation Inhibitor - (04/17/17)
     
  6015. CROI: PHARMACOKINETICS OF RILPIVIRINE AFTER SWITCHING FROM EFAVIRENZ IN ADOLESCENTS - - (04/17/17)
     
  6016. CROI: Substantially Lower Rilpivirine Plasma Concentrations during Pregnancy - - (04/17/17)
     
  6017. CROI: Low HIV-1 Resistance in Subjects Using Darunavir Once-daily Regimens Across Studies - - (04/17/17)
     
  6018. CROI: EXERCISE, OXIDATIVE STRESS AND FIBRINOLYTIC FUNCTION IN HIV-1 INFECTED ADULTS - - (04/17/17)
     
  6019. CROI: Blood Brain Barrier function, ART neuroactivity and risk of CSF HIV escape / BBB Permeability & Neurocognitive Performance in HIV+ - - (04/12/17)
     
  6020. CROI: DEVELOPMENT OF A PKC AGONIST DERIVED FROM INGENOL FOR HIV LATENCY DISRUPTION IN VIVO - - (04/12/17)
     
  6021. CROI: FATTY LIVER DISEASE: A GROWING CONCERN - - (04/12/17)
     
  6022. Use of Recommended and Contraindicated Statins in HIV Patients - (04/11/17)
     
  6023. Disability among Middle-Aged and Older Persons with HIV Infection - (04/11/17)
     
  6024. An Increased Rate of Fracture Occurs a Decade Earlier in HIV+ Compared to HIV- men in the Multicenter AIDS Cohort Study (MACS) - (04/11/17)
     
  6025. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients - (04/11/17)
     
  6026. From One Syndrome to Many: Incorporating Geriatric Consultation into HIV Care - (04/11/17)
     
  6027. Grey and white matter abnormalities in treated HIV- disease and their relationship to cognitive function - (04/11/17)
     
  6028. Cholesterol Lowering [statins] in Intermediate-Risk Persons without Cardiovascular Disease - (04/11/17)
     
  6029. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients - (04/11/17)
     
  6030. CROI: CROI: Neurocognitive Disorders - Neurologic, Brain, Cognitive Impairment - - (04/10/17)
     
  6031. CROI: Ledipasvir/Sofosbuvir Raises Tenofovir Diphosphate Concentrations in Red Cells - - (04/10/17)
     
  6032. Decision Tools to Improve Personalized Care in Cardiovascular Disease - Value Based CVD Care
     
  6033. Value-Based Payments Likely to Survive Affordable Care Act Repeal
     
  6034. Value Based CVD Care / CMS - The Million Hearts Initiative: Preventing 1 Million Heart Attacks and Strokes
     
  6035. Value Based Personalized CVD Care - Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts -
     
  6036. Use of Recommended and Contraindicated Statins in HIV Patients - (04/07/17)
     
  6037. HIV Infection Is Associated With Worse Bone Material Properties, Independently of Bone Mineral Density [Microindentation measures Bone Material Strength index, new test for bone]- Brief Report - (04/07/17)
     
  6038. Clinical Application of Spine Trabecular Bone Score (TBS) - New Bone Test / CROI-2017 - (04/07/17)
     
  6039. CROI: HIV Infection and the Occurrence of Medically Significant Falls: Accelerated or Accentuated Aging? - - (04/06/17)
     
  6040. CROI: A RANDOMIZED TRIAL OF VITAMIN D3 (3000 VERSUS 1000 IU) IN HIV+ POSTMENOPAUSAL WOMEN - - (04/06/17)
     
  6041. CROI: VITAMIN D DEFICIENCY IMPAIRS THE BENEFICIAL EFFECTS OF STATIN IN TREATED HIV - - (04/06/17)
     
  6042. CROI: HIGH DOSE VITAMIN D3 INCREASES SPINE BONE DENSITY IN HIV+ YOUTH ON TENOFOVIR (TDF) - - (04/06/17)
     
  6043. CROI: Frailty, Bones, and Vitamin D: CROI 2017 - Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Johns Hopkins University - (04/06/17)
     
  6044. CROI: Switching from TDF To TAF in HIV-Infected Adults With Low BMD: A Pooled Analysis - - (04/05/17)
     
  6045. CROI: Ledipasvir/Sofosbuvir Raises Tenofovir Diphosphate Concentrations in Red Cells - - (04/04/17)
     
  6046. CROI: Acute HCV Drops Sharply in HIV-Positive Dutch MSM After DAA Rollout - Mark Mascolini - (04/04/17)
     
  6047. CROI: New HIV Drugs at CROI / CROI Antiretroviral Treatment Summary / Long Acting HIV Therapies - (03/31/17)
     
  6048. CROI: Use of Cocaine, Meth, Opioids Remains High in US MSM: 2008-2014 - Mark Mascolini - (03/30/17)
     
  6049. CROI: COPD Markers Linked to Tripled Mortality Risk in People With HIV - Mark Mascolini - (03/30/17)
     
  6050. CROI: Dapivirine Vaginal Ring Does Not Blunt Effectiveness of Hormonal Contraception - Mark Mascolini - (03/30/17)
     
  6051. CROI: Frailty Status and Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - - (04/05/17)
     
  6052. CROI: Antiretroviral-induced Bone Loss is Durably Suppressed by A Single Dose of Zoledronic Acid - - (04/05/17)
     
  6053. CROI: Changes in Liver Fibrosis and Steatosis in HIV Mono-Infected patients over 24 months - 50% have fatty liver at average age of 46 - (03/28/17)
     
  6054. CROI: LIVER STEATOSIS AND FIBROSIS IN AT-RISK EUROPEAN HIV-MONOINFECTED PATIENTS - 64% with steatosis among those who had elevated LFTs and/or metabolic syndrome and/or lipodystrophy - (03/28/17)
     
  6055. CROI: FATTY LIVER DISEASE: A GROWING CONCERN - highly recommended - (03/28/17)
     
  6056. CROI: Emergence of Integrase Resistance Mutations During Initial Therapy with TDF/FTC/DTG - (03/27/17)
     
  6057. CROI: Physical Function and Inflammation in Older HIV-Infected Men - (03/16/17)
     
  6058. CROI: CROI Summary 2017: Antiretroviral treatment - where we are now / New HIV Drugs & Treatments - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/06/17)
     
  6059. CROI: CROI 2017: Better Living with HIV Infection - written by - David Alain Wohl, MD - The University of North Carolina at Chapel Hill (03/01/17)
     
  6060. CROI: Impressions of CROI 2017 - written by- Pablo Tebas, MD University of Pennsylvania - (03/01/17)
     
  6061. CROI: The Kidney at CROI 2017 - written by - Christina Wyatt MD - Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY (03/01/17)
     
  6062. CROI: HIV Prevention at CROI 2017 Conference on Retroviruses and Opportunistic Infections - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/23/17)
     
  6063. CROI: Summary from CROI 2017 for Viral Hepatitis HCV elimination on its way: dream or emerging reality? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany Correspondence: Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany - (03/22/17)
     
  6064. CROI: Antiretroviral-induced Bone Loss is Durably Suppressed by A Single Dose of Zoledronic Acid - - (04/05/17)
     
  6065. GLASGOW: Utilizing Phase 3 Clinical Trial Data to Assess Adverse Event (AE) Frequency of a Potentially Interacting Medication (PIM) Amlodipine with Elvitegravir/Cobicistat (EVG/COBI) - (04/04/17)
     
  6066. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease - (04/04/17)
     
  6067. Aging of HIV-Infected: a explosive and underestimated phenomena being ignored, needs attention - special support services for patients & clinics needed-lack of federal/state response - HCV too - Commentary by Jules Levin - (04/04/17)
     
  6068. CROI: "Hooked on painkillers" before first injection among PWID in 16 US cities - CDC - (03/31/17)
     
  6069. CROI: HIV Awareness/Care in US Black Men May Explain Less HIV in Black Women - Mark Mascolini - (03/31/17)
     
  6070. CROI: New HIV Drugs at CROI / CROI Antiretroviral Treatment Summary / Long Acting HIV Therapies - (03/31/17)
     
  6071. CROI: Body Mass Index and the Risk of Serious Non-AIDS Events - Mark Mascolini - (03/31/17)
     
  6072. CROI: Rilpivirine Injected Every 8 Weeks Maintains Adequate Levels in Women: HPTN 076 - Mark Mascolini - (03/31/17)
     
  6073. Lipodystrophy Not Forgotten - Proinflammatory Markers, Insulin Sensitivity, and Cardiometabolic Risk Factors in Treated HIV Infection - in causing heart disease - (03/29/17)
     
  6074. Lipoatrophy, Lipodystrophy - Let's Not Forget their Contribution to Heart Disease in HIV - (03/29/17)
     
  6075. HIV: Finding latent needles in a haystack - CD32 Commentary: CD32a is a marker for only 50% of reservoir.... - (03/29/17)
     
  6076. International Workshop on NASH Biomarkers - May 2017 Wash DC - (03/29/17)
     
  6077. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study - (03/29/17)
     
  6078. Frailty Status and Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - (03/29/17)
     
  6079. CROI: TREND IN MULTIMORBIDITY AMONG HIV+ ADULTS IN CLINICAL CARE IN THE US - (03/29/17)
     
  6080. CROI: MRS Measures Associate with Impaired Neuropsychological Performance in Acute HIV - (03/29/17)
     
  6081. CROI: P2X receptors as therapeutic targets of HIV-1 infection and inflammation - (03/29/17)
     
  6082. CROI: LONG-TERM EFFECTS OF IMMEDIATE VERSUS DEFERRED cART IN PRIMARY HIV INFECTION - (03/29/17)
     
  6083. CROI: Prevalence of neurocognitive disorders in a well-treated and aging Swiss HIV Cohort - (03/29/17)
     
  6084. CROI: Benefit of continuous/immediate ART on disease risk: SMART & START combined analysis - (03/29/17)
     
  6085. CROI: ART in HIV persons with pre-treatment viremia <3000c/mL: the START study - (03/29/17)
     
  6086. CROI: INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPH NODE AND GUT MUCOSAL TISSUE - (03/29/17)
     
  6087. CROI: Changes In Liver Steatosis After Switching Efavirenz To Raltegravir: The STERAL Study - (03/29/17)
     
  6088. CROI: Multiple-Dose Treatment With Ritonavir Increases the Exposure of Doravirine - (03/29/17)
     
  6089. CROI: Raltegravir Switch and Biomarkers of Liver Steatosis and Metabolic Syndrome in Women - (03/29/17)
     
  6090. CROI: Cost of noninfectious comorbidities in patients with HIV - Cost of HIV CARE Increases 5 fold Due to Cost for Comorbidities from <40 to >60 - (03/23/17)
     
  6091. CROI: Comprehensive Assessment of Resistance Mutations Selected by Dolutegravir (DTG) in Subjects Failing DTG-Monotherapy after Switching from other Therapies (Redomo Study) - (03/23/17)
     
  6092. Long-Acting & Nanoparticle ARTs - Future of HIV Medication??? - (03/22/17)
     
  6093. Value Based: Sustained Participation in a Pay-for-Value Program: Impact on High-Need Patients
     
  6094. CROI: TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP) - (03/22/17)
     
  6095. CROI: INCREASED RATES OF HBV SEROCONVERSION UNDER LONG-TERM HBV ACTIVE THERAPY IN HBV/HIV - [16%] - (03/22/17)
     
  6096. CROI: Direct-Acting Antivirals Improve Access to Care and Cure for Patients with HIV and chronic Hepatitis C Virus from 2011-2015 - (03/20/17)
     
  6097. CROI: High rates of hepatitis C virus cure among black and non-black persons with HIV-infection receiving care in an urban center - (03/20/17)
     
  6098. CROI: Same same but different? Risk of DAA therapy failure in real-life HCV/HIV coinfection: The GECCO Cohort - (03/20/17)
     
  6099. CROI: HIV-HCV Coinfection in the DAA Era: "En Route for Eradication" ? - (03/20/17)
     
  6100. CROI: Effectiveness of All-Oral DAAs for HCV Genotype 3 In HIV/HCV-Coinfected Patients - (03/20/17)
     
  6101. CROI: Resistance emergence in macaques administered Cabotegravir long-acting (CAB LA) during acute infection - (03/20/17)
     
  6102. CROI: Concordant Population-level Increases in PrEP Found with Novel Public Health Methods - (03/20/17)
     
  6103. CROI: STD PARTNER SERVICES TO MONITOR AND PROMOTE PREP USE AMONG MEN WHO HAVE SEX WITH MEN - (03/20/17)
     
  6104. CROI: Text Messaging is Associated with Improved Retention in a Clinic-based PrEP Program - (03/20/17)
     
  6105. CROI: MIDWEST PHARMACISTS' KNOWLEDGE OF & WILLINGNESS TO PROVIDE PRE-EXPOSURE PROPHYLAXIS - (03/20/17)
     
  6106. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses - (03/16/17)
     
  6107. Early antibody therapy can induce long-lasting immunity to SHIV / Dual Antibody Therapy - (03/15/17)
     
  6108. Integrase inhibitors go head-to-head - Comment - (03/15/17)
     
  6109. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial - (03/15/17)
     
  6110. Comorbidities & Life Expectancy: the affect of comorbidities on Life Expectancy - (03/15/17)
     
  6111. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study - (03/15/17)
     
  6112. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study - (03/15/17)
     
  6113. CROI: Clinical Pharmacology at CROI 2017 - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (03/13/17)
     
  6114. Aging & HIV - an unaddressed timebomb waiting to explode - slide presentation by Jules Levin, NATAP - (03/14/17)
     
  6115. CROI: Exhausted T-cells and Inflammatory Monocytes are Linked to Brain Atrophy in HIV - (03/10/17)
     
  6116. CROI: Impact of smoking, hypertension, and cholesterol on myocardial infarction in HIV-infected adults...."hypertension, cholesterol & smoking are very strong drivers of MIs in HIV+" - (03/10/17)
     
  6117. CROI: Bacterial Vaginosis Does Not Affect Oral TDF/FTC PrEP Efficacy - Mark Mascolini (03/10/17)
     
  6118. CROI: Older Age Associated with both Adherence and Renal Decline in the PrEP Demo Project - (03/10/17)
     
  6119. CROI: Bone Changes With TDF-containing and Non-TDF-containing (maraviroc) Prep in U.S. Men and Women - (03/10/17)
     
  6120. CROI: IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR - (03/10/17)
     
  6121. CROI: Brief Behavioral Intervention Increases PrEP Drug Levels in a Real World Setting - (03/10/17)
     
  6122. CROI: The Challenges of Translating PrEP Interest into Uptake among Young Black MSM in Atlanta, GA - (03/10/17)
     
  6123. Value-Based Care: Focusing on High-Cost Patients - The Key to Addressing High Costs? - Perspective / Short Changing Patient Care - (03/08/17)
     
  6124. WIHS Viral Load Suppression - Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006-2009 - (03/08/17)
     
  6125. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use - (03/08/17)
     
  6126. Testosterone and Male Aging - Editorial - (03/08/17)
     
  6127. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency - 2nd study - (03/08/17)
     
  6128. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone - (03/08/17)
     
  6129. CROI: Biological-vs-Chronological Age Difference Significantly Greater With HIV - Mark Mascolini (03/08/17)
     
  6130. CROI: Novel Imaging Strategy Shows High-Level Aortic CD206+ Macrophage Infiltration in HIV ......CVD risk / inflammation - (03/08/17)
     
  6131. CROI: BONE DENSITY, MICROARCHITECTURE, AND BONE STRENGTH AFTER 1 YEAR OF TDF - (03/08/17)
     
  6132. CROI: CHANGES IN THE ORAL MICROBIOME WITH ART INITIATION / Microbiome Affects of Low Baseline CD4/High Viral Load - (03/08/17)
     
  6133. CROI: Bone density and trabecular bone score improve fracture prediction in HIV-infected women - (03/06/17)
     
  6134. CROI: Bone Micro-Architectural Changes and Fracture Risk Prediction in HIV and HCV - (03/06/17)
     
  6135. CROI: CANCER INCIDENCE AMONG PERSONS ON MODERN SUPPRESSIVE ANTIRETROVIRAL THERAPY, 2000-12 - (03/06/17)
     
  6136. CROI: Cancer risk among HIV-infected people in the U.S. during the modern treatment era - (03/06/17)
     
  6137. CROI: LOW PREVALENCE OF HIV DRUG RESISTANCE WITH MODERN AGENTS - (03/06/17)
     
  6138. CROI: INCREASED PERSISTENCE OF INITIAL ART WITH INSTI-CONTAINING REGIMENS - (03/06/17)
     
  6139. CROI: A Phase 2 Open-Label Trial of Antibody UB-421 Monotherapy as a Substitute for HAART - (03/06/17)
     
  6140. CROI: Cognitive Complaints and Development of Falls among HIV-Infected and Uninfected Women - (03/06/17)
     
  6141. CROI: A Comparison of Fracture Risk Estimates in HIV-positive and HIV-negative Subjects; Data from HIV UPBEAT (Understanding the Pathology of Bone Disease in HIV-infected Subjects) - (03/06/17)
     
  6142. CROI: The Effect of ART on Inflammation, Coagulation and Vascular Injury in START..... "Immediate ART led to reductions at 8 months of 12-21% in D-dimer, IL-6, SAA, sICAM and sVCAM levels compared with deferral of ART.".....likely reducing risk for comorbidities - (03/06/17)
     
  6143. CROI: Association of Inflammation and Coagulation with Clinical Risk in the START Trial ...... - (03/06/17)
     
  6144. CROI: CROI Summary 2017: Antiretroviral treatment - where we are now / New HIV Drugs & Treatments - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/06/17)
     
  6145. CROI: The Association Between HCV And Comorbid Conditions In 2 Large Patient Cohorts - Mark Mascolini - (03/02/17)
     
  6146. CROI: High prevalence of hepatitis C virus among HIV negative MSM in the Amsterdam PrEP project - (03/02/17)
     
  6147. CROI: HCC DEVELOPMENT IN HCV PATIENTS AFTER DAA: THE EXPERIENCE OF THE SCOLTA PROJECT - (03/02/17)
     
  6148. CROI: No Evidence of Ongoing HIV Replication After 7 Years on ART.....but clonal expansion persists/HIV-Cure implications - (03/02/17)
     
  6149. CROI: Impact of antiretroviral treatment containing tenofovir difumarate on the telomere length of aviremic HIV-infected patients / NRTIs, HIV & Telomerase, Aging, Comorbidities - (03/02/17)
     
  6150. CROI: Leukocyte Telomere Attrition is Rapid Following HIV but not HCV Seroconversion - (03/02/17)
     
  6151. CROI: Telomere length: neurocognitive biomarker in HIV-1-infected subjects - (03/02/17)
     
  6152. CROI: Elsulfavirine as Compared to Efavirenz in Combination with TDF/FTC: 48-week Study - (03/02/17)
     
  6153. CROI: Factors associated with rapid eGFR decline while receiving TDF and/or ATV - (03/02/17)
     
  6154. CROI: Current Statin Use Reduces Risk of Viral Rebound on Suppressive cART - (03/02/17)
     
  6155. CROI: Effect of cobicistat on tenofovir plasma concentrations: a cross-sectional study - (03/02/17)
     
  6156. CROI: Crushing of dolutegravir combination tablets increases dolutegravir exposure - (03/02/17)
     
  6157. CROI: HUMAN CONFIRMATION OF ORAL DOSE REDUCTION POTENTIAL OF NANOPARTICLE ANTIRETROVIRAL FORMULATIONS - (03/02/17)
     
  6158. CROI: Long Acting HIV ART - is this the future? Nanoformulations - Implants - (03/02/17)
     
  6159. CROI: A Bi-Specific Approach for Targeting IMRs in HIV-1 Latency - (03/02/17)
     
  6160. CROI: IMPAACT P1110: RALTEGRAVIR PHARMACOKINETICS AND SAFETY IN HIV-1 EXPOSED NEONATES: DOSE-FINDING STUDY - (03/02/17)
     
  6161. CROI: Bictegravir Dissociation Half-life from HIV-1 G140S/Q148H Integrase-DNA Complexes - (03/02/17)
     
  6162. CROI: CEREBRAL SMALL-VESSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON CART - (03/02/17)
     
  6163. CROI: PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update - (03/01/17)
     
  6164. CROI: CEREBRAL SMALL VESSEL DISEASE IN CART WELL-CONTROLLED HIV-INFECTED PATIENTS ANRS EP51 MICROBREAK - (02/28/17)
     
  6165. CROI: Novel HIV PI with High Resistance Barrier and Potential for Unboosted QD Oral Dosing - (02/28/17)
     
  6166. CROI: CEREBRAL SMALL VESSEL DISEASE IN CART WELL-CONTROLLED HIV-INFECTED PATIENTS ANRS EP51 MICROBREAK - (02/28/17)
     
  6167. CROI: Bictegravir Dissociation Half-life from HIV-1 G140S/Q148H Integrase-DNA Complexes - (02/28/17)
     
  6168. CROI: CEREBRAL SMALL-VESSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON CART - (02/28/17)
     
  6169. CROI: PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update - (02/28/17)
     
  6170. CROI: Novel Non-Catalytic Site Integrase Inhibitor with Improved Resistance Profile - (02/28/17)
     
  6171. CROI: Efficacy and Safety of Switching to E/C/F/TAF in Virologically Suppressed Women - (02/26/17)
     
  6172. CROI: CDC - HIV Incidence, Prevalence and Undiagnosed Infections in Men Who Have Sex With Men - HIV incidence decreased among all transmission categories except MSM - (02/26/17)
     
  6173. CROI: Viral Suppression in NYC, NYS, and LA - (02/26/17)
     
  6174. Atazanavir & Creatinine - (02/26/17)
     
  6175. Darunavir Package Inserts - US & EMA - (02/26/17)
     
  6176. CROI: Frailty Stronger Than Neurocognitive Impairment in Predicting Falls-Disability-Death - Mark Mascolini - (02/26/17)
     
  6177. CROI: Non-AIDS Illness Burden Differs by Sex, Race, and Insurance Type in Aging HIV+ Adults - HOPS - Number of Comorbidities Double from 45 to 60 Years Old/Blacks Disproportionately Affected - (02/26/17)
     
  6178. CROI: LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN'S INTERAGENCY HIV STUDY - (02/26/17)
     
  6179. CROI: Time spent with HIV viral load >1500 copies/mL among patients in HIV care, 2000-2014....viral suppression and early HAART start are top federal priority - (02/26/17)
     
  6180. CROI: Ending HIV Epidemic in NYC - Plan/Strategy IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK - (02/26/17)
     
  6181. CROI: Pharmacokinetics of Total and Unbound Rilpivirine in HIV-1-infected Pregnant Women - (02/24/17)
     
  6182. CROI: HPTN 076: TMC278 LA Safe, Tolerable and Acceptable for HIV Pre-Exposure Prophylaxis - (02/24/17)
     
  6183. CROI: LONGITUDINAL ASSESSMENT OF REGIONALLY SPECIFIC BRAIN VOLUMES IN TREATED HIV+ PATIENTS - (02/24/17)
     
  6184. CROI: IMPACT OF ADVANCING AGE ON COGNITION IN HIV+ PERSONS ON A FIRST SUPPRESSIVE REGIMEN - (02/24/17)
     
  6185. CROI: Cognitive Trajectories in Suppressed HIV Infection Indicate Evolving Disease Activity - (02/24/17)
     
  6186. CROI: Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression: HIV+ virally suppressed had worse cognitive decline in 3 domains vs HIV-neg, 4 yrs followup - (02/24/17)
     
  6187. CROI: BIOMARKERS OF AGEING IN HIV-POSITIVE INDIVIDUALS AND MATCHED CONTROLS: 8 years greater biologic age in HIV+ - (02/24/17)
     
  6188. CROI: LONGITUDINAL ANALYSIS SHOWS NO EVIDENCE FOR ACCELERATED BRAIN AGEING IN TREATED HIV - (02/24/17)
     
  6189. CROI: State-Level Estimates of HIV Incidence, Prevalence, and Undiagnosed Infections: 12.2% Undiagnosed in NYS; 15% US undiagnosed - (02/24/17)
     
  6190. CROI: Antiviral Activity of EFdA [MK-8591] Against NRTI-Sensitive and -Resistant Strains of HIV-2 - (02/24/17)
     
  6191. CROI: Dolutegravir Based cART in Vertically-HIV-1-Infected Adolescents in Real-Life Setting - (02/24/17)
     
  6192. CROI: MK-8591 Concentrations at Sites of HIV Transmission and Replication - (02/23/17)
     
  6193. CROI: A LONG-ACTING NANOFORMULATED CABOTEGRAVIR PRODRUG FOR IMPROVED ANTIRETROVIRAL THERAPY - (02/23/17)
     
  6194. CROI: DOLUTEGRAVIR PHARMACOKINETICS, SAFETY AND EFFICACY IN HIV+ CHILDREN 2 TO <6 YEARS OLD - (02/23/17)
     
  6195. CROI: Increased dolutegravir exposure in HIV patients switched from ritonavir to cobicistat - (02/23/17)
     
  6196. CROI: GS-9131 is a Novel NRTI with Activity Against NRTI-Resistant HIV-1 - (02/23/17)
     
  6197. CROI: STEADY-STATE PHARMACOKINETICS OF DOLUTEGRAVIR IN PEOPLE LIVING WITH HIV OVER THE AGE OF 60 YEARS - (02/23/17)
     
  6198. CROI: EFFECT OF DOLUTEGRAVIR PLASMA CONCENTRATION ON CENTRAL NERVOUS SYSTEM SIDE EFFECTS - (02/23/17)
     
  6199. CROI: Dolutegravir as Maintenance Monotherapy for HIV-1: a Randomized Clinical Trial - (02/23/17)
     
  6200. CROI: Promising Results of Lamivudine + Dolutegravir Maintenance Therapy in ANRS 167 Lamidol Trial - (02/23/17)
     
  6201. CROI: TLR9 AGONIST TRIGGERS POTENT INTESTINAL ANTIVIRAL RESPONSE IN HIV+ INDIVIDUALS ON ART - (02/23/17)
     
  6202. CROI: TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Complete Viral Remission - (02/23/17)
     
  6203. CROI: TLR7 Agonist GS-986 Markedly Activates T & B Cells From ART-suppressed Donors - (02/23/17)
     
  6204. CROI: TLR7 Agonist GS-9620 (Vesatolimod) Increases Immune-Mediated Clearance of HIV-Infected Cells - (02/23/17)
     
  6205. CROI: HIV Integrase Genotypic Testing and Resistance in the United States-9 U.S. Jurisdictions - (02/22/17)
     
  6206. CROI: The Emerging Potential for HIV Cure for Infants, Children, and Adults - and - ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV - (02/22/17)
     
  6207. CROI: Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D Study - (02/22/17)
     
  6208. CROI: US HIV Incidence Falling in All Transmission Risk Groups Except MSM - Mark Mascolini - (02/22/17)
     
  6209. CROI: Frailty Stronger Than Neurocognitive Impairment in Predicting Falls-Disability-Death - Mark Mascolini - (02/22/17)
     
  6210. CROI: No HIV Evolution in CHER Children With Viral Control Through 7 Years of ART - Mark Mascolini - (02/22/17)
     
  6211. CROI: Monoclonal Antibody to IL-1beta Cuts Arterial Inflammation in 10 HIV Patients - Mark Mascolini - (02/22/17)
     
  6212. CROI: Higher Bilirubin Tied to Lower CVD Risk in Veterans With or Without HIV - Mark Mascolini - (02/22/17)
     
  6213. CROI: Age, Weight, Being a Woman Tied to Falls in Veterans With/Without HIV - Mark Mascolini - (02/22/17)
     
  6214. CROI: Nonlung Cancer Incidence Drops Quickly After Smoking Stops in HIV Group - Mark Mascolini - (02/22/17)
     
  6215. CROI: Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors - D:A:D (02/22/17)
     
  6216. CROI: Oral Session Thursday: INFLAMMATION AND AGE-RELATED COMPLICATIONS - (02/20/17)
     
  6217. CROI: Psychiatric Disorders Observed in HIV+ Patients Using 6 Common 3rd Agents in OPERA - (02/20/17)
     
  6218. CROI: Neuropsychiatric Adverse Events Associated With Integrase Strand Transfer Inhibitors - (02/20/17)
     
  6219. CROI: Discontinuation of DTG, EVG/c, and RAL due to toxicity in a prospective cohort - (02/20/17)
     
  6220. CROI: Hyperbilirubinemia prevents cardiovascular disease for HIV+ and HIV-individuals - (02/20/17)
     
  6221. CROI: Darunavir/r Use and Incident Chronic Kidney Disease in HIV-positive Persons - study found increased CKD risk with ATV but not with Darunavir - D:A:D Cohort - (02/20/17)
     
  6222. CROI: Oral Session Thursday: INFLAMMATION AND AGE-RELATED COMPLICATIONS - 4 studies (1) Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors (2) Smoking Cessation & Impact on Cancers & Lung Cancer Risks in HIV+ (3) New CVD Anti-Inflammatory in Pilot Study in HIV+ (4) Hyperbillirubinemia Prevents CVD Risk - (02/20/17)
     
  6223. CROI: Acute infection with a wild-type HIV-1 virus in a PrEP user with high TDF levels - (02/20/17)
     
  6224. CROI: GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS - (02/20/17)
     
  6225. Dolutegravir monotherapy: when should clinical practice be clinical research? - Commentary - (02/18/17)
     
  6226. CROI: Frailty Progression and Recovery among Persons Aging with HIV and Substance Use - (02/18/17)
     
  6227. CROI: HIV RNA Rebound Post-Interruption in Persons Suppressed in Fiebig I Acute HIV - (02/18/17)
     
  6228. CROI: EPICARDIAL FAT, IMMUNE ACTIVATION, AND CORONARY PLAQUE AMONG HIV+ AND HIV- WOMEN - (02/18/17)
     
  6229. CROI: APPLES - The Australian Positive & Peers Longevity Evaluation Study - (02/18/17)
     
  6230. CROI: Identification of Latency Reversing Agents (LRAs) Active in Diverse Primary T-cell Models of HIV Latency - (02/18/17)
     
  6231. CROI: Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy - (02/18/17)
     
  6232. CROI: Nonlung Cancer Incidence Drops Quickly After Smoking Stops in HIV Group - written by Mark Mascolini - (02/18/17)
     
  6233. CROI: Cardiovascular Risk as Great With Darunavir as With Indinavir or Lopinavir - written by Mark Mascolini - (02/18/17)
     
  6234. CROI: Less Inflammation Tied to Lower Frailty Progression, Greater Frailty Recovery - written by Mark Mascolini - (02/18/17)
     
  6235. CROI: Earlier [cd4 350-500] Versus Delayed Antiretroviral Therapy Initiation and Risk of Cancer - written by Mark Mascolini - (02/18/17)
     
  6236. CROI: The Large Gap Between Statin Eligibility and Prescription in the NA-ACCORD - written by Mark Mascolini - (02/18/17)
     
  6237. CROI: Persistent Immune Activation Despite ART: The "Die is Cast" Before ART Initiation - (02/16/17)
     
  6238. CROI: On Demand Post-Exposure Prophylaxis with Doxycycline for MSM Enrolled in a PrEP Trial - (02/16/17)
     
  6239. CROI: On Demand Post-Exposure Prophylaxis with Doxycycline for MSM Enrolled in a PrEP Trial - (02/16/17)
     
  6240. CROI: Higher Rates of Heart Disease, Diabetes, Neuropathy in Older Men With vs Without HIV - written by Mark Mascolini - (02/16/17)
     
  6241. CROI: PEP With Doxycycline Halves Bacterial STI Rate in MSM on TDF/FTC PrEP - written by Mark Mascolini - (02/16/17)
     
  6242. CROI: "Critical Barrier" Between PrEP Interest and Uptake in Young Black MSM - written by Mark Mascolini - (02/16/17)
     
  6243. CROI: HIV Compartmentalization in Central Nervous System During Acute Infection - written by Mark Mascolini - (02/16/17)
     
  6244. CROI: HIV More Than Doubles Odds of Cerebral Small-Vessel Disease in French Study - written by Mark Mascolini - (02/16/17)
     
  6245. CROI: Viral Load Undetectable 288 Days Without ART After Stem Cell Transplant - written by Mark Mascolini - (02/16/17)
     
  6246. CROI: Steady Drop in Time Spent With Viral Load Above 1500 Copies in US Group - written by Mark Mascolini - (02/16/17)
     
  6247. CROI: Significant Efficacy and Long-term Safety Difference With TAF-Based STR in NaÏve Adults - (02/16/17)
     
  6248. CROI: 288 Day Drug-Free Remission From HIV Rebound by Allogeneic PBSCT - (02/16/17)
     
  6249. CROI: Longitudinal HIV Viral Trajectories and Co-Morbidities Longitudinal in the WIHS: Viral Suppression Key to Survival - (02/16/17)
     
  6250. CROI: Long-Term Efficacy of Dolutegravir 50 mg BID in INI-Resistant Failing HIV-1 Subjects - (02/16/17)
     
  6251. CROI: HIV Attachment Inhibitor Fostemsavir / BMS-663068, GSK3684934 - (02/16/17)
     
  6252. CROI: In Vitro -In Vivo Evaluation of a Biodegradable Implant Containing TAF for HIV PrEP - (02/16/17)
     
  6253. CROI: LONG-ACTING IBALIZUMAB IN PATIENTS WITH MULTI-DRUG RESISTANT HIV-1: A 24-WEEK STUDY - (02/16/17)
     
  6254. CROI: Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - (02/16/17)
     
  6255. CROI: DORAVIRINE IS NON-INFERIOR TO DARUNAVIR+RITONAVIR IN PHASE 3 TREATMENT-NAÏVE TRIAL AT WEEK 48 - (02/16/17)
     
  6256. CROI: Discovery of Novel Potent HIV Capsid Inhibitors with Long-Acting Potential - (02/16/17)
     
  6257. CROI: Viral Load Dynamics Among Persons with Diagnosed HIV: United States, 2014 - (02/16/17)
     
  6258. CROI: PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN 12249 TREATMENT AS PREVENTION TRIAL - (02/16/17)
     
  6259. CROI: Doravirine in Non-Inferior To Darunavir+Ritonavir in Phase 3 Treatment-Naive Trial at Week 48 - (02/16/17)
     
  6260. CROI: Clinical Pharmacology of the Unboosted HIV Integrase Strand Transfer Inhibitor (INSTI) Bictegravir (BIC) - (02/16/17)
     
  6261. CROI: Randomized Trial of Bictegravir or Dolutegravir with FTC/TAF for Initial HIV Therapy - (02/16/17)
     
  6262. CROI: SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)
     
  6263. CROI: Inflammation and Coagulation Markers Predict Clinical Risk in START Trial - written by Mark Mascolini - (02/15/17)
     
  6264. CROI: Excess Epicardial Fat Tied to Noncalcified Plaque in Women With HIV - written by Mark Mascolini - (02/15/17)
     
  6265. CROI: Cardiovascular Risk More Likely With Longer Viral Control in WIHS Women - written by Mark Mascolini - (02/15/17)
     
  6266. CROI: Monoclonal Antibody Suppresses HIV in Half With Multidrug-Resistant Virus - written by Mark Mascolini - (02/15/17)
     
  6267. CROI: New Integrase Inhibitor Attains 97% Viral Suppression Through 48 Weeks - written by Mark Mascolini - (02/15/17)
     
  6268. CROI: Only Half of Big US HIV Group Had Durable Viral Suppression in 2014 - written by Mark Mascolini - (02/15/17)
     
  6269. CROI: Three in 30 Infants Treated in First 48 Hours of Life Become PCR Negative - written by Mark Mascolini - (02/15/17)
     
  6270. Inflammation Explained - Research for Therapies / Review - Inflammation, metaflammation and immunometabolic disorders - (02/14/17)
     
  6271. New PrEP Cascade Methods Find 1 in 10 Benefit from PrEP - Uptake of HIV Pre-Exposure Prophylaxis (PrEP) in a National Cohort of Gay and Bisexual Men in the United States - (02/14/17)
     
  6272. Gilead Sciences, Inc. Medical Affairs HIV/HCV NoCo program: Toward Elimination of HCV in HIV-Infected Populations - $ 3 Million in Grants - (02/14/17)
     
  6273. CROI: ViiV Announces SWORD Study Results: Dolutegravir+Rilpivirine in Virologically Suppressed - (02/14/17)
     
  6274. CROI: Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors - (02/14/17)
     
  6275. CROI: Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV - (02/14/17)
     
  6276. TAF vs NRTI Resistance Mutations - Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse Transcriptase and Protease in Antiretroviral Treatment-Naïve Patients do not Affect Response to Tenofovir Disoproxil Fumarate- or Tenofovir Alafenamide-Containing Regimen - (02/13/17)
     
  6277. New SF General clinic treats older HIV patients / Aging Clinic 'Golden Compass' - (02/13/17)
     
  6278. Golden Compass Aging Clinic / program launches at SF General - "one-stop shop for HIV-positive people age 50 and older" - (02/13/17)
     
  6279. Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment - (02/09/17)
     
  6280. WHO IS MANAGING AGING PATIENTS & THEIR RISK FOR FALLS ? No ONE - Jules Levin, NATAP - (02/09/17)
     
  6281. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis - (02/06/17)
     
  6282. Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study - (02/06/17)
     
  6283. NIH Cure Meeting - overview by Dan Kuritzkes /Cure Research direction - Concerns, questions, treatment interruptions - (02/06/17)
     
  6284. Cure Research Review at OAR NIH Meeting, The Brain, Treatment Interruptions - (02/06/17)
     
  6285. CytoDyn's Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 - (02/06/17)
     
  6286. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010 - (02/06/17)
     
  6287. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques - (02/06/17)
     
  6288. Hormone Blockers Can Prolong Life if Prostate Cancer Recurs - (02/06/17)
     
  6289. Inflammation, Immune Activation, Immunosenescence, and Hormonal Biomarkers in the Frailty-Related Phenotype of Men With or at Risk for HIV Infection - lower CD4, detectable viral load, more inflammation, lower testosterone, HIV associated with senescence & immune activation.....Exercise & Diet recommended - (02/06/17)
     
  6290. Commonalities Between Vasculature and Bone - (02/03/17)
     
  6291. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010 - (02/03/17)
     
  6292. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis - (02/03/17)
     
  6293. Next Generation anti-HIV Agents - Capsid Inhibitors - (02/03/17)
     
  6294. CytoDyn Reports Treatment of First Several Patients With PRO 140 in Its Phase 3 Monotherapy Trial for HIV - (02/03/17)
     
  6295. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals - (02/02/17)
     
  6296. Cure Research Review at OAR NIH Meeting - (02/02/17)
     
  6297. FDA Update - EVOTAZ (atazanavir/cobicistat) label was updated to include new data - (02/01/17)
     
  6298. HIV Related Distressing Symptoms for Young & Aging HIV+ - (02/01/17)
     
  6299. New HIV Cure Research/Reports - (02/01/17)
     
  6300. CROI: A Long-Acting Biodegradable Subcutaneous Implant for Tenofovir Alafenamide Fumarate HIV PrEP - (01/31/17)
     
  6301. Aging - Death Rates of HIV+ Increase Only in those Over 60 Years Old, in Younger Groups Death Rates Decrease - (01/31/17)
     
  6302. Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors - (01/30/17)
     
  6303. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission - (01/30/17)
     
  6304. A link between antiretrovirals and perinatal outcomes? - (01/30/17)
     
  6305. Ending HIV/AIDS - LA & NY Care Continuum - (01/27/17)
     
  6306. 80% of HIV+ Are Over 45 / 20% over 60 /50% Over 50 in NY, SF, Boston, Florida - (01/27/17)
     
  6307. Evolving epidemiology of HIV-associated malignancies - (01/27/17)
     
  6308. High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines - Anal Cancer Screening in HIV+ Women Under-Screened / Routine Testing Recommended for All HIV+ Women - (01/27/17)
     
  6309. Psychiatric Symptoms in Patients Receiving Dolutegravir - (01/25/17)
     
  6310. IBALIZUMAB 24-WEEK PIVOTAL PHASE III STUDY RESULTS ACCEPTED AS A LATE BREAKER WILL BE PRESENTED AT CROI 2017 - (01/25/17)
     
  6311. TLR9, TLR7 HIV Cure Research - (01/24/17)
     
  6312. 2 New Cure HIV Antibodies Studies Reported, Combination 3 Antibodies, Two-Pronged Antibody - (01/24/17)
     
  6313. Aging & HIV : "A Call to Action - Uncharted Territory A report into the first generation growing older with HIV" UK Patient Survey Report - (01/24/17)
     
  6314. 2 New HIV Antibodies Studies Reported, combining 3 antibodies - (01/24/17)
     
  6315. TLR9, TLR7 HIV Cure Research - (01/24/17)
     
  6316. Darunavir + Genvoya [elvitegravir/cobi/FTC/TAF] in Treatment-Experienced Patients with HIV Drug Resistance - (01/24/17)
     
  6317. IL-15 HIV Cure Research - (01/20/17)
     
  6318. Inhibition of Telomerase Activity by Human Immunodeficiency Virus (HIV) Nucleos(t)ide Reverse Transcriptase Inhibitors: A Potential Factor Contributing to HIV-Associated Accelerated Aging - (01/20/17)
     
  6319. A microbial protein that alleviates metabolic syndrome - (01/20/17)
     
  6320. Cure Research Ethics, Risks for Participants - (01/20/17)
     
  6321. Darunavir + Genvoya [elvitegravir/cobi/FTC/TAF] in Treatment-Experienced Patients with HIV Drug Resistance - (01/18/17)
     
  6322. Brisk Walking & Strength Training Reduced Inflammation (CRP) & LDL/total Cholesterol - (01/18/17)
     
  6323. HIV Remodels Brain Function Study Suggests - also: illicit drug use history, comorbidities - (01/18/17)
     
  6324. Questioned - Statin Recommendations / Risk Calculator / American College of Cardiology/American Heart Association (ACC/AHA) guidelines on assessment of cardiovascular risk1 and on treatment of blood cholesterol - (01/13/17)
     
  6325. Statin Benefit vs Harm - OPINION - (01/04/16)
     
  6326. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults - (01/13/17)
     
  6327. CVD Prediction- Diabetes/Lipids/Hypertension - (01/11/17)
     
  6328. Diabetes / CVD in HIV+ / Inaccuracy of A1C - (01/11/17)
     
  6329. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network - (01/11/17)
     
  6330. Predicting HIV-Life Expectancy, Comorbidities - Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population - (01/11/17)
     
  6331. Health & AIDS Spending USA - (01/11/17)
     
  6332. CVD Prediction- Diabetes/Lipids/Hypertension - (01/10/17)
     
  6333. Medical error-the third leading cause of death in the US - (01/10/17)
     
  6334. Lipid Management Guidelines for Adults with Chronic Kidney Disease - (01/10/17)
     
  6335. The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset - (01/10/17)
     
  6336. Interpretation of the evidence for the efficacy and safety of statin therapy - (01/10/17)
     
  6337. Under Estimating HIV Cardiovascular Disease Risk / Association Between HIV and Cardiovascular Diseases - Finding a Solution to Double Jeopardy - (01/10/17)
     
  6338. Interpretation of the evidence for the efficacy and safety of statin therapy - (01/05/16)
     
  6339. An assessment by the Statin Liver Safety Task Force: 2014 update - (01/05/16)
     
  6340. 2014 Statin Safety Task Force - (01/04/16)
     
  6341. Lipid Management Guidelines for Adults with Chronic Kidney Disease - (01/04/16)
     
  6342. An assessment by the Statin Muscle Safety Task Force: 2014 update - (01/04/16)
     
  6343. Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab) - (01/04/16)
     
  6344. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients - The GLAGOV Randomized Clinical Trial - (01/04/16)
     
  6345. Statin Use for the Primary Prevention of Cardiovascular Disease in AdultsUS Preventive Services Task Force Recommendation Statement - (01/04/16)
     
  6346. Anti-PCSK9 Monoclonal Antibodies: The Future Lipid-Lowering Agent of Choice? - (01/04/16)
     
  6347. The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset - (01/03/16)
     
  6348. AGE: Medical error-the third leading cause of death in the US - (01/03/16)
     
  6349. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis - (01/03/16)
     
  6350. Lipid Management Guidelines for Adults with Chronic Kidney Disease - (01/03/16)
     
  6351. Pitavastatin: an overview of the LIVES study - (01/03/16)
     
  6352. Pitavastatin: a distinctive lipid-lowering drug - (01/03/16)
     
  6353. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study - (01/03/16)
     
  6354. GLASGOW: Neurologic Involvement in patients with Acute/Recent HIV Infection - (12/22/16)
     
  6355. After 52 Weeks, Pitavastatin is Superior to Pravastatin for LDL-C Lowering in Patients with HIV - (12/22/16)
     
  6356. HIV-Increased Stroke Rates/50% Higher - (12/22/16)
     
  6357. Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post-Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age / Inflammation / Heart Disease Problem in HIV - (12/22/16)
     
  6358. Statins Safety - pitavastatin [LIVALO] Product Insert - (12/22/16)
     
  6359. NIH Launches First Large Trial of a Long-Acting Injectable Drug for HIV Prevention - (12/21/16)
     
  6360. Aging in US - Worse Still To Come - polypharmacy, multiple comorbidities, decreased survival, impaired daily activities functioning - (12/21/16)
     
  6361. The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin - (12/21/16)
     
  6362. HIV cure strategists: ignore the central nervous system at your patients' peril - (12/21/16)
     
  6363. ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention - (12/21/16)
     
  6364. Aging & Addiction / Substance Abuse - (12/21/16)
     
  6365. ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen - (12/20/16)
     
  6366. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection - (12/20/16)
     
  6367. HIV INCIDENCE ESTIMATES NEW YORK STATE, 2014 - (12/21/16)
     
  6368. HIV Care in New York State, 2014: Linkage, Retention and Viral Suppression Among Persons Residing in New York State - (12/20/16)
     
  6369. Differential Efficacy of ABX464 and its Primary Metabolite ABX464-NGlc on HIV Replication: Implications for Treatment Strategies to Eliminate Viral Reservoirs - (12/19/16)
     
  6370. CROI: Early Evidence of Antiviral Activity and Safety of ABX464 in HIV Treatment-Naïve Patients - (10/19/16)
     
  6371. GLASGOW: Hepatic Steatosis is Highly Prevalent in HIV and Significantly Associated with Diabetes Risk - (12/15/16)
     
  6372. U.S. life expectancy declines for the first time since 1993 - (12/15/16)
     
  6373. Muscle Strength/brain-mortality/after fracture & Before / Quadriceps weakness and post-fracture mortality - (12/15/16)
     
  6374. Strong Leg Muscles Improve Brain Functioning & healthy aging....study in track & field athletes in their 80s - (12/15/16)
     
  6375. HIV-Dart: Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DCFTAF) - (12/15/16)
     
  6376. HIV Dart/2016: Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V - (12/15/16)
     
  6377. Cost of Care in Older Aging patients with Increased Comorbidities......Non-HIV care provider....Aging, Worse Still to Come? - (12/09/16)
     
  6378. Brief Report: Differential Effects of Tenofovir, Abacavir, Emtricitabine, and Darunavir on Telomerase Activity In Vitro - (12/09/16)
     
  6379. HCV/HIV Children / Young Adults in Europe - Sofosbuvir, Ledipasvir/sofosbuvir PK in aged <6 to <12 Years Old - (12/07/16)
     
  6380. PD-1 New Cancer immunotherapy Drugs Success - Adverse Events, HIV - (12/07/16)
     
  6381. Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer - (12/07/16)
     
  6382. Brain in Older HIV+ - We Do Not Understand the Brain in Older HIV+ - (12/07/16)
     
  6383. Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques - (12/06/16)
     
  6384. Atazanavir use and carotid intima media thickness progression in HIV: potential influence of bilirubin - (12/06/16)
     
  6385. NIH Webcast Strategies for an HIV Cure 2016 Meeting November 14 - 16, 2016 - (12/06/16)
     
  6386. OAR NIH Webcast Meeting on HIV Cure Nov 17 2016 - (12/06/16)
     
  6387. Efavirenz-Induced Nitric Oxide Affects Mitochondrial Function in Glial Cells - (12/05/16)
     
  6388. GLASGOW: Switch to dolutegravir in HIV patients responding to a first line antiretroviral treatment- 48 weeks results - (12/02/16)
     
  6389. AASLD: Are risk factors still relevant for HCV treatment with directly-acting agents against HCV in HIV-HCV-coinfection? Results from the German hepatitis C cohort (GECCO) - (12/01/16)
     
  6390. ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen - (12/01/16)
     
  6391. HIV Protease Inhibitors: New Class of Anti-Cancer Drugs - (12/01/16)
     
  6392. J&J vaccine plus Gilead immune booster shows promise as HIV fighter - (12/01/16)
     
  6393. AASLD: A Prospective Study of The Association of Body Morphometry With Hepatic Steatosis and Fibrosis in HIV-HCV Coinfected Patients - (11/30/16)
     
  6394. Shedding of Hepatitis C Virus Into the Rectum of HIV-infected Men Who Have Sex With Men - (11/30/16)
     
  6395. Aerobic exercise and vascular cognitive impairment - 74 Year Olds with Vascular Cognitive Impairment - (11/11/16)
     
  6396. Slow gait, white matter characteristics, and prior 10-year interleukin-6 levels in older adults - (11/11/16)
     
  6397. Infection-related and -unrelated malignancies, HIV and the aging population....older age, low CD4, viral load, smoking, HBV, [HCV].....Non-HIV Cancers Predicted to Increase - (11/11/16)
     
  6398. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy - (11/11/16)
     
  6399. Anti-Inflammation New Drug Research / Cure May Not Reverse Inflammation Damage - (11/11/16)
     
  6400. Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab. - (11/11/16)
     
  6401. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice - (11/10/16)
     
  6402. GLASGOW: Non-inferiority of dual-therapy with darunavir/ritonavir plus 3TC vs. triple therapy with darunavir/ritonavir plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014-RIS-EST45 Trial - DUAL: "DarUnavir And Lamivudine" - (11/09/16)
     
  6403. New Therapeutic Vaccine Approach in Non-Human Primates Shows Potential as Functional Cure for HIV-1 - (11/09/16)
     
  6404. CROI: Impressions from CROI - Pablo Tebas, MD University of Pennsylvania. (03/07/16)
     
  6405. Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys - Functional Cure Strategy - (11/09/16)
     
  6406. Dolutegravir use in 181 patients, 54 women and 9 pregnancies - a real life experience - (11/09/16)
     
  6407. GLASGOW: Changes in the Prevalence of Cardiovascular, Renal and Bone Co-Morbidities and Related Risk Factor in HIV-Infected Patients in The Spanish VACH Cohort: A Cross-Sectional Study in 2010 and 2014.... - (11/09/16)
     
  6408. IDSA: Long-term Effects of [Omega-3] Ω:-3 Fatty Acids in HIV: a RCT - (11/09/16)
     
  6409. IDSA: [Barriers to HCV Care] Expanded HCV Testing and Linkage to Care: Program Implementation to Overcome Barriers to Engagement in Care ....7% SVR rate..... from Jules: there remain persistent difficult barriers to HCV care in inner cities, very strong support services related to linkage to care are needed. - (11/09/16)
     
  6410. IDSA: Mass Incarceration and Economic Inequality: the Impact of the Criminal Justice System on HIV Prevalence within Neighborhoods in the US - (11/09/16)
     
  6411. GLASGOW: Helping the HIV Physician through the challenges of co-morbidities in decision making - (11/09/16)
     
  6412. GLASGOW: Discontinuation of Dolutegravir (DTG)-based Regimens in Clinical Practice - (11/09/16)
     
  6413. GLASGOW: Cognitive function and depression in HIV-positive individuals and matched controls - (11/08/16)
     
  6414. GLASGOW: Aging in France Report - (11/08/16)
     
  6415. GLASGOW: HEALTH-RELATED COSTS IN CHRONIC HIV INFECTION: A CASE-CONTROL STUDY VS. GENERAL POPULATION USING A CLAIMS-BASED APPROACH IN GERMANY....healthcare/drug costs soar for HIV+ aging compared to HIV-neg. - (11/08/16)
     
  6416. GLASGOW: COMORBITY IN CHRONIC HIV INFECTION A CASE-CONTROL STUDY IN GERMANY USING HEALTH INSURANCE CLAIMS DATA [Examines 70-80+ Year Olds. Higher Prevalence of Comorbidities in HIV+ vs HIV-neg] - (11/08/16)
     
  6417. GLASGOW: Antiretroviral Treatment Patterns in the US: An Analysis of Real World Data - (11/08/16)
     
  6418. GLASGOW: First-Line Antiretroviral Treatment Characteristics Among HIV-Infected Patients With and Without Comorbidities.....High Comorbidities Rates in 40 Year Old (SD-12) HIV+....." - (11/08/16)
     
  6419. GLASGOW: Mortality rates and excess mortality among HIV-positive persons according to age in Spain, 2004-2014 - (11/08/16)
     
  6420. GLASGOW: Discontinuation of Dolutegravir (DTG)-based Regimens in Clinical Practice - (11/08/16)
     
  6421. IDSA: Using Home-Delivery Pharmacy Triples Odds of Viral Control in Cleveland Group - Mark Mascolini (11/07/16)
     
  6422. IDSA: High Proportions With AIDS/Non-AIDS Cancers Remain Unsuppressed - Mark Mascolini (11/07/16)
     
  6423. IDSA: Caution Advised on Long-Term PPIs Because of Link to Immune Activation With HIV - Mark Mascolini (11/07/16)
     
  6424. IDSA: Viral Rebound Rate 22% in US Group--Higher in Blacks and With Lower CD4s - Mark Mascolini (11/07/16)
     
  6425. IDSA: Polypharmacy in HIV+ 50 or Older Linked to Lower CD4s, Higher CVD Rate - Mark Mascolini (11/07/16)
     
  6426. IDSA: Women Account for Virtually Half of New HIV in Bronx Group in Regular Care - Mark Mascolini (11/07/16)
     
  6427. IDSA: The Impact of Antiretroviral Tablet Burden and Polypharmacy on Viral Suppression in Treatment Naïve Patients - (11/07/16)
     
  6428. IDSA: Efficacy of Dolutegravir/Abacavir/Lamivudine (ABC/DTG/3TC) Fixed Dose Combination (FDC) compared with Ritonavir Boosted Atazanavir (ATV/r) plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naïve Women with HIV-1 Infection (ARIA Study): Analyses by Race Subgroups - (11/07/16)
     
  6429. IDSA: Renal and Bone Outcomes Among HIV-Infected Patients Exposed to EFV+TDF/FTC Compared to Other TDF-Containing Antiretroviral Regimens: Findings From the Veterans Health Administration - (11/07/16)
     
  6430. IDSA: The ART Advantage: healthcare utilization for diabetes and hypertension in rural South Africa - (11/07/16)
     
  6431. IDSA: HIV Reservoir Half-Life 12 Years in 111-Person, 477-Sample Analysis [slow decay] - - Mark Mascolini (11/05/16)
     
  6432. IDSA: An expanded HIV testing strategy leveraging the electronic medical record uncovers undiagnosed infection among hospitalized patients - (11/05/16)
     
  6433. GLASGOW: HIV PATIENTS TODAY AND 10 YEARS AGO: DO THEY HAVE THE SAME NEEDS? RESULTS FROM CROSS SECTIONAL ANALYSIS OF ANRS CO3 AQUITAINE COHORT - (11/05/16)
     
  6434. GLASGOW: Uncontrolled HIV Tied to NHL But Not Hodgkins in Large D:A:D Study - Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma: The D:A:D study - Mark Mascolini - (11/05/16)
     
  6435. Infection-related and -unrelated malignancies, HIV and the aging population....older age, low CD4, viral load, smoking, HBV, [HCV].....Non-HIV Cancers Predicted to Increase - (11/05/16)
     
  6436. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy - (11/05/16)
     
  6437. IDSA: Almost Half of Atlanta MSM Will Use PrEP, But HIV Risk Perception Often Faulty - Willingness to Use Pre-exposure Prophylaxis (PrEP) among black and white MSM in Atlanta, GA - Mark Mascolini (11/04/16)
     
  6438. IDSA: Prison Release, Poverty, Inequality Tied to Higher HIV Prevalence - Mark Mascolini (11/04/16)
     
  6439. IDSA: New HIV Diagnoses Quadruple With Electronic Testing Prompt in Bronx Hospitals - Mark Mascolini - (11/04/16)
     
  6440. IDSA: HIV Reservoir Half-Life 12 Years in 111-Person, 477-Sample Analysis - Mark Mascolini - (11/04/16)
     
  6441. IDSA: Using Home-Delivery Pharmacy Triples Odds of Viral Control in Cleveland Group - Evaluation of impact of pharmacy proximity on HIV viral suppression - Mark Mascolini - (11/04/16)
     
  6442. IDSA: Retesting of suspected low-level HIV-1 viral load blips: A new paradigm to prevent extra clinic visits and unnecessary patient anxiety - (11/04/16)
     
  6443. IDSA: Detectable Viral Load--But Not PI Use--Linked to Avascular Necrosis - Risk Factors Associated With Osteonecrosis of the Hip in an HIV-Infected Population in the New Antiretroviral Therapy Era - Mark Mascolini - (11/04/16)
     
  6444. IDSA: Should Anal Cancer Screening Get More Aggressive for Some MSM With HIV? - HPV-related disease in HIV-infected MSM with and without recent HCV - Mark Mascolini - (11/04/16)
     
  6445. IDSA: HIV Infection and PrEP Use are Independently Associated with Increasing Diagnoses of Bacterial Sexually Transmitted Infections (BSTI) in Men Accessing Care at a Boston Community Health Center (CHC): 2005-2015 - (11/04/16)
     
  6446. IDSA: Algorithm Sifting Medical Records May Predict Best PrEP Candidates - Automated Identification of Potential Candidates for HIV Pre-Exposure Prophylaxis using Electronic Health Record Data - Mark Mascolini - (11/04/16)
     
  6447. IDSA: Emergence of HIV-1 Drug Resistance Through Week 48 in the Global Women's WAVES Study: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs. Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF - (11/04/16)
     
  6448. IDSA: Efficacy and Safety of Tenofovir Alafenamide in HIV-Infected Black Adults: Subgroup Analysis of a Randomized, Double-blind Switch Study - (11/04/16)
     
  6449. IDSA: Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir DF in HIV-Infected Virologically Suppressed Older Adults at Week 48: Subgroup Analysis of a Randomized Switch Study (Study 311-1089) - (11/04/16)
     
  6450. IDSA: Sofosbuvir/Velpatasvir Plus Voxilaprevir for 6, 8, or 12 Weeks in Genotype 1-6 HCV-infected Patients: An Integrated Analysis of Safety and Efficacy from Two Phase 2 Studies - (11/04/16)
     
  6451. IDSA: Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy - (11/03/16)
     
  6452. IDSA: Depression and HIV Infection are Associated with Higher Risks of All-Cause Mortality in U.S. Veterans - Depression Adds to Mortality Risk With HIV in Large US Veterans Cohort - Mark Mascolini (11/03/16)
     
  6453. IDSA: Long-term use of proton pump inhibitors and increased immune activation in patients with chronic HIV-1 infection Contact Information - Caution Advised on Long-Term PPIs Because of Link to Immune Activation With HIV - Mark Mascolini (11/03/16)
     
  6454. IDSA: Assessing the needs of older HIV+ adults; Initial data from the CORE Healthy Aging Initiative (CHAI) - Money, Mental Health, Housing Top List of Concerns in Older HIV+ Chicago Group - Mark Mascolini (11/03/16)
     
  6455. IDSA: Uptake and virologic outcomes of one-pill versus multi-pill antiretroviral regimen among treatment-naïve non-perinatally HIV-infected youth (2006-2014) - One-Pill ART Promotes HIV Control in US Youth--But Uptake Lower in Girls/Women - Mark Mascolini (11/03/16)
     
  6456. IDSA: Uptake and virologic outcomes of one-pill versus multi-pill antiretroviral regimen among treatment-naïve non-perinatally HIV-infected youth (2006-2014) - One-Pill ART Promotes HIV Control in US Youth--But Uptake Lower in Girls/Women - Mark Mascolini - (11/02/16)
     
  6457. IDSA: A Longitudinal Analysis of Comorbidities among Human Immunodeficiency Virus (HIV) Patients and Matched non HIV Controls in the USA - (11/02/16)
     
  6458. IDSA: Fourteen-Study Analysis Summarizes Safety of Injected and Oral Cabotegravir - Cabotegravir (CAB) Safety Meta-analysis Update From 14 Phase I/IIa Studies - Mark Mascolini - (11/02/16)
     
  6459. IDSA: [11%] One in 10 MSM in Care for HIV Screened for Anal Cancer--Rate Lower in Blacks - Mark Mascolini - (11/02/16)
     
  6460. GLASGOW: Outcomes of Cabotegravir (CAB) Treatment in HIV-1 ART-Naive Patients With Chronic or Acute Hepatitis C Virus (HCV) Co-infection: Data From the Phase IIbProgramme - (11/02/16)
     
  6461. GLASGOW: Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study - (11/02/16)
     
  6462. GLASGOW: Quantifying the future clinical burden of an ageing HIV-positive population in the USA:a mathematical modelling study - (11/02/16)
     
  6463. GLASGOW: Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48 week results from the randomized, controlled, phase 3, non-inferiority TALENT study - (11/02/16)
     
  6464. GLASGOW: Tryptophan Metabolism and its Relationship with Central Nervous System Toxicity in Subjects Switching from Efavirenz to Dolutegravir - (11/02/16)
     
  6465. GLASGOW: Baseline characteristics of the TRIUMPH and DOL-ART cohorts: Use of Triumeq® (DTG/ABC/3TC) or other DTG-based ART in routine clinical care in Germany - Comorbidities/Polypharmacy - (11/02/16)
     
  6466. GLASGOW: The DOL-ART Cohort: providing evidence from real world data -Use of Dolutegravir-based regimens in routine clinical care in Germany - (11/02/16)
     
  6467. GLASGOW: Changes in the Prevalence of Cardiovascular, Renal and Bone Co-Morbidities and Related Risk Factor in HIV-Infected Patients in The Spanish VACH Cohort: A Cross-Sectional Study in 2010 and 2014.... - (11/02/16)
     
  6468. GLASGOW: HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Safety Analysis - (11/02/16)
     
  6469. ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy - (11/02/16)
     
  6470. Future challenges for clinical care of an ageing population infected with HIV: a modeling study...... - (11/02/16)
     
  6471. GLASGOW: Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV) in treatment-experienced HiV-infected patients: preliminary results at 24 weeks of the DORiViR study - (10/31/16)
     
  6472. GLASGOW: Switch to E/C/F/TAF + DRV Superior to No Switch Despite High Resistance - Resistance Profile Analysis of Treatment-Experienced HIV-1 Infected Patients Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) plus Darunavir (DRV) - Mark Mascolini - (10/30/16)
     
  6473. GLASGOW: HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Subgroup Analysis - (10/30/16)
     
  6474. GLASGOW: HIV Combinectin GSK3732394: A Long-Acting Inhibitor With Multiple Modes of Action - (10/30/16)
     
  6475. GLASGOW: Changes in the Prevalence of Cardiovascular, Renal and Bone Co-Morbidities and Related Risk Factor in HIV-Infected Patients in The Spanish VACH Cohort: A Cross-Sectional Study in 2010 and 2014.... - (10/30/16)
     
  6476. GLASGOW: Switch to E/C/F/TAF + DRV Superior to No Switch Despite High Resistance - Resistance Profile Analysis of Treatment-Experienced HIV-1 Infected Patients Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) plus Darunavir (DRV) - Mark Mascolini - (10/30/16)
     
  6477. GLASGOW: HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Subgroup Analysis - (10/30/16)
     
  6478. GLASGOW: HIV Combinectin GSK3732394: A Long-Acting Inhibitor With Multiple Modes of Action - (10/30/16)
     
  6479. GLASGOW: Changes in the Prevalence of Cardiovascular, Renal and Bone Co-Morbidities and Related Risk Factor in HIV-Infected Patients in The Spanish VACH Cohort: A Cross-Sectional Study in 2010 and 2014.... - (10/30/16)
     
  6480. IDSA: Monotherapy With Anti-CD4 Monoclonal Antibody Cuts Viral Load 10-Fold in 7 Days - Mark Mascolini - (10/31/16)
     
  6481. IDSA: One Third of HIV Group With Statin Indication Not Getting Statins - - Mt Sinai NYC, Optimizing Cardiovascular Risk Prevention in an Urban HIV Clinic - Mark Mascolini - (10/31/16)
     
  6482. IDSA: [35% Taking 12 Comedications !] - Polypharmacy in HIV+ 50 or Older Linked to Lower CD4s, Higher CVD Rate - Evaluating the Effect of Polypharmacy on Outcomes in HIV-Infected Patients Age 50 and Older - Mark Mascolini - (10/31/16)
     
  6483. IDSA: TWO REPORTED CASES OF ONLY PRIMARY INTEGRASE INHIBITOR DRUG-CLASS RESISTANCE TRANSMISSION INCLUDING THE FIRST REPORTED CASE OF PRIMARY ELVITEGRAVIR RESISTANCE TRANSMISSION - (10/31/16)
     
  6484. IDSA: Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients with Multi-Drug Resistant HIV-1 Infection - (10/31/16)
     
  6485. IDSA: Past Substance Use Affects CNS Inflammation In HIV - (10/31/16)
     
  6486. IDSA: Low Endothelial Progenitors Tied to CVD Risk, Activation in Older HIV+ Men - Endothelial Progenitor Cell Production is Suppressed and Associated with Systemic Inflammation and Monocyte Activation in Older HIV-Infected Men - Mark Mascolini - (10/31/16)
     
  6487. IDSA: Meta-Analysis Sees Much Higher STI Risk in MSM On vs Not On PrEP - Mark Mascolini - (10/31/16)
     
  6488. Future challenges for clinical care of an ageing population infected with HIV: a modeling study...... - (10/26/16)
     
  6489. GLASGOW: Smoking, Nadir CD4s, and PI Use Tied to Bone Quality in Irish Group - The relative impact of antiretroviral drugs and baseline immune status on bone quality in HIV-positive subjects: results from the HIV UPBEAT cohort - Mark Mascolini - (10/27/16)
     
  6490. GLASGOW: Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir - (10/27/16)
     
  6491. GLASGOW: Improved kidney function in patients who switch their protease inhibitor from atazanaviror lopinavir to darunavir - (10/27/16)
     
  6492. GLASGOW: Kidney Function Improves After Switch From LPV or ATV to DRV - Mark Mascolini (10/27/16)
     
  6493. GLASGOW: Kidney Function Improves After Switch From LPV or ATV to DRV - (10/27/16)
     
  6494. GLASGOW: Third ARV Does Not Affect Safety Gains in Switch From TDF/FTC to TAF/FTC - Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide vs Emtricitabine/Tenofovir Disoproxil Fumarate as a Backbone for Treatment of HIV-1 Infection in Virologically Suppressed Adults: Subgroup Analysis by 3rd Agent - (10/27/16) - Mark Mascolini
     
  6495. GLASGOW: Sofosbuvir/Velpatasvir Single Tablet Regimen in HCV Monoinfected and HIV/HCV Coinfected Patients: Comparison of Efficacy and Safety Data from Phase 3 Clinical Trials - (10/26/16)
     
  6496. GLASGOW: Lower Long-Term Risk or Death or AIDS With Lipoatrophy or Lipodystrophy - (10/26/16)
     
  6497. GLASGOW: Lower Long-Term Risk or Death or AIDS With Lipoatrophy or Lipodystrophy - (10/26/16)
     
  6498. GLASGOW: HIV DNA Vanishes ["Cure"?] After CCR5-delta32 Stem Cell Transplant, But ART Continues - Mark Mascolini (10/26/16)
     
  6499. GLASGOW: Subgroup Analyses from ONCEMRK, a Phase 3 Study of Raltegravir (RAL) 1200 mg Once Daily vs RAL 400 mg Twice Daily, in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects - (10/26/16)
     
  6500. GLASGOW: Efficacy of Dolutegravir/Abacavir/Lamivudine Fixed-Dose Combination Compared With Ritonavir-Boosted Atazanavir Plus Tenofovir Disoproxil Fumarate/Emtricitabine in Treatment-Naive Women With HIV-1 Infection (ARIA Study): Subgroup Analyses - (10/26/16)
     
  6501. GLASGOW: Psychiatric Adverse Events From the DTG ART-Naive Phase III/IIIb Clinical Trials - (10/26/16)
     
  6502. GLASGOW: Switching from cART to dolutegravir monotherapy in virologically suppressed HIV-1 infected patients: A randomized clinical trial (DOMONO) - poster - (10/26/16)
     
  6503. GLASGOW: Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide vs Emtricitabine/Tenofovir Disoproxil Fumarate as a Backbone for Treatment of HIV-1 Infection in Virologically Suppressed Adults: Subgroup Analysis by 3rd Agent - (10/25/16)
     
  6504. GLASGOW: 48 Week Results from two studies: Switching to RPV/FTC/TAF from EFV/FTC/TDF (Study 1160) or RPV/FTC/TDF (Study 1216) - (10/25/16)
     
  6505. GLASGOW: Higher Rates of Neuropsychiatric Adverse Events Leading to Dolutegravir Discontinuation in Women and Older Patients - (10/25/16)
     
  6506. GLASGOW: Proportion of US HIV Patients With 3 or More Comorbidities Will Rise 4-Fold by 2035 - Mark Mascolini - (10/25/16)
     
  6507. GLASGOW: Future challenges for clinical care of an ageing population infected with HIV: a ''geriatric HIV'' modeling study...... - (10/25/16)
     
  6508. GLASGOW: Prevalence of All Comorbidities Up From 2004 to 2014 in Big French Cohort - Mark Mascolini - (10/25/16)
     
  6509. GLASGOW: Switch to E/C/F/TAF + DRV Superior to No Switch Despite High Resistance - Mark Mascolini - (10/25/16)
     
  6510. GLASGOW: Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV) in treatment-experienced HIV-infected patients: preliminary results at 24 weeks of the DORIVIR study - Mark Mascolini - (10/25/16)
     
  6511. GLASGOW: Rates of All Age-Related Comorbidities Rise in EuroSIDA From 2006 to 2014 - (10/25/16)
     
  6512. GLASGOW: Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens - (10/24/16)
     
  6513. GLASGOW: Durability and tolerability of first-line combination including two NRTI and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation Cohort - (10/24/16)
     
  6514. HIVR4P: Use of Injectable Depot Medroxyprogesterone Acetate (DMPA) Downregulates Vaginal Epithelial Barrier Genes - Similarly to Mucosal Inflammation - (10/24/16)
     
  6515. HIVR4P: Modulation of Tenofovir (TFV) Pharmacokinetics and Antiviral Activity by Vaginal Microbiota: Implications for Topical PrEP - (10/24/16)
     
  6516. HIVR4P: Microbiome Composition & Function Drives Would-Healing Impairment in the Female Genital Tract - (10/24/16)
     
  6517. HIVR4P: Genes Tied to Mucosal Injury/Repair in Rectum of MSM Having Receptive Anal Sex - Mark Mascolini - (10/24/16)
     
  6518. HIVR4P: Tenofovir / IQP-0528 Combination Gel Effectively Inhibits HIV and Is Not Affected by Semen - (10/24/16)
     
  6519. HIVR4P: Pre-exposure Prophylaxis with EFdA Offers Strong Protection against High Dose Mucosal HIV Challenges - [Long-Acting New NRTI for Treatment & PrEP] - (10/24/16)
     
  6520. HIVR4P: Genes Tied to Mucosal Injury/Repair in Rectum of MSM Having Receptive Anal Sex - Mark Mascolini - (10/24/16)
     
  6521. HIVR4P: Can we prevent HIV infection by focusing on the HIV target cell rather than the virus? Common Anti-inflammatory Medications Reduce HIV-Target Infection Cells Apparently Reducing Inflammation/Immune Activation & Creating "Immune Quiescence" - (10/21/16)
     
  6522. HIVR4P: US Women in the HPTN 069/ACTG 5305 Phase II Maraviroc PrEP study: A substudy evaluating acceptability and experiences - (10/21/16)
     
  6523. HIVR4P: Understanding Longitudinal HIV Care Trajectories to Improve Health and Reduce HIV Transmission in North Carolina - Sub Optimal - (10/21/16)
     
  6524. HIVR4P: PrEP Knowledge and Use in San Francisco - 12,500 PrEP Users in SF - Lower use by African-Americans, age & Females - (10/21/16)
     
  6525. HIVR4P: To switch or not to switch: anticipating choices in biomedical HIV prevention - from Oral to Long Acting Injectable PrEP - 90 Men using PrEP Surveyed - (10/21/16)
     
  6526. HIVR4P: Are Ring Worries Affecting Use? Findings from the MTN-020/ASPIRE Phase III Dapivirine Ring Trial - (10/21/16)
     
  6527. HIVR4P: In San Francisco 12,500 on PrEP--But Lower Use in Young, Blacks, Women - Mark Mascolini - (10/21/16)
     
  6528. HIVR4P: HIV Mobile in Cervicovaginal Mucus of Women With Bacterial Vaginosis / Risk for HIV Aquisition - Mark Mascolini - (10/21/16)
     
  6529. HIVR4P: Five HIV Care Trajectories Seen in 15,000-Person North Carolina Study..... Poor Engagement in Care - Mark Mascolini - (10/21/16)
     
  6530. HIVR4P: Good Adherence by 58% of Women in Maraviroc PrEP Trial--But It Works - Mark Mascolini - (10/21/16)
     
  6531. Sexual Comfort of Vaginal Ring for Women - (10/21/16)
     
  6532. IWCADRH: Get Your HIV/AIDS Patients to Stop Smoking Before it Kills Them - (09/28/16)
     
  6533. Attenuated SIV causes persisting neuroinflammation in the absence of a chronic viral load and neurotoxic antiretroviral therapy - (10/18/16)
     
  6534. HIVR4P: Evaluation of MK-2048 and Vicriviroc, Formulated as Single or Combination (MK-2048A) Intravaginal Rings, for Development as a Vaginal Microbicide - (10/19/16)
     
  6535. HIVR4P: Two Thirds of Oral PrEP-Using MSM Would Switch to Long-Term Shots - Mark Mascolini - (10/19/16)
     
  6536. HIVR4P: Anal Sex May Explain One Third of New Heterosexually-Acquired HIV in Group of US Women - Mark Mascolini - (10/19/16)
     
  6537. HIVR4P: Newly Acquired HIV-1 Infection with Multi-Drug Resistant HIV-1 in a Patient on TDF/FTC-based PrEP - (10/19/16)
     
  6538. HIVR4P: Low-Dose Aspirin or Hydroxychloroquine Limits Activated Target Cells in Genital Tract - Mark Mascolini - (10/19/16)
     
  6539. HIVR4P: Novel Integrase Mutation in Macaque Cabotegravir Study--But "Limited" Clinical Impact - Mark Mascolini - (10/19/16)
     
  6540. HIVR4P: Low-Dose Aspirin or Hydroxychloroquine Limits Activated Target Cells in Genital Tract - Mark Mascolini - (10/19/16)
     
  6541. HIVR4P: Infection With Multidrug-Resistant HIV While Adherent to TDF/FTC PrEP - Mark Mascolini - (10/19/16)
     
  6542. HIVR4P: One Third of Women in US Study May Pick Up HIV During Anal Sex - Mark Mascolini - (10/19/16)
     
  6543. HIV Cascade in NYC 2006-2012 - Increase in CD4+ T-Cell Count at the Time of HIV Diagnosis and Antiretroviral Treatment Initiation Among Persons With HIV in New York City - (10/18/16)
     
  6544. Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection - (10/18/16)
     
  6545. Impact of aging on neurocognitive performance in previously antiretroviral-naïve HIV+ individuals on their first suppressive regimen - (10/18/16)
     
  6546. Associations of CSF Iron Biomarkers with Neurocognitive Function Over Time in HIV+ Adults - (10/18/16)
     
  6547. Initiation of antiretroviral therapy in early HIV infection reduces but does not abrogate chronic residual inflammation - (10/18/16)
     
  6548. Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys - (10/14/16)
     
  6549. Surprising treatment 'cures' monkey HIV infection - (10/14/16)
     
  6550. Sustained virologic control in SIV+ macaques after antiretroviral and 4β7 antibody therapy - possible functional cure - (10/14/16)
     
  6551. Current raltegravir use: clinical practice in UK centres (CRICKET - PN-807) - (10/12/16)
     
  6552. Raltegravir treatment outcomes among older patients and those with comorbidities: A sub-analysis of the CRICKET study (PN-807) - (10/12/16)
     
  6553. Exercise Reduces Cancers / Physical Activity and Digestive System Cancer Risk Still Chasing the Promise - (10/12/16)
     
  6554. Aging and HIV Identifying Care Needs - (10/11/16)
     
  6555. T-cell Reactivity to Cytomegalovirus, Inflammation, and Frailty in HIV+ and HIV- Men Who Have Sex With Men (MACS) - (10/10/16)
     
  6556. Safety and Efficacy of Dolutegravir and Maraviroc Plus Background Therapy in HIV-1 Treatment-Experienced Participants - (10/08/16)
     
  6557. EMA Tivicay Oct 1 2015 - electronic Medicines Compendium (eMC) - (10/08/16)
     
  6558. Dolutegravir in the real word: is it all plain SAILING? - (10/08/16)
     
  6559. Retrospective review of real life patient experiences with dolutegravir; virological suppression, immunological recovery and adverse events. - (10/08/16)
     
  6560. Gut - Brain Connection - Signals from the gut microbiota to distant organs in physiology and disease - (10/08/16)
     
  6561. Suboptimal cART Adherence is Associated with Higher Levels of Inflammation Despite HIV Suppression - (10/08/16)
     
  6562. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function - (10/08/16)
     
  6563. Healthcare Provider Contact and Pre-exposure Prophylaxis in Baltimore Men Who Have Sex With Men- 60% Unaware of PrEP - (10/08/16)
     
  6564. NICE [issues Evidence Summary] backs efficacy of Truvada for HIV PrEP - (10/08/16)
     
  6565. Latency reversal and viral clearance to cure HIV-1 /Review - (10/08/16)
     
  6566. Higher CMV Antibody Concentrations are Associated with Older Age and Worse Neurocognitive Performance in Adults Living with HIV Disease - (10/08/16)
     
  6567. Mitochondrial DNA damage in brain associated with HIV infection - (10/08/16)
     
  6568. Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study - (10/08/16)
     
  6569. Caring for Older Adults [aging] with the Human Immunodeficiency Virus....."advance care planning is essential in older adults with HIV" - (10/08/16)
     
  6570. HIV+ >65 on Medicare Have 2 Times More Comorbidities vs HIV-neg AND Blacks & Latinos Have 4-Fold Increased Risk for the 5 Comorbidities Examined vs Whites - CDC Report Chronic health conditions in medicare beneficiaries 65 years and older with HIV infection. - (10/08/16)
     
  6571. Blood-Brain Barrier Permeability and Neurocognitive Performance in HIV+ Adults.... - (10/07/16)
     
  6572. Caring for Older Adults [aging] with the Human Immunodeficiency Virus....."advance care planning is essential in older adults with HIV" - (10/07/16)
     
  6573. HIV+ >65 on Medicare Have 2 Times More Comorbidities vs HIV-neg AND Blacks & Latinos Have 4-Fold Increased Risk for the 5 Comorbidities Examined vs Whites - CDC Report Chronic health conditions in medicare beneficiaries 65 years and older with HIV infection. - (10/07/16)
     
  6574. Mitochondrial DNA damage in brain associated with HIV infection - (10/07/16)
     
  6575. CROI: Unexpectedly High Rate of Intolerance for Dolutegravir in Real Life Setting - (10/08/16)
     
  6576. Frailty / Aging Projections in Italy - Future challenges for clinical care of an ageing population infected with HIV: a "geriatric -HIV" modelling study - (10/07/16)
     
  6577. Comparative effectiveness of generic versus brand-name antiepileptic medications - (09/30/16)
     
  6578. AGE: Atherosclerotic CVD Risk Profile of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate - (09/30/16)
     
  6579. ASM/ICAAC: Real-World Assessment of Renal and Bone Safety Among Patients Exposed to Tenofovir Disoproxil Fumarate-Containing Single Tablet Regimens - (09/30/16)
     
  6580. AGE: Similar E/C/F/TAF Safety and Efficacy in Old vs Younger With Renal Impairment - Geriatric patients - Mark Mascolini - (09/29/16)
     
  6581. AGE: Week 96 Efficacy and Safety of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF) in Older HIV-Infected Virologically-Suppressed Adults - eGFR ≥50 - (09/29/16)
     
  6582. AGE: Week 96 Efficacy and Safety of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF) in Older, HIV-Infected Treatment-Naïve Adults - (09/29/16)
     
  6583. AGE: Non-HIV care provider....Aging, Worse Still to Come?....Aging Clinic at Weill-Cornell, NYC; aging $costs in HIV skyrocket - (09/29/16)
     
  6584. AGE: People 60 or Older Gain Fewer CD4s on ART Through 48 Months - Mark Mascolini (09/29/16)
     
  6585. Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration - (09/28/16)
     
  6586. Generics HIV ART PK Risky? - (09/28/16)
     
  6587. Editorial - The Cognition-Kidney Disease Connection: Lessons From Population-Based Studies in the United States - (09/28/16)
     
  6588. Strong Leg Muscles Improve Brain Functioning - 2 studies report - (09/28/16)
     
  6589. AGE: Excess Mitochondrial DNA Damage in Brain of People With HIV - written by Mark Mascolini - (09/28/16)
     
  6590. AGE: Frailty and the Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - (09/28/16)
     
  6591. AGE: Longitudinal Study of Falls among HIV-infected and Uninfected Women: Results from the Women's Interagency HIV Study - (09/28/16)
     
  6592. AGE: Worse Neurocognitive Score Tied to Higher CMV, Longer HIV, Lower BP - written by Mark Mascolini - (09/28/16)
     
  6593. AGE: Transitions from Disability to Ability: A Qualitative Study to Understand Exercise Barriers in Older, HIV-Infected Adults - (09/28/16)
     
  6594. IWCADRH: CT Signals of Chronic Lung Disease in HIV Patients Who Never Smoked - Mark Mascolini - (09/28/16)
     
  6595. IWCADRH: Impact of initiation of protease inhibitor/ritonavir on PCSK9 levels in HIV-infected antiretroviral-naïve patients from the ANRS C09 COPANA cohort - Mark Mascolini - (09/27/16)
     
  6596. IWCADRH: New Therapies for LDL Management - Mark Mascolini - (09/27/16)
     
  6597. IWCADRH: The impact of HIV and smoking status on bone quality: results from HIV-UPBEAT; a prospective cohort study - Mark Mascolini - (09/27/16)
     
  6598. AGE: Factors Associated with Limitations in Daily Activity Among Older HIV+ Adults....HIV+ have 2-4 times higher rates of impaired ability to perform daily functioning activities vs HIV-negatives - written by Mark Mascolini - (09/27/16)
     
  6599. AGE: Cognition, Depression, Neuropathy Predict Falls in WIHS Women With or Without HIV - written by Mark Mascolini - (09/27/16)
     
  6600. AGE: Eliminating Smoking and Hypertension Could Cut MI Rate 20% to 40% in HIV Group - [lack of prevention by providers for HIV+] - written by Mark Mascolini - (09/27/16)
     
  6601. AGE: Less Physical Activity, Less Education Tied to Daily Living Impairments [Disabilities] in Older HIV Group - ACTG5322 - written by Mark Mascolini - (09/27/16)
     
  6602. AGE: Up to Half in Older DC Cohort Not Treated for Metabolic Comorbidities - High Burden of Comorbidities in Inner City Washington DC - written by Mark Mascolini - (09/27/16)
     
  6603. AGE: Resting Metabolic Rate Higher in Older Men With Than Without HIV - written by Mark Mascolini - (09/27/16)
     
  6604. IWCADRH: Smoking Activates Neutrophils, Possibly Boosting CVD and Cancer Risk - Mark Mascolini - (09/26/16)
     
  6605. IWCADRH: Renal outcomes with EFV + TDF/FTC versus other TDF-containing antiretroviral regimens among HIV-infected Veterans: A national study - (09/26/16)
     
  6606. IWCADRH: Tenofovir disoproxil fumarate associated Fanconi syndrome in an HIV uninfected man receiving HIV pre-exposure prophylaxis - (09/26/16)
     
  6607. IWCADRH: Renal outcomes with EFV + TDF/FTC versus other TDF-containing antiretroviral regimens among HIV-infected Veterans: A national study - (09/26/16)
     
  6608. Bone and Muscle Endocrine Functions: Unexpected Paradigms of Inter-organ Communication - (09/23/16)
     
  6609. A Novel Perspective on the Biology of Bilirubin in Health and Disease....."Unconjugated bilirubin (UCB) is known to be one of the most potent endogenousantioxidant substances....to ameliorate atherosclerosis, cancer, autoimmunity, and/or neurodegenerative conditions.....BLB has also potent anti-inflammatory activities in brain tissue" - (09/23/16)
     
  6610. Impact of Strength Training on Bone Mineral Density in Patients Infected With HIV Exhibiting Lipodystrophy - (09/23/16)
     
  6611. Bone & The Brain: osteocalcin predicts brain function - (09/23/16)
     
  6612. Brain Growth with Exercise - (09/23/16)
     
  6613. Bone and Muscle Endocrine Functions: Unexpected Paradigms of Inter-organ Communication - (09/23/16)
     
  6614. "Exercise is the only way to preserve muscle function"- Exercise/Brain/Bone/Muscle Connection - (09/23/16)
     
  6615. IWCADRH: Hyperbilirubinemia During ATV/r Initiation May Slow the Progression of Carotid Wall Thickening Through its Effects on Glucose and Lipid Metabolism: - (09/22/16)
     
  6616. IWCADRH: (1) Association between bilirubin and cardiovascular and cerebrovascular disease events among persons living with HIV across the US - (2) Association between initial antiretroviral therapy regimen and cardiovascular disease events among persons living with HIV in the US - (09/22/16)
     
  6617. IWCADRH: One Third Lower MI Risk With Atazanavir Than Other ARVs in US Veterans - Mark Mascolini - (09/22/16)
     
  6618. IWCADRH: Regulation of muscle function and mass by the bone-derived hormone osteocalcin - "Exercise is the only way to preserve muscle function" - (09/22/16)
     
  6619. IWCADRH: Three-Day per Week Atripla Maintains Viral Suppression and Decreases Sub-clinical Toxicity: a Pilot Study Three-Times-a-Week Atripla Maintains Viral Suppression in 24-Week Pilot Study - Mark Mascolini - (09/22/16)
     
  6620. IWCADRH: Tolerability of integrase inhibitors in a real-life setting - Barcelona - Mark Mascolini - (09/22/16)
     
  6621. Preexisting Drug-Resistance Mutations in Treatment-Naive Patients Do Not Affect Response to Tenofovir Disoproxil Fumarate- or Tenofovir Alafenamide-Containing Regimens - (09/21/16)
     
  6622. The brain and the kidney connection - (09/21/16)
     
  6623. Albuminuria and Cognitive Decline in People with Diabetes and Normal Renal Function - (09/21/16)
     
  6624. Albuminuria and Dementia in the Elderly: A Community Study - (09/20/16)
     
  6625. Racial Disparities in New HIV Diagnosis...HCV too - (09/20/16)
     
  6626. A Cost-Effectiveness Analysis Of Pre-Exposure Prophylaxis For The Prevention Of HIV Among Los Angeles County Men Who Have Sex With Men - Editoria - (09/20/16)
     
  6627. HIV Drug Resistance in Switzerland is a well-controlled relic from the era before combination ART - (09/20/16)
     
  6628. Antiretroviral Therapy for the Prevention of HIV-1 Transmission - (09/20/16)
     
  6629. IAC: HIV CURE RESEARCH: A SURVEY OF AUSTRALIAN PEOPLE LIVING WITH HIV ON PERSPECTIVES, PERCEIVED BENEFITS AND WILLINGNESS TO PARTICIPATE IN TRIALS - (09/20/16)
     
  6630. CROI: Traditional and Viral Factors Associated With Iohexol-Based GFR Slope Over 3 Years - (09/20/16)
     
  6631. IWCADRH: Less Inflammation in Metabolically Healthy vs Unhealthy Men With HIV - Associations Between Systemic Inflammatory Perturbations and Metabolic Health Vary by HIV Serostatus and BMI - (09/19/16)
     
  6632. The ethics of talking about 'HIV cure' - (09/19/16)
     
  6633. IWCADRH: Raltegravir is Associated with Greater Abdominal Fat Increases after Antiretroviral Therapy Initiation Compared to Protease Inhibitors - (09/19/16)
     
  6634. IAC: Cure Research Ethics / Risk to Patients Who Participate - (09/19/16)
     
  6635. IWCADRH: Comparison of CD4+ and CD38+ T Cell Subsets in Blood and Adipose Tissue from HIV-infected Persons on Long-term ART..... "Compared with blood, adipose tissue from HIV+ adults is enriched for activated CD4+ & CD38+ T-cells" - (09/16/16)
     
  6636. IWCADRH: HIV duration of 20 Years in 75 year olds Doubles Multimorbidities & Polypharmacy Rates & This Causes Using HAART with Less Drugs in the Regimen - Silver champions from the GEPPO cohort (GEriatricPatients living with HIV/AIDS): a case control study of people above 75 years of age addressing Multimorbidity Polypharmacy and Antiretrovirals' Prescription in old HIV patients. - (09/16/16)
     
  6637. IWCADRH: Future challenges for clinical care of an ageing population infected with HIV: a "geriatric-HIV" modelling study - [Healthcare Costs].... Very Sobering Analysis go Aging in HIV+....60% frail - (09/15/16)
     
  6638. IWCADRH: Ischemic strokes among HIV-infected individuals in the CNICS cohort: the role of traditional and HIV-related risk factors and the impact of events secondary to other causes - Diabetes, HCV, Lipids, Low CD4s Predict Ischemic Stroke With HIV - (09/15/16)
     
  6639. IWCADRH: HIV Boosts Risk of Persistently High ALT After HCV Clearance - "Persistent Aminotransferase Elevation following HCV clearance in Adults with and without HIV" - (09/15/16)
     
  6640. IWCADRH: Exercise Reduced Comorbidities Risk A Lot / "the detrimental consequences of inactivity are exacerbated by excess visceral adiposity" - Physical Activity Consistently Linked to Comorbidity in US HIV Group - (09/15/16)
     
  6641. IWCADRH: Coronary Endothelial Dysfunction is Present in HIV+ Patients Despite a Zero Coronary Artery Calcium Score and is Related to the Degree of Inflammation and Local Epicardial Fat (heart) - (09/15/16)
     
  6642. IWCADRH: Coronary Endothelial Dysfunction is Present in HIV+ Patients Despite a Zero Coronary Artery Calcium Score and is Related to the Degree of Inflammation and Local Epicardial Fat (heart) - (09/14/16)
     
  6643. IWCADRH: Heart Disease Prevention Inadequate in Large Older HIV Cohort - Mark Mascolini - (09/14/16)
     
  6644. IWCADRH: Australian Study of BMD Changes for Men on PrEP Who Are Adherent to Daily TDF/FTC PrEP - Mark Mascolini - (09/14/16)
     
  6645. IWCADRH: BMD and Bone Markers Improve Over 18 Years in Perinatally HIV Infected - Mark Mascolini - (09/14/16)
     
  6646. IWCADRH: Slower Bone Growth May Be Risk for Young Men on TDF/FTC PrEP - (09/13/16)
     
  6647. IWCADRH: Bone Microarchitecture, Not Just BMD, Worse in Women With Than Without HIV - (09/13/16)
     
  6648. IWCADRH: Slower Bone Growth May Be Risk for Young Men on TDF/FTC PrEP - (09/13/16)
     
  6649. IWCADRH: More Than 5% BMD Loss With 1 Year of TDF/FTC PrEP in Half of Australian Group - (09/13/16)
     
  6650. Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC....22.5% / "at-risk" women - (09/12/16)
     
  6651. CROI 2016: Neurologic Complications of HIV Infection-gender; immune activation/inflammation; HIV CNS Reservoirs: implications for eradication/cure - (09/12/16)
     
  6652. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study - (09/12/16)
     
  6653. Peripheral Neuropathy in Primary HIV Infection Associates With Systemic and Central Nervous System Immune Activation - (09/12/16)
     
  6654. Aging HIV+ / Kidney disease - (09/12/16)
     
  6655. Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients - Activation and Senescence Markers in HIV Patients With Chronic Kidney Disease: "A higher CIADIS score (Higher IA and IS levels) [immune activation, senescence markers] was independently associated with advanced CKD. - (09/09/16)
     
  6656. HIV Cure Research Ethics - (09/09/16)
     
  6657. Peripheral Neuropathy in Primary HIV Infection Associates With Systemic and Central Nervous System Immune Activation - (09/07/16)
     
  6658. Association Between Depressive Disorders and Incident Acute Myocardial Infarction in Human Immunodeficiency Virus-Infected AdultsVeterans Aging Cohort Study - depression & mortality in HIV - (09/07/16)
     
  6659. Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial - (09/07/16)
     
  6660. Gut Brain Connection / Neurogastroenterology Fundamentals of Neurogastroenterology: Basic Science - (09/07/16)
     
  6661. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women - (09/07/16)
     
  6662. Clinical impact and cost-effectiveness of early infant HIV diagnosis in South Africa: Test timing and frequency - (09/06/16)
     
  6663. Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States - (09/06/16)
     
  6664. Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection - EDITORIAL COMMENTARY - (09/06/16)
     
  6665. Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals - (09/06/16)
     
  6666. CDC: 68% in HIV Care in USA had Sustained Viral Suppression - Increased antiretroviral therapy prescription and HIV viral suppression among persons receiving clinical care for HIV infection - (09/06/16)
     
  6667. Brief Report: Enhanced Normalization of CD4/CD38 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection - (09/02/16)
     
  6668. Effects of Well-Controlled HIV Infection on Complement Activation and Function - (09/02/16)
     
  6669. Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals. - (09/02/16)
     
  6670. Eating More Plant Protein Associated with Lower Risk of Death - (09/02/16)
     
  6671. Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States - (09/02/16)
     
  6672. Eplerenone Inspra FDA Product Insert - (09/02/16)
     
  6673. Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities - (09/02/16)
     
  6674. Abacavir and cardiovascular disease: A critical look at the data - (08/16/16)
     
  6675. Reyataz [atazanavir] FDA Product Insert - (08/15/16)
     
  6676. IAC: Aging at IAC / Durban 2016 , July 18-22 - (08/15/16)
     
  6677. Pharm: Pharmacokinetics, safety and efficacy of atazanavir, dolutegravir and lamivudine as maintenance regimen in HIV-infected patients: a pilot study - (08/12/16)
     
  6678. CROI: Aging & Comorbidities CROI 2016 - (08/12/16)
     
  6679. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa - (08/12/16)
     
  6680. HIV+ Falls, Fractures & Death...."impending epidemic of bone fractures".....federal officials & others continue & persist to ignore this problem - (08/12/16)
     
  6681. Switching to Genvoya + Darunavir in Treatment-Experienced Adult Patients - (08/12/16)
     
  6682. Defective proviruses rapidly accumulate during acute HIV-1 infection - (08/12/16)
     
  6683. Diabetic & HIV Neuropathy - (08/12/16)
     
  6684. Stroke/Cardiovascular Disease in Developing World is Increased in HIV+ BUT Healthcare System Barriers Prevent Decent Care - Highlighting the Emerging AGING & HIV Problem Facing the Developing World....from Jules - (08/09/16)
     
  6685. IAC: Prevalence and immuno-metabolic associations of frailty in older Australian men living with HIV: a cross-sectional analysis - (08/10/16)
     
  6686. IAC: Optimizing the frequency of kidney safety monitoring in HIV-uninfected persons using daily oral tenofovir disoproxil fumarate pre-exposure prophylaxis - (08/10/16)
     
  6687. IAC: Cure / Vaccine Research - IAC Durban 2016, July 18-22 - (08/10/16)
     
  6688. IAC: Women's Studies at IAC / Durban 2016, July 18-22 - (08/10/16)
     
  6689. IAC: IAC/Durban 2016 - Key HIV HAART Studies, TB - (08/10/16)
     
  6690. IAC: Reported changes in PrEP and condom use in MSM during the open-label extension of the ANRS IPERGAY study - (08/10/16)
     
  6691. IAC: PrEP - Truvada / PrEP+ART / Long-Acting Cabotegravir / Dapirivine Vaginal Ring / On-Demand PrEP IPERGAY / Maraviroc PrEP - (08/10/16)
     
  6692. IAC: An exploratory assessment of the feasibility and acceptability of home-based support to streamline HIV pre-exposure prophylaxis (PrEP) delivery - (08/10/16)
     
  6693. Stroke/Cardiovascular Disease in Developing World is Increased in HIV+ BUT Healthcare System Barriers Prevent Decent Care - Highlighting the Emerging AGING & HIV Problem Facing the Developing World....from Jules - (08/09/16)
     
  6694. Peripheral Neuropathy, a severe comorbidity for Aging Older HIV+ - (08/09/16)
     
  6695. Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis - (08/09/16)
     
  6696. Diet / Aging - Cretan Diet/ Exercise For HIV+ - (08/09/16)
     
  6697. Future Needs for the HIV Workforce in the U.S. ...... - (08/09/16)
     
  6698. IAC: HIV Prevention at AIDS 2016 21st International AIDS Conference Durban, South Africa 18-22 July 2016
    Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington- (08/08/16)
     
  6699. EFdA / MK-8591 - HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection - (08/05/16)
     
  6700. IAC: 21st International AIDS Conference July 18-22, 2016 Durban, South Africa - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (08/05/16)
     
  6701. New HIV Immunotherapy - HIV-1-Specific Chimeric Antigen Receptors Based on Broadly-Neutralizing Antibodies - (08/05/16)
     
  6702. NIH Scientists Discover that Defective HIV DNA Can Encode HIV-Related Proteins, in patients on cART - (08/05/16)
     
  6703. IAC: Persistence of Rilpivirine Following Single Dose of Long-Acting Injection - (08/04/16)
     
  6704. IAC: Injecting Cocaine But Not Smoking Crack Lowers HIV Control Chance in Methadone Users - Mark Mascolini (08/04/16)
     
  6705. IAC: Correlates for levels of self-reported PrEP adherence among Black men who have sex with men in 3 U.S. cities - (08/05/16)
     
  6706. IAC: HPTN 073: successful engagement of Black MSM into a culturally relevant clinical trial for pre-exposure prophylaxis (PrEP) - (08/05/16)
     
  6707. IAC: CANCER TREATMENT IN ELDERLY INDIVIDUALS - National Cancer Institute: HIV+ have lower rates of cancer treatment when <70 years old; HIV+ less likely to receive treatment quickly - (08/04/16)
     
  6708. IAC: Adherence to antiretroviral therapy and neurocognitive impairment in South Africa / 55% neurocognitively impaired / 64% nonadherent - (08/04/16)
     
  6709. IAC: Adherence to antiretroviral therapy and neurocognitive impairment in South Africa / 55% neurocognitively impaired / 64% nonadherent - (08/04/16)
     
  6710. IAC: Antiretroviral treatment adherence, viremia, and psychiatric diagnosis throughout adolescence among perinatally HIV-infected youth..... - (08/04/16)
     
  6711. IAC: Low birth weight predicts post-partum deterioration in maternal virologic control among HIV-1 infected women in Bronx, NY, USA. - (08/04/16)
     
  6712. IAC: Neurocognitive Performance and Normative Comparison Data in HIV+ and HIV-Individuals in Rakai, Uganda - (08/04/16)
     
  6713. IAC: Neurocognitive Assessment in Nigeria The ICON Cohort - (08/04/16)
     
  6714. IAC: Differences in health-related quality of life highlight the different emphases of three frailty instruments in older Australian men living with HIV ....13% had HCV coinfection - (08/04/16)
     
  6715. IAC: Attrition across the HIV cascade of care among a diverse cohort of women living with HIV in Canada - (08/04/16)
     
  6716. IAC: Raltegravir containing antiretroviral therapy for prevention of mother to child transmission in a high risk population of HIV-infected pregnant women in Buenos Aires, Argentina: maternal and neonatal outcomes.... - (08/03/16)
     
  6717. IAC: The association of injectable progestin-only contraceptives and endogenous progestins with HIV target cell frequency in the cervix and HIV acquisition risk - (08/03/16)
     
  6718. IAC: Beyond cervical cancer: gynecological malignancies and treatment in HIV+ women - (08/03/16)
     
  6719. IAC: Association of markers of gut microbial translocation and inflammation with insulin resistance in HIV-infected persons - (08/03/16)
     
  6720. IAC: Adherence With Combination Antiretroviral Therapy (cART): Do Challenges Still Persist? "31% non-adherent" - (08/03/16)
     
  6721. IAC: Truvada PrEP, Vaginal Ring, Maraviroc PrEP, vaginal ring att Durban IAC 2016 July 18-22 - (08/03/16)
     
  6722. IAC: New Evidence: Why Do Young Women in Africa Have High Rates of HIV Infection? - (08/03/16)
     
  6723. IAC: Benefits of pre-exposure prophylaxis relative to drug resistance risk - (08/03/16)
     
  6724. IAC: Contribution of T cells to RANKL/OPG imbalance and bone loss in HIV infection - (07/29/16)
     
  6725. IAC: Satisfaction, Tolerability, and Acceptability of Cabotegravir (CAB) + Rilpivirine (RPV) Long-Acting Therapy: LATTE-2 Results - (07/29/16)
     
  6726. IAC: Incidence [increased a lot with aging] of neurological disorders among HIV-infected individuals with universal health care in Taiwan, 2000 through 2010 - (07/29/16)
     
  6727. IAC: Persistence of Rilpivirine Following Single Dose of Long-Acting Injection - (07/29/16)
     
  6728. IAC: Superior Outcomes with Same-Day HIV Testing and ART Initiation - (07/29/16)
     
  6729. IAC: HIV associated neurocognitive disorder in a peri-urban HIV clinic in KwaZulu-Natal, South Africa - (07/29/16)
     
  6730. IAC: Daily is better than thrice-weekly ATT in HIV patients with culture confirmed pulmonary TB,- a RCT from South India (CTRI-476/09, NCT00933790 ) Study initiation date : 14.09.2009 - (07/29/16)
     
  6731. IAC: GETTING THERE? LIFE EXPECTANCY BY HIV STATUS AND EDUCATION IN SWITZERLAND ...former & even moreso current IDUs, and smokers have much reduced life expectancy - (07/29/16)
     
  6732. IAC: Dolutegravir-Lamivudine as initial therapy in HIV-Infected, ARV naïve patients 48 Week Results of the PADDLE trial. - (07/29/16)
     
  6733. IAC: Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects: Week 48 Results - (07/29/16)
     
  6734. IAC: CD38-Cell Exhaustions Predicts Primary HIV Infection Progression - HIV Causes CD38 Exhaustion-Occurs Early/Predicts HIV Progression - (07/29/16)
     
  6735. IAC: High Satisfaction With Injected Long-Acting CAB + RPV in LATTE-2 Trial - Mark Mascolini (07/29/16)
     
  6736. IAC: High Satisfaction With Injected Long-Acting CAB + RPV in LATTE-2 Trial - Mark Mascolini (07/28/16)
     
  6737. IAC: Which START Participants Got the Most Benefit From Early ART? - Mark Mascolini (07/28/16)
     
  6738. IAC: Only 4 New HIV Infections in 1013 HIV-Discordant Couples Using ART and PrEP - Integrated delivery of PrEP and ART results in sustained near elimination of HIV transmission in African HIV serodiscordant couples: final results from The Partners Demonstration Project - Mark Mascolini (07/28/16)
     
  6739. IAC: Which START Participants Got the Most Benefit From Early ART? - Mark Mascolini (07/28/16)
     
  6740. IAC: Post-ART and No-ART Controllers Similar in Primary Infection Trial/Cure Trials - Mark Mascolini (07/28/16)
     
  6741. IAC: Using phylogenetics of HIV to inform prevention among young black men who have sex with men in Chicago - HIV Transmission Clusters Offer Clues to HIV Risk in Young Black MSM - Mark Mascolini (07/28/16)
     
  6742. IAC: Using phylogenetics of HIV to inform prevention among young black men who have sex with men in Chicago - HIV Transmission Clusters Offer Clues to HIV Risk in Young Black MSM - Mark Mascolini (07/28/16)
     
  6743. IAC: Preventing 1 Infection With As-Needed PrEP Costs 3 to 4 Times More Than HIV Therapy - Mark Mascolini (07/27/16)
     
  6744. IAC: Higher Adherence Tied to 65% Protection With Dapivirine Vaginal Ring - Mark Mascolini (07/27/16)
     
  6745. IAC: Which START Participants Got the Most Benefit From Early ART? - Mark Mascolini (07/27/16)
     
  6746. IAC: Rilpivirine in Genital Tract 18 Months After One Long-Acting Injection - Mark Mascolini (07/27/16)
     
  6747. IAC: Only 60% of HIV Providers Can Answer 4 Easy Questions About Obamacare - National Survey of United States HIV Healthcare Providers about Affordable Care Act Knowledge and Attitudes - Mark Mascolini (07/27/16)
     
  6748. IAC: Higher Adherence Tied to 65% Protection With Dapivirine Vaginal Ring - Mark Mascolini (07/27/16)
     
  6749. IAC: Monthly Naltrexone for Alcohol Abuse Helps Viral Suppression After Prison Release - Mark Mascolini (07/27/16)
     
  6750. IAC: Incidence and correlates of STIs among black men who have sex with men participating in a US PrEP study - Mark Mascolini (07/27/16)
     
  6751. IAC: Enhanced Infection Prophylaxis Cuts Mortality 25% in ART Starters With Low CD4s - Mark Mascolini (07/27/16)
     
  6752. IAC: No HIV Infections in Clients of San Francisco PrEP Program - Mark Mascolini (07/27/16)
     
  6753. IAC: The impact of Universal Test and Treat on HIV incidence in a rural South African population ....Poor Linkage to Care Undermines Test-and-Treat in South African Trial.... - Mark Mascolini (07/27/16)
     
  6754. IAC: First-line Dolutegravir/3TC Controls HIV in 90% in Small Pilot Trial - Mark Mascolini (07/27/16)
     
  6755. IAC: Once-Daily (1200-mg) Raltegravir Noninferior to 400 mg Twice Daily - Mark Mascolini (07/27/16)
     
  6756. IAC: Adding RAL to 3-Drug First Regimen Does Not Cut Mortality in Low-CD4 Group - Mark Mascolini (07/27/16)
     
  6757. IAC: Switch to Single-Pill DTG/ABC/3TC Noninferior to Keeping Current ART - Mark Mascolini (07/27/16)
     
  6758. IAC: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (07/26/16)
     
  6759. IAC: Increased risk of suicidal behaviour with use of efavirenz: Results from the START Trial - (07/26/16)
     
  6760. IAC: Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-NaÏve HIV-1 Infected Subjects: Week 48 Results - (07/26/16)
     
  6761. IAC: Dolutegravir-Lamivudine as initial therapy in HIV-Infected, ARV naÏve patients 48 Week Results of the PADDLE trial. - (07/26/16)
     
  6762. IAC: Superior Efficacy of Dolutegravir/Abacavir/Lamivudine FDC Compared With Ritonavir-Boosted Atazanavir Plus Tenofovir Disoproxil Fumarate/Emtricitabine FDC in Treatment-Naive Women With HIV-1 Infection: ARIA Study - (07/26/16)
     
  6763. IAC: 12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely immunosuppressed African HIV-infected adults and older children: the REALITY trial - (07/26/16)
     
  6764. IAC: Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation... - (07/25/16)
     
  6765. IAC: Renewed hope for HIV vaccine, new developments - (07/25/16)
     
  6766. IAC: Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of Cabotegravir + Rilpivirine (LATTE-2) in the United States and Spain - (07/25/16)
     
  6767. IAC: Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 48 Results - (07/25/16)
     
  6768. IAC: Switching to Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination (DTG/ABC/3TC FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks - (07/25/16)
     
  6769. IAC: Effect of injectable hormonal contraceptives on vaginal epithelium thickness and genital HIV target cell density in women recently infected with HIV - (07/25/16)
     
  6770. IAC: Impact of a fat-rich diet on the pathogenesis of SIV infection in the African green monkey host - "induced microbial translocation and elevated immune activation and inflammation/ impacted survival/ altered metabolism profile and liver " - (07/25/16)
     
  6771. IAC: HIV-associated alteration in gut microbiota are associated with increased inflammation and infection of enteric CD4+ T cells - (07/25/16)
     
  6772. IAC: Love with HIV: a latent class analysis of intimate relationships among women living with HIV enrolled in Canada's largest multisite community-based research study...."Nearly half of Canadian WLWH were not in relationships" - (07/25/16)
     
  6773. IAC: An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for adolescent MSM ages 15-17 in the United States (ATN 113) - (07/22/16)
     
  6774. IAC: HIV-associated alteration in gut microbiota are associated with increased inflammation and infection of enteric CD4+ T cells - (07/22/16)
     
  6775. IAC: Aging & Inflammation: 10 yrs decreased life expectancy/T-cell activation remind high despite viral suppression/inflammation markers predict disease & death- "Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path?" talk by Peter Hunt - (07/22/16)
     
  6776. IAC: Residual dapivirine ring levels indicate higher adherence to vaginal ring is associated with HIV-1 protection ..."Results suggest ring use is associated with at least 56% and potentially >75% protection when used consistently" - (07/22/16)
     
  6777. IAC: Long-term trends in mortality and AIDS-defining events among perinatally HIV-infected children across Europe and Thailand - (07/22/16)
     
  6778. IAC: CDC Study: Why the Disparities: The First National Look at HIV-Related Risk Behaviors Among Sexual Minority Male High School Students, United States, 2015 - High rates of injection drug use increases gay teens' HIV risk - (07/22/16)
     
  6779. IAC: Randomized trial of stopping or continuing ART among post-partum women with pre-ART CD4 >400 cells/mm3 (PROMISE 1077HS) ...." Shows Mixed Results" - Mark Mascolini - (07/22/16)
     
  6780. IAC: HCV Coinfection Not Tied to Higher HIV Load in Meta-Analysis - Mark Mascolini - (07/22/16)
     
  6781. IAC: Test-and-Treat in Uganda/Kenya Attains 80% HIV Control in 2 Years.... "UN AIDS 90-90-90 Target Exceeded" - Mark Mascolini - (07/22/16)
     
  6782. IAC: Immediate ART in START Trial Linked to Better Kidney Function - Mark Mascolini - (07/22/16)
     
  6783. IAC: Impact of Aging on non-AIDS Comorbidity in Large Spanish HIV Cohort - Mark Mascolini - (07/22/16)
     
  6784. IAC: Before- and After-Sex PrEP Working Despite Low Condom Use - Mark Mascolini - (07/22/16)
     
  6785. IAC: Two Methods Offer Good Mortality Prediction in Critically Ill HIV Patients - Mark Mascolini - (07/22/16)
     
  6786. IAC: HIV Life Expectancy Jumps 34 Years in Switzerland But Lags General Population - Mark Mascolini - (07/22/16)
     
  6787. IAC: TURQUOISE-I Part 2: safety and efficacy of ombitasvir + paritaprevir/r ± dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection - (07/20/16)
     
  6788. IAC: Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and HIV Antiretrovirals in Healthy Volunteers - (07/20/16)
     
  6789. IAC: Sofosbuvir/Velpatasvir Yields 95% SVR12 in Patients With HCV/HIV - Mark Mascolini - (07/20/16)
     
  6790. IAC: Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and HIV Antiretrovirals in Healthy Volunteers-2 - Mark Mascolini - (07/20/16)
     
  6791. IAC: Understanding high rates of HIV in young women in South Africa: Implications of the new evidence - (07/22/16)
     
  6792. IAC: Uncovering the role of the vaginal microbomein undermining PrEP efficacy in women - (07/20/16)
     
  6793. IAC: Role of vaginal microbiota in genital inflammation and enhancing HIV transmission - (07/20/16)
     
  6794. IAC: HIV infection in young women in Africa: An overview - (07/20/16)
     
  6795. IAC: Study results provide critical new data to guide HIV prevention and treatment efforts for women and girls - (07/20/14)
     
  6796. IAC: FTC/TDF (Truvada) for HIV Pre-Exposure Prophylaxis (PrEP) Utilization in the United States: 2012-2015 - (07/20/16)
     
  6797. IAC: Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection (SEARCH 026) - (07/20/16)
     
  6798. IAC: HPTN 069 / ACTG A5305 Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEP in U.S. Women...."NO new infections....annual incidence rate 0%" - (07/20/16)
     
  6799. IAC: Sexual activity without condoms and risk of HIV transmission when the HIV positive partner is using suppressive ART: The PARTNER study - (07/20/16)
     
  6800. IAC: Deferred antiretroviral therapy is associated with lower eGFR in HIV-positive individuals with high CD4 counts - (07/20/16)
     
  6801. IAC: Mortality Prediction in HIV-Infected Persons with Critical Illness - (07/20/16)
     
  6802. IAC: Changes in Bone Mass after Discontinuation of PrEP with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Young Men Who Have Sex with Men (YMSM): Extension Phase Results of Adolescent Trials Network (ATN) Study 110 - (07/20/16)
     
  6803. IAC: Efficacy of "On Demand" PrEP in the ANRS IPERGAY Open-Label Extension Study - (07/20/16)
     
  6804. IAC: Integrated delivery of PrEP and ART results in sustained near elimination of HIV transmission in African HIV serodiscordant couples: - (07/20/16)
     
  6805. IAC: No Transmissions in Couples With HIV+ Partner Undetectable on ART - Mark Mascolini - (07/19/16)
     
  6806. IAC: Vorinostat, HCQ, Maraviroc Do Not Delay Time to Rebound After Interruption - Mark Mascolini - (07/19/16)
     
  6807. IAC: Dolutegravir/Rilpivirine as Simpler Maintenance After Heavy Pretreatment - Mark Mascolini - (07/19/16)
     
  6808. IAC: Allogeneic Stem Cell Transplantation in HIV-1 infected individuals; the EpiStem Consortium - (07/19/16)
     
  6809. IAC: HIV Cure research - Are you really not optimistic that a cure will be possible? - 2016 Intl AIDS Conference Durban - (07/19/16)
     
  6810. IAC: Used consistently, monthly vaginal ring may be highly effective against HIV in women, suggest new analyses from ASPIRE - (07/19/16)
     
  6811. IAC: IPM's dapivirine ring may offer significant HIV protection when used consistently, new data analyses suggest (07/18/16)
     
  6812. IAC: Vaginal Ring May Cut HIV Infection Risk if Used Consistently (07/18/16)
     
  6813. HIV/AIDS Updates/JAMA-Aging/Treatment guidelines/PrEP/Cure/Vaccine/HCV - (07/18/16)
     
  6814. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study - (07/15/16)
     
  6815. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial - (07/15/16)
     
  6816. Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States - (07/15/16)
     
  6817. Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection Editorial - (07/15/16)
     
  6818. Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States - (07/14/16)
     
  6819. Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection Editorial - (07/14/16)
     
  6820. Cardiovascular Events in a Physical Activity Intervention Compared With a Successful Aging Intervention - The LIFE Study Randomized Trial ..... aged 70 to 89 years able to walk 400 m. - (07/13/16)
     
  6821. Long-term Bone Mineral Density Changes in Antiretroviral- Treated HIV-Infected Individuals....'bone loss persists' - (07/13/16)
     
  6822. Men With HIV Age Faster According to DNA Methylation Study: "5-year age advancement in HIV/cART individuals....increasing expected mortality risk by 19%" - (07/13/16)
     
  6823. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2016 Recommendations of the International Antiviral Society-USA Panel - (07/13/16)
     
  6824. PARTNER Study - Condomless Sex With Virologically Suppressed HIV-Infected Individuals How Safe Is It? Editorial - (07/13/16)
     
  6825. PARTNER Study - Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy - (07/13/16)
     
  6826. Neurologic signs and symptoms frequently manifest in acute HIV infection - (07/12/16)
     
  6827. Major Diseases Decline in HIV-neg BUT NOT in HIV+ - (07/11/16)
     
  6828. The Medicines Patent Pool Signs New Round of Generic Manufacturing Licences for HIV and Hepatitis C Treatments - (07/10/16)
     
  6829. ICAAC: EVG, TAF, and FTC in Nanoparticles Control HIV in Humanized Mice - Written by Mark Mascolini - - (07/06/16)
     
  6830. ICAAC: Residual Viremia More Frequent and Higher With LPV/r Monotherapy Than Triple Therapy - Written by Mark Mascolini - - (07/06/16)
     
  6831. ICAAC: Pitavastatin Lowers Inflammation/Activation Markers in HIV+ Over 52 Weeks - Written by Mark Mascolini - - (07/06/16)
     
  6832. ICAAC: Over Half of NRTI Doses During Hemofiltration Too High or Too Low - Written by Mark Mascolini - - (07/06/16)
     
  6833. ICAAC: ICAAC: Under 1% in TDF/FTC PrEP Demonstration Projects Picked Up HIV - Written by Mark Mascolini - - (07/06/16)
     
  6834. ICAAC: Correlation Of Residual Viremia On Clinical Outcomes And Lipodystrophy Markers In The KRETA Study - - (07/06/16)
     
  6835. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model - (07/06/16)
     
  6836. sCD163 and Clinical Outcomes in Treated HIV: Insights into Mechanisms - Editorial - (07/06/16)
     
  6837. Plasma CD163 independently predicts all-cause mortality from HIV-1 infection - (07/06/16)
     
  6838. Changes in markers of T cell senescence and exhaustion with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s - (07/08/16)
     
  6839. Probiotic Risks/Immunocompromised Case - (07/08/16)
     
  6840. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial - (07/08/16)
     
  6841. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings - (07/05/16)
     
  6842. Senescence in HIV - Changes in markers of T cell senescence and exhaustion with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s - (07/05/16)
     
  6843. Accelerated Aging in HIV+ / Senescence - Cretan Diet/ Exercise For HIV+ - (07/05/16)
     
  6844. Probiotic / Prebiotic Foods List - Prebiotic Fiber Foods - (07/01/16)
     
  6845. The Microbiome [Gut] and Musculoskeletal Conditions of Aging: A Review of Evidence for Impact and Potential Therapeutics - (07/01/16)
     
  6846. Life Course Dietary Patterns and Bone Health in Later Life in a British Birth Cohort Study - (07/01/16)
     
  6847. A Crisis in the Treatment of Osteoporosis-Editorial; HIV 3-4 fold increased bone disease/fractures - (07/01/16)
     
  6848. Cancers in elite controllers: appropriate follow-up is essential..... - (07/01/16)
     
  6849. ICAAC: Under 1% in TDF/FTC PrEP Demonstration Projects Picked Up HIV - (06/30/16)
     
  6850. Pharm: Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype 1 and Human Immunodeficiency Virus (HIV) - (06/29/15)
     
  6851. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption - (06/27/16)
     
  6852. HIV & HCV Highlights from Recent Conferences: ASM/ICAAC - Pharmacology Workshop - DDW New HIV & HCV Drugs / Inflammation-Heart Disease-Statin, TDF PrEP new studies / Cabotegravir Update: Long-Acting Treatment & Prevention / CMV-Aging - (06/27/16)
     
  6853. PRO140 Phase III Trials Have Begun For Injectable Antibody to Fight HIV - (06/27/16)
     
  6854. Pharm: The 17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy Report by Courtney Fletcher, PharmD/Jennifer Kiser, PharmD - (06/27/16)
     
  6855. How do we test for HCV RAVs? A Technology Based Presentation / Mixed Infections - (06/24/16)
     
  6856. Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects - (06/24/16)
     
  6857. Switch to Dolutegravir plus Rilpivirine dual therapy in cART-Experienced Subjects: an Italian cohort - (06/24/16)
     
  6858. ASM/ICAAC: Tenofovir Alafenamide Has Wide Efficacious Range for Treatment of HIV-1 Infection: Pharmacokinetic-Pharmacodynamic Relationship From a Phase 3 Study - (06/24/16)
     
  6859. ASM/ICAAC: Enhanced Exposure of Tenofovir-Diphosphate in Peripheral Blood Mononuclear Cells by Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (06/24/16)
     
  6860. ASM/ICAAC: Pharmacokinetics - Pharmacodynamics of Emtricitabine/Tenofovir Alafenamide Demonstrated Wide Exposure Range Associated With Clinical Safety - (06/24/16)
     
  6861. ASM: Effects of Pitavastatin on Markers of Arterial Inflammation and Immune Activation in HIV Patients - (06/24/16)
     
  6862. Pharm: Development of Dolutegravir Combination Nanoparticle Fabrications for HIV Prophylaxis - (06/23/16)
     
  6863. ASM/ICAAC: Superior Efficacy and Improved Renal and Bone Safety After Switching From a Tenofovir Disoproxil Fumarate Regimen to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment - (06/23/16)
     
  6864. ASM/ICAAC: Switch From TDF Regimens to E/C/F/TAF Is Associated With Improved Bone Mineral Density, Decreased Serum PTH, and Decreased Bone Turnover Biomarkers - (06/23/16)
     
  6865. ASM/ICAAC: Potent Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance - (06/23/16)
     
  6866. Potent Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance [2] - (06/23/16)
     
  6867. Pharm: In Silico Pharmacokinetic/Pharmacodynamic Simulation Of Long Acting Tenofovir Injectable Formulation For Pre-exposure Prophylaxis Strategies - (06/22/16)
     
  6868. ASM/ICAAC: Darunavir and Cobicistat in Older HIV-1-Infected Patients in a 48-week Phase 3 Trial - (06/22/16)
     
  6869. PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients - (06/22/16)
     
  6870. ASM/ICAAC: Racial Characteristics of FTC/TDF for Pre-exposure Prophylaxis (PrEP) Users in the US - (06/22/16)
     
  6871. ASM: HIV-1 Seroconversion Across 17 International Demonstration Projects Using Pre-exposure Prophylaxis (PrEP) With Oral Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) - (06/22/16)
     
  6872. ASM/ICAAC: Tenofovir Alafenamide in Participants with Diabetes and Renal Impairment: Renal Safety Through 96 Weeks - (06/21/16)
     
  6873. Efficacy and Safety of Tenofovir Alafenamide in HIV-Infected Women With Renal Impairment: 96-Week Results - (06/21/16)
     
  6874. ASM/ICAAC: Switching from TDF to TAF in Patients with High Risk for CKD - (06/21/16)
     
  6875. Discovery of Bictegravir (GS-9883), a Novel, Unboosted, Once-Daily HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Improved Pharmacokinetics and In Vitro Resistance Profile - (06/20/16)
     
  6876. Antiviral Activity of Bictegravir (GS-9883), a Potent Next Generation HIV-1 Integrase Strand Transfer Inhibitor - (06/20/16)
     
  6877. Bictegravir (GS-9883), a Novel HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Optimized In Vitro Resistance Profile - (06/20/16)
     
  6878. Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV - (06/20/16)
     
  6879. Novel Integrase Strand Transfer Inhibitor Bictegravir 10 Day Monotherapy in HIV-1-Infected Patients - (06/20/16)
     
  6880. Pharm: Cabotegravir Long-Acting (LA) Injectable Nanosuspension - (06/16/15)
     
  6881. SVR Reduces Comorbidities; IDUs Have Greater Immune Activation & Thus are at Greater Risk for Comorbidities & All-Cause Death, and of course HCV & HIV+ are at double the risk - (06/16/16)
     
  6882. Pharm: Lack of Pharmacokinetic Interaction Between Emtricitabine/Tenofovir Alafenamide and Oral Contraceptive Ethinyl Estradiol/Norgestimate - (06/16/16)
     
  6883. Pharm: Lack of Clinically Relevant Effect of Food on the Pharmacokinetics of Tenofovir Alafenamide - (06/16/16)
     
  6884. Pharm: Pharmacokinetics of Dolutegravir After Switching to Abacavir/Dolutegravir/ Lamivudine From an Efavirenz-Based Regimen: A PK Sub-Study From STRIIVING - (06/16/16)
     
  6885. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine - (06/15/16)
     
  6886. The immunological footprint of CMV in HIV-1 patients stable on long-term ART..... CMV / "accelerated ageing" in HIV+ - (06/15/16)
     
  6887. Pharm: Pharmacokinetic Interaction Between Emtricitabine/ Tenofovir Alafenamide and Boosted Atazanavir - (06/14/16)
     
  6888. Pharm: Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques - (06/14/16)
     
  6889. Pharm: Targeting Tissue Drug Concentrations for HIV Prevention - What do we know? - (06/14/16)
     
  6890. Pharm: Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110) - (06/14/16)
     
  6891. Pharm: Clinical, biological and Pharmacological relevance of Ledipasvir/Sofosbuvir drug interaction with TDF containing Regimen in HCV/HIV co-infected patients. - (06/14/16)
     
  6892. Pharm: LEDIPASVIR/SOFOSBUVIR and TENOFOVIR in HIV-HCV co-infected PATIENTS: IMPACT on TENOFOVIR Ctrough and RENAL SAFETY - (06/14/16)
     
  6893. CROI: CMV Reactivation and Immune Aging in HIV-infected Individuals Virologically Suppressed on ART - (06/13/16)
     
  6894. Eplerenone for Diabetic Proteinuria/Albuminuria & Finerenone too - (06/13/16)
     
  6895. Lipoatrophy and lipohypertrophy are independently associated with hypertension - (06/13/16)
     
  6896. Adipose Tissue [belly, subcutaneous] and HIV infection / Fat Tissues - Belly, Periphery - and HIV - reservoir for HIV, Inflammation, hypertension, body changes - (06/13/16)
     
  6897. CROI: Effect of CMV and HIV replication on T cell exhaustion and senescence during ART - (06/13/16)
     
  6898. CROI: Persistent elevation of inflammation markers in HIV+ persons with Cytomegalovirus disease - (06/13/16)
     
  6899. CROI: sCD163 increase in HIV/CMV coinfected subjects included in ICONA Cohort .. ..."implicated in the accelerated development of vascular and neurological disease in general population - (06/13/16)
     
  6900. Pharm: Rilpivirine Half-Life Lower in Real-World Cohort Than Phase 3 Trials - Mark Mascolini - (06/13/16)
     
  6901. Pharm: Simulations See Protection From HIV With Long-Acting Injectable Tenofovir - Mark Mascolini - (06/13/16)
     
  6902. Pharm: Grazoprevir and Elbasvir Levels 5- and 2-Fold Higher With Stribild - Mark Mascolini - (06/13/16)
     
  6903. Pharm: Tenofovir Levels in Red Blood Cells Jump 4-Fold With Sofosbuvir/Ribavirin - Mark Mascolini - (06/13/16)
     
  6904. Pharm: HIV RNA and DNA in GALT Similar With Raltegravir and Dolutegravir - Mark Mascolini - (06/10/16)
     
  6905. Pharm: Ribavirin Levels Too High or Low in Most Patients Taking DAAs - Mark Mascolini - (06/10/16)
     
  6906. Pharm: Over Half of Netherlands Patients Starting DAAs Risk Drug-Drug Interaction - Mark Mascolini - (06/10/16)
     
  6907. Pharm: Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women - (06/10/16)
     
  6908. Pharm: Cumulative tenofovir exposure is associated with decreased BMD in young and old HIV-infected adults on tenofovir based regimens - (06/10/16)
     
  6909. Pharm: Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women** - (06/10/16)
     
  6910. Pharm: Cumulative Tenofovir Level Tied to Lower Spine BMD in Young Adults - written by Mark Mascolini - (06/8/16)
     
  6911. Pharm: Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women - (06/8/16)
     
  6912. Pharm: Darunavir Troughs Lower in Trimesters 2 and 3 With Once-Daily Dosing - written by Mark Mascolini - (05/29/16)
     
  6913. Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995-2014 / IDU Increases Comorbidities Risk: DAAs May reduce ESRD & Comorbidities Risk - (06/08/16)
     
  6914. HIV protease inhibitors activate the adipocyte renin angiotensin system - PIs/Hypertension/Metabolics/ARBs prevent effect - (06/08/16)
     
  6915. "aging implicated - body composition, involving both abdominal obesity and stavudine-induced peripheral lipoatrophy, might contribute to the higher prevalence of hypertension in HIV-1-infected patients.....Our results suggest a role for both abdominal fat accumulation and peripheral lipoatrophy in the pathophysiology of hypertension in the context of HIV." - Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure - (06/08/16)
     
  6916. CROI: Increasing PrEP Use among Men who Have Sex with Men, New York City, 2013-2015 - (06/07/16)
     
  6917. CROI: Early Adopters and Incident PrEP Prescribers in a Public Health Detailing Campaign - (06/07/16)
     
  6918. Cancer risk among the HIV-infected elderly in the United States - (06/07/16)
     
  6919. Pre-exposure Prophylaxis (PrEP) in Ambulatory Care Practices, New York City, 2012-2014 - (06/07/16)
     
  6920. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens / Cancer immunotherapy - (06/06/16)
     
  6921. Aging/HIV is the Elephant in the Room / '60 is the new 70' - (06/03/16)
     
  6922. "Phase IIa trial in HIV/AIDS patients with drug candidate ABX464"....treatment/cure - (06/01/16)
     
  6923. The aging HIV population: new challenges and market opportunities / Cure - (06/01/16)
     
  6924. "study documented extremely elevated risks of death for non-ADCs among PWA"....Non-AIDS Defining Cancer Mortality: Emerging Patterns in the Late HAART Era....."our results call for taking primary and secondary preventive actions to reduce both cancer incidence and mortality among people with HIV or AIDS." - (05/27/16)
     
  6925. History of AIDS in HIV-Infected Patients Is Associated With Higher In-Hospital Mortality Following Admission for Acute Myocardial Infarction and Stroke - (05/24/16)
     
  6926. Trends in condom use among men who have sex with men in the united states: the role of antiretroviral therapy and sero-adaptive strategies.....Condomless sex increasing - (05/24/16)
     
  6927. Disparities in cancer treatment among patients infected with the human immunodeficiency virus - HIV Patients Less Likely To Have Cancer Treatments, Study Says - (05/23/16)
     
  6928. Preventable Incidence and Mortality of Carcinoma Associated With Lifestyle Factors Among White Adults in the United States - (05/23/16)
     
  6929. Drugs / Substance Use Series: Policy/Harm to Young People - (05/23/16)
     
  6930. HIV/MSM 'Hyperendemic'/ in South Very High/CDC Comments - (05/23/16)
     
  6931. CROI: Early Markers of Renal Dysfunction Among Cocaine Users With HIV and HCV Infection - (05/17/16)
     
  6932. The CFAR/CNICS HIV Research EMR Network - (05/18/16)
     
  6933. Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients - (05/16/16)
     
  6934. Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group? - (05/16/16)
     
  6935. Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons - (05/16/16)
     
  6936. The relationship of CPE to HIV dementia - Editorial - (05/16/16)
     
  6937. Depression in the Elderly - (05/16/16)
     
  6938. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions - (05/16/16)
     
  6939. NeuroToxicity & ARTs - (05/16/16)
     
  6940. Abacavir Package Insert - (05/12/16)
     
  6941. HIV Infection Prematurely Ages People by an Average of Five Years - (05/12/16)
     
  6942. Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLA..... "our study provides a robust estimate of a 5-year age advancement in HIV/cART individuals....increasing expected mortality risk by 19%" - (05/12/16)
     
  6943. Aging with HIV program At the Center for Special Studies (CSS), the adult HIV practice at Weill Cornell Medicine/New York Presbyterian Hospital - (05/12/16)
     
  6944. Neurodegeneration and Ageing in the HAART Era... - (05/10/16)
     
  6945. Cocoa Flavanols Improve the Brain ? - (05/10/16)
     
  6946. An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition - "First Diagnosed Case of Alzheimer's Disease in HIV-Positive Individual Reported" - (05/10/16)
     
  6947. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions - Editorial The relationship of CPE to HIV dementia - (05/10/16)
     
  6948. Case Report: HIV, alzheimers, dementia - An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition - (05/10/16)
     
  6949. Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load - (05/10/16)
     
  6950. CD4, Gut & Reservoirs - Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy - (05/06/16)
     
  6951. Safety and Efficacy of Dolutegravir and Maraviroc Plus Background Therapy in HIV-1 Treatment-Experienced Participants - BHIVA April 2016 - (05/06/16)
     
  6952. "accumulating evidence that statins can cause undesirable effects on skeletal muscle mitochondrial function" / exercise vs statins - (04/14/16)
     
  6953. Simvastatin Impairs Exercise Training Adaptations / statins and mitochondrial toxicity - (04/14/16)
     
  6954. Bone & HIV...3-4 Fold increased osteoporosis & fractures, a worrisome bone future - (04/13/16)
     
  6955. Cardiovascular risk factors and the rate of change in brain structure in HIV disease - (04/13/16)
     
  6956. HIV overcomes CRISPR gene-editing attack - (04/12/16)
     
  6957. HIV & Aging in SF: age-57; 35-60% Impairment - (04/12/16)
     
  6958. Crispr-Cas9 - HIV Gene Editing for Cure, not so easy- challenges/hurdles - (04/06/16)
     
  6959. F/TAF FDA Product Insert / Label - (04/06/16)
     
  6960. U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead's Third TAF-Based HIV Therapy - (04/06/16)
     
  6961. Questions for Meredith Greene, MD: Managing HIV Infection in Older Adults....Aging Clinic at UCSF - (04/06/16)
     
  6962. Care of the Aging Patient: From Evidence to Action; Mgt of HIV+ in Advanced Age - (04/06/16)
     
  6963. Aging with HIV program At the Center for Special Studies (CSS), the adult HIV practice at Weill Cornell Medicine/New York Presbyterian Hospital - (04/06/16)
     
  6964. CROI: HIV and Cardiovascular Disease: Report back from 2016 Conference on Retroviruses and Opportunistic Infections - by Priscilla Hsue MD Professor of Medicine, UCSF - (04/04/16)
     
  6965. CROI: Understanding the Relative Contributions of IDU and HCV on Systemic Immune Activation...... .....HCV should be aggressively treated in current IDUs even more if HIV and/or HCV positive - (04/4/16)
     
  6966. CROI: HCV at CROI 2016 - (04/4/16)
     
  6967. CROI: ARTs & Mitochondrial toxicity......AZT/NNRTI induces greater adipose tissue mitochondrial toxicity than AZT/PI...... These findings support emerging data on NNRTIs contribution to thymidine-NRTI toxicity, suggesting additive MtTox as an underlying mechanism. - (04/4/16)
     
  6968. CROI: Differences in Predictors for Ischaemic and Haemorrhagic Strokes in HIV+ Individuals - (04/4/16)
     
  6969. CROI: Stroke in HIV-infected patients in the combination antiretroviral therapy era - (04/4/16)
     
  6970. CROI: Gender and Racial Disparities in Initial Antiretroviral Treatment Outcome: ACTG A5257 - (04/4/16)
     
  6971. CROI: Reduced Ovarian Reserve Relates to Monocyte Activation and Subclinical Coronary Atherosclerotic Plaque in Women with HIV - (04/4/16)
     
  6972. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions [rectal/vaginal] in rhesus macaques - (04/01/16)
     
  6973. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges - (04/01/16)
     
  6974. Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study - (04/01/16)
     
  6975. Moderate/Heavy vs No/Light Exercise Found To Be Effective in Older (age=71) With No Cognitive impairment at Baseline but Not Effective in Those With Cognitive Impairment at Baseline....suggesting pre-symptomatic exercise is recommended "before pathology may become irreversible". - (04/01/16)
     
  6976. Low bone mineral density and risk of incident fracture in HIV-infected adults.....'reconsider when to screen for low BMD with DEXA' - (04/01/16)
     
  6977. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing - (04/01/16)
     
  6978. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques - (03/31/16)
     
  6979. CROI: [2 studies] HIV Viral Load in US Clinics Over Time: Trends and Predictors from CNICS - (03/31/16)
     
  6980. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder..... - (03/31/16)
     
  6981. CCR5+Integrase - Maraviroc+Raltegravir - Improve Gut Immunity & Reduce HIV DNA - (03/31/16)
     
  6982. CROI: CROI 2016: Antiretroviral therapy and other interesting observations - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/29/16)
     
  6983. CROI: Liver Fibrosis Linked to Cognition in HIV and HCV: The Women's Interagency HIV Study - (03/29/16)
     
  6984. CROI: Persistently Increased Ischemic Stroke Risk in HIV-Infected Women - (03/29/16)
     
  6985. CROI: Comparing Cardiovascular Disease Risk Scores for Use in HIV-Infected Individuals...Optimal cardiovascular disease risk score for HIV - (03/29/16)
     
  6986. CROI: Effect of T-Cell Activation on Endothelial Dysfunction in HIV - (03/29/16)
     
  6987. CROI: Differences by HIV Serostatus in Coronary Artery Disease Severity following Stress Testing - (03/29/16)
     
  6988. CROI: Diastolic Function Correlates With Pericardial Fat [fat around the heart] and Vascular Remodeling in HIV - (03/29/16)
     
  6989. CROI: Statin Effects on oxLDL in Relationship to Plaque and Arterial Inflammation in HIV.....statin reduced LDL - (03/29/16)
     
  6990. CROI: Myocardial Infarction Risk in the NA-ACCORD Compared to MESA and ARIC - (03/29/16)
     
  6991. CROI: Design, implementation, and findings of next generation stroke adjudication in HIV - (03/29/16)
     
  6992. CROI: Impact of Depression on Mortality, Viral Load, and Adherence: Three CROI Studies - written by Mark Mascolini - (03/29/16)
     
  6993. CROI: NNRTI-resistant Mutants Are Suppressed by Doravirine at Clinically Relevant Concentrations - (03/28/16)
     
  6994. CROI: Aspirin fails to impact immune activation or endothelial function in treated HIV - (03/28/16)
     
  6995. CROI: HIV DNA Identified in Most Tissues of a Plasma Negative HIV Autopsy Cohort - (03/28/16)
     
  6996. CROI: Safety and Efficacy of E/C/F/TAF in HIV-1-Infected Treatment-Naïve Adolescents - (03/28/16)
     
  6997. CROI: Increased HIV Viral Suppression Among US Adults Receiving Medical Care, 2009-2013 - (03/28/16)
     
  6998. CROI: Immunologic Effects of Maraviroc vs. Tenofovir and Associations with Bone Loss - (03/28/16)
     
  6999. CROI: What exactly does antiretroviral therapy do to bone? Plenary on Bone at CROI By Paddy Mallon - (03/28/16)
     
  7000. CROI: Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women (ASPIRE) - (03/28/16)
     
  7001. CROI: Mitochondrial DNA Copy Number and Neurocognitive Impairment in HIV-Infected Persons....."mtDNA associated with worse cognitive outcomes".....both HIV & ART duration associated with mtDNA damage - (03/28/16)
     
  7002. CROI: Compartmentalized HIV DNA Populations Persist in CSF Despite Suppressive ART - (03/28/16)
     
  7003. CROI: MVC and TDF Reduce Neurocognitive Impairment in Initial ART - (03/28/16)
     
  7004. CROI: Real-life renal safety of "boosted TDF" in HIV/HCV-patients on SOF/LDV - (03/24/16)
     
  7005. CROI: HIV Prevention at CROI 2016 - Jared Baten MD, Connie Celum MD - Conference on Retroviruses and Opportunistic Infections Seattle, WA, USA February 22-25, 2016 Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/23/16)
     
  7006. CROI: Clinical Pharmacology at CROI 2016: TAF, PrEP- TDF-Bone, TAF (vaginal, rectal), Maraviroc, Dapivirine Vaginal Ring, Long-Acting ARTs, Peds - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (03/18/16)
     
  7007. CROI: MVC and TDF Reduce Neurocognitive Impairment in Initial ART - (03/21/16)
     
  7008. CROI: New HIV Drugs (ARTs): prevention/treatment..... - (03/21/16)
     
  7009. CROI: Is Intensive Cervical Cancer Screening Justified in Immunosuppressed Women? - (03/21/16)
     
  7010. CROI: Vitamin D Supplementation Decreases Immune Activation and Exhaustion in HIV+ Youth...high dose did best & increased Vit D levels best too - (03/17/16)
     
  7011. CROI: Update from CROI 2016: Bones, Vitamin D, Frailty - Todd T. Brown, MD, PhD Associate Professor of Medicine and Epidemiology Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (03/17/16)
     
  7012. European Medicines Agency Validates Gilead's Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B - (03/16/16)
     
  7013. CROI: Immunopathogenesis of Metabolic Complications in Treated HIV Infection - (03/15/16)
     
  7014. CROI: Belly Fat (lipodystophy) May be Caused by Metabolic Abnormalities: immune activation/inflammation/senescence - (03/15/16)
     
  7015. CROI: Adipose Tissue [belly, subcutaneous] and HIV infection - (03/15/16)
     
  7016. CROI: Frailty In HIV-infected Patients Is Associated With Increased Insulin Resistance - (03/15/16)
     
  7017. CROI: Tenofovir and the Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Persons - (03/14/16)
     
  7018. CROI: TAF / PrEP - TDF, TAF, Cabotegravir - Cabotegravir+Rilpivirine - LATTE-2, Maravoric / Dapivrine Vagnal Ring - Tenofovir Rectal / Long-Acting - MK-8591 Long Acting - BMS-986197 - (03/14/16)
     
  7019. CROI: Complications & It's Immunopathogenesis - (03/14/16)
     
  7020. CROI: "Chemsex" and High-Risk Sexual Behaviours in HIV-Positive Men Who Have Sex With Men...increased risk for HCV & STIs - (03/14/16)
     
  7021. CROI: Efavirenz Is Associated With Higher Bone Mass in South African Children With HIV....after switching to EFV from LPV/r - (03/14/16)
     
  7022. CROI: Duration of in utero exposure to tenofovir and linear growth in the first year of life - (03/14/16)
     
  7023. CROI: P1084s: Impact of maternal tenofovir disoproxil fumarate (TDF) use on HIV-exposed newborn bone mineral content - (03/14/16)
     
  7024. CROI: Effects of Vitamin D Supplementation on BMD and Bone Markers in HIV+ Youth - (03/14/16)
     
  7025. CROI: Neurotoxicity Screening of Antiretroviral Drugs With Human iPSC-Derived Neurons - (03/14/16)
     
  7026. CROI: Maternal TDF Does Not Affect Infant Bone Mineral Content in Africa - Mark Mascolini (03/14/16)
     
  7027. CROI: Fractures Occur at a Younger Age in HIV+ Men in the Multicenter AIDS Cohort Study - (03/14/16)
     
  7028. CROI: Neurotoxicity Screening of Antiretroviral Drugs With Human iPSC-Derived Neurons - (03/10/16)
     
  7029. CROI: Prevalence of Falls among Older Women in the Women's Interagency HIV Study - (03/10/16)
     
  7030. CROI: Global Burden of Cervical Cancer in HIV-Positive Women on Antiretroviral Therapy - (03/10/16)
     
  7031. CROI: Low ART Adherence Is Associated With Higher Inflammation Despite HIV Suppression...Wobbly ART Adherence Could Fuel Ongoing Inflammation - (03/10/16)
     
  7032. CROI: Global Burden of Cervical Cancer in HIV-Positive Women on Antiretroviral Therapy - (03/09/16)
     
  7033. CROI: Adherence Predicts Failure on PI-Based Second-Line ART in Rural South Africa ....High Rate of non-adherence in 1st & 2nd Line ART...."implications for Universal ART" - (03/09/16)
     
  7034. CROI: Racial Differences in Bioavailable Vitamin D and Response to Supplementation: A5280 ...... Bone, Vit D, EFV+Truvada & Blacks - (03/09/16)
     
  7035. CROI: Aging/HIV IGNORED....The aging survivors left behind by AIDS - (03/09/16)
     
  7036. CROI: Metabolic Alterations and Physical Function in Older HIV-Infected Adults.....Older HIV-infected persons have diminished physical performance compared to HIV-uninfected controls / Aging at CROI - (03/09/16)
     
  7037. CROI: 1970s HIV-1 Genomes Reveal the Early History of the North American HIV/AIDS Epidemic - (03/09/16)
     
  7038. CROI: Concentrations of TFV and TFVdp in Female Mucosal Tissues After a Single Dose of TAF - (03/08/16)
     
  7039. CROI: Cancer versus tuberculosis mortality among HIV-infected Individuals in Botswana...... cancer mortality likely exceeds mortality due to tuberculosis - (03/08/16)
     
  7040. CROI: Excess Mortality Among HIV-Infected Cancer Patients in the United States ....excessive breast cancer mortality found in young non-White females 30-49 & 50-69 years old Table 1) - (03/08/16)
     
  7041. CROI: Quarterly STI Screening Optimizes STI Detection Among PrEP Users in the Demo Project - (03/08/16)
     
  7042. CROI: STI Data from Community-Based PrEP Implementation Suggest Changes to CDC Guidelines - (03/08/16)
     
  7043. CROI: Changes in Renal Function Associated with TDF/FTC PrEP Use in the US Demo Project - (03/08/16)
     
  7044. CROI: Maraviroc induces HIV production in a RCT and in vitro, potentially via the NF-kB pathway - (03/08/16)
     
  7045. CROI: A Quantitative Model of ART Efficacy Explains the Clinical Success of Dolutegravir - (03/08/16)
     
  7046. CROI: INSTI In-class Switching on Continued Viral Suppression in the OPERA Cohort - (03/08/16)
     
  7047. CROI: Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women - (03/08/16)
     
  7048. CROI: Pharmacokinetics, Safety and Efficacy of Maraviroc in Pediatric Patients With R5 HIV - (03/08/16)
     
  7049. CROI: Tolerability and Acceptability of Cabotegravir LA Injection: Results From the ECLAIR Study - (03/08/16)
     
  7050. CROI: Comparable Viral Decay in Dual and Triple Dolutegravir-Based Antiretroviral Therapy - (03/08/16)
     
  7051. CROI: 2 Dapivirine Vaginal Ring Studies - (03/07/16)
     
  7052. CROI: The Renal Impact of Tenofovir Disoproxil Fumarate in the NA-ACCORD - (03/07/16)
     
  7053. CROI: Changes in CVD Risk Factors with Immediate and Deferred ART in the START Trial - (03/07/16)
     
  7054. CROI: Persistent HIV-1 in the CNS during therapy: evidence of a viral reservoir in the CNS - (03/07/16)
     
  7055. CROI: CROI 2016 Co-morbidities in HIV: Stroke, Cancer, Liver Disease David H Shepp, MD Associate Professor of Medicine Hofstra-Northwell School of Medicine Manhasset, NY - (03/05/16)
     
  7056. CROI: CROI Summary Report by Eric Daar, MD for NATAP 23rd Conference on Retroviruses and Opportunistic Infections - February 22-25, 2016 Boston, Massachusetts Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/05/16)
     
  7057. CROI: Ledipasvir/Sofosbuvir Controls Acute HCV in HIV+ Without Highest HCV Loads - Written by Mark Mascolini (03/07/16)
     
  7058. CROI: Abacavir (ABC) use and risk of recurrent myocardial infarction (MI) - (03/05/16)
     
  7059. CROI: Pooled Week-48 Analysis of HIV-1 Drug Resistance in E/C/F/TAF (Genvoya) Phase 3 Studies - (03/05/16)
     
  7060. CROI: Durable Viral Suppression Among HIV-diagnosed Persons - United States, 2012-2013....38% are nor durably suppressed - (03/05/16)
     
  7061. CROI: Ravidasvir/Sofosbuvir Yields Quick SVRs in Largest Genotype 4 Trial - (03/05/16)
     
  7062. CROI: Statin Dose and Type Tied to Lower Fibrosis Progression and Liver Cancer Incidence - (03/05/16)
     
  7063. CROI: TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r + Dasabuvir + RBV for HCV/HIV Co-Infection - (03/05/16)
     
  7064. CROI: Safety and Tolerability of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials - (03/05/16)
     
  7065. CROI: CROI 2016 - Themed Discussion: Rants About HCV RAVS - (03/05/16)
     
  7066. CROI: Retreatment of HCV/HIV-Coinfected Patients Who Failed 12 Weeks of LDV/SOF - (03/05/16)
     
  7067. CROI: High HCV Cure Rates for Drug Users Treated with DAAs at an Urban Primary Care Clinic - (03/05/16)
     
  7068. CROI: IMPAACT 1093: Dolutegravir in 6-12 Year Old HIV Infected Children: 48-Week Results ....Dolutegravir Effective and Safe in ART-Experienced 6- to 12-Year-Olds - Mark Mascolini - (03/03/16)
     
  7069. CROI: Almost 40% of HIV+ People in Care in US Have Detectable Viral Load - Mark Mascolini - (03/03/16)
     
  7070. CROI: Incidental Carotid Plaque in HIV and an increase in subsequent Cerebrovascular Events.....Carotid Plaque Develops More Often With HIV and Triples Stroke Risk - Mark Mascolini - (03/03/16)
     
  7071. CROI: Low CD4s, High Viral Load Tied to Progression to Advanced Liver Fibrosis - Mark Mascolini - (03/03/16)
     
  7072. CROI: Body composition changes on Darunavir/Ritonavir (DRV/r) + either Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) as first-line antiretroviral therapy. NEAT 001/ANRS 143. Body composition sub-study - Mark Mascolini - (03/03/16)
     
  7073. CROI: First Look at Big 75-and-Older HIV Group--Diagnosed at Age 62.....much higher rates of comorbidities among older HIV+ - 40% with 2 or more, 14% with 4 or more comorbidities - Mark Mascolini - (03/03/16)
     
  7074. CROI: HIV Suppression Rate Rose Significantly in US From 2009 to 2013 - Mark Mascolini - (03/03/16)
     
  7075. CROI: Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% - Mark Mascolini - (03/03/16)
     
  7076. CROI: Paroxetine and fluconazole therapy for HAND: a double-blind, placebo-controlled trial .....New Brain Treatment: Cognitive Gains With Paroxetine in Randomized Trial of HAND Patients - Mark Mascolini - (03/03/16)
     
  7077. CROI: Large Trial Finds Little Benefit in HPV Vaccine for Older HIV+ Adults - Mark Mascolini - (03/03/16)
     
  7078. CROI: Immediate ART for All Still a Long Way Off in France--and Elsewhere - Mark Mascolini - (03/03/16)
     
  7079. CROI: Intensive Cervical Cancer Screening Needed Only at Lower CD4s in HIV+ Women - Mark Mascolini - (03/03/16)
     
  7080. CROI: Avoiding HCV, HBV, Alcohol Abuse Could Avert Up to One Third of ESLD Cases With HIV - Mark Mascolini - (03/03/16)
     
  7081. CROI: Under Half in US Analysis Get Resistance Testing at Linkage to Care - Mark Mascolini - (03/03/16)
     
  7082. CROI: Following ACC/AHA Guidelines Will Undertreat Atherosclerosis in HIV Patients - Mark Mascolini - (03/03/16)
     
  7083. CROI: Each Delayed Month in Starting ART Could Trim CD4 Tallies Substantially - Mark Mascolini - (03/03/16)
     
  7084. CROI: Dolutegravir Effective and Safe in ART-Experienced 6- to 12-Year-Olds - Mark Mascolini - (03/03/16)
     
  7085. The COMPLERA (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) label was recently updated to expand the patient population for use to include pediatric patients from 12 to less than 18 years of age. Other revisions were made for consistency with the Edurant (rilpivirine) label and the major changes are summarized below. - (03/02/16)
     
  7086. CROI: Renal Safety of Tenofovir Alafenamide in Patients at High Risk of Kidney Disease - (03/05/16)
     
  7087. CROI: Longer-Term Safety of Tenofovir Alafenamide in Renal Impairment - (03/01/16)
     
  7088. CROI: Longer-Term Renal Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate - (03/01/16)
     
  7089. CROI: Ledipasvir/Sofosbuvir for 6 Weeks in HIV-Infected Patients with Acute HCV Infection - (03/01/16)
     
  7090. CROI: Interactions Between ABT-493 plus ABT-530 combination and Rilpivirine or Raltegravir - (03/01/16)
     
  7091. CROI: Protective Effect of Coffee Intake on Mortality of French HIV-HCVInfected Patients (ANRS CO13 HEPAVIH Cohort) - (03/01/16)
     
  7092. CROI: Atorvastatin and Fluvastatin are Associated with Dose-Dependent Reductions in Cirrhosis and HCC Among Patients with HCV: Results from ERCHIVES - (03/01/16)
     
  7093. CROI: Poorly Controlled HIV Infection is a Risk Factor for Liver Fibrosis in the CNICS Cohort ...CD4 & Viral load predict progression to advanced fibrosis - (03/01/16)
     
  7094. CROI: Body composition changes on Darunavir/Ritonavir (DRV/r) + either Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) as first-line antiretroviral therapy. NEAT 001/ANRS 143. Body composition sub-study - (02/29/16)
     
  7095. CROI: Aging with HIV: Emerging importance of chronic comorbidities in patients over 75 - (02/29/16)
     
  7096. CROI: Frailty is associated with NNRTI-based Initial ART and Modifiable Risks in ACTG 5322 - (02/29/16)
     
  7097. CROI: Factors Associated with Limitations in Daily Activity Among Older HIV+ Adults - (02/29/16)
     
  7098. CROI: Trends in Comorbid Conditions Mentioned with HIV Disease on Death Certificates, United States, 2000-2010 ...Comorbidities' Deaths Sharply Increasing/Leaders Ignore Problem - (02/29/16)
     
  7099. CROI: HIV Combinectin BMS-986197: A long-acting inhibitor with multiple modes of action - (02/29/16)
     
  7100. CROI: A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women - (02/29/16)
     
  7101. CROI: Chemoprophylaxis with Oral FTC/TAF Protects Macaques from Rectal SHIV Infection - (02/29/16)
     
  7102. CROI: PrEP Impact on T cell Activation and Explant Infection...HPTN 069/ACTG 5305 Substudy - (02/29/16)
     
  7103. CROI: MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel - (02/29/16)
     
  7104. CROI: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir - (02/29/16)
     
  7105. CROI: Early Antiretroviral Therapy Does Not Improve Vascular Function: A START Substudy - (02/29/16)
     
  7106. CROI: The Kidney Report - CROI 2016 - Christina Wyatt MD Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY (02/26/16)
     
  7107. CROI: ACTG A5298: A Phase 3 Trial of the Quadrivalent HPV Vaccine in Older HIV+ Adults - (02/26/16)
     
  7108. CROI: HIV-1 Infection With Multiclass Resistance Despite Preexposure Prophylaxis (PrEP) - (02/26/16)
     
  7109. CROI: Cardiovascular Biomarkers After Switching to ABC/DTG/3TC: The STRIIVING Study - (02/26/16)
     
  7110. CROI: STROKE INCIDENCE HIGHEST IN WOMEN AND BLACK HIV-INFECTED PARTICIPANTS IN ALLRT COHORT - (02/26/16)
     
  7111. CROI: Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 96 Analysis - (02/26/16)
     
  7112. CROI: Doravirine 100 mg QD vs Efavirenz +TDF/FTC in ART-NaÏve HIV+ Patients: Week 48 Results - (02/26/16)
     
  7113. CROI: It's Complicated: Renal Function & STIs in PrEP Users / Themed Discussion at CROI - (02/26/16)
     
  7114. CROI: Higher cumulative TFV/FTC levels in PrEP associated with decline in renal function - (02/26/16)
     
  7115. CROI: HPTN 069 / ACTG A5305 Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEP in Men Who Have Sex With Men (MSM) - (02/26/16)
     
  7116. CROI: Cabotegravir Long-Acting Injection Protects Macaques against Intravenous Challenge - (02/26/16)
     
  7117. CROI: Depression and Social Isolation Mediate Effect of HIV Stigma on Women's ART Adherence - (02/26/16)
     
  7118. CROI: Switching tenofovir DF to tenofovir alafenamide in virologically suppressed adults....TAF/FTC Noninferior to TDF/FTC, and Safer, in Switch Study - Mark Mascolini - (02/25/16)
     
  7119. CROI: Tenofovir Rectal Gel Safe and Acceptable in Study of MSM and TGW - Mark Mascolini - (02/25/16)
     
  7120. CROI: Injected Long-Acting Cabotegravir Protects Macaques From Injected SIV - Mark Mascolini - (02/25/16)
     
  7121. CROI: Early Antiretroviral Therapy Does Not Improve Vascular Function: A START Substudy - Mark Mascolini - (02/25/16)
     
  7122. CROI: One in 64 in US--Including 1 in 2 Black MSM--Will Get HIV in Their Lifetime - Mark Mascolini - (02/25/16)
     
  7123. CROI: 9-YEAR TRENDS IN NON-LIPID CARDIOVASCULAR DISEASE PREVENTION STRATEGIES IN HIV+ WOMEN in WIHS-women have poor control of diabetes & hypertension - Mark Mascolini - (02/25/16)
     
  7124. CROI: Poor HIV Control, Black Race, Female Sex Boost Stroke Risk in US Cohort - Mark Mascolini - (02/25/16)
     
  7125. CROI: Increasing Hypertension and Diabetes Rx for HIV+ Women, But Poor Control - Mark Mascolini - (02/25/16)
     
  7126. CROI: HIV Keeps Evolving in Cancer Tissues and Other Tissues During Suppressive ART - Mark Mascolini - (02/25/16)
     
  7127. CROI: ACTG A5340: the effect of VRC01 on viral kinetics after analytical treatment interruption .....VRC01, a Broadly Neutralizing Antibody, Does Not Maintain HIV Control When ART Stops - Mark Mascolini - (02/25/16)
     
  7128. CROI: Body composition changes on Darunavir/Ritonavir (DRV/r) + either Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) as first-line antiretroviral therapy. NEAT 001/ANRS 143. Body composition sub-study...Bigger Trunk Fat Gains With Raltegravir Than TDF/FTC (Both With DRV/r) - Mark Mascolini - (02/25/16)
     
  7129. CROI: Narrowing the gap in life expectancy for HIV+ compared with HIV- individuals...Life Expectancy Gap Between HIV+ and HIV- Narrows But Persists - Mark Mascolini - (02/25/16)
     
  7130. CROI: Antiretrovirals, fractures and osteonecrosis in a large European HIV cohort - EuroSIDA....TDF Is Only Antiretroviral Implicated in EuroSIDA Fracture Study - Mark Mascolini - (02/25/16)
     
  7131. CROI: Perception of Infectiousness in HIV-infected persons after initiating ART: ACTG A5257...Few on ART in ACTG Analysis Think They Cannot Transmit HIV - Mark Mascolini - (02/24/16)
     
  7132. CROI: Repeated TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Viral Remission - (02/24/16)
     
  7133. CROI: Three Maraviroc PrEP Regimens Largely Protective in US MSM Study - Mark Mascolini - (02/24/16)
     
  7134. CROI: Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys - (02/24/16)
     
  7135. CROI: ECLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV-Uninfected Men...Long-Acting Cabotegravir Data Suggest PrEP Injections Every 8 Week - Mark Mascolini - (02/24/16)
     
  7136. CROI: More Coffee Tied to Lower Mortality in French HIV/HCV Group - Mark Mascolini - (02/24/16)
     
  7137. CROI: More Coffee Tied to Lower Mortality in French HIV/HCV Group - Mark Mascolini - (02/24/16)
     
  7138. CROI: Primary Providers as Successful as Specialists in Treating HCV Infection - Mark Mascolini - (02/24/16)
     
  7139. CROI: Effect of Baseline Resistance-Associated Variants on SVR With the 3D Regimen Plus RBV - (02/24/16)
     
  7140. CROI: Drug Interaction Studies Between Sofosbuvir/Velpatasvir and Boosted HIV ARV Regimens - (02/24/16)
     
  7141. CROI: Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis - (02/24/16)
     
  7142. CROI: Brain Volumetric Changes After Two Years of ART Initiated During Acute HIV Infection - (02/24/16)
     
  7143. CROI: FDG PET/CT Imaging of Lymph Nodes as a Measure of the HIV Reservoir in Humans - (02/24/16)
     
  7144. CROI: HIV-1 Maturation Inhibitor BMS-955176: Pharmacokinetic and Exposure-Response Analysis - (02/24/16)
     
  7145. CROI: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment - press release - (02/24/16)
     
  7146. CROI: A Single Monotherapy Dose of MK-8591,a Novel NRTI, Suppresses HIV for Ten Days - (02/24/16)
     
  7147. CROI: Single Dose Zoledronic Acid Prevents Antiretroviral-Induced Bone Loss - (02/24/16)
     
  7148. CROI: Recovery of bone mineral density after stopping oral HIV pre-exposure prophylaxis - (02/24/16)
     
  7149. CROI: Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results - (02/24/16)
     
  7150. CROI: CD38 T-Cell HIV Impact - early ART / cure / vaccine implications / Bruce Walker Opening Session - (02/24/16)
     
  7151. CROI: Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens - press release - (02/23/16)
     
  7152. CROI: Switching to F/TAF (Tenofovir Alafenamide) from F/TDF (Tenofovir DF) based Regimen Study 311-1089: 48-Week Data - - (02/23/16)
     
  7153. CROI: Early ART in START Trial Does Not Improve Arterial Elasticity - written by Mark Mascolini - (02/23/16)
     
  7154. CROI: Dapivirine Vaginal Ring Cuts HIV Risk 27% to 56% in Two Trials in African Women - written by Mark Mascolini - (02/23/16)
     
  7155. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial - (02/19/16)
     
  7156. CCR2 inhibition: a panacea for diabetic kidney disease? - Comment - (02/19/16)
     
  7157. Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity? - (02/19/16)
     
  7158. Cancers / HIV - (02/19/16)
     
  7159. ART / Neurotoxicity - (02/19/16)
     
  7160. Bone Loss in HIV Persists Through Chronic Infection for Years - (02/16/16)
     
  7161. Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment - (02/16/16)
     
  7162. Killing HIV in the Brain / Implications for Cure - A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier....."monoclonal antibody (mAb) 2556" - (02/16/16)
     
  7163. ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions - (02/11/16)
     
  7164. Evaluation of Oral Tenofovir Disoproxil Fumarate and Topical Tenofovir GS-7340 to Protect Infant Macaques Against Repeated Oral Challenges With Virulent Simian Immunodeficiency Virus - (02/11/16)
     
  7165. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV - (02/11/16)
     
  7166. Pharmacokinetics of Long-acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis - (02/11/16)
     
  7167. Kidney Function 101 - (02/11/16)
     
  7168. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV - (02/10/16)
     
  7169. Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment - (02/10/16)
     
  7170. Research in the news: Even moderate alcohol intake may harm people with HIV - Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men - VACS - (02/10/16)
     
  7171. Maraviroc PI / Label / Product Insert - (02/10/16)
     
  7172. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection - (02/10/16)
     
  7173. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection - (02/10/16)
     
  7174. Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way? - Commentary - (02/10/16)
     
  7175. Researchers claim to find HIV sanctuaries - Controvery - (02/10/16)
     
  7176. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study / Commentary - Early HIV treatment to forestall drug resistance, Mark Wainberg - (02/08/16)
     
  7177. Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study - (02/08/16)
     
  7178. Comparison of subjective and objective adherence measures for pre-exposure prophylaxis against HIV infection among serodiscordant couples in East Africa. - Electronic Monitoring - (02/08/16)
     
  7179. Co-delivery of HIV-1 entry inhibitor and NNRTI shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy - "new strategies for HIV cure" - Nanotechnology & ARTs - (02/08/16)
     
  7180. What Causes Kidney Decline in HIV+ / Factors associated with iohexol-based glomerular filtration rate slope over 36 months in HIV-negative and HIV-positive individuals - (02/08/16)
     
  7181. Can Five HIV Prevention Strategies Bring the Epidemic to Its Knees? - (02/08/16)
     
  7182. Persistent HIV-1 replication maintains the tissue reservoir during therapy - (01/27/16)
     
  7183. European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV - (01/28/16)
     
  7184. HCV, HIV, IDUs - Local, state, groups meet to combat alarming drug rise in NC - (01/27/16)
     
  7185. HIV infection is independently associated with frailty in middle-aged HIV type 1 infected individuals compared with similar but uninfected controls..... "HIV-infected individuals were more likely to be frail (10.6 vs. 2.7%)" - (01/27/16)
     
  7186. Ritonavir FDA Product Insert - (01/27/16)
     
  7187. Respiratory co-morbidities in people with HIV - (01/27/16)
     
  7188. Broadening the debate over HIV and hormonal contraception - Comment - (01/27/16)
     
  7189. NanoART ATV/r + URMC-099, a Neuroprotective agent, Additively Reduce HIV Activity... - (01/27/16)
     
  7190. From START to finish: implications of the START study - (01/27/16)
     
  7191. Effect of PrEP for MSM in UK: considerations for scale-up - (01/27/16)
     
  7192. Combination emtricitabine and tenofovir disoproxil fumarate prevents vaginal SHIV infection in macaques harboring C. trachomatis and T. vaginalis - (01/27/16)
     
  7193. Pre-exposure prophylaxis [TDF in HBV] fails to prevent HIV-1 infection or the establishment of a significant viral reservoir - (01/25/16)
     
  7194. Cystatin C-Based Renal Function Changes After Antiretroviral Initiation: A Substudy of a Randomized Trial - (01/25/16)
     
  7195. HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial - (01/25/16)
     
  7196. Cystatin C-Based Renal Function Changes After Antiretroviral Initiation: A Substudy of a Randomized Trial - (01/25/16)
     
  7197. New HCV & HIV Drug RG-101 - (01/25/16)
     
  7198. Changes in Proteinuria and Albuminuria With Initiation of Antiretroviral Therapy: Data From a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine Versus Abacavir/Lamivudine - (01/22/16)
     
  7199. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. - (01/21/16)
     
  7200. Incidence of cervical dysplasia and cervical cancer in women living with HIV in Denmark: comparison with the general population - (01/20/16)
     
  7201. Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection - (01/20/16)
     
  7202. Toward an AIDS-Free Generation: Can Antibodies Help? / HIV-neutralizing antibody - (01/20/16)
     
  7203. Dramatic increase in preexposure prophylaxis use among MSM in Washington state - (01/20/16)
     
  7204. Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV - (01/20/16)
     
  7205. Brain large artery inflammation associated with HIV and large artery remodeling - (01/19/16)
     
  7206. Long-term impact of HIV wasting on physical function - (01/19/16)
     
  7207. Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection - (01/19/16)
     
  7208. Ruxolitinib and Tofacitinib Are Potent and Selective Inhibitors of HIV-1 Replication and Virus Reactivation In Vitro - (01/19/16)
     
  7209. Atazanavir PI Product Insert - (01/19/16)
     
  7210. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy - (01/15/16)
     
  7211. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls - (01/15/16)
     
  7212. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease....Response Guided Therapy - (01/15/16)
     
  7213. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. - (01/13/16)
     
  7214. Aging - New drugs - (01/08/16)
     
  7215. Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable Regimen for Treatment of HIV Infection - GSK744 (Cabotegrevir) + Rilpivirine - (01/08/16)
     
  7216. HIV & HBV J&J Announcements - (01/08/16)
     
  7217. GSK744 (Cabotegrevir)/Rilpivirine Long-Acting Injectable Maintenance Therapy Phase 3 Study Start Date Announced - ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV - (01/08/16)
     
  7218. ViiV Healthcare to acquire Bristol-Myers Squibb HIV R&D assets - HIV attachment & maturation inhibitors - (01/08/16)
     
  7219. HIV & HCV & Parkinsons Disease: is there an increased risk - undecided yet with mixed opinions and suggestive data - (01/08/16)
     
  7220. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study......Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study - (01/07/16)
     
  7221. Comment - Should kidney disease risk affect antiretroviral choice? - (01/07/16)
     
  7222. AASLD: Antiviral Activity of TAF Against Drug-Resistant HBV Isolates in Vitro - (01/07/16)
     
  7223. Cutting Out HIV from DNA: RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection - (01/06/16)
     
  7224. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study......Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study - (01/06/16)
     
  7225. Comment - Should kidney disease risk affect antiretroviral choice? - (01/06/16)
     
  7226. HIV & HCV & Parkinsons Disease: is there an increased risk - undecided yet with mixed opinions and suggestive data - (01/06/16)
     
  7227. Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure - (01/06/16)
     
  7228. Monitoring of kidney function in HIV-positive patients - (01/06/16)
     
  7229. EDURANT (rilpivirine) FDA Product Insert/label/2011 - (01/06/16)
     
  7230. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity - (01/06/16)
     
  7231. Perinatal HIV in the brain - Editorial - (01/06/16)
     
  7232. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters (NSAIDs/salicylates/sildenafil, tadalafil, and vardenafil) in Patients Infected With HIV Type 1 - (01/05/16)
     
  7233. The role of inflammation in depression: from evolutionary imperative to modern treatment target.... "inflammatory responses in peripheral tissues may drive inflammation in the brain leading to depression" - (01/05/16)
     
  7234. European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection - (01/05/16)
     
  7235. HIV-1 Eradication: Early Trials (and Tribulations) - (01/05/16)
     
  7236. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study - (01/05/16)
     
  7237. Cerebral injury in perinatally HIV-infected children compared to matched healthy controls....adults too - (01/05/16)
     
  7238. Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases/HIV Cure application - (01/05/16)
     
  7239. Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection - (01/05/16)
     
  7240. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report - (12/21/15)
     
  7241. Longitudinal Changes Over 10 Years in Free Testosterone Among HIV-Infected and HIV-Uninfected Men - (12/21/15)
     
  7242. ART Durability Increased in HOPS: Blacks/ Latinos, Once Daily Dosing - (12/21/15)
     
  7243. IAS: Bioequivalence of Two Dosage Strength Fixed-Dose Combination Formulations of Emtricitabine/Tenofovir Alafenamide (F/TAF) to Elvitegravir/Cobicistat/Emtricitabine/TAF (E/C/F/TAF) - (12/18/15)
     
  7244. EASL: EACS aging-related presentations - (12/18/15)
     
  7245. AGE: 6th 2015 Aging Workshop Reports (12/11/15)
     
  7246. Aging/Comorbidities Update: New Studies-Publications / Conference Aging Studies: EACS / IDSA / ICAAC / IAS / CROI - (12/10/15)
     
  7247. CROI: CROI 2015 - Metabolics / Aging, Senescence / Comorbidities / Inflammation - 3 Exercise Studies / Heart Disease / Statins / Cancers / The Kidney / Bone / TAF / The Brain - neurologic function
     
  7248. NIH Scientists (Fauci) Draw Evidence-Based Blueprint for HIV Treatment and Prevention - (12/10/15)
     
  7249. The role of healthcare providers in the roll out of preexposure prophylaxis - (12/10/15)
     
  7250. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women - (12/10/15)
     
  7251. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection - IPERGAY Study 86% Risk Reduction, 92% Risk Reduction with adherence - (12/10/15)
     
  7252. CDC Says 1.2 million indicated for PrEP: heterosexuals, IDUs, MSM at high risk - (12/10/15)
     
  7253. CDC - Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition - United States, 2015 [1.2 million: 400,000+ heterosexuals/40,000+ IDUs/212,000+ MSM] - (12/10/15)
     
  7254. Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men - (11/13/15)
     
  7255. Kidney disease & Hispanic/Latinos in US..... only 18% of individuals with CKD and 34% of those with eGFRcreat-cyst <60 ml/min per 1.73 m2 were aware of having CKD - (11/12/15)
     
  7256. NEUTRALIZING HIV:THE FUTURE OF TREATMENT AND PREVENTION - World AIDS Day Dec 3 at Rockefeller University/NYC - (11/11/15)
     
  7257. EACS: Better Virologic Control After Switch From Boosted ATV/TDF/FTC to E/C/F/TAF - Mark Mascolini - (11/06/15)
     
  7258. FDA approves new treatment for HIV: Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) - (11/06/15)
     
  7259. GS-9883 (non-boosed integrase inhibitor), F/TAF (emtricitabine/tenofovir alafenamide) - (11/06/15)
     
  7260. Gilead Sciences HIV Drug [TAF/Genoya] Wins FDA Approval - (11/06/15)
     
  7261. U.S. Food and Drug Administration Approves Gilead's Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection - (11/06/15)
     
  7262. EACS: Atazanavir plus Cobicistat versus Atazanavir plus Ritonavir, Both in Combination with Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial - (11/05/15)
     
  7263. EACS: Real-World Assessment of Renal and Bone Safety Among Patients Exposed to Tenofovir Disoproxil Fumarate-Containing Single Tablet Regimens - (11/05/15)
     
  7264. EACS: Real-World Cardiovascular Outcomes of Atazanavir - (11/05/15)
     
  7265. EACS: Bioequivalence of a Fixed-Dose Combination of Rilpivirine/Emtricitabine/Tenofovir Alafenamide to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Rilpivirine - (11/05/15)
     
  7266. EACS: Where is the greatest impact of uncontrolled HIV infection on clinical disease progression? - (11/05/15)
     
  7267. ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy - every 8 weeks rilpivirine+GSK744 - (11/05/15)
     
  7268. The LATTE study: a provocative brew - Comment - (11/04/15)
     
  7269. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial - (11/04/15)
     
  7270. Frequency and implications of HIV superinfection - (11/04/15)
     
  7271. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya - (11/04/15)
     
  7272. Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy - (11/04/15)
     
  7273. EACS: Differing cART Responses in Naive Women and Those With Short-Term cART in Pregnancy - Mark Mascolini (11/03/15)
     
  7274. EACS: HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen - (11/03/15)
     
  7275. EACS: The Effect of Food on the Pharmacokinetics of Unboosted and Boosted Tenofovir Alafenamide - (11/03/15)
     
  7276. EACS: Patient Reported Outcomes Over 48 Weeks in a Randomized, Open-Label Trial of Patients With HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) - (11/03/15)
     
  7277. EACS: Elvitegravir concentrations in seminal plasma in HIV-1 infected patients - (11/02/15)
     
  7278. EACS: Long lasting viral suppression and immune reconstitution (CD4) of great magnitude reduce the risk of cervical dysplasia in HIV-positive women - (11/02/15)
     
  7279. EACS: Integrated Analysis of Emergent Drug Resistance Through 48 Weeks from Clinical Studies of HIV-1 Treatment-Naive Subjects Receiving E/C/F/TAF - (11/02/15)
     
  7280. EACS: Evaluation of Tenofovir Alafenamide Pharmacokinetics: No Influence of Demographic or HIV Disease Factors - (11/02/15)
     
  7281. EACS: Lung Function Decline in HIV: Effects of Immediate vs. Deferred ART Treatment on Lung Function Decline in a Multi-site, International, Randomized Controlled Trial - START - (11/02/15)
     
  7282. Trauma & HIV; Women & HIV and Trauma - (10/23/15)
     
  7283. IWCADR: Decreased bone mass in perinatally HIV-infected school-aged South African children on ART - (11/02/15)
     
  7284. EACS: Ongoing contribution of AIDS deaths in the HAART era - (10/30/15)
     
  7285. EACS: PERSISTENT HIV LOW-LEVEL VIREMIA AND CARDIOVASCULAR RISK - (10/30/15)
     
  7286. EACS: The Effect of Food on the Rilpivirine/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen - (10/30/15)
     
  7287. EACS: Recurrent Lymphoma Infrequent With HIV, But Prognosis Remains Poor - Written by Mark Mascolini (10/30/15)
     
  7288. EACS: Most AIDS Deaths Involve Women, Blacks, and Younger People in UK Cohort - Written by Mark Mascolini (10/30/15)
     
  7289. EACS: Nonclassic OIs and AIDS Cancers Occurring at Higher CD4 Counts in Swiss Cohort - Written by Mark Mascolini (10/30/15)
     
  7290. EACS: Pre-ART Load, Time to Suppression, and Regimen Predict Rebound - Written by Mark Mascolini (10/30/15)
     
  7291. EACS: Pharmacokinetics of ATV/r or DRV/r in + 2 NRTIs among HIV-1-naive Patients with Severe Immunosuppression - IMEA 040-DATA sub-study - Written by Mark Mascolini (10/30/15)
     
  7292. EACS: Nonclassic OIs and AIDS Cancers Occurring at Higher CD4 Counts in Swiss Cohort...... "AIDS Defining Opportunistic Diseases in the Swiss HIV Cohort Study: A Comprehensive Review 1988-2013" - Written by Mark Mascolini (10/30/15)
     
  7293. EACS: Persistent Low Viremia Not Tied to Heart Disease, AIDS, or Death in Large Cohort - Written by Mark Mascolini (10/28/15)
     
  7294. EACS: Dual therapy with Lopinavir/ Ritonavir (LPV/r) and Lamivudine (3TC) is non-inferior to standard triple drug therapy in Naïve HIV-1 infected subjects : 48-week results of the GARDEL Study. (10/28/15)
     
  7295. EACS: Switching From Boosted Atazanavir Plus Emtricitabine /Tenofovir Disoproxil Fumarate to a Tenofovir Alafenamide-Based Single-Tablet Regimen: Week-48 Data in Virologically Suppressed Adults (10/28/15)
     
  7296. EACS: Gap in ART Response Between Women and MSM Not Narrowing in London.....women and MSW have worse virologic responses to ART than MSM (10/28/15)
     
  7297. EACS: Is the gender difference in viral load response to ART narrowing over time? Women Non-Viral Response Double vs MSM (10/28/15)
     
  7298. EACS: Low-level viremia (LLV) ranging from 50 to 500 copies/mL is associated to an increased risk of AIDS events in the Icona Foundation Cohort (10/28/15)
     
  7299. EACS: Week 48 results of the randomised, multicentre Maraviroc Switch study (MARCH) (10/28/15)
     
  7300. EACS: Switch to maraviroc (MVC) + darunavir/ritonavir (DRV/r) in virologically suppressed patients with R5-tropic virus is associated with an excess of virological failures: 48 weeks results of the GUSTA study (10/28/15)
     
  7301. EACS: Measuring Safety and Satisfaction of ABC/DTG/3TC (Triumeq) in a Switch Trial: Secondary Endpoints from the STRIVING Study (10/28/15)
     
  7302. EACS: EuroSIDA Analysis Suggests Much Lower PSA Cutoff for HIV-Positive Men - Written by Mark Mascolini (10/28/15)
     
  7303. EACS: Birth Defect Rate Low and Similar With Darunavir and Other Antiretroviral Regimens - Written by Mark Mascolini (10/27/15)
     
  7304. EACS: Viral Load of 51 to 500 Boosts Risk of AIDS But Not Serious Non-AIDS Illness - Written by Mark Mascolini (10/27/15)
     
  7305. EACS: EuroSIDA Analysis Suggests Much Lower PSA Cutoff for HIV-Positive Men - Written by Mark Mascolini (10/27/15)
     
  7306. EACS: No Neuropsych Test Difference Between Early and Delayed ART in START (10/27/15)
     
  7307. EACS: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, for Initial HIV-1 Treatment: Week 96 Results (10/27/15)
     
  7308. EACS: No Difference between the Effects of Immediate versus Deferred ART on Neuropsychological Test Performance in HIV-Positive Adults with CD4+ Cell Counts > 500 cells/μL (10/27/15)
     
  7309. EACS: Dolutegravir Monotherapy in HIV-infected Patients with Sustained Viral Suppression: A 24-week Pilot Study (10/27/15)
     
  7310. EACS: TAF in Women/WAVES Global Women's Study - The Efficacy and Safety of Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve Women With HIV-1 Infection: Week 48 Analysis of the Phase 3, Randomized, Double-blind Study (10/27/15)
     
  7311. EACS: TURQUOISE-I STUDY: USE OF OMBITASVIR/PARITAPREVIR/RITONAVIR + DASABUVIR + RIBAVIRIN IN PATIENTS WITH HCV/HIV-1 CO-INFECTION ON STABLE DARUNAVIR-CONTAINING ANTIRETROVIRAL THERAPY (10/27/15)
     
  7312. EACS: Sofosbuvir plus ledipasvir for 8 weeks in HCV-mono- and HIV-HCV-coinfected patients - Results from the German hepatitis C cohort (GECCO) (10/27/15)
     
  7313. EACS: Near-100% SVR12 With 8 Weeks of Sofosbuvir/Ledipasvir in German HIV+/HIV- Cohort - Written by Mark Mascolini (10/27/15)
     
  7314. EACS: Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients?..... "SVR -reduced incidence of liver-related death and improved overall survival" (10/27/15)
     
  7315. EACS: Dolutegravir monotherapy in patients with suppressed HIV viremia. (10/26/15)
     
  7316. EACS: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Safety Analysis (10/26/15)
     
  7317. EACS: Changes in cognitive function over 96 weeks after initiating darunavir/ritonavir with either raltegravir or tenofovir-emtricitabine; NEAT 001 / ANRS 143 randomised controlled study (10/26/15)
     
  7318. EACS: Improved Safety and Efficacy of TAF vs TDF Single-Tablet Regimen in HIV-1 Treatment-Naïve Women Through Week 48 (10/26/15)
     
  7319. EACS: Simplification to Atazanavir/Ritonavir + Lamivudine versus Maintaining Atazanavir/Ritonavir + 2NRTIs in Virologically Suppressed HIV-infected Patients: 48-weeks Data of the ATLAS-M Trial (10/26/15)
     
  7320. EACS: Week 48 results of the randomised, multicentre Maraviroc Switch study (MARCH) (10/26/15)
     
  7321. EACS: Pre-cART pro-Inflammatory Milieu, Microbial Translocation (MT) and risk of disease progression in HIV-Infected Patients, Starting Their First cART: data form the Icona Cohort Foundation (10/26/15)
     
  7322. EACS: Measuring Safety and Satisfaction of ABC/DTG/3TC in a Switch Trial: Secondary Endpoints from the STRIVING Study (10/26/15)
     
  7323. EACS: Week 48 results of the randomised, multicentre Maraviroc Switch study (MARCH) (10/26/15)
     
  7324. EACS: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Safety Analysis (10/26/15)
     
  7325. EACS: Frailty Predicts All-cause Mortality, Hospital Admission and Falls in HIV-infected and -uninfected Middle-aged Individuals (10/23/15)
     
  7326. EACS: Second-generation HIV-1 Maturation Inhibitor BMS-955176: Overall Antiviral Activity and Safety Results from the Phase IIa Proof-of-Concept Study (AI468002) (10/23/15)
     
  7327. EACS: Second Generation HIV-1 Maturation Inhibitor (MI) BMS-955176: Antiviral Activity Toward Non-B Subtype HIV-1 Viruses (10/23/15)
     
  7328. EACS: Immediate ART in START Linked to Bigger Bone Loss Over 3 Years - written Mark Mascolini (10/23/15)
     
  7329. EACS: HIV Independently Boosts Odds of Hypertension in Older HIV+/HIV- Cohort - Lipodystrophy/heart disease - written Mark Mascolini (10/23/15)
     
  7330. EACS: Pilot Study Finds Good 24-Week Response to First-Line Dolutegravir/3TC - written Mark Mascolini (10/23/15)
     
  7331. EACS: Dolutegravir-Lamivudine as Initial Therapy in HIV-infected, ARV Naïve Patients: First Results of the PADDLE Study - (10/23/15)
     
  7332. EACS: Dolutegravir-Based Regimens Viral Load Decay at week 4 Could predict Sustained Viral Suppression - (10/23/15)
     
  7333. IDSA: HCV at IDSA, Treatment Study Results in HIV/HCV Coinfected, Cascade & Barriers to Care (10/23/15)
     
  7334. EACS: HIV Independently Boosts Odds of Hypertension in Older HIV+/HIV- Cohort - (10/23/15)
     
  7335. EACS: Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV - (10/23/15)
     
  7336. IWCADR: Long-term Body Composition Changes in Antiretroviral-treated HIV-Infected Individuals - (10/23/15)
     
  7337. IWCADR: Effects of immediate versus deferred initiation of antiretroviral therapy on bone mineral density: a substudyof the INSIGHT Strategic Timing of Antiretroviral Therapy (START) study - (10/23/15)
     
  7338. Nef: target for new potential HIV treatment - UMass Medical researchers uncover promising clue to battling HIV 'New treatment possibilities' - "New HIV Treatment Target: HIV: Antiviral action countered by Nef" - "SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef" - (10/23/15)
     
  7339. IDSA: Antiretroviral Therapy in HIV-infected Adults Receiving Medical Care in the United States: Medical Monitoring Project, 2009-2012 (10/21/15)
     
  7340. IDSA: DAA Cure Rate 75% in HCV/HIV Cohort With Ongoing Barriers to Care - Mark Mascolini (10/21/15)
     
  7341. PrEP Report: Sexual behavior patterns/PrEP dosing and PrEP Report by Bob Grant: PrEP usage estimates/PrEP in SF - (10/21/15)
     
  7342. IDSA: A Study of the Knowledge And Beliefs Held by Patients Infected with HIV and Their HIV Health Care Providers Regarding Single Tablet Regimens (STR). (KNABSTR Study) - (10/19/15)
     
  7343. IDSA: Long-Term Safety and Efficacy of Dolutegravir in HIV Treatment-Experienced Adolescents - (10/19/15)
     
  7344. European CHMP Adopts Positive Opinion for Gilead's Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV - (10/19/15)
     
  7345. Researchers complete ASPIRE Phase III trial of the dapivirine vaginal ring for HIV prevention in women - (10/19/15)
     
  7346. Effective HAART Reduces HBV incidence in HIV+ MEM in MACS due perhaps to improved immunity - (10/19/15)
     
  7347. The effect of physical activity on cardiometabolic health and inflammation in treated HIV infection - (10/19/15)
     
  7348. Cancer Burden in the HIV-Infected Population in the United States: Anal & Cervical Cancers Increased -Natl Cancer Institute/NIH Report - (10/19/15)
     
  7349. IDSA: A Study of the Knowledge And Beliefs Held by Patients Infected with HIV and Their HIV Health Care Providers Regarding Single Tablet Regimens (STR). (KNABSTR Study) (10/16/15)
     
  7350. IDSA: 2014 Affordable Care Act Enrollment of AIDS Drug Assistance Program Clients and Associated HIV Outcomes.....ACA Enrollment Improves Viral Load suppression by 45% [slides presented are included in this report] (10/16/15)
     
  7351. IDSA: Affordable Care Act helps Virginia improve HIV outcomes (10/16/15)
     
  7352. IDSA: US ART Guideline Picks Linked to Better Viral Suppression, Fewer Side Effects - Mark Mascolini - (10/16/15)
     
  7353. IDSA: US Clinicians Largely Follow Guidelines in Picking First-Line Regimens - Mark Mascolini - (10/16/15)
     
  7354. IDSA: Sub-500 Current CD4 Count Linked to Unsuccessful Aging in US Clinic - Mark Mascolini - (10/16/15)
     
  7355. IDSA: Low Pneumococcal Colonization Rate in HIV+ Adults in PCV-13 Vaccine Era - Mark Mascolini - (10/16/15)
     
  7356. IDSA: Behavioral and Clinical Factors Among HIV-infected Women in Care ≥ Age 50 Years - United States, 2009-2011 ..... 37.5% >50 years of age....60-62% Black - (10/16/15)
     
  7357. IDSA: Perinatally Infected Hispanics Have Higher Resistance Rates Than Blacks in Houston - written by Mark Mascolini - (10/16/15)
     
  7358. IDSA: New US HIV Prevention Guidelines Underline Antiretroviral Use - written by Mark Mascolini - (10/16/15)
     
  7359. IDSA: Under 3% With HIV Complete HPV Vaccine Series in Large Denver Survey - written by Mark Mascolini - (10/16/15)
     
  7360. IDSA: Rectal and Pharyngeal Screening Yields Higher GC/CT Positive Rates in HIV+ Men - written by Mark Mascolini - (10/16/15)
     
  7361. IDSA: ART Feasible During Bone Marrow Transplant--Enfuvirtide a Safe Option - written by Mark Mascolini - (10/16/15)
     
  7362. IDSA: Community-Acquired Pneumonia More Frequent With HIV in Veterans Cohort - written by Mark Mascolini - (10/16/15)
     
  7363. IDSA: "Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data" - written by Mark Mascolini - (10/16/15)
     
  7364. IDSA: HIV+ Nonnative English Speakers Have Higher Odds of Neurocognitive Impairment - written by Mark Mascolini - (10/16/15)
     
  7365. IDSA: A Longitudinal Analysis of Fractures (and Osteoporisis) Among Human Immunodeficiency Virus (HIV) Patients in the USA.....incidence & prevalence increased by 50% in Medicare (10/15/15)
     
  7366. IDSA: A Prospective Comparison of Arterial Stiffness and Inflammation in Adults with HIV/Hepatitis C Co-Infection, HIV Infection and Healthy Controls..... "markers of inflammation and monocyte activation were significantly higher among HIV/HCV participants suggesting a possible mechanism for the increased risk of CVD reported in this patient group." (10/15/15)
     
  7367. IDSA: A Longitudinal Analysis of Cardiovascular Conditions and Related Comorbidities Among Human Immunodeficiency Virus (HIV) Patients in the USA (10/15/15)
     
  7368. IDSA: A Longitudinal Analysis of Cardiovascular and Fracture Rates Among HIV-infected Patients in the USA with Commercial and Medicaid Insurance (10/15/15)
     
  7369. IDSA: Switching From a TDF to a TAF-Based Single Tablet Regimen: Week 48 Data in HIV-1 Infected Virologically Suppressed Adults (10/15/15)
     
  7370. IDSA: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Subgroup Analysis (10/15/15)
     
  7371. IDSA: Lack of Drug Interactions between Boosted and Unboosted Tenofovir Alafenamide-based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir...... "R/F/TAF or E/C/F/TAF may be coadministered with LDV/SOF without dose modification." (10/15/15)
     
  7372. IDSA: Influence of Age on Outcomes in HIV-Infected Adults Initiating Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate With Elvitegravir, Cobicistat, and Emtricitabine (10/15/15)
     
  7373. IDSA: Safety and Efficacy of TAF vs TDF Single-Tablet Regimen in HIV-1 Treatment-Naïve Black and Nonblack Patients Through Week 48 (10/15/15)
     
  7374. IDSA: Long Term Testosterone Replacement Therapy (TRT) use in HIV Patients and New Cardiovascular Events (CVE) (10/15/15)
     
  7375. IDSA: Strategic Simplification: The Efficacy and Safety of Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Plus Darunavir (DRV) in Treatment-Experienced HIV-1-Infected Adults (NCT01968551) (10/13/15)
     
  7376. IDSA: Follow-up Screening Rates Low for Breast and Cervical Cancer in HIV+ Women - written by Mark Mascolini - (10/13/15)
     
  7377. IDSA: Better Renal and Bone (But Not Lipid) Changes After Switch From E/C/F/TDF to E/C/F/TAF - written by Mark Mascolini - (10/13/15)
     
  7378. IDSA: HIV+ Blacks in VA 30% More Likely to Have Poor Hypertension or Diabetes Control - written by Mark Mascolini - (10/13/15)
     
  7379. IDSA: Sustained Viral Control With Switch to E/C/F/TAF Plus DRV in Experienced - written by Mark Mascolini - (10/13/15)
     
  7380. IDSA: Switch From ADAP to Obamacare Linked to HIV Control in Virginia - written by Mark Mascolini - (10/13/15)
     
  7381. IDSA: Week-48 Subgroup Responses to Attachment Inhibitor in Phase 2b Trial - written by Mark Mascolini - (10/13/15)
     
  7382. IDSA: HIV, Hypertension, and Diabetes Control Vary Between and Within HIV Clinics - written by Mark Mascolini - (10/13/15)
     
  7383. IDSA: HIV Testing Rate Only 16% in High-Risk Hospital Pneumonia Patients - written by Mark Mascolini - (10/10/15)
     
  7384. IDSA: Urine Screening Alone Misses Most Chlamydia and Gonorrhea in HIV+ MSM - written by Mark Mascolini - (10/10/15)
     
  7385. AGE: Neurocognitive Performance Falls Faster With Age in HIV-Positive People - written by Mark Mascolini (10/09/15)
     
  7386. AGE: Depression Tied to Worse Cognitive Function in MACS Men With or Without HIV - written by Mark Mascolini (10/09/15)
     
  7387. AGE: Are frailty, precariousness and comorbidity related in HIV-infected aging patient? YES, 65% Frail/Prefrail in French Study/Mean age 57.....at the Aging Workshop Oct 2015 (10/09/15)
     
  7388. AGE: Noninfectious Conditions May Drive Neurocognitive Problems With HIV - written by Mark Mascolini (10/09/15)
     
  7389. AGE: Older Adults With HIV Spend Most Time Home, Alone, and Passive - written by Mark Mascolini (10/09/15)
     
  7390. AGE: Frailty Tied to Cardiometabolic Disorders and Death in Large HIV Cohort - written by Mark Mascolini (10/09/15)
     
  7391. Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1: cure strategy - (10/07/15)
     
  7392. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma - (10/07/15)
     
  7393. AGE: Emphysema Progression Similar With HIV and in Older HIV-Negative Heavy Smokers - written by Mark Mascolini (10/07/15)
     
  7394. AGE: CD4/CD38 Ratio Better in HIV+ Women Than Men, But Survival Similar - written by Mark Mascolini (10/07/15)
     
  7395. AGE: Rapid Rise in Frailty in First 3 Years of Menopause in HIV+ Women, Then Stable - written by Mark Mascolini (10/07/15)
     
  7396. AGE: Frailty Doubles Death/MACS) A frailty-related phenotype and death: Investigating inflammatory markers as potential mediators among men with HIV in the modern HAART era - [Interleukin 6 (IL-6), C-reactive protein (CRP), Tumor necrosis factor-receptor 2 (TNFαR2)] (10/05/15)
     
  7397. AGE: Higher Non-AIDS Cancer Rate in Men With HIV: 30-Year MACS Study - written by Mark Mascolini (10/05/15)
     
  7398. AGE: Frailty, "Precarious" Status, and Comorbidities Linked in Large French Cohort - written by Mark Mascolini (10/05/15)
     
  7399. AGE: Grip Strength Fades Faster With Age in Men With Than Without HIV - written by Mark Mascolini (10/05/15)
     
  7400. AGE: Frailty Doubles Death Risk in HIV+ Men, With Only Modest Impact of Inflammation - written by Mark Mascolini (10/05/15)
     
  7401. Aging & Comorbidities at ICAAC 2015 & IAS 2015 - (10/02/15)
     
  7402. WHO Updates Gudelines: recommends Treatment at any CD4 & PrEP; IDSA Commends - (10/02/15)
     
  7403. New HIV Treatment Target: HIV: Antiviral action countered by Nef - (10/02/15)
     
  7404. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy - (10/02/15)
     
  7405. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir: raltegravir had preferable bone profile - (10/02/15)
     
  7406. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men - (10/02/15)
     
  7407. WHO New Guidelines: start ART at any CD4; PrEP recommended for all at substantial risk - (10/02/15)
     
  7408. HIV discoverer: 'To develop a cure is almost impossible' - (09/30/15)
     
  7409. ICAAC: A Dose Escalation Study of Cyclophosphamide (CTX) to Enhance SB-728-T Engraftment - (09/30/15)
     
  7410. High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy - (09/28/15)
     
  7411. HIV+ Fat Tissue is a HIV Reservoir & Inflammation Occurs Within the Fat Tissue due to HIV - 2 studies report - (09/28/15)
     
  7412. ICAAC: Population Pharmacokinetic Assessment of Factors Associated with Tenofovir Clearance in Pregnant and Postpartum Women with HIV infection in IMPAACT P1026s - (09/28/15)
     
  7413. HIV Reservoir in Fat Tissue: inflammation, lipodystrophies - (09/25/15)
     
  7414. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial - (09/25/15)
     
  7415. BMS-663068, a safe and effective HIV-1 attachment inhibitor - commentary - (09/25/15)
     
  7416. Is it time to abandon single intervention cure trials? - (09/25/15)
     
  7417. ICAAC: Are Week-12 Results Adequate for Phase 2 Integrase Inhibitor Trials? - written by Mark Mascolini - (09/25/15)
     
  7418. ICAAC: HIV Hospital Mortality Flat From 1993 to 2013, But Non-AIDS Death Rate Surges...... Over that period the proportion of in-hospital deaths attributable to non-AIDS causes rose from 43% to 70.5% (P < 0.0001) - written by Mark Mascolini - (09/25/15)
     
  7419. ICAAC: Lower Tenofovir Levels in Pregnant Women Taking a Boosted PI - written by Mark Mascolini - (09/25/15)
     
  7420. ICAAC: Contraindicated Drugs Combos Tied to Higher Hospital Rate in HIV+ Veterans - written by Mark Mascolini - (09/25/15)
     
  7421. ICAAC: Relationship between Type of Antiretroviral Therapy, Drug-Drug Interactions, and Hospitalizations - - (09/25/15)
     
  7422. Parkinson Disease in HIV.....Does HIV Infection Alter Parkinson Disease? - (09/24/15)
     
  7423. Cure Drug HDAC Inhibitor Romidepsin Reverses HIV-1 Latency In Vivo - (09/24/15)
     
  7424. Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011..... Comorbidities Death Rates Doubled AIDS-Related death Rates: 70% of Deaths were due to Non-AIDS Related Cause, COMORBIDITIES, while only 29.5% were AIDS-related - (09/24/15)
     
  7425. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART) 2004-2008: Non-AIDS Illnesses were the majority of the causes of deaths including CVD/liver/malignancies/infections - (09/24/15)
     
  7426. ICAAC: Success of NRTI-sparing Regimens Containing Raltegravir in Therapy-experienced Patients in a German Cohort - (09/24/15)
     
  7427. ICAAC: Kinetics of release of antiretroviral drugs through a silicone vaginal ring..... Preliminary Results of a non-toxic Silicone vaginal ring to deliver antiviral drugs, protect women against HIV & herpes - (09/24/15)
     
  7428. ICAAC: Week 12 as an Early Predictor of Week 24 Outcomes in Trials of an Integrase Strand Transfer Inhibitor for HIV - (09/24/15)
     
  7429. ICAAC: Doravirine Does Not Have a Clinically Meaningful Effect on the Pharmacokinetics of Atorvastatin - (09/24/15)
     
  7430. ICAAC: Alarmingly High Comorbidity Rates Among HIV+ - (09/24/15)
     
  7431. ICAAC: Comorbidities of Patients with Human Immunodeficiency Virus (HIV) in the USA - a Longitudinal Analysis of Prevalent HIV Patients Over 11 Years - (09/24/15)
     
  7432. ICAAC: Food Does Not Affect the Bioavailability of Doravirine: Results from Two Pharmacokinetic Studies in Healthy Subjects - (09/21/15)
     
  7433. ICAAC: Protection Against Flu But Not HBV in Vaccinated Perinatally HIV-Infected Children - (09/21/15)
     
  7434. ICAAC: Cabotegravir Has No Effect on Cardiac Repolarization in Healthy Subjects - (09/21/15)
     
  7435. ICAAC: Switching to Abacavir/Dolutegravir/Lamivudine Fixed Dose Combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression - (09/21/15)
     
  7436. ICAAC: Simplification To TDF/FTC/RPV From TDF/FTC Or ABC/3TC Plus RTG In A Cohort Study - (09/21/15)
     
  7437. ICAAC: Safety of Once-Daily Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide in Participants With Glomerular Filtration Rate <50 mL/min: 48-Week Results - (09/21/15)
     
  7438. ICAAC: Switching From Atripla to a Tenofovir Alafenamide-Based Single-Tablet Regimen: Week-48 Data in Virologically Suppressed Adults - (09/21/15)
     
  7439. ICAAC: Elvitegravir (EVG)/Cobicistat (COBI)/Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Is Superior to Ritonavir (RTV)-Boosted Atazanavir (ATV) Plus FTC/TDF in Treatment-Naïve Women With HIV-1 Infection (WAVES Study) - (09/21/15)
     
  7440. ICAAC: HIV Hospital Mortality Flat From 1993 to 2013, But Non-AIDS Death Rate Surges - Written by Mark Mascolini - (09/21/15)
     
  7441. ICAAC: New Assay Probing HIV DNA Detects Mutations Found Earlier in Plasma RNA - (09/21/15)
     
  7442. ICAAC: FIB-4 Linked to All-Cause Mortality in Large Italian HIV/HCV Cohort - Written by Mark Mascolini - - (09/21/15)
     
  7443. ICAAC: No Transmission of Integrase-Resistant HIV Seen in California Cohort - Written by Mark Mascolini - - (09/21/15)
     
  7444. ICAAC: Better HIV Control, Better Bone Changes After Switch From Atripla to E/C/F/TAF - Written by Mark Mascolini - - (09/21/15)
     
  7445. ICAAC: Switch From Raltegravir to Rilpivirine Regimen Safe, Effective in Cohort Study - Written by Mark Mascolini - - (09/21/15)
     
  7446. ICAAC: Over 85% in German Group Under 50 Copies on NRTI-Sparing Raltegravir Combo - Written by Mark Mascolini - - (09/21/15)
     
  7447. ICAAC: Restored TB-Specific CD4 Response Linked to TB-IRIS Soon After ART Starts - Written by Mark Mascolini - - (09/21/15)
     
  7448. ICAAC: Doubled Hypogonadism Rate in Middle-Aged Men With HIV--Fat Is a Factor - Written by Mark Mascolini - - (09/21/15)
     
  7449. ICAAC: Switch From Raltegravir to Rilpivirine Regimen Safe, Effective in Cohort Study - Written by Mark Mascolini - - (09/21/15)
     
  7450. ICAAC: E/C/F/TAF Kind to Kidneys of People With Stable Renal Impairment - Written by Mark Mascolini - - (09/21/15)
     
  7451. "Smac mimetic and HDAC inhibitor synergize to reverse HIV-1 latency in vitro and ex vivo" - (09/18/15)
     
  7452. "Smac mimetic and HDAC inhibitor synergize to reverse HIV-1 latency in vitro and ex vivo" - (09/18/15)
     
  7453. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness: Reyataz Slows Heart Disease - (09/17/15)
     
  7454. Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study (Denmark) - (09/17/15)
     
  7455. Kidney Dysfunction and Markers of Inflammation in the Multicenter AIDS Cohort Study - (09/17/15)
     
  7456. Hypertension in HIV - (09/17/15)
     
  7457. SPRINT trial top-line results support goal under 120 mm Hg for middle age and older adults, but experts raise safety concern - (09/17/15)
     
  7458. Kidney Disease in HIV - Changing Face Reflcting Growing Burden of Comorbid Disease in Aging HIV+ Population - (09/09/15)
     
  7459. Applying a PrEP Continuum of Care for Men who Have Sex with Men in Atlanta, GA - (09/09/15)
     
  7460. PrEP Barriers in Atlanta - If PrEP decreases HIV transmission, what is impeding its uptake? Editorial Commentary - (09/09/15)
     
  7461. No New HIV Infections with Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting - (09/09/15)
     
  7462. Keeping Our Eyes on the Prize: No New HIV Infections with Increased Use of HIV Pre-exposure Prophylaxis - Commentary - (09/09/15)
     
  7463. HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment - (09/09/15)
     
  7464. Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study - (09/09/15)
     
  7465. Lower Self-Reported Quality of Life in HIV-Infected Patients on cART and With Low Comorbidity Compared With Healthy Controls - (09/09/15)
     
  7466. Pet Scans to Detect HIV Reservoirs - new research - (09/03/15)
     
  7467. Isentress FDA Product Label - Drug Interactions with ARTs - (09/03/15)
     
  7468. Dolutegravir FDA Product Information - ART Drug Interactions - (09/03/15)
     
  7469. Gilead's Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study - (09/02/15)
     
  7470. Nephropathy in Illicit Drug Abusers: A Postmortem Analysis...."Illicit drug abuse is an independent risk factor for chronic kidney disease" - (09/02/15)
     
  7471. Kidney in HIV+ ...HIV viremia and changes in kidney function - (09/02/15)
     
  7472. European Medicines Agency Validates Gilead's Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment - (09/02/15)
     
  7473. Kidney disease in HIV ....changing epidemiology ....associated with aging/comorbid diseases including diabetes & hypertension not HIV - (09/02/15)
     
  7474. Aging/Comorbities at IAS - (08/18/15)
     
  7475. Intentional Medication Non-Adherence Due to Interactive Toxicity Beliefs among HIV Positive Active Drug Users..."Results showed that 189 (35%) participants indicated that they intentionally miss their ART when they are using drugs" - (08/18/15)
     
  7476. IAS: Efficacy and Safety of Switching to Simpler Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) in HIV-1/Hepatitis B Coinfected Adults in North America and Japan (NCT02071082): Week 48 Results - (08/18/15)
     
  7477. Dolutegravir & HIV Eradication Strategy - (08/17/15)
     
  7478. Incident Hepatitis C Virus Infections Among Users of HIV Preexposure Prophylaxis in a Clinical Practice Setting - (08/14/15)
     
  7479. IAS: Antiretroviral Therapy at IAS Conference on Pathogenesis, Treatment and Prevention Vancouver, BC, Canada, July 19-22, 2015 - David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (08/12/15)
     
  7480. IAS: Relative Bioavailability of a Dolutegravir (DTG) Dispersible Tablet and the Effect of Low and High Mineral Content Water on the Tablet in Healthy Adult Volunteers - (08/12/15)
     
  7481. IAS: Can the UNAIDS 90-90-90 target be achieved? Analysis of 12 national level HIV treatment cascades - (08/12/15)
     
  7482. IAS: Prevention at IAS: (1) PrEP / (2) EARLY ART START Study - (3) Early ART (TaSP - Study HPTN052 in serodiscordant couples - Treatment as Prevention to prevent sexual transmission) - (08/12/15)
     
  7483. IAS: HIV Prevention at IAS 2015 Vancouver - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (08/07/15)
     
  7484. PrEP Aug 8 2015 Video - (08/10/15)
     
  7485. IAS: Predicting Fractures by DEXA- new technique - (08/10/15)
     
  7486. IAS: A Comparison of Daily and Non-daily Pre-exposure Prophylaxis Dosing in Thai Men Who Have Sex With Men, Bangkok - HPTN 067 / ADAPT Study - (08/07/15)
     
  7487. IAS: HPTN 067/ADAPT Background and Methods and Cape Town Results: - (08/07/15)
     
  7488. IAS: PrEP experiences among South African women in the HPTN067 (ADAPT) study: Healthy paranoia (skepticism), Ubuntu, champions and challenges to resolving PrEP dissonance...... - (08/07/15)
     
  7489. IAS: HPTN 067/ADAPT: 'PrEP Ubuntu' and experiences with open-label PrEP among South African women - (08/07/15)
     
  7490. IAS: Patterns of sex and PrEP in Bangkok MSM (HPTN 067/ADAPT Study) - (08/07/15)
     
  7491. IAS: HIV Prevention at IAS 2015 Vancouver - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (08/07/15)
     
  7492. IAS: Characteristics and Oral PrEP Adherence in the TDF2 Open-Label Extension in Botswana - (08/07/15)
     
  7493. IAS: HIV infection and vascular stiffness among older-adults taking antiretroviral therapy in rural Uganda.... arterial stiffness occurs more often in HIV+ .....aging/HIV in Africa - (08/06/15)
     
  7494. IAS: Asymptomatic neurocognitive impairment (ANI) is associated with progression to symptomatic HIV-associated neurocognitive disorders (HAND) in people with HIV: results from The Ontario HIV Treatment Network (OHTN) cohort study..... - (08/06/15)
     
  7495. IAS: Feasibility of Intermittent PrEP Among US MSM: Data from the Harlem Site - HPTN 067: ADAPT Study - (08/05/15)
     
  7496. IAS: Treat HIV Early for Prevention (HPTN-052 TaSP) and for Treatment (START) - PrEP too - (08/05/15)
     
  7497. IAS: Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs - (08/05/15)
     
  7498. IAS: Patterns of Sex and PrEP in Harlem MSM: A qualitative study (HPTN 067) [Stigma/adherence/Sex] - (08/05/15)
     
  7499. IAS: Adherence, sexual behavior and HIV/STI incidence among men who have sex with men (MSM) and transgender women (TGW) in the US PrEP demonstration (Demo) project - (08/04/15)
     
  7500. 7th Peds Wk: Atazanavir Pharmacokinetics-Pharmacodynamics in HIV-1-Infected Children Aged 3 Months to <11 Years Treated With Atazanavir Powder/Ritonavir Liquid: PRINCE-1 & -2 Studies - (08/03/15)
     
  7501. 7th Peds Wk: Safety and Efficacy of Atazanavir Powder and Ritonavir Liquid in HIV-1-Infected Infants and Children Aged From 3 Months to <11 Years: the PRINCE-2 Study - (08/03/15)
     
  7502. IAS: Myocardial Strain Abnormalities Detected by Speckle-Tracking Echocardiography in Persons with HIV - (08/03/15)
     
  7503. IAS: Heart Disease/Subclinical Heart Disease/Immune Activation/Inflammation....exercise, diet..."Squelching chronic inflammation with diet and exercise is in many ways a no-brainer" - (08/03/15)
     
  7504. IAS: ATN 110: An HIV PrEP Demonstration Project and Safety Study for Young Men (18-20) who Have (high-risk) Sex with Men in the United States, in 12 cities.....successfully identified & engaged in project - (08/03/15)
     
  7505. IAS: Pre-exposure prophylaxis (PrEP) uptake and associated factors among MSM and TGW in the PrEP Brasil demonstration project - (08/03/15)
     
  7506. Aging/Comorbidities/Immunity/Early Aging Senescence....HCV liver disease - (07/30/15)
     
  7507. IAS: Evaluation and Management of Fracture Risk in HIV Patients in the VA system: .....Fractures - HIV+ Vets NO SCREENING/PREVENTION! ..... One Quarter of HIV+ Vets Have Recurrent Fracture--After Minimal Testing or Treatment - Mark Mascolini - (07/31/15)
     
  7508. IAS: Over 80% of MSM Don't Discuss PrEP With Their Clinician--and Many Don't Talk About Sex - Mark Mascolini - (07/31/15)
     
  7509. IAS: Favourable effects on vitamin D and bone of switching from Atripla to Darunavir/Ritonavir monotherapy: a randomised controlled clinical trial - (07/31/15)
     
  7510. IAS: Switch from PI/rtv +2 nucleos(t)ides to RPV+DRV/rtv maintains HIV suppression and is well tolerated (PROBE study) - (07/31/15)
     
  7511. IAS: Poor Bone Prevention/Care in VA - (07/31/15)
     
  7512. IAS: TELOMERE LENGTH SHORTENING AND DNA METHYLATION DISRUPTIONS OCCUR EARLY FOLLOWING HIV SEROCONVERSION.... ......"This suggests that cellular aging and methylomic disruptions are likely to occur soon after contraction of HIV." - (07/31/15)
     
  7513. IAS: Serious Non-AIDS Events and Biomarker Changes in HIV-1-Infected Individuals - Inflammation Markers & Comorbidities: higher markers in HIV+ with comorbidities - (07/31/15)
     
  7514. IAS: ELICITING COGNITIVE DIFFICULTIES EXPERIENCED BY PEOPLE LIVING WITH HIV - (07/31/15)
     
  7515. What if HIV were unable to develop resistance against a new therapeutic agent? - (07/30/15)
     
  7516. IAS: HIV-1 Attachment Inhibitor Prodrug BMS-663068: Interactions with Rifabutin, with or without Ritonavir, in Healthy Subjects - (07/29/15)
     
  7517. IAS: HIV Incidence Low, Despite High STI Rate, in US MSM in Big PrEP Demo Project - Mark Mascolini - (07/29/15)
     
  7518. IAS: Hospitalizations among HIV Controllers versus Persons with Medically-Controlled HIV - Hospital Admission Rate Same for No-ART and ART HIV Controllers in US Military - Mark Mascolini - (07/29/15)
     
  7519. IAS: Mortality Steady and Non-AIDS Deaths Rising in British Columbia Since 2005 - Mark Mascolini - (07/29/15)
     
  7520. IAS: Private Insurance--and ADAP--Tied to Undetectable Viral Load in US Women - Mark Mascolini - (07/29/15)
     
  7521. IAS: Aging, Hospitalization Rates for Liver/GI - Rates Increased for Cardiovascular Disease & Non-AIDS Cancers in Italy - Mark Mascolini - (07/29/15)
     
  7522. IAS: ART Begun at Higher CD4 Count Tied to Lower Mortality in Vancouver IDUs - Mark Mascolini - (07/29/15)
     
  7523. IAS: Evaluation and Management of Fracture Risk in HIV Patients in the VA system: .....Fractures - HIV+ Vets NO SCREENING/PREVENTION! ..... One Quarter of HIV+ Vets Have Recurrent Fracture--After Minimal Testing or Treatment - (07/27/15)
     
  7524. IAS: TLR7 Agonist GS-9620 is a Potent Inhibitor of Acute HIV-1 Infection in Human PBMCs - (07/27/15)
     
  7525. IAS: PrEP at IAS Vancouver 2015 July 19-22.....Daily PrEP Appears Most Effective....more NATAP PrEP IAS Reports coming - (07/27/15)
     
  7526. IAS: Feasibility of Intermittent PrEP Among US MSM: Data from the Harlem Site - HPTN 067: ADAPT Study - (07/27/15)
     
  7527. IAS: Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men in the HPTN 067/ADAPT study - (07/27/15)
     
  7528. IAS: PrEP, Sex, and the Paradoxes of Prevention: Qualitative data from a cohort of New York City MSM participating in HPTN 067/ADAPT [Harlem, NY, USA] - (07/27/15)
     
  7529. IAS: New HIV Drugs at IAS 2015 Vancouver July 19-23 - (07/27/15)
     
  7530. IAS: TLR7 Agonist GS-9620 is a Potent Inhibitor of Acute HIV-1 Infection in Human PBMCs - (07/27/15)
     
  7531. IAS: Treatment as Prevention: Characterization of partner infections in the HIV Prevention Trials Network 052 trial - (07/27/15)
     
  7532. IAS: Raltegravir for the prevention of mother-to-child transmission of HIV - (07/27/15)
     
  7533. IAS: The HIV Continuum of Care for Adolescents and Young Adults (12-24 years) Attending 13 Urban US Centers of the NICHD-ATN-CDC-HRSA SMILE Collaborative .....Only 7% of Youth in US Study Reach an Undetectable Viral Load After HIV Diagnosis - Mark Mascolini - (07/24/15)
     
  7534. IAS: Incidence of Syphilis, Other STIs Rising Steadily in HIV+ MSM of France - Mark Mascolini - (07/24/15)
     
  7535. IAS: HIV Risk Dropped 65% in Seattle Area MSM Born After Mid-1960s - (07/24/15)
     
  7536. IAS: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Analysis of Emergent Viral Drug Resistance Through 48 Weeks of Follow-Up - (07/24/15)
     
  7537. IAS: Safety and Efficacy of DTG by Age, Race and Gender: Subgroup Analysis of 96 Week Results From Treatment-Naive Patients in Phase III Trials (SPRING-2 [ING113086], SINGLE [ING114467] and FLAMINGO [ING114915]) - (07/24/15)
     
  7538. IAS: Bone Mineral Density and Fat Distribution in Adults Randomized to Maraviroc (MVC) Once Daily With Darunavir/Ritonavir (DRV/r) vs. Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: Week 48 Results From MODERN - (07/24/15)
     
  7539. IAS: START Trial: Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection......The START trial was designed and conducted by the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)..... - (07/24/15)
     
  7540. IAS: Decrease in the proportion of HIV-positive MSM followed up in hospital likely to transmit HIV between 2003 and 2011 in France: results from national representative surveys (ANRS-VESPA1 and -VESPA2) - (07/24/15)
     
  7541. IAS: STIs incidence in MSM followed since HIV-1 primary infection in the French ANRS-PRIMO cohort..... Does Undetectable Viral Load Influence Sex Behavior - (07/24/15)
     
  7542. IAS: Women in Peril: High Levels of HIV Infection Risk among the Male Sex Partners of Low-Income, Black Women in the United States...... "Nearly 1 in 5 HIV-negative, black women included in our analysis had a male sex partner at high risk for HIV infection." - (07/24/15)
     
  7543. IAS: Evolution of HIV-1 Integrase Following Selection of R263K With Further Dolutegravir Treatment: A Case Report From the P1093 Study - (07/24/15)
     
  7544. European Commission Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults - (07/22/15)
     
  7545. Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients - (07/22/15)
     
  7546. IAS: Antiretroviral Treatment Prevents HIV Transmission: Final Results from the HPTN 052 Randomized Controlled Trial - (07/22/15)
     
  7547. IAS: Early ART Cuts HIV Transmission Rate 93% Through 2015 in HPTN 052 - written by Mark Mascolini - (07/22/15)
     
  7548. IAS: Cape Town Women Data Support Daily TDF/FTC PrEP Over As-Needed PrEP - written by Mark Mascolini - (07/22/15)
     
  7549. IAS: Kidney and Bone Marker Rally After TDF-to-TAF Switch for 48 Weeks - written by Mark Mascolini - (07/22/15)
     
  7550. IAS: (ACTG) Long-term Bone Mineral Density Changes in Antiretroviral-treated HIV-Infected Individuals, Bone Loss Continues--Though Slowly--After First 96 Weeks of ART - written by Mark Mascolini - (07/22/15)
     
  7551. IAS: More Diabetes and CVD, Shorter Survival, in HIV/HCV-Positives With Steatosis - written by Mark Mascolini - (07/22/15)
     
  7552. IAS: Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazanavir ± Ritonavir - (07/22/15)
     
  7553. IAS: Switching From a Tenofovir Disoproxil Fumarate (TDF)-Based Regimen to a Tenofovir Alafenamide (TAF)-Based Regimen: Data in Virologically Suppressed Adults Through 48 Weeks of Treatment - (07/22/15)
     
  7554. IAS: Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112 - (07/22/15)
     
  7555. IAS: Efficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results - (07/22/15)
     
  7556. IAS: Strategic Timing of AntiRetroviral Treatment (START) Study Primary Results - (07/22/15)
     
  7557. IAS: C-EDGE CO-INFECTED: Phase 3 Study of Grazoprevir / Elbasvir in Patients with HCV/HIV - (07/22/15)
     
  7558. IAS: Abbvie 3D in HCV/HIV Update ......HIGH SVR RATES IN HCV/HIV-1 CO-INFECTED PATIENTS REGARDLESS OF BASELINE CHARACTERISTICS....(note IDUs had 100% SVR) - (07/22/15)
     
  7559. IAS: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM (AI444-258) - (07/22/15)
     
  7560. IAS: Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4 - (07/22/15)
     
  7561. IAS: HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus - NIH HPTN 052 Study - (07/21/15)
     
  7562. IAS: Early ART Stalls Viral Evolution in Infant But Does Not Stop Replication - written by Mark Mascolini - (07/21/15)
     
  7563. IAS: Ipergay Analysis Suggests Both Pre- and Postsex TDF/FTC PrEP Doses Needed for Full Protection - written by Mark Mascolini - (07/21/15)
     
  7564. IAS: Intensive Case Management Improves Engagement, HIV Control in Wisconsin Study - written by Mark Mascolini - (07/21/15)
     
  7565. IAS: Shorter Treatment Breaks, More Regimens Predict Complete CD4 Response in 10 Years - written by Mark Mascolini - (07/21/15)
     
  7566. IAS: Age, IDU, Viral Load Testing Rate Predict HIV Control and Rebound in Canadian MSM - written by Mark Mascolini - (07/21/15)
     
  7567. IAS: Meth Use May Account for 1 in 5 of New HIV Infections in Seattle MSM - written by Mark Mascolini - (07/21/15)
     
  7568. IAS: Elvitegravir (EVG)/Cobicistat (COBI)/Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Is Superior to Ritonavir (RTV)-Boosted Atazanavir (ATV) Plus FTC/TDF in Treatment-Naïve Women With HIV-1 Infection (WAVES Study) - (07/21/15)
     
  7569. IAS: HIV Self-Testing Raises Testing Rate in Randomized Trial of Seattle MSM - written by Mark Mascolini - (07/21/15)
     
  7570. IAS: Rilpivirine 48-Week Results in Naive Adolescents Similar to Adult Findings - written by Mark Mascolini - (07/21/15)
     
  7571. IAS: Stribild Superior to Boosted Atazanavir in Treatment-Naive Women - written by Mark Mascolini - (07/21/15)
     
  7572. IAS: VAC-3S, a safe Immunotherapeutic HIV Vaccine decreased total HIV DNA and increased CD4/CD38 ratio: Phase I Final Results. - (07/20/15)
     
  7573. IAS: A vaccine strategy against AIDS: An HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques - (07/20/15)
     
  7574. IAS: VAC-3S, an Immunoprotective HIV Vaccine Directed to the 3S Motif of gp41, in Patients Receiving ART: Safety, Dose & Immunization Schedule Assessment - (07/20/15)
     
  7575. IAS: VAC-3S HIV Therapeutic Vaccine - "Potential Role of anti-3S antibodies in an HIV medical cure strategy?" - (07/20/15)
     
  7576. IAS: Therapeutic HIV Vaccine Boosts CD4/CD4 Ratio, Cuts HIV DNA in PBMCs in 33-Person Trial - written by Mark Mascolini - (07/20/15)
     
  7577. Scripps Research Institute-Designed Drug Candidate Significantly Reduces HIV Reactivation Rate - study points to 'Functional Cure' - (07/17/15)
     
  7578. The need for treatment interruption studies and biomarker identification in the search for an HIV cure - Opinion - (07/17/15)
     
  7579. "Grip strength is a strong predictor of cardiovascular mortality and a moderately strong predictor of incident cardiovascular disease" new study finds - (07/17/15)
     
  7580. HIV in the Older Adult, Aging/Comorbidities & Death in HIV... "Will You Still Treat Me When I'm 64? Care of the Older Adult With HIV Infection" - (07/17/15)
     
  7581. Diabetes risk high in men on HAART - (07/17/15)
     
  7582. A New Way to HIV Functional Cure: HIV Pathogenesis Sabotage with Dolutegravir - (07/14/15)
     
  7583. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors..."Evolutionary Dead-End" After Emergence of Primary Dolutegravir Resistance Mutation? - (07/14/15)
     
  7584. HIV & Aging Accelerated?: .....HIV-infection and comorbidities: a complex mix...... Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study - (07/10/15)
     
  7585. HIV & Aging: Psychosocial, mental health, and behavioral issues/services/mental health policy - (07/09/15)
     
  7586. Cost-effectiveness [and efficacy] of Collaborative Care for Depression in Human Immunodeficiency Virus Clinics - (07/09/15)
     
  7587. Depression Care Managers - new study - (07/09/15)
     
  7588. Darunavir, atazanavir and lopinavir boosted with ritonavir differentially affect endothelial functions and induce senescence of cultured human endothelial cells. Beneficial effect of pravastatin - (07/08/15)
     
  7589. Mediterranean Diet/Nuts/Olive Oil Improve Brain Function - (07/08/15)
     
  7590. HIV/Body Fat Effects - (07/08/15)
     
  7591. J&J HIV Vaccine Promising in Monkeys/Prevents Infection/Human Trial - (07/02/15)
     
  7592. Investigational HIV Vaccine Regimen Shows Encouraging Results in Non-Human Primates.....Provides Complete Protection Against HIV Infection - (07/02/15)
     
  7593. Enhancing Cognitive Aging: Clinical Highlights of a Report From the Institute of Medicine - (07/02/15)
     
  7594. New CDC PrEP Guidelines May 14 2015 - (07/02/15)
     
  7595. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) - (07/02/15)
     
  7596. Cabotegravir (GSK744) long-acting for HIV-1 prevention...... Long-acting rilpivirine for HIV prevention (2 review articles) - (06/29/15)
     
  7597. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness - (06/26/15)
     
  7598. Nationwide Study of Cancer in HIV-Infected Taiwanese Children in 1998-2009 - (06/26/15)
     
  7599. Tenofovir PrEP Adherence/Protection-After Drug Cessation - (06/26/15)
     
  7600. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials - (06/26/15)
     
  7601. Tenofovir alafenamide for HIV infection: is less more? - Comment (HBV, PrEP, Cost) - (06/26/15)
     
  7602. Genital Inflammation & HIV Acqusition Associated in Women.....STIs also associated with Inflammation & HIV Acquisition - new study - (06/26/15)
     
  7603. Safer Conception Strategies for HIV-Serodiscordant Couples: How Safe Is Safe Enough? Editorial - Benefits of PrEP as an Adjunctive Method of HIV Prevention During Attempted Conception Between HIV-uninfected Women and HIV-infected Male Partners - (06/26/15)
     
  7604. Geriatric Conditions Common in Older HIV+ (UCSF SCOPE, CROI) - (06/24/15)
     
  7605. Anti-ageing pill pushed as bona fide drug (Metformin) - (06/24/15)
     
  7606. Extending access with long-acting antiretroviral therapy: the next advance in HIV-1 therapeutics and prevention......Current state and limitations of daily oral therapy for treatment - (06/24/15)
     
  7607. Cabotegravir long-acting for HIV-1 prevention...... Long-acting rilpivirine for HIV prevention - (06/24/15)
     
  7608. Accelerated Longitudinal Gait Speed Decline in HIV-Infected Older Men. (MACS) - just published - (06/24/15)
     
  7609. Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on Statins... "Our study did not show a significant benefit of statin therapy on the incidence of MI, stroke, and all-cause mortality in PLWH" - (06/22/15)
     
  7610. Statins - Are they Effective & Safe ? - (06/22/15)
     
  7611. Fish Oil-New Study/"anti-inflammatory"....."promotes hematopoiesis in the bone marrow and spleen" - (06/22/15)
     
  7612. Exercise Improves Aging in HIV+...... CD4 Nadir Associated with Onset of Geriatric Conditions in HIV+ Men ..... Geriatric Conditions Common in HIV+ Older Men (UCSF, SCOPE) - (06/19/15)
     
  7613. Aging, Frailty African-American Women and in IDUs (managing aging & HIV) - (06/19/15)
     
  7614. START Study Commentary - (06/19/15)
     
  7615. Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? COMMENTARY... Age at entry into care, timing of antiretroviral therapy initiation, and 10-year mortality among HIV-seropositive adults in the United States - (06/19/15)
     
  7616. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation...NASH Study - (06/19/15)
     
  7617. Euro Resistance Wk: Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naive Subjects With Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) - (06/17/15)
     
  7618. Euro Resist Wk: Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) (oral slides) - (06/17/15)
     
  7619. Clinical Pharm of HIV & Hepatitis: The 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Assistant Professor School of Pharmacy University of Colorado at Denver - (06/17/15)
     
  7620. EASL: SPONTANEOUS CLEARANCE RATES INCREASE WITH HCV REINFECTION EPISODE IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN (MSM) INDEPENDENT OF HCV SUBTYPE - (06/17/15)
     
  7621. Clinical Pharm of HIV & Hepatitis Lack of Effect of Oral Cabotegravir on the Pharmacokinetics of a Levonorgestrel/Ethinyl Estradiol Containing Oral Contraceptive in Healthy Adult Females - (06/12/15)
     
  7622. Clinical Pharm of HIV & Hepatitis Nanoformulations: Update from ViiV Healthcare - (06/12/15)
     
  7623. Aging/HIV in Europe - Predictions - (06/11/15)
     
  7624. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: a Double-Blind Randomized Trial. - (06/09/15)
     
  7625. Subclinical Heart Dysfunction/Belly Fat - Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV - (06/09/15)
     
  7626. Clinical Pharm of HIV & Hepatitis Doravirine [Merck New NNRTI MK-1439] Efficacy Exposure-Response Analysis at Week 48 and Implications1 and Doravirine Pharmacokinetics After Switching from Efavirenz Therapy in Healthy Volunteers2 - (06/08/15)
     
  7627. Clinical Pharm of HIV & Hepatitis A 2-Way Steady State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir - (06/08/15)
     
  7628. Clinical Pharm of HIV & Hepatitis An Evaluation of Doravirine Pharmacokinetics When Switching From Efavirenz to Doravirine Treatment [poster] - (06/08/15)
     
  7629. Clinical Pharm of HIV & Hepatitis Doravirine Efficacy Exposure-Response Analysis at Week 48 and Implications [poster] - (06/08/15)
     
  7630. Clinical Pharm of HIV & Hepatitis Administration of a Supratherapeutic Dose of Doravirine Does not Result in a Clinically Meaningful Increase in QTc - (06/08/15)
     
  7631. Clinical Pharm of HIV & Hepatitis Moderate Hepatic Impairment Does not Affect Doravirine Pharmacokinetics - (06/08/15)
     
  7632. Clinical Pharm of HIV & Hepatitis Effect of Ketoconazole on the Pharmacokinetics of Doravirine (MK-1439), a Novel Non-Nucleoside Reverse Transcriptase Inhibitor for the Treatment of HIV-1 Infection - (06/08/15)
     
  7633. Clinical Pharm of HIV & Hepatitis Effect of Doravirine (MK-1439) on the Pharmacokinetics of an Oral Contraceptive (Ethinyl Estradiol and Levonorgestrel) - (06/08/15)
     
  7634. Cancer/HCC Immunotherapies/PD1 Inhibitors - Nivolumab targets a protein called the programmed death-1 (PD-1) receptor & for HCC/Liver Cancer - (06/03/15)
     
  7635. Exercise Improves Brain/Cognitive Function in HIV+ - (06/03/15)
     
  7636. Cardiorespiratory fitness and brain volume and white matter integrity...Exercise Associated with Improved Brain - (06/03/15)
     
  7637. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials - (06/03/15)
     
  7638. CD4 & Nadir CD4 & Viral Load Increase Risk for Comorbidities....studies from 2009-2012 - (06/03/15)
     
  7639. Clinical Pharm of HIV & Hepatitis HIV-1 Attachment Inhibitor Prodrug BMS-663068: Assessment of Interactions with Raltegravir in Treatment-Experienced HIV-1-Infected Subjects & Efficacy/Safety - (06/02/15)
     
  7640. Clinical Pharm of HIV & Hepatitis Safety, Efficacy, and Pharmacokinetics of the Integrase Inhibitor-Based E/C/F/TAF Single-Tablet Regimen in Treatment-Naïve HIV-Infected Adolescents Through 24 Weeks of Treatment - (06/02/15)
     
  7641. Clinical Pharm of HIV & Hepatitis Pharmacokinetics (PK) of Etravirine (ETR) in HIV-1-Infected Pregnant Women - (06/02/15)
     
  7642. Clinical Pharm of HIV & Hepatitis Rilpivirine population pharmacokinetic modeling in antiretroviral-naïve, HIV-1-infected adolescents in PAINT - (06/02/15)
     
  7643. Is HIV a Model of Accelerated or Accentuated Aging? - (06/01/15)
     
  7644. Clinical Pharm of HIV & Hepatitis Prediction of Intracellular (IC) Tenofovir Diphosphate (TFV-DP) and Emtricitabine Triphosphate (FTC-TP) Concentrations Following Drug Intake Cessation - (06/01/15)
     
  7645. Clinical Pharm of HIV & Hepatitis Pharmacokinetics (PK) of once-daily dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI) following drug cessation - (06/01/15)
     
  7646. Clinical Pharm of HIV & Hepatitis MICROBOOSTING OF ATAZANAVIR 300 MG WITH 50 MG VERSUS 100MG OF RITONAVIR DAILY IN HIV-INFECTED PATIENTS - (06/01/15)
     
  7647. Clinical Pharm of HIV & Hepatitis Evaluation of Drug Interactions between Dolutegravir and Daclatasvir in Healthy Subjects - (05/29/15)
     
  7648. Clinical Pharm of HIV & Hepatitis Pharmacokinetic-Pharmacodynamic Modeling and Simulation of the Virologic Response of Dolutegravir in HIV-Infected Patients with Integrase Inhibitor Resistant Virus - (05/29/15)
     
  7649. Clinical Pharm of HIV & Hepatitis Doravirine Efficacy Exposure-Response Analysis at Week 48 and Implications1 and Doravirine Pharmacokinetics After Switching from Efavirenz Therapy in Healthy Volunteers2 - (05/29/15)
     
  7650. Clinical Pharm of HIV & Hepatitis Doubling Dolutegravir Dose Has Little Impact on Controlling Resistant HIV - written by Mark Mascolini - (05/29/15)
     
  7651. Clinical Pharm of HIV & Hepatitis Antabuse (Disulfiram) Has Linear Exposure-Response Profile in Activating Latent HIV - written by Mark Mascolini - (05/29/15)
     
  7652. Clinical Pharm of HIV & Hepatitis Dolutegravir Persists Longer Than Elvitegravir After Dosing Stops - written by Mark Mascolini - (05/29/15)
     
  7653. Clinical Pharm of HIV & Hepatitis Good Response to TAF Plus EVG/COBI/FTC in Adolescents Through 24 Weeks - written by Mark Mascolini - (05/29/15)
     
  7654. Clinical Pharm of HIV & Hepatitis Low Darunavir Troughs at 800 Mg Once Daily With Stribild - written by Mark Mascolini - (05/29/15)
     
  7655. Clinical Pharm of HIV & Hepatitis Tenofovir Lower in Plasma, Higher in PBMCs, With TAF Versus TDF - written by Mark Mascolini - (05/29/15)
     
  7656. Clinical Pharm of HIV & Hepatitis Merck Sees No Dose-Response Relationship With Doravirine, a New Nonnucleoside - written by Mark Mascolini - (05/29/15)
     
  7657. REPRIEVE Study To Evaluate Statin Therapy to Prevent or Reduce Heart Disease in HIV+ - (05/29/15)
     
  7658. Geriatric Syndromes in Older HIV-Infected Adults...at 57 age...Participants had a median of 4 (IQR: 3-6) comorbidities & were taking a median of 9 (6-12) nonantiretroviral medications & (53.6%) had 2 or more geriatric syndromes - (05/20/15)
     
  7659. Computer - "Redesigned" Antibodies May Control HIV - (05/20/15)
     
  7660. HIV reservoirs as obstacles and opportunities for an HIV cure - (05/20/15)
     
  7661. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study - (05/20/15)
     
  7662. HIV infection is associated with progression of subclinical carotid atherosclerosis.....61% Greater Risk....viral load & CD4 are risks - (05/14/15)
     
  7663. Raltegravir in HIV-1 Infected Pregnant Women: Pharmacokinetics, Safety and Efficacy - (05/14/15)
     
  7664. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program - (05/14/15)
     
  7665. HIV status and the risk of ischemic stroke among men - (05/12/15)
     
  7666. Healthy eating and reduced risk of cognitive decline - (05/08/15)
     
  7667. ACTG Network Trial Update: HAILO A5322 - Long-term Follow-up of Older HIV-infected Adults: Addressing Aging, HIV Infection & Inflammation - (04/31/15)
     
  7668. Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia - (04/20/15)
     
  7669. Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial - (04/20/15)
     
  7670. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment - (04/20/15)
     
  7671. CROI: Persistently Elevated Macrophage Activation in HIV+ Women Reporting Heavy Alcohol Use (>7 drinks a week); alcohol & CVD in HIV+ VA men - (04/20/15)
     
  7672. ResisWksp: TAF Potency vs TDF-Resistant Virus - Limited Evolution of Tenofovir-Resistant Viruses after Extended TAF Resistance Selection - (04/20/15)
     
  7673. ResisWksp: Antiviral Activity of Tenofovir Alafenamide (TAF) against Major NRTI-Resistant Viruses: Improvement over TDF/TFV is Driven by Higher TFV-DP Loading in Target Cells - (04/20/15)
     
  7674. Human immune system can control re-awakened HIV, suggesting cure is possible.... "Our study is a proof of principle and the results are promising, but it is unlikely to lead to a cure for at least a decade" - (04/15/15)
     
  7675. Anal Cancer, HIV+ MSM - (04/15/15)
     
  7676. Human immune system can control re-awakened HIV, suggesting cure is possible.... "Our study is a proof of principle and the results are promising, but it is unlikely to lead to a cure for at least a decade" - (04/15/15)
     
  7677. Viremic and Virologically Suppressed HIV Infection Increases Age-Related Changes to Monocyte Activation Equivalent to 12 and 4 Years of Aging, Respectively - (04/15/15)
     
  7678. CROI: CORRELATION OF IN VIVO CABOTEGRAVIR CONCENTRATION & PREVENTION OF SIV IN MACAQUES - (04/13/15)
     
  7679. CROI: HIV PrEP at CROI - (04/13/15)
     
  7680. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117....."new modality for HIV-1 prevention, therapy and cure." - (04/09/15)
     
  7681. Antibody shows promise as treatment for HIV - (04/09/15)
     
  7682. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - (04/08/15)
     
  7683. CROI: HIV and Cardiovascular Disease: Report back from 2015 Conference on Retroviruses and Opportunistic Infections by Priscilla Hsue MD - Professor of Medicine, UCSF - (04/08/15)
     
  7684. Acceleration of Age-Associated Methylation Patterns in HIV-1-Infected Adults.... adults appeared to be approximately 14 years older than their chronologic age - (04/08/15)
     
  7685. New Study Reports HIV in Brain Very Early but other studies in the past few years have found HIV gets into the brain very soon after infection....AND studies report very early ART, as soon as possible, within days, is the best way to limit HIV's bad affect on the brain - (04/08/15)
     
  7686. CROI: CROI 2015 Metabolic Report: Vital Organs and HIV (and commentary by Jules Levin) - David Alain Wohl, MD - The University of North Carolina at Chapel Hill - (04/07/15)
     
  7687. Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up - STARTMRK - (04/06/15)
     
  7688. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy - (04/06/15)
     
  7689. CROI: Bone, Frailty and Vitamin D at CROI 2015 - Todd Brown, MD, PhD Associate Professor of Medicine and Epidemiology Johns Hopkins University - (03/30/15)
     
  7690. CROI: Less Bone Loss with a Maraviroc Regimen in HIV-infected Treatment-Naïve Subjects - (04/06/15)
     
  7691. CROI: Body Composition Changes - ART, Raltegravir - (04/06/15)
     
  7692. Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir - (04/02/15)
     
  7693. CROI: CROI 2015 - Metabolics / Aging, Senescence / Comorbidities / Inflammation - 3 Exercise Studies / Heart Disease / Statins / Cancers / The Kidney / Bone / TAF / The Brain - neurologic function - (04/01/15)
     
  7694. Gene that Controls Body Fat/Lipodystrophy in Belly (VAT & Subcutaneous Fat) - New Discovery - (04/01/15)
     
  7695. Bone, Frailty and Vitamin D at CROI 2015 - Todd Brown, MD, PhD Associate Professor of Medicine and Epidemiology Johns Hopkins University - (03/30/15)
     
  7696. CROI: Tenofovir vaginal gel fails to protect women from HIV in phase 3 placebo trial - Mark Mascolini - (04/01/15)
     
  7697. CROI: CARDIOVASCULAR DISEASE MORTALITY AMONG HIV-INFECTED PERSONS, NEW YORK CITY, 2001-2012 - (04/01/15)
     
  7698. CROI: ROSUVASTATIN VS. PROTEASE INHIBITOR SWITCH FOR HYPERCHOLESTEROLAEMIA: A RANDOMISED TRIAL - THE STATIN OR SWITCH (SoS) STUDY - (04/01/15)
     
  7699. CROI: Evaluation of the ACC/AHA CVD Risk Prediction Algorithm Among HIV-Infected Patients - (04/01/15)
     
  7700. CROI: IL-6 and CD38 Senescence Independently Associate With Atherosclerosis in Treated HIV - (04/01/15)
     
  7701. CROI: HIV-Infected Persons with Type 2 Diabetes have Evidence of Endothelial Dysfunction - (04/01/15)
     
  7702. CROI: IL-6 is a stronger predictor of clinical events than hsCRP or D-dimer in HIV disease - SMART/ESPIRIT - (04/01/15)
     
  7703. CROI: Altered Body Composition and Inflammation in HIV Infection with Type 2 Diabetes - (03/31/15)
     
  7704. CROI: Bone Turnover on DRV/r + Either RAL or TDF/FTC as First-Line ART: NEAT 001 / ANRS 143 - (03/31/15)
     
  7705. CROI: Diabetes Mellitus Among HIV-infected Adults in Care in the United States, Medical Monitoring Project, 2009-2010 - (03/31/15)
     
  7706. CROI: Impact of EFV PK/PG on Neuropsychological Performance in Older HIV+ Patients - (03/30/15)
     
  7707. CROI: Steady-state TDF/FTC in Genital, Rectal, and Blood Compartments in Males vs Females - (03/30/15)
     
  7708. CROI: Impact of TDF + PI/r on Renal Function in Sub-Saharan Africa (2LADY/ANRS 12169) - (03/30/15)
     
  7709. CROI: Obesity and Inflammation in Resource-Diverse Settings of Antiretroviral Therapy Initiation - (03/30/15)
     
  7710. CROI: HIV-1 Replication in the CNS Is Associated With Increased Neurocognitive Impairment - (03/30/15)
     
  7711. CROI: Greater CSF HIV Reduction and CSF Rapid Decay Associated with Improved Neurocognition - (03/30/15)
     
  7712. CROI: Elevated Tenofovir Exposure via Intensive Pharmacokinetic Monitoring is Associated with Progressive Kidney Function Decline - (03/30/15)
     
  7713. CROI: U.S. Population Benefits of HIV Preexposure Prophylaxis for Injection Drug Users - (03/30/15)
     
  7714. CROI: Enrollment and preliminary follow-up of injecting drug users receiving pre-exposure prophylaxis in Bangkok - (03/30/15)
     
  7715. CROI: Recent increases in PrEP Utilization at a Boston Community Health Canter 2011-2014: Transition from Research to Clinical Practice - (03/30/15)
     
  7716. CROI: Barriers to Effective Prevention: Applying a PrEP Care Continuum to a US Cohort of Black and White MSM - (03/30/15)
     
  7717. CROI: Provider Prescription of Pre-Exposure Prophylaxis (PrEP) for HIV Infection - (03/30/15)
     
  7718. CROI: Phase 1 Safety & PK Trial of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring - (03/30/15)
     
  7719. CROI: Impact of EFV PK/PG on Neuropsychological Performance in Older HIV+ Patients - (03/30/15)
     
  7720. CROI: Clinical Pharmacology at CROI 2015 - Courtney V. Fletcher, Pharm.D. Dean and Professor Anthony T. Podany, Pharm.D. Assistant Professor College of Pharmacy University of Nebraska Medical Center, Omaha, NE 68198 - (03/30/15)
     
  7721. CROI: Similar neurocognitive performance in patients on ATV/r monotherapy vs triple therapy - (03/27/15)
     
  7722. CROI: Maraviroc-Enhanced cART Improves Cognition in Virally-Suppressed HAND: A Pilot Study - (03/27/15)
     
  7723. CROI: Suppressive ART is Key to Reduce Neurocognitive Impairment in Aging HIV+ Individuals - (03/27/15)
     
  7724. CROI: HIV DNA and Neurocognitive Impairment in Older and Younger Subjects on Suppressive ART - (03/27/15)
     
  7725. CROI: INCIDENCE OF EXTRAHEPATIC COMPLICATIONS IN HIV/HCV PATIENTS WHO ACHIEVED SVR - (03/27/15)
     
  7726. CROI: Modeling the Impact of Deferring HCV Treatment [to F3/F4 vs F2 or sooner: 1 month/year after diagnosis) on Liver-Related Events in HIV+ Patients....outcomes: liver-related events & infectious duration....by Swiss HIV & HCV Cohort....model finds delay in treatment increased 2-times to 5 times risk in developing decompensation, HCC & liver-related death - (03/27/15)
     
  7727. Dolutegravir / Tivicay FDA Product Insert - Label - (03/26/15)
     
  7728. CROI: Majority of HCV/HIV-co-infected patients in the Netherlands remain in need of effective HCV treatment - (03/26/15)
     
  7729. CROI: Multiple Rounds of Activation Induce Replication-Competent HIV-1 from Resting Memory CD4+ T Cells in the Latent Reservoir - (03/26/15)
     
  7730. CROI: Summary from CROI 2015 for Hepatitis C HIV/HCV coinfected patients are no longer a difficult to treat special patient population. What can we learn from new clinical phase III studies and feedback from real-life cohorts receiving modern DAA-based therapy? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/24/15)
     
  7731. CROI: Antiretrovirals CROI 2015 Summary - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/24/15)
     
  7732. CROI: Statins Improve SVR, Reduce Fibrosis Progression and HCC Among HCV+ Persons. Statins Reduce Plaque/Halt Carotid Artery Wall Thickening/Improve Kidney - (03/23/15)
     
  7733. CROI: Antiretroviral Concentrations in Brain Tissue Are Similar to or Exceed Those in CSF - (03/23/15)
     
  7734. CROI: Ex vivo identification of highly effective latency-reversing drug combinations - (03/23/15)
     
  7735. CROI: Latency Reversing Agents activate latent reservoirs in the brain of SIV-infected macaques - (03/23/15)
     
  7736. CROI: Predictors and Outcomes of Incident High Cholesterol in Adults on ART in South Africa. Total Cholesterol Associated with Decreased Kidney Function - (03/23/15)
     
  7737. CROI: THE EARLIER cART IS INITIATED DURING PHI, THE MORE INTRACELLULAR HIV-DNA DECREASES - (03/23/15)
     
  7738. CROI: The Kidney: TAF, Inflammation, Neurocognitive decline associated with renal/CVD markers, integrate inhibitors, early ART/inflammation - (03/23/15)
     
  7739. CROI: Abacavir Use and Risk for Myocardial Infarction in the NA-ACCORD - (03/23/15)
     
  7740. CROI: Incidence and Risk of Myocardial Infarction (MI) by Type in the NA-ACCORD - (03/23/15)
     
  7741. CROI: Higher CD4 at cART Initiation Predicts Long Term Likelihood of CD4 Normalization in the HIV Outpatient Study (HOPS)..... authors: "these data confirm the hazards of delayed cART initiation and support cART initiation at CD4 ≥ 500" - (03/23/15)
     
  7742. CROI: Disparities in HIV viral load suppression among MSM, the HIV Outpatient Study, 2013 - (03/23/15)
     
  7743. CROI: Untimed Drug Levels & Resistance in Patients Experiencing Low-Level Viremia - (03/23/15)
     
  7744. CROI: Antiretrovirals CROI 2015 Summary - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/18/15)
     
  7745. CROI: ART in Acute Infection, Inflammation/Activation "Largely Disappear" - (03/18/15)
     
  7746. CROI: IL-21 Reduces Inflammation and Virus Persistence in ART-Treated SIV-Infected Macaques - (03/18/15)
     
  7747. CROI: HIV Virology and "Cure" Science at CROI 2015 - by David Margolis MD UNC Chapel Hill & the Collaboratory of AIDS Researchers for Eradication (CARE) - (03/18/15)
     
  7748. CROI: IL-6 Partially Mediates the Effect of HIV Status on Survival....Inflammation & HIV Associated with Mortality in HIV+ Vets...HIV+ with >500 viral load have 33-100% greater mortality in VA Cohort - (03/16/15)
     
  7749. CROI: Age-Related Morbidities Among HIV-Infected Adults From 2000 to 2010...high comorbidities rate among older >60 & among Blacks....rates increase with age >40 through >60 - (03/16/15)
     
  7750. Women & HIV......several selected studies regarding important issues facing women & HIV - (03/13/15)
     
  7751. CROI: HIV DNA and Neurocognitive Impairment in Older and Younger Subjects on Suppressive ART - (03/16/15)
     
  7752. CROI: Inflammatory Biomarkers Decline but Do Not Normalize after 10 Years of cART - (03/16/15)
     
  7753. CROI: Inflammation Persists Despite Early ART in Acute HIV - (03/16/15)
     
  7754. CROI: Safety, Efficacy and Pharmacokinetics of the Integrase Inhibitor-Based E/C/F/TAF Single-Tablet Regimen in Treatment-Naïve HIV-Infected Adolescents Through 24 Weeks of Treatment - (03/16/15)
     
  7755. CROI: Elvitegravir Reduces Monocyte Activation and Vascular Inflammation More than Efavirenz - (03/16/15)
     
  7756. CROI: Imaging the Spatial Distribution of Efavirenz in Intact HIV Tissue Reservoirs - (03/16/15)
     
  7757. CROI: Efavirenz Use Is Not Associated With Increased Risk of Neuropsychological Impairment - (03/16/15)
     
  7758. CROI: Body Composition Changes after Initiation of Raltegravir or Protease Inhibitors..... - (03/16/15)
     
  7759. CROI: Early ART and sustained virological suppression limits HIV-1 Proviral DNA reservoir: CHER evidence (mortality increased 76% with early ART) - (03/16/15)
     
  7760. CROI: Impact of Antiretroviral Drugs on Hypertension in HIV-positive Persons: D:A:D Study ......Hypertension in HIV+....not the ARTs...But Established/Tradional Risk Factors....age, ethnicity/Black, lipids, diabetes, lipodystrophy, BMI, eGFR, IDU - (03/16/15)
     
  7761. CROI: Premature Aging and Immune Senescence in HIV-1-Infected Children - (03/16/15)
     
  7762. CROI: HIV induces astrocyte [brain] senescence and is reversed by ß-catenin induction - (03/16/15)
     
  7763. CROI: Microbial Translocation is associated with Neuroinflammation in HIV-infected subjects on ART - (03/16/15)
     
  7764. CROI: Suppressive ART is Key to Reduce Neurocognitive Impairment in Aging HIV+ Individuals - (03/16/15)
     
  7765. CROI: Inflammation, Activation and Lipodystrophy & Comorbidities.... 4 relevant studies below - (03/16/15)
     
  7766. CROI: Geriatric Syndromes are Common Among Older HIV-Infected Adults - (03/16/15)
     
  7767. TLR7 Nature Immunology research paper & Commentary - (03/13/15)
     
  7768. CROI: Risk Factors for Transmission of HCV among HIV-Infected MSM: a Case-Control Study - (03/13/15)
     
  7769. CROI: PREDICTORS OF NEUROCOGNITIVE DECLINE AMONG AVIREMIC INDIVIDUALS IN THE CHARTER COHORT - (03/13/15)
     
  7770. CROI: Neurocognitive Decline is Associated with Antiretroviral Concentrations in Cerebral Spinal Fluid and Blood - (03/13/15)
     
  7771. CROI: Early ART, Acute HIV & Chronic HIV & Inflammation/Activation, the Gut (Microbial Translocation): "Inflammatory Biomarkers Decline but Do Not Normalize after 10 Years of cART "....."Inflammation Persists Despite Early Initiation of ART in Acute HIV Infection"...... Inflammation in Acute HIV Infection Correlates with Blood and Gut CD4 T-cell Loss and HIV Viral Burden" - (03/13/15)
     
  7772. CROI: HIV Prevention at CROI 2015 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/12/15)
     
  7773. CROI: PCSK9 is Elevated in HIV+ Patients And May Mediate HIV-Associated Dyslipidemia - (03/11/15)
     
  7774. CROI: Avoiding smoking could prevent 37% of non-AIDS cancers in adults with HIV - Mark Mascolini - (03/11/15)
     
  7775. CROI: Asymptomatic genital CMV replication in MSM linked to T-cell exhaustion - Mark Mascolini - (03/11/15)
     
  7776. CROI: Confirmed kidney deficit tied to rising cardiovascular disease incidence in D:A:D..."need intensified monitoring for all types of emerging cardiovascular disease, in particular in older individuals with continuously low eGFR levels, and cincreased focus on applying different renal and cardiovascular preventive measures in HIV-positive persons" - (03/11/15)
     
  7777. CROI: Factors Associated with extensive Cervical Lesions among HIV-infected Women Screening for ACTG Protocal A5282 - (03/11/15)
     
  7778. CROI: Impaired Cardiac Strain and Biomarkers of Immune Activation in HIV - (03/11/15)
     
  7779. CROI: T-Cell Activation and E-Selectin Associated with Coronary Plaque in HIV-Infected Youth: early predictors of potential heart disease found in HIV+ youth 22 YO - (03/11/15)
     
  7780. CROI: Cerebral Vasoreactivity is Impaired in Virally Suppressed HIV-infected Individuals - (03/11/15)
     
  7781. CROI: Immunologic Predictors of Bone Loss in a Contemporary HIV Cohort - (03/11/15)
     
  7782. CROI: The impact of physical activity on cognition in men with and without HIV - (03/11/15)
     
  7783. CROI: Selectively Eliminating HIV-Latently Infected Cells Without Viral Reactivation T-cell marker may take the "shock" out of "shock-and-kill" strategy - Mark Mascolini - (03/10/15)
     
  7784. CROI: Bystander Effect of Histone Deacetylase Inhibitors on HIV-1 Infection - (03/10/15)
     
  7785. CROI: Bone density drop over time no greater with than without HIV in Dublin cohort - Mark Mascolini - (03/10/15)
     
  7786. CROI: Access to care up--and so is sexual risk--among US black women in high-AIDS cities.....but almost 50% of US women with HIV not in regular care - Mark Mascolini - (03/10/15)
     
  7787. CROI: Asymptomatic genital CMV replication in MSM linked to T-cell exhaustion - (03/09/15)
     
  7788. CROI: ART soon after infection linked to better CD4 recovery through 10 years - (03/09/15)
     
  7789. CROI: Avoiding smoking could prevent 37% of non-AIDS cancers in adults with HIV....."Smoking Outweighs HIV-related Risk Factors for Non-AIDS-defining Cancers".....'CD4 >200 & viral load matter too in cancer prevention'....modifiable risk factors to prevent cancer - (03/09/15)
     
  7790. CROI: CD4 Measures as Predictors of Lung Cancer Risk and Prognosis in HIV Infection.....cd4 <500 & CD4/CD38 ratio <0.4 associated with increased lung cancer risk - (03/09/15)
     
  7791. CROI: New Zinc Fingers - New FDA IND - New Studies CROI "Data Demonstrate Cytoxan Preconditioning Combined with CD4/CD38 ZFN-modified T-cell Product...." - (03/09/15)
     
  7792. CROI: The Effect of Physical Activity on Cardiometabolic Health and Inflammation in HIV - (03/09/15)
     
  7793. CROI: Aerobic Exercise Attenuates Cognitive Decline and Brain Volume Loss Associated With HIV.....from Jules: real-world exercise/diet intervention studies are need - (03/09/15)
     
  7794. CROI: Effectiveness of Sofosbuvir/Simeprevir for HIV/HCV Patients in Clinical Practice - (03/09/15)
     
  7795. CROI: CXCR4-using HIV--a tiny population before stem-cell transplant-becomes major population after - (03/06/15)
     
  7796. Excess Cancers Among HIV-Infected People in the United States - (03/06/15)
     
  7797. CROI: Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV ...... "SVR Associated with reduced risks of decompensation and death..... No decompensations were observed in HIV/HCV patients who achieved SVR" - (03/06/15)
     
  7798. CROI: Has Modern ART Reduced Endstage Liver Disease Risk in HIV-Hepatitis Coinfection? ...... "No clear reduction in ESLD risk was observed over the 3 time periods" - (03/06/15)
     
  7799. CROI: Hepatitis C infection and Cognition in Older HIV+ Adults: Data from the Center of Excellence on Disparities in HIV and Aging (CEDHA) - (03/06/15)
     
  7800. CROI: Effect of HIV Co-infection on Adherence to a 12-week regimen of HCV Therapy with Ledipasvir/Sofosbuvir - (03/06/15)
     
  7801. CROI: Early ART and IPT in HIV-Infected African Adults With High CD4 Count (Temprano Trial)...."Early ART >500 CD4s Significantly reduced Severe HIV Morbidity" - (03/06/15)
     
  7802. CROI: Frailty and Cause-Specific Hospitalization among Aging HIV-Infected and Uninfected Persons - (03/06/15)
     
  7803. CROI: The Kidney at CROI 2015 - - Written by Lene Ryom PhD CHIP, Department of Infectious Diseases and Rheumatology, Section 2100, Rigshospitalet - University of Copenhagen, Denmark Christina Wyatt MD Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY - (03/06/15)
     
  7804. CROI: Chronic HIV Infection Exacerbates Cellular Aging Markers in Isolated T cell Subsets - (03/06/15)
     
  7805. CROI: Kidney Dysfunction and Markers of Inflammation in the Multicenter AIDS Cohort Study - (03/06/15)
     
  7806. CROI: Total and Unbound Pharmacokinetics of Once-Daily Darunavir/Ritonavir in HIV-1-Infected Pregnant Women - (03/05/15)
     
  7807. CROI: A Dose Escalation Study of Cyclophosphamide (CTX) to Enhance SB-728-T Engraftment - (03/05/15)
     
  7808. CROI: Integrase Resistance Correlates of Response to Dolutegravir (DTG) Through 48 Weeks - (03/05/15)
     
  7809. CROI: Dolutegravir Resistance Requires Multiple Primary Mutations in HIV-1 Integrase - (03/05/15)
     
  7810. CROI: Consistency of Dolutegravir Treatment Difference in HIV+ Treatment Naives at Week 96 - (03/05/15)
     
  7811. CROI: Cabotegravir and Rilpivirine As 2-Drug Oral Maintenance Therapy: LATTE W96 Results - (03/05/15)
     
  7812. CROI: Characterization of NNRTI & INI Resistance Mutations Observed in a Study Subject on Oral Two-Drug Maintenance Therapy with 10 mg Cabotegravir + 25 mg Rilpivirine - (03/05/15)
     
  7813. CROI: GSK2578999, an HIV-1 maturation inhibitor with an improved virology profile against gag polymorphisms - (03/05/15)
     
  7814. CROI: Rates of Non-confounded HIV-Associated Neurocognitive Disorder after Early cART..... "Our findings suggest substantial neuroprotective benefit of initiating cART during primary infection" - (03/03/15)
     
  7815. CROI: Pharmacokinetics of Etravirine (ETR) in HIV-1-Infected Pregnant Women - (03/03/15)
     
  7816. CROI: Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies - (03/03/15)
     
  7817. CROI: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation - (03/03/15)
     
  7818. CROI: CROI Big Stories: TAF safety/efficacy, new HIV ARTs attachment & maturation inhibitors; new HCV drugs study results in HIV/HCV coinfected - Harvoni, daclatasvir+sofosbuvir, Abbvie 3D - (Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin )  - written by Mark Mascolini - (03/02/15)
     
  7819. CROI: Preventing one HIV infection in US saves $229,800 in modeling analysis - written by Mark Mascolini - (03/02/15)
     
  7820. CROI: Linkage to HIV care and viral suppression climb steadily in New York City - improvements to 76%, 73% - written by Mark Mascolini - (03/02/15)
     
  7821. CROI: More time with high viral load, high VACS index, predicts MI in veterans HIV cohort, as well as time-updated viral load & CD4 - written by Mark Mascolini - (03/02/15)
     
  7822. CROI: More time with high viral load, high VACS index, predicts MI in veterans HIV cohort, as well as time-updated viral load & CD4 - written by Mark Mascolini - (03/02/15)
     
  7823. CROI: TAF noninferior to TDF through 48 weeks in elvitegravir combination - written by Mark Mascolini - (03/02/15)
     
  7824. CROI: Atorvastatin for 1 year trims coronary artery plaque volume and number in placebo trial - written by Mark Mascolini - (03/02/15)
     
  7825. CROI: Varenicline (Chantix) helps French with HIV quit smoking in 48-week placebo trial - written by Mark Mascolini - (03/02/15)
     
  7826. CROI: Modified FRAX tool underestimates fracture rates in older men with HIV - written by Mark Mascolini - (03/02/15)
     
  7827. CROI: TAF easier on kidney and bone signals than TDF in 48-week trials - written by Mark Mascolini - (03/02/15)
     
  7828. CROI: Impact of Specific Antiretroviral Drugs on Non-AIDS Mortality; the D:A:D Study - - written by Mark Mascolini - (03/02/15)
     
  7829. CROI: Smoking and heavy drinking tied to atherosclerosis in MACS men with HIV - written by Mark Mascolini - (03/02/15)
     
  7830. CROI: SVR12 in over 90% of HCV/HIV null responders stating daclatasvir/asunaprevir plus PR - written by Mark Mascolini - (03/02/15)
     
  7831. CROI: Cardiovascular Disease Risk Prediction in the HIV Outpatient Study (HOPS)..... "Among participants with any length of follow-up, the four risk prediction equations underestimated the 10-year risk of CVD" - (03/02/15)
     
  7832. CROI: High cancer risk among the HIV-infected elderly in the United States - (03/02/15)
     
  7833. CROI: Fracture incidence is increased in aging HIV-infected women (WIHS) by 30% vs HIV - (03/02/15)
     
  7834. CROI: HIGH SVR REGARDLESS OF TIME TO SUPPRESSION WITH OMBITASVIR/PARITAPREVIR/R & DASABUVIR + RBV - (03/02/15)
     
  7835. CROI: Fracture incidence is increased in aging HIV-infected women (WIHS) by 30% vs HIV - (03/02/15)
     
  7836. CROI: Cardiovascular Disease in HIV Patients: An Emerging Paradigm and Call to Action - (03/02/15)
     
  7837. CROI: Statin Therapy Reduces Coronary Noncalcified Plaque Volume in HIV-infected Patients: a Randomized Controlled Trial - (03/02/15)
     
  7838. CROI: Calcified Plaque Burden is Associated with Serum Gut Microbiota-Generated Trimethylamine in HIV - (03/02/15)
     
  7839. CROI: Anal high-risk human papillomavirus (HPV) infection among HIV-infected MSM in the SUN Study, 2004-2011 - (03/02/15)
     
  7840. CROI: Exposure to antiretrovirals and development of chronic kidney disease - D:A:D Study Group - written by Mark Mascolini - (02/27/15)
     
  7841. CROI: Fat and lean mass changes similar with raltegravir and PIs in ACTG analysis - written by Mark Mascolini - (02/27/15)
     
  7842. CROI: Rosuvastatin halts carotid artery wall thickening in placebo-controlled trial - written by Mark Mascolini - (02/27/15)
     
  7843. CROI: Do gut flora play key role in cardiovascular disease with HIV? - written by Mark Mascolini - (02/27/15)
     
  7844. CROI: Lower CD4 count, higher viral load tied to primary MIs in NA-ACCORD - written by Mark Mascolini - (02/27/15)
     
  7845. CROI: TAF easier on kidney and bone signals than TDF in 48-week trials - written by Mark Mascolini - (02/27/15)
     
  7846. CROI: Earlier ART in primary infection leads to bigger drop in cellular HIV DNA - written by Mark Mascolini - (02/27/15)
     
  7847. CROI: Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Analysis - (02/27/15)
     
  7848. CROI: Treatment with a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys - (02/27/15)
     
  7849. CROI: TLR7 Agonist GS-9620 Activates HIV-1 in PBMCs from HIV-Infected Patients on cART - (02/26/15)
     
  7850. CROI: BMS-955176: Antiviral Activity and Safety of a Second-Generation HIV-1 Maturation Inhibitor - (02/27/15)
     
  7851. CROI: Renal and Bone Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate - (02/27/15)
     
  7852. CROI: Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4 - (02/27/15)
     
  7853. CROI: Renal and Bone Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate - (02/27/15)
     
  7854. CROI: GILEAD ANNOUNCES SVR12 RATES FROM PHASE 3 STUDY EVALUATING HARVONI® FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV - (02/27/15)
     
  7855. CROI: Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies - (02/27/15)
     
  7856. CROI: HIGH SVR REGARDLESS OF TIME TO SUPPRESSION WITH OMBITASVIR/PARITAPREVIR/R & DASABUVIR + RBV - (02/27/15)
     
  7857. CROI: Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) - (02/27/15)
     
  7858. CROI: Safety of Tenofovir Alafenamide in Renal Impairment - (02/27/15)
     
  7859. CROI: HIV-1 Attachment Inhibitor Prodrug BMS-663068: Pharmacokinetics, Pharmacodynamics and Model-Based Dose Selection - (02/26/15)
     
  7860. CROI: HIV-1 Attachment Inhibitor Prodrug BMS-663068: Interactions with DRV/r and/or ETR - (02/26/15)
     
  7861. CROI: Little or no DNA reservoir draining with chemo plus autologous stem-cell transplant - written by Mark Mascolini - (02/26/15)
     
  7862. CROI: Size of active HIV reservoir predicts rebound when antiretroviral therapy stops - written by Mark Mascolini - (02/26/15)
     
  7863. CROI: Viral load above 1500 copies 23% of time in CDC study of 6 clinics - written by Mark Mascolini - (02/26/15)
     
  7864. CROI: Levonorgestrel contraception fails in 15% of women taking efavirenz - written by Mark Mascolini - (02/26/15)
     
  7865. CROI: NCI sees "sizeable absolute risk" of cancer in elderly with HIV - written by Mark Mascolini - (02/26/15)
     
  7866. CROI: Lower CD4 count, higher viral load tied to primary MIs in NA-ACCORD - written by Mark Mascolini - (02/26/15)
     
  7867. CROI: Almost half of US women with HIV not in regular care in CDC analysis - written by Mark Mascolini - (02/26/15)
     
  7868. CROI: Little or no DNA reservoir draining with chemo plus autologous stem-cell transplant - written by Mark Mascolini - (02/26/15)
     
  7869. CROI: As-Needed PrEP Cuts HIV Rate 86% in French-Canadian Ipergay Trial - written by Mark Mascolini - (02/25/15)
     
  7870. CROI: Pre-Exposure Prophylaxis for HIV Prevention: What we know and What we still need to know for implementation - (02/25/15)
     
  7871. CROI: Daily TDF/FTC PrEP Provides 86% Protection From HIV in Gay British Men - written by Mark Mascolini - (02/25/15)
     
  7872. CROI: PrEP plus ART yields "near elimination" of HIV in Partners cohort - written by Mark Mascolini - (02/25/15)
     
  7873. CROI: Wider PrEP Use in San Francisco Could Cut New HIV Rate by 70% - written by Mark Mascolini - (02/25/15)
     
  7874. CROI: As-Needed PrEP Cuts HIV Rate 86% in French-Canadian Ipergay Trial - full slide presentation below - written by Mark Mascolini - (02/25/15)
     
  7875. CROI: Early ART, continuous suppression, tied to lower HIV DNA in CHER trial children - written by Mark Mascolini - (02/25/15)
     
  7876. CROI: Poor kidney function predicts neurocognitive decline with undetectable viral load - written by Mark Mascolini - (02/25/15)
     
  7877. CROI: Doubled risk of virologic failure with 3TC vs FTC in Dutch cohort analysis - written by Mark Mascolini - (02/25/15)
     
  7878. CROI: Anal cancer diagnosed earlier in HIV+ men, but cancer-specific survival similar to HIV- men - written by Mark Mascolini - (02/25/15)
     
  7879. CROI: Poor balance confidence--not physical function--predicts falls in older men with HIV - written by Mark Mascolini - (02/25/15)
     
  7880. CROI: Extensive cervical lesions common in HIV-positive women screened for ACTG trial - written by Mark Mascolini - (02/25/15)
     
  7881. CROI: HCV recurrence after SVR 20 times more frequent with HIV/HCV than HCV alone - written by Mark Mascolini - (02/25/15)
     
  7882. Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection - (02/24/15)
     
  7883. Dose Response for Starting and Stopping HIV Preexposure Prophylaxis for Men Who Have Sex With Men - (02/23/15)
     
  7884. New HIV Vaccine, gene therapy -"preventative drug and as a treatment" - NIH Study - Potential Long-Acting HIV Therapeutic eCD4-Ig" - (02/19/15)
     
  7885. Researchers Identify Key Mechanisms Underlying HIV-Associated Cognitive Disorders - HIV/Brain Damaged reduced by Rapamycin in Mice, in Vitro - new study - (02/17/15)
     
  7886. HIV+ Women Increased Heart Disease Risk in this study....immune activation/inflammation....gut flora.....noncalcified coronary plaque - (02/17/15)
     
  7887. Immune Activation and Coronary Atherosclerosis in HIV-Infected Women: Where Are We Now, and Where Will We Go Next? - Editorial Comment - (02/17/15)
     
  7888. Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine - (02/17/15)
     
  7889. New CDC Report: HIV/Mortality Among Blacks Improved - (02/17/15)
     
  7890. Monocyte activation markers remain significantly elevated in virologically suppressed HIV+ individuals to a level equivalent to an additional 4 years of normal aging - (02/05/15)
     
  7891. PrEP/Women-Africa/Low Adherence - Editorial: VOICE Study - Preventing HIV in Women - Still Trying to Find Their VOICE - (02/05/15)
     
  7892. Final results of the HIV prevention study VOICE - press release - (02/05/15)
     
  7893. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients - (02/04/15)
     
  7894. Mitochondrial disturbances in HIV pregnancies - (01/30/15)
     
  7895. Statins in HIV+ - Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial; Should everyone ageing with HIV take a statin? - (01/30/15)
     
  7896. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial - (01/30/15)
     
  7897. Statins in HIV+ - Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial; Should everyone ageing with HIV take a statin? - (01/29/15)
     
  7898. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies - Editorial/Comment - (01/29/15)
     
  7899. Dolutegravir FDA CLINICAL REVIEW - (01/28/15)
     
  7900. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket - (01/26/15)
     
  7901. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? - (01/23/15)
     
  7902. Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-Infected Patients with Mild to Moderate Renal Impairment. - (01/23/15)
     
  7903. Recommendations for Evaluation and Management of Bone Disease in HIV - (01/23/15)
     
  7904. Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk? - (01/22/15)
     
  7905. Inflammation in Chronic HIV Infection: What can we do? Author findings suggest integrase inhibitors have benefits - (01/22/15)
     
  7906. CROI: Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals: CD4 & > F2 Associated with Liver Related Deaths in EuroSIDA - (01/20/15)
     
  7907. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge - (01/16/15)
     
  7908. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge - (01/16/15)
     
  7909. Long-acting drug (GSK744) effectively prevents HIV-like infection in monkeys - (01/16/15)
     
  7910. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV - (01/13/15)
     
  7911. FDA Approves Merck's HPV Vaccine, GARDASIL®9, to Prevent Cancers and Other Diseases Caused by Nine HPV types - Including Types that Cause About 90% of Cervical Cancer Cases - (01/13/15)
     
  7912. Elevated Levels of Monocyte Activation Markers Are Associated With Subclinical Atherosclerosis in Men With and Those Without HIV Infection - (01/09/15)
     
  7913. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients - (01/09/15)
     
  7914. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations - (01/08/15)
     
  7915. Curing HIV/CTL Responses - HIV: Seeking ultimate victory, new discovery - Editorial - (01/08/15)
     
  7916. Broad immune response may be needed to destroy latent HIV - (01/08/15)
     
  7917. Cruciferous Vegetables and Cancer Prevention - (01/05/15)
     
  7918. Changes in Glomerular Kidney Function Among HIV-1-Uninfected Men and Women Receiving Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis - A Randomized Clinical Trial - (01/05/15)
     
  7919. Tenofovir Disoproxil Fumarate Intravaginal Ring Protects High-Dose Depot Medroxyprogesterone Acetate-Treated Macaques From Multiple SHIV Exposures - (01/05/15)
     
  7920. Improvements in HIV Care Engagement and Viral Load Suppression Following Enrollment in a Comprehensive HIV Care Coordination Program - (01/05/15)
     
  7921. PrEP & PEP Update - SF recent news, NYS Plan announced during summer 2014, rectal/vaginal gels & future long-acting PrEP (injectables, vaginal rings) update from HIVR4P Conference - (12/22/14)
     
  7922. Elite control of HIV: is this the right model for a functional cure? - (12/18/14)
     
  7923. The changing virulence of HIV...."more frequent testing among people at risk and earlier ART initiation, and the need for an HIV vaccine or other interventions to reduce set-point viral load and the viral reservoir"..."These findings emphasise the important need for early HIV testing and engagement with care given the implications for treatment and prevention" - (12/18/14)
     
  7924. The HIV care continuum in black MSM in the USA - Commentary - (12/18/14)
     
  7925. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America: The ART Cohort Collaboration - (12/18/14)
     
  7926. Mediterranean Diet/Aging/Inflammation/Telomere-new study: Mediterranean diet and telomere length in Nurses' Health Study: population based cohort study - (12/17/14)
     
  7927. Early ART During Acute Infection Preserved Immunity/Reverses Immune Activation - new study finds - (12/12/14)
     
  7928. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems - (12/08/14)
     
  7929. Gut epithelial barrier and systemic inflammation during chronic HIV infection - (12/08/14)
     
  7930. Combination antiretroviral therapy reduces the detection risk of cervical human papilloma virus infection in women living with HIV - (12/08/14)
     
  7931. HAART slows progression to anal cancer in HIV-infected MSM - (12/08/14)
     
  7932. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation - (12/08/14)
     
  7933. HDAC Inhibitors -Panobinostat - Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans - (12/03/14)
     
  7934. HIV and the neuropsychology of everyday life - Editorial - asympotomatic nuerocognitive impairment, mild cognitive impairment without functional limitations, were more likely to reach disability endpoints than HIV+ people with unimpaired cognition - (12/02/14)
     
  7935. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline - (12/02/14)
     
  7936. Influence of the Timing of Antiretroviral Therapy on the Potential for Normalization of Immune Status in Human Immunodeficiency Virus 1-Infected Individuals - (11/25/14)
     
  7937. Defining Success With Antiretroviral Therapy - - (11/25/14)
     
  7938. Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection - process of brain cell inflammation and injury begins very early after infection, worsen over time & in the absence of ART, findings suggest early ART initiation reduces inflammation & neurologic injury - (11/25/14)
     
  7939. GLASGOW: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (11/18/14)
     
  7940. GLASGOW: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis and Safety Profile - oral presentation - (11/18/14)
     
  7941. GLASGOW: Phase IIIb, open-label, single-arm trial of darunavir/cobicistat: Week 48 subgroup analysis of HIV-1-infected, treatment-naïve adults - PK/virology/safety/tolerability - (11/18/14)
     
  7942. Updates to the HCV/HIV Section in HHS ART Adult/Adolescent Guidelines Nov 13 2014 - (11/14/14)
     
  7943. Treatment for Key Groups: HIV Coinfection, African-Americans, Cirrhosis/Treatment Experiencec-PI-Failures, Decompensated Cirrhosis, Genotype 3, Post-Transplant - (11/14/14)
     
  7944. HIV/HCV Coinfection SVR Rates The Same as in Monoinfected - (11/14/14)
     
  7945. GLASGOW: Week 48 efficacy analysis of the PROTEA trial: darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL at baseline - (11/13/14)
     
  7946. GLASGOW: Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis - (11/12/14)
     
  7947. GLASGOW: Efficacy of PI monotherapy versus triple therapy for 2202 patients in 12 randomised trials - (11/12/14)
     
  7948. GLASGOW: Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues - (11/12/14)
     
  7949. GLASGOW: Two Years of Truvada for Pre-Exposure Prophylaxis Utilization in the United States - (11/07/14)
     
  7950. GLASGOW: Cobicistat (COBI) in HIV-Infected Patients with Mild to Moderate Renal Impairment - (11/07/14)
     
  7951. GLASGOW: Long-Term Efficacy and Safety of E/C/F/TDF vs. EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected Treatment Naïve Subjects Age ≥ 50 Years - (11/07/14)
     
  7952. GLASGOW: Renal Safety Profile of STB in Virologically Suppressed Subjects From Two Randomized, Phase 3b Switch Trials - (11/07/14)
     
  7953. GLASGOW: Switch to Stribild vs Continuation of NVP or RPV with FTC and TDF in Virologically Suppressed HIV Adults: A STRATEGY-NNRTI Subgroup Analysis - (11/07/14)
     
  7954. GLASGOW: Simplification to Stribild vs Continuation of RTV-boosted DRV with FTC and TDF in Virologically Suppressed HIV Adults: A STRATEGY-PI Subgroup Analysis - (11/07/14)
     
  7955. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV - (11/06/14)
     
  7956. GLASGOW: Glasgow: The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects - (11/06/14)
     
  7957. GLASGOW: Glasgow: First Prospective Comparison of Genotypic vs Phenotypic Tropism Assays in Predicting Virologic Responses to Maraviroc (MVC) in a Phase 3 Study: MODERN - (11/06/14)
     
  7958. GLASGOW: Glasgow: Patient Preferences for Characteristics of Antiretroviral Therapies: Results From 5 European Countries - (11/06/14)
     
  7959. GLASGOW: GLASGOW: Dolutegravir Is Superior to Darunavir/Ritonavir in Treatment-Naive HIV-1 Infected Individuals: 96 Week Results From FLAMINGO - (11/06/14)
     
  7960. Probiotics Revisited - (11/05/14)
     
  7961. Glasgow: 48-Week Efficacy and Safety and Early CNS Tolerability of Doravirine, a Novel NNRTI, with TDF/FTC in ART-Naïve HIV-Infected Patients - (11/04/14)
     
  7962. Glasgow/poster: 48-Week Efficacy and Safety and Early CNS Tolerability of Doravirine,a Novel NNRTI, With TDF/FTC in ART-Naïve HIV-Infected Patients - (11/04/14)
     
  7963. Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients - (11/04/14)
     
  7964. 2 PrEP Studies IPERGAY & PROUD Announce Efficacy - (11/03/14)
     
  7965. Rectal/Vaginal PrEP at HIVR4P Conference/South Africa Oct 28-31 2014 - (11/03/14)
     
  7966. IDSA: A Retrospective Study to Evaluate the Effect of Switching Antiretroviral Therapy to a Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate in HIV Infected Patients With Suppressed Viral Load In a Clinical Setting - The Switch to Complera (TSC) Study - (11/03/14)
     
  7967. Eradicating HIV-1 infection: seeking to clear a persistent pathogen - Review - (10/31/14)
     
  7968. Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection... - (10/31/14)
     
  7969. AGE: Switching to Stribild from a RTV-boosted PI or NNRTI with TVD Maintains HIV Suppression at Week 48 with No New Safety Signals in Subjects Age ≥50 years - (10/29/14)
     
  7970. IDSA: Peer Recruitment Increases HIV-Positivity Rate CDC Study - Comparative effectiveness of social networks-based strategies versus standard counseling, testing and referral for HIV screening in a state-wide testing program - (10/29/14)
     
  7971. IDSA: Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis - (10/29/14)
     
  7972. "Exercise is Nonpharmacological Intervention To Reduce Inflammation...prevent metabolic diseases" Taming HIV-Related Inflammation with Physical Activity: A Matter of Timing - (10/29/14)
     
  7973. Prospective Randomized Clinical Trial of the Effects of Three Modern Antiretroviral Therapies on Carotid Intima-Media Thickness in HIV-Infected Individuals (ACTG A5260s) - (10/29/14)
     
  7974. AGE: Inflammation/Morbidity/Mortality - Coagulation and Morbidity in Treated HIV Infection - (10/27/14)
     
  7975. AGE: The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging - (10/27/14)
     
  7976. AGE: HIV, Aging, and Statins: Pros vs. Cons... - (10/27/14)
     
  7977. IDSA: Hip Fracture Rate Higher With HIV/HBV Than HIV Alone in Medicaid Analysis - Mark Mascolini - (10/25/14)
     
  7978. AGE: HCV in Australia "it is the Dallas Buyers Club scenario"...HCV therapy is much less expensive than HIV HAART...... "Australia is on the verge of a catastrophic death spiral from Hepatitis C" - Mark Mascolini (10/24/14)
     
  7979. AGE: Health Deficits Accumulate Faster With HIV Than Without in Older Adults - Mark Mascolini - (10/24/14)
     
  7980. AGE: Higher Frailty Index Tied to Lower Odds of Successful Cognitive Aging in HIV+ Over 50 - Mark Mascolini - (10/24/14)
     
  7981. AGE: Gait Speed Slows More With Age in MACS Men With Than Without HIV - Mark Mascolini - (10/24/14)
     
  7982. AGE: Kidney Disease Key Cofactor in Coronary Artery Disease Risk With HIV at 60 and Older - Mark Mascolini - (10/24/14)
     
  7983. AGE: Switch From PI or NNRTI to Stribild in People 50 or Older Effective and Safe in Trials - Mark Mascolini - (10/24/14)
     
  7984. AGE: PIs and Raltegravir Favored Over NNRTIs for Frail and Older People - Mark Mascolini - (10/24/14)
     
  7985. IDSA: Switch to Complera in Clinical Practice Usually Safe and Effective - Mark Mascolini - (10/24/14)
     
  7986. IDSA: HIV Risk Behavior Increases Between HIV Tests in Half of Wisconsin Group - Mark Mascolini - (10/24/14)
     
  7987. IDSA: Asking Patients About Sex Only Factor Tied in Syphilis Screening in HIV Group - Mark Mascolini - (10/24/14)
     
  7988. IDSA: Pregnancy Outcomes and Postdelivery Mortality in Perinatally HIV-Infected Women - Mark Mascolini - (10/24/14)
     
  7989. IDSA: Preterm Delivery Rate Doubled With HIV in Canada--Boosted PIs Key Factor - Mark Mascolini - (10/24/14)
     
  7990. IDSA: Only One Third of MSM in Routine HIV Care Tested for Gonorrhea or Chlamydia - Mark Mascolini - (10/24/14)
     
  7991. IDSA: In-Hospital Antiretroviral Errors Correctly Quickly With Two-Pronged Strategy - Mark Mascolini - (10/24/14)
     
  7992. IDSA: Current PI, White Race, Lower BMI Linked to Higher Selenium in HIV Group - Mark Mascolini - (10/24/14)
     
  7993. AGE: Testosterone Lower in AM But Not PM in MACS Men With vs Without HIV - (10/23/14)
     
  7994. AGE: Diastolic Dysfunction Tied to Impaired Exercise Capacity in Older Men With HIV - (10/23/14)
     
  7995. ACA/59% Use Specialty Meds Prescriptions: HIV/HCV Prominent-Express Scripts Report - (10/23/14)
     
  7996. IDSA: Raltegravir Containing regimen, for Post Exposure Prophylaxis (PEP) well tolerated in Health Care Workers (HCW) - (10/23/14)
     
  7997. IDSA: Tolerability, adherence and completion of new occupational post-exposure prophylaxis regimen (tenofovir + emtricitabine and raltegravir) - (10/23/14)
     
  7998. IDSA: Efavirenz & Suicidality....New analysis among Medicaid & Commercial databases finds no association, reflects current EFV use patterns & safer/proper use of EFV... - (10/23/14)
     
  7999. IDSA: Longitudinal Trends in HIV Non-Occupational Post-Exposure Prophylaxis (NPEP) at a Boston Community Health Center Between 1997 and 2013 - (10/23/14)
     
  8000. IDSA: Attitudes and Interest Toward HIV Pre-Exposure Prophylaxis (PrEP) Among Participants Using HIV Non-Occupational Post-Exposure Prophylaxis (NPEP) - (10/23/14)
     
  8001. IDSA: Veterans Aging Cohort Study (VACS) Index, Functional Status, and Other Patient Reported Outcomes in Older HIV-positive (HIV+) Adults in SF.....Poor Outcomes in HIV+ Aging age 53-61 - (10/23/14)
     
  8002. IDSA: HIV at ID Week 2014 David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (10/22/14)
     
  8003. What is Frailty in HIV?: Geriatric Syndrome to Physiologic Process - (10/22/14)
     
  8004. Food, Protein, Cancer, Diabetes, Mortality - (10/22/14)
     
  8005. IWCADR: Hypertension Increased in HIV+ vs HIV-neg in Amsterdam AgehIV Cohort Study (45% vs 31%) & HIV is Independently Associated with Hypertension - (10/17/14)
     
  8006. IWCADR: Effect of initiating antiretroviral therapy on markers of monocyte activation, endothelial dysfunction and platelet activation in HIV-1 infection - (10/17/14)
     
  8007. IWCADR: Initiating Protease Inhibitor-only therapy is associated with increased subcutaneous adipose tissue PPARG expression, reduced mitochondrial stress together with altered expression of insulin signalling genes - (10/17/14)
     
  8008. IWCADR: Persistence of HIV Associated Neurocognitive Disorders (HAND) in the Combination Antiretroviral Therapy Era (cART) - (10/17/14)
     
  8009. IDSA: Three Quarters of NPEP Users Show Interest in Trying PrEP - Mark Mascolini - (10/16/14)
     
  8010. IDSA: High Rate of NPEP Completion, Good Safety, With Raltegravir Plus TDF/FTC - Mark Mascolini - (10/16/14)
     
  8011. IDSA: Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents - a 24 Week Study - (10/16/14)
     
  8012. IDSA: Commercial and Medicaid Claims Databases Show No Evidence of Higher Suicidality With Efavirenz - Mark Mascolini - (10/15/14)
     
  8013. IDSA: Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection - (10/15/14)
     
  8014. IDSA: Factors associated with the selection of initial antiretroviral therapy: Real-world channeling - (10/15/14)
     
  8015. IDSA: A 28-Day High-Dose Safety and Pharmacokinetics Study of Raltegravir in Healthy Subjects - (10/15/14)
     
  8016. IDSA: Using Real World Data to Assess the Risk of Suicidality among Patients Initiating an Efavirenz versus an Efavirenz-Free Antiretroviral Regimen - (10/15/14)
     
  8017. IDSA: Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents - a 24 Week Study - (10/14/14)
     
  8018. IDSA: Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women - (10/14/14)
     
  8019. IDSA: Erectile Dysfunction Drug Use Tied to Sexual Risk and STIs in HIV+ US Men - written by Mark Mascolini - (10/14/14)
     
  8020. IDSA: Low Trabecular BMD, High TNF-Alpha in Women With HIV/HCV vs Only HIV or HCV - written by Mark Mascolini - (10/14/14)
     
  8021. IDSA: Almost 80% of Visits to Bronx Center Rank as Missed Chances for HIV Diagnosis - written by Mark Mascolini - (10/14/14)
     
  8022. IDSA: ROC Curves Pinpoint ART Failure Threshold at 95 Copies at Week 24 - written by Mark Mascolini - (10/14/14)
     
  8023. IWCADR: Incidence and clearance of anal high-grade squamous intraepithelial lesions (HSIL) in HIV positive and HIV negative homosexual men, preliminary interim report - (10/10/14)
     
  8024. IDSA: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (10/10/14)
     
  8025. IDSA: STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has similar efficacy and is well-tolerated compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve females at Week 96 - (10/10/14)
     
  8026. IDSA: Simplification to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from Ritonavir-Boosted Protease Inhibitor Plus Emtricitabine/Tenofovir DF Maintains HIV Suppression and Improves Fasting Triglycerides at Week 48 - (10/10/14)
     
  8027. IDSA: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (10/10/14)
     
  8028. IDSA: HIV Care Cascade Differs by Gender and Age in Large US Healthcare System - written by Mark Mascolini - (10/10/14)
     
  8029. IDSA: More Positive HIV Tests Via Social Networks Than Standard Approach - written by Mark Mascolini - (10/10/14)
     
  8030. IDSA: Risk Score and Race Predict Missed HIV Appointments in US Group - written by Mark Mascolini - (10/10/14)
     
  8031. IDSA: Gender, Depression, Heart and Liver Disease Affect First-Line ART Choice in US - written by Mark Mascolini - (10/10/14)
     
  8032. IDSA: Acute Retroviral Syndrome Tied to Higher HIV RNA and DNA in Blood, Colon, CSF - written by Mark Mascolini - (10/10/14)
     
  8033. IDSA: Delayed HIV Rebound More Frequent After Early Treatment and With NNRTIs - written by Mark Mascolini - (10/10/14)
     
  8034. IWCADR: Longitudinal Changes in Free Testosterone among Older HIV-infected and HIV-uninfected Men - (09/09/14)
     
  8035. IWCADR: Effect on lipids and reverse cholesterol transport of switching to unboosted atazanavir vs. remaining on ritonavir-boosted atazanavir in regimens with a tenofovir backbone - (09/09/14)
     
  8036. IWCADR: Heart Disease/Inflammation/Activation - T-cell Activation and E-Selectin Associated with Coronary Plaque in HIV-infected Youth - (09/09/14)
     
  8037. IWCADR: Independent Effects of Visceral Fat, Age and HIV Infection on Brain Structure .....'VAT(belly fat) associated with brain atrophy' - (10/08/14)
     
  8038. IWCADR: Self-reported Body Fat Change in HIV-infected Men is a Marker of Decline in Physical Health-related Quality of Life.... "...may be at an greater risk for decline in physical function with aging, compared to HIV-neg men" - (10/08/14)
     
  8039. IWCADR: Impaired Cardiac Strain and Biomarkers of Immune Activation in HIV - (10/08/14)
     
  8040. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients - (10/06/14)
     
  8041. Progress toward curing HIV infections with hematopoietic stem cell transplantation/NIAID Workshop - (10/02/14)
     
  8042. Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014™ Showcasing Continued Innovation in Virology - (10/02/14)
     
  8043. HCV & HIV African-American/Latino Disparities of Care.... - (10/01/14)
     
  8044. CDC Reports HIV/MSM Cascade of Care: African-Americans had lowest levels of linkage to care, retention in care, ART prescription & viral suppression - (10/01/14)
     
  8045. Curing HIV Mystery, The Berlin Patient - (09/30/14)
     
  8046. Adherence/how many Tenofovir PrEP pills worked in study - Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.....iPrEx open-label extension - (09/29/14)
     
  8047. Patterns and Correlates of PrEP Drug Detection among MSM and Transgender Women in the Global iPrEx Study. - (09/29/14)
     
  8048. HCV Screening in HIV is Poorly Implemented, MSM don't get screened adequately, only 55% get screened again after initial screen - (09/29/14)
     
  8049. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation - (09/29/14)
     
  8050. HIV & Aging - Mental Needs: Policy, Mental Health Services Program, Comorbidities, Services for Aging/Older HIV+ - (09/29/14)
     
  8051. PreP Research MSM/IDUs - TDF/FTC, GSK744 Once A Month or Every 3 Months Perhaps, TDF/FTC Vaginal Ring......new: "Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York City" - (09/29/14)
     
  8052. Elvitegravir / Vitekta FDA Approval - (09/26/14)
     
  8053. Cobicistat/Tybost FDA Approves - (09/26/14)
     
  8054. Persistence of Virus Reservoirs in ART-Treated SHIV-Infected Rhesus Macaques after Autologous Hematopoietic Stem Cell Transplant - (09/26/14)
     
  8055. Gilead's Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies - (09/24/14)
     
  8056. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.....predicting degree of reservoir reduction needed for cure - (09/22/14)
     
  8057. Dolutegravir & Rilpivirine CNS Penetration - (09/22/14)
     
  8058. ICAAC: Serum levels of soluble cellular adhesion molecules are associated with survival and liver-related events in adults coinfected with HIV/HCV - (09/16/14)
     
  8059. ICAAC: Pre-ART Profile Differs for Mortality and TB-IRIS in People Starting ART - (09/15/14)
     
  8060. ICAAC: The Effects of Interferon/Ribavirin Therapy on Bone Turnover Markers (BTMs) in HIV/HCV Co-Infected Subjects - (09/15/14)
     
  8061. ICAAC: Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep - Mark Mascolini - (09/15/14)
     
  8062. ICAAC: TDF/FTC Vaginal Ring Protects 6 of 6 Monkeys From Weekly SHIV Exposure - Mark Mascolini - (09/15/14)
     
  8063. ICAAC: PK Data and Dose Selection for Experimental NNRTI, Doravirine - Mark Mascolini - (09/15/14)
     
  8064. ICAAC: Similar 144-Week Results With Cobicistat or Ritonavir as Atazanavir Booster - Mark Mascolini - (09/15/14)
     
  8065. ICAAC: First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks - Mark Mascolini - (09/15/14)
     
  8066. ICAAC: Coronary Calcium Scores Similar in HIV+ People and Matched HIV- Controls - Florida community infectious disease office - Mark Mascolini - (09/15/14)
     
  8067. ICAAC: Subgroup Analysis of Response to Stribild vs Atripla or Atazanavir: 144 Weeks - Mark Mascolini - (09/15/14)
     
  8068. ICAAC: Less Bone Loss With DRV/RAL Than DRV/TDF/FTC at 48 and 96 Weeks - Mark Mascolini - (09/15/14)
     
  8069. ICAAC: CD38-Cell Activation, Senescence, Osteoprotegerin Tied to Atherosclerosis in Italian HIV Cohort.... (from jules: senescence marker higher in HIV+ & senescence marker associated with heart disease) - (09/12/14)
     
  8070. ICAAC: Switch From RTV to COBI To Boost a PI With Moderate Kidney Impairment - (09/12/14)
     
  8071. ICAAC: Tenofovir Nanoparticles in Vaginal Gel Protect 10 of 10 BLT Mice From HIV Challenge - (09/12/14)
     
  8072. ICAAC: One Third of HIV+ Women in Spanish Group Have Anal Cancer Precursor - (09/11/14)
     
  8073. ICAAC: Stribild Advantages vs Atripla in Blacks Through Trial Week 144 - (09/11/14)
     
  8074. Improved Single Copy Assays for Quantification of Persistent HIV-1 Viremia in Patients on Suppressive Antiretroviral Therapy - (09/10/14)
     
  8075. Gastrointestinal Tract and the Mucosal Macrophage Reservoir in HIV Infection - (09/10/14)
     
  8076. ICAAC: Metabolism, Excretion, and Mass Balance of the HIV Integrase Inhibitor, Cabotegravir (GSK1265744) in Humans - (09/10/14)
     
  8077. ICAAC: Effect of Carbamazepine (CBZ) on Dolutegravir (DTG) Pharmacokinetics - (09/10/14)
     
  8078. ICAAC: Pharmacokinetics and Drug Interaction Profile of Cobicistat-Boosted Elvitegravir with Carbamazepine - (09/10/14)
     
  8079. ICAAC: Elvitegravir Regimen Maintains Virologic Control in Blacks After PI or NNRTI - Written by Mark Mascolini - (09/10/14)
     
  8080. ICAAC: Noninduced HIV-1 Proviruses in the Latent Reservoir May Contain Drug Resistance Mutations ......full slide presentation included - Written by Mark Mascolini - (09/10/14)
     
  8081. ICAAC: Virologic Response During ART Interruption After CCR5-Cell Modification With SB-728-T (zinc fingers) - Written by Mark Mascolini - (09/10/14)
     
  8082. ICAAC: HIV Persists in Lung Macrophages of People on Suppressive ART - Written by Mark Mascolini - (09/10/14)
     
  8083. ICAAC: Elvitegravir Regimen Maintains Virologic Control in Blacks After PI or NNRTI - Written by Mark Mascolini - (09/09/14)
     
  8084. ICAAC: Four to Five HIV+ Dying in Care Yearly in Philadelphia Are Potential Organ Donors - Written by Mark Mascolini - (09/09/14)
     
  8085. ICAAC: GSK Long-Acting ART Integrase inhibitor - Cabotegravir Injected Every 1, 2, or 3 Months Yields Adequate Troughs in Simulation - Written by Mark Mascolini - (09/09/14)
     
  8086. ICAAC: High-Risk HPV 60% More Frequent in Anus Than Cervix of HIV+ Women in France - Written by Mark Mascolini - (09/09/14)
     
  8087. ICAAC: Cholelithiasis (gallstones) among patients exposed to atazanavir, other PIs, and PI-free regimens - (09/09/14)
     
  8088. ICAAC: HIV NRTI BMS-986001 in Antiretroviral-Naïve Subjects: Evaluation of Bone and Metabolic Safety Data Through Week 48 - (09/09/14)
     
  8089. ICAAC: HIV NRTI BMS-986001 in Antiretroviral-Naïve Subjects: Week 24/48 Analyses - (09/09/14)
     
  8090. ICAAC: COPD Prevalence 9% in French HIV Group--and 74% Don't Know - (09/09/14)
     
  8091. ICAAC: Drug Interactions Between Tenofovir Alafenamide and HIV Antiretroviral Agents - (09/09/14)
     
  8092. ICAAC: Switching from Ritonavir (RTV) to Cobicistat (COBI) in HIV Patients with Renal Impairment Who Are Virologically Suppressed on a Protease Inhibitor based Regimen - (09/09/14)
     
  8093. ICAAC: Subcutaneous Ibalizumab in At-Risk Healthy Subjects - (09/09/14)
     
  8094. ICAAC: HIV in Resting CD4 Cells May Contain Antiretroviral Resistance Mutations - Written by Mark Mascolini - (09/08/14)
     
  8095. ICAAC: Dolutegravir Superior to Efavirenz at 144 Weeks in SINGLE Trial - Written by Mark Mascolini - (09/08/14)
     
  8096. ICAAC: STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Is Non-Inferior Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes through Week 96 - (09/08/14)
     
  8097. ICAAC: Once-Daily Doutegravir + Abacavir/Lamivudine is Superior to Efavirenz/Tenofovir/Emtricitabine in Treatment-Naïve HIV Subjects: 144-Week Results - SINGLE Study (ING114467) - (09/08/14)
     
  8098. ICAAC: Acute hepatitis C infection in HIV negative men who have sex with men......in UK - 'sexual HCV transmission/risky sex & drug use behavior/low rates of screening/routine screening recommended for these risk group' - (09/08/14)
     
  8099. ICAAC: 48 Week Study of the First PI-based Single Tablet-Regimen (STR) Darunavir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) vs. Darunavir (DRV) boosted by Cobicistat (COBI) and Emtricitabine/Tenofovir Disoproxil Fumarate (TVD) in HIV-Infected Treatment-Naïve Adults - (09/08/14)
     
  8100. ICAAC: Pooled 144-week Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) with Subgroup Analysis - (09/08/14)
     
  8101. ICAAC: Cobicistat versus Ritonavir as Pharmacoenhancers of Atazanavir in Combination with Emtricitabine/Tenofovir DF - Phase 3 Randomized, Blinded, Active-Controlled Trial, Week 144 Results - (09/08/14)
     
  8102. ICAAC: Pharmacokinetics (PK) of Doravirine and Exposure-Response Analysis: Efficacy and Safety Implications - (09/08/14)
     
  8103. ICAAC: Switch to Elvitegravir/Cobi/FTC/TDF from PI+RTV or NNRTI plus FTC/TDF Maintains HIV Suppression at Week 48 and is Safe in Black Subjects - (09/08/14)
     
  8104. ICAAC: Efficacy and Safety of Raltegravir in Racial Groups - (09/08/14)
     
  8105. ICAAC: Long-Term Efficacy and Safety of E/C/F/TDF (STB) versus EFV/FTC/TDF (ATR) in HIV-1-Infected Treatment Naïve Black and Non-Black Subjects - (09/08/14)
     
  8106. HIV Antibodies Block Infection by Reservoir-Derived Virus in Laboratory Study - (09/05/14)
     
  8107. NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus - "Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface" - (09/05/14)
     
  8108. Rekindled HIV infection (latent reservoirs) - Perspective - (09/03/14)
     
  8109. HIV & Bone Loss/Osteopenia & Osteoporosis & Fractures - (09/03/14)
     
  8110. "HIV infection remained independently associated with a higher number of AANCC (OR 1.58) [age-associated non-communicable comorbidity]" HIV+ had more comorbidities & more than 3, 2 & 1 comorbidities respectively vs HIV-neg....new study published confirming prior studies - (09/03/14)
     
  8111. Effects of Low-Carbohydrate and Low-Fat Diets: A Randomized Trial -new study...."low-carbohydrate diet resulted in greater weight loss and reduction in cardiovascular risk factors than a low-fat diet among obese black and white adults" - (09/03/14)
     
  8112. The early cost of HIV....in the SIV gut....priobiotics: "Early Mucosal Sensing of SIV Infection by Paneth Cells Induces IL-1ß Production and Initiates Gut Epithelial Disruption" - (09/03/14)
     
  8113. Beyond Core Indicators of Retention in HIV Care: Missed Clinic Visits are Independently Associated with All-cause Mortality - (08/25/14)
     
  8114. ViiV Healthcare receives FDA approval for Triumeq® FDC - Dolutegravir/abacavir/3TC - (08/22/14)
     
  8115. IAC: Aging, Comorbidities - Inflammation/Activation-Gut, Complications - Bone, Neuro/Brain, Kidney, Heart Disease, HPV, Pnuemococcal disease - Adherence, Tolerability/Adverse Events (50 reports) - (08/22/14)
     
  8116. IAC: HIV Cure Reports, "Towards a Cure" Symposium at IAC - (08/21/14)
     
  8117. IAC: IAS pre-meeting "Towards a Cure" Symposium - written by David Margolis MD, UNC Chapel Hill - (08/21/14)
     
  8118. Beyond Core Indicators of Retention in HIV Care: Missed Clinic Visits are Independently Associated with All-cause Mortality - (08/20/14)
     
  8119. HCV Treatment & Barriers To Care in HIV/HCV-Coinfected - (08/18/14)
     
  8120. Gut/HIV-Vaccines/Neutralizing Antibodies/NIH Grant Process Unfair? - (08/18/14)
     
  8121. HIV Destroys Gut Immunity-new study - Gut Flora Influences HIV Immune Response - (08/18/14)
     
  8122. HIV and Stem Cell Transplantation - (08/18/14)
     
  8123. Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study - (08/18/14)
     
  8124. Proteinuria is Associated With Neurocognitive Impairment in Antiretroviral Therapy Treated HIV-Infected Individuals - (08/18/14)
     
  8125. IAC: Incidence and risk factors of HIV-infection among young men who have sex with men in Bangkok, Thailand - (08/15/14)
     
  8126. HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat - (08/15/14)
     
  8127. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection - (08/15/14)
     
  8128. Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes......HDACis exert negative effects - new study reports - (08/15/14)
     
  8129. IAC: Pharmacokinetics of VM-1500 20 mg and 40 mg in Healthy and HIV-Infected Patients - (08/13/14)
     
  8130. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 - (08/11/14)
     
  8131. CROI: ART in Earliest Stage of HIV Infection Preserves Cells That Maintain Gut Barrier - reverses activation...."argues for early & aggressive ART" - Mark Mascolini (08/11/14)
     
  8132. IAC: ART in Acute Infection Quells Inflammation But Does Not Restore Gut CD4s - (08/11/14)
     
  8133. IAC: Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. - (08/08/14)
     
  8134. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. - (08/08/14)
     
  8135. Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men - (08/08/14)
     
  8136. IAC: FUNCTIONAL CURE AND SEROREVERSION AFTER ADVANCED HIV DISEASE FOLLOWING 7 YEARS OF ANTIRETROVIRAL TREATMENT INTERRUPTION - (08/06/14)
     
  8137. IAC: Probiotic and IL-21 Treatment Promotes Th17 Cell Recovery in ARV-Treatment of Pigtail Macaques - (08/06/14)
     
  8138. IAC: HIV-Exposed Seronegative Men who have Sex with Men overexpress potential antiviral antiproteases in their rectal mucosa - (08/06/14)
     
  8139. IAC: Open label, randomized, crossover, single-dose, bioavailability evaluation of atazanavir/ritonavir FDC tablets 300 mg/100 mg with that of REYATAZ 300 mg and NORVIR 100 mg under fed and fasting conditions - (08/05/14)
     
  8140. IAC: Body mass index (BMI) and change in levels of immune activation post- ART initiation in diverse low- and middle-income settings - (08/05/14)
     
  8141. IAC: About 40% Who Get Under 50 Copies Have Residual Viremia in French Cohort - Mark Mascolini - (08/04/14)
     
  8142. IAC: Recent HIV Testing among U.S. Older Adults Since and Prior to Release of CDC's Routine HIV Testing Recommendations: National Findings based on the Behavioral Risk Factor Surveillance System (BRFSS) - (08/04/14)
     
  8143. IAC: IAC Plenary on HIV/Aging & NATAP Reports on HIV/Aging-Complications / HCV /Activation / Inflammation/Kidney/Anal Cancer-HSIL clearance/COPD/Neuro-Cognitive Disorders - (08/04/14)
     
  8144. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys - (08/04/14)
     
  8145. IAC: High Inflammation/Activation Markers Before and During ART Predict Death in MACS - Mark Mascolini - (08/04/14)
     
  8146. IAC: No HIV RNA or DNA, Negative Western Blot, After 7-Year ART Suspension - Mark Mascolini - (08/04/14)
     
  8147. IAC: Raltegravir May Offer Gut Microbe Advantages Compared With Nonnucleosides - Mark Mascolini - (08/04/14)
     
  8148. IAC: Health Workers Not Following CDC Advice on Testing Older Adults for HIV - Mark Mascolini - (08/04/14)
     
  8149. IAC: Sex on PrEP (08/04/14)
     
  8150. IAC: The burden of subclinical heart and lung disease detected on thoracic CT scans of HIV-infected individuals on antiretroviral therapy (08/04/14)
     
  8151. Cure setbacks force HIV researchers to reset sights - (08/01/14)
     
  8152. IAC: Raltegravir Regimen More Durable, Atazanavir Less Durable, Than Single-Tablet Atripla - Mark Mascolini - (08/01/14)
     
  8153. IAC: The HIV Care Cascade ("Cascade") Measured Over Multiple Time Periods Varies by Time Period and Method (08/01/14)
     
  8154. IAC: HPV VACCINATION IN HIV+ ADOLESCENTS AND YOUNG ADULTS INDUCES STRONG HPV-SPECIFIC CELL-MEDIATED IMMUNE RESPONSES (08/01/14)
     
  8155. IAC: HIV Prevention at AIDS 2014 - PrEP, TasP, PMTCT, Key Populations - Jared Baeten, MD PhD Kenneth Ngure, PhD, MPH Connie Celum, MD MPH University of Washington & Jomo Kenyatta University of Agriculture and Technology - (07/31/14)
     
  8156. IAC: Effect of monthly calcidiol supplementation on secondary hyperparathyroidism and bone mineral density in HIV-infected patients with vitamin D deficiency (07/31/14)
     
  8157. IAC: Darunavir (DRV)/r-based Postexposure Prophylaxis (PEP) versus standard of care (SOC) - quality of life in patients receiving PEP in a randomized study (PEPDar) (07/30/14)
     
  8158. IAC: Economic Burden of Adverse Events Associated With HIV Antiretroviral Therapy in the United States (07/30/14)
     
  8159. IAC: Monocyte activation markers remain significantly elevated in virologically suppressed HIV+ individuals to a level equivalent to an additional 4 years of normal ageing (07/30/14)
     
  8160. IAC: Safety and Efficacy of the Integrase Inhibitor-Based Stribild Single-Tablet Regimen in HIV-Infected Adolescents Through 24 Weeks of Treatment (07/29/14)
     
  8161. IAC: Pharmacokinetics of Boosted-Elvitegravir in Combination with Rifabutin, Utilizing Twice Daily Administration of Cobicistat to Overcome Induction (07/29/14)
     
  8162. IAC: Romidepsin HDAC Inhibitor Stimulates HIV from Reservoirs in Hunt to Find HIV Cure (07/29/14)
     
  8163. IAC: Treatment with the histone deacetylase inhibitor Panobinostat markedly reduces chronic inflammation in HIV-infected patients (07/29/14)
     
  8164. IAC: Real-World Adherence among Patients Receiving Single versus Multiple Tablet Regimens for HIV-1 Infection, and Associations between Adherence and Viral Suppression: A Systematic Literature Review and Meta- Analysis (07/29/14)
     
  8165. IAC: Cost-Effectiveness of Single versus Multiple Tablet Regimens for Treatment of HIV-1 Infection in the US (07/29/14)
     
  8166. IAC: Do Single Tablet Regimens Translate into More Durable HIV Treatments? Evidence from the Canadian Observational Cohort (CANOC) (07/29/14)
     
  8167. IAC: Monthly Vitamin D May Improve Bone Density in People With HIV - Mark Mascolini (07/28/14)
     
  8168. Translational challenges in targeting latent HIV infection and the CNS reservoir problem - (07/28/14)
     
  8169. Drug Use Among Gay and Bisexual Men at Weekend Dance Parties: The Role of Intentions and Perceptions of Peers' Behaviors - (07/28/14)
     
  8170. IAC: Ole, Pre-Exposure Prohylaxis (PrEP) Initiative: Open Label Extension - "Adherence Has To Be Good, Not Perfect," Say MSM PrEP Study Researchers - (07/28/14)
     
  8171. IAC: Allogeneic bone marrow transplantation in two HIV-1 infected patients shows no detectable HIV-1 RNA or DNA, and a profound reduction in HIV-1 antibodies - (07/28/14)
     
  8172. IAC: Tenofovir(TFV), Emtricitabine(FTC), Intracellular Metabolite, and Endogenous Nucleotide (EN) Concentrations as a Function of Aging in HIV+ Subjects - (07/28/14)
     
  8173. IAC: SIV-infected rhesus macaques receiving suppressive cART have continued GI damage, inflammation, immune activation and persistent low-level viral replication within lymphoid tissues..."Suggesting that HIV Cure strategies will need to address sources of residual inflammation/immune activation to be successful" - (07/28/14)
     
  8174. IAC: Efficacy and Safety of Dolutegravir Relative to Commonly-Used 3rd-Agents at 96 Weeks in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-analysis - (07/28/14)
     
  8175. IAC: Measuring Patient Views of HIV Treatments: Comparing Dolutegravir With Darunavir/r in the FLAMINGO Study - (07/28/14)
     
  8176. IAC: Diminished Physical Function in Older HIV+ Adults Despite Successful Antiretroviral Therapy - (07/28/14)
     
  8177. IAC: Week 144 Renal Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) from Two Phase 3 Randomized Controlled Trials - (07/28/14)
     
  8178. IAC: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) in HIV-Infected Patients with Mild to Moderate Renal Impairment - (07/28/14)
     
  8179. IAC: STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Maintains Non-Inferiority to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults through Week 96 with a Favorable Safety Profile for Abnormal Dreams and Dizziness - (07/28/14)
     
  8180. IAC: STRATEGY Studies (GS-115 and GS-121): Safety Analysis of Switching to STB from a RTV-Boosted PI or NNRTI Plus TVD Regimen - (07/28/14)
     
  8181. IAC: Obesity Doubles Chances of More Inflammation and Monocyte Activation With HIV - written by Mark Mascolini - (07/28/14)
     
  8182. IAC: Activation Marker Levels With Undetectable Viral Load Match Those of Uninfected People 4 Years Older - written by Mark Mascolini - (07/28/14)
     
  8183. IAC: Time to Viral Suppression With ART for Acute HIV in Pregnancy - written by Mark Mascolini - (07/28/14)
     
  8184. IAC: Pneumococcal Disease Rate Drops in HIV Group But Still Far Exceeds HIV-Negative Rate - written by Mark Mascolini - (07/28/14)
     
  8185. IAC: Gait Speed in Older HIV Group Not Fast Enough to Cross Street Safely - written by Mark Mascolini - (07/28/14)
     
  8186. IAC: SAPPHIRE-II Subgroup Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-experienced Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)
     
  8187. IAC: Neurocognitive Disorder Rates Differ by US vs Local Standards in Australian MSM - Mark Mascolini - (07/25/14)
     
  8188. IAC: No Detectable HIV RNA or DNA in 2 Bone Marrow Transplant Patients Still on ART - Mark Mascolini - (07/25/14)
     
  8189. IAC: Why Undiagnosed HIV and HIV Incidence Are Falling in SF MSM and Static in London MSM - Mark Mascolini - (07/25/14)
     
  8190. IAC: Resistance Mutations Persist in HIV DNA After 12 Years With Undetectable Viral Load - Mark Mascolini - (07/25/14)
     
  8191. IAC: Predictors of Neurocognitive Decline and Rebound in US CHARTER Group - Mark Mascolini - (07/25/14)
     
  8192. IAC: HARNESS study: ritonavir-boosted atazanavir (ATV/r)+raltegravir (RAL) switch study in virologically suppressed, HIV-1-infected patients - (07/25/14)
     
  8193. IAC: Comparing the incidence and identifying risk factors for nephrolithiasis among patients exposed to atazanavir, other PIs and PI-free regimens - (07/25/14)
     
  8194. IAC: Longer ART, Better CD4 Gain Protect From Neurocognitive Decline in ACTG Analysis - written by Mark Mascolini - (07/25/14)
     
  8195. IAC: Incidence and clearance of anal high-grade squamous intraepithelial lesions (HSIL) in HIV positive and HIV negative homosexual men (07/25/14)
     
  8196. Finding a Cure for HIV: Much Work to Do Editorial - (07/24/14)
     
  8197. IAC: MODERN Study - Maraviroc (MVC) Once Daily With Darunavir/Ritonavir(DRV/r) Compared to Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: 48-Week Results From MODERN - ViiV Press Release (07/24/14)
     
  8198. IAC: Anal Cancer Precursor More Common in HIV+ Than HIV- MSM; Clearance Rate High - written by Mark Mascolini - (07/24/14)
     
  8199. IAC: Inflammatory Cytokine/IL-10 Ratios Tied to Regional Brain Atrophy With HIV - written by Mark Mascolini - (07/24/14)
     
  8200. IAC: Efavirenz Not Tied to Neurocognitive Impairment in Large Single-Center Study - written by Mark Mascolini - (07/24/14)
     
  8201. IAC: Inflammation/Activation Markers Drop With ATV, DRV, RAL, But Not Completely - ACTG Study - written by Mark Mascolini - (07/23/14)
     
  8202. IAC: Higher One-Year Risk of CVD or Diabetes Per BMI Unit Gained on ART - written by Mark Mascolini - (07/23/14)
     
  8203. IAC: Early Data Show Good Adherence to Intermittent PrEP by MSM in French Trial - written by Mark Mascolini - (07/23/14)
     
  8204. IAC: COPD Rate 7% in Global HIV Cohort--Half With COPD Never Smoked - written by Mark Mascolini - (07/23/14)
     
  8205. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study - (07/23/14)
     
  8206. Moving HIV PrEP from research into practice - Commentary - (07/23/14)
     
  8207. IAC: Once-Daily Maraviroc Inferior to TDF/FTC in First-Line Regimens With Darunavir - written by Mark Mascolini - (07/23/14)
     
  8208. IAC: Effect of viral suppression below 20 copies of HIV-RNA /mL of plasma on virological outcome of treated HIV- infected patients - (07/23/14)
     
  8209. IAC: Failure Risk Similar With 20 to 50 Copies and Always Under 20 Copies - written by Mark Mascolini - (07/23/14)
     
  8210. IAC: Switching From First-Line ART When Suppressed Boosts Failure Chance - written by Mark Mascolini - (07/23/14)
     
  8211. IAC: Quadrivalent HPV Vaccine Elicits Antibody and Cell Responses in HIV+ Teens, Young Adults - written by Mark Mascolini - (07/23/14)
     
  8212. IAC: Good Response and Resistance Record in Naive and Experienced Starting Dolutegravir - written by Mark Mascolini - (07/23/14)
     
  8213. IAC: Successful ART Started Under Age 6 Months More Likely to Yield Negative Antibody Test - written by Mark Mascolini - (07/22/14)
     
  8214. IAC: Virologic Failure Predictors in SECOND-LINE Trial of Raltegravir vs NRTIs (07/22/14)
     
  8215. IAC: The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays (07/22/14)
     
  8216. IAC: DTG-Based Regimens Are Active in INI-Naive Patients With a History of NRTI Resistance (07/22/14)
     
  8217. IAC: Maraviroc (MVC) Once Daily With Darunavir/Ritonavir(DRV/r) Compared to Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: 48-Week Results From MODERN (Study A4001095) (07/22/14)
     
  8218. IAC: cART in First Days of Life Limits Viral Reservoir Size in 4 Canadian Children - written by Mark Mascolini - (07/22/14)
     
  8219. IAC: TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 (07/21/14)
     
  8220. IAC: High Response Rates With Triple-DAA Regimen in People With HCV and HIV: Abbvie 3D - ABT-450/ritonavir, ombitasvir, and dasabuvir, with ribavirin - written by Mark Mascolini - (07/21/14)
     
  8221. IAC: SVR12 Rate 97% With 3 DAAs Plus Ribavirin in People on Opioid Replacement - written by Mark Mascolini - (07/21/14)
     
  8222. IAC: High Response Rates With Triple-DAA Regimen in People With HCV and HIV - written by Mark Mascolini - (07/21/14)
     
  8223. IAC: SVR12 Rate 97% With 3 DAAs Plus Ribavirin in People on Opioid Replacement - written by Mark Mascolini - (07/21/14)
     
  8224. IAC: High SVR12 With Sofosbuvir/Ribavirin in HCV/HIV-Coinfected: PHOTON-2 - written by Mark Mascolini - (07/21/14)
     
  8225. IAC: Liver Markers Worse in Youth With Than Without HIV and Climb Over Time - Written by Mark Mascolini (07/21/14)
     
  8226. Social Discrimination and Resiliency Are Not Associated With Differences in Prevalent HIV Infection in Black and White Men Who Have Sex With Men - "our findings suggest that the perceived social discrimination does not explain the striking racial disparity in HIV infection between black and white MSM" - (07/21/14)
     
  8227. "Prostate cancer incidence rates are lower in HIV-positive compared with HIV-negative men, which is not explained by screening differences or the risk factors evaluated." Study reports - (07/21/14)
     
  8228. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor - (07/16/14)
     
  8229. PrEP Article in New York Magazine published July 13 2014/ new WHO Recommendation/ new CDC Recommendation - (07/16/14)
     
  8230. NYS PrEP Plan - (07/16/14)
     
  8231. Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide: An Analysis of Trial Data - (07/14/14)
     
  8232. Has the time come to abandon efavirenz for first-line antiretroviral therapy? - (07/14/14)
     
  8233. Reactivation of HIV latency by a newly modified Ingenol derivative - new group of compounds, Ingenol derivatives - (07/14/14)
     
  8234. Epicardial adipose tissue and atherogenesis: EAT your heart out EDITORIAL - (07/14/14)
     
  8235. Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food - (07/14/14)
     
  8236. New Lipodystrophy-'Sick Fat' Around the Heart in HIV+ Predicts Heart Disease: bad atypical fat independently predict measures of cardiovascular disease and atherosclerosis in HIV...... - (07/14/14)
     
  8237. "Mississippi Baby" Now Has Detectable HIV, Researchers Find - (07/14/14)
     
  8238. Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-infected Subjects on Antiretroviral Therapy: the SATURN-HIV Trial - heart, kidney, bone diseases, inflammation - (07/14/14)
     
  8239. Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection - Review - (07/14/14)
     
  8240. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study - (07/14/14)
     
  8241. Fracture risk in hepatitis C virus infected persons: Results from the DANVIR cohort study - (06/30/14)
     
  8242. Nutrition: Vitamins on trial - (06/30/14)
     
  8243. A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, ART-Naive Subjects - (06/23/14)
     
  8244. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial - (06/16/14)
     
    8245. HIV & Aging: Failure to Normalize Immunity Despite Decade of Successful HAART - (06/16/14)
     
    HIV & Aging: HIV and the aging kidney - (06/16/14)
     
    HIV & Aging: Biologic aging, frailty, and age-related disease in chronic HIV infection - (06/16/14)
     
    HIV & Aging: Immunosenescence and aging in HIV - (06/16/14)
     
    HIV & Aging: Update on metabolic issues in HIV patients - (06/16/14)
     
    HIV & Aging: Coping styles and illicit drug use in older adults with HIV/AIDS - (06/16/14)
     
    HIV & Aging: Psychosocial, mental health, and behavioral issues of aging with HIV - (06/16/14)
     
    HIV & Aging: Demographics of HIV and aging - (06/16/14)
     
    HIV & Aging: African Americans, Hispanics, Caucasians (2 MACS Studies) - (06/09/14)
     
  8245. Sex on demand: geosocial networking phone apps and risk of sexually transmitted infections among a cross-sectional sample of men who have sex with men in Los Angeles county - (06/13/14)
     
  8246. ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1 - (06/12/14)
     
  8247. Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV - (06/12/14)
     
  8248. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy - (06/12/14)
     
  8249. Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV - (06/12/14)
     
  8250. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy - (06/12/14)
     
  8251. 15th Intl Wrkshp Clinical Pharm HIV Therapy The 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Assistant Professor School of Pharmacy University of Colorado at Denver - (06/11/14)
     
  8252. 15th Intl Wrkshp Clinical Pharm HIV Therapy Week 48 pharmacokinetic and pharmacodynamic results of darunavir 800mg once daily when co-administered with cobicistat 150mg once daily in HIV-1-infected patients with no darunavir resistance-associated mutations: GS-US-216-0130 - (06/11/14)
     
  8253. New HHS HIV ART Guidelines for Adults, Adolescents - (06/11/14)
     
  8254. New Exercise/Diet Study.....lower inflammation/better metabolics/more diverse gut microbia - (06/11/14)
     
  8255. Intl Wrkshp on Antiviral Drug Resistance: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Primary Week 24 Analysis of Emergent Drug Resistance - (06/09/13)
     
  8256. Frailty & aging: African Americans, Hispanics, Caucasians (2 MACS Studies) - (06/09/14)
     
  8257. First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir) - (06/09/14)
     
  8258. Raltegravir New Formulation Once-Daily PK/Isentress Once-Daily Regimen Phase 3 Enrolling - (06/09/14)
     
  8259. HIV treatment [zinc fingers] study clears virus, sends Sangamo stock soaring - (06/09/14)
     
  8260. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial - (06/09/14)
     
  8261. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial - (06/09/14)
     
  8262. HIV immunity goes direct - Gene Therapy - (06/09/14)
     
  8263. Research into a functional cure for HIV in neonates: the need for ethical foresight - (06/09/14)
     
  8264. Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies - (06/09/14)
     
  8265. Frailty in people aging with human immunodeficiency virus (HIV) infection - (06/09/14)
     
  8266. Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects (2008) - (06/09/14)
     
  8267. Intl Wrkshp on Antiviral Drug Resistance: Doravirine (MK-1439): A Novel HIV-1 NNRTI With a Distinct Resistance Profile (06/06/13)
     
  8268. Intl Wrkshp on Antiviral Drug Resistance: Raltegravir (RAL) Resistant Isolates without Primary RAL Integrase (IN) Mutations are Cross-resistant to Elvitegravir (EVG) but not Dolutegravir (DTG) (06/06/13)
     
  8269. Intl Wrkshp on Antiviral Drug Resistance: An Analysis of Minor Variants in HIV-1 Integrase (IN) for Subjects With Only Historic Evidence of Integrase Inhibitor (INI) Resistance Enrolled in Study ING112574 (VIKING-3) (slide presentation, poster to follow) (06/06/13)
     
  8270. Intl Wrkshp on Antiviral Drug Resistance: Excellent Virological and Immunological Response to Dolutegravir despite Extensive RT, PR and INI Resistance (06/06/13)
     
  8271. CROI: NOVEL INTERVENTIONS TO TARGET INCREASED INFLAMMATION IN HIV-INFECTED INDIVIDUALS - (06/05/14)
     
  8272. Aging/HIV - Premature aging/Stress, Anxiety, Lifetime/Childhood Trauma, Race/Gender - (06/03/14)
     
  8273. Cervical Inflammation and Immunity Associated With Hormonal Contraception, Pregnancy, and HIV-1 Seroconversion - (06/01/14)
     
  8274. Social and ethical implications of HIV cure research - (06/01/14)
     
  8275. Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. - (06/01/14)
     
  8276. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV - (05/29/14)
     
  8277. HIV-1 Drug Resistance in the iPrEx Pre-Exposure Prophylaxis Trial - (05/29/14)
     
  8278. 15th Intl Wrkshp Clinical Pharm HIV Therapy Rectal Tenofovir Gel Yields Much Higher Rectal and Vaginal Levels Than Oral Tenofovir - (05/29/14)
     
  8279. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Safety of Tenofovir Alafenamide in Subjects With Mild or Moderate Hepatic Impairment - (05/29/14)
     
  8280. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Safety of Tenofovir Alafenamide in Subjects With Mild or Moderate Hepatic Impairment - (05/29/14)
     
  8281. 15th Intl Wrkshp Clinical Pharm HIV Therapy Raltegravir Levels With Once-Daily Dosing in French Observational Study - Mark Mascolini - (05/27/14)
     
  8282. CROI: A Multiple Dose Study of Raltegravir Formulations - (05/27/14)
     
  8283. 15th Intl Wrkshp Clinical Pharm HIV Therapy Unbound Darunavir Above Wild-Type EC50 With Once-Daily Dose in Pregnancy - Mark Mascolini - (05/23/14)
     
  8284. 15th Intl Wrkshp Clinical Pharm HIV Therapy DRV CONCENTRATIONS AND VIRAL LOAD IN CSF OF PATIENTS ON DRV/r 600/100 OR 800/100 mg ONCE DAILY, PLUS TWO NRTI - (05/23/14)
     
  8285. 15th Intl Wrkshp Clinical Pharm HIV Therapy Thorough QT/QTc Trial to Evaluate the Effect of the HIV-1 Attachment Inhibitor BMS-626529, Administered as its Prodrug, BMS-663068, on QTc Intervals - (05/23/14)
     
  8286. 15th Intl Wrkshp Clinical Pharm HIV Therapy A Mechanistic SimCYP Simulation Evaluating Dolutegravir and Efavirenz Pharmacokinetics Following a Switch From Once-daily Efavirenz to Once-daily Dolutegravir - (05/22/14)
     
  8287. 15th Intl Wrkshp Clinical Pharm HIV Therapy A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate - (05/22/14)
     
  8288. 15th Intl Wrkshp Clinical Pharm HIV Therapy Maraviroc and Raltegravir Quickly Distributed in Female Genital Tract - Mark Mascolini (05/22/14)
     
  8289. 15th Intl Wrkshp Clinical Pharm HIV Therapy Unbound Darunavir Above Wild-Type EC50 With Once-Daily Dose in Pregnancy - Mark Mascolini - (05/22/14)
     
  8290. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetic of raltegravir (800 mg) once-daily in switching strategies in HIV-1-infected patients with suppressed viremia - (05/21/14)
     
  8291. 15th Intl Wrkshp Clinical Pharm HIV Therapy Mucosal Tissue Pharmacokinetics of Maraviroc and Raltegravir in Women: Implications for Chemoprophylaxis [PrEP, Mucosal Tissue Compartments PK] - (05/21/14)
     
  8292. 15th Intl Wrkshp Clinical Pharm HIV Therapy Reduced Darunavir Dose Is as Effective in Maintaining HIV Suppression as the Standard Dose in Virologically Suppressed HIV-Infected Patients. The DRV600 Study - (05/21/14)
     
  8293. 15th Intl Wrkshp Clinical Pharm HIV Therapy In Vitro Drug Interaction Profile of the HIV Integrase Inhibitor, GSK1265744, and Demonstrated Lack of Clinical Interaction with Midazolam - (05/21/14)
     
  8294. 15th Intl Wrkshp Clinical Pharm HIV Therapy The Effect of Calcium and Iron Supplements on the Pharmacokinetics of Dolutegravir in Healthy Subjects - (05/21/14)
     
  8295. 15th Intl Wrkshp Clinical Pharm HIV Therapy Population PK-PD Analysis of 400 mg vs. 600 mg Efavirenz Once Daily in Treatment-Naïve HIV Patients at 48 Weeks: Results of the ENCORE1 Study - (05/21/14)
     
  8296. 15th Intl Wrkshp Clinical Pharm HIV Therapy Estimated Time to Protection and Duration of Protection With Daily TDF/FTC PrEP - written by Mark Mascolini - (05/21/14)
     
  8297. Pre-exposure prophylaxis to intensify the fight against HIV (2 publications below); HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial - (05/20/14)
     
  8298. 15th Intl Wrkshp Clinical Pharm HIV Therapy Maintenance With Lower-Dose Darunavir in Virologically Suppressed - written by Mark Mascolini - (05/20/14)
     
  8299. 15th Intl Wrkshp Clinical Pharm HIV Therapy Efavirenz Dose and Genotype Do Not Affect 48-Week Response in Low/Standard-Dose Trial - written by Mark Mascolini - (05/20/14)
     
  8300. 15th Intl Wrkshp Clinical Pharm HIV Therapy Calcium and Iron Supplements Lower Dolutegravir Levels When Taken Between Meals - written by Mark Mascolini - (05/20/14)
     
  8301. HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy - (05/19/14)
     
  8302. Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11) AND COMMENTARY follows below by Lynne M. Mofenson, D. Heather Watts - (05/19/14)
     
  8303. Zinc-finger Functional HIV Cure - Zinc-finger endonuclease targeting PSIP-1 inhibits HIV-1 integration - (05/19/14)
     
  8304. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection - (05/15/14)
     
  8305. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence - (05/15/14)
     
  8306. CDC Recommends PrEP Truvada "CDC recommends that PrEP is indicated for people who do not have HIV and are at substantial risk for HIV" - (05/15/14)
     
  8307. The transmembrane proteins contribute to immunodeficiencies induced by HIV-1 and other retroviruses - (05/09/14)
     
  8308. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000 - (05/09/14)
     
  8309. Zinc-finger nucleases make the cut in HIV [to Control HIV, "avoid taking drugs for the rest of their lives"] - (05/02/14)
     
  8310. CROI: Using HIV Networks to Inform Real Time Prevention Interventions - (05/02/14)
     
  8311. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies - (05/01/14)
     
  8312. CROI: Natural History of HIV-related Anal Dysplasia: A Multi-state Modeling Analysis - (04/28/14)
     
  8313. Risk of Melanoma in People with HIV/AIDS in the Pre- and Post-HAART Eras: A Systematic Review and Meta-Analysis of Cohort Studies - (04/25/14)
     
  8314. CROI: Impact of Low CD4 Count and HIV Persistence on Endothelial Function in Patients with Low Plasma RNA - (04/22/14)
     
  8315. Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study - (04/21/14)
     
  8316. CROI: Drug Resistance Mutations in Treatment-Naïve HIV-Infected Patients 2000-2013; [Integrase Mutations Transmitted Low (1)] - (04/21/14)
     
  8317. CROI: GSK1265744 Demonstrates Robust in Vitro Activity Against Various Clades of HIV-1 - (04/21/14)
     
  8318. CROI: Lessons from the 21st CROI - Integrating Data into Antiretroviral Treatment in the Clinic - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (04/21/14)
     
  8319. HIV eradication-from Berlin to Boston - (04/10/14)
     
  8320. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV (Zinc fingers) - (04/10/14)
     
  8321. Cyclophosphamide Enhances SB-728-T (zinc fingers) Engraftment to Levels Associated with HIV-RNA Control - (04/10/14)
     
  8322. Engineering Cellular Resistance to HIV (zinc fingers) - Editorial - (04/10/14)
     
  8323. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children - (04/10/14)
     
  8324. Persistent HIV infection in newborns: how soon is soon enough? Editorial Comments - (04/10/14)
     
  8325. Diet, Dementia, Cognitive Impairment, Diabetes: type of foods & cooking affects impact - (04/07/14)
     
  8326. Diet/Diseases/Inflammation/Survival - Oral Glycotoxins (AGEs) Determine the Effects of Calorie Restriction on Oxidant Stress, Age-Related Diseases, and Lifespan - (04/07/14)
     
  8327. CROI: Is there continued evidence for an association between abacavir and myocardial infarction risk? - (04/07/14)
     
  8328. CROI: HIV, Chronic Inflammation, and CVD: Report back from the 2014 Conference on Retroviruses and Opportunistic Infections - Priscilla Hsue, MD Professor of Medicine, UCSF Cardiology Division - (04/07/14)
     
  8329. CROI: Metabolics and Aging at CROI 2014 - David Alain Wohl, MD - The University of North Carolina - (04/06/14)
     
  8330. CROI: Inflammation in Acute HIV Infection Correlates with Blood and Gut CD4 T-cell Loss and HIV Viral Burden - (04/05/14)
     
  8331. CROI: CMV and HIV: A Double Hit On the CD4/CD38 Ratio - (04/04/14)
     
  8332. HIV-Infected Men at Increased Risk for Heart Disease, Large NIH Study Finds - (04/03/14)
     
  8333. HIV and Atherosclerosis: Moving From Associations to Mechanisms and Interventions - Editorials - (04/03/14)
     
  8334. Diet, Dementia, Cognitive Impairment, Diabetes Intersect - (04/03/14)
     
  8335. Postexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors/Raltegravir - (04/03/14)
     
  8336. CROI: Clinical Pharmacology at CROI 2014 Courtney V. Fletcher, Pharm.D. Dean and Professor Anthony T. Podany, Pharm.D. Post-Doctoral Fellow College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (04/03/14)
     
  8337. CROI: CD4:CD38 Ratio Remains Significantly Depressed Despite Viral Suppression With Effective ART - (04/02/14)
     
  8338. CROI: A Low CD4/CD38 Ratio During Effective ART Predicts Immunosenescence and Morbidity/Mortality - (04/02/14)
     
  8339. CROI: PrEP at CROI, Uptake - MSM, IDUs, Meth Use - (04/02/14)
     
  8340. CROI: Pharmacokinetics, Efficacy and Safety of an Integrase Inhibitor-Based Single-Tablet Regimen in HIV-Infected Treatment-Naïve Adolescents - (04/01/14)
     
  8341. CROI: Sex-related Inflammatory Marker Changes Pre and Post Antiretroviral Treatment (ART) Initiation - (04/01/14)
     
  8342. CROI: Rilpivirine pharmacokinetics in HIV-1-infected adolescents: a substudy of PAINT (Phase II trial) - (04/01/14)
     
  8343. CROI: HIV-replication control rates needed to prevent Neurocognitive Performance (NP) decline - (04/01/14)
     
  8344. CROI: Effective Exposure to Atazanavir during Pregnancy, Regardless of Tenofovir Use - (04/01/14)
     
  8345. CROI: Prevalence of Congenital Anomalies in Infants With In Utero Exposure to Antiretrovirals - (04/01/14)
     
  8346. CROI: Congenital Anomalies and in utero Antiretroviral Exposure in HIV-exposed Uninfected Infants - (04/01/14)
     
  8347. Abnormal Newborn Screens and Acylcarnitines in HIV-exposed and ARV-exposed Infants - (04/01/14)
     
  8348. CROI: Abnormal fatty acid oxidation in HIV-exposed, uninfected neonates in the US - (04/01/14)
     
  8349. CROI: Bioequivalence of Two Pediatric Formulations Vs Adult Tablet Formulation of Cobicistat - (04/01/14)
     
  8350. CROI: Bioequivalence of Two Pediatric Formulations Vs Adult Tablet Formulation of Elvitegravir - (04/01/14)
     
  8351. CROI: Safety Pharmacokinetics and Efficacy of Dolutegravir in Treatment Experienced HIV + Children - (04/01/14)
     
  8352. CROI: Safety and Efficacy of Dolutegravir in HIV Treatment-Experienced Adolescents: 48-Week Results - (04/01/14)
     
  8353. CROI: Osteoporosis (bone), Frailty, and Vitamin D: CROI 2014 - Todd T. Brown, MD, PhD Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University - (04/01/14)
     
  8354. CROI: Mechanism of Bone Disease in HIV and HCV: Impact of Tenofovir Exposure and Severity of Liver Disease - (04/01/14)
     
  8355. Once-Daily Regimens Modestly Improve Adherence, Not Viral Control, in Meta-Analysis - (03/28/14)
     
  8356. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials - (03/28/14)
     
  8357. Protein Protects Aging Brain....new research published....NIH HIV Brain Research Studies - (03/28/14)
     
  8358. CROI: The Kidney at CROI 2014 -Christina M. Wyatt, MD Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY - (03/25/14)
     
  8359. CROI: Rosuvastatin Reduces Immune Activation and Inflammation in Treated HIV Infection - (03/28/14)
     
  8360. CROI: Rosuvastatin Lowers Cystatin C in HIV-infected Subjects on Antiretroviral Therapy: SATURN-HIV - (03/28/14)
     
  8361. CROI: Atazanavir and Tenofovir Attenuate the Benefit of Antiretroviral Therapy on Cystatin C: ACTG A5224s - (03/28/14)
     
  8362. CROI: Implementation of PrEP in STD Clinics and a Community Health Center: High Uptake and Drug Levels among MSM in the Demo Project - (03/28/14)
     
  8363. CROI: Willingness to Use Pre-Exposure Prophylaxis Among Community-Recruited Injection Drug Users - (03/28/14)
     
  8364. CROI: Early Adopters: Socio-demographic and Behavioral Correlates of Chemoprophylaxis Use in a Recent National Online Sample of Men who have Sex with Men in the U.S. - (03/28/14)
     
  8365. CROI: PrEP Interest, Uptake and Adherence among Young Men Who Have Sex with Men (YMSM) in the United States - (03/28/14)
     
  8366. CROI: Contingency Management Facilitates PEP Completion among Stimulant-Using MSM - (03/28/14)
     
  8367. CROI: HIV Infection and the Risk of Cardiovascular Disease in Women - (03/28/14)
     
  8368. CROI: HIV Infection and the Risk of Cardiovascular Disease in Women - (03/26/14)
     
  8369. CROI: HIV Pathogenesis, Innate Defense against HIV, and HIV Cure at CROI 2014, Boston - By David Margolis MD UNC Chapel Hill & the Collaboratory of AIDS Researchers for Eradication (CARE) (03/25/14)
     
  8370. CROI: 21st Conference on Retroviruses and Opportunistic Infections: Review - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/21/14)
     
  8371. CROI: Faster Lung Function Decline With HIV Linked to sCD14 Activation Marker - written Mark Mascolini - (03/21/14)
     
  8372. CROI: Spine/Hip Bone Density Drops More in 96 Weeks With PIs Than With Raltegravir - written Mark Mascolini - (03/21/14)
     
  8373. CROI: FIB-4 Alone Proves Best Predictor of ESLD in People With HCV/HIV - written Mark Mascolini - (03/21/14)
     
  8374. CROI: Post-SVR Liver Decompensation Rate Similar With HCV/HIV and HCV Alone - written Mark Mascolini - (03/21/14)
     
  8375. CROI: Antiviral Therapy and Smoking Associated with Coronary Vessel Wall Thickening in HIV-Infected Youth - (03/21/14)
     
  8376. CROI: Lower CD4 Count, Detectable Viral Load, & Traditional CVD Risk Factors are Associated with Increased Risk of Primary Myocardial Infarction in the CNICS cohort....IDU associated with secondary MI - (03/21/14)
     
  8377. CROI: Inflammation/Viral Replication/HIV Persistence....Reservoirs....Anti-Inflammation HIV Cure Strategies....VX-765, a small-molecule inhibitor of caspase-1, a potential anti-inflammatory drug/Cure Strategy to reduce reservoir?????......IP-10.... anti-inflammatory/HIV Cure strategy - (03/21/14)
     
  8378. CROI: CROI 2014: Inflammation in HIV.....HIV cure, comorbidities, interventions to reduce inflammation - David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine (03/21/14)
     
  8379. CROI: Abdominal Obesity, Inflammation, Immune Activation and Neurocognitive Impairment - (03/19/14)
     
  8380. CROI: Blood Cell Indices and Neurocognitive Impairment in the HAART Era: A CHARTER Study - (03/19/14)
     
  8381. CROI: Determinants of Cognitive Impairment in HIV-positive Men on cART and Uninfected Controls: HIV, immune activation - (03/19/14)
     
  8382. CROI: HIV-1 Replication in Central Nervous System Increases over Time on Protease Inhibitor Only Therapy - (03/19/14)
     
  8383. CROI: Impact of Smoking on Life Expectancy among HIV-Infected Individuals: The ART Cohort Collaboration - (03/19/14)
     
  8384. CROI: Number and Diversity of Gut Microbes Lower With HIV and Tied to Activation - written by Mark Mascolini - (03/19/14)
     
  8385. CROI: Lower CD4 Nadir Linked to Geriatric Syndromes in 50-or-Older People - written by Mark Mascolini - (03/19/14)
     
  8386. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study; HIV & HCV/HIV Bone Loss - (03/19/14)
     
  8387. CROI: Impact of Plasma HIV RNA on Neurocognitive Decline --and Difference With PIs vs NNRTIs - written by Mark Mascolini - (03/18/14)
     
  8388. CROI: Greater Bone Deficits Seen in Young US Men Infected at Birth Versus in Adolescence....bone senescence - written by Mark Mascolini - (03/18/14)
     
  8389. CROI: Higher Lipids Raise Acute MI Risk 22% to 64% in Untreated HCV RNA+ Veterans - written by Mark Mascolini - (03/18/14)
     
  8390. CROI: One Quarter of HIV+ Smoker Group Has COPD--Risk Lower With Higher CD4s - written by Mark Mascolini - (03/18/14)
     
  8391. CROI: More Life Years Lost Through Smoking Than HIV in 18,000-Person Analysis - written by Mark Mascolini - (03/18/14)
     
  8392. CROI: Low/Moderate Alcohol Drinking Trims Heart Disease-Free Death Risk in HIV+ Swiss - written by Mark Mascolini - (03/18/14)
     
  8393. CROI: Partner Support Does Not Improve Second-Line Response in Randomized Trial - written by Mark Mascolini - (03/18/14)
     
  8394. CROI: Three ART Regimens Don't Differ in 144-Week "Target Not Detected" Response - written by Mark Mascolini - (03/18/14)
     
  8395. CROI: Impact of Low-Level Viremia on Clinical and Virological Outcomes in Treated HIV-Infected Patients - (03/14/14)
     
  8396. Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine - (03/14/14)
     
  8397. CROI: Cancers in HIV+ at CROI - (03/14/14)
     
  8398. CROI: Correlation between atazanavir concentrations, clinical covariates and side effects - (03/14/14)
     
  8399. CROI: Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures - (03/14/14)
     
  8400. CROI: Impact of Smoking on Risk of Cancer among HIV patients Compared to the Background Population - (03/14/14)
     
  8401. CROI: GSK1265744 Long-Acting Protects Macaques against Repeated High-Dose Intravaginal Challenges & Depo Provera-treated - (03/14/14)
     
  8402. CROI: The Clinical Impact of Viral Load Copy Years in Antiretroviral-Naïve HIV Seroconverters - (03/14/14)
     
  8403. CROI: Cumulative Viral Load Predicts All-cause and AIDS-related Mortality After Initiation of ART - (03/14/14)
     
  8404. CROI: Brisk Walking Improves Inflammatory Markers in cART-Treated Patients - (03/14/14)
     
  8405. CROI: Physical Function Impairment on Quality of Life among Persons Aging with HIV Infection - (03/14/14)
     
  8406. CROI: Dolutegravir Regimen Statistically Superior to Efavirenz/Tenofovir/Emtricitabine: 96-Week Results From the SINGLE Study (ING114467) - (03/12/14)
     
  8407. CROI: Dolutegravir in the French Named Patient Program* in Integrase HIV-2 Resistant Infected Patients - (03/12/14)
     
  8408. CROI: Switch from NNRTI plus FTC/TDF to Elvitegravir/C/F/TDF Maintains HIV Suppression and is Well-Tolerated - (03/12/14)
     
  8409. CROI: Simplification of PI + RTV + FTC/TDF to Elvitegravir/C/F/TDF Maintains HIV Suppression and is Well-Tolerated - (03/12/14)
     
  8410. CROI: HIV Prevention at CROI 2014 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/13/14)
     
  8411. CROI: Post-Transplant Survival Lower With HIV and HCV-1 Than With HCV-1 Alone - written by Mark Mascolini - (03/12/14)
     
  8412. CROI: HIV-Immune Complex Kidney Disease: Risk Factors and Progression to End-Stage Kidney Disease - (03/12/14)
     
  8413. CROI: A Chronic Kidney Disease Risk Score to Determine Tenofovir Safety in a Prospective Cohort of HIV+ Male Veterans - (03/12/14)
     
  8414. CROI: End-stage kidney disease and kidney transplantation in HIV positive patients - (03/12/14)
     
  8415. CROI: Stopping TDF Before Renal Impairment Boosts Chance of Improving eGFR - written by Mark Mascolini - (03/12/14)
     
  8416. CROI: Heavy Popper Use in Gay MACS Cohort Linked to New Heart Disease, Cancer - written by Mark Mascolini - (03/12/14)
     
  8417. CROI: Spleen and Bone Marrow May Be Key Players in Arterial Inflammation With HIV - written by Mark Mascolini - (03/12/14)
     
  8418. CROI: Drops in AIDS Deaths, Some non-AIDS Deaths Parallel ART Expansion in British Columbia - written by Mark Mascolini - (03/12/14)
     
  8419. CROI: HIV Rebounds Detailed in Two Boston Stem Cell Transplant Patients - written by Mark Mascolini - (03/12/14)
     
  8420. Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results - (03/10/14)
     
  8421. Boosting HIV Treatment Options (Cobi, RTV): Good News, New Challenges - Editorial Comment - (03/10/14)
     
  8422. CROI: Atazanavir/Cobicistat Fixed-Dose Combination is Bioequivalent to the Separate Agents - (03/10/14)
     
  8423. CROI: Bone quality determination by ultrasonometry in young South African HIV-infected children - (03/10/14)
     
  8424. CROI: Geriatric Syndromes are Common Among Older HIV-Infected Adults: in this group over age 50, 50% of participants had frailty or pre-frailty at higher frequencies than HIV-negatives" - (03/10/14)
     
  8425. CROI: Low Bone Mineral Density among Ugandan HIV infected patients on failing first line Antiretroviral Therapy; a sub-study of the EARNEST trial - (03/10/14)
     
  8426. CROI: Lower Newborn Bone Mineral Content (BMC) Associated with Maternal Use of Tenofovir Disoproxil Fumarate (TDF) - (03/10/14)
     
  8427. CROI: Comparison of Two Doses of Zoledronic Acid for the Treatment of Osteoporosis in HIV Infected Patients. Results of a Randomized Open Label Study (VIHZOL Study) - (03/10/14)
     
  8428. CROI: Longitudinal Changes in Free Testosterone among Older HIV-infected and HIV-uninfected Men: "FT decreased similarly over a 6-year interval in older HIV infected and HIV-uninfected men" - (03/10/14)
     
  8429. CROI: Frailty, Inflammation and Mortality among Aging HIV-Infected and At-Risk Injection Drug Users - (03/10/14)
     
  8430. CROI: Hand osteoarthritis, a joint disorder frequent and more severe HIV-1 patients : METAFIB OA Study - (03/10/14)
     
  8431. CROI: Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults "highlighting the potential value of DEXA screening in this population"......median age 42[35-48]....36% osteopenia/2.9% osteoporosis - (03/10/14)
     
  8432. CROI: Bone Density Changes after Antiretroviral Initiation with Protease Inhibitors or Raltegravir - (03/10/14)
     
  8433. CROI: New Fracture Risk and FRAX 10-Year Probability of Fracture in HIV-infected Adults - (03/10/14)
     
  8434. CROI: Cumulative Viral Load Predicts All-Cause and AIDS Death But Not Non-AIDS Death - written by Mark Mascolini - (03/10/14)
     
  8435. CROI: Tesamorelin Lowers Hepatic Fat in HIV+ With Excess Visceral Fat - written by Mark Mascolini - (03/10/14)
     
  8436. CROI: Arterial Inflammation Tied to High-Risk Coronary Plaques in HIV Group - written by Mark Mascolini - (03/10/14)
     
  8437. CROI: PI Regimens Tied to Cerebral Small Vessel Disease--and CSVD Tied to HAND - written by Mark Mascolini - (03/10/14)
     
  8438. CROI: Nearly Nil HIV Transmission Risk Without Condoms and (from Jules: in established couples) With HIV+ Partner on Suppressive ART - written by Mark Mascolini - (03/10/14)
     
  8439. CROI: Vitamin D/Calcium Supplements Reduce Bone Loss by 50% When Starting EFV/TDF/FTC - written by Mark Mascolini - (03/10/14)
     
  8440. CROI: Rosuvastatin Improves Hip Bone Mineral Density but Worsens Insulin Resistance - (03/07/14)
     
  8441. CROI: Viral Suppression Induced by Anti-PD-L1 Following ARV-Interruption in SIV-Infected Monkeys - (03/07/14)
     
  8442. CROI: Darunavir or Atazanavir vs Raltegravir Lipid Changes are unlinked to Ritonavir Exposure: ACTG 5257 - (03/07/14)
     
  8443. CROI: Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir; New Drug Application Accepted by FDA - (03/06/14)
     
  8444. CROI: Very Early Combination Antiretroviral Therapy in Perinatal HIV Infection: Two Case Studies - "Mississippi" baby followup & 2nd case of infant that appears to have cleared HIV/remains on cART - (03/06/14)
     
  8445. CROI: Newborns Exposed to TDF in Utero Have Lower Bone Mineral Content in US - written by Mark Mascolini - (03/06/14)
     
  8446. CROI: HIV Independently Predicts Cardiovascular Disease in US Women - written by Mark Mascolini - (03/06/14)
     
  8447. CROI: US HIV Transmission Network Study Holds Some Surprises About Women and MSM - written by Mark Mascolini - (03/06/14)
     
  8448. CROI: Second Swiftly Treated Baby Seems to Have Cleared HIV - written by Mark Mascolini - (03/06/14)
     
  8449. CROI: Quadrivalent HPV Vaccine Induces Immune Memory in US Men With HIV - written by Mark Mascolini - (03/06/14)
     
  8450. CROI: Long-Acting Integrase Inhibitor GSK744 for PrEP (Once Monthly or maybe longer) - (03/05/14)
     
  8451. CROI: Brain Markers of Inflammation Drop to Normal With Early ART - (03/05/14)
     
  8452. CROI: Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir with FTC/TDF: ACTG A5257 - (03/05/14)
     
  8453. CROI: First-Line Raltegravir (RAL) + Darunavir/Ritonavir (DRV/r) is Non-inferior to Tenofovir/Emtricitabine (TDF/FTC) + DRV/r: The NEAT 001/ANRS 143 Randomised Trial - (03/05/14)
     
  8454. CROI: Safety and Antiviral Effect of MK-1439, a Novel NNRTI, (+Truvada®) in ART-Naive HIV Infected Patients - (03/05/14)
     
  8455. CROI: GSK744 and Rilpivirine as Two Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results - (03/05/14)
     
  8456. CROI: HIV-1 Attachment Inhibitor Prodrug in Antiretroviral-Experienced Subjects: Week 24 Analysis - (03/05/14)
     
  8457. CROI: HIV Transmission Bottleneck Offers Clue to HCV Epidemic in HIV+ MSM - written by Mark Mascolini - (03/05/14)
     
  8458. CROI: Five Cancers Diagnosed at Later Stage in People With vs Without HIV - written by Mark Mascolini - (03/05/14)
     
  8459. CROI: Novel Network Score Tied to HIV Transmission Risk and Outcomes - written by Mark Mascolini - (03/05/14)
     
  8460. CROI: Low CD4/CD38 Ratio Predicts non-AIDS Illness in Large Italian Cohort - written by Mark Mascolini - (03/05/14)
     
  8461. CROI: Testosterone Falls No More With Than Without HIV Over 6 Years in MACS - written by Mark Mascolini - (03/05/14)
     
  8462. CROI: Race, Age, and Transmission Risk Affect Viral Suppression Chances in DC Cohort - written by Mark Mascolini - (03/05/14)
     
  8463. CROI: Viral Suppression Disparities: Race, Age, and Transmission Risk Affect Viral Suppression Chances in DC Cohort - written by Mark Mascolini - (03/05/14)
     
  8464. CROI: Transmitted HIV Resistance Rate Close to 20% in Large Study of US MSM - written by Mark Mascolini - (03/05/14)
     
  8465. CROI: Brain Markers of Inflammation Drop to Normal With Early ART - written by Mark Mascolini - (03/05/14)
     
  8466. Inflammation, Activation Associated with Reduced Functional Capacity in HIV+ - (03/03/14)
     
  8467. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery - (02/27/14)
     
  8468. Decline in locomotor functions over time in HIV-infected patients - (02/26/14)
     
  8469. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000.....AIDS, HCV coinfection, comorbidities--cancers/liver disease, heart disease - (02/26/14)
     
  8470. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women - (02/26/14)
     
  8471. Pharmacokinetics of raltegravir in the semen of HIV-infected men - (02/26/14)
     
  8472. Aggregate Risk of Cardiovascular Disease among Adolescents Perinatally Infected with the Human Immunodeficiency Virus - (02/26/14)
     
  8473. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors - (02/25/14)
     
  8474. Stribild, Isentress & Tivicay (dolutegravir) Prescribing Information - (02/20/14)
     
  8475. What is the significance of posttreatment control of HIV infection vis-a-vis functional cure? - (02/19/14)
     
  8476. "These data indicated that lopinavir could potentially be used topically as an anti-HPV therapeutic" - (02/18/14)
     
  8477. Switch to raltegravir decreases soluble CD14 [inflammation marker] in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial - (02/18/14)
     
  8478. Shot in the HAART: vaccine therapy for HIV; Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial - (02/14/14)
     
  8479. 2 New Studies on Disparities in HIV Care: the NA-ACCORD, a large patient cohort & the CDC Report: Blacks Receive Worse Care, Black Men Receive Worse Care than Black Women - (02/11/14)
     
  8480. Antibodies Prevent HIV Transmission in Mice - (02/11/14)
     
  8481. Disparities in the quality of HIV care when using US Department of Health and Human Services Indicators - blacks, IDUs, females - (02/10/14)
     
  8482. Experts warn of rise in gay 'slamming' in London: increased HIV & HCV transmission risk - (02/07/14)
     
  8483. Inflammation & HIV.....inflammation in the general population & in HIV+ is associated with non-AIDS comorbidities, so is immune activation - (02/07/14)
     
  8484. Inflammation, HIV, HCV & Alcohol in HIV+ - (02/07/14)
     
  8485. Immunologic predictors/Inflammation of coronary artery calcium progression in a contemporary HIV cohort - (02/07/14)
     
  8486. HIV infection and its association with an excess risk of clinical fractures and: a nation-wide case-control study - (02/07/14)
     
  8487. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges - (02/03/14)
     
  8488. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues - (01/31/14)
     
  8489. Do children infected with HIV receiving HAART need to be revaccinated? - (01/31/14)
     
  8490. Immunologic basis for revaccination of HIV-infected children receiving HAART: Immune Reconstitution, Memory Responses & Revaccination Against Measles Virus - (01/31/14)
     
  8491. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis - (01/31/14)
     
  8492. Extending HIV drug resistance testing to low levels of plasma viremia: 'Reliability and Clinical Relevance of the HIV-1 Drug-Resistance Test in Patients with Low Viremia Levels'; 'Performance of HIV-1 Drug Resistance Testing at Low Level Viraemia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naïve Individuals' - (01/31/14)
     
  8493. Association between short leukocyte telomere length and HIV infection in a cohort study; no evidence of a relationship with antiretroviral therapy - (01/31/14)
     
  8494. In Vivo Mitochondrial Function in HIV-Infected Persons Treated with Contemporary Anti-Retroviral Therapy: A Magnetic Resonance Spectroscopy Study - (01/31/14)
     
  8495. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? - (01/31/14)
     
  8496. Uptake of PrEP for HIV slow among MSM - (01/31/14)
     
  8497. Association between short leukocyte telomere length and HIV infection in a cohort study; no evidence of a relationship with antiretroviral therapy - (01/24/14)
     
  8498. Immunotherapy (monoclonal antibodies) for HIV Infection - (01/23/14)
     
  8499. New HIV Cure Research Findings-Radioimmunotherapy Therapy (RIT) - (01/23/14)
     
  8500. NYS HIV PEP/PrEP Guidance-Pre & Post Exposure Prophylaxis - (01/22/14)
     
  8501. Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009-2012; Dolutegravir Resistance Reports - (01/22/14)
     
  8502. Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years - (01/22/14)
     
  8503. Improving the health of the tuberculosis drug pipeline - (01/22/14)
     
  8504. ViiV Healthcare's new HIV medicine Tivicay® (dolutegravir) is approved in Europe - (01/21/14)
     
  8505. Immunodeficiency and Risk of Myocardial Infarction Among HIV-Positive Individuals With Access to Care - (01/21/14)
     
  8506. Antiretroviral treatment French guidelines 2013: economics influencing science - (01/21/14)
     
  8507. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence - (01/21/14)
     
  8508. Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 - (01/21/14)
     
  8509. Life Expectancy Study in Italy: CD4 Linked with Better Estimated Life Expectancy & Those with CD4 Recovery from nadir/low CD4 to >500 Estimated to have Life Expectancy Close to General Population - (01/21/14)
     
  8510. 4th Int HIV & Women: Efficacy and Safety of Raltegravir in Women - (01/21/14)
     
  8511. 4th Int HIV & Women: STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF is Safe and Well-Tolerated with Efficacy Comparable to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96 - (01/21/14)
     
  8512. Association of Coffee Consumption With All-Cause and Cardiovascular Disease Mortality - written by Mark Mascolini - (01/17/14)
     
  8513. Beneficial impact of antiretroviral therapy on non-AIDS mortality: Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals - (01/17/14)
     
  8514. 4th Int HIV & Women: Raltegravir Efficacy and Safety Similar in Naive Women and Men at 48 Weeks - written by Mark Mascolini - - (01/16/14)
     
  8515. 4th Int HIV & Women: London Women Lag MSM and Heterosexual Men in Antiretroviral Response and Durability - written by Mark Mascolini - - (01/16/14)
     
  8516. 4th Int HIV & Women: Response Rates With Complera Versus Atripla in Women at 96 Weeks in STaR - written by Mark Mascolini - - (01/15/14)
     
  8517. 4th Int HIV & Women: Immune Response to HPV Vaccine Lower in Girls With Than Without HIV - written by Mark Mascolini - - (01/15/14)
     
  8518. 4th Int HIV & Women: Clinical Characteristics and Quality of HIV Care for Women in the United States: Data from the Medical Monitoring Project, 2009 - written by Mark Mascolini - - (01/15/14)
     
  8519. 4th Int HIV & Women: Age, Lower CD4s, Winter Predict Missed Clinic Visits by HIV+ Toronto Women - written by Mark Mascolini (01/14/14)
     
  8520. 4th Int HIV & Women: US Women With HIV Get Too Little Support on STIs and HIV Transmission, CDC Says - written by Mark Mascolini (01/14/14)
     
  8521. Nuts/Lifestyle & Morbidity/Mortality - (01/13/14)
     
  8522. HAART & The Brain: "CNS Toxicity of Antiretroviral Drugs", "Can antiretroviral therapy prevent HIV-associated cognitive disorders?" - (01/13/14)
     
  8523. HIV Cure: T Memory Stem Cells - Hideouts Of HIV Against Any Antiviral Treatment - new - (01/13/14)
     
  8524. Age, Race/Ethnicity, and Behavioral Risk Factors Associated With Per Contact Risk of HIV Infection Among Men Who Have Sex With Men in the United States - (01/12/14)
     
  8525. Vitamin D supplementation: bones of contention - commentary - (01/12/14)
     
  8526. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: Results from the ANRS CO13 HEPAVIH cohort study. Association of Coffee Consumption With All-Cause and Cardiovascular Disease Mortality - 2 new studies - (12/31/13)
     
  8527. How HIV Destroys Immune Cells, Blocking HIV Cell Death with Vertex Drug- 2 new studies. Scientists Discover How Key Immune Cells Die During HIV Infection and Identify Potential Drug to Block AIDS - (12/27/13)
     
  8528. Are We Prepped for PrEP? Provider Opinions on the Real-World Use of PrEP in the U.S. and Canada - (12/27/13)
     
  8529. Drugs for neuropathic pain - (12/23/13)
     
  8530. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis - (12/23/13)
     
  8531. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada - (12/23/13)
     
  8532. Isentress (raltegravir) - FDA Approves New Dosage Form for Oral Suspension for Pediatrics - (12/22/13)
     
  8533. HIV Cured In Mice? German Scientists Use Stem Cells To Cut Out Virus With 'Molecular Scissors' - (12/22/13)
     
  8534. Dietary Fibre Can reduce Cardiovascular/Heart Disease Risk - (12/22/13)
     
  8535. Eat more fibre Editorial (reduces heart disease risk) - (12/22/13)
     
  8536. Dual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function - (12/19/13)
     
  8537. Anti-PD-L1 immunotherapy in ARV-suppressed rhesus monkeys - (12/19/13)
     
  8538. Farnesyl-Transferase inhibitors: Identification and validation of a class which reactivates HIV latent expression and is synergistic with other mechanisms in vitro - (12/19/13)
     
  8539. Highlights on HIV eradication in 2013 - (12/18/13)
     
  8540. 6th Intl Workshop on HIV Persistance during Therapy Report Summary - Report by David Margolis MD, UNC Chapel Hill and the Collaboratory of AIDS Researchers for Eradication (CARE) - (12/15/13)
     
  8541. Renal safety of atazanavir-based regimens in human immunodeficiency virus (HIV) infected patients - (12/12/13)
     
  8542. Effects of interferon-α treatment on anti-HIV-1 intrinsic immunity in vivo - (12/09/13)
     
  8543. AASLD: Telaprevir combination therapy in treatment-naïve and experienced patients co-infected with HCV and HIV - (12/06/13)
     
  8544. HIV virus returns after cure hope rose - (12/06/13)
     
  8545. EACS: Low HDL Cholesterol Is Main Lipid Abnormality in HIV+/HIV- Comparison in HIV UPBEAT Study - (12/06/13)
     
  8546. VACCINATION IMPORTANT FOR IMMUNOCOMPROMISED PATIENTS - (12/04/13)
     
  8547. Where Will Obama Find $100 Million for the New HIV Cure Initiative? - (12/04/13)
     
  8548. British scientists to trial potential HIV cure: HDAC Inhibitor + HIV Vaccine - (12/03/13)
     
  8549. A 90-Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV Prophylaxis - (12/03/13)
     
  8550. Intravaginal ring could block HIV transmission to women - (12/03/13)
     
  8551. Development and Pharmacokinetics of a 90-Day Intravaginal Ring for the Sustained Co-Delivery of the Microbicide Tenofovir and Contraceptive Levonorgestrel ....presented Nov 10 2013 at Annual Meeting for the American Ass. Of Pharmaceutical Scientists - (12/03/13)
     
  8552. NIH announces plan to increase funding toward a cure for HIV/AIDS - (12/03/13)
     
  8553. Dolutegravir plus Abacavir-Lamivudine vs Efavirenz/TDF/FTC Once Daily for the Treatment of HIV-1 Infection - (12/03/13)
     
  8554. HIV Protein Causes Metabolic/Fat Abnormalities, New Study: HIV-1 Vpr Induces Adipose Dysfunction in Vivo Through Reciprocal Effects on PPAR/GR Co-Regulation - (12/03/13)
     
  8555. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis (Partners PrEP Study) - (11/20/13)
     
  8556. New HIVMA Guidelines/Comorbidities - (11/16/13)
     
  8557. New American Heart Association/American College of Cardiology 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk - (11/15/13)
     
  8558. Controversy Over Statins for Older Patients/New AHA Guidelines - (11/15/13)
     
  8559. Towards an HIV Cure: science and debate from the International AIDS Society 2013 symposium - (11/15/13)
     
  8560. AGE: Poor Physical Function in Older Women on ART Tied to Comorbidities, Inflammation - Written by Mark Mascolini - (11/14/13)
     
  8561. AGE: Prescriptions Rise With Age in Ontario HIV+, But Drug-Related Problems Don't - Written by Mark Mascolini - (11/14/13)
     
  8562. AGE: Cardiovascular Risk Linked to Poor Memory Independently of Age in HIV+ - Written by Mark Mascolini - (11/14/13)
     
  8563. AGE: Moderate Exercise Linked to Better Executive Function in Older HIV+ People - Written by Mark Mascolini - (11/03/13)
     
  8564. AGE: Prior Meth Use Tied to Worse Neurocognitive Function in Older But Not Younger HIV+ - Written by Mark Mascolini - (11/03/13)
     
  8565. AGE: Multimorbidity and Non-AIDS Rates Differ With HIV Duration in Older Adults - Written by Mark Mascolini - (11/03/13)
     
  8566. HIV Antibody Infusions Show Promise for Treating SHIV-Infected Monkeys - (11/01/13)
     
  8567. 2 New Studies - HIV Antibodies Advance the search for a cure/Supercharged antibodies fight HIV-related virus in monkeys - (10/31/13)
     
  8568. AGE: Carotid Plaques Develop More Often With vs Without HIV in Metabolic Syndrome Patients - Written by Mark Mascolini - (10/31/13)
     
  8569. AGE: "Successful Cognitive Aging" in Only One Fifth of US HIV Group 50 or Older - Written by Mark Mascolini - (10/31/13)
     
  8570. New HIV & HCV Rapid Tests - (10/30/13)
     
  8571. Sangamo: Maintained Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks, Data were presented at the Annual Meeting of the European Society of Gene and Cell Therapy (ESGCT and SETGyC Collaborative Congress) which is being held in Madrid from October 25-28, 2013 - (10/30/13)
     
  8572. Inflammation Associated with Heart Disease, Cancers, Diabetes, Viral Load & CD4 Count - (10/29/13)
     
  8573. EACS: Differing Effects of Low- and High-Fat Meals on New Raltegravir Formulation - Written by Mark Mascolini - (10/28/13)
     
  8574. EACS: PI Use, Female Gender, HCV, Detectable Sub-50 Viral load Predict Rebound From Under 50 Copies in Italian Group - Written by Mark Mascolini - (10/28/13)
     
  8575. Mississippi Baby HIV Cure Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant - (10/28/13)
     
  8576. Can HIV Be Cured? - (10/28/13)
     
  8577. Is HIV a Model of Accelerated or Accentuated Aging? - (10/28/13)
     
  8578. Exercise Benefits Aging Brain - (10/28/13)
     
  8579. HIV Increases Risk for Heart Disease; Nadir CD4 & Heart Disease in HIV - (10/28/13)
     
  8580. EACS: Lean Mass Inches Out Fat Mass as Predictor of Low Bone Density With HIV, HIV UPBEAT Cohort - Written by Mark Mascolini - (10/25/13)
     
  8581. EACS: Merck Presents New Pharmacokinetic Data on ISENTRESS® (raltegravir) at 14th European AIDS Conference - (10/25/13)
     
  8582. EACS: Bone Loss Worse in HIV+ vs HIV-Neg, Lower Body Weight Predicts Bone Loss in MSM: "Prevalence and determinants of reduced bone mineral density in aging HIV-1-positive and HIV-negative individuals" in AGEhIV Cohort Amsterdam - (10/25/13)
     
  8583. EACS: Neither HIV Nor Tenofovir Tied to Low Bone Density in Large Amsterdam Study (AGEhIV Cohort) - (10/25/13)
     
  8584. EACS: Lean Mass Inches Out Fat Mass as Predictor of Low Bone Density With HIV - (10/25/13)
     
  8585. IWCADR: Darunavir, atazanavir and lopinavir boosted with ritonavir differentially affect endothelial functions and induce senescence of cultured human endothelial cells. Beneficial effect of pravastatin - (10/23/13)
     
  8586. EACS: CHANGES IN BONE TURNOVER MARKERS AND ASSOCIATION WITH DECREASED TOTAL BONE MINERAL DENSITY IN TREATMENT-NAIVE SUBJECTS TAKING LOPINAVIR/RITONAVIR (LPV/r) COMBINED WITH RALTEGRAVIR (RAL) OR TENOFOVIR/EMTRICITABINE (TDF/FTC) - (10/23/13)
     
  8587. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial - (10/23/13)
     
  8588. SPRING-2 the future of antiretroviral therapy - Commentary - (10/23/13)
     
  8589. The challenge of HIV associated neurocognitive disorder - Commentary - (10/23/13)
     
  8590. HIV-associated neurocognitive disorder - (10/23/13)
     
  8591. EACS: Classic Risk Factors, But Not HIV, Linked to Arterial Stiffness in Middle-Aged - Written by Mark Mascolini - (10/23/13)
     
  8592. EACS: Bone Turnover Marker Changes Early in ART Predict Bone Loss After 96 Weeks - Written by Mark Mascolini - (10/23/13)
     
  8593. EACS: Statin Use Cuts All-Cause Mortality 75% in Spanish HIV Cohort - Written by Mark Mascolini - (10/23/13)
     
  8594. EACS: Meta-Analysis of Dolutegravir vs Guideline-Recommended Agents for Naive - Written by Mark Mascolini - (10/23/13)
     
  8595. EACS: Once-Daily ART v Twice-Daily/Pill Burden Meta-Analysis Evaluates Adherence/Viral Control - Written by Mark Mascolini - (10/23/13)
     
  8596. EACS: 48 weeks outcomes of atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: interim analysis results of the MODAt Study - (10/23/13)
     
  8597. EACS: Osteoporosis Triples Risk of Later Fracture in 1000-Person US HIV Group - Written by Mark Mascolini - (10/21/13)
     
  8598. EACS: Twice-Higher Latest Vitamin D Almost Halves Odds of Death in EuroSIDA - Written by Mark Mascolini - (10/21/13)
     
  8599. EACS: Once-Daily Raltegravir for 48 Weeks as Maintenance Therapy in Paris - Written by Mark Mascolini - (10/21/13)
     
  8600. EACS: 'Acute HCV BUT No HBV Reported' - Reports of Viral Hepatitis B and C in HIV Patients Participating in Clinical Trials of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF and Cobicistat-boosted Atazanavir plus Emtricitabine/Tenofovir DF - (10/21/13)
     
  8601. EACS: Safety and Tolerability of Switching from Twice Daily Raltegravir plus Truvada to STRIBILD in Virologically Suppressed, HIV-1 Infected Subjects - (10/21/13)
     
  8602. EACS: STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Maintains Non-Inferiority to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults Week 96 Results - (10/21/13)
     
  8603. EACS: Dual therapy with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) is non-inferior to standard triple drug therapy in naive HIV-1 infected subjects: 48-week results of the GARDEL study - (10/21/13)
     
  8604. EACS: Retrospective Comparison of Etravirine and Darunavir/Ritonavir as Dual Therapy in Early Treatment-Experienced Subjects (INROADS) to a Matched Historical Control Cohort - (10/21/13)
     
  8605. EACS: Virological Efficacy, Durability and Safety of Darunavir/r plus Etravirine (DRV/r-ETV) Dual Regimen in ART-Experienced Patients - (10/21/13)
     
  8606. EACS: Simplification to dual therapy containing raltegravir and darunavir/ritonavir in HIV-infected patients on virologically suppressive therapy including nucleoside/nucleotide analogues and ritonavir-boosted boosted protease inhibitors - (10/21/13)
     
  8607. EACS: Substantial rates of Acute Hepatitis C Reinfection in European HIV-positive Patients - (10/21/13)
     
  8608. EACS: STARTVerso 4 Phase iii trial of faldaprevir once-daily plus peg interferon α -2a and ribavirin (PR) in patients with HiV and HCV genotype-1 co-infection - (10/20/13)
     
  8609. EACS: Simeprevir (TMC435) in combination with peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: Primary analysis of the C212 study - (10/20/13)
     
  8610. EACS: Simeprevir with peginterferon/ribavirin in treatment-naïve or experienced patients with chronic HCV genotype 4 infection: Interim results of a Phase III trial - (10/20/13)
     
  8611. EACS: Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus Ns3/4A protease inhibitor - (10/20/13)
     
  8612. EACS: Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults - (10/20/13)
     
  8613. EACS: Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons: results from the EuroSIDA cohort study - (10/18/13)
     
  8614. EACS: Final Week 48 Analysis of Cenicriviroc (CVC) Compared to Efavirenz (EFV), in Combination with Emtricitabine/Tenofovir (FTC/TDF), in Treatment-Naïve HIV-1-Infected Adults with CCR5-Tropic Virus (Study 652-2-202; NCT01338883) - (10/18/13)
     
  8615. EACS: Week 96 Renal Safety Update of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from Two Phase 3 Randomized Controlled Trials - (10/18/13)
     
  8616. EACS: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-naïve HIV-1 Infected Patients: Week 144 Results - (10/18/13)
     
  8617. EACS: Once-Daily Oral GSK1265744 (744) as Part of Combination Therapy in Antiretroviral-Naive Adults: 24-Week Safety and Efficacy Results From the LATTE Study (LAI116482) - (10/18/13)
     
  8618. Systemic Effects of Inflammation on Health during Chronic HIV Infection - (10/17/13)
     
  8619. Immune clearance of highly pathogenic SIV infection - (10/17/13)
     
  8620. EACS: A Single Dose Food Effect Study of Raltegravir (RAL) Formulations Once Daily Tablet - (10/17/13)
     
  8621. EACS: Once-Daily Dolutegravir Versus Darunavir/Ritonavir in Antiretroviral Naïve Adults: 48 Week Subgroup Analyses from FLAMINGO - (10/17/13)
     
  8622. EACS: 48-Week Efficacy of Dolutegravir Relative to Commonly Used 3rd Agents in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-analysis - (10/16/13)
     
  8623. EACS: Bristol-Myers Squibb Launches Initiative to support search for a cure in chronic viral diseases (HIV/HBV/HCV) - (10/16/13)
     
  8624. EACS: Activity of Dolutegravir (DTG) 50 mg BID vs Placebo (PBO) Over 7 Days of Functional Monotherapy in Patients Harbouring Raltegravir- and/or Elvitegravir-Resistant Virus: Primary Endpoint Results of the VIKING-4 Study (ING116529) - (10/16/13)
     
  8625. ID Week: Acute HCV Treatment/HIV+ MSM/HCV Screening/New HCV Therapies: "Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus" - (10/16/13)
     
  8626. ID Week: Polypharmacy in HIV: "Differences in calculated adherence rates of ART and non-ART medications among HIV positive veterans" - (10/16/13)
     
  8627. IAS: Single tablet regimens do not necessarily translate into more durable HIV treatments: "initial use of RAL-based regimens was associated with a better outcome....patients starting HAART with RAL were less likely to change regimen...... the main reason for 1st line discontinuation/switch remain the adverse effects, very few virological failure were observed" - (10/16/13)
     
  8628. ICAAC: Good Results With No-NRTI Strategy in ART Experienced: Small Retrospective Study - Written by Mark Mascolini - (10/16/13)
     
  8629. Vitamin D Supplementation New Study/Commentary - (10/16/13)
     
  8630. ID Week: ID Week 2103: Polypharmacy in HIV - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13)
     
  8631. ID Week: ID Week 2013: Co-morbidities - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13)
     
  8632. ID Week: ID Week 2013: Antiretroviral Therapy - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13)
     
  8633. Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population - (10/15/13)
     
  8634. ID Week: (CDC) Differences in Demographic, Behavioral and Clinical Characteristics between HCV Mono-infected and HCV/HIV Co-infected Adults in Outpatient Primary Care - (10/11/13)
     
  8635. ID Week: Clinicians May Overlook CD4 Percent in HIV+ When Deciding on PCP Prophylaxis - Written by Mark Mascolini - (10/11/13)
     
  8636. ID Week: Barriers to Effective Antenatal Hepatitis C Virus (HCV) Screening - (10/11/13)
     
  8637. ID Week: Effects of aging and antiretroviral therapy on B Cell phenotypes in HIV infected subjects - (10/11/13)
     
  8638. ID Week: (72% of women had Vit D Deficiency) Vitamin D supplementation increases Vitamin D levels but does not improve inflammatory markers in HIV Infected Women; a Chicago Women's Interagency HIV study (WIHS) study - (10/11/13)
     
  8639. ID Week: Metabolic, Bone, Renal, Inflammatory and Lipodystrophic Marker Analysis in INROADS, a Multicenter, Single-Arm, Open-Label Study of a Once-Daily Nucleoside/tide-Sparing Regimen of Etravirine (ETR) and Darunavir/Ritonavir (DRV/r) as Dual Therapy in Early Treatment-Experienced Subjects - (10/11/13)
     
  8640. ID Week: HIV TREATMENT CASCADE AMONG TRANSGENDER WOMEN IN A SAN FRANCISCO RESPONDENT DRIVEN SAMPLING STUDY - (10/11/13)
     
  8641. ID Week: SPIRIT: Simplification to Rilpivirine/Emtricitabine/Tenofovir DF Single-Tablet Regimen from Boosted Protease Inhibitor Maintains HIV-1 Suppression and Improves Fasting Lipids at Week 48 - (10/10/13)
     
  8642. ID Week: Higher Mortality With vs Without HIV After Acute Coronary, But Not With High CD4s - (10/10/13)
     
  8643. ID Week: "ART-naïve HIV+ adults, but not controls, had BMD loss at the total hip and trochanter sites over 48 weeks" - ART-Naive Adults More Likely to Lose Trochanter BMD Than HIV-Negatives - Writted by Mark Mascolini - (10/10/13)
     
  8644. ID Week: Program for Prescribers Cuts Antiretroviral Errors in Hospital Population - Writted by Mark Mascolini - (10/10/13)
     
  8645. ID Week: Cumulative Viral Load Predicts Morbidity/Mortality in Perinatally Infected Children - written by Mark Mascolini - (10/07/13)
     
  8646. ID Week: Rash in 10% of Taiwanese Starting Once-Daily Darunavir--and 7% Dropout Rate - written by Mark Mascolini - (10/07/13)
     
  8647. ID Week: 15% of HIV+ Adults in NY Clinics Still Seronegative for Measles, Mumps, Rubella - written by Mark Mascolini - (10/07/13)
     
  8648. ID Week: Six-Month HIV Suppression Better With Single-Tablet Regimens Than Multitablet Combos - written by Mark Mascolini - (10/07/13)
     
  8649. ID Week: Low Risk but Twice Higher Risk of Suicidal Thoughts or Acts on First-Line Efavirenz - written by Mark Mascolini - (10/07/13)
     
  8650. ID Week: Lack of ART Tied to Tripled Mortality in Veterans With Community-Acquired Pneumonia - written by Mark Mascolini - (10/07/13)
     
  8651. ID Week: Cumulative Viremia-Copy Years Predicts Morbidity and Mortality in Perinatally HIV-Infected Children - (10/07/13)
     
  8652. ID Week: Assessing Vitamin D Testing and Supplementation Patterns in a Large Inner City Clinic - (10/07/13)
     
  8653. ID Week: Current Alcohol and Substance Use in HIV-infected and HIV/HCV-co-infected Patients in Routine Clinical Care across the U.S. - (10/07/13)
     
  8654. ID Week: Single tablet regimens do not necessarily translate into more durable HIV treatments: "initial use of RAL-based regimens was associated with a better outcome....patients starting HAART with RAL were less likely to change regimen...... the main reason for 1st line discontinuation/switch remain the adverse effects, very few virological failure were observed" - (10/07/13)
     
  8655. ID Week: Pilot Study to Evaluate Intramyocardial Lipid Accumulation in HIV+ Patients Receiving Highly Active Antiretroviral Therapy (HAART) - (10/07/13)
     
  8656. ID Week: Long-Term Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Compared to Efavirenz/Emtricitabine/Tenofovir DF in HIV-1-Infected, Treatment-Naïve, Black Versus Non-Black Subjects - (10/07/13)
     
  8657. ID Week: STaR Study: Association of Efficacy Outcomes with Baseline HIV-1 RNA and CD4 Count and Adherence Rate for the Single-Tablet Regimens Rilpivirine/Emtricitabine/Tenofovir DF and Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults - (10/07/13)
     
  8658. ID Week: HIV+ Individuals on ART Are At Risk of Polypharmacy: More Medication Increases Mortality - (10/04/13)
     
  8659. ID Week: Comorbidity prevalence and its influence on non-ARV comedication burden among HIV positive patients - (10/04/13)
     
  8660. ID Week: Safety and Efficacy of Dolutegravir (DTG; GSK1349572) in Treatment-Experienced HIV-1 Infected Adolescents: 24-week Results from IMPAACT P1093 - (10/04/13)
     
  8661. ID Week: Outcomes Differ for HIV-Infected Patients Receiving Care at Hospital vs. Community-Based Clinics - (10/04/13)
     
  8662. ID Week: "The Clinical Role and Cost-effectiveness of Long-acting Antiretroviral Formulations" - Long-Acting ARV Formulations Could Improve Survival in People With Poor Adherence - written by Mark Mascolini - (10/04/13)
     
  8663. ID Week: Comorbidity Rate, Non-ARV Prescriptions Higher in HIV-Positives Than Matched Controls - written by Mark Mascolini - (10/04/13)
     
  8664. ID Week: Non-AIDS Death Rate Jumps From Early to Recent ART Era in Large Single-Site Study - written by Mark Mascolini - (10/04/13)
     
  8665. ID Week: Higher Intramyocardial Lipids in Antiretroviral-Treated Men Than in HIV-Negatives - written by Mark Mascolini - (10/04/13)
     
  8666. ID Week: Dolutegravir Effective at 24 Weeks in Adolescents Replacing Failing Regimen - written by Mark Mascolini - (10/04/13)
     
  8667. ID Week: Once-Daily Etravirine Effective Through 24 Weeks in Three-Center Study - written by Mark Mascolini - (10/04/13)
     
  8668. ID Week: Community or Hospital HIV Clinic? Patient Profiles, Outcomes Differ in 4-Year Study - written by Mark Mascolini - (10/04/13)
     
  8669. SR9009 "counter disturbed sleep that commonly afflicts elderly people/jetlag" - (10/02/13)
     
  8670. (SR9009) Regulation of circadian behaviour and metabolism by REV-ERB- and REV-ERB-ß - (10/02/13)
     
  8671. Drug discovery (SR9009): Time in a bottle - (10/02/13)
     
  8672. SR9009 decreased inflammation (IL-6), decreased cholesterol & triglycerides & plasma glucose & plasma insulin levels..... - (10/02/13)
     
  8673. SR9009 Reversed Effect of Mitochondrial Damage, Increased Exercise Capacity in Mice - (10/02/13)
     
  8674. ICAAC: Efficacy and Safety of Rilpivirine-Based Regimens in Treatment-Experienced HIV-1 Infected Patients: A Prospective Cohort Study - (09/31/13)
     
  8675. ICAAC: Acute C hepatitis in Japanese HIV-infected patients in this decade - (09/31/13)
     
  8676. New Tenofovir Intravaginal Ring Protects Monkeys from HIV & In ICAAC Presentation Researchers Report Protection After After High Doses of DMPA - (09/31/13)
     
  8677. PrEP/(ART) Update- Once Monthly or Every 3 Months PrEP & ART: Rilpivirine Long-Acting; tenofovir intravaginal ring for PrEP; combination PrEP & ART injections Every Month or 3 Months with 2 long-acting drugs GSK744 - (09/27/13)
     
  8678. Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention - (09/27/13)
     
  8679. Is Intrapartum Intravenous Zidovudine for Prevention of Mother-to-Child HIV-1 Transmission Still Useful in the Combination Antiretroviral Therapy Era? - (09/25/13)
     
  8680. HHS: Premiums Under ACA Will Be Lower Than Expected. - (09/25/13)
     
  8681. USPSTF Outlines Use of Breast Cancer Prevention Drugs - recommends primary prevention drugs should be offered to high-risk women at low risk for side effects - (09/24/13)
     
  8682. ICAAC: Tenofovir Intravaginal Ring - (09/24/13)
     
  8683. ICAAC: ICAAC: Pigtailed Macaques Under High Doses of Depot Medroxyprogesterone are Protected from Multiple SHIV Exposures with a Tenofovir Disoproxil Fumarate Intravaginal Ring - (09/24/13)
     
  8684. Video of US Senate Hearing on HIV & Aging Sept 18, 2013 - (09/23/13)
     
  8685. HIV Infection and Older Americans: The Public Health Perspective - soon 50% of HIV+ will be over 50 yrs old - (09/23/13)
     
  8686. Tenofovir Alafenamide (TAF)- Gilead Press Release & Links to TAF Studies - (09/23/13)
     
  8687. New LDL Lowering Drugs, Big LDL drops with PCSK9 inhibition in grouped phase-2 studies - "drug reduces LDL cholesterol by 43% to 64%" - (09/20/13)
     
  8688. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients - (09/20/13)
     
  8689. What Causes Neurological Impairment in HIV+ - (09/20/13)
     
  8690. African-Americans & HIV Study Participation: barriers to study participation for African-Americans - (09/20/13)
     
  8691. A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects - (09/20/13)
     
  8692. ICAAC: Worse Response to PegIFN/RBV for HCV After Transplant in HIV/HCV+ vs HCV+ - Written by Mark Mascolini - (09/20/13)
     
  8693. ICAAC: Nearly 10% Screened for Syphilis Test Positive at California HIV Clinic - Written by Mark Mascolini - (09/20/13)
     
  8694. ICAAC: Almost Half of Pneumocystis Patients in France Already in HIV Care at PCP Diagnosis - Written by Mark Mascolini - (09/20/13)
     
  8695. ICAAC: HIV at ICAAC PrEP 2103 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  8696. ICAAC: HIV at ICAAC "Mother-To-Child Transmission" 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  8697. ICAAC: HIV at ICAAC "HIV Cure" 2013 Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  8698. ICAAC: HIV at ICAAC Comorbidities 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  8699. ICAAC: HIV at ICAAC TAF 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  8700. ICAAC: HIV at ICAAC Dolutegravir 2013 - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (09/20/13)
     
  8701. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study - (09/19/13)
     
  8702. (Diet/Exercise/Lifestyle Improve Aging Measure - telomerase) Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study - (09/19/13)
     
  8703. Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation - (09/19/13)
     
  8704. Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study - (09/19/13)
     
  8705. 5-year Safety Evaluation of Maraviroc in HIV-1-Infected, Treatment-Experienced Patients - (09/19/13)
     
  8706. ICAAC: Worse Response to PegIFN/RBV for HCV After Transplant in HIV/HCV+ vs HCV+ - Written by Mark Mascolini - (09/18/13)
     
  8707. ICAAC: Tenofovir Vaginal Ring Protects 5 of 6 Macaques From SHIV After High-Dose Depo-Provera - Written by Mark Mascolini - (09/18/13)
     
  8708. ICAAC: Valacyclovir Has No Impact on CD4s or HIV Load in Placebo Trial of HSV-2+ - Written by Mark Mascolini - (09/18/13)
     
  8709. ICAAC: Combinations of HIV-1 Reverse Transcriptase Mutations L100I+K103N/S and L100I+K103R+V179D Reduce Susceptibility to Rilpivirine - (09/18/13)
     
  8710. ICAAC: Once-Daily Darunavir/Ritonavir (DRV/r) Versus Atazanavir/Ritonavir (ATV/r) on Insulin Sensitivity in HIV-Infected Persons Over 48 Weeks - (09/18/13)
     
  8711. ICAAC: CLINICAL CHARACTERIZATION OF HIV/HCV CO-INFECTED PATIENTS TREATED WITH DIRECT ACTING ANTIVIRAL AGENTS - (09/18/13)
     
  8712. ICAAC: Ritonavir Boosts Levels of MK-1439, a New Nonnucleoside--TDF Has No Impact - Written by Mark Mascolini - (09/17/13)
     
  8713. ICAAC: Identifying High Responder Populations to Crofelemer for Treatment of Noninfectious Diarrhea in HIV+ Individuals - (09/17/13)
     
  8714. ICAAC: Single-Tablet Regimen More Effective Impact of HAART Regimen on Adherence and Risk of Hospitalization in HIV/AIDS Patients Using VA Data - (09/17/13)
     
  8715. ICAAC: HIV Does Not Affect Chance of HCV Genotype 2 or 3 Responding to PegIFN/RBV - Written by Mark Mascolini - (09/17/13)
     
  8716. ICAAC: Raltegravir Safe for Pregnant Women and Their Newborns in 31-Case Study - Written by Mark Mascolini - (09/16/13)
     
  8717. ICAAC: Adherence Better, In-Hospital Rate Lower With Single-Tablet ART in US Veterans - Written by Mark Mascolini - (09/16/13)
     
  8718. ICAAC: Faster Bone Turnover With Atripla Than With Dolutegravir/ABC/3TC in 48 Weeks - Written by Mark Mascolini - (09/16/13)
     
  8719. ICAAC: SVR Tied to Lower Progression, Mortality in HIV/HCV+ With Moderate Fibrosis - the importance of treating coinfected patients - Written by Mark Mascolini - (09/16/13)
     
  8720. ICAAC: Host Immune Environment Significantly Impact the Level of CD4 Reconstitution and the Effects on Latent Reservoir in HIV Subjects Receiving ZFN CCR5 Modified CD4 T-cells (SB-728-T) - (09/16/13)
     
  8721. ICAAC: Host Immune Environment Significantly Impact the Level of CD4 Reconstitution and the Effects on Latent Reservoir in HIV Subjects Receiving ZFN CCR5 Modified CD4 T-cells (SB-728-T) - (09/16/13)
     
  8722. ICAAC: Sangamo BioSciences announces presentation of clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects treated with SB-728-T - (09/16/13)
     
  8723. ICAAC: Functional Control of Viremiain CCR5-Δ32 Heterozygous (Δ32HZ) HIV+ Subjects Following Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified AutologousCD4 T-cells (SB-728-T) - (09/16/13)
     
  8724. ICAAC: 48 Week Study of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF), Each in a Single Tablet Regimen (STR) with Elvitegravir, Cobicistat, and Emtricitabine [E/C/F/TAF vs. E/C/F/TDF] for Initial HIV Treatment - (09/16/13)
     
  8725. ICAAC: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF and to Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir DF in Patients ≥50 Years at Week 96 - (09/16/13)
     
  8726. ICAAC: Dolutegravir in Key Demographic Subgroups of Treatment-Experienced HIV-Infected Populations - (09/16/13)
     
  8727. ICAAC: Simplification to Abacavir/Lamivudine (ABC/3TC) + Atazanavir (ATV) From Tenofovir/Emtricitabine (TDF/FTC) + ATV/Ritonavir (r) Maintains Viral Suppression and Improves Bone Biomarkers: 48 Week ASSURE - (09/16/13)
     
  8728. ICAAC: SPIRIT: Simplifying to Rilpivirine/Emtricitabine/Tenofovir DF Single-Tablet Regimen from Boosted Protease Inhibitor Regimen Maintains HIV Suppression in the Black Subgroup Week 48 Results - (09/16/13)
     
  8729. ICAAC: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) has Durable Efficacy and Differentiated Long-Term Safety and Tolerability Versus Efavirenz/Emtricitabine/Tenofovir DF (ATR) at Week 144 in Treatment-Naïve HIV Patients - (09/16/13)
     
  8730. ICAAC: STaR: Virologic Outcomes and Safety in ART-Naïve Adult Females for Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Compared to Efavirenz/Emtricitabine/Tenofovir DF at Week 48 - (09/16/13)
     
  8731. ICAAC: Multicentre Open-Label Study of Switching from Atripla to Eviplera for Possible Efavirenz Associated CNS Toxicity* - (09/16/13)
     
  8732. ICAAC: Bioequivalence of a Dolutegravir, Abacavir and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food - (09/16/13)
     
  8733. ICAAC: Pharmacokinetics (PK) and Safety of Dolutegravir (DTG) in Subjects With Severe Renal Impairment and Healthy Controls - (09/16/13)
     
  8734. ICAAC: Pharmacokinetics (PK) and PK-Pharmacodynamic (PD) Relationship of Dolutegravir (DTG) in Integrase Inhibitor (INI)-Naive Subjects - (09/16/13)
     
  8735. ICAAC: Similar Cognition Outcomes After 48 Weeks for Tenofovir (TDF)/Emtricitabine (FTC) + Atazanavir/Ritonavir (ATV/r)-Experienced HIV+ Patients or Those Simplifying to Abacavir (ABC)/Lamivudine (3TC) + ATV - (09/16/13)
     
  8736. ICAAC: Fosamprenavir/Ritonavir (FPV/r) in Hepatically Impaired Subjects: An Observational Multi-Cohort Study - (09/16/13)
     
  8737. ICAAC: Efficacy and Safety of Raltegravir Among Latin American Patients in STARTMRK - (09/16/13)
     
  8738. ICAAC: Strong Correlation Between The Reduction Of Cellular HIV-DNA Load And Achievement Of HIV Plasma Viremia<2.5 Copies/ml In An Observation Period Of 4 Years Of Effective Antiretroviral Therapy In Naïve Patients - (09/16/13)
     
  8739. ICAAC: Lack of Clinically Relevant Drug Interactions Between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Telaprevir - (09/12/13)
     
  8740. ICAAC: Hepatitis C Eradication Reduces Liver Decompensation, HIV progression, and Death in HIV/HCV-coinfected Patients with non-Advanced Liver Fibrosis - (09/12/13)
     
  8741. ICAAC: Low Aspirin or Statin Use for Primary MI/Stroke Prevention at HIV Clinic - Written by Mark Mascolini - (09/14/13)
     
  8742. ICAAC: Low Aspirin or Statin Use for Primary MI/Stroke Prevention at HIV Clinic - Written by Mark Mascolini - (09/14/13)
     
  8743. ICAAC: One in 5 HIV+ Women in Spanish Group Has Anal Dysplasia, Predicted by Warts - Written by Mark Mascolini - (09/14/13)
     
  8744. ICAAC: Routine Vaccination Rates Highly Variable in French Adults With HIV - Written by Mark Mascolini - (09/14/13)
     
  8745. ICAAC: Adverse Event Rates Similar With High-Dose ATV/r and LPV/r During Pregnancy - Written by Mark Mascolini - (09/14/13)
     
  8746. ICAAC: Raltegravir Top PIs and NNRTIs in Retrospective Look at Cancer Patients - Written by Mark Mascolini - (09/14/13)
     
  8747. ICAAC: Second- and Third-Line ART Cost 24% and 41% More Than First Line in US - Written by Mark Mascolini - (09/14/13)
     
  8748. ICAAC: Darunavir and Atazanavir Have Similar Modest Impact on Insulin Sensitivity - Written by Mark Mascolini - (09/14/13)
     
  8749. ICAAC: Ritonavir Boosts Levels of MK-1439, a New Nonnucleoside--TDF Has No Impact - Written by Mark Mascolini - (09/14/13)
     
  8750. ICAAC: Stribild and Comparison Combinations Have Similar Efficacy in Over-50s and Under-50s - Written by Mark Mascolini - (09/14/13)
     
  8751. ICAAC: HPV-39 Predicts AIN and Anal Cancer in Spanish Group of Men With HIV - Written by Mark Mascolini - (09/14/13)
     
  8752. ICAAC: Dolutegravir Superior to Darunavir at 48 Weeks in Open-Label ART-Naive Trial (The FLAMINGO Study) - Written by Mark Mascolini - (09/14/13)
     
  8753. ICAAC: 48 Week Bone Marker Changes in Dolutegravir (DTG; GSK1349572) Plus Abacavir/Lamivudine (ABC/3TC) vs Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE Trial - (09/13/13)
     
  8754. ICAAC: Raltegravir Top PIs and NNRTIs in Retrospective Look at Cancer Patients - Written by Mark Mascolini - (09/12/13)
     
  8755. ICAAC: Erectile Dysfunction Drug Use Doubles Odds of Syphilis in US Men With HIV - Written by Mark Mascolini - (09/12/13)
     
  8756. ICAAC: Complera Not Inferior to Atripla Among Men and Women in 786-Person Trial - Written by Mark Mascolini - (09/12/13)
     
  8757. ICAAC: Crofelemer Effective for Severe or PI-Related Diarrhea in Placebo Trial - Written by Mark Mascolini - (09/12/13)
     
  8758. ICAAC: Status of Truvada (TVD) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States: An Early Drug Utilization Analysis - (09/12/13)
     
  8759. ICAAC: Meta-analysis of Safety Data From 8 Clinical Studies With GSK1265744, an HIV Integrase Inhibitor, Dosed Orally or as Injection of Long-Acting Parenteral Nanosuspension (LAP) - (09/12/13)
     
  8760. ICAAC: Switch from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir DF: Efficacy and Pharmacokinetics - (09/12/13)
     
  8761. ICAAC: Lack of Effect of Tenofovir Alafenamide (TAF) on Primary Osteoblasts In Vitro at Clinically Relevant Drug Concentrations - (09/12/13)
     
  8762. ICAAC: Long-Term Tolerability of Elvitegravir/cobicistat/emtricitabine/tenofovir DF Compared to Efavirenz/emtricitabine/tenofovir DF or Ritonavir-Boosted Atazanavir Plus Emtricitabine/tenofovir DF in Treatment-Naive HIV-1-Infected Subjects - (09/12/13)
     
  8763. ICAAC: Burden of Illness in a US Commercially Insured HIV Population: Treatment Patterns and Costs - (09/12/13)
     
  8764. ICAAC: Single-Pill Rilpivirine Regimen Maintains Suppression After Switch From Boosted PI - Written by Mark Mascolini - (09/11/13)
     
  8765. ICAAC: Second- and Third-Line ART Cost 24% and 41% More Than First Line in US - Written by Mark Mascolini - (09/11/13)
     
  8766. ICAAC: Cellular HIV DNA Predicts Plasma Load Under 2.5 Copies in 181-Person Study - Written by Mark Mascolini - (09/11/13)
     
  8767. ICAAC: Safety Analysis Gives Edge to Elvitegravir vs Efavirenz or Atazanavir at 96 Weeks - Written by Mark Mascolini - (09/11/13)
     
  8768. ICAAC: Good Safety Profile With Long-Acting Integrase Inhibitor, GSK744 - Written by Mark Mascolini - (09/11/13)
     
  8769. ICAAC: TAF, a Tenofovir Prodrug, Not Preferentially Loaded or Toxic in Osteoblasts - Written by Mark Mascolini - (09/11/13)
     
  8770. ICAAC: TDF/FTC-to-ABC/3TC Switch Maintains Viral Suppression, Eases Bone Markers - Written by Mark Mascolini - (09/11/13)
     
  8771. ICAAC: Almost Half of Early US PrEP Are Women, Often in Southern States - Written by Mark Mascolini - (09/11/13)
     
  8772. ICAAC: Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects - Written by Mark Mascolini - (09/11/13)
     
  8773. ICAAC: Novel Mutation Combinations Linked to Resistance to Rilpivirine - Written by Mark Mascolini - (09/11/13)
     
  8774. ICAAC: Tricky Pharmacokinetics May Not Matter in Switch From Efavirenz to Stribild - Written by Mark Mascolini - (09/11/13)
     
  8775. The CD4:CD38 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery - (09/11/13)
     
  8776. Cancers in HIV - (09/10/13)
     
  8777. Cancers in HIV+, recent published studies - (09/10/13)
     
  8778. Endurance Athletes/Exercise & Longevity in Tour de France Cyclcists & Risk of arrhythmias in 52 755 long-distance cross-country skiers & Relation of Vigorous Exercise to Risk of Atrial Fibrillation (3 studies) - (09/09/13)
     
  8779. Increased risk of neurological, cognitive deficits in youth with HIV - (08/30/13)
     
  8780. Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for HIV-Related Lymphoma - (08/30/13)
     
  8781. Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068 - (08/30/13)
     
  8782. Safety and Tolerability of Tenofovir for Preexposure Prophylaxis Among Men Who Have Sex With Men - Editorial - (08/30/13)
     
  8783. Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States - (08/30/13)
     
  8784. Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV-Negative Men After Single and Multiple Dosing - (08/30/13)
     
  8785. Physical exercise is associated with less neurocognitive impairment among HIV-infected adults - (08/29/13)
     
  8786. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial - (08/29/13)
     
  8787. The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/μL in the Post-Combination Antiretroviral Therapy Era - (08/29/13)
     
  8788. Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft - (08/28/13)
     
  8789. African-Americans & HIV Study Participation - (08/28/13)
     
  8790. New US Fed HIV Post Exposure Prophylaxis Guidelines (PEP) - (08/19/13)
     
  8791. FDA approves new drug Integrase Dolutegravir to treat HIV infection - (08/19/13)
     
  8792. Risk of AIDS-defining cancers among HIV1-infected patients in France between 1992 and 2009: Results from the FHDH-ANRS CO4 cohort - (08/16/13)
     
  8793. Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women - (08/14/13)
     
  8794. New York state - UPDATE: HIV Prophylaxis Following Occupational Exposure - (08/14/13)
     
  8795. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis - (08/14/13)
     
  8796. Switching to Unboosted Atazanavir Combined with Tenofovir and Emtricitabine Is Effective as Maintenance Therapy - (08/14/13)
     
  8797. Life Expectancy in HIV - (08/14/13)
     
  8798. Dolutegravir Global Access ViiV's new HIV drug wins US approval - (08/14/13)
     
  8799. Recent Bone/aging Studies - (08/14/13)
     
  8800. ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1 - (08/13/13)
     
  8801. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men - (08/12/13)
     
  8802. Use of Highly Active Antiretroviral Therapy Is Associated With Lower Prevalence of Anal Intraepithelial Neoplastic Lesions and Lower Prevalence of Human Papillomavirus in HIV-Infected Men Who Have Sex With Men - (08/12/13)
     
  8803. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system - (08/12/13)
     
  8804. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men - (08/12/13)
     
  8805. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999-2009 - (08/12/13)
     
  8806. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily - (08/12/13)
     
  8807. CD4 Decline Is Associated With Increased Risk of Cardiovascular Disease, Cancer, and Death in Virally Suppressed Patients With HIV - (08/12/13)
     
  8808. IAS: IAS Towards an HIV Cure Symposium, 29th-30th June 2013, Kuala Lumpur - Written for NATAP by David Margolis MD, UNC Chapel Hill and the Collaboratory of AIDS Researchers for Eradication (CARE) - (08/05/13)
     
  8809. How Exercise Changes Fat and Muscle Cells - (07/31/13)
     
  8810. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons - (07/30/13)
     
  8811. IAS: Cure Strategies: "Viral and Immune-Targeted Interventions: Hit Me with Your Best Shot" - Oral Session at IAS 2013 Kulala Lumpur June 30-July 3 - (07/30/13)
     
  8812. HPV Vaccine Reduced Oral HPV Prevalence - new study - (07/26/13)
     
  8813. CROI: HIV is an Independent Predictor of Lower Bone Mineral Density in HIV-positive Subjects Compared to HIV-negative Subjects - (07/24/13)
     
  8814. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study - (07/24/13)
     
  8815. Antiretroviral therapy: dolutegravir sets SAIL(ING) - Comment - (07/24/13)
     
  8816. Natural history of oral papillomavirus infection in men - (07/24/13)
     
  8817. IAS: Maraviroc Safety & Efficacy in Children Aged 2-18 - (07/24/13)
     
  8818. IAS: Update from Study A4001031: maraviroc pharmacokinetics in CCR5-tropic HIV-1-infected children aged 2-<18 years - (07/24/13)
     
  8819. IAS: Transmitted NNRTI Resistance Rate Climbing in US But Flat in Big European Countries - (07/24/13)
     
  8820. IAS: Number of regimens rather than cumulative exposure to antiretrovirals associated with lower bone mineral density in HIV-positive subjects - (07/22/13)
     
  8821. U.S. Congress Moves Closer to Lifting Ban on Transplanting Organs From HIV-Positive Donors - (07/22/13)
     
  8822. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis - (07/22/13)
     
  8823. High sensitive CRP is an independent risk factor for all fractures and vertebral fractures in elderly men: The MrOS Sweden study - (07/20/13)
     
  8824. IAS: In Utero HAART Exposure Associated with Decreased Growth among HIV-Exposed Uninfected Breast Fed Infants in Botswana - (07/20/13)
     
  8825. Evaluation of Risk for Late Language Emergence after In Utero Antiretroviral Drug Exposure in HIV-Exposed Uninfected Infants - (07/20/13)
     
  8826. IAS: Risk of cancer among HIV-positive women in British Columbia, Canada: Importance of screening and detection programs - (07/20/13)
     
  8827. IAS: Telaprevir Regimen for HIV/HCV Patients With PegIFN/RBV Failure and Cirrhosis - written by Mark Mascolini - (07/20/13)
     
  8828. IAS: Switching HIV Clinics Linked to Higher Mortality in Large Austrian Study - written by Mark Mascolini - (07/20/13)
     
  8829. IAS: Number of ART Regimens But Not Time on ART or Tenofovir Tied to Low Bone Density - written by Mark Mascolini - (07/20/13)
     
  8830. IAS: Maintenance Maraviroc/Raltegravir Controls HIV in Preliminary 10-Person Analysis - written by Mark Mascolini - (07/20/13)
     
  8831. IAS: ART Linked to Lower Sexual (But Not Drug-Injecting) Risk Behavior in Meta-Analysis - written by Mark Mascolini - (07/20/13)
     
  8832. IAS: MSM HIV Sex/Substance Abuse Risk Intervention in South Florida: Single 1-on-1 Session Works as Well as 4 Group Sessions in Trimming MSM Risk Behavior - written by Mark Mascolini - (07/20/13)
     
  8833. IAS: Rates of 2 Non-AIDS Cancers Higher With HIV in British Columbia Women - written by Mark Mascolini - (07/19/13)
     
  8834. IAS: Less Education Linked to Later HIV Diagnosis, Higher Mortality in 13-Cohort European Study - written by Mark Mascolini - (07/19/13)
     
  8835. IAS: No Dose Adjustment With Etravirine Plus ATV/r in Treatment Experienced: Randomized Trial - written by Mark Mascolini - (07/19/13)
     
  8836. IAS: Additional Vaccine-Covered HPV Genotypes Found Yearly in Older HIV+/HIV- Gay Men - written by Mark Mascolini - (07/19/13)
     
  8837. IAS: Maintenance Maraviroc/Raltegravir Controls HIV in Preliminary 10-Person Analysis - written by Mark Mascolini - (07/19/13)
     
  8838. IAS: Boosted PI (Kaletra) + NNRTIs Successful as 2nd-Line ART in Africa: EARNEST Study - "A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial" - (07/18/13)
     
  8839. IAS: Obesity Rate Differs by HIV Status, Gender, Race, and ARV Use in North Carolina - written by Mark Mascolini - (07/18/13)
     
  8840. IAS: HIV Detectable in Semen of MSM Despite Suppression in Blood: First Longitudinal Study - written by Mark Mascolini - (07/18/13)
     
  8841. IAS: Bioequivalence of darunavir (800mg) co-administered with cobicistat (150mg) as either a fixed-dose combination tablet or as single agents under fasted and fed conditions in healthy volunteers - (07/18/13)
     
  8842. IAS: Longitudinal study of bone mineral density and vitamin D levels among perinatally HIV-infected Thai adolescents receiving long-term antiretroviral therapy - (07/18/13)
     
  8843. IAS: HPV-16 Tied to Development and Clearance of Anal Cancer Precursor in Gay HIV+/HIV- Men - written by Mark - (07/18/13)
     
  8844. Interview with Study Investigator Andrea Savarino MD. "New HIV Cure Drug Combination Study - Drug-free remission of AIDS in monkeys: from anecdotal reports towards a globally scalable strategy" - "Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS" - (07/17/13)
     
  8845. IAS: HIV Detectable in Semen of MSM Despite Suppression in Blood: First Longitudinal Study - written by Mark Mascolini - (07/16/13)
     
  8846. Link Between Omega-3 Fatty Acids & Increased Prostate Cancer Risk - (07/16/13)
     
  8847. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey (HIV+ Men/heterosexual discordant couples) - (07/16/13)
     
  8848. New HIV Cure Combination Drug Study - (07/16/13)
     
  8849. IAS: Provider-Initiated Testing Turns Up Large Portion of Acute HIV Cases in MSM - (07/15/13)
     
  8850. IAS: Intimate Partner Violence in Half of US MSM Group Affects Condom-Negotiating Skills - (07/15/13)
     
  8851. IAS: In HIV-Discordant Gays, Viral Load Perception Strongly Linked to Unprotected Anal Sex - (07/15/13)
     
  8852. IAS: "Evolutionary Dead-End" After Emergence of Primary Dolutegravir Resistance Mutation? - (07/15/13)
     
  8853. IAS: HIV infection was associated with an increased risk of hip fracture, independently of age, gender and co-morbidities: a population-based cohort study - (07/15/13)
     
  8854. IAS: High Transplacental Transfer of Atazanavir But No Hyperbilirubinemia in Neonates - (07/15/13)
     
  8855. IAS: Efavirenz, Tenofovir, and FTC Levels Higher in Colonic Tissue Than Blood - (07/15/13)
     
  8856. Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers - (07/13/13)
     
  8857. IAS: The Effect of HIV Infection, ART and Ageing on Renal Function in PLHIV, Chelsea and Westminster Hospital London, UK 1996-2012 - (07/13/13)
     
  8858. IAS: Etravirine 200mg twice daily combined with atazanavir/ritonavir 300/100mg or 400/100mg once daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial - (07/13/13)
     
  8859. IAS: Intelence and prezista Once A Day Study (INROADS): A Multicenter, Single-Arm, Open-Label Study of Once Daily Combination of Etravirine (ETR) and Darunavir/Ritonavir (DRV/r) as Dual Therapy in Early Treatment-Experienced Subjects - (07/13/13)
     
  8860. IAS: Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years: Week 48 analysis of the ARIEL trial - (07/12/13)
     
  8861. IAS: ART Started in Primary Infection May "Block Immunologic Storm" in French OPTIPRIM - (07/12/13)
     
  8862. IAS: Starting ART Above 500 CD4s Cuts HIV DNA in PBMCs, Prompts Bigger CD4 Rebound - written by Mark Mascolini - (07/12/13)
     
  8863. IAS: Standard Triple Therapy Controls HIV Better Than Raltegravir/Darunavir at 48 Weeks RADAR Study - written by Mark Mascolini - (07/12/13)
     
  8864. IAS: High Levels of Two Antiretrovirals With Monthly or Quarterly Injections in Healthy Volunteers: GSK744 LAP + TMC278 LA - written by Mark Mascolini - (07/12/13)
     
  8865. IAS: Long term therapeutic success of etravirine in switch and naive patients - written by Mark Mascolini - (07/12/13)
     
  8866. FDA Approves New U.S. Labeling for ISENTRESS® (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients - (07/10/13)
     
  8867. Interleukin-7 promotes HIV persistence during antiretroviral therapy - "IL-7 does not represent a suitable candidate therapeutic strategy for HIV eradication"....(AIDS Clinical Trials Group protocol 5214) - (07/10/13)
     
  8868. IAS: Association between HMG-CoA reductase inhibitors (statins) use and cancer occurrence among HIV-1 treated patients - Statin use reduced incidence of cancers - (07/11/13)
     
  8869. IAS: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine (STB) and Cobicistat (COBI) in HIV Infected Patients with Mild to Moderate Renal Impairment - (07/11/13)
     
  8870. IAS: Early initiation of antiretroviral therapy for individuals with HIV infection: A systematic review - (07/11/13)
     
  8871. IAS: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Integrated Week 96 Subgroup Analyses - (07/11/13)
     
  8872. IAS: EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF) TO ABACAVIR (ABC)-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART), WITH OR WITHOUT ATAZANAVIR - (07/11/13)
     
  8873. IAS: STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Has Non-Inferior Efficacy Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes - (07/11/13)
     
  8874. IAS: Lower bone mineral density independently associated with both increased bone turnover and HIV-1 infection in HIV-positive subjects compared to HIV-negative subjects - (07/11/13)
     
  8875. IAS: HIV Prevention at IAS 2013 - Jared Baeten, MD PhD Andrew Mujugira, MBChB MSc MPH Connie Celum, MD MPH University of Washington - (07/10/13)
     
  8876. IAS: Non-Infectious Complications of HIV and Antiretroviral Therapy - IAS 2013 (Kuala Lumpur, Malaysia) written by Roger Bedimo, MD VA North Texas Health Care System - (07/10/13)
     
  8877. IAS: Stem-cell transplants may purge HIV..... Post-Transplant and Off Drugs, H.I.V. Patients Are Apparently Virus-Free - (07/10/13)
     
  8878. IAS: Dolutegravir is Non-Inferior to Raltegravir and Shows Durable Response Through 96 Weeks: Results From the SPRING-2 Trial - (07/09/13)
     
  8879. IAS: Lower Peak Viral Load, Higher CD4/CD38 Ratio Linked to Low PBMC Reservoir - written by Mark Mascolini - (07/09/13)
     
  8880. IAS: BIT225, a Novel Assembly Inhibitor, Cuts HIV Load in Monocyte Reservoir - written by Mark Mascolini - (07/09/13)
     
  8881. IAS: Independent Predictors of Carotid Intimal Thickness Differ Between HIV+ and HIV- Patients with Respect to Traditional Cardiac Risk Factors, Risk Calculators, Lipid Subfractions, & Inflammatory Markers (poster) - (07/09/13)
     
  8882. IAS: Independent Predictors (slides) of Carotid Intimal Thickness Differ Between HIV+ and HIV- Patients with Respect to Traditional Cardiac Risk Factors, Risk Calculators, Lipid Subfractions, and Inflammatory Markers (slide presentation) - (07/09/13)
     
  8883. IAS: Overall First-Line ART Efficacy Only 60% at 82 Weeks in Meta-Analysis - written by Mark Mascolini - (07/09/13)
     
  8884. IAS: Life Expectancy With HIV Jumps 15 Years From 2000-2002 to 2006-2007 in US, Canada - written by Mark Mascolini - (07/09/13)
     
  8885. IAS: Sustained Response to Dolutegravir Through 96 Weeks in Antiretroviral Naive - written by Mark Mascolini - (07/09/13)
     
  8886. IAS: Different Predictors of ART Switches in IDUs and non-IDUs - written by Mark Mascolini - (07/09/13)
     
  8887. IAS: Higher Rate of Triple-Class Failure in Pernitally Infected Than Heterosexually Infected - written by Mark Mascolini - (07/09/13)
     
  8888. IAS: Quick CNS Improvement After Switch From Efavirenz to Raltegravir - written by Mark Mascolini - (07/05/13)
     
  8889. IAS: Maintenance Therapy With Raltegravir/Etravirine: Virologic Failure Rate 5% at 12 Months - written by Mark Mascolini - (07/05/13)
     
  8890. IAS: Bid to cure HIV ramps up, New Baby Cure Study/IMPAACT - (07/05/13)
     
  8891. IAS: First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety, and tolerability in healthy adults - (07/05/13)
     
  8892. IAS: In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm3 achieves better HIV-1 reservoirs' depletion (HIV-DNA) and T cell count restoration - (07/05/13)
     
  8893. IAS: Short-Term ART in Primary HIV-Infection & Decrease in HIV-DNA...... "....showed that 12 or 48 weeks of ART significantly decreases the cell-associated HIV-DNA. Also that viral load at 'baseline' associates with HIV-DNA levels at baseline and after therapy" - (07/05/13)
     
  8894. IAS: HIV[ART] and HCV infections independently contribute to lower bone mineral density but have different effects on bone turnover markers - (07/05/13)
     
  8895. IAS: Less Bone Loss With Raltegravir Than NRTIs in Second-Line Regimens - written by Mark Mascolini - (07/05/13)
     
  8896. IAS: Low-Dose (400-mg) Efavirenz vs Standard 600-mg Dose Studied, Found Non-Inferior Low-Dose (400-mg) Efavirenz Not Inferior to Standard 600-mg Dose - written by Mark Mascolini - (07/05/13)
     
  8897. IAS: Kidney Function Improves With TDF-to-ABC Switch Regardless of Atazanavir Use - written by Mark Mascolini - (07/05/13)
     
  8898. IAS: Dolutegravir Effective at 24/48 Weeks in People With Integrase Inhibitor Mutations - written by Mark Mascolini - - (07/03/13)
     
  8899. IAS: Dolutegravir Superior to Raltegravir at 48 Weeks in Integrase Inhibitor Naive - written by Mark Mascolini - - (07/03/13)
     
  8900. IAS: Renal Safety Similar With Dolutegravir, Raltegravir, and Efavirenz in Antiretroviral Naive - written by Mark Mascolini - - (07/03/13)
     
  8901. IAS: Two Boston Stem-Cell Transplant Patients Stop Antiretrovirals With No Rebound - written by Mark Mascolini - - (07/03/13)
     
  8902. IAS: Dolutegravir (DTG) is Superior to Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: Week 48 Results From SAILING (ING111762) - (07/03/13)
     
  8903. IAS: Once-Daily Dolutegravir (DTG; GSK1349572) Has a Renal Safety Profile Comparable to Raltegravir (RAL) and Efavirenz in Antiretroviral (ART)-Naive Adults: 48 Week Results From SPRING-2 (ING113086) and SINGLE (ING114467) - (07/03/13)
     
  8904. IAS: WHO issues new ART HIV recommendations calling for earlier treatment - More Conservative Than HHS ART Guidelines - (07/03/13)
     
  8905. IAS: Aging & Cure - a talk by Steve Deeks, MD at the IAS Conference in Kuala Lumpur - (07/03/13)
     
  8906. IAS: Phase 3 Assessment of Dolutegravir (DTG) 50 mg Twice Daily (BID) in HIV-1-Infected Subjects With Raltegravir (RAL) and/or Elvitegravir (EVG) Resistance in VIKING-3: Week 24 Results of All 183 Subjects Enrolled - (07/03/13)
     
  8907. IAS: New HIV 'Cure' Drug To Activate HIV Replication Cyclic Panobinostat (LBH589) dosing in HIV-1 patients: Findings from the CLEAR trial - (07/03/13)
     
  8908. IAS: SAFETY OF RIBAVIRIN-CONTAINING REGIMENS OF ABT-450/r, ABT-333, AND ABT-267 FOR THE TREATMENT OF HCV GENOTYPE 1 INFECTION AND EFFICACY IN SUBJECTS WITH RIBAVIRIN DOSE REDUCTIONS - (07/03/13)
     
  8909. IAS: End-Stage Renal Disease Incidence 2 to 4 Times Higher With HIV in North America - written by Mark Mascolini - (07/02/13)
     
  8910. IAS: Systemic Review Sees Evidence for Advantage to Starting ART Above 500 CD4s - written by Mark Mascolini - (07/02/13)
     
  8911. IAS: Immune Activation Tied to Viral Blips in People Taking Suppressive ART - written by Mark Mascolini - (07/02/13)
     
  8912. IAS: Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals - (07/02/13)
     
  8913. IAS: Pharmacokinetic (PK) interactions between Boceprevir (BOC) and Atazanavir/r (ATV/r) or Raltegravir (RAL) in HIV/HCV coinfected patients (pts) - (07/02/13)
     
  8914. IAS: Functional cure after long term HAART initiated during early HIV infection - a case study - (07/02/13)
     
  8915. IAS: 5-drug HAART during Primary HIV Infection Leads to a Reduction of Proviral DNA Levels in Comparison to Levels Achievable during Chronic Infection - (07/02/13)
     
  8916. IAS: Effects of renal tubular dysfunction on bone - (07/02/13)
     
  8917. IAS: Cardiac steatosis (the fatty heart) in cardiovascularly asymptomatic persons with HIV infection - (07/02/13)
     
  8918. IAS: HIV Detectable in Semen of MSM Despite Suppression in Blood: First Longitudinal Study - written by Mark Mascolini - (07/01/13)
     
  8919. IAS: Efficacy and Tolerability of Maraviroc for Children With Antiretroviral Experience - written by Mark Mascolini - (07/01/13)
     
  8920. IAS: Acute Retroviral Syndrome Score Correlates With Signals of Progression - written by Mark Mascolini - (07/01/13)
     
  8921. IAS: New HIV Life Expectancy study: Women and Aboriginals in British Columbia Fall Far Short of Normal Life Expectancy - written by Mark Mascolini - (07/01/13)
     
  8922. IAS: Low CD4/CD38 Ratio Predicts Non-AIDS Morbidity, Mortality in ART Responders - written by Mark Mascolini - (07/01/13)
     
  8923. IAS: Good 48-Week Response to Darunavir in Children With Antiretroviral Experience - written by Mark Mascolini - (07/01/13)
     
  8924. IAS: Low-Dose Lopinavir/Ritonavir Tablet Noninferior to Full Dose in Thai Children - written by Mark Mascolini - (07/01/13)
     
  8925. IAS: Long-term virological outcome in HIV-infected children on ART in the UK/Ireland - Higher Failure Rate With Nevirapine Than Efavirenz or PIs in Children in UK and Ireland - written by Mark Mascolini - (07/01/13)
     
  8926. HIV-1 Prevention With ART and PrEP: Mathematical Modeling Insights Into Resistance, Effectiveness, and Public Health Impact - Editorial - (06/27/13)
     
  8927. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study - CD4 & viral load matter: restore or maintain the CD4 count above 500; early treatment initiation - (06/26/13)
     
  8928. Kidney-injury analysis "reassuring" for high-potency statins in PROVE-IT, A to Z - (06/26/13)
     
  8929. Invasive Meningococcal Disease in Men Who Have Sex With Men - (06/26/13)
     
  8930. CROI: CMV and HIV Infections Have Opposite Effects on CD38+ T Cell Differentiation and Proliferation - (06/23/13)
     
  8931. CROI: Phenotypic CD38+ T cell Defects in Treated HIV Infection are Distinct from Those of Aging, Predict Mortality, and May Be Prevented by Earlier ART - (06/23/13)
     
  8932. IDU Tenofovir PrEP Study Commentaries - (06/23/13)
     
  8933. Universal Antiretroviral Therapy for HIV Infection: Should U.S. Treatment Guidelines Be Applied to Resource-Limited Settings? - (06/23/13)
     
  8934. HIV/Aging >50 Majority in SF/More Comorbidities in HIV+ vs HIV- Study - (06/23/13)
     
  8935. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population - (06/23/13)
     
  8936. ResisWksp: Report on International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies - June 4-8, 2013 Toronto, Canada written by Mark A. Wainberg McGill University AIDS Centre, Montreal, Canada (06/17/13)
     
  8937. World Health Organization Issues Interim Guidance on Bedaquiline - (06/17/13)
     
  8938. HIV pre-exposure prophylaxis in injecting drug users - Comment - (06/17/13)
     
  8939. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial - (06/14/13)
     
  8940. A cure for HIV: where we've been, and where we're headed - (06/14/13)
     
  8941. Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1-Infected Subjects & BMS626529 Attachment Inhibitor - (06/14/13)
     
  8942. ResisWksp: Primary and Secondary Analyses of Emergent Drug Resistance through Week 48 from the STaR Study: Rilpivirine/Emtricitabine/Tenofovir DF vs. Efavirenz/Emtricitabine/Tenofovir DF Single-Tablet Regimens (06/14/13)
     
  8943. ResisWksp: Genotypic Analyses of Pre-Existing HIV-1 Drug Resistance in Proviral HIV-1 DNA from PBMCs in Suppressed Patients Switching to RPV/FTC/TDF (06/14/13)
     
  8944. ResisWksp: Primary and Secondary Analyses of Emergent Drug Resistance through Week 96 from the Phase 3 Studies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (06/14/13)
     
  8945. AGE: Comorbidities and coinfections among HIV patients 50 years and older compared to HIV-negs in large US healthcare database - (06/12/10)
     
  8946. ResisWksp: Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B (06/12/13)
     
  8947. Vegetarian diet linked to longer life, less CVD - (06/12/13)
     
  8948. ResisWksp: Advanced Mechanistic Studies of GSK1265744, a New HIV Integrase Inhibitor (INI) Dosed by Oral Administration or Long-Acting Parenteral Injection (06/11/13)
     
  8949. ResisWksp: Integrase Genotypic and Phenotypic Predictors of Antiviral Response to Dolutegravir (DTG) in Subjects With Resistance to Integrase Inhibitors (INIs) (06/11/13)
     
  8950. ResisWksp: Evolution of Integrase in Virus at Protocol-Defined Virologic Failure From the VIKING-3 Study (06/11/13)
     
  8951. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Evaluation of the Drug Interaction Potential Between the Pharmacokinetic Enhancer Cobicistat and Tenofovir Disoproxil Fumarate in Healthy Subjects - (06/11/13)
     
  8952. CROI: CROI 2013 Adult Neurology Presentation and Abstracts Written for NATAP by Kevin R. Robertson, Ph.D.1, Charles Upton2 contributions by Jules Levin - (06/10/13)
     
  8953. ResisWksp: Antiviral Activity of Tenofovir Alafenamide (TAF) against Major NRTI-Resistant Viruses: Improvement over TDF/TFV is Driven by Higher TFV-DP Loading in Target cells (06/09/13)
     
  8954. ResisWksp: Analysis and Characterization of treatment-Emergent Resistance in ART-Experienced, Integrase Inhibitor-Naïve Subjects With Dolutegravir (DTG) vs Raltegravir (RAL) in SAILING (ING111762) (06/09/13)
     
  8955. ResisWksp: Epidemiology of Dolutegravir (DTG) Resistance in ~700 RAL-Resistant Isolates (06/09/13)
     
  8956. Lactobacillus Bacteremia Associated With Probiotic Use in a Pediatric Patient With Ulcerative Colitis - (06/05/13)
     
  8957. Coenzyme Q10 supplementation reduces HF admissions and improves survival: Q-SYMBIO - (06/05/13)
     
  8958. 'People Think It's Over' - Spared Death, Aging People With H.I.V. Struggle to Live - (06/05/13)
     
  8959. Probiotic Safety and Risk Factors - (06/04/13)
     
  8960. Frequency and implications of HIV superinfection - (05/31/13)
     
  8961. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials - (05/31/13)
     
  8962. Dynamics of CD38 T-Cell Activation After Discontinuation of HIV Treatment Intensification - (05/31/13)
     
  8963. People fifty years or older now account for the majority of AIDS cases in San Francisco, California, 2010 - (05/29/13)
     
  8964. Resistance Patterns and Response to Entecavir Intensification Among HIV-HBV-Coinfected Adults With Persistent HBV Viremia - (05/29/13)
     
  8965. Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach (WIHS) - (05/29/13)
     
  8966. Two studies address diabetes risks with statins-one good news, one so-so - (05/29/13)
     
  8967. Autonomic Nervous System Dysfunction & Inflammation: Autonomic-mediated immunomodulation and potential clinical relevance - (05/29/13)
     
  8968. CROI: CROI 2013: Comorbidities- Aging/Kidney/Heart/Belly Fat/HCV/Bone/Statins/Frailty - (05/27/13)
     
  8969. CROI: Very Early Viral Infection of the Central Nervous System without Evidence of Compartmentalization During Acute HIV-1 Infection - (05/27/13)
     
  8970. CROI: VLA-4 (Tysabri) Treatment Blocks Virus Traffic to the Gut and Brain Early, and Stabilizes CNS Injury Late in Infection - (05/27/13)
     
  8971. CROI: Lower Baseline CD4 is Associated with Greater Loss of Bone Mineral Density after ART Initiation - (05/27/13)
     
  8972. CROI: Symptoms of Autonomic Dysfunction in HIV-Infected Patients Receiving Stable ART: "The biggest difference was seen within the male sexual dysfunction domain with 47% of the HIV group experiencing symptoms, compared to 11% of the control group experiencing symptoms" - (05/27/13)
     
  8973. Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability - (05/27/13)
     
  8974. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1 infected men who have sex with men - (05/27/13)
     
  8975. Grand Challenges: Improving HIV Treatment Outcomes by Integrating Interventions for Co-Morbid Mental Illness - (05/27/13)
     
  8976. Fish oils to prevent CHD . . . it's now official: A definite "no go" - (05/27/13)
     
  8977. Underestimate of HIV reservoirs threatens purging approach - (05/27/13)
     
  8978. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Maraviroc, Boceprevir, Telaprevir PK in Healthy Volunteers: The effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers - (05/26/13)
     
  8979. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Dolutegravir, Boceprevir, Telaprevir PK: The effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics, in Healthy Adult Subjects - (05/26/13)
     
  8980. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetic (PK) interactions between Boceprevir (BOC) and Atazanavir/r (ATV/r) or Raltegravir (RAL) in HIV/HCV coinfected patients (pts) - (05/26/13)
     
  8981. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml - (05/26/13)
     
  8982. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1-Infected Pregnant Women - (05/26/13)
     
  8983. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Establishing darunavir dosing recommendations in treatment-naïve and treatment-experienced pediatric patients - (05/26/13)
     
  8984. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Pharmacodynamics of Once-Daily Etravirine and Darunavir/Ritonavir in Early Treatment-Experienced Subjects - (05/26/13)
     
  8985. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents in healthy volunteers - (05/26/13)
     
  8986. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics, Metabolism and Excretion of Tenofovir Alafenamide (TAF) - (05/26/13)
     
  8987. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Evaluation of the Drug Interaction Potential Between the Pharmacokinetic Enhancer Cobicistat and Tenofovir Disoproxil Fumarate in Healthy Subjects - (05/26/13)
     
  8988. Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T - (05/22/13)
     
  8989. CROI: Aging with HIV: Where do we stand after CROI 2013? David Alain Wohl, MD - Associate Professor, Division of Infectious Diseases, The University of North Carolina at Chapel Hill - (05/20/13)
     
  8990. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Clinical Pharmacology at the 14th Workshop on Clinical Pharmacology of HIV Therapy and HCV - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (05/20/13)
     
  8991. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Darunavir Dosing Determined for Naive and Experienced Children and Teens - written by Mark Mascolini - (04/29/13)
     
  8992. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy No Clinically Significant Interactions Between Boceprevir or Telaprevir and Dolutegravir - written by Mark Mascolini - (04/29/13)
     
  8993. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Protease Inhibitors Boost Levels of Cenicriviroc, a CCR5/CCR2 Antagonist - written by Mark Mascolini - (04/29/13)
     
  8994. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Ribavirin Trough Affects Early HCV Response With Unfavorable IL28B Profile - written by Mark Mascolini - (04/29/13)
     
  8995. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Once-Daily Etravirine Plus Darunavir/Ritonavir With No NRTIs: 48-Week PKs - written by Mark Mascolini - (04/25/13)
     
  8996. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Tenofovir Exposure Moderately Higher With vs Without Cobicistat in Healthy Volunteers - written by Mark Mascolini - (04/25/13)
     
  8997. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Split Dosing Versus Single Dose of Long-Acting Injected Integrase Inhibitor - written by Mark Mascolini - (04/24/13)
     
  8998. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Gender and Weight Affect Long-Acting Rilpivirine Levels in Healthy Volunteers - written by Mark Mascolini - (04/24/13)
     
  8999. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Labs Inaccurate in 18% of Darunavir, Etravirine, or Raltegravir Measures - written by Mark Mascolini - (04/23/13)
     
  9000. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Variable Boceprevir Impact on Levels of Atazanavir and Raltegravir - written by Mark Mascolini - (04/23/13)
     
  9001. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy Higher Maraviroc Levels With HCV Agents Boceprevir and Telaprevir - written by Mark Mascolini - (04/23/13)
     
  9002. 14th Intrntnl Wrkshp Clinical Pharm HIV Therapy In-Hospital Antiretroviral Prescribing Errors Common and Often Uncorrected - written by Mark Mascolini - (04/23/13)
     
  9003. Using Ultradeep Pyrosequencing to Study HIV-1 Co-receptor Usage in Primary and Dual Infection - (04/20/13)
     
  9004. Effect of HIV on Liver Fibrosis Among HCV-Infected African Americans - (04/20/13)
     
  9005. HIV-1 Concentrations in Human Breast Milk Before and After Weaning 'ART recommended' - (04/19/13)
     
  9006. A light in the cognitive fog? Editorial on CPE/ART Neuro Penetraion - (04/19/13)
     
  9007. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia - (04/19/13)
     
  9008. Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202 - (04/16/13)
     
  9009. L-Carnitine - Good or Bad for Your Heart? Culprit in Heart Disease Goes Beyond Meat's Fat (there are 3 articles in this report) - (04/15/13)
     
  9010. A New Endorsement for Fish - (04/15/13)
     
  9011. Association of Functional Impairment with Inflammation and Immune Activation in HIV-1-Infected Adults on Effective Antiretroviral Therapy - (04/15/13)
     
  9012. Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse transcriptase inhibitors induces genotoxicity persistent for up to 3 years of age - (04/15/13)
     
  9013. Antiretroviral Therapy and Pre-exposure Prophylaxis: Combined Impact on HIV-1 Transmission and Drug Resistance in South Africa/Editorial - (04/15/13)
     
  9014. Molecule in meat may increase heart disease risk - (04/15/13)
     
  9015. L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis - (04/15/13)
     
  9016. Plasma Phospholipid Long-Chain ω-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults: A Cohort Study - (04/15/13)
     
  9017. Interferon-a as a "Curative Strategy" or Harmful? - (04/12/13)
     
  9018. Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation - (04/11/13)
     
  9019. HIV and Recent Illicit Drug Use Interact to Affect Verbal Memory in Women - (04/11/13)
     
  9020. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis - (04/11/13)
     
  9021. About That Baby Who Was 'Cured' of HIV - (04/10/13)
     
  9022. A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007) - see published study below - (04/10/13)
     
  9023. CROI: Neuroimaging Correlates of Prior Immunosuppression and Cognitive Status in HIV - (04/10/13)
     
  9024. CROI: Gold Nanoparticles to Improve Drug Delivery to the Central Nervous System - (04/10/13)
     
  9025. CROI: Research Spotlight: Nanomedicines for HIV therapy - (04/10/13)
     
  9026. CROI: Small Magnetite Antiretroviral (SMART) Nanoparticles for Targeted Drug Delivery to Viral Reservoirs - (04/10/13)
     
  9027. CROI: Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles...."Studies to determine whether bioequivalence can be obtained with a lower dose of SDN are now planned in healthy volunteers" - (04/10/13)
     
  9028. CROI: New Approaches to ART Drug Delivery: long-acting ARTs, nanoparticles - (04/10/13)
     
  9029. Framingham scores could predict cognitive decline better than a standard dementia score - (04/09/13)
     
  9030. Molecule in meat may increase heart disease risk - (04/09/13)
     
  9031. CROI: High Grade Liver Steatosis and Cognitive Impairment in HIV+ patients - (04/09/13)
     
  9032. CROI: Cognitive Rehabilitation Protocol in HIV/AIDS outpatients with ANI and MND: results and clinical applicability - (04/09/13)
     
  9033. CROI: Associations Between Regional Fat Deposition and Neurocognitive Function in the Multicenter AIDS Cohort Study - (04/09/13)
     
  9034. CROI: Detectable HIV DNA is Associated with Reduced Cerebellar and Subcortical Gray Matter Volumes - (04/08/13)
     
  9035. Amount of HIV DNA in Peripheral Blood Mononuclear Cells is Proportional to the Severity of HIV-1-Associated Neurocognitive Disorders - (04/08/13)
     
  9036. Regional Cortical Thinning Associated with Detectable Levels of HIV DNA....."Our findings support initiation of HAART during the primary phase of infection for optimal depletion of the PBMC HIV DNA reservoir" - (04/08/13)
     
  9037. CROI: Maraviroc plus Raltegravir dual Therapy in Aviremic HIV infected Patients with Lipodystrophy : Results from the ROCnRAL ANRS 157 Study. - (04/07/13)
     
  9038. CROI: Maraviroc Intensification in Virally Suppressed HIV Infected Subjects Leads to Improvement in Neurocognitive Test Performance and Declines in Immune Activation - (04/07/13)
     
  9039. CROI: Impact of Interleukin 7 and Raltegravir plus Maraviroc intensification on total HIV DNA reservoir: Results from ERAMUNE 01 - (04/07/13)
     
  9040. CROI: HIV Controllers Have Inflammation & ART Should Be "Considered", study investigators say - (04/06/13)
     
  9041. CROI: Fall Frequency and Associated Factors among Men and Women with or at Risk for HIV Infection - (04/05/13)
     
  9042. CROI: Clinical Pharmacology at CROI 2013 - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (04/04/13)
     
  9043. CROI: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of MK-1439, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects - (04/04/13)
     
  9044. CROI: SINGLE AND MULTIPLE DOSE DOLUTEGRAVIR PHARMACOKINETICS IN THE GENITAL TRACT AND COLORECTUM OF HIV NEGATIVE MEN AND WOMEN - (04/04/13)
     
  9045. CROI: Dolutegravir Has No Effect on the Pharmacokinetics of Methadone or Oral Contraceptives With Norgestimate and Ethinyl Estradiol - (04/04/13)
     
  9046. Sustained Viral Suppression and Higher CD4+ T-Cell Count Reduces the Risk of Persistent Cervical High-Risk Human Papillomavirus Infection in HIV-Positive Women - (04/04/13)
     
  9047. Exposure to Antiretrovirals (ARVs) and Risk of Renal Impairment among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study - (04/04/13)
     
  9048. Nephrotoxicity of Antiretroviral Agents: Is the List Getting Longer? Editorial - (04/04/13)
     
  9049. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs - (04/03/13)
     
  9050. CROI: A Longitudinal Study of the Effects of Ageing and HIV-1 Infection on Cognitive Performance - (04/02/13)
     
  9051. CROI: Follow-up of HIV-Associated Neurocognitive Disorders in the cART Era: the Neuradapt Study - (04/02/13)
     
  9052. CROI: Pharmacokinetic study of raltegravir in HIV-infected patients with end stage liver disease: LIVERAL ANRS 148 study - (04/02/13)
     
  9053. CROI: Cardiovascular-related Deaths in HIV-infected Patients between 2000 and 2010, The ANRS EN20 Mortalite 2010 Survey: the 3rd leading cause of death was liver disease 10.8%, non-AIDS cancers 22.1%, AIDS 25%, CVD deaths/sudden deaths 13.6% - (04/02/13)
     
  9054. CROI: Hodgkin Lymphoma Is Almost As Prevalent As Non-Hodgkin Lymphoma in HIV+ Patients With Sustained Viral Suppression And Limited Immune Deficiency - (04/01/13)
     
  9055. The cost-effectiveness of expanded HIV screening in the United States (more frequent testing recommended, every 3 months for high-risk individuals) - (04/01/13)
     
  9056. Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers - (04/01/13)
     
  9057. HIV and the Kidney Review - (03/31/13)
     
  9058. Chronic Kidney Disease: A Clinical Model of Premature Aging - (04/01/13)
     
  9059. Talk of HIV cure goes viral - (04/01/13)
     
  9060. CROI: Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-Infection - (04/01/13)
     
  9061. CROI: Hepatitis C Co-infection and the Risk of Chronic Kidney Disease in HIV-infected Individuals: Does Hepatitis C Viremia Matter? - (04/01/13)
     
  9062. CROI: Factors Associated with Tenofovir-related Adverse Events and Drug Exposure in HIV-positive Patients - (04/01/13)
     
  9063. CROI: Common Conditions - Age, Low BMI, Mild Renal Impairment, Ritonavir Use - Increase Tenofovir Exposure in a Large Unselected Cohort of HIV+ Women - (04/01/13)
     
  9064. CROI: Hype and the HIV cure (baby/CROI) - (04/01/13)
     
  9065. CROI: Doctors claim to have cured girl of HIV (baby/CROI) - (04/01/13)
     
  9066. CROI: Hepatitis C Co-infection and the Risk of Chronic Kidney Disease in HIV-infected Individuals: Does Hepatitis C Viremia Matter? - (04/01/13)
     
  9067. CROI: Protease Inhibitor Monotherapy Is Not Associated with a Higher Rate or a Different Pattern of Neurocognitive Impairment than Triple Drug Therapy - (04/01/13)
     
  9068. CROI: HIV is an Independent Predictor of Lower Bone Mineral Density in HIV-positive Subjects Compared to HIV-negative Subjects - (04/01/13)
     
  9069. CROI: 25-hydroxy Vitamin D and Bone Mineral Density (BMD) Increased with Intermittent ART versus Continuous ART in the SMART Body Composition Substudy - (04/01/13)
     
  9070. CROI: Fall Frequency and Associated Factors among Men and Women with or at Risk for HIV Infection - (04/01/13)
     
  9071. CROI: Changing CSF Concentrations of Neurofilament Light Chain, Tau and Amyloid Proteins, Characterize Evolving CNS Injury in HIV-1 Infection - (04/01/13)
     
  9072. CROI: Low-Level HIV RNA Declines Over Time in CSF but not in Plasma, "HIV between 2-50 c/ml .....worse cognitive functioning" - (04/01/13)
     
  9073. CROI: Reduced Region-Specific Corpus Callosum Volumes Correlate with Low Nadir CD4 an Decreased Cognition in HIV-Infected Carriers of the ApoE4 Allele - (04/01/13)
     
  9074. CROI: Continued Declines in AIDS and non-AIDS Related Mortality with Persistently Higher Death Rates among Blacks and the Publicly Insured in the HIV Outpatient Study (HOPS), 1996-2009 - (04/01/13)
     
  9075. CROI: Prevalence of Chronic Kidney Disease Among HIV-infected Adults in Care in the United States Medical Monitoring Project, 2009 - (04/01/13)
     
  9076. CROI: Update from 20th CROI: Bones, Vitamin D, Frailty - Todd T. Brown, MD, PhD Association Professor of Medicine and Epidemiology Division of Endocrinology and Metabolism Johns Hopkins University - (04/01/13)
     
  9077. CROI: A Randomized, Controlled Trial of a CNS-Targeted Antiretroviral Therapy (ART) Strategy for HIV-Associated Neurocognitive Disorders - (03/29/13)
     
  9078. CROI: Triple Combination Therapy Telaprevir vs Boceprevir, in Spain, Early Results, in Mono- and Coinfected - (03/29/13)
     
  9079. CROI: HIV Protease Inhibitors & HIV Recombinant Proteins Induce Senescence & Alter Fate of Human Bone Marrow Mesenchymal Stem Cells - (03/28/13)
     
  9080. CROI: Proteinuria is Associated with Neurocognitive Impairment in HIV Infected Subjects Enrolled in the AIDS Clinical Trials Group (ACTG) Longitudinal Cohort Study (ALLRT) - (03/28/13)
     
  9081. CROI: Cardiac function is altered in Aged Transgenic AIDS Mice in vivo: Insights into Age-related HIV-1 Changes in Patients - (03/28/13)
     
  9082. CROI: Increased Hot Flash Severity and Burden among Perimenopausal HIV-infected Women - (03/28/13)
     
  9083. CROI: Change in Lean Body Mass and Association with Bone Mineral Density Change in Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202 - (03/28/13)
     
  9084. CROI: Fracture Among Older and Younger HIV+ Medicare Beneficiaries - (03/28/13)
     
  9085. CROI: HIV+ Status, Low Income, and Active Hepatitis C Virus Infection are Associated with Shorter Leukocyte Telomere Length in a Cohort of HIV+ and HIV- Adults - (03/28/13)
     
  9086. CROI: SECOND-LINE: Ritonavir-Boosted-Lopinavir with 2-3N(t)RTI or Raltegravir in HIV-Positive Subjects Virologically Failing First-Line NNRTI/2N(t)RTI antiretroviral therapy - (03/28/13)
     
  9087. CROI: Reversibility of tenofovir-associated decline in renal function - (03/22/13)
     
  9088. CROI: Tenofovir Alafenamide Pharmacokinetics in Renal Impairment: Potential for Administration without Dose Adjustment - (03/22/13)
     
  9089. CROI: End Organ HIV Reservoirs - Integrated HIV DNA and Associated Histiocyte Marker mRNA in Autopsy Samples of Non-lymphoid Tissue Including the CNS - (03/22/13)
     
  9090. CROI: The Kidney A Potential HIV Reservoir - Bidirectional Passage of HIV Between T cells and Renal Epithelial cells through Virological Synapse Formation - (03/22/13)
     
  9091. CROI: Evaluation of Glomerular Function, Renal Blood Flow, and Exposure-Safety Relationship Following Administration of EVG/COBI/FTC/TDF - (03/21/13)
     
  9092. CROI: The Kidney at CROI 2013 - Christina M. Wyatt, MD Assistant Professor, Medicine/ Nephrology Mount Sinai School of Medicine New York, NY - (03/21/13)
     
  9093. CROI: Statin therapy and mortality in HIV-infected individuals; A Danish nationwide population-based cohort study. - (03/20/13)
     
  9094. CROI: Every Year of Statin Therapy Boosts Diabetes Risk 10% in US HIV Cohort - written by Mark Mascolini - (03/20/13)
     
  9095. CROI: Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study - (03/20/13)
     
  9096. CROI: Is Statin Use Associated with Incident Diabetes Mellitus among Patients in the HIV Outpatient Study (HOPS)? - (03/20/13)
     
  9097. CROI: Neuropsychological Performance in Acute HIV - (03/20/13)
     
  9098. CROI: Complications of HIV and its treatment, Impressions from the 20th CROI - Pablo Tebas, MD University of Pennsylvania - (03/20/13)
     
  9099. CROI: CROI REPORT: New Drugs for HIV Treatment and other random thoughts - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/20/13)
     
  9100. CROI: Revealing the Reservoir, and A Second Cure? - Ronald Swanstrom PhD, UNC Chapel Hill - (03/18/13)
     
  9101. French Study Indicates Some Patients Can Control H.I.V. After Stopping Treatment, 'Functional Cure', Visconti Study - NY Times - (03/19/13)
     
  9102. CROI: NEW HIV DRUGS at CROI - (03/19/13)
     
  9103. CROI: IL-6 Plus D-dimer Predict Non-AIDS Diagnoses and Death in 3-Cohort HIV Group - written by Mark Mascolini - (03/19/13)
     
  9104. CROI: The impact of age on the prognostic capacity of CD38+ T-cell activation during suppressive antiretroviral therapy - (03/19/13)
     
  9105. CROI: The Effect of Statins on Immune activation and Inflammation in HIV-Infected Subjects on Antiretroviral Therapy: a Randomized Placebo Controlled Trial - (03/19/13)
     
  9106. CROI: Impact of Statin Exposure on Mortality and Non-AIDS Complications in HIV Patients on HAART - (03/19/13)
     
  9107. Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients - (03/18/13)
     
  9108. CROI: HIV Care Cascade Analysis Not So Dire in Large US Healthcare System - written by Mark Mascolini - (03/18/13)
     
  9109. CROI: Noncalcified Coronary Plaque and Macrophage Activation are Increased in HIV-Infected Women - (03/18/13)
     
  9110. CROI: HIV Protease Inhibitors & HIV Recombinant Proteins Induce Senescence & Alter Fate of Human Bone Marrow Mesenchymal Stem Cells - (03/18/13)
     
  9111. CROI: Trends in and factors associated with virological failure among women conceiving on cART in Western Europe - (03/18/13)
     
  9112. CROI: CROI Report 2013: Observations on the "Cure Agenda" - By David Margolis MD, UNC Chapel Hill and the Collaboratory of AIDS Researchers for Eradication (CARE) (03/18/13)
     
  9113. CROI: 20th Conference on Retroviruses and Opportunistic Infections: Eradication/Cure, Prevention, Novel Strategies for administration of PrEP (delivery alternatives) Antiretroviral Therapy/drug resistance/new drugs/Comorbidities - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/17/13)
     
  9114. CROI: HCV at CROI - (03/17/13)
     
  9115. CROI: Heart Disease/CROI - (03/17/13)
     
  9116. CROI: European cART Failure Rate During Pregnancy 19% and Falling Fast - written by Mark Mascolini - (03/17/13)
     
  9117. CROI: One Quarter of US Pregnant Insured Women Not Tested for HIV, Despite CDC Advice - written by Mark Mascolini - (03/17/13)
     
  9118. CROI: Lower Pretreatment CD4s Tied to More Bone Loss After 96 Weeks of ART - written by Mark Mascolini - (03/17/13)
     
  9119. CROI: Bisexual HIV+ US Men Differ in Key Ways from HIV+ Heterosexuals and Gays - CDC Study - written by Mark Mascolini - (03/17/13)
     
  9120. CROI: The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/16/13)
     
  9121. CROI: Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV Infected Individuals - (03/16/13)
     
  9122. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study - (03/15/13)
     
  9123. A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial - (03/15/13)
     
  9124. CROI: Emergent Drug Resistance from the HIV-1 Phase 3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Studies through Week 96 - (03/15/13)
     
  9125. CROI: Weight Gain Inflates Diabetes Risk More in Veterans With Than Without HIV - written by Mark Mascolini - (03/15/13)
     
  9126. CROI: Lower Current CD4s--But Not Tenofovir--Predict Advanced CKD/ESRD in D:A:D - written by Mark Mascolini - (03/15/13)
     
  9127. CROI: Hepatic Fibrosis and Immune Phenotypes Vary by Hepatitis C Viremia in HIV Infection: A Women's Interagency HIV Study.....[from Jules: HCV Viremia Increased Fibrosis/Immune-Dysregulation; HIV Drives Immune Activation but HCV Contributes to Immune Activation] - (03/15/13)
     
  9128. CROI: Non-AIDS Cancer Rate Higher With Longer PI (But Not NNRTI) Therapy in D:A:D - written by Mark Mascolini - (03/14/13)
     
  9129. CROI: HIV and HIV/HCV Boost Risk of Venous Thromboembolism in Large Veterans Cohort - written by Mark Mascolini - (03/14/13)
     
  9130. CROI: Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested US clinical samples: 2006 to 2012 - (03/14/13)
     
  9131. CROI: High Prevalence and Severity of Pulmonary Emphysema is Associated with Cardiovascular Morbidity - (03/14/13)
     
  9132. CROI: HIV and Coronary Artery Calcium Score: Comparison of the Hawaii Aging with HIV Cardiovascular Study (HAHC-CVD) and the Multi-Ethnic Study of Atherosclerosis (MESA) - (03/14/13)
     
  9133. CROI: Human Immunodeficiency Virus Infection and Risk of Venous Thromboembolism - (03/14/13)
     
  9134. CROI: Older Age and Neurocognitive Function in the Multi-Center AIDS Cohort Study - (03/14/13)
     
  9135. CROI: Homology models of the attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action - (03/13/13)
     
  9136. CROI: Association Between Early Virologic Response and Immunologic Outcomes in Raltegravir-treated Patients - (03/13/13)
     
  9137. CROI: Soluble Markers of Inflammation & Coagulation, but not T-Cell Activation, Predict Non-AIDS Defining Events During Suppressive Antiretroviral Therapy (ART) - (03/13/13)
     
  9138. CROI: The Contribution of Intestinal Epithelial Cell Damage, Microbial Translocation, and HIV Status to an Inflammaging Phenotype - (03/13/13)
     
  9139. CROI: Obesity Affects Almost One Quarter of HIV-Positive US People in Care in CDC Analysis - written by Mark Mascolini - (03/13/13)
     
  9140. CROI: HIV Prevention at CROI 2013 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/12/13)
     
  9141. CROI: Virologic Failure in 40% of Perinatally Infected US Children--Regimen Switching Slow - written by Mark Mascolini - (03/12/13)
     
  9142. CROI: Framingham Score May Underestimate CHD Risk With HIV, HCV, and HIV/HCV - written by Mark Mascolini - (03/12/13)
     
  9143. CROI: Long-Term Changes in Renal Parameters in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, a Sub-study of A5202 - (03/12/13)
     
  9144. CROI: Projecting CVD risks in HIV-infected individuals in the US: competing risks and premature aging - (03/12/13)
     
  9145. CROI: Inflammation, Monocyte Activation in CVD & Non-AIDS Events - (03/12/13)
     
  9146. CROI: Cardiovascular-related Deaths in HIV-infected Patients between 2000 and 2010 - The ANRS EN20 Mortalite 2010 Survey - (03/12/13)
     
  9147. CROI: Soluble CD14 Declines in Virologically Suppressed Women Switching from PI or NNRTI to Raltegravir: The Women, Integrase, and Fat Accumulation Trial - (03/12/13)
     
  9148. CROI: Inflammation and HIV at CROI 2013: Focus on the Monocyte/Macrophage Axis and Innate Immunity - David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (03/11/13)
     
  9149. CROI: CROI 2013: Cardiovascular Disease and Co-morbidities in HIV - written by David H. Shepp, MD Associate Professor of Medicine, Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY (03/11/13)
     
  9150. CROI: The Incidence of AIDS Defining Events (ADEs) at a Current CD4 Count > 200/mm3 in the Post Combination Antiretroviral Therapy Era - (03/11/13)
     
  9151. CROI: A Tenofovir Disoproxil Fumarate Intravaginal Ring Completely Protects Against Repeated SHIV Vaginal Challenge in Nonhuman Primates - (03/11/13)
     
  9152. 50% Increased Risk for Myocardial Infarction (MI) Rate in HIV+ in Veterans Cohort (VACS) - (03/11/13)
     
  9153. CROI: HIV-Infected Adults Are at Greater Risk for Myocardial Infarction (MI), End-stage Renal Disease (ESRD), and Non-AIDS-defining Cancers, But Events Occur at Similar Ages Compared to HIV-uninfected Adults (VA) - (03/11/13)
     
  9154. CROI: Subclinical Heart Disease is Greater Among HIV+ vs HIV- & Increases with Age in MACS - (03/11/13)
     
  9155. CROI: Short-Term Mortality After Heart Attack With HIV Fell Over Past Decade in D:A:D - written by Mark Mascolini - (03/11/13)
     
  9156. CROI: Proportion of HIV Deaths Due to Heart Disease Almost Doubles in France From 2000 to 2010 - written by Mark Mascolini - (03/11/13)
     
  9157. CROI: Fewer CD4s at HIV Diagnosis Tied to Higher Risk of non-AIDS Deaths - written by Mark Mascolini - (03/11/13)
     
  9158. CROI: Resistance to Darunavir Falling Since Approval of the Protease Inhibitor in 2006 - written by Mark Mascolini - (03/11/13)
     
  9159. CROI: Lower Baseline CD4 is Associated with Greater Loss of Bone Mineral Density after ART Initiation - (03/09/13)
     
  9160. CROI: Prevalence of CSF Alzheimer's Disease-like profiles in middle-aged HIV+ individuals, relation to APOE genotyping and HIV disease markers - (03/09/13)
     
  9161. CROI: Rise in Heart Disease Risk With Age Slightly Greater With HIV Than in General Population...[DAD study also shows that reducing risk factors can have a big impact on reducing heart disease] - written by Mark Mascolini - (03/09/13)
     
  9162. CROI: Over 10% in Older HIV Group Fit Alzheimer's Biomarker Risk Profile - written by Mark Mascolini - (03/08/13)
     
  9163. CROI: Tenofovir in Intravaginal Ring Protects 6 of 6 Macaques From SHIV Challenge - written by Mark Mascolini - (03/08/13)
     
  9164. CROI: Longitudinal Association of HIV-associated neurocognitive disorder (HAND) with Frailty in HIV+ Men - (03/08/13)
     
  9165. CROI: New HIV Rate High After iPrEx Men Stop Truvada PrEP (or Placebo): when taking Truvada PrEP it works - written by Mark Mascolini - (03/08/13)
     
  9166. CROI: CCR5/CCR2 Antagonist Cenicriviroc: 24-Week Data vs Efavirenz in ART-Naive - written by Mark Mascolini - (03/08/13)
     
  9167. CROI: Week 24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with FTC/TDF, in Treatment-naïve HIV-1 Infected Adults with CCR5-tropic virus - (03/08/13)
     
  9168. CROI: Frailty and Circulating Markers of Inflammation in HIV+ and HIV- Men in the Multicenter AIDS Cohort Study - (03/07/13)
     
  9169. CROI: Long-Term Efavirenz Use is Associated with Worse Neurocognitive Functioning - (03/07/13)
     
  9170. CROI: PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys - (03/07/13)
     
  9171. CROI: Higher CD4 Gains With 2nd-Line Regimen Excluding NRTIs in Randomized Trial - written by Mark Mascolini - (03/07/13)
     
  9172. CROI: CD4 Count Affects Non-AIDS Risk in People Yet to Start Antiretrovirals - written by Mark Mascolini - (03/07/13)
     
  9173. CROI: Simeprevir (TMC435) with peginterferon/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: Week-24 interim analysis of the TMC435-C212 study - (03/07/13)
     
  9174. CROI: Similar Cognition Outcomes After 24 Weeks for Tenofovir/FTC + Atazanavir/r (ATV/r)-Experienced HIV+ Subjects or Those Simplifying to Abacavir/3TC+ATV - (03/06/13)
     
  9175. CROI: Distribution and Antiviral Activity in Cerebrospinal Fluid (CSF) of the Integrase Inhibitor, Dolutegravir (DTG): ING116070 Week 16 Results - (03/06/13)
     
  9176. CROI: Dolutegravir (DTG) Versus Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: 24-Week Interim Results From SAILING (ING111762) - (03/06/13)
     
  9177. CROI: Baby Cure at CROI - (03/06/13)
     
  9178. CROI: NRTI-Sparing Second-Line Regimen Holds Its Own in Randomized Trial - written by Mark Mascolini - (03/06/13)
     
  9179. CROI: Peak Bone Mass Lower in Young HIV+ vs HIV- Men--and Bone Structure Abnormal - written by Mark Mascolini - (03/06/13)
     
  9180. CROI: Dolutegravir Superior to Raltegravir in ART-Experienced Integrase Inhibitor Naive at 24 Weeks - written by Mark Mascolini - (03/06/13)
     
  9181. CROI: Wide US Study Finds 16% With Newly Diagnosed HIV Carry Resistant Virus - written by Mark Mascolini - (03/06/13)
     
  9182. CROI: Safety and Antiviral Activity of MK-1439, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), In Treatment-Naïve HIV-Infected Patients - (03/05/13)
     
  9183. CROI: Seven-Day Monotherapy With New NNRTI Yields Sharp Viral Load Drop - written by Mark Mascolini - (03/05/13)
     
  9184. CROI: Smoking Rate Twice Higher With Than Without HIV in First National US Study - written by Mark Mascolini - (03/05/13)
     
  9185. CROI: Long-Term Efavirenz Linked to Worse Neurocognitive Function in US CHARTER Group - written by Mark Mascolini - (03/05/13)
     
  9186. CROI: Coronary Artery Danger Signals More Common in Young HIV+ Men Than HIV- Men - written by Mark Mascolini - (03/05/13)
     
  9187. LA JOLLA INSTITUTE IDENTIFIES MOLECULAR SWITCH ENABLING IMMUNE CELLS TO BETTER FIGHT DISEASE - (03/05/13)
     
  9188. CROI: Age Raises Rate of Dangerous Coronary Artery Plaques in HIV+ But Not HIV- MACS Men - written by Mark Mascolini - (03/05/13)
     
  9189. CROI: Higher MI, ESRD, Cancer Rates With HIV--But Not Necessarily at Younger Age - written by Mark Mascolini - (03/05/13)
     
  9190. CROI: Age Raises Rate of Dangerous Coronary Artery Plaques in HIV+ But Not HIV- MACS Men - written by Mark Mascolini - (03/05/13)
     
  9191. CROI: Was An Infant Cured Of HIV? - (03/04/13)
     
  9192. CROI: For First Time, Baby Is Cured of H.I.V., Doctors Say - (03/04/13)
     
  9193. CROI: Long-Acting Integrase Inhibitor Shields Macaques From Anal Simian HIV - written by Mark Mascolini - (03/04/13)
     
  9194. CROI: HIV Prevention Fails in All Three VOICE Arms, as Daily Truvada PrEP Falls - written by Mark Mascolini - (03/04/13)
     
  9195. CROI: "Functional Cure" of HIV Claimed for Baby Treated 30 Hours After Birth - written by Mark Mascolini - (03/04/13)
     
  9196. Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis - (03/01/13)
     
  9197. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study - (03/01/13)
     
  9198. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women - (02/28/13)
     
  9199. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml - (02/28/13)
     
  9200. Renal Impairment in Patients Receiving a Tenofovir-cART Regimen: Impact of Tenofovir Trough Concentration - (02/27/13)
     
  9201. Cognitive Neurorehabilitation of HIV-associated Neurocognitive Disorders: A Qualitative Review and Call to Action - (02/25/13)
     
  9202. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring - (02/25/13)
     
  9203. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis - (02/25/13)
     
  9204. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure - (02/25/13)
     
  9205. New FDA Approval Process: "Breakthrough therapy" - (02/22/13)
     
  9206. Updating the HIV-Testing Guidelines - A Modest Change with Major Consequences Perspective - (02/21/13)
     
  9207. Routine HIV Testing, Public Health, and the USPSTF - An End to the Debate Perspective - (02/21/13)
     
  9208. When to Start ART in Africa - An Urgent Research Priority Perspective - (02/21/13)
     
  9209. The Final Word on Proton Pump Inhibitors and Osteoporosis? - editorial - (02/20/13)
     
  9210. ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection - (02/19/13)
     
  9211. Aspirin attenuates platelet activation and immune activation in HIV-infected subjects on antiretroviral therapy: A Pilot Study - (02/15/13)
     
  9212. Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses - (02/19/13)
     
  9213. Differential Penetration of Raltegravir throughout Gastrointestinal Tissue: Implications for Eradication and Cure - (02/15/13)
     
  9214. HIV Coreceptor Tropism With Reflex to Ultradeep Sequencing - (02/15/13)
     
  9215. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Updated Feb 12 2013 - (02/15/13)
     
  9216. Markers of microbial translocation and risk of AIDS-related lymphoma - (02/13/13)
     
  9217. Microbial translocation and AIDS-associated lymphomas: crux of the problem "....Chronic inflammation..." - Editorial - (02/13/13)
     
  9218. Monitoring cellular immune markers in HIV infection: from activation to exhaustion - (02/11/13)
     
  9219. Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein - (02/11/13)
     
  9220. Increased Coronary Atherosclerotic Plaque Vulnerability by Coronary Computed Tomography Angiography in HIV-Infected Men - (02/11/13)
     
  9221. Monitoring cellular immune markers in HIV infection: from activation to exhaustion - (02/08/13)
     
  9222. Soluble biomarkers of HIV transmission, disease progression and comorbidities - (02/08/13)
     
  9223. Patterns and Correlates of Linkage to Appropriate HIV Care After HIV Diagnosis in the US Medicaid Population......"Overall, 21.0% of patients linked to appropriate care within 1 year of the Test...." - (02/06/13)
     
  9224. Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort - (02/04/13)
     
  9225. Treating HIV Very Early Enhances Immunity - (02/04/13)
     
  9226. Trends and Predictors of Non AIDS-Defining Cancers in Men and Women With Hiv-Infection. A Single-Institution Retrospective Study Before and After the Introduction of Haart - (02/04/13)
     
  9227. Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202 - (02/04/13)
     
  9228. Association Between Tenofovir Exposure and Reduced Kidney Function in a Cohort of HIV-Positive Patients: Results From 10 Years of Follow-up - (02/04/13)
     
  9229. Lipids in 2012: HDL cholesterol studies-more of the same? - (01/31/13)
     
  9230. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts - (01/31/13)
     
  9231. Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration - (01/25/13)
     
  9232. Interferon Alfa Therapy: Toward an Improved Treatment for HIV Infection Editorial - (01/25/13)
     
  9233. New Studies Show Which Anti-HIV Drug Combinations Work Better Than Others -- And Why And How They Do It - (01/24/13)
     
  9234. Disparities in Study Findings on Neurologic Function in HIV - (01/24/13)
     
  9235. New assays for monitoring residual HIV burden in effectively treated individuals - (01/22/13)
     
  9236. Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy - (01/22/13)
     
  9237. An Exploratory Trial of Cyclooxygenase Type 2 Inhibitor in HIV-1 Infection: Downregulated Immune Activation and Improved T Cell-Dependent Vaccine Responses - (01/22/13)
     
  9238. Immune modulatory effects of cyclooxygenase type 2 inhibitors (NSAIDS) in HIV patients on combination antiretroviral treatment - (01/22/13)
     
  9239. Persistent immune activation in chronic HIV infection: do any interventions work? (cure research) - (01/22/13)
     
  9240. 3rd Intl Wrkshp on HIV & Women: SAFETY AND EFFICACY OF LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN PREGNANT WOMEN: A SYSTEMATIC REVIEW - (01/17/12)
     
  9241. Short-Course Antiretroviral Therapy in Primary HIV Infection - (01/17/13)
     
  9242. Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy - (01/17/13)
     
  9243. Antiretroviral Therapy in Early HIV Infection - - (01/17/13)
     
  9244. Safety, efficacy and pharmacokinetic of Darunavir/Ritonavir containing regimen in pregnant HIV-infected women - (01/16/13)
     
  9245. A Comparison of the Pharmacokinetics of Darunavir, Atazanavir and Ritonavir during Pregnancy and Post-partum - (01/16/13)
     
  9246. Generic Antiretrovirals and the Uncertain Future of HIV Care in the United States - Editorial & study - (01/16/13)
     
  9247. Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review - (01/16/13)
     
  9248. 3rd Intl Wrkshp on HIV & Women: Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1-Infected Pregnant Women - (01/16/12)
     
  9249. 3rd Intl Wrkshp on HIV & Women: Nine-Study Review Raises No Lopinavir Efficacy or Safety Concerns in Pregnancy - written by Mark Mascolini (01/16/12)
     
  9250. 3rd Intl Wrkshp on HIV & Women: High Rate of Obstetric Problems in HIV+ Ottawa Women With Free Care - written by Mark Mascolini (01/16/12)
     
  9251. 3rd Intl Wrkshp on HIV & Women: Twice-Daily Darunavir/Ritonavir in Regimens for Pregnant Women - written by Mark Mascolini (01/16/12)
     
  9252. 3rd Intl Wrkshp on HIV & Women: Risk of Progression to Fibrosis Twice Higher in Women Than Men With HCV/HIV - written by Mark Mascolini (01/16/12)
     
  9253. 3rd Intl Wrkshp on HIV & Women: Lower Cognitive Scores in Women With HCV/HIV Than With HIV Alone - written by Mark Mascolini - (01/15/12)
     
  9254. 3rd Intl Wrkshp on HIV & Women: Psych and Substance Abuse Disorders Frequent and Persistent in US Mothers With HIV - written by Mark Mascolini - (01/15/12)
     
  9255. 3rd Intl Wrkshp on HIV & Women: Depression Scores Rise Yearly After Age 40 for HIV+ Women But Not Men - written by Mark Mascolini - (01/15/12)
     
  9256. 3rd Intl Wrkshp on HIV & Women: HIV Transmission Risk Essentially 0 if Heterosexual Partner Has Undetectable Viral Load - written by Mark Mascolini - (01/15/12)
     
  9257. Tenofovir-associated proteinuria - (01/14/13)
     
  9258. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals - (01/14/13)
     
  9259. Cognitive disorders in HIV-infected patients: are they HIV-related? - (01/14/13)
     
  9260. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART Body Composition substudy - (01/12/13)
     
  9261. Dolutegravir for treatment of HIV: SPRING forwards? Commentary - (01/12/13)
     
  9262. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study - (01/12/13)
     
  9263. New Therapeutic HIV Vaccine Study Results.. A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication - (01/10/13)
     
  9264. Low Bone Mineral Density, Regardless of HIV Status, in Men Who Have Sex With Men - (01/07/13)
     
  9265. FDA approves first anti-diarrheal drug for HIV/AIDS patients - (01/07/13)
     
  9266. Etiology and Pharmacologic Management of Noninfectious Diarrhea in HIV-Infected Individuals in the Highly Active Antiretroviral Therapy Era - - (01/03/13)
     
  9267. Rapid Progression to Decompensated Cirrhosis, Liver Transplantation, and Death in HIV-infected Men after Primary HCV Infection - (01/04/13)
     
  9268. Effect Of HCV Infection On Cause-Specific Mortality Following HIV Seroconversion Before And After 1997 - (01/04/13)
     
  9269. 2 Studies reporting increased heart disease risk in HIV+ using Framingham Score & Imaging/Markers (Glasgow 2012) - (01/03/13)
     
  9270. Endothelial Function-what is it? - (01/03/13)
     
  9271. The Rising Challenge of Non-AIDS-Defining Cancers in HIV-Infected Patients - (01/03/13)
     
  9272. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease: nadir CD4 <350 associated with worse endothelial CVD function - (01/03/13)
     
  9273. Mortality Attributable to Smoking Among HIV-1-Infected Individuals: A Nationwide, Population-Based Cohort Study: smokers have 5-fold increased risk for death caused by heart disease & cancer, shorter life expectancy by 15 years & loss of life-years for smokers was twice as high as HIV...."60% of deaths in cohort due to smoking" - (01/03/13)
     
  9274. Resveratrol Improves Intrahepatic Endothelial Dysfunction and Reduces Hepatic Fibrosis and Portal Pressure in Cirrhotic Rats - (01/03/13)
     
  9275. Higher Dose Flu Vaccine in HIV+ - Improved Immunogenicity With High-Dose Seasonal Influenza Vaccine in HIV-Infected Persons: A Single-Center, Parallel, Randomized Trial - (01/03/13)
     
  9276. HIV-Infection Incidence in Women in Inner Urban Cities Similar Rates to in Africa, Higher (0.32%) than CDC Estimates (0.05%) for Black Women in USA - (01/03/13)
     
  9277. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort (ACTG) - (12/20/12)
     
  9278. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients (Spain): role of antiretroviral therapy HCV/HIV Coinfection 2nd Most Frequent Event...aging cirrhotics - (12/20/12)
     
  9279. Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers - (12/20/12)
     
  9280. Raltegravir based post exposure prophylaxis (PEP): A safe, well tolerated alternative regimen (Glasgow 2012) - (12/20/12)
     
  9281. Effect of hepatitis C treatment with interferon and ribavirin in body composition measurement by DEXA in HIV/HCV coinfected patients (Glasgow 2012) - (12/19/12)
     
  9282. Neurocognitive Impairment (NCI), Depression, and Anxiety in HIV-1 Infected Patients Across Western Europe and Canada, The CRANIum Study- Ethnicity analysis (Glasgow 11/2012) - (12/19/12)
     
  9283. Safety and efficacy of a raltegravir based dual antiretroviral therapy in clinical practice (Glasgow 2012) - (12/19/12)
     
  9284. IDUs 2.6% of US Population, MSM 3.9%/6.9% Ever Engaged - CDC - (12/19/12)
     
  9285. Raltegravir 800 mg Once Daily Is Efficacious in Patients Already Virologically Suppressed (Glasgow 2012) - (12/19/12)
     
  9286. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study - (12/19/12)
     
  9287. Maraviroc: A Drug Used to Treat HIV Might Defuse Deadly Staph Infections - (12/18/12)
     
  9288. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection - (12/18/12)
     
  9289. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Clinically Significant Drug Interaction Between Colchicine and Ritonavir in Healthy Adults - (12/14/12)
     
  9290. Pharmacokinetic and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir in the ODIN trial - (12/13/12)
     
  9291. Kidney Disease Review: The Top 10 Things Nephrologists Wish Every Primary Care Physician Knew - (12/13/12)
     
  9292. Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis - Review - (12/13/12)
     
  9293. Have You Missed Diagnosing HIV Among The Aging Population? Learn From The Experience of Washington, D.C. - (12/10/12)
     
  9294. Diabetes-Statin Link Hinges on Risk Factors - (12/10/12)
     
  9295. Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain - (12/03/12)
     
  9296. Risk of hip fracture associated with hepatitis c virus infection and hepatitis C/human immunodeficiency virus coinfection - (12/03/12)
     
  9297. Prescription of physical activity: an undervalued intervention - irrespective of whether dyslipidaemic patients took statins exercise reduced death by 60-70% - (11/30/12)
     
  9298. New practical guidance for improved patient care in HIV-associated neurocognitive disorder - Assessment, Diagnosis and Treatment of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders (HAND): A Consensus Report of the Mind Exchange Program - (11/30/12)
     
  9299. Grapefruit-Drug Interaction Seen With More Drugs - (11/29/12)
     
  9300. 11th Intl Congress Drug Therapy HIV Infection: Raltegravir switch improves Hepatitis C transaminitis in HIV-1 and Hepatitis C (HCV) co-infected individuals - (11/29/12)
     
  9301. Improvement in the Health of HIV-Infected Persons in Care: Reducing Disparities - HIV & HCV Health Disparities, HIV Life Expectancy/Aging, Hopkins Moore Clinic, Ryan White Care Act future - (11/28/12)
     
  9302. HCV in MSM, ex-US vs USA Politics/Inner City HCV - Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic - (11/28/12)
     
  9303. 3rd Wrkshp on HIV & Aging: Higher VACS Index Linked to Neurocognitive Impairment With HIV - Written by Mark Mascolini (11/26/11)
     
  9304. 11th Intl Congress Drug Therapy HIV Infection: Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1-Infected Pregnant Women - (11/26/12)
     
  9305. 11th Intl Congress Drug Therapy HIV Infection: Generalised additive model analysis of the relationship between darunavir pharmacokinetics and pharmacodynamics following once-daily darunavir/ ritonavir 800/100mg treatment in the Phase III trials, ARTEMIS and ODIN - (11/26/12)
     
  9306. 11th Intl Congress Drug Therapy HIV Infection: Rilpivirine efficacy, virology and safety in antiretroviral treatment-naïve patients with baseline viral load ≤100,000 HIV-1 RNA copies/mL: ECHO and THRIVE 96-week pooled dataset - (11/26/12)
     
  9307. 11th Intl Congress Drug Therapy HIV Infection: Enabling clinical development of an HIV attachment inhibitor through innovative pharmaceutical development: novel extended-release delivery of a prodrug - (11/20/12)
     
  9308. 11th Intl Congress Drug Therapy HIV Infection: Enabling clinical development of an HIV attachment inhibitor through innovative pharmaceutical development: novel extended-release delivery of a prodrug - (11/20/12)
     
  9309. 11th Intl Congress Drug Therapy HIV Infection: Genotypic and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in a short-term monotherapy study with its prodrug BMS-663068 - (11/20/12)
     
  9310. 11th Intl Congress Drug Therapy HIV Infection: The HIV NRTI BMS-986001 does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle and subcutaneous fat - (11/20/12)
     
  9311. 3rd Wrkshp on HIV & Aging: Less Resilient Older HIV-infected Persons Evidence Instrumental Activities of Daily Living Declines - (11/19/11)
     
  9312. 3rd Wrkshp on HIV & Aging: Accelerated Cardiovascular Aging in Treated HIV Males: Analysis of the Difference Between Chronologic & Vascular Age - (11/19/11)
     
  9313. 11th Intl Congress Drug Therapy HIV Infection: STaR Study: Single-Tablet Regimen Emtricitabine/Rilpivirine/Tenofovir DF is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults Week 48 Results - (11/16/12)
     
  9314. 11th Intl Congress Drug Therapy HIV Infection: Gilead 's Complera® Non-Inferior to Atripla® Among Treatment-Naïve HIV Patients - (11/16/12)
     
  9315. 11th Intl Congress Drug Therapy HIV Infection: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Efavirenz/Emtricitabine/Tenofovir DF (ATR) in Treatment-naïve HIV-1 Infected Patients: Week 96 Results - (11/16/12)
     
  9316. 11th Intl Congress Drug Therapy HIV Infection: Gilead 's Once-Daily Single Tablet Regimen Stribild™ Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naïve HIV Patients - press release - (11/16/12)
     
  9317. 11th Intl Congress Drug Therapy HIV Infection: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-naïve HIV-1 Infected Patients: Week 96 Results - (11/16/12)
     
  9318. 11th Intl Congress Drug Therapy HIV Infection: Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B and/or C Virus: Complete Data from Phase III Double-Blind Studies - (11/16/12)
     
  9319. 11th Intl Congress Drug Therapy HIV Infection: ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy and Safety in Adult Patients Co-Infected with HIV-1 and Hepatitis B and/or C in a Subgroup Analysis at 240 Weeks - (11/16/12)
     
  9320. 3rd Wrkshp on HIV & Aging: Inflammatory Markers Linked to Frailty in HIV-Positive MACS Men - Written by Mark Mascolini (11/16/11)
     
  9321. 3rd Wrkshp on HIV & Aging: "Lung Age" 3 Years Older in Middle-Aged HIV+ Versus HIV- IDU Group - Written by Mark Mascolini (11/16/11)
     
  9322. 3rd Wrkshp on HIV & Aging: Tenofovir May Speed Bone Mineral Loss in First Years After Menopause - Written by Mark Mascolini (11/16/11)
     
  9323. 3rd Wrkshp on HIV & Aging: Higher VACS Index Linked to Neurocognitive Impairment With HIV - Written by Mark Mascolini (11/16/11)
     
  9324. 11th Intl Congress Drug Therapy HIV Infection: ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults - (11/16/12)
     
  9325. 11th Intl Congress Drug Therapy HIV Infection: Antiviral Activity of Dolutegravir in Subjects with Failure on an Integrase Inhibitor-Based Regimen: Week 24 Phase 3 Results from VIKING-3 (2) Oral - (11/16/12)
     
  9326. 11th Intl Congress Drug Therapy HIV Infection: Antiviral Activity of Dolutegrevir in Subjects With Failure on an Integrase Inhibitor-Based Regimen: Week 24 Phase 3 Results From VIKING-3 (1) Poster - (11/16/12)
     
  9327. 11th Intl Congress Drug Therapy HIV Infection: Increasing Subject Compliance in Pivotal Phase III Clinical Trials of Dolutegravir (DTG, S/GSK1349572) in HIV-Infected, ART-Naive Subjects - (11/16/12)
     
  9328. 11th Intl Congress Drug Therapy HIV Infection: Dolutegravir Treatment Response by Baseline Viral Load and NRTI Backbone in Treatment-Naive, HIV-Infected Individuals - (11/16/12)
     
  9329. 11th Intl Congress Drug Therapy HIV Infection: LONG TERM DURABILITY OF NEVIRAPINE BASED ART IN A COHORT OF 84 PATIENTS AFTER INDUCTION WITH PROTEASE INHIBITOR TREATMENT - (11/16/12)
     
  9330. 11th Intl Congress Drug Therapy HIV Infection: Long-term (96 and 144 Week) Efficacy and Safety From the VERxVE Trial Comparing Nevirapine Extended-Release (NVP XR) 400 mg Once a Day to Nevirapine Immediate- Release (NVP IR) 200 mg Twice a Day in Combination With Emtricitabine/Tenofovir in Treatment-Naïve HIV-1 Patients - (11/16/12)
     
  9331. 3rd Wrkshp on HIV & Aging: The Prevalence of a Positive Screen for Neurocognitive Impairment and Anxiety/Depression in HIV-1 Infected Patients Across Western Europe and Canada - The CRANIum Study: Age Analysis - (11/08/11)
     
  9332. 3rd Wrkshp on HIV & Aging: Comparable Efficacy With QUAD, Atripla, ATV/r in Younger and Older Groups - Written by Mark Mascolini - (11/08/11)
     
  9333. 3rd Wrkshp on HIV & Aging: Vascular Age Exceeds Actual Age in HIV-Positive Men in Metabolic Clinic - Written by Mark Mascolini - (11/08/11)
     
  9334. 3rd Wrkshp on HIV & Aging: AIDS, Depression, Diabetes, Kidney Disease Predict Frailty in HIV-Positive Gays: frailty double in HIV+ MSM in MACS - Written by Mark Mascolini - (11/08/11)
     
  9335. 3rd Wrkshp on HIV & Aging: Response Rates Similar With Rilpivirine and Efavirenz Above and Below 50 Years of Age - Written by Mark Mascolini - (11/07/11)
     
  9336. 3rd Wrkshp on HIV & Aging: HIV+ People Over 50 Have No More Depression or Anxiety Than Younger Adults - Written by Mark Mascolini - (11/07/11)
     
  9337. HIV infection: what should be considered in approaches for a cure? - (11/07/12)
     
  9338. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? - (11/07/12)
     
  9339. Heart Disease & Blacks - (11/07/12)
     
  9340. High Cardiovascular Risk Factors Among Hispanics/Lainos - (11/07/12)
     
  9341. Fractures after antiretroviral initiation - (11/07/12)
     
  9342. 3rd Wrkshp on HIV & Aging: Effect of Aerobic Exercise Training in Older HIV-Infected Patients: Exercise Strategies Needed to Target Aging/HIV Pathogenesis' - (11/08/11)
     
  9343. 3rd Wrkshp on HIV & Aging: HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker - Written by Mark Mascolini - (11/08/11)
     
  9344. 3rd Wrkshp on HIV & Aging: Exercise Program Improves Aerobic Function and Endurance in Older HIV+ Men - Written by Mark Mascolini - (11/08/11)
     
  9345. 3rd Wrkshp on HIV & Aging: Muscle, Fat Predict Functional Status Better Than BMD in HIV+ 45- to 65-Year-Olds - Written by Mark Mascolini - (11/08/11)
     
  9346. 3rd Wrkshp on HIV & Aging: Less Resilience in Older People With vs Without HIV Tied to Drops in Daily-Living Activities - Written by Mark Mascolini - (11/08/11)
     
  9347. 3rd Wrkshp on HIV & Aging: HIV Neurocognitive Disorder Linked to Frailty in Study of US Gay Men - Written by Mark Mascolini - (11/08/11)
     
  9348. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis - (11/08/12)
     
  9349. The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults - (11/08/12)
     
  9350. Anal cancer rate still high in HIV, even with combination ART - (10/29/12)
     
  9351. IDSA: Lopinavir/Ritonavir Monotherapy Pilot Study: the MONDAKAL Study - (10/29/12)
     
  9352. IDSA: Analysis of EVG/COBI/FTC/TDF Compared to EFV/FTC/TDF By Race in Treatment Naïve Patients - (10/29/12)
     
  9353. IDSA: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF in Patients with Adherence <95% and <90% - (10/29/12)
     
  9354. Kidney stones and kidney function loss: a cohort study - (10/23/12)
     
  9355. High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy - (10/23/12)
     
  9356. IDSA: Simeprevir (TMC435) in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and -experienced patients (PILLAR and ASPIRE Trials) - (10/23/12)
     
  9357. IDSA: National trends in hospitalization and mortality for patients with HIV, HCV, or HIV/HCV co-infection: HCV Hospitalization Rates Increasing - (10/23/12)
     
  9358. IDSA: Describing the Burden of Hepatitis C (HCV) in a large public health care system (Chicago); Initial response to the National Viral Hepatitis Action Plan - (10/23/12)
     
  9359. Neurologic disorders incidence in HIV+ vs HIV- men - (10/22/12)
     
  9360. IDSA: Correlates of HIV, HCV and HIV/HCV Co-Infection in a Northeastern Inner City Population - (10/22/12)
     
  9361. IDSA: Recovery of Renal Function and Virologic Suppression Following Tenofovir Discontinuation - (10/22/12)
     
  9362. IDSA: Worsening Endothelial Function with Efavirenz Compared to Protease Inhibitors: A 12-Month Prospective Study - (10/22/12)
     
  9363. IDSA: Inflammatory Biomarkers in HIV Patients in Vermont - (10/22/12)
     
  9364. IDSA: Association Between Emergent Antiretroviral Drug Resistance and Baseline CD4 Cell Count in Treatment-Naive Patients Initiating Protease-Inhibitor-Based Therapy in Clinical Trials - (10/22/12)
     
  9365. IDSA: HIV-infected adults with suppressed viremia on antiretroviral therapy have dysfunctional HDL that is associated with T cell activation - (10/22/12)
     
  9366. IDSA: The Pharmacokinetic Interactions of the HCV Protease Inhibitor Simeprevir (TMC435) With HIV Antiretroviral Agents in Healthy Volunteers - (10/19/12)
     
  9367. IDSA: Effects of adherence and baseline viral load on virologic response, with resistance, dyslipidemia/lipodystrophy and bone mineral density analyses, among women compared to men in the Phase III Week 96 ECHO and THRIVE trials - (10/19/12)
     
  9368. IDSA: The Pharmacokinetics of Telaprevir and Selected ART Medications in HCV/HIV Coinfected Patients - (10/19/12)
     
  9369. IDSA: [poor] Quality of Hepatitis C care at an urban tertiary medical center - (10/19/12)
     
  9370. Brain on stress: How the social environment gets under the skin ......key to aging: managing stressors of physical & mental health..... - (10/17/12)
     
  9371. Two Novel Equations to Estimate Kidney Function in Persons Aged 70 Years or Older - (10/16/12)
     
  9372. Predicting Cognitive Decline by Neuroimaging: Amyloid-ß assessed by florbetapir F 18 PET and 18-month cognitive decline - (10/16/12)
     
  9373. Predicting Cognitive Decline with Neuroimaging: From Alois to Amyvid - Editorial - (10/16/12)
     
  9374. Neuroimging to Predict.... Alzheimer's: Amyloid Eclipses Genetic Risk - (10/16/12)
     
  9375. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study - (10/15/12)
     
  9376. Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV-Infected Men: The HIPVIRG Cohort Study - (10/15/12)
     
  9377. HRT cuts CVD by 50%, latest "unique" data show - new study - (10/15/12)
     
  9378. Rhabdomyolysis after co-prescription of statin and fusidic acid - (10/15/12)
     
  9379. Seroprevalence of hepatitis C, hepatitis B virus and syphilis in HIV-1 infected patients in Shandong, China: HCV/HIV coinfection rate; HCV sexual transmission - (10/09/12)
     
  9380. ICAAC: Zinc Finger CD4 Increases: Preferential Expansion of Transitional and Central Memory CD4 T-cells following Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified AutologousCD4 T-cells (SB-728-T) - (10/09/12)
     
  9381. ICAAC: HCV/HIV co-infection and the degree of liver fibrosis as risk factors of HAART-associated nephrotoxicity - (10/09/12)
     
  9382. Association of kidney disease measures with poor outcomes - (10/09/12)
     
  9383. Relationship Between a Frailty-Related Phenotype and Progressive Deterioration of the Immune System in HIV-Infected Men: CD4 predicted frailty in MACS, viral load associated - (10/09/12)
     
  9384. Investigating A Sexual Network of Black Men Who Have Sex with Men: Implications for Transmission and Prevention of HIV Infection in the United States- 29% HIV Prevalence - (10/09/12)
     
  9385. HIV Helps Explain Rise of Anal Cancer in US Males - (10/09/12)
     
  9386. A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients - (10/09/12)
     
  9387. Another Use for Rapid Home H.I.V. Test: Screening Sexual Partners - (10/09/12)
     
  9388. Association of kidney disease measures with poor outcomes - (10/05/12)
     
  9389. Dendritic spine injury induced by the 8-hydroxy metabolite of Efavirenz - (10/05/12)
     
  9390. Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV - (10/04/12)
     
  9391. Infectious Complications of Bio-Alcamid Filler Used for HIV-Related Facial Lipoatrophy - (10/04/12)
     
  9392. Increasing Exercise Performance - Serotonin and central nervous system fatigue: nutritional considerations - (10/04/12)
     
  9393. Merck's HPV Vaccine Gardasil Shown Safe in Kaiser Study - (10/02/12)
     
  9394. Increased Risk of Stomach and Esophageal Malignancies in People With AIDS - (10/02/12)
     
  9395. Aspirin and Chemoprevention of Cancer: Reaching Beyond the Colon - (10/02/12)
     
  9396. Predicting Early HIV Disease Progression: Early HLA-B*57-Restricted CD38+ T Lymphocyte Responses Predict HIV-1 Disease Progression - (10/01/12)
     
  9397. New Study Suggests HIV Causes Lipodystrophy - Adipogenic/Lipid, Inflammatory, and Mitochondrial Parameters in Subcutaneous Adipose Tissue of Untreated HIV-1-Infected Long-Term Nonprogressors: Significant Alterations Despite Low Viral Burden - (10/01/12)
     
  9398. New York State Guidelines Kidney Disease Mgt in HIV Sept 18 2012 - (09/24/12)
     
  9399. Sexual Frequency and Planning Among At-Risk Men Who Have Sex With Men in the United States: Implications for Event-Based Intermittent Pre-Exposure Prophylaxis - (09/24/12)
     
  9400. Transmitted Drug Resistance and Phylogenetic Relationships Among Acute and Early HIV-1-Infected Individuals in New York City - (09/24/12)
     
  9401. Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004) - (09/24/12)
     
  9402. ICAAC: A Switch from FTC/TDF to Raltegravir in Patients on a Boosted Protease Inhibitor Is Effective in Reducing Proteinuria and Increasing GFR - (09/23/12)
     
  9403. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care - (09/23/12)
     
  9404. ICAAC: PREVALENCE AND RISK FACTORS OF LOW GRADE PROTEINURIA IN HIV INFECTED PATIENTS - (09/21/12)
     
  9405. Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors - (09/21/12)
     
  9406. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients - (09/21/12)
     
  9407. HHS Adult ARV Guidelines Panel: Use of EVG/COBI/TDF/FTC - (09/20/12)
     
  9408. Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function - (09/20/12)
     
  9409. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial - (09/20/12)
     
  9410. Quad's in it for antiretroviral therapy? Comment - (09/20/12)
     
  9411. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks - (09/20/12)
     
  9412. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients - (09/20/12)
     
  9413. HIV protease inhibitors in combination with boceprevir: are drug-drug interactions the same for all patients? - (09/20/12)
     
  9414. Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events, A Systematic Review and Meta-analysis - (09/13/12)
     
  9415. All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection......'HCV/HIV Coinfected Death Rates 11 Times Higher than in the general population in Spain' - (09/13/12)
     
  9416. ICAAC: High Anal Intraepithelial Neoplasia Progression in Spanish Gay/Bisexual Men - written by Mark Mascolini - (09/14/12)
     
  9417. ICAAC: Antiretrovirals Do Not Stop HSV Shedding in Genital or Anal Tract in Canada - written by Mark Mascolini - (09/14/12)
     
  9418. ICAAC: Pneumococcal Disease Risk 30 Times Higher With Than Without HIV in Denmark - written by Mark Mascolini - (09/14/12)
     
  9419. Underutilization of Aspirin for Primary Prevention of Cardiovascular Disease among HIV-Infected Patients - (09/13/12)
     
  9420. No Association of Abacavir Use with Myocardial Infarction: Findings of an FDA Meta-analysis - (09/13/12)
     
  9421. ICAAC: CD4 Gains and Side Effect Rates Differ With Age in Phase 3 QUAD Trials - written by Mark Mascolini - (09/13/12)
     
  9422. ICAAC: Older Patients Showed Similar Efficacy and Safety Results Compared With Younger Patients Over 96 Weeks in the Phase III ECHO and THRIVE Trials of Treatment-Naïve HIV-1-Infected Patients Treated With Rilpivirine or Efavirenz - (09/13/12)
     
  9423. ICAAC: Virological Profiling of GS 7340, a Next-generation Tenofovir Prodrug with Superior Potency over Tenofovir DF - (09/13/12)
     
  9424. ICAAC: Atazanavir (ATV) and Darunavir (DRV) Cristalluria and High ATV and DRV Concentrations in Urine of Asymptomatic Patients Receiving ATV and DRV Based Regimens - (09/13/12)
     
  9425. ICAAC: HIV/HCV Coinfected and HCV Monoinfected Patients Have Similar Early Hepatitis C Viral Kinetics with the Potent HCV Nucleotide Polymerase Inhibitor Sofosbuvir (SOF) - (09/13/12)
     
  9426. ICAAC: Persistent Low-level Viraemia in HIV-1-infected Patients: Swiss HIV Cohort Study - (09/13/12)
     
  9427. ICAAC: BONE STATUS ASSESSMENT IN HIV-INFECTED PATIENTS : AN OBSERVATIONAL STUDY OF 199 PATIENTS - (09/12/12)
     
  9428. ICAAC: Lack of Pharmacokinetic (PK) Interaction Between Rilpivirine and the Integrase Inhibitors Dolutegravir and S/GSK1265744 - (09/12/12)
     
  9429. ICAAC: Prevalence of HIV-1 Seminal Shedding in HIV-1 Infected Men who Have Sex with Men (MSM) and Association with the Size of Intracellular HIV-1 Reservoir (ANRS EP49): "We show that HIV RNA can be detected in semen of HIV-1 infected MSM despite sustained successful cART, with a significantly higher prevalence than in heterosexual men (7.6 vs 3.1% p=0.016)" - (09/12/12)
     
  9430. ICAAC: Pharmacokinetics of Cobicistat-Boosted Elvitegravir Administered in Combination with Methadone or Buprenorphine/Naloxone - (09/12/12)
     
  9431. ICAAC: GS-7340 Stronger Than TDF in Human Serum, Synergistic With Other ARVs - written by Mark Mascolini - (09/12/12)
     
  9432. ICAAC: Raltegravir Efficacy and Safety Through 3 to 5 Years With HBV or HCV Coinfection - written by Mark Mascolini - (09/12/12)
     
  9433. ICAAC: Resistance Findings on Experimental S/GSK Long-Acting Integrase Inhibitor - written by Mark Mascolini - (09/12/12)
     
  9434. ICAAC: RNA and CD4 Responses, Side Effect Rates, Similar Across Age Groups in Rilpivirine Trials - written by Mark Mascolini - (09/12/12)
     
  9435. ICAAC: Ongoing HIV Infection of CD4s May Explain Poor CD4 Gains With Sub-50 Load - written by Mark Mascolini - (09/12/12)
     
  9436. ICAAC: HIV in Semen of More than 1 in 10 Gay Men With Sub-50 Plasma Load - written by Mark Mascolini - (09/12/12)
     
  9437. ICAAC: Over 10% With Persistent Low-Level Viremia Have Virologic Failure Within Year - written by Mark Mascolini - (09/12/12)
     
  9438. ICAAC: Raltegravir Level at End of Dosing Interval High in Male and Female Genital Tract - written by Mark Mascolini - (09/12/12)
     
  9439. ICAAC: Hospital Admission May Not Signal Poor Healthcare Engagement in DC HIV Group - written by Mark Mascolini - (09/11/12)
     
  9440. ICAAC: Tenofovir Replacing AZT of ABC, Keeping 3TC, Suppresses HBV DNA - written by Mark Mascolini - (09/11/12)
     
  9441. ICAAC: Integrase Inhibitor Dolutegravir First ARV Superior to Efavirenz in ART-Naive - written by Mark Mascolini - (09/11/12)
     
  9442. ICAAC: 4-in-1 Pill With Elvitegravir/Cobicistat Versus Atripla or Atazanavir Regimen - written by Mark Mascolini - (09/11/12)
     
  9443. ICAAC: New gp41 Fusion Inhibitor Has Long Half-Life, Anti-HIV Activity in HIV+ Naïve - written by Mark Mascolini - (09/11/12)
     
  9444. ICAAC: Chart Review Confirms Worse Virologic Response to PIs Than Efavirenz in Women - written by Mark Mascolini - (09/11/12)
     
  9445. ICAAC: Bone Markers Improve After Switch From TDF/FTC to ABC/3TC, While Dropping RTV - written by Mark Mascolini - (09/11/12)
     
  9446. ICAAC: Blacks Have 50% Lower Chance of HIV Control Than Nonblacks in 6-Study Analysis - written by Mark Mascolini - (09/11/12)
     
  9447. ICAAC: MK-1439, a New NNRTI, Has Good Resistance Profile in Cell Studies - written by Mark Mascolini - (09/11/12)
     
  9448. ICAAC: Low-Grade Proteinuria in German HIV Group Tied to Tenofovir, ART Duration - written by Mark Mascolini - (09/11/12)
     
  9449. ICAAC: Safety and Efficacy of Once Daily Raltegravir to Enhance Adherence and Efficacy of HAART in Vulnerable HIV-Infected Patients - (09/11/12)
     
  9450. ICAAC: Renal Safety Profile of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) and of Cobicistat-boosted Atazanavir plus Emtricitabine/Tenofovir DF in HIV Patients - (09/11/12)
     
  9451. ICAAC: Cobicistat Does Not Affect the In Vitro Renal Transport or Cytotoxicity of Tenofovir - (09/11/12)
     
  9452. ICAAC: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine/Tenofovir DF and to Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF in Patients ≥50 Years - (09/11/12)
     
  9453. ICAAC: Gender Stratification Analysis of HIV-1 Infected Patients Receiving Atazanavir (ATV) Compared to ATV/Ritonavir (RTV), Each in Combination With Abacavir/Lamivudine (ABC/3TC), After Initial Suppression With ABC/3TC + ATV/RTV Through 144 Weeks on Therapy - (09/11/12)
     
  9454. ICAAC: Prevalence of HLA-B*5701 Allele in HIV-Infected Subjects in North America and Reductions in Risk for Development of Abacavir Associated Hypersensitivity Reaction - (09/11/12)
     
  9455. ICAAC: Safety & Efficacy of Raltegravir Over 3-5 Years in Patients Co-infected With HIV and Hepatitis B and/or C Virus - (09/11/12)
     
  9456. ICAAC: Comparison of In-Hospital Mortality From Acute Myocardial Infarction in HIV Sero-Positive Versus Sero-Negative Individuals - (09/11/12)
     
  9457. ICAAC: In-Hospital Mortality from Acute Myocardial Infarction: HIV Seropositive vs. Seronegative Individuals - (09/10/12)
     
  9458. ICAAC: Antiviral Characteristics Of S/GSK1265744, An HIV Integrase Inhibitor (INI) Dosed By Oral Or Long-acting Parenteral Injection....once monthly or 3 months dosing/PrEP/HAART - (09/10/12)
     
  9459. ICAAC: Integrated Week 48 Analysis of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF - (09/10/12)
     
  9460. ICAAC: Switching to the Single-Tablet Regimen (STR) Emtricitabine / Rilpivirine / Tenofovir DF from a Ritonavir-boosted Protease Inhibitor & 2 NRTI Regimen Maintains HIV Suppression and is Well Tolerated in HIV+ Subjects at Week 24 Regardless of Age: SPIRIT Study - (09/10/12)
     
  9461. ICAAC: Simplification to Abacavir/Lamivudine + Atazanavir from Tenofovir/Emtricitabine + Atazanavir/Ritonavir Maintains Viral Suppression and Improves Bone Biomarkers - (09/10/12)
     
  9462. ICAAC: Antiviral Activity and In Vitro Mutation Development Pathways of MK-1439: A Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) - (09/10/12)
     
  9463. ICAAC: Dolutegravir (DTG; S/GSK1349572) + Abacavir/Lamivudine Once Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 48-Week Results - SINGLE (ING114467) - (09/10/12)
     
  9464. ICAAC: Osteopenia/Osteoporosis Linked to Age and BMI, But Not TDF, in French Cohort - Written by Mark Mascolini - (09/09/12)
     
  9465. ICAAC: Poorly Controlled HIV Infection Raises Risk of Pneumococcal Disease in French Study - Written by Mark Mascolini - (09/09/12)
     
  9466. ICAAC: In-Hospital Mortality With Acute MI Higher With Than Without HIV - Written by Mark Mascolini - (09/09/12)
     
  9467. ICAAC: Partial or No Antiretroviral Adherence Raises Chance of Hospital Stay 50% in US Study - Written by Mark Mascolini - (09/09/12)
     
  9468. ICAAC: Late Catheterization and Significant Coronary Artery Disease in US HIV Group - Written by Mark Mascolini - (09/09/12)
     
  9469. IAC: HIV Treatment 19th International AIDS Conference July 22-27, 2012 Washington, D.C. - written by Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (09/09/12)
     
  9470. Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects - (09/07/12)
     
  9471. U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008 - (09/07/12)
     
  9472. IAC: Effects of Raltegravir (RAL) Combined with Tenofovir (TDF) and Emtricitabine (FTC) on Body Shape, Bone Density and Lipids in HIV+ African-Americans Initiating Therapy: Metabolic Outcomes of The UNC-REAL Study - (09/04/12)
     
  9473. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Incidence of hypertriglyceridemic waist (HTW) phenotype in a randomized prospective trial comparing atazanavir/ritonavir (ATV/r) and lopinavir/ritonavir (LPV/r) each in combination with tenofovir DF/emtricitabine (TDF/FTC) in antiretroviral naive HIV-1 infected subjects, a sub-study of CASTLE - (09/03/12)
     
  9474. IAC: Metabolics/Inflammation and Such At IAC - written by David Alain Wohl, MD - The University of North Carolina (09/03/12)
     
  9475. IAC: Obese HIV-infected Persons have Higher Levels of Select Inflammatory Markers and Co-Morbid Illnesses - (09/03/12)
     
  9476. IAC: Unexpected Complications: High 30 Day Readmission Rates among Persons Living with HIV - (09/03/12)
     
  9477. IAC: Non-AIDS, AIDS events and death in a cohort of antiretroviral naïve HIV-infected patients with a CD4 T cell count above 500 cells/mm3 in Barcelona, Spain: nadir CD4 <350 & detectable viral load predict non-AIDS events: cancers/cardiovascular/neuropsych/liver/end-stage renal; "data suggest earlier ART could prevent nonAIDS events in viral controllers" - (09/03/12)
     
  9478. Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic: increasing incidence rate among HIV+ MSM - (08/30/12)
     
  9479. IAC: New Agents for the Treatment of HIV-1: Is the pipeline opening up? - written by Joe Eron, MD University of North Carolina - (08/27/12)
     
  9480. Detectable Viral Load Aggravates Immunosenescence Features of CD38 T-Cell Subsets in Vertically HIV-Infected Children - (08/23/12)
     
  9481. Racial/Ethnic Disparities in ART Adherence in the United States: Findings From the MACH14 Study - (08/23/12)
     
  9482. Osteonecrosis of Jaw & Bone Drug Bisphosphonate Triggered by Dental Work - (08/21/12)
     
  9483. IAC: Type 2 diabetes is associated with lower cognitive performances in a cohort of HIV-infected patients. ANRS CO3 Aquitaine Cohort, Bordeaux, France, 2007-2009 - (08/20/12)
     
  9484. IAC: Severity of Illness and Fracture Risk: risk factors in HIV for bone fracture in Veterans & Aging Cohort/Men - (08/20/12)
     
  9485. IAC: Associations of Inflammatory Markers with AIDS and non-AIDS Clinical Events after Initiation of Antiretroviral Therapy (ART): AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202 - (08/20/12)
     
  9486. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Renal function improves with long-term telbivudine therapy in patients with chronic hepatitis B Analysis of the Clinical data Base - (08/20/12)
     
  9487. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Increased Risk of Serious non-AIDS defining Events and Mortality among Immunological Non-Responders to Antiretroviral Therapy - (08/20/12)
     
  9488. Pathogenesis of HIV in the Central Nervous System: Cognitive impairment persists despite effective cART - (08/20/12)
     
  9489. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors - (08/20/12)
     
  9490. Green Tea/Dark Choc NeuroProtective??: Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway - (08/20/12)
     
  9491. IAC: Effect of Second Generation Antipsychotics on Metabolic Variables in HIV-infected Adults on Long Term Antiretroviral Therapy - (08/17/12)
     
  9492. IAC: Very Early Initiation of Combination Antiviral Therapy Results in Normalization of Markers of Immune Activation - (08/17/12)
     
  9493. Exercise Reduces Inflammation Markers CRP & IL-6 - new study - (08/17/12)
     
  9494. IAC: Co-Morbidities Report from 14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV and XIX International AIDS Conference -Written by Todd Brown, MD, PhD Associate Professor of Medicine and Epidemiolog Johns Hopkins University - (08/17/12)
     
  9495. IAC: Carotid artery intima-media thickness and coronary artery calcium progress in HIV-infected participants over 6 years of follow-up - (08/15/12)
     
  9496. IAC: Incidence and clinical features of cerebrovascular events in HIV-infected adults in the Southeastern United States - (08/15/12)
     
  9497. IAC: HIV & Black MSM - (08/14/12)
     
  9498. IAC: Will and Should Women in the U.S. Use PrEP? Findings from a Focus Group Study of At-risk HIV-negative Women in Oakland, Memphis, San Diego, and Washington, DC - (08/13/12)
     
  9499. IAC: Tenofovir Plasma Pharmacokinetics in AIDS Clinical Trials Group Study A5202 - (08/10/12)
     
  9500. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs - (08/10/12)
     
  9501. Synergistic Effects of HIV Infection and Older Age on Daily Functioning - (08/10/12)
     
  9502. IAC: Trends in Aggregate Plasma HIV RNA Levels at a Public Health HIV/AIDS Clinic in San Francisco from 2001-2011 - (08/09/12)
     
  9503. IAC: Impact of single tablet regimens on the HIV switch market - (08/09/12)
     
  9504. IAC: The clinical and economic impact of a generic first-line antiretroviral regimen in the U.S. - (08/09/12)
     
  9505. IAC: Transmission of HIV-1 Exhibiting Resistance to Protease, Reverse Transcriptase and Integrase Inhibitors in a Previously Documented HIV-1 Negative Patient - (08/08/12)
     
  9506. IAC: CDC Reports: Disparities in Health in HIV: "BLACKS TENDED TO HAVE WORSE CONTINUUM OF CARE COMPARED TO WHITES" - (08/08/12)
     
  9507. IAC: SBI for HIV Diarrhea - (08/08/12)
     
  9508. IAC: Exposure to nucleoside reverse transcriptase inhibitors (NRTIs) induces genotoxicity persistent for up to three years in Erythrocebus patas monkeys - (08/07/12)
     
  9509. Does Perinatal Antiretroviral Therapy Create an Iatrogenic Cancer Risk? Commentary - (08/07/12)
     
  9510. IAC: Low-Dose Aspirin for Activation: Increased platelet activity and immune activation in HIV-positive subjects on antiretroviral therapy is attenuated with low-dose aspirin - (08/06/12)
     
  9511. IAC: HIV Prevention at AIDS 2012 -written Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (08/06/12)
     
  9512. IAC: International AIDS Society (IAS) Symposium "Towards an HIV Cure" July 20-21 2012 Wash DC - written for NATAP by David Margolis MD, University of North Carolina - (08/06/12)
     
  9513. IAC: Low Level Viral Load Detection in Blood and Mucosal Sites in Elite Controllers and HAART suppressed Women Enrolled in the Women's Interagency HIV (WIHS) Cohort - (08/06/12)
     
  9514. IAC: Similar prevalence of baseline HIV-1 minority variants among responders and virologic failures, as well as increased detection of HIV-1 minority variants at treatment failure, in rilpivirine patients from the ECHO and THRIVE Phase III studies - (08/06/12)
     
  9515. IAC: Prevalence of rilpivirine resistance-associated mutations in US samples received for routine resistance testing - (08/06/12)
     
  9516. IAC: Gender Differences in Virologic Outcomes in a Meta-Analysis of Randomized Controlled Clinical Trials in HIV-1-Infected Patients on Antiretroviral Therapy - 'Women 28% Less Likely to Achieve <50 c/ml' - (08/06/12)
     
  9517. IAC: A Meta-Analysis of the Differences in ART Virologic Failure Rates in Randomized Clinical Trials: Do Blacks Consistently Have Lower ART Efficacy and Poor Treatment Outcomes? - (08/06/12)
     
  9518. IAC: 2 New Studies at IAC Finding 'Functional Cure' - (08/03/12)
     
  9519. IAC: "scientists optimistic about a cure"......argument for treating patients with HAART early" - (08/03/12)
     
  9520. IAC: HCV/HIV Coinfection Higher Rates of Hepatic Decompnsation, Liver Cancer & Severe Liver Events - (08/01/12)
     
  9521. Janssen's HIV Cure Effort: High throughput screening for HIV reactivating compounds - (08/01/12)
     
  9522. IAC: Immune Activation, Inflammation and Complications of HIV 19th IAC 2012: Written by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine - (07/31/12)
     
  9523. IAC: IMPAACT P1066: Raltegravir (RAL) safety and efficacy in HIV infected (+) youth 2 to 18 years of age through week 48 - (07/31/12)
     
  9524. IAC: Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-Containing Regimens in HIV-Infected 4 Weeks to <2-Year-Old Children 48-Week Data From Study APV20002 - (07/31/12)
     
  9525. IAC: Evidence of Coronary Vessel Wall Thickening in Asymptomatic Young HIV-Infected Patients Using Non-invasive MRI - (07/31/12)
     
  9526. IAC: Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir-Containing Regimens in HIV-Infected 2 to 18 Year-Old Children (48-Week Data, Study APV29005, a Prospective, Open-label, Multi-centre, 48-Week Cohort Study) - (07/31/12)
     
  9527. IAC: Drug Resistance and Mutational Profile in Fosamprenavir-Treated HIV-Infected Children Aged 2 Months to 18 Years at Start of Therapy - (07/31/12)
     
  9528. IAC: HCV viremia affects immune phenotypes in Elite controllers of HIV infection- A Women's Interagency HIV Study - (07/30/12)
     
  9529. IAC: HIV & Aging Plenary at IAC by Judy Currier: Intersection of Non-Communicable Diseases (comorbidities) and Ageing in HIV - (07/30/12)
     
  9530. IAC: Stroke in human immunodeficiency virus (HIV) infected patients - (07/30/12)
     
  9531. IAC: Slower Time to AIDS and TB in Immediate-Treatment Arm of HPTN 052 - Written by Mark Mascolini - (07/30/12)
     
  9532. IAC: Predictors of HIV Transmission in a US Test-and-Treat Population: 29% in care don't use condoms - Written by Mark Mascolini - (07/30/12)
     
  9533. IAC: Differences in CD4+ T-cell Immune Activation in HIV, Hepatitis C (HCV), and HIV/HCV Coinfection are Influenced by HIV and HCV Infection Status - (07/30/12)
     
  9534. IAC: Incident bone fracture in men with, or at risk for, HIV-infection in the Multicenter AIDS Cohort Study (MACS), 1996-2011 - (07/30/12)
     
  9535. Going door-to-door to fight HIV in Philadelphia - (07/30/12)
     
  9536. IAC: Factors associated with elevated D-dimer levels in HIV-infected individuals: 'viral replication associated with D-dimer' - (07/30/12)
     
  9537. IAC: Gold nanoparticles to improve drug delivery to the CNS: Targeting HIV reservoirs in the brain (raltegravir) - (07/30/12)
     
  9538. IAC: A randomized trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients : ANRS 12 180 REFLATE TB trial. - (07/27/12)
     
  9539. IAC: Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents: PIANO 48-week results - (07/27/12)
     
  9540. IAC: Comorbidity and ageing with HIV A prospective comparative cohort study - (07/27/12)
     
  9541. IAC: Low Rates of Integrase Resistance for Elvitegravir and Raltegravir through Week 96 in the Phase 3 Clinical Study GS-US-183-0145 - (07/27/12)
     
  9542. IAC: Reduced skeletal muscle mitochondrial function in older HIV-infected men is associated with low aerobic exercise capacity - (07/27/12)
     
  9543. HPV Testing in HIV-Positive Women May Help Reduce Frequent Cervical Cancer Screening - (07/27/12)
     
  9544. AIDS Cure Quest Advances as Cancer Drug Finds Hidden HIV - (07/27/12)
     
  9545. IAC: Survey Challenges Assumptions About Aging With HIV in United States - Written by Mark Mascolini - (07/27/12)
     
  9546. IAC: Aspirin Quiets Platelet and Immune Activation in Antiretroviral Responders - Written by Mark Mascolini - (07/27/12)
     
  9547. IAC: Age at Stroke 15 Years Younger in HIV-Positives vs Negatives in New York City - Written by Mark Mascolini - (07/27/12)
     
  9548. IAC: Non-AIDS Illness Rate Higher in Older HIV-Positives Than in Similar non-HIV Group - Written by Mark Mascolini - (07/27/12)
     
  9549. IAC: Chances of Virologic Response Halved in Blacks vs Nonblacks in ART Trials - Written by Mark Mascolini - (07/27/12)
     
  9550. IAC: Diabetes Linked to Poor Cognitive Function in HIV-Positive Adults - Written by Mark Mascolini - (07/27/12)
     
  9551. IAC: Inflammation Markers Predict AIDS and non-AIDS Disease in ACTG Study - Written by Mark Mascolini - (07/27/12)
     
  9552. IAC: A randomized trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients : ANRS 12 180 REFLATE TB trial. - (07/27/12)
     
  9553. IAC: Once-Daily Dolutegravir(DTG; S/GSK1349572) is Non-Inferior to Raltegravir (RAL) in Antiretroviral-naïve Adults. 48 Week results from SPRING-2 (ING113086) - (07/26/12)
     
  9554. IAC: Effect of Early versus Delayed Initiation of Antiretroviral Therapy (ART) on Clinical Outcomes in the HPTN 052 Randomized Clinical Trial - (07/26/12)
     
  9555. IAC: Adding Nitazoxanide to PEG/RBV Does Not Improve SVR With HIV/HCV Genotype 1 - Written by Mark Mascolini - (07/26/12)
     
  9556. IAC: Maraviroc Plus Darunavir Vulnerable With Pretreatment Load Above 100,000? - Written by Mark Mascolini - (07/26/12)
     
  9557. IAC: Good 4-Week Dolutegravir Response in Experienced Adolescents--PKs Comparable to Adults - Written by Mark Mascolini - (07/26/12)
     
  9558. IAC: HIV Prevalence and Risks in a New Generation of US Injection Drug Users - Written by Mark Mascolini - (07/26/12)
     
  9559. IAC: Systematic Review Finds HPV Doubles HIV Risk in Women and Men - Written by Mark Mascolini - (07/26/12)
     
  9560. IAC: Quadrivalent HPV Vaccine Immunogenic in HIV+ Women With CD4s Over 200 - Written by Mark Mascolini - (07/26/12)
     
  9561. IAC: Obesity Linked to Inflammation, cIMT, Low Vitamin D in US HIV Group - Written by Mark Mascolini - (07/26/12)
     
  9562. IAC: Robust Response to Quadrivalent HPV Vaccine in Young HIV-Positive Women - Written by Mark Mascolini - (07/26/12)
     
  9563. IAC: Mitochondrial Upsets May Underlie Metabolic Disorders in HIV-Positive Adolescents - Written by Mark Mascolini - (07/26/12)
     
  9564. IAC: Depression Risk Steers MDs From EFV, But EFV Takers Still Have Higher Depression Rate - Written by Mark Mascolini - (07/26/12)
     
  9565. IAC: Phase 1/2, Multicenter, Open-label, Pharmacokinetic, Safety, Tolerability, and Antiviral Activity Study of Dolutegravir (DTG), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children, and Adolescents: P1093 - (07/26/12)
     
  9566. IAC: Analysis of Efficacy by Baseline HIV RNA - Week 48 Results from a Phase 3 Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects - (07/26/12)
     
  9567. IAC: Risk of common cancers by age 60 for HIV-infected patients in the United States and Canada - (07/26/12)
     
  9568. Coronary Artery Walls Thicker in Young Adults With Early-Acquired HIV - (07/25/12)
     
  9569. Public health: Towards a cure for HIV - (07/25/12)
     
  9570. Radical Prostatectomy versus Observation for Localized Prostate Cancer - (07/25/12)
     
  9571. Aging and HIV-Related Cognitive Loss - (07/25/12)
     
  9572. Inflammation, Immune Activation, and CVD Risk in Individuals With HIV Infection - Editorial - (07/25/12)
     
  9573. Arterial Inflammation in Patients With HIV - (07/25/12)
     
  9574. IAC: ART Soon After Infection Yields Normal Immune Activation Markers in Small Study - Written by Mark Mascolini - (07/25/12)
     
  9575. IAC: Timely ART Start Rates Climbing Steadily Across US and Canada - Written by Mark Mascolini - (07/25/12)
     
  9576. IAC: Response to Etravirine Regimen in Experienced Children and Adolescents - Written by Mark Mascolini - (07/25/12)
     
  9577. IAC: Raltegravir Formulations Effective for ART-Experienced Teens and Children - Written by Mark Mascolini - (07/25/12)
     
  9578. IAC: Antiretroviral Treatment of Adult HIV Infection2012 Recommendations of the International Antiviral Society-USA Panel - (07/25/12)
     
  9579. IAC: Long-Term Safety and Efficacy of Raltegravir (RAL)-Based VersusEfavirenz (EFV)-Based Combination Therapy in Treatment-Naïve HIV-1 Infected Patients:Final 5-Year Double-Blind Results from STARTMRK - (07/25/12)
     
  9580. IAC: Final 5-Year Results of the BENCHMRK Studies: Sustained Antiretroviral Effect of Raltegravir, and Exploratory Analysis of Late Outcomes Based on Early Virologic Response - (07/25/12)
     
  9581. IAC: THE HIV NRTI BMS-986001 DOES NOT DEGRADE MITOCHONDRIAL DNA IN LONG TERM PRIMARY CULTURES OF CELLS ISOLATED FROM HUMAN KIDNEY, MUSCLE AND SUBCUTANEOUS FAT - (07/25/12)
     
  9582. IAC: Activity of the HIV-1 attachment inhibitor BMS-626529 against HIV-1 envelopes resistant to other entry inhibitors - (07/25/12)
     
  9583. IAC: Analysis of Efficacy by Baseline Viral Load: Phase 3 Study Comparing Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects: Week 48 Results - (07/25/12)
     
  9584. IAC: Absence of renal and bone toxicity in non-clinical studies of BMS-986001, a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus (HIV) - (07/25/12)
     
  9585. IAC: Pharmacokinetics, Safety and Tolerability of the HIV Integrase Inhibitor S/GSK1265744 Long Acting Parenteral Nanosuspension Following Single Dose Administration to Healthy Adults - (07/25/12)
     
  9586. IAC: Fractures at Earlier Age in HIV+ Men Versus HIV-Negatives in MACS - Written by Mark Mascolini - (07/24/12)
     
  9587. IAC: PIs, Proton Pump Inhibitors, Stroke Raise Fracture Risk in HIV+ Veterans - Written by Mark Mascolini - (07/24/12)
     
  9588. IAC: Mitochondrial Upsets May Underlie Metabolic Disorders in HIV-Positive Adolescents - Written by Mark Mascolini - (07/24/12)
     
  9589. IAC: Observational Studies Confirm Preventive Impact of ART in HIV-Discordant Couples: transmission rate cut by 98% when CD4>350 - Written by Mark Mascolini - (07/24/12)
     
  9590. IAC: Antiretroviral-Treated People in HPTN 052 Start Having Safer Sex - Written by Mark Mascolini - (07/24/12)
     
  9591. IAC: Poor CD4 Responders Have Almost Doubled Risk of Non-AIDS Disease - Written by Mark Mascolini - (07/24/12)
     
  9592. IAC: CD4 Count Under 700 Linked to All-Cause Mortality in Veterans Cohort - Written by Mark Mascolini - (07/24/12)
     
  9593. IAC: Hospital Readmission Rate in HIV Group 44% Higher Than in US Population - Written by Mark Mascolini - (07/24/12)
     
  9594. IAC: Maraviroc vs TDF/FTC + Reyataz/r - Written by Mark Mascolini - (07/24/12)
     
  9595. IAC: Cobicistat Noninferior to Ritonavir as Atazanavir Booster at 48 Weeks - Written by Mark Mascolini - (07/24/12)
     
  9596. IAC: Switch From Boosted PI to Single-Tablet Rilpivirine/TDF/FTC Maintains Suppression - Written by Mark Mascolini - (07/24/12)
     
  9597. IAC: Elvitegravir Noninferior to Raltegravir at Week 96 in Treatment-Experienced - Written by Mark Mascolini - (07/24/12)
     
  9598. IAC: Efficacy and Safety Results from a Randomized, Double-Blind, Active-Controlled Trial of Elvitegravir (Once-Daily) vs. Raltegravir (Twice-Daily) in Treatment-Experienced HIV-Infected Patients: Long Term 96-Week Data - (07/24/12)
     
  9599. IAC: Cobicistat versus Ritonavir as Pharmacoenhancers in Combination with Atazanavir Plus Tenofovir DF/Emtricitabine: Phase 3 Randomized, Double Blind, Active-Controlled Trial, Week 48 Results - (07/24/12)
     
  9600. IAC: SPIRIT Study: Switching boosted PI to Rilpivirine In Combination with Truvada as a Single-Tablet Regimen Week 24 Results (07/24/12)
     
  9601. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Estimated Glomerular Filtration Rates (eGFR) through 144 Weeks on Therapy in HIV-infected Subjects Receiving Atazanavir/ Ritonavir and Abacavir/Lamivudine or Simplified to Unboosted Atazanavir/Abacavir/Lamivudine - (07/23/12)
     
  9602. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Effects on post-prandial lipids and arterial stiffness of atazanavir/ritonavir versus darunavir/ritonavir in HIV-uninfected adults - (07/23/12)
     
  9603. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Skeletal muscle toxicity associated with raltegravir-based combination anti-retroviral therapy in HIV-infected adults - (07/23/12)
     
  9604. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: The Impact of Raltegravir and Lopinavir/ritonavir on lipid subfractions, vascular and inflammatory markers in HIV Negative Subjects - (07/23/12)
     
  9605. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: SPIRIT Study: Switching boosted PI to Rilpivirine In-combination with Truvada as a Single-Tablet Regimen Week 24 Results - (07/23/12)
     
  9606. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Predicting Risk of Cancer During HIV Infection: The Role of Inflammatory and Coagulation Biomarkers - (07/23/12)
     
  9607. NIH to test maraviroc-based drug regimens for HIV prevention - (07/19/12)
     
  9608. The Ethics of Switch/Simplify in Antiretroviral Trials: Non-Inferior or Just Inferior? - (07/19/12)
     
  9609. Physical Activity Is the Key Determinant of Skeletal Muscle Mitochondrial Function in Type 2 Diabetes - 'exercise reversed mitochondrial dysfynction in diabetics'....so perhaps exercise would reverse mitochondrial dysfunction in HIV+: from Jules - (07/17/12)
     
  9610. FDA Approves First Medication Truvada to Reduce HIV Risk - (07/17/12)
     
  9611. Exercise Improves The Brain - How HIV Causes Brain Damage - (07/16/12)
     
  9612. Chronic Anxiety Speeds Aging - (07/16/12)
     
  9613. Bringing HIV Out Of Hiding - new HIV cure research - (07/16/12)
     
  9614. Potential cause of HIV-associated dementia revealed - (07/13/12)
     
  9615. How HIV Affects the Brain-new study: Human Immunodeficiency Virus Type 1 Alters Brain-Derived Neurotrophic Factor Processing in Neurons - (07/12/12)
     
  9616. Herpes Zoster among Persons Living with HIV in the Current ART Era - (07/12/12)
     
  9617. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana - (07/12/12)
     
  9618. 3 Newly Published PrEP Studies: Preexposure Prophylaxis for HIV Infection among African Women - (07/12/12)
     
  9619. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women - (07/12/12)
     
  9620. Preexposure Prophylaxis Case Studies for HIV Prevention - (07/12/12)
     
  9621. Preexposure Prophylaxis for HIV (PrEP)- Where Do We Go from Here? Editorial - (07/12/12)
     
  9622. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/HCV co-infected patients - "routine screening for insulin resistance among co-infected persons may be warranted" - (07/10/12)
     
  9623. The rising challenge of Non-AIDS Defining Cancers in HIV-infected patients - (07/10/12)
     
  9624. New Zinc-Therapy Gene Therapy: Targeted gene knockout by direct delivery of zinc-finger nuclease proteins - (07/10/12)
     
  9625. Vitamin D - Baseline Status and Effective Dose - Editorial - (07/9/12)
     
  9626. Carotid Intima-Media Thickness (IMT) Among Human Immunodeficiency Virus-Infected Patients Without Coronary Calcium: subclinical heart disease in HIV+ - (07/9/12)
     
  9627. Comparison of Ischemic Stroke Incidence in HIV-Infected and Non-HIV-Infected Patients in a US Health Care System - (07/9/12)
     
  9628. Therapeutic strategies for the eradication of persistent viral reservoirs.... - (07/9/12)
     
  9629. Time to Initiate Antiretroviral Therapy Between 4 Weeks and 12 Weeks of Tuberculosis Treatment in HIV-Infected Patients: Results From the TIME Study - (07/9/12)
     
  9630. Use of Highly Active Antiretroviral Therapy Is Associated With Lower Prevalence of Anal Intraepithelial Neoplastic Lesions and Lower Prevalence of Human Papillomavirus in HIV-Infected Men Who Have Sex With Men - (07/9/12)
     
  9631. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals - (07/9/12)
     
  9632. Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/μl - (07/9/12)
     
  9633. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals - (07/9/12)
     
  9634. HIV and Aging: State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group - (06/27/12)
     
  9635. A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model: 'functional cure?' - (06/25/12)
     
  9636. Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection : functional cure - (06/27/12)
     
  9637. TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 - (06/27/12)
     
  9638. Researchers identify cervical cells most susceptible to HPV infection - (06/27/12)
     
  9639. Gilead HIV Eradication Program - (06/27/12)
     
  9640. Intl Wksp HIV/Hep Drug Resist: Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance associated variants at baseline (part II) (06/26/12)
     
  9641. Intl Wksp HIV/Hep Drug Resist: Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance-associated variants at baseline (06/26/12)
     
  9642. Immunosenescence and HIV - (06/25/12)
     
  9643. Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection - (06/21/12)
     
  9644. Bone Loss in Young HIV+ Men 'Lifestyle Risk' - (06/20/12)
     
  9645. Intl Wksp HIV/Hep Drug Resist: Jak inhibitors exhibit a novel mechanism of HIV inhibition in primary human and rhesus macaque macrophages and lymphocytes: 'functional cure?' (06/20/12)
     
  9646. Intl Wksp HIV/Hep Drug Resist: Report from International Workshop on HIV & Hepatitis Virus Drug Resistance 2nd Report, June 5-9 2012 Sitges, Spain - Written for NATAP by Mark A. Wainberg, PhD, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada (06/20/12)
     
  9647. 1st Report - Intl Wksp HIV/Hep Drug Resist: Report from International Workshop on HIV & Hepatitis Virus Drug Resistance 5-9 June 2012, Sitges, Spain - Written for NATAP by Mark A. Wainberg, PhD, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada (06/19/12)
     
  9648. Diagnoses of HIV Infection Among Hispanics/Latinos in 40 States and Puerto Rico, 2006-2009 - (06/19/12)
     
  9649. Mitochondrial Evolution in HIV-Infected Children Receiving First- or Second-Generation Nucleoside Analogues - (06/19/12)
     
  9650. A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults - (06/19/12)
     
  9651. Bone Loss in the HIV-Infected Patient: Evidence, Clinical Implications, and Treatment Strategies- Review - (06/14/12)
     
  9652. Intl Wksp HIV/Hep Drug Resist: Reverse transcriptase connection-domain mutations were not associated with virologic failure or phenotypic resistance in rilpivirine-treated patients from the ECHO and THRIVE Phase III trials (Week 96 analysis) (06/18/12)
     
  9653. Intl Wksp HIV/Hep Drug Resist: Comparison of the Antivirogram and PhenoSense assays to determine phenotypic susceptibility to rilpivirine in patient samples from the Phase III ECHO and THRIVE trials (06/18/12)
     
  9654. Intl Wksp HIV/Hep Drug Resist: Integrated Analysis of Emergent Drug Resistance from the HIV-1 Phase 3 QUAD Studies through Week 48 (06/18/12)
     
  9655. Intl Wksp HIV/Hep Drug Resist: Effect of Primary Elvitegravir Resistance Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness (06/18/12)
     
  9656. Intl Wksp HIV/Hep Drug Resist: Genotypic and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in a short-term monotherapy study with its prodrug BMS-663068 (06/15/12)
     
  9657. Intl Wksp HIV/Hep Drug Resist: The in vitro cross-resistance profile of the NRTI BMS-986001 against known NRTI resistance mutations (06/15/12)
     
  9658. Intl Wksp HIV/Hep Drug Resist: Resistance and Potency of GS-7340, a Next-Generation Tenofovir Prodrug (06/15/12)
     
  9659. Intl Wksp HIV/Hep Drug Resist: Switching the NNRTI or the PI/r to Maraviroc in Aviremic Subjects Infected with RS HIV by V3 Loop Population Sequencing: 48 week, Prospective, Controlled, Pilot Study (06/15/12)
     
  9660. Intl Wksp HIV/Hep Drug Resist: Combinations of Primary and Secondary Integrase Mutations in the VIKING Pilot Study: Effects on and Rationale for Dolutegravir Dissociation (06/15/12)
     
  9661. Intl Wksp HIV/Hep Drug Resist: Dolutegravir Treatment of HIV Subjects With Raltegravir Resistance: Integrase Resistance Evolution in Cohort II of the VIKING Study (06/15/12)
     
  9662. Intl Wksp HIV/Hep Drug Resist: High Barrier to Resistance for Dolutegravir (DTG, S/GSK1349572) Against Raltegravir-Resistant Y143 Mutants: An In Vitro Passage Study (06/15/12)
     
  9663. Traces Of Virus In Man Cured Of HIV Trigger Scientific Debate - (06/13/12)
     
  9664. Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial - (06/13/12)
     
  9665. The Berlin Patient: New Research Presented at the HIV Resistance Workshop in Sitges, Spain Two Days Ago - (06/12/12)
     
  9666. Evidence That Man Cured of HIV Harbors Viral Remnants Triggers Confusion - Commentary Science Mag - (06/12/12)
     
  9667. The Critical Role of Metabolic Pathways in Aging - (06/12/12)
     
  9668. Guidelines Ease Up on Glycemic Control for Some Patients With Type 2 Diabetes - (06/12/12)
     
  9669. 13th Intrntl Wrkshp Clinical Pharm HIV: Differential Exposure of Raltegravir Throughout Gut---associated Lymphoid Tissue: "High concentrations of raltegravir within GALT...Raltegravir may be useful for combination with eradication strategies" - (06/12/12)
     
  9670. The Rates of HIV Superinfection and Primary HIV Incidence in a General Population in Rakai, Uganda - (06/08/12)
     
  9671. Number of Cancer Cases Worldwide Could Go Up by 75% by 2030, New Study in The Lancet Reports: "Cancer is set to become a major cause of morbidity and mortality in the coming decades in every region of the world" - (06/05/12)
     
  9672. (PrEP/PEP) Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV: Safety, Tolerability, and Adherence - (06/03/12)
     
  9673. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis: "HBV, HCV, HPV, and H pylori were together responsible for 1·9 million cases worldwide" - (06/05/12)
     
  9674. Mortality Due to HCV-Related Disease in HIV+ - (06/03/12)
     
  9675. Calcium supplements: bad for the heart? Editorial - (06/01/12)
     
  9676. HCV Sustained Viral Response in HIV Coinfected Reduces Non-Liver Related Mortality & Liver-Related Disease: cancers/CVD - (06/01/12)
     
  9677. Bispohosphonates Bone Therapy: duration of therapy; new study on atypical femoral fracture risk, commentary - (05/23/12)
     
  9678. PrEP FDA Hearing May 10 2012: US HIV Epidemiology & Risk, Susan Buchbinder MD SF Dept of Public Health, UCSF - (05/23/12)
     
  9679. Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants? Editorial - (05/23/12)
     
  9680. Effects of Contemporary ART Regimens on Inflammatory Markers - (05/23/12)
     
  9681. Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir - (05/23/12)
     
  9682. Glitazones & Bladder Cancer - (05/23/12)
     
  9683. 13th Intrntl Wrkshp Clinical Pharm HIV: Population Pharmacokinetics of Cobicistat-Boosted Elvitegravir in Adult Healthy Subjects and HIV-infected Patients - (04/21/12)
     
  9684. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics of Elvitegravir and Cobicistat in Subjects with Severe Renal Impairment - (04/21/12)
     
  9685. 13th Intrntl Wrkshp Clinical Pharm HIV: Safety/Tolerability, Pharmacokinetics, and Boosting of Twice-daily Cobicistat Administered Alone or in Combination with Darunavir or Tipranavir - (04/21/12)
     
  9686. 13th Intrntl Wrkshp Clinical Pharm HIV: Lack of Clinically Relevant Drug Interactions Between GS-7340 and Efavirenz - (04/21/12)
     
  9687. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics, Safety, and Tolerability of the HIV Integrase Inhibitor Dolutegravir Co-Administered with Rifabutin in Healthy Subjects - (04/21/12)
     
  9688. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-Elvitegravir with Atazanavir, Rosuvastatin or Rifabutin - (04/21/12)
     
  9689. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics of a Novel EVG/COBI/FTC/GS-7340 Single Tablet Regimen - (04/21/12)
     
  9690. 13th Intrntl Wrkshp Clinical Pharm HIV: Etravirine Has No Effect on the Pharmacokinetics of S/GSK1265744, a Novel HIV Integrase Inhibitor - (04/21/12)
     
  9691. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics of EVG/COBI/FTC/TDF Single Tablet Regimen following Treatment with EFV/FTC/TDF (Atripla) in Healthy Subjects - (04/21/12)
     
  9692. 13th Intrntl Wrkshp Clinical Pharm HIV: Pharmacokinetics and Safety of Boosted-Elvitegravir in Subjects with Hepatic Impairment - (04/18/12)
     
  9693. 13th Intrntl Wrkshp Clinical Pharm HIV: Metabolism & Drug-Drug Interaction Profile of Dolutegravir (DTG, S/GSK1349572) - (04/21/12)
     
  9694. Bisphosphonates for Osteoporosis - Where Do We Go from Here?/Duration of Therapy - Perspective - (05/17/12)
     
  9695. Doubt Cast on the 'Good' in 'Good Cholesterol' - 2 Lancet articles below - (05/17/12)
     
  9696. Statins benefit those at much lower CV risk - 2 Lancet articles below - (05/17/12)
     
  9697. PrEP Truvada/2nd Generation; FDA Advisors Endorse Truvada PrEP--But Big Questions Remain - (05/16/12)
     
  9698. HIV Linked to Risk of Sudden Cardiac Death - (05/15/12)
     
  9699. A New Equation to Estimate Glomerular Filtration Rate - (05/15/12)
     
  9700. FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV - (05/15/12)
     
  9701. Intermittent Prophylaxis with Oral (Gel) Truvada Protects Macaques from Rectal SHIV Infection - (05/15/12)
     
  9702. 13th Intrntl Wrkshp Clinical Pharm HIV: Clinical Pharmacology at the 13th Workshop on Clinical Pharmacology of HIV Therapy - Courtney V. Fletcher, Pharm.D. - (05/14/12)
     
  9703. CROI: INTRAVAGINAL RING DELIVERY OF THE PYRIMIDINEDIONE IQP-0528 RESULTS IN PROTECTIVE CONCENTRATIONS IN VAGINAL BIOPSIES OF PIGTAILED MACAQUES - NOVEL MODELS TO ASSESS PK/PD - (04/14/12)
     
  9704. CROI: Intermittent Oral PrEP with Truvada Prevents Vaginal SHIV Transmission in Macaques - (04/14/12)
     
  9705. CROI: Safety, Acceptability and Pharmacokinetic Assessment (Adherence) of Monthly Dapivirine Vaginal Microbicide Rings (Ring-004) for HIV Prevention - (04/14/12)
     
  9706. CROI: Next/2nd Generation PrEP for Men & Women: intravaginal rings, injectables, long-acting, rectal gel, intermittent PrEP - (04/14/12)
     
  9707. FDA Advisors Vote Overwhelmingly to Recommend Truvada for PrEP written by Mark Mascolini - (05/11/12)
     
  9708. FDA Offers Generally Favorable Review of Truvada for PrEP written by Mark Mascolini - (05/10/12)
     
  9709. How Working the Muscles May Boost Brainpower - (05/09/12)
     
  9710. Rapid HIV tests: from meta-analysis to field application - (05/09/12)
     
  9711. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis - (05/09/12)
     
  9712. Premature Aging with HIV Infection: More Evidence AIDS - (05/09/12)
     
  9713. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial - (05/09/12)
     
  9714. Is There a Drug-Drug Interaction Between Darunavir/Ritonavir and Raltegravir? - (05/07/12)
     
  9715. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus - (05/07/12)
     
  9716. HIV & Sleep Disturbances - (05/04/12)
     
  9717. HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges - Editorial - (05/04/12)
     
  9718. Prevalence and Factors Associated With Sleep Disturbances Among Early-Treated HIV-Infected Persons: 'Forty-six percent of HIV-infected persons had insomnia, 38% in HIV-unifected, no statistical difference found' - (05/04/12)
     
  9719. Combination Treatment (metformin, rosi, lifestyle intervetion) New Study- For Diabetic Kids - (05/04/12)
     
  9720. TODAY - A Stark Glimpse of Tomorrow, Editorial Combination Therapy for Diabetes for Kids - (05/04/12)
     
  9721. HIV as an independent risk factor for incident lung cancer - (05/04/12)
     
  9722. 13th Intrntl Wrkshp Clinical Pharm HIV: Twice-Daily Cobicistat Effect Differs With Darunavir and Tipranavir - written by Mark Mascolini - (04/25/12)
     
  9723. 13th Intrntl Wrkshp Clinical Pharm HIV: Efavirenz PKs Highly Variable and Driven by CYP2B6 Genotype in Youngsters - written by Mark Mascolini - (04/25/12)
     
  9724. 13th Intrntl Wrkshp Clinical Pharm HIV: Switching to QUAD After Atripla Has No Telling Impact on Elvitegravir Levels - written by Mark Mascolini - (04/25/12)
     
  9725. 13th Intrntl Wrkshp Clinical Pharm HIV: Etravirine Levels 25% Lower With HCV Protease Inhibitor Boceprevir - written by Mark Mascolini - (04/18/12)
     
  9726. 13th Intrntl Wrkshp Clinical Pharm HIV: Lack of a clinically significant drug interaction between BMS-663068, a novel HIV-1 attachment inhibitor, and tenofovir disoproxil fumarate when administered in combination at steady state - written by Mark Mascolini - (04/18/12)
     
  9727. 13th Intrntl Wrkshp Clinical Pharm HIV: Cobicistat Doubles to Triples Exposure of GS-7340 (a Tenofovir Prodrug) and Resulting Tenofovir - written by Mark Mascolini - (04/18/12)
     
  9728. 13th Intrntl Wrkshp Clinical Pharm HIV: Antiviral activity, exposure-response, and resistance analyses of monotherapy with the novel HIV nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 in antiretroviral treatment-experienced subjects -1 - (04/18/12)
     
  9729. 13th Intrntl Wrkshp Clinical Pharm HIV: Antiviral activity, exposure-response, and resistance analyses of monotherapy with the novel HIV nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 in antiretroviral treatment-experienced subjects -2 - (04/18/12)
     
  9730. 13th Intrntl Wrkshp Clinical Pharm HIV: Etravirine With 300/100 or 400/100 mg of ATV/r in Treatment-Experienced People - written by Mark Mascolini - (04/18/12)
     
  9731. 13th Intrntl Wrkshp Clinical Pharm HIV: Darunavir/Cobicistat Formulation Yields Darunavir Level Close to Darunavir/Ritonavir - written by Mark Mascolini - (04/18/12)
     
  9732. 13th Intrntl Wrkshp Clinical Pharm HIV: No Relevant Interactions Between Telaprevir and Two Newest Nonnucleosides Rilpivirine & Etravirine - written by Mark Mascolini - (04/18/12)
     
  9733. HIV Raises Anal Cancer Risk in Women: "High Prevalence of High Grade Anal Intraepithelial Neoplasia in HIV-infected Women Screened for Anal Cancer".... "Given the high rate of high grade AIN in screened HIV-infected women, as well as an aging population of HIV-infected patients, measures to increase routine AC screening should be strongly considered" - (04/17/12)
     
  9734. 13th Intrntl Wrkshp Clinical Pharm HIV: Raltegravir 400 mg Once Daily With Atazanavir/Ritonavir Plus 2 NRTIs - written by Mark Mascolini - (04/17/12)
     
  9735. 13th Intrntl Wrkshp Clinical Pharm HIV: Injected Rilpivirine for PrEP Stays in Plasma for 84 Days in Women and Men - written by Mark Mascolini - (04/17/12)
     
  9736. 13th Intrntl Wrkshp Clinical Pharm HIV: Rifabutin Cuts Elvitegravir Levels, But No Critical Elvitegravir Interactions With Atazanavir or Rosuvastatin - written by Mark Mascolini - (04/17/12)
     
  9737. 13th Intrntl Wrkshp Clinical Pharm HIV: Impact of Atazanavir/Ritonavir on Antifungal Depends on CYP2C19 Genotype - written by Mark Mascolini - (04/17/12)
     
  9738. 13th Intrntl Wrkshp Clinical Pharm HIV: Drug Interactions With Integrase Inhibitor Dolutegravir Identified - written by Mark Mascolini - (04/17/12)
     
  9739. 13th Intrntl Wrkshp Clinical Pharm HIV: Good Virologic Response in 10-Day Study of Festinavir, a New NRTI - written by Mark Mascolini - (04/17/12)
     
  9740. 13th Intrntl Wrkshp Clinical Pharm HIV: Efavirenz Concentrations Do Not Signal Discontinuation in Swiss Study - written by Mark Mascolini - (04/17/12)
     
  9741. CROI: Brain tCho/Cr is Elevated in Acute HIV within the First Month of Infection: 'brain inflammation in acute infection/immediate HAART may normalize or improve inflammation or perhaps prevent damage' - (04/16/12)
     
  9742. CROI: Mortality in Patients with Well Controlled HIV and High CD4 Counts in the Continuous ART Arms of the SMART and ESPRIT Trials Compared to the General Population - (03/16/12)
     
  9743. CROI: Distribution of age at death and effects of immunosuppression and ART duration vary according to cause of death in HIV-1 positive people - (03/16/12)
     
  9744. HIV Suppressed, Cd4s Increased with New Stem Cell Based Gene Therapy in Mice - (04/16/12)
     
  9745. Prevent Drug Craving and Relapse: A Memory Retrieval-Extinction Procedure - New Published Research - (04/16/12)
     
  9746. CROI: Earlier Initiation of Antiretroviral Therapy Results in Better Neurocognitive Functioning - (04/13/12)
     
  9747. CROI: Signs of Peripheral Neuropathy Associate with Elevated Inflammatory Biomarkers in Blood and Cerebrospinal Fluid in Primary HIV Infection - (04/13/12)
     
  9748. CROI: Older Subjects with HIV Infection Have increased Memory Deficit Compared to Younger Subjects - (04/13/12)
     
  9749. CROI: Cancer Stage, Age at Diagnosis and Survival Comparing HIV(+) and HIV(-) Individuals with Common Non-AIDS-Defining Cancers - (04/11/12)
     
  9750. CROI: DISPARITIES IN RATES OF HIV TREATMENT INITIATION AND VIRAL LOAD SUPPRESSION ACROSS U.S. STATES, 2001-2007 - (04/11/12)
     
  9751. CROI: Early Missed Office Visits Post-HIV Diagnosis and Mortality in a Large Healthcare System - (04/11/12)
     
  9752. Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men - (04/11/12)
     
  9753. Should statins be used in primary prevention? - (04/11/12)
     
  9754. Predicting and Preventing Cardiovascular Disease in HIV-Infected Patients Perspective - (04/10/12)
     
  9755. Flavonoids- Apple A Day Improves Brain(prevent Parkinsons) & Orange A Day Improves Inflammation-CVD - (04/10/12)
     
  9756. HIV and Aging (Developing World/Africa)- Preparing for the Challenges Ahead - Perspective - (04/05/12)
     
  9757. CROI: Mutation Y188L of HIV-1 Reverse Transcriptase is Strongly Associated with Reduced Susceptibility to Rilpivirine - (04/05/12)
     
  9758. CROI: HIV Infection Is Associated with Greater Amounts of Non-Calcified Coronary Artery Plaque: the Multicenter AIDS Cohort Study (MACS) - (04/04/11)
     
  9759. The Association of Race, Sociodemographic, and Behavioral Characteristics With Response to Highly Active Antiretroviral Therapy in Women: 'depression, black/latino women, HAART discontinuation, higher death rates, drug use all related' - (04/03/12)
     
  9760. Comparison of risk-assessment strategies favors "statins for all" - (04/03/12)
     
  9761. CROI: CROI 2012: "The Long & Winding Road of HIV Complications" - (04/04/12)
     
  9762. CROI: Metabolics, Inflammation, Complications, and Aging at CROI - written by David Alain Wohl, MD - The University of North Carolina - (04/03/12)
     
  9763. CROI: Intima Media Thickness Is Associated with Residual Plasma Viremia in Treated Patients with Controlled HIV Infection - (04/03/12)
     
  9764. CROI: Higher Levels of Interleukin-6 and Soluble Tumor Necrosis Factor-Alpha Receptor I are Associated with Increased Coronary Atherosclerotic Plaque in the Multicenter AIDS Cohort Study (MACS) - (04/03/12)
     
  9765. CROI: Progression of Atherosclerosis: Understanding RAGE (Receptor for Advanced Glycation Endproducts): NWCS 332 - (04/03/12)
     
  9766. CROI: The Association of Race with Death from AIDS in Continuous HAART Users in the Women's Interagency HIV Study (WIHS): Being Black, death, depression, history of illicit drug use & non-adherence are all associated - (04/03/12)
     
  9767. CROI: Rate and Predictors of Carotid Intima Media Thickness Progression in ARV-Naïve HIV-Infected and Uninfected Adults: A 48-Week Prospective Matched Cohort - (04/02/12)
     
  9768. CROI: Ultrasonographic Measures of Cardiovascular Disease Risk in a Modern Cohort of Antiretroviral Treatment (ART)-Naïve Individuals with HIV Infection: Baseline Results from ACTG Study 5260s - (04/02/12)
     
  9769. CROI: Subclinical Carotid Atherosclerosis Is Related to HIV Infection and Low Adherence to a Mediterranean Diet - (04/02/12)
     
  9770. CROI: Comprehensive Cardiac Magnetic Resonance Reveals HIV is Associated with a High Burden of Myocardial Disease - (04/02/12)
     
  9771. CROI: D:A:D Sees No Link Between Atazanavir and Myocardial Infarction or Stroke - (03/30/12)
     
  9772. CROI: Kidney Function in D:A:D With TDF, ATV, and LPV - (03/30/12)
     
  9773. Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267 - (03/30/12)
     
  9774. Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial - (03/30/12)
     
  9775. NEW HIV Guidelines Recommends HAART When CD4 >500 (BIII: moderate recommendation based on expert opinion) & Aging UPDATE.... - (03/30/12)
     
  9776. Women & HIV: Medical Care for Menopausal and Older Women With HIV Infection - (03/29/12)
     
  9777. Women & HIV: Testosterone & HIV+ Women - adverse events - (03/29/12)
     
  9778. Women & HIV: Gender Gap in CVD: The Epidemiology of Cardiovascular Disease in Postmenopausal Women-see article below - (03/29/12)
     
  9779. Women & HIV: Sex Differences in the Pharmacologic Effects of Antiretroviral Drugs: Potential Roles of Drug Transporters and Phase 1 and 2 Metabolizing Enzymes - (03/29/12)
     
  9780. Women & HIV: Women & HIV: Black Women in USA; trauma; childhood sex abuse; heart disease in HIV+ women - (03/29/12)
     
  9781. Women & HIV: Heart Disease & Women HIV+, inflammation: Obesity and Dyslipidemia in Behaviorally HIV-Infected Young Women: Adolescent Trials Network Study 021 - (03/29/12)
     
  9782. Women & HIV: Gender differences in the treatment of HIV infection - review - (03/29/12)
     
  9783. In this trial, temporary cART during PHI was found to transiently lower the viral set point and defer the restart of cART during chronic HIV infection. - (03/28/12)
     
  9784. Starting HAART Reduces Endothelial Dysfunction Marker ADMA. ADMA higher levels is associated with CVD & mortality in general population..... - (03/28/12)
     
  9785. New Monoclonal Antibody Lowers LDL: Biologic Wows for Lipid Lowering - (03/28/12)
     
  9786. Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol - (03/28/12)
     
  9787. CROI: Comparison of Gut-Associated Lymphoid Tissue HIV RNA and DNA Levels in HIV-infected Controllers, Non-controllers, and HAART-suppressed Individuals: 'Untreated non-controllers have reservoir....lymphoid tissues are an active reservoir of HIV in controllers.....treatment should be considered for these individuals' - (03/28/12)
     
  9788. CROI: Hyperparathyroidism Associated with Vitamin D Deficiency in HIV-Infected Adults - (03/28/12)
     
  9789. CROI: Clinical Pharmacology at CROI 2012 PrEP, HCV, Cure(residual replication in reservoirs), TB-dolutegravir, orally inhaled steroids, GS-7340, older age CSF ART levels, TDF levels/bone/renal - written by - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (03/27/12)
     
  9790. CROI: CROI Summary 2012 Inflammation, metabolic complications and strategies for eradication. - written by  Pablo Tebas University of Pennsylvania (03/26/12)
     
  9791. CROI: HIV Replication, Inflammation, and the Effect of Starting Antiretroviral Therapy on Plasma Asymmetric Dimethylarginine (ADMA), A Novel Marker of Endothelial Dysfunction (HAART Improves Endothelial Dysfunction Marker ADMA which in the general pop is associated with CVD & mortality) - (03/26/12)
     
  9792. CROI: HAART Reduces Endothelial Activation: Asymmetric dimethylarginine (ADMA) concentrations decrease in patients with HIV infection under antiretroviral therapy - (03/26/12)
     
  9793. CROI: Lower CD4+ Counts and Detectable HIV Viral Load are Associated With Elevated Levels of ADMA in HIV+ Patients - (03/26/12)
     
  9794. CROI: Vitamin D deficiency may impair CD4 recovery among Women's Interagency HIV Study (WIHS) participants on HAART - (03/26/12)
     
  9795. CROI: ADMA Levels are Associated With Elevated Pulmonary Artery Pressure in HIV-Infected Individuals - (03/26/12)
     
  9796. CROI: Morphine Induction of HIV Co-receptors and its Role in HIV Disease Progression - (03/26/12)
     
  9797. CROI: Gut Epithelial Barrier Dysfunction, Inflammation, and Coagulation Predict Higher Mortality during Treated HIV/AIDS - (03/26/12)
     
  9798. CROI: Gender Difference in Mucosal Integrity Impacts Response to HAART in HIV Infection - (03/26/12)
     
  9799. CROI: Effect of Combined Antiretroviral Therapy (cART) on Bacterial Translocation, Inflammation, Coagulation and Immune Activation in Advanced (<100 CD4+ cells/mm3) Antiretroviral-Naïve Patients at Week 48 (EFV or Reyataz/r) - (03/26/12)
     
  9800. CROI: Gut Epithelium is an Early Target of the Virus in the SIV Model of AIDS - (03/26/12)
     
  9801. CROI: Immune activation in HIV-1 patients experiencing transiently detectable viremia during antiretroviral treatment - (03/26/12)
     
  9802. CROI: CD4+ T Cells and Th17 Cells Repopulation in ART-Treated HIV-Infected Individuals - (03/26/12)
     
  9803. CROI: Gut Mucosa T Lymphocyte Restoration in Chronically HIV+ Patients Treated with Recombinant Interleukin-7 - (03/26/12)
     
  9804. CROI: Probiotic Supplementation of ARV Treatment during SIV Infection of Pigtail Macaques Results in Enhanced GI Tract CD4+ T Cell Frequency and Immunological Function - (03/26/12)
     
  9805. CROI: Impact of Switching from Zidovudine/Lamivudine to Tenofovir/Emtricitabine on Bone Mineral Density and Bone Metabolism in Virologically Suppressed HIV-1+ Patients: A Sub-study of the PREPARE Study - (03/26/12)
     
  9806. CROI: OLDER AGE IS ASSOCIATED WITH HIGHER ANTIRETROVIRAL CONCENTRATIONS IN CEREBROSPINAL FLUID IN HIV-INFECTED INDIVIDUALS - (03/26/12)
     
  9807. The Bilirubin-Increasing Drug Atazanavir Improves Endothelial Function in Patients With Type 2 Diabetes Mellitus - (03/23/12)
     
  9808. The Pervasive Effects of Childhood Sexual Abuse: Challenges for Improving HIV Prevention and Treatment Interventions EDITOIRAL - (03/23/12)
     
  9809. Childhood Trauma and Health Outcomes in HIV-Infected Patients: An Exploration of Causal Pathways - (03/23/12)
     
  9810. Associations of Sexual Identity or Same-Sex Behaviors With History of Childhood Sexual Abuse and HIV/STI Risk in the United States - (03/23/12)
     
  9811. Study of the Day: 1 in 4 Adults With HIV Were Sexually Abused as Kids - (03/23/12)
     
  9812. CROI: Peripheral Neuropathy in ART-experienced Patients: Prevalence and Risk Factors - (03/23/12)
     
  9813. CROI: CNS Penetration Effectiveness of cART and Neuropsychological Outcomes: Cross-sectional Results from the OHTN Cohort Study - (03/23/12)
     
  9814. CROI: Microbial Translocation Independently Predicts Future Hypertension in HIV-Infected Individuals - (03/23/12)
     
  9815. CROI: HIV Status, Burden of Comorbid Disease and Biomarkers of Inflammation, Altered Coagulation and Microbial Translocation-VA Study: important study because it finds cd4 & viral load & comorbid conditions independently associated with inflammation - (03/23/12)
     
  9816. CROI: Improved Low Bone Mineral Density and Bone Turnover Markers with Switch from Tenofovir to Raltegravir in Virologically Suppressed HIV-1+ Adults at 48 Weeks: The TROP Study - (03/22/12)
     
  9817. CROI: Changes in Inflammation and Endothelial Activation Markers in ARV-naïve Subjects Randomized to Abacavir/Lamivudine or Tenofovir/Emtricitabine along with Efavirenz or Atazanavir/ritonavir: AIDS Clinical Trials Group A5224s, a Sub-study of ACTG A5202 - (03/22/12)
     
  9818. CROI: The Impact of Elevated and Pre-hypertensive Systolic Blood Pressure and the Risk of Acute Myocardial Infarction in HIV+ and HIV- Veterans - (03/22/12)
     
  9819. Recent Trauma is Associated with Antiretroviral Failure and HIV Transmission Risk Behavior Among HIV-Positive Women and Female-Identified Transgenders - (03/20/12)
     
  9820. Trauma Drives HIV Epidemic in Women - (03/20/12)
     
  9821. CROI: HIV Latency and Eradication at CROI 2012 -written by   David Margolis, MD University of North Carolina - (03/19/12)
     
  9822. CROI: CROI Report: Bones, Frailty, and Vitamin D -written by   Todd Brown, MD, PhD Associate Professor of Medicine Division of Endocrinology and Metabolism Johns Hopkins University - (03/19/12)
     
  9823. CROI: ACEi or HMG-CoA Reductase Inhibitor (Statin) Treatment as Adjunct Therapy for Persons with HIV infection: A Pilot Study - (03/20/12)
     
  9824. CROI: Changes in Cardiovascular Biomarkers in Subjects Switching from Ritonavir- Boosted Protease Inhibitors to Raltegravir: The SPIRAL Study - (03/20/12)
     
  9825. CROI: Longitudinal analysis of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy - (03/20/12)
     
  9826. CROI: End-Stage Renal Disease Up in Whites, Down in Blacks in 22-Year German Study - written by Mark Mascolini - (03/19/12)
     
  9827. CROI: Untreated Depression and Refusing ART Common in Seattle-Area HIV+ Deaths - written by Mark Mascolini - (03/19/12)
     
  9828. CROI: NNRTI Treatment Breaks Boost Risk of Resistant HIV RNA in Female Genital Tract - written by Mark Mascolini - (03/19/12)
     
  9829. CROI: CROI 2012: HIV Persistence, Latency and Eradication - written by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY (03/19/12)
     
  9830. CROI: Antiretroviral Therapy at CROI - PHASE III, PHASE II, PHASE I -written by Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/19/12)
     
  9831. CROI: Pharmacokinetics of Dolutegravir in Subjects With Moderate Hepatic Impairment - (03/19/12)
     
  9832. CROI: Pharmacokinetics of a Dolutegravir Pediatric Granule Formulation in Healthy Adult Subjects - (03/19/12)
     
  9833. CROI: Interferon-alpha & Inflammation: interferon stimulates activation/inflammation, therapies to quell activation - (03/19/12)
     
  9834. Interferon-alpha & Inflammation: interferon stimulates activation/inflammation, therapies to quell activation - (03/19/12)
     
  9835. HIV infection and aging: enhanced Interferon- and Tumor Necrosis Factor-alpha production by the CD38+ CD28- T subset - (03/19/12)
     
  9836. Innate immune responses contribute to immune activation and inflammation in HIV infected women: Distinct role of IFN-a in chronic HIV Infection - (03/19/12)
     
  9837. CROI: Incomplete HIV Control During ART Triples Risk of non-Hodgkin Lymphoma - written by Mark Mascolini - (03/16/12)
     
  9838. CROI: Oral Cancer Rate Higher With HIV--Lower CD4s Implicated in People Over 49 - written by Mark Mascolini - (03/16/12)
     
  9839. CROI: Glucose-Lowering Drugs May Limit Progression to Symptomatic Peripheral Neuropathy - written by Mark Mascolini - (03/16/11)
     
  9840. CROI: Antiretrovirals May Cut Neurosyphilis Risk and Improve Response to Neurosyphilis Therapy - written by Mark Mascolini - (03/16/12)
     
  9841. CROI: Cardiovascular Risk Tied to MRS-Defined Brain Injury in 45-and-Older Men With HIV - written by Mark Mascolini - (03/16/12)
     
  9842. CROI: Over Half of HIV+ 60 and Older Have Cognitive Deficit in San Francisco Study - written by Mark Mascolini - (03/16/11)
     
  9843. CROI: Higher CMV Antibody Linked to Lower CD4 Nadir and Worse Neurocognitive Function - written by Mark Mascolini - (03/16/12)
     
  9844. CROI: Sub-100 Latest CD4 Count Tied to Stroke and Cardiovascular Disease in D:A:D - written by Mark Mascolini - (03/16/12)
     
  9845. CROI: Pilot Study Explores ACE Inhibitor and Statin as Anti-inflammatory Therapy for HIV - written by Mark Mascolini - (03/16/12)
     
  9846. CROI: Associations between Anatomic Fat Depots with Total, Calcified, Non-Calcified and Mixed Coronary Plaque in the Multicenter AIDS Cohort Study (MACS) - (03/16/12)
     
  9847. CROI: The Effect of a Local "Universal Antiretroviral Therapy" Policy on HIV RNA levels among Patients Entering Care with a CD4 Count Greater than 500/µl in a Public Health Clinic Setting - (03/16/12)
     
  9848. CROI: Impact of HAART Initiation on Immune Regulation (activation/senescence) in Aging HIV-infected Women -Women's Interagency HIV Study - (03/16/12)
     
  9849. CROI: Metformin Prevented CAC Progression But Lifestyle Modification Did Not - (03/16/12)
     
  9850. CROI: 19th Conference on Retroviruses and Opportunistic Infections Report: prevention/PrEP, eradication, the brain, new HIV antiretroviral drugs - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine - (03/16/12)
     
  9851. CROI: CROI 2012: Studies on Inflammation in HIV - written by   David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (03/16/12)
     
  9852. CROI: NeuroAIDS at CROI 2012 - written by David Alain Wohl, MD - The University of North Carolina - (03/16/12)
     
  9853. CROI: Higher CMV Antibody Linked to Lower CD4 Nadir and Worse Neurocognitive Function - written by Mark Mascolini - (03/15/12)
     
  9854. CROI: Cerebrospinal Fluid Concentrations of Key Antiretrovirals Increase With Age - written by Mark Mascolini - (03/15/12)
     
  9855. CROI: Predictors of Overall and Late-Onset Lab Abnormalities With Contemporary Regimens - written by Mark Mascolini - (03/15/12)
     
  9856. CROI: Virologic Impact of Starting ART Above 500 CD4s at San Francisco General Hospital - written by Mark Mascolini - (03/15/12)
     
  9857. CROI: Drop in Transmitted Drug Resistance May Have Stopped in UK After 2005: may be increasing except for NNRTIs - written by Mark Mascolini - (03/15/12)
     
  9858. CROI: Respiratory Disease May Be Underdiagnosed in Men With HIV - written by Mark Mascolini - (03/15/12)
     
  9859. CROI: HIV Independently Raises Risk of Ischemic Stroke in 4300-Person US Study - written by Mark Mascolini - (03/15/12)
     
  9860. CROI: "Asymptomatic" HIV Neurocognitive Impairment Not So Benign After All? - written by Mark Mascolini - (03/15/12)
     
  9861. CROI: Elvitegravir-Containing Quad Noninferior to Atazanavir Regimen at 48 Weeks - written by Mark Mascolini - (03/15/12)
     
  9862. CROI: TDF/FTC and TDF Alone Slash HIV Risk in Partners PrEP HIV-Discordant Couples - written by Mark Mascolini - (03/15/12)
     
  9863. CROI: Longer D-Drug Exposure and Higher Glucose Boost Risk of Steatosis Progression - written by Mark Mascolini - (03/15/12)
     
  9864. CROI: Frailty Predicts Mortality in a Cohort of HIV-Infected and At-Risk Injection Drug Users: being HIV+ & frail increased mortality risk 8-fold in this group - (03/14/12)
     
  9865. CROI: David Margolis, UNC researchers find cancer drug that may help fight HIV - (03/14/12)
     
  9866. CROI: Zinc Fingers 'Cure' Therapy - (03/14/12)
     
  9867. CROI: Renal Update CROI 2012 - Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine - (03/14/12)
     
  9868. CROI: HEPATITIS C INCIDENCE IN THE SWISS HIV COHORT STUDY: A CHANGING EPIDEMIC - (03/14/12)
     
  9869. CROI: HIV Prevention at CROI 2012 - written by Jared Baeten, MD PhD, Connie Celum, MD MPH, University of Washington - (03/14/12)
     
  9870. CROI: Biomarkers of Microbial Translocation and Macrophage Activation Are Associated with Progression of Atherosclerosis in HIV Infection: ACTG NWCS 332/A5078 Study - (03/14/12)
     
  9871. CROI: HIV Incidence in Women at Risk for HIV Acquisition in the United States: HPTN 064 (ISIS Study): 5x higher HIV rates in USA women of color than CDC estimates, comparable to HIV rates in sub-Saharan Africa. Webinar Update see details below. - (03/14/12)
     
  9872. New HIV Eradication Research paper Published by Siliciano et al: Johns Hopkins breakthrough may end AIDS patients' need for lifelong drugs below - (03/11/12)
     
  9873. CROI: Safety, Tolerability, and PK of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily with Rifampin - Results of a Phase 1 Study among Healthy Volunteers - (03/11/12)
     
  9874. CROI: Relationship between combination of baseline viral load and CD4 cell count, and Week 48 or 96 responses to rilpivirine (RPV)or efavirenz (EFV) in treatment-naïve HIV-1-infected adults: pooled analysis from the Phase III ECHO and THRIVE trials - (03/11/12)
     
  9875. CROI: Effect of Statin Therapy on Reducing the Risk of Serious Non-AIDS-Defining Events and Non-Accidental Death in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Cohort - (03/11/12)
     
  9876. CROI: Frailty Predicts Mortality in a Cohort of HIV-Infected and At-Risk Injection Drug Users: being HIV+ & frail increased mortality risk 8-fold in this group - (03/11/11)
     
  9877. CROI: Low muscle mass in HIV infected patients: prevalence, predictors and clinical implication: change in leg fat (surrogate for lipoatrophy) predicted low muscle mass, & low muscle mass predicts mortality; low muscle mass may be part of aging phenotype in HIV+ - (03/11/12)
     
  9878. CROI: FRAILTY AND PRE-FRAILTY IN A CONTEMPORARY COHORT OF HIV-INFECTED INDIVIDUALS IN THE SUN STUDY - (03/11/12)
     
  9879. CROI: HIV Eradication Study by David Margolis: Administration of Vorinostat, cancer drug, Disrupts HIV-1 Latency in Patients on ART - (03/11/12)
     
  9880. CROI: Lack of Resistance Development to the HIV-1 Attachment Inhibitor BMS-626529 During Short-Term Monotherapy with its Prodrug BMS-663068 - (03/9/12)
     
  9881. CROI: Colonoscopy Spots Abnormalities in 60% of German HIV Group--and Cancer in 4% - written by Mark Mascolini - (03/9/12)
     
  9882. CROI: Central Obesity Raises Neurocognitive Impairment Risk in US CHARTER Cohort - written by Mark Mascolini - (03/9/12)
     
  9883. CROI: DATA SHOW GILEAD'S QUAD REGIMEN FOR HIV NON-INFERIOR TO PROTEASEBASED REGIMEN AT 48 WEEKS IN SECOND PIVOTAL PHASE 3 STUDY - (03/9/12)
     
  9884. CROI: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF "Quad" Compared to Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF in Treatment Naive HIV-1 Infected Subjects - (03/9/12)
     
  9885. CROI: Frailty & Muscle Loss Increase Mortality & Are Common in HIV+ - (03/9/12)
     
  9886. CROI: Higher Death Rate With 350-499 CD4s vs 500+ in Virologic Responders - written by Mark Mascolini - (03/8/12)
     
  9887. CROI: Low-Dose, Cell-Homing Tenofovir Prodrug Outdoes TDF in 10-Day Study - written by Mark Mascolini - (03/8/12)
     
  9888. CROI: Not Taking Antiretrovirals Linked to 60% Higher Risk of Neurocognitive Decline in US - written by Mark Mascolini - (03/8/12)
     
  9889. CROI: Kidney Renal Markers Signal Linked to Higher Tenofovir Plasma Levels - written by Mark Mascolini - (03/8/12)
     
  9890. CROI: Higher Rate and Extent of Noncalcified Coronary Artery Plaque in HIV+ MACS Men - written by Mark Mascolini - (03/8/12)
     
  9891. CROI: Quad Not Inferior to Efavirenz Combo at 48 Weeks in Phase 3 Trial - written by Mark Mascolini - (03/8/12)
     
  9892. CROI: GILEAD'S QUAD SINGLE TABLET REGIMEN FOR HIV NON-INFERIOR TO ATRIPLA® IN PIVOTAL PHASE 3 STUDY - (03/8/12)
     
  9893. CROI: The Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF ("Quad") Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Naïve HIV-1 Infected Subjects: Primary Results of Study GS-US-236-0102 - (03/8/12)
     
  9894. CROI: Dolutegravir ViiV Integrase Inhibitor phase 2b SPRING Study 96-Week Results in Treatment-Naives - (03/8/12)
     
  9895. CROI: Poor Adherence May Explain FEM-PrEP Failure to Find Protection From HIV With Truvada - written by Mark Mascolini - (03/7/12)
     
  9896. CROI: CD38 Activation and Naive CD4s Predict CD4 Gains Through 10 to 15 Years of ART - written by Mark Mascolini - (03/7/12)
     
  9897. CROI: Black Women in US Have Doubled Risk of AIDS Death, Regardless of Adherence - written by Mark Mascolini - (03/7/12)
     
  9898. CROI: HIV Risk in US Black MSM Traced to Age Issues and Care Barriers--Not to Risk Behavior - written by Mark Mascolini - (03/7/12)
     
  9899. CROI: Adherence Critical to Protection From HIV in Partners PrEP Trial of TDF and TDF/FTC - written by Mark Mascolini - (03/7/12)
     
  9900. CROI: Rectal Tenofovir Gel Clears Hurdle of Safety and Acceptability Study - written by Mark Mascolini - (03/7/12)
     
  9901. CROI: Over Half of US HIV+ People in Care Are Sexually Active, But Most Take Precautions - written by Mark Mascolini - (03/7/12)
     
  9902. CROI: Studies Disagree on Danger in Detectable Viral Load Under 50 Copies - written by Mark Mascolini - (03/7/12)
     
  9903. CROI: Slower Virologic Response in Pregnant Women Starting ART in France - written by Mark Mascolini - (03/7/12)
     
  9904. CROI: Tenofovir PrEP Reduces HIV Transmission Risk By Up To 99%: Adherence Critical to Protection From HIV in Partners PrEP Trial of TDF and TDF/FTC - written by Mark Mascolini - (03/7/12)
     
  9905. CROI: CDC: HIV Rate in Young US MSM Twice Higher Than in Sub-Saharan Africa - written by Mark Mascolini - (03/7/12)
     
  9906. CROI: The Effect of CD4+ T-Cell Count on Cardiovascular Risk in Treated HIV Disease - (03/7/12)
     
  9907. CROI: Suppression of Formation Threatens Delayed-Phase Bone Loss in Virologically Suppressed HIV-infected Individuals on Chronic ART - (03/7/12)
     
  9908. Hormonal Contraception & HIV Transmission Risk: 3 Recent Studies Published, 'Condoms Critical To Prevent Transmission' - (03/03/12)
     
  9909. WHO World Health Organization Reviews Contraception in light of 3 recent studies published: 'Condoms Best Protection'....Dual Protection Recommended - (03/03/12)
     
  9910. Intrinsic HIV/antiviral immunity: recent advances in understanding of the roles of intrinsic antiviral factors that restrict infection by HIV and influenza virus - (02/28/12)
     
  9911. HIV Protein called SAMHD1: New HIV Research Advance Reveals How Protein Protects Cells from HIV Infection - Potential New Drug Therapy - (02/28/12)
     
  9912. Quantifying ARTs & Combination Effectiveness by R Silciano et al - (02/25/12)
     
  9913. Mortality Risk Quantified for Diabetes Plus Kidney Disease - (02/25/12)
     
  9914. A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs - (02/25/12)
     
  9915. Drug Effectiveness Explained: The Mathematics of Antiviral Agents for HIV - Perspective - (02/25/12)
     
  9916. A quantitative basis for antiretroviral therapy for HIV-1 infection by R Siliciano et al - (02/23/12)
     
  9917. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy - (02/16/12)
     
  9918. Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors: VA Study/risk factors - (02/16/12)
     
  9919. Mediterranean Diet Appears to Protect Brain & Small Vessel Disease/Reduce the Risk for Stroke & Memory Loss: Mediterranean Diet and White Matter Hyperintensity Volume in the Northern Manhattan Study - (02/15/12)
     
  9920. Belly Fat Linked to Cognitive Deficits in HIV, new published study in Neurology from HIV CHARTER Study - (02/15/12)
     
  9921. 2nd International Workshop on HIV & Women Reports/Presentations Orals - (02/14/12)
     
  9922. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial - (02/14/12)
     
  9923. Electrode Zap to Brain Boosts Memory, 'Maybe Used to Improve Memory in Aging & Early Alzheimers' - (02/13/12)
     
  9924. Kidney/TDF Study Authors: Tenofovir: Q&A for Patients and Providers - (02/13/12)
     
  9925. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn - (02/13/12)
     
  9926. Association of tenofovir exposure with kidney disease risk in HIV infection - (02/13/12)
     
  9927. E138K Mutation & M184I/V, Etravirine - (02/10/12)
     
  9928. Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes - (02/10/12)
     
  9929. Rilpivirine Drug Resistance: E138K, 184I, M184V, Interactions Between E138K & M184I - (02/10/12)
     
  9930. The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness - (02/10/12)
     
  9931. Independent Effects of HIV, Aging, and HAART on Brain Volumetric Measures: 'HIV Atrophies Brain Despite HAART/HIV Aged Brain 17 Yrs Faster/Evaluation Tests' - (02/09/12)
     
  9932. 11C-PiB Imaging of Human Immunodeficiency Virus-Associated Neurocognitive Disorder: biomarker for Alzheimers in HIV - (02/09/12)
     
  9933. HIV infection induces age-related changes to monocytes and innate immune activation in young males which persist despite cART - (02/08/12)
     
  9934. Fractures/Bone Loss in HIV: 'traditional risk factors more important' but HIV & ARV exposure have some impact, Vit D may Improve Bone Health & Reduce Fracture Risk, New Studies - (02/08/12)
     
  9935. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case control analysis in a health-insured population - (02/08/12)
     
  9936. Prevention of Recurrent High-Grade Anal Neoplasia With Quadrivalent Human Papillomavirus Vaccination of Men Who Have Sex With Men: A Nonconcurrent Cohort Study: "Among patients infected with oncogenic HPV, qHPV was associated with decreased risk of recurrent HGAIN at 2 years after study entry" - pdf attached - (02/07/12)
     
  9937. Role of CD38 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence - Review - (02/07/12)
     
  9938. Vitamin D and UVB Radiation: How Much Is Necessary? "Exposure to a UVB dose of 1 SED every second week to ~88% body area is sufficient for maintaining summer 25(OH)D levels during the winter." - pdf attached - (02/03/12)
     
  9939. Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke D.A.D - (01/24/12)
     
  9940. Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection - (01/23/12)
     
  9941. Vitamin D Supplementation, HIV, HAART, Bone Health, Fractures - (01/23/12)
     
  9942. Vitamin D Improves Bone Health/Reduces Fracture Risk-Bone Loss: IOM, Endocrine Society - How Much Vit D Supp?/Calcium - (01/23/12)
     
  9943. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection - (01/19/12)
     
  9944. Coping with HIV/Aging: managing health & psychological factors & HCV - (01/15/12)
     
  9945. 2nd Intl Wrkshp HIV & Women: Sexual Abuse as Child Raises Heart Disease Risk in HIV-Positive Women - (01/14/12)
     
  9946. Viral Load Key to HIV Transmission - (01/13/12)
     
  9947. Probability of Heterosexual HIV-1 Transmission per Coital Act in Sub-Saharan Africa - Editorial - (01/13/12)
     
  9948. Determinants of Per-Coital-Act HIV-1 Infectivity Among African HIV-1-Serodiscordant Couples - (01/13/12)
     
  9949. 2nd Intl Wrkshp HIV & Women: Gardasil Study - Most Young HIV-Positive Women Still Negative for Key HPV Genotypes (01/11/12)
     
  9950. 2nd Intl Wrkshp HIV & Women: Week 96 Safety and Efficacy by Gender and Race Subgroups in Treatment-Naïve HIV-1-Infected Patients in the Phase III ECHO and THRIVE Trials (01/11/12)
     
  9951. Plasma HIV-1 RNA Levels During Antiretroviral Therapy: How Low Is Low Enough? - Editorial - - (01/10/12)
     
  9952. Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy - (01/10/12)
     
  9953. 2nd Intl Wrkshp HIV & Women: Lopinavir Side Effects Differ by Weight in Women, But RNA Response Does Not (01/11/12)
     
  9954. 2nd Intl Wrkshp HIV & Women: Differences Between Women and Men on Rilpivirine vs Efavirenz for 96 Weeks (01/11/12)
     
  9955. 2nd Intl Wrkshp HIV & Women: Hormonal Contraceptives Tied to Non-AIDS Disease or Death in HIV+ US Women: 'doubles Non-AIDS Risks' (01/11/12)
     
  9956. 2nd Intl Wrkshp HIV & Women: Treatment Access Biggest Trial Plus in Survey of Women/Minority GRACE Study (01/11/12)
     
  9957. 2nd Intl Wrkshp HIV & Women: One Third of HIV+ South Carolina Women Not Getting Regular Pap Test (01/10/12)
     
  9958. 2nd Intl Wrkshp HIV & Women: US Girls With HIV Have Doubled Rate of Anal HPV and Related Conditions (01/10/12)
     
  9959. 2nd Intl Wrkshp HIV & Women: More Depression in HIV+ Women Than Men, Regardless of ART, in 15-Country Study (01/10/12)
     
  9960. 2nd Intl Wrkshp HIV & Women: Cervical Lesion Excision Does Not Boost Genital HIV Shedding in Small Cohort (01/10/12)
     
  9961. (Issentress) Raltegravir for Pediatrics: Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (CT) Formulation in Children 2-5 Years - CROI 2011 Presentation & attached FDA Label containing pediatric safety, PK, dosing, efficacy - (01/09/12)
     
  9962. Herpes simplex virus: a new era? commentary - shedding persisted in study despite acyclovir, valaciclovir therapy - (01/09/12)
     
  9963. Efficacy Results of a Trial of a Herpes Simplex Vaccine - HSV2 Efficacy Not Observed - (01/09/12)
     
  9964. Hi Fat Diet Injures Brain in mice - Obesity is associated with hypothalamic injury in rodents and humans - (01/09/12)
     
  9965. Hi Fat Diet May Injure Brain - Alteration of hypothalamic cellular dynamics in obesity - Commentary - (01/09/12)
     
  9966. Remodeling of the arcuate nucleus energy-balance circuit is inhibited in obese mice - (01/09/12)
     
  9967. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials - (01/07/12)
     
  9968. Electrocautery Ablation of High-Grade Anal Squamous Intraepithelial Lesions in HIV-Negative and HIV-Positive Men who have sex with Men - (01/07/12)
     
  9969. A Comparison of 3 Regimens to Prevent Nevirapine Resistance Mutations in HIV-Infected Pregnant Women Receiving a Single Intrapartum Dose of Nevirapine - (01/05/12)
     
  9970. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons - (01/04/12)
     
  9971. Preventing Deaths in Persons With HIV/Hepatitis B Virus Coinfection: A Call to Accelerate Prevention and Treatment Efforts - EDITORIAL - (01/02/12)
     
  9972. Hepatitis B Virus Coinfection Negatively Impacts HIV Outcomes in HIV Seroconverters - (01/02/12)
     
  9973. The Economic Cost of Advanced Liver Disease - (01/02/12)
     
  9974. Breakthrough of the Year, 2011 Science 23 December 2011: "in May of this year, the 052 clinical trial conducted by the HIV Prevention Trials Network reported that ARVs reduced the risk of heterosexual transmission by 96% - (01/02/12)
     
  9975. A New Link Between Aging Cells and Aging People - (01/02/12)
     
  9976. Vitamin D, Calcium Intakes Guidelines - 3 Reports - (01/02/12)
     
  9977. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force - (01/02/12)
     
  9978. AntiAging Cancer Drug - Ageing: A midlife longevity drug? - (01/02/12)
     
  9979. Blocking Vif, HIV protein, Can Block HIV Replication - (01/02/12)
     
  9980. Global landscape of HIV-human protein complexes: "We aimed to identify host proteins associated with HIV-1 proteins" - (01/02/12)
     
  9981. Viramune HIV Infant Prophylaxis Safe: "Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial" - (01/02/12)
     
  9982. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial - (01/02/12)
     
  9983. Testosterone replacement therapy and polycythemia in HIV-infected patients - (01/02/12)
     
  9984. Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use: 'comorbidities cause work cessation' - (01/02/12)
     
  9985. Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging - (01/02/12)
     
  9986. HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer - (12/22/11)
     
  9987. First data to show antihypertensive therapy prolongs life - (12/21/11)
     
  9988. Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival - (12/21/11)
     
  9989. HIV Persistence during Therapy 5th International Workshop (Dec 6-9 2011 St Martin, West Indies) - Written by David Margolis MD, University of North Carolina at Chapel Hill (12/21/11)
     
  9990. How might HPV testing be integrated into cervical screening? - (12/17/11)
     
  9991. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial - (12/17/11)
     
  9992. HPV Screen Detects Lesions Earlier than Pap Test - (12/17/11)
     
  9993. 3 Integrase Inhibitors..... - (12/17/11)
     
  9994. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells - (12/17/11)
     
  9995. Treating HIV Early After Infection - new study - (12/16/11)
     
  9996. Neither Branded Nor Generic Lopinavir/Ritonavir Produces Adequate Lopinavir Concentrations at a Reduced Dose of 200/50 mg Twice Daily - (12/15/11)
     
  9997. A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz - (12/15/11)
     
  9998. Emotional Impact of Premature Aging Symptoms in Long-Term Treated HIV-Infected Subjects - (12/15/11)
     
  9999. Men Who Have Sex With Men Have a 140-Fold Higher Risk for Newly Diagnosed HIV and Syphilis Compared With Heterosexual Men in New York City - (11/30/11)
     
  10000. HIV+ & HIV/HCV(tripled) Have Higher Fracture Rates Compared to General Population in Denmark - (11/28/11)
     
  10001. Association of Low Level Viremia with Inflammation and Mortality in HIV-Infected Adults: "We conclude that there is little association of low level viremia with levels of CRP, fibrinogen, and IL-6" - (11/28/11)
     
  10002. Projected life expectancy of people with HIV according to timing of diagnosis - (11/28/11)
     
  10003. HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer: 'cd4 & viral load implicated as risk factors' - (11/28/11)
     
  10004. HIV Infection, Immune Suppression, and Uncontrolled Viremia Are Associated With Increased Multimorbidity Among Aging Injection Drug Users (ALIVE Study): unrecognized high rates of of multucomordibities - (11/28/11)
     
  10005. Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors? - (11/21/11)
     
  10006. NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN) - (11/21/11)
     
  10007. A Randomized, Controlled, Open-Label Study of the Long-Term Effects of NGX-4010, a High-Concentration Capsaicin Patch, on Epidermal Nerve Fiber Density and Sensory Function in Healthy Volunteers - (11/21/11)
     
  10008. A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-associated Distal Sensory Polyneuropathy - (11/21/11)
     
  10009. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy: "results suggest that NGX-4010 could provide a promising new treatment for painful HIV neuropathy" - (11/21/11)
     
  10010. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders - (11/04/11)
     
  10011. Aging/Wk: Statin Blocks PIs' Negative Impact on Bone Formation in Cell Studies - Written by Mark Mascolini - (11/03/11)
     
  10012. EACS: Pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy (11/02/11)
     
  10013. IDSA: Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Subjects: 96-Week Efficacy and Safety Results of the PROGRESS Study - (11/02/11)
     
  10014. IDSA: A Seven-Year Review of AIDS and Non-AIDS related Malignancies in a Large HIV/AIDS Center in New York - (11/02/11)
     
  10015. IDSA: Treatment of high grade anal lesions in high risk patients: outcome at an urban community health center - (11/02/11)
     
  10016. Aging/Wk: Antiretroviral Levels With Two Common Regimens in Nonfrail Older Patients - see slides below report - Written by Mark Mascolini - (11/01/11)
     
  10017. Aging/Wk: Cognitive Therapy Gives Boost to 50-Year-Olds With Long-Term HIV - Written by Mark Mascolini - (11/01/11)
     
  10018. IDSA: Risk of Muscle Breakdown in HIV - see slides below article - (11/01/11)
     
  10019. IDSA: Prevalence and Patterns of Echocardiographic Abnormalities in HIV-Infected, Black Individuals in an Inner City Teaching Hospital in Washington DC - (11/01/11)
     
  10020. Early HIV Therapy in Patients With TB Saves Lives - (11/01/11)
     
  10021. Integration of Antiretroviral Therapy with Tuberculosis Treatment - (11/01/11)
     
  10022. Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis - (10/28/11)
     
  10023. Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis - (10/31/11)
     
  10024. IDSA: Peripheral mechanisms of CD4 T cell regeneration in HIV-1 elite controllers: naïve CD4s are severely depleted in elite controllers - (10/31/11)
     
  10025. Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias: "Patients with AD were around half as likely to be prescribed ARBs" - (10/31/11)
     
  10026. Aging/Wk: Half of HIV+ Middle-Aged Meet Social Security Disability Threshold in Walk Test - Written by Mark Mascolini - (10/31/11)
     
  10027. Aging/Wk: CD4 Changes on Effective ART Similar in People Under and Over 50 Years Old - Written by Mark Mascolini - (10/31/11)
     
  10028. Aging/Wk: CMV Antibody Levels Linked to Heart Disease Markers in Women On and Off ART - Written by Mark Mascolini - (10/31/11)
     
  10029. Aging/Wk: HIV Linked to Frailty in Middle-Aged IDUs, Especially With Poor HIV Control - Written by Mark Mascolini - (10/31/11)
     
  10030. Aging/Wk: Renal Function Drops With Age--and More With PIs--in London HIV Clinic - Written by Mark Mascolini - (10/31/11)
     
  10031. Testosterone replacement therapy and polycythemia in HIV-infected patients - - (10/28/11)
     
  10032. Risk of Cataract Surgery in HIV-Infected Individuals: A Danish Nationwide Population-Based Cohort Study - (10/28/11)
     
  10033. Aging/Wk: Duration of ART and Specific Antiretrovirals Tied to Hypophosphatemia and Albuminuria - Written by Mark Mascolini - (10/28/11)
     
  10034. Aging/Wk: Drug Interaction Rate No Higher With HIV Than Without in French Group Over 60 - Written by Mark Mascolini - (10/28/11)
     
  10035. Aging/Wk: Falling Rate Similar in 45-to-65-Year-Olds With HIV and HIV-Negatives Over 65 - Written by Mark Mascolini - (10/28/11)
     
  10036. 4 Aging Published Reports This Week: - (10/27/11)
     
  10037. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia - (10/27/11)
     
  10038. IDSA: Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network - (10/25/11)
     
  10039. IDSA: Efficacy and hepatic safety of rilpivirine (RPV, TMC278) in treatment-naïve, HIV-1-infected patients co-infected with hepatitis B and/or C: pooled 96-week analysis of the Phase III ECHO and THRIVE trials - (10/25/11)
     
  10040. IDSA: Analysis of lipid levels and neuropsychiatric events in treatment-naïve HIV-1-infected adults treated with rilpivirine or efavirenz over 96 weeks in ECHO and THRIVE - (10/25/11)
     
  10041. IDSA: Rilpivirine Week 96 safety and efficacy by gender and race subgroups in treatment-naïve HIV-1-infected patients in the Phase III ECHO and THRIVE trials - (10/24/11)
     
  10042. Updated NYS Syphillis in HIV+ Guidelines - (10/24/11)
     
  10043. Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients - (10/24/11)
     
  10044. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study - published The Lancet - (10/24/11)
     
  10045. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial - (10/24/11)
     
  10046. Assessment of population-level effect of Avahan, an HIV-prevention initiative in India - (10/24/11)
     
  10047. EACS: High non-AIDS-related mortality among a cohort of HIV-positive men who have sex with men (MSM) in Stockholm Insulin resistance is a strong predictor of mortality- a 12 year follow (10/24/11)
     
  10048. IDSA: Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (10/23/11)
     
  10049. IDSA: Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naïve Patients: 192 Week Results from STARTMRK - (10/23/11)
     
  10050. EACS: Predictors of Hepatitis C RNA Levels in HIV Co-infected Individuals in a Prospective Cohort Study (10/23/11)
     
  10051. EACS: Factors influencing neurocognitive function in a large cohort of HIV infected patients on effective antiretroviral therapy (10/20/11)
     
  10052. Premature Aging and Premature Age-Related Comorbidities in HIV-Infected Patients: Facts and Hypotheses - (10/21/11)
     
  10053. Increased Coronary Artery Calcium Score and Noncalcified Plaque Among HIV-Infected Men: Relationship to Metabolic Syndrome and Cardiac Risk Parameters - (10/21/11)
     
  10054. Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study - (10/21/11)
     
  10055. Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population - (10/21/11)
     
  10056. Screening for Cognitive Impairment in Human Immunodeficiency Virus - (10/20/11)
     
  10057. Viremia Copy-Years (Cumulative Viral Load Exposure) Predicts Mortality Among Treatment-Naive HIV-Infected Patients Initiating Antiretroviral Therapy - (10/20/11)
     
  10058. EACS: Rilpivirine vs Efavirenz for 96 Weeks: Baseline Viral Load and Side Effect Details - Written by Mark Mascolini (10/19/11)
     
  10059. EACS: IL28B gene polymorphisms and all-cause mortality in HIV infected patients (10/19/11)
     
  10060. EACS: IL28B Genotype Linked to All-Cause Mortality in HIV+ People on cART - written by Mark Mascolini - (10/18/11)
     
  10061. EACS: Half With Undetectable Plasma Load Have Neurocognitive Impairment in UK Group - written by Mark Mascolini - (10/18/11)
     
  10062. EACS: Dolutegravir (GSK/ViiV Integrase) Treatment (with 50mg Once & Twice Daily) of HIV Subjects with Raltegravir Resistance & 3-Class ART Resistance: viral suppression at Week 24 in the VIKING Study (10/17/11)
     
  10063. Gut Bacteria Influence Statin Treatment Response - (10/17/11)
     
  10064. (Gut Bacteria) Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment - (10/17/11)
     
  10065. EACS: Switching from Efavirenz/Emtricitabine/Tenofovir DisoproxilFumarate(EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir DisoproxilFumarate(FTC/RPV/TDF) STR in VirologicallySuppressed, HIV-1 Infected Subjects (10/17/11)
     
  10066. EACS: Sustained Efficacy with Low and Similar Rates of Virologic Failures in Second Year Observed with Rilpivirine (RPV) versus Efavirenz (EFV) plus Emtricitabine/Tenofovir DF (FTC/TDF) in Treatment-Naïve, HIV-1 Infected Adults - Pooled 96-Week ECHO and THRIVE Analysis (10/17/11)
     
  10067. EACS: Non-AIDS Cancer Incidence Remains the Same Over 2004-2010 in D:A:D Study Group - written by Mark Mascolini - (10/17/11)
     
  10068. EACS: Half of HIV+ in France Still Coming to Care Late--With High Death Risk written by Mark Mascolini (10/17/11)
     
  10069. EACS: Body Fat Distribution Changes After 96 Weeks of Therapy with Lopinavir/ritonavir (LPV/r) Plus Raltegravir (RAL) Compared with LPV/r Plus Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral (ARV)-Naïve, HIV-1-Infected Subjects from the PROGRESS Study (10/17/11)
     
  10070. EACS: Efficacy and viral resistance are comparable when maraviroc is administered once daily or twice daily with boosted protease inhibitors in treatment-experienced patients (10/17/11)
     
  10071. EACS: Pilot study evaluating an intensification of antiretroviral therapy with maraviroc in HIV-1-infected patients with controlled viral load exhibiting insufficient immune restoration (10/17/11)
     
  10072. EACS: The incidence of serious non-AIDS bacterial infections in the EuroSIDA cohort (10/17/11)
     
  10073. EACS: Interleukin-6 and C-reactive Protein Levels after 144 Weeks of Efficacy of Darunavir /Ritonavir Monotherapy versus DRV/r + 2NRTIs in the MONET Trial for Patients with HIV RNA < 50 Copies/mL at Baseline: COINFECTED PATIENTS HAD HIGHER IL-6, INFLAMMATION LEVELS (In SMART >3 mg/L was associated with progression), YOU CAN SEE 15% to 19% of PATIENTS HAD VERY HIGH hs-CRP (inflammation) (>3 mg/L), INFLAMMATION WAS MORE LIKELY TO BE HIGHER IF VIRAL LOAD WAS DETECTABLE (10/17/11)
     
  10074. EACS: Long-term Efficacy of Raltegravir or Efavirenz Combined with TDF/FTC in Treatment-naïve HIV-1-infected Patients: Week-192 Subgroup Analyses from STARTMRK (10/14/11)
     
  10075. Life expectancy in HIV - EDITORIAL, Better, but not good enough - (10/13/11)
     
  10076. HIV Life Expectancy Increases In UK - 'life expectancy still 15 years lower with HIV compared to general population....starting HAART earlier matters' - (10/13/11)
     
  10077. Initial Viral Decay (predicts viral suppression) to Assess the Relative Antiretroviral Potency of PI-, NNRTI- and NRTI-Sparing Regimens for First Line Therapy of HIV Infection - (10/12/11)
     
  10078. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study - (10/11/11)
     
  10079. Vitamin and Mineral Supplement Use in Relation to All-Cause Mortality in the Iowa Women's Health Study - Comment on "Dietary Supplements and Mortality Rate in Older Women" - (10/11/11)
     
  10080. ICAAC: Pre-Therapy Detection of Transmitted Low-abundance HIV-1 Resistance Mutation-containing Variants in Antiviral-naïve Subjects and Implications for Subsequent Clinical Therapy Response - (10/10/11)
     
  10081. ICAAC: Comparison of Population Genotype and Ultradeep Sequencing Results from Subjects with Virologic Failure in ARIES: Impact of Low-abundance HIV Variants on Outcome - (10/10/11)
     
  10082. HIV Found in New Brain Cells, Should HAART Start Earlier To Prevent Brain Damage - (10/09/11)
     
  10083. Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconverters - (10/09/11)
     
  10084. ICAAC: Pre-Therapy Detection of Transmitted Low-abundance HIV-1 Resistance Mutation-containing Variants in Antiviral-naïve Subjects and Implications for Subsequent Clinical Therapy Response - (10/10/11)
     
  10085. Changes in brain function in early HIV infection: A reliable indicator of disease prognosis? - (10/07/11)
     
  10086. HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types - May Explain Persistent HIV Brain Damage - (10/07/11)
     
  10087. ICAAC: Significant Reductions in the Prevalence of Protease Inhibitor and 3-Class Resistance: Recent Trends in a Large HIV-1 Protease/Reverse Transcriptase Database - (10/08/11)
     
  10088. ICAAC: Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients - (10/08/11)
     
  10089. Vitamin D, cardiovascular disease and mortality - (10/06/11)
     
  10090. Vitamin B12, cognition, and brain MRI measures - - (10/05/11)
     
  10091. Vitamins B12, B6, and folic acid Supplementationfor cognition in older men - (10/05/11)
     
  10092. Hormonal contraception and HIV: an unanswered question EDITORIAL - (10/05/11)
     
  10093. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study - (10/05/11)
     
  10094. Oral Contraceptive Increases HIV Risk (for both men & women) - (10/05/11)
     
  10095. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy - (10/05/11)
     
  10096. ICAAC: Kidney Function Change With Cobicistat Calculated in HIV-Negative Volunteers - Written by Mark Mascolini - (09/30/11)
     
  10097. ICAAC: Intracellular Raltegravir Concentrations Better With Twice-Daily Than Once-Daily Dosing - Written by Mark Mascolini - (09/30/11)
     
  10098. ICAAC: TMC435 in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection: Week 24 interim analyses of Phase IIB PILLAR and ASPIRE trials - (09/30/11)
     
  10099. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients - (09/29/11)
     
  10100. ICAAC: HAART Treatment Interruption Following Adoptive Transfer of Zinc Finger Nuclease (ZFN) CCR5 Modified AutologousCD4 T-cells (SB-728-T) to HIV-infected Subjects Demonstrates Durable Engraftment and Suppression of Viral Load - (09/29/11)
     
  10101. ICAAC: ICAAC 2011: Medically Important Highlights - David H Shepp, MD, Hofstra NSLIJ Medical School Division of Infectious Diseases North Shore University Hospital - Manhasset- (09/29/11)
     
  10102. ICAAC: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17-20, 2011 Chicago, IL - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA (09/29/11)
     
  10103. ICAAC: Responder-relapser (RR) patients might obtain benefit in liver fibrosis, after anti-HCV chemotherapy, in comparison to non-responders (NR) or non-treated (control) HIV- HCV coinfected patients - (09/27/11)
     
  10104. ICAAC: Longitudinal assessment of liver fibrosis (LF) by non-invasive methods in HIV- HCV coinfected patients, after HCV chemotherapy - (09/27/11)
     
  10105. ICAAC: Dolutegravir vs Resistant Mutants: Selective Advantage Profiles of HIV-1 Integrase Mutants in the Presence of Dolutegravir - (09/26/11)
     
  10106. ICAAC: Liver Stiffness (LS) change in HIV/Hepatitis C (HCV) co-infected patients treated with CCR5 inhibitor based antiretroviral Therapy - (09/26/11)
     
  10107. ICAAC: Under 10% in Large Canadian Cohort Reach Normal CD4/CD38 Ratio - (09/26/11)
     
  10108. ICAAC: An Open-Label, Placebo-controlled Study to Evaluate the Effect of Dolutegravir (DTG, S/GSK1349572) on Iohexol and Para-aminohippurate Clearance in Healthy Subjects - Written by Mark Mascolini - (09/26/11)
     
  10109. ICAAC: Dolutegravir & Creatinine Clearance - Written by Mark Mascolini - (09/26/11)
     
  10110. ICAAC: Pharmacokinetic analysis of nevirapine extended release 400 mg QD vs immediate release 200 mg BID in patients with HIV-1 infection - (09/24/11)
     
  10111. ICAAC: Nevirapine Concentrations With Once- Versus Twice-Daily Dosing - Written by Mark Mascolini - (09/24/11)
     
  10112. ICAAC: Fosamprenavir/RTV Cuts Dolutegravir Levels: No Dose Change Needed for Naive - Written by Mark Mascolini - (09/24/11)
     
  10113. ICAAC: HCV and Homocysteine Boost Risk of Covert Atherosclerosis in Spanish HIV Group - Written by Mark Mascolini - (09/24/11)
     
  10114. ICAAC: Novel Boehringer-Ingelheim Integrase Inhibitor Retains Full Activity Against Raltegravir-Resistant Virus - Written by Mark Mascolini - (09/24/11)
     
  10115. ICAAC: Effect of Fosamprenavir/Ritonavir on the Pharmacokinetics of the Integrase Inhibitor, Dolutegravir, in Healthy Subjects - (09/24/11)
     
  10116. ICAAC: Safety, Tolerability, and Efficacy of Raltegravir (RAL) in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study - (09/22/11)
     
  10117. ICAAC: Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race - (09/21/11)
     
  10118. ICAAC: Durable and Consistent Efficacy of Raltegravir (RAL) With Tenofovir (TDF) and Emtricitabine (FTC) Across Demographic and Baseline Prognostic Factors In Treatment-naïve Patients (pts) From STARTMRK at Wk 156 - (09/22/11)
     
  10119. ICAAC: Rilpivirine (TMC278) tolerability over the first 12 weeks of treatmentin the Phase III ECHO and THRIVE studies - (09/22/11)
     
  10120. ICAAC: Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified Autologous CD4 T-cells (SB-728-T) to Aviremic HIV-infected Subjects with Suboptimal CD4 Counts (200-500 cells/mm3) - (09/22/11)
     
  10121. ICAAC: Safety, Efficacy, and Pharmacokinetics of Ibalizumab in Treatment-Experienced HIV-1 Infected Patients: a Phase 2b Study - (09/22/11)
     
  10122. ICAAC: The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers - (09/21/11)
     
  10123. ICAAC: Recruiting Young LA Gays for HIV Survey by Social-Networking App - Written by Mark Mascolini (09/21/11)
     
  10124. ICAAC: ART-HCV Protease Inhibitor BI-201335 Interactions - (09/21/11)
     
  10125. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women - (09/21/11)
     
  10126. ICAAC: Sangamo HIV Gene Therapy Data Reported at ICAAC Sept 19 2011 - (09/21/11)
     
  10127. ICAAC: The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers - (09/21/11)
     
  10128. ICAAC: (New BI Integrase Inhibitor) Safety and pharmacokinetics (PK) of single rising oral doses of a novel HIV integrase inhibitor in healthy volunteers - (09/21/11)
     
  10129. ICAAC: BI 224436, a Non-Catalytic Site Integrase Inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1 - (09/21/11)
     
  10130. ICAAC: Pharmacodynamics of BI 224436 for HIV-1 in an in vitro hollow fiber infection model system - (09/21/11)
     
  10131. ICAAC: Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic Site Integrase Inhibitor - (09/21/11)
     
  10132. ICAAC: Effect of Cobicistat on Glomerular Filtration Rate in Subjects with Normal and Impaired Renal Function - (09/21/11)
     
  10133. ICAAC: HIV Risk Perception Does Not Match PrEP Interest in US Heterosexual Group - (09/21/11)
     
  10134. ICAAC: Rate of Stopping Atripla for Side Effects Steady Through 96 Weeks in London Cohort - Written by Mark Mascolini - (09/21/11)
     
  10135. ICAAC: Rate of Stopping Atripla for Side Effects Steady Through 96 Weeks in London Cohort - Written by Mark Mascolini - (09/20/11)
     
  10136. ICAAC: Randomized Switch From Suppressive PI to Etravirine Safe and Effective - Written by Mark Mascolini - (09/20/11)
     
  10137. ICAAC: Insulin Resistance Quadruples Liver Cancer Risk in People With HIV/HCV - Written by Mark Mascolini - (09/20/11)
     
  10138. ICAAC: Switching From TDF/FTC to Raltegravir Improves Kidney Markers - Written by Mark Mascolini - (09/20/11)
     
  10139. ICAAC: Higher Osteoprotegerin Linked to Lower Atherosclerosis Risk in Men With HIV - Written by Mark Mascolini - (09/20/11)
     
  10140. ICAAC: Switching From Atripla to Complera Safe and Effective in 12-Week Study - Written by Mark Mascolini - (09/20/11)
     
  10141. ICAAC: Risk of Neurosyphilis With Early Syphilis in German Group With HIV - Written by Mark Mascolini - (09/20/11)
     
  10142. ICAAC: PHA Better Than PLA for HIV Facial Atrophy at 96 Weeks, But More Painful - Written by Mark Mascolini - (09/20/11)
     
  10143. ICAAC: High Rates of SVR24 for BMS-790052, an NS5A Replication Complex Inhibitor, in Combination With PegIFN-alfa-2a and Ribavirin: Phase 2a Trial in Treatment-Naive HCV Genotype 1 Subjects - (09/19/11)
     
  10144. ICAAC: BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients - (09/19/11)
     
  10145. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women - (09/19/11)
     
  10146. ICAAC: Better 1-Month Safety With Rilpivirine Than Efavirenz in Treatment-Naive - (09/19/11)
     
  10147. ICAAC: Switching from Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV-1 Infected Subjects - (09/19/11)
     
  10148. ICAAC: Detection of Baseline Resistance and HIV RNA Suppression to Week 48 in the SENSE Trial: Etravirine versus Efavirenz in Treatment Naïve Participants - (09/19/11)
     
  10149. ICAAC: PI and 3-Class Resistance Drop Sharply in Monogram Database: 2003-2010 - Written by Mark Mascolini - (09/19/11)
     
  10150. ICAAC: "Ultradeep" Detection of Pretreatment Mutations Has Little Impact on Long-Term PI (Reyataz/r) Response - Written by Mark Mascolini - (09/19/11)
     
  10151. ICAAC: One Penicillin Dose as Good as Three for Early Syphilis in Men With HIV - Written by Mark Mascolini - (09/19/11)
     
  10152. ICAAC: Adding Maraviroc May Reduce Liver Stiffness in People With HCV and HIV - Written by Mark Mascolini - (09/19/11)
     
  10153. ICAAC: Some Lipids Improve With Switch From ABC/3TC to TDF/FTC, HIV Control Rates Similar - Written by Mark Mascolini - (09/19/11)
     
  10154. ICAAC: Resistance Rates and Patterns Similar With Extended- and Immediate-Release Nevirapine - Written by Mark Mascolini - (09/19/11)
     
  10155. ICAAC: Hospital Rate Lower With Atripla Than Other Combos in Medicaid Patients - Written by Mark Mascolini - (09/19/11)
     
  10156. ICAAC: Delayed HIV Care Persists in Chicago Minorities Years After CDC Screening Advice - Written by Mark Mascolini - (09/19/11)
     
  10157. ICAAC: Chicago Hospital Study Finds 11+ HIV Prescribing Errors Per 100 Patient-Days - Written by Mark Mascolini - (09/19/11)
     
  10158. ICAAC: Gender or Race Does Not Affect Raltegravir Response in Diverse Group - Written by Mark Mascolini - (09/19/11)
     
  10159. ICAAC: Dropping Inactive NRTI Does Not Compromise 4- or 5-Drug Salvage Combos - Written by Mark Mascolini - (09/19/11)
     
  10160. ICAAC: "Selective Advantage" Analysis Sees Low Risk of Cross-Resistance With Dolutegravir - Written by Mark Mascolini - (09/19/11)
     
  10161. ICAAC: Zinc Finger-Modified CD4-Cell Booster Transplant Working in Pilot Trial - Written by Mark Mascolini - (09/19/11)
     
  10162. ICAAC: Pretreatment Mutations Do Not Affect Etravirine or Efavirenz Response in SENSE - Written by Mark Mascolini - (09/19/11)
     
  10163. ICAAC: Large Sample Analysis Confirms Impact of Known Rilpivirine Mutations - Written by Mark Mascolini - (09/19/11)
     
  10164. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons - (09/09/11)
     
  10165. Hepatitis delta in HIV-infected individuals in Europe - (09/07/11)
     
  10166. The Brittleness of Aging Bones - more than a Loss of Bone mass - (09/07/11)
     
  10167. First study to quantify benefits of exercise on CHD risk Dose Response Between Physical Activity (15/day, 150, 300, 750-week minutes) and Risk of Coronary Heart Disease [reduced 14-25%] - (09/07/11)
     
  10168. Menopause Role in Heart Risk Disputed (see editorial, full text below) - (09/07/11)
     
  10169. HIV-Infection of Human Astrocytes Disrupts Blood-Brain Barrier Integrity by a Gap Junction-Dependent Mechanism - (09/07/11)
     
  10170. Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of "Heart Positive," a Randomized, Controlled Trial - (09/07/11)
     
  10171. Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus Raltegravir in Treatment-Naive HIV-1-infected Patients (ACTG A5262) - (09/07/11)
     
  10172. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults - (09/06/11)
     
  10173. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy: "initiation of CART as early as possible might reduce the risk of developing HAND, the most common source of NPI among HIV-infected individuals" - (09/06/11)
     
  10174. Phase 2 double-blind, randomised trial of etravirine versus efavirenz in treatment-naive patients: 48 week results - (09/06/11)
     
  10175. Cholesterol Lowering Diet Foods Reduce LDL-Cholesterol by 14% - (08/24/11)
     
  10176. Coronary Calcium Better than CRP to Stratify Risk - (08/20/11)
     
  10177. Even Short Workout (15 minutes) Could Extend Life Expectancy - (08/19/11)
     
  10178. Minimum amount (15 minutes) of physical activity for reduced mortality and extended life expectancy: a prospective cohort study - (08/19/11)
     
  10179. Editorial - Survival benefit associated with low-level physical activity: "the direct health benefits of exercise are irrefutable. Exercise can reduce cardiovascular mortality and, in particular, coronary mortality by many mechanisms, including improvements in endothelial function, autonomic tone, inflammation, and risk-factor control" - (08/19/11)
     
  10180.  Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy - (08/19/11)
     
  10181. Cardiovascular Disease Risk in Pediatric HIV: The Need for Population-Specific Guidelines/for HIV-infected children - (08/18/11)
     
  10182. Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine Among Treatment-Naive HIV-Infected Patients Initiating Therapy - (08/17/11)
     
  10183. Depression Increases Stroke Risk in Older Women - (08/15/11)
     
  10184. HIV Cure Discovery: Functional HIV Cure in Rhesus Macaque Monkey Can Be Model for Humans - (08/15/11)
     
  10185. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease - (08/15/11)
     
  10186. Phase 2 Study of Cobicistat versus Ritonavir each with Atazanavir plus Fixed-Dose Emtricitabine/Tenofovir DF in the Initial Treatment of HIV Infection - (08/06/11)
     
  10187. Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients: statins improve mortality - (08/04/11)
     
  10188. IAS: Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents (6 to <18 years): Week 24 primary analysis of the Phase II PIANO study - (08/04/11)
     
  10189. IAS: The MONET trial: Week 144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA <50 copies/mL at baseline - (08/04/11)
     
  10190. IAS: The SENSE trial: Final 48-week analysis of etravirine (ETR) versus efavirenz (EFV) in treatment-naïve patients - (08/04/11)
     
  10191. IAS: Long-term safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in ARTEMIS - (08/04/11)
     
  10192. IAS: STEAL Study 2 Yrs Followup: Tenofovir Speeds BMD Loss vs Abacavir, But Does Not Raise Fracture Risk Over 2 Years Followup; Lower Fat Mass Also Predicts Bone Loss - written by Mark Mascolini - (08/01/11)
     
  10193. IAS: HIV Complications & It's Treatment, Opportunistic Infections, New ART Drugs, Preventing HIV Transmission: IAS. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome 17-20 July, 2011 Written by Pablo Tebas, MD University of Pennsylvania. - (08/01/11)
     
  10194. Relative Muscle Mass Is Inversely Associated with Insulin Resistance and Prediabetes. Findings from The Third National Health and Nutrition Examination Survey - (08/01/11)
     
  10195. IAS: Women With HIV Have Lower Mortality Than Men in Europe, But Not in North America - written by Mark Mascolini - (08/01/11)
     
  10196. IAS: Bone Loss Boosts Cardiovascular Risk 77% in French Aquitaine Cohort - written by Mark Mascolini - (08/01/11)
     
  10197. IAS: Kidney Risk & ARTs in Aquitaine Cohort - written by Mark Mascolini - (08/01/11)
     
  10198. IAS: HIV Prevention Report at IAS 2011 by Jared Baeten, MD & Connie Cellum, MD - (08/01/11)
     
  10199. IAS: High Rates of Airflow Obstruction, Emphysema in Heavy-Smoking Spanish Group: average age 45...37% emphysema...marijuana doubled risk - (07/29/11)
     
  10200. The Effect of Vitamin D on Falls: A Systematic Review and Meta-Analysis - (07/28/11)
     
  10201. IAS: Microbial Translocation and Hepatitis C Disease Progression among HIV-infected Women - (07/27/11)
     
  10202. IAS: Efficacy of maraviroc administered once-daily or twice-daily with boosted protease inhibitors to treatment-experienced patients - (07/27/11)
     
  10203. IAS: 48 Week Results of Once-Daily Maraviroc (MVC) 150 mg in Combination with Ritonavir-Boosted Atazanavir (ATV/r) Compared to Emtricitabine/Tenofovir (FTC/TDF) + ATV/r in Treatment-Naïve Patients Infected with R5 HIV-1 (Study A4001078) - (07/27/11)
     
  10204. IAS: Biomarkers Predict Hepatic Flares and Death in Hepatitis-Coinfected People Starting ART - written by Mark Mascolini - (07/26/11)
     
  10205. IAS: Age, Race, Gender--But Not HIV--Tied to Hearing Loss in HIV+ People - written by Mark Mascolini - (07/26/11)
     
  10206. IAS: Short-Term ART After Early Infection Does Not Delay AIDS or Death - written by Mark Mascolini - (07/26/11)
     
  10207. IAS: Virologic Failure Rate Plummets From 31% to 5% in France From 1997 Through 2009 - written by Mark Mascolini - (07/26/11)
     
  10208. IAS: Progressive Histological Liver Improvement After SVR in HCV/HIV Coinfected Patients Using Transient Elastography (Fibroscan) - (07/25/11)
     
  10209. IAS: Temporal Trends in Liver-Related Mortality in a Prospective Cohort of HIV-Infected Patients in Spain 1997-2008: HCV/HIV Coinfected Death Rates Increase While Rates Decline Among HCV-/HIV+ - (07/25/11)
     
  10210. IAS: Sustained Efficacy and Tolerability of Raltegravir after 240 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients: Final Analysis of Protocol 004 - (07/25/11)
     
  10211. IAS: DIONE - 24 week efficacy, safety, tolerability and pharmacokinetics of DRV/r QD in treatment-na·ve adolescents, 12 to <18 years - (07/25/11)
     
  10212. IAS: Cognitive Impairment Persists: Prevalence and risk factors for HIV associated neurococognitive disorders (HAND), 1996 to 2010: results from an observational cohort - (07/25/11)
     
  10213. IAS: Prevalence and risk factors for HIV associated neurococognitive disorders (HAND), 1996 to 2010: results from an observational cohort - (07/25/11)
     
  10214. IAS: Doubled Rate of Nonmelanoma Skin Cancer With HIV in California Comparison - written by Mark Mascolini - (07/24/11)
     
  10215. IAS: Minority species resistance (Ultra-Deep Sequencing) present at screening does not affect outcomes at Week 48 in lersivirine (UK-453,061) Phase 2b study A5271015 in treatment-naïve patients - (07/24/11)
     
  10216. IAS: Efficacy and safety of lersivirine vs efavirenz in antiretroviral treatment-naïve HIV-1-infected patients: Week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase 2b trial (Study A5271015) - (07/23/11)
     
  10217. IAS: More Than 25% in HIV-Positive SUN Study Cohort Have Insulin Resistance - written by Mark Mascolini - (07/22/11)
     
  10218. IAS: CD4 Gains on cART Lower AIDS/Death Risk Even With High Starting CD4 Count - written by Mark Mascolini - (07/22/11)
     
  10219. IAS: TDF/FTC PrEP Durable in MSM, But MSM and Transgender Responses Differ - written by Mark Mascolini - (07/22/11)
     
  10220. IAS: Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, France, 2004-2008 - (07/23/11)
     
  10221. IAS: Safety Profile of Dolutegravir (DTG, S/GSK1349572), a Next Generation Integrase Inhibitor (INI) in Combination Therapy in Antiretroviral (ART)-naïve and ART-experienced Adults from Phase 2b Studies - (07/23/11)
     
  10222. IAS: Switching from ABC/3TC to TDF/FTC Trims Risk of Virologic Failure - written by Mark Mascolini - (07/22/11)
     
  10223. IAS: SWIFT Study: Switching From Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF) - (07/22/11)
     
  10224. Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men --- New York City, 2005--2010 - (07/22/11)
     
  10225. IAS: ViiV 'Next Generation' Integrase Dolutegravir, 48 Weeks SPRING-1 Study Naives - (07/21/11)
     
  10226. IAS: First-Line Once-Daily Maraviroc Plus ATV/r Versus Triple Therapy - written by Mark Mascolini - (07/20/11)
     
  10227. IAS: A Look Back at Once-Daily 150-mg Maraviroc for Experienced in MOTIVATE Trials - written by Mark Mascolini - (07/20/11)
     
  10228. IAS: Frailty Rate in HIV+ mid-50 Women Matches Rate in 70-Year-Olds Without HIV - written by Mark Mascolini - (07/20/11)
     
  10229. IAS: Heart Disease Signal and Low Femoral Density Linked in People With HIV - written by Mark Mascolini - (07/20/11)
     
  10230. IAS: Elvitegravir Not Inferior to Raltegravir in Treatment-Experienced: Phase 3 - written by Mark Mascolini - (07/20/11)
     
  10231. IAS: Tobira Therapeutics Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults - (07/20/11)
     
  10232. IAS: IAS: PrEP Results Surprised Researchers - (07/20/11)
     
  10233. IAS: Elvitegravir Once Daily is Non-Inferior to Raltegravir Twice Daily in Treatment-Experienced Patients: 48 Week Results From a Phase 3 Multicenter, Randomized Double-Blind Study - (07/20/11)
     
  10234. IAS: Natural controllers of HIV infection are susceptible to immune perturbations similar to those associated with normal aging - implications for women aging with HIV infection - (07/20/11)
     
  10235. IAS: Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults - (07/20/11)
     
  10236. IAS: Interaction of Vascular and Bone Disease in HIV Infected Patients: Coronary Artery Calcification is associated with femoral but not lumbar spine mineral density - (07/19/11)
     
  10237. IAS: Atazanavir Without Ritonavir as Simpler Maintenance: 144-Week ARIES Results - written by Mark Mascolini - (07/19/11)
     
  10238. IAS: Late HIV Diagnosis Raises ICU Admission Rate 5 Times in London Group - written by Mark Mascolini - (07/19/11)
     
  10239. IAS: Two More Randomized Trials Show that Daily TDF/FTC Protects From HIV - written by Mark Mascolini - (07/19/11)
     
  10240. IAS: Good Kidney and Liver Transplant Results in Large Study of People With HIV - written by Mark Mascolini - (07/19/11)
     
  10241. IAS: Slow Drop in HIV Neurocognitive Disorder in Italian HIV Cohort: 'cognitive impairment persists in HIV-positive people.....' - written by Mark Mascolini - (07/19/11)
     
  10242. IAS: Rilpivirine (TMC278) vs Efavirenz at 96 Weeks in Antiretroviral Naive - written by Mark Mascolini - (07/19/11)
     
  10243. IAS: Lersivirine, a New NNRTI, Versus Efavirenz as First-Line Therapy: 48 Weeks - written by Mark Mascolini - (07/19/11)
     
  10244. IAS: Similar 48-Week Response Rates With New Integrase Inhibitor and Efavirenz in Naives - written by Mark Mascolini - (07/19/11)
     
  10245. IAS: Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents - written by Mark Mascolini - (07/18/11)
     
  10246. IAS: Brain-Breaching Antiretroviral Score Not Tied to Neuropsych Function in Canada - written by Mark Mascolini - (07/18/11)
     
  10247. IAS: Antiretroviral Therapy Lowers HIV Transmission Risk in HIV+/HIV- Couples: "96% reduction in HIV transmission risk to an HIV-negative partner..... definitive proof of the concept that antiretroviral therapy lowers the risk HIV transmission" - written by Mark Mascolini - (07/18/11)
     
  10248. IAS: Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents - (07/18/11)
     
  10249. Immediate ART No Better Than Deferred in Asian Kids With Moderate CD4 Loss ! - Written by Mark Mascolini - (07/17/11)
     
  10250. TMC278, Rilpivirine: 2 Phase 3 Studies ECHO/THRIVE Published & Commentary pdfs attached - (07/17/11)
     
  10251. Intl Wrkshp Advrse Reactions & Comorbids HIV: Metabolic Risk Factors in Responders to Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, in HIV-Infected Patients with Excess Abdominal Fat - (07/17/11)
     
  10252. Intl Wrkshp Advrse Reactions & Comorbids HIV: Bone Mineral Density (BMD) Analysis in Antiretroviral (ART)-Naïve Subjects Taking Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) for 96 weeks in the PROGRESS Study - (07/17/11)
     
  10253. Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary Cells - pdf attached - (07/13/11)
     
  10254. Neurocognitive Impact of Substance Use in HIV Infection - (07/13/11)
     
  10255. New MRI Protocol Refines CAD Risk Assessment - full text pdf publication attached - (07/13/11)
     
  10256. CT Scan Detects Silent CV Risk (coronary calcium buildup) - (07/12/11)
     
  10257. A Frailty-Related Phenotype Before HAART Initiation as an Independent Risk Factor for AIDS or Death After HAART Among HIV-Infected Men - pdf attached - (07/05/11)
     
  10258. Human Immunodeficiency Virus Infection of Human Astrocytes Disrupts Blood-Brain Barrier Integrity by a Gap Junction-Dependent Mechanism - (07/05/11)
     
  10259. Senescent phenotypes and telomere lengths of peripheral blood T-cells mobilized by acute exercise in humans - (07/05/11)
     
  10260. Aging, Persistent Viral Infections, and Immunosenescence: Can Exercise ''Make Space''? - (07/05/11)
     
  10261. Int'l Wrkshp HIV & HCV Resist & Curative Strategies: Report on the International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies - June 7- 11, Cabo, Mexico - (06/30/11)
     
  10262. Int'l Wrkshp HIV & HCV Resist & Curative Strategies: International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies - June 7- 11, Cabo, Mexico - (06/30/11)
     
  10263. Mitochondria are sensors for HIV drugs - (06/28/11)
     
  10264. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway - (06/28/11)
     
  10265. HIV Itself Causes Mitochondrial Damage - (06/28/11)
     
  10266. Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors - (06/28/11)
     
  10267. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations - (06/27/11)
     
  10268. (AZT Shortens Telomerase)Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines - (06/27/11)
     
  10269. (AZT Shortens Telomerase) The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena - (06/27/11)
     
  10270. Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study - (06/27/11)
     
  10271. Increases in T Cell Telomere Length in HIV Infection after Antiretroviral Combination Therapy for HIV-1 Infection Implicate Distinct Population Dynamics in CD4+ and CD38+ T Cells - (06/27/11)
     
  10272. T cell activation predicts carotid artery stiffness among HIV-infected women - (06/27/11)
     
  10273. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis - (06/21/11)
     
  10274. Low CD4 Count Is Associated With an Increased Risk of Fragility Fracture in HIV-Infected Patients - (06/20/11)
     
  10275. Vitamin D Deficiency in HIV-Infected and HIV-Uninfected Women in the United States - (06/20/11)
     
  10276. Elevated triglycerides and risk of MI in HIV-positive persons, the D:A:D study - (06/20/11)
     
  10277. IL-32 and HIV Persistence - (06/20/11)
     
  10278. HIV Reservoir Size - (06/20/11)
     
  10279. Risk of cerebrovascular events in persons with and without HIV: A Danish nationwide population-based cohort study - (06/17/11)
     
  10280. Vitamin D and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis - (06/17/11)
     
  10281. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study: Vit D levels associated with HIV progression & mortality - (06/13/11)
     
  10282. Premature aging seen as issue for AIDS survivors - (06/13/11)
     
  10283. Increased Metabolic Rate May Lead to Accelerated Aging - (06/10/11)
     
  10284. Sirtuins, Aging, and Medicine - (06/10/11)
     
  10285. (Vitamin D Guidelines) Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline - (06/09/11)
     
  10286. 'Exercise Cuts Stroke Risk in Elderly' - (06/09/11)
     
  10287. Non-AIDS-Defining Malignancies in HIV-1-Infected Patients Receiving Combination Antiretroviral Therapy (ATHENA Cohort): "Cumulative exposure to CD4+ cell counts <200 cells/mm3 during cART was associated with an increased risk of infection-related non-AIDS-defining malignancies." - (06/01/11)
     
  10288. High Calcium Intake No Better for Bone Health - full text pdf below - (05/25/11)
     
  10289. Men Who Have Sex With Men, Risk Behavior, and HIV Infection: Integrative Analysis of Clinical, Epidemiological, and Laboratory Databases - (05/25/11)
     
  10290. Past as Prologue: The Refractory and Evolving HIV Epidemic Among Men Who Have Sex With Men editorial - (05/25/11)
     
  10291. Increasing Clarity on Bone Loss Associated With Antiretroviral Initiation - editorial - (05/24/11)
     
  10292. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of US women - (05/24/11)
     
  10293. Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 - pdf attached - (05/24/11)
     
  10294. Researchers Develop Molecular (gene therapy) Microbicide Protection Against HIV Infection: put gene therapy into CD4s in mice & this prevented HIV transmission - (05/23/11)
     
  10295. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up - pdf attached Original Article - (05/21/11)
     
  10296. Calcium supplements and cardiovascular risk - 2 Letters To Editor (response below) - (05/21/11)
     
  10297. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals: 'and to CD4 change after starting ART' - pdf attached - (05/19/11)
     
  10298. Low Vitamin D Levels Seen in Parkinson's Patients - full text of study below - - (05/19/11)
     
  10299. Vitamin D Status of HIV-Infected Women and Its Association with HIV Disease Progression, Anemia, and Mortality: "Women in the highest vitamin D quintile had a 42% lower risk of all-cause mortality, compared to the lowest quintile. Vitamin D status had a protective association with HIV disease progression, all-cause mortality" - (05/19/11)
     
  10300. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons - (05/18/11)
     
  10301. Cancer survivorship and sexual orientation - pdf attached - (05/11/11)
     
  10302. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors - pdf attached - (05/10/11)
     
  10303. Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy - pdf attached - (05/10/11)
     
  10304. Could we - should we - calculate a risk exposure score for an HIV-negative individual in a serodiscordant couple? Editorial Comment - (05/09/11)
     
  10305. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients - (05/09/11)
     
  10306. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007 - (05/09/11)
     
  10307. Prostate cancer risk (and Metabolics) in the Swedish AMORIS study - pdf attached - (05/09/11)
     
  10308. Metabolic risk factors in prostate cancer - Editorial - (05/09/11)
     
  10309. Vaginal Microbicide Gel New NNRTI for Delivery of IQP-0528, a Pyrimidinedione Analog with a Dual Mechanism of Action against HIV-1 - pdf attached - (05/09/11)
     
  10310. Bisphosphonate Use and Atypical Fractures of the Femoral Shaft - (05/07/11)
     
  10311. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure - (05/04/11)
     
  10312. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? - (05/02/11)
     
  10313. HIV Infection Ups Heart Failure Risk: "rate of incident heart failure was 7.12 per 1,000 person-years among those with HIV and 4.82 per 1,000 person-years in the rest of the cohort.....But the risk was not seen if baseline and recent HIV levels were less than 500 copies/mL" - (04/26/11)
     
  10314. Wrkshp Clin Pharm HIV: 12th International Workshop on Clinical Pharmacology of HIV Therapy Report by Courtney Fletcher, PharmD - Courtney V. Fletcher, Pharm.D. - (04/26/11)
     
  10315. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment - - (04/23/11)
     
  10316. Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality - 'more profound inflammatory state in those HIV-HCV patients with decompensated cirrhosis....inflammation predicts mortality in these patients' - (04/23/11)
     
  10317. Raltegravir in Salvage: Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors - (04/23/11)
     
  10318. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection - (04/23/11)
     
  10319. Peripheral neuropathy (persists) in HIV: prevalence and risk factors - (04/23/11)
     
  10320. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment - - (04/23/11)
     
  10321. Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality - 'more profound inflammatory state in those HIV-HCV patients with decompensated cirrhosis....inflammation predicts mortality in these patients' - (04/23/11)
     
  10322. Raltegravir in Salvage: Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors - (04/23/11)
     
  10323. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection - (04/23/11)
     
  10324. Peripheral neuropathy (persists) in HIV: prevalence and risk factors - (04/23/11)
     
  10325. How TRIM5 fights HIV - pdf attached - (04/20/11)
     
  10326. Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice: HIV invades CNS within 1-2 weeks after infection, progressive viral infection correlated with loss of neuronal integrity. - pdf attached - (04/20/11)
     
  10327. Wrkshp Clin Pharm HIV: Food and Fat Have Little Impact on Dolutegravir, a New Integrase Inhibitor - written by Mark Mascolini - (04/18/11)
     
  10328. Wrkshp Clin Pharm HIV: Once-Daily 150-mg Maraviroc Explored in People Taking Atazanavir/Ritonavir - written by Mark Mascolini - (04/18/11)
     
  10329. Wrkshp Clin Pharm HIV: Lopinavir Troughs Lower in Children on Once-Daily Dose Plus Efavirenz - written by Mark Mascolini - (04/18/11)
     
  10330. Wrkshp Clin Pharm HIV: Atazanavir Levels Indicate Need for Higher Dose During Pregnancy - written by Mark Mascolini - (04/18/11)
     
  10331. Wrkshp Clin Pharm HIV: Four-in-One Drug Affects Levels of Oral Contraceptives Components - written by Mark Mascolini - (04/18/11)
     
  10332. Wrkshp Clin Pharm HIV: Older Age May Slow Clearance of Once-Daily Darunavir, Which Penetrates Cells Well - written by Mark Mascolini - (04/18/11)
     
  10333. Wrkshp Clin Pharm HIV: Etravirine Lowers Levels of Maraviroc Given at 300 or 600 mg Twice Daily - written by Mark Mascolini - (04/18/11)
     
  10334. Wrkshp Clin Pharm HIV: Impact of Stomach Acid Reducers on Cobicistat and Elvitegravir - written by Mark Mascolini - (04/18/11)
     
  10335. Wrkshp Clin Pharm HIV: Levels of Novel HIV Attachment Inhibitor With or Without Ritonavir - (04/15/11)
     
  10336. Wrkshp Clin Pharm HIV: Half-Dose Lamivudine Not Equivalent to Full Dose in Plasma or Cells - (04/15/11)
     
  10337. Wrkshp Clin Pharm HIV: HIV Infection Affects Cellular Pharmacology of Zidovudine and Lamivudine: 3TC for prevention - (04/15/11)
     
  10338. Wrkshp Clin Pharm HIV: Cobicistat Has Little Impact on Key Drug-Metabolizing Enzymes - (04/14/11)
     
  10339. Wrkshp Clin Pharm HIV: No Dolutegravir (GSK572, integrase) Dose Adjustment Needed With Efavirenz or Tipranavir/Ritonavir - (04/14/11)
     
  10340. Distribution of cancers in the HIV/AIDS population is shifting; New study finds a decrease in AIDS-defining cancers, offset by an increase in other cancers - pdf attached - (04/13/11)
     
  10341. Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission - pdf attached - (04/13/11)
     
  10342. Distribution of cancers in the HIV/AIDS population is shifting; New study finds a decrease in AIDS-defining cancers, offset by an increase in other cancers - pdf attached - (04/12/11)
     
  10343. CROI: Inflammation and Intervention: how does HIV cause AIDS and how does it cause disease despite ART - David Margolis, MD University of North Carolina - (04/11/11)
     
  10344. CROI: Vitamin D3 Supplementation Decreases Parathyroid Hormone (PTH) in HIV-Infected Youth Being Treated with Tenofovir-Containing Combination Antiretroviral Therapy: Randomized, Double-blind, Placebo-controlled Multicenter Trial Adolescent Trials Network (ATN) study 063 - (03/29/11)
     
  10345. CROI: No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis - (03/29/11)
     
  10346. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues - (03/29/11)
     
  10347. "Test and Treat": Is It Enough? - (03/28/11)
     
  10348. The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection - (03/28/11)
     
  10349. No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT - (03/28/11)
     
  10350. CROI: Risk of Fractures Associated with HIV/Hepatitis C Coinfection - (03/28/11)
     
  10351. CROI: Bone and Vitamin D at CROI 2011 - By Todd T. Brown, MD, PhD - (03/26/11)
     
  10352. CROI: Changes in Body Composition after Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir in Virologically Suppressed HIV-1-Infected Patients (SPIRAL-LIP substudy) - (03/26/11)
     
  10353. CROI: Bone & HIV CROI 2011 - (03/26/11)
     
  10354. CROI: COMPREHENSIVE LIPID EVALUATION IN PATIENTS SWITCHING FROM RITONAVIR BOOSTED PROTEASE INHIBITOR (PI/r)-BASED TO RALTEGRAVIR-BASED ANTIRETROVIRAL THERAPY: THE SPIRAL-met SUBSTUDY - (03/26/11)
     
  10355. CROI: Antiretroviral CNS Penetration-Effectiveness (CPE) 2010 ranking predicts CSF viral suppression only in patients with undetectable HIV-1 RNA in plasma - (03/24/11)
     
  10356. CROI: Early HAART in TB-Treated Patients Recommended in 2 Studies at CROI for Patients with <50 CD4s - (03/24/11)
     
  10357. CROI: Turnover Following Viral Control Correlates with Markers of Microbial Translocation in Treatment-Naïve Patients Receiving Raltegravir (RAL)- based Antiretroviral Therapy (ART): Preliminary Results from ACTG A5248 - (03/24/11)
     
  10358. CROI: CD4 Nadir Drives Persistence of Monocytes and T Lymphocytes Activation in Virologically Suppressed HIV-infected Patients - (03/24/11)
     
  10359. CROI: Biomarkers of Inflammation, Coagulation and Monocyte Activation Are Strongly Associated with the VACS Index among Veterans on cART - (03/24/11)
     
  10360. Quantification of Coronary Atherosclerosis and Inflammation to Predict Coronary Events and All-Cause Mortality J Am Coll Cardiol, March 29 2011 - (03/23/11)
     
  10361. Calcium and C-Reactive Protein Hot Enough to Predict the Future? - (03/23/11)
     
  10362. CROI: Bone Loss in HIV-Negatives in PrEP Study: 'a surprising percent of HIV-neg MSM had low bone mineral density before starting TDF, drug use associated with bone mineral density loss - vitamin D/calcium supplementation was protective'; in some HIV+ persons low BMD likely predated HIV-infection....in summary Kathy Mulligan said "it is not known whether there will be any long-term clinically important effects of PrEP with TDF/3TC (Truvada) on bone health" - (03/23/11)
     
  10363. CROI: CROI 2011 Immunology Report - written by David Margolis, MD, University of North Carolina (03/22/11)
     
  10364. CROI: BMD Loss in HIV TDF PrEP - 2 studies - (03/22/11)
     
  10365. CROI: Advances in PrEP - (03/22/11)
     
  10366. CROI: Adding Maraviroc Does Not Boost CD4s or Quiet T-Cell Activation - written by Mark Mascolini - (03/22/11)
     
  10367. CROI: Risk of Stage 1 AIDS Dementia 12% Over 2 Years in Asymptomatic People - written by Mark Mascolini - (03/22/11)
     
  10368. CROI: Sustained Response to Anti-HCV Therapy Higher During Acute Infection in HIV Positives - written by Mark Mascolini - (03/22/11)
     
  10369. CROI: Boceprevir Boosts Sustained Virologic Response Rate With HCV Genotype 1 - written by Mark Mascolini - (03/22/11)
     
  10370. CROI: Boceprevir Improves SVR With PegIFN/RBV After Failure or Relapse With HCV-1 - written by Mark Mascolini - (03/22/11)
     
  10371. Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients: "MVC achieves concentrations within the EC90 range in CSF. All patients with undetectable plasma viral load although receiving nucleoside-sparing regimens including new drugs showed viral suppression in CSF." - (03/21/11)
     
  10372. CROI: US Youngsters Start Antiretrovirals Late and Stop Early in HIV Research Network - written by Mark Mascolini - (03/21/11)
     
  10373. CROI: HIV Affects Brain Immediately After Infection with HIV RNA in the CSF & Inflammation & Brain Injury Continues Unfolding During Chronic Infection & There is a Need for Routine Monitoring - (03/21/11)
     
  10374. CROI: Lowest CD4 Count Below 200, by Itself, Raises Heart Disease Risk With HIV: HIV Is a Risk Factor for Heart Disease - (03/21/11)
     
  10375. CROI: HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors - (03/21/11)
     
  10376. CROI: High incidence rate of HCV reinfection after treatment of acute HCV infection in HIV-infected MSM in Amsterdam - (03/21/11)
     
  10377. CROI: Therapeutic Darunavir and Etravirine Concentrations in Cerebrospinal Fluid - (03/21/11)
     
  10378. CROI: Early Clearance of HCV RNA in HCV Genotype 1 Treatment-naïve Patients Treated with Telaprevir, Peginterferon and Ribavirin: Pooled Analysis of the Phase 3 Trials ADVANCE and ILLUMINATE - (03/21/11)
     
  10379. CROI: Trunk and Visceral Fat Gains With Atazanavir & Efavirenz in ACTG A5224s - written by Mark Mascolini - (03/20/11)
     
  10380. CROI: Vitamin D Supplements May Limit Tenofovir Bone Toxicity - written by Mark Mascolini - (03/20/11)
     
  10381. CROI: Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members - (03/19/11)
     
  10382. CROI: Comprehensive Lipid Evaluation in Patients Switching from PI/r-based cART to a RAL-based cART: The SPIRAL Substudy - (03/19/11)
     
  10383. CROI: US Youngsters Start Antiretrovirals Late and Stop Early in HIV Research Network - written by Mark Mascolini - (03/19/11)
     
  10384. CROI: On-Treatment Viral Loads Fell Steadily Since 1997 in Large US-Canadian Analysis: diaparities for Blacks & IDUs - written by Mark Mascolini - (03/19/11)
     
  10385. CROI: Minocycline Does Not Improve HIV-Associated Neurocognitive Disorder - written by Mark Mascolini - (03/19/11)
     
  10386. CROI: Early Brain Injury Visualized in People With Recent HIV Infection - written by Mark Mascolini - (03/19/11)
     
  10387. CROI: Carotid Atherosclerosis Is Related to HIV Duration and Anti-inflammatory Profile and Not to ARV Exposure: The CHIC Controlled Study - (03/17/11)
     
  10388. CROI: D-dimer Levels Correlate with Inflammatory and Endothelial Activation Markers in HIV-infected Adults - (03/17/11)
     
  10389. CROI: (NIH Study) Circulating Markers of Endothelial Dysfunction, Coagulation and Tissue Fibrosis Prior to Incident Venous Thromboembolism in Patients with HIV Infection - (03/17/11)
     
  10390. CROI: Kinetics of Platelet Counts following Interruption of ART: Results from the SMART Study (coagulation pathways, HIV replication itself or inflammation) - (03/17/11)
     
  10391. CROI: Switch and Stop Rates 25% and 12% in First ART Year in 18-Cohort Study - written by Mark Mascolini - (03/17/11)
     
  10392. CROI: ATN 083: Longitudinal Changes in Cardiovascular Risk Markers among HIV Infected and at Risk Adolescents: "Endothelial dysfunction as measured by sVCAM-1 is higher in HIV+ adolescents than HIV- individuals" - (03/16/11)
     
  10393. CROI: Endothelial Dysfunction More Common in HIV-Positive Than Negative Adolescents - written by Mark Mascolini - (03/16/11)
     
  10394. CROI: Mortality With Acute Coronary Syndrome Higher in People With HIV - written by Mark Mascolini - (03/15/11)
     
  10395. CROI: Coronary Artery Plaque Linked to Low Fat in MACS Men With HIV - written by Mark Mascolini - (03/15/11)
     
  10396. CROI: Integrating Integrase Inhibitors and other antiretroviral stories - Joe Eron MD Professor of Medicine; UNC Chapel Hill - (03/15/11)
     
  10397. CROI: The Effect of Low-dose Ritonavir on the Pharmacokinetics of the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/15/11)
     
  10398. CROI: Low CD4 Count on Effective HAART is Associated With Immunologic and Vascular Dysfunction - (03/15/11)
     
  10399. CROI: Clinical Pharmacology at CROI 2011 (HIV & HCV) - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center (03/14/11)
     
  10400. CROI: Viral Load (But Not Antiretrovirals) and HCV Tied to 10-Year Fracture Risk: fracture risk higher in HIV+ vs HIV-neg - written by Mark Mascolini - (03/14/11)
     
  10401. CROI: Survival After Cancer Diagnosis Improves in US HIV Cohort: 'Incidence (new diagnoses) of AIDS cancers dropped, as did incidence of non-AIDS infection-related cancers. But incidence of non-AIDS cancers not related to infection rose since the arrival of triple antiretroviral therapy' - written by Mark Mascolini - (03/14/11)
     
  10402. CROI: Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/r) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/r) help explain limited loss of bone mineral density over first 12 months after antiretroviral therapy (ART) initiation (03/14/11)
     
  10403. CROI: Firstline HAART Causes Bone Loss (03/14/11)
     
  10404. CROI: Glycated Hemoglobin A1C as Screening for Diabetes Mellitus in HIV Infected Individuals (03/13/11)
     
  10405. CROI: Update on the "cure" and metabolic complications - written by Pablo Tebas MD University of Pennsylvania (03/13/11)
     
  10406. CROI: LOW BONE MASS IN BEHAVIORALLY HIV-INFECTED YOUNG MEN ON ANTIRETROVIRAL THERAPY: Adolescent Trials Network (ATN) Protocol 021B (03/13/11)
     
  10407. CROI: HAART-induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS (03/13/11)
     
  10408. CROI: Changes in Bone Biomarkers in ARV-naïve HIV+ Men Randomized to NVP/LPV/r or AZT/3TC/LPV/r Help Explain Limited Loss of Bone Mineral Density over the First 12 Months after ART Initiation (03/13/11)
     
  10409. CROI: Recombinant Interleukin-7 (CYT107) Expands CD4 T Cells in Peripheral Blood and Gut Mucosa of Chronically HIV-Infected Immunological Non-Responder Patients (03/13/11)
     
  10410. Increased Rates of Bone Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared with the US General Population, 2000-2006 - pdf attached - (03/12/11)
     
  10411. Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection (SMART Study): - pdf attached - (03/12/11)
     
  10412. CROI: Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks (03/12/11)
     
  10413. CROI: Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 datafrom the randomized, double-blind, Phase III ECHO and THRIVE trials (03/12/11)
     
  10414. Mediterranean [and exercise] Diet Helps Prevent Metabolic Syndrome, Abdominal Obesity, Elevated Lipids, Hypertension - pdf attached - (03/11/11)
     
  10415. CROI: Bone Effects of Rosiglitazone in HIV-Infected Patients with Lipoatrophy (03/11/11)
     
  10416. CROI: Recombinant IL-7 Expands CD4 T Cells in Peripheral Blood and Gut Mucosa of Chronically HIV-infected Immunological Non-responder Patients (03/11/11)
     
  10417. CROI: Chronic Inflammation and HIV: CROI 2011 - David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine (03/10/11)
     
  10418. HIV and Cancer in Germany - pdf attached - (03/10/11)
     
  10419. CROI: Nutritional Intervention with NR100157 Restores Gut Microbiota in HIV-1-infected Adults Not on HAART and Reduces Systemic Immune Activation (03/10/11)
     
  10420. CROI: Prompt, Significant Reduction of Activation and Proliferation Markers in CD4+ and CD38+ T Cell Subsets despite Incomplete Viral Suppression: Proof-of-Concept for AV-HALT-A New Class of Anti-HIV Therapeutics Inhibiting Both HIV Replication and Immune Activation (03/10/11)
     
  10421. CROI: Immunomodulatory Effects of Hydroxychloroquine in HIV-Infected ART-Treated Immunological Non Responders: 'reduces inflammation & activation' (03/10/11)
     
  10422. CROI: HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors (03/10/11)
     
  10423. CROI: Diabetes Mellitus in Treated HIV-Infected Patients: Incidence over Ten Years in 1,046 patients from the ANRS CO8 APROCO-COPILOTE Cohort (03/10/11)
     
  10424. CROI: Invasive Anal Cancer Seen With Relatively High CD4s and Low HIV Loads - written by Mark Mascolini - (03/9/11)
     
  10425. CROI: Statins May Lower Risk of non-Hodgkin Lymphoma in People With HIV - written by Mark Mascolini - (03/9/11)
     
  10426. CROI: Earlier Occurrence of the Frailty Phenotype in HIV-1-infected Men than in HIV-uninfected Men in the Multicenter AIDS Cohort Study (MACS) - (03/9/11)
     
  10427. CROI: Prevalence and Prognostic Factors of Chronic Kidney Disease in HIV-infected Patients, HIV-NAT 006 Cohort, Thailand: "high prevalence of advanced chronic kidney disease...more diabetes/hypertension" - pdf attached - (03/9/11)
     
  10428. CROI: Aging and Non-HIV-associated Co-morbidity in HIV+ Persons: The SHCS - pdf attached - (03/9/11)
     
  10429. CROI: Microbial Translocation (MT)-induced Immune Activation Associates to Atherosclerosis in cART treated HIV pos Patients - (03/9/11)
     
  10430. CROI: Immunologic Failure Despite Suppressive ART Is Related to Increased Inflammation and Evidence of Microbial Translocation and Inflammation & Activation Persist Even Despite Immune Success - (03/9/11)
     
  10431. CROI: Renal Insufficiency among HIV-infected, ART-naïve Individuals in Lilongwe, Malawi: Implications for Tenofovir use in antiretroviral treatment and prevention of mother to child transmission programs. - (03/9/11)
     
  10432. CROI: Earlier Occurrence of the Frailty Phenotype in HIV+ Men than in HIV- Men: The MACS - (03/9/11)
     
  10433. CROI: Renal Insufficiency, Nephrotoxicity, and Mortality among HIV-infected Adults on TDF in a South African Cohort: A Marginal Structural Models Analysis - pdf attached - (03/9/11)
     
  10434. CROI: Cystain C - 'Lipid Particle Concentrations and Markers of Renal Disease: SMART' - Unfavorable lipoprotein levels were associated with elevated cystatin C levels, but not with impaired eGFR. Cystatin C may better detect earlier reductions in kidney function - (03/9/11)
     
  10435. CROI: Changing Patterns of Causes of Death in the Swiss HIV Cohort Study (SHCS) 2005-2009 - (03/9/11)
     
  10436. CROI: QDMRK, A Phase III Study of the Safety & Efficacy of Once Daily (QD) Versus Twice Daily (BID) Raltegravir (RAL) in Combination Therapy for Treatment-Naïve HIV-Infected Patients (Pts) - (03/9/11)
     
  10437. CROI: CROI 2011 Report Selected Topics - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine - (03/8/11)
     
  10438. CROI: Telapravir Promotes Early Clearance of HCV RNA With PEG-IFN/RBV, Early Response Predicts Outcome (weeks 1,2,4) - written by Mark Mascolini - (03/8/11)
     
  10439. CROI: Fibrosis Predicts Renal Trouble With Tenofovir in HIV/HBV-Coinfected - written by Mark Mascolini - (03/8/11)
     
  10440. CROI: Liver Death Rate Twice Higher With HBV Than HCV in Gay HIV+ Men of MACS - written by Mark Mascolini - (03/8/11)
     
  10441. CROI: HIV, Black Race, and Multiple Partners Raise Risk of Repeat Syphilis in California Gays - written by Mark Mascolini - (03/8/11)
     
  10442. CROI: CD4 Decline Before ART Faster in More Recent Years in ATHENA Cohort: "may have implications for planning on when to start cART." - written by Mark Mascolini - (03/8/11)
     
  10443. CROI: The Kidney at CROI - Christina M. Wyatt, MD Assistant Professor, Medicine Nephrology Mount Sinai School of Medicine New York, NY - (03/8/11)
     
  10444. CROI: HIV Prevention at CROI 2011 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/8/11)
     
  10445. CROI: Steady-state pharmacokinetic parameters of nevirapine extended release formulation tablets in children with HIV-1 infection: an open-label, multiple-dose, cross-over study - (03/7/11)
     
  10446. CROI: Raltegravir (RAL) Demonstrates Durable Virologic Suppression and Superior Immunologic Response with a Favorable Metabolic Profile Through 3 Years of Treatment (Tx): 156 Week (Wk) Results from STARTMRK - (03/7/11)
     
  10447. CROI: Change in Vitamin D Levels Smaller and Risk of Development of Severe Vitamin D Deficiency Lower Among HIV-1-Infected, Treatment-naïve Adults Receiving TMC278 Compared with Efavirenz: 48-week Results from the Phase III ECHO Trial - (03/7/11)
     
  10448. CROI: The Effect of Bimonthly Supplementation with Oral Cholecalciferol and Calcium on 2 Year Bone Mass Accrual in HIV-infected Children and Adolescents - (03/7/11)
     
  10449. CROI: Renal Impairment in Patients Receiving a TDF-based cART Regimen: Impact of TDF Concentration? - (03/7/11)
     
  10450. CROI: Central Fat Accumulation in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, a Substudy of ACTG A5202 - (03/7/11)
     
  10451. CROI: Decreased Limb Muscle and Increased Central Adiposity Are Associated with 5-Year All-cause Mortality in HIV Infection - (03/7/11)
     
  10452. CROI: Predictors of Chronic Kidney Disease in the SMART trial - (03/7/11)
     
  10453. Safety Review update of Abacavir: no statistically significant association seen between myocardial infarction and ABC - (03/05/11)
     
  10454. CROI: Maraviroc 300mg Once Daily + Darunavir/Ritonavir 800/100mg Once Daily Provides Maraviroc Trough Concentrations Comparable to Trough Concentrations in HIV-1 Patients Taking Maraviroc 300mg Twice Daily + Truvada: Implications for Phase 3 Studies - (03/5/11)
     
  10455. Once Daily Administration of Maraviroc Submitted to EMA & FDA - (03/05/11)
     
  10456. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy - pdf attached - (03/05/11)
     
  10457. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient: 2nd case report - pdf attached - (03/05/11)
     
  10458. Commentary Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule - pdf attached - (03/05/11)
     
  10459. CROI: Genotypic Analysis of Cellular HIV V3 DNA to Predict Virologic Response to Maraviroc: Performance of Population-based and 454 Deep V3 Sequencing - (03/5/11)
     
  10460. CROI: Gut-associated Lymphoid Tissue Fibrosis Is Associated with CD4+ T Cell Activation and Poor HIV-specific CD38+ T cell Responses During Suppressive Antiretroviral Therapy - (03/5/11)
     
  10461. CROI: Impaired Endothelial Function Is Associated with Increased Frequencies of CCR5+ and HIV-specific T cells During Treated HIV Infection - (03/5/11)
     
  10462. CROI: The Immunomodulatory Effects of Maraviroc Intensification among ART-suppressed Patients with Incomplete CD4 Recovery - (03/5/11)
     
  10463. CROI: Antiretroviral Therapy Initiation during Acute/Early HIV Infection vs. Later ART Initiation is Associated with Improved Immunologic and Virologic Parameters during Suppressive ART - (03/5/11)
     
  10464. CROI: Predicting maraviroc responses according to number or percentage of X4-using virus among treatment-experienced patients - (03/4/11)
     
  10465. CROI: Neuroprotective MVC Monotherapy in SIV-infected Macaques - (03/4/11)
     
  10466. CROI: Relative performance of ESTA, Trofile, 454 deep sequencing and "reflex" testing for HIV tropism in the MOTIVATE screening population of therapy experienced patients - (03/4/11)
     
  10467. CROI: Interrupted Antiretrovirals Raise Chronic Kidney Disease Risk 50% in SMART - written by Mark Mascolini - (03/4/11)
     
  10468. CROI: New Integrase Inhibitor Controls Toughest Raltegravir-Resistant Virus - written by Mark Mascolini - (03/4/11)
     
  10469. CROI: Diabetes Incidence in People With HIV Falling Since 1999-2000 in France - written by Mark Mascolini - (03/4/11)
     
  10470. CROI: Male-Female and White-Black ART Disparities Persist in US - written by Mark Mascolini - (03/4/11)
     
  10471. CROI: Fracture Risk Highest in First 2 Years of ART--and Maybe in First 12 Weeks - written by Mark Mascolini - (03/4/11)
     
  10472. CROI: Post-Menopausal Women Have increased HIV transmission risk and Higher TDF Blood Levels - (03/3/11)
     
  10473. CROI: Creating an HIV-resistant Immune System: Using CXCR4 ZFN to Edit the Human Genome - (03/3/11)
     
  10474. CROI: Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference - (03/2/11)
     
  10475. CROI: Telaprevir + Peginterferon and Ribavirin: phase 2a study in coinfected patients on HAART Reported at CROI March 2 2011 - (03/2/11)
     
  10476. CROI: Interim Analysis of Phase 2a Study of Telaprevir + Peginterferon/Ribavirin in HCV/HIV Coinfected Patients - (03/2/11)
     
  10477. CROI: GSK1349572 Integrase in Raltegravir Resistant Patients - (03/2/11)
     
  10478. CROI: Diabetes and cIMT Linked to Worse Neurocognitive Performance With HIV written by Mark Mascolini - (03/2/11)
     
  10479. CROI: Poor CD4 Response Despite Undetectable Load Marked by Vascular and T-Cell Dysfunction written by Mark Mascolini - (03/2/11)
     
  10480. CROI: Vitamin D3 Supplements May Thwart Diabetes Emergence in People With HIV written by Mark Mascolini - (03/2/11)
     
  10481. CROI: Fracture Risk Highest in First 2 Years of ART--and Maybe in First 12 Weeks written by Mark Mascolini - (03/2/11)
     
  10482. CROI: Duration of PIs or NNRTIs Has No Consistent Impact on Non-AIDS Cancer Rates written by Mark Mascolini - (03/2/11)
     
  10483. CROI: Low Limb Muscle, High Visceral Fat Double 5-Year Risk of Death in US Cohort written by Mark Mascolini - (03/2/11)
     
  10484. CROI: Vitamin D Boost Does Not Improve Endothelial Function With HIV written by Mark Mascolini - (03/2/11)
     
  10485. CROI: FDA Trial Meta-Analysis Does Not See Higher MI Risk With Abacavir written by Mark Mascolini - (03/2/11)
     
  10486. CROI: Cancer Risk Remains High for People Who Had AIDS as a Child written by Mark Mascolini - (03/2/11)
     
  10487. CROI: Sangamo's Gene Therapy for HIV is Safe, Helps Immune Cells in Early Trial - (03/2/11)
     
  10488. CROI: Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions - (03/2/11)
     
  10489. CROI: Pharmacokinetic Interactions Between Antiretroviral Agents and the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/2/11)
     
  10490. CROI: Lower "Community Viral Load" in SF Linked to Fewer New HIV Cases written by Mark Mascolini - (03/1/11)
     
  10491. CROI: Higher Fracture Rate With HIV + HCV Than With Either Virus Alone written by Mark Mascolini - (03/1/11)
     
  10492. CROI: Intensification With Raltegravir Has No Impact on Reservoir of Replicating Virus written by Mark Mascolini - (03/1/11)
     
  10493. CROI: Viral Load and CD4 Changes With Ritonavir-Boosted and Unboosted Attachment Inhibitor written by Mark Mascolini - (03/1/11)
     
  10494. CROI: HIV Duration, Not ART, Tied to Atherosclerosis Marker in Large Case-Control Study written by Mark Mascolini - (03/1/11)
     
  10495. CROI: Black Race Tied to Virologic Failure in ACTG Trials--But Blacks Gained More CD4s written by Mark Mascolini - (03/1/11)
     
  10496. CROI: Lower CD4 Count Before ART Tied to Higher Risk of Three Non-AIDS Diseases written by Mark Mascolini - (03/1/11)
     
  10497. CROI: In Gay Men Over 50, Frailty More Common With HIV Than Without (MACS) written by Mark Mascolini - (03/1/11)
     
  10498. CROI: Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, a Potentially First-in-Class Oral HIV Attachment Inhibitor - (03/1/11)
     
  10499. High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial - pdf attached - (02/26/11)
     
  10500. Statins as Anti-inflammatory Therapy in HIV Disease? Editorial - pdf attached - (02/26/11)
     
  10501. The Dual Impact of HIV-1 Infection and Aging on Naïve CD4+ T-Cells: Additive and Distinct Patterns of Impairment - From the Multicenter AIDS Cohort - (02/26/11)
     
  10502. Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial - pdf attached - (02/18/11)
     
  10503. Testosterone Treatment of Older Men-Why Are Controversies Created? Editorial - (02/18/11)
     
  10504. Do the Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, And Quality of Life Persist Six Months after Treatment in Intermediate-Frail and Frail Elderly Men? - pdf attached - (02/18/11)
     
  10505. Why Is Androgen Replacement in Males Controversial? - CLINICAL REVIEW- pdf attached - (02/18/11)
     
  10506. HIV Regimens Similar but Not Equivalent - ACTG5202 efavirenz vs Reyataz/r + TDF/FTC or abacavir/3TC - (02/17/11)
     
  10507. Weighing the Benefits and Costs of HPV Vaccination of Young Men Perspective - (02/14/11)
     
  10508. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males - pdf attached - (02/14/11)
     
  10509. Gardasil in Older Women Aged 24-45 yrs old - (02/14/11)
     
  10510. HAART Reduces HPV - (02/14/11)
     
  10511. HIV CareLink newsletter for HIV/AIDS Primary Care Providers (Florida/Caribbean AIDS Education and Training Center - (02/14/11)
     
  10512. Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection - pdf attached - (02/14/11)
     
  10513. 'HIV Exposure Harms Infant Immunity' Maternal HIV Infection and Antibody Responses Against Vaccine-Preventable Diseases in Uninfected Infants - pdf attached - (02/14/11)
     
  10514. Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis - pdf attached - (02/14/11)
     
  10515. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression - pdf attached - (02/14/11)
     
  10516. FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women - (02/12/11)
     
  10517. Reyataz (atazanavir) label revised, adding dosing recommendations for pregnancy and postpartum period - (02/12/11)
     
  10518. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry - pdf attached - (02/12/11)
     
  10519. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death - pdf attached - (02/12/11)
     
  10520. Associations between microalbuminuria and animal foods, plant foods, and dietary patterns in the Multiethnic Study of Atherosclerosis - pdf attached - (02/06/11)
     
  10521. Association of Dietary Patterns With Albuminuria and Kidney Function Decline in Older White Women: A Subgroup Analysis From the Nurses' Health Study - pdf attached - (01/26/11)
     
  10522. HIV Infection, Inflammation, Immunosenescence, and Aging - pdf attached - (02/06/11)
     
  10523. 1st Int. Workshop on HIV & Aging Published REPORT pdf attached. 4 -5 October 2010, Baltimore, USA - (01/27/11)
     
  10524. Bone Mineral Density and Testicular Failure: Evidence for a Role of Vitamin D 25-Hydroxylase in Human Testis - pdf attached - (01/27/11)
     
  10525. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know - pdf attached - (01/27/11)
     
  10526. What Do We Tell Our Patients about Calcium and Vitamin D Supplementation? EDITORIAL pdf attached - (01/27/11)
     
  10527. New Research Finds HIV causes rapid aging in key infection-fighting cells: "Successful ART treatment does not fully reconstitute the CD31-CD4+ naive T-cell subset"- pdf attached - (01/27/11)
     
  10528. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients - pdf attached - (01/24/11)
     
  10529. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy - pdf attached - (01/24/11)
     
  10530. Increasing incidence of ischemic stroke in patients with HIV infection: HIV, HAART, metabolics, median age 50, absolute numbers small - pdf attached - (01/20/11)
     
  10531. Gender, South, Race Affect Health Outcomes in HIV: - (01/19/11)
     
  10532. 1st Intrnl Wrkshp HIV & Women: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/ritonavir (ATV/r) Once Daily Given in Combination With Twice Daily AZT/3TC During Pregnancy: Results of Study AI424182 - (01/19/11)
     
  10533. 1st Intrnl Wrkshp HIV & Women: Reyataz During Pregnancy - written by Mark Mascolini - (01/16/11)
     
  10534. Triple antiretroviral prophylaxis during pregnancy and breastfeeding is safe and reduces the risk of HIV transmission to infants. pdf attached - (01/16/11)
     
  10535. 1st Intrnl Wrkshp HIV & Women: Efficacy, Safety and Tolerability of Lopinavir/ritonavir (LPV/r) in HIV-Infected Women: Results of a Meta-Analysis of 7 Prospective, Randomized Clinical Trials (RCTs) Through 48 Weeks - (01/15/11)
     
  10536. 1st Intrnl Wrkshp HIV & Women: RNA and CD4 Response to Lopinavir Similar in Women and Men in 7-Trial Analysis - written by Mark Mascolini - (01/14/11)
     
  10537. 1st Intrnl Wrkshp HIV & Women: Sex Transmission: Defining Mucosal Immune Factors That Stymie HIV Remains Tough Job - written by Mark Mascolini - (01/14/11)
     
  10538. 1st Intrnl Wrkshp HIV & Women: Registry Sees No Increased Overall Birth Defect Risk With First-Trimester Antiretrovirals - written by Mark Mascolini - (01/11/11)
     
  10539. 1st Intrnl Wrkshp HIV & Women: Low Bone Density Not Linked to Lipodystrophy in Small Group of Canadian Women (see report from Workshop below) - written by Mark Mascolini - (01/11/11)
     
  10540. Low Vitamin D among HIV-Infected Adults: Prevalence of and Risk Factors for Low Vitamin D Levels in a Cohort of HIV-Infected Adults and Comparison to Prevalence among Adults in the US General Population - pdf attached (this was presented in poster at CROI) - (01/14/11)
     
  10541. The Effect of Antiretrovirals on Vitamin D - pdf attached - (01/14/11)
     
  10542. HIV & Aging Slide Talk CME - (01/12/11)
     
  10543. Immune Activation & HCV-Infection: Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection - pdf attached - (01/12/11)
     
  10544. Fractures In Aging >50 Yrs Old: associated with antiepileptic drugs, comorbidities, hypertension osteoprotective - pdf attached - (01/12/11)
     
  10545. 1st Intrnl Wrkshp HIV & Women: Trough Levels of Four Key Antiretroviral Higher in Women Than General Population - written by Mark Mascolini - (01/11/11)
     
  10546. 1st Intrnl Wrkshp HIV & Women: Women Report Better Quality-of-Life Gains Than Men in GRACE Trial of Darunavir - written by Mark Mascolini - (01/11/11)
     
  10547. 1st Intrnl Wrkshp HIV & Women: Gender Not Linked to Liver Disease Progression in HIV/HCV+ Canadians - written by Mark Mascolini - (01/11/11)
     
  10548. 1st Intrnl Wrkshp HIV & Women: Association of Sex and Race with Health-related Quality of Life in Patients Treated with Darunavir/ritonavir-based Therapy in the GRACE (Gender, Race And Clinical Experience) Trial - (01/12/11)
     
  10549. 1st Intrnl Wrkshp HIV & Women: Switch to Opt-Out HIV Screening Promotes Testing in Women of Washington, DC - (01/11/11)
     
  10550. 1st Intrnl Wrkshp HIV & Women: Half of HIV-Positive Women in Ontario Survey Have Unintended Pregnancies - (01/11/11)
     
  10551. 1st Intrnl Wrkshp HIV & Women: ART Response and Rebound Worse in Female IDUs Than Male IDUs - (01/11/11)
     
  10552. Liver Disease (ALTs/Fatty Liver) a Possible Predictor of Stroke - (01/11/11)
     
  10553. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort - pdf attached - (01/11/11)
     
  10554. Eradication/CNS Penetration: 'Eradication of HIV from the brain: reasons for pause' - pdf attached - (01/11/11)
     
  10555. Immune Senescence & Activation Associated with Heart Disease in HIV+ editorial - (01/11/11)
     
  10556. T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women - pdf attached - (01/11/11)
     
  10557. Aging with HIV: As HIV population grows older, diseases of aging are a new dilemma New Aging Study/Clinic at SFGH - (01/08/11)
     
  10558. Male circumcision and HPV transmission to female partners - Editorial - (01/08/11)
     
  10559. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda - pdf attached - (01/08/11)
     
  10560. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml - published pdf attached - (01/08/11)
     
  10561. Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study - pdf attached - (01/07/11)
     
  10562. Inflammation (lipodystrophy) Associated with Physical Performance Decline - (01/05/11)
     
  10563. Gait speed was associated with survival in older adults - (01/05/11)
     
  10564. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease - published pdf attached - (01/03/11)
     
  10565. Inflammation & Kidney Disease - (01/03/11)
     
  10566. Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl: kidney anti-inflammation drug - (01/03/11)
     
  10567. Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease - press release - (01/03/11)
     
  10568. 'Urinary Protein & Albumin Both Predict Mortality & Renal Outcomes' - Comparison of Urinary Albumin and Urinary Total Protein as Predictors of Patient Outcomes in CKD - (01/03/11)
     
  10569. Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates - published pdf attached - (12/30/10)
     
  10570. Preventing Cancer in HIV+: keep CD4 >700 & viral load undetectable, start HAART Early, control inflammation - (12/30/10)
     
  10571. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  10572. The Steady State Pharmacokinetics (PK) of Atazanavir/Ritonavir (ATV/RTV) During Pregnancy in HIV+ Women - (12/22/10)
     
  10573. 10th Congress Drug Therapy HIV: Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10)
     
  10574. Patterns of neonatal bilirubin following atazanavir/ritonavir (ATV/r) treatment of mothers during pregnancy: clinical and pharmacogenetic factors identified in study AI424182 - (12/19/10)
     
  10575. Editorial NeuroAIDS review - pdf attached - (12/22/10)
     
  10576. Brain Research Urged in Paper in AIDS: "HIV-1 infection and cognitive impairment in the cART-era: a review" - "studies....report abnormal scores on neuropsychological assessments in 15 - 50% of patients.....clinical course should be followed closely in large cohorts of patients.....promising therapies should be studied" - published pdf attached - (12/22/10)
     
  10577. Association of Higher Levels of High-Density Lipoprotein Cholesterol in Elderly Individuals and Lower Risk of Late-Onset Alzheimer Disease - pdf attached - (12/22/10)
     
  10578. Relationship between Vitamin D, Parathyroid Hormone, and Bone Health (vit D insufficiently defined)- publication pdf attached - (12/22/10)
     
  10579. 10th Congress Drug Therapy HIV: Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10)
     
  10580. Alternate Marker (Cystatin C) Picks Out High-Risk CKD Patients - published text below, pdf attached - (12/19/10)
     
  10581. Lipoatrophy/Metabolics & Genetics: European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142 - pdf attached - (12/19/10)
     
  10582. Mitochondrial damage in adipose tissue of untreated HIV-infected patients - publication pdf attached - (12/19/10)
     
  10583. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations - publication pdf attached - (12/19/10)
     
  10584. Update on U.S. Prescribing Information for ZERIT (stavudine) - (12/19/10)
     
  10585. Capsid: New Class of HIV Drugs - (12/14/10)
     
  10586. Testosterone Deficiency and Replacement in Older Men - Editorial - (12/09/10)
     
  10587. Adverse Events Associated with Testosterone Administration - publication pdf attached - (12/09/10)
     
  10588. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study: 40-83% Neuro Impaired/33% asymptomatic/low nadir cd4 predicts/comorbidities contribute - published pdf attached - (12/08/10)
     
  10589. The persistence of HIV-associated neurocognitive dysfunction and the effects of comorbidities - Editorial - (12/08/10)
     
  10590. Insulin metabolism and the risk of Alzheimer disease - full txt from Neurology below pdf attached - (12/05/10)
     
  10591. 10th Congress Drug Therapy HIV: Nevirapine Versus Ritonavir-Boosted Atazanavir CombinedWith Tenofovir/ Emtricitabine in First-LineTherapy: NEWART 48-Week Data - (12/05/10)
     
  10592. Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System - published pdf attached - (12/02/10)
     
  10593. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know - publication pdf attached - (12/02/10)
     
  10594. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study - pdf attached - (12/01/10)
     
  10595. mtDNA Damage & Heart Disease/End Organ Disease: Role of Pyrimidine Depletion in the Mitochondrial Cardiotoxicity of Nucleoside Analogue Reverse Transcriptase Inhibitors - pdf attached - (12/01/10)
     
  10596. A randomized crossover study to compare efavirenz and etravirine treatment - pdf attached - (12/01/10)
     
  10597. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine - published pdf attached - (12/01/10)
     
  10598. Surgical correction of HIV-associated facial lipoatrophy - publication pdf attached - (12/01/10)
     
  10599. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort - pdf attached - (12/01/10)
     
  10600. Merck Reports Initial Results of Phase III Study of ISENTRESS® (raltegravir) Investigational Once-Daily Dosing in Treatment-Naïve Adult Patients Infected with HIV-1 - (11/30/10)
     
  10601. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men - publication pdf attached - (11/29/10)
     
  10602. Oral Preexposure Prophylaxis for HIV - Another Arrow in the Quiver? Editorial - (11/29/10)
     
  10603. Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection - published pdf attached - (11/29/10)
     
  10604. The Lesser-Known Complications (Bone) of HIV/AIDS (aging, complications) - (11/29/10)
     
  10605. Telomerase reverses ageing process (full text; published pdf attached) - (11/29/10)
     
  10606. 10th Congress Drug Therapy HIV: Analysis of BENCHMRK-1&2 Using PhenoSense Assay for Darunavir (DRV/r) Resistance and Exploration of Functional Monotherapy with RAL vs DRV - (11/29/10)
     
  10607. 10th Congress Drug Therapy HIV: 48 Wk Efficacy and Safety of Switching Virologically Stable HIV-1 Patients from Nevirapine IR 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) (2) - (11/22/10)
     
  10608. Race/ethnic differences in bone mineral densities in older men - pdf attached - (11/21/10)
     
  10609. Kidney Transplants in HIV+ Study published in NEJM: Tackling the Unknowns in HIV-Related Kidney Diseases/Editorial - full published study follows editorial below - pdf attached - (11/21/10)
     
  10610. 10th Congress Drug Therapy HIV: 48 Wk Efficacy and Safety of Switching Virologically Stable HIV-1 Patients from Nevirapine IR 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) - (11/18/10)
     
  10611. 10th Congress Drug Therapy HIV: Population and Ultra-Deep Sequencing for Tropism Determination Are Correlated With Trofile-ES. Genotypic Re-Analysis of the A4001078 Maraviroc Study - (11/18/10)
     
  10612. 10th Congress Drug Therapy HIV: No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects - (11/18/10)
     
  10613. 10th Congress Drug Therapy HIV: The 10-Year Safety and Efficacy of Tenofovir DF (TDF)-Containing HAART in Antiretroviral Naïve Patients - (11/18/10)
     
  10614. 10th Congress Drug Therapy HIV: Adherence to Antiretroviral Treatment Regimens and Correlation with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States - (11/18/10)
     
  10615. 10th Congress Drug Therapy HIV: The 5 Year Safety and Efficacy of the Once-Daily Antiretroviral-Naïve Patient Regimen of Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF) - (11/18/10)
     
  10616. 10th Congress Drug Therapy HIV: Adherence to Antiretroviral Treatment Regimens and Correlation with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States - (11/18/10)
     
  10617. 10th Congress Drug Therapy HIV: Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) Plus EFV Leads to Improved Perceptions of Treatment: Results from the ROCKET 1 Study - (11/18/10)
     
  10618. 10th Congress Drug Therapy HIV: New Nonnucleoside Retains Activity Against Some Virus Resistant to Etravirine - (11/18/10)
     
  10619. 10th Congress Drug Therapy HIV: Activity of Integrase Inhibitor, S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Week 24 Results of VIKING Study (ING112961) - (11/17/10)
     
  10620. 10th Congress Drug Therapy HIV: PK/PD Modeling Supports Dose Escalation Decision in VIKING (50 mg twice-daily for highly raltegravir resistant patients) - (11/17/10)
     
  10621. 10th Congress Drug Therapy HIV: Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile (activity vs etravirine resistance) - (11/17/10)
     
  10622. 10th Congress Drug Therapy HIV: Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc, Zidovudine and Lamivudine (CBV) in Treatment-Naive Patients - (11/17/10)
     
  10623. 10th Congress Drug Therapy HIV: Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc in Treatment-Naive Patients - (11/17/10)
     
  10624. 10th Congress Drug Therapy HIV: Once-Daily S/GSK1349572 Combination Therapy in Antiretroviral-Naïve Adults: Rapod and Potent 24-Week Antiviral Responses on SPRING-1 Antiviral Responses - (11/17/10)
     
  10625. 10th Congress Drug Therapy HIV: The SENSE trial: Etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients - (11/16/10)
     
  10626. 10th Congress Drug Therapy HIV: Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE - (11/16/10)
     
  10627. 10th Congress Drug Therapy HIV: Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the Phase III ECHO and THRIVE trials - (11/16/10)
     
  10628. 10th Congress Drug Therapy HIV: Neuropscyh Side Effect Rate Lower With Etravirine Than Efavirenz at 12 Weeks - Written by Mark Mascolini - (11/15/10)
     
  10629. 12th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Comparison of Bone and Renal Toxicities in the ASSERT Study: Final 96-Week Results From a Prospective Randomised Safety Trial - (11/15/10)
     
  10630. 10th Congress Drug Therapy HIV: METABOLIK: Week 48 Comparison of Metabolic Parameters and Biomarkers in Subjects Receiving Darunavir/ritonavir or Atazanavir/ritonavir - (11/15/10)
     
  10631. 10th Congress Drug Therapy HIV: Switching from Kivexa (KVX) + Efavirenz (EFV) to Atripla (ATR) Reduces Total Cholesterol in Hypercholesterolemic Subjects: Final Results of a 24-week, Randomised Study - (11/15/10)
     
  10632. 10th Congress Drug Therapy HIV: Pooled Week 48 safety and efficacy results from the ECHO and THRIVE Phase III trials comparing TMC278 vs efavirenz in treatment-naïve HIV-1-infected patients - (11/15/10)
     
  10633. 10th Congress Drug Therapy HIV: European Panel Recommends Either Geno (g2p) or Pheno (ESTA) for Tropism Testing - Written by Mark Mascolini - (11/12/10)
     
  10634. 10th Congress Drug Therapy HIV: New S/GSK Integrase Inhibitor Looks Good at 24 Weeks in Phase 2 Trial - Written by Mark Mascolini - (11/12/10)
     
  10635. 10th Congress Drug Therapy HIV: Higher AIDS and non-AIDS Rates With Uncontrolled HIV Despite CD4s Over 350 - Written by Mark Mascolini - (11/12/10)
     
  10636. 10th Congress Drug Therapy HIV: Major and Minor PI Mutations in MONET Darunavir Monotherapy Trial - Written by Mark Mascolini - (11/12/10)
     
  10637. 10th Congress Drug Therapy HIV: Vitamin D Deficiency in EuroSIDA Linked to All-Cause Mortality and AIDS - Written by Mark Mascolini - (11/12/10)
     
  10638. 10th Congress Drug Therapy HIV: Long-Term T-cell Changes With Maraviroc in Four Randomized Trials - Written by Mark Mascolini - (11/12/10)
     
  10639. 10th Congress Drug Therapy HIV: Adding Maraviroc Does Not Boost CD4s in Randomized Trial - Written by Mark Mascolini - (11/12/10)
     
  10640. 10th Congress Drug Therapy HIV: Pretreatment Coreceptor Preference Affects Virologic Response in Naive - Written by Mark Mascolini - (11/12/10)
     
  10641. 10th Congress Drug Therapy HIV: Atazanavir/RTV Stopped Less Than Other Key First-Line Drug in Large French Analysis - Written by Mark Mascolini - (11/12/10)
     
  10642. 10th Congress Drug Therapy HIV: Muscle Weakness or Pain Analyzed as Possible Raltegravir Side Effect - Written by Mark Mascolini - (11/12/10)
     
  10643. 10th Congress Drug Therapy HIV: Switch to Twice-Daily Unboosted Atazanavir Outdoes Switch to Once-Daily Dose - Written by Mark Mascolini - (11/12/10)
     
  10644. 10th Congress Drug Therapy HIV: Switching From ABC/3TC to TDF/FTC Cuts Lipids in Randomized Trial - Written by Mark Mascolini - (11/12/10)
     
  10645. 10th Congress Drug Therapy HIV: Dual Combo of Darunavir/Ritonavir and Etravirine Assessed in London Clinic - Written by Mark Mascolini - (11/10/10)
     
  10646. 10th Congress Drug Therapy HIV: NRTI Exposure Tied to Age-Linked Mitochondrial DNA Deletions - Written by Mark Mascolini - (11/10/10)
     
  10647. 10th Congress Drug Therapy HIV: Anemia in SMART Study Tied to Risk of non-AIDS Disease and Death - Written by Mark Mascolini - (11/10/10)
     
  10648. 10th Congress Drug Therapy HIV: Vitamin D Deficiency in HCV/HIV-Coinfected People in the UK - Written by Mark Mascolini - (11/10/10)
     
  10649. 10th Congress Drug Therapy HIV: Differing HCV Response Rates Depending on HIV in Prospective German Cohort - Written by Mark Mascolini - (11/10/10)
     
  10650. 10th Congress Drug Therapy HIV:Extensive Three-Class Resistance May No Longer Predict Progression or Death - Written by Mark Mascolini - (11/09/10)
     
  10651. 10th Congress Drug Therapy HIV:Darunavir Mutation Rate Dropping in Large Clinical Sample Survey - Written by Mark Mascolini - (11/09/10)
     
  10652. 10th Congress Drug Therapy HIV:More Drugs in Regimen--Not Just More Pills--Hurt Adherence - Written by Mark Mascolini - (11/09/10)
     
  10653. 10th Congress Drug Therapy HIV:PI MONOTHERAPY - Darunavir Monotherapy Equivalent to Triple Therapy in Meta-Analysis - Written by Mark Mascolini - (11/09/10)
     
  10654. 10th Congress Drug Therapy HIV:Switch From Suppressive PI to Abacavir Combo Not Effective in French Cohort Study - Written by Mark Mascolini - (11/09/10)
     
  10655. 10th Congress Drug Therapy HIV:Small But Significant CD4 Gains When Switching Antiretrovirals With Sub-50 Load - Written by Mark Mascolini - (11/09/10)
     
  10656. 10th Congress Drug Therapy HIV:One Third in Large UK HIV Survey Have Fractures, 14% of Them Osteoporotic - Written by Mark Mascolini - (11/09/10)
     
  10657. 10th Congress Drug Therapy HIV: Lifetime Spine Fracture Risk Greater With Than Without HIV in UK Comparison - Written by Mark Mascolini - (11/08/10)
     
  10658. 10th Congress Drug Therapy HIV: Long-Term Resistance Rate Low When Starting ART Within Year of HIV Diagnosis - Written by Mark Mascolini - (11/08/10)
     
  10659. 10th Congress Drug Therapy HIV: Good Adherence Lowers Hospital Risk 40% in Insured US Patients With HIV - Written by Mark Mascolini - (11/08/10)
     
  10660. FDA and CONRAD Chart U.S. Regulatory Path for 1% Tenofovir Gel for HIV Prevention: FDA has granted Fast Track approval designation for 1% tenofovir gel - (11/01/10)
     
  10661. Aspirin to prevent colorectal cancer: time to act? Editorial - (10/28/10)
     
  10662. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials - pdf attached - (10/28/10)
     
  10663. Calcium & Heart Disease - (10/28/10)
     
  10664. Cancer and viral infections in immunocompromised individuals - pdf attached - (10/26/10)
     
  10665. Cancer incidence and risk factors after solid organ transplantation - pdf attached - (10/26/10)
     
  10666. Excess Mortality for Non-AIDS-Defining Cancers among People with AIDS - (10/22/10)
     
  10667. Novel Bone Drug (odanacatib, cathepsin K inhibitor) Found Safe After Four Years - (10/22/10)
     
  10668. Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study - pdf attached - (10/22/10)
     
  10669. Low Bone Mineral Density with Tenofovir: Does Statistically Significant Mean Clinically Significant? - EDITORIAL COMMENTARY - (10/22/10)
     
  10670. Immunosenescence & Aging in HIV - (10/22/10)
     
  10671. Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens - pdf attached - (10/22/10)
     
  10672. Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV - pdf attached - (10/22/10)
     
  10673. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals: does low-level viremia cause non-AIDS comorbidities? - (10/21/10)
     
  10674. Mixed Analysis Findings Adds to Evidence of Unusual Bone Fractures and Bisphosphonates - (10/21/10)
     
  10675. Early Bone Loss Marker Predicts Fracture Risk Later - (10/21/10)
     
  10676. Low-Carb Diets and Mortality - (10/20/10)
     
  10677. Teriparatide for Bone Loss in the Jaw - Editorial - (10/19/10)
     
  10678. "initiating HAART at higher CD4 cell counts for older individuals may be useful- NA-ACCORD Study" - pdf attached - (10/18/10)
     
  10679. Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw - (10/18/10)
     
  10680. Teriparatide and Osseous Regeneration in the Oral Cavity - (10/18/10)
     
  10681. Symposium: Optimizing Vitamin D Intake for Populations with Special Needs: Barriers to Effective Food Fortification and Supplementation - (10/18/10)
     
  10682. Symposium: Optimizing Vitamin D Intake for Populations with Special Needs: Barriers to Effective Food Fortification and Supplementation - (10/16/10)
     
  10683. Boosting Dose Ritonavir Does Not Alter Peripheral Insulin Sensitivity in Healthy HIV-Seronegative Volunteers - (10/16/10)
     
  10684. Biomarkers of impaired renal function - pdf attached - (10/16/10)
     
  10685. Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort - pdf attached - (10/16/10)
     
  10686. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey - pdf attached - (10/16/10)
     
  10687. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study - pdf attached - (10/14/10)
     
  10688. Aging Wrkshp: CD4 Counts Lower on Entry Into Care Among People 50 and Older: NA-ACCORD - (10/13/10)
     
  10689. ICAAC: A Phase-Ib/IIa dose-escalation study for evaluation of the safety, tolerability, and pharmacokinetics of OBP-601 (4'-ethynyl-d4T, Festinavir) in treatment-experienced, HIV-1-infected patients - (10/13/10)
     
  10690. Insulin Resistance a Possible Causal and Treatable Risk Factor for Ischemic Stroke - editorial - pdf attached - full text from original study below - (10/13/10)
     
  10691. HCV Neurotoxicity & Inflammation Additive in Brain in HIV+ Person - pdf attached - (10/13/10)
     
  10692. Aging Wrkshp: Low Vitamin D Not Linked to Bone Density or Liver Fibrosis in HIV/HCV Group - Written by Mark Mascolini - (10/08/10)
     
  10693. Aging Wrkshp: Multiple non-AIDS Diseases More Frequent in Aging IDUs With Versus Without HIV - Written by Mark Mascolini - (10/08/10)
     
  10694. Aging Wrkshp: Family History of Dementia Predicts Worse Neuropsych Function With HIV (dementia defined below) - Written by Mark Mascolini - (10/08/10)
     
  10695. Severe Hypoglycemia and Risks of Vascular Events and Death - (10/07/10)
     
  10696. Aging Wrkshp: Aging HIV+ Hospitalized More Often: Non-AIDS Infections, Heart and GI Disease Explain Most Hospitalizations in Over-50 People With HIV - Written by Mark Mascolini - (10/07/10)
     
  10697. Aging Wrkshp: HIV-Infected in 40s Have Multiple Non-HIV Illnesses as Often as HIV-Negatives in 50s - Written by Mark Mascolini - (10/07/10)
     
  10698. Aging Wrkshp: Comorbidity Rates Higher in Over-49 HIV Group Than in Matched HIV Negatives - Written by Mark Mascolini - (10/07/10)
     
  10699. HIV and Premature Aging: A Field Still in Its Infancy - Editorial: "Age at Cancer Diagnosis Among Persons With AIDS in the United States" (pdf of published study attached) - (10/06/10)
     
  10700. Aging Wrkshp: Sexual Function Worse With HIV Than Diabetes or No Chronic Illness in Older Men - Written by Mark Mascolini - (10/06/10)
     
  10701. Aging Wrkshp: Older Age, HIV, and Antiretrovirals Linked to Neurodegenerative Marker - Written by Mark Mascolini - (10/06/10)
     
  10702. Aging Wrkshp: More Non-HIV Illnesses With HIV Than Without, But Less Treatment; New HCV therapy will add to burden - Written by Mark Mascolini - (10/06/10)
     
  10703. Aging Wrkshp: Older Women With HIV Report "Premature Aging" Strikingly More Often Than Men - Written by Mark Mascolini - (10/06/10)
     
  10704. Aging Wrkshp: Higher Risk of Potential Drug-Drug Interactions in Toronto HIV Patients Over 60 - Written by Mark Mascolini - (10/05/10)
     
  10705. Aging Wrkshp: Lipoatrophy and Efavirenz Tied to Vitamin D Deficiency in Ontario - Written by Mark Mascolini - (10/05/10)
     
  10706. Aging Wrkshp: Pretreatment CD4s and CD4/CD38 Ratio Lower in Trial Participants Over 50 - Written by Mark Mascolini - (10/05/10)
     
  10707. Aging Wrshp: Age Raises Fracture Risk More in People With Than Without HIV - Written by Mark Mascolini - (10/05/10)
     
  10708. The new face of HIV/AIDS in Jacksonville (Black women): Rising disease rates strip away our stereotypes - (10/04/10)
     
  10709. ICAAC: ICAAC 2010 Report by David Margolis MD University of North Carolina - (10/04/10)
     
  10710. ICAAC: Associations between Protease Inhibitors (PIs) and QTc and PR Interval Durations in the Strategies for Management of Antiretroviral Therapy (SMART) Trial - poster pdf attached - (10/04/10)
     
  10711. ICAAC: Association Between Early Virologic Response and Immunologic Outcomes in Raltegravir-treated Patients: "Early vRNA decay is significantly correlated with greater increases in CD4 (absolute and %) change from baseline at Wk 96" - (10/04/10)
     
  10712. ICAAC: HIV At ICAAC 2010: Complications & Co-Infections - Written by David H Shepp, MD Associate Professor of Medicine, Hofstra University School of Medicine Division of Infectious Diseases, North Shore University Hospital-Manhasset - (09/28/10)
     
  10713. Early HAART, Within 6 Months of Infection Preserves Immunity Better Than HAART in Chronic Infection - (09/27/10)
     
  10714. Osteoporosis: adherence needs to top two-thirds to cut fracture risk - (09/27/10)
     
  10715. Long-term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals With Type 2 Diabetes Mellitus (this can work in HIV for anyone) - pdf attached - (09/27/10)
     
  10716. Diabetes, Alzheimer disease, and vascular dementia: Diabetes at baseline doubled the incidence of dementia, AD, and VaD, and increased mortality - pdf attached - (09/27/10)
     
  10717. ICAAC: ICAAC PK Report - (09/26/10)
     
  10718. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues - pdf attached - (09/25/10)
     
  10719. Body Fat & Bone Loss: lipoatrophy & belly fat accumulation BOTH lead to bone loss - (09/25/10)
     
  10720. Bisphosphonates and Reports of Unusual Broken Bones in the Femur (Thigh Bone) - (09/24/10)
     
  10721. GRACE Study in HIV+ Women of Color: racial & gender health disparities in HIV - (09/24/10)
     
  10722. GRACE Study: Sex-Based Outcomes (88% of women were women of color in the study, 67% black women, so results reflect on needs of black women with HIV in the USA) were of Darunavir-Ritonavir Therapy A Single-Group Trial - pdf attached - (09/24/10)
     
  10723. Coronary Aging in HIV-Infected Patients - (09/23/10)
     
  10724. Coronary Aging in HIV-Infected Patients: "Increased vascular age was observed in 162 patients (40.5%), with an average increase of 15 years"...."you are 50 years old but your heart's age is 65" - pdf attached - (09/23/10)
     
  10725. Immune senescence in aged nonhuman primates Review - (09/23/10)
     
  10726. Prevalence and Correlates of Sexual Behavior and Risk Management Among HIV-Positive Adults Over 50 - pdf attached - (09/23/10)
     
  10727. Persistence of Racial Differences in Attitudes Toward Homosexuality in the United States.....may help to explain disparities in HIV-infection rates between black & white MSM - pdf attached - (09/23/10)
     
  10728. ICAAC: Once-Daily Nevirapine XR Noninferior to Continued Twice-Daily Nevirapine - Written by Mark Mascolini - (09/19/10)
     
  10729. ICAAC: Clinical, Virological and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 (09/19/10)
     
  10730. ICAAC: Use of Genotypic and Maraviroc (MVC) Clinical Trial Data to Develop Statistical Models for Predicting Response in a Treatment-Naive (TN) Population (09/19/10)
     
  10731. ICAAC: 48-week resistance and efficacy subgroup analysis of once- versus twice-daily darunavir/ritonavir in ODIN (09/19/10)
     
  10732. ICAAC: Comparison of Quest Diagnostics to Trofile and Trofile-ES Coreceptor Tropism Assays for Predicting Virologic Response to Maraviroc (MVC), a CCR5 Antagonist (09/19/10)
     
  10733. ICAAC: Long-Term Outcome of Individuals Experiencing a Phenotypic Switch in HIV-1 Co-receptor Use in the MERIT Study (09/19/10)
     
  10734. ICAAC: Raltegravir Pharmacokinetics during Pregnancy (09/16/10)
     
  10735. ICAAC: Advanced Fibrosis Triples All-Cause Mortality With HCV and HIV - Written by Mark Mascolini - (09/16/10)
     
  10736. ICAAC: CCR5 Antagonists Have No Special CD4-Boosting Power in Meta-Analysis (from Jules: I don't buy this) - Written by Mark Mascolini - (09/16/10)
     
  10737. ICAAC: Once-Daily Nevirapine Noninferior to Twice-Daily Dose in Treatment Naive - Written by Mark Mascolini - (09/16/10)
     
  10738. Ageing and HIV/AIDS (Aging/HIV Clinic in London): A dedicated clinical service for HIV-infected individuals over 50 years of age (09/16/10)
     
  10739. Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers - pdf attached - "we recommend a DXA scan for all HIV-infected post-menopausal women and men >50 years" - (09/17/10)
     
  10740. ICAAC: 48 Week Efficacy, Pharmacokinetics, and Safety of Once a Day 400 mg Nevirapine (Viramune) Extended Release Formulation for Treatment of Antiretroviral Naïve HIV-1 Infected Patients (09/15/10)
     
  10741. ICAAC: Efficacy and Long-Term Safety of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor (GRF) Analogue, in Sub-Populations of HIV-Infected Patients with Excess Abdominal Fat (09/15/10)
     
  10742. ICAAC: The Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF; "QUAD") Maintains a High Rate of Virologic Suppression, and Cobicistat (COBI) is an Effective Pharmacoenhancer Through 48 Weeks (09/15/10)
     
  10743. Development of new HIV drug targeting a cofactor of the cell - Ledgins - Pfizer - pdf attached - (09/15/10)
     
  10744. ICAAC: Insulin Resistance Correlates With HCV Load and SVR in HCV/HIV-Coinfected - Written by Mark Mascolini - (09/15/10)
     
  10745. ICAAC: GSK New NNRTI Selects No Resistance Mutations in 7 Days of Monotherapy - Written by Mark Mascolini - (09/15/10)
     
  10746. ICAAC: Atazanavir Without Ritonavir Sustains Virologic Suppression 120 Weeks in ARIES - Written by Mark Mascolini - (09/15/10)
     
  10747. ICAAC: Lipids Drop After Switch From ABC/3TC/Efavirenz to Atripla - Written by Mark Mascolini - (09/15/10)
     
  10748. ICAAC: Final Results from Stage 1 of a Double-Blind, Placebo-Controlled Trial with TMC207 in Patients with Multi-Drug Resistant (MDR) Tuberculosis (TB) (09/15/10)
     
  10749. ICAAC: Switching from ABC/3TC + Efavirenz [EFV] to TDF/FTC/EFV [Atripla, ATR] Reduces Cholesterol in Hypercholesterolemic Subjects: 24-Week Final Results of a Randomised Study (09/15/10)
     
  10750. ICAAC: New GSK761 NNRTI (09/15/10)
     
  10751. ICAAC: GSK2248761, an NNRTI with Activity Against Common NNRTI Resistance Mutants, Did Not Select for NNRTI Resistance Mutations in Two 7-Day Monotherapy Studies (09/15/10)
     
  10752. ICAAC: TMC-278 Phase 3 ECHO/THRIVE Studies Resistance Profile Rilpivirine - Written by Mark Mascolini - (09/15/10)
     
  10753. ICAAC: Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study - press release (09/15/10)
     
  10754. ICAAC: Four-Drug Single-Pill Antiretroviral Equivalent to Atripla at 48 Weeks - Written by Mark Mascolini - (09/15/10)
     
  10755. ICAAC: High Rates of Bone Loss and Progression With HIV in Longitudinal Study - Written by Mark Mascolini - (09/15/10)
     
  10756. ICAAC: Top Integrase Polymorphisms Do Not Confer Resistance to S/GSK1349572 or Raltegravir - Written by Mark Mascolini - (09/15/10)
     
  10757. ICAAC: Raltegravir Re-Use Response After Failure Depends on Mutation Pattern - Written by Mark Mascolini - (09/15/10)
     
  10758. ICAAC: Long-Term Outcomes Good After Coreceptor Switch in Maraviroc Failure - Written by Mark Mascolini - (09/15/10)
     
  10759. ICAAC: Longer Antiretroviral Therapy Favors Return to Normal HDL-C - Written by Mark Mascolini - (09/15/10)
     
  10760. ICAAC: Novel Mutations and Shifting Susceptibility to Darunavir and Tipranavir - Written by Mark Mascolini - (09/15/10)
     
  10761. ICAAC: Characterization of the resistance profile of TMC278: 48-week analysis of the Phase III studies ECHO and THRIVE - (09/15/10)
     
  10762. ICAAC: 24 Wk Efficacy and Safety of Transitioning Virologically Stable HIV-1 Patients from IR Nevirapine 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) - (09/15/10)
     
  10763. ICAAC: Induction/Maintenance-Simplification: Sustained Virologic Efficacy of Atazanavir (ATV) Versus Atazanavir/Ritonavir (ATV/r), each in Combination with Abacavir/Lamivudine (ABC/3TC) over 120 Weeks: the ARIES Trial - (09/15/10)
     
  10764. ICAAC: TMC-207 New TB Drug from Tibotec - New Drug Speeds Response in MDR TB - (09/15/10)
     
  10765. ICAAC: Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study - press release - (09/14/10)
     
  10766. ICAAC: Two Doses of Hep A Vaccine in HIV+ Men Equivalent to One Dose in HIV- Men - Written by Mark Mascolini - (09/14/10)
     
  10767. ICAAC: Reduction in Visceral Adipose Tissue (VAT) with Tesamorelin Correlates with Changes in Anthropometric, and Patient-Reported Outcome (PRO) Parameters in HIV+ Patients with Excess Abdominal Fat - (09/14/10)
     
  10768. ICAAC: Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (09/14/10)
     
  10769. ICAAC: Vitamin D Deficiency & Bone Loss in Europe - (09/14/10)
     
  10770. Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid - published pdf attached - (09/13/10)
     
  10771. Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells - (09/13/10)
     
  10772. AIDS Cure Quest to Kill 'Sleeping' Viruses Enlists Merck Cancer Medicine - (09/13/10)
     
  10773. PARKINSONISM IN HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY - (09/13/10)
     
  10774. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort - (09/13/10)
     
  10775. HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection - pdf attached - (09/13/10)
     
  10776. Aging Exacerbates Extrapyramidal Motor Signs in the Era of HAART - (09/13/10)
     
  10777. ICAAC: ECG Abnormalities With PIs Versus NNRTIs in SMART Trial - Written by Mark Mascolini - (09/13/10)
     
  10778. ICAAC: One Third on First-Line Antiretrovirals Have Clinically Significant Drug Interactions - Written by Mark Mascolini - (09/13/10)
     
  10779. ICAAC: Maintenance With Raltegravir/Atazanavir Usually Effective for 48 Weeks (low troughs, a few viral rebounds) - Written by Mark Mascolini - (09/13/10)
     
  10780. ICAAC: Staph Rate Falling in HIV+ Danes, But Still High vs General Population - Written by Mark Mascolini - (09/13/10)
     
  10781. Microalbuminuria Is Associated With All-Cause and AIDS Mortality in Women With HIV Infection - pdf attached - (09/10/10)
     
  10782. New UCSF Anal Cancer Information Website - (09/09/10)
     
  10783. Packaging PrEP to Prevent HIV: An Integrated Framework to Plan for Pre-Exposure Prophylaxis Implementation in Clinical Practice - (09/09/10)
     
  10784. Oral bisphosphonates and oesophageal cancer - 'evidence inconclusive' Editorial - (09/09/10)
     
  10785. Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer - 2nd study 'no difference in risk' - (09/09/10)
     
  10786. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers Free, Centralized Resource Designed to Help Overcome Some Barriers to Supportive Care - (09/07/10)
     
  10787. Nevirapine Reuse Possible in Exposed Children With HIV - (09/07/10)
     
  10788. IAC: Vienna Intl AIDS Conference Thoughts from Jules Levin, NATAP - (07/23/10)
     
  10789. IAC/Vienna AIDS Conference: Encouraging Advances Amid Funding Worries for Global Treatment - JAMA - (09/07/10)
     
  10790. 'Low' viral load depletes CD4s: Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion - pdf attached - (09/07/10)
     
  10791. 'hypercholesterol, hypertension, prior CVD associated with poor neurologic performance in SMART' factors: 'reported Increased vascular aging in HIV, inflammation, Hepatitis, immunosenescence, insulin resistance...... - (09/07/10)
     
  10792. 'IL28B Predicts SVR in Coinfection, Associated With 2-Fold Higher Rate of SVR' - published pdf attached - (09/07/10)
     
  10793. Is It Safe to Discontinue Primary Pneumocystis jiroveci Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/µL? - (08/30/10)
     
  10794. High Rates of Asymptomatic Neurocognitive Impairment in Vertically Acquired HIV-1-Infected Adolescents Surviving to Adulthood - (08/29/10)
     
  10795. High prevalence of reduced bone mineral density in primary HIV-1-infected men - (08/29/10)
     
  10796. CD4 Predicts acute renal failure: Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure - (08/29/10)
     
  10797. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses - (08/29/10)
     
  10798. Opioid Use & Bone Loss: Prospective study of bone mineral density changes in aging men with or at risk for HIV infection - (08/29/10)
     
  10799. IAC: Webcast Complications Plenary at IAC Vienna: The Double-Edged Sword: Long-Term Complications of ART and HIV - (08/29/10)
     
  10800. Neurologic disease burden in treated HIV/AIDS predicts survival A population-based study - (08/26/10)
     
  10801. Identification of a gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein as a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor - published pdf attached - (08/25/10)
     
  10802. Potential HIV Drug Keeps Virus out of Cells: "PIE12-trimer is an entry-inhibitor, has the potential to work as a microbicide to prevent people from contracting HIV and as a treatment for HIV infected people." published study pdf attached - (08/25/10)
     
  10803. Development of National and Multiagency HIV Care Quality Measures - (08/19/10)
     
  10804. Quality of Care for Patients Infected with HIV - EDITORIAL COMMENTARY - (08/19/10)
     
  10805. IAC: IAC Summary on New Drugs and New Combinations - How will They Change What We Do? - Written by Joe Eron, Univ of North Carolina - (08/16/10)
     
  10806. IAC: A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1 Infected Subjects: 48 Week Results - (08/15/10)
     
  10807. IAC: Transmission of Integrase Strand-Transfer Inhibitor Multi-drug Resistant HIV: Case Report and Natural History of Response to Raltegravir-containing Antiretroviral Therapy - (08/15/10)
     
  10808. IAC: Abacavir/Lamivudine with Fosamprenavir/Ritonavir or Efavirenz in Underrepresented, Antiretroviral-Naïve, HIV-Infected Subjects (SUPPORT): Tolerability, Safety, and Efficacy after 24 Weeks - (08/15/10)
     
  10809. HIV and Low CD4 Increases Risk for Heart Disease - (08/13/10)
     
  10810. After CAPRISA 004: time to re-evaluate the HIV lexicon - 'oral PrEP has greater likelihood for success' - (08/13/10)
     
  10811. Cardiovascular effects of marine omega-3 fatty acids - Review - publication pdf attached - (08/13/10)
     
  10812. Cognitive Decline Biomarkers-HIV Studies Needed !!!! - (08/13/10)
     
  10813. Plasma β-Amyloid and Cognitive Decline - publication pdf attached - (08/12/10)
     
  10814. Raltegravir Intensification Did Not Reduce Residual Viremia PLoS Medicine published - (08/11/10)
     
  10815. IAC: SWITCH-EE Study (Swiss-Cohort): A Randomized Cross-over Study to Compare Etravirine and Efavirenz treatment - (08/10/10)
     
  10816. IAC: The SENSE Trial: Etravirine (ETR) shows fewer Neuropsychiatric Adverse Events than Efavirenz (EFV) in Treatment-naïve HIV-1 Infected Patients - (08/10/10)
     
  10817. Persistent Microbial Translocation and Immune Activation in HIV-1-Infected South Africans Receiving Combination Antiretroviral Therapy - (08/10/10)
     
  10818. Can HIV be cured with stem cell therapy? commentary - (08/10/10)
     
  10819. IAC: Efficacy of NGX-4010 (QUTENZA), an 8% capsaicin patch, in patients with HIV-associated distal sensory polyneuropathy: results of integrated analyses - (08/10/10)
     
  10820. IAC: The SENSE trial: etravirine (ETR) QD shows fewer neuropsychiatric adverse events than efavirenz (EFV) in treatment-naïve HIV-1 infected patients - (08/10/10)
     
  10821. IAC: Abacavir/lamivudine (ABC/3TC) with fosamprenavir/ritonavir (FPV/r) or efavirenz (EFV) in underrepresented, antiretroviral (ARV) naïve, HIV-infected subjects (SUPPORT): tolerability, safety, and efficacy after 24 weeks - (08/10/10)
     
  10822. IAC: A pilot study of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naive HIV-1 infected subjects: 48-week results - (08/10/10)
     
  10823. IAC: HBV related complications in HIV positive patients during HAART therapy - LAM resistance and high serum HBV-DNA & advancd liver disease - (08/10/10)
     
  10824. IAC: Vienna Declaration: 'decriminalize illicit drug use as an HIV prevention measure' - (08/10/10)
     
  10825. High prevalence of reduced bone mineral density in primary HIV-1-infected men - publication pdf attached - (08/08/10)
     
  10826. C-Reactive Protein Levels Increase During HIV-1 Disease Progression in Rakai, Uganda, Despite the Absence of Microbial Translocation - publication pdf attached - (08/07/10)
     
  10827. HPV-associated head and neck cancer: a virus-related cancer epidemic Review - pdf attached - (08/07/10)
     
  10828. Immune Exhaustion Occurs Concomitantly With Immune Activation and Decrease in Regulatory T Cells in Viremic Chronically HIV-1-Infected Patients - publication pdf attached - (08/07/10)
     
  10829. Lopinavir Tablet Pharmacokinetics With an Increased Dose During Pregnancy - publication pdf attached - (08/07/10)
     
  10830. IAC: Highlights of the Vienna International AIDS Conference by Pablo Tebas, MD, University of Pennsylvania. - (08/07/10)
     
  10831. IAC: High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women - (08/06/10)
     
  10832. Albuminuria and Estimated Glomerular Filtration Rate Independently Associate with Acute Kidney Injury - (08/04/10)
     
  10833. Heart Disease in HIV: 64-slice multidetector row computed tomography coronary angiography predicts outcome, are we evaluating risk for heart disease in HIV correctly? - (08/04/10)
     
  10834. Failing Heart Linked to Failing Brain - attached are both pdfs, the article & a commentary from the Jnl of the Am Heart Ass Epub - (08/04/10)
     
  10835. Following is a statement by the National Osteoporosis Foundation on Bone Mineral Density Testing - (08/04/10)
     
  10836. Kidney function and the risk of cardiovascular events in HIV-1-infected patients - (08/04/10)
     
  10837. IAC: Bioequivalence of the Co-Formulation of Emtricitabine/Rilpivirine/Tenofovir DF - (08/04/10)
     
  10838. IAC: Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone - (08/04/10)
     
  10839. IAC: Switching from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] Reduces High Cholesterol: Results of a 12 Week Randomized, Controlled Study (ROCKET II) - (08/04/10)
     
  10840. IAC: Switching to Atripla (EFV/FTC/TDF) from ABC/3TC FDC (Kivexa/Epzicom) + Efavirenz (EFV) Improves Lipid Levels Towards NCEP Recommendations: Primary Endpoint Results of a 24-week Randomised Study - (08/04/10)
     
  10841. IAC: The impact of switching to etravirine on efavirenz-related CNS toxicity - (08/04/10)
     
  10842. IAC: Meta-analysis Shows Abacavir Has No Effect on Cardiovascular Adverse Events: Presented at AIDS 2010 - (08/04/10)
     
  10843. IAC: Use of genotypic and maraviroc (MVC) clinical trial data to develop statistical models for predicting response to a MVC-containing regimen in a treatment-experienced (TE) population - (08/04/10)
     
  10844. IAC: Low Risk of Malignancy With Maraviroc in Treatment-Experienced and Treatment-Naïve Patients Across the Maraviroc Clinical Development Program - (08/04/10)
     
  10845. IAC: Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: "34% Reduction in Mortality in Early Arm" - (08/04/10)
     
  10846. IAC: Abacavir Use and Cardiovascular Disease Events: A Meta-Analysis of Published & Unpublished Data - (08/04/10)
     
  10847. IAC: Darunavir/Ritonavir Monotherapy Fails Primary Noninferiority Test at MONET Week 96 - written by Mark Mascolini - (07/29/10)
     
  10848. IAC: HIV Prevention at AIDS 2010 Vienna - written by Jared Baeten, MD PhD and Connie Celum, MD MPH University of Washington (07/29/10)
     
  10849. Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus-Infected Patients - full text pdf attached - (07/27/10)
     
  10850. IAC: Viral Control and Switch/Stop Rates Similar With ABC/3TC and TDF/FTC in Canada - written by Mark Mascolini - (07/27/10)
     
  10851. IAC: Resistance and Bilirubin Derail Twice-Daily Raltegravir/Atazanavir - written by Mark Mascolini - (07/27/10)
     
  10852. IAC: Tenofivir Once-Daily PrEP in MSM Friday Late Breaker - (07/27/10)
     
  10853. IAC: The Monet Trial 96 Weeks: drunavir Monotherapy vs darunavir + 2 NRTIs inpatients with HIV RNA < 50 copies/ml at baseline - (07/27/10)
     
  10854. IAC: Abacavir vs Tenofovir - Similar times to virologic suppression and switching or stopping for abacavir/3TC and tenofovir/FTC in naives in Canadian Observational Cohort Collaboration - (07/27/10)
     
  10855. IAC: Coronary CT Sees Blockage in Half of HIV Group With No Heart Disease Symptoms - written by Mark Mascolini - (07/27/10)
     
  10856. IAC: Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen - written by Mark Mascolini - (07/26/10)
     
  10857. IAC: Metabolic Marker Changes Similar After 12 Weeks of Darunavir and Atazanavir - written by Mark Mascolini - (07/26/10)
     
  10858. IAC: HIV Infection Tied to Lower Risk of Vitamin D Deficiency in US Women's Study - (07/26/10)
     
  10859. IAC: Individual Antiretrovirals Not Tied to Vitamin D Deficiency in London HIV Clinic - (average age 48, 50% vit D low/deficient, 40% osteopenia, 13% oseoporosis) - (07/26/10)
     
  10860. IAC: Infection With Resistant Virus More Than Doubles Risk of Virologic Failure - (07/26/10)
     
  10861. IAC: HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients - (07/26/10)
     
  10862. IAC: 80% Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients in Italy - (07/26/10)
     
  10863. IAC: Oral Poster discussion: Shining Light on Vitamin D deficiency - (07/26/10)
     
  10864. IOF position statement: vitamin D recommendations for older adults - Position Paper - (07/23/10)
     
  10865. IAC: Benefits and Risks of Stepdown to Atazanavir/Ritonavir Plus Lamivudine - (07/23/10)
     
  10866. IAC: HIV Raises Heart Disease Risk 60% in People Over 49 - (07/23/10)
     
  10867. IAC: HAART Initiation and Clinical Outcomes: insights from the CASCADE Cohort on 'When To Start' - (07/23/10)
     
  10868. IAC: Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10)
     
  10869. IAC: Association of Antiretroviral Therapy, Immunologic and Virologic Factors with Myocardial Infarction Rates in a U.S. Health Care System - (07/23/10)
     
  10870. IAC: Nadir CD4 is a Predictor of HIV Neurocognitive Impairment (NCI) in the era of Combination Antiretroviral Therapy (CART): Results from the CHARTER Study - (07/23/10)
     
  10871. IAC: Increased Rate of HIV Neurocognitive Impairment (NCI) among non-AIDS Cases in the Post-CART versus Pre-CART era - (07/23/10)
     
  10872. IAC: Gardasil Effective in Preventing AIN and Anal Cancer Related to HPV: 'Quadrivalent HPV Vaccine Efficacy against HPV 6/11/16/18 Infection and Disease in Men' - (07/23/10)
     
  10873. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats - pdf attached - (07/22/10)
     
  10874. IAC: HPV Vaccine Prevents HPV Lesions and Infection in Men - written by Mark Mascolini - (07/22/10)
     
  10875. IAC: Cognitive Impairment Rate Rising in HIV+ Without AIDS: CHARTER - written by Mark Mascolini - (07/22/10)
     
  10876. IAC: Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (07/22/10)
     
  10877. IAC: Once-Daily Maraviroc (MVC) + Atazanavir/Ritonavir(ATV/r) vs. Emtricitabine/Tenofovir(TDF/FTC) + ATV/r in Treatment Naïve Patients: A Week 24 Planned Interim Analysis - (07/22/10)
     
  10878. IAC: The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (ATV+RAL) in Treatment-Naïve HIV-Infected Subjects - (07/22/10)
     
  10879. IAC:VERxVE study demonstrates efficacy and safety of 400mg once daily nevirapine (Viramune) extended release (NVP XR) formulation - BI press release - (07/22/10)
     
  10880. IAC: Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients - (07/22/10)
     
  10881. IAC: TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures - written by Mark Mascolini - (07/22/10)
     
  10882. IAC: Once-Daily S/GSK1349572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING-1 (ING112276) - (07/22/10)
     
  10883. IAC: S/GSK1349572 Works Fast in Phase 2 Study of Treatment Naive - written by Mark Mascolini - (07/22/10)
     
  10884. IAC: Nadir CD4 Count Strongly Predicts Neurocognitive Impairment in CHARTER - written by Mark Mascolini - (07/22/10)
     
  10885. IAC: Two to Three Times Higher Hodgkin Risk in First Months of ART - written by Mark Mascolini - (07/22/10)
     
  10886. IAC: Five Times Higher Risk of Intracranial Hemorrhage With HIV - written by Mark Mascolini - (07/22/10)
     
  10887. IAC: Types of Kidney Problems May Be Changing as HAART Era Matures - written by Mark Mascolini - (07/22/10)
     
  10888. IAC: Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor (NRTI) Selection on 96 Week Bone Mineral Density (BMD): Results from ACTG 5142 - (07/22/10)
     
  10889. IAC: Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients - (07/22/10)
     
  10890. IAC: METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks - (07/22/10)
     
  10891. IAC: Lipodystrophy and Inflammation Predict Grip Strength in HIV-Infected Men: the MACS Body Composition Sub-study - (07/22/10)
     
  10892. IAC: New, Deadly, but Rare Encephalitis Described in 14 French HIV Patients - written by Mark Mascolini - (07/21/10)
     
  10893. Tesamorelin FDA Briefing Document pdf attached - (07/21/10)
     
  10894. IAC: Low CD4s Trump Other MI Risk Factors in 6500-Person US Analysis - written by Mark Mascolini - (07/21/10)
     
  10895. IAC: CDC Study Confirms Rising Non-AIDS Cancer Rate in With HIV - written by Mark Mascolini - (07/21/10)
     
  10896. IAC: Cancer Rates in HIV+ in Atlanta: 'Non-AIDS Cancers Found 10 to 15 Years Earlier in People With HIV' - written by Mark Mascolini - (07/21/10)
     
  10897. IAC: A Year of ART Does Not Ease Anal Cancer Harbingers in Men - written by Mark Mascolini - (07/21/10)
     
  10898. IAC: Higher CD4 Count at Lung Cancer Diagnosis Predicts Survival - written by Mark Mascolini - (07/21/10)
     
  10899. IAC: HCV SVR Rate Higher With Nevirapine Than Lopinavir in Multicenter Study - written by Mark Mascolini - (07/21/10)
     
  10900. IAC: Congresswoman Barbara Lee Calls for $6 Billion for Global Fund - (07/21/10)
     
  10901. IAC: S/GSK1265744: A Next Generation Integrase Inhibitor (INI) with Activity Against Raltegravir-Resistant Clinical Isolates - (07/21/10)
     
  10902. IAC: Activity of the Next Generation Integrase Inhibitor S/GSK1349572 and Two First Generation Inhibitors Across a Broad Panel of HIV Subtype Isolates in PBMCs and MDMs - (07/21/10)
     
  10903. IAC: HIV Integrase Genotypic and Phenotypic Changes Between Day 1 and Day 11 in Subjects with Raltegravir Resistant HIV Treated with S/GSK1349572: Results of VIKING Study - (07/21/10)
     
  10904. IAC: 'Start HIV Therapy Earlier, IAS-USA Panel Recommends' - (07/20/10)
     
  10905. IAC: Bill Clinton on HIV/AIDS: Much More Needs to be Done - (07/20/10)
     
  10906. IAC: Bill Clinton, Gates: Fight AIDS more efficiently - (07/20/10)
     
  10907. IAC: Tenofovir AIDS gel protects women in study - (07/20/10)
     
  10908. IAC: Tenofovir Gel found to reduce AIDS risk in women - (07/20/10)
     
  10909. IAC: New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10)
     
  10910. IAC: New Tenofovir Gel Cuts Risk of HIV Infection for Women in Study - WSJ Report - (07/20/10)
     
  10911. IAC: Number Globally of HIV-positive in treatment rose by a quarter last year - (07/20/10)
     
  10912. IAC: Gays With Well-Controlled HIV Not Protected From Lymphogranuloma Venereum - written by Mark Mascolini - (07/20/10)
     
  10913. IAC: Long-Term Nonprogression Rare and Transient in Large CASCADE Cohort Study - written by Mark Mascolini - (07/20/10)
     
  10914. IAC: Liver Death Rate in Spain Similar With and Without HIV, But Only in HCV-Negative - written by Mark Mascolini - (07/20/10)
     
  10915. IAC: Death Rate Has Not Dropped in Certain Disadvantaged HIV+ US Groups - written by Mark Mascolini - (07/20/10)
     
  10916. IAC: Fatal Liver Failure Still 8 Times More Common With HIV in Large US Cohort - written by Mark Mascolini - (07/20/10)
     
  10917. IAC: HCV in HIV-Positives Raises Osteoporotic Fracture Risk Over 40% - written by Mark Mascolini - (07/20/10)
     
  10918. IAC: Once- Versus Twice-Daily Raltegravir When Switching From a PI - written by Mark Mascolini - (07/19/10)
     
  10919. IAC: Antioxidants With ART Boost CD4s, Ease Mitochondrial Damage in 8-Week Trial - written by Mark Mascolini - (07/19/10)
     
  10920. IAC: Trading a Ritonavir-Boosted PI for Twice-Daily Raltegravir in SPIRAL - written by Mark Mascolini - (07/19/10)
     
  10921. IAC: Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint - Abbott Press Release - (07/19/10)
     
  10922. IAC: Impact of prior NRTI failure in the ODIS trial, a study conducted in HIV+ patients with undetectable viremia on protease inhibitors who switched to raltegravir qd versus bid - (07/19/10)
     
  10923. IAC: TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection - Inflammation - (07/19/10)
     
  10924. IAC: Tenofovir Gel Reduced HIV Transmission - pdf of Science Mag publication attached - (07/19/10)
     
  10925. IAC: First-Line Lopinavir/r/Raltegravir (With No NRTIs) in Treatment Naive - written by Mark Mascolini - (07/19/10)
     
  10926. IAC: Activity of Next Generation Integrase Inhibitor (INI) S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961) - (07/19/10)
     
  10927. IAC: Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) Demonstrated Similar Antiviral Efficacy and Safety as LPV/r Combined with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naïve HIV-1-Infected Subjects: PROGRESS 48 week results (07/19/10)
     
  10928. IAC: Raltegravir Resistance Pattern Critical in Early Response to S/GSK1349572 - written by Mark Mascolini - (07/19/10)
     
  10929. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection - Editorial Review - (07/19/10)
     
  10930. Untreated HIV: harmful even at high CD4 cell counts - Editorial - 'When To Begin HAART' - (07/19/10)
     
  10931. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per µL in Europe and North America: a pooled cohort observational study - (07/19/10)
     
  10932. IAC: New Guidelines Urge Earlier Therapy for HIV Patients - (07/19/10)
     
  10933. IAC: Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study - (07/19/10)
     
  10934. IAC: AIDS group fears annual HIV costs may hit $35 bln - (07/19/10)
     
  10935. IAC: HIV/AIDS numbers from around the world - (07/19/10)
     
  10936. IAC: CDC Study Reports Poverty Among Minorities Doubles HIV Infection Rate - (07/19/10)
     
  10937. IAC: Julio Montaner AIDS Conference Chief Lashes Out At World Leaders for Not Funding Global HIV - (07/19/10)
     
  10938. IAC: 18th Int'l AIDS Conference opens in Vienna - (07/19/10)
     
  10939. IAC: World AIDS Conference (IAC) Opens -to hear progress on drugs, money worries - (07/19/10)
     
  10940. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes - (07/15/10)
     
  10941. Early vs Standard HAART Start in Haiti Randomized Study NEJM - pdf attached - (07/15/10)
     
  10942. Alzheimer disease and HIV A tangled story - Editorial - (07/15/10)
     
  10943. Geron Provides Update on Telomerase Anti-Aging Therapy Activation Program - (07/15/10)
     
  10944. HIV & Alzheimers: are HIV+ At Greater Risk for Alzheimers - pdf full text attached - (07/14/10)
     
  10945. HIV/Aging & Antiaging Therapy - (07/12/10)
     
  10946. CD4 Predicts Cardiovascular Disease (CVD), nadir cd4 too perhaps - (07/12/10)
     
  10947. Model Forecasting Test & Treat Impact - CID August 2010 - pdf attached - (07/12/10)
     
  10948. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients - pdf of full text attached - (07/12/10)
     
  10949. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors - (07/10/10)
     
  10950. NIH-Led Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells - 2 pdfs attaced of both Science mag published reports - (07/10/10)
     
  10951. HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals - Review - pdf attached - (07/10/10)
     
  10952. Advance in Quest for HIV Vaccine - (07/10/10)
     
  10953. Inflammation Predicts Mortality in FRAM - (07/08/10)
     
  10954. Telomere Length and Risk of Incident Cancer and Cancer Mortality - (07/08/10)
     
  10955. Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs: Analysis of Claims Data - (07/07/10)
     
  10956. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment - (07/07/10)
     
  10957. Depressive symptoms and risk of dementia - The Framingham Heart Study - (07/07/10)
     
  10958. New Gene Therapy Zinc Fingers Research Published: 'doctors may someday control HIV virus using stem cells without using anti-retroviral drugs' - (07/07/10)
     
  10959. Raltegravir Switch from PI Effective - Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study - pdf attached - (07/05/10)
     
  10960. Long-term use of anabolic steroids associated with reduced LV ejection fraction - (07/04/10)
     
  10961. Neurological Symptoms-HIV ART Drug Resistance & Discordant CNS & Plasma Viral Load, Patients Suppressed on ART - pdf attached - (07/04/10)
     
  10962. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication - pdf of publication attached - (07/02/10)
     
  10963. Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia - (07/01/10)
     
  10964. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study - (06/30/10)
     
  10965. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy - (06/30/10)
     
  10966. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients - (06/30/10)
     
  10967. Immunosenescence and Vaccination - Commentary - (06/29/10)
     
  10968. Mechanisms of immunosenescence Short report - (06/29/10)
     
  10969. New Inhaled Insulin for Diabetes 2 - (06/25/10)
     
  10970. Hypertension Strongest Predictor of Stroke: and includes waist-to-hip ratio, regular exercise, smoking, diabetes, depression, stress - (06/23/10)
     
  10971. Diabetes & Liver Disease: does diabetes cause liver disease - pdf of article attached - (06/23/10)
     
  10972. Immunosenescence comes of age. Symposium on Aging Research in Immunology: The Impact of Genomics - (06/23/10)
     
  10973. Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes' - (06/23/10)
     
  10974. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation - (06/23/10)
     
  10975. Diabetes & Liver Disease: does diabetes cause liver disease - pdf of article attached - (06/22/10)
     
  10976. HIV-associated lipodystrophy: from fat injury to premature aging - Review - pdf of article attached - (06/22/10)
     
  10977. Mitochondrial Dysfunction in HIV+ CNS/Muscular Organ Systems Disorders in HIV+ Children, and perhaps related to accelerated aging in older HIV+ adults - (06/20/10)
     
  10978. ResisWksp: Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - poster - (06/18/10)
     
  10979. ResisWksp: Analysis of the HIV-1 gp120 V3 Loop at Screening for Treatment-Experienced Patients in the MOTIVATE Studies With CCR5-Tropic Virologic Failure - poster - (06/18/10)
     
  10980. ResisWksp: Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment "Deep" Sequencing Results - poster - (06/18/10)
     
  10981. ResisWksp: Long-Term Outcome of Individuals Experiencing a Phenotypic Switch in HIV-1 Co-receptor Use in the Merit Study - (06/18/10)
     
  10982. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era - (06/16/10)
     
  10983. ResisWksp: Intl Resistance Workshop Report by Mark Wainberg, PhD, McGill University, Montreal - (06/16/10)
     
  10984. Immunologic and Virologic Events in Early HIV Infection Predict Subsequent Rate of Progression - MAJOR ARTICLE - (06/11/10)
     
  10985. Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression - (06/11/10)
     
  10986. EACS: New EACS (European AIDS Clinical Society) HIV Guidelines: HIV treatment, comorbidities (prevention and management of metabolic diseases), management and treatment of chronic hepatitis B and C coinfection in HIV+
     
  10987. (Test & Treat) HIV Prevention, Diagnosis and Treatment A Best Practices Symposium at Albert Einstein School of Medicine, Bronx, NY -pdf attached
     
  10988. ResisWksp: Strong Inhibition of Wild-Type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572 - (06/15/10)
     
  10989. ResisWksp: Strong Inhibition of Wild-type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572, poster report: "S/GSK1349572 had stronger and faster binding to mutant IN than RAL" - (06/15/10)
     
  10990. ResisWksp: S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir when Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
     
  10991. ResisWksp: HIV Integrase Resistance Profiles and S/GSK1349572 Baseline Phenotypic Susceptibility for Subjects Experiencing Virologic Failure on Raltegravir (RAL) in the VIKING Study (ING112961) - (06/15/10)
     
  10992. ResisWksp: S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir When Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
     
  10993. ResisWksp: Structural Models of HIV-1 Integrase and DNA in Complex with S/GSK1349572, Raltegravir and Elvitegravir: Structure-based Rationale for INI Resistance Profiles - (06/15/10)
     
  10994. Study reveals promise for New/Improved HIV testing & Reporting Results on Internet - (06/15/10)
     
  10995. Common genetic determinants of vitamin D insufficiency: a genome-wide association study - (06/15/10)
     
  10996. A Finite Course of ART during Early HIV-1 Infection Modestly Delays Need for Subsequent ART Initiation: ACTG A5217, the SETPOINT Study - (06/12/10)
     
  10997. ResisWksp: Only Two Major PI Mutations (But No Resistance) in Darunavir Monotherapy Trial - written by Mark Mascolini - (06/12/10)
     
  10998. ResisWksp: US/Canadian HIV Transmission Clusters Largely Male, White, and Gay - written by Mark Mascolini - (06/12/10)
     
  10999. ResisWksp: Infection With 3TC/FTC Mutant Virus Favors Lower Pretreatment Viral Load - written by Mark Mascolini - (06/12/10)
     
  11000. ResisWksp: Treatment Success Rates High, Resistance Rates Lower, in France in 2009, but integrase resistance is present among failures - written by Mark Mascolini - (06/12/10)
     
  11001. ResisWksp: HIV CSF/Plasma Ratio and Genetic Distance in People With Neurologic Disorders - written by Mark Mascolini - (06/12/10)
     
  11002. ResisWksp: Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment Deep Sequencing Results - (06/11/10)
     
  11003. ResisWksp: Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - (06/11/10)
     
  11004. ResisWksp: Use of the Enhanced Sensitivity Tropism Assay (ESTA) to Predict On-Treatment Detection of CXCR4-using Virus and Impact on Virologic Outcomes in a Vicriviroc (VCV) Phase 2 Treatment Experienced Study (VICTOR-E1) - (06/11/10)
     
  11005. ResisWksp: Mutation Rate in Antiretroviral-Naive Falling in One US Patient Population (GSK studies in USA) - written by Mark Mascolini - (06/11/10)
     
  11006. ResisWksp: Are Single Transmitted Mutants the Tip of a Resistance Iceberg? - written by Mark Mascolini - (06/11/10)
     
  11007. ResisWksp: New Mutations Found in 43% of People With Low But Detectable Viral Loads - written by Mark Mascolini - (06/11/10)
     
  11008. ResisWksp: Study Clarifies Risk of Switch to Raltegravir From Suppressive PI - written by Mark Mascolini - (06/11/10)
     
  11009. ResisWksp: Truvada Protects Macaques From Rectal Exposure to FTC-Resistant Virus - written by Mark Mascolini - (06/11/10)
     
  11010. ResisWksp: Transmitted Resistance Imperils First-Line Response in 10,000-Person Study - written by Mark Mascolini - (06/11/10)
     
  11011. ResisWksp: "Deep" Sequencing Finds X4 Virus in Screening Samples of Maraviroc Failures - written by Mark Mascolini - (06/10/10)
     
  11012. ResisWksp: Pairwise Comparison of genotypic tropism prediction between one reference center and 10 European laboratories - (06/10/10)
     
  11013. ResisWksp: Better Etravirine Response Predicted After Efavirenz Than Nevirapine - written by Mark Mascolini - (06/10/10)
     
  11014. ResisWksp: Over Half of European Raltegravir Failures Without Apparent Integrase Mutations - written by Mark Mascolini - (06/10/10)
     
  11015. ResisWksp: GSK Integrase Following Raltergavir Use: When Is It Risky to Use S/GSK1349572 After Raltegravir? - written by Mark Mascolini - (06/10/10)
     
  11016. ResisWksp: Debate Follows Data on Genotypic Predictions of HIV Tropism - written by Mark Mascolini - (06/10/10)
     
  11017. Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1-Infected Subjects at 48 Weeks - (06/10/10)
     
  11018. The Effects of Opiate Use and Hepatitis C Virus Infection on Risk of Diabetes Mellitus in the Women's Interagency HIV Study: history of opiate use & HCV both increase risk for diabetes - (06/10/10)
     
  11019. Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials - (06/10/10)
     
  11020. ResisWksp: Resistance Emergence With Raltegravir Versus Efavirenz in Treatment Naive - written by Mark Mascolini - (06/10/10)
     
  11021. ResisWksp: Temporal Order of Resistance Emergence for Lamivudine/Emtricitabine, Efavirenz, and Raltegravir in Treatment-Naïve Patients - (06/10/10)
     
  11022. ResisWksp: Differing Integrase Dissociation Rates With S/GSK1349572 and Raltegravir - written by Mark Mascolini - (06/10/10)
     
  11023. Beyond Hemoglobin A1c-Need for Additional Markers of Risk for Diabetic Microvascular Complications - commentary - (06/08/10)
     
  11024. Does Lipoatrophy Persist ? - Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy - pdf attached (I suggest reading the pdf closely) - (06/07/10)
     
  11025. Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria - pdf full text attached - (06/07/10)
     
  11026. Circulating mitochondrial DAMPs cause inflammatory responses to injury - (06/07/10)
     
  11027. "mitochondria.....might initiate inflammation....mitochondria are probably released in patients with infectious disease" - (06/07/10)
     
  11028. Immunology & Mitochondria - Clinical immunology: Culprits with evolutionary ties - (06/07/10)
     
  11029. The Mitochondrion - A Trojan Horse That Kicks Off Inflammation? - (06/07/10)
     
  11030. Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study - (06/03/10)
     
  11031. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia - (06/03/10)
     
  11032. HIV-associated neurocognitive disorders: is there a hidden epidemic? - Editorial Comment - (06/03/10)
     
  11033. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening - (06/03/10)
     
  11034. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens - (06/03/10)
     
  11035. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers Free, Centralized Resource Designed to Help Overcome Some Barriers to Supportive Care - (05/30/10)
     
  11036. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada - (05/30/10)
     
  11037. The Gap between Human Immunodeficiency Virus (HIV) Infection and Advances in HIV Treatment - EDITORIAL - (05/30/10)
     
  11038. HPV and Therapeutic Vaccines: Where are We in 2010? - pdf attached - (05/29/10)
     
  11039. M2010: Press briefings at International Microbicides Conference, May 22-25 - (05/28/10)
     
  11040. M2010: Using ARVs to Prevent HIV Could Result in Drug Resistance if Routine Screening is Not Done New Research Presented at International Microbicides Conference - (05/28/10)
     
  11041. M2010: Researchers Searching For New Ways (micobicides: tablets, gel, film, vaginal rings) To Protect Women Against HIV - (05/28/10)
     
  11042. M2010: Lubricant Use May Raise HIV Infection Risk During Anal Sex - (05/28/10)
     
  11043. M2010: Vaginal gel with integrase inhibitor shows promise in monkeys; Darunavir/Maraviroc/NNRTis/Fusion - (05/28/10)
     
  11044. M2010: New ARTs Research Takes The Lead: HIV Microbicides Conference Report - (05/28/10)
     
  11045. In this analysis of almost 3400 HIV-1 serodiscordant heterosexual couples from seven African countries, ART use by the infected person was accompanied by a 92% reduction in risk of HIV-1 transmission to their partner - (05/28/10)
     
  11046. HIV drugs for treatment, and for prevention Editorial - (05/28/10)
     
  11047. Tesamorelin & IGF-1 Levels - (05/28/10)
     
  11048. Tesamorelin Reduces VAT: FDA Hearing - (05/28/10)
     
  11049. VOTE: 16-0 to recommend approval for tesamorelin - 'benefit outweighs risk' - (05/28/10)
     
  11050. FDA: Possible Fracture Risk with High Dose, Long-term Use of Proton Pump Inhibitors - (05/26/10)
     
  11051. New CVD Anti-Inflammation Drug: Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome - pdf full text attached - (05/26/10)
     
  11052. People with AIDS more likely to develop cancers, research says - (05/26/10)
     
  11053. Tesamorelin FDA Briefing Document pdf attached - (05/26/10)
     
  11054. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation - pdf attached - (05/25/10)
     
  11055. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals - (05/25/10)
     
  11056. Cholesterol Crystals Incite Inflammation in Coronary Arteries, Research Finds - (05/25/10)
     
  11057. Cholesterol crystals incite inflammation in coronary arteries - (05/25/10)
     
  11058. 11th Wrkshp Adverse Drug Reactions Omega-3 fatty acids supplementation may improve inflammation and endothelial activation in HIV-infected adults on stable antiretroviral therapy - (05/24/10)
     
  11059. 11th Wrkshp Adverse Drug Reactions Vitamin D and Efavirenz - (05/24/10)
     
  11060. 11th Wrkshp Adverse Drug ReactionsAssociation between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D - (05/24/10)
     
  11061. Study pinpoints how a normally defensive immune response can help HIV - journal commentary included - (05/24/10)
     
  11062. New Aging/HIV Study-blocking inflammation: Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease - (05/24/10)
     
  11063. Visceral fat is associated with lower brain volume in healthy middle-aged adults - (05/20/10)
     
  11064. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis - (05/18/10)
     
  11065. Low Vitamin D Levels Associated with Genotype 1, Fibrosis, Inflammation, with SVR, with waist circumference, Low HDL - (05/18/10)
     
  11066. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men - (05/17/10)
     
  11067. "A higher 25(OH)D (vit D) was associated with better dietary quality, lower %BF (body fat, central obesity), and lower number of MetD (metabolic disturbances including CRP, glucose)"...dairy in diet helped vit D levels - pdf attached - (05/13/10)
     
  11068. Denosumab Inhibits Bone Loss in RA - (05/13/10)
     
  11069. High Dose Vitamin D Increased Fall & Fracture Rate - (05/13/10)
     
  11070. High-Dose Vitamin D Supplementation, Too Much of a Good Thing? - (05/12/10)
     
  11071. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model - (05/12/10)
     
  11072. HPV, Genital wart virus may raise men's risk of HIV - link to free full text JID article - (05/12/10)
     
  11073. Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection - (05/07/10)
     
  11074. Inflammation and Complications of HIV Disease - EDITORIAL COMMENTARY - (05/07/10)
     
  11075. Pre-HAART Immune Activation Associated with Developing Cancers & Death - (05/07/10)
     
  11076. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection (and HCV) - (05/07/10)
     
  11077. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy - (05/05/10)
     
  11078. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations - (05/05/10)
     
  11079. Experimental NYC HIV Anal Cancer Screening Clinic - (05/05/10)
     
  11080. An aged T cell phenotype: A prognostic indicator in liver transplant recipients? Editorial - (05/03/10)
     
  11081. Features of immune senescence in liver transplant recipients with established grafts - (05/03/10)
     
  11082. ACCORD Glycemia (intensive control <6% A1C) Results Continue to Puzzle Editorial - (05/03/10)
     
  11083. Intensive Sugar Control HbA1C <6% Is Beneficial; Unsuccessful intensive therapy the culprit in ACCORD - (05/03/10)
     
  11084. (Low A1C <6% Reduces Death) Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial - (05/03/10)
     
  11085. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients - (04/29/10)
     
  11086. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis - (04/29/10)
     
  11087. PK Workshop: 11th International Workshop on Clinical Pharmacology of HIV Therapy (April 2010) Report - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (04/27/10)
     
  11088. Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial - (04/26/10)
     
  11089. Statins for Primary Prevention in Older Adults: Who Is High Risk, Who Is Old, and What Denotes Primary Prevention? Editorial - (04/26/10)
     
  11090. PK Workshop: Evaluation of Ritonavir-boosted Elvitegravir PK upon Co-administration with a Second Potent CYP3A inhibitor, Ketoconazole - (04/23/10)
     
  11091. PK Workshop: Metabolism and Excretion in Humans of the Pharmacoenhancer GS-9350 - (04/22/10)
     
  11092. Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody - (04/22/10)
     
  11093. PK Workshop: Relative Bioavailability and Pharmacokinetics of Darunavir when boosted with the Pharmacoenhancer GS-9350 versus Ritonavir - (04/21/10)
     
  11094. Sequential Acquisition of Human Papillomavirus (HPV) Infection of the Anus and Cervix: The Hawaii HPV Cohort Study. - (04/13/10)
     
  11095. HAART Reduces HPV - Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women - (04/13/10)
     
  11096. The role of secondary lymphatic tissue in immune deficiency of HIV infection, and aging - (04/13/10)
     
  11097. HIV Drug Resistance over the Long Haul - EDITORIAL COMMENTARY - (04/13/10)
     
  11098. PK Workshop: GRACE PK Study: Median (range) AUC12h and C0h were similar between women and men, and across black, Hispanic and white patients; Pharmacokinetic results from GRACE demonstrated no clinically relevant differences in exposure to DRV across a range of covariates, including sex, race/ethnicity, use of ETR, use of TDF, age, body weight and hepatitis B co-infection status - (04/13/10)
     
  11099. PK Workshop: Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone - (04/13/10)
     
  11100. PK Workshop: Higher Darunavir and Raltegravir Levels in Small Study of People With Liver Disease - written by Mark Mascolini - (04/13/10)
     
  11101. PK Workshop: Limited Risk of Serious Interaction Between TMC278 and Methadone - written by Mark Mascolini - (04/13/10)
     
  11102. PK Workshop: More Than Half in Barcelona HIV Clinic Use Alternative Therapies - written by Mark Mascolini - (04/13/10)
     
  11103. PK Workshop: Cell Levels of Once-Daily Raltegravir Adequate in Pilot Study - written by Mark Mascolini - (04/13/10)
     
  11104. PK Workshop: Older Age Impairs Kidney Function During Tenofovir Therapy - written by Mark Mascolini - (04/13/10)
     
  11105. PK Workshop: Etravirine Lowers Levels of S/GSK Integrase Inhibitor, But PIs Counter Effect - written by Mark Mascolini - (04/13/10)
     
  11106. PK Workshop: Darunavir Boosting with GS-9350 (Cobicistat) or Ritonavir in Healthy Volunteers - written by Mark Mascolini - (04/13/10)
     
  11107. PK Workshop: Extra CYP3A Inhibitor Has Modest Impact on Already-Boosted Elvitegravir - written by Mark Mascolini - (04/13/10)
     
  11108. PK Workshop: What Will It Take To Replace Ritonavir as the Prime PK Booster? ...Debate Ritonavir v GS9350 - written by Mark Mascolini - (04/13/10)
     
  11109. PK Workshop: Higher Atazanavir Levels Sync With Higher Raltegravir Levels in Dual Combo - written by Mark Mascolini - (04/13/10)
     
  11110. PK Workshop: The Effect of Food Intake on Reyataz Blood Levels - written by Mark Mascolini - (04/13/10)
     
  11111. PK Workshop: Darunavir Levels Not Tied to Detectable HIV RNA in MONET Monotherapy Trial - written by Mark Mascolini - (04/13/10)
     
  11112. PK Workshop: Darunavir Levels Not Affected by Gender, Race, or Age in GRACE Trial - written by Mark Mascolini - (04/13/10)
     
  11113. PK Workshop: Impact of Pravastatin on Raltegravir Levels in Healthy Volunteers - written by Mark Mascolini - (04/13/10)
     
  11114. PK Workshop: Efavirenz Troughs Higher in People Over 50 Years Old - written by Mark Mascolini - (04/13/10)
     
  11115. PK Workshop: Women With Tight HIV Control Have Higher Antiretroviral Troughs Than General Population - written by Mark Mascolini - (04/13/10)
     
  11116. Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials - (04/06/10)
     
  11117. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management - (04/06/10)
     
  11118. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients - (04/06/10)
     
  11119. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy - (04/06/10)
     
  11120. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience - (04/06/10)
     
  11121. CROI: HAART Reduces New Infections - Decreases in Community Viral Load Are Associated with a Reduction in New HIV Diagnoses in San Francisco (CROI) - (04/05/10)
     
  11122. Conspiracy Beliefs About HIV Are Related to Antiretroviral Treatment Nonadherence Among African American Men With HIV - (04/05/10)
     
  11123. 45% of Eligible Patients Receive HIV Drug Resistance Testing - (04/05/10)
     
  11124. The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART) - (04/05/10)
     
  11125. Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States - (04/05/10)
     
  11126. CROI: Prolonged Control of Viremia After Transfer of Autologous CD4 T Cells Genetically Modified with a Lentiviral Vector Expressing Long Antisense to HIV env (VRX496) - (04/04/10)
     
  11127. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function - (04/03/10)
     
  11128. Inflammation, CRP & new test (DTI, difussion tensor imaging) - Are white matter signal abnormalities clinically relevant? Editorial - (04/03/10)
     
  11129. Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome - (04/03/10)
     
  11130. Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis - (03/28/10)
     
  11131. Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss - (03/28/10)
     
  11132. Evolving Data about Subtrochanteric Fractures and Bisphosphonates-EDITORIAL - (03/25/10)
     
  11133. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur - (03/25/10)
     
  11134. NYS Guidelines recommendations on anal pap smears - (03/25/10)
     
  11135. CROI: HIV Persistence, Raltegravir/Maravoric Intensification, Immunology: Some Impressions from San Francisco: CROI 2010 - written by David Margolis MD University of North Carolina - (03/24/10)
     
  11136. MRSA Risk 6-Fold Higher in HIV+: Community-Associated Methicillin-Resistant Staphylococcus aureus and HIV: Intersecting Epidemics - (03/24/10)
     
  11137. CROI: Management of Treatment-Experienced Patients: darunavir, raltegravir, raltegravir intensification, maraviroc, vicriviroc - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida - (03/23/10)
     
  11138. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects - pdf attached - (03/22//10)
     
  11139. Short-Course Raltegravir Intensification Does Not Reduce Persistent Low-Level Viremia in Patients with HIV-1 Suppression during Receipt of Combination Antiretroviral Therapy - (03/22/10)
     
  11140. Benefit or Toxicity from Neurologically Targeted Antiretroviral Therapy? EDITORIAL COMMENTARY - (03/22/10)
     
  11141. Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1-Infected Individuals Commencing cART? A Randomized, Controlled Study - (03/22/10)
     
  11142. CROI: Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)
     
  11143. CROI: Antiviral and Immunological Effects of Intensification of Suppressive ART with Maraviroc, a CCR5 Antagonist - (03/22/10)
     
  11144. CROI: No Evolution of HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of Raltegravir-containing Therapy in Patients with Controlled Viremia: A Sub-study of the Randomized EASIER-ANRS 138 Trial - (03/22/10)
     
  11145. CROI: Effect of the Intensification with a CCR5 Antagonist on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - (03/22/10)
     
  11146. CROI: No Decrease in Intrathecal Immunoactivation or Residual CSF Viremiaduring Treatment Intensification in Patients on Stable ART - (03/22/10)
     
  11147. CROI: Quantification of Persistent Viremia in Cerebrospinal Fluid and Plasma: Initial Experience in a Raltegravir Intensification Study - (03/22/10)
     
  11148. CROI: Differences in HIV Burden throughout the Gut of Patients on Suppressive ART: Implications for HIV Persistence - (03/21/10)
     
  11149. CROI: HIV-1 Replication and Immune Dynamics Are Impacted by Raltegravir Intensification of HAART-suppressed Patients - (03/21/10)
     
  11150. CROI: Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response - (03/21/10)
     
  11151. Test & Treat-what is the impact? Can antiretroviral therapy eliminate HIV transmission? The lancet 2009 - (03/20//10)
     
  11152. Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection - (03/19//10)
     
  11153. CROI: Efficacy of Intermittent Prophylaxis with Tenofovir and Emtricitabine against Rectal SHIV Transmission in Macaques and Relationship to Systemic and Mucosal Drug Levels - (03/19/10)
     
  11154. CROI: Protection of Rhesus Macaques from Vaginal Infection by Maraviroc (solution), an Inhibitor of HIV-1 Entry via the CCR5 Co-receptor - (03/19/10)
     
  11155. CROI: Clinical Pharmacology at CROI 2010: Advances in Antiretroviral Discovery, Drug Interactions, Compartmental Penetration, and Adverse Reactions - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center- (03/14/10)
     
  11156. CROI: CROI: Inflammation/activation linked to diseases of organ systems (heart, kidney, liver) & death in USA and now reported as well in Africa - HIV accelerated aging will be bigger problem in undeveloped countries - (03/18/10)
     
  11157. CROI: INFLAMMATORY MARKERS DURING TREATMENT OF OIs ARE PREDICTIVE OF LATE VIROLOGIC AND IMMUNOLOGIC RESPONSES: Sub-study of A5164 - (03/16/10)
     
  11158. CROI:Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large italian cohort - (03/15/10)
     
  11159. CROI: Bone/Osteoporosis/Vitamin D CROI 2010 Update - written by Michael Yin, MD MS Assistant Professor of Clinical Medicine Columbia University Medical Center New York, NY- (03/14/10)
     
  11160. Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study - (03/11/10)
     
  11161. CROI: Longitudinal Analysis of Bone Mineral Density in Aging Men With or at Risk for HIV Infection: heroin causes bone loss; accelerated bone loss progressed over 3 years in HIV+ - (03/10/10)
     
  11162. CROI: Changes in Bone Mineral Density: two-years follow-up of the ANRS CO3 Aquitaine Cohort - Bone Metabolism Evolves- in 11% from osteopenia to osteoporosis and to osteopenia, bone markers worsen in 41% - (03/10/10)
     
  11163. Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate - (03/09/10)
     
  11164. Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy - (03/09/10)
     
  11165. CROI: Non-AIDS-defining Events among HAART-treated Adults in an Urban US vs an Urban Sub-Saharan African Setting: 'high non-AIDS events rate in Africa' - (03/09/10)
     
  11166. CROI: Low CD4 Cell Count and Impaired Renal Function (eGFR) Are Independent Risk Factors for ARF (acute renal failure) in HIV-infected Patients - (03/09/10)
     
  11167. CROI: Prevalence of Hepatitis Coinfection among HIV-Infected Nigerian Children in the Harvard PEPFAR ART Program - (03/09/10)
     
  11168. CROI: Persistent Low-level Viremia Is Associated with Increased Risk of Virologic Failure and Mortality - (03/09/10)
     
  11169. CROI: Association of IL28B Haplotypes with Chronic HCV Infection in HIV/HCV Co-infected Individuals - (03/09/10)
     
  11170. CROI: Genetic Variation in IL28B and Treatment-induced Clearance of HCV in HCV/HIV Co-infected Patients - (03/09/10)
     
  11171. CROI: Sustained Virological Response to Interferon plus Ribavirin Reduces HIV Progression and Non-liver-related Mortality in Patients Co-infected with HIV and HCV - (03/09/10)
     
  11172. CROI: HIV Prevention at CROI 2010 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/07/10)
     
  11173. CROI: 5-Year Tenofovir Therapy Is Associated with Maintained HBV Response and Renal Toxicity in HIV/HBV Co-infected Patients - (03/06/10)
     
  11174. CROI: Determinants of Incident Chronic Kidney Disease in a Cohort of HIV-infected Patients with Free Access to Care - (03/06/10)
     
  11175. CROI: Predictors for Change in Estimated Glomerular Filtration Rate in HIV-infected Individuals with or without cART: The Swiss HIV Cohort Study - (03/06/10)
     
  11176. CROI: Improved Correlation of Coronary Atherosclerosis with Estimated Glomerular Filtration Rate Assessed with Chronic Kidney Disease Epidemiology Collaboration Equation than with MDRD and Cockcroft-Gault in HIV-infected Patients - (03/06/10)
     
  11177. CROI: HAART Is Associated with Improved Kidney Function in Patients with Impaired Kidney Function at Baseline but Was Associated with Slight Worsening of Kidney Function in Patients with Normal Baseline Kidney Function - (03/06/10)
     
  11178. CROI: Chronic Renal Failure in HIV-Infected Patients: Incidence and Risk Factors (ANRS CO3 Aquitaine Cohort, France) - (03/06/10)
     
  11179. CROI: Episodes of HIV Viremia and the Risk of Non-AIDS Events among Successfully Treated Patients (503) - (03/06/10)
     
  11180. HbA1C Predicts Diabetes & CVD: Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults - (03/05/10)
     
  11181. CROI: DNA Damage and p16-mediated Growth Arrest in HIV-1-specific CD38+ T Cells - (03/05/10)
     
  11182. CROI: Ritonavir and Lopinavir Boosted with Ritonavir Induce Endothelial dysfunction and Premature Senescence in Cultured Human Coronary Artery Endothelial Cells - (03/05/10)
     
  11183. CROI: In vitro Effect of CCR5 Antagonists on Innate Immune System: Maraviroc Inhibits the Migration of Neutrophils, Macrophages and Dendritic Cells - (03/05/10)
     
  11184. CROI: Vicriviroc Phase 3 at CROI 2010 - (03/05/10)
     
  11185. CROI: Plasma Levels of Soluble CD14 (activation marker) Predict Mortality in HIV Infection - (03/05/10)
     
  11186. CROI: Short-Term Raltegravir Monotherapy Does Not Predispose Patients to Develop RAL Resistance During Subsequent Combination Therapy: Analysis of Samples From Protocol 004 - (03/05/10)
     
  11187. CROI:Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth - (03/05/10)
     
  11188. CROI:Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patient - (03/04/10)
     
  11189. CROI: Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus - (03/04/10)
     
  11190. CROI: A Pharmacokinetic Comparison of Adult and Pediatric Formulations of Raltegravir (RAL) in Healthy Adults - (03/04/10)
     
  11191. CROI: Screening for Hepatocellular Carcinoma (HCC) in HIV/HCV-Coinfected Patients: Impact on Staging, Therapy, and Survival - (03/04/10)
     
  11192. CROI: Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naïve Patients infected with non-B HIV-1 subtypes - (03/04/10)
     
  11193. CROI: Determining HIV-1 Coreceptor Tropism Using PBMC Proviral DNA Derived from Aviremic Blood Samples, for Patients with Undetectable Viral Load - (03/04/10)
     
  11194. CROI: The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK - (03/04/10)
     
  11195. CROI: Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/04/10)
     
  11196. CROI: Effect of the Intensification with a CCR5 Antagonist Maraviroc on the Decay of the HIV-1 Latent Reservoir and Residual Viremia - reduced activation - (03/04/10)
     
  11197. CROI:Effect of CCL3L1 Copy Number Variation on CD4+ Cell Recovery in Treatment-Naïve Patients: 96-Week Results from the Maraviroc in Treatment-Naïve Patients (MERIT) Study - (03/04/10)
     
  11198. CROI: Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment-Experienced Patients Enrolled Into the MOTIVATE Studies and Who Received Maraviroc + Optimized Background Therapy - (03/03/10)
     
  11199. CROI:Population-based Sequencing of the V3-loop is Comparable to the Enhanced Sensitivity Trofile Assay (ESTA) in Predicting Virologic Response to Maraviroc of Treatment-naïve Patients in the MERIT Trial - (03/03/10)
     
  11200. CROI:Mechanisms of Virologic Failure With Maraviroc in Treatment-Naïve HIV-1-Infected Patients Through 96 Weeks - (03/03/10)
     
  11201. CROI:Large-Scale Application of "Deep" Sequencing Using 454 Technology to HIV Tropism Screening - (03/03/10)
     
  11202. CROI:HIV Did Not Worsen H1N1 Severity in Spanish Case-Control Study - written by Mark Mascolini - (03/03/10)
     
  11203. CROI:Failure to Respond to HBV Vaccine Linked to Higher Cancer Risk With HIV - written by Mark Mascolini - (03/03/10)
     
  11204. CROI:Prediction of X4-tropic Human Immunodeficiency Virus from Proviral Envelope Sequence in Patients with Suppressed Viral Load on Antiretroviral Therapy (ART). - (03/03/10)
     
  11205. CROI: Four Non-AIDS Cancers on the Rise With HIV in Big North American Cohort - written by Mark Mascolini - (03/03/10)
     
  11206. CROI:Correlation of Inflammatory Biomarkers with the Framingham Coronary Risk Score in Antiretroviral-naïve HIV-1 Infected Patients - (03/03/10)
     
  11207. CROI:Trends in Cumulative Incidence of Cancer among HIV-infected Patients in North America: high cancer rates in HIV+ - (03/03/10)
     
  11208. CROI: Prevalence (59%) and Correlates of Minor Neurocognitive Disorders in Asymptomatic HIV-infected Outpatients - (03/03/10)
     
  11209. CROI: Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve management of Hepatitis coinfection in HIV-Infected Patients? - written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/03/10)
     
  11210. CROI: The Kidney at CROI - written by Christina M. Wyatt, MD Assistant Professor, Medicine/ Nephrology Mount Sinai School of Medicine New York, NY - (03/03/10)
     
  11211. CROI: Chronic Inflammation in HIV: CROI 2010 - written by David H Shepp, MD Associate Professor of Medicine, Hofstra University School of Medicine Division of Infectious Diseases, North Shore University Hospital-Manhasset - (03/03/10)
     
  11212. CROI: Modest Lipid and Body Fat Changes With Raltegravir vs Efavirenz in 96-Week Trial - written by Mark Mascolini - - (03/02/10)
     
  11213. CROI: CDC Finds 1 in 6 Newly Diagnosed With HIV Had Resistant Virus in 2007 - written by Mark Mascolini - - (03/02/10)
     
  11214. CROI: Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: The EuroSIDA Study - abstract 107LB - (03/02/10)
     
  11215. CROI: Higher Levels of Heart Cell Peptide Tied to Cardiovascular Disease in SMART Study Patients - written by Mark Mascolini - (03/01/10)
     
  11216. CROI: D-Dimer But Not hsCRP Predicts Impending Cardiovascular Disease in Case-Control Study - written by Mark Mascolini - (03/01/10)
     
  11217. CROI:Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)
     
  11218. CROI:Risk of Non-AIDS Death in HIV/HCV-Coinfected People in SMART - written by Mark Mascolini - (03/01/10)
     
  11219. CROI: T cell Senescence and Proliferation Defects Persist in Treated HIV-infected Individuals Maintaining Viral Suppression and Are Associated with Poor CD4+ T Cell Recovery - (03/01/10)
     
  11220. CROI: Impact of CD38+ T Cell Activation on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating Antiretroviral Therapy - (03/01/10)
     
  11221. CROI: Valganciclovir Reduces CD38+ T Cell Activation among HIV-infected Patients with Suboptimal CD4+ T cell Recovery During Antiretroviral Therapy - (03/01/10)
     
  11222. CROI:CD4 at HAART Initiation Predicts Long Term CD4 Responses and Mortality from AIDS and non-AIDS Causes in the HIV Outpatient Study (HOPS) - (03/01/10)
     
  11223. CROI: Improved Genotypic Algorithm for Predicting Etravirine Susceptibility: Comprehensive List of Mutations Identified Through Correlation with Matched Phenotype - (03/01/10)
     
  11224. CROI:Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir when Combined in Treatment Experienced Patients: a Substudy of the ANRS 139 TRIO Trial - (03/01/10)
     
  11225. CROI: Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of Healthy Male Volunteers after Single and Multiple Dosing - (03/01/10)
     
  11226. CROI: Antiretrovirals For Prevention: tenofovir, FTC, maraviroc; rectal, vaginal, semen. - (03/01/10)
     
  11227. CROI:Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients - (03/01/10)
     
  11228. CROI: Effect of Raltegravir-containing Intensification on HIV burden and T cell Activation in the Gut of HIV+ Adults on Suppressive Antiretroviral Therapy (ART) - reduced activation - (03/01/10)
     
  11229. CROI:Nadir CD4 Count Under 350 Predicts Arterial Stiffness in Case-Control Study - written by Mark Mascolini - (02/28/10)
     
  11230. CROI: Sociobehavioral Factors Affect Clinical Outcomes Apart From HIV Factors in Swiss Cohort - written by Mark Mascolini - (02/28/10)
     
  11231. CROI:Darunavir Penetrates Semen Well With High Levels Through 24 Hours - written by Mark Mascolini - (02/28/10)
     
  11232. CROI: Darunavir Concentrations in Seminal Plasma in patients receiving Darunavir/ritonavir(DRV/r) monotherapy: a MONOI-ANRS 136 substudy - (02/28/10)
     
  11233. CROI: Darunavir Monotherapy Increased Limb Fat - Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial : Results at 48 weeks - (02/28/10)
     
  11234. CROI: Maraviroc Levels in Cerebrospinal Fluid (CSF) and Seminal Plasma from HIV-Infected Patients - (02/28/10)
     
  11235. CROI: Correlates of Time-to-Loss-of-Viral-Response in CSF and Plasma in the CHARTER Cohort: CPE Score predicts CSF suppression (02/27/10)
     
  11236. CROI: Neuropsychological Performance is Better in HIV-Infected Subjects Treated with Neuroactive HAART (02/27/10)
     
  11237. CROI: Plasma HIV Load Strongest Predictor of CSF Load in CHARTER Cohort - written by Mark Mascolini - (02/26/10)
     
  11238. CROI: Early Initiation of Antiretroviral Therapy in HIV-Infected Individuals Is Associated with Reduced Arterial Stiffness: a low nadir CD4+ T-cell counts are associated with arterial stiffness as assessed by Aix and PWV - (02/26/10)
     
  11239. CROI:Inflammation Is Associated with Endothelial Dysfunction Among Individuals with Treated and Suppressed HIV Infection - (02/26/10)
     
  11240. CROI:High Prevalence of Severe Vitamin D Deficiency in cART Naïve and Successfully Treated Swiss HIV Patients - (02/26/10)
     
  11241. CROI: Vitamin D Deficiency and Bacterial Vaginosis among HIV-infected and -uninfected Women in the United States - (02/26/10)
     
  11242. CROI:Assessment of Vitamin D Levels Among HIV-infected Persons in the Study To Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) - (02/26/10)
     
  11243. CROI: The Discovery of S/GSK1349572: A Once Daily Next Generation Integrase Inhibitor with a Superior Resistance Profile - (02/25/10)
     
  11244. CROI: Positive HBV Vaccine Response Halves HIV Progression and Death Risk in US Military - written by Mark Mascolini - (02/25/10)
     
  11245. CROI: Cell Studies Point to Antiinflammatory Activity of Maraviroc - written by Mark Mascolini - (02/25/10)
     
  11246. CROI: Elvucitabine Versus 3TC in First-Line Regimens for 96 Weeks - see slides from poster below - written by Mark Mascolini - (02/25/10)
     
  11247. CROI:Early Antiretrovirals in People Diagnosed With AIDS May Quell Inflammation Faster - written by Mark Mascolini - (02/25/10)
     
  11248. CROI: The US Epidemic - Disparities in HIV Disease for African-Americans (02/25/10)
     
  11249. CROI:Maraviroc (MVC) Intensification for Suboptimal CD4+ Response Despite Sustained Virologic Suppression: ACTG 5256 (02/25/10)
     
  11250. CROI:CNS Toxicity of Antiretroviral Drugs (02/25/10)
     
  11251. CROI:Inflammation and Mortality in HIV-infected Adults: Analysis of the FRAM Study Cohort (02/25/10)
     
  11252. CROI:Effect of Atazanavir and Atazanavir/Ritonavir on the Pharmacokinetics of the Next Generation Integrase Inhibitor, S/GSK1349572 (02/25/10)
     
  11253. CROI:S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor and Demonstrates a Superior Resistance Profile Substantiated with 60 Integrase Mutant Molecular Clones (02/23/10)
     
  11254. CROI:Worse Neuropsych Scores Tied to Viral Rebounds in CSF and Plasma; CPE Score Tied to CSF Rebound - written by Mark Mascolini - (02/23/10)
     
  11255. CROI:Low CD4 Nadir Predicts Neurocognitive Problems Despite Good CD4 Gains - written by Mark Mascolini - (02/23/10)
     
  11256. CROI: Metabolic complications of HIV infection at CROI 2010 (Feb 16-19) -Pablo Tebas, University of Pennsylvania. Philadelphia.- (02/23/10)
     
  11257. CROI:Standard First Regimens Less Effective in US Blacks Than Others - written by Mark Mascolini - (02/23/10)
     
  11258. Activation of CD38 T Cells Predicts Progression of HIV Infection in Women Coinfected with Hepatitis C Virus - (02/24/10)
     
  11259. Can the further clinical development of bevirimat be justified? editorial - (02/24/10)
     
  11260. CROI:ART Improves Cerebral Blood Flow--But Not to Levels in HIV-Negatives - written by Mark Mascolini - (02/23/10)
     
  11261. CROI: Bone & Limb Fat Outcomes in ACTG5202- More Bone Loss With TDF/FTC Than ABC/3TC - written by Mark Mascolini - (02/23/10)
     
  11262. CROI:Bone Fractures at CROI 2010 - see slides below - (02/23/10)
     
  11263. CROI:Elevated Cancer Risks Remains in HAART Era: increasing mortality risk due to non-AIDS cancers- increased risk for these no-AIDS cancers - anal, liver, Hodgkin lymphoma, lung - (02/23/10)
     
  11264. CROI:Recent CD4 Predicts Risk for Cancers; Increased Risk for Anal/liver/Hodgkin Lymphoma/oral cavity pharynx cancers in HIV+ - (02/23/10)
     
  11265. CROI: Mixed Findings on Value of Brain-Penetrating Antiretroviral Scores - written by Mark Mascolini - (02/22/10)
     
  11266. CROI: Bone Disease: Risk Factors - (02/22/10)
     
  11267. CROI: Raltegravir Concentrations in the Cervicovaginal Compartment Exceed the Median Inhibitory Concentration in HIV-1-infected Women Treated with a Raltegravir-containing Regimen: DIVA 01 Study - (02/22/10)
     
  11268. CROI: Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients - (02/22/10)
     
  11269. CROI: Rapid Progression of Atherosclerosis at the Carotid Bifurcation Is Linked to Inflammation in HIV-infected Patients - "These data strongly suggest that inflammation contributes to the higher risk of atherosclerosis noted in HIV-infected persons." - (02/22/10)
     
  11270. CROI: CROI (2010 Feb 16-19) Selected Neurocognitive Abstracts - (02/22/10)
     
  11271. CROI: Vitamin D Deficiency Prevalence and Associations - (02/22/10)
     
  11272. CROI: A 48 week randomized study of uridine supplementation versus switch to tenofovir on limb fat, mitochondrial function, inflammation, and bone mineral density in HIV lipoatrophy - (02/22/10)
     
  11273. CROI: Uridine supplementation in the management of HIV lipoatrophy: Results of ACTG 5229 - (02/22/10)
     
  11274. CROI: Safety and Efficacy of TBR-652, a Chemokine Receptor 5 (CCR5) Antagonist, in HIV-1-Infected, Antiretroviral (ARV) Treatment-Experienced, CCR5 Antagonist-Naïve Patients - (02/22/10)
     
  11275. CROI: Discovery of Potent HIV-1 Capsid Assembly Inhibitors - (02/22/10)
     
  11276. CROI: T-cell Senescence and T-cell Activation Predict Carotid Atherosclerosis in HIV-infected Women - (02/22/10)
     
  11277. CROI: T-Cell Activation and Senescence Linked to Carotid Lesions in HIV+ Women - written by Mark Mascolini - (02/21/10)
     
  11278. CROI: Heart Risk Factors Tied to Neurocognitive Skills in SMART Substudy - written by Mark Mascolini - (02/21/10)
     
  11279. CROI:Baseline Liver Disease is Independently Associated with Risk of Death among HIV/HCV co-infected Adults with Histologic Staging - (02/20/10)
     
  11280. CROI:Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation in Children 6-11 Years - (02/20/10)
     
  11281. CROI:High Triglycerides Independently Raise MI Risk in DAD Study - written by Mark Mascolini - (02/20/10)
     
  11282. CROI: Three Years With More Than 500 CD4s Normalizes Mortality in HIV+ Men - written by Mark Mascolini - (02/20/10)
     
  11283. CROI:Life Expectancy Approaches Normal in Dutch Without HIV Symptoms - written by Mark Mascolini - (02/20/10)
     
  11284. CROI: Chronic HIV and HCV Swell Stroke Risk in Veterans Aging Cohort - written by Mark Mascolini - (02/20/10)
     
  11285. CROI: Fast ART in Late Disease Means Slower Progression in Europe and Canada - written by Mark Mascolini - (02/20/10)
     
  11286. CROI:Heart Risk Falls With Time Since Quitting Smoking in DAD - written by Mark Mascolini - (02/20/10)
     
  11287. CROI: Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up - (02/20/10)
     
  11288. CROI:Chronic kidney disease and exposure to ARTs in a large cohrt with long-term follow-up: EuroSida - (02/20/10)
     
  11289. CROI: Bone & Limb Fat Outcomes in ACTG5202 Substudy: abacavir/3TC, tenofivir/FTC, efavirenz, atazanavir/r - (02/20/10)
     
  11290. CROI: Inflammation and Fibrosis Markers Tied to AIDS or Death After Good Virologic Response - written by Mark Mascolini - (02/19/10)
     
  11291. CROI:Inflammation Tied to Endothelial Dysfunction Despite Tight HIV Control - written by Mark Mascolini - (02/19/10)
     
  11292. CROI:Antiretroviral Risk Factors for Kidney Disease in EuroSIDA: Tenofovir Is Not Alone - written by Mark Mascolini - (02/19/10)
     
  11293. CROI:Most Non-AIDS Cancers Not Diagnosed at Earlier Age in People With AIDS - written by Mark Mascolini - (02/19/10)
     
  11294. CROI:HIV Load Tied to Fibrosis Signal in Women Without Hepatitis or Alcohol Abuse - written by Mark Mascolini - (02/19/10)
     
  11295. CROI: QUAD Four-in-One Pill as Strong as Atripla, But a Kidney Concern Arises - written by Mark Mascolini - (02/18/10)
     
  11296. CROI: Maraviroc Does Not Boost Stalled CD4s in Virologically Suppressed People - written by Mark Mascolini - (02/18/10)
     
  11297. CROI: Vicriviroc Does Not Outdo Placebo Regimen in Phase 3 Trials - written by Mark Mascolini - (02/18/10)
     
  11298. CROI: Older Age, Lower CD4 Nadir, NNRTI Use Predict Slow CD4 Recovery in ATHENA - written by Mark Mascolini - (02/18/10)
     
  11299. CROI: High Rate of Coronary Artery Problems in Young People Tied to TDF/FTC - written by Mark Mascolini - (02/18/10)
     
  11300. CROI: Low-Level Viremia Quadruples Death Risk in Canadian Cohort Study - written by Mark Mascolini - (02/18/10)
     
  11301. CROI: Side Effect and CD4 Differences in Four ACTG 5202 Arms at 96 Weeks - written by Mark Mascolini - (02/18/10)
     
  11302. CROI: RNA Spikes Predict Heart Disease, CD4s Predict Liver and Kidney Disease - written by Mark Mascolini - (02/18/10)
     
  11303. CROI: ODIN: efficacy and safety at 48 weeks of once-daily versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients with no darunavir resistance-associated mutations - (02/18/10)
     
  11304. CROI: Bristol-Myers Squibb Media Statement on ACTG 5202 - (02/18/10)
     
  11305. CROI: ACTG5202 - (02/11/10)
     
  11306. CROI: New Data on ISENTRESS (raltegravir) Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) - Merck announcement - (02/18/10)
     
  11307. CROI: Bristol-Myers Squibb Media Statement on ACTG 5202 - (02/18/10)
     
  11308. CROI: The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of Virologic Suppression and GS-9350 is an Effective Booster - (02/18/10)
     
  11309. Aciclovir reduced risk of HIV-1 disease progression by 16% - (02/15/10)
     
  11310. Treating HIV infection with drugs for HSV-2 infection? Commentary - (02/15/10)
     
  11311. Early Immune Senescence in HIV Disease - (02/15/10)
     
  11312. Barriers To Retention in Care in HIV and HCV - (02/10/10)
     
  11313. FDA approves expanded rosuvastatin label, Includes CRP - (02/10/10)
     
  11314. Neurologic Disease Despite Undetectable Viral Load & The Use of Drugs That Penetrate Well the CSF - pdf of full article attached - (02/08/10)
     
  11315. Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension - pdf attached - (02/08/10)
     
  11316. HIV Brain Impairment - (02/08/10)
     
  11317. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis - (02/08/10)
     
  11318. C-reactive protein and cardiovascular risk: more fuel to the fire - Comment - (02/08/10)
     
  11319. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero - (02/08/10)
     
  11320. Immunosupportive therapies in aging - pdf attached - (02/05/10)
     
  11321. The rate of mother-to-child HIV transmission among infants is 23 times higher for blacks than whites, the CDC reported. - (02/05/10)
     
  11322. Bone Loss in HIV+ Premenopausal Women & Fracture Risk - (02/04/10)
     
  11323. Protein in Urine Presages More Severe Problems - free full text link below - (02/04/10)
     
  11324. Hepatitis C and the Risk of Kidney Disease and Mortality in Veterans With HIV: "veterans coinfected with HCV have significantly higher rates of CKD and mortality" - (02/04/10)
     
  11325. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women (and men) - (01/29/10)
     
  11326. NYS AIDS Institute guidelines on Acute HIV Seroconversion Updated Jan 2010 - (01/28/09)
     
  11327. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV - Workshop report - (01/28/10)
     
  11328. Life Expectancy & Comorbidities in HIV: - (01/27/09)
     
  11329. Diagnosis and management of vitamin D deficiency - (01/27/09)
     
  11330. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study - (01/27/09)
     
  11331. Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings - (01/27/09)
     
  11332. The anal Pap test as a screening tool- EDITORIAL - (01/27/09)
     
  11333. Kidney function and the risk of cardiovascular events in HIV-1-infected patients - (01/27/09)
     
  11334. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor and HIV protease inhibitors - (01/27/09)
     
  11335. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users - (01/27/09)
     
  11336. Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection - (01/27/09)
     
  11337. Vicriviroc Effective in Treatment-Experienced Patients in Phase 2 Study VICTOR-E1 - (01/26/09)
     
  11338. Proinflammatory IL-18 Increased in HIV+ Despite HAART - (01/26/09)
     
  11339. Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection - (01/26/09)
     
  11340. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters in SMART - (01/25/09)
     
  11341. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction - (01/25/09)
     
  11342. HIV Infection and Aging Independently Affect Brain Function as Measured by Functional Magnetic Resonance Imaging - BRIEF REPORT - (01/25/09)
     
  11343. Estimating the proportion of patients infected with HIV who will die of comorbid diseases - pdf attached - (01/20/09)
     
  11344. Fish Oil Slows Telomere Aging - (01/20/09)
     
  11345. Hormonal Contraception and Metabolic Outcomes in Women With or at Risk for HIV Infection - (01/19/09)
     
  11346. HIV Life Expectancy Study Published - pdf attached - (01/19/09)
     
  11347. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies - (01/19/09)
     
  11348. Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV-Infected Individuals during the Past 20 Years - (01/17/09)
     
  11349. Aerobic Exercise Improved Cognitive Function in Older Adults with Mild Cognitive Impairment - (01/17/09)
     
  11350. Moderate Mid-Life Exercise Prevents Mild Cognitive Impairment - (01/17/09)
     
  11351. Will HIV Drug Resistance Rates Increase? Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection - (01/17/09)
     
  11352. Treatment of HIV-Related Inflammatory Cerebral Cryptococcoma with Adalimumab - brief report - (01/17/09)
     
  11353. Quality-Of-Life Predicts Survival in HIV: HIV & aging - (01/17/09)
     
  11354. The MONET trial: darunavir/ritonavir (monotherapy) with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml - (01/16/09)
     
  11355. Visceral Fat Causes Inflammation and Cytokines Leading To Bone Loss - (01/16/09)
     
  11356. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men - (01/15/09)
     
  11357. Antihypertensive agents and prevention of dementia - Editorial - (01/14/09)
     
  11358. Hypertension Medications Use To Prevent Dementia & Alzheimer's - (01/14/09)
     
  11359. Study: Certain hypertension drugs may reduce Alzheimer's risk - (01/14/09)
     
  11360. Raltegravir SWITCHMRK Study Published in The Lancet jan 13 2010 - publication pdf attached - (01/14/09)
     
  11361. Association of C-Reactive Protein With Cognitive Impairment - (01/13/09)
     
  11362. GS-9148 Nucleotide Active Against Resistance - (01/13/09)
     
  11363. Chloroquine To Block Immune Activation - pdf attached - (01/13/09)
     
  11364. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study - BMJ Jan 2010 - (01/12/09)
     
  11365. Update on HIV Eradication.... Report from the 4th HIV Persistence Intl Wksp (Dec 8-11 2009, David Margolis, MD - written by David Margolis MD, University of North Carolina at Chapel Hill - (01/12/09)
     
  11366. Investigational HIV agents for salvage - (01/11/09)
     
  11367. HIV-Infected Postmenopausal Women at High Risk for Bone Fractures - pdf publication attached - (01/11/09)
     
  11368. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/10/09)
     
  11369. Cardiac Risk: Not So Simple - EDITORIAL COMMENTARY D.A.D Study - (01/10/09)
     
  11370. Pioglitazone Compared with Metformin Increases Pericardial Fat Volume in Patients with Type 2 Diabetes Mellitus - (01/10/09)
     
  11371. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes - publication pdf attached - (01/10/09)
     
  11372. Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients - (01/10/09)
     
  11373. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/07/09)
     
  11374. Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral Therapy - (01/07/09)
     
  11375. hsCRP/inflammation & CVD in Patients with with low Framingham risk score & median CD4 of 500 & <50 HIV RNA - (01/07/09)
     
  11376. (EPO) Erythropoiesis-Stimulating Agents - Time for a Reevaluation - (01/07/09)
     
  11377. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa - (01/05/09)
     
  11378. Many Americans Have Pre-Diabetes and Should Be Considered for Metformin Therapy - (01/05/09)
     
  11379. Delay in Diagnosis of Diabetes Is Not the Patient's Fault - (01/05/09)
     
  11380. Comparison of A1C and Fasting Glucose Criteria to Diagnose Diabetes Among U.S. Adults - (01/05/09)
     
  11381. CD4 Recovery Severely Blunted After HAART Treatment Interruption - (01/05/09)
     
  11382. CCR5 Deficiency Is a Risk Factor for Early Clinical Manifestations of West Nile Virus Infection but not for Viral Transmission - (12/29/09)
     
  11383. Double-Edged Genetic Swords and Immunity: Lesson from CCR5 and Beyond EDITORIAL COMMENTARY - (12/29/09)
     
  11384. Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients - (12/29/09)
     
  11385. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (12/29/09)
     
  11386. Bypass Anemia Drugs in Chronic Kidney Disease, Expert Says - (12/29/09)
     
  11387. Treatment of Anemia in Chronic Kidney Disease - Strategies Based on Evidence EDITORIAL - (12/29/09)
     
  11388. Gender & Racial Differences in Discontinuation of HAART JAIDS Nov 2009 - (12/23/09)
     
  11389. Factors Associated with HCV Transmission from Male to Female with No IDU History in WIHS - (12/23/09)
     
  11390. Enhanced Reyataz & Efavirenz Co-Pay Benefit Program - (12/21/09)
     
  11391. Testosterone: More Is Not Always Better - EDITORIAL - (12/21/09)
     
  11392. Thyroid Function and Longevity: New Insights into an Old Dilemma - EDITORIAL - (12/21/09)
     
  11393. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals - (12/17/09)
     
  11394. White House Community Discussions in 14 Cities Videos - (12/17/09)
     
  11395. EACS: Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne (2) - (11/20/09)
     
  11396. Paying the Price for Late Starts and Early Stops: Racial and Sex Disparities in HIV-Related Mortality - EDITORIAL COMMENTARY - (12/15/09)
     
  11397. Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy - (12/15/09)
     
  11398. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men (AIDS Dec 7 2009)-- pdf full text attached for you to download - (12/14/09)
     
  11399. EACS: The Impact of Maraviroc on Insulin Sensitivity, Lipids and Adipokines after 2 weeks in HIV Negative Male Volunteers - (12/10/09)
     
  11400. EACS: Pros and Cons of Boosted PI Monotherapy - (12/10/09)
     
  11401. Mediterranean Diet and Late-Life Cognitive Impairment -Editorial - (12/09/09)
     
  11402. Physical Activity, Diet, and Risk of Alzheimer Disease: In this study, both higher Mediterranean-type diet adherence and higher physical activity were independently associated with reduced risk for AD. - (12/09/09)
     
  11403. New Changes in DHHS Guidelines- HAART Recommended Earlier in HIV; new What To Start; DHHS Reasons for Changes - (12/04/09)
     
  11404. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial - (12/04/09)
     
  11405. Updated European (EACS) & USA Treatment Guidelines (DHHS) - (12/04/09)
     
  11406. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (12/03/09)
     
  11407. Physical Exercise Prevents Cellular Senescence in Circulating Leukocytes and in the Vessel Wall - (12/01/09)
     
  11408. When and how to use maraviroc in HIV-infected patients - (12/01/09)
     
  11409. New WHO HIV recommendations on HIV ART treatment, prevention & infant feeding to improve health, reduce infections and save lives - (12/01/09)
     
  11410. Long-Term Evolution and Determinants of Renal Function in HIV-Infected Patients Who Began Receiving Combination Antiretroviral Therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE - BRIEF REPORT - (11/30/09)
     
  11411. Low Bone Mineral Density, Renal Dysfunction, and Fracture Risk in HIV Infection: A Cross-Sectional Study - (11/30/09)
     
  11412. EACS: New EACS (European AIDS Clinical Society) HIV Guidelines: HIV treatment, comorbidities (prevention and management of metabolic diseases), management and treatment of chronic hepatitis B and C coinfection in HIV+
     
  11413. IAS: HIV-1 INFECTION IN SUBJECTS OLDER THAN 70: A MULTICENTER CROSS-SECTIONAL ASSESSMENT IN CATALONIA, SPAIN - (11/29/09)
     
  11414. EACS: The ARTEN study: 48 week efficacy data stratified by screening viral load and CD4+ cell count - (11/30/09)
     
  11415. EACS: Pharmacokinetic interaction study between TMC278,an NNRTI, and the contraceptives norethindrone plus ethinylestradiol - (11/30/09)
     
  11416. EACS: Absorption, metabolism and excretion of TMC278, an NNRTI, after a single oral dose of 150mg in healthy male volunteers - (11/30/09)
     
  11417. EACS: Absence of a teratogenic potential from a novel next-generation NNRTI, TMC278 - (11/24/09)
     
  11418. EACS: TMC278 25mg qd has no effect on corrected QT interval in a study in HIV-negative volunteers - (11/24/09)
     
  11419. EACS: Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (11/30/09)
     
  11420. EACS: A Pilot Study of Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral Naive HIV-1 Infected Subjects - (11/30/09)
     
  11421. EACS: Detrimental effect of current patient-reported drug holidays on long-term sub-optimal treatment out-come in advanced naive subjects initiating cART - (11/30/09)
     
  11422. EACS: Association of effectiveness and adherence of antiretroviral treatment - (11/30/09)
     
  11423. EACS: Impact of different types of adherence behaviours and of cART characteristics on plasma HIV-1 RNA detection under lower limit of quantification at real-time assay - (11/30/09)
     
  11424. EACS: Moving from risk factor assessment to atherosclerosis imaging to select the most appropriate patient for primary prevention: CVD algorithms underestimate risk in HIV+ - (11/30/09)
     
  11425. Oral Gonorrhea for Men & Women: pharynx a reservoir for gonorrhea - (11/24/09)
     
  11426. Chlamydia trachomatis and Neisseria gonorrhoeae Transmission from the Oropharynx to the Urethra among Men Who Have Sex with Men - (11/24/09)
     
  11427. FDA Approves Expanded Use of Selzentry for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time - (11/24/09)
     
  11428. EACS: Adherence to and quality of life of a one-pill once-a-day HAART (Atripla). Results of the ADONE study - (11/24/09)
     
  11429. EACS: The Effect of Antiretroviral Therapy Without CCR5-Antagonists on HIV-1 Tropism in the MOTIVATE Studies of Maraviroc in Treatment-Experienced Patients With R5 HIV-1 - (11/24/09)
     
  11430. EACS: Safety Profile of HIV-1 Patients Co-Infected With Hepatitis B or C in the Maraviroc Expanded Access Program - (11/24/09)
     
  11431. EACS: ASSESSMENT OF THE STEADY STATE PK PARAMETERS OF TWO EXTENDED RELEASE (XR) NEVIRAPINE (NVP) TABLETS 400 MG AND 300 MG QD COMPARED WITH IMMEDIATE RELEASE (IR) NVP TABLETS 200 MG BID IN HIV-1 INFECTED PATIENTS - THE ERVIR STUDY - (11/24/09)
     
  11432. EACS: Gender-Based Differences in Antiretroviral-Naïve Patients Treated With Ritonavir-Boosted Protease Inhibitors: Results From the CASTLE Study Through 96 Weeks - (11/24/09)
     
  11433. EACS: Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne - (11/20/09)
     
  11434. EACS: Viral Load Over 50 and Low CD4/CD38 Ratio Hoist MI Risk in French Cohort - Written Mark Mascolini - (11/20/09)
     
  11435. EACS: Risk of Cardiovascular Disease in ART-Naive People Without Heart Symptoms, Carotid Artery Ultrasonography May Be Useful - Written Mark Mascolini - (11/20/09)
     
  11436. EACS: Abdominal Adiposity Not Waning With Newer Antiretrovirals in France - Written Mark Mascolini - (11/20/09)
     
  11437. EACS: Metabolic Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV-infected Patients with Excess Abdominal Fat over a Period of 52 Weeks. A Pooled Analysis of 2 Multicenter, Double- blind, Placebo-controlled Phase 3 Trials with 816 Randomized Patients - (11/20/09)
     
  11438. EACS: "Deep" Sequencing to Identify Treatment-Experienced Patients Who Respond to Maraviroc (MVC) - (11/20/09)
     
  11439. EACS: Optimization of Clinically Relevant Cutpoints for the Determination of HIV Co-Receptor Usage to Predict Maraviroc Responses in Treatment Experienced (TE) Patients Using Population V3 Genotyping - (11/20/09)
     
  11440. EACS: Improved Treatment Compliance with Once-Daily (QD) Compared to Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) in HIV-1-Infected, Antiretroviral-Experienced Subjects - (11/20/09)
     
  11441. EACS: Impact of Baseline Resistance on Virologic Outcome with Once-Daily (QD) or Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) through 48 Weeks of Combination Antiretroviral Therapy in Treatment-Experienced, HIV-1-Infected Subjects - (11/20/09)
     
  11442. EACS: Diagnosis and management of cognitive disorders during successful HIV treatment - (11/20/09)
     
  11443. EACS: Simplified Antiretroviral Therapy in Special Populations: Clinical Outcomes at Week 48 of Lopinavir/ritonavir (LPV/r) Tablet Dosed Once Daily (QD) or Twice Daily (BID), Administered with ≥2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-experienced Subjects, Analyzed by Gender, Age, Race, Ethnicity, and Hepatitis Co-infection Status (Study M06-802) - (11/18/09)
     
  11444. EACS: Etravirine demonstrates a favourable safety and tolerability profile versus placebo irrespective of hepatitis co-infection: Week 96 analysis from the DUET trials - (11/24/09)
     
  11445. EACS: Kaletra QD Resistance Report: Lopinavir/ritonavir (LPV/r) with Tenofovir DF (TDF) and Emtricitabine (FTC) in Antiretroviral (ARV)-naïve Subjects - (11/18/09)
     
  11446. EACS: Etravirine demonstrates a favourable safety and tolerability profile: pooled 96-week results from the Phase III DUET trials - (11/18/09)
     
  11447. EACS: Safety and pharmacokinetics of etravirine in pregnant HIV-infected women - (11/18/09)
     
  11448. EACS: Tesamorelin Health-Related Quality of Life in HIV+ regarding belly and weight image - (11/18/09)
     
  11449. EACS: MIs, Cocaine/IVDUs French Database - (11/17/09)
     
  11450. EACS: S/GSK1349572 Integrase Inhibitor Resistance Profile - (11/17/09)
     
  11451. EACS: Potent Antiviral Activity of GSK Integrase S/GSK1349572 - (11/17/09)
     
  11452. EACS: A Phase II, open-label trial in treatment-naive, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/17/09)
     
  11453. EACS: Twice Daily Darunavir to Replace Dual Boosted Protease Inhibitors in Virologically Suppressed Patients - (11/17/09)
     
  11454. EACS: Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in adults with HIV infection: meta-analysis of two randomised, non-inferiority trials BICOMBO and STEAL - (11/17/09)
     
  11455. EACS: Fatty Liver in HIV & HCV - (11/17/09)
     
  11456. EACS: A Phase II, open-label trial in treatment-naïve, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/15/09)
     
  11457. EACS: Darunavir Maintenance Monotherapy - (11/15/09)
     
  11458. EACS: Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naïve HIV-1 infected patients: ARTEN Study Week 48 results - (11/15/09)
     
  11459. EACS: Body Composition Changes in Treatment-Naive Patients Treated with Boosted Protease Inhibitors Plus Tenofovir/Emtricitabine: Results From the CASTLE Study Through 96 Weeks - (11/15/09)
     
  11460. EACS: Assessment of Safety and Efficacy of Abacavir/Lamivudine and Tenofovir/Emtricitabine in Treatment-Naïve HIV-1 Infected Subjects ASSERT: 48-Week Result - (11/15/09)
     
  11461. EACS: Once-Daily Dosing Ups Risk of Stopping Antiretrovirals in Single-Clinic Study - written by Mark Mascolini - (11/15/09)
     
  11462. EACS: Lower Intracellular Carbovir (Abacavir) Levels With Darunavir/Ritonavir - written by Mark Mascolini - (11/15/09)
     
  11463. EACS: Darunavir Troughs Lower With Raltegravir in Cross-Sectional Study - written by Mark Mascolini - (11/15/09)
     
  11464. EACS: More Evidence of Low Vitamin D in People Taking Antiretrovirals - written by Mark Mascolini - (11/15/09)
     
  11465. EACS: Study of Once-Daily Boosted Darunavir Monotherapy as First-Line Therapy Had Difficulty - written by Mark Mascolini - (11/15/09)
     
  11466. EACS: Multicohort Study Confirms Continuing Hodgkin Lymphoma Risk With HAART - written by Mark Mascolini - (11/15/09)
     
  11467. EACS: Good 4-Year HIV Response in People Over 60, But High Cancer and Heart Disease Rates - written by Mark Mascolini - (11/15/09)
     
  11468. EACS: Later Year and Age Over 50 Tied to Better Response After Triple-Class Failure - written by Mark Mascolini - (11/15/09)
     
  11469. EACS: Hodgkin Lymphoma, Liver Cancer, Anal Cancer More Common With HIV - written by Mark Mascolini - (11/13/09)
     
  11470. EACS: Mortality High With Non-AIDS Cancers in EuroSIDA Despite HAART - written by Mark Mascolini - (11/13/09)
     
  11471. EACS: More Than Half in HIV Patient Series Carry High-Risk Human Papillomavirus - written by Mark Mascolini - (11/13/09)
     
  11472. EACS: Rough Group Sex--Not Just Anal Sex--May Explain HCV Epidemic in HIV+ Gays - written by Mark Mascolini - (11/13/09)
     
  11473. EACS: MONET Paints Noninferiority Picture With Darunavir/Ritonavir Monotherapy - written by Mark Mascolini - (11/13/09)
     
  11474. EACS: Twice-Daily Darunavir/Ritonavir to Replace Double-Boosted PIs - written by Mark Mascolini - (11/13/09)
     
  11475. Aging is a significant risk factor for cognitive impairment. As the HIV cohort ages, further investigation is needed into the effects of aging on HIV cognitive impairment. - (11/10/09)
     
  11476. ViiV Healthcare Launches: GSK/Pfizer New HIV Company - (11/10/09)
     
  11477. AASLD: HCV/MSM Sex Transmission in HIV+ in New York City - (11/05/09)
     
  11478. IDSA: 144Week Efficacy & Safety of Raltegravir in TreatmentExperienced Patients, TripleClass Resistant - (11/01/09)
     
  11479. IDSA: (IDSA) TMC278 25mg qd has no effect on corrected QT interval in HIV-negative volunteers - (11/01/09)
     
  11480. IDSA: (IDSA) Predictors of Response in GRACE (Gender, Race And Clinical Experience) - (11/01/09)
     
  11481. IDSA: (IDSA) Darunavir, Ritonavir, and Etravirine Steady-state Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-infected Women Enrolled in the GRACE Study - (11/01/09)
     
  11482. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study - (11/01/09)
     
  11483. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials - (11/01/09)
     
  11484. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials - (11/01/09)
     
  11485. Characteristics of non-Hodgkin lymphoma arising in HIV-infected patients with suppressed HIV replication - (11/01/09)
     
  11486. Role of metabolic syndrome components in HIV-associated sensory neuropathy - (11/01/09)
     
  11487. HIV infection and the risk of cancers with and without a known infectious cause - (11/01/09)
     
  11488. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Both once-daily saquinavir / ritonavir and atazanavir / ritonavir, when combined with tenofovir / emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reductions in glomerular filtration rate over 48 weeks: the BASIC trial - (10/28/09)
     
  11489. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naive HIV-1 infected patients: ARTEN Study Week 48 results - (10/28/09)
     
  11490. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Neuropsychiatric adverse events in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 copies/mL at screening - (10/27/09)
     
  11491. 11th Wrkshp Adverse Drug Reactions Co-morbidities: Correlation between laboratory parameters and use or discontinuation of nucleoside analogues in the MONET trial - (10/27/09)
     
  11492. 11th Wrkshp Adverse Drug Reactions Co-morbidities: 48 week changes in Quality of Life and adherence in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 at screening - (10/27/09)
     
  11493. Cardiovascular Diseases and Risk of Hip Fracture - (10/27/09)
     
  11494. ACG: ACE Inhibitor Use Linked to Liver Toxicity - (10/27/09)
     
  11495. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America - (10/27/09)
     
  11496. Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe - BRIEF REPORT - (10/27/09)
     
  11497. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy - (10/25/09)
     
  11498. CDC Updated Oct 21 Interim Recommendations for H1N1 Influenza for HIV-Infected Adults and Adolescents - (10/25/09)
     
  11499. Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection - (10/25/09)
     
  11500. Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection - (10/25/09)
     
  11501. Increased Peripheral Proinflammatory Cytokines in HIV-1-Infected Patients With Prolonged Viral Suppression Suffering From High Psychological Stress - (10/25/09)
     
  11502. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand - (10/20/09)
     
  11503. HIV Vaccine Trial Results - An Opening for Further Research EDITORIAL - (10/20/09)
     
  11504. Adverse health effects of non-medical cannabis use - (10/17/09)
     
  11505. High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial - (10/16/09)
     
  11506. IL-2 in HIV: associated with vascular events, inflammation, and no clinical benefit despite CD4 increase - (10/16/09)
     
  11507. New Approach To Targeting The Hidden Reservoir Of HIV: Siliciano Can Screen Compounds with new system - (10/16/09)
     
  11508. Bone Loss in HCV/HIV Coinfection - (10/16/09)
     
  11509. ICAAC:TBR-652, A CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST, DEMONSTRATES GOOD ORAL BIOAVAILABILITY AND DESIRABLE PHARMACOKINETIC (PK) AND SAFETY PROFILES IN HEALTHY VOLUNTEERS - (10/13/09)
     
  11510. ICAAC: IN VITRO ANTI-HIV EFFICACY OF THE CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST TBR-652 IN COMBINATION WITH FOUR OTHER CLASSES OF ANTIRETROVIRAL AGENTS - (10/13/09)
     
  11511. Target HbA1c levels still the subject of much debate, but tailored therapy should be the aim - (10/12/09)
     
  11512. Clumsy FDA Antiviral Advisory Committee (Maraviroc hearing) for both HIV & HCV in the future - (10/12/09)
     
  11513. Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects: more colon lesions in HIV+ - (10/09/09)
     
  11514. FDA Antivirals Advisory Panel Recommends Maraviroc for Naives Approval 10-4 - (10/09/09)
     
  11515. "Current CD4 cell count was the most predictive risk factor for all malignancies apart from anal cancer" - - (10/09/09)
     
  11516. Diabetes Can Impair Exercise Capacity: Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus - (10/07/09)
     
  11517. Subcutaneous (lipoatrophy) Rather than Visceral Adipose Tissue Is Associated with Adiponectin Levels and Insulin Resistance in Young Men - (10/07/09)
     
  11518. Sex Hormones and Frailty in Older Men: The Osteoporotic Fractures in Men (MrOS) Study - (10/07/09)
     
  11519. Frontostriatal fiber bundle compromise in HIV infection without dementia - (10/06/09)
     
  11520. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels - (10/06/09)
     
  11521. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy - (10/06/09)
     
  11522. New Approach To Targeting The Hidden Reservoir Of HIV - (10/05/09)
     
  11523. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial - (10/04/09)
     
  11524. Fall Prevention: how much vitamin D do you need? - (10/04/09)
     
  11525. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial - (10/04/09)
     
  11526. Doctors Prescribe Caution With Insulin's Cancer Ties - (10/04/09)
     
  11527. ICAAC: HIV-Associated Neurocognitive Disorders in the Era of Potent Antiretroviral Therapy: risk factors/prevalence, CSF HIV-RNA, HCV, ART PK/penetration, assessment tools - (10/04/09)
     
  11528. Lipoatrophy & Mortality, CVD - (09/30/09)
     
  11529. A1C Underestimates Glycemia in HIV Infection - (09/30/09)
     
  11530. Diabetes 2 Caused Brain Atrophy in Older Individuals - (09/30/09)
     
  11531. Vitamin D Improves Muscle Function - (09/29/09)
     
  11532. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells (HIV eradication) - (09/29/09)
     
  11533. Renal function with use of a tenofovir-containing initial antiretroviral regimen - (09/29/09)
     
  11534. CCR5 antagonism in HIV infection: ways, effects, and side effects - (09/29/09)
     
  11535. Evaluation of Adherence and Factors Affecting Adherence to Combination Antiretroviral Therapy Among White, Hispanic, and Black Men in the MACS Cohort - (09/29/09)
     
  11536. Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz Discontinuations - (09/29/09)
     
  11537. Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers - (09/29/09)
     
  11538. Incidence of Non-AIDS-Defining Malignancies Higher in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression - (09/26/09)
     
  11539. ICAAC: Acute HBV & HCV Infection Among MSM: CDC Data from Population-Based Surveillance, 2006-2008 - (09/25/09)
     
  11540. Serum Immune Activation Markers Are Persistently Increased in Patients with HIV Infection after 6 Years of Antiretroviral Therapy despite Suppression of Viral Replication and Reconstitution of CD4+ T Cells - (09/25/09)
     
  11541. ICAAC: Differential Effects of Maraviroc (MVC) and Efavirenz (EFV) on Markers of Immune Activation (IA) and Inflammation and Their Association with CD4 Cell Rises: A Sub-analysis of the MERIT (09/21/09)
     
  11542. ICAAC: MERIT: Week 96 Virologic Response and Tropism at Virologic Failure by Baseline CD4+ Cell Count (09/21/09)
     
  11543. ICAAC: Maraviroc (MVC) is Similar to Efavirenz (EFV) for Virologic Response (VR) Across Subgroups: MERIT 96-Week (09/21/09)
     
  11544. Tenofovir Gel & Tablets PrEP Study: Clinical Trial of Antiretroviral-based HIV Prevention Strategies for Women Now Under Way (study in 5,000 women) - (09/21/09)
     
  11545. ICAAC:Renal Disease in Diabetics with HIV: "higher rate of microalbuminuria than either HIV-positive patients without diabetes or diabetics without HIV infection" - (09/21/09)
     
  11546. National HIV/AIDS and Aging Awareness Day (09/20/09)
     
  11547. ICAAC: Safety and Effectiveness of Raltegravir-based HAART in HIV-Subjects after Solid Organ Transplantation (09/20/09)
     
  11548. ICAAC: 24 Week Safety and Efficacy from IMPAACT P1066: A Phase I/II, Multicenter, Open-Label, Noncomparative Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth (09/20/09)
     
  11549. National HIV/AIDS and Aging Awareness Day (09/20/09)
     
  11550. ICAAC: Phenotypic Screening for HIV Tropism versus both Population-based and "Deep" Sequencing (09/20/09)
     
  11551. ICAAC: Direct comparison with 454 pyrosequencing validates V3-loop based genotyping in patients eligible for Maraviroc initiation (09/20/09)
     
  11552. ICAAC: Prediction of HIV Disease Progression Using a Modification of the Enhanced Sensitivity (ES) Trofile Assay (09/20/09)
     
  11553. ICAAC:Prevalence of HIV-1 CCR5 Co-Receptor Tropism Differs by Env (gp41) Subtype in a Large Commercial Dataset (09/20/09)
     
  11554. ICAAC: The composition of dual-mixed HIV-1 populations can be discerned from the level of CXCR4-mediated infectivity (09/20/09)
     
  11555. ICAAC: Incorporation of Optimized Primers into the Trofile Assay Substantially Improves Determination of Viral Tropism in Genetically Diverse HIV Subtypes (09/20/09)
     
  11556. ICAAC: "Deep" Sequencing to Quantify in vivo Viral Fitness after Transmission of Resistant HIV (09/20/09)
     
  11557. ICAAC:Raltegravir in CSF: "Raltegravir Concentrations in CSF Exceed The Median Inhibitory Concentration" (09/20/09)
     
  11558. ICAAC: Darunavir in the CSF: "Darunavir Concentrations in CSF Exceed The Median Inhibitory Concentration" (09/20/09)
     
  11559. ICAAC: ART Helps Bring Lungs Up to Par in Nonsmokers, But Not Smokers - written by Mark Mascolini - (09/19/09)
     
  11560. ICAAC: Pharmacokinetics and Safety of a Novel 100 mg Tablet Formulation of MPC-4326 in Subjects with HIV-1 Infection (09/19/09)
     
  11561. ICAAC: The Effect of Ritonavir-Boosted Protease Inhibitors on the HIV Integrase Inhibitor, S/GSK1349572, in Healthy Subjects (09/19/09)
     
  11562. ICAAC: Lack of Interaction between the HIV Integrase Inhibitor, S/GSK1349572, and Tenofovir Disoproxil Fumarate (TDF) in Healthy Subjects (09/19/09)
     
  11563. ICAAC: Meta-Analysis of Safety for Short-term Dosing of an HIV Integrase Inhibitor, S/GSK1349572, from Seven Clinical Studies (09/19/09)
     
  11564. ICAAC: In Vitro Passage of Drug Resistant HIV-1 against a Next Generation Integrase Inhibitor (INI), S/GSK1349572 (09/19/09)
     
  11565. ICAAC: Evaluation of Antacid and Multivitamin (MVI) Effects on S/GSK1349572 Pharmacokinetics (PK) in Healthy Subjects (09/19/09)
     
  11566. ICAAC: Endothelial Function Drops in First Month of Antiretroviral Therapy - written by Mark Mascolini - (09/18/09)
     
  11567. ICAAC: Peripheral Endothelial Function is Reduced after Initiation of Antiretroviral Therapy in Treatment Naïve HIV Patients: A Prospective Longitudinal Study (09/18/09)
     
  11568. ICAAC: Steady State Evaluation of Two Extended Release (XR) Nevirapine (NVP) Tablets 400 mg QD Compared with Immediate Release (IR) NVP Tablets 200 mg BID in HIV-1 Infected Patients (09/18/09)
     
  11569. ICAAC: Pharmacokinetic interaction between etravirine and lopinavir/ritonavir (09/18/09)
     
  11570. ICAAC: Bevirimat Antiviral Activity & Safety, 14-Day Monotherapy Study (09/18/09)
     
  11571. ICAAC: GRACE (Gender, Race And Clinical Experience): Outcomes by Race at Week 48 (09/17/09)
     
  11572. Eradication Drug Research: Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors - (09/17/09)
     
  11573. ICAAC: Sharp Drop in ICU Mortality After Introduction of HAART in Netherlands - written by Mark Mascolini - (09/17/09)
     
  11574. ICAAC: Vicriviroc Long-term Safety and Efficacy: 96-Week Results from the Extension of VICTOR-E1 Stud - (09/17/09)
     
  11575. ICAAC: INSPIRE Study: Effects of r-hIL-7 on T Cell Recovery and Thymic Output in HIV-infected Patients Receiving c-ART - Interim Analysis of a Phase I/IIa Multicenter Study - (09/17/09)
     
  11576. ICAAC: Pharmacokinetic Boosting of Atazanavir with the Pharmacoenhancer GS-9350 versus Ritonavir - (09/17/09)
     
  11577. ICAAC: Effect of Food on Pharmacokinetics of Elvitegravir, Emtricitabine, Tenofovir DF and the Pharmacoenhancer GS-9350 as a Fixed- Dose Combination Tablet - (09/17/09)
     
  11578. ICAAC: Fasted Lipid Changes after Administration of Maraviroc or Efavirenz, both with Zidovudine and Lamivudine, to Treatment-Naive HIV-Infected Patients: 96-Week Results from MERIT - (09/17/09)
     
  11579. ICAAC: Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects GSK press release - (09/17/09)
     
  11580. ICAAC: Improvement in Fasting Lipids but Minimal Recovery of Limb Fat Were Seen 96 Weeks After Switching from Lamivudine/Zidovudine Plus Efavirenz to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-Infected Patients - (09/17/09)
     
  11581. ICAAC: Phase 2a Study of PRO 140 in HIV-Infected Adults - (09/17/09)
     
  11582. ICAAC: Can IL-7 Succeed Where IL-2 Failed in People With HIV? - written by Mark Mascolini - (09/17/09)
     
  11583. ICAAC: Once-Daily Replacement Raltegravir as Good as Twice-Daily in Pilot Trial - written by Mark Mascolini - (09/17/09)
     
  11584. ICAAC: Another Small Study Suggests Viability of Unboosted Atazanavir/Raltegravir Maintenance - written by Mark Mascolini - (09/17/09)
     
  11585. ICAAC: Faster Viral Decay With Nevirapine Than Atazanavir/Ritonavir in ARTEN Trial - written by Mark Mascolini - (09/17/09)
     
  11586. ICAAC: Gut-Shielding Mix Slows CD4 Drop in People Not Taking Antiretrovirals - written by Mark Mascolini - (09/17/09)
     
  11587. ICAAC: Gilead GS-9350 Protease Inhibitor Booster - written by Mark Mascolini - (09/17/09)
     
  11588. ICAAC: Raltegravir Reaches Good Nervous System Levels 4.3 Fold x EC50 - written by Mark Mascolini - (09/17/09)
     
  11589. ICAAC: GSK "Backup" Integrase Inhibitor Looks Strong in People With HIV: 10-day monotherapy study - written by Mark Mascolini - (09/17/09)
     
  11590. ICAAC: Early Virological and Immunological Response is Comparable between Nevirapine and RTV-boosted Atazanavir: An ARTEN Sub-analysis - (09/17/09)
     
  11591. ICAAC: A Pilot Study assessing Raltegravir QD versus BID in HIV patients included in a Simplification Trial - (09/17/09)
     
  11592. ICAAC: Dual Maintenance Therapy with Raltegravir 400 mg BID with Atazanavir 400 mg qD in Patients with no Prior PI Resistance and Intolerance to Other ARV Regimens: Preliminary Report - (09/17/09)
     
  11593. ICAAC: SCHERING-PLOUGH REPORTS LONG-TERM VICRIVIROC DATA FROM PHASE II OPEN-LABEL EXTENSION STUDY IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS - Schering-Plough press releaser - (09/17/09)
     
  11594. ICAAC: Discovery of GS-9350: A Novel Pharmacoenhancer without Anti-HIV Activity - (09/17/09)
     
  11595. ICAAC: Pharmacokinetics (PK) and Safety in Healthy and HIV-Infected Subjects and Short-Term Antiviral Efficacy of S/GSK1265744, a Next Generation Once Daily HIV Integrase Inhibitor - (09/17/09)
     
  11596. ICAAC: Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 48-Week Data - (09/17/09)
     
  11597. ICAAC: Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects - (09/14/09)
     
  11598. Gardasil HPV vaccine for boys - FDA Hearing Oct 21 - (09/11/09)
     
  11599. ICAAC: Weighted Antiretroviral Sensitivity Score May Be Better Predictor of Short-Term Response - written by Mark Mascolini - (09/14/09)
     
  11600. ICAAC: Seven Short Studies Suggest Good Safety Profile of New Integrase Inhibitor - written by Mark Mascolini - (09/14/09)
     
  11601. ICAAC: Merck's ISENTRESS (raltegravir) Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients - Merck press release - (09/14/09)
     
  11602. ICAAC: Raltegravir Demonstrates Durable Efficacy Through 96 Weeks: Results from STARTMRK, A Phase III Study of Raltegravir-based vs. Efavirenz-based Therapy in Treatment-Naïve HIV+ Patients - (09/14/09)
     
  11603. ICAAC: Effects of CYP2B6 Single Nucleotide Polymorphisms (SNPs) and Substance Abuse on Efavirenz (EFV) Pharmacokinetics - (09/14/09)
     
  11604. ICAAC: Tobacco and Marijuana Uses Significantly Decrease Atazanavir (ATV) Trough Concentrations in HIV Infected Individuals - (09/14/09)
     
  11605. ICAAC: Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and buprenorphine/naloxone - (09/14/09)
     
  11606. ICAAC: Early Changes in HCV Viral Load During the First 24 Hours of Treatment Exhibit a Very High Negative Predictive Value of Sustained Virological Response in HCV/HIV Coinfected Patients - (09/14/09)
     
  11607. ICAAC:Role for Short-Term Enfuvirtide to Boost CD4s After Late Diagnosis? - written by Mark Mascolini - (09/14/09)
     
  11608. ICAAC: Lab Study Suggests High Barrier to Resistance With New Integrase Inhibitor - written by Mark Mascolini - (09/14/09)
     
  11609. ICAAC: Smoking and Drinking Alcohol Linked to Lower Efavirenz Levels - written by Mark Mascolini - (09/14/09)
     
  11610. ICAAC: Tobacco and Marijuana Tied to Lower Atazanavir Concentrations - written by Mark Mascolini - (09/14/09)
     
  11611. ICAAC: DC Emergency Patients Who Decline HIV Test Have Twice Higher HIV Rate - written by Mark Mascolini - (09/14/09)
     
  11612. ICAAC: Impact of One-Time or Annual HIV Screening on Life Expectancy in France - written by Mark Mascolini - (09/14/09)
     
  11613. ICAAC: HCV Load Decay in First Day of PegIFN Treatment Predicts Long-Term Failure - written by Mark Mascolini - (09/14/09)
     
  11614. HIV and Aging: The Long-term Consequences of Successful Antiretroviral Therapy - (09/11/09)
     
  11615. HIV, HAART & Brain Damage & Repair - (09/11/09)
     
  11616. Effect of HAART on Risk of Sexual Transmission of HIV & Superinfection - CDC Report - (09/11/09)
     
  11617. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients - (09/11/09)
     
  11618. Sex Steroids & Fracture Risk in Men - (09/06/09)
     
  11619. Lipodystrophy & Bone Loss - (09/06/09)
     
  11620. Vitamin D, Diabetes & Bone in African-Americans - (09/06/09)
     
  11621. Inflammation & Diabetes, Interventions - (09/06/09)
     
  11622. The model for end-stage liver disease score (MELD) is the best prognostic factor in HIV 1-infected patients with end-stage liver disease: A prospective cohort study - (09/03/09)
     
  11623. Viable strategies to facilitate liver transplantation for HIV/HCV coinfection - Editorial - (09/03/09)
     
  11624. A Potential Role for Vitamin D on HIV Infection? - (09/03/09)
     
  11625. Vitamin D Immunomodulator EDITORIAL - (09/03/09)
     
  11626. Low Vitamin D Levels Increased Risk for HIV MTCT: Perinatal Outcomes, Including Mother-to-Child Transmission of HIV, and Child Mortality and Their Association with Maternal Vitamin D Status in Tanzania - (09/03/09)
     
  11627. Resting cerebral blood flow A potential biomarker of the effects of HIV in the brain - (09/03/09)
     
  11628. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients in TITAN - (09/03/09)
     
  11629. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people - (08/29/09)
     
  11630. Neurological Impairment Persists Despite HAART: "adjunctive therapies needed" - (08/29/09)
     
  11631. Insulin Resistance Is Associated With Cognition Among HIV-1-Infected Patients: The Hawaii Aging With HIV Cohort - (08/29/09)
     
  11632. HCV Coinfection & Neurologic Impairment - (08/29/09)
     
  11633. 5th IAS: Association between activation of inflammatory and coagulation pathways and mortality during long-term follow up in SMART - (08/29/09)
     
  11634. 5th IAS: HAART Interruption Increased Inflammation - IMPACT OF HAART INTERRUPTION ON PLASMA INFLAMMATORY MARKERS ASSOCIATED WITH CARDIOVASCULAR DISEASE FINAL 36-MONTH RESULTS FROM A RANDOMIZED STUDY - (08/29/09)
     
  11635. 5th IAS: HAART Did Not Control Immune Activation - (08/29/09)
     
  11636. 5th IAS: HAART Interruption Increases Immune Activation - (08/29/09)
     
  11637. 5th IAS: Kaletra Protects Mitochondria - (08/29/09)
     
  11638. Untreated HIV Infection and Large and Small Artery Elasticity - "Untreated HIV infection is associated with impaired arterial elasticity" - (08/28/09)
     
  11639. Higher CPE Score Improved Cognition, Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders - (08/28/09)
     
  11640. 5th IAS: Prevalence of HIV-1-Associated Neurocognitive Disorders in Argentina - (08/28/09)
     
  11641. Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone loss - pdf attached - (08/27/09)
     
  11642. Mild Glucose Intolerance In Pregnancy May Be Associated With Cardiovascular Risk - (08/26/09)
     
  11643. The clot thickens-oxidized lipids and thrombosis - (08/26/09)
     
  11644. Oxidized lipids: a key to heart disease? - (08/26/09)
     
  11645. Aging/HIV Clinical Care & Research - New IDSA Guidelines - (08/26/09)
     
  11646. Thyroid Dysfunction, Hypogonadism, Testosterone, Bone, Prostate Cancer, HIV & HAART - (08/26/09)
     
  11647. Aging & HIV Recognized as a Serious Concern But No Real Discussion, Still Ignored. 2007 NIH Workshop recommendations - (08/26/09)
     
  11648. Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse-Transcriptase Inhibitor-Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA) - (08/21/09)
     
  11649. Vitamin D Deficiency/Muscle Function/Frailty - (08/21/09)
     
  11650. GSK says latest Avandia findings are flawed: new pio vs rosiglitazone study - (08/20/09)
     
  11651. Diagnosis and management of neuropathic pain - Clinical Review - (08/20/09)
     
  11652. NIH Workshop on HIV in Older Adults Oct 20 2007 - (08/18/09)
     
  11653. A serum 25-hydroxyvitamin D level below 50 nmol/l has been associated with increased body sway and a level below 30 nmol/l with decreased muscle strength. - (08/18/09)
     
  11654. Vitamin D deficiency, muscle function, and falls in elderly people1,2 Review Article - (08/18/09)
     
  11655. 5th IAS: IAS: darunavir & etravirine studies - (08/16/09)
     
  11656. New IDSA HIV Guidelines Push 'Adherence to Care' - (08/17/09)
     
  11657. FDA Approves Generic Fixed Dose Efavirenz/FTC/Tenofovir - (08/14/09)
     
  11658. 5th IAS: Kaletra Once-Daily Dosing, IAS Summary - (08/14/09)
     
  11659. 5th IAS: Reyataz Studies at IAS - (08/14/09)
     
  11660. 5th IAS: Maraviroc IAS Reports: MERIT (naives), Genotype vs Tropism (MOTIVATE), Malignancies Report (MOTIVATE) - (08/14/09)
     
  11661. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a - (08/14/09)
     
  11662. Coinfection with Hepatitis C Virus and HIV: More than Double Trouble - EDITORIAL COMMENTARY - (08/14/09)
     
  11663. 5th IAS: Abacavir & MIs - IAS Summary - (08/12/09)
     
  11664. 5th IAS: Cancers & HIV at IAS Summary Report - (08/12/09)
     
  11665. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy (HCV, IVDU) - (08/12/09)
     
  11666. New Expanded Access Rules to Investigational Drugs for Treatment Use and Charging for Investigational Drugs - (08/12/09)
     
  11667. FDA Expands Access to Investigational Drugs - (08/12/09)
     
  11668. Lipoatrophy and lipohypertrophy are independently associated with hypertension - (08/12/09)
     
  11669. Physical Activity, Diet, and Risk of Alzheimer Disease (65% reduction in risk) - (08/12/09)
     
  11670. Mediterranean Diet and Late-Life Cognitive Impairment EDITORIAL - (08/12/09)
     
  11671. tenofovir & abacavir - Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients  - (08/12/09)
     
  11672. Study Suggests Immune Systems of Untreated HIV-Infected Individuals May Deteriorate Faster than Previously Thought - NIH BULLETIN - (08/12/09)
     
  11673. Midlife Serum Cholesterol and Increased Risk of Alzheimer's and Vascular Dementia Three Decades Later- pdf attached - (08/12/09)
     
  11674. Structural biology: Aerial view of the HIV genome - (08/12/09)
     
  11675. Oral Cancer In Men Associated With HPV - (08/12/09)
     
  11676. Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir - New UK CHIC Study BRIEF REPORT - (08/12/09)
     
  11677. Thiazolidinediones and Fractures in Men and Women - (08/12/09)
     
  11678. Bone Guidelines Excerpted From New IDSA Guidelines- pdf of full paper attached  - (08/12/09)
     
  11679. Prevalence and Associations of 25-Hydroxyvitamin D Deficiency in US Children: NHANES 2001-2004 - pdf of published report attached - (08/12/09)
     
  11680. 5th IAS: New Drugs, New strategies - written by Joe Eron MD - (08/12/09)
     
  11681. WHO May Recommend HAART for PMTCT: IAS - (08/07/09)
     
  11682. Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine Used for Prevention of HIV-1 Mother-to-Child Transmission - (08/07/09)
     
  11683. WHO may change ARV guidelines for pregnant mothers: HAART reduces HIV transmission while breastfeeding - (08/07/09)
     
  11684. New review endorses CV benefits of fish oil - (08/06/09)
     
  11685. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases - (08/06/09)
     
  11686. HIV-associated brain dysfunction in the era of HAART - Editorials, Reasons for hope, but continued concern - (08/06/09)
     
  11687. The Pathogenetic Role of Cortisol in the Metabolic Syndrome (and lipodystrophy): A Hypothesis - (08/06/09)
     
  11688. Continuous antiretroviral therapy decreases bone mineral density in SMART - (08/06/09)
     
  11689. 5th IAS: Similar Declines in HIV-1 RNA (Viral load, VL) from Baseline (BL) to 96 Weeks Observed in Subjects Randomized to ABC/3TC or TDF/FTC each with Lopinavir/Ritonavir (LPV/r) in the HEAT Trial (EPZ104057) - (08/04/09)
     
  11690. 5th IAS: Efficacy, safety and tolerability of dual therapy with raltegravir 400mg bid and atazanavir 200mg bid in antiretroviral experienced patients. - (08/04/09)
     
  11691. 5th IAS: 91% Have Low Vitamin D Levels in UK Cohort, 34% Severely Deficient; Efavirenz use is associated with severe Vitamin D deficiency in a large, ethnically diverse, urban UK HIV cohort - (08/04/09)
     
  11692. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women - it accumulated at high levels quickly in CVF & vaginal tissue - (08/04/09)
     
  11693. Bone mineral density and disorders of mineral metabolism in chronic liver disease: Cirrhotics Have Low Bone Density & Low Vitamin D Levels - (08/04/09)
     
  11694. -2.5% Bone Loss Over 96 Weeks on PI or NNRTI in study reported - (08/04/09)
     
  11695. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial -- attached is pdf and appendix with adverse events - (08/04/09)
     
  11696. Scientists learn why even treated genital herpes sores boost the risk of HIV infection - (08/04/09)
     
  11697. 5th IAS: Earlier HAART at 350 CD4 Instead of Current 200 in Developing World Recommended - (08/01/09)
     
  11698. 5th IAS: Preliminary analyses suggest a higher rate of HIV seroconversion among men who were HPV positive at baseline - (08/01/09)
     
  11699. 5th IAS: Virologic Suppression on Maraviroc in Treatment-Naive Patients With R5 HIV-1 is Similar to Efavirenz at High Baseline Viral Load, and Maraviroc Discontinuations for Adverse Events are Less Likely to Show Drug Resistance: 48-Week Results From the MERIT Study - (08/01/09)
     
  11700. 5th IAS: Duration of Viral Suppression Strongly Modifies the Adherence-Viral Rebound Relationship - (08/01/09)
     
  11701. Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure - (07/31/09)
     
  11702. 5th IAS: Neurocognitive Disorders Despite Undetectable HIV RNA - (07/31/09)
     
  11703. 5th IAS: Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD Professor of Clinical Medicine Division of Infectious Diseases University of Miami Leonard M. Miller School of Medicine Miami, Florida (07/31/09)
     
  11704. 5th IAS: 48 week lipid- and glucose-related safety profile of darunavir/ritonavir in treatment-experienced, paediatric patients in DELPHI - (07/31/09)
     
  11705. 5th IAS: HIV Infection Modulates Cellular Proteins Associated With Cardiovascular Disorders - (07/31/09)
     
  11706. 5th IAS: Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1 Infected Patients: Final Results of the Randomized ANRS 138 Trial (EASIER). - (07/31/09)
     
  11707. CROI: Unexpectedly high failure rate in LPV/r monotherapy arm, involving CNS, and association with low nadir CD4 count in the MOST study - (06/02/09)
     
  11708. 5th IAS: HIV Prevention at IAS 2009 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (07/30/09)
     
  11709. 5th IAS: Genital HIV-1 RNA Concentrations and Heterosexual HIV-1 Transmission Risk: 'higher genital HIV levels increase HIV sex transmission risk' - (07/30/09)
     
  11710. 5th IAS: MIs & ARTs: Nested Control Study in Quebec Cohort - (07/30/09)
     
  11711. 5th IAS: Predictive factors of serious vascular events in HIV patients in LATINA (LATInamerican Network on AIDS) - (07/30/09)
     
  11712. 5th IAS: Influence of patient baseline clinical and demographic characteristics on choice of initial antiretroviral therapy regimen: evidence of channeling bias in HIV clinical care - (07/30/09)
     
  11713. 5th IAS: Metabolic Complications of HIV infection Update form the 5th IAS Conference in Cape Town - Pablo Tebas MD, University of Pennsylvania - (07/30/09)
     
  11714. 5th IAS: Persistence and Progression of HIV-associated Neurocognitive Impairment (NCI) in the Era of Combination Antiretroviral Therapy (CART) and the Role of Comorbidities: The CHARTER Study - (07/30/09)
     
  11715. Bioavailability of Efavirenz Capsule Contents (Sprinkles) Mixed with a Small Amount of Food Compared with Intact Capsules in Healthy Adults - (07/29/09)
     
  11716. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  11717. 5th IAS: Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV Infection in Africa in the DART trial - (07/30/09)
     
  11718. 5th IAS: Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring - press release - (07/30/09)
     
  11719. 5th IAS: DART Study Slide Presentation at IAS - (07/30/09)
     
  11720. 5th IAS: Omega-3 polyunsaturated fatty acids inhibit the release of matrix metalloproteinases: therapeutic implications for HIV-associated immune activation - (07/30/09)
     
  11721. CHMP Recommends Expanded Use of ISENTRESS® (raltegravir), from MSD, in Treatment-Naïve Adult Patients with HIV-1 Infection - (07/29/09)
     
  11722. 5th IAS: Efavirenz Linked to Severe Vitamin D Deficit in Diverse London Clinic - written by Mark Mascolini - (07/29/09)
     
  11723. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz - (07/29/09)
     
  11724. HIV Can Kill Chimps; Infectious diseases: An ill wind for wild chimps? - (07/29/09)
     
  11725. 5th IAS: What CD4 Cell Count Levels are Associated With a Reduced Risk of Cancer? 'When To Begin HAART' - (07/29/09)
     
  11726. 5th IAS: HIV Regimens Lacking Nucleosides Tied to Higher SVR Rate With HCV Therapy - written by Mark Mascolini - (07/29/09)
     
  11727. 5th IAS: Varying Risk of AIDS and Non-AIDS Cancers in Diverse CD4 Brackets - written by Mark Mascolini - (07/29/09)
     
  11728. 5th IAS: Half in US HIV Group Have Neurocognitive Impairment, Which Improves With NNRTIs - written by Mark Mascolini - (07/29/09)
     
  11729. 5th IAS: Two Triple PEP Regimens With Truvada Look Safer Than Older PEPs - written by Mark Mascolini - (07/29/09)
     
  11730. 5th IAS: TB Rate in South African Township Plummets After Antiretrovirals Arrive - written by Mark Mascolini - (07/29/09)
     
  11731. 5th IAS: Anal Cancer Rates Keep Climbing in US HIV Group Despite HAART - written by Mark Mascolini - (07/29/09)
     
  11732. 5th IAS: Triple Antiretrovirals Cut Breastfeeding HIV Transmission Rate Below 1% - written by Mark Mascolini - (07/29/09)
     
  11733. 5th IAS: Adding Raltegravir to Suppressive Regimen Does Not Cut Low-Level Viremia - written by Mark Mascolini - (07/29/09)
     
  11734. 5th IAS: More Time With Low CD4 Count Boosts Non-AIDS Cancer Risk - written by Mark Mascolini - (07/29/09)
     
  11735. 5th IAS: THE FOTOSTUDY 48 week Results to assess durability of the strategy of taking Efavirenz, Tenofovir and Emtricitabine Five-days-On, Two-days-Off each week in virologically suppressed patients - (07/29/09)
     
  11736. 5th IAS: ARTEMIS: Week 96 safety and efficacy of darunavir/r by gender, age and race - (07/29/09)
     
  11737. 5th IAS: Efficacy and Safety of Atazanavir/RTV vs. Lopinavir/RTV in Treatment-Naïve Patients with Advanced Disease: CASTLE Study 96-Week Results - (07/29/09)
     
  11738. 5th IAS: Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)
     
  11739. 5th IAS: Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results - (07/29/09)
     
  11740. 5th IAS: Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials - (07/29/09)
     
  11741. 5th IAS: Efficacy and Safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial - (07/29/09)
     
  11742. 5th IAS: Comparable Safety and Efficacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-naïve, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730 - (07/28/09)
     
  11743. 5th IAS: Highly prevalent vitamin D deficiency and insufficiency among an urban cohort of human immunodeficiency virus (HIV)-infected men under care - (07/28/09)
     
  11744. 5th IAS: ARTs Cause Bone Loss - (07/28/09)
     
  11745. 5th IAS: Bone mineral density (BMD) in a population of healthy HIV-negative young African adults enrolling in a pre-exposure prophylaxis (PrEP) trial in Botswana - (07/28/09)
     
  11746. 5th IAS: Cumulative & Current Viral Replication & Low CD4 Increases NHL Risk: Immune deficiency, uncontrolled HIV replication and non-Hodgkin's lymphoma, ANRS CO3 Aquitaine Cohort, 1998-2006. - (07/28/09)
     
  11747. 5th IAS: ISENTRESS (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy - (07/23/09)
     
  11748. Tight Glucose Control Raises Mortality Risk in Heart Failure in a New Study - (07/23/09)
     
  11749. HIV & Kidney Disease: African-Americans with HIV are more susceptible to type of kidney disease known as HIVAN - (07/23/09)
     
  11750. 5th IAS: Screening for HIV Tropism using Population-based V3 Genotypic Analysis: a Retrospective Virologic Outcome Analysis Using Stored Plasma Screening Samples from the MOTIVATE Studies of Maraviroc in Treatment Experienced Patients - (07/23/09)
     
  11751. 5th IAS: Abacavir Not Associated with MIs, 2 Studies Report at IAS - (07/23/09)
     
  11752. 5th IAS: Swiss Suicide Risk Still High With HIV, But HAART Made a Difference - written by Mark Mascolini - (07/22/09)
     
  11753. 5th IAS: Atazanavir Effective After Atazanavir/Ritonavir Induction in Naive Patients - written by Mark Mascolini - (07/22/09)
     
  11754. 5th IAS: Kaletra Once vs Twice Daily - (07/22/09)
     
  11755. 5th IAS: Once- and Twice-Daily Lopinavir/Ritonavir Equivalent in Antiretroviral Experienced - written by Mark Mascolini - (07/22/09)
     
  11756. 5th IAS: Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study - written by Mark Mascolini - (07/22/09)
     
  11757. 5th IAS: Lower Glucose and HIV Load Linked to Fibrosis Regression in 5-Year Study; HCV Therapy Quadrupled Chance For Fibrosis Regression - written by Mark Mascolini - (07/22/09)
     
  11758. 5th IAS: Second Trial of Darunavir Monotherapy Seems Less Convincing - written by Mark Mascolini - (07/22/09)
     
  11759. 5th IAS: Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naive, HIV-1-infected ARTEMIS patients at Week 96 - (07/22/09)
     
  11760. 5th IAS: Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/22/09)
     
  11761. 5th IAS: Reyataz Induction/Maintenance From Boosted to Unboosted: Similar Efficacy and Tolerability of Atazanavir (ATV) Compared to Atazanavir/Ritonavir (ATV/r), each with Abacavir/Lamivudine (ABC/3TC) after Initial Suppression with ABC/3TC + ATV/r: 84 Week Results of the ARIES Trial - (07/22/09)
     
  11762. 5th IAS: Genetic Test Predicts Response to Maraviroc in Treatment-Experienced HIV Patients - press release - (07/22/09)
     
  11763. 5th IAS: EPZICOM + atazanavir regimen provided comparable efficacy to EPZICOM + atazanavir/ritonavir regimen in treatment-naive HIV-infected patients - press release - (07/22/09)
     
  11764. 5th IAS:Incidence and Risk Factors for Malignancies in Treatment-experienced (TE) Patients in the MOTIVATE Studies of Maraviroc (MVC) + Optimized Background Therapy (OBT): 96-Week Follow-up - (07/22/09)
     
  11765. 5th IAS: A randomized multicenter study to compare the efficacy of a monotherapy of darunavir to a triple therapy with 2 nucleosides analogues combined to darunavir/r in HIV infected patients with full viral suppression: MONOI ANRS 136 - (07/22/09)
     
  11766. 5th IAS: Long-Term Bone Loss Similar With PI- and NRTI-Sparing Regimens - written by Mark Mascolini - (07/21/09)
     
  11767. 5th IAS: Blacks and Women Have Worse Virologic Response in Trial of ABC/3TC vs TDF/FTC - written by Mark Mascolini - (07/21/09)
     
  11768. 5th IAS: Raltegravir Rescue Regimens Do Well With or Without a PI - written by Mark Mascolini - (07/21/09)
     
  11769. 5th IAS: Nevirapine Combo May Work for Some Kids Exposed to Single-Dose Nevirapine - written by Mark Mascolini - (07/21/09)
     
  11770. 5th IAS: Adding More NRTIs to Salvage May Lower Chance of Response - written by Mark Mascolini - (07/21/09)
     
  11771. 5th IAS: Once-Daily Darunavir Monotherapy Effective for 48 Weeks After Viral Control - written by Mark Mascolini - (07/21/09)
     
  11772. 5th IAS: New Once-Daily Integrase Inhibitor Looks Strong in Early Trial - written by Mark Mascolini - (07/21/09)
     
  11773. 5th IAS: Attacking LDL Cholesterol in People on ARVs Has Mixed Results - written by Mark Mascolini - (07/21/09)
     
  11774. 5th IAS: Recovery of Functional Immunity over 48 Weeks with Darunavir-based Therapy in the GRACE Immunology Substudy - (07/21/09)
     
  11775. 5th IAS: The MONET trial: darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL at baseline - (07/21/09)
     
  11776. 5th IAS: Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study - GSK press release - (07/21/09)
     
  11777. 5th IAS: The MERIT Study of Maraviroc in Antiretroviral-Naive Patients With R5 HIV-1: 96-Week Results - (07/21/09)
     
  11778. 5th IAS: 96-Week Merit Es Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naive HIV Patients; Results Consistent With 48-Week Analysis - Pfizer press release - (07/21/09)
     
  11779. 5th IAS: Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naïve HIV-1-Infected Patients: ING111521 Protocol - (07/21/09)
     
  11780. 5th IAS: Sustained Antiretroviral Efficacy of Raltegravir as part of Combination ART in Treatment-Naive HIV-1 infected patients: 144-week data - (07/21/09)
     
  11781. 5th IAS: Pharmacokinetic (PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572, a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients - (07/21/09)
     
  11782. 5th IAS: Pharmacokinetics (PK) and Safety in Healthy Subjects of S/GSK1349572, a Next Generation, Once-Daily HIV Integrase Inhibitor (INI) - (07/21/09)
     
  11783. 5th IAS: GRACE: New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies - (07/21/09)
     
  11784. 5th IAS: African-American Women Need Services is Highlighted in: GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women - (07/21/09)
     
  11785. 5th IAS: Differences in Virologic Response Among African Americans and Females Regardless of Therapy in the HEAT Study: African-Americans Have Lower Viral Response Rates - (07/21/09)
     
  11786. Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1-Infected Individuals - (07/20/09)
     
  11787. 5th IAS: One Third With Undetectable HIV RNA Have Asymptomatic Neurocognitive Impairment - written by Mark Mascolini - (07/20/09)
     
  11788. 5th IAS: Raltegravir and Unboosted Atazanavir as Simple Maintenance Regimen - written by Mark Mascolini - (07/20/09)
     
  11789. 5th IAS: Abacavir Heart Attack Controversy: Kidney Disease Appears to Matter - written by Mark Mascolini - (07/20/09)
     
  11790. 5th IAS: New results from ARTEN study of nevirapine plus tenofovir and emtricitabine (TDF/FTC) versus boosted protease inhibitor regimen of atazanavir/ritonavir plus TDF/FTC revealed - BI Press Release For U.S. Media Only - (07/20/09)
     
  11791. 5th IAS: S/GSK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy - (07/20/09)
     
  11792. 5th IAS: 96-WEEK SAFETY AND EFFICACY FINDINGS PRESENTED FOR INTELENCETM (ETRAVIRINE) AS PART OF HIV COMBINATION THERAPY - Tibotec press release - (07/20/09)
     
  11793. 5th IAS: S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor - (07/20/09)
     
  11794. 5th IAS: Prospective randomised comparison of Nevirapine and Atazanavir/ritonavir both combined with Tenofovir DF/Emtricitabine in treatment-naive HIV-1 infected patients: ARTEN Study week 48 results - (07/20/09)
     
  11795. 5th IAS: NEW HIV STUDY SHOWS THAT LARGE NUMBERS OF WOMEN AND PEOPLE OF COLOR CAN BE SUCCESSFULLY ENROLLED IN U.S. HIV CLINICAL STUDIES - Tibtec press release - (07/20/09)
     
  11796. 5th IAS: IAS Opening Session - Recession Impact - (07/20/09)
     
  11797. 5th IAS: Thinking Through the CNS: The Importance of Considering the Blood-Brain Barrier. Slide talk by Scott Letende, GSK satellite meeting at IAS 2009 - (07/19/09)
     
  11798. 5th IAS: European Researchers Issuing Guidelines on Bone Disease - (07/19/09)
     
  11799. HIV-1 Infection Is Associated With an Earlier Occurrence of Frailty....in MACS - (07/18/09)
     
  11800. Male Circumcision Didn't Reduce HIV Transmission To Women in African Study - (07/18/09)
     
  11801. Male circumcision and HIV risks and benefits for women - EDITORIAL - (07/18/09)
     
  11802. Mortality in WIHS, Women of Color: non-AIDS Events, Viral Replication & low CD4, Depression, Violence, HCV/HBV, Drug Use: Federal AIDS funding neglects inner-city women of color - (07/17/09)
     
  11803. HIV Viral Replication Causes Non-AIDS Events - (07/17/09)
     
  11804. TMC278+Truvada Coformulation Announced by Gilead & Tibotec - (07/17/09)
     
  11805. Lopinavir/Ritonavir in Pregnancy - (07/16/09)
     
  11806. Vicriviroc/Reyataz Nuke-Sparing HAART: Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV - (07/16/09)
     
  11807. Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study - (07/16/09)
     
  11808. Growth Hormone and Sex Steroid Effects on Serum Glucose, Insulin, and Lipid Concentrations in Healthy Older Women and Men - (07/16/09)
     
  11809. MRI Findings May Track Risk of Cognitive Impairment in Healthy Seniors - (07/16/09)
     
  11810. Lower Testosterone Levels Predict Incident Stroke and Transient Ischemic Attack in Older Men - (07/16/09)
     
  11811. Low Serum Testosterone and Estradiol Predict Mortality in Elderly Men - (07/16/09)
     
  11812. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population - (07/15/09)
     
  11813. DDI Associated with NonCirrhotic Portal Hypertension - (07/14/09)
     
  11814. Grinding to a Halt: The Effects of the Increasing Regulatory Burden on Research and Quality Improvement Efforts - IDSA POLICY PRINCIPLES - (07/10/09)
     
  11815. FDA: Isentress (raltegravir) indication extended for the treatment of HIV-1 infection in treatment-naïve patients - (07/10/09)
     
  11816. Glutamic Acid (Vegetables) May Lower Blood Pressure - (07/10/09)
     
  11817. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women - A preliminary study - (07/10/09)
     
  11818. New HIV Research Finds Early Disabled Immune Response - (07/09/09)
     
  11819. Independent effects of physical activity in patients with nonalcoholic fatty liver disease: exercise improves fatty liver & metabolics - (07/08/09)
     
  11820. Nitrates May Be Environmental Trigger For Alzheimer's, Diabetes And Parkinson's Disease - (07/08/09)
     
  11821. Global Consequences of the Future of Aging with HIV - (07/08/09)
     
  11822. Stepped-Dose vs. Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events A Randomized Trial - (07/08/09)
     
  11823. Study finds no increased progression of retinopathy with sanofi-aventis' Lantus - (07/08/09)
     
  11824. Epidemilogical Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer's Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis - (07/08/09)
     
  11825. A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection - full text pdf attached - (07/07/09)
     
  11826. IL-21R on T Cells Is Critical for Sustained Functionality and Control of Chronic Viral Infection - pdf full text attached - (07/07/09)
     
  11827. IL-21 Is Required to Control Chronic Viral Infection - pdf full text attached - (07/07/09)
     
  11828. Immunology Controlling Chronic Viral Infections, EDITORS' CHOICE - (07/07/09)
     
  11829. A Chronic Need for IL-21 EDITORIAL - (07/07/09)
     
  11830. Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy - (07/04/09)
     
  11831. Evidence That Proton-Pump Inhibitor Therapy Induces the Symptoms it Is Used to Treat EDITORIAL - (07/04/09)
     
  11832. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy - (07/04/09)
     
  11833. Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events? - (07/03/09)
     
  11834. IL-7 Increased T-Cells CD4/CD38/Naive/Memory: In HIV, Cytokine Boosts Immune System  - (07/03/09)
     
  11835. Association of Serum C-Reactive Protein Level with Sex-Specific Type 2 Diabetes Risk: A Prospective Finnish Study - (07/03/09)
     
  11836. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance - (07/03/09)
     
  11837. Data are lacking for quantifying HIV transmission risk in the presence of effective antiretroviral therapy EDITORIAL - (07/03/09)
     
  11838. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients - (07/03/09)
     
  11839. Metabolic bone disease in HIV infection: HIV, ART Implicated EDITORIAL - (07/02/09)
     
  11840. First line AZT/3TC/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir - (07/02/09)
     
  11841. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (07/02/09)
     
  11842. Inflammation Marker hsCRP & CVD- Cause or Effect: Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease - (07/02/09)
     
  11843. Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community: "Minimal Benefit In Predicting CVD Compared To Traditional Risk Factors" - (07/02/09)
     
  11844. Biomarkers and Cardiovascular Disease: Determining Causality and Quantifying Contribution to Risk Assessment - Editorial - (07/02/09)
     
  11845. CRP, other biomarkers, not clinically useful to predict CVD risk - (07/02/09)
     
  11846. New meta-analysis: Statins of benefit in primary prevention: improved survival & CVD risk in patients with only risk factors - (07/02/09)
     
  11847. HIV Resistance Wksp: Bulk sequence-detectable resistance mutations in peripheral RNA following single-dose nevirapine are associated with poorer treatment responses but do not adequately explain treatment failure (06/26/09)
     
  11848. HIV Resistance Wksp: Addition of extended zidovudine to extended nevirapine prophylaxis reduces resistance in infants who were HIV-infected in utero: the PEPI- Malawi Study - (06/28/09)
     
  11849. HIV Resistance Wksp: Resistance mutations detected by OLA of HIV-1 DNA at the initiation of nevirapine containing ART are associated with virologic failure - (06/28/09)
     
  11850. HIV Resistance Wksp: Pre-Existing Low-Levels of the K103N HIV-1 RT Mutation Above a Threshold is Associated with Virological Failure in Treatment-Naïve Patients Undergoing EFV-Containing Antiretroviral Treatment (06/16/09)
     
  11851. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants - (06/27/09)
     
  11852. Monitoring bone mineral density during antiresorptive treatment for osteoporosis - Editorial - (06/27/09)
     
  11853. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data - (06/27/09)
     
  11854. The Value of Bone Density Testing - (06/27/09)
     
  11855. Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study - (06/27/09)
     
  11856. Head-to-head 96-week study shows EPZICOM® was comparable to Truvada® -- in efficacy and safety measures -- for HIV treatment-naïve patients - (06/27/09)
     
  11857. HIV Resistance Wksp: Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants - (06/27/09)
     
  11858. HIV Resistance Wksp: CCR5 Tropism Genotype vs Trofile - (06/27/09)
     
  11859. HIV Resistance Wksp: Virco: Population and clonal tropism phenotyping of clinical isolates and comparison with next generation sequencing and prediction tools - (06/27/09)
     
  11860. HIV Resistance Wksp:Quest Tropism Assay: Performance of an HIV-1 Co-receptor Tropism Assay Utilizing Replicate V3 Loop Sequencing and Heteroduplex Analysis with Capillary Electrophoresis - (06/27/09)
     
  11861. HIV Resistance Wksp: Virco: Detection limit of X4 minority virus in abundant R5-tropic virus populations in standard genotypic and phenotypic assays - (06/27/09)
     
  11862. HIV infection and the risk of diabetes mellitus in Vets - (06/26/09)
     
  11863. Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction - (06/26/09)
     
  11864. Analysis of HIV-1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy - (06/26/09)
     
  11865. New HIV Eradication Theory: 2nd reservoir identified, HAART + IL-7 Inhibition - (06/26/09)
     
  11866. HIV Resistance Wksp: HIV Reservoirs and Potential Eradication - Written by Mark A. Wainberg, Ph.D. Professor and Director, McGill University AIDS Centre - (06/26/09)
     
  11867. HIV Resistance Wksp: PERSISTENCE, RESERVOIRS AND ELIMINATION STRATEGIES - Reported by David Margolis, University of North Carolina (06/26/09)
     
  11868. New Anti-Inflammation Modulator Improves Kidney/Diabetes Functions; for CNS disease too - (06/21/09)
     
  11869. Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys - (06/19/09)
     
  11870. HIV Resistance Wksp: Phenotypic Resistance and Response to Tipranavir, evidence for Hypersusceptibility (06/19/09)
     
  11871. HIV Resistance Wksp: Emergence of mutations and phenotypic resistance with tipranavir treatment in protease inhibitor experienced patients (06/19/09)
     
  11872. HIV Resistance Wksp: Tipranavir & Darunavir, Prevalences of mutations in patients with discordant phenotypic resistance from Monogram Biosciences database of routine clinical samples from 2006 - 2008 (06/19/09)
     
  11873. HIV Resistance Wksp: Tipranavir - Phenotypic protease inhibitor resistance in the clinic from 2006 to 2008: available treatment options (06/19/09)
     
  11874. Interleukin-2: Trials and Tribulations; IL-2 Fails Again, EDITORIAL COMMENTARY - (06/17/09)
     
  11875. HIV Resistance Wksp: Genotypic, Phenotypic and Virtual Phenotypic Resistance Patterns for Darunavir and Tipranavir: An Independent Analysis of a Quebec HIV-1 Cohort Highly Resistant to all Other Protease Inhibitors (06/17/09)
     
  11876. HIV Resistance Wksp: Amino Acid Changes in gp41 of HIV-1 Associated with Coreceptor Tropism (06/17/09)
     
  11877. HIV Resistance Wksp: Transitions from CCR5 to CXCR4 use in the absence of antiretroviral drug pressure proceed incrementally and may occur through a multitude of genetic pathways: Monogram Report, Vs loop changes vary (06/17/09)
     
  11878. HIV Resistance Wksp: PI-Resistant Virus Seems More Prone to Emergence of Bevirimat Mutations - written by Mark Mascolini (06/16/09)
     
  11879. HIV Resistance Wksp: Genotypic and Phenotypic Weighted Optimized Background Therapy Susceptibility Scores Are Similarly Strong Predictors of Virologic Response <50 Copies/mL at Week 48 in MOTIVATE 1 and 2 (06/16/09)
     
  11880. HIV Resistance Wksp: 48-Week Results From the Phase 3 Study A4001026 (MERIT) -"Time to Loss of Virologic Response" Virology Analysis of Failures in the Enhanced Trofile®-Censored Subpopulation (06/16/09)
     
  11881. 7th Euro HIV Drug Resis Wrkshp: Ultradeep pyrosequencing and phenotypic analysis to characterize the V3 genetic diversity among HIV-1 primary isolates and their responses to maraviroc - (06/16/09)
     
  11882. HIV Resistance Wksp: High -Prevalence of bevirimat resistance mutations in non-B subtypes and in PI resistant HIV isolates (06/16/09)
     
  11883. HIV Resistance Wksp: Resistance Mutations in the Viral Protease Alter Bevirimat Resistance Patterns in vitro (06/16/09)
     
  11884. HIV Resistance Wksp: Prevalence and Clinical Significance of Transmitted Drug Resistant HIV Mutations by Ultra-Deep Sequencing in HIV-Infected ARV-Naïve Subjects in the CASTLE Study (06/16/09)
     
  11885. HIV Resistance Wksp: Confirmation of the negative impact of protease mutations I47V, I54M, T74P and I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir (06/16/09)
     
  11886. HIV Resistance Wksp: Swiss Cohort Analysis Reveals Clusters of Transmitted Resistant HIV: "make sure patient names remain unlinked to transmission analyses" - written by Mark Mascolini - (06/16/09)
     
  11887. HIV Resistance Wksp: Low-Level K103N in Primary Infection Can Reappear After Suppressive Therapy - written by Mark Mascolini - (06/16/09)
     
  11888. HIV Resistance Wksp: CCR5 and CCR5 Screening Assays Comparisons: genotype, 454 Ultra-Deep Sequencing and Trofile (06/15/09)
     
  11889. HIV Resistance Wksp: Screening for HIV Tropism Using Population-Based V3 Genotypic Analysis: A Retrospective Virological Outcome Analysis Using Stored Plasma Screening Samples From MOTIVATE 1 (06/15/09)
     
  11890. HIV Resistance Wksp: In-vitro resistance profile of TMC278, a next-generation NNRTI: evidence of a higher genetic barrier and a more robust resistance profile than first-generation NNRTIs (06/15/09)
     
  11891. HIV Resistance Wksp: Weighted Genotype and Phenotypic Scores Predict Response to Maraviroc - written by Mark Mascolini - (06/15/09)
     
  11892. HIV Resistance Wksp: Key Etravirine Mutations Also Render HIV Resistant to Rilpivirine - written by Mark Mascolini - (06/15/09)
     
  11893. HIV Resistance Wksp: STD History Tied to Infection With Resistant HIV in San Francisco - written by Mark Mascolini - (06/15/09)
     
  11894. HIV Resistance Wksp: Low-Level Etravirine Mutations With K103N After NNRTI Failure - written by Mark Mascolini - (06/15/09)
     
  11895. HIV Resistance Wksp: Low-Level Q148R in People Without Integrase Inhibitor Experience - written by Mark Mascolini - (06/15/09)
     
  11896. HIV Resistance Wksp: Evolving Mutation Patterns Traced During Elvitegravir Failure - written by Mark Mascolini - (06/15/09)
     
  11897. HIV Resistance Wksp: Rising Rates of 3-Class Exposure But Falling Failure Rate in US Cities - written by Mark Mascolini - (06/15/09)
     
  11898. HIV Resistance Wksp: Transmitted Multidrug-Resistant HIV Persists in PBMC DNA for Years - written by Mark Mascolini - (06/15/09)
     
  11899. HIV Resistance Wksp: The HIV-1 RT Mutant Q151L Shows Decreased Replication Capacity, Selective High-Level Resistance to GS-9148 and Hypersusceptibility to Tenofovir and Zidovudine - (06/15/09)
     
  11900. HIV Resistance Wksp: HBV Resistance to Lamivudine at Undetectable and Low Levels of Viremia - written by Mark Mascolini - (06/15/09)
     
  11901. HIV Resistance Wksp: Early Response to Maraviroc Equivalent With Coreceptor Genotyping and Trofile Phenotyping - written by Mark Mascolini - (06/15/09)
     
  11902. HIV Resistance Wksp: Most Low-Level Pretreatment Mutations Did Not Affect Outcome in PI Trial - written by Mark Mascolini - (06/15/09)
     
  11903. HIV Resistance Wksp: Cutoffs Suggested for Predicting Efavirenz Failure With Low-Level K103N - written by Mark Mascolini - (06/15/09)
     
  11904. HIV Resistance Wksp: Regimens Lacking CCR5 Antagonists Have Minimal Impact on Coreceptor Use - written by Mark Mascolini - (06/12/09)
     
  11905. HIV Resistance Wksp: Lower M184V Rates With FTC/TDF Than With 3TC/TDF - written by Mark Mascolini - (06/12/09)
     
  11906. HIV Resistance Wksp: Raltegravir Did Not Lower HIV DNA Levels in Cell Reservoirs in Salvage Patients in 24 Weeks - written by Mark Mascolini - (06/12/09)
     
  11907. HIV Resistance Wksp: Intensification of Already Suppressive Therapy with Raltegravir Had No Impact on Low-Level (sub-50-copy) Viremia - written by Mark Mascolini - (06/12/09)
     
  11908. HIV Resistance Wksp: HIV Genetic Diversity Does Not Change Much After Complete Viral Control - written by Mark Mascolini - (06/12/09)
     
  11909. HIV Resistance Wksp: NNRTI/PI Regimen More Prone to Resistance Than Standard Triple Combos - written by Mark Mascolini - (06/12/09)
     
  11910. HIV Resistance Wksp: Success Rate With Genotype-Guided First Regimen Near 90% in California - written by Mark Mascolini - (06/12/09)
     
  11911. Thiazolidinediones and clinical outcomes in type 2 diabetes Comment - (06/09/09)
     
  11912. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial - (06/09/09)
     
  11913. PPI Use & Risk For Hip Fracture (Tagamet & Zantac to) - (06/09/09)
     
  11914. Drug Interactions with New and Investigational Antiretrovirals: darunavir, etravirine, rilpivirine (TMC278), maraviroc, vicriviroc, raltegravir, elvitegravir, INCB 9471 (CCR5), bevirimat [Review Articles] - (06/09/09)
     
  11915. Can HIV Be Eradicated? - (06/08/09)
     
  11916. Study in Neurology journal (Aug 2008) Reports Alzheimers Appears to Precede Frailty and Study in Jnl of Geronotology (2007) in the MACS Cohort Reports Risk of Frailty Higher in HIV+ vs HIV-; is early onset of Alzheimers or some other brain or cognitive dysfunction related to early onset and higher rates of frailty among HIV+? - (06/08/09)
     
  11917. DATA ON INVESTIGATIONAL DRUG TMC207 FOR TREATMENT OF MDR-TUBERCULOSIS, PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE - Tibotec announcement - (06/05/09)
     
  11918. TMC207, New Drug for TB MultiDrug Resistant (MDR) & XDR (extensively drug resistant) - (06/05/09)
     
  11919. Aspirin in CVD primary prevention: sex and baseline risk matter - (06/04/09)
     
  11920. Gardasil in Older Women Aged 24-45 Years - (06/04/09)
     
  11921. FDA Approves Zoledronic Acid - Reclast(R) - to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing, Once Every 2 Years - (06/03/09)
     
  11922. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy - (06/03/09)
     
  11923. Maraviroc Safety/CD4 - A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1 - (06/03/09)
     
  11924. HIV Viremia and the Development of AIDS-Related Lymphoma in Patients Treated with Highly Active Antiretroviral Therapy - EDITORIAL COMMENTARY - (06/03/09)
     
  11925. Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictor of AIDS-Related Lymphoma - (06/03/09)
     
  11926. CROI: Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (06/02/09)
     
  11927. Antiaging Therapy with TAT2: Telomerase-Based Pharmacologic Enhancement of Antiviral Function of Human CD38+ T Lymphocytes - (06/02/09)
     
  11928. Modulation of T Lymphocyte Replicative Senescence via TNF-{alpha} Inhibition: Role of Caspase-31 - (06/01/09)
     
  11929. Duration of antihypertensive drug use and risk of dementia: "Antihypertensive drug use was associated with 8% risk reduction of dementia per year of use for persons <75 years." - (05/29/09)
     
  11930. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons - (05/29/09)
     
  11931. Hypertension and late-life dementia - Editorial - (05/29/09)
     
  11932. Routine Use of Antihypertensive Medications Recommended For All Older People Even Those Who Do Not Have High Blood Pressure - (05/29/09)
     
  11933. Give blood pressure drugs to all - Criticism/Commentary - (05/29/09)
     
  11934. Editorials Management of blood pressure in primary care - (05/29/09)
     
  11935. In NFL, Higher Rates of Hypertension/Prehypertension & BMI (large size) Associated with Increased Cardiovascular Risk - (05/28/09)
     
  11936. Review of Prostate Cancer Treatment A 64-Year-Old Man With Low-Risk Prostate Cancer - (05/28/09)
     
  11937. Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients - (05/28/09)
     
  11938. Improvement in Lipid Profiles in Antiretroviral-Experienced HIV-Positive Patients With Hyperlipidemia After a Switch to Unboosted Atazanavir - (05/28/09)
     
  11939. Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis - (05/28/09)
     
  11940. Lipoatrophy Influenced by Genetics - (05/28/09)
     
  11941. Lipoatrophy and lipohypertrophy (belly fat not associated after BMI factored in) are independently associated with hypertension - (05/27/09)
     
  11942. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? - (05/27/09)
     
  11943. Hyperglycaemia and coronary heart disease: the meta picture - EDITORIAL - (05/27/09)
     
  11944. It is "premature to conclude that glucose control has no part to play." - (05/27/09)
     
  11945. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials - (05/27/09)
     
  11946. The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals - (05/27/09)
     
  11947. Sustained release of microbicides by newly engineered vaginal rings - TMC120/tenofovir/AZT - (05/26/09)
     
  11948. Interaction of Ginkgo biloba with efavirenz - (05/26/09)
     
  11949. Efavirenz and bone health - (05/22/09)
     
  11950. Maturation Inhibitor Bevirimat, now called MPC-4326, Starting Phase 2b in 2nd Half 2009 - (05/22/09)
     
  11951. Efavirenz and bone health - (05/22/09)
     
  11952. Maturation Inhibitor Bevirimat, now called MPC-4326, Starting Phase 2b in 2nd Half 2009 - (05/22/09)
     
  11953. Does HIV Increase Prostate Cancer Risk? - (05/21/09)
     
  11954. Effects of Oxidation and Inflammation, Cancer, Prostate Cancer - (05/21/09)
     
  11955. ACTG 5142 Published: Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment - (05/21/09)
     
  11956. HIV viremia and changes in kidney function - (05/21/09)
     
  11957. ACTG 5164 Published: Early HAART Reduces AIDS/Death in Individuals with Acute OIs - (05/21/09)
     
  11958. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men - (05/21/09)
     
  11959. Immune Exhaustion in Aging and AIDS: Parallel Mechanisms and Possible Solutions - (05/21/09)
     
  11960. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis - (05/20/09)
     
  11961. Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men - (05/18/09)
     
  11962. Kidney Damage in Metabolic Syndrome: Nip It in the Bud - EDITORIAL - (05/18/09)
     
  11963. Kidney Pathological Changes in Metabolic Syndrome: A Cross-sectional Study - (05/18/09)
     
  11964. C-Reactive Protein, Statins, and Cardiovascular Risk: What Can JUPITER Teach Us? - (05/18/09)
     
  11965. 10th Int PK Wrkshp: 10th International Workshop on Clinical Pharmacology of HIV Therapy Written by Courtney V. Fletcher, Pharm.D. - (05/18/09)
     
  11966. Predicting risk of dementia in older adults. The late-life dementia risk index - Aging !!!! - (05/15/09)
     
  11967. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence - REVIEW ARTICLE - (05/15/09)
     
  11968. Ejaculation Frequency and Subsequent Risk of Prostate Cancer - "high ejaculation frequency was related to decreased risk of total prostate cancer." - (05/15/09)
     
  11969. Data on the Use of GARDASIL in Men Presented at the 25th Annual International Papillomavirus Conference - (05/15/09)
     
  11970. THE EFFFICACY OF QUADRIVALENT HPV (TYPES 6/11/16/18) VACCINE AGAINST HPV-RELATED GENITAL DISEASE AND INFECTION IN YOUNG MEN - (05/15/09)
     
  11971. Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects - (05/14/09)
     
  11972. Association between hypothyroidism and hepatocellular carcinoma: A case-control study in the United States; Increased Hypothyroidism Reported un HIV+ - (05/14/09)
     
  11973. Elevated A1C in Adults Without a History of Diabetes in the U.S. - (05/14/09)
     
  11974. Tenative approval of lamivudine/zidovudine fixed dose combination tablets plus nevirapine tablets - (05/14/09)
     
  11975. Raltegravir+Etravirine - Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort - (05/14/09)
     
  11976. Increased Reporting of Detectable Plasma HIV-1 RNA Levels at the Critical Threshold of 50 Copies per Milliliter With the Taqman Assay in Comparison to the Amplicor Assay - (05/14/09)
     
  11977. Implementation of HIV Testing at 2 New York City Bathhouses: From Pilot to Clinical Service (4% HIV+) - (05/14/09)
     
  11978. Availability of HIV Postexposure Prophylaxis Services in Los Angeles County - (05/14/09)
     
  11979. RNA Testing for HIV Instead of Antibody Testing Could Detect Early Stage of HIV Infection And Would Likely Improve Prevention AND Allow for Early HAART' Could it Prevent Accelerated Aging? - (05/13/09)
     
  11980. Dementia with features of Alzheimer's disease and HIV-associated dementia in an elderly man with AIDS (case study) - (05/13/09)
     
  11981. Cancers in HIV Review in AIDS May 15 2009 - (05/13/09)
     
  11982. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial - (05/13/09)
     
  11983. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival (NA-ACCORD): deferring HAART til <500 CD4s increased risk of death 94% - (05/11/09)
     
  11984. WHO Guidance for HIV Patient Care & Swine Flu - (05/11/09)
     
  11985. HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials - (05/11/09)
     
  11986. Hypoglycemia Increased Risk for Death in Diabetics with Chronic Kidney Disease: - (05/11/09)
     
  11987. 10th Int PK Wrkshp: First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Negative Women - (04/30/09)
     
  11988. Interim Results of Abbott's PROGRESS Study Show Rapid Viral Decline in Dual-Therapy Regimen of Kaletra® (lopinavir/ritonavir) and Raltegravir - Abbott press release - (04/30/09)
     
  11989. Sunlight and Vitamin D Both Good for Cardiovascular Health - (04/22/09)
     
  11990. Tight Glycemic Control NOT Recommended for Diabetics in Annals Review - (04/22/09)
     
  11991. A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart Disease - (04/22/09)
     
  11992. 10th Int PK Wrkshp: Raltegravir Levels in Cervicovaginal Fluid May Prompt PEP and PrEP Studies - written by Mark Mascolini - (04/21/09)
     
  11993. 10th Int PK Wrkshp: Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor - written by Mark Mascolini - (04/20/09)
     
  11994. 10th Int PK Wrkshp: Differing Darunavir Troughs With Once- and Twice-Daily Dosing in Practice - written by Mark Mascolini - (04/20/09)
     
  11995. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial - (04/20/09)
     
  11996. Glucocorticoid-induced osteoporosis: hope on the HORIZON-COMMENT once yearly infusion therapy better than once weekly - (04/20/09)
     
  11997. Reversing HIV T-Cell Aging - (04/20/09)
     
  11998. HIV-1 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty: HIV+ men in MACS 10-Times More Likely to Exhibit Frailty than HIV-negative Men. - (04/20/09)
     
  11999. MACS Frailty/HIV/CD4 Study Misses The Point - (04/20/09)
     
  12000. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance - (04/20/09)
     
  12001. PrEP, Microbicides and IL-2 - (04/20/09)
     
  12002. 15th Annual British HIV Conference April 1-3 2009 Abstracts/Presentations - (04/20/09)
     
  12003. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up - (04/20/09)
     
  12004. Lopinavir/Ritonavir (LPV/r) Combined With Raltegravir (RAL) Provides More Rapid Viral Decline Than LPV/r Combined With Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-naïve HIV-1 Infected Subjects - (04/20/09)
     
  12005. Ignoring Addiction in Prison/Jails Increases HIV & HCV Infections - (04/20/09)
     
  12006. Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus - (04/20/09)
     
  12007. the REYATAZ and SUSTIVA Co-pay Benefit Program - (04/20/09)
     
  12008. Treatment Interruption Revisited with LOTTI Study: authors reported interruptions were not inferior to continuous HAART in this study - (04/20/09)
     
  12009. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases - (04/20/09)
     
  12010. 10th Int PK Wrkshp: Unboosted Atazanavir Plus Raltegravir Analyzed as Two-Drug Replacement Regimen - written by Mark Mascolini - (04/20/09)
     
  12011. 10th Int PK Wrkshp: Etravirine Levels Higher When Added After Darunavir vs With Darunavir - written by Mark Mascolini - (04/20/09)
     
  12012. 10th Int PK Wrkshp: Enfuvirtide-to-Raltegravir Switch Lowers Levels of Darunavir and Tipranavir - written by Mark Mascolini - (04/20/09)
     
  12013. CROI: Prevention of Rectal Simian HIV Transmission in Macaques by Intermittent Pre-exposure Prophylaxis with Oral Truvada - (04/17/09)
     
  12014. 10th Int PK Wrkshp: Efavirenz Lowers Levels of Darunavir Given as 900/100 mg Once Daily With Ritonavir - (04/16/09)
     
  12015. 10th Int PK Wrkshp: Early Look at Once-Daily Darunavir/Ritonavir for Treatment-Experienced Patients - written by Mark Mascolini - (04/16/09)
     
  12016. 10th Int PK Wrkshp: How Much (or How Little) Ritonavir Do You Need to Boost Another PI? - written by Mark Mascolini - (04/16/09)
     
  12017. 10th Int PK Wrkshp: Lopinavir/Ritonavir Monotherapy as an Antiretroviral Stopping Strategy - written by Mark Mascolini - (04/16/09)
     
  12018. 10th Int PK Wrkshp: Genetic Markers Tied to Early Discontinuation of Three Antiretrovirals - (04/16/09)
     
  12019. IDUs Risky Behavior: < 32% share syringes/63% have unprotected vaginal sex, CDC Study - (04/10/09)
     
  12020. Screening for Albuminuria Identifies Individuals at Increased Renal Risk - (04/10/09)
     
  12021. Should the CD4 threshold for starting ART be raised? Commentary - (04/10/09)
     
  12022. Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints - (04/10/09)
     
  12023. Vitamin D Deficiency in Older Men - (04/09/09)
     
  12024. Relationships of Serum 25-Hydroxyvitamin D to Bone Mineral Density and Serum Parathyroid Hormone and Markers of Bone Turnover in Older Persons - (04/09/09)
     
  12025. The Relationship Between Prolonged Antiretroviral Therapy and Cryptogenic Liver Disease - (04/09/09)
     
  12026. Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome? EDITORIAL - (04/09/09)
     
  12027. Leptin Improved Belly Fat/Dyslipidemia - The Effects of Recombinant Human Leptin on Visceral Fat, Dyslipidemia, and Insulin Resistance in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy and Hypoleptinemia - Pilot Study - (04/09/09)
     
  12028. Belly Fat & Women. Adipokines, Inflammation, and Visceral Adiposity across the Menopausal Transition: A Prospective Study - (04/09/09)
     
  12029. Broccoli sprouts appear to reduce risk for stomach cancer, reduced inflammation in stomach. - (04/08/09)
     
  12030. End-Stage Liver Disease in HIV+ in France A Leading Cause of Death - (04/03/09)
     
  12031. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study - (04/03/09)
     
  12032. 'When to Start HAART' Experts Disagree-NEJM Study - (04/03/09)
     
  12033. Does Inflammation Fuel the Fire in CKD? - (04/03/09)
     
  12034. HPV Test vs Cytologic Testing or Visual Inspection: HPV Screening for Cervical Cancer in Rural India - (04/03/09)
     
  12035. When to Start Antiretroviral Therapy - Ready When You Are? EDITORIAL (NA-ACCORD) - (04/03/09)
     
  12036. Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes - (04/02/09)
     
  12037. Aspirin, salicylates, and cancer - (03/31/09)
     
  12038. JUPITER Study Reports Reducing hsCRP & LDL to Low Levels with Statin rosuvastatin Further Reduced Cardiovascular Risk - (03/31/09)
     
  12039. JUPITER: Rosuvastatin reduces risk of VTE in healthy subjects - (03/31/09)
     
  12040. EHDRW: Comparison of two etravirine weighted genotypic scores with phenotypic susceptibility and virological response data (03/31/09)
     
  12041. EHDRW: No Darunavir & Kaletra Major PI Mutations in ARTEMIS 96 Weeks (03/31/09)
     
  12042. EHDRW: Low-Level Transmitted K103N Mutation Predicts Virologic Failure - Written by Mark Mascolini (03/31/09)
     
  12043. EHDRW: No Resistance to Darunavir or Lopinavir After 96 Weeks in ARTEMIS - Written by Mark Mascolini (03/31/09)
     
  12044. EHDRW: Weighted Genotyping Scores Work Equally Well in Predicting Response to Etravirine - Written by Mark Mascolini (03/31/09)
     
  12045. EHDRW: Weighted Genotypic Score Predicts Response to Maraviroc in MOTIVATE Trials - Written by Mark Mascolini (03/30/09)
     
  12046. ART Interruption in Pregnancy Increases MTCT - (03/30/09)
     
  12047. Tight glucose control may increase mortality in critically ill patients - (03/30/09)
     
  12048. Intensive versus Conventional Glucose Control in Critically Ill Patients The NICE-SUGAR Study Investigators - (03/30/09)
     
  12049. Glucose Control in the ICU - How Tight Is Too Tight? EDITORIAL - (03/30/09)
     
  12050. Transfer of HIV between T Cells Captured on Video - (03/30/09)
     
  12051. Application of Lower Sodium Intake Recommendations to Adults --- United States, 1999--2006 - (03/30/09)
     
  12052. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study - (03/30/09)
     
  12053. Prevalence and Pathogenesis of Diabetes Mellitus in HIV-1 Infection Treated With Combined Antiretroviral Therapy - (03/30/09)
     
  12054. EHDRW: Genotyping for Coreceptor Use Concordant With Trofile in PBMCs and Plasma: from Jules- genotyping this falls short - Written by Mark Mascolini - (03/27/09)
     
  12055. EHDRW: HIV-Induced CD4 Declines Affect Immune Response to HBV in Untreated People - Written by Mark Mascolini - (03/27/09)
     
  12056. Prevention of Viral Sexually Transmitted Infections - Foreskin at the Forefront (male circumcision) EDITORIAL - (03/27/09)
     
  12057. Midlife Patients With HIV or AIDS Require Care for Chronic Conditions: "HIV simulates aging" - (03/27/09)
     
  12058. Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV-Infected Men: The HIPVIRG Cohort Study - (03/27/09)
     
  12059. Avexa Reaches First Critical Evaluation Point for new NRTI ATC's Phase III Trial - (03/27/09)
     
  12060. Tight glucose control may increase mortality in critically ill patients - (03/27/09)
     
  12061. Male Circumcision for the Prevention of HSV-2 and HPV Infections and Syphilis: circumcision prevents HSV-2 and HPV - (03/27/09)
     
  12062. EHDRW: Viral Loads--But Not Transmission of Resistant Virus--Falling in Italian Cohort - Written by Mark Mascolini - (03/27/09)
     
  12063. EHDRW: Resistance Testing Is Not Standard-of-Care After Antiretroviral Failure in Europe - Written by Mark Mascolini - (03/27/09)
     
  12064. EHDRW: Cumulative Resistance Score Gives Broader View of Potential Antiretroviral Activity - Written by Mark Mascolini - (03/27/09)
     
  12065. CROI: Non-HIV Markers Add to HIV Signals in Predicting VA Cohort Deaths - written by Mark Mascolini - (03/25/09)
     
  12066. CROI: US and Canadian Studies Trace Impact of Resistance Results on Mortality - written by Mark Mascolini - (03/25/09)
     
  12067. CROI: Higher Rate of Non-AIDS Infection-Related Cancers With HIV May Be Waning in HAART Era - written by Mark Mascolini - (03/25/09)
     
  12068. ISHLVD: Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) - (03/25/09)
     
  12069. ISHLVD: Developing HBV/HCV Associated Liver Cancer At A Young Age < 40 Yrs Old - (03/25/09)
     
  12070. ISHLVD: Estimated Prevalence of Chronic Hepatitis B (CHB) in Foreign-Born (FB) Persons Living in the United States (U.S.) by Country/Region of Origin - (03/23/09)
     
  12071. ISHLVD: Federal Government's Response to Viral Hepatitis - (03/23/09)
     
  12072. ISHLVD: Key Health Care Provisions in Stimulus Legislation - (03/23/09)
     
  12073. ISHLVD: HCV Burden of Disease and Associated Costs: An Overview - (03/23/09)
     
  12074. ISHLVD: Barriers to HCV Care - (03/23/09)
     
  12075. Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-Treated HIV Infection - (03/24/09)
     
  12076. Is HIV Eradication Feasible? - (03/20/09)
     
  12077. CROI: Neurologic Complications of HIV Disease and Their Treatment - written by Scott L. Letendre, M.D. et al - (03/19/09)
     
  12078. HIV-Specific IgG in Cervicovaginal Secretions of Exposed HIV-Uninfected Female Sexual Partners of HIV-Infected Men - (03/19/09)
     
  12079. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants: ART before age 3 months dramatically reduces AIDS/death - (03/19/09)
     
  12080. Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhbitor - (03/19/09)
     
  12081. Vicriviroc Does Not Increase Epstein-Barr Virus Replication: CCR5 and lymphoma - (03/19/09)
     
  12082. Changes in Cancer Mortality among HIV-infected Patients: The Mortalite 2005 Survey - (03/19/09)
     
  12083. Malignancy-Related Deaths among HIV-Infected Patients: increasing problems with cancers & non-AIDS events - EDITORIAL COMMENTARY - (03/19/09)
     
  12084. New Apricitabine 96 Week Data, Phase 3 Data Expected - (03/19/09)
     
  12085. Depletion of CD4+ T Cells in Semen During HIV Infection and Their Restoration Following Antiretroviral Therapy - (03/19/09)
     
  12086. Relationship Between HIV Coreceptor Tropism and Disease Progression in Persons With Untreated Chronic HIV Infection: naives with D/m progress more quickly, early ART? - (03/19/09)
     
  12087. CROI: Mitochondrial DNA Levels in Pregnancy Are Not Decreased in ARV-treated Women Compared to HIV- Controls - (03/18/09)
     
  12088. CROI: Raltegravir In Children and Adolescents: The French Expanded Access Program - (03/18/09)
     
  12089. CROI: Prognosis of Non-Hodgkin's Lymphoma in HIV-infected Patients - (03/18/09)
     
  12090. CROI: Influence of ART on Incidence and Prognosis of HIV-1-associated Non-Hodgkin's Lymphoma: European Multi-Cohort Study, CD4 Predicts Non-Hodgkin's Lymphoma - (03/18/09)
     
  12091. CROI: Effect of HIV Co-infection on the Outcome of Viral Cirrhosis Liver Transplant Candidates on the Waiting List at a Reference Center from 2001 to 2008 - (03/17/09)
     
  12092. CROI: Liver Transplantation in 88 HIV-infected Patients - (03/17/09)
     
  12093. CROI: HCV Causes Neurcognitive Impairment in HIV+ - (03/17/09)
     
  12094. CROI: HCV Inflames the Brain in HIV Coinfected in Acute HCV - (03/17/09)
     
  12095. CROI: Review of HIV+ Patient's Immunological Response Rate to High-dose HBV Re-vaccination Series: Cd4 & viral load predict response - (03/17/09)
     
  12096. CROI: 5-Year Survival of HCV/HIV-co-infected Liver Transplant Recipients in Spain: A Case/Control Study - (03/17/09)
     
  12097. CROI: Predictors of Chronic HBV Infection in HIV-infected Individuals: HAART Can Prevent Chronic HBV - (03/17/09)
     
  12098. CROI: Interruption of ART and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in Strategies for Management of ART Viral Hepatitis-co-infected Participants and Matched Controls - (03/17/09)
     
  12099. CROI: Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Co-infected Patients - (03/17/09)
     
  12100. CROI: The Long-term Use of Tenofovir in HIV/HBV Co-infection Induces a Marked Decrease in Liver Fibrosis - (03/17/09)
     
  12101. CROI: ART Reinitiation and HBV Rebound among HIV/HBV-co-infected Patients following ART Interruption in the Strategies for the Management of ART Study - (03/17/09)
     
  12102. CROI: Association of Non-cirrhotic Portal Hypertension in HIV-infected Persons and ART with Didanosine - (03/17/09)
     
  12103. CROI: Prolonged ART and Risk for Chronic Elevation of Alanine Aminotransferase in HIV-infected Persons without HBV or HCV Co-infections - (03/17/09)
     
  12104. CROI: Incidence and Predictors of Acute Renal Failure in an Urban Cohort of Patients with HIV and Hepatitis C Co-infection - (03/17/09)
     
  12105. CROI: High Prevalence of Hepatic Fibrosis and Steatosis in HIV/AIDS Patients without Chronic Viral Hepatitis but with Chronically Elevated Transaminases on ART - (03/17/09)
     
  12106. CROI: Progression of Liver Fibrosis in a Large Cohort of HIV Patients Over 4 Years: Emerging Contribution of Antiretrovirals and Metabolic Abnormalities - (03/17/09)
     
  12107. Human Immunodeficiency Virus in Semen and Plasma: Investigation of Sexual Transmission Risk Behavioral Correlates - (03/16/09)
     
  12108. CROI: Rosiglitazone Improves Lipoatrophy in Patients Receiving Thymidine-sparing Regimens - (03/16/09)
     
  12109. CROI: Platelet Hyper-Reactivity in HIV-1-infected Patients on Abacavir-containing ART - (03/16/09)
     
  12110. CROI: Association of Abacavir and HIV Disease Factors with Endothelial Function in Patients on Long-Term Suppressive Antiretroviral Therapy - (03/16/09)
     
  12111. CROI: HIV in Semen Despite Undetectable in Blood: "residual risk of transmission is still possible during unprotected intercourse" - (03/16/09)
     
  12112. HIV-1 Can Persist in Aged Memory CD4+ T Lymphocytes With Minimal Signs of Evolution After 8.3 Years of Effective Highly Active Antiretroviral Therapy - (03/12/09)
     
  12113. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults - (03/12/09)
     
  12114. CROI: Inflammatory Markers among Abacavir and non-Abacavir Recipients in the Womens' Interagency HIV Study and the Multicenter AIDS Cohort Study - (03/13/09)
     
  12115. CROI: High-density Lipoprotein Particles but Not Low-density Lipoprotein Particles Predict Cardiovascular Disease Events in HIV Patients: Strategies for Management of ART Study - (03/13/09)
     
  12116. How Inflammatory Disease Causes Fatigue: chronic inflammation infiltrates the brain but can be blocked - (03/10/09)
     
  12117. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction - (03/10/09)
     
  12118. New Microbcide Discovery in Monkeys from Ashley Haase - (03/10/09)
     
  12119. CROI: Microbicide gel PRO 2000 may help against HIV -Commentary - (03/10/09)
     
  12120. Response (safety, efficacy) to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection - (03/10/09)
     
  12121. National Women and Girls HIV/AIDS Awareness Day March 10, 2009 - - (03/10/09)
     
  12122. Use of Cognitive Enhancement Drugs - (03/10/09)
     
  12123. CROI: Antiretroviral agents that inhibit CCR5-utilizing HIV-1 - written by Eric S. Daar, M.D. (03/10/09)
     
  12124. CROI: Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (03/10/09)
     
  12125. CROI: Association between Modifiable and Non-modifiable Risk Factors and Specific Causes of Death in the HAART Era: The Data Collection on Adverse Events of Anti-HIV Drugs Study -DAD Study - (03/09/09)
     
  12126. CROI: Activation (Inflammation) and Coagulation Biomarkers are Independent Predictors for the Development of Opportunistic Disease in Patients with HIV Infection - (03/09/09)
     
  12127. CROI: Biological Determinants of Immune Reconstitution following Long-term HAART: host factors & persistent gut microbial translocation drive chronic immune activation - (03/09/09)
     
  12128. The Challenge of Finding a Cure for HIV Infection - (03/09/09)
     
  12129. CROI: HIV+ Die More Quickly in FRAM & Low CD4 Predicts Death - (03/09/09)
     
  12130. CROI: Inflammation, Cancers and Other Life Threats for People Living with HIV - written by David Alain Wohl, MD - (03/06/09)
     
  12131. WHO | The unexplored story of HIV and ageing - (03/05/09)
     
  12132. CROI: Osteopenia and Osteoporosis in HIV-infected Patients Are Associated with Reduced Frequency of Central Memory CD38+CD127+ T Cells: T-cell activation/senescence associated with bone loss - (03/05/09)
     
  12133. CROI: Evidence of persistent low-level viremia in long-term HAART-suppressed individuals - (03/05/09)
     
  12134. CROI: Brain Damage, Comorbidities and Early Death Threaten HIV+ - (03/05/09)
     
  12135. CROI: Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study: boosted PI+TDF associated with renal function - (03/05/09)
     
  12136. CROI: Viral Hepatitis is Associated with Reduced Bone Mineral Density in HIV-Infected Women but Not Men - (03/04/09)
     
  12137. CROI: First Report of Dose/Response Data of HIV-infected Men Treated with Vitamin D3 Supplements - (03/04/09)
     
  12138. CROI: Effects of Aging on HIV-1 Pathogenesis: HIV causes inflammation & T-cell activation, reported here to be more in postmenopausal women - (03/04/09)
     
  12139. CROI: Raltegravir Intensification, Viral Replication, HIV Reservoirs & HAART - (03/04/09)
     
  12140. CROI: Bone/Osteoporosis CROI 2009 Update - written by Todd Brown, MD, PhD (03/04/09)
     
  12141. CROI: Persisting High Prevalence of HIV Distal Sensory Peripheral Neuropathy in the Era of Combination ART: Correlates in the CHARTER Study - (03/04/09)
     
  12142. CROI: Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome and Mortality during a Randomized Trial of Early versus Deferred ART in the Setting of Acute Opportunistic Infections (ACTG A5164) - (03/04/09)
     
  12143. CROI: The Long Term Use of Tenofovir Disoproxil in HIV-HBV Co-Infection Induces a Marked Decrease in Liver Fibrosis - (03/04/09)
     
  12144. CROI: Viro-Immunologic Abnormalities in Gut Associated Lymphoid Tissue Caused by Acute HIV Infection are not Reverted by Early Initiation of HAART - (03/04/09)
     
  12145. CROI: Ongoing Viral Replication in the Gut Despite HAART Suppressive Viral Control: Lack of Compartmentalization of HIV HIV-1 Quasispecies and Circulation of CXCR4 using HIV-1 between Gut Associated Lymphoid Tissue (GALT) and the Peripheral Blood (PB) - (03/04/09)
     
  12146. CROI: HIV-1 Induces Apoptosis in primary Osteoblasts: an Alternative Mechanism in the Osteopenia/Osteoporosis Development - (03/04/09)
     
  12147. CROI: GENDER AND GONADAL FUNCTION DIFFERENCES IN THE PREVALENCE OF BONE MASS REDUCTION: higher rates of osteopenia and osteoporosis for men vs women and at early ages, in their 40s. - (03/04/09)
     
  12148. CROI: Immune Senescence, Activation and Abnormal T cell Homeostasis Despite Effective HAART, A Hallmark of Early Aging in HIV Disease - (03/03/09)
     
  12149. CROI: Changes in Bone Turnover, OPG/RANKL, and Inflammation with ART Initiation: A Comparison of Tenofovir- and Non-Tenofovir-Containing Regimens - (03/03/09)
     
  12150. CROI: Evaluation of peripheral DEXA Bone Densitometry to identify low bone mineral density in HIV- infected men in UK: 60% osteopenia, 13% osteoporosis- median age 41 yrs; t-score/dexa predicts fracture in HIV - (03/03/09)
     
  12151. CROI: Clinical Determinants of Bone Mineral Density (BMD) in Perinatally HIV-Infected Children - (03/03/09)
     
  12152. CROI: HIV Drug Pipeline at CROI - (03/03/09)
     
  12153. CROI: Bone Mineral Density in HIV+ Women: Relationship to Body Composition - (03/03/09)
     
  12154. CROI: Preferential Bone Demineralization at the Hip in Treated HIV+ Males: Another Example of Premature Aging? - (03/03/09)
     
  12155. CROI: Determinants (HIV, Cytokines) of Low Bone Density in Postmenopausal HIV+ Women - (03/03/09)
     
  12156. CROI: Short term bone loss in HIV infected premenopausal women - (03/03/09)
     
  12157. CROI: Back to Basics: the science at CROI focuses the tough questions that remain in HIV pathogenesis, Part 2 (focal points for new therapies.) - written by David Margolis MD, University of North Carolina - (03/03/09)
     
  12158. CROI: Back to Basics: the science at CROI focuses on the tough questions that remain in HIV pathogenesis - written by David Margolis, MD, University of North Carolina - (02/24/09)
     
  12159. CROI: HIV-Associated Peripheral Neuropathy in the HAART Era: Results from AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Protocol A5001 - (03/02/09)
     
  12160. Kaletra + Raltegravir PROGRESS Study - (03/02/09)
     
  12161. Kidney Disease in Patients with HIV Infection and AIDS - (03/02/09)
     
  12162. CROI: Metabolic Syndrome, Diabetes, and Cognitive Impairment in the Era of Combination Antiretroviral Therapy - (03/02/09)
     
  12163. CROI: HIGH FREQUENCY (50%) OF NEUROCOGNITIVE DISORDERS IN OLDER (>60 yrs) HIV-INFECTED PATIENTS DESPITE A SUSTAINED VIROLOGICAL AND IMMUNOLOGICAL RESPONSE ON CART: THE SIGMA STUDY - (03/02/09)
     
  12164. CROI: Microbicide PRO 2000/0.5% Gel Shows Promise - (03/02/09)
     
  12165. CROI: Summary of Antiretroviral Treatment Naïve Studies from CROI: Still Looking for a Consensus on When to Start - written by Susan J. Little, M.D. Associate Professor of Medicine University of California San Diego, USA - (02/27/09)
     
    -
  12166. Dairy Food, Calcium, and Risk of Cancer in the NIH-AARP Diet and Health Study - (02/27/09)
     
  12167. Telbivudine has activity against HIV-1 - (02/27/09)
     
  12168. HAART Does Not Reverse Premature T-Cell Aging Caused by HIV - (02/27/09)
     
  12169. Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment - (02/27/09)
     
  12170. EDITORIAL COMMENTARY The Paradox of Incomplete CD4+ Cell Count Restoration Despite Successful Antiretroviral Treatment and the Need to Start Highly Active Antiretroviral Therapy Early - (02/27/09)
     
  12171. CROI: HBV Blippers and Rebounders under Treatment with Tenofovir in HIV/HBV Co-infection - (02/27/09)
     
  12172. CROI: Aging with HIV - Lessons from CROI 2009 - Victor Valcour MD - (02/27/09)
     
  12173. CROI: Cognitive Impairment & Neuropathy Persist Despite HAART and Are Associated With Metabolic Syndrome - (02/27/09)
     
  12174. CROI: Phase 1, Single Ascending Oral Dose Study of the Safety, Tolerability, and Pharmacokinetics of MPC-9055 a Novel HIV-1 Maturation Inhibitor in HIV Negative Healthy Subjects - (02/27/09)
     
  12175. CROI: Anti-viral Characterization in vitro of a Novel Maturation Inhibitor, MPC-9055 - (02/27/09)
     
  12176. CROI: RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses - (02/27/09)
     
  12177. CROI: In Vitro Resistance Selection Study and Favorable Human Pharmacokinetic Properties of RDEA427, a New HIV NNRTI - (02/27/09)
     
  12178. CROI: Clinical Pharmacology at CROI 2009: Pharmacoenhancement, Pharmacogenetics, Drug Interactions and the Pharmacotherapy of HIV Infection - written by Courtney V. Fletcher, Pharm.D. - (02/26/09)
     
  12179. CROI: Pharmacology at the 2009 Conference on Retroviruses and Opportunistic Infections - written by Stephen Becker MD - (02/26/09)
     
  12180. CROI: Cervicovaginal Shedding of HIV-1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota - (02/26/09)
     
  12181. CROI: Forty-Fold Elevated Risk for Lymphoepithelial Carcinoma of Salivary Gland Among People with AIDS in the United States written by Kishor Bhatia, F Shebl, and E Engels NCI, NIH, Bethesda, MD, - (02/26/09)
     
  12182. CROI: Update on Kidney Disease in HIV Infection: CROI 2009 - written by Christina M. Wyatt and Paul E. Klotman, Mt Sinai Hospital, New York City - (02/26/09)
     
  12183. CROI: Impairment in Kidney Tubular Function in Patients Receiving Tenofovir Is Associated with Higher Plasma Tenofovir Levels - (02/26/09)
     
  12184. CROI: HIV & HAART Interruption Increase Inflammation and Disease - (02/26/09)
     
  12185. CROI: Weekly and Biweekly Subcutaneous PRO 140 Demonstrates Potent, Sustained Antiviral Activity: 2-week study - (02/26/09)
     
  12186. CROI: Lopinavir/ritonavir+Tenofovir/Emtricitabine Is Superior to Nevirapine+Tenofovir/Emtricitabine for Women with prior Exposure to Single-dose Nevirapine: A5208 ("OCTANE") - (02/25/09)
     
  12187. CROI: No Association of Abacavir (ABC) Use with Risk of Myocardial Infarction (MI) or Severe Cardiovascular Disease Events (SCVD): Results from ACTG A5001/ALLRT - (02/25/09)
     
  12188. CROI: Progression of High-grade Anal Intraepithelial Neoplasia to Invasive Anal Cancer among HIV+ Men Who Have Sex with Men - (02/25/09)
     
  12189. CROI: Prevalence of Cervical Cancer Screening Among HIV-Infected Women in the United States: 23% Did Not Receive Pap tests within last year - (02/25/09)
     
  12190. CROI: Serious Fatal and Non-fatal Non-AIDS-defining Illnesses in Europe: most common no-AIDS events malignancies/CVD/liver in EuroSida - (02/25/09)
     
  12191. CROI: Causes of Death in Patients Treated with ART (IDUs vs non-IDUs), 1996 to 2006: Collaborative Analysis of 13 Cohort Studies - (02/25/09)
     
  12192. CROI: Relationship between Current Level of Immunodeficiency and Non-AIDS-defining Malignancies, EuroSida: "Immunosuppression ...current CD4 count....was associated with an excess risk of NADM" - (02/25/09)
     
  12193. CROI: Infection-related Non-AIDS-defining Cancer Risk in HIV-infected and -uninfected Persons: Increased Rates in HIV+ vs HIV-negatives in Kaiser - (02/25/09)
     
  12194. CROI: New HIV Agents - written by Joe Eron, MD, University of North Carolina - (02/25/09)
     
  12195. CROI: Resistance Report - written by Mark A. Wainberg McGill University AIDS Centre, Montreal - (02/25/09)
     
  12196. CROI: New HIV Drug Candidates in Pre-Clinical Development - (02/24/09)
     
  12197. CROI: A Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OBP-601, a Novel NRTI, in Healthy Subjects - (02/24/09)
     
  12198. CROI: CMX157 Conjugate of tenofovir, prodrug: Hexadecyloxypropyl Tenofovir Associates Directly with HIV and Subsequently Inhibits Viral Replication in Untreated Cells - (02/24/09)
     
  12199. CROI: Inhibitors of the RNase H Activity of Reverse Transcriptase as an Approach to New HIV-1 Antiretroviral Agents: Merck program - (02/24/09)
     
  12200. CROI: Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve outcome of Hepatitis coinfection in HIV-Infected Patients? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (02/24/09)
     
  12201. CROI: High HCV Viral Load Is Associated with an Increased Risk for Mortality in HIV/HCV-co-infected Individuals - (02/24/09)
     
  12202. CROI: A Pilot Study to Determine the Effect on Dyslipidemia of the Addition of Tenofovir to Stable ART in HIV-infected Subjects: Results from A5206 Study Team v - (02/24/09)
     
  12203. CROI: Single Dose Tenofovir Disoproxil Fumarate (TDF) with and without Emtricitabine (FTC) in HIV-1 Infected Pregnant Women and Their Infants: Pharmacokinetics (PK) and Safety - - (02/24/09)
     
  12204. CROI: Cardiovascular complications 16th CROI - written by Pablo Tebas, MD University of Pennsylvania - (02/24/09)
     
  12205. CROI: Back to Basics: the science at CROI focuses on the tough questions that remain in HIV pathogenesis - written by David Margolis, MD, University of North Carolina - (02/24/09)
     
  12206. CROI: HIV Infection May Make the Brain 15 to 20 Years Older: HIV slows cerebral blood flow and stimulus response in MRI study - written by Mark Mascolini - (02/23/09)
     
  12207. CROI: Framingham Risk Score Linked to Other Heart Risk Factors in HIV Cohort - written by Mark Mascolini - (02/23/09)
     
  12208. CROI: No Residual Raltegravir Activity After Resistance Emerges - written by Mark Mascolini - (02/23/09)
     
  12209. CROI: Effects of Aging on HIV Pathogenesis: aging is associated with higher t-cell activation in women than men, effects of menopause on inflammation and immune activation...." (02/23/09)
     
  12210. CROI: Bone Loss at Baseline and Week 144 in Study 903 TDF vs d4T + EFV (02/23/09)
     
  12211. CROI: Safety and Efficacy of Raltegravir (RAL) in Pediatric HIV Infection. Preliminary Analysis From IMPAACT P1066 (02/23/09)
     
  12212. CROI: Telbivudine Has Activity against HIV (02/23/09)
     
  12213. CROI: Abacavir Use is Not Associated with Lack of Virologic Response in ARV-treated HIV/HCV-Coinfected Patients Receiving PEG-IFN and Ribavirin (02/23/09)
     
  12214. CROI: Telbivudine Has No In Vitro Activity Against Laboratory and Clinical HIV-1, Including 5 Clades and Drug Resistant Clinical Isolates (02/23/09)
     
  12215. CROI: Heart Disease Marker Rises in Women During 96 Weeks of Suppressive Efavirenz - written by Mark Mascolini - (02/20/09)
     
  12216. CROI: Liver Fibrosis Marker Rises in SMART Interrupters and Predicts Non-AIDS Deaths - written by Mark Mascolini - (02/20/09)
     
  12217. CROI: Diverse Disease Markers Up in SMART Patients Regardless of Antiretroviral Therapy: inflammation markers linked to death, ART interruption, HIV, aging, & ART - written by Mark Mascolini - (02/20/09)
     
  12218. CROI: Immune Activators Stay High Despite Long-Term HIV Suppression With Antiretrovirals: affects CD4 recovery - written by Mark Mascolini - (02/20/09)
     
  12219. CROI: Pharmacokinetics and Safety of Twice Daily Atazanavir 300 mg and Raltegravir 400 mg in Healthy Subjects - (02/20/09)
     
  12220. CROI: Epidemic of Acute HCV Among MSM in Europe and New York City - (02/20/09)
     
  12221. CROI: Neurocognitive Disorders Threaten HIV+ - (02/20/09)
     
  12222. CROI: Immune Senescence, Activation, and Abnormal T Cell Homeostasis despite Effective HAART, a Hallmark of Early Aging in HIV Disease: "HIV-infected subjects (median 56 years) with good immune reconstitution and viral suppression had immune changes comparable to older (median 88 years) HIV-negative subjects" - (02/20/09)
     
  12223. CROI: High Prevalence of Hepatic Fibrosis and Steatosis in HIV/AIDS Patients without Chronic Viral Hepatitis but with Chronically Elevated Transaminases on ART: 35% without HCV or HBV had significant liver disease - (02/20/09)
     
  12224. CROI: CCR5-tropic Resistance to Maraviroc is Uncommon Even Among Patients on Functional MVC Monotherapy or with Ongoing Low-level Replication - (02/20/09)
     
  12225. CROI: Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD University of Miami, Jackson Memorial Hospital (02/20/09)
     
  12226. CROI: HIV Prevention at CROI 2009 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (02/20/09)
     
  12227. CROI: New HIV Drugs: NNRTI, PRO140, Maturation (02/19/09)
     
  12228. CROI: Markers of Inflammation, Coagulation and Renal Function in HIV-infected Adults in SMART and in two Large Population-Based Studies, CARDIA and MESA: HIV+ have higher levels of inflammatory markers on and off HAART, "markers appear to predict mortality & disease progression in HIV" (02/19/09)
     
  12229. CROI: No Association of Abacavir Use with Risk of Myocardial Infarction or Severe Cardiovascular Disease Events: Results from ACTG A5001 (02/19/09)
     
  12230. CROI: Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir (RAL)-Based vs Efavirenz (EFV)-Based Combination Therapy in Treatment-Naive HIV-Infected Patients (02/19/09)
     
  12231. CROI: Factors affecting virologic response to darunavir/ritonavir and lopinavir/ritonavir in treatment-naive HIV-1-infected patients in ARTEMIS at 96 weeks (02/19/09)
     
  12232. CROI: Characterization of virologic failures in the randomized, controlled, Phase III ARTEMIS trial in treatment-naive patients (Week 96 analysis) (02/19/09)
     
  12233. CROI: Emerging Patterns of Resistance to Integrase Inhibitors (02/19/09)
     
  12234. CROI: Assessment of Renal Findings of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FTC) in Combination with QD Lopinavir/Ritonavir (LPV/r) Over 96 Weeks in the HEAT Study (02/19/09)
     
  12235. CROI: Similar Reductions in Markers of Inflammation and Endothelial Activation after Initiation of Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) in the HEAT Study (02/19/09)
     
  12236. CROI: Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-Daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study (02/19/09)
     
  12237. CROI: HIV-1 INFECTION IS ASSOCIATED WITH ACCELERATED VASCULAR AGING (02/18/09)
     
  12238. CROI: SIMPLIFICATION WITH FIXED-DOSE TENOFOVIR-EMTRICITABINE OR ABACAVIRLAMIVUDINE IN ADULTS WITH SUPPRESSED HIV REPLICATION (THE STEAL STUDY): A RANDOMIZED, OPEN-LABEL, 96-WEEK, NON-INFERIORITY TRIAL (02/18/09)
     
  12239. CROI: Neurocognitive (and neuropathy) Impairment Rate Remains High in Diverse US Cohort - written by Mark Mascolini - (02/18/09)
     
  12240. CROI: Antiretrovirals Have Not Banished Brain Injury in 7-Center US Imaging Study: brain damage persists despite HAART- inflammation and neuronal damage - written by Mark Mascolini - (02/18/09)
     
  12241. CROI: HCV Independently Adds to Hospital, Emergency Room, and Disability Days With HIV: days in hospital doubled - written by Mark Mascolini - (02/18/09)
     
  12242. CROI: Suspending Antiretrovirals Has Fast Negative Impact on HDL Particle Concentrations: interruptions reduce HDL and this predicts risk for cardiovascular disease in SMART - written by Mark Mascolini - (02/18/09)
     
  12243. CROI: First Double-Blind HIV+ Trial of Ezetimibe Plus Statin Finds Falling LDL Cholesterol - written by Mark Mascolini - (02/18/09)
     
  12244. CROI: Endothelial Function, Inflammatory Markers Do Not Change 24 Weeks After Switch to Atazanavir - written by Mark Mascolini - (02/18/09)
     
  12245. CROI: Two Inflammation Markers (hsCRP & IL-6) Predict Higher Risk of Opportunistic Disease in SMART - written by Mark Mascolini - (02/18/09)
     
  12246. CROI: Platelet Function & Heart Attacks in HIV+ & ART (02/17/09)
     
  12247. CROI: Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive (02/17/09)
     
  12248. CROI: HIV Progression Not Affected by Hormonal Contraception in Africa Study (02/17/09)
     
  12249. CROI: The Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-naive Patients Through Seven Years (02/17/09)
     
  12250. CROI: HIV, Cancer and Immunity (02/17/09)
     
  12251. CROI: HIV Sometimes Detectable in Semen When Undetectable in Blood - written by Mark Mascolini - (02/13/09)
     
  12252. CROI: Low-Level HIV in CSF When HIV-RNA is < 50 Tied to Type of ART and Worse Cognitive Function - written by Mark Mascolini - (02/13/09)
     
  12253. CROI: Multicohort D:A:D Study Pinpoints Non-HIV Death Risk Factors People Can Change - written by Mark Mascolini - (02/13/09)
     
  12254. CROI: Helping HIV Patients Stop Smoking--Worthy Goal But Tough Work - written by Mark Mascolini - (02/13/09)
     
  12255. CROI: HIV Has as Much Impact on Heart Health as Traditional Risk Factors - written by Mark Mascolini - (02/13/09)
     
  12256. CROI: K103N and Efavirenz vs Nevirapine Tied to Better Response to Etravirine - written by Mark Mascolini - (02/13/09)
     
  12257. CROI: Preclinical and Early Clinical Evaluation of SPI-452, a New Pharmacokinetic Enhancer (PKE) - (02/12/09)
     
  12258. CROI: Review of Cancer Incidence in Raltegravir (RAL) Clinical Trials - (02/12/09)
     
  12259. CROI: 96-Week Results from BENCHMRK 1&2, Phase III Studies of Raltegravir (RAL) in Patients (pts) Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV - (02/12/09)
     
  12260. CROI: Abacavir - (02/12/09)
     
  12261. CROI: 3 Studies on Abacavir & MI Risk: French Cohort, D.A.D. (slides), ALLRT with 2 Different Results - (02/12/09)
     
  12262. CROI: Switch to Raltegravir From Lopinavir in Highly Treatment-Experienced Patient Group: SWITCHMRK 1 & 2 Studies - written by Mark Mascolini - (02/12/09)
     
  12263. CROI: Replacing Enfuvirtide With Raltegravir in France - written by Mark Mascolini - (02/12/09)
     
  12264. CROI: Lower CD4 Count Linked to Non-AIDS Cancers in EuroSIDA Study - written by Mark Mascolini - (02/12/09)
     
  12265. CROI: Risk of non-Hodgkin Lymphoma Death Still Higher With HIV Infection - written by Mark Mascolini - (02/12/09)
     
  12266. CROI: Extra CD4s With IL-2 Confer No Clinical Benefit in Two Randomized Trials - written by Mark Mascolini - (02/12/09)
     
  12267. CROI: High HCV Load Doubles the Death Risk in People Coinfected With HIV - written by Mark Mascolini - (02/12/09)
     
  12268. CROI: Peginterferon (Pegasys) and Weight-Based Ribavirin for 72 Weeks in HIV+ Early Responders - written by Mark Mascolini - (02/12/09)
     
  12269. CROI: MI Rates Converge in California Health System Groups With and Without HIV: trend down in HIV+ - written by Mark Mascolini - (02/12/09)
     
  12270. CROI: Non-AIDS Illness More Common Than AIDS--and More Deadly--in EuroSIDA - written by Mark Mascolini - (02/12/09)
     
  12271. CROI: French Hospital Study and Further D:A:D Analyses Suggest MI Risk With Abacavir - written by Mark Mascolini - (02/12/09)
     
  12272. BMS Co-Payment Assistance Program - (02/11/09)
     
  12273. CROI: GS-9350: A Pharmacoenhancer Without anti-HIV Activity - (02/11/09)
     
  12274. CROI: Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350 - (02/11/09)
     
  12275. CROI: Complete Protection against Repeated Vaginal Simian HIV Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine - (02/11/09)
     
  12276. CROI: Switching from Stable Lopinavir/Ritonavir (LPV/r)-Based to Raltegravir (RAL)-Based Combination Antiretroviral Therapy (ART) Resulted In a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24 (SWITCHMRK) - (02/11/09)
     
  12277. CROI: Smoking Emerges as Top Death Risk Factor in FRAM Participants With HIV - written by Mark Mascolini - (02/11/09)
     
  12278. CROI: HIV and Diabetes/Hyperlipidemia Cause Kidney Decline - written by Mark Mascolini - (02/11/09)
     
  12279. Causes of Accelerated Aging in HIV: HIV Induces Aging of T-Cells - (02/10/09)
     
  12280. CROI: World Health Organization CD4 Criteria Fall Far Short in Predicting Antiretroviral Failure written by Mark Mascolini - (02/10/09)
     
  12281. Does Early Antiretroviral Treatment Prevent Liver Fibrosis in HIV/HCV-Coinfected Patients? [Letters to the Editor] - (02/07/09)
     
  12282. Vitamin D's Expanding Role EDITORIAL - (02/07/09)
     
  12283. Vitamin D Status and Muscle Function in Post-Menarchal Adolescent Girls - (02/07/09)
     
  12284. GSK Acquires New HIV NNRTI IDX899 From Idenix - (02/07/09)
     
  12285. Is Dual Therapy With Raltegravir and Protease Inhibitors a Feasible Option in Rescue Strategy in HIV-1 Infection? [Letters to the Editor] - (02/07/09)
     
  12286. Use of Saliva as a Lubricant in Anal Sexual Practices Among Homosexual Men - (02/07/09)
     
  12287. FDA grants traditional approval of Isentress (raltegravir) - (02/06/09)
     
  12288. Patient Information Page from The Hormone Foundation: Vitamin D, Calcium, and Bone Health - (02/06/09)
     
  12289. Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine) - (02/06/09)
     
  12290. Once-Daily Prezista® (darunavir) for Treatment-Naive Adults with HIV-1 Receives Approval in the European Union as Part of Combination Therapy - (02/06/09)
     
  12291. Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women - (02/05/09)
     
  12292. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients - (02/05/09)
     
  12293. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men - (02/05/09)
     
  12294. Oral Cancer In Men Associated With HPV - (02/05/09)
     
  12295. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study - (02/05/09)
     
  12296. New Gene Therapy Disrupts CCR5/HIV Entry: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases - (02/04/09)
     
  12297. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS - (02/04/09)
     
  12298. High Frequency of Vitamin D Deficiency in Ambulatory HIV-Positive Patients - (02/03/09)
     
  12299. Vitamin D Deficiency in Older Men - (01/30/09)
     
  12300. New Norvir Tablet Application Submitted to FDA by Abbott - (01/29/09)
     
  12301. Ultrasensitive Assessment of Residual HIV Viraemia in HAART-Treated Patients With Persistently Undetectable Plasma HIV-RNA: A Cross-Sectional Evaluation - (01/29/09)
     
  12302. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity: review by Steve Deeks and Andrew Phillips - (01/28/09)
     
  12303. Aerobic + Strength Exercise is Optimal for Insulin Resistance and Improved Health & Frailty in Study of Obese and Older, Average Age 67 Yrs - (01/28/09)
     
  12304. Methicillin-Resistant Staphylococcus aureus (MRSA) Strain ST398 Is Present in Midwestern U.S. Swine and Swine Workers - (01/28/09)
     
  12305. Heart Association Recommends Daily Intake of Omega-6 Fatty Acids - (01/28/09)
     
  12306. TNX-355 survives Tanox: new Phase 2 Dose-Finding StudyStudy - (01/28/09)
     
  12307. VRX496 Update, Novel HIV Gene Therapy - (01/27/09)
     
  12308. FRONTLINE: the age of aids: interviews: martin delaney | PBS - (01/27/09)
     
  12309. Fauci Statement - Martin Delaney - (01/27/09)
     
  12310. Martin Delaney, HIV treatment activist, dies at 63 - (01/27/09)
     
  12311. AIDS Activist Martin Delaney Honoured By NIAID - (01/27/09)
     
  12312. AGING AND INFECTIOUS DISEASES: effects of aging; Immunosenescence and Vaccination in Nursing Home Residents - (01/22/09)
     
  12313. Once-Daily HAART Modestly Beats Twice-Daily on Adherence & Viral Suppression: meta-analysis - (01/22/09)
     
  12314. Reduced susceptibility to lamivudine and emtricitabine associated with the novel K66N mutation in HIV-1 reverse transcriptase - (01/22/09)
     
  12315. HIV Prematurely Accelerates Aging - (01/22/09)
     
  12316. HIV Super-Infection Not Found Among MSM Couples: Immunity to HIV-1 Is Influenced by Continued Natural Exposure to Exogenous Virus - (01/21/09)
     
  12317. Effects of Omeprazole on Plasma Levels of Raltegravir - (01/21/09)
     
  12318. New Article Criticizes Term "on the Down low": Moving beyond "the Down Low": A critical analysis of terminology guiding HIV prevention efforts for African American men who have secretive sex with men - (01/21/09)
     
  12319. Persistent Minority K103N Mutations among Women Exposed to Single-dose Nevirapine and Virologic Response to Nonnucleoside reverse-Transcriptase Inhibitor-Based Therapy - (01/21/09)
     
  12320. Single-Dose Nevirapine to Prevent Mother-to-Child Transmission of HIV Type 1: Balancing the Benefits and Risks EDITORIAL COMMENTARY - (01/21/09)
     
  12321. YouTube - Anthony Fauci Tribute to Martin Delaney - (01/20/09)
     
  12322. NIAID Honors AIDS Activist Martin Delaney - (01/20/09)
     
  12323. CDC Updates New HIV Cases Surveillance Estimates: "the disease continues to affect the MSM population more than any other in the United States" - (01/14/09)
     
  12324. Risk Factors for Early and Late Transmission of HIV via breast-feeding among Infants Born to HIV-Infected Women in a Randomized Clinical Trial in Botswana - (01/17/09)
     
  12325. ICAAC: The New Antitubercular Drugs SQ109 and TMC207 Act Synergistically In Vitro to Kill M. tuberculosis - (01/17/09)
     
  12326. ICAAC: Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis: effective and safe - (01/17/09)
     
  12327. CDC Updates New HIV Cases Surveillance Estimates: "the disease continues to affect the MSM population more than any other in the United States" - (01/14/09)
     
  12328. C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study - (01/14/09)
     
  12329. Researchers Identify IL-7 New Regulatory Circuit Controlling Immune Cell Production in Mice - (01/13/09)
     
  12330. Prolonged Nevirapine Use In Breast-Fed Babies Prevents HIV, Increased Resistance Risk - (01/13/09)
     
  12331. Factors Associated with Acquisition and Clearance of Human Papillomavirus Infection in a Cohort of US Men: A Prospective Study - (01/13/09)
     
  12332. Our results suggest that HIV-1 infection induces an accelerated aging of T lymphocytes, which is associated with the clinical progression to AIDS and death - (01/13/09)
     
  12333. Insulin Resistance (25%) Is Associated With Advanced Liver Fibrosis and High Body Mass Index in HIV/HCV-Coinfected Patients [Letters to the Editor] - (01/12/09)
     
  12334. Cardiovascular Complications in HIV Management: Past, Present, and Future [Critical Review: Clinical Science] - (01/12/09)
     
  12335. Predictive Factors for Long-Term Non-Progressors - (01/12/09)
     
  12336. Racial Disparities in HIV Virologic Failure: Do Missed Visits Matter? - (01/12/09)
     
  12337. The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options - (01/12/09)
     
  12338. Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384 - (01/12/09)
     
  12339. CD4+ T Cell Recovery with Antiretroviral Therapy: More Than the Sum of the Parts, EDITORIAL COMMENTARY - (01/12/09)
     
  12340. Increased Melanoma Rates in USA Are Real and Aging/HIV - (01/09/09)
     
  12341. Public Citizen issues list of 56 drugs to be avoided with Erectyle Dysfunction therapies - (01/07/09)
     
  12342. Prospective study of physical fitness, adiposity, and inflammatory markers in healthy middle-aged men and women - (01/07/09)
     
  12343. ICAAC: New CCR5 Drug PRO 140 Reduced Viral Load by 2 Logs With Single 10 mg Intravenous Dose; 5/5 patients with single 10 mg dose had >2 log reduction in viral load - (01/06/09)
     
  12344. Osteonecrosis of the Jaw & Bisphohosphonates for Osteoporosis Treatment - (01/06/09)
     
  12345. Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy - (01/06/09)
     
  12346. Childhood Trauma and Neurological Development and Stress, and Chronic Fatigue Syndrome - (01/06/09)
     
  12347. AIDS Denialism by South African Govt Leader Pres Mbeki Loses 330,000 Lives & 35,000 HIV+ Babies Born - (01/05/09)
     
  12348. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era - (01/05/09)
     
  12349. Long-term consequences of the delay between virologic failure of HAART and regimen modification - (01/05/09)
     
  12350. Minority Quasispecies of Drug-Resistant HIV-1 That Lead to Early Therapy Failure in Treatment-Naive and -Adherent Patients - (01/05/09)
     
  12351. The Management of Treatment-Experienced HIV-Infected Patients: New Drugs and Drug Combinations - (01/05/09)
     
  12352. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials - (01/02/09)
     
  12353. Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy - (01/02/09)
     
  12354. Keeping Blood Sugar Low May Help Stem Geriatric Memory Loss - (01/02/09)
     
  12355. History and Death of AIDS Denialist Christine Maggiore and Her Dead Daughter - (12/31/08)
     
  12356. Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial - (12/30/08)
     
  12357. Once A Year Zoledronate Bone Therapy Increased Bone Density & T-Scores - (12/30/08)
     
  12358. Thyroid Dysfunction & Bone Disease in HIV & HCV; Thyroid Testing Recommended by UK Group - (12/30/08)
     
  12359. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients - (12/30/08)
     
  12360. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study - (12/30/08)
     
  12361. Generic FTC 200 mg Caps Approved - (12/30/08)
     
  12362. Report on the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV - written by Jacqueline Capeau MD - (12/23/08)
     
  12363. Central obesity and increased risk of dementia more than three decades later - (12/22/08)
     
  12364. Visceral Fat & Neurotoins, Insulin Resistance & Alzheimer Disease/Dementia EDITORIAL - (12/22/08)
     
  12365. Impaired insulin secretion increases the risk of Alzheimer disease - (12/22/08)
     
  12366. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes - (12/22/08)
     
  12367. Associations between Male Anogenital Human Papillomavirus Infection and Circumcision by Anatomic Site Sampled and Lifetime Number of Female Sex Partners - (12/22/08)
     
  12368. Effect of a Low-Glycemic Index or a High-Cereal Fiber Diet on Type 2 Diabetes: "6-month treatment with a low-glycemic index diet resulted in moderately lower HbA1c levels compared with a high-cereal fiber diet." - (12/19/08)
     
  12369. The START Study Controversy: conducting a "When To Begin Study" - (12/19/08)
     
  12370. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV - (12/19/08)
     
  12371. Low atazanavir concentrations in cerebrospinal fluid - (12/18/08)
     
  12372. Male Circumcision and [reduced] Risk of HIV Infection among Heterosexual African American Men Attending Baltimore Sexually Transmitted Disease Clinics - (12/18/08)
     
  12373. Associations between Male Anogenital Human Papillomavirus Infection and Circumcision by Anatomic Site Sampled and Lifetime Number of Female Sex Partners - (12/22/08)
     
  12374. The Role of Male Circumcision in the Prevention of Human Papillomavirus and HIV Infection - EDITORIAL COMMENTARY - (12/18/08)
     
  12375. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin - (12/18/08)
     
  12376. Federal Government NIAID Aging Funding Opportunities - (12/16/08)
     
  12377. HIV & Kidney Disease: ART Interruption In SMART - (12/16/08)
     
  12378. 10th Intl Workshp Adverse Drug Reactions & Lipo: Report from the 10th Intl Workshop on Adverse Drug Reactions and Lipodystrophy in HIV - written by Michael Dube, MD - (12/13/08)
     
  12379. ICAAC: Perceptions of Care by HIV-Infected Women of Color in the United States - (12/15/08)
     
  12380. ICAAC: Roles of Race, Drug Use & Health Insurance in Use of HAART Among HIV-Positive Women: 2002-2005 - (12/15/08)
     
  12381. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women: "Our findings show that the prevalence of AIN among HIV-infected women is high and significantly increased above a comparison group of HIV-uninfected women." - (12/15/08)
     
  12382. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study - (12/15/08)
     
  12383. DART: Hydroxyurea+ddI Returns, Franco Lori Presents: A "Virostatic" Approach to Antiretroviral Therapy: Beyond ddI/Hydroxyurea? - Written for NATAP by Mark Mascolini - (12/15/08)
     
  12384. DART: This is Your Brain Off Drugs: Neurocognitive Function before and after Antiretroviral Treatment Discontinuation in Patients with High CD4 Nadir (ACTG A5170). - (12/15/08)
     
  12385. DART: Women's HIV Care and Treatment Access for African-Americans and the GRACE Study - (12/15/08)
     
  12386. Merck Announces FDA Acceptance of Supplemental New Drug Application for ISENTRESS (raltegravir) in Adult Patients Previously Untreated for HIV-1 - (12/12/08)
     
  12387. DART: Raltegravir Efficacy and Safety After 96 Weeks of Phase 2 Trial - Written for NATAP by Mark Mascolini - (12/12/08)
     
  12388. DART: Darunavir vs Lopinavir at 96 Weeks in People With Naïve Advanced HIV - ARTEMIS Study - Written for NATAP by Mark Mascolini - (12/12/08)
     
  12389. DART: Dropout Rate in Study of US Minority Women Near 25% at 24 Weeks Written for NATAP by Mark Mascolini - (12/11/08)
     
  12390. DART: Siliciano Proposes Novel Gauge of Antiretroviral Activity Written for NATAP by Mark Mascolini - (12/11/08)
     
  12391. DART: Foot-Fractures in HIV+ Men Written for NATAP by Mark Mascolini - (12/11/08)
     
  12392. DART: Early Results With Antiretrovirals Plus Immunotoxins That Target Viral Reservoirs Written for NATAP by Mark Mascolini - (12/11/08)
     
  12393. Coregulation of CD38+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection - (12/11/08)
     
  12394. Enhancing SIV-specific immunity in vivo by PD-1 blockade - (12/11/08)
     
  12395. Antibody fights AIDS-like disease in monkeys - (12/11/08)
     
  12396. ICAAC: DELPHI: Safety, tolerability and efficacy of darunavir/ritonavir over 48 weeks in ARV treatment-experienced children and adolescents Final analysis (12/11/08)
     
  12397. Targeting HIV Entry: 4th Interntnl Wrkshp: Enfuvirtide-Plus-Raltegravir Salvage Trial Cuts Off Recruitment Early - Written by Mark Mascolini - (12/10/08)
     
  12398. Targeting HIV Entry: 4th Interntnl Wrkshp: HIV Becomes More Flexible in CCR5 and CXCR4 Use as Infection Progresses - Written by Mark Mascolini - (12/10/08)
     
  12399. Targeting HIV Entry: 4th Interntnl Wrkshp: Low Enfuvirtide and Maraviroc Penetration of CSF--and CSF Resistance to Enfuvirtide - written by Mark Mascolini - (12/10/08)
     
  12400. Targeting HIV Entry: 4th Interntnl Wrkshp: Vicriviroc Phase 3 Trial and Naive Study May Afford New Angle on Role of CCR5 Blockers - written by Mark Mascolini - (12/10/08)
     
  12401. Targeting HIV Entry: 4th Interntnl Wrkshp: Almost 40% of Viruses in Treatment-Experienced German Group Use CXCR4 - written by Mark Mascolini - (12/10/08)
     
  12402. Neurological/Cognitive Impairment on HAART: 50% on HAART have cognitive impairment - (12/10/08)
     
  12403. ICAAC: AIDS-Defining Conditions (ADCs) in the BENCHMRK -1 and -2 Trials: 48 Week Analysis (12/10/08)
     
  12404. ICAAC: Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from BENCHMRK-1 and -2 (12/10/08)
     
  12405. ICAAC: Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir (RAL) in Phase III Studies in Treatment Experienced HIV- Infected Patients Following 48 Weeks of Treatment (12/10/08)
     
  12406. 10th Intl Workshp Adverse Drug Reactions & Lipo: A Comparison of Cardiac Function Between HIV-Infected and HIV-Seronegative People With and Without the Metabolic Syndrome. - (12/10/08)
     
  12407. 10th Intl Workshp Adverse Drug Reactions & Lipo: COMPARISON OF THE EFFECTS OF NEVIRAPINE RESPECT TO EFAVIRENZ ON DIFFERENTIATING AND MATURE HUMAN ADIPOCYTES IN CULTURE - (12/10/08)
     
  12408. 9th Interntl Drug Thrpy HIV: The Effect of Food on Ritonavir Bioavailability Following Administration of Ritonavir 100 mg Film-Coated Tablet in Healthy Adult Subjects - (12/09/08)
     
  12409. 9th Interntl Drug Thrpy HIV: Population Pharmacokinetic/Pharmacodynamic Analyses of Lopinavir and Ritonavir in Subjects Receiving the Tablet Formulation - (12/09/08)
     
  12410. 9th Interntl Drug Thrpy HIV: Pharmacokinetics of Once-Daily Etravirine (ETR) Without and With Once-Daily Darunavir/ Ritonavir (DRV/r) in Antiretroviral-Naï ve HIV-1 Infected Adults - (12/09/08)
     
  12411. The cell biology of bone metabolism - (12/09/08)
     
  12412. Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy - (12/09/08)
     
  12413. Statins and primary prevention of cardiovascular events- Editorials - (12/09/08)
     
  12414. ddi + hydroxyurea making comeback - (12/09/08)
     
  12415. Hepatitis Virus Coinfection in the Strategic Management of Antiretroviral Therapy (SMART) Study: A Marker for Nonliver, Non-Opportunistic Disease Mortality - (12/09/08)
     
  12416. Nut-Enriched Mediterranean Diet Helps Reverse Metabolic Syndrome - (12/09/08)
     
  12417. Webcasts from the 10th Intl Workshop on Adverse Drug Reactions & Lipodystrophy
     
  12418. 9th Interntl Drug Thrpy HIV: Adherence with Lopinavir/ritonavir (LPV/r) Tablet and Soft-Gel Capsule (SGC)-Based Antiretroviral Regimens and Predictors of Early Treatment Compliance - (12/08/08)
     
  12419. 9th Interntl Drug Thrpy HIV: Metabolic Evaluation of Study M05-730 through Week (Wk) 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naï ve (ARV) HIV-1 Infected Subjects - (12/08/08)
     
  12420. 9th Interntl Drug Thrpy HIV: Topics from the Drug Therapy in HIV Infection Meeting - written by Stephen Becker, MD - (12/08/08)
     
  12421. ICAAC: DOUBLING THE DOSE OF RALTEGRAVIR (RAL) DOES NOT INCREASE TROUGH LEVELS IN THE PRESENCE OF RIFAMPIN (RIF) (12/08/08)
     
  12422. ICAAC: Omeprazole Increases Plasma Levels of Raltegravir (RAL) in Healthy Subjects (12/08/08)
     
  12423. ICAAC: Raltegravir (RAL) Pharmacokinetics in Individuals with UGT1A1*1/*1 and UGT1A1*28/*28 Genotypes (12/08/08)
     
  12424. ICAAC: Pharmacokinetic (PK) Evaluation of Darunavir/Ritonavir (DRV/r) and Raltegravir (RAL) in Healthy Subjects (12/08/08)
     
  12425. ICAAC: Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from BENCHMRK-1 and -2 (12/08/08)
     
  12426. Pfizer's Novel HIV/AIDS Treatment SELZENTRY(TM) Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients - (12/03/08)
     
  12427. Vitamin K Linked to Insulin Resistance in Older Men - (12/03/08)
     
  12428. "elevations in inflammatory markers seen in insulin resistance, metabolic syndrome, and diabetes are not causative but a consequence of these abnormalities." - (12/02/08)
     
  12429. Metabolic Syndrome Predicts New Onset of Chronic Kidney Disease in 5,829 Patients With Type 2 Diabetes - (12/02/08)
     
  12430. Endothelial Activation Markers Are Linked to HIV Status and Are Independent of Antiretroviral Therapy and Lipoatrophy - (12/02/08)
     
  12431. Inflammation May Be Associated with AIDS Progression - (12/02/08)
     
  12432. Uric Acid Levels Increase Risk for New-Onset Kidney Disease - Editorial - (12/02/08)
     
  12433. ICAAC: Performance Characteristics and Validation of the PhenoSense® Integrase Assay (12/02/08)
     
  12434. ICAAC: Raltegravir Pharmacokinetics and Safety in Adolescents: Preliminary Results from IMPAACT P1066 (12/02/08)
     
  12435. ICAAC: Validation of an Enhanced Sensitivity Trofile™ HIV-1 Co-receptor Tropism Assay (12/02/08)
     
  12436. ICAAC: Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) (12/02/08)
     
  12437. ICAAC: Chronic Hepatitis B Virus (HBV) Infection in the HIV Outpatient Study (HOPS), 1996-2006: Prevalence in the Era of Evolving Interventions (12/02/08)
     
  12438. Cancer Rates Doubled in HIV+ - (11/24/08)
     
  12439. ICAAC: Continuous Antiretroviral Therapy Decreases Bone Mineral Density: Results from the SMART Study (11/24/08)
     
  12440. ICAAC: Bone Loss in SMART Study - Written by Mark Mascolini - (10/30/08)
     
  12441. 9th Interntl Drug Thrpy HIV: Switching from enfuvirtide to etravirine - efficacy results from the etravirine early access programme - (11/24/08)
     
  12442. 9th Interntl Drug Thrpy HIV: Etravirine protects the activity of darunavir in the DUET trials - (11/24/08)
     
  12443. 9th Interntl Drug Thrpy HIV: Antiretroviral treatment use and HIV RNA suppression rates for 941 European patients in the etravirine early access programme - (11/24/08)
     
  12444. 9th Interntl Drug Thrpy HIV: Safety and tolerability of etravirine in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results - (11/24/08)
     
  12445. 9th Interntl Drug Thrpy HIV: Atazanavir Is Safe and Efficacious in HBV and HCV Coinfected Patients: Results of AI424138 (CASTLE) - (11/24/08)
     
  12446. CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater - (11/21/08)
     
  12447. Statin induced myopathy - (11/21/08)
     
  12448. Physicians Reluctant to Follow CDC Call for Routine HIV Testing - (11/21/08)
     
  12449. 9th Interntl Drug Thrpy HIV: The pharmacokinetic interaction between omeprazole and TMC278, an investigational NNRTI - (11/21/08)
     
  12450. 9th Interntl Drug Thrpy HIV: Activity of etravirine on different HIV-1 subtypes: Week 48 data of the pooled DUET trials and in-vitro susceptibility in treatment-naïve patients - (11/21/08)
     
  12451. 9th Interntl Drug Thrpy HIV: Simplification of Antiretroviral Therapy with Efavirenz/Emtricitabine/Tenofovir DF Single Tablet Regimen vs. Continued Antiretroviral Therapy in Suppressed, HIV-1-Infected Patients - (11/20/08)
     
  12452. 9th Interntl Drug Thrpy HIV: Incidence of Infections in Treatment-experienced Patients Infected with R5 HIV-1 in the MOTIVATE Studies of Maraviroc in Combination with Optimized Background Therapy - (11/20/08)
     
  12453. 9th Interntl Drug Thrpy HIV: Phase III TITAN Week 96 final analysis: efficacy/safety of darunavir/ritonavir versus lopinavir/ritonavir in lopinavir/ritonavir-naïve, treatment-experienced patients - (11/20/08)
     
  12454. 10th Intl Workshp Adverse Drug Reactions & Lipo: Effect of HAART on insulin sensitivity, autonomic nervous system function and beta-adrenergic mediated lipolysis (11/20/08)
     
  12455. 10th Intl Workshp Adverse Drug Reactions & Lipo: Efavirenz induces alterations in lipid metabolism through AMPK activation (11/20/08)
     
  12456. 10th Intl Workshp Adverse Drug Reactions & Lipo: COMPARISON OF THE EFFECTS OF LOPINAVIR/RITONAVIR AND EFAVIRENZ ON GENE EXPRESSION AND DIFFERENTIATION OF HUMAN ADIPOCYTES (11/20/08)
     
  12457. Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART - (11/19/08)
     
  12458. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy - (11/19/08)
     
  12459. HIV TAT Protein Infects Brain Shortly After HIV-Infection and Disrupts Brain Normal Activity, Affects Mitochondria-- Pretreatment with the RyR antagonist, dantrolene mediated these pathologic effects.....dantrolene has side effects but these findings could lead to research for therapy to block this mechanism of action "RyR may be a crucial target for neuroprotection in HIV-associated neurologic disease" - (11/19/08)
     
  12460. Statin (Crestor) Prevents Heart Disease, Lowers LDL and Inflammation in Healthy with Normal Lipids - (11/18/08)
     
  12461. Statin Therapy for Prevention? EDITORIAL Expanding the Orbit of Primary Prevention - Moving beyond JUPITER - (11/18/08)
     
  12462. JUPITER hits New Orleans: Landmark study shows statins benefit healthy individuals with high CRP levels - (11/18/08)
     
  12463. Crestor Study Will Boost Statin Demand - (11/18/08)
     
  12464. The role of HIV in serious diseases (non-AIDS diseases) other than AIDS - (11/18/08)
     
  12465. Silent cardiac dysfunction and exercise intolerance in HIV+ men receiving combined antiretroviral therapies - (11/18/08)
     
  12466. Higher frequency of dementia in older HIV-1 individuals The Hawaii Aging with HIV-1 Cohort - (11/18/08)
     
  12467. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis - (11/18/08)
     
  12468. Proinflammatory Markers, Insulin Sensitivity, and Cardiometabolic Risk Factors in Treated HIV Infection - (11/18/08)
     
  12469. 9th Interntl Drug Thrpy HIV: Patient Reported Outcomes after Simplification to a Single Tablet Regimen of Efavirenz (EFV) / Emtricitabine (FTC) / Tenofovir DF (TDF) - (11/17/08)
     
  12470. 9th Interntl Drug Thrpy HIV: Two HAART Interruption Studies Presented at Glasgow HIV Conference Nov 10 2008 - (11/17/08)
     
  12471. The relationship between an adverse effect of cART and underlying risk illustrated by number needed to treat to harm (NNTH) - Risk of myocardial infarction and abacavir use - (11/13/08)
     
  12472. Evolution and Predictors of Change in Total Bone Mineral Density Over Time in HIV-Infected Men and Women in the Nutrition for Healthy Living Study - (11/13/08)
     
  12473. 9th Interntl Drug Thrpy HIV: Raltegravir Clinical Efficacy Against B Subtype and Non-B Subtype HIV-1 is Similar - (11/17/08)
     
  12474. 9th Interntl Drug Thrpy HIV: Efficacy and Safety (malignancies) of Maraviroc in Treatment-Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies - (11/17/08)
     
  12475. 9th Interntl Drug Thrpy HIV: Better CD4 Gains on Antiretrovirals Linked to Clearance of Cancer-Causing HPV - Written by Mark Mascolini - (11/17/08)
     
  12476. 9th Interntl Drug Thrpy HIV: Risks and Benefits of 5 Days On/2 Days Off in the FOTO Study - Written by Mark Mascolini - (11/17/08)
     
  12477. 9th Interntl Drug Thrpy HIV: No Evidence of Virologic Benefit With Higher Lopinavir Dose for Children - Written by Mark Mascolini - (11/17/08)
     
  12478. 9th Interntl Drug Thrpy HIV: More Time With Sub-500 Load on First Regimen Cuts Risk of Second-Line Failure - Written by Mark Mascolini - (11/17/08)
     
  12479. 9th Interntl Drug Thrpy HIV: Lipid effects in the ARTEMIS and TITAN trials: effects of demographics, HIV disease stage, treatment arm and lipid-lowering drugs - (11/17/08)
     
  12480. 9th Interntl Drug Thrpy HIV: OI and Death Rates With Low CD4s and High vs Low Viral Load - Undetectable Viral Load Matters - Written by Mark Mascolini - (11/13/08)
     
  12481. 9th Interntl Drug Thrpy HIV: Failure Rate Twice Higher With Second-Line Versus First-Line HAART - Written by Mark Mascolini - (11/13/08)
     
  12482. 9th Interntl Drug Thrpy HIV: Lower Failure and Resistance Rates With Darunavir Than Lopinavir at 96 Weeks of TITAN - Written by Mark Mascolini - (11/13/08)
     
  12483. 9th Interntl Drug Thrpy HIV: Slow CD4 Gain With HAART Raises AIDS Rate 5 Times in Virologic Responders - Written by Mark Mascolini - (11/13/08)
     
  12484. 9th Interntl Drug Thrpy HIV: Cardiovascular disease; HIV, ART, immunodeficiency, pro-inflammation and other factors - (11/13/08)
     
  12485. 9th Interntl Drug Thrpy HIV: Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: Week 96 data from TMC278-C204 - (11/13/08)
     
  12486. 9th Interntl Drug Thrpy HIV: Efficacy and Safety by Baseline HIV RNA and CD4 Count in Treatment-Naïve Patients Treated With Atazanavir/RTV and Lopinavir/RTV in the CASTLE Study - (11/13/08)
     
  12487. 9th Interntl Drug Thrpy HIV: Efficacy and safety of switching from Lopinavir/r to Atazanavir/r in suppressed patients receiving a LPV/r containing HAART: ATAZIP 96 weeks results - (11/13/08)
     
  12488. ICAAC: Earlier Chance at HIV Diagnosis Probably Often Missed in Prison written by Mark Mascolini (11/12/08)
     
  12489. ICAAC: Pharmacology at ICAAC-IDSA - The Maraviroc and Raltegravir Interaction: Do We Know How to Dose When Using These Two Important Agents? Written by Stephen Becker, MD (11/12/08)
     
  12490. ICAAC: Summary from ICAAC/IDSA for Treatment Naïve patients written by Joseph J. Eron Jr. MD (11/12/08)
     
  12491. ICAAC: HIV drug resistance at IDSA/ICAAC written by David Margolis, MD (11/12/08)
     
  12492. 9th Interntl Drug Thrpy HIV: High HIV Load Stymies Calcium Deposition in Bone-Forming Cells - Written by Mark Mascolini - (11/12/08)
     
  12493. 9th Interntl Drug Thrpy HIV: Response Rate, Resistance, and Side Effects After 96 Weeks of TMC278 - Written by Mark Mascolini - (11/12/08)
     
  12494. 9th Interntl Drug Thrpy HIV: D:A:D Cohort Group Offers Tool to Predict Short-Term Diabetes With HIV - Written by Mark Mascolini - (11/12/08)
     
  12495. 9th Interntl Drug Thrpy HIV: Will Etravirine Work Once Daily--With Once-Daily Darunavir? - Written by Mark Mascolini - (11/12/08)
     
  12496. 9th Interntl Drug Thrpy HIV: Salvage With Raltegravir, Etravirine, and Darunavir Works Fast in Small Case Series - Written by Mark Mascolini - (11/12/08)
     
  12497. 9th Interntl Drug Thrpy HIV: Potent Multidrug Salvage Without PIs or NRTIs: Raltegravir + Maraviroc + Etravirine - Written by Mark Mascolini - (11/12/08)
     
  12498. 9th Interntl Drug Thrpy HIV: CD4 Gains During Suppressive Therapy Differ by Pretreatment T-Cell Count - Written by Mark Mascolini - (11/12/08)
     
  12499. 9th Interntl Drug Thrpy HIV: Three Cohorts See No RNA Disadvantage With Abacavir/Lamivudine - Written by Mark Mascolini - (11/12/08)
     
  12500. 9th Interntl Drug Thrpy HIV: Renal Tubule Damage With Tenofovir Despite Normal Glomerular Function - Written by Mark Mascolini - (11/12/08)
     
  12501. 9th Interntl Drug Thrpy HIV: Inflammation and Coagulation Markers Askew in Children With Higher HIV RNA - Written by Mark Mascolini - (11/12/08)
     
  12502. 10th Intl Wrkshp Drug Reactions & Lipo: Impact of body changes on the quality of life of HIV-positive treatment experienced patients An online community-based survey (11/10/08)
     
  12503. 10th Intl Wrkshp Drug Reactions & Lipo: Skeletal muscle mitochondrial proteins discordantly regulated by insulin in HIV+ with insulin resistance: a mass spectrometry-based muscle proteomics study (11/10/08)
     
  12504. 10th Intl Wrkshp Drug Reactions & Lipo: Association between Peripheral Lipoatrophy and Bone Demineralisation in Treated HIV-positive Males (11/10/08)
     
  12505. 10th Intl Wrkshp Drug Reactions & Lipo: Effect of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor (GRF) Analogue, on Visceral Adipose Tissue (VAT) in HIV-Infected Patients with Excess Abdominal Fat: Impact of Antiretroviral Therapy Regimen (11/10/08)
     
  12506. 10th Intl Wrkshp Drug Reactions & Lipo: CD4 and Undetectable Viral Load Predict Non-AIDS Cancers: "AIDS and non-AIDS defining malignancies in HIV-infected patients - The 2006 ONCOVIH French study" (11/10/08)
     
  12507. 10th Intl Wrkshp Drug Reactions & Lipo: Comparison of Directly Measured and Estimated Glomerular Filtration Rates in Virologically Suppressed Patients Switching to Tenofovir or Continuing Zidovudine (11/10/08)
     
  12508. ICAAC: Complications of HIV infection. A summary form the IDSA/ICAAC conference in Washington DC. written by Pablo Tebas (11/07/08)
     
  12509. ICAAC: An enhanced assay to refine the use of CCR5 inhibitors - Written by David Margolis, MD (11/07/08)
     
  12510. Revised Guidelines for the Use of AntiretroviralAgents in HIV-1-Infected Adults and Adolescents - abacavir - (11/06/08)
     
  12511. ICAAC: HbA1c Underestimates Plasma Glucose in People Taking Antiretrovirals - Written by Mark Mascolini - (11/06/08)
     
  12512. ICAAC: Longer Antiretroviral Therapy Means Bigger Coronary Plaques - Written by Mark Mascolini - (11/03/08)
     
  12513. ICAAC: KS, NHL, and Encephalopathy Getting Diagnosed at Higher CD4 Counts in US Cohort - Written by Mark Mascolini - (11/03/08)
     
  12514. ICAAC: Nonalcoholic Fatty Liver in One Third of Naval Center Patients With HIV - Written by Mark Mascolini - (11/03/08)
     
  12515. ICAAC: Body Fat and Bone Changes After 96 Weeks of Fosamprenavir/Ritonavir - Written by Mark Mascolini - (11/03/08)
     
  12516. ICAAC: Antiretrovirals at CD4 Counts Above 350 May Quell HCV-Related Liver Inflammation - Written by Mark Mascolini - (11/03/08)
     
  12517. ICAAC: Limb and Trunk Fat Changes by Total Body DEXA After 96 Weeks of Treatment with Once-Daily (QD) Fosamprenavir Boosted with Either 100 mg or 200 mg of Ritonavir (/r) plus Abacavir (ABC)/lamivudine (3TC): COL100758 - (11/03/08)
     
  12518. ICAAC: Comparative Analysis of HIV+ and HIV- Interaction with Testosterone on Bone Mineral Density - (11/03/08)
     
  12519. ICAAC: HIV Infection and the Risk of Diabetes Mellitus - (11/03/08)
     
  12520. HIV CRISIS: AIDS is the leading cause of death for African-American women ages 25-34 today - (10/31/08)
     
  12521. HIV Doctors May Treat All Infected, Adding Thousands: When To Start HAART Debate - (10/31/08)
     
  12522. ICAAC: CD4+ Cell Increases at 48 Weeks in the Maraviroc Treatment-naive MERIT Trial - (10/31/08)
     
  12523. ICAAC: Adverse Event Profile of Maraviroc in Treatment-experienced Patients Infected with R5 HIV-1 - (10/31/08)
     
  12524. ICAAC: Unremitting Kaposi Sarcoma in HIV infected patients with viral suppression on antiretrovirals - (10/31/08)
     
  12525. ICAAC: Should Vitamin D Be Prescribed with Tenofovir/FTC? - (10/31/08)
     
  12526. ICAAC: Substitution of Nevirapine (NVP) for Efavirenz (EFV) Toxicity in ACTG A5095 - (10/31/08)
     
  12527. ICAAC: Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and rifabutin - (10/31/08)
     
  12528. ICAAC: Treatment Response among HIV Patients Co-enrolled in the Etravirine (ETR) and Raltegravir (RAL) Expanded Access Programs (EAPs) at Kaiser Permanente - (10/31/08)
     
  12529. ICAAC: Pharmacokinetics and pharmacodynamics of etravirine in treatment-experienced HIV-1-infected patients: pooled 48-week results of DUET-1 and DUET-2 - (10/31/08)
     
  12530. ICAAC: Renal Function after Use of Tenofovir as Part of the Initial ART Regimen - (10/31/08)
     
  12531. ICAAC: Prevalence and Risk Factors of Chronic Kidney Disease in an HIV Infected Minority Urban Population - (10/31/08)
     
  12532. ICAAC: A Phase II Safety and Efficacy Study of Bevirimat in Heavily Treatment-Experienced HIV+ Patients Identifies the Target Phase III Study Profile - (10/30/08)
     
  12533. ICAAC: Low Vitamin D Tied to High Bone Marker Levels in Men Taking Tenofovir - Written by Mark Mascolini - (10/30/08)
     
  12534. ICAAC: Bone Loss in SMART Study - Written by Mark Mascolini - (10/30/08)
     
  12535. ICAAC: Pulmonary Hypertension Rate 5.5% in Antiretroviral-Treated US Navy Group - Written by Mark Mascolini - (10/30/08)
     
  12536. ICAAC: Darunavir or Raltegravir in Rescue Regimen Raises Chance of Success 3 to 4 Times - Written by Mark Mascolini - (10/30/08)
     
  12537. ICAAC: High Rash Rate in Healthy Volunteers Combining Raltegravir and Darunavir - Written by Mark Mascolini - (10/30/08)
     
  12538. ICAAC: Did HIV Become More Virulent in First Decade of US Epidemic? - Written by Mark Mascolini - (10/30/08)
     
  12539. ICAAC: Hospital Admission Rate Stays Higher for First 90 Days of HAART - Written by Mark Mascolini - (10/30/08)
     
  12540. ICAAC: Doubled Risk of Failure After 1 Year Under 50 Copies in Women and Steady Blippers - Written by Mark Mascolini - (10/30/08)
     
  12541. ICAAC: Long-Term Safety of Vicriviroc: out to 4 yrs (10/29/08)
     
  12542. ICAAC: A Pharmacokinetic Study to Evaluate an Interaction between Maraviroc and Raltegravir in Healthy Adults (10/29/08)
     
  12543. ICAAC: Pharmacokinetic (PK) Evaluation of Darunavir/Ritonavir (DRV/r) and Raltegravir (RAL) in Healthy Subjects (10/29/08)
     
  12544. ICAAC: Three-year Efficacy of Lopinavir/ritonavir Monotherapy in the OK04 Trial (10/29/08)
     
  12545. ICAAC: Single Agent Therapy with Lopinavir/Ritonavir Suppresses HIV-1 Viral Replication in ARV Naive Patients: IMANI II - 96 Week Final Results (10/29/08)
     
  12546. ICAAC: Darunavir Makes HIV Undetectable in Half of Heavily Pretreated Children - Written by Mark Mascolini - (10/28/08)
     
  12547. ICAAC: Phase 2 Trial Confirms Baseline Mutation Risk With Maturation Inhibitor - Written by Mark Mascolini - (10/28/08)
     
  12548. ICAAC: Lower CD4 Count With HIV Ups Risk of Anal Cancer in Case-Control Study - Written by Mark Mascolini - (10/28/08)
     
  12549. ICAAC: Antiretroviral Therapy Lowers MRSA Risk 84% in US Cohort Study - Written by Mark Mascolini - (10/28/08)
     
  12550. ICAAC: Antiretroviral Trial Strictures Make Outcomes Harder to Interpret in Clinic: HIV trials need patients with 'major illnesses or more advanced HIV disease' - Written by Mark Mascolini - (10/28/08)
     
  12551. ICAAC: Lower Risk of Diabetes With HIV in US Veterans Affairs Cohort - Written by Mark Mascolini - (10/28/08)
     
  12552. ICAAC: Characterization of Virologic Failure Over 96 Weeks by Drug Resistance and Antiviral Response in ART Naïve Patients Receiving Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) Each with Lopinavir/Ritonavir QD in the HEAT Study (10/28/08)
     
  12553. ICAAC: The Impact of Tenofovir on Insulin Sensitivity and Lipids in Healthy Volunteers (10/28/08)
     
  12554. ICAAC: Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-Resistance to Other NNRTIs (10/28/08)
     
  12555. ICAAC: RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV Patients (10/28/08)
     
  12556. ICAAC: Elvucitabine Phase II 48 Week Interim Results Show Safety and Efficacy Profiles Similar to Lamivudine in Treatment Naive HIV-1 Infected Patients with a Unique Pharmacokinetic Profile (10/28/08)
     
  12557. ICAAC: Safety and Efficacy of Raltegravir-Based Versus Efavirenz-Based Combination Therapy in Treatment-Naive HIV-1 Infected Patients (10/28/08)
     
  12558. ICAAC: 96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ® (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients - BMS Press Release (10/28/08)
     
  12559. ICAAC: Reanalysis of the MERIT Study with the Enhanced Trofile Assay (MERIT-ES) (10/28/08)
     
  12560. ICAAC: Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naïve Adults, Tibotec press release (10/27/08)
     
  12561. ICAAC: Efficacy and safety of darunavir/ritonavir 800/100mg once-daily versus lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients at 96 weeks: ARTEMIS (TMC114-C211) (10/27/08)
     
  12562. ICAAC: Response to Vicriviroc in HIV-Infected Treatment-Experienced Subjects using an Enhanced Version of the Trofile HIV Co-receptor Tropism Assay: Reanalysis of ACTG 5211 Results (10/27/08)
     
  12563. ICAAC: ATRIPLA: Simplification of Antiretroviral Therapy with Efavirenz/Emtricitabine/Tenofovir DF Single Tablet Regimen vs. Continued Unmodified Antiretroviral Therapy in Virologically-Suppressed, HIV-1-Infected Patients (10/27/08)
     
  12564. ATRIPLA: The 48-Week Efficacy and Safety of Switching to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-1-Infected Patients Receiving HAART (11/18/08)
     
  12565. ICAAC: Atazanavir/Ritonavir vs Lopinavir/Ritonavir in Antiretroviral-Naive HIV-1-Infected Patients: CASTLE 96 Week Efficacy and Safety (10/27/08)
     
  12566. ICAAC: Atazanavir/Ritonavir (ATV/r) + Abacavir/Lamivudine (ABC/3TC) in Antiretroviral (ART)-Naïve, HIV-1 Infected, HLA-B*5701 Negative Subjects Demonstrates Efficacy and Safety: the ARIES Trial (10/27/08)
     
  12567. ICAAC: Effects of NRTI backbone on efficacy of first-line boosted PI based HAART: meta-analysis comparing TDF to ABC (10/27/08)
     
  12568. ICAAC: Steady Evolution of Integrase Mutations After Raltegravir Fails - Written by Mark Mascolini - (10/27/08)
     
  12569. ICAAC: Results on First-Line ABC/3TC With RNA Above 100,000: ARIES Study of abacavir/3TC plus atazanavir/r - Written by Mark Mascolini - (10/27/08)
     
  12570. ICAAC: Independent Analysis Suggests TDF/FTC Outdoes ABC/3TC With First-Line PIs - Written by Mark Mascolini - (10/27/08)
     
  12571. ICAAC: Enhanced Trofile Assays Shifts Results of ACTG 5211 Vicriviroc Trial - Written by Mark Mascolini - (10/27/08)
     
  12572. ICAAC: First-Line Raltegravir Controls HIV as Well as Efavirenz for 48 Weeks - Written by Mark Mascolini - (10/27/08)
     
  12573. ICAAC: Risk of Death 70% Higher When Delaying ART With CD4s at 351 to 500 - Written by Mark Mascolini - (10/27/08)
     
  12574. ICAAC: Black Women in US Less Likely to Get Antiretrovirals, Regardless of Insurance - Written by Mark Mascolini - (10/27/08)
     
  12575. ICAAC: In-Hospital Death Risk 4 Times Higher in Blacks Than Whites With HIV - Written by Mark Mascolini - (10/27/08)
     
  12576. ICAAC: Frequent Sexual Activity by Brooklyn Teens Infected With HIV at Birth - Written by Mark Mascolini - (10/27/08)
     
  12577. ICAAC: Greater Lipodystrophy Risk in Older US Children With Low Viral Load - Written by Mark Mascolini - (10/27/08)
     
  12578. ICAAC: Half of Black US Women Switch HIV Clinicians Because of Communication Problems - Written by Mark Mascolini - (10/27/08)
     
  12579. Mechanisms of Neuronal Injury and Death in HIV-1 Associated Dementia - (10/24/08)
     
  12580. Risk for Opportunistic Disease and Death after Reinitiating Continuous Antiretroviral Therapy in Patients with HIV Previously Receiving Episodic Therapy SMART - (10/24/08)
     
  12581. EMEA Extends Prezista Indication (darunavir) - (10/24/08)
     
  12582. The CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study - (10/23/08)
     
  12583. Variable Cognitive Function Response to HAART: HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients - (10/23/08)
     
  12584. Neurotoxic effect of HIV: HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people - (10/23/08)
     
  12585. U.S. Food and Drug Administration (FDA) Approves PREZISTA Once-Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1 - (10/22/08)
     
  12586. Diabetes in D.A.D. Study - (10/21/08)
     
  12587. Non-AIDS Deaths In HIV Positive Patients Linked To Inflammation And Coagulation Markers...and ART interruption - (10/21/08)
     
  12588. Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients - (10/21/08)
     
  12589. Association of White Blood Cell Subfraction Concentration with Fitness and Fatness - (10/17/08)
     
  12590. B Vitamins for Prevention of Cognitive Decline - Editorial - (10/16/08)
     
  12591. Emergence and Persistence of CXCR4-Tropic HIV-1 in a Population of Men from the Multicenter AIDS Cohort Study - (10/15/08)
     
  12592. HIV-1 Tropism, Disease Progression, and Clinical Management - (10/15/08)
     
  12593. Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-Naive Subjects with HIV-1 Infection - (10/15/08)
     
  12594. Aging with HIV Increases Risk for Comorbidities: Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity? - (10/14/08)
     
  12595. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen - (10/14/08)
     
  12596. Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes - (10/10/08)
     
  12597. Baseline Serum 25-Hydroxy Vitamin D Is Predictive of Future Glycemic Status and Insulin Resistance - (10/10/08)
     
  12598. Discrimination, Distrust, and Racial/Ethnic Disparities in Antiretroviral Therapy Adherence Among a National Sample of HIV-Infected Patients - (10/10/08)
     
  12599. Prospective Study of Dietary Fiber, Whole Grain Foods, and Small Intestinal Cancer - (10/09/08)
     
  12600. Mitochondria and Aging - (10/09/08)
     
  12601. New Genetic Model For Parkinson's Disease: mitochondrial damage - (10/09/08)
     
  12602. Mitochondria Damage & Aging - (10/09/08)
     
  12603. The Effect of Strength and Endurance Training on Insulin Sensitivity and Fat Distribution in Human Immunodeficiency Virus-Infected Patients with Lipodystrophy - (10/08/08)
     
  12604. Link Between Circumcision and HIV Risk Unclear in MSM - (10/08/08)
     
  12605. Circumcision for MSM May Be Effective: New Debate Over Circumcision, HIV Reduction - (10/08/08)
     
  12606. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors - (10/08/08)
     
  12607. Home use of vegetable oils, markers of systemic inflammation, and endothelial dysfunction among women - (10/08/08)
     
  12608. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients - (10/08/08)
     
  12609. Researchers to Evaluate a Once-Daily Investigational Dose of Raltegravir, Merck's Integrase Inhibitor, in an Investigational Population, Patients Previously Untreated for HIV-1 - (10/08/08)
     
  12610. CD4 Predicts Death: HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies - (10/08/08)
     
  12611. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression - (10/08/08)
     
  12612. HAART Did Not Appear To Fully Correct the Adverse Effect of HIV on HCV Progression - (10/07/08)
     
  12613. New Inhibitor of HIV gp120: N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery - (10/07/08)
     
  12614. Reports of KS in Aging SF Patients - (10/06/08)
     
  12615. Can We Cure Aging? - (10/06/08)
     
  12616. New HIV Targets Discovered - (10/06/08)
     
  12617. New CDC HIV Prevalence Estimates -- United States, 2006 - (10/06/08)
     
  12618. Assessment of a hypothetical HIV chemoprophylaxis program among men who have sex with men in NYC - (10/06/08)
     
  12619. Prevalence of Human Papillomavirus (HPV) Genotypes in HIV-1 Infected Women in Seattle, WA and Nairobi, Kenya - (10/06/08) -
     
  12620. Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection - (10/03/08)
     
  12621. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection - (10/03/08)
     
  12622. HIV Existed 100 Years Ago Study Reports, Urbanization of Africa Spread HIV (3 Nature articles below) - (10/03/08)
     
  12623. U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients - (10/03/08)
     
  12624. Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults - (10/03/08)
     
  12625. Progenics (PRO 140) Announces Progress and Presentations in HIV Therapy Program - (10/03/08)
     
  12626. Central obesity and increased risk of dementia more than three decades later - (10/03/08)
     
  12627. Impaired insulin secretion increases the risk of Alzheimer disease - (10/03/08)
     
  12628. Visceral Adiposity & Insulin Impairment & Dementia/Alzheimer's - (10/03/08)
     
  12629. Big Pharma, Pfizer, GSK Refocus, Big Pharma prunes R&D as times get tough - (10/03/08)
     
  12630. Drug-Susceptible HIV-1 Infection Despite Intermittent Fixed-Dose Combination Tenofovir/Emtricitabine as Prophylaxis Is Associated With Low-Level Viremia, Delayed Seroconversion, and an Attenuated Clinical Course [Rapid Communication] - (09/29/08)
     
  12631. HIV Serosorting in Men Who Have Sex With Men: Is It Safe? - (09/29/08)
     
  12632. Estimating GFR Using Cystatin Alone & in Combination with Creatinine: analysis of 3,418 with CKD - (09/26/08)
     
  12633. Chronic Kidney Disease Prevalence Higher in the USA: related to hypertension, diabetes, aging - (09/26/08)
     
  12634. CKD in the Elderly-Old Questions and New Challenges: CKD in the elderly as a new challenge for research, clinical practice, and public health. - (09/26/08)
     
  12635. A paradox of immunodeficiency and inflammation in human aging: lessons learned from apoptosis - (09/26/08)
     
  12636. DDI Delayed Release Generic Approved - (09/26/08)
     
  12637. Cancers in HIV: immunity/ART - (09/26/08)
     
  12638. Switch HAART Quickly After Viral Rebound-- Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study - (09/26/08)
     
  12639. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle - (09/23/08)
     
  12640. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV - (09/23/08)
     
  12641. Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility - (09/23/08)
     
  12642. The Gut (Microbial translocation) is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy [Research Letters] - (09/23/08)
     
  12643. Lipoatrophy and lipohypertrophy are independently associated with hypertension (FRAM): the effect of lipoatrophy but not lipohypertrophy on hypertension is independent of obesity - (09/22/08)
     
  12644. IAS: In Mexico City Viva Metabolics! - David Alain Wohl, MD - The University of North Carolina - (09/22/08) -
     
  12645. Breast milk purged of HIV virus by Nipple Shield+Chemical - (09/22/08)
     
  12646. Elevated Uric Acid Increases the Risk for Kidney Disease - (09/22/08)
     
  12647. HAART Reduced Comoditities - (09/22/08)
     
  12648. 2 New Osteoporosis Drugs in the Works: Biologic Osteoporosis Drugs Denosumab and Odanacatib Show Promise in Clinical Trials - (09/22/08)
     
  12649. Update in Osteoporosis and Metabolic Bone Disorders - (09/22/08)
     
  12650. Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate - (09/22/08)
     
  12651. Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased BMD Over Two Years at Key Fracture Sites in Phase IIB Study - (09/22/08)
     
  12652. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women: phase 3 results - (09/22/08)
     
  12653. Subclinical Glucose Abnormalities & Undiagnosed Diabetes Noted in HCV+ - (09/18/08)
     
  12654. Inaugural Conference of the BHIVA Hepatitis Working Group (BHWG) - Oct 8 2008 London - (09/18/08)
     
  12655. Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians - (09/18/08)
     
  12656. HAART, Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire - (09/18/08)
     
  12657. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy - (09/18/08)
     
  12658. Myriad Genetics Announces Topline Results of Phase 1 Trial of Vivecon for HIV Trial Indicates Favorable Safety and Pharmacokinetics Profiles - (09/18/08)
     
  12659. Myriad Genetics Submits IND on Vivecon New HIV Maturation Inhibitor - (09/18/08)
     
  12660. New HIV Maturation Inhibitor MPC-9055 - (09/18/08)
     
  12661. (Increased) Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study - (09/17/08)
     
  12662. HCV/HIV Coinfection Progressed More Quickly than HCV Despite HAART - (09/17/08)
     
  12663. Adherence to Mediterranean diet and health status (reduces mortality): meta-analysis - (09/17/08)
     
  12664. Cystatin C Level as a Marker of Kidney Function in Human Immunodeficiency Virus Infection - (09/17/08)
     
  12665. FDA Issues (generic drugs) Warning Letters to Ranbaxy Laboratories Ltd., and an Import Alert for Drugs from Two Ranbaxy Plants in India - (09/17/08)
     
  12666. Racivir - New HIV Drug - (09/17/08)
     
  12667. Depression in the United States Household Population, 2005-2006 - (09/16/08)
     
  12668. Acyclovir Could Help Control HIV, Study Finds - (09/16/08)
     
  12669. tentative approval of abacavir sulfate 60 mgscored tablet for pediatric dosing - (09/16/08)
     
  12670. HIV-associated Alzheimer's disease in the Future? - (09/16/08)
     
  12671. Statins for Slowing Kidney Disease Progression: An as yet Unproven Indication - (09/16/08)
     
  12672. Trimeris 2nd Generation Fusion Inhibitor TRI-1144 Update - (09/16/08)
     
  12673. Frailty Defined in Older Adults Evidence for a Phenotype - (09/16/08)
     
  12674. Physical Frailty Could Predict Alzheimer's Disease - (09/16/08)
     
  12675. CDC MMWR Analysis Provides New Details on HIV Incidence in U.S. Populations: highest in MSM-African-Americans, Latinos and Black Women - (09/16/08)
     
  12676. TNF-α and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo - (09/16/08)
     
  12677. Alzheimer's Disease Risk Factors: exercise, metabolics, lifestyle, genetics - (09/16/08)
     
  12678. Intensive Blood Glucose Control Has Positive Outcomes in ADVANCE Study - (09/12/08)
     
  12679. Trimeris Reports Financial Results for the Second Quarter 2008 and Top-Line Results from Its Phase 1 Clinical Study of TRI-1144 - (09/12/08)
     
  12680. ACTG Bone Study Group Established; More Bone Issues Need Attention - (09/12/08)
     
  12681. Influence of HAART on the Clinical Course of HIV-1-Infected Patients With Progressive Multifocal Leukoencephalopathy: Results of an Observational Multicenter Study - (09/12/08)
     
  12682. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis - (09/12/08)
     
  12683. Analysis of Nevirapine (NVP) Resistance in Ugandan Infants Who Were HIV Infected Despite Receiving Single-Dose (SD) NVP versus SD NVP Plus Daily NVP Up to 6 Weeks of Age to Prevent HIV Vertical Transmission - (09/8/08)
     
  12684. Approach to the Patient with Prediabetes - (09/8/08)
     
  12685. HIV and prostate cancer: a systematic review of the literature - (09/8/08)
     
  12686. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients - (09/5/08)
     
  12687. Risk factors for decreased bone density and effects of HIV on bone in the elderly - (09/3/08)
     
  12688. The near absence of osteoporosis treatment in older men with fractures - (09/3/08)
     
  12689. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection [EPIDEMIOLOGY AND SOCIAL] - (09/3/08)
     
  12690. HIV Infection and Bone Mineral Density in Middle-Aged Women - (09/3/08)
     
  12691. BMD Is Reduced in HIV-Infected Men Irrespective of ART Treatment - (09/3/08)
     
  12692. Bone and Mineral Metabolism in Human Immunodeficiency Virus Infection - (09/2/08)
     
  12693. Inflammatory Markers and Incident Fracture Risk in Older Men and Women: The Health Aging and Body Composition Study - (09/2/08)
     
  12694. Running slows the aging clock, Stanford researchers find - (09/2/08)
     
  12695. Sexual transmission- MSM & Natural Pregnancy: blood & semen viral load associated, and Herpes-2 with HIV transmission; Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract - (09/2/08)
     
  12696. FDA Update on Norvir Label Change QT/QTc Interval & PR Interval Prolongation - (09/2/08)
     
  12697. HCV Coinfection Increases Risk for HIV-Related Kidney Disease - (08/29/08)
     
  12698. IAS: ddI/FTC/ATV QD vs AZT/3TC bid+Efavrienz QD - Mark Mascolini - (08/29/08) -
     
  12699. Long-term use of bisphosphonates in the treatment of HIV-related bone pain in perinatally infected pediatric patients [Correspondence] - (08/29/08)
     
  12700. INTELENCE (etravirine) Receives Marketing Authorisation In The European Union For HIV Combination Therapy - (08/29/08)
     
  12701. Genetics Influence Lipodystrophy - (08/29/08)
     
  12702. Long-term safety (52 weeks) and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation [BASIC SCIENCE] - (08/29/08)
     
  12703. Clinical impact of patient racial/ethnic population differences and genomic variation in efavirenz therapy [EDITORIAL REVIEW] - (08/29/08)
     
  12704. Aging with HIV; Early Cognitive Decline - (08/28/08)
     
  12705. IAS: The Inflammatory Debate: Is it the Virus, the Drugs, or the Host? Reviewed by Charles Hicks, MD; Duke University Medical Center - (08/28/08) -
     
  12706. IAS: Highly-sensitive C-reactive protein (hsCRP) is associated with body mass index (BMI) and serum lipids in HIV-infected patients with low cardiovascular disease (CVD) risk and virologic suppression on antiretroviral therapy (ART) - (08/28/08) -
     
  12707. IAS: Clinicians Fail to Routinely Provide Reproductive Counseling to HIV-Infected Women in the United States - (08/27/08) -
     
  12708. IAS: Societal Stigma of Pregnant HIV-Infected Women in the United States - (08/27/08) -
     
  12709. Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The Mortalite 2000 and 2005 Surveys (ANRS EN19 and Mortavic) [Epidemiology and Social Science] - (08/27/08)
     
  12710. Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-Coinfected Patients [Brief Report: Clinical Science] - (08/27/08)
     
  12711. Decrease in Cardiovascular risk on HAART - Coronary Artery Calcification on Electron Beam Computed Tomography: A 6-Year Follow-Up Study of HIV-Infected Patients [Letters to the Editor] - (08/27/08)
     
  12712. Genotyping of Human Papillomavirus DNA in Anal Biopsies and Anal Swabs Collected From HIV-Seropositive Men With Anal Dysplasia [Clinical Science] - (08/27/08)
     
  12713. Characteristics of HIV Infection Among Hispanics, United States 2003-2006 [Epidemiology and Social Science] - (08/27/08)
     
  12714. Earlier HAART Suggested for African-Americans At-Risk for Kidney Disease - (08/27/08)
     
  12715. IAS: IAC Mexico City 2008 Summary Report - Written by Mark Wainberg - (08/26/08) -
     
  12716. IAS: Efavirenz Stops HIV Better Than Lopinavir When Starting With Few CD4s - Mark Mascolini - (08/26/08) -
     
  12717. IAS: IDX899, Novel HIV-1 NNRTI with High Barrier to Resistance, Provides Suppression of HIV Viral Load in Treatment-Naïve HIV-1-Infected Subjects - (08/26/08) -
     
  12718. IAS: Efficacy and safety profile of APTIVUS oral solution or capsules co-administered with low dose ritonavir (APTIVUS/r) in treatment experienced children and teenagers after two years of treatment (Phase I/IIa study) - (08/25/08) -
     
  12719. FDA: Important updates to the Reyataz (atazanvir) label - (08/25/08)
     
  12720. Genetic Variation Linked to Body Changes & Abnormal Lipids: Genetic analysis implicates resistin in HIV lipodystrophy [BASIC SCIENCE] - (08/25/08)
     
  12721. Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men [EPIDEMIOLOGY AND SOCIAL: CONCISE COMMUNICATIONS] - (08/25/08)
     
  12722. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America [Research Letters] - (08/25/08)
     
  12723. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma [Research Letters] - (08/25/08)
     
  12724. 650 Cd4s 55% Better Than 500, less death/AIDS: Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count [BASIC SCIENCE] - (08/25/08)
     
  12725. Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases [Clinical Science] - (08/25/08)
     
  12726. In Vitro Characterization of Multidrug-Resistant HIV-1 Isolates From a Recently Infected Patient (NYC 2005 Case) Associated With Dual Tropism and Rapid Disease Progression [Basic Science] - (08/25/08)
     
  12727. Muscular Strength & Mortality in Men - (08/25/08)
     
  12728. Increased cardiovascular risk in HIV infection: drugs, virus and immunity, EDITORIAL COMMENTS - (08/22/08)
     
  12729. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men - (08/22/08)
     
  12730. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicenter AIDS Cohort Study - (08/22/08)
     
  12731. Chemical liberated (LPS) by leaky gut may allow HIV to infect the brain, Einstein scientists find - (08/20/08)
     
  12732. Medical Policy Guideline for Trofile(TM) Established By Wellpoint, Inc: insurer says Trofile is only assay for testing tropism - (08/20/08)
     
  12733. Routine reporting of estimated glomerular filtration rate: not ready for prime time - (08/20/08)
     
  12734. IAS: Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients: Results of a Large Retrospective Database Study - (08/20/08) -
     
  12735. IAS: Coagulation factor levels are not affected by tipranavir (TPV/r) capsules or Vitamin E-containing solution formulations nor by comparator protease inhibitors (PI) - (08/20/08) -
     
  12736. IAS: Gender-Based Differences in ART-Naives in CASTLE Study: viral response, lipids, adverse events; and Other Gender-Based Studies at IAC - (08/19/08) -
     
  12737. IAS: CD4+ T-cell Counts < 350 cells/mm3 Are a Risk Factor for Cardiovascular Disease in the HIV Outpatient Study (HOPS) - (08/19/08) -
     
  12738. IAS: (NCEP)-based IDSA/ACTG Guidelines for Management of Cardiovascular Risk in the HIV Outpatient Study (HOPS) - (08/19/08) -
     
  12739. IAS: At IAC Meeting on AIDS, Focus Shifts to Long Haul - (08/19/08) -
     
  12740. IAS: Women's Rights Equals Women's Lives - from Mexico - (08/19/08) -
     
  12741. IAS: HIV Crosses the Gender Divide - (08/19/08) -
     
  12742. IAS: Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus an Optimized Background Therapy (OBT) Versus Placebo Plus OBT in the MOTIVATE 1 and 2 Trials - (08/19/08) -
     
  12743. IAS: Switching to Fosamprenavir (FPV) Led to Similar Efficacy and Safety in HIV-1-infected Subjects on their First PI Regimen: a Prospective, Open-label, Multicenter, Randomized Trial (ESS100290) - (08/18/08) -
     
  12744. IAS: HLA-B*5701 Screening Reduces Abacavir Hypersensitivity Reactions (ABC HSR); Multiple Lines of Evidence to Establish a New Standard of Care - (08/18/08) -
     
  12745. IAS: HIV-1 viral load in cerebrospinal fluid (CSF) of successfully treated patients on long-term HAART - (08/18/08) -
     
  12746. IAS: Baseline evaluation in CSF and neuropsycho-logical testing in patients starting Monotherapy - (08/18/08) -
     
  12747. IAS: Cognitive Disorders Despite Undetectable Viremia: Low Scores in The HIV Dementia Scale (HDS) - (08/18/08) -
     
  12748. Transmission of HIV-1 from a Patient Who Developed AIDS to an Elite Suppressor: CD38 T-cell reponse in elite suppressor appears to prevent HIV replication - (08/15/08)
     
  12749. IAS: The Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naive Patients Through Seven Years - (08/15/08) -
     
  12750. IAS: TMC278 long acting - a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers - (08/15/08) -
     
  12751. IAS: Dose selection and pharmacokinetics-pharmacodynamics of darunavir coadministered with low-dose ritonavir in the DELPHI (TMC114-C212) trial in treatment-experienced, HIV-1-infected children and adolescents - (08/15/08) -
     
  12752. IAS: HCV Increased Risk for MI and Stroke in HIV+, Study Reported at IAC - (08/13/08) -
     
  12753. IAS: Renal Safety Profile of Tenofovir DF (TDF)-containing vs. Thymidine Analog-containing Regimens Through 144 Weeks in Antiretroviral-naive Patients - (08/13/08) -
     
  12754. IAS: The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1-Infected Patients: A Four-Year Follow-up - (08/13/08) -
     
  12755. IAS: Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naive Patients Through Seven Years - (08/13/08) -
     
  12756. IAS: Efficacy, Safety and Tolerability of Etravirine With and Without Darunavir and/or Raltegravir in Treatment-Experienced Patients: Preliminary Analysis of TMC125-C214 Early Access Program (EAP) in the US - (08/13/08) -
     
  12757. IAS: Impact of Gender on Response to Lopinavir/ritonavir (LPV/r) Tablets Dosed QD or BID Administered with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) in Antiretroviral-naive (ARV) Subjects: Results from Study M05-730 - (08/12/08) -
     
  12758. IAS: Long-Term Impact of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, on Body Image Parameters in HIV-Infected Patients with Abdominal Fat Accumulation - (08/12/08) -
     
  12759. IAS: Results from the 26-week Confirmatory, Phase 3 Trial of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV Patients with Excess Abdominal Fat: A Multicenter, Double-blind, Placebo-controlled Study with 404 Randomized Patients - (08/12/08) -
     
  12760. IAS: Week-96 end of trial analysis of antiretroviral-naive patients randomized to the lopinavir/ritonavir single drug arm in the MONARK trial - (08/12/08) -
     
  12761. IAS: Maraviroc Exposure-efficacy (<50 copies/mL) Analysis in HIV-1-infected Treatment-naive Subjects - ITT Population (MERIT Study) - (08/12/08) -
     
  12762. IAS: ARTEMIS: lipid tolerability and safety of darunavir and lopinavir in antiretroviral-naive patients - (08/12/08) -
     
  12763. IAS: Switching NRTI Backbone to Tenofovir Plus Emtricitabine (Truvada, TVD) Promptly Improves Triglycerides and LDL-cholesterol Levels in Dyslipidemic HIV-1 Infected Patients: The TOTEM Randomised Trial - (08/12/08) -
     
  12764. IAS: Metabolic Outcomes from Prospective, Randomized Clinical Trials of Tenofovir DF (TDF) Compared to Thymidine Analog-containing Efavirenz-based Regimens in Antiretroviral-Naive Patients - (08/12/08) -
     
  12765. IAS: Lopinavir/ritonavir (LPV/r) in Pregnancy: ART Pregnancy Registry - (08/12/08) -
     
  12766. IAS: CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist - (08/12/08) -
     
  12767. IAS: A Comparison of the Single Dose Bioavailability of a Ritonavir Tablet Formulation Relative to the Ritonavir Soft Gelatin Capsule in Healthy Adult Subjects - (08/12/08) -
     
  12768. Reduced Disability and Mortality Among Aging Runners - (08/12/08)
     
  12769. IAS: Lopinavir-ritonavir plus Nevirapine as a Strategy to Improve Nucleoside-Related Mitochondrial Toxicity in Chronically Treated HIV-Infected Patients: 48 Week Follow-Up of MULTINEKA Study - (08/12/08) -
     
  12770. IAS:IAS: Maraviroc Exposure-safety Biomarker (Transaminases and Creatine Kinase) Analyses in MOTIVATE 1 and 2 Studies in HIV-1-infected Treatment-experienced Subjects - (08/12/08) -
     
  12771. IAS:CD4+ Cell Restoration after 48 Weeks in the Maraviroc Treatment-experienced Trials MOTIVATE 1 and 2 - (08/12/08) -
     
  12772. IAS: Clinical Predictors of Tenofovir-Associated Nephrotoxicity - written by Mark Mascolini - (08/11/08)
     
  12773. IAS: Twelve-Study Analysis Implicates Certain PIs and NRTIs in Lipid Jumps - written by Mark Mascolini - (08/11/08)
     
  12774. IAS: Cohort Studies Disagree on Tenofovir Role in Kidney Trouble - written by Mark Mascolini - (08/11/08)
     
  12775. IAS: Heart Marker (hsCRP) Tied to Lipids and Weight in People With Tight HIV Control - written by Mark Mascolini - (08/11/08)
     
  12776. IAS: Responding to Darunavir/Etravirine For Patients With Resistance - written by Mark Mascolini - (08/11/08)
     
  12777. IAS: Nevirapine Is Best Semen Penetrator in Study of Six PIs and Nonnucleosides - written by Mark Mascolini - (08/11/08)
     
  12778. IAS: Similarity in Efficacy and Safety of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FTC) in Combination with QD Lopinavir/Ritonavir (LPV/r) Over 96 Weeks in the HEAT Study - (08/11/08) -
     
  12779. IAS: New Norvir Tablet Bioequivalence - (08/11/08) -
     
  12780. IAS: NATAP Summary of IAC 2008 Clinical Late Breaker Abstracts - written by Andrew Zolopa, MD Stanford University - (08/11/08) -
     
  12781. IAS: RAL-KAL: PHARMACOKINETICS OF COADMINISTERED RALTEGRAVIR AND LOPINAVIR-RITONAVIR IN HEALTHY ADULTS - (08/11/08) -
     
  12782. IAS: High Rate of Bone Thinning in Healthy Gay Men Without HIV - written by Mark Mascolini - (08/08/08)
     
  12783. IAS: HCV Emerging as New Sexually Transmitted Disease in MSM With HIV - written by Mark Mascolini - (08/08/08)
     
  12784. IAS: Studies Disagree on Faster Failure With First-Line Abacavir/Lamivudine ACTG 5202 - (08/08/08)
     
  12785. IAS: Abacavir and Heart Disease - written by Mark Mascolini - (08/08/08)
     
  12786. IAS: Safety, Tolerability and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Women With HIV Infection: 24-Week Interim Analysis of GRACE (Gender, Race, And Clinical Experience) - (08/07/08)
     
  12787. IAS: Study Suggests HIV Itself Unleashes Body-Fat-Change Cascade, Gene Study Suggests - written by Mark Mascolini - (08/07/08)
     
  12788. IAS: Dangerous Liver Problem Seen After Switch to Raltegravir With Tipranavir - written by Mark Mascolini - (08/07/08)
     
  12789. IAS: Response in Etravirine Expanded Access With Diverse Background Regimens - written by Mark Mascolini - (08/07/08)
     
  12790. IAS: The incidence of rash observed with the NNRTI etravirine in the Phase III DUET trials using pooled 48-week data - (08/07/08)
     
  12791. IAS: Incidence and severity of nervous system and psychiatric events are similar with etravirine versus placebo: pooled 48-week data from the Phase III DUET studies - (08/07/08)
     
  12792. IAS: Pharmacokinetics of etravirine are not affected by sex, age, race, treatment duration or use of enfuvirtide in HIV-1-infected subjects - (08/07/08)
     
  12793. IAS: Efficacy and Safety By Racial Group in ARV-Naive Subjects Treated With Atazanavir/Ritonavir or Lopinavir/Ritonavir: 48-Week Results for the CASTLE Study - (08/07/08)
     
  12794. IAS: TMC278 (rilpivirine), an investigational next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96-week results of study C204 - (08/06/08)
     
  12795. IAS: Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines - (08/06/08)
     
  12796. IAS: Raltegravir 96 Weeks data from Phase II Study in Treatment-Naive - (08/06/08)
     
  12797. IAS: Combined darunavir and etravirine resistance analysis of the pooled DUET trials: when can we spare the other new classes? - (08/06/08)
     
  12798. IAS: Compelling 96-Week Findings on Raltegravir as First-Line Option - written by Mark Mascolini - (08/06/08)
     
  12799. IAS: Nonnucleoside TMC-278 Slated for First-Line Use Looks Good Through 96 Weeks - written by Mark Mascolini - (08/06/08)
     
  12800. IAS: Lower CD4 Count Despite Undetectable Load Raises Risks of AIDS and Death - written by Mark Mascolini - (08/06/08)
     
  12801. Abbott Prepares to Submit Heat-Stable Norvir Tablet for Registration by End of Year - (08/05/08)
     
  12802. Hepatitis C Virus Coinfection Does Not Affect CD4 Restoration in HIV-Infected Patients after Initiation of Antiretroviral Therapy - (08/05/08)
     
  12803. Lack of Effectiveness of Microbicide Cellulose Sulfate Gel for the Prevention of Vaginal HIV Transmission - (08/05/08)
     
  12804. Enhancement of HIV Infection by Cellulose Sulfate - (08/05/08)
     
  12805. Visceral fat predicts liver inflammation: A key mediator of steatohepatitis in metabolic liver disease; metabolic syndrome - (08/05/08)
     
  12806. Bush signs PEPFAR, expansion of U.S. global AIDS programs - (08/05/08)
     
  12807. CASTLE Study: Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results - (08/05/08)
     
  12808. HIV Incidence, New HIV Infections: CDC Announcement - (08/05/08)
     
  12809. Injection Drug Users Respond As Well To HAART - (08/05/08)
     
  12810. Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation - (08/05/08)
     
  12811. IAS: Switch to Atazanavir/Ritonavir Does Not Trim Trunk Fat in 48 Weeks - written by Mark Mascolini - (08/05/08)
     
  12812. IAS: Resistance Test Before ART Erases Risk of Poor Viral Response - written by Mark Mascolini - (08/05/08)
     
  12813. IAS: Mental Development Equivalent in ARV-Exposed and Unexposed Kids Without HIV - written by Mark Mascolini - (08/05/08)
     
  12814. IAS: CDC underestimated new HIV cases by 40 percent - (08/02/08)
     
  12815. IAS: Africa the worst hit by AIDS, by far - (08/02/08)
     
  12816. IAS: PrEP for Prevention Has Arrived-Researchers Look to Daily Pill to Avert H.I.V. - (08/02/08)
     
  12817. IAS: New Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel; Earlier HAART Recommended - (08/02/08)
     
  12818. IAS: Africa the worst hit by AIDS, by far - (08/02/08)
     
  12819. IAS: CDC Reports Higher Rates of New HIV Cases, Causes Controversy - (08/02/08)
     
  12820. IAS: AIDS hitting Asian gays at high rates - UN - (08/02/08)
     
  12821. 3rd Intl Wrkshp HIV Transmission: WHO Updates List of Transmitted Mutations for Surveillance Studies - written by Mark Mascolini - (08/04/08)
     
  12822. 3rd Intl Wrkshp HIV Transmission: Recently HIV-Infected Quebec Residents Cause More Than Half of New Cases - written by Mark Mascolini (08/04/08)
     
  12823. 3rd Intl Wrkshp HIV Transmission: Intermittent Truvada PrEP Offers Monkeys Some Protection - written by Mark Mascolini (08/04/08)
     
  12824. 3rd Intl Wrkshp HIV Transmission: Tenofovir/Emtricitabine Gel Protects Female Monkeys From SHIV - written by Mark Mascolini (08/04/08)
     
  12825. 3rd Intl Wrkshp HIV Transmission: Are T-Cell-Based HIV Vaccines "Hanging by a Thread"? - written by Mark Mascolini (08/04/08)
     
  12826. 3rd Intl Wrkshp HIV Transmission: Common Estimate of Heterosexual HIV Transmission Risk Sometimes Far Too Low - written by Mark Mascolini (08/04/08)
     
  12827. 3rd Intl Wrkshp HIV Transmission: Syphilis and Other STIs May Drive HIV Spread in German Gays - written by Mark Mascolini (08/04/08)
     
  12828. 3rd Intl Wrkshp HIV Transmission: German Gays - written by Mark Mascolini (08/04/08)
     
  12829. Routine HIV Screening Recommended for All Women, Regardless of Individual Risk Factors; ACOG Pushes Routine Prenatal HIV Testing - American College of Obstetricians and Gynecologists - (08/01/08)
     
  12830. Merck Freezes Integrase Isentress (raltegravir) Price - (08/01/08)
     
  12831. GILEAD SCIENCES AND MERCK & CO., INC. ENTER INTO AN AGREEMENT TO REGISTER AND DISTRIBUTE HIV MEDICATION ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) IN TWELVE COUNTRIES, INCLUDING IN LATIN AMERICA AND THE ASIA-PACIFIC REGION - (08/01/08)
     
  12832. Enhancement of HIV Infection by Cellulose Sulfate - (07/31/08)
     
  12833. Lack of Effectiveness of Microbicide Cellulose Sulfate Gel for the Prevention of Vaginal HIV Transmission - (07/31/08)
     
  12834. Drinking Alcohol That Exceeded US Dietary Guidelines (>1 drink per drinking day for men & >2 drinks per drinking day for men) Increased Risk of Metabolic Syndrome by 60%; binge drinking >/=once per week increased risk by 51% - (07/31/08)
     
  12835. Liver Fibrosis during an Outbreak of Acute Hepatitis C Virus Infection in HIV-Infected Men: A Prospective Cohort Study - (07/30/08)
     
  12836. Managing Metabolic Changes in Protease Inhibitor-Naive Patients Treated for 1 Year With Lopinavir/Ritonavir - (07/30/08)
     
  12837. MDR HIV Can Have High-Level Replication and Virulence - (07/30/08)
     
  12838. APOBEC3G, hA3G expression affects the establishment of the viral set point and may therefore function as a host determinant in the pathogenesis of HIV-1 infection, developing AIDS more quickly - (07/30/08)
     
  12839. Life Expectancy Increases Due to HAART: study estimates extended life of 43 yrs for 20 yr old and 32 yrs for 35 yr old starting HAART, and this doesn't include new and future advances - (07/29/08)
     
  12840. Many Gays Don't Tell Doctors Their Sexuality, Study Finds - (07/29/08)
     
  12841. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1- discordant couples in Rakai, Uganda - (07/29/08)
     
  12842. Risk of HIV transmission in discordant couples - (07/29/08)
     
  12843. Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases; Earlier HAART (>350 CD4s) Prevents AIDS/NonAIDS Events - (07/29/08)
     
  12844. Fish-Heavy Diet May Slow Hardening of Arteries: - (07/29/08)
     
  12845. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study - (07/29/08)
     
  12846. HIV Infection and the Gut: Scarred for Life? EDITORIAL COMMENTARY - (07/28/08)
     
  12847. HIV Infection and the Gut: Scarred for Life; Should HAART Be Started Early? EDITORIAL COMMENTARY - (07/28/08)
     
  12848. Does HIV/AIDS still require an exceptional response? - (07/28/08)
     
  12849. Discordant Heterosexual Couples: condom use required or New HIV Cases Will Double Over 10 Years - (07/28/08)
     
  12850. 3 New GSK Integrase Inhibitors in Studies - (07/25/08)
     
  12851. Viagra for Women with Antidepressant-Associated Sex Dysfunction - (07/25/08)
     
  12852. AGING AND INFECTIOUS DISEASES- NIH-NIAID Workshop on HIV Infection and Aging: What Is Known and Future Research Directions - (07/25/08)
     
  12853. NNRTIs & mtDNA Toxicity: Lymphocyte Mitochondrial Depolarization and Apoptosis in HIV-1-Infected HAART Patients - (07/25/08)
     
  12854. Efavirenz in Human Breast Milk, Mothers', and Newborns' Plasma - (07/25/08)
     
  12855. HIV Vaccine Research: The Way Forward - (07/25/08)
     
  12856. Whither or Wither Microbicides? Commentary - (07/25/08)
     
  12857. Chronic Kidney Disease Prevalence and Risk Factors Among HIV-Infected Patients In Spain - (07/24/08)
     
  12858. TIBOTEC RECRUITING FOR TWO PIVOTAL PHASE III CLINICAL TRIALS STUDYING TMC278 IN TREATMENT-NAIVE ADULTS WITH HIV - (07/24/08)
     
  12859. No Impairment of Endothelial Dysfunction or Insulin Sensitivity with 4 Weeks of Reyataz or Kaletra in Healthy Subjects - (07/24/08)
     
  12860. No Impairment of Endothelial Dysfunction or Insulin Sensitivity with 4 Weeks of Reyataz or Kaletra in Healthy Subjects - (07/24/08)
     
  12861. HbA1c 6.5% or greater should be accepted as a criterion for diagnosing diabetes - (07/24/08)
     
  12862. GILEAD INITIATES PHASE III CLINICAL TRIAL OF ELVITEGRAVIR, AN INVESTIGATIONAL INTEGRASE INHIBITOR FOR HIV - (07/24/08)
     
  12863. FDA Approves Updated Labeling for ZIAGEN - (07/24/08)
     
  12864. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection - (07/24/08)
     
  12865. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection - (07/24/08)
     
  12866. Efffects of 3 Diets: Mediterranean, Low-Fat, & Low-Carb on Weight Loss, Lipids, Glucose, Metabolics - (07/17/08)
     
  12867. High-Dose HBV Vaccination Rechallenge - (07/16/08)
     
  12868. HIV and Kidney Disease - (07/16/08)
     
  12869. Incidence and Epidemiology of Anal Cancer in the Multicenter AIDS Cohort Study - (07/16/08)
     
  12870. HAART Prevents AIDS-Cancers & Non-Cancer AIDS - (07/16/08)
     
  12871. Incidence and Epidemiology of Anal Cancer in the Multicenter AIDS Cohort Study - (07/16/08)
     
  12872. FRAX Bone Treatment Algorithm: A Revised Clinician's Guide to the Prevention and Treatment of Osteoporosis- commentary - (07/15/08)
     
  12873. Serial Assessment of Serum Bone Metabolism Markers Identifies Women with the Highest Rate of Bone Loss and Osteoporosis Risk - (07/15/08)
     
  12874. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen [Research Letters] - (07/15/08)
     
  12875. Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications [Correspondence] - (07/15/08)
     
  12876. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir - (07/15/08)
     
  12877. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells - (07/15/08)
     
  12878. Liver ultrastructural morphology and mitochondrial DNA levels in HIV/hepatitis C virus coinfection: no evidence of mitochondrial damage with highly active antiretroviral therapy [Research Letters] - (07/15/08)
     
  12879. Roche Limits HIV R&D But Emphasizes HCV Research - commentary - (07/14/08)
     
  12880. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics: risk for HIV drug resistance - (07/11/08)
     
  12881. ARTEMIS Study: Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 - (07/11/08)
     
  12882. Revised 2008 PhRMA CODE ON INTERACTIONS WITH HEALTHCARE PROFESSIONALS - (07/11/08)
     
  12883. Detection of Nonnucleoside Reverse-Transcriptase Inhibitor-Resistant HIV-1 after Discontinuation (Interruption) of Virologically Suppressive Antiretroviral Therapy - (07/09/08)
     
  12884. CLINICIAN'S GUIDE TO PREVENTION AND TREATMENT OF OSTEOPOROSIS (National Osteoporosis Foundation Guidelines) - (07/07/08)
     
  12885. Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture - (07/04/08)
     
  12886. Use of Antidepressants and Rates of Hip Bone Loss in Older Women - (07/04/08)
     
  12887. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis (increased 13% risk): A systematic review - (07/02/08)
     
  12888. Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population: high rates of improved mortality among HIV diagnosed - (07/02/08)
     
  12889. Fracture Prevalence Among HIV-Infected versus Non HIV-Infected Patients in a Large U.S. Healthcare System - (07/02/08)
     
  12890. Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome - (07/01/08)
     
  12891. Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife. The Whitehall II Study - (07/01/08)
     
  12892. Low Levels Of Good Cholesterol Linked To Memory Loss, Dementia Risk - (07/01/08)
     
  12893. Important FDA Label changes to Viramune (nevirapine) oral solution and tablets - (06/30/08)
     
  12894. Antiretroviral Therapy is Associated With an Atherogenic Lipoprotein Phenotype Among HIV-1-Infected Men in the Multicenter AIDS Cohort Study - (06/27/08)
     
  12895. Prevalence and Predictors of Metabolic Syndrome Among HIV-Infected and HIV-Uninfected Women in the Women's Interagency HIV Study: metabolic syndrome 50% in HIV+ women - (06/27/08)
     
  12896. Kidney and Bladder Cancers Among People With AIDS in the United States - (06/27/08)
     
  12897. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes - (06/27/08)
     
  12898. New pediatric dosing information for Kaletra, patients 14 days to 6 months and 12-18 years of age and update information on coadministration with midazolam - (06/24/08)
     
  12899. European Commission Approves REYATAZ(R) (Atazanavir Sulfate 100mg, 150mg, 200mg, 300mg), in Combination With Other Antiretroviral Medicinal Products, for use in Treatment Naive HIV-1 Infected Adults - (06/24/08)
     
  12900. CVD is a "Major Killer" in HIV+ Patients, but Underrecognized by Doctors. Complicated interplay between risks from anti-HIV drugs, risks from virus itself, and traditional risk factors which tend to be prevalent among HIV-infected - (06/24/08)
     
  12901. ResisWksp: Low frequency K103N mutations are strongly associated with inadequate virologic responses to NNRTI-based therapy. sdNVP & K103N - (06/26/08)
     
  12902. ResisWksp: Identifying Low-Level CXCR4 Virus with Roche 454 Life Sciences Sensitive Assay - (06/25/08)
     
  12903. ResisWksp: Comparable in-vitro susceptibility and virological outcome to darunavir in patients infected with subtype B and non-subtype B HIV isolates participating in the ARTEMIS Phase III trial - (06/25/08)
     
  12904. ResisWksp: Detection of Low Abundance Drug Resistant HIV Variants in Treatment Experienced Subjects by Ultra Deep Sequencing (454 Life Sciences/Roche Test) - (06/25/08)
     
  12905. ResisWksp: NNRTI Resistance in Naives 16%. Changes in Regional Prevalence, Clade and Epidemiology of HIV-1 Drug Resistance Mutations and Clade among Antiviral Therapy-Naive Patients in the United States (US) from 2000 to 2007 - (06/25/08)
     
  12906. Weight Gain Increases Risk for Kidney Disease - (06/24/08)
     
  12907. ResisWksp: HIV-1 resistance in Mozambican infants following prophylaxis with single-dose nevirapine (sdNVP) - (06/24/08)
     
  12908. ResisWksp: Report on the XV11 International Drug Resistance Workshop, June 10-14, 2008, Sitges, Spain - Written by Mark A Wainberg - (06/24/08)
     
  12909. ResisWksp: Virological evolution in HIV treatment-experienced patients with raltegravir-based salvage regimens - (06/24/08)
     
  12910. ResisWksp: Antiretroviral Intensification Does Not Reduce HIV-1 Viremia in Patients Suppressed on Standard Combination Therapy - (06/24/08)
     
  12911. ResisWksp: No effect of subtype on susceptibility and virologic response to TPV/r for treatment experienced patients - (06/24/08)
     
  12912. ResisWksp: Mutations 24I, 50L/V, 54L, and 76V, selected by other protease inhibitors, predict durable response to tipranavir in treatment experienced patients when two or more are present - (06/24/08)
     
  12913. ResisWksp: Dynamics of emergence of CXCR4-using HIV in clinical samples as detected by Trofile and MT-2 assays - (06/23/08)
     
  12914. ResisWksp: Technical Validation of an Enhanced Sensitivity Trofile HIV Co-receptor Tropism Assay for Selecting Patients for Therapy with Entry Inhibitors Targeting CCR5 - (06/23/08)
     
  12915. ResisWksp: Virological Response and Resistance in Multi-Experienced Patients Treated with Raltegravir - (06/20/08)
     
  12916. ResisWksp: Slightly Revised Darunavir Resistance Profile from Tibotec - (06/20/08)
     
  12917. ResisWksp: Virologic and Immunologic Outcomes in a Cohort of Subjects Failing Integrase Inhibitors - (06/20/08)
     
  12918. ResisWksp: Tibotec Analysis: Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR) - (06/20/08)
     
  12919. ResisWksp: Monogram Analysis: Loss of Raltegravir Susceptibility in Treated Patients is Conferred by Multiple Non-overlapping Genetic Pathways - (06/20/08)
     
  12920. ResisWksp: Minority quasispecies of drug-resistant HIV-1 leading to early therapy failure in treatment-naive and adherent patients - (06/20/08)
     
  12921. ResisWksp: Tibotec Etravirine Weighted Genotype Score to Predict Response - (06/20/08)
     
  12922. ResisWksp: Resistance Mutations in HIV-1 Integrase Selected with Raltegravir or Elvitegravir Confer Reduced Susceptibility to a Diverse Panel of Integrase Inhibitors - (06/19/08)
     
  12923. ResisWksp: Integrase Inhibitor Resistance (elvitegravir/raltegravir) Involves Complex Interactions Among Primary and Secondary Resistance Mutations: A Novel Mutation L68V/I Associates with E92Q and Increases Resistance - (06/19/08)
     
  12924. THERATECHNOLOGIES REPORTS POSITIVE 26-WEEK RESULTS FOR ITS SECOND TESAMORELIN PHASE 3 TRIAL - (06/19/08)
     
  12925. ResisWksp: Increased Phenotypic Susceptibility to Etravirine in HIV-1 with NRTI Resistance - (06/19/08)
     
  12926. ResisWksp: HIV DNA Viral Load Evolution under a Raltegravir-based Therapy: modest decline, authors say "these findings suggest raltegravir may be protective from infection to newly CD4 cells generated during treatment" - (06/19/08)
     
  12927. ResisWksp: Increased Phenotypic Susceptibility to Etravirine in HIV-1 with NRTI Resistance - (06/18/08)
     
  12928. ResisWksp: Virco Etravirine Clinical Cutoffs - (06/18/08)
     
  12929. ResisWksp: Monogram HIV-1 Genotype Algorithms for Prediction of Etravirine Susceptibility: Novel Mutations and Weighting Factors Identified Through Correlations to Phenotype - (06/18/08)
     
  12930. ResisWksp: Merck's Longitudinal Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from P005 a Phase 2 Study in Treatment Experienced Patients - (06/18/08)
     
  12931. ResisWksp: Mechanism by which the HIV Integrase Active Site Mutation N155H Confers Resistance to Raltegravir - (06/18/08)
     
  12932. ResisWksp: Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled Week 24 results of the DUET-1 and DUET-2 trials - (06/17/08)
     
  12933. ResisWksp: Biological and Clinical Cutoff Analyses for Etravirine in the PhenoSense HIV Assay - (06/17/08)
     
  12934. ResisWksp: Monogram Devises Weighted Genotypic Score to Predict Etravirine Response - Written by Mark Mascolini - (06/17/08)
     
  12935. ResisWksp: Low-End Clinical Cutoff Proposed for Etravirine - Written by Mark Mascolini - (06/17/08)
     
  12936. ResisWksp: Early Hints on Potency and Cross-Resistance With New NNRTI - Written by Mark Mascolini - (06/16/08)
     
  12937. ResisWksp: Low-Level Pretreatment NNRTI Mutation May Imperil Virologic Response - Written by Mark Mascolini - (06/16/08)
     
  12938. ResisWksp: Impact of Raltegravir on HIV DNA--and Fitness of Raltegravir-Resistant Virus - Written by Mark Mascolini - (06/16/08)
     
  12939. ResisWksp: Gene-Based Tools Getting Better at Predicting Coreceptor Use - Written by Mark Mascolini - (06/16/08)
     
  12940. ResisWksp: Multidrug Resistance in Antiretroviral Therapy-Experienced Patients in North America: 2000-2005 - (06/16/08)
     
  12941. ResisWksp: Early Clues From Raltegravir Failure in Clinical Practice; Diverse Patterns of Resistance Mutations - Written by Mark Mascolini - (06/16/08)
     
  12942. ResisWksp: HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-457) (06/16/08)
     
  12943. ResisWksp: Response to Vicriviroc in HIV-Infected Treatment-Experienced Subjects using an Enhanced Version of the Trofile HIV Co-receptor Tropism Assay: Reanalysis of ACTG5211 Results. Using Enhanced Tropism Assay Improves Outcomes. (06/16/08)
     
  12944. ResisWksp: Early Hints on Potency and Cross-Resistance With New NNRTI - Written by Mark Mascolini - (06/13/08)
     
  12945. ResisWksp: Hexadecyloxypropyltenofovir (CMX157) has enhanced potency in vitro against NRTI-resistant HIV relative to tenofovir and a favorable preclinical profile - (06/13/08)
     
  12946. ResisWksp: Hexadecyloxypropyl Tenofovir (CMX157) Has Enhanced Potency in Vitro against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile (06/13/08)
     
  12947. ResisWksp: Hexadecyloxpropyl Tenofovir (CMX157) Has Enhanced Potency In Vitro Against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile (06/13/08)
     
  12948. ResisWksp: New Trofile Assay Would Have Improved Vicriviroc Response in ACTG 5211 - Written by Mark Mascolini - (06/13/08)
     
  12949. ResisWksp: Cumulative Resistance Catalog Gives Clearer Picture of Salvage Picks - Written by Mark Mascolini - (06/13/08)
     
  12950. ResisWksp: Supersensitive Genotyping Spots More Mutations in Lopinavir Monotherapy Trial - Written by Mark Mascolini - (06/13/08)
     
  12951. ResisWksp: Intensifying Standard Regimens Does Not Lower Residual Plasma HIV RNA - Written by Mark Mascolini - (06/11/08)
     
  12952. ResisWksp: Triple-Class Resistance Halved in Catalonia From 2002 to 2005 - Written by Mark Mascolini - (06/11/08)
     
  12953. ResisWksp: Resistance Mutation Rate Rising in Treatment-Naive US Trial Enrollees - Written by Mark Mascolini - (06/11/08)
     
  12954. ResisWksp: Resistance Risk Higher in Injecting Drug Users, Regardless of Adherence - Written by Mark Mascolini - (06/11/08)
     
  12955. ResisWksp: Multiclass Resistance Rate--But Not All-Class Resistance--Falls in US and Canada - Written by Mark Mascolini - (06/11/08)
     
  12956. ResisWksp: Novel Integrase Mutation Boosts Resistance to Elvitegravir and Raltegravir - Written by Mark Mascolini - (06/11/08)
     
  12957. ResisWksp: Five Mutations Tied to Better Tipranavir Response at 48 Weeks - Written by Mark Mascolini - (06/11/08)
     
  12958. ResisWksp: NNRTI Mutation Rates With Failing EFV vs NVP in EuroSIDA - Written by Mark Mascolini - (06/11/08)
     
  12959. ResisWksp: In Vitro Cross-Resistance Profile for a Next-Generation NNRT I: IDX899 (06/11/08)
     
  12960. ResisWksp: Antiviral Activity, Safety and Pharmacokinetics of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance, in Treatment-Naïve HIV-1-Infected Subjects (06/11/08)
     
  12961. ResisWksp: In Vitro Cross-Resistance Profile, Antiviral Activity, Safety and Pharmacokinetics in HIV-1 Infected Subjects of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance (06/11/08)
     
  12962. ResisWksp: Mutually Exclusive Resistance Paths Seen With Raltegravir Failure - Written by Mark Mascolini - (06/11/08)
     
  12963. ResisWksp: Q148 Mutations Emerge as Primary Raltegravir Resistance Pathway - Written by Mark Mascolini - (06/11/08)
     
  12964. ResisWksp: Routes to Cross-Resistance With Raltegravir and Elvitegravir - Written by Mark Mascolini - (06/11/08)
     
  12965. Effects of Early, Abrupt Weaning for HIV-free Survival of Children in Zambia - (06/11/08)
     
  12966. Breast-Feeding, Antiretroviral Prophylaxis, and HIV - (06/11/08)
     
  12967. Heroin Use Higher Among Hispanic Students: drugs, sex, life-style among students and ethnic disparities - (06/11/08)
     
  12968. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy - (06/11/08)
     
  12969. Intensive Glycemic Control in the ACCORD and ADVANCE Trials EDITORIAL - (06/11/08)
     
  12970. Glycemic Targets and Cardiovascular Disease EDITORIAL - (06/11/08)
     
  12971. Effects of Intensive Glucose Lowering in Type 2 Diabetes - (06/11/08)
     
  12972. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes - (06/11/08)
     
  12973. Delayed Immune-Mediated Adverse Effects of Polyalkylimide Dermal Fillers - (06/09/08)
     
  12974. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay - (06/09/08)
     
  12975. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies - (06/09/08)
     
  12976. Brain chemical serotonin helps us tolerate foul play and appears to cause aggressive angry behavior response - (06/09/08)
     
  12977. Regional Brain Abnormalities Associated With Long-term Heavy Cannabis Use - (06/04/08)
     
  12978. Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in Heterosexual Men - (06/04/08)
     
  12979. BRIEF REPORT Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects - (06/04/08)
     
  12980. Regional Brain Abnormalities Associated With Long-term Heavy Cannabis Use - (06/03/08)
     
  12981. Resurgent HIV Among Men Who Have Sex With Men: What is to be done? Microbicides and Pre-Exposure Prophylaxis is the Only Answer - (06/03/08)
     
  12982. Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease - (06/02/08)
     
  12983. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus - (06/02/08)
     
  12984. Regional Adipose Tissue and Elevations in Serum Aminotransferases in HIV-Infected Individuals - (05/30/08)
     
  12985. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study - (05/29/08)
     
  12986. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy in The Netherlands - (05/29/08)
     
  12987. 41% of HIV+ MSM in UK Unaware of Status: Sexual risk behaviour and knowledge of HIV status among community samples of gay men in the UK - (05/29/08)
     
  12988. New Option for HIV Testing Now Available - (05/29/08)
     
  12989. Sustained Benefits in Vascular Function Through Flavanol-Containing Cocoa in Medicated Diabetic Patients - (05/29/08)
     
  12990. Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data - (05/28/08)
     
  12991. Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992-2003 - (05/28/08)
     
  12992. Early Intensive Insulin Therapy for Newly Diagnosed Diabetes - (05/28/08)
     
  12993. Inflammation, Lipids and Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies - (05/28/08)
     
  12994. New HIV Vaccine Research Funding, Where is Money for USA Needs - (05/28/08)
     
  12995. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study - (05/28/08)
     
  12996. Lifestyle intervention, diabetes, and cardiovascular disease EDITORIAL - (05/28/08)
     
  12997. The global challenge of diabetes, Editorial - (05/28/08)
     
  12998. Diabetes care for south Asian patients: a special case, EDITORIAL - (05/28/08)
     
  12999. Flavanol-Rich Cocoa: A Promising New Dietary Intervention to Reduce Cardiovascular Risk in Type 2 Diabetes? EDITORIAL COMMENT - (05/28/08)
     
  13000. Sustained Benefits in Vascular Function Through Flavanol-Containing Cocoa in Medicated Diabetic Patients - (05/28/08)
     
  13001. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study - (05/28/08)
     
  13002. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy in The Netherlands - (05/28/08)
     
  13003. Pioglitazone in chronic hepatitis C with Insulin Resistance not responding to pegylated interferon-β and ribavirin - (05/27/08)
     
  13004. Liver and heart: A new link? - ALT Predicts Heart Disease - (05/27/08)
     
  13005. Bioavailability of Generic Ritonavir and Lopinavir/ritonavir Tablet Products in a Dog Model - (05/27/08)
     
  13006. Controversies in Hypertension: diet, exercise Weight Loss and Blood Pressure Control (Pro) - (05/27/08)
     
  13007. Sex, drugs, and HIV/AIDS in China - (05/27/08)
     
  13008. Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial - (05/22/08)
     
  13009. Acute Meningoencephalitis in Chronic HIV Infection: Clinical Resolution with Lopinavir-Ritonavir-Containing Therapy - (05/21/08)
     
  13010. Insulin Resistance and Risk of Chronic Kidney Disease in Nondiabetic US Adults - (05/21/08)
     
  13011. Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults - (05/21/08)
     
  13012. Metabolic Syndrome, Proteinuria, and the Risk of Progressive CKD in Hypertensive African Americans - (05/21/08)
     
  13013. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes - (05/19/08)
     
  13014. Biomarkers in Heart Failure EDITORIAL - (05/19/08)
     
  13015. Class-Sparing Regimens for Initial Treatment of HIV-1 Infection. ACTG 5142 Efavirenz v Kaletra v Efavirenz+Kaletra - (05/19/08)
     
  13016. ACTG 5142, Efavirenz v Kaletra v Kaletra+Efavirenz Class Sparing Study. Initial Treatment for HIV Infection - An Embarrassment of Riches EDITORIAL - (05/19/08)
     
  13017. Chronic Kidney Disease Incidence, and Progression to End-Stage Renal Disease, in HIV-Infected Individuals: A Tale of Two Races - (05/19/08)
     
  13018. HIV and the Kidney: A Spotlight on Racial Disparities EDITORIAL COMMENTARY - (05/19/08)
     
  13019. FDA Approves Generic Nevirapine - (05/19/08)
     
  13020. New Darunavir 600 mg Tablet Available - (05/19/08)
     
  13021. Viracept Use in Pregnancy- Important News - (05/19/08)
     
  13022. GSK Response Letters to Abacavir Article in the The Independent - (05/15/08)
     
  13023. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. - (05/10/08)
     
  13024. Comparative Efficacy between therapies for bone disease: What We Know, What We Need to Know, and How We Can Get There EDITORIAL - (05/10/08)
     
  13025. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. "Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians" - (05/10/08)
     
  13026. Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance? [RESEARCH LETTERS] - (05/07/08)
     
  13027. HAART Can Eliminate HIV Mother-To-Child Transmission (MTCT). Properly Timed Effective Use of HAART Can Prevent MTCT - (05/07/08)
     
  13028. Bone health & Antiepileptic Drugs - (05/02/08)
     
  13029. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy - (05/02/08)
     
  13030. Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid-Lowering Drugs in HIV-Infected Individuals and Impact on Myocardial Infarction - (05/02/08)
     
  13031. EASL: NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease - (05/02/08)
     
  13032. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women - (05/01/08)
     
  13033. Diabetes drugs (glitazones) double fracture risk: Swiss study - (05/01/08)
     
  13034. EASL: NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH HIGHER OVERALL MORTALITY AND LIVER RELATED MORTALITY - (04/25/08)
     
  13035. EASL: NEW HCV DRUGS at EASL Apr 23-27, 2008 Milan - (04/23/08)
     
  13036. EASL: Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 - (04/23/08)
     
  13037. EASL: HCV Drug Resistance - (04/23/08)
     
  13038. The 3rd International Workshop on Clinical Pharmacology of Hepatitis Therapy - Written by Jennifer J. Kiser, Pharm.D. - (04/22/08)
     
  13039. 9th International Workshop on Clinical Pharmacology of HIV Therapy - Written by Jennifer J. Kiser, Pharm.D. and Courtney V. Fletcher, Pharm.D. (04/22/08)
     
  13040. Insulin Resistance Confounds Heart Disease Studies in HIV: Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy - (04/22/08)
     
  13041. CD4 Count & Viral Load Predict non-AIDS & AIDS diseases: CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection - (04/22/08)
     
  13042. Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study - (04/21/08)
     
  13043. Inferior Clinical Outcome of the CD4+ Cell Count-Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up - (04/21/08)
     
  13044. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study - (04/21/08)
     
  13045. CROI: Women, Younger Age & Black Race Associated with Shorter Time to Viral Failure: Effect of Baseline Characteristics on Treatment Outcomes in ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection - (04/21/08)
     
  13046. DASH Diet Reduces Heart Disease Risk by 24% - (04/18/08)
     
  13047. The Impact of HIV Tropism on Decreases in CD4 Cell Count, Clinical Progression, and Subsequent Response to a First Antiretroviral Therapy Regimen. - (04/18/08)
     
  13048. Gut (liver), inflammation and osteoporosis: basic and clinical concepts - (04/16/08)
     
  13049. SCHERING-PLOUGH INITIATES PHASE II STUDY WITH VICRIVIROC IN TREATMENT-NAIVE HIV-INFECTED PATIENTS: Novel Nucleoside-Sparing Regimen Designed to Avoid Risk of Toxicity Associated with Nucleoside Class of HIV Drugs - (04/15/08)
     
  13050. TMC125 safety and tolerability in treatment-experienced hepatitis B or C coinfected patients in DUET-1 and DUET-2 - (04/15/08)
     
  13051. 9th Int Wrkshp Pharm HIV: Safety, Tolerability and Activity of KP-1461 a Novel Viral Mutagen in HIV Infected Adults - (04/15/08)
     
  13052. Walking and primary prevention: a meta-analysis of prospective cohort studies - (04/14/08)
     
  13053. Maximal oxygen intake and independence in old age: aorobic exercise adds 12 years of life - (04/14/08)
     
  13054. 9th Int Wrkshp Pharm HIV: Does HCV or HBV co-infection influence saquinavir exposure in HIV-infected patients without liver function impairment? - (04/14/08)
     
  13055. 9th Int Wrkshp Pharm HIV: The effect of different types of food on the bioavailability of TMC278, an investigational NNRTI - (04/14/08)
     
  13056. 9th Int Wrkshp Pharm HIV: Pharmacokinetic/Pharmacodynamic (PK/PD) analyses for Raltegravir (RAL) in phase II and III studies in treatment experienced HIV-infected patients - (04/14/08)
     
  13057. 9th Int Wrkshp Pharm HIV: The effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral (ARV)-naive HIV-1-infected patients (04/10/08)
     
  13058. 9th Int Wrkshp Pharm HIV: Is Twice-Daily Unboosted Atazanavir 200 mg Worth a Harder Look? (04/10/08)
     
  13059. 9th Int Wrkshp Pharm HIV: Black Race and Drug Interactions Affect Nonnucleoside Levels in TDM Analysis (04/10/08)
     
  13060. Survey highlights lack of sleep: higher insulin levels; heart disease; inflammation; mental/cognitive disorders - (04/10/08)
     
  13061. Sleep and HIV illness. - (04/10/08)
     
  13062. Insomnia in HIV Infection: A Systematic Review of Prevalence, Correlates, and Management - (04/10/08)
     
  13063. High Prevalence of Insomnia in an Outpatient Population With HIV Infection - (04/10/08)
     
  13064. 9th Int Wrkshp Pharm HIV: CASTLE Study: Pharmacokinetics and Inhibitory Quotient of Atazanavir/ritonavir 300/100 mg Once Daily Compared to Lopinavir/ritonavir 400/100 mg Twice Daily, Each in Combination with Fixed Dose Tenofovir-Emtricitabine Once Daily, Are Supportive of 48 Week Efficacy and Safety in HIV-1 Infected, Treatment-Naive Subjects (04/10/08)
     
  13065. 9th Int Wrkshp Pharm HIV: Single-Dose Pharmacokinetics of Enteric-Coated Didanosine in Subjects with Hepatic Impairment Compared to Healthy Adult Subjects (04/10/08)
     
  13066. 9th Int Wrkshp Pharm HIV: Effect of Atazanavir with and without Ritonavir on the Pharmacokinetics of the CYP2C8 Probe Rosiglitazone in Healthy Subjects (04/10/08)
     
  13067. 9th Int Wrkshp Pharm HIV: A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients (04/10/08)
     
  13068. 9th Int Wrkshp Pharm HIV: The pharmacokinetic (PK) profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 hours (04/10/08)
     
  13069. 9th Int Wrkshp Pharm HIV: Raltegravir Levels Down With Tipranavir and Up With Atazanavir (04/10/08)
     
  13070. 9th Int Wrkshp Pharm HIV: Once-Daily Darunavir/Ritonavir Keeps Levels High in Healthy Volunteers - written by Mark Mascolini (04/09/08)
     
  13071. 9th Int Wrkshp Pharm HIV: Vicriviroc Troughs Correlate With Response in VICTOR-E1 Salvage Study - written by Mark Mascolini (04/09/08)
     
  13072. 9th Int Wrkshp Pharm HIV: Raltegravir Levels May Drop With Lopinavir/Ritonavir - written by Mark Mascolini (04/09/08)
     
  13073. 9th Int Wrkshp Pharm HIV: Pharmacokinetic Profile of Darunavir (DRV) Co-Administered With Low-Dose Ritonavir (DRV/r) in Treatment-Experienced Women and Men With HIV Infection: 4-Week Analysis in a Substudy of the GRACE (Gender, Race, and Clinical Experience) Study (04/09/08)
     
  13074. 9th Int Wrkshp Pharm HIV: Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-1-infected subjects; tenofovir and HCV affect levels (04/09/08)
     
  13075. 9th Int Wrkshp Pharm HIV: Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study (04/09/08)
     
  13076. 9th Int Wrkshp Pharm HIV: Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ritonavir in HIV-1-infected patients: results of a randomized, controlled, Phase III study (ARTEMIS) (04/09/08)
     
  13077. 9th Int Wrkshp Pharm HIV: Darunavir and Ritonavir Levels in Black and Hispanic Women - Written by Mark Mascolini (04/08/08)
     
  13078. 9th Int Wrkshp Pharm HIV: Higher Efavirenz Levels--But No More Toxicity--in Nonwhites vs Whites: EuroSIDA - Written by Mark Mascolini (04/08/08)
     
  13079. 9th Int Wrkshp Pharm HIV: Etravirine Levels - Written by Mark Mascolini (04/08/08)
     
  13080. 9th Int Wrkshp Pharm HIV: Tenofovir, Hepatitis, and Weight Moderately Affect Etravirine Levels - Written by Mark Mascolini (04/08/08)
     
  13081. New Abbott Kaletra (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe - (04/08/08)
     
  13082. DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel's Communication Regarding Abacavir - April 4, 2008 - (04/08/08)
     
  13083. HPV in Heterosexuals. Prevalence and factors associated with anal lesions mediated by human papillomavirus in men with HIV/AIDS - (04/08/08)
     
  13084. Osteoporosis in Men - (04/07/08)
     
  13085. EHDRW: Efficacy of DRV/r in the randomised, controlled, Phase III ARTEMIS trial in treatment-naive, HIV-1-infected patients is independent of HIV-1 subtype (04/07/08)
     
  13086. ALT Predicts Mortality & General Health - (04/04/08)
     
  13087. Liver transplantation in HIV/HCV co-infected patients remains difficult: strategies to get these patients to earlier transplantation are needed - (04/04/08)
     
  13088. Bone Disease in HIV: study finds, heavily pre-treated patients had Vitamin D deficiency & serum marker abnormalities & perhaps serum markers may be better for assessing patient risk than total BMD by DEXA - (04/03/08)
     
  13089. EHDRW: One in 10 Genotyped Britons Started Therapy With Resistant HIV - Written by Mark Mascolini - (04/02/08)
     
  13090. EHDRW: Resistance Measured by Clinical Cutoff Drops Sharply From 1998 to 2007 - Written by Mark Mascolini - (04/02/08)
     
  13091. EHDRW: Identification of mutations predictive of a diminished response to darunavir/ritonavir (refined profile): analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2 (04/02/08)
     
  13092. CROI: Metabolic Complications: A CROI 2008 Summary Written by David Alain Wohl, MD - The University of North Carolina - (04/03/08)
     
  13093. Mitochondrial Toxicity and HCV Liver Disease Progression in Coinfection - (04/02/08)
     
  13094. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration - (04/02/08)
     
  13095. Risk of myocardial infarction and nucleoside analogues Comment - (04/02/08)
     
  13096. Abacavir and the potential risk of myocardial infarction Correspondence - (04/02/08)
     
  13097. EHDRW: Prevalence of Darunavir-Linked Mutations Stays Low After Licensing - Written by Mark Mascolini - (03/31/08)
     
  13098. EHDRW: Update on the prevalence of the 2007 darunavir resistance-associated mutations in samples received for routine clinical resistance testing - (03/31/08)
     
  13099. EHDRW: Has Pretreatment Genotyping Improved Therapy? Answers From Germany - Written by Mark Mascolini - (03/31/08)
     
  13100. EHDRW: Combined protease inhibitor (PI) and NNRTI resistance analysis of the pooled DUET trial: towards a regimen-based resistance interpretation (03/31/08)
     
  13101. EHDRW: Virco Proposes Preliminary Biological Cutoffs for Integrase Inhibitors - Written by Mark Mascolini - (03/31/08)
     
  13102. EHDRW: More Major Mutations in Newly Diagnosed, Untreated Italian Patients - Written by Mark Mascolini - (03/31/08)
     
  13103. Early Communication about an Ongoing Safety Review of Ziagen (Abacavir) and Videx (Didanosine) from the FDA, March 27, 2008 - (03/28/08)
     
  13104. Osteoporosis and Fractures Missing the Bridge? Commentary - (03/28/08)
     
  13105. EHDRW: Nevirapine and Slow Genotyping Raise Risk of Resistance to Etravirine - Written by Mark Mascolini - (03/28/08)
     
  13106. EHDRW: People With Subtype A or C May Respond More Rapidly to HAART - Written by Mark Mascolini - (03/28/08)
     
  13107. EHDRW: "Historic" Resistance Profile Helps Predict PI and Overall Salvage Failure - Written by Mark Mascolini - (03/28/08)
     
  13108. EHDRW: Single Mutations at Raltegravir Failure Suggest Low Resistance Barrier - Written by Mark Mascolini - (03/28/08)
     
  13109. EHDRW: Background Drugs and Bad Adherence Explain Most Maraviroc Failures - Written by Mark Mascolini - (03/28/08)
     
  13110. EHDRW: Trofile Assay Usually Matches Cell Test in Figuring Coreceptor Use - Written by Mark Mascolini - (03/28/08)
     
  13111. EHDRW: "Staggering" Did Not Ward Off NNRTI Resistance in SMART Drug Breaks - Written by Mark Mascolini - (03/27/08)
     
  13112. EHDRW: Steady Drop in Resistant Virus Rates at Virologic Failure in Italy - Written by Mark Mascolini - (03/27/08)
     
  13113. EHDRW: "Staggering" Did Not Ward Off NNRTI Resistance in SMART Drug Breaks - Written by Mark Mascolini - (03/27/08)
     
  13114. EHDRW: Steady Drop in Resistant Virus Rates at Virologic Failure in Italy - Written by Mark Mascolini - (03/27/08)
     
  13115. EHDRW: Transmitted AZT/d4T-Resistant Virus Persists Up 4 Years Without Treatment - Written by Mark Mascolini - (03/27/08)
     
  13116. EHDRW: Tibotec Refines List of Darunavir-Specific Mutations - Written by Mark Mascolini - (03/27/08)
     
  13117. EHDRW: Classic Nonnucleoside Mutations Emerge Upon Etravirine Failure - Written by Mark Mascolini - (03/27/08)
     
  13118. EHDRW: Up to Four 'Combined' Darunavir/Etravirine Mutations Needed for Sub-50-Copy Response. New Concept in Resistance: Combined Resistance to Multiple Drugs in Regimen - Written by Mark Mascolini - (03/27/08)
     
  13119. Clinical Inertia in the Management of Low-Density Lipoprotein Abnormalities in an HIV Clinic - (03/26/08)
     
  13120. Steatohepatitis (fatty liver): Risk factors and impact on disease severity in HIV/hepatitis C virus coinfection - (03/26/08)
     
  13121. Pregnancy May Not Protect Against HIV Disease Progression - (03/25/08)
     
  13122. Association of antiretroviral therapy with fibrinogen levels in HIV-infection - (03/25/08)
     
  13123. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients - (03/25/08)
     
  13124. TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals - (03/25/08)
     
  13125. d4T/3TC/Nevirapine Fixed Dose Generic Approved by FDA - (03/25/08)
     
  13126. Merck AIDS Vaccine Failure May Doom Promising Study - (03/25/08)
     
  13127. CROI: Bone Disease Is Increased in HIV; Cancer Risk Increases with Age & Immune Deficiency - (03/25/08)
     
  13128. CROI: Review of Bone Posters at CROI 2008 - Written by Turner Overton, M.D. - (03/24/08)
     
  13129. CROI: HIV and Aging at CROI 2008 - (03/24/08)
     
  13130. Randomized Trial of Once-Weekly PTH(1-84) on Bone Mineral Density and Remodeling - (03/20/08)
     
  13131. HIV and hepatitis B co-infection in Africa Reflection and Reaction - (03/20/08)
     
  13132. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa Review - (03/20/08)
     
  13133. CROI: Immunopathogenesis of Hepatic Flares after Initiation of ART in HIV/HBV-co-infected Individuals - (03/19/08)
     
  13134. Effects of Alendronate on BMD and Fracture Risk: The FOSIT Study - (03/17/08)
     
  13135. Osteopenia: intervention & therapy - (03/17/08)
     
  13136. Ten Years' Experience with Alendronate (5, 10 and 20 mg daily) for Osteoporosis in Postmenopausal Women - (03/17/08)
     
  13137. HIV Proteins Accelerate Liver Disease; HIV Increases HCV Replication in a TGF-ß1-Dependent Manner - (03/14/08)
     
  13138. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy - (03/14/08)
     
  13139. CROI: Hepatitis C Viremia following Sustained Virological Response to Pegylated Interferon and Ribavarin in HIV+ Men Who Have Sex with Men-Re-infection or Late Relapse? (03/13/08)
     
  13140. Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws - (03/14/08)
     
  13141. Smoking Increases Bone Loss and Decreases Intestinal Calcium Absorption - (03/14/08)
     
  13142. Clinical Use of Serum and Urine Bone Markers in the Management of Osteoporosis - (03/14/08)
     
  13143. 10 vs 5 Years of Bisphosphonate Treatment for Postmenopausal Osteoporosis EDITORIAL - (03/14/08)
     
  13144. The attainment of peak bone mass: what is the relationship between muscle growth and bone growth? - (03/13/08)
     
  13145. Osteoporosis and chronic kidney disease - (03/13/08)
     
  13146. Benefit of Low-Fat Over Low-Carbohydrate Diet on Endothelial Health in Obesity - (03/13/08)
     
  13147. FDA Issues New Prezista (Darunavir) Label Changes - (03/13/08)
     
  13148. Tenofovir DF Plus Lamivudine or Emtricitabine for Nonoccupational Postexposure Prophylaxis (NPEP) in a Boston Community Health Center - (03/13/08)
     
  13149. CROI: Risk for Cardiovascular Disease and Regional Adipose Tissue Depots Among HIV-infected Men and Women in the Study of Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) (03/12/08)
     
  13150. CROI: Inflammatory Markers Correlate with Carotid Intima-Media Thickness and Endothelial Activation in HIV-infected Patients (03/12/08)
     
  13151. CROI: HIV and the Brain: Report from the 15th Conference on Retroviruses and Opportunistic Infections. - Written by Scott Letendre, J. Allen McCutchan, and Ronald J. Ellis (03/10/08)
     
  13152. Bone disorders in chronic liver disease - (03/10/08)
     
  13153. Medicare Spending to Surge; Chronic Diseases Increase; Hospitals Express Fear - (03/10/08)
     
  13154. Challenges in Using Observational Studies to Evaluate Adverse Effects of Treatment: DAD Study - (03/10/08)
     
  13155. CROI: Influence of NRTI Choice and Efavirenz Versus Lopinavir Treatment Options on Lipoatrophy-Associated Adipose Tissue Toxicity: A Longitudinal Study - (03/07/08)
     
  13156. CROI: Liver histology and hepatic mitochondrial function in HIV-1-infected patients on antiretroviral therapy with chronic transaminase elevation - (03/07/08)
     
  13157. CROI: MELD is the Best Predictor of Pre-transplant Mortality in HIV-infected Liver Transplant Candidates???? NO - (03/07/08)
     
  13158. It's More Than a Health Crisis: Economics Fuels HIV/AIDS for Black Americans; what drives the AIDS epidemic? - (03/07/08)
     
  13159. CROI: Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated Women, Compared to HIV-uninfected Women - (03/07/08)
     
  13160. CROI: Diastolic Dysfunction is Common in Asymptomatic HIV Patients - (03/07/08)
     
  13161. CROI: Lipoatrophy and lipohypertrophy are independently associated with hypertension (FRAM): the effect of lipoatrophy but not lipohypertrophy on hypertension is independent of obesity - (03/07/08)
     
  13162. CROI: Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis - (03/07/08)
     
  13163. CROI: The Effect of Hepatitis C Infection on Metabolic Parameters following Initial Therapy of HIV Infected Subjects with Nucleoside +/- NNRTI Regimens - (03/07/08)
     
  13164. CROI: PF-232798, a Second Generation Pfizer Oral CCR5 Antagonist - (03/07/08)
     
  13165. Hemochromatosis Gene Polymorphisms, Mitochondrial Haplogroups, and Peripheral Lipoatrophy during ART - (03/05/08)
     
  13166. Low Testosterone Levels are Common and Associated with Insulin Resistance in Men with Diabetes - (03/05/08)
     
  13167. Efavirenz Potent Activity Across all CD4 & Viral Load Levels in Treatment-Naives - (03/05/08)
     
  13168. Nevirapine (HSR) Hypersenstivity Reaction Safety & CD4 & Viral Load - (03/05/08)
     
  13169. CROI: Endothelial Activation Markers Are Linked to HIV Status and Are Independent of ART and Lipoatrophy - (03/05/08)
     
  13170. CROI: Prevalence and Risk Factors in HIV-infected Persons for Echocardiographic Abnormalities in the Era of Modern HAART - (03/05/08)
     
  13171. HIV-Associated Lipoatrophy: Letting the Genome Out of the Bottle (Genetic Predisposition & Chronic Inflammation) EDITORIAL COMMENTARY - (03/05/08)
     
  13172. US healthcare spending: the next ten years (expected to double) - (03/04/08)
     
  13173. Name-based HIV reporting doesn't deter testing - (03/04/08)
     
  13174. CROI: HIV-Specific Risk Factors for Nonalcoholic Fatty Liver Still Elusive - Written by Mark Mascolini (03/04/08)
     
  13175. Safety, Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in HIV-1-Infected Patients - (03/03/08)
     
  13176. Human Papillomavirus (HPV) Genotype 84 Infection of the Male Genitalia: Further Evidence for HPV Tissue Tropism? CORRESPONDENCE - (03/03/08)
     
  13177. GlaxoSmithKline Comments on Epzicom Data Concerning Epzicom from ACTG Study - (03/03/08)
     
  13178. Long-Term Survival and Serious Cardiovascular Events in HIV-Infected Patients Treated With Highly Active Antiretroviral Therapy in VA [Brief Report: Clinical Science] - (03/03/08)
     
  13179. The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital Tract - (03/03/08)
     
  13180. Effects of HIV & antiretroviral therapy on semen quality - (03/03/08)
     
  13181. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study - (03/03/08)
     
  13182. Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men - (03/03/08)
     
  13183. Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom - (03/03/08)
     
  13184. New Approach Stops HIV At Earliest Stage Of Infection - (02/28/08)
     
  13185. NIAID Modifies HIV Antiretroviral Treatment Study Combination Therapy that Includes ABC/3TC Found Less Effective in Subgroup of Antiretroviral-Naive Individuals - (02/28/08)
     
  13186. CROI: Week 4 or 12 Response to PegIFN Predicts Sustained Response With HCV/HIV - Written by Mark Mascolini (02/28/08)
     
  13187. Tests of new Tenofovir gel show promise for microbicide for women: phase II study reports safe. Tolerable, acceptable, adherence - (02/27/08)
     
  13188. Short-Term Exercise Improves ß-cell Function and Insulin Resistance in Older People with Impaired Glucose Tolerance - (02/27/08)
     
  13189. CROI: Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir - (02/27/08)
     
  13190. CROI: GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Peripheral Glucose Disposal in a Healthy Rodent Model System - (02/27/08)
     
  13191. CROI: Inefficient Renal Transport of Nucleotide Reverse Transcriptase Inhibitor GS-9148 Indicates Its Low Potential for Nephrotoxicity - (02/27/08)
     
  13192. CROI: EVOLUTION OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN HIV-INFECTED PATIENTS: INCIDENCE, CHARACTERISTICS AND PREDICTORS - (02/27/08)
     
  13193. CROI: 48-Week Raltegravir Data Confirm Salvage Potency Across Pretreatment Variables - Written by Mark Mascolini - (02/27/08)
     
  13194. CROI: Bone Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation: A Randomized Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ritonavir (LPV/r)-Containing Regimen with Simplification to LPV/r Monotherapy - (02/27/08)
     
  13195. CROI: Efficacy and Safety of Double-Boosted Saquinavir (SQV)/Lopinavir/Ritonavir (LPV/r) in Nucleoside Pretreated Children at 96 Weeks - (02/26/08)
     
  13196. CROI: Darunavir EvaLuation in Pediatric HIV-1-Infected treatment-experienced patients, DELPHI (Trial TMC114-C212) - (02/26/08)
     
  13197. CROI: Effects of Diet and Exercise and/or Rosiglitazone on Body Composition and Lipids including Oxidized LDL in HIV+ and HIV- Men and Women - (02/26/08)
     
  13198. CROI: Do Lipid Signals Favor Maraviroc Over Efavirenz in Untreated People? - Written by Mark Mascolini - (02/26/08)
     
  13199. CROI: New NRTI Apricitabine Versus 3TC in 3TC-Experienced Patients: 24-Week Results - Written by Mark - (02/26/08)
     
  13200. CROI: Failure and Resistance Differences Between Darunavir and Lopinavir in TITAN - Written by Mark - (02/26/08)
     
  13201. CROI: Pharmacokinetics and Potent Anti-HIV-1 Activity of Amdoxovir Plus Zidovudine in a Randomized Double-blind Placebo-controlled Study - (02/26/08)
     
  13202. CROI: New Nucleoside, Amdoxovir (DAPD), Potent When Combined With AZT Written by Mark Mascolini - (02/26/08)
     
  13203. CROI: Sustained Treatment With Tesamorelin Needed to Keep Belly Fat Off - Written By Mark Mascolini - (02/26/08)
     
  13204. CROI: Limb Fat Loss Must Reach 30% Before Patients and Physicians See It - Written By Mark Mascolini - (02/26/08)
     
  13205. CROI: Insufficient Virus Suppression during HAART Is a Strong Predictor for the Development of AIDS-related Lymphoma: German CLINSURV Cohort - (02/25/08)
     
  13206. CROI: Immunodeficiency and Risk of AIDS-defining and Non-AIDS-defining Cancers: ANRS CO3 Aquitaine Cohort, 1998 to 2006 - (02/25/08)
     
  13207. CROI: Dose Escalation, Safety, Tolerability and Pharmacokinetics of a Novel HIV-1 NNRTI, IDX899 in Healthy Subjects - (02/25/08)
     
  13208. CROI: Genotypic Resistance and Phenotypic Cross-Resistance Profile in vitro for a Novel NNRTI: IDX899 - (02/25/08)
     
  13209. CROI: Therapeutic Drug Monitoring of Lopinavir and Saquinavir in Thai HIV-infected Children - (02/25/08)
     
  13210. CROI: New and emerging antiretrovirals, Comparative ART Trials, and when to begin HAART after an OI- now or later - written by David Margolis, MD (02/25/08)
     
  13211. Intensive glucose lowering arm of diabetes trial is stopped after excess deaths: ADVANCE study suggests different results - (02/22/08)
     
  13212. Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men - (02/22/08)
     
  13213. CROI: PF-232798, a Second Generation Pfizer Oral CCR5 Antagonist - (02/22/08)
     
  13214. CROI: Risk Factors for Reduced Bone Mineral Density In HIV-Infected Individuals In The Modern HAART Era - (02/22/08)
     
  13215. CROI: On-treatment responses at weeks 4 and 12 can be used to predict sustained virologic response rates in HIV HCV co-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (02/22/08)
     
  13216. CROI: Incidence Anal Squamous Intraepithelial Lesions (SIL) and Predictors of in the SUN Study after One Year of Follow-up - (02/22/08)
     
  13217. CROI: Data on 52-Week Safety and Efficacy of Tesamorelin, a Growth Hormone-releasing Factor Analogue, in HIV-infected Patients with Abdominal Fat Accumulation - (02/22/08)
     
  13218. The Impact of Episodic CD4 Cell Count-Guided Antiretroviral Therapy in SMART on Quality of Life - (02/21/08)
     
  13219. Abbott Receives FDA Approval for SIMCOR (Niaspan / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management - (02/20/08)
     
  13220. CROI: Bone Metabolism in HIV: CROI 2008 Update - written by Todd T. Brown, MD, PhD - (02/21/08)
     
  13221. CROI: Steady State Pharmacokinetics and Safety of Atazanavir (ATV) After Treatment with ATV 300 mg/Ritonavir 100 mg (ATV/r) QD + ZDV/3TC During the 3rd Trimester of Pregnancy in HIV+ Women - (02/20/08)
     
  13222. CROI: Multicenter, Retrospective Study of Incidence and Predictors of Adverse Events Associated With Nevirapine Use in a Cohort of Pregnant and Nonpregnant Women Treated at 3 Urban HIV Clinics in the United States - (02/20/08)
     
  13223. CROI: Risk Factors for for Kidney Disease in EuroSida: Climbing CD4 Count Cuts Risk of Worsening Kidney Function - Written by Mark Mascolini (02/20/08)
     
  13224. CROI: Racial Disparity in Kidney Disease At Hopkins: Sharp Racial Disparities in Kidney Trouble and End-Stage Disease in HIV+ Cohort - Written by Mark Mascolini - (02/20/08)
     
  13225. CROI: Clinical Pharmacology at CROI 2008: Drug Delivery and Disposition, Drug Interactions, Pharmacogenetics and Applications to Patient Care - written by Courtney V. Fletcher, Pharm.D.(02/20/08)
     
  13226. CROI: Co-Receptor Tropism, ENV Genotype, and in vitro Susceptibility to CCR5 Antagonists During Monotherapy Study with INCB9471 - (02/20/08)
     
  13227. CROI: An Enhanced Version of the Trofile HIV Co-receptor Tropsim Assay Predicts Emergence of CXCR4 Use in ACTG5211 Vicriviroc Trial Samples - (02/19/08)
     
  13228. CROI: Detection of Viral Co-receptor Tropism Changes with a High Sensitivity Phenotypic Assay among HIV-infected Patients with Drug-resistant Viremia - (02/19/08)
     
  13229. CROI: Long-acting TMC278, a parenteral depot formulation delivering sustained NNRTI plasma concentrations in preclinical and clinical settings - (02/19/08)
     
  13230. CROI: Switching from Combivir [CBV] (AZT/3TC) to Truvada [TVD] (TDF/FTC) Preserves Limb Fat: Results of a DEXA Sub-Study of a 48 Week Randomised Study - (02/19/08)
     
  13231. CROI: Lower Noninfectious Disease Rates With HAART in All CD4 Brackets - Written by Mark Mascolini (02/19/08)
     
  13232. CROI: Fat Changes Boost Heart Disease and Diabetes Risk in HIV-Infected Men - Written by Mark Mascolini (02/19/08)
     
  13233. CROI: HIV & ART Led to Bone Loss (02/19/08)
     
  13234. CROI: Worse HIV Control--Not Antiretrovirals--Linked to Low Bone Density in Vancouver; ART risk factor in 2nd study - Written by Mark Mascolini (02/19/08)
     
  13235. Persistence of HIV in Gut-Associated Lymphoid Tissue despite Long-Term Antiretroviral Therapy - (02/15/08)
     
  13236. Immunity Not Mormalized Despite HAART: Normalization of B Cell Counts and Subpopulations after Antiretroviral Therapy in Chronic HIV Disease - (02/15/08)
     
  13237. HIV Persists in the Gut Despite Long-Term HIV Therapy - (02/15/08)
     
  13238. Blood and Guts and HIV: Preferential HIV Persistence in GI Mucosa EDITORIAL COMMENTARY - (02/15/08)
     
  13239. Major international diabetes study does not confirm increased risk of death reported by US trial - (02/15/08)
     
  13240. HLA-B*5701 Screening for Hypersensitivity to Abacavir - (02/14/08)
     
  13241. Risks in "improving" control of blood glucose - (02/14/08)
     
  13242. Diabetes Study Partially Halted After Deaths - (02/14/08)
     
  13243. CROI: Reinfection Explains All MDR/XDR TB Cases With HIV at South African Flashpoint - Written by Mark Mascolini (02/14/08)
     
  13244. CROI: Liver Fibrosis in an Outbreak of Acute HCV in HIV-infected MSM; accelerated HCV progression if HIV is contracted before HCV (02/14/08)
     
  13245. CROI: Sustained Virological Response to Interferon plus Ribavirin Reduces Liver-related Complications and Mortality in HIV/HCV-co-infected Patients by 9-Fold (02/14/08)
     
  13246. CROI: CCR5 Antagonists, Tropism Assays: Entry and Entry Inhibitors at 15th Conference on Retroviruses and Opportunistic Infections 2008 -Written by Eric S. Daar, M.D. (02/14/08)
     
  13247. CROI: Kidney - Proteinuria, Glomerular Filtration Rate Reductions, and Associated Factors among HIV-Infected and Uninfected Men in the Multicenter AIDS Cohort Study (MACS) (02/14/08)
     
  13248. CROI: Clinical Associations of Extremity Fat Loss from ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Antiretroviral Therapy (ART) of Naive, HIV-1 infected Subjects (02/14/08)
     
  13249. CROI: Kaletra Tablets Once vs Twice Daily - Written by Mark Mascolini (02/14/08)
     
  13250. CROI: Etravirine With Darunavir Stays Strong Through 48 Weeks in DUET Trials - Written by Mark Mascolini (02/14/08)
     
  13251. CROI: Metabolic Syndrome Does Not Up Death Risk in HIV Cohort--But Bad Lipids Do - Written by Mark Mascolini (02/14/08)
     
  13252. CROI: SLAM-C Study: Maintenance Therapy in Coinfected (02/12/08)
     
  13253. CROI: HLA-B*5701 Screening for Hypersensitivity to Abacavir (02/12/08)
     
  13254. CROI: Renal Report by Wyatt/Klotman Mt Sinai (02/12/08)
     
  13255. CROI: Multistudy Analysis Shows Enhanced CD4 Gain With CCR5 Antagonists - Written by Mark Mascolini (02/12/08)
     
  13256. CROI: Reinfection Explains All MDR/XDR TB Cases With HIV at South African Flashpoint - Written by Mark Mascolini (02/12/08)
     
  13257. CROI: Immediate Antiretrovirals During Acute OI Lower Death Risk: ACTG A5164 - Written by Mark Mascolini (02/12/08)
     
  13258. CROI: Cardiovascular Risk Markers Greatly Inflate Death Risk in People With HIV; interruptions increase risk - Written by Mark Mascolini (02/12/08)
     
  13259. CROI: Still Hard to Prove Therapeutic Benefit With Therapeutic Drug Monitoring - Written by Mark Mascolini (02/12/08)
     
  13260. CROI: Clinical Study Demonstrates Similar Effectiveness Of Once-Daily vs. Twice-Daily Dosing of Abbott's Kaletra(lopinavir/ritonavir) Tablet in HIV-Infected Patients New to Antiretroviral Therapy. Abbott press release (02/12/08)
     
  13261. CROI: Even at Counts Over 350, More CD4s Lower Death Risk in Untreated HIV+ People (02/12/08)
     
  13262. CROI: Resistance After First Failure Looms as Larger Problem in Poor vs Rich Countries (02/12/08)
     
  13263. CROI: Faster Death May Be the Price Paid for Delayed Switching After Failure (02/12/08)
     
  13264. CROI: Abacavir (But Not Efavirenz) Weaker in Cohort Study Than in Clinical Trial (02/12/08)
     
  13265. CROI: Maraviroc 48-Weeks Safety, Efficacy in Treatment-Experienced MOTIVATE 1 and 2 Study Pooled Analysis (02/12/08)
     
  13266. CROI: Clinical Study Demonstrates Similar Effectiveness Of Once-Daily vs. Twice-Daily Dosing of Abbott's Kaletra(lopinavir/ritonavir) Tablet in HIV-Infected Patients New to Antiretroviral Therapy. Abbott press release (02/08/08)
     
  13267. CROI: A phase I study to explore the activity and safety of SCH 532706, a small molecule chemokine receptor-5 (CCR5) antagonist in HIV-1 infected subjects (02/08/08)
     
  13268. CROI: Tenofovir Bolsters Response to IFN/RBV in People With HCV/HIV - Written by Mark Mascolini (02/07/08)
     
  13269. CROI: Prevalence of etravirine (ETR; TMC125) resistance-associated mutations in a large panel of clinical isolates (02/07/08)
     
  13270. CROI: DUET-1:Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients (02/07/08)
     
  13271. CROI: Characterization of virologic failures on darunavir/ritonavir in the randomized, controlled, Phase III TITAN trial in treatment-experienced patients (02/07/08)
     
  13272. CROI: This is a BMS press release CASTLE STUDY SHOWED SIMILAR EFFICACY BETWEEN ONCE-DAILY REYATAZ (atazanavir sulfate)/RITONAVIR AND TWICE-DAILY LOPINAVIR/RITONAVIR AT 48 WEEKS IN PREVIOUSLY UNTREATED HIV-INFECTED ADULT PATIENTS (02/07/08)
     
  13273. CROI: New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy - Tibotec press release at end of title (02/07/08)
     
  13274. CROI: VICRIVIROC DEMONSTRATES POTENT AND SUSTAINED VIRAL SUPPRESSION THROUGH 48 WEEKS OF THERAPY IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS (02/07/08)
     
  13275. CROI: Vicriviroc in Combination Therapy With an Optimized Antiretroviral Regimen for Treatment-Experienced Subjects: The VICTOR-E1 Trial (02/07/08)
     
  13276. CROI: The Effect of Vicriviroc Upon Viral Load in HIV/HCV Co-infected Patients Receiving a Ritonavir-containing Protease Inhibitor Regimen (02/07/08)
     
  13277. CROI: Pharmacokinetics and pharmacodynamics of the NNRTI etravirine (ETR; TMC125) in treatment-experienced HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET-2 (02/07/08)
     
  13278. CROI: Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study (02/07/08)
     
  13279. CROI: Once-Daily Darunavir Troughs Stay in Active Range for All ARTEMIS Patients - Written by Mark Mascolini (02/12/08)
     
  13280. CROI: Pharmacokinetics of the next-generation NNRTI etravirine (ETR; TMC125) in HIV-infected children between 6 and 17 years, inclusive (02/07/08)
     
  13281. CROI: Tropism Change from Screening to Baseline Matters: Virological Correlates Associated with Treatment Failure at Week 48 in the Phase 3 Study of Maraviroc in Treatment-Naive Patients - Written by Mark Mascolini (02/06/08)
     
  13282. CROI: Dramatic Drop in Second-Line Antiretroviral Failures Across US and Canada - Written by Mark Mascolini (02/06/08)
     
  13283. CROI: "No Treatment Options" No Longer a Growing Problem in Switzerland - Written by Mark Mascolini (02/06/08)
     
  13284. CROI: Firstline Nukes Evaluated: What Makes a First Regimen Work? Answers From 79 Trials and Cohorts - Written by Mark Mascolini (02/06/08)
     
  13285. CROI: Even Totally Controlled HIV Linked to Atherosclerosis Risk - Written by Mark Mascolini (02/06/08)
     
  13286. CROI: "Elite Controller" Study Suggests No "Harmless" Level of HIV, Lose CD4s Faster - Written by Mark Mascolini (02/06/08)
     
  13287. CROI: 48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 (02/06/08)
     
  13288. CROI: 48-Week Results from BENCHMRK-1, a Phase III Study of Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 (02/06/08)
     
  13289. CROI: Study M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naive (ARV) HIV-1 Infected Subjects (02/06/08)
     
  13290. CROI: Boosted Atazanavir Noninferior to Lopinavir in Previously Untreated People - Written by Mark Mascolini (02/05/08)
     
  13291. CROI: Abacavir & MI (myocardial infarction) Risk in D.A.D Study - Written by Mark Mascolini (02/05/08)
     
  13292. CROI: What Explains Maraviroc Failures in the MERIT Trial of Naive Patients? - Written by Mark Mascolini (02/05/08)
     
  13293. CROI: Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-Daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study - (02/05/08)
     
  13294. CROI: Abacavir/3TC vs TDF/FTC: The HEAT Study - Written by Mark Mascolini (02/05/08)
     
  13295. CROI: Dramatic Drop in Second-Line Antiretroviral Failures Across US and Canada - Written by Mark Mascolini (02/05/08)
     
  13296. CROI: Efficacy and Safety of Boosted Once-Daily Atazanavir and Twice-Daily Lopinavir Regimens in Treatment-Naive HIV-1 Infected Subjects CASTLE: 48-Week Results (02/05/08)
     
  13297. CROI: Fasted Lipid Changes after Administration of Maraviroc or Efavirenz in Combination with Zidovudine and Lamivudine (Combivir) for 48 Weeks to Treatment-naive HIV-infected Patients (02/05/08)
     
  13298. CROI: Longer ART Drug Regimen Found to Help Babies Avoid HIV From Breastfeeding in Africa (02/05/08)
     
  13299. CROI: Resuming Therapy Can't Reverse Progression Risk With Off-and-On Therapy - Written by Mark Mascolini (01/04/08)
     
  13300. ORAL CANCER IN MEN CAUSED BY HPV VIRUS - (02/04/08)
     
  13301. CROI: Circumcision Cuts HSV-2 Risk in Ugandan Men and STDs in Their Wives - Written by Mark Mascolini (01/04/08)
     
  13302. CROI: Two Schering CCR5 Antagonists Get Spotlight at HIV Conference - Written by Mark Mascolini (01/04/08)
     
  13303. CROI: Male Circumcision Challenges in African Study (01/04/08)
     
  13304. CROI: Microbicide Protein Identified (01/04/08)
     
  13305. CROI: Two New CCR5 Inhibitors, Actually 3 (01/04/08)
     
  13306. CROI: Circumcising Men Slows Herpes Spread by 25%, May Reduce HIV Risk (01/04/08)
     
  13307. Does Boosted PI Monotherapy Have Future Utility? Kaletra Monotherapy Studies: the OK Study and MONARK Study - (01/30/08)
     
  13308. Insulin Resistance Prevents Response to Peinterferon in Coinfection, study reports - (01/29/08)
     
  13309. Episodic HAART in SMART Study Has Worse Quality of Life - (01/29/08)
     
  13310. When to Start HAART: CD4 <350 & Viral Load >100,000 Increase Risk for AIDS & Death - (01/29/08)
     
  13311. Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily HAART Regimens in ART-Naive Patients - (01/28/08)
     
  13312. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006 - (01/28/08)
     
  13313. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen - (01/28/08)
     
  13314. VAT (belly fat) is Increased in HIV+ Men, New Study Reports - Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities - (01/28/08)
     
  13315. Influence of Cannabis Use on Severity of Hepatitis C Disease - (01/25/08)
     
  13316. New Bone Therapy Denosumab vs Fosamax - (01/25/08)
     
  13317. Bone Loss 62% in HIV+ - (01/23/08)
     
  13318. Factors Associated with Low Bone Mineral Density (BMD) in a Large Cohort of HIV-Infected U.S. Adults - Baseline Results from the SUN Study -CROI 2007 - (01/23/08)
     
  13319. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial - (01/23/08)
     
  13320. Cardiovascular risks of calcium supplements in women Editorials - (01/23/08)
     
  13321. 80% Bone Abnormalities in France Aquitane Cohort, 27% Osteoporosis - (01/23/08)
     
  13322. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? - (01/22/08)
     
  13323. Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease - (01/22/08)
     
  13324. Tenofovir/FTC Prevents Vaginal HIV Infection in Mice - (01/22/08)
     
  13325. High Prevalence of Anal Human Papillomavirus (HPV) Infection and Anal Cancer Precursors among HIV-Infected Persons in the Absence of Anal Intercourse - (01/22/08)
     
  13326. FDA Approves INtELENCE(tM) (etravirine) for HIV Combination therapy; - INtELENCE is the first NNRtI to show antiviral activity in patients with NNRtI-resistant virus - - (01/22/08)
     
  13327. FDA Approves New HIV Drug After Priority Review Etravirine tablets used in combination with other antiretroviral agents - (01/22/08)
     
  13328. Etravirine (TMC-125) FDA Package Insert in PDF Format - (01/22/08)
     
  13329. Emergence of Multidrug-Resistant, Community-Associated, Methicillin-Resistant Staphylococcus aureus (MRSA) Clone USA300 in Men Who Have Sex with Men - (01/15/08)
     
  13330. Low Serum Testosterone Caused Fractures, study found - (01/15/08)
     
  13331. Statins for people with diabetes Comment - (01/14/08)
     
  13332. Statins for all diabetics urged - (01/14/08)
     
  13333. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis - (01/14/08)
     
  13334. 273 New HIV Host Proteins Discovery Reported HIV Gets By With a Lot of Help From Human Host - (01/14/08)
     
  13335. NASH may be trash: causes of NASH - (01/14/08)
     
  13336. linolenic acid (PUFAs) & peripheral neuropathy - (01/14/08)
     
  13337. Researchers Find Cell Protein That Nips HIV in the Bud: DC-SIGN EFFICIENTLY BLOCKS HIV VIRAL BUDDING - (01/14/08)
     
  13338. Non-Hodgkin Lymphoma Rare After HAART - (01/11/08)
     
  13339. The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves ß-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose - (01/09/08)
     
  13340. FDA ALERT: Bisphosphonates Can Cause Severe Musculoskeletal Pain - (01/08/08)
     
  13341. "Is there a" The coming problem of HIV-associated Alzheimer's disease??? - (01/08/08)
     
  13342. AIDS Patients Face Downside of Living Longer, Need for more Research on Diseases Associated with Aging - (01/07/08)
     
  13343. Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial - (01/04/08)
     
  13344. Oral Bispohosphonates (Fosomax) Found To protect Against Osteonecrosis of Jaw in Osteoporosis - (01/04/08)
     
  13345. Frequent Occurrence of Chronic Hepatitis B Virus Infection among West African HIV Type-1-Infected Children - (01/03/08)
     
  13346. Hepatitis B Virus and HIV Coinfection in Low-Income Countries: Unmet Needs EDITORIAL COMMENTARY - (01/03/08)
     
  13347. Tenofovir-Based Rescue Therapy for Advanced Liver Disease in 6 Patients Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine BRIEF REPORT - (01/03/08)
     
  13348. Tenofovir Nephrotoxicity: Focusing Research Questions and Putting Them into Clinical Context EDITORIAL COMMENTARY - (01/02/08)
     
  13349. Greater Tenofovir-Associated Renal Function Decline with Protease Inhibitor-Based versus Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy - (01/02/08)
     
  13350. MOST WOMEN WITH HIV AND THEIR HEALTH CARE PROVIDERS HAVE NOT DISCUSSED HOW HIV MIGHT AFFECT THEM DIFFERENTLY THAN MEN - (12/28/07)
     
  13351. Plasma Levels, Safety, and 60-Week Efficacy of a Once-Daily Double-Boosted Protease Inhibitor Regimen of Atazanavir, Saquinavir, and Ritonavir [Letters to the Editor] - (12/27/07)
     
  13352. Infrared Coagulator Treatment of High-Grade Anal Dysplasia in HIV-Infected Individuals: An AIDS Malignancy Consortium Pilot Study - (12/27/07)
     
  13353. HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term HAART Reach Same Mortality Rates as the General Population - (12/27/07)
     
  13354. Darunavir Full Approval & For Naives: Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration - (12/21/07)
     
  13355. ISENTRESS(R) (raltegravir) from MSD, First Integrase Inhibitor, Approved by the European Union Commission - (12/21/07)
     
  13356. Generic Efavirenz FDA Approved - (12/21/07)
     
  13357. Monogram Trofile Assay Superior to Pathway SensiTrop Assay - (12/19/07)
     
  13358. Monogram Statement 'Study Reaffirms Superiority of Trofile(TM) Assay' - (12/19/07)
     
  13359. BMD in Older Women Predicts Vertebral Fractures; vertebral fractures reduced survival; a single measure of BMD predicted vertebral factures - (12/18/07)
     
  13360. GB Virus C Reduced HCV-Liver Disease in HIV/HCV Coinfected - (12/18/07)
     
  13361. EUROPEAN COMMISSION APPROVES ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), THE FIRST ONCE-DAILY SINGLE TABLET REGIMEN FOR VIROLOGICALLY SUPPRESSED ADULTS WITH HIV-1 INFECTION - (12/17/07)
     
  13362. Predictive factors of vascular intima media thickness in HIV-positive subjects - (12/17/07)
     
  13363. HIV and mitochondrial toxicity in children (& adults) - (12/17/07)
     
  13364. EU to approve one-pill-a-day treatment for HIV patients - (12/17/07)
     
  13365. Low Incidence of Drug Resistance after Virologic Failure in HIV-1 Infected Subjects Randomized to Remain on their Current Protease Inhibitor (PI) or Switched to a Fosamprenavir Regimen for 24 Weeks (ELECT Study) - (12/14/07)
     
  13366. Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes - (12/12/07)
     
  13367. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes - (12/12/07)
     
  13368. Study: 2 thiazolidinediones diabetes drugs raise heart risks - (12/12/07)
     
  13369. Active Smoking and the Risk of Type 2 Diabetes, Increased 44% Risk - (12/12/07)
     
  13370. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted. - (12/12/07)
     
  13371. Mortality and morbidity improved following early ART (>350 CD4) initiation in HIV-infected adults in West Africa - (12/12/07)
     
  13372. HIV Entry 3rd Wrkshp: Preclinical Work Suggests Advantages of New Fusion Inhibitor Versus Enfuvirtide - Written by Mark Mascolini - (12/12/07)
     
  13373. HIV Entry 3rd Wrkshp: Analysis of the Protease Inhibitor/Reverse Transcriptase Inhibitor/Fusion Inhibitor Resistance Pattern of Treatment-emergent CXCR4-using Virus from Six Patients in the MOTIVATE Studies Shows no Evidence of Different Drug Resistance Profiles Being Archived in the CCR5-tropic versus CXCR4-using Populations - (12/11/07)
     
  13374. HIV Entry 3rd Wrkshp: A band of optimists considers the road towards a distant goal: eradication; Report from HIV Eradication Conference, 3rd Intl Workshop on HIV Persistence during Therapy, West Indies, St Maartin - written by David Margolis MD, University of North Carolina at Chapel Hill- (12/11/07)
     
  13375. HIV Entry 3rd Wrkshp: Viruses Utilizing Both CCR5 and CXCR4 Are Found in 5-13% of Acute HIV-1 Infections - (12/11/07)
     
  13376. HIV Entry 3rd Wrkshp: Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic Virus in MOTIVATE 1 and 2 - (12/11/07)
     
  13377. Higher Vitamin D Supplements Advised for Older Black Women - (12/11/07)
     
  13378. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C - (12/11/07)
     
  13379. A band of optimists considers the road towards a distant goal: eradication; Report from HIV Eradication Conference, 3rd Intl Workshop on HIV Persistence during Therapy, West Indies, St Maartin - (12/11/07)
     
  13380. BMS/Gilead ATRIPLA Commercialization in Europe - (12/11/07)
     
  13381. HIV Entry 3rd Wrkshp: Low Sensitivity of Gene-Based Tools in Predicting Coreceptor Use - Written by Mark Mascolini - (12/09/07)
     
  13382. HIV Entry 3rd Wrkshp: Correlates of Coreceptor Tropism in Three Large Cohorts: Does lower CD4 predict tropism switch? - Written by Mark Mascolini - (12/09/07)
     
  13383. HIV Entry 3rd Wrkshp: CXCR4-Using HIV Found in 8.5% During Early HIV Infection - Written by Mark Mascolini - (12/09/07)
     
  13384. HIV Entry 3rd Wrkshp: New More Sensitive Monogram Tropism Assay; Tweaked Trofile Assay Stronger in Spotting Dual/Mixed-Tropic Virus - Written by Mark Mascolini - (12/09/07)
     
  13385. HIV Entry 3rd Wrkshp: Maraviroc Failure With X4 Virus Does Not Spur New Resistance to Other ARVs - Written by Mark Mascolini - (12/09/07)
     
  13386. HIV Entry 3rd Wrkshp: Enhancements to the Trofile HIV Co-receptor Tropism Assay Enable Improved Detection of CXCR4-using Subpopulations and Earlier Detection of CXCR4-using Viruses in Sequential Patient Samples - (12/09/07)
     
  13387. HIV Entry 3rd Wrkshp: Background Drugs and Low Maraviroc Levels Explain Resistance in MOTIVATE - Written by Mark Mascolini - (12/09/07)
     
  13388. HIV Entry 3rd Wrkshp: Preclinical Work Suggests Advantages of New Fusion Inhibitor Versus Enfuvirtide - Written by Mark Mascolini - (12/09/07)
     
  13389. Risk of extensive virological failure to the three original ART drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study - (12/07/07)
     
  13390. Screening for diabetes and prediabetes COMMENTARY - (12/07/07)
     
  13391. Metabolic Effects of a Growth Hormone-Releasing Factor (GHRH) in Patients with HIV - (12/06/07)
     
  13392. Manipulation of the Growth Hormone Axis in Patients with HIV Infection EDITORIAL - (12/06/07)
     
  13393. Cardiorespiratory Fitness and Adiposity as Mortality Predictors in Older Adults: Cardio fitness predicts mortality better than BMI, fat - (12/06/07)
     
  13394. CDC may raise its estimate of annual HIV cases by 50% - (12/04/07)
     
  13395. Generic Tenofovir Approved by FDA - (12/04/07)
     
  13396. Changes in the DHHS ART Treatment Guidelines for Adults & and Adolescents - (12/04/07)
     
  13397. HIV drug resistance 'on the rise' in China - (12/04/07)
     
  13398. GSK responds quickly to query Avandia link to osteoporosis - (12/04/07)
     
  13399. BRISTOL-MYERS SQUIBB JOINS WITH NJ CHILDREN'S HOSPITAL IN LAUNCHING NEW CENTER FOR IMMUNE SYSTEM DISORDERS AND INFECTIOUS DISEASES INCLUDING HIV/AIDS - (11/30/07)
     
  13400. Do HIV/HCV coinfected have worse neurocognitive function - (11/30/07)
     
  13401. Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095 - (11/30/07)
     
  13402. A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy - (11/30/07)
     
  13403. Joint Statement from Drs. Elias Zerhouni, Jack Whitescarver, and Anthony Fauci of the National Institutes of Health on World AIDS Day NIH Announces 2007 World AIDS Day Award Recipients - (11/30/07)
     
  13404. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer - (11/30/07)
     
  13405. EACS: An Open, Randomized, Two-Period, Crossover Study in Two Cohorts to Investigate the Effect of Steady-State TMC125 (etravirine) and the Combination of TMC125/Darunavir/Ritonavir on the Steady-State Pharmacokinetics of Oral Maraviroc in Healthy Subjects - (11/29/06)
     
  13406. losing the battle against heart disease, editorial comment - (11/28/07)
     
  13407. Heart disease mortality increases for young women 35-44 and negative trend for young men too - (11/28/07)
     
  13408. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer - (11/28/07)
     
  13409. Low BMD Associated with Both Low & High Trauma Accidents Causing Fractures in HIV-Negatives - (11/28/07)
     
  13410. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis - (11/28/07)
     
  13411. Magic Johnson & Abbott Events in NYC 11/30: Aims to Reduce New HIV Infections Among African-Americans by 50% by 5 Years - (11/28/07)
     
  13412. New more sensitive assay to detect drug-resistant HIV - (11/28/07)
     
  13413. Baseline Metabolic Syndrome Predicts Diabetes, study finds - (11/28/07)
     
  13414. African-Americans at Risk for Kidney Disease - (11/28/07)
     
  13415. The Reemerging HIV/AIDS Epidemic in Men Who Have Sex With Men - (11/28/07)
     
  13416. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients - (11/28/07)
     
  13417. EACS: Low-Level HIV-1 Viral Load Monitoring in Cerebrospinal Fluid: Possible Correlation to Antiretroviral Drug Penetration - (11/27/06)
     
  13418. EACS: TMC278, a next-generation NNRTI, demonstrates potent and sustained efficacy in antiretroviral (ARV)-naive patients: Week 48 primary analysis of study TMC278-C204 - (11/27/06)
     
  13419. EACS: Lower lipid levels in antiretroviral (ARV)-naive patients receiving the investigational NNRTI TMC278 versus efavirenz (EFV) - (11/27/06)
     
  13420. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV - (11/26/07)
     
  13421. Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression - (11/26/07)
     
  13422. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease Data from the PROactive Study (PROactive 08) - (11/26/07)
     
  13423. Dietary Cod Protein Improves Insulin Sensitivity in Insulin-Resistant Men and Women - (11/26/07)
     
  13424. Long-Term Predictors of Insulin Resistance Role of lifestyle and metabolic factors in middle-aged men - (11/26/07)
     
  13425. EACS: Tipranavir/r (TPV/r) maintains long term virological suppression - Three year follow-up of RESIST - (11/26/06)
     
  13426. EACS: Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score - (11/26/06)
     
  13427. EACS: Genotypic tipranavir scores as predictors of response - (11/26/06)
     
  13428. EACS: Risk Factors for Kidney Complications - Written by Mark Mascolini - (11/20/06)
     
  13429. Vitamin D Supplements Appear to Be Associated With Lower Mortality - (11/19/07)
     
  13430. EACS: Hepatic profile of tipranavir in treatment experienced HIV-1 infected individuals - (11/19/06)
     
  13431. EACS: Linear modeling to estimate the contribution of each drug component of the regimens of highly treatment-experienced patients in RESIST - (11/19/06)
     
  13432. EACS: Patients who responded to tipranavir/r (500/200 mg BID) plus new enfuvirtide (ENF) at Week 16 of RESIST studies maintain superior virologic and immunologic outcomes through Week 96; effects of adding 1 new class to potent protease inhibitor in highly treatment-experienced patients - (11/19/06)
     
  13433. Merck Integrase raltegravir drug gets positive nod from EU - (11/16/07)
     
  13434. Merck HIV vaccine trial data - (11/15/07)
     
  13435. Improved cognitive function as a consequence of hepatitis C virus treatment - (11/15/07)
     
  13436. Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra (lopinavir/ritonavir) Tablet for Pediatric HIV Patients - (11/15/07)
     
  13437. Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy - (11/15/07)
     
  13438. FDA Adds Boxed Warning for Heart Attacks to Anti-Diabetes Drug Avandia - (11/15/07)
     
  13439. Increase in STDs-CDC Reports Worrisome Trends - (11/15/07)
     
  13440. High HIV Rates in MSM in South Florida
    1 in 11 gay white men in Broward County (Ft Lauderdale) has HIV
    1 in 22 gay, bisexual men in Florida has HIV, study says     - (11/15/07)
     
  13441. Prevalence of Chronic Kidney Disease in the United States - (11/08/07)
     
  13442. EACS: Predictors of New Darunavir Resistance Mutations Upon Darunavir Failure - Mark Mascolini - (11/08/06)
     
  13443. End-Stage Renal Disease Prevalence Climbing as Baby Boomers Age (11/07/07)
     
  13444. Monogram Obtains Coverage for Trofile(TM) Assay from California ADAP Program (11/07/07)
     
  13445. Single-dose tenofovir and emtricitabine for reduction of viral resistance to NNRTIs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial (11/07/07)
     
  13446. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine, Commentary (11/07/07)
     
  13447. EACS: Co-Receptor Tropism Predictions Based on V3 Loop Sequence in Antiretroviral-Experienced Patients are Specific but Insensitive for the Detection of CXCR4-using Variants - (11/05/06)
     
  13448. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics (11/05/07)
     
  13449. EACS: Insulin Resistance Imperils Response to Interferon in People With HCV/HIV - (11/04/06)
     
  13450. Viral Load Predicts CD4 Decline to <350, Takes 2.5 Yrs (11/02/07)
     
  13451. Generic Oral d4T Approved (11/02/07)
     
  13452. EACS: Spontaneous HCV Clearance With HIV Lower Than Previously Thought? - Written by Mark Mascolini - (11/1/06)
     
  13453. EACS: Body Composition Changes in ARV-Naive Subjects Treated with Atazanavir or Atazanavir/Ritonavir-Based Once-Daily HAART: 96-Week CT and DEXA Data - (10/31/06)
     
  13454. GSK Launches Abacavir Genetic Testing Program: doctor survey, education and complimentary tests (10/31/07)
     
  13455. AIDS virus invaded U.S. from Haiti: study (10/30/07)
     
  13456. AIDS Entered USA From Haiti in 1969 HIV's Path Out Of Africa: Haiti, The US Then The World (10/30/07)
     
  13457. HIV Among Black Women in USA & Colorado (10/30/07)
     
  13458. EACS: Once-Daily Fosamprenavir (FPV) Boosted with Either 100mg or 200mg of Ritonavir (r) Along with Abacavir (ABC)/Lamivudine (3TC): 48 Week Safety and Efficacy Results from COL100758 - (10/30/06)
     
  13459. EACS: Single agent lopinavir/ritonavir (LPV/r) is as effective at maintaining viral suppression as continuation of standard ART at 24 weeks in patients who already have HIV RNA <50 copies/mL - (10/30/06)
     
  13460. EACS: Single Agent Therapy (SAT) with Lopinavir/ritonavir (LPV/r) Controls HIV-1 Viral Replication in the Female Genital Tract - (10/30/06)
     
  13461. EACS: Switching from Combivir (CBV, AZT/3TC) to Truvada (TVD, TDF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study - (10/30/06)
     
  13462. FDA Approves Administration of LEXIVA with Lower Dose of "Boosting" Medication Ritonavir (10/29/07)
     
  13463. EACS: High Death Risk With HIV, HCV, and Decompensated Cirrhosis - Written by Mark Mascolini - (10/29/06)
     
  13464. EACS: Do HCV Genotype and Load Affect Mortality With HIV? - Written by Mark Mascolini - (10/29/06)
     
  13465. EACS: Switch to Atripla from Undetectable HAART - (10/29/06)
     
  13466. EACS: Continuation of BID Boosted PI vs Switch to Once-daily Boosted Atazanavir in Subjects with Truncal Adiposity - (10/29/06)
     
  13467. EACS: Good News and Bad News on Survival With Neurologic AIDS - Written by Mark Mascolini - (10/29/06)
     
  13468. EACS: After First Year of HAART in 1996, Mortality Stable With Advanced Disease - Written by Mark Mascolini - (10/29/06)
     
  13469. EACS: An assessment of HIV-HCV co-infection management in Spain: The ABHACO survey; 61-69% OF HIV infected patients are co-infected with the HCV too - (10/29/06)
     
  13470. EACS: Long-term (4 years) efficacy of Lopinavir/ritonavir monotherapy for maintenance of HIV suppression - (10/29/06)
     
  13471. EACS: Boosted Versus Unboosted Atazanavir After Long-Term Lopinavir - Written by Mark Mascolini - (10/26/06)
     
  13472. EACS: ARTEMIS: Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naive patients - (10/29/06)
     
  13473. EACS: ARTEMIS Study: Once-Daily Darunavir, Once-Daily Lopinavir, and Twice-Daily Lopinavir Compared - Written by Mark Mascolini - (10/26/06)
     
  13474. EACS: Prognostic Factors of Virological Success in Antiretroviral-naive Patients Receiving LPV Monotherapy in the MONARK trial - (10/29/06)
     
  13475. EACS: Lopinavir/ritonavir monotherapy versus lopinavir/ritonavir and two nucleosides for maintenance therapy of HIV. Ninety-six week results of a randomized, controlled, open-label clinical trial (OK04 Study) (10/26/06)
     
  13476. EACS: Pooled 24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine; ETR) in treatment-experienced HIV-1-infected patients (10/26/06)
     
  13477. EACS: The Incidence of Severe Liver Enzyme Abnormalities and Hepatic Adverse Events in the Maraviroc Clinical Development Programme (10/26/06)
     
  13478. EACS: Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2 Phase III clinical trials (10/26/06)
     
  13479. EACS: Efficacy of Raltegravir, an HIV Integrase Inhibitor, in Combination with Regimens Containing Enfuvirtide, Darunavir, or Tipranavir in Patients with Triple-class Resistant Virus: Combined Results from BENCHMRK-1 and BENCHMRK-2 (10/26/06)
     
  13480. EACS: Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) safety and tolerability in treatment-experienced, HIV-1-infected patients (10/26/06)
     
  13481. Panacos Announces Greater than 1 Log10 Mean Reduction in 300 mg Bevirimat Cohort (10/25/07)
     
  13482. EACS: Why Do British Docs Follow Antiretroviral Rules Less and Less? - Written by Mark Mascolini - (10/25/06)
     
  13483. EACS: Saquinavir/r (SQV/r) vs lopinavir/r (LPV/r) plus emtricitabine/tenofovir (FTC/TDF) as initial therapy in HIV-1 infected patients The Gemini Study (10/25/06)
     
  13484. EACS: Long-Term Kidney Damage From Indinavir But Not Tenofovir - Written by Mark Mascolini - (10/25/06)
     
  13485. EACS: Cocaine Boosts Cardiovascular Risk in Spanish Patients With HIV - Written by Mark Mascolini - (10/25/06)
     
  13486. EACS: Lopinavir Monotherapy Fails More in People With Non-B Subtypes - Written by Mark Mascolini - (10/25/06)
     
  13487. EACS: Final Gemini Study Results Confirm Boosted Invirase Was as Effective as Kaletra While Providing an Improved Triglyceride Profile for HIV Patients (press release from Roche) - Written by Mark Mascolini - (10/25/06)
     
  13488. EACS: Combined 24-Week Efficacy Data on the Integrase Inhibitor Raltegravir - Written by Mark Mascolini - (10/25/06)
     
  13489. EACS: Efficacy and Safety of Maraviroc (MVC) Plus Optimized Background Therapy (OBT) In Viraemic, Antiretroviral Treatment-Experienced Patients Infected with CCR5-Tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-Week Results - (10/25/06)
     
  13490. EACS: Two Tools for Sharpening Darunavir Response Predictions - Written by Mark Mascolini - - (10/17/06)
     
  13491. EACS: Response to Nonnucleoside TMC278 Sustained Through 48 Weeks - Written by Mark Mascolini - - (10/17/06)
     
  13492. EACS: Four Double-DUET Analyses Give Closer Look at New NNRTI - Written by Mark Mascolini - - (10/17/06)
     
  13493. Abbott's FDC Simvastatin+Niaspan (10/24/07)
     
  13494. Liver Fat in the Metabolic Syndrome (10/24/07)
     
  13495. Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE network (10/24/07)
     
  13496. Physical Activity and Reduced Risk of Cardiovascular Events Potential Mediating Mechanisms (10/24/07)
     
  13497. Keeping quiet: microRNAs in HIV-1 latency; commentary by Siliciano and Han (10/22/07)
     
  13498. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes (10/22/07)
     
  13499. UCSF Anal Cancer Information Website: screening, treatment, and referral list of doctors in numerous cities (10/22/07)
     
  13500. Hearing loss with erectile dysfunction drugs (10/22/07)
     
  13501. Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid (10/22/07)
     
  13502. HAART Drop-out rate of African AIDS patients causes concern (10/22/07)
     
  13503. High Rates of HIV Among Black & Latino MSM (10/19/07)
     
  13504. New Study: HIV+ Blacks Have High Rates of End-Stage Renal Disease in USA VA (10/19/07)
     
  13505. European licence for Roche HIV drug Viracept re-established by European Commission (10/19/07)
     
  13506. HEALTH CANADA APPROVES ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), THE FIRST ONCE-DAILY SINGLE TABLET REGIMEN FOR HIV (10/17/07)
     
  13507. Thailand's FDA Registers Generic of Abbott's Aluvia Under Compulsory Licensing Program (10/17/07)
     
  13508. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults (10/15/07)
     
  13509. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores [Research Letters] (10/15/07)
     
  13510. Fuzeon Sales Increased; Trimeris Reports Third Quarter 2007 FUZEON Sales Results (10/15/07)
     
  13511. Maraviroc approved in Canada to treat HIV, first new class in 10 years (10/15/07)
     
  13512. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART [Research Letters] (10/15/07)
     
  13513. Merck Gets FDA Approval For New HIV Treatment Integrase Inhibitor Raltegravir (10/15/07)
     
  13514. HIV/AIDS Among Hispanics --- United States, 2001--2005 (10/15/07)
     
  13515. FDA Approves of Isentress (raltegravir) (10/15/07)
     
  13516. FDA Approves ISENTRESS (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor (10/15/07)
     
  13517. HIV's Striking Impact on HCV. HCV-HIV Coinfection: Simple Messages from a Complex Disease (10/15/07)
     
  13518. Implementing Routine HIV Testing: The Role of State Law; CDC recommendation for routine testing is not being implemented, why? (10/15/07)
     
  13519. Routine HIV screening becomes California law (10/15/07)
     
  13520. Prevalence and factors associated with dry skin in HIV infection: the FRAM study (10/15/07)
     
  13521. MOST WOMEN WITH HIV AND THEIR HEALTH CARE PROVIDERS HAVE NOT DISCUSSED HOW HIV MIGHT AFFECT THEM DIFFERENTLY THAN MEN (10/11/07)
     
  13522. Psychological Stress and Disease (HIV/AIDS) (10/11/07)
     
  13523. Psychosis in a 12-Year-Old HIV-Positive Girl with an Increased Serum Concentration of Efavirenz (10/11/07)
     
  13524. IDSA: Safety and tolerability of KP-1461 in phase 1, dose-ranging study in highly ART experienced HIV infected persons - (10/11/07)
     
  13525. Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26 (10/10/07)
     
  13526. Onions Reduce Pancreatic Cancer Risk: Flavonols and Pancreatic Cancer Risk (10/10/07)
     
  13527. Aptivus (tipranavir) Capsules Granted Full Approval by the U.S. FDA (10/10/07)
     
  13528. IDSA: 48-Week Safety and Efficacy of Maraviroc in Combination with Optimized Background Therapy (OBT) for the Treatment of Antiretroviral-Experienced Patients Infected with Dual/Mixed-Tropic HIV-1 - (10/9/07)
     
  13529. IDSA: Switching from Lopinavir/Ritonavir (LPV/r) Soft Gel Capsule (SGC) to Tablet Formulation improves Tolerability in Indigent AIDS Clinic - (10/9/07)
     
  13530. IDSA: HIV & Aging: Overweight & Hypertension Increasing - (10/9/07)
     
  13531. IDSA: TMC125 safety and tolerability: 24-week results of the pooled DUET-1 and -2 trials - (10/9/07)
     
  13532. IDSA: Pooled 24-week results of DUET-1 and -2: efficacy of TMC125 in treatment-experienced HIV-1-infected patients - (10/9/07)
     
  13533. IDSA: Influence of Baseline Factors on Virologic Response to Darunavir/Ritonavir (DRV/r) vs Lopinavir/r (LPV/r): Week 48 Outcome in TITAN - (10/9/07)
     
  13534. Roche/Trimeris gives up on device to inject HIV drug (10/05/07)
     
  13535. Trends in perimortal conditions and mortality rates among HIV-infected patients: HIV deaths decline 75%; Hepatitis deaths Up 4-Fold (10/05/07)
     
  13536. ICAAC: Antiretroviral Therapy at 47th ICAAC 2007 (Sept 2007): RTV-boosted PIs in treatment-naives; CCR5 antagonists; integrase inhibitors - written by Eric S. Daar, M.D. - (10/02/07)
     
  13537. ICAAC: In Vitro Antiviral Potency and Preclinical Pharmacokinetics of GSK364735 Predict Clinical Efficacy in a Phase 2a Study - (10/01/07)
     
  13538. ICAAC: GSK364735 is a Potent Inhibitor of HIV Integrase and Viral Replication - (10/01/07)
     
  13539. ICAAC: Resistance Mechanisms of the K70E HIV-1 Reverse Transcriptase Mutant to GS-9148 and Other NRTIs - (10/01/07)
     
  13540. ICAAC: Novel 2'-Fluoro Substituted Nucleotide HIV Reverse Transcriptase Inhibitor GS-9148 Exhibits Low Potential for Mitochondrial Toxicity In Vitro - (10/01/07)
     
  13541. ICAAC: Novel Nucleotide Inhibitor GS-9148 Selects for a K70E Mutation in HIV-1 Reverse Transcriptase and Low-Level Resistance In Vitro - (10/01/07)
     
  13542. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events (09/28/07)
     
  13543. 7 Pharma firms join forces to identify patients at risk of adverse events by developing genetic tests (09/28/07)
     
  13544. Diabetes Care Very Hard for Patients: Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments (09/28/07)
     
  13545. ICAAC: Interrupting antiretroviral therapy does not reduce CVD risk and activates the immune system - (09/28/07)
     
  13546. ICAAC: Efficacy and Safety of Protease Inhibitor Replacemet for Nevirapine In Patients with High CD4 Lymphocyte Cell Counts: A Systematic Review - (09/28/07)
     
  13547. ICAAC: Prediction of disease progression by HIV co-receptor tropism (CRT) in persons (P) with untreated chronic HIV infection - (09/27/07)
     
  13548. ICAAC: Co-receptor Tropism Predictions Based on V3 Loop Sequence in Antiretroviral-Experienced Patients are Specific but Insensitive for the Detection of CXCR4-using Variants - (09/27/07)
     
  13549. ICAAC: Enhancements to the Trofile™ HIV Co-receptor Tropism Assay Enable Improved Detection of CXCR4-using Subpopulations - (09/27/07)
     
  13550. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine (09/26/07)
     
  13551. Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate (09/26/07)
     
  13552. PFIZER'S CELSENTRI (Maraviroc) APPROVED IN THE EUROPEAN UNION, PROVIDING A NOVEL TREATMENT OPTION FOR TREATMENT-EXPERIENCED HIV PATIENTS (09/26/07)
     
  13553. Chronic kidney disease in HIV infection: an urban epidemic [RESEARCH LETTERS] (09/26/07)
     
  13554. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART [RESEARCH LETTERS] (09/26/07)
     
  13555. Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. [Correspondence] (09/26/07)
     
  13556. Prevalence of Colorectal (cancer) Neoplasm Among Patients With Newly Diagnosed Coronary Artery Disease, and the Metabolic Syndrome (09/26/07)
     
  13557. Safety of Statin Therapy in HIV/Hepatitis C Virus-Coinfected Patients [Letters to the Editor] (09/26/07)
     
  13558. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study [Rapid Communication] (09/26/07)
     
  13559. ICAAC: Abacavir-Containing HAART Reduces the Chances for Sustained Virological Response to Pegylated-Interferon pllus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C - (09/26/07)
     
  13560. ICAAC: Antiviral Effects and Tolerability of the CCR5 Monoclonal antibody PRO 140: A Proof of Concept Study in HIV-Infected Individuals - (09/25/07)
     
  13561. ICAAC: Cancer Rates Higher in HIV+, CD4s Lower - (09/25/07)
     
  13562. ICAAC: Lopinavir (LPV) Cerebrospinal Fluid (CSF) Trough Concentrations in HIV-infected Adults - (09/25/07)
     
  13563. ICAAC: Pharmacokinetics of TMC125 in HIV-negative volunteers with mild or moderate hepatic impairment - (09/25/07)
     
  13564. ICAAC: Raltegravir (RAL) Dose Proportionality and Effect of Food - (09/24/07)
     
  13565. ICAAC: Limb Fat Increased by 25% 3 Years After Switch to TDF from d4T - (09/24/07)
     
  13566. ICAAC: Development of resistance in patients with virologic failure (VF) on darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r): results of a randomized, controlled, Phase III trial in treatment-experienced patients (TITAN) - (09/20/07)
     
  13567. The HIV Integrase Inhibitor Elvitegravir (EVG/r) Has Potent and Durable Antiretroviral Activity in Treatment-Experienced Patients with Active Optimized Background Therapy (OBT) (09/20/07)
     
  13568. ICAAC: The HIV Integrase Inhibitor Elvitegravir (EVG/r) Has Potent and Durable Antiretroviral Activity in Treatment-Experienced Patients with Active Optimized Background Therapy (OBT) - (09/19/07)
     
  13569. ICAAC: Efficacy and Safety of Darunavir/ritonavir versus Lopinavir/ritonavir in ARV Treatment-Naive HIV-1-Infected Patients at Week 48: ARTEMIS (TMC114-C211) - (09/19/07)
     
  13570. ICAAC: Efficacy and Safety of Maraviroc in Antiretroviral-Experienced Patients Infected With CCR5-Tropic HIV-1: 48-Week Results of MOTIVATE 1 - (09/19/07)
     
  13571. ICAAC: Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials - (09/19/07)
     
  13572. ICAAC: Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) versus placebo in treatment-experienced HIV-1-infected patients - (09/19/07)
     
  13573. ICAAC: 48 Week Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-Class Resistant Virus, Phase II Protocol 005 - (09/19/07)
     
  13574. ICAAC: Studies Highlight Superior Performance of Trofile(TM) Assay - (09/19/07)
     
  13575. ICAAC: Two-Year Follow-up of Treatment-Experienced Patients on Vicriviroc (VCV) - (09/19/07)
     
  13576. ICAAC: New HIV Drugs, Final Oral Slide Session at ICAAC 2007 - (09/19/07)
     
  13577. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir [Research Letters] (09/18/07)
     
  13578. Urolithiasis (kidney stones) in HIV-Positive Patients Treated with Atazanavir (09/18/07)
     
  13579. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients (09/18/07)
     
  13580. Eltrombopag Phase III study to Initiate and Maintain Interferon Antiviral Treatment to Subjects With Hepatitis C Related Liver Disease (09/18/07)
     
  13581. ICAAC: Fosamprenavir or Atazanavir Boosted with Ritonavir Given Once Daily with Tenofovir /Emtricitabine in Antiretroviral Naive HIV-Infected Patients: ALERT Study Virology Analysis Through 48 Weeks - (09/17/07)
     
  13582. ICAAC: Clinical Presentation of Hypersensitivity Reaction to Abacavir (ABC HSR) by HLA-B*5701 Status - (09/17/07)
     
  13583. ICAAC: Long-term Efficacy and Safety of Fosamprenavir + Ritonavir (FPV/r) Versus Lopinavir/Ritonavir (LPV/r) over 96 Weeks - (09/17/07)
     
  13584. Defining HIV Susceptibility to New Antiretroviral Agents-Darunavir EDITORIAL (09/14/07)
     
  13585. DHHS Perinatal and Pediatric Nelfinavir Notice and Recommendations (09/13/07)
     
  13586. Trends of prevalence of primary HIV drug resistance (9%) in Germany (09/13/07)
     
  13587. Can the Risk of Cardiovascular Disease in HIV-Infected Patients Be Estimated from Conventional Risk Prediction Tools? (09/13/07)
     
  13588. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus (09/12/07)
     
  13589. Cardiovascular Risk and the Thiazolidinediones EDITORIAL (09/12/07)
     
  13590. Viracept Warning-Dear Dr Letter (09/11/07)
     
  13591. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States (09/11/07)
     
  13592. 3-Fold Increase in Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005 (09/11/07)
     
  13593. Can Vitamin D Reduce Total Mortality? EDITORIAL (09/11/07)
     
  13594. Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment (09/11/07)
     
  13595. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients (09/11/07)
     
  13596. Mediterranean Diet Improves LDL-Cholesterol (09/11/07)
     
  13597. Acute Loss of Intestinal CD4+ T Cells Is Not Predictive of Simian Immunodeficiency Virus Virulence (09/10/07)
     
  13598. SIV infection of natural hosts provides new insights into HIV disease complexity (09/10/07)
     
  13599. Virally Induced CD4+ T Cell Depletion Is Not Sufficient to Induce AIDS in a Natural Host (09/10/07)
     
  13600. Merck Updated Data on Malignancies-Raltegravir (09/10/07)
     
  13601. Sidelining Safety - The FDA's Inadequate Response to the IOM PERSPECTIVE (09/07/07)
     
  13602. IAS: Relationships between markers of immunodeficiency and non AIDS related causes of death in cART era, CASCADE Study Group (09/07/06)
     
  13603. Raltegravir Approval Expected in October Merck & Co's AIDS drug Isentress is backed by FDA panel (09/06/07)
     
  13604. Building an HIV-Proof Immune System: New HIV Gene Therapy Trials (09/06/07)
     
  13605. Raltegravir (MK-0518) FDA Hearing Sept 5 2007 (09/05/07)
     
  13606. Pregnancy Does Not Accelerate HIV In Women Good News for Women Living with HIV (09/04/07)
     
  13607. HIV drug Protease Inhibitors tackles cancer cells Tumour growth blocked by anti-HIV agent (09/04/07)
     
  13608. Crestor/fenofibrate combination moves into Phase III trials (09/04/07)
     
  13609. Fatty Liver Common in HIV (42%), study finds (09/04/07)
     
  13610. Who is Henry Wellcome; The Wellcome Trust (09/04/07)
     
  13611. GSK (The Wellcome Trust) Renews Donation to Africa, 15 million pounds (09/04/07)
     
  13612. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy (09/04/07)
     
  13613. Raltegravir PK, safety, efficacy, tolerability, interactions, special populations, phase III, mechanism of action, resistance, food effect- From Merck Briefing Document (09/04/07)
     
  13614. Raltegravir FDA Safety Report (08/31/07)
     
  13615. Raltegravir FDA Clinical Development Summary (08/31/07)
     
  13616. Merck AIDS Pill Isentress Effective, FDA Staff Says (08/31/07)
     
  13617. Benefits of Merck HIV Drug Outweigh Risks, FDA Says (08/31/07)
     
  13618. Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE network (08/31/07)
     
  13619. HIV-discordant couples and parenthood: how are we dealing with the risk of transmission? [Correspondence] (08/31/07)
     
  13620. ART drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis (08/31/07)
     
  13621. HSV-2 Coinfection Seems to Slow Early CD4 Drop With HIV (08/30/07)
     
  13622. Whole Grains Reduced Diabetes Risk by 21% to 37% (08/30/07)
     
  13623. The prevalence and incidence of neurocognitive impairment in the HAART era (08/30/07)
     
  13624. Risk of cancers during interrupted antiretroviral therapy in the SMART study (08/30/07)
     
  13625. HAD and the need for new trial design methodology (08/30/07)
     
  13626. Role of Peginterferon In HIV Salvage Therapy (08/30/07)
     
  13627. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score (08/30/07)
     
  13628. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials) (08/30/07)
     
  13629. Transmission Wksp: TFV/FTC and TFV/3TC Formulated into Vaginal and Rectal Gels - Written by Mark Mascolini - (08/29/07)
     
  13630. Transmission Wksp: Two Doses of Tenofovir/FTC Protect Monkeys From Rectal Simian HIV - Written by Mark Mascolini - (08/28/07)
     
  13631. Transmission Wksp: Rapid HIV Test Misses Infections Spotted Later by Older Methods - Written by Mark Mascolini - (08/28/07)
     
  13632. Transmission Wksp: Superinfection Leads to Recombination and Boosts Viral Load - Written by Mark Mascolini - (08/28/07)
     
  13633. Transmission Wksp: Seminal HIV Load Linked to Higher Transmission Risk in MSM - Written by Mark Mascolini - (08/28/07)
     
  13634. Crystal Meth Use High (6%) Among Gay Men in the North Carolina: hi rates of HIV, anal sex without condom use, STDs, sex with females, Viagra use (08/28/07)
     
  13635. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis - (08/27/07)
     
  13636. Calcium and vitamin D for osteoporotic fracture risk COMMENT - (08/27/07)
     
  13637. Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers - (08/27/07)
     
  13638. Alcohol & HIV Progression - (08/24/07)
     
  13639. New European Hypertension Guidelines 2007 - (08/23/07)
     
  13640. A Study of Sexuality and Health among Older Adults in the United States - (08/23/07)
     
  13641. Resis Wksp: Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic HIV-1 in MOTIVATE 1 and MOTIVATE 2s (08/23/07)
     
  13642. Proteinuria and Endothelial Dysfunction in Stable HIV-Infected Patients: A Pilot Study - (08/22/07)
     
  13643. Conspiracy Beliefs and Trust in Information About HIV/AIDS Among Minority Men Who Have Sex With Men: 54% of Black MSMs vs 27% of White MSMs believe HIV doesn't cause AIDS - (08/22/07)
     
  13644. Transient Viremia, Plasma Viral Load, and Reservoir Replenishment in HIV-Infected Patients on Antiretroviral Therapy: viral blips are bad & preventable - (08/22/07)
     
  13645. Prevalence of Hepatitis B and C Virus Infections in Children Infected with HIV in USA & Developing World - (08/22/07)
     
  13646. Male Circumcision for Prevention of HIV Transmission: What the New Data Mean for HIV Prevention in the United States - (08/21/07)
     
  13647. HIV Denial in the Internet Era - (08/21/07)
     
  13648. Monogram Biosciences Introduces New Co-Receptor Tropism Assay, Trofile, Availability - (08/21/07)
     
  13649. High-Density Lipoprotein (HDL) Cholesterol as a Therapeutic Target: not such a great target for aggressive drug intervention - (08/21/07)
     
  13650. IAS: SMART Yields More Reasons To Shun Drug Breaks Written by Mark Mascollni (08/21/06)
     
  13651. High-Density Lipoprotein (HDL) Cholesterol as a Therapeutic Target: not such a great target for aggressive drug intervention - (08/21/07)
     
  13652. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir - (08/21/07)
     
  13653. Continuous evidence of fast HIV disease progression related to class-wide resistance to antiretroviral drugs: a 6 year follow-up analysis of a large observational database - (08/21/07)
     
  13654. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Dyslipidemia & Body Changes in Vertically Infected Children & Youth on PI ART: preliminary results of PACTG 1045 - (08/21/07)
     
  13655. Testing for Chronic Kidney Disease: A Position Statement From the National Kidney Foundation - (08/20/07)
     
  13656. Risk factors (AZT) for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin - (08/17/07)
     
  13657. Prevalence and Long-Term Effects of Occult Hepatitis B Virus Infection in HIV-Infected Women - (08/17/07)
     
  13658. How Safe Is Unprotected Sex Between Discordant Couples to Conceive in the Highly Active Antiretroviral Therapy Era? [Letters to the Editor] - (08/17/07)
     
  13659. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Report from the 9th Intenational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Sydney, Australia. July 19-21, 2007 - Written by Mike Dube - (08/16/07)
     
  13660. IAS: Baseline CD4 Cell Count and Immune Reconstitution During Combination Antiretroviral Therapy in ACTG 384 (08/16/06)
     
  13661. Study unpicks how AIDS causes dementia - (08/16/07)
     
  13662. Aids virus is a 'double hit' to the brain - (08/16/07)
     
  13663. Metabolic correlates of nonalcoholic fatty liver in women and men: insulin resistance, body changes cause liver fat - (08/16/07)
     
  13664. Labeling Change for Viramune (nevirapine) tablets/oral solution including Change to Pregnancy Category B - (08/16/07)
     
  13665. IAS: Report from the 9th Intenational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Sydney, Australia. July 19-21, 2007 - written by Mike Dube - (08/15/06)
     
  13666. Treatment for lipoatrophy: facing the real costs; should be reimbursed EDITORIAL COMMENT - (08/15/07)
     
  13667. HIV, ARTs, Aging & Body Changes - (08/15/07)
     
  13668. ART exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study: NRTI but not PI nor NNRTI associated with diabetes - (08/15/07)
     
  13669. Pio and Rosi-'Glitazone' diabetes drugs get stronger 'black box' warning from FDA - (08/15/07)
     
  13670. Pneumocystis jiroveci pneumonia (PCP) prophylaxis is not required with a CD4+ T-cell count < 200 cells/μl when viral replication is suppressed - (08/14/07)
     
  13671. A new approach for 'deep salvage' trials in advanced HIV infection [OPINION] - (08/14/07)
     
  13672. Stopping antiretroviral therapy [OPINION] - (08/14/07)
     
  13673. Improved survival in HIV-infected persons: consequences and perspectives - (08/14/07)
     
  13674. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count and high viral load: >650 CD4s and viral load <10,000 better - (08/14/07)
     
  13675. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Lack of metabolic abnormalities and mitochondrial toxicity with enfuvirtide (T-20): a double-blind, placebo-controlled, crossover study with random sequence assignation in healthy adult volunteers - (08/14/07)
     
  13676. IAS: Major clinical outcomes in patients not treated with antiretroviral therapy (ART) at baseline in SMART; A rationale for a trial to examine early treatment of HIV disease - (08/10/06)
     
  13677. IAS: Initiation of Antiretroviral Therapy at CD4+ Cell Counts ≥350 cells/mm3 Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal Insufficiency in the HIV Outpatient (HOPS) Cohort - (08/10/06)
     
  13678. IAS: A CD4 threshold below 350 cells/mm3 for initiation of HAART is associated with a higher risk of AIDS, ATHENA Cohort - (08/10/06)
     
  13679. IAS: Hepatitis C Viral Kinetics During Treatment With Weekly Versus Twice Weekly Peg IFN-alpha-2a in HIV/HCV Co-infected Patients - (08/10/06)
     
  13680. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals? - (08/13/07)
     
  13681. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Lack of Association between Antiretroviral Therapy and Predictors of Endothelial Function and Cardiovascular Disease (CVD) Risk Among HIV-Infected Persons on Long-Term HAART pioglitazone increased limb fat, exercise reduced limb fat - (08/13/07)
     
  13682. IAS: Once-Daily Abacavir/Lamivudine (ABC/3TC) and Boosted Atazanavir (ATV/r): 48-Week Analysis from COL102060 (SHARE) - (08/10/06)
     
  13683. IAS: An Open-Label, Two-Period, Crossover, PK Study of Abacavir (ABC) and Its Intracellular Anabolite Carbovir Triphosphate (CBV-TP) Following 600mg Once-Daily and 300mg Twice-Daily Administration of Abacavir in HIV-Infected Subjects - (08/10/06)
     
  13684. IAS: New Data on Gains From Starting Antiretrovirals Earlier - Written by Mark Mascolini - (08/10/06)
     
  13685. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Pioglitazone ± exercise training reduces liver lipid content and improves insulin sensitivity in HIV with impaired glucose tolerance; pioglitazone increased limb fat, exercise reduced limb fat - (08/09/07)
     
  13686. IAS: Tipranavir/ritonavir (500/200 mg BID) demonstrated potent and durable virologic responses, and a favourable safety profile, in HIV-1 positive women participating in RESIST - (08/09/06)
     
  13687. IAS: A Randomized Comparative Trial of First-line Antiretroviral Therapy with Regimens Containing Either Nevirapine, or Efavirenz, Together with Stavudine and Lamivudine. Three-Year Extended Follow-Up of the 2NN Study. - (08/09/06)
     
  13688. IAS: EZETIMIBE COMBINED WITH LOW DOSE STATIN EFFECTIVELY LOWERS LDL IN PROTEASE INHIBITOR TREATED PATIENTS; Kaletra PK - (08/09/06)
     
  13689. IAS: Less than 95% adherence to ritonavir-boosted protease inhibitors leads to viral suppression: an update to address currently prescribed antiretroviral regimens - (08/09/06)
     
  13690. The neuroprotective effects of caffeine - (08/10/07)
     
  13691. FDA approves AZT+3TC Combo Generic - (08/10/07)
     
  13692. IAS: Sydney AIDS Conference: Scientific Advances Undercut by Rights Abuses - (08/08/06)
     
  13693. IAS: Global AIDS conference kicks off in Australia: Stop talking about cure for AIDS says Fauci - (08/08/06)
     
  13694. IAS: HIV/AIDS conference opens in Sydney - (08/08/06)
     
  13695. IAS: HIV-Drug Tenofovir Tested on Virus-Free People for Prevention PreP - (08/08/06)
     
  13696. IAS: Aussie mum tells of life with HIV at Sydney Conference Opening Session - (08/08/06)
     
  13697. IAS: International Experts and Women Living With HIV Discuss Urgent Needs of HIV-Positive Women at International AIDS Society (IAS) Congress - (08/08/06)
     
  13698. IAS: Aussie Govt promises $400m to fight HIV - (08/08/06)
     
  13699. IAS: Efficacy and safety of switching from boosted Lopinavir (LPV/r) to boosted Atazanavir (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: The ATAZIP study - (08/08/06)
     
  13700. IAS: HIV Viral Tropism in Vicriviroc VICTOR-E1 Trial: Correlations With Clinical Variables - (08/08/06)
     
  13701. IAS: Safety of Vicriviroc in ARt-Experienced Subjects: 12-Week VICTOR-E1 Results With Updated 24-Week Data - (08/08/06)
     
  13702. IAS: Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with impaired hepatic function - (08/08/06)
     
  13703. IAS: Effect of baseline and on-treatment mutations on the antiretroviral activity of darunavir/ritonavir and lopinavir/ritonavir: results of a randomised, controlled, Phase III study (TITAN) - (08/08/06)
     
  13704. Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis. Coffee, 2 Cups Daily, May Reduce Risk for Liver Disease, ALT Elevations - (08/08/07)
     
  13705. More Comments-Pfizer's AIDS Drug Maraviroc Wins U.S. Approval - (08/08/07)
     
  13706. PFIZER'S SELZENTRYTM (MARAVIROC) TABLETS, NOVEL TREATMENT FOR HIV, APPROVED BY FDA - (08/06/07)
     
  13707. Despite advances, HIV care still a challenge (UAB) - (08/06/07)
     
  13708. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Effects of tipranavir/r in comparison with lopinavir/r on changes in body composition and metabolic parameters in ARV-naive patients over 48 weeks - (08/06/07)
     
  13709. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Effects of alternate treatment protocols (discontinuation vs viral suppression) on the incidence of electrocardiographic abnormalities among HIV-infected adults in the SMART trial - (08/06/07)
     
  13710. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Racial Differences in Long-Term Changes in Metabolic and Body Composition Parameters in Antiretroviral Naive Persons Initiating HAART: Results of the CPCRA 061 Metabolic Study - (08/06/07)
     
  13711. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Zidovudine/lamivudine persistently contributes to peripheral insulin resistance by a body composition-independent mechanism demonstrated by repeated clamp studies during 2 years of first line ART with zidovudine/lamivudine/lopinavir/r - (08/06/07)
     
  13712. IAS: Single-agent Therapy with Lopinavir/ritonavir Suppresses Plasma HIV-1 Viral Replication in HIV-1 Naive Subjects: IMANI-2 48-Week Results - (08/03/06)
     
  13713. IAS: LPV/r-based 2-drug HAART vs LPV/r-based 3-drug HAART: Comparable virological efficacy and tolerability in HIV-1-infected naive subjects (Kalead1 study) - 48-Week results - (08/03/06)
     
  13714. IAS: Lower prevalence of small, dense low-density lipoprotein (sd-LDL) in hypertriglyceridemic HIV-infected patients than in non-HIV-infected subjects - (08/03/06)
     
  13715. Medical Marijuana Risks Kaposi's Sarcoma - (08/03/07)
     
  13716. Cannabis Increased Risk for Psychosis Later in Life - (08/03/07)
     
  13717. Kaletra Tablet Pediatric Formula Filing in Thailand - (08/03/07)
     
  13718. Abbott's New Aluvia (lopinavir/ritonavir) Tablet Approved in Nineteen African Countries - (08/03/07)
     
  13719. Specialists debunk statin link to cancer - (08/03/07)
     
  13720. NYC Offers AIDS Education to Elderly - (08/03/07)
     
  13721. Tibotec Submits Marketing Authorisation Application for Investigational HIV Treatment TMC125 in Europe - (08/03/07)
     
  13722. Rosi/Pioglitazone: new study published in Diabetes Care reports risk for heart attack, see text from published article below - (08/03/07)
     
  13723. A Genetic Knack for Tackling HIV - (08/03/07)
     
  13724. IAS: Treatment Breaks Boosted Bacterial Pneumonia Risk in SMART Trial - Written by Mark Mascolini - - (08/02/06)
     
  13725. IAS: Starting ART at Higher CD4 Count Lowers Nucleoside Toxicity Risk - Written by Mark Mascolini - - (08/02/06)
     
  13726. IAS: Evidence of international transmission of HCV in pan-European study of HIV-positive men who have sex with men (MSM) - (08/02/06)
     
  13727. IAS: Clash over drug access at Australia AIDS/HIV conference - (08/02/06)
     
  13728. IAS: A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naive HIV/HBV coinfected patients in Thailand: 48 week findings - (08/02/06)
     
  13729. IAS: HCV/HBV Coinfected at Greater Risk in SMART - (08/01/06)
     
  13730. IAS: Higher rate of HAART reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study - (08/01/06)
     
  13731. IAS: New Data Suggest Boosted Invirase Has Similar Efficacy to Boosted Lopinavir in HIV Patients at 24 Weeks, Press Release from Roche - Written by Mark Mascolini - (08/01/06)
     
  13732. IAS: Saquinavir/r bid vs Kaletra bid Efficacy Analysis 24 Weeks Gemini Study - (08/01/06)
     
  13733. IAS: Saquinavir/r bid vs Kaletra bid GEMINI Study, 24 weeks Interim Lipids Analysis - (08/01/06)
     
  13734. IAS: Twice-Daily Maraviroc Compared to Efavirenz in Treatment Naive - (08/01/06)
     
  13735. IAS: Determination of Body Composition Changes by Total Body Dual-Energy X-ray Absorptiometry after 48 Weeks of Treatment with Once-Daily Fosamprenavir (FPV) Boosted with Two Different Doses of Ritonavir(r) plus Abacavir(ABC)/ Lamivudine(3TC): COL100758 - (08/01/06)
     
  13736. IAS: Randomized Trials Results Back Gene Screening for Abacavir Reaction: PREDICT 1 and SHAPE - Written by Mark Mascolini - (07/31/06)
     
  13737. IAS: RESPONSE TO DARUNAVIR/RITONAVIR (DRV/R) COMBINED WITH ENFUVIRTIDE (ENF)-CONTAINING ARV IN TRIPLE-CLASS EXPERIENCED PATIENTS WAS NOT PREDICTED BY BASELINE DARUNAVIR (DRV) SENSITIVITY OR VIRAL TROPISM (VT): THE BLQ STUDY PRELIMINARY RESULTS - (07/31/06)
     
  13738. IAS: Six Year Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naive Patients - (07/31/06)
     
  13739. IAS: Fuzeon Improved Maraviroc Response in MOTIVATE and Genotypic Sensitivity Score Matters - (07/31/06)
     
  13740. IAS: Efficacy and Safety of Once-Daily (QD) Compared with Twice-Daily (BID) Maraviroc plus Optimized Background Therapy (OBT) in treatment-experienced Patients Infected with CCR5-tropic HIV-1: 24-week Combined Analysis of the MOTIVATE 1 & 2 Studies - (07/31/06)
     
  13741. IAS: Fosamprenavir/r QD v Reyataz/r ALERT Study 48 Weeks - (07/31/06)
     
  13742. IAS: Three-year Safety and Efficacy of Emtricitabine (FTC)/Tenofovir DF (TDF) and Efavirenz (EFV) Compared to Fixed Dose Zidovudine/Lamivudine (AZT/3TC) and EFV in Antiretroviral Treatment-Naive Patients - (07/31/06)
     
  13743. IAS: Randomized Trials Results Back Gene Screening for Abacavir Reaction: PREDICT 1 and SHAPE Studies - Written by Mark Mascolini - (07/30/06)
     
  13744. IAS: ABC107442 (SHAPE) Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation - (07/30/06)
     
  13745. IAS: Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada) vs. abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study - (07/30/06)
     
  13746. IAS: Phase II Study of the Safety and Efficacy of New CCR5 Drug Vicriviroc (VCV) in HIV+ Treatment-Experienced Subjects: 48-week Results - ACTG 5211 - (07/30/06)
     
  13747. IAS: Changes in Lipid Parameters During Treatment with Lopinavir/ritonavir (LPV/r) Plus Zidovudine/lamivudine (ZDV/3TC) Induction Followed by Maintenance on LPV/r Monotherapy Compared to Efavirenz (EFV) + ZDV/3TC Through 96 Weeks - (07/30/06)
     
  13748. IAS: No Change in Glucose Tolerance with Lopinavir/ritonavir (LPV/r)+ ZDV/3TC Induction Followed by LPV/r Monotherapy Through 96 Weeks - (07/30/06)
     
  13749. IAS: Treatment Simplification to an Atazanavir-Containing Regimen: Impact on Patients' Perception of Symptom Severity - (07/30/06)
     
  13750. IAS: Six Factors Predict Kidney Problems in French HIV Cohort - Written by Mark Mascolini - (07/27/06)
     
  13751. IAS: Giving Efavirenz With Rifampin Does Not Hurt 3-Year HIV/TB Outcome - Written by Mark Mascolini - (07/27/06)
     
  13752. IAS: Bristol-Myers Squibb's "SECURE THE FUTURE" Program Offers New Approach To Replicate Successful HIV Treatment Support Model - (07/27/06)
     
  13753. IAS: Push for early HAART treatment - (07/27/06)
     
  13754. IAS: Medical "brain drain" hindering AIDS battle; Lack of Medical Infrastructure in Developing Countries - (07/27/06)
     
  13755. IAS: HIV no longer a death sentence, Sydney conference told - (07/27/06)
     
  13756. IAS: Atazanavir modestly increases plasma levels of MK-0518 - (07/27/06)
     
  13757. IAS: Once-Daily CCR5 Antagonist Has Highly Sustained Effect - Written by Mark Mascolini - (07/27/06)
     
  13758. IAS: Likely Resistance to Etravirine Possibly Under 2% in French Cohort - Written by Mark Mascolini - (07/27/06)
     
  13759. IAS: Integrase Inhibitor Troughs One Third Lower With NNRTI Etravirine - Written by Mark Mascolini - (07/27/06)
     
  13760. IAS: Hints on Integrase Inhibitor Cross-Resistance From Two Case Studies - Written by Mark Mascolini - (07/27/06)
     
  13761. IAS: RNA Response, Coreceptor Swaps, and Cancers After 48 Weeks of Vicriviroc - Written by Mark Mascolini - (07/27/06)
     
  13762. IAS: Better Lipid Scores With TMC278 Than With Efavirenz - Written by Mark Mascolini - (07/27/06)
     
  13763. IAS: Once-Daily CCR5 Antagonist Has Highly Sustained Effect - Written by Mark Mascolini - (07/27/06)
     
  13764. IAS: Smoking Raises Death Risk--and Lung Disease Common--With HIV - Written by Mark Mascolini - (07/27/06)
     
  13765. IAS: Integrase Inhibitor Matches Efavirenz for 48 Weeks in Treatment-Naive - Written by Mark Mascolini - (07/27/06)
     
  13766. IAS: Raltegravir 48-week Naives potent; No Lipids Elevations - (07/27/06)
     
  13767. IAS: The metabolic profile of TMC278, an investigational NNRTI - (07/27/06)
     
  13768. IAS: Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV-infected patients - (07/27/06)
     
  13769. IAS: Integrase Inhibitor Matches Efavirenz for 48 Weeks in Treatment-Naive - Written By Mark Mascolini - (07/26/06)
     
  13770. IAS: Brain disorders likely in HIV patients in Developing Asian Countries - (07/26/06)
     
  13771. IAS: Microbicide Viva Gel could stop HIV and herpes - (07/26/06)
     
  13772. IAS: New Incyte CCR5 Drug Shows Good Activity: 14 day monotherapy study - (07/26/06)
     
  13773. IAS: Efficacy and Safety of Atazanavir-Based Therapy in Antiretroviral-Naive HIV-1-Infected Subjects, Both With and Without Ritonavir: 96-Week Results From AI424-089 - (07/26/06)
     
  13774. IAS: Darunavir and Lopinavir Resistance Differences in TITAN - Written By Mark Mascolini - (07/26/06)
     
  13775. IAS: Comparison of 48-week efficacy and safety of darunavir/ritonavir (DRV/r) with lopinavir/ritonavir (LPV/r) in LPV/r-naive, treatment-experienced, patients: a randomised, controlled Phase III trial (TITAN) - (07/26/06)
     
  13776. IAS: A Multicenter, Randomized, Double-Blind, Comparative Trial of a Novel CCR5 Antagonist, Maraviroc Versus Efavirenz, both in Combination with Combivir (Zidovudine/Lamivudine), for the Treatment of Antiretroviral-Naive Subjects Infected with R5 HIV 1: Week 48 Results of the MERIT Study - (07/26/06)
     
  13777. IAS: Randomized Trial Results Back Gene Screening for Abacavir Reaction - Written By Mark Mascolini - (07/26/06)
     
  13778. IAS: MARAVIROC REDUCES HIV VIRAL LOAD IN TREATMENT-NAIVE PATIENTS, 48 WEEK DATA SHOW: Pfizer Press Release - (07/26/06)
     
  13779. IAS: DUET-1 and DUET-2: TMC125 versus placebo in treatment-experienced HIV-1-infected patients - (07/26/06)
     
  13780. IAS: Immediate Antiretrovirals Cut Death Risk by 76% in Infected Infants in South Africa Study - Written By Mark Mascolini - (07/26/06)
     
  13781. IAS: Slight Advantage Possible With Switch to Truvada vs Kivexa - Written By Mark Mascolini - (07/26/06)
     
  13782. IAS: Two Trials Find Lower Atherosclerosis Risk With Antiretrovirals - Written By Mark Mascolini - (07/26/06)
     
  13783. IAS: Post-sex washing 'doesn't lower HIV' - (07/26/06)
     
  13784. A Genetic Knack for Tackling HIV - (07/20/07)
     
  13785. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Effects of 4 weeks of atazanavir, lopinavir/ritonavir, or placebo on endothelial function and insulin sensitivity in healthy men - (07/20/07)
     
  13786. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Relationship of body composition, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects: lipoatrophy associated with endothelial dysfunction - (07/20/07)
     
  13787. IAS: 'HIV eradication now possible' - (07/20/06)
     
  13788. IAS: Significant rise in HIV in Australia: study - (07/20/06)
     
  13789. PFIZER RECEIVES APPROVABLE LETTER FROM FDA FOR MARAVIROC - (07/20/07)
     
  13790. Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra and Aluvia (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS - (07/20/07)
     
  13791. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Lack of evidence of Metabolic Abnormalities and Mitochondrial Toxicity with Enfuvertide: a double-blind, placebo-controlled, cross-over study with random sequence assignation in healthy adult volunteers - (07/20/07)
     
  13792. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: HIV, ART & Endothelial Dysfunction - (07/20/07)
     
  13793. Diaphragm and lubricant gel + Condom for prevention of HIV acquisition in southern African women: a randomised controlled trial - (07/19/07)
     
  13794. New Trial to Study Investigational Integrase Inhibitor in Combination with FUZEON(R) Once-Daily Dosing Strategy for Triple HIV Drug Class Experienced - (07/19/07)
     
  13795. New Drug Application for Investigational HIV Treatment TMC125 Submitted to U.S. Food and Drug Administration - (07/19/07)
     
  13796. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression (<50 copies/ml) who are taking combination antiretroviral therapy: an observational cohort study - (07/19/07)
     
  13797. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Nevirapine Increases High Density Lipoprotein-Cholesterol (HDL-C) by Stimulation of Apolipoprotein AI Synthesis - (07/19/07)
     
  13798. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: Nevirapine Hypersensitivity is Different for Treatment-Experienced - (07/19/07)
     
  13799. 9th Intl Wrkshp on Adverse Drug Reactions and Lipo: TH9507, Growth Hormone Releasing Factor - (07/19/07)
     
  13800. IAS: One in 350 patients is HIV-positive and they don't even know it in Singapore - (07/19/06)
     
  13801. IAS: Journalists flood Australia for AIDS conference - (07/19/06)
     
  13802. IAS: Report Card on Global AIDS Treatment Access Disappointments; MISSING THE TARGET #4: - (07/19/06)
     
  13803. IAS: New Report Critical of Global HIV Treatment Access: Zackie Achmat and Other Global AIDS Activist Leaders Release New Report on AIDS Treatment Scale Up - (07/19/06)
     
  13804. IAS: World struggling to treat HIV-AIDS - report - (07/19/06)
     
  13805. U.S. NIH Funded Trial of VivaGel in Sexually Active Young Women Commences - (07/17/07)
     
  13806. FDA Approves Generic Efavirenz - (07/16/07)
     
  13807. HIV Type 1 Superinfection with a Dual-Tropic Virus and Rapid Progression to AIDS: A Case Report - (07/16/07)
     
  13808. The Effect of Low-Dose Ritonavir Monotherapy on Fasting Serum Lipid Concentrations - (07/16/07)
     
  13809. HIV and CVD: Protease Inhibitors Block Cholesterol Transport, but Antioxidants May Help - (07/16/07)
     
  13810. HIV and Metabolic Syndrome: A Comparison With the General Population in Italy. Metabolic Syndrome Higher in HIV+ ART Untreated & Treated Compared to HIV-negatives - (07/13/07)
     
  13811. HIV+ With Nonalcoholic Fatty Liver Disease Have a Lower Body Mass Index and Are More Physically Active Than HIV-Negative Patients - (07/13/07)
     
  13812. Unprotected Sex Among Discordant Heterosexual Couples: 1/1000 to 1/10,000 Infection Per Sex Act - (07/13/07)
     
  13813. High Rates of Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors in Paris, France - (07/13/07)
     
  13814. Rapid and early virological response to chronic hepatitis C treatment with IFN a2b (PegIntron) or PEG-IFN 2b plus ribavirin in HIV/HCV co-infected patients - (07/12/07)
     
  13815. Socioeconomic, Racial/Ethnic, and Geographic Characteristics: A Systematic Review and Meta-Regression Analysis - (07/12/07)
     
  13816. The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-Analysis - (07/12/07)
     
  13817. Long-Term Hormone Replacement Therapy Increased Heart Disease - (07/12/07)
     
  13818. Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens: 80-Week Data From a Phase 2 Study - (07/11/07)
     
  13819. Can Earlier HAART Reduce Non-AIDS Events ? NIH/DAIDS Proposes "When To Begin HAART" Study - (07/11/07)
     
  13820. Resis Wksp: Sensitive Testing Demonstrates a High Prevalence of Transmitted Drug Resistance among Conventionally Genotyped Wildtype HIV-1 Infections (07/09/07)
     
  13821. Resis Wksp: Inferring Virological Response from Genotype: With or without predicted phenotypes? (07/09/07)
     
  13822. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial - (07/06/07)
     
  13823. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial - (07/06/07)
     
  13824. TITAN & DUET Studies COMMENTARY - (07/06/07)
     
  13825. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial - (07/06/07)
     
  13826. Cancer Risk in HIV+ - (07/06/07)
     
  13827. HCV/HIV Coinfection in Asia - (07/05/07)
     
  13828. Resis Wksp: Intermittent Antiretroviral Prophylaxis with Tenofovir and Emtricitabine (FTC) Protects Macaques Against Repeated Rectal SHIV Exposures (07/05/07)
     
  13829. Resis Wksp: Integrase/CCR5/TMC125 Resistance, New Drugs, GAG, Ultra-Deep Sequencing for Low-Level ART Drug Resistance, Abbreviated TDF/FTC PreP Therapy Effective in Monkeys. Barbados - Report by David Margolis, MD (07/05/07)
     
  13830. Cystatin C Good Predictor of Mortality & CVD in Advanced Kidney Disease - (07/05/07)
     
  13831. Transmitted HIV-1 Drug Resistance: Are We Seeing Just the Tip of an Epidemiological Iceberg?.... it behooves investigators to design and support randomized clinical trials to validate the utility of highly sensitive resistance testing. EDITORIAL - (07/05/07)
     
  13832. Long-Term Persistence of Transmitted HIV Drug Resistance in Male Genital Tract Secretions: Implications for Secondary Transmission - (07/05/07)
     
  13833. HCV Replication Found in CNS in HIV+ - (07/03/07)
     
  13834. Lipitor to Reduce LDL in CVD - (07/03/07)
     
  13835. HIV Cure? HIV-1 Proviral DNA Excision Using an Evolved Recombinase - (07/02/07)
     
  13836. "He Won't Use Condoms": HIV-Infected Women's Struggles in Primary Relationships With Serodiscordant Partners - (07/02/07)
     
  13837. Resis Wksp: Biochemical Characterizations and drug sensitivity of the Effect of Mutations Selected in HIV-1 Integrase Gene Associated with Failure to Raltegravir (MK-0518) (07/02/07)
     
  13838. Resis Wksp: Prior Emergence of K103N after Single Dose Nevirapine Predicts Detection of K103N after Exposure to Single Dose Nevirapine in a Subsequent Pregnancy (07/02/07)
     
  13839. FDA Priority Review Granted for ISENTRESS (raltegravir), Merck's Investigational Integrase Inhibitor for HIV - (06/28/07)
     
  13840. rHGH Reduced Belly Fat; Safety Concerns: glucose, limb fat - (06/28/07)
     
  13841. Resis Wksp: Highly Potent Protease Inhibitors with Novel Escape Pathways (06/27/07)
     
  13842. Resis Wksp: Genotypic relationships between tipranavir and darunavir resistance in protease inhibitor experienced patients (06/26/07)
     
  13843. Echocardiogram May predict Heart Disease & Visceral Fat in HIV: Epicardial fat suggests subclinical atherosclerosis in HIV patients - (06/25/07)
     
  13844. Resis Wksp: Resistance and Cross-Resistance to First Generation Integrase Inhibitors: Insights from a Phase 2 Study of Elvitegravir (GS-9137) (06/25/07)
     
  13845. Resis Wksp: Roche NNRTI Potent Against TMC125 & TMC278 Resistance In Vitro (06/25/07)
     
  13846. Resis Wksp: New Roche CCR5 Potent Against Maraviroc Resistance In Vitro (06/25/07)
     
  13847. Resis Wksp: Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2 (06/25/07)
     
  13848. Resis Wksp: A Structural Basis for Resistance to PL-100, a New (unboosted) Protease Inhibitor for PI Resistance (06/25/07)
     
  13849. Resis Wksp: Resistance to the HIV-Integrase Inhibitor Raltegravir: Analysis of Protocol 005, a Phase 2 Study in Patients with Triple-Class Resistant HIV-1 Infection (06/22/07)
     
  13850. Resis Wksp: Resistance to the HIV-Integrase Inhibitor Raltegravir: Analysis of Protocol 005, a Phase 2 Study in Patients with Triple-Class Resistant HIV-1 Infection (06/22/07)
     
  13851. HBV Drug entecavir: effect on HIV replication - (06/22/07)
     
  13852. LEXIVA Liquid Approved for Treatment of HIV in Pediatric Patients - (06/22/07)
     
  13853. PFIZER RECEIVES APPROVABLE LETTER FROM FDA FOR MARAVIROC - (06/22/07)
     
  13854. Fasting Glucose Linked to Cardiovascular Risk - (06/22/07)
     
  13855. Dietary Calcium May Be Superior to Supplements for Protecting Bones - (06/21/07)
     
  13856. Resis Wksp: In vivo Emergence of HIV-1 Resistance to the CCR5 Antagonist Vicriviroc: Findings from ACTG 5211 (06/21/07)
     
  13857. Resis Wksp: Mapping of Vicriviroc Resistance Mutations in HIV-1 gp120 Generated by in vitro Selection of a Primary HIV-1 Isolate in PM-1 Cells (06/21/07)
     
  13858. Effects of Weight, Body Composition, and Testosterone on Bone Mineral Density in HIV-Infected Women - (06/20/07)
     
  13859. 67% Steatosis in HCV/HIV Coinfected: : Liver inflammation, HCV genotype 3, and BMI are associated with steatosis, a common finding in HCV-HIV-coinfected patients. - (06/20/07)
     
  13860. New Noninvasive Type 2 Diabetes Screening: Superior sensitivity to fasting plasma glucose and A1C - (06/20/07)
     
  13861. Resis Wksp: Protease Gene Mutations in a Trial Comparing First Line LPV/r Monotherapy to LPV/r + AZT/3TC (MONARK Trial) (06/20/07)
     
  13862. Resis Wksp: CXCR4-using Virus Detected in Patients Receiving Maraviroc in the Phase 3 studies MOTIVATE 1 and 2 Originates from a Pre-existing Minority of CXCR4-using Virus (06/20/07)
     
  13863. Resis Wksp: An Open, Randomized, 2-Way Crossover Study to Investigate the Effect of Darunavir/Ritonavir on the Pharmacokinetics of Maraviroc in Healthy Subjects (06/20/07)
     
  13864. Resis Wksp: Resistance Profile after Viral Rebound on Atazanavir-Containing Therapy: Focus on Protease Inhibitor Naive Subjects in the IMPACT Study (BMS AI424-128) (06/19/07)
     
  13865. Resis Wksp: Antiviral Efficacy and Emergent PI Substitutions in Treatment-Naive Subjects Receiving Atazanavir +/- Ritonavir-Based HAART in Subtype B and Non-Type B HIV-1 Infection(06/19/07)
     
  13866. Resis Wksp: Prediction of Reyataz Clinical Response Rate by Phenotypic Fold Change Using Kaplan-Meier Estimate in the AI424-045 Study(06/19/07)
     
  13867. Resis Wksp: Low NNRTI Levels Before Drug Breaks Predict Resistance - Written by Mark Mascolini - (06/18/07)
     
  13868. Resis Wksp: New Method Spots Hidden Mutations That Predict Failure - Written by Mark Mascolini - (06/18/07)
     
  13869. Resis Wksp: Pluses and Minuses of First-Line Lopinavir Versus Efavirenz: drug resistance in ACTG 5142 - Written by Mark Mascolini - (06/18/07)
     
  13870. Resis Wksp: Lower Barrier to Resistance with Lopinavir/Ritonavir Monotherapy - Written by Mark Mascolini - (06/18/07)
     
  13871. Resis Wksp: Transmitted Resistance Worse in North American Than in Europe - Written by Mark Mascolini - (06/18/07)
     
  13872. Resis Wksp: Online Coreceptor Algorithm Predictors Won't Work in Clinic - Written by Mark Mascolini - (06/18/07)
     
  13873. Resis Wksp: Ultra Deep Sequencing Identifies HIV Drug Resistance At Early Stage (06/18/07)
     
  13874. Resis Wksp: Sensitive Genotype Testing Finds Twice As Many Mutations Compared to Standard Genotyping and Study Reports This is associated with Virologic Failure (06/18/07)
     
  13875. Resis Wksp: Impact of high baseline resistance to approved protease inhibitors (and fosamprenavir) on darunavir/r virologic response in treatment-experienced patients in POWER 1, 2 and 3 (06/18/07)
     
  13876. Boehringer Ingelheim Initiates SPRING Study of Aptivus (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients - (06/15/07)
     
  13877. Resis Wksp: HIV Seems Not to "Switch" Coreceptors in Maraviroc Failure, But Is From X4 Reservoir - Written by Mark Mascolini - (06/15/07)
     
  13878. Resis Wksp: Mutations Don't Explain Vicriviroc Failure in ACTG Trial - Written by Mark Mascolini - (06/15/07)
     
  13879. Resis Wksp: Maraviroc Analysis Highlights Difficulties in Defining Resistance - Written by Mark Mascolini - (06/15/07)
     
  13880. Resis Wksp: Mutations Outside V3 Loop May Further Resistance to CCR5 Drugs - Written by Mark Mascolini - (06/15/07)
     
  13881. Resis Wksp: How Dangerous Is CCR5 Antagonist Failure? - Written by Mark Mascolini - (06/15/07)
     
  13882. Resis Wksp: R1206, a representative of a new class of potent diphenylether non-nucleoside reverse transcriptase inhibitors broadly active against NNRTI resistant HIV-1 variants and achieving high systemic exposures and benign safety profiles in animal species - (06/15/07)
     
  13883. Resis Wksp: In vitro resistance profile of the human immunodeficiency virus type 1 to two new HIV-1 protease inhibitors: CRS-074 and CRS-075 - (06/15/07)
     
  13884. Resis Wksp: IDX12899 anti-HIV-1 activity and resistance profile is superior to efavirenz - (06/15/07)
     
  13885. Resis Wksp: Cross-Resistance Between Integrase Inhibitors Looks Likely - (07/14/07)
     
  13886. Resis Wksp: Thirteen NNRTI Mutations Linked to Etravirine Resistance - (07/14/07)
     
  13887. Resis Wksp: Covert Mutations in Both Recently and Chronically Infected People - (07/14/07)
     
  13888. Resis Wksp: Transmitted Resistance in Rural US (north Carolina) Matches That in Cities - (07/14/07)
     
  13889. Resis Wksp: New HIV Drugs at Drug Resistance Workshop 6/12 Barbados - (07/13/07)
     
  13890. VIRACEPT RECALL: advice from Roche; Important information for patients - (06/08/07)
     
  13891. The safety of statins in clinical practice Review - (06/08/07)
     
  13892. Pfizer Clarification: Roche Viracept Recall - (06/07/07)
     
  13893. Food Omega-3 Fatty Acids Lower Blood Pressure & Should Impact Heart Disease/Dyslipidemia, study finds - (06/07/07)
     
  13894. Coronary Heart Disease Deaths Halved Due to Treatment & Risk Reduction - (06/07/07)
     
  13895. Vicriviroc Phase II study Results. CCR5 Inhibitors: Promising yet Challenging - (06/06/07)
     
  13896. Depression Reduces Survival: The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART - (06/04/07)
     
  13897. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel - (06/04/07)
     
  13898. Metabolic Issues Associated With Protease Inhibitors - (06/04/07)
     
  13899. GSK maintains Avandia is safe in Lancet letter - (06/04/07)
     
  13900. GSK Defends Rosiglitazone in Letter to The Lancet: "Cardiovascular safety of rosiglitazone" - (06/04/07)
     
  13901. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System - (06/04/07)
     
  13902. US regulators turn down fast-track review for GSK's Cervarix - (06/04/07)
     
  13903. Ischemic Heart Disease in HIV-Infected and Uninfected Individuals: A Population-Based Cohort Study - (06/04/07)
     
  13904. Protease Inhibitor-Based Regimens for HIV Therapy: Safety and Efficacy - (06/04/07)
     
  13905. When To Initiate HIV Antiretroviral Therapy: Do Benefits Other Than Survival Deserve Greater Attention? - (06/04/07)
     
  13906. CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater - (06/04/07)
     
  13907. Switching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid Levels: Results of a Prospective Randomized Trial (AIDS Clinical Trial Group 5125s) - (06/04/07)
     
  13908. Bush Requests $30 Billion to Fight AIDS - (06/04/07)
     
  13909. Longitudinal Incidence and Prevalence of Adverse Outcomes of Diabetes Mellitus in Elderly Patients - (05/29/07)
     
  13910. Study Test of Rosiglitazone Drug for Diabetes in Jeopardy - (05/29/07)
     
  13911. HIV Infection Is Associated with an Increased Risk for Lung Cancer, Independent of Smoking, study finds - (05/29/07)
     
  13912. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos' Bevirimat - (05/29/07)
     
  13913. Prediction of Incident Diabetes Mellitus in Middle-aged Adults - (05/29/07)
     
  13914. Effect of Aerobic Exercise Training on Serum Levels of HDL-Cholesterol - (05/29/07)
     
  13915. Effect of Soy Nuts on Blood Pressure and Lipid Levels in Hypertensive, Prehypertensive, and Normotensive Postmenopausal Women - (05/29/07)
     
  13916. CROI: Cardiovascular, Lipid, and Metabolic Complications of ART - written by Carl J. Fichtenbaum, M.D. - (05/29/07)
     
  13917. CROI: Lipoatrophy & Mitochondrial Toxicity - written by Carl J. Fichtenbaum, M.D. - (05/29/07)
     
  13918. CROI: Session 126 - Complications of ART in exposed and infected HIV children - written by Carl J. Fichtenbaum, M.D. - (05/29/07)
     
  13919. Effect of Aerobic Exercise Training on Serum Levels of HDL-Cholesterol - (05/29/07)
     
  13920. Effect of Soy Nuts on Blood Pressure and Lipid Levels in Hypertensive, Prehypertensive, and Normotensive Postmenopausal Women - (05/29/07)
     
  13921. Focus shifts to Merck's Gardasil as new adverse events uncovered - (05/25/07)
     
  13922. Prevalence of and Risk Factors for Pubic Lipoma (fat pad) Development in HIV-Infected Persons - (05/24/07)
     
  13923. Analysts start to survey aftermath of Avandia meta-analysis - (05/24/07)
     
  13924. Rosiglitazone: seeking a balanced perspective - (05/24/07)
     
  13925. Lancet calls for calm as Avandia fiasco spirals - (05/24/07)
     
  13926. Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens in WIHS (Women) - (05/22/07)
     
  13927. Hysterectomy Among Women With HIV: Indications and Incidence - (05/22/07)
     
  13928. Depression Raises Risk of Diabetes, Study Finds - (05/22/07)
     
  13929. Heavy Multivitamin Use May Be Linked to Advanced Prostate Cancer - (05/22/07)
     
  13930. Study Finds Genetic Abacavir Allergy Screening Useful - (05/22/07)
     
  13931. Effects of a Low-Glycemic Load vs Low-Fat Diet in Obese Young Adults - (05/22/07)
     
  13932. Serosorting can potentially increase HIV transmissions [Research Letters] - (05/22/07)
     
  13933. Will there be an HIV vaccine in the next 10 years? - (05/22/07)
     
  13934. HPV Vaccine Blocks Vulval and Vaginal Pre-Cancer Lesions - (05/22/07)
     
  13935. Eradication of HIV After 8 Years by HAART Started in Early Infection, NIH researchers hypothesize - (05/22/07)
     
  13936. Peregrine Pharmaceuticals to Initiate New Bavituximab HCV Clinical Trial in Patients Co-Infected With HIV - (05/22/07)
     
  13937. Rosiglitazone and Cardiovascular Risk EDITORIAL - (05/22/07)
     
  13938. GlaxoSmithKline responds to NEJM article on Avandia - (05/22/07)
     
  13939. Glaxo's Avandia Raises Heart - Death Risk: Study - (05/22/07)
     
  13940. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes FULL STUDY TEXT - (05/22/07)
     
  13941. 8th Wrkshp Pharmacology: 8th International Workshop on Clinical Pharmacology of HIV Therapy - Written by Jennifer J. Kiser and Courtney V. Fletcher - (05/21/07)
     
  13942. Imaging Techniques Reveal that HIV Infects Host Cells Using a Molecular Entry Claw - (05/10/07)
     
  13943. Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS Trial of Nevirapine vs Reyataz/ritonavir - (05/10/07)
     
  13944. China and HIV - A Window of Opportunity - (05/10/07)
     
  13945. Missing Doctor Visits Can Reduce Survival, CD4 Count & Affects Viral Load: Retention in Care: A Challenge to Survival with HIV Infection - (05/10/07)
     
  13946. Gardasil 100% Effective in Preventing Anogenital Diseases - (05/10/07)
     
  13947. HPV Vaccine Gardasil 98% Effective in Preventing HPV-16 or HPV-18 Related Disease, 2 Major Cancer Causing Strains - (05/10/07)
     
  13948. HPV Vaccine, 6 Editorials/Perspectives/ Letter To The Editor - (05/10/07)
     
  13949. HPV Associated With Oropharyngeal Cancers - (05/10/07)
     
  13950. Oral-Genital Sex & Throat Cancer - (05/10/07)
     
  13951. 44% HIV+ Undiagnosed in London, UK - (05/04/07)
     
  13952. Eliminating Persistent HIV Infection: Getting to the End of the Rainbow EDITORIAL - (05/04/07)
     
  13953. Decay of the HIV Reservoir in Patients Receiving Antiretroviral Therapy for Extended Periods: Implications for Eradication of Virus - (05/04/07)
     
  13954. Treatments for Osteoporosis - Looking beyond the HORIZON EDITORIAL - (05/03/07)
     
  13955. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis - (05/03/07)
     
  13956. Alendronate and Atrial Fibrillation - (05/03/07)
     
  13957. Resistance to Antiretroviral Drugs: A Threat to the Prevention and Treatment of Pediatric HIV Infection EDITORIAL COMMENTARY - (05/03/07)
     
  13958. Early Archiving and Predominance of NNRTI-Resistant HIV-1 among Recently Infected Infants Born in the United States - (05/03/07)
     
  13959. Thailand, Drug Patents, Compulsory Licensing: HIV, HCV, Heart Disease - (05/02/07)
     
  13960. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084 - (05/02/07)
     
  13961. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy: CCR5 Antagonist PRO 140 - (05/01/07)
     
  13962. Kaletra Efficacy with Low Adherence Levels - (05/01/07)
     
  13963. EASL: Influence of ARTs in the Progression of Liver Fibrosis in HCV/HIV Coinfected Patients: effect of hepatoxicity and metabolic abnormalities - (05/01/07)
     
  13964. EASL: Insulin Resistance Causes Fibrosis - (05/01/07)
     
  13965. EASL: Tenofovir + 3TC or FTC Efficacy in HBV/HIV Coinfection: 85% <1000 IU/ml - (05/01/07)
     
  13966. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children - (04/29/07)
     
  13967. New CCR5 Drug INCB9471 from Incyte Corp. - (04/29/07)
     
  13968. Switch to Unboosted Reyataz Maintains Viral Suppression, Improves Lipids SWAN Study 48 Weeks Published in CID - (04/29/07)
     
  13969. D.A.D. Study: 2nd EDITORIAL, Challenges in Using Observational Studies to Evaluate Adverse Effects of Treatment - (04/27/07)
     
  13970. HIV, ART, Traditional Risk Factors, and Heart Disease - (04/26/07)
     
  13971. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction, The DAD Study Group - (04/26/07)
     
  13972. Cardiovascular Risks of Antiretroviral Therapy: traditional risk factors more worrisome than ART EDITORIAL - (04/26/07)
     
  13973. Maraviroc Recommended for Accelerated Approval Unanimously by FDA Panel: panel discussions - (04/25/07)
     
  13974. Thiazolidinediones: New Evidence of Bone Loss Editorial - (04/25/07)
     
  13975. Rosiglitazone Decreased Bone Formation & Bone Mineral Density in Healthy Postmenopausal Women - (04/25/07)
     
  13976. HIV Infection Appears To Increase Risk Of Heart Attack: doubled risk in HIV+ vs HIV-negative in Mass Gen Hosp study - (04/25/07)
     
  13977. FDA Panel Backs HIV Drug, Wall St Jnl - (04/25/07)
     
  13978. 8th Wrkshp Pharmacology: Atazanavir Trough-Mutation Relation (GIQ Cutoff) Predicts Response Written for NATAP by Mark Mascolini - (04/24/07)
     
  13979. 8th Wrkshp Pharmacology: Lower Maraviroc Dose Needed With Darunavir Written for NATAP by Mark Mascolini - (04/24/07)
     
  13980. EASL: EFFECTS OF INSULIN SENSITIZING AGENTS IN NONALCOHOLIC FATTY LIVER DISEASE, METABOLICS: metformin, rosiglitazone, metformin+rosiglitazone - (04/23/07)
     
  13981. Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension: Low Vitamin D Levels Linked to Hypertension - (04/17/07)
     
  13982. 8th Wrkshp Pharmacology: Pravastatin Levels 81% Higher With Darunavir/Ritonavir Written for NATAP by Mark Mascolini - (04/17/07)
     
  13983. EASL: Abbott HCV Polymerase Inhibitor - (04/18/07)
     
  13984. 8th Wrkshp Pharmacology: Vicriviroc Levels Predict Early Salvage Response Written for NATAP by Mark Mascolini - (04/17/07)
     
  13985. 8th Wrkshp Pharmacology: Higher Tipranavir Levels in People With Liver Fibrosis Written for NATAP by Mark Mascolini - (04/17/07)
     
  13986. 8th Wrkshp Pharmacology: Maraviroc Levels Up One Third in People With Liver Impairment Written for NATAP by Mark Mascolini - (04/17/07)
     
  13987. 8th Wrkshp Pharmacology: Efavirenz Levels Normal in People Coinfected with HBV or HCV Written for NATAP by Mark Mascolini - (04/17/07)
     
  13988. Resistance to New HCV Antivirals - (04/17/07)
     
  13989. CROI: Predictors of response to TPV/r in pediatric patients: results of BI1182.14/PACTG1051 (04/10/07)
     
  13990. EHDRW: Estimated potency of six different boosted protease inhibitors regimens in antiretroviral-experienced HIV patients - Impact of baseline protease resistance mutations (04/09/07)
     
  13991. Metabolic Syndrome in HIV+ Predicts Heart Disease Just As It Does in HIV-Negatives - (04/09/07)
     
  13992. Abnormal Glucose is a Risk Factor for Cancer - (04/05/07)
     
  13993. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/05/07)
     
  13994. Darunavir: promising initial results COMMENTARY - (04/05/07)
     
  13995. Darunavir POWER 1 & 2 Pooled 48 Week Results Published in The Lancet - (04/05/07)
     
  13996. OraSure Technologies Signs Agreement for Development of Counseling and Referral System for Home Use Rapid HIV Test Kit & Over-The Counter Sales - (04/04/07)
     
  13997. Circumcision for HIV Prevention: Failure to Fully Account for Behavioral Risk Compensation EDITORIAL - (04/04/07)
     
  13998. Assessment of Birth Defects According to Maternal Therapy Among Infants in the Women and Infants Transmission Study (WITS) - (04/03/07)
     
  13999. Use of ART in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis - (04/03/07)
     
  14000. FDA Approves Accelerated Dosing Schedule for GlaxoSmithKline's Twinrix(R) - (04/03/07)
     
  14001. Purified Fish Oil+Statin Reduces Risk for Heart Disease in Japan More Than Statin Alone - (04/03/07)
     
  14002. Impact of Hepatitis D Virus Infection on the Long-Term Outcomes of Patients with Hepatitis B Virus and HIV Coinfection in the Era of Highly Active Antiretroviral Therapy: A Matched Cohort Study - (04/03/07)
     
  14003. The Probable Source of Both the Primary Multidrug-Resistant (MDR) HIV-1 Strain Found in a Patient with Rapid Progression to AIDS and a Second Recombinant MDR Strain Found in a Chronically HIV-1-Infected Patient - (04/03/07)
     
  14004. The Effects of Calcium and Vitamin D Supplementation on Blood Glucose and Markers of Inflammation in Nondiabetic Adults - (04/02/07)
     
  14005. Calcium+Vitamin D Reduces Risk for Colorectal Cancer - (04/02/07)
     
  14006. Rosuvaststin Improves Lipids & Slows Progression in Low Risk Group with Sub-Clinical Atherosclerosis - (04/02/07)
     
  14007. CROI: 10% Resistance Rate in USA, Most Common Mutations in Naive Newly Diagnosed: CDC Report (04/02/07)
     
  14008. EHDRW: First ART Response After Genotyping: T215 Revertants Signal Danger (04/02/07)
     
  14009. EHDRW: Good HBV Response to Tenofovir After Lamivudine Failure (04/02/07)
     
  14010. EHDRW: HBV Mutations With Monotherapy Versus Combination Therapy (04/02/07)
     
  14011. EHDRW: Upper and Lower Clinical Cutoffs Proposed for Darunavir from Monogram (04/02/07)
     
  14012. EHDRW: Darunavir Phenotype Predicts Response Better Than Genotype (04/02/07)
     
  14013. EHDRW: Total Mutation Number--and Specific Mutations--Predict Death (04/02/07)
     
  14014. EHDRW: Response to Darunavir, Tipranavir, or Lopinavir After Atazanavir Failure (03/30/07)
     
  14015. EHDRW: Few Integrase Inhibitor (INI) Mutations in INI-Naive People (03/30/07)
     
  14016. EHDRW: Accuracy of Monogram's Trofile Assay in Determining Tropism and New Tropism Assays in Development (03/30/07)
     
  14017. EHDRW: Several Genotyping Systems Offer Hope as Tropism Predictors (03/30/07)
     
  14018. EHDRW: Prediction of HIV-1 coreceptor usage based on structural descriptors of the gp120 V3 loop (03/30/07)
     
  14019. EHDRW: Evolving Resistance Pattern Before Antiretroviral Therapy Starts (03/30/07)
     
  14020. EHDRW: Correlation of Resistance Algorithms for Tipranavir Susceptibility with Response to Tipranavir Containing Regimens in the RESIST Trials (03/30/07)
     
  14021. EHDRW: Mutations associated with cross-resistance to tipranavir in patients previously treated with two or more protease inhibitors (03/30/07)
     
  14022. EHDRW: Darunavir Exhibits High Levels of In Vitro Antiviral Activity against Clinical Samples with Different Levels of Susceptibility to Atazanavir/Ritonavir (03/30/07)
     
  14023. EHDRW: Waning Incidence of Multidrug-Resistant HIV in Europe? - written by Mark Mascolini (03/29/07)
     
  14024. CROI: This is your brain off drugs: the neurocognitive effects of treatment interruption - Written By David Margolis, MD (03/29/07)
     
  14025. EHDRW: Rescue Regimen Success Rises 18% Yearly in Italian Cohort - written by Mark Mascolini (03/29/07)
     
  14026. EHDRW: Hard to Pinpoint Factors Favoring Infection With Resistant HIV - written by Mark Mascolini (03/29/07)
     
  14027. EHDRW: Prevalence of Darunavir Resistance-Associated Mutations in Samples Received for Routine Clinical Resistance Testing (03/29/07)
     
  14028. EHDRW: Low Rates of Darunavir Mutations After Failure of Other PIs - written by Mark Mascolini (03/29/07)
     
  14029. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis - (03/28/07)
     
  14030. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients POWER 2 Study - (03/28/07)
     
  14031. Therapeutic management of bone demineralization in the HIV-infected population - (03/28/07)
     
  14032. Don't Stay on Virologically Failing Regimens - (03/28/07)
     
  14033. Do HIV Care Providers Appropriately Manage Hepatitis B in Coinfected Patients Treated with Antiretroviral Therapy? - (03/28/07)
     
  14034. JANUVIA™ Approved in the European Union for the Treatment of Type 2 Diabetes - (03/27/07)
     
  14035. Anal pre-cancer test for HIV+ men - (03/27/07)
     
  14036. Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis - (03/27/07)
     
  14037. Long-Term study Finds Both Abstainers From Coffee and In Women Only, Heavy Consumers (>6 cups/day) Have Lower Risks of Hypertension Than Do Low Coffee Consumers (>0-3 Cups/day - (03/27/07)
     
  14038. Intra-rectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1 - (03/27/07)
     
  14039. Occult HBV May Not Be Clinically Significant in HIV - (03/27/07)
     
  14040. Occult HBV May Be Clinically Significant - (03/27/07)
     
  14041. Do n-3 fatty acids prevent osteoporosis? - (03/26/07)
     
  14042. 50% of New HIV Infections Occur When Transmitter is Newly Infected - (03/26/07)
     
  14043. CROI: ART Interruptions Increase Cardiovascular Disease Risk by 57% in SMART Study (03/27/07)
     
  14044. CROI: PK Atazanavir-based HAART in pregnancy (03/27/07)
     
  14045. CROI: Atazanavir Use in Pregnancy: a report of 33 cases (03/27/07)
     
  14046. Endurance & Strength Exercise Prevents Insulin Resistance in general Populations - (03/26/07)
     
  14047. CROI: Interruption of ART & Risk of Cardiovascular Disease: findings from SMART (02/22/07)
     
  14048. CROI: In NYC: Liver Fibrosis During Acute HCV Infection of HIV-infected Men (03/21/07)
     
  14049. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection - (03/21/07)
     
  14050. HCV Replication is Associated with Mitochondrial Depletion in Coinfected Patients - (03/21/07)
     
  14051. Roche-Trimeris Change TRI-1144 Deal - (03/21/07)
     
  14052. 50% of New HIV Infections Occur When Transmitter is Newly Infected - (03/21/07)
     
  14053. HAART Causes Decline in Moratlity Gap Among Black Significant Decrease in the Black-White Life Expectancy Gap Over the Past 10 Years: Study - (03/21/07)
     
  14054. New NRTI Apricitabine Completes Phase IIB - (03/21/07)
     
  14055. Update in Osteoporosis and Metabolic Bone Disorders - (03/20/07)
     
  14056. HAART Associated With Accelerated Fibrosis Progression, study reports - (03/20/07)
     
  14057. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection - (03/20/07)
     
  14058. GlaxoSmithKline Introduces HIV Education Initiative for Community-Based AIDS Service Organizations - (03/20/07)
     
  14059. Generic 3TC Gets FDA Approval - (03/20/07)
     
  14060. Impact of Maternal HIV Coinfection on the Vertical Transmission of Hepatitis C Virus: A Meta-analysis - (03/20/07)
     
  14061. CROI: Safety and Antiviral Activity of Fosamprenavir (FPV)-Containing Regimens in HIV-Infected 2 to 18 Year Old Pediatric Subjects (Interim Data, Study APV29005) (03/19/07)
     
  14062. CROI: Safety and Antiviral Activity of Fosamprenavir/Ritonavir (FPV/RTV) QD Regimens in HIV-Infected Pediatric Subjects Ages 2 to 18 Years (48 week Interim Data, Study APV20003) (03/19/07)
     
  14063. CROI: Abbott Reports 4 Viral Decay Phases: Low-Level Viremia Decays Over 7+ Years to a Residual Level Correlated with Baseline HIV-1 RNA (03/19/07)
     
  14064. CROI: PK of Reyataz & Reyataz/r: viral response, lipids, bilirubin, AEs (03/19/07)
     
  14065. CROI: Effects of tipranavir/ritonavir (TPV/r) on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein (P-gp): implications for drug interactions (03/19/07)
     
  14066. HIV in India - A Complex Epidemic - (03/16/07)
     
  14067. CROI: Efficacy and safety of Atazanavir With & Without Ritonavir in Antiretroviral-Naive Subjects (03/16/07)
     
  14068. CROI: Predicted Risk of Coronary Heart Disease (CHD) with Tipranavir Exposure Compared to Conventional PI in the RESIST Trial (03/16/07)
     
  14069. CROI: TMC125, Tenofovir, LPV/r Interactions (03/16/07)
     
  14070. CROI: Mortality & Causes of Death--and Chances of Avoiding It--With HIV Today (03/13/07)
     
  14071. Association Between Rates of HIV Testing and Elimination of Written Consents in San Francisco - (03/12/07)
     
  14072. CROI: Darunavir-Amprenavir Cross-Resistance in Clinical Samples Submitted for Phenotype-Genotype Combination Resistance Testing (03/13/07)
     
  14073. CROI: CLINICAL PHARMACOLOGY AT THE 14TH CROI - Written by John G. Gerber, MD Jennifer J. Kiser, Pharm D (03/13/07)
     
  14074. CROI: Acute hepatitis C in men who have sex with men (MSM) is not only confined to those infected with HIV and they continue to increase (03/13/07)
     
  14075. CROI: Assessing HIV-1 Tropism in ACTG A5211: A Comparison of Assays Using Replication-competent Virus from Peripheral Blood Mononuclear Cells (PBMC) Versus Plasma-derived Pseudotyped Virions (03/13/07)
     
  14076. CROI: Simpler genotype score to predict response to tipranavir (03/13/07)
     
  14077. CROI: New Details on Resistance to Darunavir and Tipranavir: TMC & Tipranavir not cross-resistant; new tipranavir genotypic resistance profile; TMC114 & amprenavir not cross-resistant; selection of mutations conferring resistance to TMC114 (03/13/07)
     
  14078. CROI: Tipranavir & TMC114 Not Cross-Resistant in Clinical Isolates Study: An Investigation into the influence of the Tipranavir-associated V82L/T mutations on the susceptibility to darunavir and brecanavir (03/13/07)
     
  14079. CROI: TMC114 High Genetic Barrier To Resistance Due to Tight Binding to MDR HIV & Wild-Type (03/13/07)
     
  14080. CROI: Prior utilization/resistance to amprenavir at screening has minimal impact on the 48-week response to darunavir/r in the POWER 1, 2 and 3 studies (03/13/07)
     
  14081. CROI: HIV Pathogenesis in Humans & Monkeys - Written By David Margolis, MD (03/12/07)
     
  14082. CROI: Baseline Viral Load Predicts HIV Disease Progression & Baseline CD4 Count Predicts CD4 Decline in ART-Naives (03/12/07)
     
  14083. Predictive Value of Plasma HIV RNA Level on Rate of CD4 T-Cell Decline in Untreated HIV Infection - (03/13/07)
     
  14084. Panacos Announces Bevirimat Phase 2b Dose Escalation Strategy - (03/13/07)
     
  14085. Explaining, Predicting, and Treating HIV-Associated CD4 Cell Loss, After 25 Years Still a Puzzle, EDITORIAL - (03/13/07)
     
  14086. Who Will Benefit from CCR5 Inhibitors? - (03/13/07)
     
  14087. HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211 - (03/13/07)
     
  14088. HIV Coreceptor Use in Heavily Treatment-Experienced Patients: Does It Take Two to Tangle? EDITORIAL - (03/13/07)
     
  14089. CROI: Viral Load is Best Predictor of AIDS & Death In Long Term (03/12/07)
     
  14090. NIAID Announces Leadership for Newly Restructured HIV/AIDS Clinical Trials Networks - (03/12/07)
     
  14091. Procrit/Epogen FDA Safety Warning - (03/12/07)
     
  14092. Pioglitazone, FDA Warning: more bone fractures in women - (03/12/07)
     
  14093. CROI: Should We Start HAART Early Due to Gut Immune Depletion by HIV (03/12/07)
     
  14094. CROI: ART Drug Concentrations in the Genital Tract of HIV-Infected Women (03/12/07)
     
  14095. CROI: The Effects of Intermittent, CD4-Guided Antiretroviral Therapy on Peripheral Limb Fat and Metabolic Parameters: The SMART Body Composition Substudy (03/12/07)
     
  14096. CROI: Leptin Reduced VAT by 30%/Improved Metabolics in Pilot Study (03/12/07)
     
  14097. CROI: Factors Associated with the Incidence of Diabetes Mellitus Type 2 in HIV-Infected Participants of the Swiss HIV Cohort Study (03/12/07)
     
  14098. CROI: Improved Cardiac Disease Management, Risk for Myocardial Infarction Stabilizes (03/12/07)
     
  14099. CROI: Gut CD4s May Not Recover After HAART - Written By David Margolis, MD (03/12/07)
     
  14100. CROI: Sensitive Genotypic Testing Uncovers Drug Resistance Associated with Viral Failure (03/12/07)
     
  14101. Blacks 51% of New HIV/AIDS Cases, Racial/Ethnic Disparities in Diagnoses of HIV/AIDS --- 33 States, 2001--2005 - (03/09/07)
     
  14102. Belly fat may drive inflammatory processes associated with disease: diabetes, cancer, heart disease, hypertension - (03/09/07)
     
  14103. CROI: Higher ART TDF/FTC Potency Correlates with Increased Protection against Rectal SHIV Transmission (03/09/07)
     
  14104. CROI: Are HIV Docs Managing Lipids Correctly? (03/09/07)
     
  14105. CROI: Hepatitis B Virus (HBV) Dynamics in HIV-HBV Co-infected Patients: Significant Difference in the Viral Activity of Adefovir (ADV) or Tenofovir (TDF) (03/09/07)
     
  14106. CROI: Pfizer Tropism Assay: Evaluation of an Ultra-deep Sequencing Method to Identify Minority Sequence Variants in the HIV-1 env Gene from Clinical Samples (03/09/07)
     
  14107. CROI: Substantial CD4+ T-cell Recovery and Reconstitution of Tissue Architecture in Gut-associated Lymphoid Tissue in Advanced HIV-1 Infection following Initiation of HAART with Nevirapine plus Trizivir (03/09/07)
     
  14108. CROI: Efficacy and Safety of Tenofovir DF (TDF)-containing versus non-TDF-containing Regimens in Black Antiretroviral-Naive Patients (03/09/07)
     
  14109. CROI: RNase H Inhibitors: Obstacles to Developments - Reported by David Margolis (03/09/07)
     
  14110. CROI: FTC/Tenefovir as a Rectal Gel Microbicide (03/09/07)
     
  14111. CROI: Two New HIV Drugs: NNRTI TMC278 and CCR5 Antagonist Maraviroc (03/07/07)
     
  14112. CROI: Increased Prostate Cancer Incidence in Aging Population (03/07/07)
     
  14113. CROI: Effects of atazanavir or saquinavir QD with ritonavir 100 mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal; a randomised open-label study (03/07/07)
     
  14114. CROI: Evaluation of Intracranial Hemorrhage in 49,610 HIV-Infected Veterans and California Medicaid Recipients (03/07/07)
     
  14115. CROI: Important New Findings on HIV Control in the Brain, Neurocognitive Dysfunction, ART CNS-Penetration (03/07/07)
     
  14116. CROI: A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor GSK364735 in Healthy Subjects (GRZ105655) (03/07/07)
     
  14117. CROI: Effect of Famotidine 20 and 40 mg Dosing Regimens on the Bioavailability of Atazanavir with Ritonavir in Combination with Tenofovir in Healthy Subjects (03/07/07)
     
  14118. CROI: In Vitro Resistance Profile of HIV-1 Mutants Selected by the HIV-1 Integrase Inhibitor, GS-9137 (JTK-303) (03/07/07)
     
  14119. CROI: Hepatic Steatosis (30%) and Liver Function Abnormalities among HIV-Infected Persons (03/07/07)
     
  14120. CROI: Predictors of Loss of Virologic Response in Subjects Who Deintensified to Lopinavir/ritonavir Monotherapy After Achieving Plasma HIV-1 RNA <50 copies/mL on Lopinavir/ritonavir Plus Zidovudine/lamivudine (03/07/07)
     
  14121. CROI: HIV Transmission Risk is Higher During ART Interruptions (03/07/07)
     
  14122. CROI: Single Agent Therapy with Lopinavir/ritonavir Controls HIV-1 Replication in the Central Nervous System (03/07/07)
     
  14123. CROI: Alendronate Modestly Improved BMD in 48 Week ACTG Study (03/07/07)
     
  14124. CROI: SUN Study: 10% Osteoporosis, 51% Osteopenia (03/07/07)
     
  14125. CROI: Bioequivalence of Pilot Tablet Formulations of Ritonavir (RTV) to the Marketed Soft gel Capsule (SGC) at a Dose of 100 mg (03/06/07)
     
  14126. Newly infected spread half of HIV - (03/06/07)
     
  14127. Bono talks about HIV/AIDS in Oakland - (03/06/07)
     
  14128. CROI: Bioequivalence of Pilot Tablet Formulations of Ritonavir (RTV) to the Marketed Soft gel Capsule (SGC) at a Dose of 100 mg (03/06/07)
     
  14129. CROI: Opening last week in L.A.: the era of integrase inhibition? - Reported by David Margolis, MD (03/06/07)
     
  14130. CROI: HIV in CSF Associated with Neurological Impairment (03/06/07)
     
  14131. CROI: Longitudinal Evaluation of Viral Co-receptor Tropism Switches among HIV-infected Patients with Drug-resistant Viremia (03/06/07)
     
  14132. CROI: Metabolic Outcomes of ACTG 5142: A Prospective, randomized Phase III Trial of NRTI, PI, and NNRTI-sparing Regimens for Initial Treatment of HIV (03/05/07)
     
  14133. CROI: Significant Sparing of Peripheral Lipoatrophy by HIV Treatment with LPV/r (Kaletra) + AZT/3TC Induction Followed by LPV/r Monotherapy Compared with EFV +AZT/3TC (03/05/07)
     
  14134. CROI: Body Composition Changes in ARV-Naive Subjects Treated With Atazanavir or Atazanavir/Ritonavir-Based Once-Daily HAART: 48-Week CT and DEXA Data (03/05/07)
     
  14135. CROI: Entecavir HBV Therapy: does it have HIV activity? (03/05/07)
     
  14136. CROI: Insulin Resistance Predicts Rapid Response in People With HCV and HIV - written by Mark Mascolini (03/05/07)
     
  14137. CROI: CD4 Count Predicts Fatal Non-AIDS Cancers: Traditional Malignancies May also be AIDS-Related - Reported by David Alain Wohl (03/05/07)
     
  14138. CROI: Higher CD4 Count Prevents End-Organ Diseases (03/05/07)
     
  14139. CROI: HIV-Related Kidney Disease, ART Effects - Written by Christina Wyatt, MD, and Paul Klotman, MD (03/05/07)
     
  14140. CROI: Acute HIV infection: Transmitted Resistance in Newly Infected Patients - written by Charles Hicks, M.D. (03/05/07)
     
  14141. CROI: Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of Raltegravir (MK-0518), a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus (03/05/07)
     
  14142. CROI: Motivate 1 Study: Efficacy and Safety of Maraviroc plus Optimized Background Therapy In Viremic, ART-Experienced Patients Infected With CCR5-Tropic HIV-1: 24-Week Results of Phase 2b/3 Studies (03/05/07)
     
  14143. CROI: Increase in AIDS Cases (03/02/07)
     
  14144. CROI: Disparities in Life Expectancy Due to Suboptimal HIV Care in the US: Impact of Gender, Ethnicity and Race: (03/02/07)
     
  14145. CROI: Osteopenia in HIV: risk factors for screening - written by Carl J. Fichtenbaum, M.D. (03/02/07)
     
  14146. CROI: Preclinical Data From Two Novel NNRTI Idenix Compounds for the Treatment of HIV Presented at Conference on Retroviruses and Opportunistic Infections (CROI) (03/02/07)
     
  14147. CROI: Results from Two Phase III Studies on ISENTRESS (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI) - Press Release (03/02/07)
     
  14148. CROI: Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients - Press Release (03/02/07)
     
  14149. CROI: Metabolic and Cardiovacular Complications in HIV - written by Carl J. Fichtenbaum, M.D. (03/01/07)
     
  14150. CROI: Maraviroc Combined Analysis & MOTIVATE 2 (Europe, Australia, USA): 24 week Results (03/01/07)
     
  14151. CROI: Gilead Integrase Inhibitor Outdoes New PIs in Salvage Therapy - written by Mark Mascolini (03/01/07)
     
  14152. CROI: TMC278 Matches Efavirenz in Treatment-Naive People - written by Mark Mascolini (03/01/07)
     
  14153. CROI: Three new drugs promise options for HIV patients (03/01/07)
     
  14154. CROI: Lipodystrophy/Metabolic Complications of ART in South Africa - written by Carl J. Fichtenbaum (03/01/07)
     
  14155. CROI: Adverse Events/Complications of ART in Africa - written by Carl J. Fichtenbaum (03/01/07)
     
  14156. CROI: 48-week primary analysis of trial TMC278- C204: TMC278 demonstrates potent and sustained efficacy in ARV-naive patients (03/01/07)
     
  14157. CROI: The HIV Integrase Inhibitor GS-9137 Has Potent Antiretroviral Activity in Treatment-Experienced Patients (03/01/07)
     
  14158. CROI: New HIV Drugs; Intl Drug Resistance (02/28/07)
     
  14159. CROI: Do Trace Levels of HIV Drug Resistance Transmitted During Infection Affect Virological Response? - written by Mark Mascolini (02/28/07)
     
  14160. CROI: Pfizer CCR5 Maraviroc 24 Weeks In Treatment-Experienced (02/28/07)
     
  14161. CROI: Lower CD4 Counts Boost Risk of "Non-AIDS" Cancers - written by Mark Mascolini (02/28/07)
     
  14162. CROI: People With HIV Infection Eat Too Much Saturated Fat - written by Mark Mascolini (02/28/07)
     
  14163. CROI: Integrase Inhibitor Adds More Punch to Salvage Regimens - written by Mark Mascolini (02/28/07)
     
  14164. CROI: Life Expectancy With HIV Still Low in High-Income Countries - written by Mark Mascolini (02/28/07)
     
  14165. CROI: CCR5 Blocker Looks Strong in Two International Salvage Trials - written by Mark Mascolini (02/28/07)
     
  14166. Beta-blockers not first choice for high blood pressure - study - (02/27/07)
     
  14167. CROI: Nations Defend HIV Drugs With Tests for Hardy Strains (02/26/07)
     
  14168. CROI: Drug-resistant TB that kills HIV patients is spreading (02/26/07)
     
  14169. CROI: Alendronate with Calcium and Vitamin D Supplementation Is Superior to Calcium and Vitamin D Alone in the Management of Decreased Bone Mineral Density in HIV-infected patients: Results of ACTG 5163 (02/26/07)
     
  14170. CROI: Metabolic Outcomes of ACTG 5142: A Prospective, Randomized phase III trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial treatment of HIV-1 (02/26/07)
     
  14171. CROI: Effects of TH9507, a Growth Hormone Releasing Factor Analog, on HIV-associated Abdominal Fat Accumulation: A Multicenter, Double-blind Placebo-controlled Trial with 412 Randomized Patients (02/26/07)
     
  14172. CROI: Starting Antiretrovirals Later May Hurt Cognitive Function - written by Mark Mascolini (02/26/07)
     
  14173. CROI: Ezetimibe Reduces LDL-C for HIV+ on HAART (02/26/07)
     
  14174. CROI: How Antiretroviral Breaks May Raise Heart Disease Risk - written by Mark Mascolini (02/26/07)
     
  14175. CROI: CD4 Counts Predict Non-AIDS Disease Risk in FIRST Trial - written by Mark Mascolini (02/26/07)
     
  14176. CROI: Therapies for Improved Lipids, Belly Fat, and Limb Fat (02/26/07)
     
  14177. Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin - (02/23/07)
     
  14178. Dose-Ranging Phase 1 Study of TMC120, a Promising Vaginal Microbicide, in HIV-Negative and HIV-Positive Female Volunteers - (02/23/07)
     
  14179. Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes - (02/23/07)
     
  14180. Combined Use of Rosiglitazone and Fenofibrate in Patients With Type 2 Diabetes - (02/23/07)
     
  14181. Hopkins Recommends Attention Be Directed at Non-AIDS Causes of Death in HIV Such as HCV - (02/23/07)
     
  14182. Early Structural and Functional Changes of the Vasculature (Heart) in HIV-Infected Children - (02/23/07)
     
  14183. Prediabetic Women May Have Greater Risk Factors For Faster Acceleration to Diabetes & Heart Disease Than Men - (02/23/07)
     
  14184. Clinical Implications of the DREAM Study: should prediabetes be treated to prevent diabetes or heart disease EDITORIAL - (02/23/07)
     
  14185. TMC114 Approved in European Union - (02/16/07)
     
  14186. CCR5 Maraviroc EAP, Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay - (02/15/07)
     
  14187. HIV reveals site of vulnerability, gp120; Potential vaccine target identified - (02/15/07)
     
  14188. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 - (02/15/07)
     
  14189. White House Criticizes HIV-Neuropathy Pot Study - (02/14/07)
     
  14190. HIV-Pot Advocates Call for Congressional Hearings - (02/14/07)
     
  14191. Medical pot cuts HIV-Neuropathy pain, study finds - (02/14/07)
     
  14192. Cannabis in painful HIV-associated sensory neuropathy, Study Results - (02/14/07)
     
  14193. PFIZER'S MARAVIROC TO RECEIVE ACCELERATED REGULATORY REVIEWS IN THE U.S. AND EUROPE - (02/14/07)
     
  14194. Evidence of Ongoing Immune Reconstitution in Subjects with Sustained Viral Suppression following 6 Years of Lopinavir-Ritonavir Treatment - (02/14/07)
     
  14195. Fibrosis Progression Rates Double in Coinfected Within 2 Years - (02/12/07)
     
  14196. FDA Maraviroc Approval Hearing April 24 - (02/12/07)
     
  14197. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database - (02/12/07)
     
  14198. Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy - (02/09/07)
     
  14199. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation - (02/09/07)
     
  14200. Metabolic Syndrome in HIV-Infected Patients: No Different than the General Population? COMMENTARY - (02/09/07)
     
  14201. Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient Population - (02/09/07)
     
  14202. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation - (02/08/07)
     
  14203. National Black HIV/AIDS Awareness Day Feb 7, 2007 - (02/08/07)
     
  14204. 18 Million US Men Have Erectyle Dysfunction - (02/08/07)
     
  14205. Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis - (02/08/07)
     
  14206. Progression From Newly Acquired Impaired Fasting Glusose to Type 2 Diabetes - (02/08/07)
     
  14207. Valproic Acid Did Not Accelerate Decay of HIV Reservoir - (02/01/07)
     
  14208. Fuzeon Label Changes Reported by FDA - (02/01/07)
     
  14209. Sustiva Label Change - (02/01/07)
     
  14210. Dynamics of HIV viral load in blood and semen of patients under HAART: impact of therapy in assisted reproduction procedures - (02/01/07)
     
  14211. Valproic Acid Did Not Accelerate Decay of HIV Reservoir - (01/31/07)
     
  14212. NEFA: Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients - (01/31/07)
     
  14213. Serological Response to Syphilis Treatment in HIV Infected and Uninfected Patients Attending STD Clinic at Johns Hopkins - (01/30/07)
     
  14214. Persistence of K103N-Containing HIV-1 Variants after Single-Dose Nevirapine for Prevention of HIV-1 Mother-to-Child Transmission - (01/30/07)
     
  14215. Survival of Persons with and without HIV Infection in Denmark, 1995-2005 - (01/26/07)
     
  14216. Suppression of Human Immunodeficiency Virus Type 1 Viral Load With Selenium Supplementation - (01/25/07)
     
  14217. Early Virologic Rebound in a Pilot Trial of Ritonavir-Boosted Atazanavir as Maintenance Monotherapy - (01/24/07)
     
  14218. Early Initiation of Antiretroviral Therapy: The Current Best Way to Reduce Liver-Related Deaths in HIV/Hepatitis C Virus-Coinfected Patients - (01/23/07)
     
  14219. Drug & Lifestyle Intervention Prevents Diabetes in Impaired Glucose Tolerance - (01/22/07)
     
  14220. Elevated blood pressure in subjects with lipodystrophy - (01/19/07)
     
  14221. Safety of nevirapine in pregnancy - (01/19/07)
     
  14222. Risks of Interruptions, TIBET Study - (01/19/07)
     
  14223. A Randomized, Double-Blind, Placebo-Controlled Trial of Combined Nevirapine and AZT Compared with Nevirapine Alone in the Prevention of Perinatal Transmission of HIV in Zimbabwe - (01/19/07)
     
  14224. Lymphogranuloma Venereum in the United Kingdom - (01/19/07)
     
  14225. HIV-hepatitis C virus co-infection is associated with decreased plasmatic IL-7 levels [Research Letters] - (01/18/07)
     
  14226. Risk Factors for Early Myocardial Infarction in South Asians Compared With Individuals in Other Countries - (01/18/07)
     
  14227. Utility of Standard Genotyping among ART-Naive Individuals with Unknown Duration of Infection; 25% with Drug Resistance in San Diego study - (01/18/07)
     
  14228. Failures in Screening for Acute HIV Infection: Lessons Learned - (01/18/07)
     
  14229. Erectyle Dysfunction is Reversible: 35% in this study reversed it - (01/18/07)
     
  14230. HIV-associated nephropathy [EDITORIAL REVIEW] - (01/18/07)
     
  14231. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review - (01/18/07)
     
  14232. 24% False HCV-Negative: among HCV-Antibody Negative, 24% Are HCV RNA+ If IDU & CD4 <200 - (01/17/07)
     
  14233. When should antiretroviral therapy for HIV be started? EDITORIAL - (01/16/07)
     
  14234. Pharmaceutical firms disclosing more data more completely - (01/16/07)
     
  14235. Higher Rates of Colorectal Cancer in HIV+ - (01/16/07)
     
  14236. Elevated risk of lung cancer among people with AIDS - (01/16/07)
     
  14237. HIV, Diabetes & Impaired Glucose Tolerance: prevalence, diagnosing, treatment - (01/16/07)
     
  14238. New Neuropathy Drug - (01/16/07)
     
  14239. 8th Intl Wrkshp Adverse Drug & Lipo: Risk Factors for Bone Loss in HIV Appear to be Associated with Weight Loss and Additional Risk Factors Found in General Population - (01/12/07)
     
  14240. 8th Intl Wrkshp Adverse Drug & Lipo: Genetic Basis for Body Fat Loss - (01/12/07)
     
  14241. Theratechnologies Reports Phase 3 Results for TH9507 in HIV associated Lipodystrophy: 15% reduction in VAT - (01/11/07)
     
  14242. ddI Clinical Cutoffs from the Jaguar Study - (01/11/07)
     
  14243. Case-Control Study of Shigellosis in San Francisco: The Role of Sexual Transmission and HIV Infection; oral-anal sex, MSM - (01/11/07)
     
  14244. New Highly Sensitive HIV test may predict drug resistance at 0.1-.01% - (01/11/07)
     
  14245. 'When To Begin HAART' Study Proposal, Reemerges - (01/11/07)
     
  14246. Sex, Drugs, Prisons, and HIV - (01/11/07)
     
  14247. Response to ART after a Single, Peripartum Dose of Nevirapine - (01/11/07)
     
  14248. TMC125, New NNRTI for Patients with NNRTI-Drug Resistance - (01/11/07)
     
  14249. New Incyte CCR5 Antagonist 14-Day Study Results - (01/10/07)
     
  14250. Starting HAART at >350 CD4s Results In Greater CD4 Increases; Study Recommends Starting HAART When CD4 Count is >350 - (01/10/07)
     
  14251. Cirrhosis is Associated with Low CD4 Counts - (01/10/07)
     
  14252. Cirrhosis Is Associated with Low CD4+ T Cell Counts: Implications for HIV-Infected Patients with Liver Disease EDITORIAL - (01/10/07)
     
  14253. Pharmacokinetic interaction between TMC114/r and omeprazole or ranitidine in HIV-negative healthy volunteers - (01/10/07)
     
  14254. Relation of d4T Discontinuation to Anthropometric Changes Among HIV-Infected Women in WIHS - (01/05/07)
     
  14255. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals - (01/05/07)
     
  14256. Frequent methamphetamine use is associated with primary NNRTI resistance - (01/05/07)
     
  14257. Uridine supplementation antagonizes zalcitabine (DDC)-induced microvesicular steatohepatitis in mice - (01/05/07)
     
  14258. Interruption of Enfuvirtide in HIV-1-Infected Adults with Incomplete Viral Suppression on an Enfuvirtide-Based Regimen - (01/05/07)
     
  14259. Enfuvirtide Antiviral Activity despite Rebound Viremia and Resistance Mutations: Fitness Tampering or a Case of Persistent Braking on Entering? Editorial - (01/05/07)
     
  14260. Cervical Shedding of HIV-1 RNA Among Women With Low Levels of Viremia While Receiving HAART - (01/04/07)
     
  14261. Discontinuation of ART Postpartum: No Evidence for Altered Viral Set Point [Letters to the Editor] - (01/04/07)
     
  14262. Extra-Hepatic HCV in HIV+ Women: Negative-Strand Hepatitis C Virus (HCV) RNA in Peripheral Blood Mononuclear Cells from Antibody HCV-Positive/HIV-Infected Women - (01/03/07)
     
  14263. Effects of Continuing or Stopping Alendronate After 5 Years of Treatment - (01/03/07)
     
  14264. Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture - (01/03/07)
     
  14265. FDA Approves Radiesse, Cosmetic Treatment for Facial Lipoatrophy - (01/03/07)
     
  14266. Intermittent therapy for the treatment of chronic HIV infection, EDITORIAL REVIEW - (01/03/07)
     
  14267. FDA analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients - (01/03/07)
     
  14268. Many Factors Cause Hepatotoxicity in HIV Therapy - (12/21/06)
     
  14269. Panacos Announces First Cohort Results of PA-457 Phase 2b Study - (12/21/06)
     
  14270. HAART Controls Gut Microbes & decreases immune activation - (12/21/06)
     
  14271. Gut microbes out of control in HIV infection - (12/21/06)
     
  14272. Hormonal contraception and incident HIV-1 infection: new insight and continuing challenges EDITORIAL - (12/21/06)
     
  14273. Long-term follow-up of patients with NAFLD and elevated liver enzymes - (12/19/06)
     
  14274. Coinfection with Hepatitis C Virus Increases Lymphocyte Apoptosis in HIV-Infected Patients - (12/19/06)
     
  14275. Serum Uric Acid Predicts Incident Hypertension in a Biethnic Cohort. IN PDF - (12/19/06)
     
  14276. NNRTI Resistance Increasing in SF; 13% Primary ART Resistance: Acute & New HIV-Infections - (12/19/06)
     
  14277. Surgical Outcomes in HIV+ Patients in the Era of HAART - (12/19/06)
     
  14278. Nadir CD4 Impairs Response to HCV, Suggest to Start HAART Earlier in HCV+; Coinfection With Both HIV And Hepatitis C Virus, A Growing Problem - (12/19/06)
     
  14279. Lower Nadir CD4 Count Reduces Immune Response to HCV - (12/15/06)
     
  14280. Fish Reduces Risk of Dementia by 47% in Framingham Heart Study - (12/18/06)
     
  14281. Diabetes mellitus and the risk of dementia - (12/18/06)
     
  14282. Procrit/EP- Safety Alert from FDA - (12/18/06)
     
  14283. Epoetin Alfa and Risk for Complications - (12/18/06)
     
  14284. Correction of Anemia - Payoffs and Problems EDITORIAL - (12/18/06)
     
  14285. HIV Causes Heart Disease - (12/18/06)
     
  14286. TMC114 (Prezista) Receives Positive Opinion from the European Committee for Human Medicinal Products for Treatment Of HIV - (12/15/06)
     
  14287. Increased carotid intima-media thickness in HIV patients is associated with increased (CMV) cytomegalovirus-specific T-cell responses; chronic viral Infections appear associated with Increased risk for heart disease - (12/15/06)
     
  14288. Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving ART - (12/15/06)
     
  14289. HIV-DART: TMC114/r Metabolic Changes (lipids/glucose) in Healthy Volunteers Compared to Reyataz/r (12/15/06)
     
  14290. NIH Comments: Hormonal Contraception Does Not Appear To Increase HIV Risk - (12/14/06)
     
  14291. Hormonal contraception and the risk of HIV acquisition - (12/14/06)
     
  14292. HIV-DART: The role of NNRTIs in treatment experienced patients - an update on TMC125 (12/14/06)
     
  14293. HIV-DART: Safety and efficacy of darunavir in combination with low-dose ritonavir: 48-week results from the POWER studies (12/13/06)
     
  14294. HIV-DART: Single-center experience of darunavir (DRV) in 38 HIV-infected adults enrolled in US expanded access program (12/13/06)
     
  14295. HIV-DART: Prevalence of darunavir-associated mutations in samples received for routine clinical resistance testing (12/13/06)
     
  14296. HIV-DART: Examination of factors influencing response to darunavir combined with low-dose ritonavir in POWER 1, 2, and 3: Pooled 48-week analysis (12/13/06)
     
  14297. 8th Int Congress on Drug Therapy Fosamprenavir boosted with a single 100 mg capsule of ritonavir as part of a once daily first line regimen in naive patients (12/13/06)
     
  14298. Pravastain + Exetimibe for LDL - (12/11/06)
     
  14299. 8th Int Congress on Drug Therapy TMC125, Darunavir, and Predicting Rescue Failure: -- TMC125 runs into a resistance wall -- Once- vs twice-daily enfuvirtide, and predictors of failure -- Susceptibility to--and drug interactions with--darunavir -- Trizivir plus tenofovir after toxicity or failure (and nuke preexisting resistance & predicting failure) -- Drug breaks with loads above 400 up risk of later rebound - Written for NATAP by Mark Mascolini (12/12/06)
     
  14300. Rosiglitazone Improved Fat Loss & Insulin in HIV+ with Insulin Resistance and Fat Redistribution - (12/12/06)
     
  14301. PPL-100 Phase I Report: New PI from Merck - (12/12/06)
     
  14302. In HIV-1 pathogenesis the die is cast during primary infection: the gut and mucosa, early sites of infection; impact of therapy & vaccines [EDITORIAL REVIEW] - (12/12/06)
     
  14303. Genetic factors influencing atazanavir/r plasma concentrations and the risk of severe hyperbilirubinemia - (12/12/06)
     
  14304. Merck Filing MK-0518 with FDA in 2nd Quarter 2007 Merck seeks OK of HIV, cholesterol drugs - (12/12/06)
     
  14305. Correction on Kaiser Report That Bush Signed RWCA - (12/12/06)
     
  14306. Carotid Intimal Medial Thickness in Human Immunodeficiency Virus-Infected Women: Effects of Protease Inhibitor Use, Cardiac Risk Factors, and the Metabolic Syndrome - (12/11/06)
     
  14307. Does rHGH Help or Harm Body Composition? - (12/11/06)
     
  14308. rences in components of the metabolic syndrome betwe - (12/11/06)
     
  14309. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins - (12/11/06)
     
  14310. Longitudinal Anthropometric Changes in HIV-Infected and HIV-Uninfected Men - (12/11/06)
     
  14311. Techniques for measuring regional body fat: computed tomography may be suitable for evaluation of facial lipoatrophy - (12/11/06)
     
  14312. Incidence of Metabolic Syndrome in a Cohort of HIV-Infected Adults and Prevalence Relative to the US Population (National Health and Nutrition Examination Survey) - (12/11/06)
     
  14313. Improved Triglycerides and Insulin Sensitivity with 3 Months of Acipimox in HIV+ Patients with Hypertriglyceridemia - (12/11/06)
     
  14314. How Safe Are Facial Injectables? - (12/11/06)
     
  14315. Primary Prevention of Cardiovascular Diseases With Statin Therapy - (12/11/06)
     
  14316. Does HIV Cause Cardiovascular Disease? - (12/11/06)
     
  14317. Rosiglitazone Increased Subcutaneous Fat - (12/11/06)
     
  14318. New Weight Loss/Diabetes/Lipids Drug - (12/11/06)
     
  14319. Human Papilloma Virus (HPV) Infection of the Anus Is More Prevalent and Diverse than Cervical HPV Infection among HIV-Infected Women in the SUN Study - (12/08/06)
     
  14320. Natural Pregnancies in HIV-Serodiscordant Couples Receiving Successful Antiretroviral Therapy - (12/08/06)
     
  14321. Editorial. Which Policy to ADAP-T: Waiting Lists or Waiting Lines? - (12/08/06)
     
  14322. Partially Suppressive HAART Risks Future Drug Options - (12/08/06)
     
  14323. Tipranavir RESIST-2 Published Results - (12/08/06)
     
  14324. Lipoatrophy Improves After Switch to Abacavir or Tenofovir RAVE Study - (12/08/06)
     
  14325. HIV Screening in Health Care Settings Public Health and Civil Liberties in Conflict? - (12/08/06)
     
  14326. Vegetables Preserve Cognitive Powers with Aging - (12/08/06)
     
  14327. Magic Johnson HIV Testing in the Bronx Dec 14 and Philadelphia Dec 12 - (12/08/06)
     
  14328. 8th Int Congress on Drug Therapy Fosamprenavir/r 1400/100 Once Daily Looks Promising - Written for NATAP by Mark Mascolini (12/07/06)
     
  14329. 8th Int Congress on Drug Therapy Tipranavir 500/100 or 200 vs Kaletra in Naives - Written for NATAP by Mark Mascolini (12/07/06)
     
  14330. 8th Int Congress on Drug Therapy SQV/r vs Kaletra, Gemini Study - Written for NATAP by Mark Mascolini (12/07/06)
     
  14331. 8th Int Congress on Drug Therapy Boosted PIs and Other First-Line Strategies - Written for NATAP by Mark Mascolini (12/07/06)
     
  14332. Patients >50 Yrs Develop More Comorbidities on ART Compared to Younger Patients - (12/06/06)
     
  14333. Compromise Ryan White Care Act Passes Senate, Enzi Press Release - (12/06/06)
     
  14334. In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other ARTs in Human Renal Proximal Tubule Cells - (12/05/06)
     
  14335. Coreceptor test for CCR5 Drug Maraviroc Expanded Access Program: Monogram Provides Update On Trofile(TM) Co-Receptor Tropism Assay - (12/05/06)
     
  14336. Young African American Adults At High Risk for HIV, STDs Even In Absence of High-Risk Behaviors - (12/05/06)
     
  14337. RYAN WHITE ACT SET FOR PASSAGE - (12/05/06)
     
  14338. Rosiglitazone Beats Metformin in Diabetes Study in Treatment-Naives - (12/05/06)
     
  14339. Thiazolidinediones for Initial Treatment of Type 2 Diabetes? EDITORIAL - (12/05/06)
     
  14340. Green tea shows promise in HIV fight - (12/04/06)
     
  14341. HIV+ Minorities & Poor Get Poor Care - (12/04/06)
     
  14342. Researchers Project Lifetime Cost And Life Expectancy For Current HIV Care In The United States - (12/04/06)
     
  14343. 38% of AIDS Diagnosis Test Late in SF - (12/04/06)
     
  14344. 41% in South Carolina Test Late; - (12/04/06)
     
  14345. 45% Late Testers in 16 City CDC Study - (12/04/06)
     
  14346. Late AIDS Diagnosis 1994-99 - (12/04/06)
     
  14347. ART and the prevalence of osteopenia and osteoporosis: a meta-analytic review - (12/04/06)
     
  14348. HIV May Infect Cells Other Than CD4s in Essential Organs - (12/04/06)
     
  14349. Pioneers in AIDS Care - Reflections on the Epidemic's Early Years - (12/04/06)
     
  14350. TDF Did Not Reduce Renal Function in RTV-Boosted PI Regimens After 1 Year Preliminary Analysis - (12/04/06)
     
  14351. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/μl - (12/01/06)
     
  14352. ALCOHOL MAY INCREASE RISK OF HIV FROM ORAL SEX - (12/01/06)
     
  14353. High Uric Acid Levels Signal Hypertension in Blacks - (12/01/06)
     
  14354. NNRTI Resistance Increasing in SF; 13% Primary ART Resistance: Acute & New HIV-Infections - (12/01/06)
     
  14355. Radioactive antibodies hunt out HIV-infected cells - (12/01/06)
     
  14356. NNRTI Resistance Increasing in SF; 13% Primary ART Resistance: Acute & New HIV-Infections - (12/01/06)
     
  14357. Low-Carbohydrate-Diet Score and the Risk of Coronary Heart Disease in Women - (12/01/06)
     
  14358. An updated systematic overview of triple combination therapy in ART-naive HIV+ adults - (12/01/06)
     
  14359. Evaluation of nevirapine-switch strategies for HIV treatment - (12/01/06)
     
  14360. Lipid Protective Effect of HCV Coinfection - (12/01/06)
     
  14361. International AIDS Day to raise awareness - (12/01/06)
     
  14362. Tenofovir, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis - (12/01/06)
     
  14363. HIV to be top health problem within 25 years AIDS set to become world's biggest problem disease. - (12/01/06)
     
  14364. PFIZER ANNOUNCES PLANS TO ESTABLISH EXPANDED ACCESS PROGRAM FOR MARAVIROC, INVESTIGATIONAL HIV CCR5 ANTAGONIST - (11/30/06)
     
  14365. Smoking Boosts Cervical Cancer Risk - (11/30/06)
     
  14366. HIV+ Men & Women Who Have Anal Neoplasia - (11/30/06)
     
  14367. GSK, Sanofi and Novartis share US flu contracts; GSK Pandemic Flu H5N1 Vaccine Filing with FDA - (11/30/06)
     
  14368. Tipranavir Without Ritonavir Does Not Acutely Induce Peripheral Insulin Resistance in a Rodent Model - (11/30/06)
     
  14369. Covering All the Bases: Targeting HIV-1 Integrase - (11/30/06)
     
  14370. Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals - (11/30/06)
     
  14371. New Nationwide AIDS campaign is aimed at minorities - (11/30/06)
     
  14372. CD4+ Count-Guided Interruption of Antiretroviral Treatment, The Strategies for Management of Antiretroviral Therapy (SMART) Study Group - (11/30/06)
     
  14373. Study: Break From Medications Dangerous - (11/30/06)
     
  14374. Stop-and-start HIV treatment increases risks, study finds - (11/30/06)
     
  14375. Stop-and-Start HIV Treatment Too Risky - (11/30/06)
     
  14376. Getting Smarter - The Toxicity of Undertreated HIV Infection - EDITORIAL - (11/30/06)
     
  14377. CD4+ Count-Guided Interruption of Antiretroviral Treatment, The Strategies for Management of Antiretroviral Therapy (SMART) Study Group - (11/30/06)
     
  14378. IAC: Panacos Fusion Inhibitor Drug Discovery Program: developing oral fusion inhibitor active against Fuzeon resistance (11/30/06)
     
  14379. 8th Int Congress on Drug Therapy Optimal Kaletra Adherence During 1st Few Weeks on HAART Key To Achieving Viral Suppression (12/01/06)
     
  14380. 8th Int Congress on Drug Therapy Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir (11/29/06)
     
  14381. 8th Int Congress on Drug Therapy Three More Looks at First-Line Efavirenz vs Lopinavir - Written for NATAP by Mark Mascolini (11/29/06)
     
  14382. 8th Int Congress on Drug Therapy Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and methadone (11/28/06)
     
  14383. 8th Int Congress on Drug Therapy Fixed Dose, Single Pill Truvada Preferred to TDF+FTC (11/28/06)
     
  14384. 8th Int Congress on Drug Therapy The Safety And Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) Through 5 Years in Antiretroviral-naive Patients (11/28/06)
     
  14385. 8th Int Congress on Drug Therapy Tenofovir/FTC+Efavirenz Compared to Combivir+Efavrienz, Safety & Efficacy at 96 Weeks. 934 Study (11/28/06)
     
  14386. 8th Int Congress on Drug Therapy Gene Screening Lowers Rate of Abacavir Reaction - Written for NATAP by Mark Mascolini (11/28/06)
     
  14387. 8th Int Congress on Drug Therapy Response to TMC114 is Based on Genotypic/Phenotypic Resistance: POWER 1/2/3 pooled analysis (11/28/06)
     
  14388. 8th Int Congress on Drug Therapy Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine and sertraline (11/28/06)
     
  14389. 8th Int Congress on Drug Therapy Lack of Sex Differences in Once Daily Lopinavir/ritonavir Pharmacokinetic Profile (11/28/06)
     
  14390. 8th Int Congress on Drug Therapy A PILOT 48-WEEK STUDY OF ONCE-DAILY (180 MG QD) VERSUS TWICE-DAILY (90 MG BID) ENFUVIRTIDE (11/28/06)
     
  14391. 8th Int Congress on Drug Therapy Genetic Screening Test for Abacavir Hypersensitivity -- PREDICT-1: Description of a Novel Randomised Prospective Study Design to Determine the Clinical Utility of Prognostic Screening for HLA-B*5701 (11/28/06)
     
  14392. 8th Int Congress on Drug Therapy More Details on Renal and Bone Toxicity With Tenofovir - Written for NATAP by Mark Mascolini (11/28/06)
     
  14393. 8th Int Congress on Drug Therapy Combined analysis of RESIST 96 week data: durability and efficacy of tipranavir/r in treatment-experienced patients (11/28/06)
     
  14394. 8th Int Congress on Drug Therapy Week 48 efficacy of TPV/r treatment is enhanced in patients with higher numbers of genotypically available background drugs in RESIST 1 and 2 (11/27/06)
     
  14395. 8th Int Congress on Drug Therapy Hypertension in HIV (11/27/06)
     
  14396. 8th Int Congress on Drug Therapy Kaletra Tablets Improve Adherence, Tolerability, Diarrhea, and Side Effects Regardless of Ethnicity. Survey of 332 Patients: Blacks, Whites, Hispanics (11/27/06)
     
  14397. 8th Int Congress on Drug Therapy Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir after switching from BID soft-gel capsule (SGC) to BID Tablets (11/27/06)
     
  14398. 8th Int Congress on Drug Therapy Antilipid Tactics, Diabetes, and Abacavir Reactions: (1) prescribe a lipid lowering drug or switch to NNRTI; (2) Atazanavir, lipids, and cardiovascular risk; (3) antilipid drug rosuvastatin; (4) Diabetes risk factors in D:A:D: d4T, ddI, AZT increase risk, nevirapine protective; (5) abacavir genetic testing prevents hypersensitivity reaction - Written for NATAP by Mark Mascolini (11/27/06)
     
  14399. 8th Int Congress on Drug Therapy Tenofovir Renal Affects in Mild Renal Impairment and Hypertension/Diabetes (11/21/06)
     
  14400. 8th Int Congress on Drug Therapy Kaletra Tablets Improve Tolerability/Diarrhea Compared to Soft-Gel Capsules (11/21/06)
     
  14401. 8th Int Congress on Drug Therapy Study Reports No Frequent Reporting of TMC125 Neurological or Psychiatric Events (11/20/06)
     
  14402. 8th Int Congress on Drug Therapy Saquinavir/r 500mg Pills Once or Twice Daily: efficacy, lipids, ALT (11/20/06)
     
  14403. 8th Int Congress on Drug Therapy Lipids & ALTs in SQV 500mg in Spanish Study (11/20/06)
     
  14404. 8th Int Congress on Drug Therapy SQV 500mg (1000/100) in Exp/Naives (11/20/06)
     
  14405. 8th Int Congress on Drug Therapy Switching to Saquinavir 500-mg Based Regimens in ART-Experienced (11/20/06)
     
  14406. 8th Int Congress on Drug Therapy Trough Concentrations in HIV patients Receiving Boosted Hard-Gel Capsules (HGC) and 500 mg Film-Coated Tablet (FCT) Formulations of Saquinavir (11/20/06)
     
  14407. 8th Int Congress on Drug Therapy Boosted Saquinavir Does Not Affect Methadone (11/20/06)
     
  14408. 8th Int Congress on Drug Therapy Once Daily Fosamprenavir/RTV 1400/100mg + FD ABC/3TC Pilot study (11/17/06)
     
  14409. 8th Int Congress on Drug Therapy TMC114 PK & Drug Interactions (11/17/06)
     
  14410. 8th Int Congress on Drug Therapy Tipranavir 500/100 & 500/200 vs Kaletra in Naives (11/17/06)
     
  14411. 8th Int Congress on Drug Therapy Tipranavir 500/100, 500/200 vs Kaletra in Naives (11/17/06)
     
  14412. 8th Int Congress on Drug Therapy TMC125 in combination with other medications: summary of drug-drug interactions (11/17/06)
     
  14413. An updated systematic overview of triple combination therapy in ART-naive HIV+ adults - (11/16/06)
     
  14414. A Prospective Controlled Study of Neurodevelopment in HIV-Uninfected Children Exposed to Combination Antiretroviral Drugs in Pregnancy - (11/16/06)
     
  14415. Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment - (11/16/06)
     
  14416. New Risk Factors: Predictors of Antiretroviral-Related Hepatotoxicity in the Adult AIDS Clinical Trial Group (1989-1999) - (11/16/06)
     
  14417. Insulin Resistance is Associated with Cognitive Dysfunction in HIV+ - (11/16/06)
     
  14418. Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes - (11/16/06)
     
  14419. Fish Protects Against Dementia, Alzheimer Disease, EDITORIAL - (11/16/06)
     
  14420. 8th Int Congress on Drug Therapy No Higher Risk of Toxicity-Related ART Stops in Older People - Written for NATAP by Mark Mascolini (11/16/06)
     
  14421. 8th Int Congress on Drug Therapy Treatment Breaks With >400 Copies Raise Risk of Later Rebound - Written for NATAP by Mark Mascolini (11/16/06)
     
  14422. 8th Int Congress on Drug Therapy a More Ribavirin, Longer Course Control HCV Better in HIV Patients - Written for NATAP by Mark Mascolini (11/16/06)
     
  14423. 8th Int Congress on Drug Therapy Maraviroc, Changes in CD4 & Tropism in ART-EXperienced 1029 Study (11/16/06)
     
  14424. 8th Int Congress on Drug Therapy What's Better for High Lipids: Antilipid Drugs or NNRTI Switch? - Written for NATAP by Mark Mascolini (11/16/06)
     
  14425. 8th Int Congress on Drug Therapy Antiretrovirals May be Double-Edged Sword for Liver Fibrosis: glucose levels associated with advancing fibrosis and increased CD4 count associated with slower fibrosis progression - Written for NATAP by Mark Mascolini (11/16/06)
     
  14426. Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes - (11/15/06)
     
  14427. 8th Int Congress on Drug Therapy The Metabolic Syndrome at Baseline in the D:A:D study 20% (11/15/06)
     
  14428. 8th Int Congress on Drug Therapy d4T and Lipodystrophy Raise Diabetes Risk in D:A:D Cohort; Nevirapine Protects (11/15/06)
     
  14429. 8th Int Congress on Drug Therapy First-Line Lopinavir Versus Efavirenz in Two European Studies - Written for NATAP by Mark Mascolini (11/15/06)
     
  14430. 8th Int Congress on Drug Therapy Atazanavir Switch Improved Lipids But Limited Impact on Cardiovascular Risk Score; Should Intervene with Other Risk Factors - Written for NATAP by Mark Mascolini (11/15/06)
     
  14431. 8th Int Congress on Drug Therapy Impact of NNRTI and NRTI Resistance on the Response to the Regimen of TMC125 Plus 2 NRTIs in Study TMC125-227 (11/14/06)
     
  14432. 8th Int Congress on Drug Therapy TMC125 Controversial Response in Early Study - Written for NATAP by Mark Mascolini (11/14/06)
     
  14433. 8th Int Congress on Drug Therapy Nonnucleoside Levels High in HIV-Infected Cirrhotics - Written for NATAP by Mark Mascolini (11/14/06)
     
  14434. 8th Int Congress on Drug Therapy Resistance Rates on the Wane in Southern Europe - Written for NATAP by Mark Mascolini (11/14/06)
     
  14435. 8th Int Congress on Drug Therapy SAQUINAVIR/R BID VS. LOPINAVIR/R BID PLUS FTC/TENOFOVIR QD IN ARV-NAIVE HIV-1 INFECTED PATIENTS: GEMINI STUDY - (11/14/06)
     
  14436. 8th Int Congress on Drug Therapy Ritonavir Boosted Saquinavir 1000/100 twice daily vs Kaletra: Preliminary Study Report After 24 Weeks - Written for NATAP by Mark Mascolini (11/14/06)
     
  14437. 8th Int Congress on Drug TherapyTrizivir Maintenance After Efavirenz vs Lopinavir Induction - Written for NATAP by Mark Mascolini (11/14/06)
     
  14438. ICAAC: Analysis of CCR5 Binding Kinetics and Coupling States Reveals Distinctive Binding Properties of Small Molecule CCR5 Antagonists (10/31/06)
     
  14439. CD4 Count Based ADAP Eligibility Proposed - (10/26/06)
     
  14440. How Important Is Diabetes as a Risk Factor for Cardiovascular and Other Diseases in Older Adults? - (10/26/06)
     
  14441. One Study Calls Fish a Lifesaver, Another Is More Cautious - (10/26/06)
     
  14442. Fish Intake, Contaminants, and Human Health - (10/26/06)
     
  14443. Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin - (10/26/06)
     
  14444. Roche and Trimeris Provide Update on Development of Needle-Free Administration for FUZEON - (10/26/06)
     
  14445. Nicotine receptors on kidneys may speed kidney damage - (10/26/06)
     
  14446. Updated Change in DHHS HIV Treatment Guidelines as of October 10, 2006: Reyataz/r & FosAPV/r added to Preferred Regimens for Naives - (10/26/06)
     
  14447. New Test for Acute HIV Approved by FDA - (10/26/06)
     
  14448. Coffee, diabetes, lipids, and weight control - (10/26/06)
     
  14449. Fatty Liver Associated with Increased Mortality - (10/26/06)
     
  14450. Fuzeon Helped Patients in Merck Integrase Study - (10/26/06)
     
  14451. TMC114 Access & Reimbursement Hotline - (10/26/06)
     
  14452. 8th Intl Wrkshp Adverse Drug & Lipo: Improved Triglycerides and Insulin Sensitivity with 3 mos of Acipimox in HIV-infected Patients with Hypertriglyceridemia - (10/24/06)
     
  14453. IDSA: PL-100, a Next Generation Protease Inhibitor Against Drug-Resistant HIV: In Vitro and In Vivo Metabolism - (10/24/06)
     
  14454. 8th Intl Wrkshp Adverse Drug & Lipo: Comparison of the Effects on Body Composition of Rosiglitazone, Pravastatin, and Growth Hormone Alone and in Combination in the HIV-associated Lipoatrophy Treatment (HALT) Study - (10/17/06)
     
  14455. 8th Intl Wrkshp Adverse Drug & Lipo: Mitochondrial function, morphology, and metabolic parameters improve after switching from a stavudine- to a tenofovir-containing regimen: SNAP (Switch Nucleoside Analogues Protocol) - (10/17/06)
     
  14456. 8th Intl Wrkshp Adverse Drug & Lipo: Anti-inflammatory effects on body composition and metabolic alterations in HIV lipodystrophy: a pilot study - (10/17/06)
     
  14457. ICAAC: Resistance Before Therapy, Hidden Mutations, and Blips - Written for NATAP by Mark Mascolini - (10/24/06)
     
  14458. ICAAC: Adherence Slips & Viral Blips - Written for NATAP by Mark Mascolini - (10/24/06)
     
  14459. ICAAC: Resistance analysis of TDF/FTC-versus-AZT/3TC trial - Written for NATAP by Mark Mascolini - (10/24/06)
     
  14460. ICAAC: Standard Genotyping Does Not Pick Up All Resistance - Written for NATAP by Mark Mascolini - (10/24/06)
     
  14461. ICAAC: Resistance to Tipranavir & other PIs - Written for NATAP by Mark Mascolini - (10/24/06)
     
  14462. ICAAC: U.S. Resistance & NNRTI Rates Still Rising in Untreated - Written for NATAP by Mark Mascolini - (10/24/06)
     
  14463. Updated Perinatal Guidelines by the DHHS - (10/20/06)
     
  14464. IDSA: Predictors of Response to TMC114 in POWER 1/2/3 - (10/17/06)
     
  14465. IDSA: Pharmacokinetic interaction between TMC114 and ketoconazole, in the absence and presence of low-dose ritonavir - (10/17/06)
     
  14466. IDSA: Pharmacokinetic interaction between the antiretroviral agents TMC114 and nevirapine, in the presence of low-dose ritonavir - (10/17/06)
     
  14467. IDSA: Pharmacokinetic interaction between the HIV protease inhibitors TMC114 and saquinavir, in the presence of low-dose ritonavir - (10/17/06)
     
  14468. IDSA: TMC114/r tolerability in treatment-experienced, hepatitis B or C (HBV/HCV) co-infected patients in POWER 1 and 3 - (10/17/06)
     
  14469. IDSA: Efficacy and Safety Results of Darunavir/ritonavir in Treatment-experienced Patients: POWER 3 - (10/17/06)
     
  14470. IDSA: Safety/Lipids & Durability of Viral Load Suppression of TMC114 in POWER 1/2 Week 48 - (10/17/06)
     
  14471. IDSA: Higher Rectal HIV RNA Levels in Men who have Sex with Men (MSM) with Concurrent Rectal HSV Shedding - (10/17/06)
     
  14472. ICAAC: Tenofovir and Lopinavir Levels in Pregnant Women and Infants - Written for NATAP by Mark Mascolini - (10/16/06)
     
  14473. ICAAC: Complications of Three Simplifying Strategies - Written for NATAP by Mark Mascolini - (10/16/06)
     
  14474. ICAAC: Cell Studies Predict Cross-Resistance Among Integrase Inhibitors - Written for NATAP by Mark Mascolini -- (10/16/06)
     
  14475. ICAAC: Age, Depression, and CD4 Gains - Written for NATAP by Mark Mascolini - (10/16/06)
     
  14476. ICAAC: Distribution Of Susceptibility Among HIV-1 Clinical Samples Submitted For Enfuvirtide (ENF) Resistance Testing - (10/16/06)
     
  14477. ICAAC: Baseline viral load (400,000 IU/mL) as a predictor of SVR rate with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in HCV/HIV Coinfected in Apricot Study - (10/16/06)
     
  14478. ICAAC: Needle-free administration (Biojector) of enfuvirtide significantly reduces incidence of painful injection site reactions: results from a single blind, randomized, controlled study - (10/16/06)
     
  14479. ICAAC: Increased Risk of Clinical Event if CD4 <200 After Starting HAART - (10/16/06)
     
  14480. ICAAC: Defining Lower (L) and Upper (U) Phenotypic Clinical Cutoffs (CCO's) for Tipranavir/r (TPV), Lopinavir/r (LPV), Saquinavir (SQV) and Amprenavir (APV) Co-Administered with Ritonavir (r) Within the RESIST Dataset by the PhenoSense Assay - (10/16/06)
     
  14481. ICAAC: Atazanavir/ritonavir (ATV/RTV) and Efavirenz (EFV) NRTI-Sparing Regimens in Treatment-Naive Adults - (10/16/06)
     
  14482. ICAAC: Abacavir Once Daily Had Fewer HSR than Twice Daily (ALOHA Study) - (10/06/06)
     
  14483. ICAAC: Needle-free administration (Biojector) of enfuvirtide significantly reduces incidence of painful injection site reactions: results from a single blind, randomized, controlled study - (10/06/06)
     
  14484. ICAAC: Good News and Mixed News on New Antiretrovirals: Integrase and CCR5 Inhibitors, a Nuke, and a Nonnuke - Written for NATAP by Mark Mascolini - (10/05/06)
     
  14485. ICAAC: Affect of R5 & X4/R5 Tropism on CD4 Count, HIV-RNA, and Response to HAART - (10/05/06)
     
  14486. Lung Cancer Particularly Aggressive in Patients with HIV - (10/05/06)
     
  14487. ICAAC: Clinical course of increased LFTs and hepatic events associated with ritonavir (RTV)-boosted tipranavir (TPV/r) based therapy in the RESIST trials - (10/04/06)
     
  14488. ICAAC: Impact of protease mutations L33 F/I, V82A, I84V, and L90M on ritonavir-boosted protease inhibitor susceptibility - (10/04/06)
     
  14489. ICAAC: Incidence of Drug Resistance Mutations in ART Naives from 2000 to 2005 in USA - (10/04/06)
     
  14490. ICAAC: New CCR5 Drug HGS004 Study Results - (10/04/06)
     
  14491. ICAAC: New CCR5 Drug HGS004 Phase 1 Study Results - (10/04/06)
     
  14492. IAC: Combination of TMC114/r and TMC125 in Patients with Multidrug Resistant HIV (10/03/06)
     
  14493. ICAAC: Lower Reported Rate of Suspected Hypersensitivity Reactions (HSR) to Abacavir (ABC) Among Black Patients - (10/03/06)
     
  14494. ICAAC: TMC114 Susceptibility Against 56,000 Patient Samples - (10/03/06)
     
  14495. ICAAC: Contamination of Environmental Surfaces During Normal Daily Activities of Hotel Guests with Rhinovirus Colds - (10/03/06)
     
  14496. Thiazolidinedione Use (glitazones), Fluid Retention, and Congestive Heart Failure - (10/03/06)
     
  14497. Tenofovir 5 Year Efficacy/Safety Reported at Lipodystrophy Workshop - (10/03/06)
     
  14498. Safety, Tolerability & Efficacy of Abacavir/Lamivudine/Zidovudine vs. Atazanavir & Lamivudine/Zidovudine in Antiretroviral Naive Subjects - (10/02/06)
     
  14499. 8th Intl Wrkshp Adverse Drug & Lipo: Switching to lopinavir/ritonavir (LPV/r) Tablets once daily (TAB-QD) from soft-gel capsule dosed BID/QD (SGC-BID/SGC-QD) led to significant improvements in tolerability, diarrhea, antidiarrheal medication use, and satisfaction - (10/01/06)
     
  14500. 8th Intl Wrkshp Adverse Drug & Lipo: Significant Improvements in Self-Reported Gastrointestinal Tolerability, Quality of Life, Patient Satisfaction, and Adherence with Lopinavir/ritonavir After Switching from BID Soft-Gel Capsules (SGC) to BID Tablets - (09/28/06)
     
  14501. ICAAC: Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus: 24 Week Data - (10/02/06)
     
  14502. ICAAC: Darunavir Equally Effective After LPV, FPV, or TPV Failure - Written for NATAP by Mark Mascolini - (10/02/06)
     
  14503. ICAAC: Efavirenz/Tenofovir Fails as 2-Drug Maintenance Regimen - Written for NATAP by Mark Mascolini - (10/02/06)
     
  14504. ICAAC: Integrase Inhibitor Shows Strength in Treatment Experienced - Written for NATAP by Mark Mascolini - (10/02/06)
     
  14505. ICAAC: CD4s Plateau at Lower Level When Treatment Starts Late - Written for NATAP by Mark Mascolini - (10/02/06)
     
  14506. ICAAC: Fosamprenavir/RTV 1400/100 Once Daily vs Reyataz/RTV Once Daily - (10/02/06)
     
  14507. ICAAC: HCV-796 Displays Potent Antiviral Activity in Replicon and in Chimeric Mice Infected with Hepatitis C Virus (HCV) - (10/02/06)
     
  14508. ICAAC: Efficacy and Novel Pharmacology of Elvucitabine in a 7 Day Placebo Controlled Monotherapy Study - (10/02/06)
     
  14509. ICAAC: Roche HCV Polymerase Inhibitor: two preclinical studies - (10/02/06)
     
  14510. Tenofovir 5 Year Efficacy/Safety Reported at Lipodystrophy Workshop - (09/29/06)
     
  14511. Switch from Stavudine (d4T) to Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) Resulted in Continued Virologic Suppression and Improvement in Lipoatrophy Through 2 Years in HIV-Infected Patients - (09/29/06)
     
  14512. Tibotec Therapeutics Announces Initiation of the Largest U.S. Clinical Study Examining HIV Treatment in Treatment-Experienced Adult Women called GRACE Study - (09/29/06)
     
  14513. ICAAC: Week 24 Results and Baseline Phenotypic Susceptibility in Treatment Experienced Patients Initiating the Combination of TMC114/r and TMC 125 - (09/29/06)
     
  14514. ICAAC: "Hidden" Mutations Contribute to Failure of Trizivir/Tenofovir - Written for NATAP by Mark Mascolini - (09/29/06)
     
  14515. ICAAC: Another Look at Three Nukes (Trizivir)--Versus Unboosted Atazanavir - (09/29/06)
     
  14516. ICAAC: Slips in Adherence Tied to Transient Viremia ("Blips") - Written for NATAP by Mark Mascolini - (09/29/06)
     
  14517. ICAAC: Nucleoside-Sparing Regimen Coupling Atazanavir/Ritonavir and Efavirenz - Written for NATAP by Mark Mascolini - (09/29/06)
     
  14518. ICAAC: Critical Interactions Between Darunavir (TMC114), Lopinavir, Viagra, and Oral Contraceptives - Written for NATAP by Mark Mascolini - (09/28/06)
     
  14519. ICAAC: HIV May Like Different Coreceptors in Blood and Brain - Written for NATAP by Mark Mascolini - (09/28/06)
     
  14520. ICAAC: PL-100, a Next Generation Protease Inhibitor Against Drug-Resistant HIV: In vitro & IN Vivo Metabolism - (09/28/06)
     
  14521. ICAAC: Cell Studies Predict Cross-Resistance Among Integrase Inhibitors - Written for NATAP by Mark Mascolini - (09/28/06)
     
  14522. ICAAC: Integrase Inhibitor Has Little 24-Week Impact on Lipids - Written for NATAP by Mark Mascolini - (09/28/06)
     
  14523. ICAAC: Integrase MK-0518 Does Not Increase Lipids After 24 Weeks in Naives - (09/28/06)
     
  14524. 8th Intl Wrkshp Adverse Drug & Lipo: A six-months ART interruption in HIV-infected patients improves adipose tissue morphology and gene expression (ANRS EP29 Lipostop) - (09/28/06)
     
  14525. 8th Intl Wrkshp Adverse Drug & Lipo: Leptin Improves Visceral Belly Fat, Dyslipidemia, and Insulin Resistance - (09/28/06)
     
  14526. 8th Intl Wrkshp Adverse Drug & Lipo: Pioglitazone Improves Limb Fat Loss - (09/26/06)
     
  14527. Diabetes is Strong Predictor of Early Death & Acute Organ Failure - (09/26/06)
     
  14528. 8th Intl Wrkshp Adverse Drug & Lipo: Systemic Errors in Estimating Renal Function by Cockroft-Gault or MDRD Equations - (09/26/06)
     
  14529. 8th Intl Wrkshp Adverse Drug & Lipo: Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Patients After Switch to Atazanavir/Ritonavir (ATV/RTV): A Prospective Study Using Hyperinsulinemic, Euglycemic Clamp Testing - (09/26/06)
     
  14530. 8th Intl Wrkshp Adverse Drug & Lipo: Risk of Hepatotoxicity in Virologically Suppressed HIV+ Patients switching to Nevirapine According to Gender & CD4 Count - (09/26/06)
     
  14531. 8th Intl Wrkshp Adverse Drug & Lipo: Limb Fat Loss: nelfinavir, efavirenz, nukes - (09/26/06)
     
  14532. Interactions between Natural Health Products and Antiretroviral Drugs: Pharmacokinetic and Pharmacodynamic Effects - (09/22/06)
     
  14533. Prevalence of HPV Infection among Men: A Systematic Review of the Literature - (09/22/06)
     
  14534. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide - (09/22/06)
     
  14535. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection - (09/22/06)
     
  14536. The role of tenofovir in the prevention of HIV infections - (09/22/06)
     
  14537. Screening HIV-Infected Individuals for Anal Cancer Precursor Lesions: A Systematic Review - (09/21/06)
     
  14538. HIV-Associated Anal Squamous Cell Cancer: An Otherwise Preventable Disease - (09/21/06)
     
  14539. Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings - (09/21/06)
     
  14540. Fatty Fish Consumption Reduces Renal Cell Cancer in Women - (09/19/06)
     
  14541. Serum prostate-specific antigen levels in older men with or at risk of HIV infection - (09/19/06)
     
  14542. Antiretroviral Medication Errors among Hospitalized Patients with HIV Infection - (09/19/06)
     
  14543. The Changing Face of HIV Care: Common Things Really Are Common-Heart Disease, IVDU, Ling Cancer, diabetes, and Routine HIV Testing EDITORIAL - (09/19/06)
     
  14544. Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City - (09/19/06)
     
  14545. New CVD, Blood pressure Drugs - (09/18/06)
     
  14546. Antiretroviral Therapy for Hepatitis B Virus-HIV-Coinfected Patients: Promises and Pitfalls - (09/18/06)
     
  14547. Adherence to Antiretroviral Therapy: How Much Is Enough? Editorial, Trip Gulick, MD - (09/18/06)
     
  14548. Is HIV out of control in the UK? An example of analysing patterns of HIV spreading using incidence-to-prevalence ratios - (09/18/06)
     
  14549. IAC: CCR5 Antagonists: When Should They be Used? - Written by Mark Mascolini - (09/18/06)
     
  14550. IAC: Efavirenz Nonadherence in Blacks & Whites - Written by Mark Mascolini - (09/18/06)
     
  14551. Diet & Exercise Counseling Program Improved Cardiovascular Risk Indices and Lipodystrophy - (09/18/06)
     
  14552. Glucose lowering and diabetes prevention: are they the same? COMMENTARY - (09/18/06)
     
  14553. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial - (09/18/06)
     
  14554. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial - (09/18/06)
     
  14555. The PROactive study: some answers, many questions - (09/18/06)
     
  14556. Bristol-Myers Squibb Company And Medivir AB Announce Worldwide Collaboration To Develop And Commercialize NNRTI MIV-170 For The Treatment Of HIV-1 Infection In Adults - (09/15/06)
     
  14557. Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1-Infected Patients with Detectable Viremia - (09/15/06)
     
  14558. Incorporating Drug-Resistance Measurements into the Clinical Management of HIV-1 Infection, Andrew Zolopa, MD - (09/15/06)
     
  14559. Chemoprophylaxis of HIV Infection: Moving Forward with Caution - (09/15/06)
     
  14560. Green Tea (5 cups) Daily Reduced Mortality & Cardiovascular Mortality - (09/15/06)
     
  14561. Autoimmune Hepatitis Triggered by Statins - (09/15/06)
     
  14562. A Multicenter Observational Study of the Potential Benefits of Initiating Combination Antiretroviral Therapy during Acute HIV Infection - (09/15/06)
     
  14563. Immunological and Virological Impact of Highly Active Antiretroviral Therapy Initiated during Acute HIV-1 Infection - (09/15/06)
     
  14564. Treatment of Acute HIV-1 Infection: Is It Coming of Age? - (09/15/06)
     
  14565. IAC: Early treatment does not protect CD4s in gut - Written by Mark Mascolini - (09/13/06)
     
  14566. IAC: Does Treating Primary HIV-Infection Do Any Good? - Written by Mark Mascolini - (09/13/06)
     
  14567. Hypertension-Related Mortality Among Hispanic Subpopulations --- United States, 1995--2002 - (09/12/06)
     
  14568. Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities - (09/12/06)
     
  14569. The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-Term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs - (09/12/06)
     
  14570. IAC: Resistance Profile after Treatment with an Atazanavir-Containing Regimen: First Interim Analysis Results from the IMPACT Study (BMS AI424-128) (09/12/06)
     
  14571. IAC: Nonnukes vs PIs: Digesting the Latest Data - Written by Mark Mascolini - (09/12/06)
     
  14572. Lithium improves HIV-associated neurocognitive impairment - (09/08/06)
     
  14573. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically - (09/08/06)
     
  14574. Micronutrient Supplementation Increases CD4 Count in HIV-Infected Individuals on Highly Active Antiretroviral Therapy - (09/08/06)
     
  14575. Enhancing the potential benefits of HIV post-exposure prophylaxis EDITORIAL - (09/08/06)
     
  14576. A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen - (09/08/06)
     
  14577. HAART Interruption: Predictors and Virological and Immunologic Consequences (20% Interrupt HAART in this study) - (09/06/06)
     
  14578. Longitudinal Analysis of Bone Density in HIV-Infected Women - (09/06/06)
     
  14579. IAC: Monotherapy With Two Drugs: Is Lopinavir/Ritonavir Enough? - Written by Mark Mascolini - (09/06/06)
     
  14580. IAC: Questions and answers from clinical trials of lopinavir/ritonavir monotherapy presented at WAC in Toronto - Written by Jose Arribas, MD - (09/06/06)
     
  14581. IAC: Select Highlights from IAC 2006: Gates & Clinton, TB, integrase, HIV testing... - (09/06/06)
     
  14582. IAC: Factors associated with seronegative chronic hepatitis C virus infection in HIV-infection - (09/06/06)
     
  14583. IAC: New Antiretrovirals - Written by Mike Youle - (09/06/06)
     
  14584. IAC: PCP prophylaxis is not required with a CD4+ T cell count < 200 cells/uL when viral replication is effectively suppressed - (09/06/06)
     
  14585. IAC: Safety of Atazanavir (ATV) and ATV/Ritonavir (ATV/RTV) in Patients Co-infected With HIV and Hepatitis B and/or C: 1100 Patient-years of Treatment Exposure - (09/06/06)
     
  14586. Diagnostic and Clinical Implications of Anorectal Lymphogranuloma Venereum in Men Who Have Sex with Men: A Retrospective Case-Control Study - (09/05/06)
     
  14587. Lymphogranuloma venereum among men having sex with men; what have we learned so far? - (09/05/06)
     
  14588. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study - (09/05/06)
     
  14589. Exercise After Fatty Meal Reverses Arterial Dysfunction - (08/31/06)
     
  14590. Regimen Simplification to Atazanavir-Ritonavir Alone as Maintenance Antiretroviral Therapy After Sustained Virologic Suppression - (08/31/06)
     
  14591. Fruit & Juice May Prevent Alzheimers/Prostate Cancer - (08/31/06)
     
  14592. IAC: New Fusion Inhibitor Peptides, TRI-999 and TRI-1144, are Potent Inhibitors of Enfuvirtide and T-1249 Resistant Isolates - (08/29/06)
     
  14593. IAC: Planned Treatment Breaks: Long Looks at SMART, DART, and BASTA - (08/29/06)
     
  14594. Drug Transporter and Metabolizing Enzyme Gene Variants and NNRTI Hepatotoxicity - (08/30/06)
     
  14595. Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration - (08/30/06)
     
  14596. Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study - (08/30/06)
     
  14597. IAC: 47% of African- Americans Support HIV Conspiracy Theory, Study Finds - (08/29/06)
     
  14598. IAC: Patient Survey: Fuzeon Biojector Improves Pain & ISRs, Adherence, Injection Concerns, and Interference with Daily Activities; 75% prefer Biojector to the standard needles/syringes - (08/29/06)
     
  14599. Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study - (08/29/06)
     
  14600. Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients - (08/29/06)
     
  14601. Evaluation of Oral Tenofovir Disoproxil Fumarate and Topical Tenofovir GS-7340 to Protect Infant Macaques Against Repeated Oral Challenges With Virulent Simian Immunodeficiency Virus - (08/29/06)
     
  14602. Lack of Decay of HIV-1 in (GALT) Gut-Associated Lymphoid Tissue Reservoirs in Maximally Suppressed Individuals - (08/29/06)
     
  14603. Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis - (08/29/06)
     
  14604. TMC114/r is well tolerated by treatment-experienced patients in POWER 1, 2 and 3: integrated clinical safety analysis - (08/29/06)
     
  14605. A Novel Pattern of Lipoaccumulation in HIV-Infected Men - (08/29/06)
     
  14606. IAC: Reyataz Lipid Changes - (08/29/06)
     
  14607. IAC: TMC114/r in treatment-experienced HIV patients in POWER 3: 24-week efficacy and safety analysis - (08/29/06)
     
  14608. IAC: Risk of discontinuation of nevirapine due to toxcities in antiretroviral naive and experienced patients with high and low CD4 counts - (08/29/06)
     
  14609. IAC: TMC114/r in treatment-experienced patients in POWER 1, 2 and 3: integrated analysis of laboratory parameters - (08/29/06)
     
  14610. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects - (08/28/06)
     
  14611. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues - (08/28/06)
     
  14612. Mitochondrial dysfunction: prevention of HIV-1 mother-to-infant transmission outweighs fear - (08/28/06)
     
  14613. IAC: Absence of TMC114 exposure-efficacy and exposure-safety relationships in POWER 3 - (08/28/06)
     
  14614. IAC: CD4 Increases in Patients with Ongoing Viral Replication while Receiving Enfuvirtide are Associated with V38 and other Mutations in gp41 - (08/28/06)
     
  14615. IAC: Clinical pharmacology of TMC114 - a new HIV protease inhibitor - (08/28/06)
     
  14616. FDA Approves Generic FDC ATZ/3TC - (08/25/06)
     
  14617. Kaletra Cream Attacks HPV, May Stop Cervical cancer - (08/25/06)
     
  14618. Liver Related Disease Causes Most Frequent Non-AIDS Deaths; 76% Due to HCV or HBV Coinfection - (08/25/06)
     
  14619. IAC: Efavirenz-based Regimens are Potent in Treatment-Naive Patients Across a Wide Range of Pre-Treatment HIV-1 RNA and CD4 Cell Counts - (08/24/06)
     
  14620. IAC: Increase in New HIV Diagnosis from 14% to 32% in NYC - (08/24/06)
     
  14621. IAC: IDUs in NYC Have Risky Sexual Behavior - (08/24/06)
     
  14622. IAC: Syringe Exchange in NYC Reduces Number of HIV Cases Among IDUs - (08/24/06)
     
  14623. IAC: Comparisons of HIV risk behaviors between foreign-born and US-born men who have sex with men (MSM) in New York City - (08/24/06)
     
  14624. IAC: Older Age Associated with Reduced HAART Tolerabilty - (08/24/06)
     
  14625. IAC: Kaletra Monotherapy Induction-Maintenance in Naives Compared to Efavirenz, 96 Weeks - (08/23/06)
     
  14626. Changing the Paradigm for HIV Testing - The End of Exceptionalism - (08/23/06)
     
  14627. AIDS in 2006 - Moving toward One World, One Hope? - (08/23/06)
     
  14628. Body-Mass Index and Mortality in Korean Men and Women - (08/23/06)
     
  14629. IAC: Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs) - (08/23/06)
     
  14630. IAC: Dramatic increase in the incidence of anal cancer despite HAART in the French hospital database of HIV - (08/23/06)
     
  14631. IAC: TMC120 Vaginal Ring Promising As Microbicide Carrier - (08/23/06)
     
  14632. IAC: Impact of prior PI usage on Week 48 responses to tipranavir boosted with ritonavir (TPV/r) - (08/23/06)
     
  14633. IAC: Pharmacokinetic interaction study with TMC125 and TMC114/r in HIV-negative volunteers - (08/23/06)
     
  14634. IAC: EFV +TDF/FTC or Combivir 96 Wks Study 934: limb fat/renal/resistance/safety/viral efficacy - (08/22/06)
     
  14635. IAC: Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, as part of Combination ART in Treatment -Naive HIV-1 infected Patients - (08/22/06)
     
  14636. IAC: Pharmacogenetic (PG) Investigation of Hypersensitivity to Abacavir - (08/22/06)
     
  14637. IAC: Phase II Study of the Safety and Efficacy of Vicriviroc (VCV) in HIV+ Treatment-Experienced Subjects - (08/22/06)
     
  14638. IAC: EFV +TDF/FTC or Combivir 96 Wks Study 934: limb fat/renal/resistance/safety/viral efficacy - (08/21/06)
     
  14639. On prisons, blacks, HIV - (08/21/06)
     
  14640. Syringe Exchange: lack of acceptance - (08/21/06)
     
  14641. How HIV 'burns out' the human immune system - (08/21/06)
     
  14642. IAC: Switch from Kaletra to Reyataz (SWAN Study 48 weeks): lipids, viral suppression - (08/21/06)
     
  14643. IAC: Recombinant human Growth Hormone (r-hGH) to treat HIV-associated Adipose Redistribution Syndrome (HARS): 12-week Induction and 24-Week Maintenance Therapy - (08/21/06)
     
  14644. IAC: Safety and Efficacy of MARAVIROC (MVC), a Novel CCR5 Antagonist, When Used in Combination with Optimized Background Therapy (OBT) for the Treatment of Antiretroviral-Experienced Subjects Infected with Dual/Mixed-Tropic HIV-1: 24-Week Results of a Phase 2b Exploratory Trial - (08/21/06)
     
  14645. IAC: HIV Rapid Testing Has Arrived - (08/21/06)
     
  14646. IAC: Kaletra BID vs LEXIVA BID, Both with EPIVIR and Abacavir QD, in ART-Naive Patients: The KLEAN Study; Activity/lipids/safety - (08/21/06)
     
  14647. IAC: No structure to this strategy: reports of Treatment Interruption studies - Reported by David Margolis - (08/21/06)
     
  14648. IAC: 48-week analysis of LPV/r monotherapy compared to LPV/r + AZT/3TC in antiretroviral-naive patients: MONARK trial - (08/18/06)
     
  14649. IAC: Lopinavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: Forty-eight week results of a randomized, controlled, open label, clinical trial (OK04 Study) - (08/18/06)
     
  14650. IAC: Maraviroc Study in Dual/Mixed Tropic Patients - (08/18/06)
     
  14651. IAC: Phase 2 Efficacy and Safety of the Novel Viral Entry Inhibitor, TNX-355, in Combination with Optimized Background Regimen (OBR) - (08/18/06)
     
  14652. IAC: More Than Doubled Risk of Progression in African Interruption Trial - (08/18/06)
     
  14653. IAC: Risks With Lopinavir "Monotherapy" After 3-Drug Suppression - (08/18/06)
     
  14654. IAC: Vicriviroc CCR5 Drug, 24 Week Results in Treatment-Experienced; New Study with Higher Doses Starting - (08/18/06)
     
  14655. IAC: Kaletra, Efavirenz, and Kaletra+Sustiva Compared (ACTG 5142) - (08/18/06)
     
  14656. Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients with Limited Available Treatment Options - (08/16/06)
     
  14657. IAC: 17% Increase in HIV in USA in Last 4 Yrs; Blacks Most Disproportionately Affected - (08/17/06)
     
  14658. IAC: HIV+ Women in WIHS: 33% have Metabolic Syndrome - (08/17/06)
     
  14659. IAC: Multiple Factors Predict Metabolic Syndrome in Women With HIV - (08/17/06)
     
  14660. IAC: Wider Waists and Hips: Sorting Effects of Age, HIV, and Antiretrovirals - (08/17/06)
     
  14661. IAC: Risky Anal Intercourse Common in Young US Adults - (08/17/06)
     
  14662. IAC: What Explains Disease Progression in SMART's Drug Break Group? - (08/17/06)
     
  14663. IAC: Study of Tenofovir As a Pre-Exposure Prophylaxis Against HIV Infection - (08/16/06)
     
  14664. IAC: Transmitted Drug Resistance 9-10% in Europe - (08/16/06)
     
  14665. IAC: Clinton greeted as a star for work fighting epidemic - (08/16/06)
     
  14666. IAC: Experts Warn Scientific Gains on H.I.V. Not Enough - (08/16/06)
     
  14667. IAC: Emergence of X4 Virus at High CD4 Counts in MACS Cohort - (08/16/06)
     
  14668. IAC: Male sex sending HIV out of control in Asia-group - (08/16/06)
     
  14669. IAC: Sex Workers, Drug Use Spread HIV Infection in Asia - (08/16/06)
     
  14670. IAC: Circumcision touted as HIV defense - (08/16/06)
     
  14671. IAC: Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223 - (08/16/06)
     
  14672. IAC: Do People Over 50 Get Less or More From Antiretrovirals? - (08/16/06)
     
  14673. IAC: Poor Adherence Threatens Efavirenz More in Blacks Than Whites - (08/16/06)
     
  14674. IAC: First-Line NNRTIs Beat PIs in a 5-Year Trial, But . . . - (08/16/06)
     
  14675. IAC: TMC-114 48 Week Study Results: lipids, potency, safety - (08/16/06)
     
  14676. IAC: Gilead Announces Licensing Agreements with Three India-Based Companies for Manufacturing and Distribution of Generic Versions of Viread in the Developing World - (08/16/06)
     
  14677. IAC: Gates Foundation to develop oral pills to prevent HIV transmission - (08/16/06)
     
  14678. IAC: HIV Therapy's Impact on Heart Disease Small but Bears Watching - (08/15/06)
     
  14679. IAC: Little Gain From Drug Breaks After Treating Primary Infection - (08/15/06)
     
  14680. IAC: Causes of Severe Illness at High CD4 Counts in French Cohort - (08/15/06)
     
  14681. IAC: ANALYSIS PROVIDES ADDITIONAL DATA FOR PREZISTA AS PART OF HIV COMBINATION THERAPY - (08/15/06)
     
  14682. IAC: 96-WEEK DATA FROM GILEAD'S STUDY 934 COMPARING VIREAD AND EMTRIVA TO COMBIVIR BOTH IN COMBINATION WITH SUSTIVA PRESENTED - (08/15/06)
     
  14683. IAC: IAC: Older HIV Patients May Face More Adverse Effects - (08/15/06)
     
  14684. IAC: GlaxoSmithKline and Shionogi Complete Initial Clinical Study for HIV Integrase Inhibitor - (08/15/06)
     
  14685. IAC: IAC: New Goals Set for HIV Salvage Therapy - (08/15/06)
     
  14686. IAC: New 2006 Recommendations of the International AIDS Society-USA Panel - (08/14/06)
     
  14687. IAC: New 2006 Recommendations of the International AIDS Society-USA Panel - (08/14/06)
     
  14688. IAC: 'Big Noise Over a Big issue' - (08/14/06)
     
  14689. IAC: Gates criticises HIV abstinence policies - (08/14/06)
     
  14690. IAC: Black America Must Confront AIDS - (08/14/06)
     
  14691. IAC: Melinda Gates, of the Gates Foundation, has called on government from across the globe to stop ignoring sex workers in their HIV/Aids programmes - (08/14/06)
     
  14692. IAC: HAART Support Services in USA & Internationally - (08/14/06)
     
  14693. IAC: Viread Has Encouraging Results As HIV Prevention Drug - (08/14/06)
     
  14694. IAC: Merck Integrase Inhibitor 24 Week Study Results in Treatment-Naives - (08/14/06)
     
  14695. Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection - (08/14/06)
     
  14696. GILEAD SCIENCES AND MERCK ESTABLISH AGREEMENT FOR DISTRIBUTION OF ATRIPLA IN DEVELOPING COUNTRIES - (08/14/06)
     
  14697. Changes in Body Composition and Mitochondrial Nucleic Acid Content in Patients Switched from Failed Nucleoside Analogue Therapy to Ritonavir-Boosted Indinavir and Efavirenz - (08/11/06)
     
  14698. Efficacy and tolerability of 10-day monotherapy with SPD574 (apricitabine) in antiretroviral-naive, HIV-infected patients - (08/11/06)
     
  14699. Diagnosis/Mgt of Body Changes & Lipid Abnormalities, Hyperlactatemia - (08/11/06)
     
  14700. Genital Human Papillomavirus Infection - (08/11/06)
     
  14701. AIDS Groups Battle Over Federal Funding - (08/11/06)
     
  14702. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients - (08/11/06)
     
  14703. Coinfected with Normal ALT Have HCV Disease - (08/11/06)
     
  14704. Hi Rates of Transmitted HIV Drug Resistance in NYC: 13-24% in NYC; NNRTI Rate Increased from 5.5% to 13.4% from 2001-02 to 2003-04 - (08/11/06)
     
  14705. Antiretrovirals Induce Direct Endothelial Dysfunction In Vivo - (08/08/06)
     
  14706. AIDS vaccine research becomes 'big science' - (08/08/06)
     
  14707. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic - (08/08/06)
     
  14708. Microbicides: stopping HIV at the gate - (08/08/06)
     
  14709. PREZISTA*(TMC114) APPROVED FOR TREATMENT OF HIV BY HEALTH CANADA - (08/08/06)
     
  14710. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial - (08/08/06)
     
  14711. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors - (08/08/06)
     
  14712. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study - (08/08/06)
     
  14713. CD4 percentage is an independent predictor of survival in patients starting HAART with absolute CD4 cell counts between 200 and 350 cells/μL - (08/08/06)
     
  14714. PA-457 - (08/07/06)
     
  14715. FDA Requests New TNX-355 Study - (08/07/06)
     
  14716. Gilead Gives Up Trade Secrets to Get AIDS Drugs to Poor Nations - (08/07/06)
     
  14717. A hard look at HIV in Latin America and the Caribbean - (08/04/06)
     
  14718. Endothelial Function in Patients with HIV Infection - (08/04/06)
     
  14719. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection - (08/04/06)
     
  14720. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients - (08/04/06)
     
  14721. Hypertension in HIV patients - (08/04/06)
     
  14722. Trends in cancer risk among people with AIDS in the United States 1980-2002 - (08/04/06)
     
  14723. Mainstreaming Rapid Oral HIV testing - (08/04/06)
     
  14724. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy - (08/04/06)
     
  14725. Gout/hyperuricemia Increases Risk for Heart Disease - (08/04/06)
     
  14726. HCV Coinfection Reduces HAART Adherence - (08/04/06)
     
  14727. HCV Accelerated Death in HIV+: Danish Study - (08/04/06)
     
  14728. New Study of HIV in the Gut - (07/31/06)
     
  14729. BMI, Waist Size, and Fitness & Central Adiposity Associated with NAFLD (nonalcoholic fatty liver disease) - (07/30/06)
     
  14730. GlaxoSmithKline announces FDA approval and the launch of Avandamet (rosiglitazone maleate and metformin HCl) as inital therapy in the treatment of type 2 diabetes - (07/30/06)
     
  14731. Counseling plus Buprenorphine-Naloxone Maintenance Therapy for Opioid Dependence - (07/28/06)
     
  14732. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases - (07/28/06)
     
  14733. Investigation of a New Diagnosis of Multidrug-Resistant, Dual-Tropic HIV-1 Infection --- New York City, 2005 - (07/28/06)
     
  14734. Viral genetic differences are possible key to HIV dementia - (07/27/06)
     
  14735. Fat Distribution in Women With HIV Infection (FRAM) - (07/27/06)
     
  14736. Unsafe Sex Among MSM Associated with Mental HRQL - (07/27/06)
     
  14737. Impact of Inversion of the CD4/CD38 Ratio on the Natural History of HIV-1 Infection - (07/27/06)
     
  14738. NNRTI TMC125 Early Access Program Pending - (07/24/06)
     
  14739. Routine HIV Testing Successful in Botswana - (07/21/06)
     
  14740. Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults: A Pilot Study - (07/20/06)
     
  14741. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients - (07/20/06)
     
  14742. High serum urate in HIV-infected persons: the choice of the antiretroviral drug matters - (07/20/06)
     
  14743. Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors - (07/20/06)
     
  14744. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA - (07/19/06)
     
  14745. Perspectives in HIV Drug Resistance - (07/19/06)
     
  14746. HIV Drug Resistance Testing Survey Find Gaps in Knowledge About Tests - (07/19/06)
     
  14747. Drug Resistance Wksp: Development of virco®TYPE Resistance Analysis, including Clinical Cut-offs, for TMC114 (07/19/06)
     
  14748. HIV & Other Viruses Transmission from Monkey to Human - (07/18/06)
     
  14749. HIV/AIDS at the G8 Summit - (07/18/06)
     
  14750. Further Information on the Administration of H2-Receptor Antagonists With Atazanavir - (07/18/06)
     
  14751. HIV Adherence Survey in Italy: dosing, adverse events, body shape changes - (07/18/06)
     
  14752. Incyte to Discontinue Development of DFC (Reverset) as a Treatment for HIV - (07/17/06)
     
  14753. Virological response to a triple nucleoside/nucleotide analogue regimen (AZT/3TC/tenofovir) over 48 weeks in HIV-1-infected adults in Africa - (07/17/06)
     
  14754. The mother-to-child HIV transmission epidemic in Europe (Ukraine & Eastern Europe): evolving in the East and established in the West - (07/17/06)
     
  14755. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir- 48 weeks results - (07/14/06)
     
  14756. FDA Approves Atripla: the 1st 3-drug HAART pill contains Sustiva+Truvada (FTC+tenofovir) - (07/12/06)
     
  14757. FDA APPROVES ATRIPLA: the 1st Once daily Single Tablet HAART Regimen: (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) - (07/12/06)
     
  14758. Colorectal Cancer Screening in HIV-Infected Patients 50 Years of Age and Older: Missed Opportunities for Prevention - (07/11/06)
     
  14759. Drug Resistance Wksp: Hepatitis C virus resistance to new antivirals (07/11/06)
     
  14760. Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China - (07/11/06)
     
  14761. Rescue Therapy With Once-Daily Atazanavir-Based Regimens for Antiretroviral-Experienced HIV-Infected Patients - (07/11/06)
     
  14762. Anti-CD4 antibody TNX-355 synergistic with enfuvirtide against HIV-1 - (07/11/06)
     
  14763. Resistance to Enfuvirtide, Vicriviroc, and TMC125 Written for NATAP by: Mark Mascolini - (07/11/06)
     
  14764. HIV-infected patients present with colorectal cancer at a younger age, with more advanced and with more poorly differentiated disease - (07/11/06)
     
  14765. Association of Cigarette Smoking With HIV Prognosis Among Women in the HAART Era: A Report From the Women's Interagency HIV Study - (07/11/06)
     
  14766. New 3-Drug HIV Pill of Sustiva+Truvada: approval close, perhaps 'this week' - (07/11/06)
     
  14767. Endothelial function in HIV-infected patients with low or mild cardiovascular risk - (07/07/06)
     
  14768. Aminotransferase Elevations in Healthy Adults Receiving 4 Grams of Acetaminophen Daily - (07/07/06)
     
  14769. HIV Risk, Prevention, and Testing Behaviors --- United States, National HIV Behavioral Surveillance System: Men Who Have Sex with Men, November 2003--April 2005 - (07/07/06)
     
  14770. Hepatitis B Vaccination Coverage Among Adults --- United States, 2004 - (07/07/06)
     
  14771. Knowledge of HIV Status Reduces Risk of Sexual HIV Transmission by 68% - (07/06/06)
     
  14772. Immunosuppression, Hepatitis C Infection, and Acute Renal Failure in HIV-Infected Patients - (07/06/06)
     
  14773. Detection of Low-Level NNRTI Drug Resistance Using a Highly Sensitive Genotypic Resistance Test, may be associated with therapy failure - (07/06/06)
     
  14774. Coadministration of Esomeprazole With Fosamprenavir Has No Impact on Steady-State Plasma Amprenavir Pharmacokinetics - (07/06/06)
     
  14775. Knowledge of HIV Status Reduces Risk of Sexual HIV Transmission by 68% - (07/05/06)
     
  14776. Tipranavir Warning Issued by FDA Explained Further - (07/05/06)
     
  14777. Osteonecrosis in Patients Infected With HIV: Clinical Epidemiology and Natural History in a Large Case Series From Spain - (07/05/06)
     
  14778. Drug Resistance Wksp: Impact of optimised background regimen on virological response to TMC114 with low-dose ritonavir in POWER 1, 2 and 3, as measured by the phenotypic susceptibility score (07/05/06)
     
  14779. Drug Resistance Wksp: Everything you wanted to know (almost) about resistance to darunavir; discussion of cross-resistance and comparisons with tipranavir Written for NATAP by: Mark Mascolini - (07/05/06)
     
  14780. HIV-1 Coreceptor Use in Triple-Class Treatment-Experienced Patients: Baseline Prevalence, Correlates, and Relationship to Enfuvirtide Response - (06/30/06)
     
  14781. Diabetes Associated with Earlier Cardiovascular Disease - (06/30/06)
     
  14782. Transmission of mitochondrial DNA disorders: possibilities for the future - (06/30/06)
     
  14783. Mitochondrial disease - (06/30/06)
     
  14784. Reports of Adverse Events From Bone [Loss] Drugs Prompt Caution - (06/29/06)
     
  14785. Hepatic Steatosis Is Associated with Fibrosis, Nucleoside Analogue Use, and Hepatitis C Virus Genotype 3 Infection in HIV-Seropositive Patients: Steatosis was present in 69% of patients - (06/29/06)
     
  14786. Dideoxynucleoside Analogues Should Be Used Cautiously in Patients with Hepatic Steatosis - (06/29/06)
     
  14787. Drug Resistance Wksp: Primary infection with drug-resistant HIV Resistance Workshop Review: Part 4 Written for NATAP by: Mark Mascolini - (06/29/06)
     
  14788. Drug Resistance Wksp: Phenotypic Susceptibility to TMC-114 and Tipranavir Before and After Lopinavir/ritonavir-based Treatment in Subjects Demonstrating Evolution of Lopinavir Resistance - (06/27/06)
     
  14789. Drug Resistance Wksp: Clinically Relevant Virco Phenotypic Resistance and Cross Resistance to Tipranavir Among Recent Routine Clinical Isolates - (06/27/06)
     
  14790. Fuzeon (T-20) Use in TMC114 Study - (06/27/06)
     
  14791. Drug Resistance Wksp: Patterns of Tipranavir Susceptibility and Cross-Resistance Among Patient Samples Submitted for Routine Resistance Testing - (06/27/06)
     
  14792. Drug Resistance Wksp: ANALYSES OF SUSCEPTIBILITY AND CROSS-RESISTANCE BETWEEN TMC114 AND OTHER PROTEASE INHIBITORS AMONG >56,000 ROUTINE SAMPLES, USING LINEAR REGRESSION MODEL-BASED FOLD CHANGE PREDICTIONS - (06/27/06)
     
  14793. D.C. Wants HIV Testing for All Residents 14 to 84 - (06/26/06)
     
  14794. Risk of Interruption SMART Study - (06/26/06)
     
  14795. Risk of HAART interuptions in Africa and the USA: The risk of treatment versus the risk of HIV replication (treatment interruptions) - (06/26/06)
     
  14796. Drug Resistance Wksp: Preventing HIV transmission: prophylactic TDF/FTC and resistance to a vaginal microbicide Written for NATAP by: Mark Mascolini - (06/26/06)
     
  14797. Drug Resistance Wksp: Prevalence of Three-class Resistance in North Carolina cohort study; K65R & tenofovir response, and predicting salvage response to fosamprenavir/r Written for NATAP by: Mark Mascolini - (06/23/06)
     
  14798. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors - (06/23/06)
     
  14799. Osteoporosis - (06/22/06)
     
  14800. New Study Showed Vytorin Significantly More Effective than Crestor at Lower LDL - (06/22/06)
     
  14801. Drug Resistance Wksp: Initial Virologic Failure with HIV Drug Resistance and Impact of Resistance on Disease Progression and Death for Patients Beginning PI, NNRTI or PI+NNRTI Based Strategies: The FIRST Study - (06/22/06)
     
  14802. Drug Resistance Wksp: Low-level Viremia Persists for at Least 7 years in Patients on Suppressive Antiretroviral Therapy, using real-time RT-PCR assay with single-copy sensitivity - (06/22/06)
     
  14803. Drug Resistance Wksp: Resistance Workshop Review: Part 1 PI monotherapy, Boosted vs unboosted atazanavir, STIs, first-line options (NNRTIs vs boosted PI vs unboosted PI) Written for NATAP by: Mark Mascolini - (06/21/06)
     
  14804. Drug Resistance Wksp: Evaluation of Resistance Patterns in Treatment-naive Subjects with Virologic Failure on Atazanavir- or Atazanavir/Ritonavir-containing Regimens - (06/21/06)
     
  14805. Drug Resistance Wksp: Brecanavir: new PI, resistance report from phase II study - (06/21/06)
     
  14806. Biggest Reduction in Bad Cholesterol Ever Achieved in a Clinical Trial after Trial with a combination of two lipid lowering agents - (06/20/06)
     
  14807. Drug Resistance Wksp: Impact of baseline K103N or Y181C on the virological response to the NNRTI TMC125: analysis of study TMC125-C223 - (06/20/06)
     
  14808. Drug Resistance Wksp: De-selection of the I50V mutation occurs in clinical isolates during Aptivus/r (tipranavir/ritonavir)-based therapy - (06/20/06)
     
  14809. Drug Resistance Wksp: Drug Resistance Outcomes in a Trial Comparing Lopinavir/ritonavir (LPV/r) Monotherapy to LPV/r + Zidovudine/Lamivudine (MONARK Trial) in treatment naives - (06/20/06)
     
  14810. Drug Resistance Wksp: More Drug Resistance Observed on NNRTIs than Boosted PI Regimens in Swiss HIV Cohort Study, Study Reports - (06/20/06)
     
  14811. Drug Resistance Wksp: Sensitive Genotyoic Test Detects Low-Level K65R Which Impairs Viral Response - (06/20/06)
     
  14812. Drug Resistance Wksp: Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3 - (06/20/06)
     
  14813. Drug Resistance Wksp: Drug Resistance Outcomes in a Trial Comparing Lopinavir/ritonavir (LPV/r) Monotherapy to LPV/r + Zidovudine/Lamivudine (MONARK Trial) in treatment naives - (06/19/06)
     
  14814. Drug Resistance Wksp: Selection of Protease Inhibitor Resistance Mutations During Virologic Failure of Lopinavir/ritonavir Monotherapy in an Induction-Maintenance Study - (06/19/06)
     
  14815. Drug Resistance Wksp: Selection of NNRTI resistant HIV-1 after discontinuation of a virologically suppressive regimen: standard genotype test does not detect all resistance - (06/19/06)
     
  14816. Drug Resistance Wksp: Antiviral Activity of SPI- 256 Against Wild- Type and Multidrug Resistant Strains - (06/19/06)
     
  14817. Drug Resistance Wksp: In Vitro Selection Strategy and Characterization of Resistance to a Novel Highly potent HIV Protease Inhibitor SPI-256 - (06/19/06)
     
  14818. Drug Resistance Wksp: Jules Levin's TOP 10 STORIES FROM Resistance Workshop - (06/16/06)
     
  14819. Drug Resistance Wksp: Protease Mutations Outside of Protease Gene Found in GAG Gene - (06/16/06)
     
  14820. Drug Resistance Wksp: AMBRILIA REPORTS POSITIVE PHASE IA RESULTS FOR ITS LEAD HIV/AIDS PROTEASE INHIBITOR PPL-100 - (06/16/06)
     
  14821. The HIV-1 Protease Inhibitor PL-100 Has a High Genetic Barrier and Selects a Novel Pattern of Mutations - (06/16/06)
     
  14822. Drug Resistance Wksp: SPI-256: a novel highly potent HIV protease inhibitor - (06/15/06)
     
  14823. Drug Resistance Wksp: Antiviral activity of SPI-256 against WT and MDR Strains - (06/15/06)
     
  14824. Drug Resistance Wksp: Tenofovir/FTC Prevents SHIV Transmission in Monkeys - (06/15/06)
     
  14825. Drug Resistance Wksp: New HIV Protease Inhibitor PL-100 - (06/15/06)
     
  14826. In Vitro Development of Resistance to Human Immunodeficiency Virus Protease Inhibitor GW640385 - (06/12/06)
     
  14827. Single-Dose Safety and Pharmacokinetics of Brecanavir (GW640385) , a Novel Human Immunodeficiency Virus Protease Inhibitor - (06/12/06)
     
  14828. Reversible Hepatic and Lipid Abnormalities with Nonprescription Anabolic-Androgenic Steroid Use in 2 HIV-Infected Men - (06/09/06)
     
  14829. Bone Disease and HIV Infection - (06/09/06)
     
  14830. Genetic Screening to Prevent Abacavir Hypersensitivity Reaction: Are We There Yet? - (06/09/06)
     
  14831. Time to Translate New Knowledge into Practice: A Call for a National Genital Herpes Control Program - (06/08/06)
     
  14832. Efavirenz More Potent Than Abacavir in HAART, observational cohort study finds - (06/08/06)
     
  14833. HAART Increased AIDS Survival At least 13 Years; HIV Testing Should Routinized - (06/05/06)
     
  14834. Incyte Begins Phase I Study of New HIV Drug in Healthy Volunteers - (06/05/06)
     
  14835. Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing - (05/31/06)
     
  14836. Poverty fuels HIV among black heterosexuals - (05/30/06)
     
  14837. Herpes Simplex: affect of HAART, HIV-RNA, CD4 Count - (05/30/06)
     
  14838. Immune Reconstitution Syndrome in HIV: Validating a Case Definition and Identifying Clinical Predictors in Persons Initiating Antiretroviral Therapy - (05/26/06)
     
  14839. HIV-like virus found in wild chimps - (05/25/06)
     
  14840. Efficacy and Safety of a Once-Daily Fixed-Dose Combination of Abacavir/Lamivudine Compared With Abacavir Twice Daily and Lamivudine Once Daily as Separate Entities in Antiretroviral-Experienced HIV-1-Infected Patients (CAL30001 Study) - (05/17/06)
     
  14841. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients - (05/17/06)
     
  14842. Trends in Tuberculosis-United States, 2005 - (05/17/06)
     
  14843. Testing a CCR5 drug? Avoid mosquito bites/West Nile Virus - (05/17/06)
     
  14844. High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men - (05/17/06)
     
  14845. When To Begin HAART-- Impact of baseline viral load (>100,000) and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥ 200 cells/μl - (05/17/06)
     
  14846. Unexpected improvement of sexual dysfunction during atazanavir therapy.....and nevirapine - (05/17/06)
     
  14847. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women - (05/17/06)
     
  14848. Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir - (05/16/06)
     
  14849. African Americans & HIV: Overview - (05/10/06)
     
  14850. CDC to Urge Routine HIV Tests For a Broad Swath of Americans - (05/09/06)
     
  14851. 7th Inter Wrkshp HIV SUMMARY OF THE 7TH INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY OF HIV THERAPY - (05/08/06)
     
  14852. As AIDS Drugs Fail Thousands, 'Salvage' Is Key: 'you must add 2-3 Novel Drugs Simultaneously' - (05/08/06)
     
  14853. Vaccine for cervical cancer approval expected soon: reaching adolescents in sub-Saharan Africa - (05/05/06)
     
  14854. Tanox Reports 48-Week Results from TNX-355 Phase 2 Clinical Trial - (05/05/06)
     
  14855. Bristol, Gilead file for HIV 3-drug combo drug approval - (04/28/06)
     
  14856. HIV Infection and Dementia in Older Adults: should we be concerned? - (04/25/06)
     
  14857. Endothelial Function [Impaired] in HIV-Infected Persons - (04/25/06)
     
  14858. Senate Hearing April 26 on HIV Care Disparities - (04/24/06)
     
  14859. Few Men Found to Get HIV in Prison- CDC Report - (04/24/06)
     
  14860. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial - (04/24/06)
     
  14861. New Assisted Reproduction Methods Completely Removed HIV-RNA & Proviral DNA, study reports - (04/24/06)
     
  14862. HAART & Fetal death/Pre-eclampsia - (04/24/06)
     
  14863. Antioxidant supplementation in pre-eclampsia: Commentary - (04/24/06)
     
  14864. Heart Disease Prevention in Women (men too) - (04/24/06)
     
  14865. Diabetes, Heart Disease, Prediabetes, Blood Pressure, Hypertension, Metabolic Syndrome, Cholesterol, Triglycerides & PREVENTION - (04/24/06)
     
  14866. Heart Disease & Dietary Recommendations - (04/24/06)
     
  14867. Genomic Mechanisms of Metabolic Complications & Management, 13th CROI 2006 - (04/19/06)
     
  14868. K103N Mutant Found to Decay Over Time- Does NVP K103N Mutant Reduce NNRTI Efficacy - (04/11/06)
     
  14869. Why isn't HIV testing routine yet? - (04/11/06)
     
  14870. Landmark Discovery of a Kaposi's Sarcoma-Associated Herpesvirus Receptor Provides New Perspectives on Disease Associated with HIV/AIDS - (04/11/06)
     
  14871. HAART Potency & Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy: A Systematic Overview - (04/11/06)
     
  14872. Interactions Between PPIs & Reyataz/r - (04/11/06)
     
  14873. Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link? - (04/11/06)
     
  14874. Management of chronic hepatitis B and C in HIV-coinfected patients: critical issues - (04/10/06)
     
  14875. PK of TMC114 + TMC125 - (04/10/06)
     
  14876. Experimental Stem Cell Study in HIV+ - (04/10/06)
     
  14877. HIV Law Debate Continues NYC Health commish Clarifies Draft Bill - (04/10/06)
     
  14878. New study: Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy - (04/10/06)
     
  14879. Mitochondrial disease: Powerhouse of disease-insulin resistance/diabetes - (04/10/06)
     
  14880. Sculptra for Facial Lipoatrophy: New face sculpting changes lives for HIV patients - (04/10/06)
     
  14881. Growth hormone secretion among HIV+ patients: effects of gender, race and fat distribution - (04/10/06)
     
  14882. HAART & Elevated Blood Pressure - (04/10/06)
     
  14883. Pravastatin Improves Fat Loss/Lipoatrophy - (04/10/06)
     
  14884. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report - (04/07/06)
     
  14885. Proposed Clinical Phenotypic Cutoffs for Tipranavir by Virco Assay and 87 protease gene mutations and pairs of mutations significant in predicting tipranavir fold-change - (04/07/06)
     
  14886. 72,000 new HIV cases, high-risk group is problem Controversial pre-marital HIV testing by India - (04/06/06)
     
  14887. Online SRD/HIV Prevention Counseling & Prevention Programs by Health Officials in SF & LA - (04/06/06)
     
  14888. Blacks Account for 51% of HIV Diagnoses; Racial/Ethnic Disparities in Diagnoses of HIV/AIDS-33 States, 2001-2004 - (04/06/06)
     
  14889. Abbott Files in South Africa for Registration of New Tablet Form of Kaletra - (04/05/06)
     
  14890. Psychotropic Medications and HIV - (04/05/06)
     
  14891. NYC DOH Responds to New HIV Law Controversy HIV Law Debate - (04/03/06)
     
  14892. New Study: Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance - (04/03/06)
     
  14893. SCULPTRA (Newfill) for HIV FACIAL LIPOATROPHY APPROVED BY FDA - (04/03/06)
     
  14894. POWER 3: 24-week efficacy and safety results of TMC114/r in treatment experienced HIV patients - (04/03/06)
     
  14895. Sculptra, a procedure for facial lipoatrophy, is it for you? - (04/03/06)
     
  14896. HIV Global cases reach plateau and decline in India, study says - (03/30/06)
     
  14897. HIV Epidemic Slowing in India - (03/30/06)
     
  14898. Has global HIV incidence peaked? - (03/30/06)
     
  14899. Trends in HIV-1 in young adults in south India from 2000 to 2004: a prevalence study - (03/30/06)
     
  14900. Effect of baseline protease genotype & phenotype on HIV response to atazanavir/ritonavir & lopinavir/r in treatment-experienced patients, study 045 - (03/30/06)
     
  14901. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting - (03/30/06)
     
  14902. Poly-L-Lactic Acid for Facial Lipoatrophy - 2 years Followup - (03/30/06)
     
  14903. Trizivir 96 weeks - impact on lipids: effect of sex & ethnicity - (03/30/06)
     
  14904. Preclinical Evaluation of Synthetic -2 RANTES as a Candidate Vaginal Microbicide To Target CCR5 - (03/29/06)
     
  14905. Kids with HIV often have behavioral problems - (03/29/06)
     
  14906. 2 drugs (tenofovir+FTC) used to treat HIV may also help prevent it... - (03/29/06)
     
  14907. Cognitive Performance & Neuroactive ART Drugs - (03/29/06)
     
  14908. New NRTI SPD754 Active Against Resistant HIV & Suggestion of Low Propensity to Cause Mitochondrial Toxicity - (03/29/06)
     
  14909. CXCR4 AMD070 - New Study Data in Patients - (03/22/06)
     
  14910. HAART Associated with Subclinical Carotid Atherosclerosis, study finds - (03/22/06)
     
  14911. South Florida has Highest AIDS Rates in USA - (03/22/06)
     
  14912. Ultrasound Technology Reduces Belly Fat - (03/22/06)
     
  14913. HIV services in UK face unprecedented cuts - (03/22/06)
     
  14914. Bioject on Airplanes - (03/22/06)
     
  14915. Syphillis Increases Among MSM, Blacks, Hispanics - (03/22/06)
     
  14916. Cost-Effectiveness of Enfuvirtide in HIV Therapy for Treatment-Experienced Patients in the United States - (03/22/06)
     
  14917. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection - (03/22/06)
     
  14918. HIV & Black Women - (03/15/06)
     
  14919. Neutropenia in HIV+ Women; survival. Data From the Women's Interagency HIV Study - (03/15/06)
     
  14920. HIV & Black Women - (03/15/06)
     
  14921. Neutropenia in HIV+ Women; survival. Data From the Women's Interagency HIV Study - (03/15/06)
     
  14922. Errors in Celia Farber's March 2006 article in Harper's Magazine - (03/15/06)
     
  14923. National Women and Girls HIV/AIDS Awareness Day - (03/09/06)
     
  14924. Addition of pioglitazone improved glycaemic control and components of the lipid profile & weight gain - (03/09/06)
     
  14925. AZT/3TC/Efavirenz copackaged- FDA Grants Tentative Approval - (03/09/06)
     
  14926. FDA GRANTS TRADITIONAL APPROVAL FOR GILEAD' S ONCE-DAILY HIV MEDICATIONS TRUVADA AND VIREAD - (03/09/06)
     
  14927. SCHERING-PLOUGH PROVIDES UPDATE ON PHASE II STUDY OF VICRIVIROC - (03/08/06)
     
  14928. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients - (03/08/06)
     
  14929. Ritonavir-Boosted GS-9137 Vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. phase II study - (03/07/06)
     
  14930. Sex/Erectile Dysfunction Caused by Elevated LDL, Atorvastatin Helped - (03/07/06)
     
  14931. Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-Treated Patients - (03/07/06)
     
  14932. Biojector Improved Fuzeon ISRs, Ease of Use, with PK The Same - (03/07/06)
     
  14933. Reyataz/r vs Kaletra Study 045 96 Wks Experienced Patients - (03/07/06)
     
  14934. CROI: 62% Steatosis in Coinfected; Abacavir & Nevirapine May Be Protective (03/07/06)
     
  14935. CROI: Origins of HIV Traced to Chimps in Cameroon (03/07/06)
     
  14936. CROI: Tenofovir + Lamivudine (3TC) for HBV/HIV Coinfection (03/07/06)
     
  14937. NATAP LAUDS COBURN RYAN WHITE CARE ACT BILL'S RECOGNITION OF CO-INFECTION NEEDS AND ADAP IMPROVEMENTS. - (02/28/06)
     
  14938. There are consequences, legal and moral, for withholding HIV status in Sex Relations - (03/03/06)
     
  14939. Combination therapy improves survival rates in AIDS-related lymphoma - (03/01/06)
     
  14940. EDITORIAL: Penalizing Success: Is Comprehensive HIV Care Sustainable? - (02/28/06)
     
  14941. Health Care Costs for HIV Patients - (02/28/06)
     
  14942. Study TMC114-C226: TMC114 Expanded Access Program (EAP), Co-enrollment in MK-0518 Phase III studies - (02/28/06)
     
  14943. HIV-Positive Latina Immigrants in California - (02/28/06)
     
  14944. Kidney, liver, and cardiac disease overtaking opportunistic infections as leading causes of death among HIV-infected patients in the United States - (02/28/06)
     
  14945. CROI: Abacavir vs Nevirapine, Safety 1st-Line ART in Uganda (02/28/06)
     
  14946. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors - (02/24/06)
     
  14947. CROI: Metabolic Analyses within A5095: Effect of Efavirenz against an All-nucleoside/Nucleotide Background: 3 Nukes; TDF Regimen vs EFV Regimens (02/27/06)
     
  14948. CROI: Tipranavir RESIST Analysis (02/27/06)
     
  14949. CROI: Rapid Emergence of Drug-resistant SIV in Tenofovir-treated Macaques: Implications for Tenofovir Chemoprophylaxis against HIV (02/27/06)
     
  14950. CROI: Projection to 2010 of trends in multi-drug resistant HIV in infectious gay men in the UK - Written by Andrew Phillips, UCL, London (02/27/06) (02/27/06)
     
  14951. Merck Integrase Study for Patients with HIV Drug Resistance - (02/24/06)
     
  14952. Battling H.I.V. Where Sex Meets Crystal Meth Crystal Meth & Minorities in NYC - (02/24/06)
     
  14953. Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation - (02/24/06)
     
  14954. Tenofovir may be safe as vaginal HIV microbicide - (02/24/06)
     
  14955. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors - (02/24/06)
     
  14956. CROI: Early, Uninterrupted ART Is Associated with Improved Outcomes and Fewer Toxicities in the HIV Outpatient Study (HOPS) (02/23/06)
     
  14957. CROI: Analysis of Cardiovascular Risk Factors in the HIV Outpatient Study (HOPS) Cohort (02/23/06)
     
  14958. CROI: Risk of Heart Disease Appears to Level Off in Kaiser in Northern California (02/23/06)
     
  14959. CROI: D.A.D. Study: risk of myocardial infarction (02/22/06)
     
  14960. CROI: Tenofovir Associated Kidney Dysfunction: The Controversy Continues - Written for NATAP by Judith Aberg, MD, Bellevue Hospital, New York University Medical Center (02/23/06)
     
  14961. CROI: Tenofovir & Renal Dysfunction (02/23/06)
     
  14962. CROI: CLINICAL PHARMACOLOGY AT THE 13th CROI - John G. Gerber, M.D. Professor of Medicine and Pharmacology Divisions of Clinical Pharmacology and Infectious Diseases University of Colorado Health Sciences Center Denver, Colorado (02/23/06)
     
  14963. CROI: Hepatitis D Virus Can Worsen the Outcome of HBV-HIV Coinfected Patients (02/23/06)
     
  14964. CROI: Antiretroviral Pharmacology for PrEP (pre-exposure prophylaxis) - Written by Angela DM Kashuba, BScPhm, PharmD, DABCP Associate Professor of Pharmacy Director, UNC CFAR Clinical Pharmacology and Analytical Chemistry Core University of North Carolina at Chapel Hill (02/23/06)
     
  14965. CROI: Symposia & Plenary Reviews: 13th CROI - Written for NATAP by David Margolis, MD University of North Carolina (02/23/06)
     
  14966. CROI: Are We Ready For Circumcision: The Role of Circumcision as a Potential Preventive Measure to Stop the Spread of HIV Infection (02/22/06)
     
  14967. CROI: D.A.D. Study: risk of myocardial infarction (02/22/06)
     
  14968. CROI: Pulmonary Hypertension: Another Look - Written for NATAP by Judith Aberg, MD, Bellevue Hospital, New York University Medical Center (02/21/06)
     
  14969. CROI: Fish Oil for Triglycerides Study (02/21/06)
     
  14970. CROI: Recent Epidemic & Increase in Acute HCV: Sexual Transmission of HCV Among MSM; WHY? (02/21/06)
     
  14971. CROI: Sexual Transmission of Hepatitis C for MSM & Heterosexual Women Facilitated by STDs, HIV, Unsafe Sex Practices (02/21/06)
     
  14972. CROI: Is 24-week HCV therapy useful in coinfection? (02/21/06)
     
  14973. CROI: The Take Home from CROI on Body Shape - Written for NATAP By David Alain Wohl, MD - The University of North Carolina AIDS Clinical Research and Treatment Unit (02/17/06)
     
  14974. CROI: Treatment Interruption: you might not like the pills, but the alternative seems worse - Written for NATAP by David Margolis, MD, University of North Carolina (02/17/06)
     
  14975. CROI: Treatment Interruptions (STIs) - Written by Mike Youle, MD Royal Free Hospital, London, UK (02/17/06)
     
  14976. CROI: Lack of Effect of Acid Reducing Agents on the Pharmacokinetics (PK) of Lopinavir/Ritonavir (LPV/r) Tablet Formulation (02/16/06)
     
  14977. CROI: TMC114 & TMC125 at 13th CROI, TMC114 Expanded Access Program (02/16/06)
     
  14978. BRISTOL-MYERS SQUIBB SEEKS TO EXPAND ACCESS TO ITS MOST RECENTLY APPROVED HIV/AIDS MEDICINE - (02/16/06)
     
  14979. Chemical 'blocks HIV infection' - (02/15/06)
     
  14980. CROI: Development of Novel Orally Bioavailable CXCR4 Antagonists, KRH-3955 and KRH-3140: Binding Specificity, Pharmacokinetics and Anti-HIV-1 Activity in vivo and in vitro (02/15/06)
     
  14981. CROI: DAPD, NRTI - Modestly Reduced Viral Load & No Safety Issues (02/15/06)
     
  14982. CROI: Pharmacokinetics (PK) and antiretroviral (ARV) response to TMC114/r and TMC 125 combination in patients with high level viral resistance (02/15/06)
     
  14983. CROI: New PI GRL-02031, Potent Against Resistant HIV in vitro (02/15/06)
     
  14984. CROI: Reverset Resistance (02/15/06)
     
  14985. CROI: Pharmacokinetic/pharmacodynamic (PK/PD) analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients (02/15/06)
     
  14986. CROI: Antiretrovirals at Denver: 13th CROI 2006 - "Future Seems Bright" - Written for NATAP by Mike Youle, MD, Royal Free Hospital, London, UK (02/15/06)
     
  14987. CROI: Week 48 Resistance Surveillance of HIV/HBV Co-Infected Patients Treated with Entecavir in Study AI463038 (02/14/06)
     
  14988. CROI: Schering CCR5 Vicriviroc- details on why study in treatment-naives was stopped but new dose is being explored (02/14/06)
     
  14989. CROI: Schering-Plough Press Release- Vicriviroc Clinical Study Results Presented at 13th Conference on Retroviruses and Opportunistic Infections (02/14/06)
     
  14990. CROI: Early HAART Associated with Improved Outcomes & Fewer Toxicities (02/14/06)
     
  14991. CROI: ARTs to Prevent HIV Sexual Transmission (02/14/06)
     
  14992. CROI: A Prospective, Open-label, Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone as Maintenance Antiretroviral Therapy after Sustained Virologic Suppression (ACTG 5201) (02/14/06)
     
  14993. CROI: TESTOSTERONE EFFECT ON FAT MASS & DISTRIBUTION (02/13/06)
     
  14994. CROI: Effect of pioglitazone on HIV-1 lipoatrophy : a randomised, double-bind, placebo-controlled trial (ANRS 113) (02/13/06)
     
  14995. CROI: Metformin + Rosiglitazone for Lipodystrophy -Combination Study (02/13/06)
     
  14996. CROI: Metformin for Lipodystrophy (02/13/06)
     
  14997. CROI: Prevention of Rectal SHIV Transmission in Macaques by Tenofovir/FTC Combination (02/13/06)
     
  14998. CROI: Tenofovir Achieves High Levels in the Genital tract of Men & Women and Reduces HIV RNA in Genital Tract of Men & Women (02/13/06)
     
  14999. CROI: 'SMART' Study: Strategies for Management of Antiretroviral Therapy Study (02/13/06)
     
  15000. CROI: Schering CCR5 Drug Vicriviroc Study Continues (02/10/06)
     
  15001. CROI: HIV hits blacks harder in U.S., 51% of New Infections are Black, study finds (02/10/06)
     
  15002. CROI: TMC-125, Potent Against NNRTI Resistant HIV (02/10/06)
     
  15003. CROI: TMC-114 Resistance Profile (02/10/06)
     
  15004. CROI: Boehringer Ingelheim Announces 48-week Results from Aptivus (tipranavir) RESIST Studies: stratified RESIST results by CD4 and viral load (02/10/06)
     
  15005. CROI: Pioglitazone Improved Limb Lipoatrophy (02/10/06)
     
  15006. CROI: Gilead HIV-1 Integrase Inhibitor: GS-9137 (JTK-303) Exhibits Potent Antiviral Activity in Treatment-Naive and Experienced Patients (02/09/06)
     
  15007. CROI: Gilead Integrase Inhibitor: JTK-303/GS-9137, a Novel Small Molecule Inhibitor of HIV-1 Integrase: Anti-HIV Activity Profile and Pharmacokinetics in Animals (02/09/06)
     
  15008. CROI: Gilead Integrase Inhibitor: Safety and Pharmacokinetics of Single Oral Dose of JTK- 303/GS- 9137, a Novel HIV Integrase Inhibitor, in Healthy Volunteers (02/09/06)
     
  15009. CROI: JTK-303/GS-9137, a Novel Small Molecule Inhibitor of HIV-1 Integrase: Anti-HIV Activity Profile and Pharmacokinetics in Animals (02/09/06)
     
  15010. CROI: Gilead Integrase Inhibitor: Safety and Pharmacokinetics of Single Oral Dose of JTK- 303/GS- 9137, a Novel HIV Integrase Inhibitor, in Healthy Volunteers (02/09/06)
     
  15011. CROI: HIV Drug Resistance Appears Low in Some Developing Countries (02/09/06)
     
  15012. CROI: CD4 Count-Guided Therapy May Increase Risk of HIV Disease Progression (02/09/06)
     
  15013. CROI: Early HIV Therapy Yields Better Outcomes and Fewer Toxicities (02/09/06)
     
  15014. CROI: Integrase Inhibitors- 2 new drugs (02/09/06)
     
  15015. CROI: Analysis: Tracking the source of AIDS (02/09/06)
     
  15016. Report Highlights AIDS Risk to Black Men and Women - (02/08/06)
     
  15017. New York health director urges overhaul of HIV test requirements - (02/08/06)
     
  15018. ADAP Watch Says 954 HIV-Positive People in 10 States are on Waiting Lists - (02/08/06)
     
  15019. Back Gay man tapped to lead CDC's HIV division Fenton says top goal is addressing complacent gay, bisexual men - (02/08/06)
     
  15020. CROI: SPI-256, a Highly Potent HIV Protease Inhibitor with Broad Activity Against MDR (02/08/06)
     
  15021. CROI: HIV hits blacks harder in U.S., 51% of New Infections are Black, study finds (02/08/06)
     
  15022. CROI: GS9148: A Novel Nucleotide Active Against HIV-1 Variants with Drug Resistance Mutations in Reverse Transcriptase (02/08/06)
     
  15023. CROI: Next Generation HIV Peptide Fusion Inhibitor Candidates Achieve Potent, Durable Suppression of Virus replication in vitro and Improved Pharmacokinetic Properties (02/08/06)
     
  15024. President Bush's New HIV Plan: 'Reform & Reauthorize' Ryan White Care Act, 'Target Resources to Meet the Greatest Needs'; $70 Million for ADAP - (02/02/06)
     
  15025. Corticosteroids + Protease Inhibitors May Interact & Cause Bone Damage - (02/02/06)
     
  15026. HIV In Pres Bush's State of the Union Address - (02/01/06)
     
  15027. Hepatitis C's effect on HIV disease remains elusive despite three new studies; Coinfection Death Rate - (02/01/06)
     
  15028. HCV coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort - (02/01/06)
     
  15029. First-line use of Fuzeon-containing HAART regimen with dramatic clinical and immunological improvement in three cases - (01/31/06)
     
  15030. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects - (01/31/06)
     
  15031. WISE Study of Women and Heart Disease Yields Important Findings on Frequently Undiagnosed Coronary Syndrome - (01/31/06)
     
  15032. Intl Coinfection Wrkshp: Fibrosis Progression in HIV/HCV Coinfected Patients with Paired Liver Biopsies: evaluation of risk factors (01/30/06)
     
  15033. TMC-125: new NNRTI- resistance and patient study results - (01/30/06)
     
  15034. Inhaled Insulin Gets FDA OK - (01/30/06)
     
  15035. FDA Approves First Ever Inhaled Insulin Combination Product for Treatment of Diabetes - (01/30/06)
     
  15036. STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? - (01/27/06)
     
  15037. HIV Sexual Transmission Risks: during acute & chronic with <400 c/ml - (01/27/06)
     
  15038. Experimental vaginal gel inhibits HIV and HSV - (01/25/06)
     
  15039. Effects of Omega-3 Fatty Acids on Cancer Risk - (01/25/06)
     
  15040. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? - (01/25/06)
     
  15041. NYC Starts Diabetes Registry Mandatory Monitoring diabetes treatment in New York City - (01/25/06)
     
  15042. Pfizer Discontinues the Maraviroc 300 mg once-daily Dosing Arm in the Treatment-naive Program - (01/25/06)
     
  15043. Is cannabis use psychotogenic? - (01/25/06)
     
  15044. Intl Coinfection Wrkshp: Fatigue may be misdiagnosed as depression during anti-HCV therapy in HIV coinfected (01/25/06)
     
  15045. Intl Coinfection Wrkshp: Accelerated HCV Progression in HIV: paired liver biopsies (01/25/06)
     
  15046. Race, ethnicity & HIV drug impact - (01/24/06)
     
  15047. S.M.A.R.T. Study Stopped: continuous HAART vs CD4 Guided Interruptions - (01/24/06)
     
  15048. Rosiglitazone/metformin Warns of Eye Complication that Appears to Occur Rarely - (01/19/06)
     
  15049. Efavirenz and CYP2B6 Polymorphism: Implications for Drug Toxicity and Resistance EDITORIAL - (01/19/06)
     
  15050. GSK Perpective on Tenofovir 934 study in NEJM - (01/19/06)
     
  15051. Incidence and Risk Factors for Immune Reconstitution Inflammatory Syndrome in an Ethnically Diverse HIV Type 1Infected Cohort - (01/19/06)
     
  15052. PK & Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study - (01/19/06)
     
  15053. CCR5 Deficiency Appears to Increase Risk of Developing Symptomatic West Nile Virus - (01/19/06)
     
  15054. CCR5 deficiency increases risk of symptomatic West Nile virus infection - (01/19/06)
     
  15055. CCR5 Deletion May Increase Risk for West Nile Virus - (01/19/06)
     
  15056. Roche and Trimeris Announce Selection of Two Next Generation HIV Fusion Inhibitor Drug Candidates for Development - (01/19/06)
     
  15057. Increased Deaths Due to Heart & Liver Disease in HIV - (01/19/06)
     
  15058. Roche Helps with ART Manufacturing in Africa - (01/18/06)
     
  15059. Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract - (01/18/06)
     
  15060. Maintenance PegIntron Study in HCV/HIV Coinfected Patients - (01/18/06)
     
  15061. Intl Coinfection Wrkshp: Spanish Cohort of HIV+ Patients with Orthotopic Liver Transplantation (OLT): Evaluation of 50 Cases in HAART Era (2002-05) (01/18/06)
     
  15062. Intl Coinfection Wrkshp: HIV May Cause Steatosis- 50% rates of steatosis in HIV & HCV (01/18/06)
     
  15063. Intl Coinfection Wrkshp: Liver Transplantation in HIV Infected Patients (01/17/06)
     
  15064. Intl Coinfection Wrkshp: Optiming Response Rates to Peg/RBV in Coinfected Patients: increased Ribavirin dosing; extending therapy duration (01/13/06)
     
  15065. Intl Coinfection Wrkshp: TDM for ART Hepatoxicity (01/12/06)
     
  15066. VIVAGEL RECEIVES FAST TRACK STATUS FROM FDA - (01/12/06)
     
  15067. Lipids are Lower in Chronic HCV - (01/11/06)
     
  15068. Psychosocial, Medical, and Gynecologic Complications in a Cohort of HIV-Infected Women From an Underserved Minority Community in Los Angeles, California - (01/11/06)
     
  15069. Abacavir+3TC+AZT in 730 ART-Naive - (01/11/06)
     
  15070. TIBOTEC SUBMITS MARKETING AUTHORISATION APPLICATION FOR INVESTIGATIONAL HIV PROTEASE INHIBITOR TMC114 IN EUROPE - (01/11/06)
     
  15071. Coinfection Should Be Addressed Immediately - (01/11/06)
     
  15072. Diabetes and Its Awful Toll Quietly Emerge as a Crisis: higher death rates than AIDS in NYC - (01/09/06)
     
  15073. Diabetes, part 2 Living at an Epicenter of Diabetes, Defiance and Despair Bad Blood - (01/10/06)
     
  15074. Medically assisted procreation and transmission of hepatitis C virus: absence of HCV RNA in purified sperm fraction in HIV co-infected patients - (01/10/06)
     
  15075. Transmitted HIV Drug Resistance Persists & HAART May Be Suboptimal - (01/10/06)
     
  15076. ICAAC: Abnormal Thyroid Function in Children With HIV Written for NATAP by Mark Mascolini (01/09/06)
     
  15077. Pioglitazone May Reduce Signs of Metabolic Syndrome & Cardiovascular Risk in Nondiabetics as well as in Diabetics - (01/09/06)
     
  15078. Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva (efavirenz) and Truvada (FTC and tenofovir) - (01/09/06)
     
  15079. Gilead Announces the Advancement of HIV Integrase Inhibitor GS 9137 to a Phase II Clinical Trial - (01/09/06)
     
  15080. Herpes in pregnancy may raise HIV risk for baby - (01/06/06)
     
  15081. Virological Control during the First 6-18 Months after Initiating HAART as a Predictor for Outcome in HIV-Infected Patients: A Danish, Population-Based, 6-Year Follow-Up Study - (01/06/06)
     
  15082. ICAAC: Non-AIDS "Events," Lipids, and Crusty Coronary Arteries Written for NATAP by Mark Mascolini (01/05/06)
     
  15083. ICAAC: Insulin Resistance, Low risk of Efavirenz Rash after NVP Rash, Preventing Newfill/Sculptra Papules Written for NATAP by Mark Mascolini (01/05/06)
     
  15084. ICAAC: Antiretroviral Interactions With Anti-TB Drugs Written for NATAP by Mark Mascolini (01/05/06)
     
  15085. ICAAC: HIV/HCV Coinfection: Impact of Antiretrovirals-and peg-IFN Without Antiretrovirals-on HIV Load Written for NATAP by Mark Mascolini (01/05/06)
     
  15086. Milk Thistle Interactions - (01/05/06)
     
  15087. PRO 2000 Gel Inhibits HIV and Herpes Simplex Virus Infection Following Vaginal Application: A Double-Blind Placebo-Controlled Trial - (01/05/06)
     
  15088. Microbicides to Prevent HIV Transmission: Overcoming Obstacles to Chemical Barrier Protection - (01/05/06)
     
  15089. Virological Control during the First 6-18 Months after Initiating HAART as a Predictor for Outcome in HIV-Infected Patients: A Danish, Population-Based, 6-Year Follow-Up Study - (01/05/06)
     
  15090. Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions - (01/05/06)
     
  15091. Impact of HAART on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients - (01/05/06)
     
  15092. HPV Vaccines Hold Promise for Reducing Cervical Cancer - (01/05/06)
     
  15093. Generic Liquid Nevirapine-FDA Tentative Approval - (01/05/06)
     
  15094. Fuzeon- 48 weeks Efficacy in TORO 1 & 2: subgroup analyses - (01/05/06)
     
  15095. T-20 Safety & Side Effects in TORO 1-2 - (01/05/06)
     
  15096. HIV <500 May Be Less Risky than >500 - (01/03/06)
     
  15097. Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions - (01/03/06)
     
  15098. Renal Safety: TDF + 3TC/EFV (144 wks, Phase 3 Study 903) - (01/03/06)
     
  15099. Tenofovir Bone Density in HIV+ Children - (01/03/06)
     
  15100. ICAAC: Novel First-Line Tactic: Are They Necessary? Written for NATAP by Mark Mascolini (12/29/05)
     
  15101. CDC Statement on HIV Oral Test - (12/28/05)
     
  15102. AIDS pill Tenofovir as party drug? 'Taking a T' - (12/28/05)
     
  15103. Congress May Strip $12 Million Funding for Oral HIV Test - (12/28/05)
     
  15104. Erectile Dysfunction and Subsequent Cardiovascular Disease - (12/28/05)
     
  15105. New Drug Application for Investigational HIV Protease Inhibitor TMC114 Submitted to U.S. Food & Drug Administration - (12/28/05)
     
  15106. Illinois to track HIV using names Confidentiality will remain, officials say - (12/28/05)
     
  15107. HIV-related Lymphoma Survival Increasing - (12/28/05)
     
  15108. EACS: Second-Line and Salvage Strategies, (Good News and Bad With TMC125), When to change a failing regimen, Kaletra & Fosamprenavir/r for PI Resistance, How efavirenz affects new lopinavir tablet, Lopinavir/ritonavir inhibits CYP2D6, Omeprazole hoists saquinavir levels, Antiretroviral switch = failure, or not? Mark Mascolini (12/27/05)
     
  15109. ICAAC: TNX-355, New HIV Drug, at ICAAC (12/27/05)
     
  15110. ICAAC: In Vitro Antiretroviral Activity of the Humanized Anti-CD4 Monoclonal Antibody, TNX-355, against CCR5, CXCR4, and Dual-Tropic Isolates and Synergy with Enfuvirtide (12/27/05)
     
  15111. ICAAC: Differences in Treatment Compliance Between Lopinavir/ritonavir (LPV/r) Given Once (QD) Versus Twice (BID) Daily Do Not Affect Virologic or Immunologic Outcomes (12/27/05)
     
  15112. ICAAC: News on Four New Antiretrovirals From ICAAC (12/27/05)
     
  15113. ICAAC: The Different Clinical Pharmacology of Elvucitabine (B-L-Fd4C) Enables the Nuke Drug to be Given in a Safe and Effective Manner with Innovative Dosing Regimens (12/27/05)
     
  15114. ICAAC: Four Drugs Versus Three-and a Four-Nucleoside Combo Written for NATAP by Mark Mascolini (12/27/05)
     
  15115. ICAAC: African-Americans in ACTG 5095 & HCV Coinfected had shorter time to virologic failure Written for NATAP by Mark Mascolini (12/27/05)
     
  15116. Liver Fibrosis and Antiretroviral Therapy - (12/21/05)
     
  15117. ICAAC: African-Americans Have Faster Viral failure in 5095 (12/20/05)
     
  15118. TMC114 Expanded Access Program - (12/20/05)
     
  15119. Reyataz- body changes, metabolics -48 weeks - (12/20/05)
     
  15120. Interaction Between Atazanavir and Fosamprenavir in the Treatment of HIV-Infected Patients - (12/20/05)
     
  15121. TMC114 Expanded Access Program - (12/20/05)
     
  15122. Six Sites Drop Oral HIV Test - due to false positives - (12/20/05)
     
  15123. Katrina Links / Reports / Information - (10/07/05)
     
  15124. ICAAC: TNX-355 in combination with Optimized Background Regimen (OBR) Exhibits Greater Antiviral Activity than OBR Alone in HIV-Treatment Experienced Patients (12/20/05)
     
  15125. ICAAC: Increased ARV Potency by the Addition of Fuzeon to 4-Drug Regimen in ARV Naive (12/20/05)
     
  15126. ICAAC: Rising Multiple-Dose Assessment of Vicriviroc - Similar Safety, Tolerability, and Pharmacokinetics in Uninfected and HIV-Infected Adults (12/20/05)
     
  15127. ICAAC: In Vitro Anti-HIV-1 Activity of Vicriviroc (SCH 417690) in Combination With Other Antiretroviral Drugs and Against Resistant HIV-1 Strains (12/20/05)
     
  15128. ICAAC: Prospective Study of Glucose Metabolism in Antiretroviral Naive HIV-Infected Patients: Incidence of Insulin Resistance at 48 Weeks of HAART (12/20/05)
     
  15129. ICAAC: ATV vs NFV: heart disease risk (12/20/05)
     
  15130. ICAAC: Kaletra Tablet: PK/adverse events in healthy volunteers (12/20/05)
     
  15131. ICAAC: New CCR5 Inhibitor Zinc Finger Proteins (12/20/05)
     
  15132. ICAAC: Towards Gene Knock Out Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs) (12/20/05)
     
  15133. ICAAC: 13% Insulin Resistance in ART-Naive; Nevirapine is Only drug associated with Not causing insulin resistance development (12/20/05)
     
  15134. ICAAC: TMC114/r POWER 2: Adverse events & Safety profile (12/19/05)
     
  15135. ICAAC: Efficacy and tolerability of TMC125 in HIV patients with NNRTI and PI resistance at 24 weeks: TMC125-C223 (12/19/05)
     
  15136. ICAAC: POWER 2 (TMC114-C202 study) Week 24 efficacy analysis (12/19/05)
     
  15137. ICAAC: Safety and Antiviral Activity of PA-457, the First-In-Class Maturation Inhibitor, in a 10-Day Monotherapy Study in HIV-1 Infected Patients (12/19/05)
     
  15138. ICAAC: Entecavir in HIV/HBV Coinfection - week 48 Results (ETV-038) (12/19/05)
     
  15139. ICAAC: New Protease Inhibitor GW640385/RTV (12/19/05)
     
  15140. Insulin Resistance Raises Risk for Pancreatic Cancer, Study Finds - (12/14/05)
     
  15141. 7th Int Wrkshp Drug & Lipo: Testosterone gel switch strategy: perceptions of non-response specific to sexual function/satisfaction and dose titration issues of HIV-positive men (12/14/05)
     
  15142. 7th Int Wrkshp Drug & Lipo: Sexual dysfunction in HIV-infected men: prevalence and associated factors (12/14/05)
     
  15143. TMC-125 + TMC-114 Combination Study - (12/14/05)
     
  15144. 7th Int Wrkshp Drug & Lipo: Endothelial function is impaired in non-alcoholic steatohepatitis (12/14/05)
     
  15145. 7th Int Wrkshp Drug & Lipo: Psychosocial adjustment to facial lipoatrophy in people with HIV (12/14/05)
     
  15146. 7th Int Wrkshp Drug & Lipo: Office-based assessment of body composition abnormalities in patients under HAART (12/14/05)
     
  15147. 7th Int Wrkshp Drug & Lipo: Patient Perspective on Lipoatrophy Quality of Life (12/14/05)
     
  15148. 7th Int Wrkshp Drug & Lipo: Visceral fat-mass (belly fat accumulation) in 175 HAART-treated HIV-infected patients (12/14/05)
     
  15149. 7th Int Wrkshp Drug & Lipo: Bone Loss in HIV (12/14/05)
     
  15150. 7th Int Wrkshp Drug & Lipo: Autologous fat transfer for the treatment of HIV-related face lipoatrophy: 1-year follow-up (12/14/05)
     
  15151. 7th Int Wrkshp Drug & Lipo: Polylactic Acid vs Polyacrylamide for Facial Lipoatrophy (12/14/05)
     
  15152. 7th Int Wrkshp Drug & Lipo: Effectiveness and durability of polyacrylamide hydrogel injections for treating HIV-related facial lipoatrophy (12/14/05)
     
  15153. 7th Int Wrkshp Drug & Lipo: A practical classification for the surgical filling of facial lipoatrophy (12/14/05)
     
  15154. 7th Int Wrkshp Drug & Lipo: Report from the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (12/13/05)
     
  15155. 7th Int Wrkshp Drug & Lipo: Insulin Sensitivity: Reyataz/r & Lopinavir/r (12/12/05)
     
  15156. HIV taking heavy toll in Mississippi - (12/12/05)
     
  15157. New Guidelines for Oral HIV Testing Due to False Positive Tests - (12/12/05)
     
  15158. New Agent TMC125 Effective in Patients with HIV and NNRTI and PI Resistance: Presented at EACS - (12/12/05)
     
  15159. 7th Int Wrkshp Drug & Lipo: Hepatic steatosis: the common denominator for insulin resistance in obese and lipoatrophic subjects (12/09/05)
     
  15160. Rosiglitazone lowers insulin resistance in nondiabetics - (12/09/05)
     
  15161. Rosiglitazone improves exercise function in type 2 diabetes - (12/09/05)
     
  15162. AIDS-Related Hospitalizations Down, but Up for women; Payment Trends - (12/09/05)
     
  15163. Special Access Request for TMC114 & 125 - (12/07/05)
     
  15164. HIV Vaccine Development Barrier: random immune response to HIV - (12/07/05)
     
  15165. NYU med school testing HIV vaccine in experiment - (12/07/05)
     
  15166. EACS: Tipranavir response in RESIST Stratified by Previous PI Use, & Baseline Viral Load & CD4 Count (12/06/05)
     
  15167. EACS: Tipranavir Response by HCV/HBV Coinfected (12/06/05)
     
  15168. New Fusion Inhibitors from Trimeris/Roche - (12/05/05)
     
  15169. Adherence to Fixed Dose Combination 3 Times Better - (12/05/05)
     
  15170. Pfizer Statement on CCR5 Drug 1 Case of Hepatotoxicity - (12/05/05)
     
  15171. FDA Issues Approvable Letter In Response to Application for Use of FUZEON with Needle-Free Injection Device - (12/02/05)
     
  15172. Progenics Pharmaceuticals Initiates Clinical Trial of Viral-Entry Inhibitor PRO 140 in HIV-Infected Patients; Monoclonal Antibody Designed to Block HIV Infection of Immune System Cells - (12/02/05)
     
  15173. EACS: FTC Had Less M184 than 3TC (12/02/05)
     
  15174. EACS: Pretreatment Questions and First-Line Options written for NATAP by Mark Mascolini (12/02/05)
     
  15175. EACS: FTC Had Less M184 than 3TC (12/01/05)
     
  15176. EACS: Resistance in EFV/TDF/FTC Study 934 (12/01/05)
     
  15177. EACS: Lipoatrophy Improved: RAVE Study (12/01/05)
     
  15178. EACS: Tenofovir/3TC/EFV 4 Yr Followup: limb fat, bones, efficacy (12/01/05)
     
  15179. EACS: The Pharmacokinetic Interaction Between Fosamprenavir/Ritonavir and Atazanavir in Healthy Adult Subjects (APV10018) (12/01/05)
     
  15180. EACS: Heart Disease and Mortality Trends in People With HIV Written for NATAP by Mark Mascolini (11/30/05)
     
  15181. EACS: Antiretrovirals and other stuff! Reported by Mike Youle, MD, Royal Free HIV Clinic, London, UK (11/29/05)
     
  15182. EACS: Switch to Unboosted Reyataz (11/29/05)
     
  15183. Coadministration with Esomeprazole Does Not Affect Blood Levels of LEXIVA - - (11/29/05)
     
  15184. HIV, HAART & Brain Damage - (11/29/05)
     
  15185. Trends in HIV/AIDS Diagnoses -- 33 States, 2001--2004 - (11/29/05)
     
  15186. International HIV Trends: HIV infection rates decreasing in Several Countries but global number of people living with HIV CONTINUES TO RISE - (11/29/05)
     
  15187. FDA Issues Approvable Letter In Response to Application for Use of FUZEON with Needle-Free Injection Device - (11/29/05)
     
  15188. EACS: Seven Year Follow-up of a Lopinavir/ritonavir (LPV/r)-Based Regimen in Antiretroviral (ARV)-Naive Subjects (11/28/05)
     
  15189. EACS: Tipranavir 48 weeks (RESIST Studies): efficacy & safety (11/28/05)
     
  15190. EACS: Boehringer Ingelheim Announces 48-Week Results from Aptivus(Rtv) (tipranavir) RESIST Studies (11/28/05)
     
  15191. EACS: A Look at Lipoatrophy Predictors and Reversers Written for NATAP by Mark Mascolini (11/28/05)
     
  15192. EACS: Is Liver Toxicity a CCR5 Antagonist Class Effect? 2NN & Hepatoxicity; D.A.D. study & liver related death; Liver toxicity & HIV, Italian study Written for NATAP by Mark Mascolini (11/28/05)
     
  15193. Tibotec Announces Start of TMC125 Phase III Trials Innovative trial design offers two investigational antiretrovirals in combination - (11/18/05)
     
  15194. EACS: TMC-125: efficacy & safety in highly resistant patients (11/18/05)
     
  15195. EACS: MK-0518, the first Integrase Inhibitor for HIV, No Blarney (11/18/05)
     
  15196. EACS: TMC-125, new NNRTI for Resistance (11/18/05)
     
  15197. Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir(R) to Once-Daily Truvada(R) in Patients with HIV Presented at 10th European AIDS Conference (11/18/05)
     
  15198. EACS: Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir(R) to Once-Daily Truvada(R) in Patients with HIV Presented at 10th European AIDS Conference (11/18/05)
     
  15199. 7th Int Wrkshp Drug & Lipo: Mixed Results With Creatine During Exercise in People With HIV (11/17/05)
     
  15200. 7th Int Wrkshp Drug & Lipo: Pravastatin for 12 Weeks Boosts Limb Fat in HIV+ Men (11/17/05)
     
  15201. 7th Int Wrkshp Drug & Lipo: Dangerously High Lactates in Black Women Starting d4T (11/17/05)
     
  15202. 7th Int Wrkshp Drug & Lipo: Can a "Polypill" Cut Heart Disease Risk in People With HIV? (11/17/05)
     
  15203. 7th Int Wrkshp Drug & Lipo: Fatty Liver Found in Half of Study Group With HIV (11/17/05)
     
  15204. 7th Int Wrkshp Drug & Lipo: Improving Lipoatrophy: Uridine and Pravastatin studies raise hope of new interventions to combat fat loss Dr Graeme Moyle Chelsea and Westminster Hospital, London (11/17/05)
     
  15205. 7th Int Wrkshp Drug & Lipo: More Evidence Against Link Between Fat Loss and Gain With HIV (11/17/05)
     
  15206. AASLD: Liver Disease The Leading Cause of Death in HIV: Hepatitis screening campaign launched. AASLD Liver Conference Starts Nov 10 in SF (11/11/05)
     
  15207. AASLD: EVIDENCE FOR SEXUAL TRANSMISSION OF HCV IN RECENT EPIDEMIC IN HIV-INFECTED MEN IN SOUTHEAST ENGLAND (11/14/05)
     
  15208. AASLD: 24% with HCV Are HIV+ at NYC Hospitals Studied (11/14/05)
     
  15209. AASLD: COST-EFFECTIVENESS OF TREATMENT FOR CHRONIC HCV IN PATIENTS COINFECTED WITH HIV (11/14/05)
     
  15210. AASLD: Liver Disease The Leading Cause of Death in HIV: Hepatitis screening campaign launched. AASLD Liver Conference Starts Nov 10 in SF (11/11/05)
     
  15211. AASLD: Diabetes Death & Complications May triple in Next 20 years (11/11/05)
     
  15212. Roche says on track to raise Tamiflu production - (11/11/05)
     
  15213. Belly Fat Accumulation in Children - (11/11/05)
     
  15214. Insulin resistance: A metabolic pathway to chronic liver disease - (11/07/05)
     
  15215. Flash-heating destroys HIV in breast milk, preserves nutrients - (11/07/05)
     
  15216. Patterns of the hazard of death after AIDS through the evolution of ART: 1984-2004 - (11/04/05)
     
  15217. At-home HIV test could spur early treatment-US panel - (11/04/05)
     
  15218. Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles? - (11/03/05)
     
  15219. Merck Wins New Jersey Jury Trial Over Pain Drug Vioxx - (11/03/05)
     
  15220. Dose-dependent influence of ddI on immune recovery in HIV+ treated with tenofovir - (11/03/05)
     
  15221. Cheap, rapid check to quantify CD4 developed - (11/03/05)
     
  15222. Abbott & New Kaletra Tablets Pricing - (11/03/05)
     
  15223. New Kaletra Tablets FDA Approved: Abbott Press Release - (11/01/05)
     
  15224. Less Than the Sum of Its Parts: Failure of a Tenofovir-Abacavir-Lamivudine Triple-Nucleoside Regimen - (11/01/05)
     
  15225. Early Viral Rebound After T20 Discontinuation in HIV-infected Patients on Long Lasting Supression - (11/01/05)
     
  15226. Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV-Infected Antiretroviral-Naive Subjects - (11/01/05)
     
  15227. New Kaletra Tablets (meltrex) Approved by FDA - (11/01/05)
     
  15228. New Safety Syringe in Fuzeon Convenience Kit - (11/01/05)
     
  15229. Guidelines for Tipranavir Use - (11/01/05)
     
  15230. EFV CNS Effects & Blood levels - (10/28/05)
     
  15231. Kaletra Monotherapy Pilot Study: 48 weeks - (10/28/05)
     
  15232. Transient Viremia in HIV-Infected Patients and Use of Plasma Preparation Tubes - (10/28/05)
     
  15233. Impact of Coinfection With HIV-1 and GB Virus C in Patients Receiving a Ritonavir-Boosted HAART Regimen: A Substudy to the MaxCmin1 Tria - (10/28/05)
     
  15234. Predictors of Body Changes - (10/28/05)
     
  15235. Vaginal Microbicide Gel Phase III Study Enrolled - (10/28/05)
     
  15236. Vaginal Gel Trials Start in South Africa - (10/28/05)
     
  15237. EU commission approves Aptivus for the treatment of HIV - (10/27/05)
     
  15238. FDA to Consider Rapid, At-Home HIV Test - (10/27/05)
     
  15239. Tanox Reports Positive Results from Phase 2 Clinical Trial of TNX-355, an Entry Inhibitor to Treat HIV - (10/27/05)
     
  15240. Maraviroc (UK-427,857): preclinical study results - (10/27/05)
     
  15241. New NNRTI GW678248: preclinical resistance profile - (10/27/05)
     
  15242. Tibotec Announces U.S. Expanded Access Program for TMC114 - (10/27/05)
     
  15243. Provision or Distribution of Growth Hormone for "Antiaging" - (10/27/05)
     
  15244. GlaxoSmithKline stops phase 3 studies of HIV drug aplaviroc due to safety issues - (10/25/05)
     
  15245. NIAID Launches First Phase II Trial of a "Global" HIV/AIDS Vaccine - (10/25/05)
     
  15246. Circumcision 'reduces HIV risk' - (10/25/05)
     
  15247. GLAXOSMITHKLINE TERMINATES PATIENT ENROLLMENT FOR PHASE 3 STUDIES OF INVESTIGATIONAL HIV ENTRY INHIBITOR APLAVIROC (GW873140) - (10/25/05)
     
  15248. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings - (10/24/05)
     
  15249. Fish Oil Improved Triglycerides - (10/21/05)
     
  15250. Fish Oil for Treatment of Hypertriglyceridemia in HIV Infection: Fish or Foul? - (10/21/05)
     
  15251. Unexpected improvement of sexual dysfunction during atazanavir therapy - (10/21/05)
     
  15252. HIV Antiretroviral Postexposure Prophylaxis: A Cautionary Note - (10/21/05)
     
  15253. Kaletra 4 Yr Followup in Treatment-Experienced; New Formulation of Kaletra - (10/21/05)
     
  15254. Carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients - (10/21/05)
     
  15255. New Adherence Survey Conducted by BMS - (10/19/05)
     
  15256. 20% Drug Resistance found in HIV Seroconverters Using Sensitive Assay - (10/19/05)
     
  15257. Bayer Offers New Antibiotic With Promise in Fight on TB - (10/19/05)
     
  15258. Efavirenz & AZT/3TC Did Not Cause Limb Fat Loss in ACTG 364 - (10/19/05)
     
  15259. DSMB Recommends maraviroc (Pfizer CCR5 drug) phase 2b/3 studies continue as designed - (10/18/05)
     
  15260. Evaluation of the Drug Interaction between Rifabutin and Efavirenz in Patients with HIV and Tuberculosis - (10/18/05)
     
  15261. Retroviral (HIV) superinfection resistance - (10/18/05)
     
  15262. Government action needed to improve HIV situation in Russia - UNDP - (10/18/05)
     
  15263. Serono To Pay $704M in Settlement - (10/18/05)
     
  15264. US considers rapid home HIV test - (10/14/05)
     
  15265. Fuzeon Use Supported by HHS Updated Treatment Guidelines - (10/14/05)
     
  15266. FDA TO WEIGH AT- HOME TESTING FOR AIDS VIRUS at Public Hearing - (10/14/05)
     
  15267. National Latino AIDS Awareness Day, October 15, 2005 - (10/13/05)
     
  15268. Nukes, Lactate, and Insulin Resistance - (10/13/05)
     
  15269. A Randomized Trial of the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087 - (10/13/05)
     
  15270. Retroviral Rebound Syndrome with Fatal Outcome after Discontinuation of Antiretroviral Therapy - (10/13/05)
     
  15271. One Time Viral 'Blips' IN PIs vs NNRTIs- study finds same outcome - (10/13/05)
     
  15272. Seminal Reservoirs during an HIV-1 Eradication Trial - (10/13/05)
     
  15273. TMC-114 Expanded Access Program - (10/12/05)
     
  15274. Normal Blood Sugar May Belie Diabetes Risk - (10/12/05)
     
  15275. TMC-114 (protease inhibitor) Expanded Access Program - (10/11/05)
     
  15276. HHS HIV Treatment Guidelines Updates by Panel and MANAGEMENT OF THE TREATMENT - EXPERIENCED PATIENT - (10/11/05)
     
  15277. Pioglitazone Reducd Risk for Heart Disease for Diabetics - (10/07/05)
     
  15278. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 - (10/07/05)
     
  15279. HIV Preexposure Prophylaxis Therapy Trials: Promote HIV Chemoprophylaxis Research, Don't Prevent It - (10/06/05)
     
  15280. Merck's Investigational Vaccine GARDASIL Prevented 100 Percent of Cervical Pre-cancers and Non-invasive Cervical Cancers Associated with HPV Types 16 and 18 in New Clinical Study - (10/06/05)
     
  15281. Temporary Employment, Absence of Stable Partnership, and Risk of Hospitalization or Death During the Course of HIV Infection in France - (10/06/05)
     
  15282. Merck's Experimental Vaccine Prevents Cancer Caused by Virus; Seeking FDA Approval This Year - (10/06/05)
     
  15283. Patients with spontaneous viral control may shed light on HIV - (10/06/05)
     
  15284. Organ Transplants for Patients with HIV - (10/05/05)
     
  15285. Efavirenz & Nonoccupational HIV Postexposure Prophylaxis - (10/05/05)
     
  15286. Prolonged Q-Tc interval in mild portal hypertensive cirrhosis: QTc Prolongation in HIV- is it due to HAART, PIs or just liver dysfunction - (10/05/05)
     
  15287. Intl HIV Drug Pricing & Kaletra - (10/05/05)
     
  15288. Fat Distribution in Men With HIV Infection - (10/03/05)
     
  15289. MSM "POZ Parties" Signal Potential to Spread HIV "Superinfection" - (10/03/05)
     
  15290. Herpes Zoster in Women With and at Risk for HIV: Data From the Women's Interagency HIV Study - (09/30/05)
     
  15291. Protease Inhibitors Adversely Affect Coronary Artery Function - (09/29/05)
     
  15292. Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance - (09/29/05)
     
  15293. High rate of virological failure with didanosine and tenofovir in treatment-experienced patients - (09/29/05)
     
  15294. Response to hepatitis A vaccine in HIV patients in the HAART era: CD4 count at time of vaccination determines response to vaccine - (09/29/05)
     
  15295. Protease inhibitors and NNRTIs have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens - (09/29/05)
     
  15296. DRUG-DRUG INTERACTIONS BETWEEN HAART, MEDICATIONS USED IN SUBSTANCE USE TREATMENT, AND RECREATIONAL DRUGS - (09/27/05)
     
  15297. Low CD4 Count May Accelerate Liver-Associated Deaths, and Heart & Malignancy Associated Deaths: D.A.D Study - (09/27/05)
     
  15298. House Bill Pushes Study of Topical Microbicides as HIV Prevention for Women - (09/27/05)
     
  15299. Reyataz & Methadone: no drug interaction observed - (09/27/05)
     
  15300. DHHS Recommendations for Care of HIV+ Individuals Displaced by Hurricanes - (09/27/05)
     
  15301. HIV+ Should Register with FEMA Diaster Assistance - (09/27/05)
     
  15302. Interview with Beth Scalco, Louisiana AIDS Director - (09/27/05)
     
  15303. Insulin Resistance in HIV-Infected Men and Women in the Nutrition for Healthy Living Cohort - (09/27/05)
     
  15304. Fat Distribution in Men With HIV Infection (FRAM) - (09/27/05)
     
  15305. Presence of Neurocognitive Impairment Requires More Potent HAART & Special Considerations - (09/27/05)
     
  15306. Appointing New FDA Commissioner - (09/27/05)
     
  15307. New Supply Chain Set Up for HIV Medicine in Africa - (09/27/05)
     
  15308. Incyte Announces Outcome of Discussions with FDA Regarding Reverset - (09/27/05)
     
  15309. Safety and distribution of cellulose acetate 1,2-benzenedicarboxylate (CAP), a candidate anti-HIV microbicide in rhesus macaques - (09/26/05)
     
  15310. Effect of HAART Interruption on mtDNA - (09/26/05)
     
  15311. alphaHGA - A Completely Novel anti-HIV Mechanism - (09/26/05)
     
  15312. PA-457 Panacos Drug May Combat Resistant AIDS Strains - (09/26/05)
     
  15313. HIV Transmission in the Adult Film Industry --- Los Angeles, California, 2004 - (09/26/05)
     
  15314. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients - (09/26/05)
     
  15315. Has Today's HIV Become Less Potent Over Time? - (09/26/05)
     
  15316. Resistance Testing for Treatment-Naives is Recommended - (09/26/05)
     
  15317. Interruption of Treatment with Individual Therapeutic Drug Classes (PIs or NRTIs) in Adults with Multidrug-Resistant HIV-1 Infection - (09/26/05)
     
  15318. Broadeining Hepatitis B Vaccination considered for all adults - (09/26/05)
     
  15319. HBV and HIV co-infection in sub-Saharan Africa: a call for further investigation - (09/21/05)
     
  15320. 6.3% Prevalence of hepatitis B and C in pregnant women who are infected with HIV - (09/21/05)
     
  15321. AZT Generics Approved by FDA - (09/20/05)
     
  15322. 25 CD4+ Cell Count Increase Predicts Clinical Benefits in Patients with Advanced HIV Disease and Persistent Viremia after 1 Year of Combination Antiretroviral Therapy - (09/20/05)
     
  15323. AZT Patent Expires - (09/20/05)
     
  15324. Superinfection can confer HIV drug resistance - (09/20/05)
     
  15325. HIV, ADAP in Texas; HIV Doc's Story of Being Stranded in New Orleans in Ritz Carlton - (09/16/05)
     
  15326. America's Pharmaceutical Companies Increase Katrina Donations - (09/16/05)
     
  15327. New GSK CCR5 Drug Finds Severe Hepatoxocity in Naives - (09/16/05)
     
  15328. Fatigue among HIV+ patients in the era of HAART - (09/15/05)
     
  15329. HAART & Heart Disease: Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins - (09/15/05)
     
  15330. Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: evaluation of accuracy and reproducibility - (09/15/05)
     
  15331. Once Daily HAART vs Twice Daily: patient surve - (09/14/05)
     
  15332. PK of Once Daily Regimen: Fosamprenavir/r, Tenofovir and FTC in Naives - (09/14/05)
     
  15333. United Kingdom HIV Drug Resistance - (09/14/05)
     
  15334. Fuzeon Drug Resistance - (09/14/05)
     
  15335. Protease Inhibitor Use in 233 Pregnancies - (09/14/05)
     
  15336. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults - (09/09/05)
     
  15337. Drug-resistant HIV may have diminished fitness - (09/09/05)
     
  15338. Risk of Selecting De Novo Drug-Resistance Mutations during Structured Treatment Interruptions in Patients with Chronic HIV Infection - (09/09/05)
     
  15339. Superiority of Protease Inhibitors over NNRTs when HAART Is Resumed after Treatment Interruption - (09/09/05)
     
  15340. Compromised CD4 Recovery in Treatment-Experienced Patients with HIV Receiving Both Tenofovir + ddI in the TORO Studies - (09/09/05)
     
  15341. Characterization of Anemia in HIV+ Subjects Treated with ART With and Without Zidovudine in 54 Clinical Trials (09/13/05)
     
  15342. Abacavir/3TC+EFV: two pills once daily(09/13/05)
     
  15343. IAS: Antiretrovirals: New and novel use thereof - Reported by Mike Youle, MD, Royal Free Hospital, London, UK (09/09/05)
     
  15344. ADAP Response to katrina - (09/09/05)
     
  15345. HIV Emergency Gulf Coast Coverage - (09/09/05)
     
  15346. GSK Clinical Trials & Katrina - (09/09/05)
     
  15347. National AIDS Fund KATRINA HIV/AIDS EMERGENCY FUND - (09/09/05)
     
  15348. Gilead Provides HIV Meds to Katrina Victims Emergency Medication Needs - Hurricane Katrina - (09/06/05)
     
  15349. Once Daily HAART vs Twice Daily: patient survey - (09/06/05)
     
  15350. Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy: results suggest improvements in lipoatrophy associated with rosiglitazone. - (09/06/05)
     
  15351. An Editorial Update: Annus horribilis for Vitamin E - (09/06/05)
     
  15352. HIV Infection and Aging: Emerging Research on the Horizon - (09/06/05)
     
  15353. Effect of Soybean Protein on Blood Pressure: A Randomized, Controlled Trial - (09/06/05)
     
  15354. Study finds ddI but not d4T associated with risk for symptomatic mitochondrial toxicity in RIBAVIC during IFN/RBV therapy - (09/02/05)
     
  15355. Effect of Antioxidants on Glucose Metabolism and Plasma Lipids in HIV-Infected Subjects With Lipoatrophy - (09/02/05)
     
  15356. MITOCHONDRIAL DYSFUNCTION: TOXICITY & PATIENT MANAGEMENT - (09/02/05)
     
  15357. Therapy-associated severe hyperlactatemia rare in HIV patients - (09/02/05)
     
  15358. 2 Articles on Pregnancy in HIV: HAART & Congential Abnormalities; Mitochondrial Toxicity in Uninfected Newborns - (09/02/05)
     
  15359. Obesity on the rise in African American women on anti-HIV treatment - (09/02/05)
     
  15360. Obesity on the rise in African American women on anti-HIV treatment - (09/02/05)
     
  15361. GW640385X, new Protease Inhibitor - (09/02/05)
     
  15362. Lack of Antagonism Between Abacavir, Lamivudine, and Tenofovir Against Wild-Type and Drug-Resistant HIV-1 - (09/02/05)
     
  15363. Erectile Dysfunction Drugs & HIV Transmission Conference - (09/02/05)
     
  15364. Vioxx verdict casts long shadow over Merck's future - (09/02/05)
     
  15365. Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir - (09/02/05)
     
  15366. CD4 Lymphoctye Percentage versus Absolute CD4 Lymphocyte Count in Predicting HIV Disease Progression: An Old Debate Revisited EDITORIAL - (09/02/05)
     
  15367. Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management, 3.5% 3-Class Resistant - (09/02/05)
     
  15368. GILEAD REDUCES PRICES FOR VIREAD AND TRUVADA IN THE DEVELOPING WORLD - (09/02/05)
     
  15369. New d4T-like NRTI Potent vs NRTI Resistant HIV - (09/02/05)
     
  15370. Effectiveness of HAART in Reducing Heterosexual Transmission of HIV - (09/02/05)
     
  15371. A Case of Superinfection - (09/02/05)
     
  15372. Going to Fight HIV in China: Merck, Pfizer, Bayer, Gallo - (09/02/05)
     
  15373. Anal intraepithelial neoplasia in the HAART era among HIV+ MSM - (09/02/05)
     
  15374. Can We Cure HIV: "Depletion of latent HIV-1 infection in vivo: a proof-of-concept study" - (09/02/05)
     
  15375. ICAAC and Hurricane Katrina Update - Wednesday, August 31, 3:30pm EST - (09/02/05)
     
  15376. CD4 Lymphoctye Percentage versus Absolute CD4 Lymphocyte Count in Predicting HIV Disease Progression: An Old Debate Revisited EDITORIAL - (09/02/05)
     
  15377. PK of Once Daily Regimen: Fosamprenavir/r, Tenofovir and FTC in Naives (08/31/05)
     
  15378. HIV+ Patient Survey: 52% Dissatisfied with Quality of Life (08/31/05)
     
  15379. Uridine In Vitro Improves Mitochondrial Effect of Nukes (08/31/05)
     
  15380. Tipranavir & Effect of Using Active HIV Drugs (08/30/05)
     
  15381. Tipranavir: long-term safety/tolerability (08/30/05)
     
  15382. The Pharmacokinetics (PK) of Single-dose and Steady-state Tipranavir/Ritonavir (TPV/r) 500 mg/200 mg in Subjects With Mild or Moderate Hepatic Impairment (08/30/05)
     
  15383. PK of Once Daily Regimen: Fosamprenavir/r, Tenofovir and FTC in Naives (08/30/05)
     
  15384. Abacavir vs d4T: changes in viral load, diabetes, lipids, body changes, cytokines (08/30/05)
     
  15385. 6% New Onset Diabetes in D.A.D. Study: Risk factors for new onset diabetes mellitus (DM) in HIV patients (08/30/05)
     
  15386. IAS: New NNRTI GW695634: safety & antiviral activity; 7-day monotherapy study - (08/17/05)
     
  15387. IAS: "Thyroid Dysfunction in Individuals with HIV Infection: the effect of HAART" (08/15/05)
     
  15388. Methamphetamine Abuse, HIV Infection Cause Changes in Brain Structure Alterations May Be Related to Cognitive Deficits - (08/12/05)
     
  15389. Fixed Dose Combination TDF/EFV/FTC Not Bioequivalent - (08/11/05)
     
  15390. HIV Antiretroviral Treatment: Early Versus Later - (08/09/05)
     
  15391. IAS: PATIENTS TREATED WITH RITONAVIR-BOOSTED SAQUINAVIR" (08/09/05)
     
  15392. IAS: Invirase/r: No PI Resistance in viral failures (08/09/05)
     
  15393. IAS: Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naive HIV-Infected Patients: a 4-Year Follow-Up (08/09/05)
     
  15394. IAS: Tenofovir Resistance Report (08/09/05)
     
  15395. IAS: Simplification to Kaletra Monotherapy (08/05/05)
     
  15396. IAS: Atazanavir Use in Pregnancy (08/05/05)
     
  15397. IAS: Cirrhotic Non-Responders Improve Liver Condition with Pegasys/RBV in APRICOT Study (08/05/05)
     
  15398. IAS: Tipranavir & TDM (08/04/05)
     
  15399. TH9507, New Growth Hormone - (08/03/05)
     
  15400. HIV drug resistance acquired through superinfection - (08/03/05)
     
  15401. IAS: Once-Daily vs.Twice-Daily Lopinavir/ritonavir in Antiretroviral-Naive Patients: 96-Week Results (08/03/05)
     
  15402. IAS: New Gas-Powered T20 Injection Device: 48 week study (08/03/05)
     
  15403. IAS: Abacavir+3TC: Changes in ALT/AST in Coinfected (08/03/05)
     
  15404. IAS: 24 vs 48 weeks Pegasys/RBV in HCV Genotype 2/3 Coinfection: does this study answer the question (08/01/05)
     
  15405. IAS: Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers (08/01/05)
     
  15406. IAS: TMC114-C213 study Week 24 primary analysis Highly Treatment Experienced Patients (08/01/05)
     
  15407. IAS: TMC114/r is well tolerated in 3-class-experienced patients: Week 24 primary safety analysis of POWER 1 (TMC114-C213) (08/01/05)
     
  15408. IAS: Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation: healthy volunteers (08/01/05)
     
  15409. IAS: GlaxoSmithKline begins Phase III trials with aplaviroc (873140) - an entry inhibitor for HIV treatment (07/29/05)
     
  15410. IAS: CCR5 Inhibitor SCH417690: antiviral activity (07/29/05)
     
  15411. IAS: Switch to Reyataz: lipids, viral load (07/29/05)
     
  15412. IAS: Improvement in Facial & Limb Lipoatrophy at 48 Wks After Switch to Abacavir or Tenofovir (07/28/05)
     
  15413. IAS: CCR5 INHIBITOR MARAVIROC (UK-427,857) (07/28/05)
     
  15414. IAS: Overview of Phase 1 and 2a Safety and Efficacy Data of Maraviroc (UK-427,857) (07/28/05)
     
  15415. IAS: New Kaletra Tablet PK Study (07/28/05)
     
  15416. IAS: Tenofovir+FTC+Efavrienz vs Combivir+EFV: 48 Week Final Results Study 934 (07/28/05)
     
  15417. IAS: TMC-114/r: 24 week efficacy & safety (07/26/05)
     
  15418. IAS: Reverset (d4FC), new NRTI: phase IIb data (07/26/05)
     
  15419. IAS: Report 1. International AIDS Conference (IAS) in Rio de Janeiro, July 24-27, 2005 (07/25/05)
     
  15420. Instability of lopinavir/ritonavir capsules at ambient temperatures in sub-Saharan Africa: relevance to WHO antiretroviral guidelines - (07/25/05)
     
  15421. The management of HIV-1 protease inhibitor pharmacokinetic interactions - (07/22/05)
     
  15422. Adherence to trizivir plus tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol - (07/22/05)
     
  15423. We Must Not Let Protestors Derail Trials of Pre-Exposure Prophylaxis for HIV (tenofovir) - (07/22/05)
     
  15424. Current perspectives on HIV-associated lipodystrophy syndrome - (07/22/05)
     
  15425. Unsafe Sex and Increased Incidence of Hepatitis C Virus Infection among HIV-Infected Men Who Have Sex with Men: The Swiss HIV Cohort Study - (07/21/05)
     
  15426. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? - (07/21/05)
     
  15427. Metabolics, Fatty Liver, Heart Disease Circulatory dysfunction in NAFLD - Which is first, which is last, and what do we do in between? EDITORIAL - (07/21/05)
     
  15428. Fatty Liver Predicted Heart Disease - (07/20/05)
     
  15429. Lipodystrophy: defined, risk factors, switch studies - (07/20/05)
     
  15430. High Rate of Recurrence of Cervical Intraepithelial Neoplasia After Surgery in HIV-Positive Women - (07/20/05)
     
  15431. FDA Grants Priority Review for New Kaletra Tablets - (07/20/05)
     
  15432. Update to the "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents" (July 15, 2005) - (07/20/05)
     
  15433. ADAP Tipranavir Coverage in Discussions - (07/20/05)
     
  15434. Alcohol Accelerates HIV in Monkeys Increased Viral Replication in Simian Immunodeficiency Virus/Simian-HIV-Infected Macaques With Self-Administering Model of Chronic Alcohol Consumption - (07/20/05)
     
  15435. HIV Pediatrics Studies: Belated Charge Ignites Furor Over AIDS Drug Trial - (07/20/05)
     
  15436. Report Finds High Rates of Cervical Cancer Indicate Broader Problems in Access to Care - (07/20/05)
     
  15437. Roche and Trimeris Announce FDA Filing of FUZEON sNDA for Administration with a Needle-Free Injection Device - (07/20/05)
     
  15438. FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385) - (07/20/05)
     
  15439. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use - (07/20/05)
     
  15440. Tenofovir and Changes in Renal Function - (07/20/05)
     
  15441. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive - (07/13/05)
     
  15442. Pioglitazone shows anti-inflammatory, anti-atherogenic effects - (07/13/05)
     
  15443. Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients - (07/13/05)
     
  15444. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study - (07/13/05)
     
  15445. FDA Approves Megace ES for Anorexia, Cachexia, or Unexplained, Significant Weight Loss in Patients With AIDS - (07/13/05)
     
  15446. Atazanavir trough plasma concentration monitoring on HAART; NVP Reduced Reyataz trough levels - (07/13/05)
     
  15447. Chinese Company Develops Fusion Inhibitor - (07/13/05)
     
  15448. Brazil Pact on AIDS Drugs Kaletra - (07/13/05)
     
  15449. Abbott Statement on Agreement With Brazilian Government for Kaletra(R) (Lopinavir/Ritonavir) - (07/11/05)
     
  15450. TMC114/r in 3-Class Experienced Patients: 24-week interim analysis - (07/11/05)
     
  15451. Safety, Acceptability, and Potential Efficacy of a Topical Penile Microbicide Wipe - (07/08/05)
     
  15452. Genotypic Resistance Testing Benefits: Response to 'Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis' - (07/08/05)
     
  15453. Efficacy & Tolerability of NRTI-Sparing Combination of Kaletra and Efavirenz - (07/08/05)
     
  15454. Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study - (07/08/05)
     
  15455. Expression of Chemokine Receptors CCR5 and CXCR4 on CD4+ T Cells and Plasma Chemokine Levels During Treatment of Active Tuberculosis in HIV-1-Coinfected Patients - (07/08/05)
     
  15456. Simplification Study to Trizivir or Combivir+Nevirapine - (07/08/05)
     
  15457. New Formulation of Generic d4T Receives Tentative Approval by FDA - (07/08/05)
     
  15458. Induction HIV Therapy: Trizivir/Efavirenz - (07/08/05)
     
  15459. US Monitoring Brazil Plan to Break AIDS Drug Patent - (07/08/05)
     
  15460. The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors: Implications for Once-Daily Dosing - (07/06/05)
     
  15461. 14th International HIV Drug Resistance Workshop Reported for NATAP by David Margolis, MD, University of North Carolina (07/6/05)
     
  15462. Brazil & Kaletra, mixed opinions As Brazil Aims for Cheaper AIDS Drug - (07/05/05)
     
  15463. Intl AIDS: Asian Conference Ongoing Now; Caribbean Update - (07/05/05)
     
  15464. Pfizer discontinues Development of capravirine, for hiv/aids - (07/01/05)
     
  15465. Survival Improves After Cancer Diagnosis in Persons With AIDS - (07/01/05)
     
  15466. Patch Test for Abacavir Hypersensitivity: Clinical and immunogenetic correlates of abacavir hypersensitivity - (07/01/05)
     
  15467. Induction HIV Therapy: Trizivir/Efavirenz - (07/01/05)
     
  15468. US Monitoring Brazil Plan to Break AIDS Drug Patent - (06/29/05)
     
  15469. Mitochondria and the Toxicity in HIV Disease and Antiretroviral Agents    Modena, Italy May 2005 Written for NATAP by Mike Youle, MD Royal Free Hospital, Director Centre for HIV Medicine London, UK Contributions by Andrea Cossarizza, MD PhD Univ. of Modena and Reggio Emilia - (06/27/05)
     
  15470. HIV Prevalence, Unrecognized Infection, and HIV Testing Among Men Who Have Sex with Men --- Five U.S. Cities, June 2004--April 2005: - (06/27/05)
     
  15471. Tipranavir: new protease inhibitor approved by the FDA for patients with extensive treatment-experience - (06/27/05)
     
  15472. HIV Drug resistance Predicts AIDS & Death - (06/24/05)
     
  15473. Prevalence of, Evolution of, and Risk Factors for Fat Atrophy and Fat Deposition in a Cohort of HIV-Infected Men and Women - (06/24/05)
     
  15474. Heart Disease: pioglitazone & fish - (06/24/05)
     
  15475. FDA Announcement of Tipranavir Approval - (06/23/05)
     
  15476. Therapeutic Drug Monitoring of Nevirapine Reduces Pharmacokinetic Variability But Does Not Affect Toxicity or Virologic Success in the ATHENA Study - (06/23/05)
     
  15477. TMC114: two studies for patients with treatment-experience - (06/22/05)
     
  15478. Gilead Announces Initiation of Phase I/II Clinical Trial Evaluating HIV Integrase Inhibitor GS 9137 - (06/22/05)
     
  15479. Kaletra Pricing & ADAP Price Freeze - (06/22/05)
     
  15480. As the President's Advisory Council on HIV and AIDS (PACHA) Meets in DC This Week, AHF Offers Input on Redesign of Nation's Premier AIDS Program - (06/21/05)
     
  15481. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen - (06/21/05)
     
  15482. Drug Resistance: Kaletra-NFV (study 863): using 1 copy viral load test may predict viral outcomes (06/20/05)
     
  15483. A new meeting place: chatting on the Internet, e-dating and sexual risk behaviour among Dutch men who have sex with men - (06/20/05)
     
  15484. HIV Drug resistance Predicts AIDS & Death - (06/20/05)
     
  15485. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia - (06/20/05)
     
  15486. Viral Blips in 8 patients treated by NNRTI-based regimen Did Not Result in Viral Failure - (06/20/05)
     
  15487. New Oral Diabetes Drug Compared to Pioglitazone - (06/17/05)
     
  15488. FDA grants Fast Track designation to Schering-Plough's vicriviroc for HIV - (06/17/05)
     
  15489. Crystal Meth Use Fuels Rise in HIV Cases Among White MSM; 'Down Low' Term Should Apply To All Races, Studies Say - (06/17/05)
     
  15490. Resistance Testing--Accuracy, Precision, and Consistency of Expert HIV Type 1 Genotype Interpretation: An International Comparison (The GUESS Study) - (06/17/05)
     
  15491. Tenofovir & Nuke Resistance Mutations & Patterns (06/17/05)
     
  15492. Drug Resistance: Reduced susceptibility to protease inhibitors (PI) in the absence of primary PI resistance-associated mutations (06/16/05)
     
  15493. Changing Patterns in NRTI & NtRTI Mutations - (06/16/05)
     
  15494. HIV-Positive U.S. Women More Concentrated in South, Among Minorities, CDC Says at HIV Prevention Conference in Atlanta - (06/16/05)
     
  15495. DDI + Tenofovir Interaction Study: no intracellular interaction, but high TDF levels after discontinuation - (06/16/05)
     
  15496. Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients - (06/16/05)
     
  15497. Figuring ddI Resistance: Clinically Relevant Genotype Interpretation of Resistance to Didanosine - (06/16/05)
     
  15498. Highlighted HIV Prevention Programs at Natl Conference - (06/16/05)
     
  15499. TMC114 Protease Inhibitor Available Soon - (06/15/05)
     
  15500. Drug Resistance: Virologic Response to Antiretroviral Therapy in the Setting of the K65R Mutation (06/14/05)
     
  15501. Drug Resistance: Emergence of Drug Resistance Mutations During Treatment Interruption in Patients with Undetectable Viral Loads (06/14/05)
     
  15502. Single-Dose Nevirapine and Drug Resistance: The More You Look, the More You Find - (06/14/05)
     
  15503. Diabetic Retinopathy Occurs in Pre-Diabetes - (06/14/05)
     
  15504. New Entry Inhibitor Discovery Program Trimeris and ChemBridge Research Laboratories Sign Antiviral Drug Discovery and Development Agreement; Collaboration to Target Discovery and Development of Small Molecule Entry Inhibitors of the Human Immunodeficiency Virus - (06/14/05)
     
  15505. Drug Resistance: Integrase Inhibitor in Phase II (06/13/05)
     
  15506. Drug Resistance: BILR 355: New NNRTI (06/13/05)
     
  15507. Drug Resistance: PL-100, New Protease Inhibitor (06/13/05)
     
  15508. Drug Resistance: Methamphetamine and Sildenafil (Viagra) use are Associated with High-Risk Sexual Behavior with HIV-uninfected Partners & Transmission of HIV Drug Resistance (06/13/05)
     
  15509. Drug Resistance: Resistance to UK-427,857 does not result in cross-resistance to other entry inhibitors (06/13/05)
     
  15510. Drug Resistance: GSK CCR5 '140' (06/13/05)
     
  15511. Drug Resistance: Schering CCR5 Drug: Resistant viruses showed cross-resistance to other CCR5 inhibitors (06/13/05)
     
  15512. Drug Resistance: Tipranavir: predicting viral response (06/13/05)
     
  15513. Drug Resistance: Reyataz parameters predicting outcomes (06/13/05)
     
  15514. Drug Resistance: 9% of Patients with Multi-Drug Resistant HIV Died Within 2 Years - (06/9/05)
     
  15515. Drug Resistance: Nevirapine Resistance in Mother-To-Child Transmission - (06/9/05)
     
  15516. Drug Resistance: Host Genetics & HIV (06/13/05)
     
  15517. Prevalence of, Evolution of, and Risk Factors for Fat Atrophy and Fat Deposition in a Cohort of HIV-Infected Men and Women - (06/7/05)
     
  15518. NASH: a mitochondrial disease - (06/7/05)
     
  15519. Multidrug-resistant, dual-tropic HIV-1 and rapid progression - (06/7/05)
     
  15520. NYC Case HIV MDR: "AIDS Experts Awaken to a False Alarm" - (06/7/05)
     
  15521. TDM - (06/7/05)
     
  15522. Roche Discontinues Fortovase for Invirase: Dear Health Care Provider Letter - (06/7/05)
     
  15523. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial - (06/2/05)
     
  15524. Diabetes risk high in men on HAART - (06/1/05)
     
  15525. Pioglitazone: heart disease, lipids, diabetes - (05/31/05)
     
  15526. Fatty Liver & ART in HIV (05/31/05)
     
  15527. Fatty Liver Is Worse in HIV "IMPACT of HIV COINFECTION on the DEVELOPMENT of STEATOSIS (FATTY LIVER) in PATIENTS with Chronic HCV Infection" - (05/31/05)
     
  15528. Bone Disease in HIV: study finds, heavily pre-treated patients had Vitamin D deficiency & serum marker abnormalities & perhaps serum markers may be better for assessing patient risk than total BMD by DEXA - (05/31/05)
     
  15529. The Use of a Triple Nucleoside-Nucleotide Regimen for Nonoccupational HIV Post-Exposure Prophylaxis - (05/31/05)
     
  15530. Trizivir Receives FDA Traditional Approval - (05/26/05)
     
  15531. Cognitive Impairment, HCV, HIV & Meth "Risk of Cognitive Impairment High in HCV-HIV Coinfection and Methamphetamine Addiction" - (05/26/05)
     
  15532. Micronutrients: current issues for HIV care providers - (05/24/05)
     
  15533. Metabolic benefits, 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine, NEFA Study   - (05/24/05)
     
  15534. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure - (05/24/05)
     
  15535. Switching to Atazanavir Improves Metabolic Disorders in Antiretroviral-Experienced Patients With Severe Hyperlipidemia - (05/23/05)
     
  15536. FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval for Investigational Anti-HIV Drug Tipranavir   - (05/20/05)
     
  15537. DDW: Pioglitazone Improves Fatty Liver (05/16/05)
     
  15538. Norvir (ritonavir) available in new package size - (05/16/05)
     
  15539. Viread (tenofovir) Labeling Revision from FDA - (05/16/05)
     
  15540. Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America - (05/13/05)
     
  15541. Early antiretroviral therapy decreases progression of perinatal HIV - (05/13/05)
     
  15542. HIV-infected patients with isolated anti-HBc antigen may require HBV vaccine - (05/13/05)
     
  15543. Tenofovir Prevention Study: Commentary in Support "Outside View: An HIV pill that offers hope" - (05/13/05)
     
  15544. The Pessimist AIDS Activist Larry Kramer, Hoarse From Speaking Truth to Power - (05/13/05)
     
  15545. 6th Clin Pharm: SUMMARY OF THE 6TH INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY OF HIV THERAPY (05/12/05)
     
  15546. Fatty Diets May Lead to Cirrhosis - (05/09/05)
     
  15547. Risk of HIV transmission greatest during early-stage infection; risk by number of sex acts.. - (05/09/05)
     
  15548. Associated Press's John Solomon Says AIDS Researchers Enrolled Foster Kids in AIDS Research Studies Without Independent Advocate Protection - (05/05/05)
     
  15549. Lipodystrophy Is Associated With a Low Rate of Treatment Failure in HIV-Positive Patients Switched to Atazanavir - (05/04/05)
     
  15550. Body Changes in Women Associated with Heart Disease Risk: "Increased Cardiovascular Disease Risk Indices in HIV-Infected Women" - (05/04/05)
     
  15551. Antiretroviral therapies for treatment-experienced patients: current status and research challenges - (05/04/05)
     
  15552. New Kaletra Formulation-FDA Application by Abbott - (05/03/05)
     
  15553. FDA Approves Once Daily Kaletra For Therapy Naive Patients - (05/02/05)
     
  15554. EASL: Tenofovir in HIV/HBV Coinfection (05/02/05)
     
  15555. EASL: Tenofovir in HIV/HBV Coinfection (05/02/05)
     
  15556. 6th Clin Pharm: GSK Reports new PK Data on Fosamprenavir (Lexiva) (04/27/04)
     
  15557. EASL: Diabetes & Lipids Associated with Liver Disease (04/27/04)
     
  15558. Truvada + Sustiva Fixed Dose Bioequivalence Study - (04/27/05)
     
  15559. HIV Drug Resistance Rates, worldwide (04/25/04)
     
  15560. HIV load and CD4+ cell count affect HPV detection in HIV-infected women - (04/22/05)
     
  15561. Voluntary weight reduction tied to bone loss in older men - (04/22/05)
     
  15562. EURO: Lopinavir/r + Atazanavir for Salvage; Genotypic Inhibitory Quotient; p-glycoprotein Inhibitor may limit resistance (04/21/04)
     
  15563. EURO: HAART-Multiregimen Failure (04/21/04)
     
  15564. EURO: HIV Subtype Diversity in Drug Resistance (04/21/04)
     
  15565. EURO: CCR5 Antagonists Resistance Report (04/19/04)
     
  15566. EURO: Tipranavir, a potent PI Against Resistant HIV: more about its resistance profile (04/16/04)
     
  15567. EURO: Fuzeon Resistance (04/16/04)
     
  15568. EURO: European Resistance Workshop-Part 1. Tenofovir, Nucleosides, and Nonnucleosides (TMC278, NVP in MTCT, ddI/TDF/EFV viral failure) (04/06/04)
     
  15569. CROI: Tenofovir and Kidney Toxicity: What do the studies show? - Written for NATAP Judith Aberg, MD, Bellevue Hospital, New York University Medical Center (04/14/04)
     
  15570. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy - (04/12/05)
     
  15571. Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence - (04/12/05)
     
  15572. Pharmacogenomics and HIV Therapeutics (and lipid disorders) - (04/12/05)
     
  15573. Undetectable Viremia without Antiretroviral Therapy in Patients with HIV Seroconversion: An Uncommon Phenomenon? - (04/12/05)
     
  15574. Unrecognized HIV Infection, Risk Behaviors, and Perceptions of Risk Among Young Men Who Have Sex With Men: Opportunities for Advancing HIV Prevention in the Third Decade of HIV/AIDS - (04/12/05)
     
  15575. Avascular Necrosis in HIV-Infected Patients: A Case-Control Study from the Aquitaine Cohort, 1997Ü2002, France - (04/12/05)
     
  15576. Sustiva & Pregnancy: Change in Label from Pregnancy Category C to D - (04/12/05)
     
  15577. Reyataz/r in Treatment Experienced: 48 wks-lipids, virologic responses - (04/11/05)
     
  15578. Type 2 diabetes: principles of pathogenesis and therapy - (04/11/05)
     
  15579. Cardiovascular disease in HIV-positive patients - (04/11/05)
     
  15580. HIV-Exposed but Uninfected, Why? - (04/11/05)
     
  15581. Merck wins approval for combined Fosamax Once Weekly treatment for Osteoporosis - (04/11/05)
     
  15582. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients - (04/09/05)
     
  15583. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis - (04/09/05)
     
  15584. HCV/HIV Coinfection: challenges & strategies for care & treatment - (04/09/05)
     
  15585. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus - (04/09/05)
     
  15586. 3rd European HIV Drug Resistance Workshop: European Resistance Workshop-Part 1. Tenofovir, Nucleosides, and Nonnucleosides (TMC278, NVP in MTCT, ddI/TDF/EFV viral failure) (04/08/04)
     
  15587. CROI: Enfuvirtide (ENF, T-20) Resistance, fast and pretty complete, studies from 12th CROI - Written for NATAP by Nancy Shulman, MD, Stanford University (04/06/04)
     
  15588. CROI: Body Shape Changes in HIV-Infected Persons - Written for NATAP David Alain Wohl, MD - The University of North Carolina AIDS Clinical Research and Treatment Unit (04/06/04)
     
  15589. Renal Dysfunction & Tenofovir - (04/04/05)
     
  15590. Enfuvirtide Resistance Mutations: Impact on Human Immunodeficiency Virus Envelope Function, Entry Inhibitor Sensitivity, and Virus Neutralization - (04/04/05)
     
  15591. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy - (04/04/05)
     
  15592. RNA interference- New Drug Discovery for Hepatitis B Therapy - (04/04/05)
     
  15593. Antidepressant Treatment Improves Adherence to ART Among Depressed HIV+ Patients - (04/04/05)
     
  15594. Increasing Trend to Stop HAART in MACS - (04/04/05)
     
  15595. 25% of Women in WIHS Stop HAART for at least 6 Months - (04/01/05)
     
  15596. Sustiva & Pregnancy: Change in Label from Pregnancy Category C to D - (04/01/05)
     
  15597. Single HIV Genotypic Resistance Test Can Underestimate Degree of Drug Resistance - (04/01/05)
     
  15598. "Women At Risk: The Health of Women in New York City" Report Released - (04/01/05)
     
  15599. UPDATE ON THE INVESTIGATION OF A RARE STRAIN OF HIV IN A NEW YORK CITY RESIDENT - (04/01/05)
     
  15600. Statins and hepatotoxicity: Focus on patients with fatty liver - (03/31/05)
     
  15601. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection? - (03/31/05)
     
  15602. Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor - (03/22/05)
     
  15603. High Rates of ART Resistance Reported in Naives - (03/22/05)
     
  15604. Treatment of Facial Lipoatrophy With Intradermal Injections of Polylactic Acid in HIV-Infected Patients - (03/21/05)
     
  15605. R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy - (03/21/05)
     
  15606. Alendronate, Vitamin D, and Calcium for the Treatment of Osteopenia/Osteoporosis Associated With HIV Infection - (03/21/05)
     
  15607. NYC Case: Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report - (03/21/05)
     
  15608. CROI: Key clinical studies in initial and switch therapy - Dr Graeme Moyle MD, MBBS (03/17/04)
     
  15609. CROI: Resistance part II (ddI and tipranavir resistance news) - Report Written by Nancy Shulman (03/17/04)
     
  15610. CROI: Nevirapine MTCT--Drug resistance at the 12th CROI - Report Written by Nancy Shulman (03/17/04)
     
  15611. Prevention With HIV-Seropositive Men Who Have Sex With Men: Lessons From the Seropositive Urban Men's Study (SUMS) and the Seropositive Urban Men's Intervention Trial (SUMIT) - (03/17/05)
     
  15612. CROI: Nevirapine MTCT--Drug resistance at the 12th CROI - Report Written by Nancy Shulman (03/17/04)
     
  15613. Company Announces Sculptra Physician Locator - (03/15/05)
     
  15614. Tanox completes enrollment of Phase 2 clinical trial of TNX-355 in HIV Treatment-Experienced Patients - (03/15/05)
     
  15615. Predictors of Residual Viremia in HIV-Infected Patients Successfully Treated with Efavirenz and Lamivudine plus either Tenofovir or Stavudine - (03/15/05)
     
  15616. CROI: Switch to Tenofovir Improved Lipids, Fat Loss - (03/15/04)
     
  15617. CROI: FDA Reports Higher Abacavir Hypersensitivity, 8% vs 5% - (03/15/04)
     
  15618. CROI: New Antiretrovirals at 12th CROI - Reported for NATAP by Mike Youle, MD - (03/10/04)
     
  15619. Intermittent HIV-1 Viremia (Blips) and Drug Resistance in 10 Patients Receiving HAART - (03/09/05)
     
  15620. CROI: Prevention of mother-to-child transmission and nevirapine resistance - Reported for NATAP by David Margolis, MD - (03/09/04)
     
  15621. CROI: Innate Immunity: natural cellular mechanisms that battle HIV - Reported for NATAP by David Margolis, MD - (03/09/04)
     
  15622. CROI: Predicting Response to DDI - Reported for NATAP by David Margolis, MD - (03/09/04)
     
  15623. CROI: Choosing When to Use Tipranavir - Reported for NATAP by David Margolis, MD - (03/09/04)
     
  15624. CROI: HIV latency and persistent, low-level viremia - Reported for NATAP by David Margolis, MD - (03/09/04)
     
  15625. CROI: Leading Causes of Death in HIV....liver disease, AIDS, heart disease, malignancies - Reported for NATAP by David Margolis, MD - (03/09/04)
     
  15626. CROI: 12th CROI HCV Report - (03/08/04)
     
  15627. CROI: CLINICAL PHARMACOLOGY AT THE 12th CROI- John G. Gerber, M.D. (03/08/04)
     
  15628. CROI: Liver Transplants in Hepatitis/HIV Coinfection at 12th CROI - (03/08/04)
     
  15629. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy - (03/07/05)
     
  15630. CROI: Effect of Aging on Epidemiologic and Clinical Features in HIV-infected Individuals with Neurological Disorders - (03/07/04)
     
  15631. CROI: Impact of HAART on NeuroAIDS - (03/07/04)
     
  15632. CROI: Kaletra Independently Reduces HIV Replication in Cerebrospinal Fluid - (03/07/04)
     
  15633. CROI: DAPD + Fuzeon Pilot Study: ACTG 5118 - (03/07/04)
     
  15634. CROI: Advancing towards the therapeutic use of chemokine receptor blockade (CCR5-Entry Inhibitors) - Reported for NATAP by David Margolis, MD - - (03/07/04)
     
  15635. CROI: Improved Lipids After Switch to Reyataz - (03/04/04)
     
  15636. CROI: Switch to ATV/r Improves Lipids - (03/04/04)
     
  15637. CROI: Tenofovir for HBV/HIV Coinfection - (03/03/04)
     
  15638. CROI: "Beyond Serum Creatinine: Identification of Renal Insufficiency Using GFR: Implications for Clinical Research and Care" - (03/03/04)
     
  15639. CROI: Reyataz/r: 96 week Study 045 results - (03/03/04)
     
  15640. CROI: Improving the Clinical Assessment of Renal Function in HIV - (03/02/05)
     
  15641. CROI: Decline in Renal Function Associated with Tenofovir DF (TDF) Compared to Nucleoside Reverse Transcriptase Inhibitor (NRTI) Treatment - (03/02/04)
     
  15642. CROI: Switch for Lipoatrophy to Abacavir or LPV/r+NVP - (03/02/05)
     
  15643. New HIV Entry Inhibitor Program Announced - (03/02/05)
     
  15644. CROI: "Entecavir in HIV/HBV Co-Infected Patients: Safety and Efficacy in a Phase II Study (ETV-038)" - (03/02/05)
     
  15645. CROI: Switching to Tenofovir or Lower d4T Dose Improves Lipids/Limb & Total Fat - (03/02/04)
     
  15646. CROI: Triple NRTI Regimen: Combivir+Tenofovir - (03/02/05)
     
  15647. CCR5 Did Not Effect HCV - (03/02/05)
     
  15648. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate - (03/02/05)
     
  15649. HCV, HIV & Non-Hodgins Lymphoma - (03/02/05)
     
  15650. CROI: HIV Prevalence Among Blacks Increases in Federal Govt Survey - (03/01/04)
     
  15651. CROI: Two New Viruses Reported Belonging to AIDS Family - (03/01/04)
     
  15652. CROI: TMC278, new NNRTI, 7-day study results - (03/01/04)
     
  15653. CROI: PA-457, new HIV drug, maturation inhibitor - (03/01/04)
     
  15654. CROI: RAVE Study: switch to tenofovir or abacavir from AZT or d4T - (03/01/04)
     
  15655. CROI: Merck Integrase Inhibitor: -1.8 log reduction in 10-day study - (03/01/04)
     
  15656. CROI: TMC114/r in 3-Class Experienced Patients: 24-week interim analysis - (03/01/04)
     
  15657. CROI: 24 Week RESIST Study Analysis: the efficacy of tipranavir/ritonavir is superior to lopinavir/r, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR) - (03/01/04)
     
  15658. FDA Approves Pegasys and Copegus as Only Hepatitis C Treatment for HIV Patients - (02/28/05)
     
  15659. CROI: Switching to Thymidine Analogue Sparing or Nuke Sparing Regimen improves Lipoatrophy: 24 week results of a prospective randomized clinical trial, AACTG 5110 - (02/25/04)
     
  15660. CROI: Switching off AZT or d4T to Tenofovir or Abacavir Improves Limb Fat After 48 weeks - (02/25/04)
     
  15661. CROI: IMPACT OF BASELINE GENOTYPIC RESISTANCE ON RESPONSE TO TIPRANAVIR/r in RESIST STUDIES - (02/25/04)
     
  15662. CROI: 24 Week RESIST Study Analysis: tipranavir/r - (02/25/04)
     
  15663. Alarm Over Single AIDS Case Is Challenged by Questioners - (02/22/05)
     
  15664. H.I.V. Strain Adds Urgency to Changes in NY City AIDS Program - (02/16/05)
     
  15665. Pioglitazone Improved Metabolic Syndrome - (02/16/05)
     
  15666. Suggestions to Curb Unsafe Sex to Prevent HIV Transmission & Drug Resistance - (02/15/05)
     
  15667. More on the NYC Case of HIV Resistant to 3 HIV Classes of HIV Drugs - (02/15/05)
     
  15668. Case of Fast Progressing Resistant HIV in NYC: more responses - (02/14/05)
     
  15669. Multi-Drug-Resistant, Fast-Progressing Strain of HIV Discovered in a NYC Resident - (02/14/05)
     
  15670. Interaction Between Reyataz & Prilosec - (02/10/05)
     
  15671. Experts Want H.I.V. Testing for All Adults - (02/10/05)
     
  15672. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma (liver cancer) - (02/09/05)
     
  15673. HIV-associated dementia tied to proviral DNA levels - (02/09/05)
     
  15674. Interaction-Rifampin & SQV/r (1000/100): drug interaction warning - (02/08/05)
     
  15675. CD4 Cell Count--Guided Treatment Interruption: Be Smart and Wait for More Evidence - (02/07/05)
     
  15676. Herpes Zoster in Women With and at Risk for HIV: Data From the Women's Interagency HIV Study - (02/07/05)
     
  15677. Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV - (02/03/05)
     
  15678. Liver & Kidney Transplant in HIV Study - (02/03/05)
     
  15679. 2 Cases of Rare Sex Disease Are Diagnosed in New York - (02/03/05)
     
  15680. Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV--Infected, Treatment-Naive Patients: Implications for Routine Resistance Screening before Initiation of Antiretroviral Therapy - (02/02/05)
     
  15681. Prevention of Mother-to-Child Transmission of HIV Infection (and Caesarean Section Delivery) - (02/02/05)
     
  15682. Abacavir Compared to Protease Inhibitors as Part of HAART Regimens for Treatment of HIV Infection: Patient Satisfaction and Implications for Adherence - (02/02/05)
     
  15683. Body Habitus in a Cohort of HIV-Seropositive and HIV-Seronegative Injection Drug Users - (02/02/05)
     
  15684. GB Virus C Coinfection and HIV-1 Disease Progression: The Amsterdam Cohort Study - (02/02/05)
     
  15685. Study Finds that Severity of Liver Damage May Predict Risk for Hepatotoxicity on HAART - (02/02/05)
     
  15686. New Treatment Interruptions Study & Editorial - (02/02/05)
     
  15687. Fuzeon Sales Improves - (02/02/05)
     
  15688. Increasing HDL May Reduce Heart Disease Risk - (02/01/05)
     
  15689. FosAPV+LPV/r Combination Reduced LPV & APV Levels - (01/31/05)
     
  15690. U.S. Is Close to Eliminating AIDS in Infants, Officials Say - (01/31/05)
     
  15691. Managing Cardiovascular Risk in Patients With HIV Infection - (01/28/05)
     
  15692. Buffalo Hump May be Associated with High Insulin - (01/27/05)
     
  15693. Early Viral failure of NNRTI+ddI/TDF - (01/27/05)
     
  15694. Boosted Saquinavir Montherapy - (01/27/05)
     
  15695. New CCR5 Drug Starts Phase I in Patients - (01/27/05)
     
  15696. New Treatment for HIV Lymphoma: Stem-Cell Transplants - (01/26/05)
     
  15697. FDA Approves AZT/3TC+NVP Fixed Dose Combination - (01/25/05)
     
  15698. New Merck HIV Vaccine Study is Starting - (01/25/05)
     
  15699. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures: 48 weeks - (01/24/05)
     
  15700. Encephalitis Developed After HAART Interruption - (01/24/05)
     
  15701. CDC Recommends Post HIV Exposure Prophylaxis For All - (01/21/05)
     
  15702. FDA Public Health Advisory for Nevirapine (Viramune) - (01/20/05)
     
  15703. Effect of concurrent AZT use on the resistance pathway selected by abacavir-containing regimens - (01/19/05)
     
  15704. Diabetes, BMI, Belly Fat & Heart Disease - (01/19/05)
     
  15705. Treatment Interruptions in Chronic HIV Infection - (01/19/05)
     
  15706. Predictors of HIV Drug-Resistance Mutations in a Large Antiretroviral-Naive Cohort Initiating Triple Antiretroviral Therapy - (01/19/05)
     
  15707. Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study) - (01/18/05)
     
  15708. Semen-Specific Genetic Characteristics of HIV Type 1 env - (01/14/05)
     
  15709. New Protein That Stops HIV From Replicating - (01/14/05)
     
  15710. New Nevirapine Label Change - (01/14/05)
     
  15711. Rare sexual transmitted disease with GI features may be on the rise - (01/12/05)
     
  15712. Therapeutic Drug Monitoring - (01/12/05)
     
  15713. Red meat consumption linked to colorectal cancer - (01/12/05)
     
  15714. Diabetes, high glucose levels linked to cancer in Korean study - (01/12/05)
     
  15715. Rosiglitazone & Pioglitazone Treatment for Lipodystrophy, diabetes, effects on lipids - (01/10/05)
     
  15716. PPAR{gamma}-mediated insulin sensitization: the importance of fat versus muscle - (01/10/05)
     
  15717. Diabetes, Insulin Resistance, and Dementia Among HIV-1-Infected Patients - (01/10/05)
     
  15718. Panacos Pharmaceuticals Announces Initiation of Phase 2 Clinical Development of its HIV Drug Candidate, PA-457 - (01/07/05)
     
  15719. SCIENTISTS DISCOVER KEY GENETIC FACTOR IN DETERMINING HIV/AIDS RISK - (01/06/05)
     
  15720. Statins for Atherosclerosis — As Good as It Gets?, Editorial - (01/06/05)
     
  15721. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease - (01/06/05)
     
  15722. C-Reactive Protein Levels and Outcomes after Statin Therapy - (01/06/05)
     
  15723. Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults - (01/06/05)
     
  15724. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction - (01/05/05)
     
  15725. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study - (01/05/05)
     
  15726. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication - (01/05/05)
     
  15727. Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 cells - (01/04/05)
     
  15728. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine - (01/04/05)
     
  15729. Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine - (01/04/05)
     
  15730. Interleukin-7 May Flush out Latent HIV-1 Reservoirs - (01/04/05)
     
  15731. FDA Approves Rapid HIV Test - (12/30/04)
     
  15732. FDA Recommends Not Using IDV in Pregnant Women - (12/30/04)
     
  15733. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality - (12/28/04)
     
  15734. Diabetes Deaths Increasing in NYC - (12/23/04)
     
  15735. GSK Gets European Approval For Kivexa™, HIV Medication - (12/23/04)
     
  15736. Hep C Maintenance Therapy Study in Coinfection: ACTG Study - (12/23/04)
     
  15737. NIH SUSPENDS USE of NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SUSPENDED IN LARGE ALZHEIMER'S DISEASE PREVENTION TRIAL - (12/23/04)
     
  15738. Reyataz Interaction with Prilosec & PPIs - (12/23/04)
     
  15739. BMS & Gilead Announce Development of EFV+Truvada One Pill Once Daily - (12/23/04)
     
  15740. U.S. FDA Approves New 500 mg Tablet Formulation of INVIRASE(R) - (12/21/04)
     
  15741. Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing Nevirapine - (12/21/04)
     
  15742. Fat Distribution in HIV-Infected Women in the United States: DEXA Substudy in the Women's Interagency HIV Study - (12/21/04)
     
  15743. Loss of Subcutaneous Adipose Tissue in HIV-Associated Lipodystrophy Is Not Due to Accelerated Apoptosis - (12/21/04)
     
  15744. NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial - (12/21/04)
     
  15745. NEVIRAPINE Story - (12/16/04)
     
  15746. New Survey of State AIDS Drug Assistance Programs (ADAPs) Shows Waiting Lists for Medications Persist - (12/16/04)
     
  15747. Viral Suppression of Once Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks In ART-naive Subjects, According to Study Presented at DART - (12/15/04)
     
  15748. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with HAART in Europe - (12/15/04)
     
  15749. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naïve patients - (12/15/04)
     
  15750. New CCR5 Inhibitor UK-427,857 Study for Treatment-Experienced Patients - (12/13/04)
     
  15751. New CCR5 Inhibitor UK-427,857 Study for Treatment-Naives - (12/13/04)
     
  15752. Prevalence of hepatic steatosis (fatty liver) in an urban population in the United States: Impact of ethnicity - (12/13/04)
     
  15753. New Study of SCH '690' CCR5 Inhibitor for Treatment-experienced Patients - (12/13/04)
     
  15754. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy - (12/08/04)
     
  15755. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome - (12/08/04)
     
  15756. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir - (12/08/04)
     
  15757. AIDS Up in N.C. for Third Year; Infections Rise Among Poor Women, Blacks - (12/08/04)
     
  15758. Prevalence of Anal HPV in HIV-Negative MSM - (12/08/04)
     
  15759. Protease Inhibitor and NNRTI Concentrations in the Genital Tract of HIV+ Women - (12/06/04)
     
  15760. Long-Term Persistence of Primary Genotypic Resistance After HIV-1 Seroconversion - (12/06/04)
     
  15761. HIV-Associated Anal Cancer: Has Highly Active Antiretroviral Therapy Reduced the Incidence or Improved the Outcome? - (12/06/04)
     
  15762. Diagnoses of HIV/AIDS --- 32 States, 2000--2003 - (12/03/04)
     
  15763. Capravirine, a Nonnucleoside Reverse-Transcriptase Inhibitor in Patients Infected with HIV-1: A Phase 1 Study - (12/03/04)
     
  15764. Single-Slice Computed Tomography and Anthropometric Skinfold Analysis for Evaluation of Facial Lipoatrophy in HIV-Infected Patients - (12/03/04)
     
  15765. Scientists seeking HIV in all the wrong places - (12/03/04)
     
  15766. Case-Control Study of Diabetes Mellitus in HIV-Infected Patients - (12/01/04)
     
  15767. Therapeutic HIV Vaccine Shows Promise in Patients - (12/01/04)
     
  15768. NIH STATEMENT: On World AIDS Day, December 1, 2004 - (12/01/04)
     
  15769. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection - (12/01/04)
     
  15770. Mitochondrial Abnormalities in HIV-Infected Lipoatrophic Patients Treated With Antiretroviral Agents - (12/01/04)
     
  15771. Boehringer Ingelheim Announces U.S. Expanded Access Program for Anti-HIV Drug Tipranavir - (12/01/04)
     
  15772. ICAAC: Tenofovir + FTC & Efavirenz vs Fixed Dose Combination Combivir (AZT/3TC): 24 week results, study 934 - (11/29/04)
     
  15773. Long-Term Followup- HAART in Advanced HIV - (11/29/04)
     
  15774. The Case for Earlier Treatment of HIV Infection - (11/22/04)
     
  15775. International Congress on Drug Therapy: Tenofovir+Abacavir: is there a risk for K65R associated increased failure - (11/19/04)
     
  15776. Vitamin E Supplements: Good in Theory, but Is the Theory Good? - (11/17/04)
     
  15777. FDA Warns About ddI+TDF + NNRTI - (11/15/04)
     
  15778. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality - (11/15/04)
     
  15779. ICAAC: Side Effect Update: Hypersensitivity, Heart, Bones by Mark Mascolini - (11/15/04)
     
  15780. Intrauterine insemination via HIV-infected men can be safe - (11/12/04)
     
  15781. Vitamin E warning sounded - (11/12/04)
     
  15782. ACTG Salvage Study: DAPD + MMF - (11/12/04)
     
  15783. ICAAC: Gains in Understanding Drug-Resistant HIV by Mark Mascolini - (11/12/04)
     
  15784. ICAAC: ICAC ART Report: New HIV Drugs- tipranavir/r; Reverset; GSK CCR5 Inhibitor 140 by Mark Mascolini - (11/12/04)
     
  15785. IWADRL: Effects of Reyataz & Reyataz+ RTV on Lipids In Vitro by Graeme Moyle MD - (11/12/04)
     
  15786. IWADRL: Lipids--the Liver & Heart Disease in HIV by Jacqueline Capeau - (11/12/04)
     
  15787. ICAAC: What's Wrong With ddI Plus Tenofovir? by Mark Mascolini - (11/10/04)
     
  15788. ICAAC: 873140, A Novel CCR5 Antagonist - (11/10/04)
     
  15789. ICAAC: Tipranavir-New Protease Inhibitor- for Resistance: 24-week results - (11/10/04)
     
  15790. ICAAC: ICAAC Report: Evolving Antiretroviral Strategies by Mark Mascolini - (11/09/04)
     
  15791. AASLD: Body Changes, Diabetes, Fatty Liver & HIV & HCV - (11/05/04)
     
  15792. ICAAC: Failure of PegIFN/RBV in People With HCV/HIV Predicted at 12 Weeks by Mark Mascolini - (11/02/04)
     
  15793. ICAAC: More Early Failures With ddI, Tenofovir, and Efavirenz by Mark Mascolini - (11/01/04)
     
  15794. ICAAC: Better Early Response to Tenofovir/FTC Than to AZT/3TC by Mark Mascolini - (11/01/04)
     
  15795. ICAAC: Tipranavir/Ritonavir Outdoes Other Boosted PIs in Phase 3 Trial by Mark Mascolini - (11/01/04)
     
  15796. Health Officials Put Safer-Sex Message Online - (10/27/04)
     
  15797. 24% of patients in care who engaged in unprotected sex did so with resistant virus - (10/26/04)
     
  15798. Boehringer Ingelheim Submits New Drug Application to U.S. Food and Drug Administration for Tipranavir - (10/25/04)
     
  15799. Kaletra Label Revisions from the FDA - (10/22/04)
     
  15800. Gilead Discontinues Development of GS 9005 and GS 7340; Company Continues Commitment to Research Efforts in HIV - (10/22/04)
     
  15801. Transmission of Primary and Secondary Syphilis by Oral Sex --- Chicago, Illinois, 1998--2002 - (10/22/04)
     
  15802. Fuzeon Granted Traditional Approval by FDA - (10/22/04)
     
  15803. More on K65R & Tenofovir: important information - (10/21/04)
     
  15804. K65R: the Mutation of the year - (10/21/04)
     
  15805. Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis - (10/21/04)
     
  15806. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy - (10/21/04)
     
  15807. HIV in People >50; Response to HAART, French study - (10/21/04)
     
  15808. New Osteoporosis Drug Dosed by IV Every 2/3 Mos - (10/19/04)
     
  15809. Seven Good foods for you - (10/19/04)
     
  15810. mtDNA Depletion & Coenzyme Q10 - (10/19/04)
     
  15811. Trends in AIDS-Defining and Non--AIDS-Defining Malignancies among HIV-Infected Patients: 1989--2002 - (10/19/04)
     
  15812. Early Research on Integrase Inhibitors: 2 classes of compounds identified - (10/18/04)
     
  15813. Vitamin D & HIV - (10/18/04)
     
  15814. Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1-Infected Patients - (10/18/04)
     
  15815. FDA Grants Full traditional Approval for Fuzeon - (10/18/04)
     
  15816. Anal Intraepithelial Neoplasia in Heterosexual and Homosexual HIV-Positive Men with Access to Antiretroviral Therapy - (10/15/04)
     
  15817. Can HIV Be Eradicated? - (10/15/04)
     
  15818. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure - (10/15/04)
     
  15819. After the Recall, Merck Talks About a Successor to Vioxx - (10/15/04)
     
  15820. CCR5 Inhibitor Prevents HIV transmission in Monkeys - (10/14/04)
     
  15821. Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: Prospective multicentre study - (10/12/04)
     
  15822. IL-2 Therapy Effective in Acute HIV & HAART - (10/12/04)
     
  15823. President Bush's $20 Million ADAP Initiative - (10/12/04)
     
  15824. Celebrex & Vioxx Backlash on FDA - (10/08/04)
     
  15825. Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations: TDM - (10/07/04)
     
  15826. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations - (10/05/04)
     
  15827. Pfizer says it sees no safety concerns in Celebrex studies - (10/05/04)
     
  15828. BMI Predicts Survival as well as <200 CD4s - (10/05/04)
     
  15829. HAART Resolves Life-Threatening Anemia in Women - (10/05/04)
     
  15830. NEW DRUG TNX-355 & STUDY FOR PATIENTS WITH EXTENSIVE HIV DRUG RESISTANCE; study sites listed - (10/04/04)
     
  15831. Hep A Vaccine-High Seroconversion Rate in HIV+ <300 Cd4s - (10/04/04)
     
  15832. Vioxx, Other "Super Aspirins" Are Super Disasters -- Other Cox-2 Alternatives Have Safety Problems Too - (10/04/04)
     
  15833. Merck's Vioxx-A Widely Used Arthritis Drug Is Withdrawn - (10/04/04)
     
  15834. FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Withdraws the Product - (10/04/04)
     
  15835. High-Risk Sexual Behavior by HIV-Positive Men Who Have Sex with Men --- 16 Sites, United States, 2000—2002 - (10/01/04)
     
  15836. Fatty Liver Accelerates Fibrosis: diabetes, mitochondrial dyfunction, obesity associated - (09/30/04)
     
  15837. After 20 years, AIDS vaccine still seems a distant dream - (09/29/04)
     
  15838. Acute hepatitis C in HIV-infected men who have sex with men - (09/28/04)
     
  15839. Valacyclovir and Acyclovir for Suppression of Shedding of Herpes Simplex Virus in the Genital Tract - (09/28/04)
     
  15840. Adipose tissue expression of IL-18 and HIV-associated lipodystrophy - (09/28/04)
     
  15841. Invitation to Advanced Course in Antiretroviral Therapy CME in NY & SF, OCT/NOV - (09/27/04)
     
  15842. Women & HIV-CDC Updates HIV/AIDS Surveillance Among Women in US - (09/27/04)
     
  15843. Glaxo AIDS Drugs to Be Tested In Topical Form, as Microbicide - (09/24/04)
     
  15844. Heart Transplant in HIV+: Bob Zackin, AIDS Researcher - (09/24/04)
     
  15845. Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection - (09/22/04)
     
  15846. HIV-Producing T Cells in Cerebrospinal Fluid - (09/22/04)
     
  15847. HIV and Syphilis Testing Among Men Who Have Sex With Men Attending Sex Clubs and Adult Bookstores - San Francisco, 2003 - (09/22/04)
     
  15848. Switch to Nevirapine Improves Lipids - (09/22/04)
     
  15849. Low-Level HIV Viremia May Cause Failure - (09/22/04)
     
  15850. Depression & No HAART Increases Risk for AIDS-Death Among HIV+ Women in WIHS - (09/21/04)
     
  15851. Immunomodulating Drugs for the Treatment of HIV, Costermano 2004 - (09/20/04)
     
  15852. Perceived viral load, but not actual HIV-1-RNA load, is associated with sexual risk behaviour among HIV-infected homosexual men - (09/16/04)
     
  15853. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men - (09/16/04)
     
  15854. ROCHE ANNOUNCES FREE 60-DAY FUZEON ACCESS FOR TIPRANAVIR EXPANDED ACCESS PROGRAM - (09/13/04)
     
  15855. Clinical Trial Registration: Editorial - (09/13/04)
     
  15856. Will the dietary intake of fish prevent atherosclerosis in diabetic women? - (09/10/04)
     
  15857. NIH Proposes Free Access For Public to Research Data - (09/09/04)
     
  15858. Fuzeon Used To Prevent Mother-To-Child-Transmission of HIV - (09/08/04)
     
  15859. When To Begin HAART: new study & 2 different opinions - (09/08/04)
     
  15860. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection - (09/08/04)
     
  15861. Cardio- and cerebrovascular events in HIV-infected persons - (09/08/04)
     
  15862. IAVI May Halt Two Lead HIV Vaccines' Development - (09/07/04)
     
  15863. Nelfinavir Plasma Concentrations Are Low during Pregnancy - (09/07/04)
     
  15864. The Effects of Low-Dose Growth Hormone in HIV-Infected Men with Fat Accumulation: A Pilot Study - (09/07/04)
     
  15865. Mitochondrial Effects of HIV In ART-Naive - (09/07/04)
     
  15866. Fuzeon Health-Related Quality of Life Study - (09/02/04)
     
  15867. Can We Really Identify HIV-1 Long-Term Nonprogressors? - (09/02/04)
     
  15868. Effect of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial DNA Synthesis in Rats and Humans - (09/02/04)
     
  15869. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy - (09/01/04)
     
  15870. Safety and tolerability of vaginal tenofovir gel (TFV) in HIV-uninfected and HIV-infected women (HPTN 050) - (08/30/04)
     
  15871. Abacavir + 3TC Fixed Dose Combination (One Pill Once Daily): - (08/30/04)
     
  15872. Sustiva Package Insert to Include 168-Week Data on Long-Term Durability, Safety & Tolerability - (08/30/04)
     
  15873. Fatty Liver & its impact: HIV, treatment, pathogenesis - (08/30/04)
     
  15874. Simvastatin has long-term survival benefit: heart disease & cancer examined - (08/30/04)
     
  15875. Tolerability and Safety of HIV Protease Inhibitors in Adults: heart, bones, lipids, body changes, diabetes - (08/27/04)
     
  15876. Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV - (08/26/04)
     
  15877. Risk of HIV & Hepatitis Infections From Blood & Tissue Donors - (08/25/04)
     
  15878. Frequent Reactivation of Herpes Simplex Virus among HIV+ Patients Treated with HAART - (08/25/04)
     
  15879. Mitochondrial DNA Changes in PBMCs and Lipoatrophy & Nukes - (08/25/04)
     
  15880. The Ideal Nucleoside/Nucleotide Backbone - (08/23/04)
     
  15881. New Nucleoside/Nucleotide Backbone Options: A Review of Recent Studies - (08/23/04)
     
  15882. The Role of Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Backbones in Antiretroviral Therapy - (08/23/04)
     
  15883. Pharmacokinetic Properties of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors - (08/23/04)
     
  15884. MITOCHONDRIAL DYSFUNCTION: TOXICITY & PATIENT MANAGEMENT - (08/23/04)
     
  15885. North Carolina ADAP Rescued - (08/20/04)
     
  15886. Metabolic complications of HIV therapy in children: lipodystrophy, dyslipidemias, insulin resistance, bones disease, avascular necrosis, mitochondrial toxicity - (08/20/04)
     
  15887. Neuropsychiatric impact of hepatitis C on advanced HIV - (08/20/04)
     
  15888. Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy - (08/19/04)
     
  15889. FDA LABEL CHANGES FOR EFAVIRENZ (SUSTIVA) - (08/19/04)
     
  15890. XV International AIDS Conference in Bangkok: Passive Immunotherapy Drug: HRG214 - (08/17/04)
     
  15891. XV International AIDS Conference in Bangkok: NEW NNRTI 695634: safety, PK, tolerability in healthy subjects - (08/17/04)
     
  15892. XV International AIDS Conference in Bangkok: RE-EXAMINING WHEN TO BEGIN HIV THERAPY & D4T USE & LIPOATROPHY - (08/17/04)
     
  15893. XV International AIDS Conference in Bangkok: UK-427,857, a new CCR5 (entry) Inhibitor: viral load, safety QTc interval, tolerability, food effect in 10 day monotherapy study - (08/17/04)
     
  15894. XV International AIDS Conference in Bangkok: Lopinavir/ritonavir (LPV/r) Safety, Tolerability and Efficacy & Liver Safety in Hep C and/or Hep B-infected Patients: Review of Kaletra Trials - (08/17/04)
     
  15895. Invirase 500 mg Tablet Granted FDA Priority Review- (Roche Press Release) - (08/17/04)
     
  15896. Facing Middle Age and AIDS - (08/17/04)
     
  15897. Scientists Discover New Approaches to Manipulating AIDS Virus to Possibly Eradicate HIV - (08/17/04)
     
  15898. Niacin in HIV-Infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy - (08/17/04)
     
  15899. Acetyl-l-carnitine treatment for ART-associated Neuropathy - (08/17/04)
     
  15900. Maintaining Failing HAART Promotes HIV Drug Resistance & May Limit Future Options - (08/11/04)
     
  15901. HAART restores balance of mucosal immunity in advanced AIDS - (08/09/04)
     
  15902. Links Between Prison and AIDS Affecting Blacks Inside and Out - (08/09/04)
     
  15903. Patients With H.I.V. Seen as Separated by a Racial Divide - (08/09/04)
     
  15904. XV International AIDS Conference in Bangkok: Extensive Resistance Testing During 5 Years of Lopinavir/ritonavir Treatment in Antiretroviral-Naive HIV-infected Patients: Results from Study 720 - (08/06/04)
     
  15905. XV International AIDS Conference in Bangkok: Once Daily Kaletra plus Tenofovir & FTC: PK, resistance, antiviral activity - (08/05/04)
     
  15906. Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV - (08/05/04)
     
  15907. XV International AIDS Conference in Bangkok: PHARMACOKINETIC INTERACTIONS OF ATAZANAVIR AND SAQUINAVIR IN ARITONAVIR BOOSTED DOUBLE-PROTEASE INHIBITOR THERAPY REGIMEN: ATSAQ Cohort Study - (08/04/04)
     
  15908. FDA APPROVES GILEAD'S TRUVADA, A ONE-TABLET, ONCE-A-DAY FIXED-DOSE CO-FORMULATION OF VIREAD AND EMTRIVA (Tenofovir+FTC) - (08/04/04)
     
  15909. FDA Approves EPZICOM -- Ziagen+3TC Combining Two Antiretrovirals in One Tablet Dosed Once a Day; Initiates Voucher Program - (08/04/04)
     
  15910. SCULPTRA for HIV FACIAL LIPOATROPHY APPROVED BY FDA - (08/04/04)
     
  15911. Merck Grants License for Generic Efavirenz to South African Company Thembalami Pharmaceuticals - (07/30/04)
     
  15912. XV International AIDS Conference in Bangkok: Risk of Metabolic Syndrome (MetSyn) Among Highly Treatment-Experienced HIV-Infected Patients -- 48 Week Results from BMS Study AI424-045 - (07/29/04)
     
  15913. XV International AIDS Conference in Bangkok: Higher Doses of Lopinavir/ritonavir (LPV/r) in Highly Treatment-Experienced, HIV-Infected Patients: 48-Week Safety/Efficacy Evaluation - (07/27/04)
     
  15914. XV International AIDS Conference in Bangkok: 8 Studies at IAC Bangkok on Tenofovir Renal Safety - (07/27/04)
     
  15915. ABBOTT LABORATORIES ANNOUNCES SUBMISSION FOR ONCE-DAILY KALETRA (LOPINAVIR/RITONAVIR) IN UNITED STATES, EUROPE - (07/27/04)
     
  15916. XV International AIDS Conference in Bangkok: Efavirenz (Sustiva)-Based HAART: 168 Weeks of Follow-Up (3-4 yrs) of original 006 EFV pivotal Study - (07/27/04)
     
  15917. Effect of Nukes on HIV Resting Cells & Implication for Viral Suppression, Selecting Nukes: AZT, abacavir, 3TC - (07/26/04)
     
  15918. Ejaculation Frequency and Subsequent Risk of Prostate Cancer - (07/26/04)
     
  15919. XV International AIDS Conference in Bangkok: Changes in Body Fat on Reyataz & Sustiva - (07/26/04)
     
  15920. XV International AIDS Conference in Bangkok: 908/r: 48 WEEK RESULTS in PI-EXPERIENCED (CONTEXT STUDY) - (07/22/04)
     
  15921. XV International AIDS Conference in Bangkok: IMPACT OF HCV VIREMIA ON HIV DISEASE PROGRESSION IN WOMEN: HCV INCREASES RISK FOR AIDS (WIHS) - (07/22/04)
     
  15922. XV International AIDS Conference in Bangkok: 908/r QD in Treatment-Naïve 96 weeks Followup of SOLO - (07/22/04)
     
  15923. XV International AIDS Conference in Bangkok: SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients - (07/20/04)
     
  15924. XV International AIDS Conference in Bangkok: Lipids Changes in Reyataz Expanded Access Program - (07/20/04)
     
  15925. Anal carcinoma: incidence and effect of cumulative infections - (07/20/04)
     
  15926. High Viral Load & Low CD4 Predicts Failure to Nefinavir but not to Kaletra - (07/19/04)
     
  15927. XV International AIDS Conference in Bangkok: Tenofovir vs d4T + EFV/3TC, study 903: 144 weeks in men & women - (07/19/04)
     
  15928. XV International AIDS Conference in Bangkok: ONCE DAILY PI REGIMEN 1600/100 SQV-hgc/r: 24 week results - (07/19/04)
     
  15929. XV International AIDS Conference in Bangkok: Single-drug HAART (Lopinavir/r) for maintenance of HIV viral suppression - (07/19/04)
     
  15930. XV International AIDS Conference in Bangkok: Treatment Interruption Studies at Bangkok IAC - (07/19/04)
     
  15931. XV International AIDS Conference in Bangkok: High prevalence and late diagnosis of HIV among Black men aged 40-54 in New York City - (07/16/04)
     
  15932. XV International AIDS Conference in Bangkok: Lopinavir/ritonavir- versus efavirenz-based therapy as the two first-line HAART regimens for naive HIV-infected subjects - (07/16/04)
     
  15933. XV International AIDS Conference in Bangkok: Safety and tolerability of vaginal tenofovir gel (TFV) in HIV-uninfected and HIV-infected women (HPTN 050) - (07/16/04)
     
  15934. XV International AIDS Conference in Bangkok: Peter Piot, UNAIDS, Plenary Address for Closing Ceremony - (07/16/04)
     
  15935. XV International AIDS Conference in Bangkok: Effect on Glucose Metabolism by Adding Lo-Dose RTV to Reyataz: In Vitro study - (07/16/04)
     
  15936. XV International AIDS Conference in Bangkok: HCV Coinfection May Affect CD4 Response to HAART - (07/16/04)
     
  15937. XV International AIDS Conference in Bangkok: PA-457, New HIV Drug; & Research for new Fusion Inhibitors - (07/16/04)
     
  15938. XV International AIDS Conference in Bangkok: BANGKOK: Reyataz/rtv Approved for Treatment-Experienced; Once Daily PI Regimen- Invirase/rtv (1600/100mg), pilot study results - (07/16/04)
     
  15939. XV International AIDS Conference in Bangkok: Simplification from HAART to Kaletra Monotherapy: 2 pilot studies - (07/16/04)
     
  15940. XV International AIDS Conference in Bangkok: BANGKOK IAC Daily Highlights, Thurs July 17: microbicides, Global AIDS, treatment in Thailand - (07/15/04)
     
  15941. XV International AIDS Conference in Bangkok: BANGKOK INTL AIDS CONFERENCE: Daily Highlights - (07/15/04)
     
  15942. XV International AIDS Conference in Bangkok: NEW FUZEON STUDY RESULTS: 2 years follow-up - (07/14/04)
     
  15943. XV International AIDS Conference in Bangkok: FUZEON & FOSAMPRENAVIR STUDY RESULTS - (07/13/04)
     
  15944. XV International AIDS Conference in Bangkok: KALETRA MONOTHERAPY - (07/13/04)
     
  15945. XV International AIDS Conference in Bangkok: New NRTI Reverset for Patients with Nuke Resistance and in Treatment naive: 10-day monotherapy studies - (07/13/04)
     
  15946. XV International AIDS Conference in Bangkok: REPORT FROM BANGKOK - (07/12/04)
     
  15947. XV International AIDS Conference in Bangkok: U.S. Works As Vietnam Ally in War on AIDS - (07/12/04)
     
  15948. XV International AIDS Conference in Bangkok: Asian AIDS crisis, prevention in focus at Bangkok - (07/09/04)
     
  15949. XV International AIDS Conference in Bangkok: UPDATE on SCHERING'S PLOUGH'S ENTRY INHIBITOR (CCR5 Inhibitor) IN PHASE II CLINICAL DEVELOPMENT - (07/09/04)
     
  15950. Switch from PI to Abacavir: affect on fat, glucose - (07/09/04)
     
  15951. XV International AIDS Conference in Bangkok: ON THE ROAD TO BANGKOK: HIV IN THAILAND & ASIA—the latest information out today - (07/08/04)
     
  15952. New Dosing Regimen for REYATAZ/ritonavir in Treatment-Experienced Patients - (07/08/04)
     
  15953. Clinical nutrition: Omega-3 fatty acids in cardiovascular care - (07/08/04)
     
  15954. XV International AIDS Conference in Bangkok: UNAIDS Full Executive Summary 2004 Report on the global AIDS epidemic - (07/07/04)
     
  15955. XV International AIDS Conference in Bangkok: Global HIV/AIDS & ASIA - (07/07/04)
     
  15956. Diet and the Risk of Prostate Cancer & Heart Disease - (07/07/04)
     
  15957. FDA UPDATE ON VIREAD (TENOFOVIR) LABEL - (07/06/04)
     
  15958. XV International AIDS Conference in Bangkok: Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost? - (07/06/04)
     
  15959. XV International AIDS Conference in Bangkok: HIV/AIDS in Asia - (07/06/04)
     
  15960. XV International AIDS Conference in Bangkok: Generic HAART Studied in Cameroon: d4T/NVP/3TC, 80% <400 copies/ml - (07/06/04)
     
  15961. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults - (07/06/04)
     
  15962. - (07/06/04)
     
  15963. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe - (07/01/04)
     
  15964. Cancer Risk Among Participants in the Women's Interagency HIV Study - (06/30/04)
     
  15965. The Pharmacokinetics, Safety, and Initial Virologic Response of a Triple-Protease Inhibitor Salvage Regimen Containing Amprenavir, Saquinavir, and Ritonavir - (06/30/04)
     
  15966. Beliefs About HIV Reinfection (Superinfection) and Sexual Behavior Among a Diverse Sample of HIV-Positive Men Who Have Sex With Men - (06/30/04)
     
  15967. Perinatal Transmission and Viral Evolution of Hepatitis C Virus Quasispecies in Infants Coinfected With HIV - (06/30/04)
     
  15968. Isolated Presence of Antibody to Hepatitis B Core Antigen in Patients Coinfected With HIV - (06/30/04)
     
  15969. 13th Intl HIV Resistance Workshop: Nevirapine Resistance After Single Dose to Prevent Mother-To-Child HIV Transmission - (06/29/04)
     
  15970. Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy--Naive and --Experienced Patients Coinfected with HIV-1 and Hepatitis B Virus - (06/28/04)
     
  15971. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection - (06/28/04)
     
  15972. Higher Levels of HIV in Rectal Secretions Among MSM - (06/28/04)
     
  15973. HAART 7 Days On/ 7 Days Off Cycling- Once Daily ddI/3TC/EFV - (06/28/04)
     
  15974. Tenofovir-related nephrotoxicity in HIV-infected patients - (06/28/04)
     
  15975. Sperm mitochondrial DNA deletions as a consequence of long term highly active antiretroviral therapy - (06/28/04)
     
  15976. Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery - (06/28/04)
     
  15977. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir - (06/28/04)
     
  15978. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase - (06/28/04)
     
  15979. Persistance of HPV in HIV+ Adolescent Girls - (06/28/04)
     
  15980. Ritonavir boosted indinavir treatment as a simplified maintenance 'mono'-therapy for HIV infection - (06/28/04)
     
  15981. The Pharmacogenetics of Antiretroviral Therapy: A Review of Studies to Date - (06/28/04)
     
  15982. 13th Intl HIV Resistance Workshop: Best Genotypic Resistance Tests To Evaluate Sensitivity To Kaletra - (06/28/04)
     
  15983. 13th Intl HIV Resistance Workshop: Isolated Report of Kaletra Resistance - Written by David Margolis, M.D. (06/24/04)
     
  15984. 13th Intl HIV Resistance Workshop: Report from the 13th International Workshop on HIV Drug Resistance - Written by David Margolis, M.D. (06/23/04)
     
  15985. GB Virus Inhibits HIV & May Spur New Drug Research - (06/23/04)
     
  15986. Invirase (saquinavir) - New 500 mg Tablet To Simplify Dosing Regimens - (06/23/04)
     
  15987. Harm Reduction for Substance Abuse in the Psychiatric Setting - (06/23/04)
     
  15988. Interaction Studies Between Fuzeon & Ritonavir or Ritonavir Boosted Saquinavir - (06/23/04)
     
  15989. Viral Response, Kaletra vs Nelfinavir, Study 653 in Treatment-Naive - (06/23/04)
     
  15990. Polyunsaturated Ethyl Esters of n-3 Fatty Acids in HIV-Infected Patients With Moderate Hypertriglyceridemia: Comparison With Dietary and Lifestyle Changes, and Fibrate Therapy - (06/22/04)
     
  15991. Recombinant Interferon-1b as Adjunctive Therapy for AIDS-Related Acute Cryptococcal Meningitis - (06/22/04)
     
  15992. Maternal Toxicity With Continuous Nevirapine in Pregnancy: Results From PACTG 1022 - (06/22/04)
     
  15993. The prevalence of antiretroviral drug resistance in the United States - (06/22/04)
     
  15994. HIV-1 co/super-infection in intravenous drug users - (06/22/04)
     
  15995. 13th Intl HIV Resistance Workshop: Tenofovir in salvage therapy: K65R, TAMS, Kaletra - (06/22/04)
     
  15996. 13th Intl HIV Resistance Workshop: Tenofovir & Correlates of the K65R Mutation - (06/17/04)
     
  15997. 13th Intl HIV Resistance Workshop: Reyataz and It's I50L Mutation - (06/17/04)
     
  15998. 13th Intl HIV Resistance Workshop: Reyataz Viral Response in Experienced Patients -genotypic mutation score - (06/17/04)
     
  15999. 13th Intl HIV Resistance Workshop: Sustiva + Kaletra: no mutations developed - (06/17/04)
     
  16000. 13th Intl HIV Resistance Workshop: Predicting Response to ddI in Experienced Patients - (06/16/04)
     
  16001. 13th Intl HIV Resistance Workshop: High Rates of Viral failure/Resistance to HAART-need for new drugs - (06/16/04)
     
  16002. 13th Intl HIV Resistance Workshop: Predicting Response to d4T - (06/16/04)
     
  16003. 13th Intl HIV Resistance Workshop: Fuzeon Resistance - (06/16/04)
     
  16004. 13th Intl HIV Resistance Workshop: Predictors of selection of K65R: tenofovir use and lack of TAMs - (06/16/04)
     
  16005. 13th Intl HIV Resistance Workshop: In vitro resistance development for a second-generation NNRTI: TMC125 - (06/16/04)
     
  16006. 13th Intl HIV Resistance Workshop: Viral Blips May Affect CD4 Response to HAART - (06/16/04)
     
  16007. 13th Intl HIV Resistance Workshop: Replication Capacity Affects CD4 Response to HAART - (06/16/04)
     
  16008. 13th Intl HIV Resistance Workshop: Transmitted HIV Drug Resistance Persists & May Reduce Response to HAART - (06/16/04)
     
  16009. 13th Intl HIV Resistance Workshop: Experts Differ In Interpretation of Resistance Testing Results - (06/16/04)
     
  16010. 13th Intl HIV Resistance Workshop: Pre-Existing L74V is a Risk for Virologic Non-Response and Development of K65R in Patients Taking Tenofovir - (06/16/04)
     
  16011. Ronald Reagan & AIDS Remembered - (06/14/04)
     
  16012. 13th Intl HIV Resistance Workshop: Risk Of Developing Resistance Mutations During Treatment Interruptions - (06/14/04)
     
  16013. 13th Intl HIV Resistance Workshop: GigHAART Study: treatment interruption with advanced HIV - (06/14/04)
     
  16014. 13th Intl HIV Resistance Workshop: Transmitted NNRTI Drug Resistance Results in Higher Viral Loads - (06/14/04)
     
  16015. 13th Intl HIV Resistance Workshop: Tipranavir Virally Effective in Patients with Extensive PI Resistance - (06/14/04)
     
  16016. 13th Intl HIV Resistance Workshop: Two New Protease Inhibitors; Novel Mechanism Leading to PI Resistance - (06/10/04)
     
  16017. 13th Intl HIV Resistance Workshop: New HIV Protease Inhibitor at 13th Intl HIV Resistance Workshop - (06/08/04)
     
  16018. Brief but Efficient: Acute HIV Infection and the Sexual Transmission of HIV - (06/07/04)
     
  16019. Body Changes in HIV+ Monkeys - (06/07/04)
     
  16020. The Epidemiology of Antiretroviral Drug Resistance among Drug-Naive HIV-1--Infected Persons in 10 US Cities: resistance testing prior to initiating HAART in treatment-naïve patients - (06/07/04)
     
  16021. Contraceptive Use in HIV-Positive Women - (06/07/04)
     
  16022. Predicting Kaletra Response in Treatment-Experienced Patients - (06/07/04)
     
  16023. Genes, Ethnicity, and Efavirenz Response: Clinical Pharmacology Update from the 11th CROI - (06/07/04)
     
  16024. Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count - (06/07/04)
     
  16025. Long-Term Efficacy (108 weeks) and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir - (06/07/04)
     
  16026. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen - (06/03/04)
     
  16027. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection - (06/03/04)
     
  16028. Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground - (06/03/04)
     
  16029. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study - (06/03/04)
     
  16030. Fuzeon Consensus Recommendations: clinical management with Fuzeon for treatment-experienced patients - (06/02/04)
     
  16031. Can HIV Be Eradicated or Cured? - (06/01/04)
     
  16032. HIV-associated nephropathy: a disease of ethnic disparity for Blacks - (06/01/04)
     
  16033. NIH Norvir Price Hearing: Abbott & Community Points of View - (06/01/04)
     
  16034. Viracept (nelfinavir) Now in 625 mg Tablets: press release from Pfizer - (06/01/04)
     
  16035. Where Does HIV Live? - (05/27/04)
     
  16036. U.S. FDA GRANTS PRIORITY REVIEW TO GILEAD'S FIXED DOSE CO-FORMULATION OF VIREAD AND EMTRIVA FOR HIV - (05/26/04)
     
  16037. Decline in lung function, impaired response to salbutamol in HCV+ asthmatics - (05/25/04)
     
  16038. ADAP May 2004 REPORT - (05/24/04)
     
  16039. BRISTOL-MYERS SQUIBB, GILEAD SCIENCES AND MERCK & CO., INC. ANNOUNCE PLANS TO DEVELOP FIXED-DOSE COMBINATION OF THREE HIV MEDICINES - (05/17/04)
     
  16040. Drug-resistant HIV often transmitted among intravenous drug users - (05/17/04)
     
  16041. NRTIs and Intracellular Activity and Toxicities for Women, Advanced HIV & Hepatitis - (05/17/04)
     
  16042. High Plasma Level of Interleukin-18 in HIV-Infected Subjects With Lipodystrophy - (05/12/04)
     
  16043. Lipoatrophy & Switch to Abacavir: Mitox Study - (05/11/04)
     
  16044. Occult HBV: Clinical Significance of Hepatitis B Core Antibody Positivity in HCV-Infected and HCV/HIV Coinfected Individuals - (05/10/04)
     
  16045. Smoking Increases Risk for Cervical Cancer in HIV+ - (05/10/04)
     
  16046. Atazanavir (Reyataz) and the I50L Mutation - (05/10/04)
     
  16047. Famcyclovir for Herpes Simplex Virus Shedding in Women - (05/10/04)
     
  16048. HBV/HIV Coinfection & Tenofovir - (05/10/04)
     
  16049. Gender, Pregnancy, and PKs - (05/10/04)
     
  16050. TDM - (Therapeutic Drug Monitoring); PK (drug levels) - (05/07/04)
     
  16051. Factors Associated with Severe Impact of Lipodystrophy on the Quality of Life of Patients Infected with HIV-1 - (05/04/04)
     
  16052. Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies - (05/04/04)
     
  16053. High Resolution Anoscopy Findings for Men Who Have Sex with Men: Inaccuracy of Anal Cytology as a Predictor of Histologic High-Grade Anal Intraepithelial Neoplasia and the Impact of HIV Serostatus - (05/04/04)
     
  16054. Directly Observed Therapy for HAART in an Urban US Setting - (05/04/04)
     
  16055. Recommendations for the Nonclinical Development of Topical Microbicides for Prevention of HIV Transmission: An Update - (05/04/04)
     
  16056. HAART & Neurocognitive Function - (05/04/04)
     
  16057. HCV/HIV Coinfection & Lipid Abnormalities - (05/04/04)
     
  16058. Workshop on Clinical Pharmacology: 5th International Workshop on Clinical Pharmacology of HIV Therapy Special Report Written for NATAP by Jennifer King, Pharm.D. - (05/03/04)
     
  16059. Breastfeeding and maternal HIV-1 disease progression and mortality - (05/03/04)
     
  16060. Renal safety of tenofovir in HIV treatment-experienced patients - (05/03/04)
     
  16061. Beneficial effects of oral uridine in mitochondrial toxicity - (05/03/04)
     
  16062. Herpes Vaccine Test Runs into Recruiting Hurdle - (05/03/04)
     
  16063. TMC125 (Phase II Study) in 150 HIV+ Patients with Resistance to NNRTIs and 3 or More Protease Inhibitor Mutations - (05/03/04)
     
  16064. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir - (05/03/04)
     
  16065. Sustiva Compared to Trizivir: ACTG 5095 - (05/03/04)
     
  16066. Trizivir & ACTG 5095: GSK Response - (04/29/04)
     
  16067. IL-2 Appears Effective in Sustaining CD4 Cell Counts - (04/27/04)
     
  16068. Abbott defends AIDS drug price - (04/27/04)
     
  16069. Hepatitis C Virus (HCV) Diversity in HIV-HCV Coinfected Subjects Initiating Highly Active Antiretroviral Therapy - (04/22/04)
     
  16070. EASL: First Major Study Showing 12 Week Viral Response to Pegasys/ribavirin in Coinfected Patients Predicts Outcome - (04/22/04)
     
  16071. Tenofovir (Viread) Patient Assistance Program Redesigned to Allow Access on the Same Day They Visit Care Provider - (04/21/04)
     
  16072. EASL: Study Finds Undetectable HIV Viral Load Slows Liver Disease Progression in HCV/HIV Coinfection - (04/19/04)
     
  16073. Herpes & HIV - (04/12/04)
     
  16074. ADAP in Trouble, April Report - (04/12/04)
     
  16075. SURVEY SUGGESTS LACK OF AWARENESS HEIGHTENS RISK FOR SEXUALLY TRANSMITTED DISEASE - (04/08/04)
     
  16076. K65R HIV Drug Mutation: resistance, prevalence, & associations - (04/07/04)
     
  16077. Fosamprenavir (908, LEXIVA) Antivirial Activity Report - (04/07/04)
     
  16078. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers - (04/05/04)
     
  16079. Antiretroviral Therapy and the Clinical Evolution of Human Papillomavirus Associated Genital Lesions in HIV-Positive Women - (04/05/04)
     
  16080. Hepatitis A - (04/05/04)
     
  16081. Crystal Methamphetamine, Its Analogues, and HIV Infection: Medical and Psychiatric Aspects of a New Epidemic - (04/05/04)
     
  16082. 384 HIV+ Men found to have Body Abnormalities Compared to 314 HIV- Men - (04/05/04)
     
  16083. Hepatotoxicity Associated With Nevirapine Use - (04/02/04)
     
  16084. Samaritan's HIV Drug Shows Promise as Viral Entry Inhibitor - (04/01/04)
     
  16085. HIV in Semen, Effect of HAART, Sexual Transmission of HIV, & Relevance in Getting Pregnant - (03/31/04)
     
  16086. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine - (03/31/04)
     
  16087. European HIV Drug Resistance Workshop, Rome 2004 - written for NATAP by Mike Youle, MD, Director of HIV Clinical Research, Royal Free Center for HIV (03/29/04)
     
  16088. REDUCED RISK OF HIV AMONG CIRCUMCISED MEN IN INDIA RELATED TO BIOLOGY, NOT BEHAVIOR, STUDY SAYS - (03/29/04)
     
  16089. Report 2 on Sculptra (Newfill): FDA study review; advocacy issues - (03/29/04)
     
  16090. FDA Approves First Oral Fluid Based Rapid HIV Test Kit - (03/29/04)
     
  16091. HAART Treatment During Acute HIV-Infection Not Recommended - (03/24/04)
     
  16092. Reyataz Drug Interactions: Tenofovir; Viagra/Cialis/Levitra; buffered ddI; Antacids: dosing recommendations from the FDA - (03/24/04)
     
  16093. CROI: Treating Acute HIV Infection and Treatment Interruptions to Boost Immune Control: an experiment comes to an end - Written by David Margolis, MD (03/24/04)
     
  16094. ADAPs Running Low on Funds - (03/22/04)
     
  16095. CROI: CROI Report: Pharmacology of HIV Drugs - Written for NATAP by Peter Anderson, PhD (03/18/04)
     
  16096. Gilead Requests FDA Approval For One Pill daily of Emtriva/Viread (FTC/tenofovir) - (03/17/04)
     
  16097. CROI: Hypertension and HIV & ART - Written for NATAP by Judith A. Aberg, M.D. (03/17/04)
     
  16098. CROI: Alendronate And Osteopenia and Osteoporosis - (03/17/04)
     
  16099. HIV and Aging: HIV, Dementia & HAART - (03/17/04)
     
  16100. HIV and Aging: Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms - (03/17/04)
     
  16101. HIV and Aging: Introduction: HIV/AIDS and Aging - (03/17/04)
     
  16102. CROI: Insulin Resistance/Diabetes and HIV and Hepatitis C; Aging/HIV & diabetes - written by Judith A. Aberg, M.D. (03/12/04)
     
  16103. NIH budget approved at $28 billion: Concerns over FY 2005 funding - (03/12/04)
     
  16104. More AIDS Patients Get Organ Transplants: New 5 yr NIH Study of Liver Transplantation in HIV/HCV+ - (03/10/04)
     
  16105. Reduced bone density in HIV-infected women - (03/10/04)
     
  16106. Harmless Virus Associated with Longer Life for Some HIV-Positive Men - (03/08/04)
     
  16107. SCIENTISTS FIND HIV-BLOCKING PROTEIN IN MONKEYS - (03/08/04)
     
  16108. Hepatotoxicity and Protease Inhibitors: nelfinavir, Kaletra, IDV/r, SQV/RTV - (03/08/04)
     
  16109. Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors - (03/08/04)
     
  16110. AIDS research changes threaten PWAs - (03/08/04)
     
  16111. CROI: Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/r or Nelfinavir-based Therapy - (03/08/04)
     
  16112. Food-drug interaction: grapefruit juice augments drug bioavailability/mechanism, extent and relevance - (03/05/04)
     
  16113. CROI: CROI Resistance Report 7: New Drugs—Reyataz; TMC-114; Reverset - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/05/04)
     
  16114. CROI: CROI Resistance Report 6: Single Drug Interruption Strategy--nrti, nnrti, pi - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/05/04)
     
  16115. CROI: CROI Resistance Report 5: the K65R Mutation, its relevance, prevalence, & mechanism of action - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/05/04)
     
  16116. CROI: CROI Resistance Report 4: Certain, But Not All, Triple Nuke Regimens Have High Viral Failure Rate - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/03/04)
     
  16117. CROI: CROI Resistance Report 3: Nevirapine Effect & The Development of Drug Resistance in Preventing Mother to Child HIV Transmission - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/03/04)
     
  16118. CROI: CROI Resistance Report, Part 2; Transmission of Drug Resistance, it Persists; Global Trends; Impact of Transmitted Resistance on Initial Response to HAART - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/03/04)
     
  16119. CROI: CROI: HIV-1 Drug Resistance Review Report 1: Low Level NNRTI Resistance May Not Be Detected by Standard Genotype Tests; Sensitive Genotype Tests - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/03/04)
     
  16120. CROI: CROI Report: HIV-1 Drug Resistance Review - (03/03/04)
     
  16121. Not All Triple Nucleoside Therapies are the Same - (03/02/04)
     
  16122. CXCR4 ansd CCR5 HIV Drugs in Development - (03/02/04)
     
  16123. CROI: Renal Function and Tenofovir - (03/02/04)
     
  16124. CROI: PK Report-Double Boosted Protease Inhibitor Regimens: Reyataz/SQV/r; SQV/Fosamprenavir/r; PK highlights - Written for NATAP By Ronald Reisler MD MPH, Institutes of Human Virology University of Maryland Medical School (03/02/04)
     
  16125. CROI: Protease Inhibitors and Utility Of Inhibitory Quotients: high dose Kaletra may overcome PI resistance; Reyataz Expanded Access; Lipids & Kaletra Drug levels - Written for NATAP By Ronald Reisler MD MPH, Institutes of Human Virology University of Maryland Medical School (03/01/04)
     
  16126. CROI: Reyataz Expanded Access: lipids, viral response, safety - (02/26/04)
     
  16127. CROI: Interesting CROI Poster Highlights: nukes/RBV, CSF/HAART, 3-PI regimens, APV/Kaletra, single drug interruption, fitness - Reported by David Margolis, MD, University of Texas, Southwestern Medical Center (02/26/04)
     
  16128. CROI: HIV Latency: still trying to figure it out; is HIV curable? - Report by David Margolis, MD, University of Texas, Southwestern Medical Center (02/26/04)
     
  16129. CROI: Neuropathogenic Manifestations of HIV Infection and Its Therapy: report from CROI - Written by Justin C. McArthur, MBBS, MPH, Johns Hopkins University Medical School (02/26/04)
     
  16130. CROI: HCV/HIV Coinfection May Cause Depression & Cognitive Dysfunction Compared to HIV Monoinfection - (02/26/04)
     
  16131. CROI: Nevirapine Resistance Develops in Therapy to Prevent Mother-To-Child Transmission - Written by David Margolis, MD, University of Texas Southwestern Medical Center (02/26/04)
     
  16132. CROI: Once-Daily vs.Twice-Daily Lopinavir/ritonavir in Antiretroviral-NaÔve Patients: 48-Week Results - (02/26/04)
     
  16133. More HIV Infections Tied to Heterosexual Sex: Minorities & Women Affected Most - (02/23/04)
     
  16134. CROI: High Dose Kaletra in Highly Experienced Patients - (02/23/04)
     
  16135. CROI: HIV Microbocides at the 11th Retrovirus Conference - (02/23/04)
     
  16136. CROI: Incidence of Non-AIDS defining Malignancies in the HIV Outpatient Study (HOPS) Higher Than General Population - (02/23/04)
     
  16137. CROI: Troubling Persistence of Transmitted HIV Drug Resistance - (02/20/04)
     
  16138. CROI: Standard Genotype Tests May Not Detect Low Level Resistance; new Super-Sensitive Resistance Tests - (02/20/04)
     
  16139. CROI: Kaletra Once Daily (48 Week results) - (02/20/04)
     
  16140. CROI: GW873140, New HIV Drug, Novel CCR5 Inhibitor - (02/20/04)
     
  16141. CROI: Tolerance and Potent AntiHIV Activity of Reverset Following 10 Days of Monotherapy in Treatment Naïve Individuals - (02/20/04)
     
  16142. CROI: 1 vs 2 Protease Inhibitors in Patients With Viral Failure on Initial PI Regimen: CPCRA 057 - (02/20/04)
     
  16143. CROI: Protease Inhibitor (PI) Experienced patients: therapeutic approaches, ritonavir-boosted regimens - (02/20/04)
     
  16144. CROI: New antiretroviral agents at 2004 Retrovirus Conference - (02/20/04)
     
  16145. CROI: TNX-355, new HIV Drug, is Safe & Effective in Multiple Dose Phase 1 Study: - (02/20/04)
     
  16146. CROI: PegIntron Plus Ribaivin in HCV/HIV Coinfection: French RIBAVIC Study - (02/19/04)
     
  16147. CROI: ACTG 5071: Pegasys plus Ribavirin vs IFN/RBV in HCV/HIV Coinfection - (02/19/04)
     
  16148. CROI: Body Shape at CROI: rosiglitazone, Newfill, Fuzeon, PI-switch study, d4T-XR, FTC, face ultrasound, Atlantic & NEFA studies - Written by David Alain Wohl, MD (02/19/04)
     
  16149. CROI: The Effect of Atazanavir vs Lopinavir/ritonavir on Insulin-Stimulated Glucose Disposal Rate in Healthy Subjects - (02/17/04)
     
  16150. CROI: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial - (02/17/04)
     
  16151. CROI: SCH-D, CCR5 Receptor Inhibitor, new HIV Drug in New Class of Drugs: - (02/13/04)
     
  16152. CROI: HIV Vaccine $$, ADAP & Hepatitis - (02/13/04)
     
  16153. CROI: New HIV Drug & New Class of HIV Drugs: BMS-488043, an attachment Inhibitor - (02/12/04)
     
  16154. CROI: Ribavirin-NRTIs Interaction Study - (02/12/04)
     
  16155. CROI: High HIV Rates in NYC & Among Black & MSM/W College Students; Men On The 'Down Low' - (02/12/04)
     
  16156. CROI: Reyataz/r Compared to Kaletra (study 045): 48 week data - (02/11/04)
     
  16157. CROI: Incidence of HIV Superinfection Following Primary Infection - (02/09/04)
     
  16158. CROI: Tenofovir Tested for HIV Prevention & Microbicide - (02/09/04)
     
  16159. New Viramune (nevirapine) Safety Information - (02/09/04)
     
  16160. Analyzing Sleep Abnormalities in HIV-Infected Patients Treated with Efavirenz - (02/09/04)
     
  16161. Abbott Labs Dear Doctor Letter Regarding Norvir Price Increase Controversy - (02/06/04)
     
  16162. The effect of hormonal contraception on genital tract shedding of HIV-1 - (02/06/04)
     
  16163. Monitoring ddI & d4T Intracellular Concentrations - (02/06/04)
     
  16164. Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients - (02/05/04)
     
  16165. SUPERINFECTION IN HIV - (02/05/04)
     
  16166. Antiretroviral nucleoside and nucleotide analogues and mitochondria - (02/05/04)
     
  16167. Dietary and circulating antioxidant vitamins in relation to carotid plaques in middle-aged women - (02/02/04)
     
  16168. Moderate vs Low Fat Diets: effects on lipids & heart disease risk - (02/02/04)
     
  16169. Vitamin E Benefits Improve With Enhanced food Intake - (02/02/04)
     
  16170. Increased HIV Viral Loads in Active Methamphetamine Users Are Explained by Reduced Effectiveness of Antiretroviral Therapy - (02/02/04)
     
  16171. Methamphetamine: medical implications, HIV & Hepatitis - (02/02/04)
     
  16172. ADHERENCE in HIV: difficulties in evaluating - (01/30/04)
     
  16173. MAC immune reconstitution disease can recur during HAART - (01/30/04)
     
  16174. Using Peer Recruitment and OraSure to Increase HIV Testing - (01/28/04)
     
  16175. HIV-1 superinfections: omens for vaccine efficacy? - (01/27/04)
     
  16176. T-cell dynamics during acute SIV infection - (01/27/04)
     
  16177. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program in WIHS Study - (01/26/04)
     
  16178. Researchers Criticize NIH AIDS Vaccine $119 Million Study; What About ADAP - (01/23/04)
     
  16179. U.S.-Backed AIDS Vaccine Trial in Thailand Is Questioned - (01/22/04)
     
  16180. Norvir Price Increase: comparison of HIV drug prices - (01/22/04)
     
  16181. Immune Response Controls HIV- During ART-Drug Resistance - (01/22/04)
     
  16182. Induction and Maintenance Therapy with Intermittent Interleukin-2 in HIV-1 Infection - (01/22/04)
     
  16183. Q151M-Mediated Multinucleoside Resistance: Prevalence, Risk Factors, and Response to Salvage Therapy - (01/20/04)
     
  16184. Optimizing the Care of Minority Patients with HIV/AIDS - (01/20/04)
     
  16185. A stable partner slows progression of HIV - (01/20/04)
     
  16186. Antiretroviral Activity of the Anti-CD4 Monoclonal Antibody TNX-355 in Patients Infected with HIV Type 1 - (01/16/04)
     
  16187. NORVIR PRICE INCREASE, REQUESTS ABBOTT BOYCOTT: activists' letter - (01/15/04)
     
  16188. THE TREATMENT OF ACUTE HEPATITIS C INFECTION IN HIV-COINFECTED PATIENTS - A RETROSPECTIVE ANALYSIS OF 8 CASES IN A MULTICENTER SETTING - (01/15/04)
     
  16189. DEPRESSIVE SYMPTOMS AFTER INITIATION OF INTERFERON IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENTS WITH CRONIC HEPATITIS C - (01/15/04)
     
  16190. Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication - (01/15/04)
     
  16191. T-1249 Fusion Inhibitor Update - (01/14/04)
     
  16192. Acute myocardial infarction in patients infected with HIV - (01/14/04)
     
  16193. Increased Human Immunodeficiency Virus Loads in Active Methamphetamine Users Are Explained by Reduced Effectiveness of Antiretroviral Therapy - (01/14/04)
     
  16194. HIV PREVENTION: "Survival sex" and substance abuse may hinder HIV prevention efforts - (01/08/04)
     
  16195. ACTG 384 -- Complicated, but Worth the Work - (01/08/04)
     
  16196. Update on Fuzeon and T-1249 Fusion Inhibitor Halted Development - (01/07/04)
     
  16197. Reyataz vs Nelfinavir: phase II study - (01/06/04)
     
  16198. HAART Reduces HIV Sexual Transmission - (01/06/04)
     
  16199. Lipoatrophy Improvement Following switch to Abacavir or AZT from d4T - (01/05/04)
     
  16200. PI Substitution Strategies -- The Definitive Study (For Now) - (01/05/04)
     
  16201. Retinoids and Drugs of Abuse: Implications for Neurological Disease Risk in HIV-1 Infection - (01/05/04)
     
  16202. Progressive reversion of HIV-1 mutations may have serious consequences - (01/05/04)
     
  16203. Effector CTL activity an ominous sign in long-term HIV nonprogressors - (01/05/04)
     
  16204. AZT Monotherapy To Prevent Perinatal Transmission - (01/05/04)
     
  16205. Accelerated Progression of HCV/HIV in Europe - (01/05/04)